0001193125-24-25203910-Q TEVA PHARMACEUTICAL INDUSTRIES LTD 20241106202411061606261606261606260 0001193125-24-252039 10-Q 99 20240930 20241106 20241106 TEVA PHARMACEUTICAL INDUSTRIES LTD 0000818686 2834 000000000 L3 1231 10-Q 34 001-16174 241430911 TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 972 (3) 914-8213 TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 10-Q 1 d874174d10q.htm 10-Q 10-Q Table of Contents falseQ30000818686--12-3100-0000000ILInterest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c.If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.In October 2024, Teva repaid $685 million of its 1.13% senior notes due 2024 at maturity.If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.In April 2024, Teva repaid $956 million of its 6% senior notes due 2024 at maturity.Including impairments related to exit and disposal activities.The contingent consideration presented in the tables above for the three and nine months ended September 30, 2023 have been revised as discussed in note 1c.Includes adjustments for foreign currency translation.Other revenues in the first nine months of 2024 include the sale of certain product rights.Other revenues in the third quarter of 2024 include the sale of certain product rights.On September 29, 2023, Teva purchased $40 million of subordinated convertible bonds of Alvotech. On June 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024 (see note 2).The plan includes shares to be sold solely to cover tax withholding obligations.The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c.Amounts do not include a $84 million loss from foreign currency translation adjustments attributable to non-controlling interests.Amounts do not include a $6 million loss from foreign currency translation adjustments attributable to non-controlling interests.On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. The agreement was terminated in the first quarter of 2024 and resulted in cash proceeds of $16 million.Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan for the nine months ended September 30, 2023 have been revised as discussed in note 1c.The fair value was estimated based on quoted market prices.Cumulative goodwill impairment as of September 30, 2024 and December 31, 2023 was approximately $29.0 billion and $28.3 billion, respectively. 0000818686 2024-01-01 2024-09-30 0000818686 2024-09-30 0000818686 2023-12-31 0000818686 2024-07-01 2024-09-30 0000818686 2023-07-01 2023-09-30 0000818686 2023-01-01 2023-09-30 0000818686 2023-01-01 2023-12-31 0000818686 2019-08-31 0000818686 2024-06-30 0000818686 2018-08-21 2022-08-21 0000818686 2008-07-31 0000818686 2005-02-28 0000818686 2013-04-01 2013-04-30 0000818686 2013-09-01 2013-09-30 0000818686 2023-06-01 2023-06-30 0000818686 2024-04-01 2024-06-30 0000818686 2023-09-30 0000818686 2023-12-31 2023-12-31 0000818686 2021-07-08 0000818686 2024-01-01 2024-03-31 0000818686 2024-03-28 0000818686 2024-03-31 0000818686 2023-11-07 2023-11-07 0000818686 2022-11-09 2022-11-09 0000818686 2022-12-31 0000818686 2023-06-30 0000818686 teva:RestrictedCashMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000818686 teva:RestrictedCashMember 2023-12-31 0000818686 teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember 2023-12-31 0000818686 teva:Seniornotesandconvertibleseniordebenturesmember 2023-12-31 0000818686 teva:ProductRightsMember 2023-12-31 0000818686 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000818686 us-gaap:TradeNamesMember 2023-12-31 0000818686 us-gaap:ConvertibleDebtMember 2023-12-31 0000818686 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000818686 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000818686 us-gaap:OtherNoncurrentAssetsMember teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000818686 us-gaap:OtherNoncurrentAssetsMember teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:NondesignatedMember 2023-12-31 0000818686 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000818686 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000818686 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000818686 teva:ShortCreditAgreement2026Member 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2036Member 2023-12-31 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029OneMember 2023-12-31 0000818686 teva:SustainabilityLinkedSeniorNotesDue2030Member 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2025ThreeMember 2023-12-31 0000818686 teva:SustainabilityLinkedSeniorNotesDue2031OneMember 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2046Member 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2026OneMember 2023-12-31 0000818686 teva:SustainabilityLinkedSeniorNotesDue2027OneMember 2023-12-31 0000818686 teva:SustainabilityLinkedSeniorNotesDue2027Member 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2024OneMember 2023-12-31 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029TwoMember 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2025TwoMember 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2025Member 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2024Member 2023-12-31 0000818686 teva:SustainabilityLinkedSeniorNotesDue2031TwoMember 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2027Member 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2028TwoMember 2023-12-31 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029Member 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2025OneMember 2023-12-31 0000818686 teva:SubsidiarySeniorNotesDue2028OneMember 2023-12-31 0000818686 teva:OtherDebentures2026Member 2023-12-31 0000818686 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000818686 teva:AccountsReceivableSecuritizationFacilityMember 2023-12-31 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000818686 us-gaap:MoneyMarketFundsMember 2024-09-30 0000818686 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0000818686 us-gaap:DemandDepositsMember 2024-09-30 0000818686 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0000818686 teva:OtherRestrictedCashMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0000818686 teva:OtherRestrictedCashMember 2024-09-30 0000818686 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0000818686 us-gaap:EquitySecuritiesMember 2024-09-30 0000818686 teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember 2024-09-30 0000818686 teva:Seniornotesandconvertibleseniordebenturesmember 2024-09-30 0000818686 us-gaap:TradeNamesMember 2024-09-30 0000818686 teva:ProductRightsMember 2024-09-30 0000818686 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0000818686 us-gaap:ConvertibleDebtMember 2024-09-30 0000818686 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateSwapMember 2024-09-30 0000818686 us-gaap:InterestRateSwapMember 2024-09-30 0000818686 teva:ShortCreditAgreement2026Member 2024-09-30 0000818686 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-09-30 0000818686 us-gaap:OtherNoncurrentAssetsMember teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000818686 us-gaap:OtherNoncurrentAssetsMember teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:NondesignatedMember 2024-09-30 0000818686 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000818686 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000818686 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2024Member 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2024OneMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025Member 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025OneMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025TwoMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025ThreeMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2026OneMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2027Member 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029TwoMember 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2030Member 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2031OneMember 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2031TwoMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2036Member 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2046Member 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2027Member 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2027OneMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2028OneMember 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2028TwoMember 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029Member 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029OneMember 2024-09-30 0000818686 teva:OtherDebentures2026Member 2024-09-30 0000818686 us-gaap:MeasurementInputDiscountRateMember srt:MinimumMember 2024-09-30 0000818686 us-gaap:MeasurementInputDiscountRateMember srt:MaximumMember 2024-09-30 0000818686 srt:WeightedAverageMember 2024-09-30 0000818686 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0000818686 us-gaap:FairValueInputsLevel2Member teva:OptionsAndForwardContractsDerivativeLiabilitiesMember 2024-09-30 0000818686 teva:OptionsAndForwardContractsDerivativeLiabilitiesMember 2024-09-30 0000818686 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000818686 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000818686 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000818686 teva:ModafinilSettlementAgreementMember 2024-09-30 0000818686 teva:RoyaltyPharmaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2024-09-30 0000818686 teva:AccountsReceivableSecuritizationFacilityMember 2024-09-30 0000818686 srt:RestatementAdjustmentMember 2024-09-30 0000818686 teva:BiolojicDesignLtdMember us-gaap:CollaborativeArrangementMember 2024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000818686 teva:AndaMember teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:OtherProductsMember teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:AustedoMember teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:BendekaAndTreandaMember teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:COPAXONEMember teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:UzedyMember teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:GenericsMediciansMember teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:AjovyMember teva:UnitedStatesSegmentMember 2023-01-01 2023-09-30 0000818686 teva:EuropeSegmentMember 2023-01-01 2023-09-30 0000818686 teva:GenericsMediciansMember teva:EuropeSegmentMember 2023-01-01 2023-09-30 0000818686 teva:OtherProductsMember teva:EuropeSegmentMember 2023-01-01 2023-09-30 0000818686 teva:AjovyMember teva:EuropeSegmentMember 2023-01-01 2023-09-30 0000818686 teva:COPAXONEMember teva:EuropeSegmentMember 2023-01-01 2023-09-30 0000818686 teva:RespiratoryProductMember teva:EuropeSegmentMember 2023-01-01 2023-09-30 0000818686 teva:COPAXONEMember teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 teva:OtherProductsMember teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 teva:GenericsMediciansMember teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 teva:AjovyMember teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000818686 us-gaap:OtherRestructuringMember 2023-01-01 2023-09-30 0000818686 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-09-30 0000818686 srt:MaximumMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000818686 us-gaap:LicenseMember country:US 2023-01-01 2023-09-30 0000818686 us-gaap:LicenseMember 2023-01-01 2023-09-30 0000818686 us-gaap:DistributionServiceMember country:US 2023-01-01 2023-09-30 0000818686 us-gaap:ProductMember country:US 2023-01-01 2023-09-30 0000818686 us-gaap:ProductMember teva:OtherActivitiesMember 2023-01-01 2023-09-30 0000818686 us-gaap:ProductMember srt:EuropeMember 2023-01-01 2023-09-30 0000818686 country:US 2023-01-01 2023-09-30 0000818686 srt:EuropeMember 2023-01-01 2023-09-30 0000818686 teva:OtherActivitiesMember 2023-01-01 2023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 us-gaap:DistributionServiceMember teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 us-gaap:DistributionServiceMember teva:OtherActivitiesMember 2023-01-01 2023-09-30 0000818686 us-gaap:ProductMember teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember srt:EuropeMember 2023-01-01 2023-09-30 0000818686 us-gaap:LicenseMember teva:InternationalMarketsMember 2023-01-01 2023-09-30 0000818686 us-gaap:LicenseMember srt:EuropeMember 2023-01-01 2023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember teva:OtherActivitiesMember 2023-01-01 2023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0000818686 us-gaap:LicenseMember teva:OtherActivitiesMember 2023-01-01 2023-09-30 0000818686 us-gaap:DistributionServiceMember 2023-01-01 2023-09-30 0000818686 us-gaap:ProductMember 2023-01-01 2023-09-30 0000818686 teva:EmployeeTerminationMember 2023-01-01 2023-09-30 0000818686 teva:OtherExitAndDisposalMember 2023-01-01 2023-09-30 0000818686 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0000818686 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000818686 us-gaap:ParentMember 2023-01-01 2023-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000818686 teva:ConversionOptionMember 2023-01-01 2023-09-30 0000818686 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2023-01-01 2023-09-30 0000818686 teva:OtherSalesReservesAndAllowancesMember 2023-01-01 2023-09-30 0000818686 teva:ReturnsMember 2023-01-01 2023-09-30 0000818686 teva:ChargebacksMember 2023-01-01 2023-09-30 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2023-01-01 2023-09-30 0000818686 teva:RebatesMember 2023-01-01 2023-09-30 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2023-01-01 2023-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember teva:FinancialExpensesMember 2023-01-01 2023-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMember teva:FinancialExpensesMember 2023-01-01 2023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember teva:NetRevenuesMember 2023-01-01 2023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember teva:FinancialExpensesMember 2023-01-01 2023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMember teva:FinancialExpensesMember 2023-01-01 2023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMember teva:NetRevenuesMember 2023-01-01 2023-09-30 0000818686 us-gaap:NondesignatedMember teva:FinancialExpensesMember 2023-01-01 2023-09-30 0000818686 us-gaap:NondesignatedMember teva:NetRevenuesMember 2023-01-01 2023-09-30 0000818686 teva:ProductRightsMember 2023-01-01 2023-09-30 0000818686 teva:UpdatedMarketAssumptionsMember teva:ProductRightsMember country:JP 2023-01-01 2023-09-30 0000818686 teva:DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember us-gaap:InProcessResearchAndDevelopmentMember teva:GenericPipelineProductsMember 2023-01-01 2023-09-30 0000818686 teva:RegulatoryPriceAndVolumeOfProductsMember teva:ProductRightsMember 2023-01-01 2023-09-30 0000818686 teva:AllerganTransactionMember 2023-01-01 2023-09-30 0000818686 teva:NovetideTransactionMember 2023-01-01 2023-09-30 0000818686 teva:EagleTransactionMember 2023-01-01 2023-09-30 0000818686 srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-09-30 0000818686 srt:RestatementAdjustmentMember 2023-01-01 2023-09-30 0000818686 us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0000818686 us-gaap:CorporateMember 2023-01-01 2023-09-30 0000818686 teva:SegmentsAndOtherActivitiesMember 2023-01-01 2023-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000818686 teva:RespiratoryProductMember teva:EuropeSegmentMember 2023-07-01 2023-09-30 0000818686 teva:OtherProductsMember teva:EuropeSegmentMember 2023-07-01 2023-09-30 0000818686 teva:EuropeSegmentMember 2023-07-01 2023-09-30

0000818686 teva:GenericsMediciansMember teva:EuropeSegmentMember 2023-07-01 2023-09-30 0000818686 teva:AjovyMember teva:EuropeSegmentMember 2023-07-01 2023-09-30 0000818686 teva:COPAXONEMember teva:EuropeSegmentMember 2023-07-01 2023-09-30 0000818686 teva:AndaMember teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:OtherProductsMember teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:GenericsMediciansMember teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:AustedoMember teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:COPAXONEMember teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:AjovyMember teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:BendekaAndTreandaMember teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:UzedyMember teva:UnitedStatesSegmentMember 2023-07-01 2023-09-30 0000818686 teva:OtherProductsMember teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 teva:COPAXONEMember teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 teva:GenericsMediciansMember teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 teva:AjovyMember teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 us-gaap:OtherRestructuringMember 2023-07-01 2023-09-30 0000818686 us-gaap:EmployeeSeveranceMember 2023-07-01 2023-09-30 0000818686 srt:MaximumMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000818686 srt:EuropeMember 2023-07-01 2023-09-30 0000818686 teva:OtherActivitiesMember 2023-07-01 2023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember teva:OtherActivitiesMember 2023-07-01 2023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0000818686 us-gaap:DistributionServiceMember teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 us-gaap:DistributionServiceMember teva:OtherActivitiesMember 2023-07-01 2023-09-30 0000818686 country:US 2023-07-01 2023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember srt:EuropeMember 2023-07-01 2023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 us-gaap:LicenseMember srt:EuropeMember 2023-07-01 2023-09-30 0000818686 us-gaap:LicenseMember teva:OtherActivitiesMember 2023-07-01 2023-09-30 0000818686 us-gaap:DistributionServiceMember 2023-07-01 2023-09-30 0000818686 us-gaap:ProductMember 2023-07-01 2023-09-30 0000818686 us-gaap:ProductMember teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 us-gaap:LicenseMember country:US 2023-07-01 2023-09-30 0000818686 us-gaap:LicenseMember 2023-07-01 2023-09-30 0000818686 us-gaap:DistributionServiceMember country:US 2023-07-01 2023-09-30 0000818686 us-gaap:ProductMember country:US 2023-07-01 2023-09-30 0000818686 us-gaap:ProductMember teva:OtherActivitiesMember 2023-07-01 2023-09-30 0000818686 us-gaap:ProductMember srt:EuropeMember 2023-07-01 2023-09-30 0000818686 us-gaap:LicenseMember teva:InternationalMarketsMember 2023-07-01 2023-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0000818686 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000818686 us-gaap:ParentMember 2023-07-01 2023-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember teva:FinancialExpensesMember 2023-07-01 2023-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMember teva:FinancialExpensesMember 2023-07-01 2023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember teva:NetRevenuesMember 2023-07-01 2023-09-30 0000818686 us-gaap:NondesignatedMember teva:FinancialExpensesMember 2023-07-01 2023-09-30 0000818686 us-gaap:NondesignatedMember teva:NetRevenuesMember 2023-07-01 2023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMember teva:NetRevenuesMember 2023-07-01 2023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember teva:FinancialExpensesMember 2023-07-01 2023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMember teva:FinancialExpensesMember 2023-07-01 2023-09-30 0000818686 teva:ProductRightsMember 2023-07-01 2023-09-30 0000818686 teva:DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember us-gaap:InProcessResearchAndDevelopmentMember teva:GenericPipelineProductsMember 2023-07-01 2023-09-30 0000818686 srt:MinimumMember 2023-07-01 2023-09-30 0000818686 srt:MaximumMember 2023-07-01 2023-09-30 0000818686 srt:ScenarioPreviouslyReportedMember 2023-07-01 2023-09-30 0000818686 srt:RestatementAdjustmentMember 2023-07-01 2023-09-30 0000818686 us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0000818686 us-gaap:CorporateMember 2023-07-01 2023-09-30 0000818686 teva:SegmentsAndOtherActivitiesMember 2023-07-01 2023-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000818686 teva:AjovyMember teva:EuropeSegmentMember 2024-01-01 2024-09-30 0000818686 teva:OtherProductsMember teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:BendekaAndTreandaMember teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:COPAXONEMember teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:AndaMember teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:GenericsMediciansMember teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:AjovyMember teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:AustedoMember teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:UzedyMember teva:UnitedStatesSegmentMember 2024-01-01 2024-09-30 0000818686 teva:GenericsMediciansMember teva:EuropeSegmentMember 2024-01-01 2024-09-30 0000818686 teva:OtherProductsMember teva:EuropeSegmentMember 2024-01-01 2024-09-30 0000818686 teva:COPAXONEMember teva:EuropeSegmentMember 2024-01-01 2024-09-30 0000818686 teva:RespiratoryProductMember teva:EuropeSegmentMember 2024-01-01 2024-09-30 0000818686 teva:EuropeSegmentMember 2024-01-01 2024-09-30 0000818686 teva:OtherProductsMember teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 teva:AjovyMember teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 teva:GenericsMediciansMember teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 teva:COPAXONEMember teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-09-30 0000818686 us-gaap:OtherRestructuringMember 2024-01-01 2024-09-30 0000818686 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-09-30 0000818686 srt:MaximumMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000818686 us-gaap:LicenseMember teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 us-gaap:ProductMember teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 us-gaap:LicenseMember teva:OtherActivitiesMember 2024-01-01 2024-09-30 0000818686 us-gaap:DistributionServiceMember 2024-01-01 2024-09-30 0000818686 us-gaap:ProductMember 2024-01-01 2024-09-30 0000818686 us-gaap:LicenseMember 2024-01-01 2024-09-30 0000818686 us-gaap:DistributionServiceMember country:US 2024-01-01 2024-09-30 0000818686 us-gaap:ProductMember country:US 2024-01-01 2024-09-30 0000818686 us-gaap:ProductMember teva:OtherActivitiesMember 2024-01-01 2024-09-30 0000818686 country:US 2024-01-01 2024-09-30 0000818686 srt:EuropeMember 2024-01-01 2024-09-30 0000818686 teva:OtherActivitiesMember 2024-01-01 2024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 us-gaap:LicenseMember country:US 2024-01-01 2024-09-30 0000818686 us-gaap:LicenseMember srt:EuropeMember 2024-01-01 2024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember teva:OtherActivitiesMember 2024-01-01 2024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-09-30 0000818686 us-gaap:DistributionServiceMember teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 us-gaap:DistributionServiceMember teva:OtherActivitiesMember 2024-01-01 2024-09-30 0000818686 us-gaap:ProductMember srt:EuropeMember 2024-01-01 2024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember srt:EuropeMember 2024-01-01 2024-09-30 0000818686 us-gaap:EmployeeTerminationMember 2024-01-01 2024-09-30 0000818686 teva:OtherExitAndDisposalMember 2024-01-01 2024-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0000818686 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000818686 us-gaap:ParentMember 2024-01-01 2024-09-30 0000818686 srt:NorthAmericaMember 2024-01-01 2024-09-30 0000818686 teva:OtherCountriesMember teva:MedisReportingUnitsMember 2024-01-01 2024-09-30 0000818686 teva:OtherCountriesMember teva:TevasApiReportingUnitMember 2024-01-01 2024-09-30 0000818686 teva:InternationalMarketsMember 2024-01-01 2024-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000818686 teva:RedemptionOfConvertibleDebtSecurityMember 2024-01-01 2024-09-30 0000818686 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000818686 teva:ShortCreditAgreement2026Member 2024-01-01 2024-09-30 0000818686 us-gaap:IsraelTaxAuthorityMember 2024-01-01 2024-09-30 0000818686 teva:ChargebacksMember 2024-01-01 2024-09-30 0000818686 teva:ReturnsMember 2024-01-01 2024-09-30 0000818686 teva:OtherSalesReservesAndAllowancesMember 2024-01-01 2024-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2024-01-01 2024-09-30 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2024-01-01 2024-09-30 0000818686 teva:RebatesMember 2024-01-01 2024-09-30 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2024-01-01 2024-09-30 0000818686 teva:MabxienceMember 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2026OneMember 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2031TwoMember 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2027Member 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2024OneMember 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025ThreeMember 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2031OneMember 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025TwoMember 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029Member 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025OneMember 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2028OneMember 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2024Member 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2046Member 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025Member 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2027OneMember 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2027Member 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2028TwoMember 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029TwoMember 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2030Member 2024-01-01 2024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2036Member 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029OneMember 2024-01-01 2024-09-30 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember teva:FinancialExpensesMember 2024-01-01 2024-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMember teva:FinancialExpensesMember 2024-01-01 2024-09-30 0000818686 us-gaap:NondesignatedMember teva:FinancialExpensesMember 2024-01-01 2024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember teva:NetRevenuesMember 2024-01-01 2024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember teva:FinancialExpensesMember 2024-01-01 2024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMember teva:NetRevenuesMember 2024-01-01 2024-09-30 0000818686 us-gaap:NondesignatedMember teva:NetRevenuesMember 2024-01-01 2024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMember teva:FinancialExpensesMember 2024-01-01 2024-09-30 0000818686 teva:ProductRightsMember 2024-01-01 2024-09-30 0000818686 teva:DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember us-gaap:InProcessResearchAndDevelopmentMember teva:GenericPipelineProductsMember 2024-01-01 2024-09-30 0000818686 teva:NovetideTransactionMember 2024-01-01 2024-09-30 0000818686 teva:EagleTransactionMember 2024-01-01 2024-09-30 0000818686 teva:AllerganTransactionMember 2024-01-01 2024-09-30 0000818686 us-gaap:RevolvingCreditFacilityMember 2024-01-01 2024-09-30 0000818686 us-gaap:IsraelTaxAuthorityMember teva:TwoThousandEightThrough2020TaxPayableMember 2024-01-01 2024-09-30 0000818686 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-09-30 0000818686 us-gaap:CorporateMember 2024-01-01 2024-09-30 0000818686 teva:SegmentsAndOtherActivitiesMember 2024-01-01 2024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000818686 teva:OneTimePremiumPaymentMember srt:MinimumMember 2024-01-01 2024-09-30 0000818686 teva:InterestRateIncreaseMember srt:MinimumMember 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029OneMember teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember srt:MinimumMember 2024-01-01 2024-09-30 0000818686 teva:OneTimePremiumPaymentMember srt:MaximumMember 2024-01-01 2024-09-30 0000818686 teva:InterestRateIncreaseMember srt:MaximumMember 2024-01-01 2024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029OneMember teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember srt:MaximumMember 2024-01-01 2024-09-30 0000818686 teva:OneTimePremiumPaymentMember 2024-01-01 2024-09-30 0000818686 teva:OtherProductsMember teva:EuropeSegmentMember 2024-07-01 2024-09-30 0000818686 teva:EuropeSegmentMember 2024-07-01 2024-09-30 0000818686 teva:AjovyMember teva:EuropeSegmentMember 2024-07-01 2024-09-30 0000818686 teva:COPAXONEMember teva:EuropeSegmentMember 2024-07-01 2024-09-30 0000818686 teva:RespiratoryProductMember teva:EuropeSegmentMember 2024-07-01 2024-09-30 0000818686 teva:GenericsMediciansMember teva:EuropeSegmentMember 2024-07-01 2024-09-30 0000818686 teva:OtherProductsMember teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:AustedoMember teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:COPAXONEMember teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:AndaMember teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:BendekaAndTreandaMember teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:UzedyMember teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:GenericsMediciansMember teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:AjovyMember teva:UnitedStatesSegmentMember 2024-07-01 2024-09-30 0000818686 teva:AjovyMember teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 teva:OtherProductsMember teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 teva:GenericsMediciansMember teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 teva:COPAXONEMember teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 us-gaap:OtherRestructuringMember 2024-07-01 2024-09-30 0000818686 us-gaap:EmployeeSeveranceMember 2024-07-01 2024-09-30 0000818686 srt:MaximumMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000818686 us-gaap:DistributionServiceMember teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 us-gaap:DistributionServiceMember teva:OtherActivitiesMember 2024-07-01 2024-09-30 0000818686 us-gaap:ProductMember teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember srt:EuropeMember 2024-07-01 2024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 us-gaap:LicenseMember srt:EuropeMember 2024-07-01 2024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember teva:OtherActivitiesMember 2024-07-01 2024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember 2024-07-01 2024-09-30 0000818686 us-gaap:ProductMember country:US 2024-07-01 2024-09-30 0000818686 us-gaap:ProductMember teva:OtherActivitiesMember 2024-07-01 2024-09-30 0000818686 us-gaap:ProductMember srt:EuropeMember 2024-07-01 2024-09-30 0000818686 us-gaap:LicenseMember teva:OtherActivitiesMember 2024-07-01 2024-09-30 0000818686 us-gaap:DistributionServiceMember 2024-07-01 2024-09-30 0000818686 us-gaap:ProductMember 2024-07-01 2024-09-30 0000818686 teva:OtherActivitiesMember 2024-07-01 2024-09-30 0000818686 us-gaap:LicenseMember teva:InternationalMarketsMember 2024-07-01 2024-09-30 0000818686 us-gaap:LicenseMember country:US 2024-07-01 2024-09-30 0000818686 us-gaap:LicenseMember 2024-07-01 2024-09-30 0000818686 us-gaap:DistributionServiceMember country:US 2024-07-01 2024-09-30 0000818686 country:US 2024-07-01 2024-09-30 0000818686 srt:EuropeMember 2024-07-01 2024-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0000818686 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000818686 us-gaap:ParentMember 2024-07-01 2024-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000818686 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000818686 teva:AlvotechMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember teva:FinancialExpensesMember 2024-07-01 2024-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMember teva:FinancialExpensesMember 2024-07-01 2024-09-30 0000818686 us-gaap:NondesignatedMember teva:FinancialExpensesMember 2024-07-01

2024-09-30 0000818686 us-gaap:NondesignatedMember teva:NetRevenuesMember 2024-07-01 2024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMember teva:FinancialExpensesMember 2024-07-01 2024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMember teva:NetRevenuesMember 2024-07-01 2024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember teva:FinancialExpensesMember 2024-07-01 2024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember teva:NetRevenuesMember 2024-07-01 2024-09-30 0000818686 teva:TevasApiReportingUnitMember 2024-07-01 2024-09-30 0000818686 teva:ProductRightsMember 2024-07-01 2024-09-30 0000818686 teva:MabxienceMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0000818686 teva:RoyaltyPharmaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2024-07-01 2024-09-30 0000818686 teva:AbingworthMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0000818686 us-gaap:AllOtherSegmentsMember 2024-07-01 2024-09-30 0000818686 teva:SegmentsAndOtherActivitiesMember 2024-07-01 2024-09-30 0000818686 us-gaap:CorporateMember 2024-07-01 2024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000818686 us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0000818686 us-gaap:InProcessResearchAndDevelopmentMember srt:MinimumMember 2023-09-30 0000818686 us-gaap:InProcessResearchAndDevelopmentMember srt:MaximumMember 2023-09-30 0000818686 srt:ScenarioPreviouslyReportedMember 2023-09-30 0000818686 srt:RestatementAdjustmentMember 2023-09-30 0000818686 srt:RestatementAdjustmentMember 2022-01-01 2022-12-31 0000818686 srt:NorthAmericaMember 2023-01-01 2023-12-31 0000818686 country:US 2023-01-01 2023-12-31 0000818686 srt:EuropeMember 2023-01-01 2023-12-31 0000818686 teva:InternationalMarketsMember 2023-01-01 2023-12-31 0000818686 teva:OtherCountriesMember teva:TevasApiReportingUnitMember 2023-01-01 2023-12-31 0000818686 teva:OtherCountriesMember teva:MedisReportingUnitsMember 2023-01-01 2023-12-31 0000818686 srt:MaximumMember 2023-01-01 2023-12-31 0000818686 teva:AlvotechMember 2023-01-01 2023-12-31 0000818686 srt:RestatementAdjustmentMember 2023-01-01 2023-12-31 0000818686 teva:AlvotechMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0000818686 teva:MedincellMember 2024-04-01 2024-06-30 0000818686 teva:MabxienceMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0000818686 teva:RoyaltyPharmaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2024-04-01 2024-06-30 0000818686 teva:BiolojicDesignLtdMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-01-31 0000818686 teva:RoyaltyPharmaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2023-10-01 2023-12-31 0000818686 teva:RoyaltyPharmaMember 2023-11-09 2023-11-09 0000818686 teva:RoyaltyPharmaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2024-01-01 2024-03-31 0000818686 teva:SanofiMember us-gaap:CollaborativeArrangementMember 2023-10-03 0000818686 teva:ModagMember 2021-10-01 2021-10-31 0000818686 teva:ModagMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-10-01 2021-12-31 0000818686 teva:AlvotechMember 2021-01-01 2021-12-31 0000818686 teva:AlvotechMember 2024-01-01 2024-06-30 0000818686 teva:LitigationWithUsHospitalsAndOtherHealthcareProvidersMember 2024-07-01 2024-07-31 0000818686 teva:TevaMember 2023-09-29 0000818686 teva:AlvotechMember teva:SubordinatedConvertibleBondsMember 2023-09-29 0000818686 teva:AlvotechMember 2024-06-26 2024-06-26 0000818686 teva:TakedaMember 2016-12-01 2016-12-31 0000818686 teva:TakedaMember 2022-04-01 2022-06-30 0000818686 teva:MedincellMember 2021-08-01 2021-08-31 0000818686 teva:MedincellMember 2022-07-01 2022-09-30 0000818686 us-gaap:DemandDepositsMember 2024-06-30 0000818686 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 us-gaap:MoneyMarketFundsMember 2024-06-30 0000818686 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 us-gaap:EquitySecuritiesMember 2024-06-30 0000818686 teva:OtherRestrictedCashMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 teva:OtherRestrictedCashMember 2024-06-30 0000818686 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2024-06-30 0000818686 us-gaap:ConvertibleDebtSecuritiesMember 2024-06-30 0000818686 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateSwapMember 2024-06-30 0000818686 us-gaap:InterestRateSwapMember 2024-06-30 0000818686 teva:TevasUnitedStatesEuropeInternationalMarketsAndMedisReportingUnitsMember 2024-06-30 0000818686 us-gaap:FairValueInputsLevel2Member teva:OptionsAndForwardContractsDerivativeLiabilitiesMember 2024-06-30 0000818686 teva:OptionsAndForwardContractsDerivativeLiabilitiesMember 2024-06-30 0000818686 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000818686 us-gaap:FairValueInputsLevel2Member 2024-06-30 0000818686 us-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 teva:ModafinilSettlementAgreementMember 2024-06-30 0000818686 teva:OpioidLitigationMember 2024-06-30 0000818686 teva:InternationalMarketsMember 2023-01-01 2023-06-30 0000818686 us-gaap:RevolvingCreditFacilityMember teva:AmendedRevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2025-01-01 2025-12-31 0000818686 us-gaap:RevolvingCreditFacilityMember teva:AmendedRevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2026-07-01 2026-09-30 0000818686 us-gaap:RevolvingCreditFacilityMember teva:AmendedRevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2027-01-01 2027-03-31 0000818686 teva:AccountsReceivableSecuritizationFacilityMember teva:PncBankMember 2022-07-11 0000818686 teva:AccountsReceivableSecuritizationFacilityMember teva:PncBankMember 2022-11-07 2022-11-07 0000818686 teva:AccountsReceivableSecuritizationFacilityMember teva:PncBankMember teva:NovemberTwoThousandAndTwentyFiveMember 2022-11-07 2022-11-07 0000818686 teva:AccountsReceivableSecuritizationFacilityMember teva:PncBankMember teva:NovemberTwoThousandAndTwentyThreeMember 2022-11-07 0000818686 teva:AccountsReceivableSecuritizationFacilityMember teva:MizuhoBankMember teva:NovemberTwoThousandAndTwentyFiveMember 2023-06-30 0000818686 teva:AccountsReceivableSecuritizationFacilityMember teva:MizuhoBankMember teva:NovemberTwoThousandAndTwentyThreeMember 2023-06-30 0000818686 teva:AccountsReceivableSecuritizationFacilityMember teva:PncBankMember teva:NovemberTwoThousandAndTwentyFiveMember 2023-09-30 2023-09-30 0000818686 teva:AccountsReceivableSecuritizationFacilityMember teva:PncBankMember 2023-11-07 0000818686 teva:AlvotechMember us-gaap:SubsequentEventMember teva:OctoberTwoThousandAndTwentyFourAmendmentAgreementMember 2024-10-01 2024-10-29 0000818686 teva:SettlementAndLicenseAgreementAlvotechAndTevaMember teva:JohnsonAndJohnsonMember 2023-06-12 2023-06-12 0000818686 teva:AlvotechMember 2020-01-01 2020-12-31 0000818686 us-gaap:IsraelTaxAuthorityMember teva:TwoThousandEightThrough2020TaxPayableMember 2024-06-23 2024-06-23 0000818686 us-gaap:IsraelTaxAuthorityMember teva:TwoThousandEightThrough2020TaxPayableMember srt:MinimumMember 2024-06-23 2024-06-23 0000818686 us-gaap:IsraelTaxAuthorityMember teva:TwoThousandEightThrough2020TaxPayableMember srt:MaximumMember 2024-06-23 2024-06-23 0000818686 us-gaap:IsraelTaxAuthorityMember 2022-12-12 0000818686 us-gaap:SubsequentEventMember 2024-10-31 0000818686 us-gaap:SeniorNotesMember 2024-10-31 0000818686 us-gaap:SeniorNotesMember 2024-04-30 0000818686 us-gaap:RevolvingCreditFacilityMember teva:AmendedRevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2024-01-01 2024-12-31 0000818686 us-gaap:RevolvingCreditFacilityMember teva:AmendedRevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2026-01-01 2026-03-31 0000818686 us-gaap:RevolvingCreditFacilityMember teva:AmendedRevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2026-04-01 2026-06-30 0000818686 us-gaap:RevolvingCreditFacilityMember teva:AmendedRevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2026-10-01 2026-12-31 0000818686 teva:SPVAmendmentAgreementOctoberTwoThousandAndTwentyFourMember teva:AccountsReceivableSecuritizationFacilityMember teva:PncBankMember us-gaap:SubsequentEventMember 2024-10-29 0000818686 teva:AndroGelRateAtOnePercentageMember 2019-08-31 0000818686 teva:DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember teva:FineForViolatingTheAntitrustLawsMember 2023-08-21 0000818686 teva:DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember teva:DonationOfClotrimazoleAndTobramycinMember 2023-08-21 0000818686 teva:CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember us-gaap:SubsequentEventMember 2024-10-10 2024-10-10 0000818686 teva:CivilActionInRespectOfDonationsToPatientAssistanceProgrammersMember us-gaap:SubsequentEventMember 2024-10-10 0000818686 teva:CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember us-gaap:SubsequentEventMember 2024-10-10 0000818686 teva:CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember teva:TwoThousandAndTwentyFourMember us-gaap:SubsequentEventMember 2024-10-10 0000818686 teva:CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember teva:TwoThousandAndTwentyFiveMember us-gaap:SubsequentEventMember 2024-10-10 0000818686 teva:LitigationWithUsHospitalsAndOtherHealthcareProvidersMember 2023-07-01 2023-07-31 0000818686 teva:OntarioTeachersSecuritiesLitigationMember us-gaap:SettledLitigationMember 2022-06-02 2022-06-02 0000818686 srt:EuropeMember 2021-01-01 2021-09-30 0000818686 teva:EosinophilicEsophagitisMember country:US 2021-01-01 2021-09-30 0000818686 teva:EosinophilicEsophagitisMember 2021-01-01 2021-09-30 0000818686 teva:EmployeeTerminationMember 2022-12-31 0000818686 teva:OtherExitAndDisposalMember 2022-12-31 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000818686 us-gaap:ParentMember 2022-12-31 0000818686 us-gaap:NoncontrollingInterestMember 2022-12-31 0000818686 us-gaap:CommonStockMember 2022-12-31 0000818686 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000818686 us-gaap:RetainedEarningsMember 2022-12-31 0000818686 us-gaap:TreasuryStockCommonMember 2022-12-31 0000818686 teva:EmployeeTerminationMember 2023-09-30 0000818686 teva:OtherExitAndDisposalMember 2023-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2022-12-31 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2022-12-31 0000818686 teva:RebatesMember 2022-12-31 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2022-12-31 0000818686 teva:ChargebacksMember 2022-12-31 0000818686 teva:ReturnsMember 2022-12-31 0000818686 teva:OtherSalesReservesAndAllowancesMember 2022-12-31 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2023-09-30 0000818686 teva:ChargebacksMember 2023-09-30 0000818686 teva:ReturnsMember 2023-09-30 0000818686 teva:OtherSalesReservesAndAllowancesMember 2023-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2023-09-30 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2023-09-30 0000818686 teva:RebatesMember 2023-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2023-09-30 0000818686 us-gaap:CommonStockMember 2023-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000818686 us-gaap:RetainedEarningsMember 2023-09-30 0000818686 us-gaap:TreasuryStockCommonMember 2023-09-30 0000818686 us-gaap:ParentMember 2023-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000818686 us-gaap:RetainedEarningsMember 2023-06-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000818686 us-gaap:TreasuryStockCommonMember 2023-06-30 0000818686 us-gaap:ParentMember 2023-06-30 0000818686 us-gaap:NoncontrollingInterestMember 2023-06-30 0000818686 us-gaap:CommonStockMember 2023-06-30 0000818686 teva:EmployeeTerminationMember 2023-12-31 0000818686 teva:OtherExitAndDisposalMember 2023-12-31 0000818686 us-gaap:CommonStockMember 2023-12-31 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000818686 us-gaap:RetainedEarningsMember 2023-12-31 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000818686 us-gaap:TreasuryStockCommonMember 2023-12-31 0000818686 us-gaap:ParentMember 2023-12-31 0000818686 us-gaap:NoncontrollingInterestMember 2023-12-31 0000818686 teva:EmployeeTerminationMember 2024-09-30 0000818686 teva:OtherExitAndDisposalMember 2024-09-30 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2023-12-31 0000818686 teva:RebatesMember 2023-12-31 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2023-12-31 0000818686 teva:ChargebacksMember 2023-12-31 0000818686 teva:ReturnsMember 2023-12-31 0000818686 teva:OtherSalesReservesAndAllowancesMember 2023-12-31 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2023-12-31 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2024-09-30 0000818686 teva:RebatesMember 2024-09-30 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2024-09-30 0000818686 teva:ChargebacksMember 2024-09-30 0000818686 teva:ReturnsMember 2024-09-30 0000818686 teva:OtherSalesReservesAndAllowancesMember 2024-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2024-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000818686 us-gaap:RetainedEarningsMember 2024-09-30 0000818686 us-gaap:TreasuryStockCommonMember 2024-09-30 0000818686 us-gaap:ParentMember 2024-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2024-09-30 0000818686 us-gaap:CommonStockMember 2024-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000818686 teva:OtherCountriesMember teva:MedisReportingUnitsMember 2024-09-30 0000818686 teva:OtherCountriesMember teva:TevasApiReportingUnitMember 2024-09-30 0000818686 teva:InternationalMarketsMember 2024-09-30 0000818686 srt:EuropeMember 2024-09-30 0000818686 country:US 2024-09-30 0000818686 srt:NorthAmericaMember 2024-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000818686 us-gaap:ParentMember 2024-06-30 0000818686 us-gaap:NoncontrollingInterestMember 2024-06-30 0000818686 us-gaap:CommonStockMember 2024-06-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000818686 us-gaap:RetainedEarningsMember 2024-06-30 0000818686 us-gaap:TreasuryStockCommonMember 2024-06-30 0000818686 country:US 2022-12-31 0000818686 srt:EuropeMember 2022-12-31 0000818686 teva:InternationalMarketsMember 2022-12-31 0000818686 teva:OtherCountriesMember teva:TevasApiReportingUnitMember 2022-12-31 0000818686 teva:OtherCountriesMember teva:MedisReportingUnitsMember 2022-12-31 0000818686 srt:NorthAmericaMember 2022-12-31 0000818686 srt:NorthAmericaMember 2023-12-31 0000818686 country:US 2023-12-31 0000818686 srt:EuropeMember 2023-12-31 0000818686 teva:InternationalMarketsMember 2023-12-31 0000818686 teva:OtherCountriesMember teva:TevasApiReportingUnitMember 2023-12-31 0000818686 teva:OtherCountriesMember teva:MedisReportingUnitsMember 2023-12-31 iso4217:USD xbrli:shares xbrli:pure utr:Year iso4217:EUR iso4217:CHF teva:Segment iso4217:USD xbrli:shares Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â Â FORM 10-Q Â Â Â Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR Â Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 Â Â TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Â Â Â Â Israel Â Â Not Applicable (State or other jurisdiction ofincorporation or organization) Â (IRS EmployerIdentification Number) 124 Dvora HaNeviâ€™a St., Tel Aviv, ISRAEL Â 6944020 (Address of principal executive offices) Â (Zip code)+972 (3)Â 914-8213 (Registrantâ€™s telephone number, including area code) Â Â Securities registered pursuant to SectionÂ 12(b) of the Act: Â Title of each class Â TradingSymbol(s) Â Name of each exchangeon which registered American Depositary Shares, each representing one Ordinary Share Â TEVA Â New York Stock ExchangeIndicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90 days.â€fYesâ€,â˜’â€fNoâ€,â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).â€fYesâ€ ,â˜’â€fNoâ€,â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer Â â˜’ Â Â AcceleratedÂ filer Â â˜ Non-accelerated filer Â â˜ Â Â SmallerÂ reportingÂ company Â â˜ Emerging growth company Â â˜ Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided

pursuant to SectionÂ 13(a) of the Exchange Act.â€‚â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).â€ƒYesâ€‚â˜â€ƒNoâ€‚â˜’ As of
SeptemberÂ 30, 2024, the registrant had 1,133,050,214 ordinary shares outstanding. Â Â Â Table of Contents http://fasb.org/us-
gaap/2024#IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments2026-04-30http://fasb.org/us-
gaap/2024#Liabilitieshttp://www.tevapharm.com/20240930#ImpairmentsRestructuringAndOthershttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-
gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrentTEVA PHARMACEUTICAL INDUSTRIES LIMITED For
an accessible version of this Quarterly Report on FormÂ 10-Q, please visit www.tevapharm.com INDEX Â PART I. Â Financial Statements (unaudited) Â Â Item 1. Â Financial Statements
(unaudited) Â Â Â Consolidated Balance Sheets Â Â Â 5 Â Â Consolidated Statements of Income (loss) Â Â Â 6 Â Â Consolidated Statements of Comprehensive Income (loss) Â Â Â 7 Â Â
Consolidated statements of changes in equity Â Â Â 8 Â Â Consolidated Statements of Cash Flows Â Â Â 10 Â Â Notes to Consolidated Financial Statements Â Â Â 11 Â Item 2. Â
Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â Â Â 57 Â Item 3. Â Quantitative and Qualitative Disclosures about Market Risk Â Â Â 85 Â
Item 4. Â Controls and Procedures Â Â Â 85 Â PARTÂ II. Â OTHER INFORMATION Â Â Item 1. Â Legal Proceedings Â Â Â 87 Â Item 1A. Â Risk Factors Â Â Â 87 Â Item 2. Â
Unregistered Sales of Equity Securities and Use of Proceeds Â Â Â 87 Â Item 3. Â Defaults Upon Senior Securities Â Â Â 87 Â Item 4. Â Mine Safety Disclosures Â Â Â 87 Â Item 5. Â
Other Information Â Â Â 88 Â Item 6. Â Exhibits Â Â Â 89 Â Â Signatures Â Â Â 90 Â Â 2 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Â INTRODUCTION AND USE
OF CERTAIN TERMS Unless otherwise indicated, all references to the â€œCompany,â€ â€œwe,â€ â€œourâ€ and â€œTevaâ€ refer to Teva Pharmaceutical Industries Limited and its
subsidiaries, and references to â€œrevenuesâ€ refer to net revenues. References to â€œU.S. dollars,â€ â€œdollars,â€ â€œU.S. $â€ and â€œ$â€ are to the lawful currency of the United States
of America, and references to â€œNISâ€ are to new Israeli shekels. References to â€œADS(s)â€ are to Tevaâ€™s American Depositary Share(s). References to â€œMSâ€ are to multiple
sclerosis. Market data, including both sales and share data, is based on information provided by IQVIA, a provider of market research to the pharmaceutical industry (â€œIQVIAâ€), unless
otherwise stated. References to â€œR&Dâ€ are to Research and Development, references to â€œIPR&Dâ€ are to in-process R&D, references to â€œS&Mâ€ are to Selling and Marketing and
references to â€œG&Aâ€ are to General and Administrative. Some amounts in this report may not add up due to rounding. All percentages have been calculated using unrounded amounts. This
report on Form 10-Q contains many of the trademarks and trade names used by Teva in the United States and internationally to distinguish its products and services. Any third-party trademarks
mentioned in this report are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS In addition to historical information, this Quarterly
Report on Form 10-Q, and the reports and documents incorporated by reference in this Quarterly Report on Form 10-Q, may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, which are based on managementâ€™s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and
unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these
forward-looking statements by the use of words such as â€œshould,â€ â€œexpect,â€ â€œanticipate,â€ â€œestimate,â€ â€œtarget,â€ â€œmay,â€ â€œproject,â€ â€œguidance,â€ â€œintend,â€
â€œplan,â€ â€œbelieveâ€ and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.Â Important factors that
could cause or contribute to such differences include risks relating to: Â Â â€¢ Â our ability to successfully compete in the marketplace, including: that we are substantially dependent on our
generic products; concentration of our customer base and commercial alliances among our customers; delays in launches of new generic products; our ability to develop and commercialize
biopharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize
additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably
commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; and the
effectiveness of our patents and other measures to protect our intellectual property rights, including any potential challenges to our Orange Book patent listings in the U.S.; Â Â â€¢ Â our
substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a future downgrade of our
credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; Â Â â€¢ Â our business and operations in general, including: the impact of global
economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or
any other public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrate and retain highly skilled personnel; interruptions in our supply chain or problems
with internal or third party manufacturing; disruptions of information technology systems; breaches of our data security challenges associated with conducting business globally, including
political or economic instability, major hostilities or terrorism, such as the ongoing conflict between Russia and Ukraine and the state of war declared in Israel; costs and delays resulting from
the extensive pharmaceutical regulation to which we are subject; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate
acquisitions; and our prospects and opportunities for growth if we sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively
consummate such sales and divestitures, including our planned divestiture of our API business; Â Â â€¢ Â compliance, regulatory and litigation matters, including: failure to comply with
complex legal and regulatory environments; the effects of governmental and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare
regulation and reductions in pharmaceutical pricing, reimbursement and coverage; increased legal and regulatory action in connection with public concern over the abuse of opioid medications;
our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of NarcanÂ® (naloxone hydrochloride nasal spray) in the
amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate
under our deferred prosecution agreement (â€œDPAâ€) with the U.S. Department of Justice (â€œDOJâ€); potential liability for intellectual property right infringement; product liability claims;
failure to comply with complex Medicare, Medicaid and other governmental programs reporting and payment obligations; compliance with anti-corruption, sanctions and trade control laws;
environmental risks; and the impact of sustainability issues; Â 3 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Â Â â€¢ Â the impact of the state of war declared in Israel
and the military activity in the region, including the risk of disruptions to our operations and facilities, such as our manufacturing and R&D facilities, located in Israel, the impact of our
employees who are military reservists being called to active military duty, and the impact of the war on the economic, social and political stability of Israel; Â Â â€¢ Â other financial and
economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts
including the state of war declared in Israel and the conflict between Russia and Ukraine; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or of a change in our business; and our ability to remediate an existing material weakness in our internal control over
financial reporting; and other factors discussed in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, including in the section
captioned â€œRisk Factorsâ€. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Â 4
Table of Contents PART I â€” FINANCIAL INFORMATION Â ITEMâ€‰1. FINANCIAL STATEMENTS TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in millions, except for share data) (Unaudited) Â Â Â Â SeptemberÂ 30, Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â 2023 Â ASSETS Â Â Â Current assets: Â Â Â Cash and cash
equivalents Â Â $ 3,319 Â Â $ 3,226 Â Accounts receivables, net of allowance for credit losses of $91Â million and $95Â million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 Â Â Â
3,462 Â Â Â 3,408 Â Inventories Â Â Â 3,959 Â Â Â 4,021 Â Prepaid expenses Â Â Â 1,127 Â Â Â 1,255 Â Other current assets Â Â Â 445 Â Â Â 504 Â Assets held for sale Â Â Â 2 Â
Â Â 70 Â Â Â Â Â Â Â Â Â Â Total current assets Â Â Â 12,314 Â Â Â 12,485 Â Deferred income taxes Â Â Â 2,070 Â Â Â 1,812 Â Other non-current assets Â Â Â 459 Â Â Â 470 Â
Property, plant and equipment, net Â Â Â 5,672 Â Â Â 5,750 Â Operating lease right-of-use assets, net Â Â Â 364 Â Â Â 397 Â Identifiable intangible assets, net Â Â Â 4,756 Â Â Â
5,387 Â Goodwill Â Â Â 16,124 Â Â Â 17,177 Â Â Â Â Â Â Â Â Â Â Total assets Â Â $ 41,758 Â Â $ 43,479 Â Â Â Â Â Â Â Â Â Â LIABILITIES AND EQUITY Â Â Â Current
liabilities: Â Â Â Short-term debt Â Â $ 2,580 Â Â $ 1,672 Â Sales reserves and allowances Â Â Â 3,785 Â Â Â 3,535 Â Accounts payables Â Â Â 2,371 Â Â Â 2,602 Â Employee-related
obligations Â Â Â 619 Â Â Â 611 Â Accrued expenses Â Â Â 2,984 Â Â Â 2,771 Â Other current liabilities Â Â Â 1,241 Â Â Â 1,044 Â Liabilities held for sale Â Â Â 216 Â Â Â 13 Â
Â Â Â Â Â Â Â Â Â Total current liabilities Â Â Â 13,797 Â Â Â 12,247 Â Long-term liabilities: Â Â Â Deferred income taxes Â Â Â 538 Â Â Â 606 Â Other taxes and long-term
liabilities Â Â Â 4,344 Â Â Â 4,019 Â Senior notes and loans Â Â Â 16,400 Â Â Â 18,161 Â Operating lease liabilities Â Â Â 295 Â Â Â 320 Â Â Â Â Â Â Â Â Â Â Total long-term
liabilities Â Â Â 21,578 Â Â Â 23,106 Â Â Â Â Â Â Â Â Â Â Commitments and contingencies, see note 10 Â Â Â Total liabilities Â Â Â 35,375 Â Â Â 35,353 Â Â Â Â Â Â Â Â Â Â
Equity: Â Â Â Teva shareholdersâ€™ equity: Â Â Â Ordinary shares of NIS 0.10 par value per share; SeptemberÂ 30, 2024 and DecemberÂ 31, 2023: authorized 2,495Â million shares; issued
1,240Â million shares and 1,227Â million shares, respectively Â Â Â 58 Â Â Â 57 Â Additional paid-in capital Â Â Â 27,860 Â Â Â 27,807 Â Accumulated deficit Â Â Â (14,956) Â Â
(13,534)Â Accumulated other comprehensive loss Â Â Â (2,769)Â Â Â (2,697)Â Treasury shares as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023: 106Â million ordinary shares Â Â Â
(4,128)Â Â Â (4,128)Â Â Â Â Â Â Â Â Â Â Â Â Â 6,065 Â Â Â 7,506 Â Â Â Â Â Â Â Â Â Â Non-controlling interests Â Â Â 319 Â Â Â 620 Â Â Â Â Â Â Â Â Â Â Total equity
Â Â Â 6,383 Â Â Â 8,126 Â Â Â Â Â Â Â Â Â Â Total liabilities and equity Â Â $ 41,758 Â Â $ 43,479 Â Â Â Â Â Â Â Â Â Â Amounts may not add up due to rounding. The
accompanying notes are an integral part of the financial statements. Â 5 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF INCOME
(LOSS) (U.S. dollars in millions, except share and per share data) (Unaudited) Â Â Â Â ThreeÂ monthsÂ ended SeptemberÂ 30, Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â
2023 Â Â 2024 Â Â 2023 Â Net revenues Â Â $ 4,332 Â Â $ 3,850 Â Â $ 12,315 Â Â $ 11,389 Â Cost of sales Â Â Â 2,183 Â Â Â 1,999 Â Â Â 6,372 Â Â Â 6,159 Â Gross profit Â Â
Â 2,148 Â Â Â 1,851 Â Â Â 5,943 Â Â Â 5,230 Â Research and development expenses Â Â Â 240 Â Â Â 253 Â Â Â 751 Â Â Â 726 Â Selling and marketing expenses Â Â Â 626 Â Â
Â 576 Â Â Â 1,891 Â Â Â 1,726 Â General and administrative expenses Â Â Â 298 Â Â Â 268 Â Â Â 859 Â Â Â 870 Â Intangible assets impairments Â Â Â 28 Â Â Â 47 Â Â Â 169
Â Â Â 289 Â Goodwill impairment Â Â Â 600 Â Â Â â€”â€‚ Â Â Â 1,000 Â Â Â 700 Â Other assets impairments, restructuring and other items Â Â Â (23)Â Â Â 57 Â Â Â 931 Â Â Â
276 Â Legal settlements and loss contingencies Â Â Â 450 Â Â Â 314 Â Â Â 638 Â Â Â 1,009 Â Other loss (income) Â Â Â (21)Â Â Â (9)Â Â Â (22)Â Â Â (43)Â Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Operating income (loss) Â Â Â (51) Â Â 344 Â Â Â (274) Â Â (323)Â Financial expenses, net Â Â Â 272 Â Â Â 280 Â Â Â 763 Â Â Â 808 Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Income (loss) before income taxes Â Â Â (324) Â Â 64 Â Â Â (1,037) Â Â (1,131)Â Income taxes (benefit) Â Â Â 69 Â Â Â (12)Â Â Â 648 Â Â Â (48)Â
ShareÂ in (profits)Â losses ofÂ associatedÂ companies, net Â Â Â (3)Â Â Â Â§ Â Â Â (1)Â Â Â (1)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) Â Â Â (390) Â Â 77 Â
Â Â (1,684) Â Â (1,082)Â Net income (loss) attributable to non-controlling interests Â Â Â 47 Â Â Â 8 Â Â Â (262)Â Â Â (60)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income
(loss) attributable to Teva Â Â Â (437) Â Â 69 Â Â Â (1,422) Â Â (1,022)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Earnings (loss) per share attributable to ordinary shareholders: Â Â
Â Â Â Basic Â Â $ (0.39) Â $ 0.06 Â Â $ (1.26) Â $ (0.91)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Diluted Â Â $ (0.39) Â $ 0.06 Â Â $ (1.26) Â $ (0.91)Â Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Weighted average number of shares (in millions): Â Â Â Â Â Basic Â Â Â 1,133 Â Â Â 1,121 Â Â Â 1,130 Â Â Â 1,119 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Diluted Â Â Â 1,133 Â Â Â 1,135 Â Â Â 1,130 Â Â Â 1,119 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Amounts may not add up due
to rounding. The accompanying notes are an integral part of the financial statements. Â 6 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS
OF COMPREHENSIVE INCOME (LOSS) (U.S. dollars in millions) (Unaudited) Â Â Â Â ThreeÂ monthsÂ ended SeptemberÂ 30, Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â
2023 Â Â 2024 Â Â 2023 Â Net income (loss) Â Â $ (390) Â $ 77 Â Â $ (1,684) Â $ (1,082)Â Other comprehensive income (loss), net of tax: Â Â Â Â Â Currency translation adjustment
Â Â Â 174 Â Â Â (255)Â Â Â (94)Â Â Â (173)Â Unrealized gain (loss) from derivative financial instruments, net Â Â Â 7 Â Â Â 7 Â Â Â 21 Â Â Â 19 Â Unrealized loss on defined
benefit plans Â Â Â (1)Â Â Â (1)Â Â Â (2)Â Â Â (2)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total other comprehensive income (loss) Â Â Â 180 Â Â Â (249)Â Â Â (75)Â Â Â
(156)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total comprehensive income (loss) Â Â Â (210) Â Â (172) Â Â (1,759) Â Â (1,238)Â Comprehensive income (loss) attributable to non-
controlling interests Â Â Â 114 Â Â Â (8)Â Â Â (268)Â Â Â (144)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Comprehensive income (loss) attributable to Teva Â Â $ (324) Â $ (164)
Â $ (1,491) Â $ (1,094)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Amounts may not add up due to rounding. The accompanying notes are an integral part of the financial statements. Â 7
Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Â Â Â Teva shareholdersâ€™ equity Â Â Â Â Â Â Â Â Â
Ordinary shares Â NumberÂ of shares (in millions) Â Â Stated value Â Â Additional paid-in capital Â Â Retained earnings
(accumulated deficit) Â Â Accumulated other comprehensive (loss) Â Â Treasury shares Â Â Total Teva shareholdersâ€™ equity Â Â Non-controlling interests Â Â Total equity Â Â Â Â Â
Â (U.S. dollars in millions) Â Balance at JuneÂ 30,
2024 Â Â 1,239 Â Â Â 58 Â Â Â 27,829 Â Â Â (14,519)Â Â Â (2,881)Â Â Â (4,128)Â Â Â 6,359 Â Â Â 204 Â Â Â 6,563 Â Net Income (loss) Â Â Â Â Â (437) Â Â Â Â (437) Â
Â 47 Â Â Â (390) Other comprehensive income (loss) Â Â Â Â Â Â 113 Â Â Â Â 113 Â Â Â 67 Â Â Â 180 Â Issuance of Shares Â Â 1 Â Â Â * Â Â Â * Â Â Â Â Â Â * Â Â Â Â *
Â Stock-based compensation expense Â Â Â Â 29 Â Â Â Â Â Â 29 Â Â Â Â 29 Â Balance
at SeptemberÂ 30, 2024 Â Â 1,240 Â Â $ 58 Â Â $ 27,860 â€„Â Â $ (14,956) Â $ (2,769)Â Â $ (4,128)Â Â $ 6,065 â€„Â Â $ 319 â€„Â Â $ â€„6,383 â€„Â Â Â Â Â Â Â Â Â Â Â Â
Â * Represents an amount less than 0.5Â million. Â Â Â Teva shareholdersâ€™ equity Â Â Â Â Â Â Â Â Â Ordinary
shares Â NumberÂ of shares (in millions) Â Â Stated value Â Â Additional paid-in capital Â Â Retained earnings (accumulated
deficit) Â Â Accumulated other comprehensive (loss) Â Â Treasury shares Â Â Total Teva shareholdersâ€™ equity Â Â Non-controlling interests Â Â Total equity Â Â Â Â Â Â Â Â Â
Â (U.S. dollars in millions) Â Balance at DecemberÂ 31, 2023 Â
Â 1,227 Â Â Â 57 Â Â Â 27,807 Â Â Â (13,534)Â Â Â (2,697)Â Â Â (4,128)Â Â Â 7,506 Â Â Â 620 Â Â Â 8,126 Â Net Income (loss) Â Â Â Â Â (1,422) Â Â Â Â (1,422) Â Â
(262)Â Â Â (1,684) Other comprehensive income (loss) Â Â Â Â Â Â (69)Â Â Â Â (69)Â Â Â (6)Â Â Â (75)Â Issuance of Shares Â Â 13 Â Â Â 1 Â Â Â * Â Â Â Â Â Â 1 Â Â Â
Â 1 Â Stock-based compensation expense Â Â Â Â 89 Â Â Â Â Â Â 89 Â Â Â â€”â€‚ Â Â Â 89 Â Proceeds from exercise of options Â Â Â Â 7 Â Â Â Â Â Â 7 Â Â Â Â 7 Â Dividend
to non-controlling interests** Â Â Â Â Â Â Â Â Â (18)Â Â Â (18)Â Purchase of shares from non-controlling interests*** Â Â Â Â (45)Â Â Â Â (3)Â Â Â Â (48)Â Â Â (16)Â Â Â
(64)Â Balance at SeptemberÂ 30, 2024 Â Â 1,240 Â Â $ 58 Â Â $ 27,860 Â Â $ (14,956) Â
$ (2,769)Â Â $ (4,128)Â Â $ 6,065 Â Â $ 319 Â Â $ 6,383 Â * Represents an amount less
than $0.5Â million. ** In connection with dividends to non-controlling interests in Tevaâ€™s joint venture in Japan. *** Purchase of shares from non-controlling interests in a Tevaâ€™s
subsidiary in Switzerland. Â 8 Table of Contents Â Â Teva shareholdersâ€™ equity Â Â Â Â Â Â Â Â Â Ordinary shares Â Â
NumberÂ of shares (in millions) Â Â Stated value Â Â Additional paid-in capital Â Â Retained earnings (accumulated deficit) Â Â Accumulated other comprehensive (loss) Â Â Treasury
shares Â Â Total Teva shareholdersâ€™ equity Â Â Non-controlling interests Â Â Total equity Â (U.S. dollars
in millions) Â Balance at JuneÂ 30, 2023 ** Â Â 1,227 Â Â Â 57 Â Â Â 27,748 Â Â Â (14,066)Â Â Â (2,677)Â
Â Â (4,128)Â Â Â 6,936 Â Â Â 656 Â Â Â 7,592 Â Net Income (loss)** Â Â Â Â Â 69 Â Â Â Â Â Â 69 Â Â Â 8 Â Â Â 77 Â Other comprehensive income (loss) Â Â Â Â Â Â (233)Â
Â Â Â (233)Â Â Â (16)Â Â Â (249) Issuance of shares Â Â Â Â * Â Â Â Â Â Â * Â Â Â Â * Â Stock-based compensation expense Â Â Â Â 31 Â Â Â Â Â Â 31 Â Â Â Â 31 Â

Dividend to non-controlling interest *** Â Â Â Â Â Â Â Â Â (67)Â Â Â (67)Â Balance at SeptemberÂ 30, 2023 ** Â Â 1,227 Â Â $ 57 Â Â $ 27,780 Â Â $ (13,995)Â Â $ (2,910)Â Â $ (4,128)Â Â $ â€„6,804 Â Â $ 582 Â Â $ â€„7,387 Â * Represents an amount less than $0.5Â million. ** The data presented for prior periods has been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. For additional information, see note 1c. *** In connection with a declaration on dividend to non-controlling interest in Tevaâ€™s joint venture in Japan. Â Â Â Teva shareholdersâ€™ equity Â Â Â Â Â Â Â Â Â Ordinary shares Â NumberÂ of shares (in millions) Â Â Stated value Â Â Additional paid-in capital Â Â Retained earnings (accumulated deficit) Â Â Accumulated other comprehensive (loss) Â Â Treasury shares Â Â Total Teva shareholdersâ€™ equity Â Â Non-controlling interests Â Â Total equity Â (U.S. dollars in millions) Â Balance at DecemberÂ 31, 2022 ** Â Â 1,217 Â Â Â 57 Â Â Â 27,688 Â Â Â (12,975)Â Â Â (2,838)Â Â Â (4,128)Â Â Â 7,804 Â Â Â 794 Â Â Â 8,598 Â Net Income (loss) Â Â Â Â Â (1,022) Â Â Â Â (1,022) Â Â (60)Â Â Â (1,082)Â Other comprehensive income (loss) Â Â Â Â Â Â (72)Â Â Â Â (72)Â Â Â (84)Â Â Â (156)Â Issuance of Shares Â Â 10 Â Â Â * Â Â Â * Â Â Â Â Â Â * Â Â Â Â * Â Stock-based compensation expense Â Â Â Â 93 Â Â Â Â Â Â 93 Â Â Â â€”â€, Â Â Â 93 Â Dividend to non-controlling interest *** Â Â Â Â Â Â Â Â Â (67)Â Â Â (67)Â Balance at SeptemberÂ 30, 2023 ** Â Â 1,227 Â Â $ 57 Â Â $ 27,780 Â Â $ (13,995)Â Â $ (2,910)Â Â $ (4,128)Â Â $ 6,804 Â Â $ 582 Â Â $ 7,387 Â * Represents an amount less than $0.5Â million. ** The data presented for prior periods has been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. For additional information, see note 1c. *** In connection with a declaration on dividend to non-controlling interest in Tevaâ€™s joint venture in Japan. Amounts may not add up due to rounding. The accompanying notes are an integral part of the financial statements. Â 9 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in millions) (Unaudited) Â Â Â Â ThreeÂ monthsÂ ended SeptemberÂ 30, Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating activities: Â Â Â Â Â Net income (loss) Â Â $ (390) Â Â 77 Â Â $ (1,684) Â Â (1,082)Â Adjustments to reconcile net income (loss) to net cash provided by operations: Â Â Â Â Â Depreciation and amortization Â Â Â 259 Â Â Â 283 Â Â Â 790 Â Â Â 887 Â Impairment of goodwill Â Â Â 600 Â Â Â â€”â€, Â Â Â 1,000 Â Â Â 700 Â Impairment of long-lived assets and assets held for sale Â Â Â (51) Â Â 48 Â Â Â 758 Â Â Â 310 Â Net change in operating assets and liabilities Â Â Â 317 Â Â Â (227)Â Â Â (190) Â Â (364)Â Deferred income taxes â€“ net and uncertain tax positions Â Â Â (53)Â Â Â (199)Â Â Â (666)Â Â Â (349)Â Stock-based compensation Â Â Â 29 Â Â Â 31 Â Â Â 89 Â Â Â 93 Â Other items * Â Â Â 2 Â Â Â (5)Â Â Â 597 Â Â Â 18 Â Net loss (gain) from sale of business and long-lived assets Â Â Â (21)Â Â Â (3)Â Â Â (22)Â Â Â (29)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net cash provided by (used in) operating activities Â Â Â 693 Â Â Â 5 Â Â Â 672 Â Â Â 184 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Investing activities: Â Â Â Â Â Beneficial interest collected in exchange for securitized accounts receivables Â Â Â 339 Â Â Â 362 Â Â Â 951 Â Â Â 1,056 Â Purchases of property, plant and equipment and intangible assets Â Â Â (148)Â Â Â (149)Â Â Â (369)Â Â Â (407)Â Proceeds from sale of business and long-lived assets Â Â Â 38 Â Â Â 10 Â Â Â 39 Â Â Â 68 Â Acquisition of businesses, net of cash acquired Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â (15)Â Â Â â€”â€, Â Purchases of investments and other assets Â Â Â (1)Â Â Â (38)Â Â Â (56)Â Â Â (44)Â Proceeds from sale of investments Â Â Â 40 Â Â Â â€”â€, Â Â Â 40 Â Â Other investing activities Â Â Â â€”â€, Â Â Â (1)Â Â Â â€”â€, Â Â Â (6)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net cash provided by (used in) investing activities Â Â Â 268 Â Â Â 184 Â Â Â 590 Â Â Â 667 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financing activities: Â Â Â Â Â Repayment of senior notes and loans and other long term liabilities Â Â Â â€”â€, Â Â Â (1,000)Â Â Â (956)Â Â Â (4,152)Â Purchase of shares from non-controlling interests Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â (64)Â Â Â â€”â€, Â Dividends paid to non-controlling interests Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â (78)Â Â Â â€”â€, Â Proceeds from senior notes, net of issuance costs Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â 2,451 Â Proceeds from short term debt Â Â Â â€”â€, Â Â Â 700 Â Â Â â€”â€, Â Â Â 700 Â Repayment of short term debt Â Â Â â€”â€, Â Â Â (200)Â Â Â â€”â€, Â Â Â (200)Â Other financing activities Â Â Â â€”â€, Â Â Â (76)Â Â Â (19)Â Â Â (136)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net cash provided by (used in) financing activities Â Â Â â€”â€, Â Â Â (576)Â Â Â (1,117)Â Â Â (1,337)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Translation adjustment on cash and cash equivalents Â Â Â 100 Â Â Â (33)Â Â Â (53)Â Â Â (98)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net change in cash, cash equivalents and restricted cash Â Â Â 1,061 Â Â Â (420)Â Â Â â€”â€,92 Â Â Â (584)Â Balance of cash, cash equivalents and restricted cash at beginning of period Â Â Â 2,258 Â Â Â 2,670 Â Â Â 3,227 Â Â Â 2,834 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance of cash, cash equivalents and restricted cash at end of period Â Â $ 3,319 Â Â Â 2,250 Â Â Â 3,319 Â Â Â 2,250 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â Â Â 3,319 Â Â Â 2,249 Â Â Â 3,319 Â Â Â 2,249 Â Restricted cash included in other current assets Â Â Â â€”â€, Â Â Â 1 Â Â Â â€”â€, Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total cash, cash equivalents and restricted cash shown in the statement of cash flows Â Â Â 3,319 Â Â Â 2,250 Â Â Â 3,319 Â Â Â 2,250 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Non-cash financing and investing activities: Â Â Â Â Â Beneficial interest obtained in exchange for securitized accounts receivables Â Â $ 332 Â Â Â 376 Â Â $ 964 Â Â Â 1,090 Â Dividend declared to non-controlling interests Â Â $ â€”â€, Â Â Â 67 Â Â $ â€”â€, Â Â Â 67 Â * Adjustment in the nine-months period ended SeptemberÂ 30, 2024 mainly relates to an agreement with the Israeli Tax Authorities to settle certain litigation in an amount of $495Â million relating to taxes payable for the years 2008 through 2020. Amounts may not add up due to rounding The accompanying notes are an integral part of the financial statements. Â 10 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Note 1 â€“ Basis of presentation: Â Â a. Basis of presentation The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, as filed with the Securities and Exchange Commission (â€œSECâ€). The year-end balance sheet data was derived from the audited consolidated financial statements as of DecemberÂ 31, 2023, but not all disclosures required by generally accepted accounting principles in the United States (â€œU.S. GAAPâ€) are included. In preparing the Companyâ€™s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. In preparing the Companyâ€™s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of IPR&D assets, marketed product rights and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could be impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. Government actions taken to address macroeconomic developments, as well as their economic impact on Tevaâ€™s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. In February 2022, Russia launched an invasion of Ukraine. As of the date of these consolidated financial statements, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Tevaâ€™s International Markets segment results. Teva has no manufacturing or R&D facilities in these markets. During the three and nine months ended SeptemberÂ 30, 2024, the impact of this conflict on Tevaâ€™s results of operation and financial condition continues to be immaterial. In October 2023, Israel was attacked by a terrorist organization and entered a state of war on several fronts. As of the date of these consolidated financial statements, sustained conflict in the region is ongoing. Israel is included in Tevaâ€™s International Markets segment results. Tevaâ€™s global headquarters and several manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. Teva continues to maintain contingency plans with backup production locations for key products. During the three and nine months ended SeptemberÂ 30, 2024, the impact of this war on Tevaâ€™s results of operations and financial condition is immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war. Tevaâ€™s results of operations for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. Â Â b. Significant accounting policies Recently adopted accounting pronouncements None. Recently issued accounting pronouncements, not yet adopted In December 2023, the FASB issued ASU 2023-09 â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after DecemberÂ 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â Â 11 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â In November 2023, the FASB issued ASU 2023-07 â€œSegment Reporting: Improvements to Reportable Segment Disclosuresâ€. This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segmentâ€™s profit or loss and assets. The guidance is effective for fiscal years beginning after DecemberÂ 15, 2023, and interim periods within fiscal years beginning after DecemberÂ 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entityâ€™s financial statements. The Company does not expect the adoption of the ASU to have a material impact on its consolidated financial statements related disclosures. In October 2023, the FASB issued ASU 2023-06 â€œDisclosure Improvements: Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiative,â€ which incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification (â€œCodificationâ€). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification topics, allow investors to more easily compare entities subject to the SECâ€™s existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SECâ€™s regulations. The effective date for each amendment will be the date on which the SECâ€™s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this ASU should be applied prospectively. The Company does not expect ASU 2023-06 will have a material impact to its consolidated financial statements. Â Â c. Revision of Previously Reported Consolidated Financial Statements In connection with the preparation of the consolidated financial statements as of and for the year ended DecemberÂ 31, 2023, the Company identified errors in a single contingent consideration liability and related expenses in connection with estimated future royalty payments, along with corresponding deferred tax adjustments, that aggregated into an understatement of the contingent consideration liability of approximately $132Â million, of which $98Â million related to 2022 and $34Â million related to 2023. These errors resulted from the exclusion of royalty payments that should have been included in the fair value re-measurement calculation of the contingent consideration liability as of and for the year ended DecemberÂ 31, 2022, and the quarterly and year-to-date periods ended JuneÂ 30, SeptemberÂ 30 and DecemberÂ 31, 2022, and MarchÂ 31, JuneÂ 30 and SeptemberÂ 30, 2023. These errors did not impact the Companyâ€™s actual royalty payments, as well as total cash flows from operating activities, financing activities and investing activities in the periods stated above. The Company evaluated the errors, individually and in the aggregate, considering both qualitative and quantitative factors, and concluded that these errors did not have a material impact on any of the prior periods stated above. However, the aggregate amount of the prior period errors in 2022, would have been material to the consolidated financial statements for fiscal year 2023. Therefore, the Company has revised the prior periods impacted for these errors. The tables below present the impact of the revision on the line items within the Companyâ€™s consolidated financial statements for the relevant periods: Â Â Â Â Three months ended Â Â Nine months ended Â Â Â Â SeptemberÂ 30, 2023 Â Â SeptemberÂ 30, 2023 Â Â Â Â U.S $ in millions (except per share amounts) Â Â Â Â (Unaudited) Â Â Â Â As previously reported Â Â Adjustment Â Â AsÂ revised Â Â AsÂ previously reported Â Â Adjustment Â Â AsÂ revised Â Other asset impairments, restructuring and other items Â Â $ 46 Â Â Â 11 Â Â Â 57 Â Â $ 241 Â Â Â 34 Â Â Â 276 Â Operating income (loss) Â Â Â 355 Â Â Â (11)Â Â Â 344 Â Â Â (289)Â Â Â (34)Â Â Â (323)Â Income (loss) before income taxes Â Â Â 75 Â Â Â (11)Â Â Â 64 Â Â Â (1,097)Â Â Â (34)Â Â Â (1,131)Â Income taxes (benefit) Â Â Â (12)Â Â Â Â§ Â Â Â (12)Â Â Â (48)Â Â Â Â§ Â Â Â (48)Â Net income (loss) Â Â Â 88 Â Â Â (11)Â Â Â 77 Â Â Â (1,048)Â Â Â (34)Â Â Â (1,082)Â Net income (loss) attributable to Teva Â Â Â 80 Â Â Â (11)Â Â Â 69 Â Â Â (988)Â Â Â (34)Â Â Â (1,022)Â Earnings (loss) per share attributable to ordinary shareholders: Â Â Â Â Â Â Â Basic and diluted loss per share Â Â $ 0.07 Â Â Â (0.01)Â Â Â 0.06 Â Â $ (0.88)Â Â Â (0.04)Â Â Â (0.91)Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â 12 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Â Â Â SeptemberÂ 30, 2023 Â Â Â Â As previously reported Â Â Â Adjustment Â Â Â AsÂ revised Â Â Â Â (Unaudited) Â Deferred income taxes Â Â $ 1,748 Â Â Â Â 7 Â Â Â Â 1,755 Â Total assets Â Â Â 42,088 Â Â Â Â 7 Â Â Â Â 42,095 Â Other taxes and long-term liabilities Â Â Â 3,818 Â Â Â Â 132 Â Â Â Â 3,950 Â Total long-term liabilities Â Â Â 23,182 Â Â Â Â 132 Â Â Â Â 23,314 Â Total liabilities Â Â Â 34,576 Â Â Â Â 132 Â Â Â Â 34,708 Â Teva shareholdersâ€™ equity: Â Â Â Â Â Â Accumulated deficit Â Â Â (13,870)Â Â Â Â (125)Â Â Â Â (13,995)Â Total equity Â Â Â 7,512 Â Â Â Â (125)Â Â Â Â 7,387 Â Total liabilities and equity Â Â $ 42,088 Â Â Â Â 7 Â Â Â Â 42,095 Â Â Â 13 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 2 â€“ Certain transactions: The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Companyâ€™s most significant agreements of this nature are summarized below. mAbxience In April 2024, Teva announced it entered into a strategic licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Under the terms of the licensing agreement, mAbxience will develop and produce the biosimilar product and Teva will lead the regulatory processes and commercialization in multiple global markets, including Europe and the U.S. In September 2024, Teva and mAbxience entered into an amendment to the licensing agreement whereby, similar to the initial licensing agreement, mAbxience will lead the development and production of an anti-PD-1 oncology biosimilar candidate and Teva will manage regulatory approvals and oversee commercialization in the designated markets. Under the initial agreement, in the second quarter of 2024, Teva paid mAbxience upfront and milestone payments in a total amount of $20Â million, which were recorded as R&D expenses. Pursuant to the amendment of the licensing agreement, in the third quarter of 2024 Teva recognized upfront and milestone payments in a total amount of $15Â million as R&D expenses, of which $5Â million were paid in October 2024, and the remaining is due by the end of 2024. mAbxience may be eligible for additional future development, regulatory and commercial milestone payments, in an aggregate amount of up to $320Â million. Launch Therapeutics and Abingworth On MarchÂ 28, 2024, Teva and Launch Therapeutics, Inc. (â€œLaunch Therapeuticsâ€) entered into a clinical collaboration agreement to further accelerate the clinical research program of Tevaâ€™s ICS-SABA (TEV-â€˜248). As part of this clinical collaboration agreement Teva also entered into a development funding agreement with funds affiliated with Abingworth LLP (â€œAbingworthâ€). Under the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, the global investment firm, will have the lead role in the operational execution and management of the planned clinical trials. Teva will retain primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization. ICS-SABA (TEV-â€™248) is currently in Phase 3 for the treatment of asthma symptoms addressing both immediate symptoms and long-term inflammation. Under the development funding agreement, Abingworth will provide Teva up to $150Â million to fund ongoing development costs for ICS-SABA (TEV-â€˜248). In exchange and subject to regulatory approval, Teva will pay Abingworth a milestone payment in the amount actually funded by Abingworth up to $150Â million, as well as success payments based on ICS-SABA (TEV-â€˜248) sales. During the third quarter of 2024, Teva recorded $20Â millionÂ as reimbursement for R&D expensesÂ incurred in connection with this agreement. Biolojic Design On NovemberÂ 26, 2023, Teva entered into a license agreement with Biolojic Design Ltd. (â€œBiolojicâ€), pursuant to which Teva received exclusive rights to develop, manufacture and globally commercialize a BD9 multibody for the potential treatment of Atopic Dermatitis and Asthma. In exchange, Teva paid an upfront payment in an amount of

$10Â million in January 2024, which was recorded as an R&D expense in the fourth quarter of 2023. Biolojic may be eligible to receive additional development and commercial milestone payments of up to approximately $500Â million, over the next several years, based on the achievement of certain pre-clinical, clinical and regulatory milestones, with the majority of the payments based on future salesÂ achievements. Royalty Pharma On NovemberÂ 9, 2023, Teva entered into a funding agreement with Royalty Pharma plc. (â€œRoyalty Pharmaâ€) to further accelerate the clinical research program for Tevaâ€™s olanzapine LAI (TEV-â€™749). Under the terms of the funding agreement, Royalty Pharma will provide Teva up to $100Â million to fund ongoing development costs for olanzapine LAI (TEV-â€˜749), with an option to increase the total funding amount to $125Â million, which expired in the second quarter of 2024. In exchange and subject to regulatory approval, Teva will pay Royalty Pharma a milestone payment in the amount actually funded by Royalty Pharma, paid over 5 years, in addition to royalties upon commercialization. Teva will continue to lead the development and commercialization of the product globally. During the fourth quarter of 2023, and the first, second and third quarters of 2024, Teva recorded $35Â million, $27Â million, $19Â million and $18Â million respectively, as reimbursement for R&D expenses incurred in connection with this agreement, which collectively amounted to the total funding Royalty Pharma was to provide Teva ofÂ $100Â million. Olanzapine LAI (TEV-â€™749) is currently in Phase 3 for the treatment of schizophrenia (see also MedinCell transaction below). Â Â 14 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Sanofi On OctoberÂ 3, 2023, Teva entered into an exclusive collaboration with Sanofi to co-develop and co- commercialize Tevaâ€™s duvakitug (anti-TL1A, TEV-â€™574) asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohnâ€™s disease, two types of inflammatory bowel disease, which is currently in Phase 2b clinical trials. Under the terms of the collaboration agreement, in partial consideration of the licenses granted to Sanofi, Teva received an upfront payment of $500Â million in the fourth quarter of 2023, recognized as revenue. Additionally, Teva may receive up to $1Â billion in development and launch milestones. Each company will equally share the remaining development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement, and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. MODAG In October 2021, Teva announced a license agreement with MODAG GmbH (â€œModagâ€) providing Teva with an exclusive global license to develop, manufacture and commercialize Modagâ€™s lead compound, emrusolmin (TEV-â€™286) and a related compound (TEV-â€™287). Emrusolmin (TEV-â€™286) was initially developed for the treatment of Multiple System Atrophy (â€œMSAâ€) and Parkinsonâ€™s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimerâ€™s disease. Teva has initiated a Phase 2 clinical trial. In the fourth quarter of 2021, Teva made an upfront payment of $10Â million to Modag, recorded as an R&D expense. Modag may be eligible for additional future development milestone payments, in an aggregate amount of up to $30Â million, as well as future commercial milestones and royalties. Alvotech In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contained biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to HumiraÂ® (adalimumab) and StelaraÂ® (ustekinumab). Under the terms of the agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the U.S. In July 2023, Alvotech and Teva amended their collaboration agreement, adding two new biosimilar candidates as well as line extensions of two current biosimilar candidates to their partnership. Teva made upfront and milestone payments in an aggregate amount of $78Â million in 2020, 2021 and 2023. Teva made additional milestone payments of $27Â million in the second quarter of 2024 and $19Â million in the third quarter of 2024. Additional development and commercial milestone payments of up to approximately $380Â million, in addition to royalty and milestone payments related to the amendment of the collaboration agreement entered into in July 2023, may be payable by Teva over the next few years. Teva and Alvotech will share revenue from the commercialization of these biosimilars. The amendment of the collaboration agreement entered into in July 2023 includes increased involvement by Teva regarding manufacturing and quality at Alvotechâ€™s manufacturing facility. Additionally, pursuant to the amendment, on September 29, 2023, Teva purchased $40 million of subordinated convertible bonds of Alvotech. On June 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds for $44 million, including accrued interest, which were paid to Teva in July 2024. On FebruaryÂ 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDIÂ® (adalimumab-ryvk) injection, as an interchangeable biosimilar to HumiraÂ®, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohnâ€™s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. On AprilÂ 17, 2024, Alvotech and Teva amended their collaboration agreement to enable the purchase by Quallent of a private label adalimumab-ryvk injection from Alvotech for the U.S. market, with Alvotech sharing profits with Teva on the private label sales. On MayÂ 20, 2024, Alvotech and Teva announced that SIMLANDI is available in the United States. Â 15 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â With respect to the proposed biosimilar to StelaraÂ®, on JuneÂ 12, 2023, Alvotech and Teva reached a settlement and license agreement with JohnsonÂ & Johnson, granting a licensed entry date in the U.S. no later than February 21, 2025. On AprilÂ 16, 2024, Alvotech and Teva announced that the FDA approved SELARSDITM (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to StelaraÂ®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients six years and older, and on OctoberÂ 22, 2024, announced that the FDA approved SELARSDI in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion, expanding its label to include treatment of adults with Crohnâ€™s disease and ulcerative colitis. Takeda In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (â€œTakedaâ€), for the research, development, manufacture and commercialization of ATTENUKINETM technology. Teva received a $30Â million upfront payment and a milestone payment of $20Â million in 2017. During the second quarter of 2022, Takeda initiated its Phase 2 study of modakafusp alfa (formerly TAK-573 or TEV â€™573) and as a result paid Teva a milestone payment of $25Â million, which was recognized as revenue in the second quarter of 2022. In April 2024, Takeda informed Teva of its intent to terminate the agreement with respect to such product candidate, which product rights will revert back to Teva in early 2025. Takeda continues to have rights under the license agreement with respect to other product candidates. MedinCell In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (â€œLAIâ€) products. Teva leads the clinical development and regulatory process and is responsible for the commercialization of these products. The lead product is risperidone LAI (formerly known as TV-46000). On AprilÂ 28, 2023, the FDA approved UZEDYÂ® (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults, which was launched in the U.S. in May 2023. MedinCell may be eligible for future sales-based milestones of up to $105Â million with respect to UZEDY. Teva also pays MedinCell royalties on net sales. The second selected product candidate is olanzapine LAI (TEV-â€™749) for the treatment of schizophrenia. In the third quarter of 2022, Teva decided to progress development of the product to Phase 3 and, as a result, paid a $3Â million milestone payment to MedinCell, which was recognized as R&D expenses. On MayÂ 8, 2024, Teva and MedinCell announced positive phase 3 efficacy results from a trial evaluating olanzapine LAI as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia. Additional safety and efficacy results are planned in the first half of 2025. MedinCell may become eligible for further development and commercial milestones of up to $108Â million, as well as royalties on sales of olanzapine LAI (TEV-â€™749). Assets and Liabilities Held for Sale: General Assets and liabilities held for sale as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, included certain businesses in Tevaâ€™s International Markets segment that are expected to be sold within the next year, mainly the business venture in Japan. In connection with the held for sale classification, in the first quarter of 2024, Teva recorded expenses of $577Â million due to an expected loss upon sale, including $369Â million of expected loss from reclassification of currency translation adjustments to the statements of income upon sale, in other assets impairments, restructuring and other items. In the second quarter of 2024, Teva recorded an additional expense of $67Â million related to the expected loss from reclassification of currency translation adjustments referred to above. In the third quarter of 2024, Teva recorded a favorable adjustment of $83Â million, primarily related to the change in expected loss from reclassification of currency translation adjustments referred to above. See note 12. Â 16 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â The table below summarizes all of Tevaâ€™s assets and liabilities included as held for sale as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023: Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Inventories Â Â Â 169 Â Â Â Â 12 Â Accounts receivables Â Â Â 123 Â Â Â Â â€”â€, Â Goodwill Â Â Â 48 Â Â Â Â 30 Â Identifiable intangible assets, net Â Â Â 67 Â Â Â Â â€”â€, Â Property, plant and equipment, net Â Â Â 10 Â Â Â Â 5 Â Other current and non-current assets Â Â Â 40 Â Â Â Â 23 Â Expected loss on sale* Â Â Â (455)Â Â Â Â â€”â€, Â Â Â Â Â Â Â Â Â Â Â Total assets of the disposal group classified as held for sale in the consolidated balance sheets Â Â $ 2 Â Â Â $ 70 Â Â Â Â Â Â Â Â Â Â Â Accounts payables Â Â Â (76)Â Â Â Â â€”â€, Â Other liabilities Â Â Â (34)Â Â Â Â (13)Â Expected loss on sale* Â Â Â (106)Â Â Â Â â€”â€, Â Â Â Â Â Â Â Â Â Â Â Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets Â Â $ (216)Â Â Â $ (13)Â Â Â Â Â Â Â Â Â Â Â * Includes an expected loss from reclassification of currency translation adjustments to the consolidated statements of income (loss) upon sale. Â 17 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 3 â€“ Revenue from contracts with customers: Disaggregation of revenue The following table disaggregates Tevaâ€™s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. Â Â Â Â Three months ended SeptemberÂ 30, 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalMarkets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 1,822 Â Â Â Â 1,214 Â Â Â 568 Â Â Â Â 121 Â Â Â Â 3,794 Â Licensing arrangements Â Â Â 23 Â Â Â Â 9 Â Â Â 6 Â Â Â Â 8 Â Â Â Â 45 Â Distribution Â Â Â 380 Â Â Â Â Â§ Â Â Â 10 Â Â Â Â â€”â€, Â Â Â Â 390 Â Other Â Â Â Â§ Â Â Â Â 42 Â Â Â 29 Â Â Â Â 100 Â Â Â Â 102 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 2,225 Â Â Â $ 1,265 Â Â $ â€‡â€‰613 Â Â Â $ 229 Â Â Â $ â€‡4,332 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Three months ended SeptemberÂ 30, 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 1,500 Â Â Â Â 1,117 Â Â Â 556 Â Â Â Â 130 Â Â Â Â 3,303 Â Licensing arrangements Â Â Â 30 Â Â Â Â 13 Â Â Â 9 Â Â Â Â 1 Â Â Â Â 53 Â Distribution Â Â Â 366 Â Â Â Â Â§ Â Â Â 11 Â Â Â Â â€”â€, Â Â Â Â 377 Â Other Â Â Â Â§ Â Â Â Â 15 â€„Â Â Â 15 Â Â Â Â 86 Â Â Â Â 117 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,896 Â Â Â $ 1,146 Â Â $ â€‡â€‰591 Â Â Â $ 217 Â Â Â $ â€‡3,850 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Nine months ended SeptemberÂ 30, 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 4,857 Â Â Â Â 3,668 Â Â Â 1,708 Â Â Â Â 399 Â Â Â Â 10,701 Â Licensing arrangements Â Â Â 68 Â Â Â Â 26 Â Â Â 17 Â Â Â Â 10 Â Â Â Â 121 Â Distribution Â Â Â 1,134 Â Â Â Â Â§ Â Â Â 28 Â Â Â Â â€”â€, Â Â Â Â 1,163 Â Other Â Â Â Â§ Â Â Â Â 54 â€„Â Â Â 49 Â Â Â Â 295 Â Â Â Â 330 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 6,060 Â Â Â $ 3,749 Â Â $ 1,802 Â Â Â $ 703 Â Â Â $ 12,315 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â 18 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Â Â Â Nine months ended SeptemberÂ 30, 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 4,210 Â Â Â Â 3,446 Â Â Â Â 1,656 Â Â Â Â 412 Â Â Â Â 9,724 Â Licensing arrangements Â Â Â 72 Â Â Â Â 38 Â Â Â Â 21 Â Â Â Â 4 Â Â Â Â 134 Â Distribution Â Â Â 1,183 Â Â Â Â Â§ Â Â Â Â 29 Â Â Â Â â€”â€, Â Â Â Â 1,212 Â Other Â Â Â Â§ Â Â Â Â 8 Â Â Â Â 44 Â Â Â Â 265 Â Â Â Â 318 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 5,465 Â Â Â $ 3,493 Â Â Â $ 1,750 Â Â Â $ 681 Â Â Â $ 11,389 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. â€ƒ Variable consideration Variable consideration mainly includes sales reserves and allowances (â€œSR&Aâ€), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. SR&A to U.S. customers comprised approximately 67% of the Companyâ€™s total SR&A as of SeptemberÂ 30, 2024, with the remaining balance primarily related to customers in Canada and Germany. The changes in SR&A for third-party sales for the nine months ended SeptemberÂ 30, 2024 and 2023 were as follows: Â Â Â Â Sales Reserves and Allowances Â Â Â Â Reserves included in Accounts Receivable,Â net Â Â Rebates Â Â Medicaid and other governmental allowances Â Â Chargebacks Â Â Returns Â Â Other Â Â TotalÂ reserves included in SalesÂ Reserves andÂ Allowances Â Â Total Â Â Â Â (U.S.$ in millions) Â Balance at JanuaryÂ 1, 2024 Â Â $ 61 Â Â $ 1,603 Â Â $ 540 Â Â $ 859 Â Â $ 436 Â Â $ 97 Â Â $ 3,535 Â Â $ 3,596 Â Provisions related to sales made in current year period Â Â Â 294 Â Â Â 3,436 Â Â Â 579 Â Â Â 5,925 Â Â Â 191 Â Â Â 146 Â Â Â 10,277 Â Â Â 10,571 Â Provisions related to sales made in prior periods Â Â Â â€”â€, Â Â Â 16 Â Â Â 26 Â Â Â (11)Â Â Â (28)Â Â Â (2)Â Â Â 1 Â Â Â 1 Â Credits and payments Â Â Â (292)Â Â Â (3,269)Â Â Â (556)Â Â Â (5,877)Â Â Â (209)Â Â Â (121)Â Â Â (10,032)Â Â Â (10,324)Â Translation differences Â Â Â â€”â€, Â Â Â 1 Â Â Â 3 Â Â Â 1 Â Â Â (1)Â Â Â â€”â€, Â Â Â 4 Â Â Â 4 Â Â Â Balance at SeptemberÂ 30, 2024 Â Â $ 63 Â Â $ 1,787 Â Â $ 592 Â Â $ 897 Â Â $ 389 Â Â $ 120 Â Â $ 3,785 Â Â $ 3,848 Â Â Â 19 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Â Â Â Sales Reserves and Allowances Â Â Â Â Reserves included in Accounts Receivable,Â net Â Â Rebates Â Â Medicaid and other governmental allowances Â Â Chargebacks Â Â Returns Â Â Other Â Â TotalÂ reserves included in Sales Reserves andÂ Allowances Â Â Total Â Â Â Â Â (U.S.$ in millions) Â Balance at JanuaryÂ 1, 2023 Â Â $ 67 Â Â $ 1,575 Â Â $ 663 Â Â $ 991 Â Â $ 455 Â Â $ 66 Â Â $ 3,750 Â Â $ 3,817 Â Provisions related to sales made in current year period Â Â Â 262 Â Â Â 2,968 Â Â Â 468 Â Â Â 5,636 Â Â Â 205 Â Â Â 73 Â Â Â 9,350 Â Â Â 9,612 Â Provisions related to sales made in prior periods Â Â Â â€”â€, Â Â Â (22)Â Â Â (33)Â Â Â (21)Â Â Â 24 Â Â Â â€”â€, Â Â Â (52)Â Â Â (52)Â Credits and payments Â Â Â (268)Â Â Â (2,989)Â Â Â (617)Â Â Â (5,768)Â Â Â (251)Â Â Â (53)Â Â Â (9,678)Â Â Â (9,946)Â Translation differences Â Â Â â€”â€, Â Â Â (8)Â Â Â (2)Â Â Â (3)Â Â Â â€”â€, Â Â Â (6)Â Â Â (19)Â Â Â (19)Â Â Â Balance at SeptemberÂ 30, 2023 Â Â $ 61 Â Â $ 1,524 Â Â $ 479 Â Â $ 835 Â Â $ 433 Â Â $ 80 Â Â $ 3,351 Â Â $ 3,412 Â Â Â 20 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 4 â€“ Inventories: Inventories, net of reserves, consisted of the following: Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Finished products Â Â $ 2,314 Â Â Â $ 2,346 Â Raw and packaging materials Â Â Â 926 Â Â Â Â 993 Â Products in process Â Â Â 524 Â Â Â Â 500 Â Materials in transit and payments on account Â Â Â 195 Â Â Â Â 183 Â Â Â Â Â Â Â Â Â Â Â Â Â $ 3,959 Â Â Â $ 4,021 Â Â Â Â Â Â Â Â Â Â Â NOTE 5 â€“ Identifiable intangible assets: Identifiable intangible assets consisted of the following: Â Â Â Â Gross carrying amount net of impairment Â Â Â Accumulated amortization Â Â Â Net carrying amount Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Product rights Â Â $ 16,408 Â Â Â $ 17,981 Â Â Â $ 12,235 Â Â Â $ 13,274 Â Â Â $ 4,173 Â Â Â $ 4,707 Â Trade names Â Â Â 586 Â Â Â Â 583 Â Â Â Â 296 Â Â Â Â 269 Â Â Â Â 290 Â Â Â Â 314 Â In process research and development Â Â Â 294 Â Â Â Â 366 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 294 Â Â Â Â 366 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 17,287 Â Â Â $ 18,930 Â Â Â $ 12,531 Â Â Â $ 13,543 Â Â Â $ 4,756 Â Â Â $ 5,387 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product rights and trade names Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products in various therapeutic categories from various acquisitions with a weighted average life period of approximately 9 years. Amortization of intangible assets was $146Â million and $145Â million in the three months ended SeptemberÂ 30, 2024 and 2023, respectively. Amortization of intangible assets was $444Â million and $471Â million in the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. IPR&D Tevaâ€™s IPR&D are assets that have not yet been approved in its major markets. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. Intangible assets impairments Impairments of long-lived intangible assets for the three months ended SeptemberÂ 30, 2024 and 2023 were $28Â million and $47Â million, respectively. Impairments in the third quarter of 2024 consisted of: Identifiable product rights of $28Â million, mainly due to updated market assumptions regarding price and volume of products mainly in the U.S. Â 21 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Impairments in the third quarter of 2023 consisted of: Â Â (a) IPR&D assets of $29Â million, mainly due to generic pipeline products resulting from

development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date); and Â Â (b) Identifiable product rights of
$18Â million mainly due to updated market assumptions regarding price and volume of products. Impairments of long-lived intangible assets for the nine months ended SeptemberÂ 30, 2024
and 2023 were $169Â million and $289Â million, respectively. Impairments in the first nine months of 2024 consisted of: Â Â (a) Identifiable product rights of $136Â million, mainly due to
updated market assumptions regarding price and volume of products mainly in the U.S.; and Â Â (b) IPR&D assets of $33Â million, mainly due to generic pipeline products resulting from
development progress and changes in other key valuation indications mainly in the U.S. (e.g., market size, competition assumptions, legal landscape and launch date). Impairments in the first
nine months of 2023 consisted of: Â Â (a) Identifiable product rights of $206Â million due to: (i) $112Â million in Japan, mainly due to regulatory pricing reductions; and (ii) $94Â million
related to updated market assumptions regarding price and volume of products; and Â Â (b) IPR&D assets of $83Â million, mainly due to generic pipeline products resulting from development
progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). The fair value measurement of the impaired intangible
assets in the nine months ended SeptemberÂ 30, 2024 is based on significant unobservable inputs in the market and thus represents a LevelÂ 3 measurement within the fair value hierarchy.
The discount rate applied ranged from 8.5% to 10%. A probability of success factor of 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&D.
Â 22 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 6 â€“ Goodwill: Changes in the carrying amount of
goodwill for the period ended SeptemberÂ 30, 2024 were as follows: Â Â Â Â NorthAmerica Â Â UnitedStates Â Â Â Europe Â Â Â InternationalMarkets Â Â Other Â Â Â Total Â Â Â
Tevaâ€™sAPI Â Â Medis Â Â Â Â Â Â Â (U.S. $ in millions) Â Â Â Â Balance as of DecemberÂ 31, 2023 (1) Â Â $ 6,459 Â Â $ â€”â€, Â Â Â $ 8,466 Â Â Â $ 675 Â Â $ 1,313 Â Â $ 265
Â Â Â $ 17,177 Â Goodwill allocation related to the shift of Canada to International Markets Â Â Â (6,459)Â Â Â 5,813 Â Â Â Â â€”â€, Â Â Â Â 646 Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â
Â â€”â€, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of JanuaryÂ 1, 2024 Â Â $ â€”â€, Â Â $ 5,813 Â Â Â $ 8,466 Â Â Â $ 1,321 Â Â $
1,313 Â Â $ 265 Â Â Â $ 17,177 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other changes during the period: Â Â Â Â Â Â Â Â Â Â Â Goodwill
impairment Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â (1,000)Â Â Â â€”â€, Â Â Â Â (1,000) Goodwill reclassified as assets held for sale Â Â Â â€”â€, Â Â Â
â€”â€, Â Â Â Â â€”â€, Â Â Â Â (29)Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â Â (29)Â Translation differences and other Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â Â 97 Â Â Â Â (131)Â Â Â 5 Â Â
Â 4 Â Â Â Â (25)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2024 (1) Â Â $ â€”â€, Â Â $ 5,813 Â Â Â $ 8,563 Â Â Â
$ 1,161 Â Â $ 318 Â Â $ 269 Â Â Â $ 16,124 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) Cumulative goodwill impairment as of SeptemberÂ 30,
2024 and DecemberÂ 31, 2023 was approximately $29.3Â billion and $28.3Â billion, respectively. Teva operates its business through three reporting segments: United States, Europe and
International Markets. Each of these business segments is a reporting unit. Additional reporting units include Tevaâ€™s production and sale of APIs to third parties (â€œTeva APIâ€) and an
out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Tevaâ€™s API and Medis reporting units are included under â€œOtherâ€ in
the table above. See note 15 for additional segment information. Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking
approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva begins with a forecast of all the expected net cash flows associated
with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Tevaâ€™s
estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital
(â€œWACCâ€), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Tevaâ€™s
assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. First Quarter Developments As further discussed in note 15, as of JanuaryÂ 1, 2024,
Canada is reported as part of Tevaâ€™s International Markets segment and not as part of Tevaâ€™s North America segment, which has been renamed as Tevaâ€™s United States segment. As a
result, Teva aligned its segment reporting and its reporting units in accordance with this change, and reallocated its goodwill to the adjusted reporting units using a relative fair value allocation.
In conjunction with the goodwill reallocation, Teva performed a goodwill impairment test for the balances in its adjusted United States and International Markets reporting units and concluded
that the fair value of each reporting unit was in excess of its carrying value. During the first quarter of 2024, management evaluated whether there were any developments that occurred during
the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of MarchÂ 31, 2024. Management concluded that no
triggering event had occurred and, therefore, no quantitative assessment was performed. Second Quarter Developments During the second quarter of 2024, Teva completed its long-range
planning (â€œLRPâ€) process. The LRP is part of Tevaâ€™s internal financial planning and budgeting processes and is discussed and reviewed by Tevaâ€™s management and its board of
directors. Â 23 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Additionally, Teva conducted a quantitative
analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. As disclosed in prior periods, the excess of the estimated fair
value of Tevaâ€™s API reporting unit over its estimated carrying amount was negligible as of DecemberÂ 31, 2023 and MarchÂ 31, 2024. The updated quantitative analysis performed in the
second quarter of 2024, which was based on the aforementioned LRP process and Tevaâ€™s Pivot to Growth strategy assumptions, resulted in a recognition of a goodwill impairment charge of
$400Â million related to Tevaâ€™s API reporting unit. Following the goodwill impairment charges recorded in relation to Tevaâ€™s API reporting unit, the carrying values of this reporting unit
equaled its fair value as of JuneÂ 30, 2024. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Tevaâ€™s
API reporting unit in the future (see â€œThird Quarter Developmentsâ€ below). Tevaâ€™s United States, Europe, International Markets and Medis reporting units had fair values in excess of
10% over their book values as of JuneÂ 30, 2024. In the second quarter of 2023, Teva recorded a goodwill impairment charge of $700Â million related to its International Markets reporting unit,
mainly due to an increase in the discount rate due to higher risk associated with country-specific characteristics of several countries. Third Quarter Developments During the third quarter of
2024, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units
was below its carrying amount as of SeptemberÂ 30, 2024. As part of this evaluation, management noted a triggering event related to Tevaâ€™s API reporting unit, which resulted from updated
assumptions in connection with Tevaâ€™s intention to divest its API business through a sale. Teva performed a quantitative assessment in the third quarter of 2024, which resulted in the
recording of a goodwill impairment charge of $600Â million related to Tevaâ€™s API reporting unit. Following this goodwill impairment charge, the carrying value of Tevaâ€™s API reporting
unit equaled its fair value as of SeptemberÂ 30, 2024. Therefore, if business conditions or expectations, including related to Tevaâ€™s intention to divest its API business, were to change
materially, it may be necessary to record further impairment charges to Tevaâ€™s API reporting unit in the future. With respect to the remaining reporting units, management concluded that it
was not more likely than not that the fair value of any of the reporting units was below its carrying amounts as of SeptemberÂ 30, 2024 and, therefore, no quantitative assessment was
performed. NOTE 7 â€“ Debt obligations: Â a. Short-term debt: Â Â Â Â Interest rate as of SeptemberÂ 30,Â 2024 Â Â Maturity Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â
2024 Â Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â (U.S. $ in millions) Â Convertible senior debentures Â Â Â 0.25 %Â Â Â 2026 Â Â Â Â 23 Â Â Â Â 23 Â Current maturities of long-term
liabilities Â Â Â Â 2,557 Â Â Â Â 1,649 Â Â Â Â Â Â Â Â Â Â Â Total short-term debt Â Â Â $ 2,580 Â Â Â $ 1,672 Â Â Â Â Â Â Â Â Â Â Â Convertible senior debentures The
principal amount of Tevaâ€™s 0.25% convertible senior debentures due in 2026 was $23Â million as of SeptemberÂ 30, 2024 and as of DecemberÂ 31, 2023. These convertible senior
debentures include a â€œnet share settlementâ€ feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the
principal amount will be paid in Teva shares. Due to the â€œnet share settlementâ€ feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet
under â€˜short-term debtâ€™. Â 24 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â b. Long-term debt: Â Â
Â Â Interest rate as of SeptemberÂ 30,Â 2024 Â Â Maturity Â Â Â SeptemberÂ 30, 2024 Â Â DecemberÂ 31, 2023 Â Â Â Â Â Â Â Â Â Â Â (U.S. $ in millions) Â Senior notes USD
1,250Â million (4) Â Â Â 6.00 %Â Â Â 2024 Â Â Â Â â€”â€, Â Â Â 956 Â Senior notes EUR 1,500Â million (5) Â Â Â 1.13 %Â Â Â 2024 Â Â Â Â 700 Â Â Â 693 Â Senior notes EUR
1,000Â million Â Â Â 6.00 %Â Â Â 2025 Â Â Â Â 459 Â Â Â 453 Â Senior notes USD 1,000Â million Â Â Â 7.13 %Â Â Â 2025 Â Â Â Â 427 Â Â Â 427 Â Senior notes EUR
900Â million Â Â Â 4.50 %Â Â Â 2025 Â Â Â Â 554 Â Â Â 547 Â Senior notes CHF 350Â million Â Â Â 1.00 %Â Â Â 2025 Â Â Â Â 417 Â Â Â 416 Â Senior notes USD 3,500Â million
Â Â Â 3.15 %Â Â Â 2026 Â Â Â Â 3,374 Â Â Â 3,374 Â Senior notes EUR 700Â million Â Â Â 1.88 %Â Â Â 2027 Â Â Â Â 781 Â Â Â 771 Â Sustainability-linked senior notes USD
1,000Â million (1)(*) Â Â Â 4.75 %Â Â Â 2027 Â Â Â Â 1,000 Â Â Â 1,000 Â Sustainability-linked senior notes EUR 1,100Â million (1)(*) Â Â Â 3.75 %Â Â Â 2027 Â Â Â Â 1,229 Â Â Â
1,215 Â Senior notes USD 1,250Â million Â Â Â 6.75 %Â Â Â 2028 Â Â Â Â 1,250 Â Â Â 1,250 Â Senior notes EUR 750Â million Â Â Â 1.63 %Â Â Â 2028 Â Â Â Â 834 Â Â Â 826 Â
Sustainability-linked senior notes USD 1,000Â million (2)(*) Â Â Â 5.13 %Â Â Â 2029 Â Â Â Â 1,000 Â Â Â 1,000 Â Sustainability-linked senior notes USD 600Â million (3)(*) Â Â Â 7.88
%Â Â Â 2029 Â Â Â Â 600 Â Â Â 600 Â Sustainability-linked senior notes EUR 800Â million (3)(*) Â Â Â 7.38 %Â Â Â 2029 Â Â Â Â 895 Â Â Â 884 Â Sustainability-linked senior notes
EUR 1,500Â million (2)(*) Â Â Â 4.38 %Â Â Â 2030 Â Â Â Â 1,676 Â Â Â 1,656 Â Sustainability-linked senior notes USD 500Â million (3)(*) Â Â Â 8.13 %Â Â Â 2031 Â Â Â Â 500 Â Â
Â 500 Â Sustainability-linked senior notes EUR 500Â million (3)(*) Â Â Â 7.88 %Â Â Â 2031 Â Â Â Â 558 Â Â Â 552 Â Senior notes USD 789Â million Â Â Â 6.15 %Â Â Â 2036 Â Â Â
Â 783 Â Â Â 783 Â Senior notes USD 2,000Â million Â Â Â 4.10 %Â Â Â 2046 Â Â Â Â 1,986 Â Â Â 1,986 Â Â Â Â Â Â Â Â Â Â Â Â Total senior notes Â Â Â Â Â Â 19,023 Â Â
Â 19,889 Â Other long-term debt Â Â Â Â Â Â 2 Â Â Â 1 Â Less current maturities Â Â Â Â Â Â (2,557)Â Â Â (1,649)Â Less debt issuance costs Â Â Â Â Â Â (68)Â Â Â (80)Â Â Â
Â Â Â Â Â Â Â Â Â Â Total senior notes and loans Â Â Â Â Â $ 16,400 Â Â $ 18,161 Â Â Â Â Â Â Â Â Â Â Â Â Â (1) If Teva fails to achieve certain sustainability performance
targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. (2) If Teva
fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including MayÂ 9, 2026. (3) If Teva fails to achieve certain
sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including SeptemberÂ 15, 2026. (4) In April 2024, Teva repaid $956Â million of its
6% senior notes due 2024 at maturity. (5) In October 2024, Teva repaid $685Â million of its 1.13% senior notes due 2024 at maturity. * Interest rate adjustments and a potential one-time
premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. Long-term debt was issued by several indirect wholly-owned
subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt
outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. Â 25 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES
LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Tevaâ€™s debt as of SeptemberÂ 30, 2024 was effectively denominated in the following currencies: 58% in U.S. dollars,
40% in euro and 2% in Swiss franc. Tevaâ€™s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily
its $1.8Â billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, as amended on FebruaryÂ 6, 2023 and on MayÂ 3, 2024 (â€œRCFâ€). The RCF
had an initial maturity date of April 2026 with two one-year extension options. In April 2024, an extension option was exercised and the RCF maturity date was extended to April 2027. The RCF
contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes
more restrictive over time. On MayÂ 3, 2024, the terms of the RCF were amended to update the Companyâ€™s maximum permitted leverage ratio under the RCF for certain periods. Under the
terms of the RCF, as amended, the Companyâ€™s leverage ratio shall not exceed (i) 4.00x in 2024, 2025 and in the first quarter of 2026, (ii) 3.75x in the second, third and fourth quarters of
2026 and (iii) 3.50x in the first quarter of 2027 and onwards. The RCF permits the Company to increase the maximum leverage ratio if it consummates or commences certain material
transactions. Under the RCF, as amended, the applicable margin used to calculate the interest rate under the RCF is linked to one sustainability performance target, the number of new
regulatory submissions in low and middle-income countries. Proceeds from borrowings under the RCF can be used for general corporate purposes, including repaying existing debt. As of
SeptemberÂ 30, 2024, and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects
that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. Under specified circumstances, including non-
compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF.
Additionally, violations of the covenants, under the circumstances referred to above, would result in an event of default in all borrowings under the RCF and, when greater than a specified
threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Companyâ€™s senior notes and
sustainability-linked senior notes due to cross-acceleration provisions. Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other
financial obligations within one year from the date that the financial statements are issued. NOTE 8 â€“ Derivative instruments and hedging activities: Â a. Foreign exchange risk management:
In the first nine months of 2024, approximately 47% of Tevaâ€™s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency
risks. The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In
addition, the Company takes measures to reduce its exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The
currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty, new Israeli shekel,
Indian rupee and other currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. The Company may choose to hedge against
possible fluctuations in foreign subsidiaries net assets (â€œnet investment hedgeâ€) and has in the past entered into cross-currency swaps and forward-contracts in order to hedge such an
exposure. Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative
transactions for trading purposes. Â 26 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â b. Interest risk
management: The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans and convertible debentures that bear fixed or
variable interest rates, as well as a syndicated sustainability-linked revolving credit facility and securitization programs that bear a variable interest rate. In some cases, the Company has
swapped from a fixed to a variable interest rate (â€œfair value hedgeâ€) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (â€œcash
flow hedgeâ€), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. As of SeptemberÂ 30, 2024, all outstanding senior notes, sustainability-
linked senior notes and convertible debentures bear a fixed interest rate. Â c. Bifurcated embedded derivatives: Upon the issuance of its sustainability-linked senior notes, Teva recognized
embedded derivatives related to interest rate adjustments and a potential one-time premium payment upon failure to achieve certain sustainability performance targets, such as access to
medicines in low-to-middle-income countries and reduction of absolute greenhouse gas emissions, which were bifurcated and are accounted for separately as derivative financial instruments. As
of SeptemberÂ 30, 2024, the fair value of these derivative instruments is negligible. d. Derivative instruments outstanding: The following table summarizes the notional amounts for hedged
items, when transactions are designated as hedge accounting: Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Cross-currency
swap - cash flow hedge (1) Â Â $ â€”â€, Â Â Â $ 169 Â Â Â Â Â Â Â Â Â Â Â The following table summarizes the classification and fair values of derivative instruments: Â Â Â Â Fair value
Â Â Â Â Designated as hedging instruments Â Â Â Not designated as hedging instruments Â Â Â Â SeptemberÂ 30, 2024 Â Â Â DecemberÂ 31, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â
DecemberÂ 31, 2023 Â Reported under Â Â (U.S. $ in millions) Â Â Â (U.S. $ in millions) Â Asset derivatives: Â Â Â Â Â Â Â Â Other current assets: Â Â Â Â Â Â Â Â Option and forward
contracts Â Â $ â€”â€, Â Â Â $ â€”â€, Â Â Â $ 32 Â Â Â $ 38 Â Other non-current assets: Â Â Â Â Â Â Â Â Cross-currency swap-cash flow hedge (1) Â Â Â â€”â€, Â Â Â Â 8 Â Â Â Â
â€”â€, Â Â Â Â â€”â€, Â Liability derivatives: Â Â Â Â Â Â Â Â Other current liabilities: Â Â Â Â Â Â Â Â Option and forward contracts Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (33)Â Â Â
Â (39)Â Â 27 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â The table below provides information regarding

the location and amount of pre-tax (gains) losses from derivatives designated in cash flow hedging relationships: Â Â Â Â Financial expenses, net Â Â Â Other comprehensive income (loss) Â Â Â Â Three months ended, Â Â Â Three months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 272 Â Â Â $ 280 Â Â Â $ 180 Â Â Â $ (249)Â Cross-currency swaps - cash flow hedge (1) Â Â Â â€”â€, Â Â Â Â (7)Â Â Â Â â€”â€, Â Â Â Â 1 Â Â Â Â Financial expenses, net Â Â Â Other comprehensive income (loss) Â Â Â Â Nine months ended, Â Â Â Â Nine months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 763 Â Â Â $ 808 Â Â Â $ (75)Â Â Â $ (156)Â Cross-currency swaps - cash flow hedge (1) Â Â Â (8)Â Â Â Â (22)Â Â Â Â 1 Â Â Â Â (4)Â The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives not designated as hedging instruments: Â Â Â Â Financial expenses, net Â Â Â Net revenues Â Â Â Â Three months ended, Â Â Â Three months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 272 Â Â Â $ 280 Â Â Â $ (4,332)Â Â Â $ (3,850)Â Option and forward contracts (2) Â Â Â 4 Â Â Â Â 4 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Option and forward contracts economic hedge (3) Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 9 Â Â Â Â (22)Â Â Â Â Financial expenses, net Â Â Â Net revenues Â Â Â Â Nine months ended, Â Â Â Nine months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 763 Â Â Â $ 808 Â Â Â $ (12,315)Â Â Â $ (11,389)Â Option and forward contracts (2) Â Â Â (33)Â Â Â Â (46)Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Option and forward contracts economic hedge (3) Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (1)Â Â Â (20)Â Â 28 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â (1) On MarchÂ 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. The agreement was terminated in the first quarter of 2024 and resulted in cash proceeds of $16Â million. (2) Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. (3) Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and some other currencies to protect its projected operating results for 2024. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the three months ended SeptemberÂ 30, 2024, the negative impact from these derivatives recognized under revenues was $9Â million. In the nine months ended SeptemberÂ 30, 2024, the positive impact from these derivatives recognized under revenues was $1Â million. In the three months ended SeptemberÂ 30, 2023, the positive impact from these derivatives recognized under revenues was $22Â million. In the nine months ended SeptemberÂ 30, 2023, the positive impact from these derivatives recognized under revenues was $20Â million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. Â Â e. Amortizations due to terminated derivative instruments: Forward-starting interest rate swaps and treasury lock agreements In 2015, Teva entered into forward-starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward-starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. Termination of these transactions resulted in a loss position of $493Â million, which was recorded as other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. With respect to these forward-starting interest rate swaps and treasury lock agreements, losses of $7Â million were recognized under financial expenses, net, for each of the three months ended SeptemberÂ 30, 2024 and 2023, and losses of $21Â million and $25Â million were recognized under financial expenses, net for each of the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. Â Â f. Securitization: U.S. securitization program On NovemberÂ 7, 2022, Teva and a bankruptcy-remote special purpose vehicle (â€œSPVâ€) entered into an accounts receivable securitization facility (â€œAR Facilityâ€) with PNC Bank, National Association (â€œPNCâ€) with a three-year term. The AR Facility provided for purchases of accounts receivable by PNC in an amount of up to $1Â billion through November 2023, and up to $500Â million from November 2023 through November 2025. On JuneÂ 30, 2023, the AR Facility agreement was amended to include an additional receivables purchaser under the agreement, in an amount of up to $250Â million through November 2025. As a result, the total commitment of PNC was reduced to an amount of up to $750Â million, effective JuneÂ 30, 2023. Under the terms of the AR facility agreement, in November 2023, the total commitment of PNC was further reduced to an amount of up to $500Â million through November 2025. On November 7, 2023, the SPV amended the agreement and increased the commitment amount to a maximum of $1Â billion by including an additional receivables purchaser in an amount of up to $250Â million through March 2024, which was then reduced by $125Â million through November 2025. As a result, the commitment amount was reduced to a maximum of $875Â million without any additional purchasers participating in the AR facility. On OctoberÂ 29, 2024, the SPV amended the agreement and increased the commitment amount to a maximum amount of $950Â million by an existing receivables purchaser increasing its commitment by $75Â million. Â 29 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Pledged accounts receivables In connection with the U.S. securitization program, accounts receivables, net of allowance for credit losses, include $934Â million and $437Â million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively, which are pledged by the SPV to PNC. Â Â g. Supplier Finance Program Obligation Teva maintains supply chain finance agreements with participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Teva to these financial institutions. Tevaâ€™s suppliers negotiate their financing agreements directly with the respective financial institutions and Teva is not a party to these agreements. Teva has no economic interest in its suppliersâ€™ decisions to participate in the program and Teva pays the financial institutions the stated amount of confirmed invoices on the maturity dates, which is generally within 120 days from the date the invoice was received. The agreements with the financial institutions do not require Teva to provide assets pledged as security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in the supplier finance program are recorded under accounts payables in Tevaâ€™s consolidated balance sheets. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively, $163Â million and $108Â million of accounts payables to suppliers participatingÂ in these supplier finance programs were outstanding. NOTE 9 â€” Legal settlements and loss contingencies: In the third quarter of 2024, Teva recorded expenses of $450Â million in legal settlements and loss contingencies, compared to expenses of $314Â million in the third quarter of 2023. Expenses in the third quarter of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONEÂ®, and an update to the estimated settlement provision for the opioid cases (mainly related to the settlement agreement with the city of Baltimore and the effect of the passage of time on the net present value of the discounted payments). Expenses in the third quarter of 2023 were mainly related to an update to the provision for the DOJ patient assistance program litigation, as well as an update to the estimated settlement provision of the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). See note 10. In the first nine months of 2024, Teva recorded expenses of $638Â million in legal settlements and loss contingencies, compared to $1,009Â million in the first nine months of 2023. Expenses in the first nine months of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE, and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore). Expenses in the first nine months of 2023 were mainly related to an estimated provision for the DOJ patient assistance program litigation, an update to the estimated settlement provision of the opioid cases, the provision for the settlement of the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, as well as the provision for the settlement of the reverse-payment antitrust litigation over certain HIV medicines. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, Tevaâ€™s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,915Â million and $4,771Â million, respectively. NOTE 10 â€” Commitments and contingencies: General From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. Teva records a provision in its consolidated financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is reasonably estimable. Based upon the status of the cases described below, managementâ€™s assessments of the likelihood of damages, and the advice of legal counsel, no material provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and substantial damages or other relief may be awarded. Accordingly, managementâ€™s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. Â 30 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the consolidated financial statements. In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Tevaâ€™s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third-party sales figures given below are based on IQVIA data. Intellectual Property Litigation From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originatorâ€™s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the â€œpatent danceâ€ procedures of the Biologics Price Competition and Innovation Act (â€œBPCIAâ€), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originatorâ€™s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Tevaâ€™s pharmaceutical products, not just its generic and biosimilar products. The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Tevaâ€™s product. The amount of lost profits would generally be based on the lost sales of the patenteeâ€™s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. In July 2014, GlaxoSmithKline (â€œGSKâ€) filed claims against Teva in the U.S. District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva began selling its carvedilol tablets (the generic version of GSKâ€™s CoregÂ®) in September 2007. A jury returned a verdict in GSKâ€™s favor, which was initially overturned by the U.S. District Court. The Court of Appeals for the Federal Circuit reinstated the $235.5Â million jury verdict, not including pre- or post-judgment interest, finding Teva liable for patent infringement. The U.S. Supreme Court denied Tevaâ€™s appeal for a rehearing. The case has been remanded to the district court for further proceedings on Tevaâ€™s other legal and equitable defenses that have not yet been considered by the district court. Teva recognized a provision based on its offer to settle the matter. Â 31 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â In January 2021, Teva initiated a patent invalidity action against the compound patent and Supplementary Protection Certificate (â€œSPCâ€) asserted to cover Bristol-Myers Squibb Companyâ€™s (â€œBMSâ€) EliquisÂ® (apixaban). In May 2022, the U.K. High Court held that the compound patent and SPC are invalid and Teva began selling its generic version of EliquisÂ® (apixaban). In May 2023, the U.K. Court of Appeal upheld this decision and denied BMSâ€™s request to appeal to the U.K. Supreme Court. On OctoberÂ 31, 2023, the U.K. Supreme Court denied BMSâ€™s application for further review, making the decision to revoke the compound patent and SPC final. Separately, in February 2021, Teva initiated a patent invalidity action against the formulation patents, which are also under opposition at the European Patent Office (â€œEPOâ€). On JulyÂ 15, 2022, the U.K. High Court held that these formulation patents were invalid but granted permission to appeal, which was subsequently stayed pending the outcome of the opposition at the EPO to one of the formulation patents. On DecemberÂ 21, 2023, the EPOâ€™s Technical Board of Appeal held its hearing on the opposition, and on MarchÂ 13, 2024, it issued a written decision revoking the patent. On MayÂ 13, 2024, BMS filed a submission to the Enlarged Board of Appeal seeking its permission to review the Technical Board of Appealâ€™s decision, a hearing for which is scheduled for DecemberÂ 3, 2024. Product Liability Litigation Tevaâ€™s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied, as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in certain or all of its markets. Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan were allegedly found in the active pharmaceutical ingredient (â€œAPIâ€) supplied to Teva by multiple API manufacturers, including by Zhejiang Huahai Pharmaceuticals Co. Ltd. Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. Multiple lawsuits have been filed in connection with this matter. Tevaâ€™s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (â€œMDLâ€) pending against Teva and other manufacturers, including one MDL in the U.S. District Court for the District of New Jersey related to, with respect to Teva, valsartan and losartan, and another MDL in the U.S. District Court for the Southern District of Florida related to ranitidine. The claims against Teva in these MDLs include individual personal injury and/or product liability claims, economic damages claims brought by consumers and end payors as putative class actions, and medical monitoring class claims. The district court in the valsartan MDL certified a series of subclasses on plaintiffsâ€™ economic loss claims as well as a medical monitoring class and originally scheduled the first trial to commence in the fourth quarter of 2024, but that trial has been postponed indefinitely by the court. Discovery is ongoing in the MDL with respect to the

losartan claims against Teva. The claims against Teva and other generic manufacturers in the ranitidine MDL have been dismissed on preemption grounds but are subject to appeal. The district court in the ranitidine MDL also excluded all of plaintiffsâ€™ general causation experts and granted summary judgment to the brand defendants on preemption grounds and later applied that general causation ruling to all defendants. This ruling is on appeal in the Eleventh Circuit Court of Appeals. Certain generic manufacturers, including Teva, have also been named in state court actions asserting allegations similar to those in the aforementioned MDLs. In particular, state court valsartan and losartan actions are pending but currently stayed in New Jersey and Delaware, with the exception of a single-plaintiff case that was later refiled in a New Jersey state court in October 2022 and is in the very initial stages of discovery. State court ranitidine cases naming Teva are also pending in coordinated proceedings in California and Pennsylvania. Teva was dismissed from all ranitidine claims pending in Illinois based on preemption grounds, which plaintiffs have appealed for final judgments as to all remaining defendants. Teva was also dismissed on preliminary objections in Pennsylvania for plaintiffs whose cases are governed by Pennsylvania law, but further motion practice may continue. The litigation in Pennsylvania has effectively been stayed pending a decision on a motion filed by plaintiffs to recuse the presiding judge which was denied but certified for interlocutory appeal. Â 32 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â In addition to the valsartan and ranitidine MDLs and coordinated state court proceedings, Teva has been named in a consolidated proceeding pending in the U.S. District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Tevaâ€™s and other generic manufacturersâ€™ metformin products. The parties are now engaged in discovery related to the surviving metformin claims. Teva was recently named in a related proceeding pending in the same district brought by end payors also seeking economic damages on behalf of a purported class of end payors who purchased Tevaâ€™s and other generic manufacturersâ€™ metformin products. This action was consolidated with the original proceeding for discovery and pretrial purposes only. Teva, along with the other defendants, have moved to dismiss the claims in this newly consolidated proceeding. Similar lawsuits are pending in Canada and Germany. Competition Matters As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Tevaâ€™s patent challenges have resulted in litigation relating to Tevaâ€™s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i)Â Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii)Â significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneysâ€™ fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial, potentially measured in multiples of the annual brand sales, particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Tevaâ€™s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (â€œFTCâ€) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This test has resulted in increased scrutiny of Tevaâ€™s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Tevaâ€™s currently pending antitrust litigations. In December 2011, three groups of plaintiffs filed claims against Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended-release venlafaxine (generic Effexor XRÂ®). The cases were filed by a purported class of direct purchasers, a purported class of indirect purchasers and certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. On SeptemberÂ 18, 2024, the district court lifted its stay of discovery and the case is now proceeding. On OctoberÂ 16, 2024, Teva and one group of plaintiffs (the â€œIndirect Purchaser Plaintiffsâ€ or â€œIPPsâ€) announced that they have reached an agreement in principle to resolve the IPPsâ€™ claims against Teva. The parties are in the process of documenting the proposed settlement, which will be subject to court approval. Annual sales of Effexor XRÂ® were approximately $2.6Â billion at the time of settlement and at the time Teva launched its generic version of Effexor XRÂ® in July 2010. Â 33 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â In February 2012, two purported classes of direct-purchaser plaintiffs filed claims against GSK and Teva in the U.S. District Court for the District of New Jersey for alleged violations of the antitrust laws in connection with their February 2005 settlement of patent litigation involving lamotrigine (generic LamictalÂ®). The plaintiffs claimed that the settlement agreement unlawfully delayed generic entry and sought unspecified damages. During FebruaryÂ 2023, a number of direct purchasers who were denied class certification filed suit as individual plaintiffs, which action was transferred to the U.S. District Court for the District of New Jersey. Discovery of the newly added individual plaintiffs is ongoing. Annual sales of LamictalÂ® were approximately $950Â million at the time of the settlement and approximately $2.3Â billion at the time Teva launched its generic version of LamictalÂ® in July 2008. In April 2013, purported classes of direct purchasers of, and end payers for, NiaspanÂ® (extended release niacin) filed claims against Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005 to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser opt-out plaintiffs filed complaints with allegations nearly identical to those of the direct purchasersâ€™ class. On AprilÂ 24, 2023, the U.S. District Courtâ€™s denial of the indirect purchasersâ€™ motion for class certification was affirmed by the Court of Appeals for the Third Circuit, and on JuneÂ 5, 2023, the Court of Appeals denied the indirect purchasersâ€™ petition for re-hearing. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. The California state court case is temporarily stayed. Annual sales of NiaspanÂ® were approximately $416Â million at the time of the settlement and approximately $1.1Â billion at the time Teva launched its generic version of NiaspanÂ® in September 2013. In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia against Teva and its affiliates alleging that the September 2006 patent litigation settlement relating to AndroGelÂ® 1% (testosterone gel) between Watson, from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (â€œSolvayâ€) violated antitrust laws. In September 2023, the plaintiffs voluntarily dismissed certain claims, and in September 2024, certain defendants, including the remaining Teva affiliates, and the plaintiffs agreed to settle the remaining claims. The litigation has been stayed pending finalization of the settlements. Annual sales of AndroGelÂ® 1% were approximately $350Â million at the time of the earlier Watson/Solvay settlement and approximately $140Â million at the time Actavis launched its generic version of AndroGelÂ® 1% in November 2015. A provision for this matter was previously included in the financial statements. Between SeptemberÂ 1, 2020 and DecemberÂ 20, 2020, plaintiffs purporting to represent putative classes of direct and indirect purchasers and opt-out retailer purchasers of BystolicÂ® (nebivolol hydrochloride) filed complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over BystolicÂ® violated the antitrust laws. The cases were coordinated, and the district court granted the defendantsâ€™ motion to dismiss all claims with prejudice. The plaintiffs appealed the district courtâ€™s grant of defendantsâ€™ motion to dismiss, and on MayÂ 13, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the district courtâ€™s dismissal with prejudice and issued a mandate on JuneÂ 4, 2024, formally ending the appeal. The plaintiffsâ€™ period to file a petition for a writ of certiorari to the U.S. Supreme Court expired. Annual sales of BystolicÂ® in the United States were approximately $700Â million at the time of Watsonâ€™s 2013 settlement with Forest. In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5Â million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021, and a judgment was issued on OctoberÂ 18, 2023 rejecting Tevaâ€™s grounds of appeal. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. On JanuaryÂ 4, 2024, Teva appealed the October 2023 judgment to the European Court of Justice. In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV (the â€œNew Mexico litigationâ€). Between September 2021 and April 2022, several private plaintiffs including retailers and health insurance providers filed similar claims in various courts, which were all removed and/or consolidated into the U.S. District Court for the Northern District of California (the â€œCalifornia litigationâ€). As they relate to Teva, the lawsuits challenged settlement agreements Teva entered into with Gilead in 2013 and/or 2014 to resolve patent litigation relating to Tevaâ€™s generic versions of VireadÂ® and/or TruvadaÂ® and AtriplaÂ®, although plaintiffs in the California litigation abandoned any claim for damages relating to the VireadÂ® settlement. In May Â 34 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â 2023, Teva and Gilead reached a settlement agreement with the retailer plaintiffs in the California litigation and Teva recognized a provision for this matter based on such settlement. On JuneÂ 30, 2023, the jury in the trial against the remaining plaintiffs in the California litigation issued a verdict in favor of Teva and Gilead, rejecting all of the remaining plaintiffsâ€™ claims. On FebruaryÂ 12, 2024, the court entered a judgment as to all claims against Teva in the California litigation and the plaintiffs have filed notices of appeal with the U.S. Court of Appeals for the Ninth Circuit, and the appeal is currently being briefed. In the New Mexico litigation, on JuneÂ 27, 2024, Teva and the State of New Mexico finalized their settlement agreement, and the New Mexico court entered a consent judgment resolving the New Mexico litigation. Teva recognized a provision for the settlement with New Mexico. Annual sales in the United States at the time of the settlement of VireadÂ®, TruvadaÂ® and AtriplaÂ® were approximately $582Â million, $2.4Â billion, and $2.9Â billion, respectively. Annual sales in the United States at the time Teva launched its generic version of VireadÂ® in 2017, TruvadaÂ® in 2020 and AtriplaÂ® in 2020 were approximately $728Â million, $2.1Â billion and $444Â million, respectively. In March 2021, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. On OctoberÂ 10, 2022, the European Commission issued a Statement of Objections, which sets forth its preliminary allegations that Teva had engaged in anti-competitive practices. On October 31, 2024, the European Commission announced its final decision, alleging that Teva had abused a dominant position in certain European member states by (i) filing and withdrawing certain divisional patents, and (ii) raising concerns about competitorsâ€™ follow-on versions of COPAXONE. The decision, which Teva intends to appeal, also includes a fine of approximately $500 million (462.6 million euros). In accordance with Accounting Standards Codification 450 â€œAccounting for Contingencies,â€ Teva recognized a provision in its financial statements in the third quarter of 2024, based on managementâ€™s current best estimate of the outcome within a range of outcomes for the final resolution of this case. Teva intends to provide the European Commission a bank guarantee to cover at least a portion of the fine. On JuneÂ 29, 2021, Mylan Pharmaceuticals (â€œMylanâ€) filed claims against Teva in the U.S. District Court for the District of NewÂ Jersey. On MarchÂ 11, 2022 and MarchÂ 15, 2022, purported purchasers of COPAXONE filed claims against Teva in the U.S. District Court for the District of New Jersey on behalf of themselves and similarly situated direct and indirect purchasers of COPAXONE. On AugustÂ 22, 2022, additional purported purchasers of COPAXONE sued Teva in the U.S. District Court for the District of Vermont on behalf of themselves and similarly situated indirect purchasers of COPAXONE. The complaints variously assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the Racketeer Influenced and Corrupt Organizations Act (â€œRICO Actâ€). Additionally, plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneysâ€™ fees and costs, and injunctive relief. Teva moved to dismiss all of the complaints, and on JanuaryÂ 22, 2024, Tevaâ€™s motion to dismiss the complaint in the District of Vermont was granted as to certain state law claims but was otherwise denied. Decisions on Tevaâ€™s remaining motions to dismiss are pending. On JulyÂ 15, 2021, the U.K. Competition and Markets Authority (â€œCMAâ€) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK, Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMAâ€™s three prior investigations into the supply of hydrocortisone tablets in the U.K., as well as the CMAâ€™s subsequent investigation relating to an alleged anticompetitive agreement with Waymade. On JanuaryÂ 9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva agreed to indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to two of the three statements of objection from the CMA (dated DecemberÂ 16, 2016 and MarchÂ 3, 2017), and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On OctoberÂ 6, 2021, Accord UK (previously Actavis UK) and Auden Mckenzie appealed to the U.K. Competition Appeal Tribunal (the â€œTribunalâ€) the CMAâ€™s decisions that the prices of hydrocortisone were unfair and excessive and that the agreements amounted to infringements of the U.K.â€™s Competition Act as so-called pay-for-delay arrangements. The hearing for the appeal concluded in the first quarter of 2023, with partial judgments handed down by the Tribunal on SeptemberÂ 18, 2023 (judgment on unfair pricing), MarchÂ 8, 2024 (judgments on pay-for-delay and due process) and AprilÂ 29, 2024 (judgment on fines). The CMA appealed to the U.K. Court of Appeals on an expedited basis against certain elements of the pay-for-delay and due process judgments that it had lost, and on SeptemberÂ 6, 2024, the U.K. Court of Appeal overturned the Tribunalâ€™s judgment on due process and, as a result, the Tribunal will now consider and issue a further judgment on fines. Accord UK and Auden Mckenzie have requested permission to appeal to the U.K. Supreme Court and have submitted to the Tribunal additional applications for permission to appeal certain other issues relating to unfair pricing and fines. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. Â 35 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â In November 2022, two complaints filed by plaintiffs purporting to represent retailer purchasers and a putative class of end-payor purchasers were filed in the U.S. District Court for the District of New Jersey against Teva and its marketing partner, Natco Pharma Limited (â€œNatcoâ€), alleging violations of the antitrust laws in connection with their December 2015 settlement of patent litigation with Celgene Corporation (which was subsequently acquired by BMS) involving the drug RevlimidÂ® (lenalidomide). The complaints also name Celgene and BMS as defendants. On JanuaryÂ 24, 2023, the complaints were consolidated for pre-trial purposes only with an earlier-filed, already consolidated Insurer Opt-Out Action filed against BMS and Celgene. On FebruaryÂ 16, 2023, plaintiffs filed amended complaints adding additional plaintiffs. On MayÂ 16, 2023, Teva and Natco, along with Celgene, moved to dismiss the complaints against them. Additionally, on OctoberÂ 6, 2023, two individual payor plaintiffs brought claims similar to those described above in the U.S. District Court for the Northern District of California, which actions were transferred to the U.S. District Court for the District of New Jersey and consolidated with the pending consolidated actions. On JuneÂ 6, 2024, the court granted in full Celgeneâ€™s motion to dismiss the Insurer Opt-Out Action, but allowed plaintiffs leave to amend most of their claims. The Court had previously administratively terminated Tevaâ€™s, Natcoâ€™s, and Celgeneâ€™s motions to dismiss the retailer and end-payor complaints pending the decision on the Insurer Opt-Out Action. The plaintiffs filed amended complaints on AugustÂ 5, 2024, and the defendantsâ€™ filed motions to dismiss on OctoberÂ 7, 2024. Annual sales of RevlimidÂ® in the United States were approximately $3.5Â billion at the time of the settlement. On DecemberÂ 2, 2022, plaintiffs purporting to represent putative classes of indirect purchasers of EpiPenÂ® (epinephrine injection) and NUVIGILÂ® (armodafinil) filed a complaint in the U.S. District Court for the District of Kansas against Teva, Cephalon, and a former Teva executive. Teva owns the New Drug Application (â€œNDAâ€) for NUVIGIL and sold the brand product, for which generic entry occurred in 2016. Teva filed an ANDA to sell generic EpiPenÂ®, which Teva launched in 2018, following receipt of FDA approval. The complaint alleges, among other things, that the defendants violated federal antitrust laws, the RICO Act, and various state laws in connection with settlements resolving patent litigation relating to those products. Plaintiffs seek injunctive relief, compensatory and punitive damages, interest, attorneysâ€™ fees and costs. On SeptemberÂ 26, 2023, plaintiffs filed a brief in opposition to Tevaâ€™s motion to dismiss the amended complaint, in which plaintiffs limited their claims only to those relating to the alleged delay of generic NUVIGIL. On MarchÂ 26, 2024, the court issued its decision, which granted Tevaâ€™s motion in part, dismissing plaintiffsâ€™ RICO claims and certain state law claims, but denied Tevaâ€™s motion regarding plaintiffsâ€™ antitrust claims. On AprilÂ 26, 2024,

Teva sought certification to seek an interlocutory appeal of the decision, which is still pending. Annual sales of NUVIGIL in the United States were approximately $300Â million at the time Teva entered into the first settlement with an ANDA filer in 2012. In May 2023, certain end-payor plaintiffs filed putative class action complaints in the U.S. District Court for the District of Massachusetts against Teva and a number of its affiliates, alleging that Teva engaged in anticompetitive conduct to suppress generic competition to its branded QVARÂ® asthma inhalers in violation of state and federal antitrust laws and state consumer protection laws. Teva moved to dismiss these claims, and on MayÂ 7, 2024, the court granted Tevaâ€™s motion in part and denied its motion in part. The court dismissed plaintiffsâ€™ claim that Teva had engaged in â€œsham litigationâ€ and certain of plaintiffsâ€™ state antitrust and consumer protection claims, but permitted the case to proceed on the remainder of plaintiffsâ€™ allegations. Following this decision, two direct purchaser plaintiffs filed similar putative class action complaints in the U.S. District Court for the District of Massachusetts. On JuneÂ 18, 2024, Teva answered in all cases and simultaneously moved for judgment on the pleadings pursuant to Rule 12(c), which remains pending. Subsequently, on JuneÂ 28, 2024, Teva stipulated to the dismissal of the two direct purchaser plaintiffsâ€™ claims, with prejudice. Government Investigations and Litigation Relating to Pricing and Marketing Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (â€œDOJâ€) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On AugustÂ 25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three-count indictment charging Teva USA with criminal felony Sherman Act violations. The indictment alleged that Teva USA had participated in three separate conspiracies with other Â 36 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: pravastatin, carbamazepine, clotrimazole, etodolac (IR and ER), fluocinonide (cream, e-cream, gel, and ointment), warfarin, nadolol, temozolomide, and tobramycin. On AugustÂ 21, 2023, Teva USA entered into a 3-year deferred prosecution agreement (â€œDPAâ€) with the DOJ. Under the terms of the DPA, Teva USA: (i)Â admitted to violating the antitrust laws by agreeing with competitors, in three instances between 2013 and 2015 involving three separate customers, not to bid on an opportunity to supply a customer with a particular generic product (in the first instance pravastatin, in the second clotrimazole, and in the third tobramycin); (ii) agreed to divest the pravastatin that it sells in the United States to a third-party buyer; (iii)Â agreed to donate $50Â million worth of clotrimazole and tobramycin, valued at wholesale acquisition cost (â€œWACâ€), to humanitarian organizations over five years; and (iv)Â agreed to pay a fine in the amount of $225Â million over 5 years, with $22.5Â million due each year from 2024 through 2027, and $135Â million due in 2028. Teva recognized a provision for the resolution of this case.â€ƒIn May 2018, Teva received a civil investigative demand from the DOJ Civil Division pursuant to the federal False Claims Act, seeking documents and information produced since JanuaryÂ 1, 2009 relevant to the Civil Divisionâ€™s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and/or price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. On OctoberÂ 10, 2024, Teva entered into a settlement agreement with the Civil Division to resolve these allegations. Teva will pay $25Â million under the terms of the settlement â€“ $10Â million in the fourth quarter of 2024, and $15Â million in 2025 â€“ which includes no admission of wrongdoing. Teva has recognized a provision for the resolution of this matter. In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. On DecemberÂ 15, 2016, the civil action that was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States was subsequently amended to include 49 states, as well as the District of Columbia and Puerto Rico as plaintiffs, and to add new allegations and state law claims against both Actavis and Teva. On MayÂ 10, 2019, most of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, which was subsequently amended on NovemberÂ 1, 2019, alleging that Teva was at the center of a conspiracy in the generic pharmaceutical industry and asserting that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain products. On JuneÂ 10, 2020, most of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the U.S. District Court for the District of Connecticut naming, among other defendants, Actavis, in a similar complaint relating to dermatological generics products, and that complaint was later amended to, among other things, add California as a plaintiff. In the various complaints described above, which also include claims against certain former employees of Actavis and Teva USA, the states seek a finding that the defendantsâ€™ actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints were transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (â€œPennsylvania MDLâ€). On MayÂ 7, 2021, the Pennsylvania MDL court chose the attorneys generalâ€™s third complaint filed on JuneÂ 10, 2020, as subsequently amended, to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. On JuneÂ 7, 2022, the Court dismissed the attorneys generalâ€™s claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law. On FebruaryÂ 27, 2023, the Court largely denied defendantsâ€™ motions to dismiss the federal claims asserted by the attorneys general in their bellwether complaint. Another motion to dismiss related to the state law claims asserted by the attorneys general in their bellwether complaint remains pending. Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022), Florida (in February 2023), Kentucky (in June 2023), South Dakota (in June 2024), and New Mexico (in June 2024). Teva paid each state an amount proportional to its share of the national population (approximately $1,000,000 for each 1% share of the national population), and the states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. These settlements, in addition to the status of ongoing negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining Â 37 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022. The States of Alabama (in March 2022) and Hawaii (in August 2023) and the territories of American Samoa (in July 2020) and Guam (in February 2023) have all voluntarily dismissed all of their claims in the litigation against Actavis and Teva USA. The dismissals by Alabama, Hawaii and Guam were with prejudice and the dismissal by American Samoa was without prejudice. Beginning on MarchÂ 2, 2016, and through July 2023, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser opt-out plaintiffs, including most recently an opt-out complaint filed by nine direct-action plaintiffs on AprilÂ 4, 2024. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. The Pennsylvania MDL court scheduled potential bellwether trials for the putative classes of direct and indirect purchasers of two drugs for August 2024. From 2019 to 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis. One plaintiff, Aetna Inc., has filed a complaint, and the defendants have moved to place all of the cases filed in the Court of Common Pleas of Philadelphia County in deferred status, which motion remains pending. Certain counties in NewÂ York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. On JanuaryÂ 31, 2024, the attorney generalsâ€™ motion to remand their three lawsuits to the District of Connecticut, where they were originally filed, was granted, and on MarchÂ 18, 2024, the Third Circuit Court of Appeals denied defendantsâ€™ petition for writ of mandamus. In April 2024, all three of the attorneys generalâ€™s lawsuits have been transferred back to the U.S. District Court for the District of Connecticut, which has adopted a schedule for summary judgment in the attorneys generalâ€™s third complaint pursuant to which multiple groups of motions will be filed during 2024 and 2025. Fact discovery in the first and second complaints is ongoing. There is also one similar complaint brought in Canada, which is in its early stages and alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. In March 2017, Teva received a subpoena from the U.S. Attorneyâ€™s office in Boston, Massachusetts requesting documents related to Tevaâ€™s donations to patient assistance programs. In August 2020, the U.S. Attorneyâ€™s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging causes of action under the federal False Claims Act and for unjust enrichment (the â€œDOJ PAP Complaintâ€). It was alleged that Tevaâ€™s donations to certain 501(c)(3) charities that provided financial assistance to multiple sclerosis patients violated the Anti-Kickback Statute, and the DOJ sought a maximum of over $1Â billion in damages, which would automatically be trebled in the event of an adverse verdict, and Teva would also be subject to mandatory statutory penalties for each false claim, the amount of which (potentially billions of U.S. dollars in additional penalties, at the high end) would be determined by the court within a statutory range. On OctoberÂ 10, 2024, Teva entered into a settlement agreement with the DOJ to resolve these claims. Teva will pay $425Â million over 6 years under the terms of the settlement â€“ $19Â million in the fourth quarter of 2024, $34Â million in 2025, $49Â million in each of 2026 and 2027, $99Â million in 2028, and $175Â million in 2029 â€“ which includes no admission of wrongdoing. Teva has recognized a provision for the resolution of this case. Additionally, on JanuaryÂ 8, 2021, Humana, Inc. (â€œHumanaâ€) filed an action against Teva in the U.S. District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. In June 2023, Teva filed a joint motion to dismiss the amended complaint, together with co-defendant Advanced Care Scripts, Inc., on the grounds that Humana lacks standing to assert RICO claims and the claims are time-barred and/or insufficiently pled, and that motion remains pending. On NovemberÂ 17, 2022, United Healthcare also filed an action against Teva in the U.S. District Court for the District of New Jersey based on the conduct alleged in the DOJ PAP Complaint, and on FebruaryÂ 29, 2024, United Healthcare filed an amended complaint. On AugustÂ 16, 2024, several MSP Recovery-related entities filed a putative class action against Teva and others in the U.S. District Court for the District of Kansas based on the alleged conduct in the DOJ PAP Complaint. Â 38 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â In April 2021, a city and county in Washington filed claims against Teva in the U.S. District Court for the Western District of Washington for alleged violations of the RICO Act, Washingtonâ€™s Consumer Protection Act, and unjust enrichment concerning Tevaâ€™s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On NovemberÂ 17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffsâ€™ claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. On MarchÂ 9, 2023, the court held a hearing on the motion to dismiss, and a decision remains pending. On DecemberÂ 1, 2022, Teva received a civil subpoena from the U.S. Attorneyâ€™s office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDOÂ® and risperidone LAI. Teva is cooperating with the request for documents. In June 2024, Teva received a civil investigative demand from the Federal Trade Commission (â€œFTCâ€) seeking documents and information regarding an investigation related to patents listed in the Food and Drug Administrationâ€™s Approved Drug Products with Therapeutic Equivalence Evaluations publication (â€œOrange Bookâ€) in connection with certain inhaler products. Teva is cooperating with the request for documents and information. On OctoberÂ 1, 2024, Teva received a civil investigative demand from the U.S. Attorneyâ€™s office in Boston, Massachusetts and the Civil Division of the Department of Justice requesting certain documents and information related to the manufacturing practices at its former manufacturing facility in Irvine, California, which Teva closed in 2022. Teva is cooperating with the request for documents and information. Opioids Litigation Since May 2014, more than 3,500 complaints have been filed by various governmental agencies and private plaintiffs in U.S. state and federal courts with respect to opioid sales and distribution against various Teva affiliates and several other pharmaceutical companies, the vast majority of which have been resolved. Cases brought by third party payers, both as individual cases and as class actions, remain. The majority of the remaining cases are consolidated in the multidistrict litigation in the Northern District of Ohio (the â€œMDL Opioid Proceedingâ€). These cases assert claims under similar provisions of different state laws and generally allege that the defendants engaged in improper marketing and distribution of Tevaâ€™s branded opioids, including ACTIQÂ® and FENTORAÂ®, and also assert claims related to Tevaâ€™s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.Â Furthermore, approximately 100 personal injury complaints allege that Anda (in addition to naming other distributors and manufacturers) failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent their abuse and diversion. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,Â non-economic damages, attorneysâ€™ fees and injunctive relief. Certain plaintiffs seek damages for all costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. All but a handful of these cases are stayed in the MDL Opioid Proceedings. In June 2023, Teva finalized and fully resolved its nationwide settlement agreement with the states and litigating subdivisions. Under the financial terms of the nationwide settlement agreement with the states and subdivisions, Teva will pay up to $4.25Â billion (including the already settled cases), spread over 13 years. This total includes the supply of up to $1.2Â billion of Tevaâ€™s generic version of NarcanÂ® (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 10 years or cash at 20% of the wholesale acquisition cost ($240 million) in lieu of product. In September 2024, Teva reached and finalized an agreement with the City of Baltimore to settle its opioid-related claims for a total of $80Â million (of which $35Â million will be paid by the end of 2024 and the remainder will be paid by JulyÂ 1, 2025), averting a trial that was scheduled to begin on SeptemberÂ 16, 2024. Â 39 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â With its settlement with the City of Baltimore, Teva has settled with 100% of the U.S. states and litigating political subdivisions and the Native American tribes (the â€œTribesâ€). Tevaâ€™s estimated cash payments between 2024 and 2028 for all opioids settlements are: $428Â million payable in 2024 (of which $392Â million was paid as of SeptemberÂ 30, 2024), $423Â million payable in 2025; $368Â million payable in 2026; $374Â million payable in 2027; and $390Â million payable in 2028. These payments are subject to change based on various factors including, but not limited to, timing of payments, most favored nations clauses associated with prior settlements, and the statesâ€™ elections to take Tevaâ€™s generic version of NarcanÂ® (naloxone hydrochloride nasal spray). The remaining payments, subject to adjustments, will be paid beyond 2028. Various Teva affiliates, along with several other pharmaceutical companies, were named as defendants in opioids cases initiated by approximately 500 U.S. hospitals and other healthcare providers asserting opioid-related claims, including public nuisance. Specifically, the lawsuits brought by the hospitals allege that they have incurred financial harm from increased operating costs for treating patients whose underlying illnesses are purportedly exacerbated or complicated by opioid addiction. In September 2024, Teva and the representatives for acute care hospitals finalized the terms of a proposed settlement agreement. Under the financial terms of the proposed national settlement agreement, Teva will pay up to $126Â million in cash, spread over 18 years, and supply up to $49Â million of Tevaâ€™s generic version of NarcanÂ® (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 7 years. The proposed settlement agreement is contingent upon Tevaâ€™s satisfaction, in its sole discretion, with the level of participation by acute care hospitals and health care systems in the proposed settlement agreement. In light of the nationwide settlement agreement between Teva and the Statesâ€™ Attorneys General and their subdivisions, Tevaâ€™s indemnification obligations arising from Tevaâ€™s acquisition of the Actavis Generics business for opioid-related claims, prior settlements reached with Louisiana, Texas, Rhode Island, Florida, San Francisco, West Virginia, New York, the Tribes, Nevada and the City of Baltimore, the agreement in principle with the hospitals discussed above, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has recorded a provision. The provision is a reasonable estimate of the ultimate costs for Tevaâ€™s opioids settlements, after discounting payments to their net present value. Opioid-related lawsuits brought against Teva by dozens of third-party payers, such as unions and welfare funds, remain pending. A reasonable upper end of a range of loss cannot be determined for the entirety of the remaining opioid-related cases. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and

adverse effect on Tevaâ€™s reputation, business, results of operations and cash flows. In addition, Teva, certain of its subsidiaries and other defendants, are defending claims and putative class action lawsuits in Canada related to the manufacture, sale, marketing and distribution of opioid medications. The lawsuits include a claim by the Province of British Columbia on behalf of itself and a putative class of other federal and provincial governments, and claims of municipalities, First Nations, and persons who used opioids on behalf of themselves and putative classes. In November and December 2023, the British Columbia Supreme Court held a hearing regarding preliminary motions, including plaintiffsâ€™ certification motion, which remain pending. Shareholder Litigation On NovemberÂ 6, 2016 and DecemberÂ 27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits subsequently were consolidated and transferred to the U.S. District Court for the District of Connecticut (the â€œOntario Teachers Securities Litigationâ€). On DecemberÂ 13, 2019, the lead plaintiff filed an amended complaint, purportedly on behalf of purchasers of Tevaâ€™s securities between FebruaryÂ 6, 2014 and MayÂ 10, 2019, asserting that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Tevaâ€™s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. From July 2017Â to June 2019, other putative securities class actions were filed in other federal courts based on similar allegations and claims, and were transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors on behalf of plaintiffs in various forums across the country, but many of those plaintiffs â€œopted-outâ€ of the Ontario Teachers Securities Litigation. On JanuaryÂ 18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $420Â million, which received final approval from the court on JuneÂ 2, 2022. The vast majority of the total settlement amount was covered by the Companyâ€™s insurance carriers, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. On JanuaryÂ 22, 2021, the Court dismissed the â€œopt-outâ€ plaintiffsâ€™ claims arising from statements made prior to the five-year statute of repose, but denied Tevaâ€™s motion to dismiss their claims under Israeli laws. Teva has settled the majority of the â€œopt-outâ€ claims, and one opt-out case remains outstanding. Teva also reached a settlement with shareholders who filed class actions in Israel with similar allegations to those raised in the Ontario Teachers Securities Litigation, which was approved by the court in Israel in November 2023. Â 40 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â On SeptemberÂ 23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On AugustÂ 10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between OctoberÂ 29, 2015 and AugustÂ 18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Tevaâ€™s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONEâ€™s commercial success and the sustainability of its revenues and resulted in the DOJ PAP Complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On AugustÂ 2, 2022, the court stayed all proceedings other than class certification proceedings pending the resolution of the DOJ PAP Complaint. On NovemberÂ 3, 2023, the court granted plaintiffâ€™s motion for class certification. On NovemberÂ 17, 2023, Teva filed a petition with the Third Circuit Court of Appeals for leave to appeal the class certification ruling, which was denied on MayÂ 16, 2024. On AugustÂ 30, 2024, the court lifted the stay. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. Environmental Matters Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Tevaâ€™s facilities or former facilities. Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of clean-up and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Tevaâ€™s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, clean-up and natural resource damages have not yet been determined, and for others Tevaâ€™s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of clean-up costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Tevaâ€™s facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Tevaâ€™s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. ItemÂ 103 of Regulation S-K promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less than $300,000. The following matter is disclosed in accordance with that requirement. On JulyÂ 8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Tevaâ€™s subsidiary in India, Teva API India Private Limited, finding non-compliance with environmental laws and assessed a penalty of $1.4Â million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On AugustÂ 5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunalâ€™s order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business. Â 41 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Other Matters On FebruaryÂ 1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalonâ€™s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.Â Among other things, the plaintiffs alleged that Cephalon had breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIRÂ® (reslizumab) for the treatment of eosinophilic esophagitis (â€œEEâ€). The plaintiffs claimed damages of at least $200Â million, an amount they alleged was equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). On DecemberÂ 28, 2018, following defendantsâ€™ motion to dismiss the complaint, the court granted the motion in part and dismissed all of plaintiffsâ€™ claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA. However, on JulyÂ 12, 2022, plaintiffs filed a new amended complaint that included claims against Teva USA but not the Company, in exchange for Teva USAâ€™s agreement to guarantee any judgment entered against Cephalon in the litigation. A bench trial for this matter was held in September 2022 and on AprilÂ 30, 2024, the court issued a memorandum opinion in favor of Cephalon and Teva USA, finding that they did not breach the merger agreement as plaintiffs had alleged. Plaintiffs have appealed that ruling to the Delaware Supreme Court, and the appeal remains pending. Gain Contingencies From time to time, Teva may directly or indirectly pursue claims against certain parties, including but not limited to patent infringement lawsuits against other pharmaceutical companies to protect its patent rights, as well as derivative actions brought on behalf of Teva. Teva recognizes gain contingencies from the defendants in such lawsuits when they are realized or when all related contingencies have been resolved. No gain has been recognized regarding the matters disclosed below, unless mentioned otherwise. In October 2017, Teva filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli LillyÂ & Co.â€™s (â€œLillyâ€) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review (â€œIPRâ€) petitions to the Patent Trial and Appeal Board (â€œPTABâ€), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on AugustÂ 16, 2021. A jury trial regarding the three method of treatment patents resulted in a verdict in Tevaâ€™s favor on NovemberÂ 9, 2022, in which the three method of treatment patents were determined to be valid and infringed by Lilly and Teva was awarded $176.5Â million in damages. On SeptemberÂ 26, 2023, the U.S. District Court for the District of Massachusetts issued a decision that reversed the juryâ€™s verdict and damages award, finding Tevaâ€™s method of treatment patents to be invalid. Teva filed its opening appeal brief on FebruaryÂ 2, 2024 and Lilly filed its responsive brief on AprilÂ 19, 2024. Teva filed its responsive brief on MayÂ 29, 2024, and Lillyâ€™s final brief was filed on JulyÂ 19, 2024. No date has been set for the appeal hearing. In March 2024, Teva filed a lawsuit in the U.S. District Court for the District of New Jersey alleging that Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited, and Amarin Corporation plc (collectively â€œAmarinâ€) engaged in a decade-long scheme to lock up the supply of icosapent ethyl to prevent and delay generic competition to its branded VascepaÂ® drug product.Â Tevaâ€™s lawsuit coincides with four other lawsuits brought by generic drug manufacturers and purchasers ofÂ branded VascepaÂ®Â alleging the same or similar conduct by Amarin.Â Tevaâ€™s requested relief includes compensatory damages for lost sales and lost profits from generic icosapent ethyl drug sales that Teva could have made absent Amarinâ€™s alleged interference. On MayÂ 24, 2024, Amarin filed a motion in the U.S. District Court for the District of Nevada, seeking to enforce the terms of an earlier Teva-Amarin agreement to settle patent litigation regarding VascepaÂ®, which Amarin asserts precludes Teva from filing the present antitrust action. Teva opposed this motion on JuneÂ 7, 2024, and Amarinâ€™s motion remains pending. As the lawsuit is still in its initial stages, it is not possible to predict its outcome and there is no guarantee that Teva will be granted its requested relief. In June 2024, Teva filed a lawsuit in the U.S. District Court for the Northern District of California alleging that Corcept Therapeutics, Inc. (â€œCorceptâ€), and Optime Care Inc. (â€œOptimeâ€) have engaged in a multifaceted, years-long scheme to stifle generic competition to Corceptâ€™s branded KorlymÂ® (mifepristone) drug product, which is indicated to treat endogenous Cushingâ€™s syndrome. Teva alleges that Corcept and Optime have suppressed competition by abusing the Â 42 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â patent and judicial systems, entering a long-term, blanket exclusive-dealing agreement that has locked up a key pharmaceutical distribution channel, and making illicit payments to physicians as compensation for prescribing KorlymÂ®. Tevaâ€™s requested relief includes compensatory damages for lost sales and lost profits from generic mifepristone drug sales that Teva could have made absent Corcept and Optimeâ€™s alleged interference, as well as injunctive relief to remove the unlawful barriers to generic competition created by Corcept and Optime. As the lawsuit is still in its initial stages, it is not possible to predict its outcome and there is no guarantee that Teva will be granted its requested relief. Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness, as well as motions for document disclosure prior to initiating derivative actions. Motions were filed with respect to several U.S. and EU settlement agreements, opioids, allegations related to the DOJâ€™s complaint regarding the COPAXONE patient assistance program in the U.S., and with respect to the European Commissionâ€™s investigation relating to COPAXONE. In May 2024, Teva settled the derivative action related to the opioids litigation, and on SeptemberÂ 16, 2024, the settlement received final approval from the Tel Aviv District Court. Â 43 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 11 â€“ Income taxes: In the third quarter of 2024, Teva recognized a tax expense of $69Â million, on a pre-tax lossÂ of $324Â million. In the third quarter of 2023, Teva recognized a tax benefit of $12Â million, on a pre-taxÂ incomeÂ of $64Â million. Tevaâ€™s tax rate for the third quarter of 2024 was mainly impacted by impairment charges with no corresponding tax effects, an adjustment to the Companyâ€™s corporate tax rate in Israel on losses related to non-qualified tax incentive activities in Israel, legal expenses with no corresponding tax effect related to the fine issued by the European Commission in connection with its antitrust investigation into COPAXONE, and recording of valuation allowance with respect to certain carry over credits outside of Israel. Tevaâ€™s tax rate for the third quarter for 2023 was mainly affected by deferred tax benefits resulting from intellectual property related integration plans, which have been adopted, among others, in an effort of addressing the global adoption of the Organization for Economic Co-operation and Development (OECD) Pillar Two minimum effective corporate tax. The pre-tax loss in the third quarter of 2023 was revised as discussed in note 1c. In the first nine months of 2024, Teva recognized a tax expense of $648Â million, on a pre-tax loss of $1,037Â million. In the first nine months of 2023, Teva recognized a tax benefit of $48Â million, on a pre-tax loss of $1,131Â million. Tevaâ€™s tax rate for the first nine months of 2024 was mainly impacted by a settlement agreement with the Israeli Tax Authorities (â€œITAâ€) as discussed below, impairment charges with no corresponding tax effects, deferred tax benefits resulting from intellectual property related integration plans, an adjustment to the Companyâ€™s corporate tax rate in Israel on losses related to non-qualified tax incentives activities in Israel, legal expenses with no corresponding tax effect related to the fine issued by the European Commission in connection with its antitrust investigation into COPAXONE, and recording of valuation allowance with respect to certain carry over credits outside of Israel. Tevaâ€™s tax rate for the first nine months of 2023 was mainly affected by deferred tax benefits from intellectual property related integration plans, impairments, legal settlements, and interest expense disallowances. The pre-tax loss in the first nine months of 2023 was revised as discussed in note 1c. The statutory Israeli corporate tax rate is 23% in 2024. Tevaâ€™s global tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits, as well as infrequent or non-recurring items. Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. A trial for this case is currently ongoing. A final and binding decision against Teva in this case may lead to a charge of $125Â million. On JuneÂ 23, 2024, Teva entered into an agreement with the ITA to settle certain litigation with respect to taxes payable for the Companyâ€™s taxable years 2008 through 2020 (the â€œAgreementâ€). Pursuant to the terms of the Agreement, the Company will pay a total amount of approximately $750Â million to the ITA spread over a six-year period beginning this year. The Company has the right to prepay, and amounts paid over time are subject to interest and increase for inflation. Such total amount includes: (i) $495Â million in corporate taxes with respect to the Companyâ€™s historical earnings that were previously considered by the Company to be exempt from taxes under the Encouragement for Capital Investment Law; and (ii)Â approximately $250Â million in corporate taxes, relating to additional disputed tax issues in the aforementioned taxable years. The Agreement resulted in an increase of $506Â million in the Companyâ€™s total income taxes in the second quarter of 2024, as certain elements had been recognized in previous periods. Additionally, under the terms of the Agreement, it was further agreed that in the future event the Company pays dividends on, or repurchases, its equity interests, the Company will pay an additional 5%-7% of the amount of such dividends or repurchases in corporate taxes, up to a maximum tax payment amount of approximately $500Â million. Any amounts due under this provision of the Agreement will be recorded in the future as incurred. Teva believes it has adequately provided for all of its uncertain tax positions, including items currently under dispute, however, adverse results could be material. The OECD introduced Base Erosion and Profit Shifting (â€œBEPSâ€) Pillar Two rules that impose a global minimum tax rate of 15% for large multinational corporations. On DecemberÂ 12, 2022, the EU Council announced that EU member states had reached an agreement to implement the minimum taxation component of 15% of the OECDâ€™s reform of international taxation. Other countries have also enacted or are expected to enact legislation to be effective as early as JanuaryÂ 1, 2024, with general implementation of a global minimum tax by JanuaryÂ 1, 2025. Teva has evaluated the potential impact on its 2024 consolidated financial statements and related disclosures and does not expect Pillar Two to have a material impact on its effective tax rate or consolidated financial statements in the foreseeable future. Â 44 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 12 â€“ Other assets impairments, restructuring and other items: Â Â Â Â ThreeÂ monthsÂ ended Â Â Â NineÂ monthsÂ ended Â Â Â Â SeptemberÂ 30, Â Â Â SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Â Â (U.S.Â $Â inÂ millions) Â Impairments of long-lived tangible assets (1) Â Â $ (80)Â Â Â $ 1 Â Â Â $ 589 Â Â Â $ 21 Â Contingent consideration (2) Â Â Â 34 Â Â Â Â 27 Â Â Â Â 305 Â Â Â Â 140 Â Restructuring Â Â Â 21 Â Â Â Â 27 Â Â Â Â 52 Â Â Â Â 93 Â Other Â Â Â 1 Â Â Â Â 2 Â Â Â Â (16)Â Â Â Â 21 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ (23)Â Â Â $ 57 Â Â Â $ 931 Â Â Â $ 276 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) Including impairments related to exit and disposal activities. (2) The contingent consideration presented in the tables above for the three and nine months ended SeptemberÂ 30, 2023

have been revised as discussed in note 1c. Impairments In the three months ended September 30, 2024, Teva recorded an income ofÂ $80Â million under impairments of tangible assets, compared to an expense of $1Â million in the three months ended September 30, 2023. The income for the three months ended SeptemberÂ 30, 2024 was mainly related to a favorable adjustment to the changes of the expected loss from reclassification of currency translation adjustments, partially offset by an additional impairment due to fair value update in connection with the classification of the business venture in Japan as held for sale. See note 2. Impairments of tangible assets for the nine months ended SeptemberÂ 30, 2024 and 2023 were $589Â million and $21Â million, respectively. The impairment for the nine months ended SeptemberÂ 30, 2024 was mainly related to the classification of the business venture in Japan as held for sale (see note 2). The impairments for the nine months ended SeptemberÂ 30, 2023 were mainly related to certain assets in the U.S. and Europe. Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its ongoing network consolidation activities and its â€œPivot to Growth Strategyâ€. Contingent consideration In the three months ended SeptemberÂ 30, 2024, Teva recorded an expense of $34Â million for contingent consideration, compared to an expense of $27Â million in the three months ended SeptemberÂ 30, 2023. The expenses in the three months ended SeptemberÂ 30, 2024 were mainly due to the effect of the passage of time on the net present value of the discounted payments. The expenses in the three months ended September 30, 2023 were mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of RevlimidÂ®) and a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The expense in the three months ended SeptemberÂ 30, 2023 was revised as discussed in note 1c. In the nine months ended SeptemberÂ 30, 2024, Teva recorded an expense of $305Â million for contingent consideration, compared to an expense of $140Â million in the nine months ended SeptemberÂ 30, 2023. The expenses in the first nine months of 2024 and 2023 were mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of RevlimidÂ®) and a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The expense in the first nine months of 2023 was revised as discussed in note 1c. Restructuring In the three months ended SeptemberÂ 30, 2024, Teva recorded $21Â million of restructuring expenses, compared to $27Â million in the three months ended SeptemberÂ 30, 2023. Expenses for the three months ended SeptemberÂ 30, 2024 and 2023 were primarily related to network consolidation activities. Â 45 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â In the nine months ended SeptemberÂ 30, 2024, Teva recorded $52Â million of restructuring expenses, compared to $93Â million in the nine months ended SeptemberÂ 30, 2023. The expenses for the nine months ended SeptemberÂ 30, 2024 and 2023 were primarily related to network consolidation activities. The following tables provide the components of the Companyâ€™s restructuring costs: Â Â Â Â ThreeÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Restructuring Â Â Â Â Employee termination Â Â $ 13 Â Â Â $ 16 Â Other Â Â Â 8 Â Â Â Â 12 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 21 Â Â Â $ 27 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€ ‚NineÂ monthsÂ endedÂ SeptemberÂ 30,â€‚ Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Restructuring Â Â Â Â Employee termination Â Â $ 33 Â Â Â $ 40 Â Other Â Â Â 19 Â Â Â Â 53 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 52 Â Â Â $ 93 Â Â Â Â Â Â Â Â Â Â Â The following table provides the components of and changes in the Companyâ€™s restructuring accruals: Â Â Â Â EmployeeÂ termination costs Â Â Â Other Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of JanuaryÂ 1, 2024 Â Â $ (75)Â Â Â $ (7)Â Â Â $ â€„(82)Â Provision Â Â Â (33)Â Â Â Â (19)Â Â Â Â (52)Â Utilization and other* Â Â Â 52 Â Â Â Â 12 Â Â Â Â 64 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2024 Â Â $ (56)Â Â Â $ (14)Â Â Â $ (70)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â EmployeeÂ termination costs Â Â Â Other Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of JanuaryÂ 1, 2023 Â Â $ (112)Â Â Â $ (7)Â Â Â $ (119)Â Provision Â Â Â (40)Â Â Â Â (53)Â Â Â Â (93)Â Utilization and other* Â Â Â 77 Â Â Â Â 53 Â Â Â Â 130 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2023 Â Â $ (75)Â Â Â $ (7)Â Â Â $ (82)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Includes adjustments for foreign currency translation. Â 46 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 13 â€“ Earnings (Loss) per share: Basic earnings and loss per share are computed by dividing net income (loss) attributable to Tevaâ€™s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (â€œRSUsâ€) and performance share units (â€œPSUsâ€) during the period, net of treasury shares. In computing diluted loss per share for the three months ended SeptemberÂ 30, 2024, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. In computing diluted earnings per share for the three months ended September 30, 2023, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. In computing diluted loss per share for the nine months ended SeptemberÂ 30, 2024 and 2023, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended SeptemberÂ 30, 2024 and 2023 were 1,133Â million shares and 1,135Â million shares, respectively. The weighted average diluted shares outstanding used for the fully diluted share calculations for the nine months ended SeptemberÂ 30, 2024 and 2023 were 1,130Â million shares and 1,119Â million shares, respectively. Basic and diluted lossÂ per share wasÂ $0.39 for the three months ended SeptemberÂ 30, 2024, compared to basic and diluted earnings per share of $0.06 for the three months ended SeptemberÂ 30, 2023. Basic and diluted earnings per share for the three months ended SeptemberÂ 30, 2023 wereÂ revised as discussed in note 1c. Basic and diluted loss per share was $1.26 for the nine months ended SeptemberÂ 30, 2024, compared to basic and diluted loss per share of $0.91 for the nine months ended SeptemberÂ 30, 2023. Basic and diluted loss per share for the nine months ended SeptemberÂ 30, 2023 wereÂ revised as discussed in note 1c. Â 47 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 14 â€“ Accumulated other comprehensive income (loss): The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: Â Â Â Â NetÂ UnrealizedÂ GainsÂ (Losses) Â Â Â BenefitÂ Plans Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â Â Derivative financial instruments Â Â Â ActuarialÂ gains (losses) and prior service (costs) credits Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of DecemberÂ 31, 2023, net of taxes Â Â $ (2,384)Â Â Â $ (266)Â Â Â $ (46)Â Â Â $ (2,697)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss) before reclassifications Â Â Â (84)Â Â Â Â â€”â€‚ Â Â Â Â 1 Â Â Â Â (83)Â Amounts reclassified to the statements of income Â Â Â â€”â€‚ Â Â Â Â 21 Â Â Â Â (3)Â Â Â Â 18 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net other comprehensive income (loss) before tax Â Â Â (84)Â Â Â Â 21 Â Â Â Â (2)Â Â Â Â (65)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corresponding income tax Â Â Â (7)Â Â Â Â â€”â€‚ Â Â Â Â â€”â€‚ Â Â Â Â (7)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net other comprehensive income (loss) after tax* Â Â Â (91)Â Â Â Â 21 Â Â Â Â (2)Â Â Â Â (72)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2024, net of taxes Â Â $ (2,475)Â Â Â $ (245)Â Â Â $ (48)Â Â Â $ (2,769)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Amounts do not include a $6Â million loss from foreign currency translation adjustments attributable to non-controlling interests. Â Â Â Â NetÂ UnrealizedÂ GainsÂ (Losses) Â Â Â BenefitÂ Plans Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â Â Derivative financial instruments Â Â Â ActuarialÂ gains (losses) and prior service (costs) credits Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of DecemberÂ 31, 2022, net of taxes Â Â $ (2,514)Â Â Â $ (295)Â Â Â $ (28)Â Â Â $ (2,838)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss) before reclassifications Â Â Â (39)Â Â Â Â (5)Â Â Â Â â€”â€‚ Â Â Â Â (44)Â Amounts reclassified to the statements of income Â Â Â â€”â€‚ Â Â Â Â 24 Â Â Â Â (2)Â Â Â Â 22 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net other comprehensive income (loss) before tax Â Â Â (39)Â Â Â Â 19 Â Â Â Â (2)Â Â Â Â (22)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corresponding income tax Â Â Â (50)Â Â Â Â â€”â€‚ Â Â Â Â â€”â€‚ Â Â Â Â (50)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net other comprehensive income (loss) after tax* Â Â Â (89)Â Â Â Â 19 Â Â Â Â (2)Â Â Â Â (72)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2023, net of taxes Â Â $ (2,603)Â Â Â $ (276)Â Â Â $ (30)Â Â Â $ (2,910)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Amounts do not include a $84Â million loss from foreign currency translation adjustments attributable to non-controlling interests. Â 48 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 15 â€“ Segments: Teva operates its business and reports its financial results in three segments: (a) United States segment. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries other than the United States and countries included in the Europe segment. In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Tevaâ€™s Chief Executive Officer (â€œCEOâ€), who is the chief operating decision maker (â€œCODMâ€), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely United States, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Tevaâ€™s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. Tevaâ€™s CEO may review its strategy and organizational structure from time to time. Based on such review, in May 2023 Teva launched its new Pivot to Growth strategy. Any additional changes in strategy may lead to a reevaluation of the Companyâ€™s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. In conjunction with a recent shift in executive management responsibilities and in alignment with Tevaâ€™s Pivot to Growth strategy, Teva decided that Canada is no longer included as part of Tevaâ€™s North America segment as of JanuaryÂ 1, 2024. From that date Canada is reported as part of the Companyâ€™s International Markets segment and Tevaâ€™s North America segment has been renamed the United States segment. Teva aligned its internal financial and segment reporting and its reporting units in accordance with this change effective JanuaryÂ 1, 2024. Prior period amounts have been recast to conform to the reporting structure for the current year. On JanuaryÂ 31, 2024, Teva announced that it intends to divest its API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with Tevaâ€™s Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be agreed or completed at all. Â Â a. Segment information: Â Â Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 2,225 Â Â Â $ 1,265 Â Â Â $ 613 Â Gross profit Â Â Â 1,265 Â Â Â Â 698 Â Â Â Â 306 Â R&D expenses Â Â Â 151 Â Â Â Â 55 Â Â Â Â 27 Â S&M expenses Â Â Â 259 Â Â Â Â 203 Â Â Â Â 134 Â G&A expenses Â Â Â 107 Â Â Â Â 67 Â Â Â Â 36 Â OtherÂ loss (income) Â Â Â Â§ Â Â Â Â 1 Â Â Â Â Â§ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 748 Â Â Â $ 373 Â Â Â $ 109 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â 49 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Â Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 1,896 Â Â Â $ 1,146 Â Â Â $ 591 Â Gross profit Â Â Â 1,060 Â Â Â Â 648 Â Â Â Â 293 Â R&D expenses Â Â Â 156 Â Â Â Â 62 Â Â Â Â 30 Â S&M expenses Â Â Â 243 Â Â Â Â 184 Â Â Â Â 116 Â G&A expenses Â Â Â 93 Â Â Â Â 66 Â Â Â Â 33 Â OtherÂ loss (income) Â Â Â (2)Â Â Â Â Â§ Â Â Â Â (2)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 571 Â Â Â $ 338 Â Â Â $ 117 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â United States Â Â Â Europe Â Â Â International Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 6,060 Â Â Â $ 3,749 Â Â Â $ 1,802 Â Gross profit Â Â Â 3,291 Â Â Â Â 2,113 Â Â Â Â 889 Â R&D expenses Â Â Â 475 Â Â Â Â 173 Â Â Â Â 85 Â S&M expenses Â Â Â 789 Â Â Â Â 605 Â Â Â Â 397 Â G&A expenses Â Â Â 300 Â Â Â Â 197 Â Â Â Â 109 Â OtherÂ loss (income) Â Â Â (1)Â Â Â Â 1 Â Â Â Â (1)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 1,727 Â Â Â $ 1,137 Â Â Â $ 299 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 5,465 Â Â Â $ 3,493 Â Â Â $ 1,750 Â Gross profit Â Â Â 2,866 Â Â Â Â 1,943 Â Â Â Â 861 Â R&D expenses Â Â Â 460 Â Â Â Â 168 Â Â Â Â 81 Â S&M expenses Â Â Â 700 Â Â Â Â 565 Â Â Â Â 353 Â G&A expenses Â Â Â 289 Â Â Â Â 196 Â Â Â Â 105 Â Other loss (income) Â Â Â (3)Â Â Â Â (2)Â Â Â Â (34)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 1,421 Â Â Â $ 1,017 Â Â Â $ 356 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 50 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â The following table presents a reconciliation of Tevaâ€™s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â ThreeÂ monthsÂ ended Â Â Â Nine months ended Â Â Â Â SeptemberÂ 30, Â Â Â SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Â Â (U.S. $ in millions) Â United States profit Â Â $ 748 Â Â Â $ 571 Â Â Â $ 1,727 Â Â Â $ 1,421 Â Europe profit Â Â Â 373 Â Â Â Â 338 Â Â Â Â 1,137 Â Â Â Â 1,017 Â International Markets profit Â Â Â 109 Â Â Â Â 117 Â Â Â Â 299 Â Â Â Â 356 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total reportable segments profit Â Â Â 1,230 Â Â Â Â 1,025 Â Â Â Â 3,163 Â Â Â Â 2,794 Â Profit (loss) of other activities Â Â Â (16)Â Â Â Â (5)Â Â Â Â (1)Â Â Â Â 22 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total segments profit Â Â Â 1,214 Â Â Â Â 1,020 Â Â Â Â 3,162 Â Â Â Â 2,816 Â Amounts not allocated to segments: Â Â Â Â Â Â Â Â Amortization Â Â Â 146 Â Â Â Â 145 Â Â Â Â 444 Â Â Â Â 471 Â Other assets impairments, restructuring and other items* Â Â Â (23) Â Â Â 57 Â Â Â Â 931 Â Â Â Â 276 Â Goodwill impairment Â Â Â 600 Â Â Â Â â€”â€‚ Â Â Â Â 1,000 Â Â Â Â 700 Â Intangible assets impairments Â Â Â 28 Â Â Â Â 47 Â Â Â Â 169 Â Â Â Â 289 Â Legal settlements and loss contingencies Â Â Â 450 Â Â Â Â 314 Â Â Â Â 638 Â Â Â Â 1,009 Â Other unallocated amounts Â Â Â 64 Â Â Â Â 112 Â Â Â Â 254 Â Â Â Â 394 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Consolidated operating income (loss) * Â Â Â (51) Â Â Â 344 Â Â Â Â (274) Â Â Â (323)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financial expenses, net Â Â Â 272 Â Â Â Â 280 Â Â Â Â 763 Â Â Â Â 808 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Consolidated income (loss) before income taxes * Â Â $ (324) Â Â $ 64 Â Â Â $ (1,037) Â Â $ (1,131)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for the three and nine months ended SeptemberÂ 30, 2024 and 2023: Â United States Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 1,094 Â Â Â $ 839 Â AJOVYÂ® Â Â Â 58 Â Â Â Â 56 Â AUSTEDO Â Â Â 435 Â Â Â Â 339 Â BENDEKAÂ® and TREANDAÂ® Â Â Â 40 Â Â Â Â 56 Â COPAXONE Â Â Â 69 Â Â Â Â 98 Â UZEDY Â Â Â 35 Â Â Â Â 2 Â Anda Â Â Â 380 Â Â Â Â 367 Â Other Â Â Â 115 Â Â Â Â 140 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 2,225 Â Â Â $ 1,896 Â Â Â Â Â Â Â Â Â Â Â 51 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Â Â United States Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 2,924 Â Â Â $ 2,471 Â AJOVY Â Â Â 144 Â Â Â Â 154 Â AUSTEDO Â Â Â 1,124 Â Â Â Â 817 Â BENDEKA and TREANDA Â Â Â 127 Â Â Â Â 185 Â COPAXONE Â Â Â 179 Â Â Â Â 224 Â UZEDY Â Â Â 75 Â Â Â Â 14 Â Anda Â Â Â 1,134 Â Â Â Â 1,183 Â Other Â Â Â 352 Â Â Â Â 417 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 6,060 Â Â Â $ 5,465 Â Â Â Â Â Â Â Â Â Â Â Â Europe Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 973 Â Â Â $ 886 Â AJOVY Â Â Â 56 Â Â Â Â 41 Â COPAXONE Â Â Â 53 Â Â Â Â 55 Â Respiratory products Â Â Â 60 Â Â Â Â 61 Â Other* Â Â Â 124 Â Â Â Â 104 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 1,265 Â Â Â $ 1,146 Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the third quarter of 2024 include the sale of certain product rights. Â Â Europe Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 2,947 Â Â Â Â Â $ 2,727 Â AJOVY Â Â Â 158 Â Â Â Â Â Â 115 Â COPAXONE Â Â Â 163 Â Â Â Â Â Â 174 Â Respiratory products Â Â Â 183 Â Â Â Â Â Â 195 Â Other* Â Â Â 299 Â Â Â Â Â Â 282 Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 3,749 Â Â Â Â Â $ 3,493 Â Â Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the first nine months of 2024 include the sale of certain product rights. Â 52 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â International markets Â Â ThreeÂ monthsÂ ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S.Â $Â inÂ millions) Â Generic products Â Â $ 477 Â Â Â $ 470 Â AJOVY Â Â Â 24 Â Â Â Â 18 Â COPAXONE Â Â Â 13 Â Â Â Â 16 Â Other* Â Â Â 99 Â Â Â Â 87 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 613 Â Â Â $ 591 Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the third quarter of 2024 include the sale of certain product rights. Â International markets Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 1,440 Â Â Â Â Â $ 1,425 Â AJOVY Â Â Â 63 Â Â Â Â Â Â 45 Â COPAXONE Â Â Â 38 Â Â Â Â Â Â 50 Â Other* Â Â Â 261 Â Â Â Â Â Â 229 Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 1,802 Â Â Â Â Â $ 1,750 Â Â Â Â Â Â Â Â Â Â Â Â Â * OtherÂ revenues in the first nine months of 2024 include the sale of certain product rights. Â 53 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â NOTE 16 â€“ Fair value measurement: Financial items carried at fair value on a recurring basis as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 are classified in the tables below in one of the three categories of fair value levels: Â Â Â Â SeptemberÂ 30, 2024 Â Â Â Â LevelÂ 1 Â Â Â LevelÂ 2 Â Â Â LevelÂ 3 Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Cash and cash equivalents: Â Â Â Â Â Â Â Â Money markets Â Â $ 1,822 Â Â Â $ â€”â€, Â Â Â $ â€”â€, Â Â Â $ 1,822 Â Cash, deposits and other Â Â Â 1,497 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 1,497 Â Investment in securities: Â Â Â Â Â Â Â Â Equity securities Â Â Â 13 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 13 Â Other Â Â Â 3 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 3 Â Derivatives: Â Â Â Â Â Â Â Â Asset derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€”â€, Â Â Â Â 32 Â Â Â Â â€”â€, Â Â Â Â 32 Â Liability derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€”â€, Â Â Â Â (33)Â Â Â Â â€”â€, Â Â Â Â (33)Â Bifurcated embedded derivatives Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â§ Â Â Â Â â€”â€, Â Contingent consideration* Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (552)Â Â Â Â (552)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 3,335 Â Â Â $ (1)Â Â Â $ (552)Â Â Â $ 2,782 Â DecemberÂ 31, 2023 Â Â Â Â LevelÂ 1 Â Â Â LevelÂ 2 Â Â Â LevelÂ 3 Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Cash and cash equivalents: Â Â Â Â Â Â Â Â Money markets Â Â $ 1,704 Â Â Â $ â€”â€, Â Â Â $ â€”â€, Â Â Â $ 1,704 Â Cash, deposits and other Â Â Â 1,522 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 1,522 Â Investment in securities: Â Â Â Â Â Â Â Â Investment in convertible bond security Â Â Â Â Â Â Â 40 Â Â Â Â 40 Â Equity securities Â Â Â 7 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 7 Â Other Â Â Â 1 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 1 Â Restricted cash Â Â Â 1 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 1 Â Derivatives: Â Â Â Â Â Â Â Â Asset derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€”â€, Â Â Â Â 38 Â Â Â Â â€”â€, Â Â Â Â 38 Â Cross-currency interest rate swap Â Â Â Â Â 8 Â Â Â Â Â Â 8 Â Liability derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€”â€, Â Â Â Â (39)Â Â Â Â â€”â€, Â Â Â Â (39)Â Bifurcated embedded derivatives Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â§ Â Â Â Â â€”â€, Â Contingent consideration* Â Â $ â€”â€, Â Â Â Â â€”â€, Â Â Â Â (517)Â Â Â Â (517)Â Total Â Â Â 3,235 Â Â Â $ 7 Â Â Â $ (477)Â Â Â $ 2,765 Â§ Represents an amount less than $0.5Â million. * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. Â 54 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Teva determined the fair value of the liabilities for contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a LevelÂ 3 measurement within the fair value hierarchy. The fair value of contingent consideration is based on several factors, such as cash flows projected from the success of unapproved product candidates; probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; time and resources required to complete the development and approval of product candidates; life of the potential commercialized products and associated risks with obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. The discount rate applied ranged from 8.5% to 11%. The weighted average discount rate, calculated based on the relative fair value of Tevaâ€™s contingent consideration liabilities, was 8.8%. Contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in the consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. A change of the discount rate by 1% would have not resulted in material changes to the contingent consideration liabilities. The investment in convertible bond security is accounted for as available for sale with changes in fair value reflected in other comprehensive income. See Alvotech transaction under note 2. The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing LevelÂ 3 inputs: Â Â Â Â Nine months endedÂ September 30, 2024 Â Â Â NineÂ months endedÂ September 30, 2023 Â Â Â Â (U.S. $ in millions) Â Fair value at the beginning of the period Â Â $ (477)Â Â Â Â (250)Â Investment in convertible bond** Â Â Â â€”â€, Â Â Â Â 25 Â Conversion option** Â Â Â â€”â€, Â Â Â Â 15 Â Redemption of convertible bond security** Â Â Â (40)Â Â Â Â â€”â€, Â Bifurcated embedded derivatives Â Â Â§ Â Â Â Â§ Â Adjustments to provisions for contingent consideration: Â Â Â Â Allergan transaction* Â Â Â (267)Â Â Â Â (111)Â Eagle transaction Â Â Â (37)Â Â Â Â (35)Â Novetide transaction Â Â Â (1)Â Â Â Â 2 Â Settlement of contingent consideration: Â Â Â Â Allergan transaction Â Â Â 227 Â Â Â Â 132 Â Eagle transaction Â Â Â 41 Â Â Â Â 61 Â Novetide transaction Â Â Â 2 Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Â Â Fair value at the end of the period Â Â $ (552)Â Â Â $ (159)Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. * The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan for the nine months ended SeptemberÂ 30, 2023 have been revised as discussed in note 1c. ** On SeptemberÂ 29, 2023, Teva purchased $40Â million of subordinated convertible bonds of Alvotech. On JuneÂ 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024 (see note 2). Â 55 Table of ContentsTEVA PHARMACEUTICAL INDUSTRIES LIMITED Notes to Consolidated Financial Statements (Unaudited) Â Financial instruments not measured at fair value Financial instruments measured on a basis other than fair value mostly consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): Â Â Â Â Estimated fair value* Â Â Â Â SeptemberÂ 30, 2024 Â Â Â DecemberÂ 31, 2023 Â Â Â Â (U.S. $ in millions) Â Senior notes and sustainability-linked senior notes included under senior notes and loans Â Â $ 16,129 Â Â Â $ 17,214 Â Senior notes and convertible senior debentures included under short-term debt Â Â Â 2,572 Â Â Â Â 1,651 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 18,701 Â Â Â $ 18,865 Â Â Â Â Â Â Â Â Â Â Â * The fair value was estimated based on quoted market prices. Â 56 Table of Contents ITEMâ€‰2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Business Overview We are a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities enables our approximately 37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. Teva was incorporated in Israel on FebruaryÂ 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. Our Business Segments We operate our business through three segments: United States (previously referred to as North America segment, see below â€œâ€”United States Segmentâ€), Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes biosimilars and OTC products, as well as innovative medicines. This structure enables strong alignment and integration between operations, commercial regions, R&D and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas. In addition to these three segments, we have other activities, primarily the sale of API to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Pivot to Growth Strategy In May 2023, we introduced our Pivot to Growth strategy, which is based on four key pillars: (i)Â delivering on our growth engines, mainly AUSTEDOÂ®, AJOVYÂ®, UZEDYÂ® and our late-stage pipeline of biosimilars; (ii)Â stepping up innovation through delivering on our late-stage innovative pipeline assets as well as building up our early-stage pipeline organically and potentially through business development activities; (iii)Â sustaining our generics medicines powerhouse with a global commercial footprint, focused portfolio, pipeline and manufacturing footprint; and (iv)Â focusing our business by optimizing our portfolio and global manufacturing footprint to enable strategic capital deployment to accelerate our near and long-term growth engines and reorganizing certain of our business units to a more optimal structure, while also reorganizing key business units to enhance operational efficiency. Macroeconomic and Geopolitical Environment In recent years, the global economy has been impacted by fluctuating foreign exchange rates. In the third quarter of 2024, approximately 45% of our revenues were denominated in currencies other than the U.S. dollar and we manufacture our products largely outside of the United States. Fluctuations in the U.S. dollar versus other currencies in which we operate may materially impact our revenues, results of operations, profits and cash flows. Additionally, high levels of inflation have recently resulted in significant economic volatility and monetary tightening by central banks through higher interest rates. Global economy has also been impacted by geopolitical tensions which have resulted in disruptions to global supply chains, including our internal supply chain. In October 2023, Israel was attacked by a terrorist organization and entered a state of war on several fronts, which as of the date of this Quarterly Report on Form 10-Q is ongoing. Our global headquarters as well as several of our manufacturing and R&D facilities are located in Israel and, while operations there currently remain largely unaffected, the impact of this war on our operations may increase, which could be material, as a result of the continuation, escalation or expansion of this war. In light of the above, supply chain disruptions could continue to result in delays in our production and distribution processes, R&D initiatives and our ability to timely respond to consumer demand. We have implemented certain measures in response to such events and are continually considering various initiatives, including price adjustments where we are not restricted contractually or regulatorily, enhanced inventory management, alternative sourcing strategies for our raw material supply and backup production plans for key products, to allow us to partially mitigate and offset the impact of these macroeconomic and geopolitical factors. However, although inflationary and other macroeconomic pressures may or have eased, the higher costs we have experienced during recent periods have already impacted our operations and will likely continue to have an effect on our financial results. Â 57 Table of Contents Highlights Significant highlights in the third quarter of 2024 included1: Â Â â€¢ Â Revenues in the third quarter of 2024 were $4,332Â million, an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to the third quarter of 2023. This increase was mainly due to higher revenues from generic products in all our segments, from AUSTEDO in our United States segment, as well as from the sale of product rights in our Europe and International Markets segments. Â Â â€¢ Â Our United States segment generated revenues of $2,225Â million and segment profit of $748Â million in the third quarter of 2024. Revenues increased by 17% and segment profit increased by 31% compared to the third quarter of 2023. Â Â â€¢ Â Our Europe segment generated revenues of $1,265Â million and segment profit of $373Â million in the third quarter of 2024. Revenues increased by 10% in U.S. dollars, or 11% in local currency terms, compared to the third quarter of 2023. Segment profit increased by 10% compared to the third quarter of 2023. Â Â â€¢ Â Our International Markets segment generated revenues of $613Â million and segment profit of $109Â million in the third quarter of 2024. Revenues increased by 4% in U.S. dollars, or 18% in local currency terms, compared to the third quarter of 2023. Segment profit decreased by 7% compared to the third quarter of 2023. Â Â â€¢ Â Our revenues from other activities in the third quarter of 2024 were $229Â million, an increase of 6% in U.S. dollars, or 5% local currency terms, compared to the third quarter of 2023. Â Â â€¢ Â Exchange rate movements during the third quarter of 2024, including hedging effects, negatively impacted overall revenues by $88Â million and operating loss by $57Â million, compared to the third quarter of 2023. Â Â â€¢ Â Gross profit margin was 49.6% in the third quarter of 2024, compared to 48.1% in the third quarter of 2023. Â Â â€¢ Â R&D expenses, net in the third quarter of 2024 were $240Â million, a decrease of 5% compared to $253Â million in the third quarter of 2023. Â Â â€¢ Â We recorded a goodwill impairment charge of $600Â million in the third quarter of 2024, related to our Teva API reporting unit. See note 6 to our consolidated financial statements. Â Â â€¢ Â We recorded legal settlements and loss contingencies of $450 million in the third quarter of 2024, compared to $314 million in the third quarter of 2023. See note 9 to our consolidated financial statements. Â Â â€¢ Â Operating loss was $51Â million in the third quarter of 2024, compared to an operating income of $344Â million in the third quarter of 2023. Â Â â€¢ Â In the third quarter of 2024, we recognized a tax expense of $69Â million, on a pre-tax loss of $324Â million. In the third quarter of 2023, we recognized a tax benefit of $12Â million, on a pre-tax income of $64Â million. See note 11 to our consolidated financial statements. Â Â â€¢ Â As of SeptemberÂ 30, 2024, our debt was $18,980Â million, compared to $19,833Â million as of DecemberÂ 31, 2023. In October 2024, we repaid at maturity $685Â million of our 1.13% senior notes due in 2024. See note 7 to our consolidated financial statements. Â Â â€¢ Â Cash flow generated from operating activities during the third quarter of 2024 was $693Â million, compared to $5Â million of cash flow generated from operating activities in the third quarter of 2023. The higher cash flow generated from operating activities in the third quarter of 2024, resulted mainly from higher profit in our United States segment, as well as from changes in working capital items, including a positive impact from accounts receivables, net of SR&A, as well as from accounts payables and inventory levels, partially offset by higher legal payments during the third quarter of 2024. Â 1Â The data included in the Highlights section with respect operating income (loss), income taxes for the prior period have been revised to reflect a revision in relation to a contingent consideration and related expenses in the consolidated financial statements. For additional information, see note 1c to our consolidated financial statements. Â 58 Table of Contents Â â€¢ Â During the third quarter of 2024, we generated free cash flow of $922Â million, which we define as comprising $693Â million in cash flow generated from operating activities, $339Â million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $38Â million in divestitures of businesses and other assets, partially offset by $148Â million in cash used for capital investment. During the third quarter of 2023, we generated free cash flow of $229Â million. The increase in the third quarter of 2024, resulted mainly from higher cash flow generated from operating activities. Results of Operations Comparison of Three Months Ended SeptemberÂ 30, 2024 to Three Months Ended SeptemberÂ 30, 2023 Segment Information United States Segment The following table presents revenues, expenses and profit for our United States segment for the three months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â 2023 Â Â Â Â (U.S. $ in millions /%Â ofÂ SegmentÂ Revenues) Â Revenues Â Â $ 2,225 Â Â Â Â 100 %Â Â $ 1,896 Â Â Â Â 100 %Â Gross profit Â Â Â 1,265 Â Â Â Â 56.9 %Â Â Â 1,060 Â Â Â Â 55.9 %Â R&D expenses Â Â Â 151 Â Â Â Â 6.8 %Â Â Â 156 Â Â Â Â 8.2 %Â S&M expenses Â Â Â 259 Â Â Â Â 11.6 %Â Â Â 243 Â Â Â Â 12.8 %Â G&A expenses Â Â Â 107 Â Â Â Â 4.8 %Â Â Â 93 Â Â Â Â 4.9 %Â Other loss (income) Â Â Â Â§ Â Â Â Â§ Â Â Â (2)Â Â Â Â Â§ Â Segment profit* Â Â $ 748 Â Â Â Â 33.6 %Â Â $ 571 Â Â Â Â 30.1 %Â * Segment profit does not include amortization and certain other items. Â§ Represents an amount less than $0.5Â million or 0.5%, as applicable. United States Revenues As part of a recent shift in executive management responsibilities and in line with our Pivot to Growth strategy, commencing JanuaryÂ 1, 2024, Canada is reported as part of our International Markets segment. Prior period amounts were recast to reflect this change. See note 15 to our consolidated financial statements. Revenues from our United States segment in the third quarter of 2024 were $2,225Â million, an increase of $329Â million, or 17%, compared to the third quarter of 2023. This increase was mainly due to higher revenues from generic products, AUSTEDO and UZEDY, partially offset by lower revenues from certain innovative products, primarily COPAXONE and BENDEKA and TREANDA. Â 59 Table of Contents Revenues by Major Products and Activities The following table presents revenues for our United States segment by major products and activities for the three months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â Three months endedSeptemberÂ 30, Â Â Â PercentageChange Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024-2023 Â Â Â Â (U.S. $ in millions) Â Â Â Â Â Generic products Â Â $ 1,094 Â Â Â $ 839 Â Â Â Â 30 %Â AJOVY Â Â Â 58 Â Â Â Â 56 Â Â Â Â 4 %Â AUSTEDO Â Â Â 435 Â Â Â Â 339 Â Â Â Â 28 %Â BENDEKA and TREANDA Â Â Â 40 Â Â Â Â 56 Â Â Â Â (28 %)Â COPAXONE Â Â Â 69 Â Â Â Â 98 Â Â Â Â (30 %)Â UZEDY Â Â Â 35 Â Â Â Â 2 Â Â Â Â N/A Â Anda Â Â Â 380 Â Â Â Â 367 Â Â Â Â 3 %Â Other Â Â Â 115 Â Â Â Â 140 Â Â Â Â (18 %)Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 2,225 Â Â Â $ 1,896 Â Â Â Â 17 %Â Â Â Â Â Â Â Â Â Â Â Â Â Generic products revenues in our United States segment (including biosimilars) in the third quarter of 2024 were $1,094Â million, an increase of 30% compared to the third quarter of 2023, the majority of which is driven by higher revenues from lenalidomide capsules (the generic version of RevlimidÂ®), and the remaining, primarily by the launch of liraglutide injection 1.8mg (an authorized generic of VictozaÂ®) and higher revenues from epinephrine injectable solution (the generic equivalent of EpiPenÂ® and EpiPen JrÂ®). Among the most significant generic products we sold in the United States in the third quarter of 2024 were lenalidomide capsules (the generic version of RevlimidÂ®), epinephrine injectable solution (the generic equivalent of EpiPenÂ® and EpiPen JrÂ®), TruximaÂ® (the biosimilar to RituxanÂ®) and liraglutide 1.8 mg injection (an authorized generic of VictozaÂ®). In the third quarter of 2024, our total prescriptions were approximately 292Â million (based on trailing twelve months), representing 7.6% of total U.S. generic prescriptions, compared to approximately 320Â million (based on trailing twelve months), representing 8.4% of total U.S. generic prescriptions in the third quarter of 2023, all according to IQVIA data. On OctoberÂ 1, 2024, Teva launched octreotide acetate for injectable suspension, the first generic version of SandostatinÂ® LAR

Depot. Octreotide acetate for injectable suspension is indicated for the treatment of acromegaly and severe diarrhea associated with carcinoid syndrome, and is available to patients in the U.S. AJOVY revenues in our United States segment in the third quarter of 2024 were $58Â million, an increase of 4% compared to the third quarter of 2023, mainly due to growth in volume. In the third quarter of 2024, AJOVYâ€™s exit market share in the United States in terms of total number of prescriptions was 29.1% compared to 24.9% in the third quarter of 2023. AJOVY is indicated for the preventive treatment of migraine in adults, and was launched in the U.S. in 2018. AJOVY is the only anti-CGRP subcutaneous product indicated for quarterly treatment. AJOVY is protected worldwide by patents expiring in 2026 at the earliest; extensions have been granted in several countries, including the United States and in Europe, until 2031. Additional patents relating to the use of AJOVY in the treatment of migraine have also been issued in the United States and will expire between 2035 and 2039. Such patents are also pending in other countries. AJOVY will also be protected by regulatory exclusivity for 12 years from marketing approval in the United States (obtained in September 2018) and 10 years from marketing approval in Europe (obtained in April 2019). In October 2017, we filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli LillyÂ & Co.â€™s (â€œLillyâ€) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review (â€œIPRâ€) petitions to the Patent Trial and Appeal Board (â€œPTABâ€), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on AugustÂ 16, 2021. A jury trial regarding the three method of treatment patents resulted in a verdict in Tevaâ€™s favor on NovemberÂ 9, 2022, in which the three method of treatment patents were determined to be valid and infringed by Lilly, and Teva was awarded $176.5Â million in damages. On SeptemberÂ 26, 2023, the U.S. District Court for the District of Massachusetts issued a decision that reversed the juryâ€™s verdict and damages award, finding Tevaâ€™s method of treatment patents to be invalid. Teva appealed this ruling on OctoberÂ 24, 2023. On FebruaryÂ 2, 2024, Teva filed its opening appeal brief, to which Lilly filed its responding brief on AprilÂ 19, 2024, which Teva responded to on MayÂ 29, 2024. Lillyâ€™s final brief was filed on JulyÂ 19, 2024. No date has been set for the appeal hearing. Â 60 Table of Contents In addition, in 2018 we entered into separate agreements with Alder Biopharmaceuticals, Inc. and Lilly, resolving the European Patent Office oppositions that they filed against our AJOVY patents. The settlement agreement with Lilly also resolved Lillyâ€™s action to revoke the patent protecting AJOVY in the United Kingdom. AUSTEDO revenues in our United States segment in the third quarter of 2024 increased by 28%, to $435Â million, compared to $339Â million in the third quarter of 2023, mainly due to growth in volume and expanded access for patients. AUSTEDO was launched in the U.S. in 2017. It is indicated for the treatment of chorea associated with Huntington disease and for the treatment of tardive dyskinesia in adults. AUSTEDO is protected in the United States by 14 Orange Book patents expiring between 2031 and 2038. We received notice letters from two ANDA filers regarding the filing of their ANDAs with paragraph (IV)Â certifications for certain of the patents listed in the Orange Book for AUSTEDO. On JulyÂ 1, 2021, we filed claims against two generic ANDA filers, Aurobindo and Lupin, in the U.S. District Court for the District of New Jersey. In addition, Apotex filed a petition for IPR by the PTAB of the patent covering the deutetrabenazine compound that expires in 2031. On MarchÂ 9, 2022, the U.S. Patent and Trademark Office denied Apotexâ€™s petition and declined to institute a review of the deutetrabenazine patent. On AprilÂ 29, 2022 and JuneÂ 8, 2022, we reached agreements with Lupin and Aurobindo, respectively, to sell their generic products beginning in April 2033, or earlier under certain circumstances. There are no further patent litigations pending regarding AUSTEDO. AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on FebruaryÂ 17, 2023, in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. In May 2024, the FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg. In July 2024, the FDA approved the 18 mg dosage for AUSTEDO XR making it a one pill, once-daily option for all available doses. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntingtonâ€™s disease, which is additional to the currently marketed twice-daily AUSTEDO. AUSTEDO XR is protected by 11 Orange Book patents expiring between 2031 and 2041. UZEDY (risperidone) extended-release injectable suspension revenues in our United States segment in the third quarter of 2024 were $35Â million. UZEDY was approved by the FDA on AprilÂ 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023. UZEDY is a subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. UZEDY is protected by nine Orange Book patents expiring between 2025 and 2033. We are moving forward with plans to launch UZEDY in other countries around the world. UZEDY faces competition from multiple other products. BENDEKA and TREANDA combined revenues in our United States segment in the third quarter of 2024 were $40Â million, a decrease of 28% compared to the third quarter of 2023, mainly due to competition from alternative therapies, as well as the entry of generic bendamustine products into the market. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022. In April 2019, we signed an amendment to the license agreement with Eagle extending the royalty term applicable to the United States to the full period for which we sell BENDEKA and increased the royalty rate. In consideration, Eagle agreed to assume a portion of BENDEKA-related patent litigation expenses. There are 18 patents listed in the U.S. Orange Book for BENDEKA with expiration dates in 2026 and 2031. In April 2020, the U.S. District Court for the District of Delaware issued a trial decision upholding the validity of all of the asserted patents and finding that four ANDA filers for generic versions of BENDEKA infringe at least one of the patents. Teva settled with one of the three ANDA filers that appealed the district courtâ€™s decision, and on AugustÂ 13, 2021, the Federal Circuit issued a Rule 36 affirmance of such decision. Litigation against the fifth ANDA filer was dismissed after withdrawal of its patent challenge, and on OctoberÂ 18, 2021, the case against a sixth ANDA filer was also settled. Teva also settled litigations against three 505(b)(2) applicants, Hospira, Inc. (â€œHospiraâ€), Dr.Â Reddyâ€™s Laboratories (â€œDRLâ€) and Accord Healthcare (â€œAccordâ€). Based on these settlement agreements, the three 505(b)(2) filers, Hospira, Accord and DRL can launch their products on NovemberÂ 17, 2027 or earlier under certain circumstances. On MayÂ 4, 2023, and JuneÂ 9, 2023, Teva and Eagle also filed suit against BendaRx Corp. in the U.S. District Court for the District of Delaware, following its filing of a 505(b)(2) NDA for a bendamustine product. In addition, on JuneÂ 16, 2023, Teva filed suit against BendaRx USA Corp. in the U.S. District Court for the District of Eastern Virginia, which was then stayed and has now been transferred to the U.S. District Court for the District of Delaware where it has been consolidated with the suits filed there. Â 61 Table of Contents In addition to the settlement with Eagle regarding its bendamustine 505(b)(2) NDA, between 2015 and 2020, we reached final settlements with 22 ANDA filers for generic versions of the lyophilized form of TREANDA and one 505(b)(2) NDA filer for a generic version of the liquid form of TREANDA, providing for the launch of generic versions of TREANDA prior to patent expiration. Currently, there are multiple generic TREANDA products on the market. COPAXONE revenues in our United States segment in the third quarter of 2024 were $69Â million, a decrease of 30% compared to the third quarter of 2023, mainly due to market share erosion and competition. The market for MS treatments continues to develop, particularly with the approval of generic versions of COPAXONE. Oral treatments for MS, such as TecfideraÂ®, GilenyaÂ® and AubagioÂ®, continue to present significant and increasing competition. COPAXONE also continues to face competition from existing injectable products, as well as from monoclonal antibodies, such as OcrevusÂ® and KesimptaÂ®. Anda revenues from third-party products in our United States segment in the third quarter of 2024 increased by 3% to $380Â million, compared to $367Â million in the third quarter of 2023, mainly due to higher volumes. Anda, our distribution business in the United States, distributes generic and innovative medicines and OTC pharmaceutical products from Teva and various third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States. Product Launches and Pipeline In the third quarter of 2024, we launched the generic version of the following branded products in the United States: Â Product Name Â Â BrandÂ Name Â Â LaunchDate Â Â Â TotalÂ AnnualÂ U.S.BrandedÂ SalesÂ atÂ Timeof Launch(U.S. $ in millions(IQVIA))* Â Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) Â Â Â Abraxane Â®Â Â Â July Â Â Â $ 809 Â Lisdexamfetamine Dimesylate Chewable Tablets CII - USA Â Â Â Vyvanse Â®Â Â Â September Â Â Â $ 200 Â Mesalamine Delayed-Release Tablets, USP Â Â Â N/A Â Â Â August Â Â Â $ 167 Â Naloxone Hydrochloride Nasal Spray (OTC) Â Â Â Narcan Â®Â Â Â September Â Â Â $ 66 **Â Metoclopramide Injection, USP Â Â Â N/A Â Â Â September Â Â Â $ 12 Â Sulfamethoxazole and Trimethoprim Injection, USP in the PREMIERProRxÂ®* Label Â Â Â N/A Â Â Â August Â Â Â $ 1 Â Â *Â The figures presented are for the twelve months ended in the calendar quarter immediately prior to our launch or re-launch. ** Represents estimated sales based on OTC sales reported through IQVIA. As of September 30, 2024, our generic products pipeline in the United States includes 125 product applications awaiting FDA approval, including 62 tentative approvals. This total reflects all pending ANDAs, supplements for product line extensions and tentatively approved applications and includes some instances where more than one application was submitted for the same reference product. Excluding overlaps, the branded products underlying these pending applications had U.S. sales for the twelve months ended JuneÂ 30, 2024 of approximately $119Â billion, according to IQVIA. Approximately 79% of pending applications include a paragraph IV patent challenge, and we believe we are first-to-file with respect to 55 of these products, or 85 products including final approvals where launch is pending a settlement agreement or court decision. Collectively, these first-to-file opportunities represent over $79Â billion in U.S. brand sales for the twelve months ended JuneÂ 30, 2024, according to IQVIA. IQVIA reported brand sales are one of the many indicators of future potential value of a launch, but equally important are the mix and timing of competition, as well as cost effectiveness. The potential advantages of being the first filer with respect to some of these products may be subject to forfeiture, shared exclusivity or competition from so-called â€œauthorized generics,â€ which may ultimately affect the value derived. Â 62 Table of Contents In the third quarter of 2024, we received tentative approvals for generic equivalents of the products listed in the table below, excluding overlapping applications. A â€œtentative approvalâ€ indicates that the FDA has substantially completed its review of an application and final approval is expected once the relevant patent expires, a court decision is reached, a 30-month regulatory stay lapses, or a 180-day exclusivity period awarded to another manufacturer either expires or is forfeited. Â Generic Name Â Â BrandÂ Name Â Â TotalÂ AnnualÂ U.S.BrandedÂ SalesÂ atÂ Timeof Launch(U.S. $ in millions(IQVIA))* Â Palbociclib Capsules Â Â Â Ibrance Â®Â Â $ 504 Â Binimetinib Tablets, 15 mg Â Â Â Mektovi Â®Â Â $ 176 Â Â *Â The figures presented are for the twelve months ended in the calendar quarter immediately prior to our launch or re-launch. For information regarding our innovative and biosimilar products pipeline, see â€œâ€”Teva Consolidated Resultsâ€”Research and Development (R&D) Expensesâ€ below. United States Gross Profit Gross profit from our United States segment in the third quarter of 2024 was $1,265Â million, an increase of 19%, compared to $1,060Â million in the third quarter of 2023. Gross profit margin for our United States segment in the third quarter of 2024 increased to 56.9%, compared to 55.9% in the third quarter of 2023. This increase was mainly due to a favorable mix of products primarily driven by higher revenues from lenalidomide capsules (the generic version of RevlimidÂ®) and AUSTEDO. United States R&D Expenses R&D expenses relating to our United States segment in the third quarter of 2024 were $151Â million, a decrease of 3%, compared to $156Â million in the third quarter of 2023. For a description of our R&D expenses in the third quarter of 2024, see â€œâ€”Teva Consolidated Resultsâ€”Research and Development (R&D) Expensesâ€ below. United States S&M Expenses S&M expenses relating to our United States segment in the third quarter of 2024 were $259Â million, an increase of 6%, compared to $243Â million in the third quarter of 2023. This increase was mainly due to promotional activities related to AUSTEDO, primarily the direct-to-consumer advertising campaign and our patient support programs. United States G&A Expenses G&A expenses relating to our United States segment in the third quarter of 2024 were $107Â million, an increase of 16% compared to $93Â million in the third quarter of 2023. United States Profit Profit from our United States segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. Profit from our United States segment in the third quarter of 2024 was $748Â million, an increase of 31% compared to $571Â million in the third quarter of 2023. This increase was mainly due to higher gross profit, partially offset by higher S&M and G&A expenses, as discussed above. Â 63 Table of Contents Europe Segment The following table presents revenues, expenses and profit for our Europe segment for the three months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â 2023 Â Â Â Â (U.S.Â $Â inÂ millionsÂ /Â %Â ofÂ SegmentÂ Revenues) Â Revenues Â Â $ 1,265 Â Â Â Â 100 %Â Â $ 1,146 Â Â Â Â 100 %Â Gross profit Â Â Â 698 Â Â Â Â 55.2 %Â Â Â 648 Â Â Â Â 56.6 %Â R&D expenses Â Â Â 55 Â Â Â Â 4.3 %Â Â Â 62 Â Â Â Â 5.4 %Â S&M expenses Â Â Â 203 Â Â Â Â 16.0 %Â Â Â 184 Â Â Â Â 16.0 %Â G&A expenses Â Â Â 67 Â Â Â Â 5.3 %Â Â Â 66 Â Â Â Â 5.7 %Â Other loss (income) Â Â Â 1 Â Â Â Â Â§ Â Â Â Â§ Â Â Â Â Â§ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit* Â Â $ 373 Â Â Â Â 29.5 %Â Â $ 338 Â Â Â Â 29.5 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Segment profit does not include amortization and certain other items. Â§ Represents an amount less than $0.5Â million or 0.5%, as applicable. Europe Revenues Our Europe segment includes the European Union, the United Kingdom and certain other European countries. Revenues from our Europe segment in the third quarter of 2024 were $1,265Â million, an increase of 10%, or $119Â million, compared to the third quarter of 2023. In local currency terms, revenues increased by 11% compared to the third quarter of 2023, mainly due to higher revenues from generic and OTC products as well as AJOVY. Our higher revenues in the third quarter of 2024 were also partly driven by the sale of certain product rights. In the third quarter of 2024, revenues were negatively impacted by exchange rate fluctuations of $6Â million, net of hedging effects, compared to the third quarter of 2023. Revenues in the third quarter of 2024, included $10Â million from a negative hedging impact, which is included in â€œOtherâ€ in the table below. Revenues in the third quarter of 2023 included $15Â million from a positive hedging impact, which is included in â€œOtherâ€ in the table below. See note 8d to our consolidated financial statements. Revenues by Major Products and Activities The following table presents revenues for our Europe segment by major products and activities for the three months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â ThreeÂ monthsÂ endedSeptemberÂ 30, Â Â Â PercentageChange Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024-2023 Â Â Â Â (U.S. $ in millions) Â Â Â Â Â Generic products Â Â $ 973 Â Â Â $ 886 Â Â Â Â 10 %Â AJOVY Â Â Â 56 Â Â Â Â 41 Â Â Â Â 37 %Â COPAXONE Â Â Â 53 Â Â Â Â 55 Â Â Â Â (5 %)Â Respiratory products Â Â Â 60 Â Â Â Â 61 Â Â Â Â (1 %)Â Other* Â Â Â 124 Â Â Â Â 104 Â Â Â Â 19 %Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 1,265 Â Â Â $ 1,146 Â Â Â Â 10 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the third quarter of 2024 include the sale of certain product rights. Â 64 Table of Contents Generic products revenues (including OTC and biosimilar products) in our Europe segment in the third quarter of 2024, were $973Â million, an increase of 10% compared to the third quarter of 2023. In local currency terms, revenues increased by 8%, mainly due to price increases as a result of market conditions such as inflationary pressures in certain markets, as well as higher revenues from recently launched products. AJOVY revenues in our Europe segment in the third quarter of 2024 increased by 37% to $56Â million, compared to $41Â million in the third quarter of 2023. In local currency terms revenues increased by 36% due to growth in volume. For information about AJOVY patent protection, see â€œâ€”United States Revenuesâ€”Revenues by Major Products and Activitiesâ€ above. COPAXONE revenues in our Europe segment in the third quarter of 2024 were $53Â million, a decrease of 5% in both U.S. dollars and local currency terms, compared to the third quarter of 2023, due to price reductions and a decline in volume resulting from availability of alternative therapies and competing glatiramer acetate products. In certain countries, Teva remains in litigation against generic companies regarding COPAXONE. Respiratory products revenues in our Europe segment in the third quarter of 2024 were $60Â million, a decrease of 1% compared to the third quarter of 2023. In local currency terms, revenues decreased by 3% compared to the third quarter of 2023, mainly due to net price reductions and lower volumes. Product Launches and Pipeline As of SeptemberÂ 30, 2024, our generic products pipeline in Europe included 412 generic approvals relating to 53 compounds in 108 formulations, with no European Medicines Agency (â€œEMAâ€) approvals received. In addition, approximately 1,508 marketing authorization applications are pending approval in 37 European countries, relating to 94 compounds in 215 formulations. Two applications are pending with the EMA relating to seven strengths in 30 markets. For information regarding our innovative medicines and biosimilar products pipeline, see â€œâ€”Teva Consolidated Resultsâ€”Research and Development (R&D) Expensesâ€ below. Europe Gross Profit Gross profit from our Europe segment in the third quarter of 2024 was $698Â million, an increase of 8% compared to $648Â million in the third quarter of 2023. Gross profit margin for our Europe segment in the third quarter of 2024 decreased to 55.2%, compared to 56.6% in the third quarter of 2023. This decrease was mainly due to a negative exchange rate impact from hedging activities. Europe R&D Expenses R&D expenses relating to our Europe segment in the third quarter of 2024 were $55Â million, a decrease of 11% compared to $62Â million in the third quarter of 2023. For a description of our R&D expenses in the third quarter of 2024, see â€œâ€”Teva Consolidated Resultsâ€”Research and Development (R&D) Expensesâ€ below. Europe S&M Expenses S&M expenses relating to our Europe segment in the third quarter of 2024 were $203Â million, an increase of 10% compared to $184Â million in the third quarter of 2023. This increase was mainly to support revenue growth in generic products and AJOVY. Europe G&A Expenses G&A expenses relating to our Europe segment in the third quarter of 2024 were $67Â million, an increase of 2% compared to $66Â million in the third quarter of 2023. Europe Profit Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. Profit from our Europe segment in the third quarter of 2024 was $373Â million, an increase of 10%, compared to $338Â million in the third quarter of 2023. This increase was mainly due to higher gross profit resulting mainly from proceeds from the sale

of certain product rights, partially offset by S&M expenses. Â 65 Table of Contents International Markets Segment The following table presents revenues, expenses and profit for our International Markets segment for the three months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â Three months endedSeptemberÂ 30, Â Â Â Â 2024 Â Â 2023 Â Â Â Â (U.S.Â $Â inÂ millionsÂ /Â %Â ofÂ SegmentÂ Revenues) Â Revenues Â Â $ 613 Â Â Â Â 100 %Â Â $ 591 Â Â Â Â 100 %Â Gross profit Â Â Â 306 Â Â Â Â 49.9 %Â Â Â 293 Â Â Â Â 49.6 %Â R&D expenses Â Â Â 27 Â Â Â Â 4.4 %Â Â Â 30 Â Â Â Â 5.1 %Â S&M expenses Â Â Â 134 Â Â Â Â 21.9 %Â Â Â 116 Â Â Â Â 19.6 %Â G&A expenses Â Â Â 36 Â Â Â Â 5.8 %Â Â Â 33 Â Â Â Â 5.5 %Â Other loss (income) Â Â Â Â§ Â Â Â Â Â§ Â Â Â (2)Â Â Â Â Â§ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit* Â Â $ 109 Â Â Â Â 17.8 %Â Â $ 117 Â Â Â Â 19.7 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Segment profit does not include amortization and certain other items. Â§ Represents an amount less than $0.5Â million or 0.5%, as applicable. International Markets Revenues Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment includes more than 35 countries, covering a substantial portion of the global pharmaceutical industry. As part of a recent shift in executive management responsibilities, commencing JanuaryÂ 1, 2024, Canada is reported under our International Markets segment and is no longer included as part of our United States segment. Prior period amounts were recast to reflect this change. See note 15 to our consolidated financial statements. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, branded generics-oriented markets, such as Russia and certain Latin America markets and hybrid markets, such as Japan. In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form 10-Q, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results and we have no manufacturing or R&D facilities in these markets. During the three months ended SeptemberÂ 30, 2024, the impact of this conflict on our International Markets segmentâ€™s results of operations and financial condition was immaterial. Consistent with our foreign exchange risk management hedging programs, in the nine months ended SeptemberÂ 30, 2024 we partially hedged our exposure to currency exchange rate fluctuations with respect to our balance sheet assets, revenues and expenses. However, as of the end of the third quarter of 2024, we hedge a small part of our projected net revenues in Russian ruble for 2024. Prior to and since the escalation of the conflict, we have been taking measures to reduce our operational cash balances in Russia and Ukraine. We have been monitoring the solvency of our customers in Russia and Ukraine and have taken measures, where practicable, to mitigate our exposure to risks related to the conflict in the region. However, the duration, severity and global implications (including potential inflation and devaluation consequences) of the conflict cannot be predicted at this time and could have an effect on our business, including on our exchange rate exposure, supply chain, operational costs and commercial presence in these markets. Revenues from our International Markets segment in the third quarter of 2024 were $613Â million, an increase of 4% compared to the third quarter of 2023. In local currency terms, revenues increased by 18% compared to the third quarter of 2023, mainly due to higher revenues from generic products in most markets, partially offset by regulatory price reductions and generic competition to off-patented products in Japan. Our higher revenues in the third quarter of 2024 were also partly driven by the sale of certain product rights. In the third quarter of 2024, revenues were negatively impacted by exchange rate fluctuations of $84Â million, including hedging effects, compared to the third quarter of 2023. Revenues in the third quarter of 2024 included $1Â million from a positive hedging impact, compared to a positive hedging impact of $7Â million in the third quarter of 2023, which are included in â€œOtherâ€ in the table below. See note 8d to our consolidated financial statements. Â 66 Table of Contents Revenues by Major Products and Activities The following table presents revenues for our International Markets segment by major products and activities for the three months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â ThreeÂ monthsÂ endedSeptemberÂ 30, Â Â Â PercentageChange Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024-2023 Â Â Â Â (U.S.Â $Â inÂ millions) Â Â Â Â Â Generic products Â Â $ 477 Â Â Â $ 470 Â Â Â Â 1 %Â AJOVY Â Â Â 24 Â Â Â Â 18 Â Â Â Â 35 %Â COPAXONE Â Â Â 13 Â Â Â Â 16 Â Â Â Â (18 %)Â Other* Â Â Â 99 Â Â Â Â 87 Â Â Â Â 14 %Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 613 Â Â Â $ 591 Â Â Â Â 4 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the third quarter of 2024 include the sale of certain product rights. Generic products revenues (including OTC and biosimilar products) in our International Markets segment were $477Â million in the third quarter of 2024, an increase of 1% compared to the third quarter of 2023. In local currency terms, revenues increased by 13% compared to the third quarter of 2023, mainly due to higher revenues in most markets, largely driven by price increases as a result of higher costs due to inflationary pressure in certain markets and higher volumes, partially offset by regulatory price reductions and generic competition to off-patented products in Japan. AJOVY was launched in certain markets in our International Markets segment, including in Canada, Japan, Australia, Israel, South Korea, Brazil and others. AJOVY revenues in our International Markets segment in the third quarter of 2024 were $24Â million, compared to $18Â million in the third quarter of 2023, due to growth in existing markets in which AJOVY was launched. COPAXONE revenues in our International Markets segment in the third quarter of 2024 were $13Â million compared to $16Â million in the third quarter of 2023. AUSTEDO was launched in China and Israel in 2021 and in Brazil in 2022, for the treatment of chorea associated with Huntingtonâ€™s disease and for the treatment of tardive dyskinesia. In February 2024, we announced a strategic partnership for the marketing and distribution of AUSTEDO in China. We continue with additional submissions in various other markets. International Markets Gross Profit Gross profit from our International Markets segment in the third quarter of 2024 was $306Â million, an increase of 4% compared to $293Â million in the third quarter of 2023. Gross profit margin for our International Markets segment in the third quarter of 2024 increased to 49.9%, compared to 49.6% in the third quarter of 2023. This increase was mainly due to price increases largely as a result of inflationary pressures in certain markets, the sale of certain product rights and a favorable mix of products, partially offset by regulatory price reductions and generic competition to off-patented products in Japan, as well as higher costs due to inflationary and other macroeconomic pressures. International Markets R&D Expenses R&D expenses relating to our International Markets segment in the third quarter of 2024 were $27Â million, a decrease of 11% compared to the third quarter of 2023. For a description of our R&D expenses in the third quarter of 2024, see â€œâ€”Teva Consolidated Resultsâ€”Research and Development (R&D) Expensesâ€ below. Â 67 Table of Contents International Markets S&M Expenses S&M expenses relating to our International Markets segment in the third quarter of 2024 were $134Â million, an increase of 16% compared to the third quarter of 2023, mainly to support revenue growth including through our strategic partnership in China for AUSTEDO. International Markets G&A Expenses G&A expenses relating to our International Markets segment in the third quarter of 2024 were $36Â million, an increase of 10% compared to the third quarter of 2023. International Markets Other Income Other income in the third quarter of 2024 was minimal, compared to $2Â million in the third quarter 2023. Other income in the third quarter of 2023 included a capital gain from the sale of assets. International Markets Profit Profit from our International Markets segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. Profit from our International Markets segment in the third quarter of 2024 was $109Â million, a decrease of 7%, compared to $117Â million in the third quarter of 2023. This decrease was mainly due to higher S&M expenses in the third quarter of 2024. Other Activities We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our United States, Europe or International Markets segments described above. On JanuaryÂ 31, 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with our Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be agreed or completed at all. Our revenues from other activities in the third quarter of 2024 were $229Â million, an increase of 6% in U.S. dollars, or 5% in local currency terms, compared to the third quarter of 2023. API sales to third parties in the third quarter of 2024 were $130Â million, reflecting an increase of 4% in both U.S. dollars and local currency terms, compared to the third quarter of 2023, following a reallocation of an immaterial business within our other activities, in line with our intention to divest our API business. Teva Consolidated Results The data presented with respect to other asset impairments, restructuring and other items, operating income (loss), income taxes, net income (loss) attributable to Teva and earnings (loss) per share for the prior period have been revised to reflect a revision in relation to a contingent consideration and related expenses in our consolidated financial statements. For additional information, see note 1c to our consolidated financial statements. Revenues Revenues in the third quarter of 2024 were $4,332Â million, an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to the third quarter of 2023. This increase was mainly due to higher revenues from generic products in all our segments, from AUSTEDO in our United States segment, as well as from the sale of product rights in our Europe and International Markets segments. See â€œâ€”United States Revenues,â€ â€œâ€”Europe Revenues,â€ â€œâ€”International Markets Revenuesâ€ and â€œâ€”Other Activitiesâ€ above. Exchange rate movements during the third quarter of 2024, including hedging effects, negatively impacted revenues by $88Â million, compared to the third quarter of 2023. See note 8d to our consolidated financial statements. Â 68 Table of Contents Gross Profit Gross profit in the third quarter of 2024 was $2,148Â million, an increase of 16% compared to $1,851Â million in the third quarter of 2023. Gross profit margin was 49.6% in the third quarter of 2024, compared to 48.1% in the third quarter of 2023. This increase was mainly due to a favorable mix of products, primarily AUSTEDO, partially offset by a negative impact from foreign exchange rate movements including hedging effects. Research and Development (R&D) Expenses, net Our R&D activities for innovative medicines and biosimilar products in each of our segments include costs of discovery research, preclinical work, drug formulation, early- and late-stage clinical development and product registration costs. These expenditures are reported net of contributions received from collaboration partners. Our spending takes place throughout the development process, including (i)Â early-stage projects in both discovery and preclinical phases; (ii)Â middle-stage projects in clinical programs up to Phase 3; (iii) late-stage projects in Phase 3 programs, including where a new drug application is currently pending approval; (iv)Â post-approval studies for marketed products; and (v)Â indirect expenses, such as costs of internal administration, infrastructure and personnel. Our R&D activities for generic products in each of our segments include both (i)Â direct expenses relating to product formulation, analytical method development, stability testing, management of bioequivalence and other clinical studies and regulatory filings; and (ii)Â indirect expenses, such as costs of internal administration, infrastructure and personnel. In the third quarter of 2024, our R&D expenses related primarily to innovative product candidates and marketed products in immunology and immuno-oncology, neuroscience (such as neuropsychiatry, including post-approval commitments) and selected other areas, as well as generic products and biosimilars. R&D expenses, net in the third quarter of 2024 were $240Â million, a decrease of 5% compared to $253Â million in the third quarter of 2023. Our lower R&D expenses, net in the third quarter of 2024 were largely driven by reimbursements from our strategic partnerships (see note 2 to our consolidated financial statements), reflecting a decrease related to our late-stage innovative pipeline, partially offset by an increase in R&D expenses relating to immunology projects. As we continue to execute on our Pivot to Growth strategy, we see higher R&D spend in some of our late-stage innovative pipeline assets. R&D expenses as a percentage of revenues were 5.5% in the third quarter of 2024, compared to 6.6% in the third quarter of 2023. Innovative Medicines Pipeline Below is a description of key products in our innovative medicines pipeline as of NovemberÂ 1, 2024: Â Â Â Phase 2 Â Phase 3 Neuroscience Â Â OlanzapineÂ LAI (TEV-â€˜749) Schizophrenia (September 2022) Immunology Â DuvakitugÂ (anti-TL1A)Â (1) (TEV-â€™574) InflammatoryÂ BowelÂ Disease Â ICS/SABA(3) (TEV-â€™248) Respiratory (February 2023) Â Emrusolmin(2) (TEV-â€˜286) Multiple System Atropy Â Â (1) In collaboration with Sanofi. (2) In collaboration with Modag. (3) In collaboration with Launch Therapeutics. Â 69 Table of Contents Biosimilar Products Pipeline We have additional biosimilar products in development internally and with our partners that are in various stages of clinical trials and regulatory review worldwide, including Phase 3 clinical trials for biosimilars to XgevaÂ® (denosumab) and XolairÂ® (omalizumab), biosimilars to EyleaÂ® (afilbercept), SimponiÂ®, Simponi AriaÂ® (golimumab) and EntyvioÂ® (vedolizymab), which are in collaboration with Alvotech for the U.S. market, as well as our proposed biosimilar to ProliaÂ® (denosumab), which was submitted for regulatory review in the U.S. and Europe. Selling and Marketing (S&M) Expenses S&M expenses in the third quarter of 2024 were $626Â million, an increase of 9% compared to the third quarter of 2023. This increase was mainly a result of the factors discussed above under â€œâ€”United States segmentâ€”S&M Expenses,â€ â€œâ€”Europe segmentâ€” S&M Expensesâ€ and â€œâ€”International Markets Segmentâ€”S&M Expenses.â€ S&M expenses as a percentage of revenues were 14.5% in the third quarter of 2024, compared to 15.0% in the third quarter of 2023. General and Administrative (G&A) Expenses G&A expenses in the third quarter of 2024 were $298Â million, an increase of 11% compared to the third quarter of 2023. G&A expenses as a percentage of revenues were 6.9% in the third quarter of 2024 compared to 7.0% in the third quarter of 2023. Intangible Asset Impairments We recorded expenses of $28Â million for identifiable intangible asset impairments in the third quarter of 2024, compared to expenses of $47Â million in the third quarter of 2023. See note 5 to our consolidated financial statements. Goodwill Impairment We recorded a goodwill impairment charge of $600Â million related to Tevaâ€™s API reporting unit in the third quarter of 2024. No goodwill impairment charge was recorded in the third quarter of 2023. See note 6 to our consolidated financial statements. Other Asset Impairments, Restructuring and Other Items We recorded income of $23Â million for other asset impairments, restructuring and other items in the third quarter of 2024, compared to expenses of $57Â million in the third quarter of 2023. See note 12 to our consolidated financial statements. Legal Settlements and Loss Contingencies We recorded expenses of $450Â million in legal settlements and loss contingencies in the third quarter of 2024, compared to expenses of $314Â million in the third quarter of 2023. See note 9 to our consolidated financial statements. Other Income (Loss) Other income in the third quarter of 2024 was $21Â million, compared to $9Â million in the third quarter of 2023. Other income in the third quarter of 2024 included a capital gain from the sale of a business in our International Markets segment. Operating Income (Loss) Operating loss was $51Â million in the third quarter of 2024, compared to an operating income of $344Â million in the third quarter of 2023. This decrease was mainly due to a goodwill impairment charge and higher legal settlements and loss contingencies, partially offset by higher gross profit in the third quarter of 2024. Operating loss as a percentage of revenues was 1.2% in the third quarter of 2024, compared to an operating income as a percentage of revenues of 8.9% in the third quarter of 2023. Â 70 Table of Contents Financial Expenses, Net In the third quarter of 2024, financial expenses, net were $272Â million, mainly comprised of net-interest expenses of $225Â million and a negative exchange rate impact driven mainly from currencies which we were unable to hedge. In the third quarter of 2023, financial expenses, net were $280Â million, mainly comprised of net-interest expenses of $247Â million and a negative exchange rate impact driven mainly from currencies which we were unable to hedge. Reconciliation Table to Consolidated Income (Loss) Before Income Taxes The following table presents a reconciliation of our segment profits to our consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â ThreeÂ monthsÂ endedSeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â United States profit Â Â $ 748 Â Â Â $ 571 Â Europe profit Â Â Â 373 Â Â Â Â 338 Â International Markets profit Â Â Â 109 Â Â Â Â 117 Â Â Â Â Â Â Â Â Â Â Â Total reportable segments profit Â Â Â 1,230 Â Â Â Â 1,025 Â Profit (loss) of other activities Â Â Â (16)Â Â Â Â (5)Â Â Â Â Â Â Â Â Â Â Â Total segments profit Â Â Â 1,214 Â Â Â Â 1,020 Â Amounts not allocated to segments: Â Â Â Â Amortization Â Â Â 146 Â Â Â Â 145 Â Other assets impairments, restructuring and other items* Â Â Â (23)Â Â Â Â 57 Â Goodwill impairment Â Â Â 600 Â Â Â Â â€"â€‚ Â Intangible assets impairments Â Â Â 28 Â Â Â Â 47 Â Legal settlements and loss contingencies Â Â Â 450 Â Â Â Â 314 Â Other unallocated amounts Â Â Â 64 Â Â Â Â 112 Â Â Â Â Â Â Â Â Â Â Â Consolidated operating income (loss) * Â Â Â (51)Â Â Â Â 344 Â Â Â Â Â Â Â Â Â Â Â Financial expenses, net Â Â Â 272 Â Â Â Â 280 Â Â Â Â Â Â Â Â Â Â Â Consolidated income (loss) before income taxes * Â Â $ (324)Â Â Â $ 64 Â Â Â Â Â Â Â Â Â Â Â * The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c to our consolidated financial statements. Income Taxes In the third quarter of 2024, we recognized a tax expense of $69Â million, on a pre-tax loss of $324Â million. In the third quarter of 2023, we recognized a tax benefit of $12Â million, on a pre-tax income of $64Â million. See note 11 to our consolidated financial statements. Net Income (Loss) Attributable to Teva Net loss was $437Â million in the third quarter of 2024, compared to a net income of $69Â million in the third quarter of 2023. This decrease was mainly due to changes in operating (income) loss discussed above. Â 71 Table of Contents Diluted Shares Outstanding and Earnings (Loss) per Share The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended SeptemberÂ 30, 2024 and 2023 was 1,133Â million shares and 1,135Â million shares, respectively. Diluted loss per share was $0.39 in the third quarter of 2024, compared to diluted earnings per share of $0.06 in the third quarter of 2023. See note 13 to our consolidated financial statements. Share Count for Market Capitalization We calculate share amounts using the outstanding number of shares (i.e., excluding treasury shares) plus shares that would be outstanding upon the exercise of options and vesting of RSUs and PSUs, and the conversion of our convertible senior debentures, in each case, at period end. As of SeptemberÂ 30, 2024 and 2023, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,167Â million shares and 1,157Â million shares, respectively. Impact of Currency Fluctuations on Results of Operations In the third quarter of 2024, approximately 45% of our revenues were denominated in currencies other than the U.S. dollar. Because our results are reported in U.S. dollars, we are subject to significant foreign currency risks. Accordingly, changes in the rate of

exchange between the U.S. dollar and local currencies in the markets in which we operate (primarily the euro, British pound, Russian ruble, Canadian dollar, Swiss franc, Japanese yen and the new Israeli shekel) impact our results. During the third quarter of 2024, the following main currencies relevant to our operations decreased in value against the U.S. dollar (each compared on a quarterly average basis): Argentinian peso by 67%, Turkish lira by 20%, Brazilian real by 12%, Ukraine hryvna by 10% and Mexican peso by 10%. The following main currencies relevant to our operations increased in value against the U.S. dollar: Polish zloty by 6%, Russian ruble by 6%, Swedish krona by 4% and the euro by 1%. As a result, exchange rate movements during the third quarter of 2024, including hedging effects, negatively impacted overall revenues by $88Â million and operating income by $57Â million, compared to the third quarter of 2023. In the third quarter of 2024, a negative hedging impact of $9Â million was recognized under revenues, and a positive hedging impact of $1Â million was recognized under cost of sales. In the third quarter of 2023, a positive hedging impact of $22Â million was recognized under revenues and a negative hedging impact of $7Â million was recognized under cost of sales. Hedging transactions against future projected revenues and expenses are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. See note 8d to our consolidated financial statements. Commencing in the third quarter of 2018, the cumulative inflation in Argentina exceeded 100% or more over a three-year period. Although this triggered highly inflationary accounting treatment, it did not have a material impact on our results of operations. Commencing in the second quarter of 2022, the cumulative inflation in Turkey exceeded 100% or more over a three-year period. Although this triggered highly inflationary accounting treatment, it did not have a material impact on our results of operations. Comparison of Nine Months Ended SeptemberÂ 30, 2024 to Nine Months Ended SeptemberÂ 30, 2023 Unless specified otherwise, the factors used to explain quarterly changes on a year-over-year basis are also relevant for the comparison of the results for the nine months ended SeptemberÂ 30, 2024 and 2023. Where there are different factors affecting the nine months comparison, we have described them below. Â 72 Table of Contents Segment Information United States Segment The following table presents revenues, expenses and profit for our United States segment for the nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â Â Â Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â 2023 Â Â Â Â (U.S.Â $Â inÂ millionsÂ /Â %Â ofÂ SegmentÂ Revenues) Â Revenues Â Â $ 6,060 Â Â Â Â 100 %Â Â $ 5,465 Â Â Â Â 100 %Â Gross profit Â Â Â 3,291 Â Â Â Â 54.3 %Â Â Â 2,866 Â Â Â Â 52.4 %Â R&D expenses Â Â Â 475 Â Â Â Â 7.8 %Â Â Â 460 Â Â Â Â 8.4 %Â S&M expenses Â Â Â 789 Â Â Â Â 13.0 %Â Â Â 700 Â Â Â Â 12.8 %Â G&A expenses Â Â Â 300 Â Â Â Â 5.0 %Â Â Â 289 Â Â Â Â 5.3 %Â Other loss (income) Â Â Â (1)Â Â Â Â Â§ Â Â Â (3)Â Â Â Â Â§ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit* Â Â $ 1,727 Â Â Â Â 28.5 %Â Â $ 1,421 Â Â Â Â 26.0 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Segment profit does not include amortization and certain other items. Â§ Represents an amount less than 0.5%. United States Revenues As part of a recent shift in executive management responsibilities and in line with our Pivot to Growth strategy, commencing JanuaryÂ 1, 2024, Canada is reported as part of our International Markets segment. Prior period amounts were recast to reflect this change. See note 15 to our consolidated financial statements. Revenues from our United States segment in the first nine months of 2024 were $6,060Â million, an increase of 11% compared to $5,465Â million in the first nine months of 2023. Revenues by Major Products and Activities The following table presents revenues for our United States segment by major products and activities for the nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â PercentageChange2024-2023 Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Â Â Â Â Generic products Â Â $ 2,924 Â Â Â $ 2,471 Â Â Â Â 18 %Â AJOVY Â Â Â 144 Â Â Â Â 154 Â Â Â Â (6 %)Â AUSTEDO Â Â Â 1,124 Â Â Â Â 817 Â Â Â Â 38 %Â BENDEKA and TREANDA Â Â Â 127 Â Â Â Â 185 Â Â Â Â (31 %)Â COPAXONE Â Â Â 179 Â Â Â Â 224 Â Â Â Â (20 %)Â UZEDY Â Â Â 75 Â Â Â Â 14 Â Â Â Â N/A Â Anda Â Â Â 1,134 Â Â Â Â 1,183 Â Â Â Â (4 %)Â Other Â Â Â 352 Â Â Â Â 417 Â Â Â Â (16 %)Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 6,060 Â Â Â $ 5,465 Â Â Â Â 11 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â 73 Table of Contents AJOVY revenues in our United States segment in the first nine months of 2024 were $144Â million, a decrease of 6% compared to $154Â million in the first nine months of 2023, mainly due to an increase in sales allowance due to a non-recurring item, partially offset by growth in volume. Anda revenues from third-party products in our United States segment in the first nine months of 2024 decreased by 4% to $1,134Â million, compared to $1,183Â million in the first nine months of 2023, mainly due to lower volume. United States Gross Profit Gross profit from our United States segment in the first nine months of 2024 was $3,291Â million, an increase of 15%, compared to $2,866Â million in the first nine months of 2023. Gross profit margin for our United States segment in the first nine months of 2024 increased to 54.3% compared to 52.4% in the first nine months of 2023. United States R&D Expenses R&D expenses relating to our United States segment in the first nine months of 2024 were $475Â million, an increase of 3%, compared to $460Â million in the first nine months of 2023. For a description of our R&D expenses in the first nine months of 2024, see â€œâ€”Teva Consolidated Resultsâ€”Research and Development (R&D) Expensesâ€ below. United States S&M Expenses S&M expenses relating to our United States segment in the first nine months of 2024 were $789Â million, an increase of 13%, compared to $700Â million in the first nine months of 2023. United States G&A Expenses G&A expenses relating to our United States segment in the first nine months of 2024 were $300Â million, an increase of 4%, compared to $289Â million in the first nine months of 2023. United States Profit Profit from our United States segment in the first nine months of 2024 was $1,727Â million, an increase of 22%, compared to $1,421Â million in the first nine months of 2023. Europe Segment The following table presents revenues, expenses and profit for our Europe segment for the nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â 2023 Â Â Â Â (U.S.Â $Â inÂ millionsÂ %Â ofÂ SegmentÂ Revenues) Â Revenues Â Â $ 3,749 Â Â Â Â 100.0 %Â Â $ 3,493 Â Â Â Â 100.0 %Â Gross profit Â Â Â 2,113 Â Â Â Â 56.3 %Â Â Â 1,943 Â Â Â Â 55.6 %Â R&D expenses Â Â Â 173 Â Â Â Â 4.6 %Â Â Â 168 Â Â Â Â 4.8 %Â S&M expenses Â Â Â 605 Â Â Â Â 16.1 %Â Â Â 565 Â Â Â Â 16.2 %Â G&A expenses Â Â Â 197 Â Â Â Â 5.2 %Â Â Â 196 Â Â Â Â 5.6 %Â Other loss (income) Â Â Â 1 Â Â Â Â Â§ Â Â Â (2)Â Â Â Â Â§ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit* Â Â $ 1,137 Â Â Â Â 30.3 %Â Â $ 1,017 Â Â Â Â 29.1 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Segment profit does not include amortization and certain other items. Â§ Represents an amount less than 0.5%. Â 74 Table of Contents Europe Revenues Our Europe segment includes the European Union, the United Kingdom, and certain other European countries. Revenues from our Europe segment in the first nine months of 2024 were $3,749Â million, an increase of 7% or $257Â million, compared to the first nine months of 2023. In local currency terms, revenues increased by 6% compared to the first nine months of 2023. Revenues by Major Products and Activities The following table presents revenues for our Europe segment by major products and activities for the nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Percentage Change 2024-2023 Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â Â Â Â Â (U.S.Â $Â inÂ millions) Â Â Â Â Â Generic products Â Â $ 2,947 Â Â Â $ 2,727 Â Â Â Â 8 %Â AJOVY Â Â Â 158 Â Â Â Â 115 Â Â Â Â 37 %Â COPAXONE Â Â Â 163 Â Â Â Â 174 Â Â Â Â (6 %)Â Respiratory products Â Â Â 183 Â Â Â Â 195 Â Â Â Â (6 %)Â Other* Â Â Â 299 Â Â Â Â 282 Â Â Â Â 6 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 3,749 Â Â Â $ 3,493 Â Â Â Â 7 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the first nine months of 2024 include the sale of certain product rights. Europe Gross Profit Gross profit from our Europe segment in the first nine months of 2024 was $2,113Â million, an increase of 9% compared to $1,943Â million in the first nine months of 2023. Gross profit margin for our Europe segment in the first nine months of 2024 increased to 56.3% compared to 55.6% in the first nine months of 2023. This increase was mainly due to price increases of generic products as a result of market conditions such as inflationary pressures in certain markets. Europe R&D Expenses R&D expenses relating to our Europe segment in the first nine months of 2024 were $173Â million, an increase of 3% compared to $168Â million in the first nine months of 2023. Europe S&M Expenses S&M expenses relating to our Europe segment in the first nine months of 2024 were $605Â million, an increase of 7% compared to $565Â million in the first nine months of 2023. Europe G&A Expenses G&A expenses relating to our Europe segment in the first nine months of 2024 were $197Â million, an increase of 1% compared to the first nine months of 2023. Europe Profit Profit from our Europe segment in the first nine months of 2024 was $1,137Â million, an increase of 12% compared to $1,017Â million in the first nine months of 2023. Â 75 Table of Contents International Markets Segment The following table presents revenues, expenses and profit for our International Markets segment for the nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â 2023 Â Â Â Â (U.S.Â $Â inÂ millionsÂ /Â %Â ofÂ SegmentÂ Revenues) Â Revenues Â Â $ 1,802 Â Â Â Â 100 %Â Â $ 1,750 Â Â Â Â 100 %Â Gross profit Â Â Â 889 Â Â Â Â 49.3 %Â Â Â 861 Â Â Â Â 49.2 %Â R&D expenses Â Â Â 85 Â Â Â Â 4.7 %Â Â Â 81 Â Â Â Â 4.6 %Â S&M expenses Â Â Â 397 Â Â Â Â 22.0 %Â Â Â 353 Â Â Â Â 20.2 %Â G&A expenses Â Â Â 109 Â Â Â Â 6.0 %Â Â Â 105 Â Â Â Â 6.0 %Â Other loss (income) Â Â Â (1)Â Â Â Â Â§ Â Â Â (34)Â Â Â Â (2.0 %)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit* Â Â $ 299 Â Â Â Â 16.6 %Â Â $ 356 Â Â Â Â 20.4 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Segment profit does not include amortization and certain other items. Â§ Represents an amount less than 0.5%. International Markets Revenues Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. As part of a recent shift in executive management responsibilities, commencing JanuaryÂ 1, 2024, Canada is reported under our International Markets segment and is no longer included as part of our United States segment. Prior period amounts were recast to reflect this change. See note 15 to our consolidated financial statements. Revenues from our International Markets segment in the first nine months of 2024 were $1,802Â million, an increase of $53Â million, or 3%, compared to the first nine months of 2023. In local currency terms, revenues increased by 19%, compared to the first nine months of 2023. In the first nine months of 2024, revenues were negatively impacted by exchange rate fluctuations of $281Â million including hedging effects, compared to the first nine months of 2023. Revenues in the first nine months of 2024 included a negligible hedging impact compared to a positive hedging impact of $12Â million in the first nine months of 2023, which are included in â€œOtherâ€ in the table below. See note 8d to our consolidated financial statements. Revenues by Major Products and Activities The following table presents revenues for our International Markets segment by major products and activities for the nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â PercentageChange2024-2023 Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Â Â Â Â Generic products Â Â $ 1,440 Â Â Â $ 1,425 Â Â Â Â 1 %Â AJOVY Â Â Â 63 Â Â Â Â 45 Â Â Â Â 39 %Â COPAXONE Â Â Â 38 Â Â Â Â 50 Â Â Â Â (23 %)Â Other* Â Â Â 261 Â Â Â Â 229 Â Â Â Â 14 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 1,802 Â Â Â $ 1,750 Â Â Â Â 3 %Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the first nine months of 2024 include the sale of certain product rights. Â 76 Table of Contents International Markets Gross Profit Gross profit from our International Markets segment in the first nine months of 2024 was $889Â million, compared to $861Â million in the first nine months of 2023. Gross profit margin for our International Markets segment in the first nine months of 2024 was 49.3%, compared to 49.2% in the first nine months of 2023. International Markets R&D Expenses R&D expenses relating to our International Markets segment in the first nine months of 2024 were $85Â million, an increase of 5% compared to $81Â million in the first nine months of 2023. International Markets S&M Expenses S&M expenses relating to our International Markets segment in the first nine months of 2024 were $397Â million, an increase of 12% compared to $353Â million in the first nine months of 2023. International Markets G&A Expenses G&A expenses relating to our International Markets segment in the first nine months of 2024 were $109Â million an increase of 3% compared to $105Â million in the first nine months of 2023. International Markets Other Income Other income in the first nine months of 2024 was $1Â million, compared to $34Â million in the first nine months of 2023. Other income in the first nine months of 2023 included a capital gain from the sale of assets. International Markets Profit Profit from our International Markets segment in the first nine months of 2024 was $299Â million, a decrease of 16%, compared to $356Â million in the first nine months of 2023. Other Activities We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our United States, Europe or International Markets segments described above. On JanuaryÂ 31, 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with our Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be agreed or completed at all. Our revenues from other activities in the first nine months of 2024 were $703Â million, an increase of 3% in both U.S. dollars and in local currency terms, compared to the first nine months of 2023. API sales to third parties in the first nine months of 2024 were $409Â million, an increase of 4% in both U.S. dollars and local currency terms, compared to the first nine months of 2023, following a reallocation of an immaterial business within our other activities, in line with our intention to divest our API business. Teva Consolidated Results The data presented with respect to other asset impairments, restructuring and other items, operating income (loss), income taxes, net income (loss) attributable to Teva and earnings (loss) per share for the prior period have been revised to reflect a revision in relation to a contingent consideration and related expenses in the consolidated financial statements. For additional information, see note 1c to our consolidated financial statements. Revenues Revenues in the first nine months of 2024 were $12,315Â million, an increase of 8% compared to the first nine months of 2023. In local currency terms, revenues increased by 10%, compared to the first nine months of 2023. Â 77 Table of Contents Exchange rate movements during the first nine months of 2024, including hedging effects, negatively impacted revenues by $249Â million, compared to the first nine months of 2023. See note 8d to our consolidated financial statements. Gross Profit Gross profit in the first nine months of 2024 was $5,943Â million, an increase of 14% compared to the first nine months of 2023. Gross profit margin was 48.3% in the first nine months of 2024, compared to 45.9% in the first nine months of 2023. Research and Development (R&D) Expenses R&D expenses in the first nine months of 2024 were $751Â million, an increase of 3% compared to the first nine months of 2023, as we continue to execute on our Pivot to Growth strategy, mainly related to investments in our innovative pipeline. R&D expenses as a percentage of revenues were 6.1% in the first nine months of 2024, compared to 6.4% in the first nine months of 2023. Selling and Marketing (S&M) Expenses S&M expenses in the first nine months of 2024 were $1,891Â million, an increase of 10% compared to the first nine months of 2023. S&M expenses as a percentage of revenues were 15.4% in the first nine months of 2024, compared to 15.2% in the first nine months of 2023. General and Administrative (G&A) Expenses G&A expenses in the first nine months of 2024 were $859Â million, a decrease of 1% compared to the first nine months of 2023. G&A expenses as a percentage of revenues were 7.0% in the first nine months of 2024, compared to 7.6% in the first nine months of 2023. Intangible Asset Impairments We recorded expenses of $169Â million for identifiable intangible asset impairments, in the first nine months of 2024, compared to expenses of $289Â million in the first nine months of 2023. See note 5 to our consolidated financial statements. Goodwill Impairment We recorded goodwill impairment charges of $1,000Â million related to Tevaâ€™s API reporting unit in the first nine months of 2024, compared to a goodwill impairment charge of $700Â million related to our International Markets reporting unit in the first nine months of 2023. See note 6 to our consolidated financial statements. Other Asset Impairments, Restructuring and Other Items We recorded expenses of $931Â million for other asset impairments, restructuring and other items in the first nine months of 2024, compared to expenses of $276Â million in the first nine months of 2023. See note 12 to our consolidated financial statements. Legal Settlements and Loss Contingencies We recorded expenses of $638Â million in legal settlements and loss contingencies in the first nine months of 2024, compared to expenses of $1,009Â million in the first nine months of 2023. See note 9 to our consolidated financial statements. Other Income (Loss) Other income in the first nine months of 2024 was $22Â million, compared to $43Â million in the first nine months of 2023. Other income in the first nine months of 2023 included a capital gain from the sale of assets in our International Markets segment. Â 78 Table of Contents Operating Income (Loss) Operating loss was $274Â million in the first nine months of 2024, compared to an operating loss of $323Â million in the first nine months of 2023. The lower operating loss in the first nine months of 2024 was mainly due to higher gross profit and lower legal settlements and loss contingencies, partially offset by higher other asset impairments, restructuring and other items as well as higher goodwill impairment charges in the first nine months of 2024. Operating loss as a percentage of revenues was 2.2% in the first nine months of 2024, compared to an operating loss as a percentage of revenues of 2.8% in the first nine months of 2023. Financial Expenses, Net In the first nine months of 2024, financial expenses, net were $763Â million, mainly comprised of net-interest expenses of $691Â million and a negative exchange rate impact driven mainly from currencies which we were unable to hedge. In the first nine months of 2023, financial expenses, net were $808Â million, mainly comprised of net-interest expenses of $723Â million and a negative exchange rate impact driven mainly from currencies which we were unable to hedge. Reconciliation Table to Consolidated Income (Loss) Before Income Taxes The following table presents a reconciliation of our segment profits to our consolidated operating income (loss) and to consolidated income (loss) before income taxes for the nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â Nine months endedSeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â United States profit Â Â $ 1,727 Â Â Â $ 1,421 Â Europe profit Â Â Â 1,137 Â Â Â Â 1,017 Â International Markets profit Â Â Â 299 Â Â Â Â 356 Â Total reportable segments profit Â Â Â 3,163 Â Â Â Â 2,794 Â Profit of other activities Â Â Â (1)Â Â Â Â 22 Â Total segments profit Â Â Â 3,162 Â Â Â Â 2,816 Â Amounts not allocated to segments: Â Â Â Â Amortization Â Â Â 444 Â Â Â Â 471 Â Other assets impairments, restructuring and other items (1) Â Â Â 931 Â Â Â Â 276 Â Goodwill impairment Â Â Â 1,000 Â Â Â Â 700 Â Intangible assets impairments Â Â Â 169 Â Â Â Â 289 Â Legal settlements and loss contingencies Â Â Â 638 Â Â Â Â 1,009 Â Other unallocated amounts Â Â Â 254 Â Â Â Â 394 Â Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â Â Â Â Â Â Â Â Consolidated operating income

(loss) (1) Â Â Â (274)Â Â Â Â (323)Â Â Â Â Â Â Â Â Â Â Â Financial expenses, net Â Â Â 763 Â Â Â Â 808 Â Â Â Â Â Â Â Â Â Â Â Consolidated income (loss) before income taxes (1) Â Â $ (1,037)Â Â $ (1,131)Â Â Â Â Â Â Â Â Â Â Â (1) The data presented for 2023 have been revised to reflect a revision in relation to a contingent consideration and related expenses in the consolidated financial statements. See note 1C to our consolidated financial statements for additional information. Income Taxes In the first nine months 2024, we recognized a tax expense of $648Â million, on pre-tax loss of $1,037Â million. In the first nine months of 2023, we recognized a tax benefit of $48Â million, on pre-tax loss of $1,131Â million. See note 11 to our consolidated financial statements. Â 79 Table of Contents Net Income (Loss) Attributable to non-controlling interests Net loss attributable to non-controlling interests was $262Â million in the first nine months of 2024, compared to a net loss attributable to non-controlling interests of $60Â million in the first nine months of 2023. The higher net loss in the first nine months of 2024 was mainly due to higher impairments of tangible assets largely related to the classification of our business venture in Japan as held for sale. See note 12 to our consolidated financial statements. Net Income (Loss) Attributable to Teva Net loss was $1,422Â million in the first nine months of 2024, compared to a net loss of $1,022Â million in the first nine months of 2023. Diluted Shares Outstanding and Earnings (Loss) per Share The weighted average diluted shares outstanding used for the fully diluted share calculations for the nine months ended SeptemberÂ 30, 2024 and 2023 was 1,130Â million shares and 1,119Â million shares, respectively. Diluted loss per share was $1.26 for the nine months ended SeptemberÂ 30, 2024, compared to diluted loss per share of $0.91 for the nine months ended SeptemberÂ 30, 2023. See note 13 to our consolidated financial statements. Impact of Currency Fluctuations on Results of Operations In the first nine months of 2024, approximately 47% of our revenues were denominated in currencies other than the U.S. dollar. Because our results are reported in U.S. dollars, we are subject to significant foreign currency risks and, accordingly, changes in the exchange rate between the U.S. dollar and local currencies in markets in which we operate (primarily the euro, British pound, Canadian dollar, Swiss franc, Russian ruble, Japanese yen and new Israeli shekel) impact our results. During the first nine months of 2024, the following main currencies relevant to our operations decreased in value against the U.S. dollar: Argentinian peso by 72%, Turkish lira by 31%, Chilean peso by 12%, Japanese yen by 9% and Russian ruble by 8% (all compared on a nine-month average basis). The following main currencies relevant to our operations increased in value against the U.S. dollar: Polish zloty by 7%, British pound by 3%, Swiss franc by 2% and Swedish krona by 1%. As a result, exchange rate movements during the first nine months of 2024, including hedging effects, negatively impacted overall revenues by $249Â million and our operating income by $124Â million, in comparison to the first nine months of 2023. In the first nine months of 2024, a positive hedging impact of $1Â million was recognized under revenues, and a negative hedging impact of $5Â million was recognized under cost of sales. In the first nine months of 2023, a positive hedging impact of $20Â million was recognized under revenues and a negative hedging impact of $8 was recognized under cost of sales. Hedging transactions against future projected revenues and expenses are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. See note 8d to our consolidated financial statements. 2024 Aggregated Contractual Obligations There have not been any material changes in our assessment of material contractual obligations and commitments as set forth in Item 7 of our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. Liquidity and Capital Resources Total balance sheet assets were $41,758Â million as of SeptemberÂ 30, 2024, compared to $43,479Â million as of DecemberÂ 31, 2023. Our working capital balance, which includes accounts receivables net of SR&A, inventories, prepaid expenses and other current assets, accounts payables, employee-related obligations, accrued expenses and other current liabilities, was negative $2,009Â million as of SeptemberÂ 30, 2024, compared to negative $1,374Â million as of DecemberÂ 31, 2023. This decrease was mainly due to a classification of the working capital balance related to our business venture in Japan as held for sale (see note 2 to our consolidated financial statements), an increase in provisions for legal settlements and loss contingencies, and a negative impact from several tax items, primarily the agreement with the Israeli Tax Authorities entered into in June 2024 (see note 11 to our consolidated financial statements), partially offset by a decrease in accounts payables. Â 80 Table of Contents Employee-related obligations, as of SeptemberÂ 30, 2024 were $619Â million, compared to $611Â million as of DecemberÂ 31, 2023. The increase in the first nine months of 2024 was mainly due to an accrual for performance incentive payments to employees for 2024, partially offset by performance incentive payments to employees for 2023. Cash investment in property, plant and equipment and intangible assets in the third quarter of 2024 was $148Â million compared to $149Â million in the third quarter of 2023. Depreciation in the third quarter of 2024 was $113Â million, compared to $138Â million in the third quarter of 2023. Cash and cash equivalents as of SeptemberÂ 30, 2024 were $3,319Â million compared to $3,226Â million as of DecemberÂ 31, 2023. Our cash on hand that is not used for ongoing operations is generally invested in bank deposits as well as liquid securities that bear fixed and floating rates. Tevaâ€™s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily our $1.8Â billion unsecured syndicated sustainability-linked revolving credit facility, entered into in April 2022, as amended in February 2023 and on MayÂ 3, 2024 (â€œRCFâ€). See note 7 to our consolidated financial statements. Debt Balance and Movements As of SeptemberÂ 30, 2024, our debt was $18,980Â million, compared to $19,833Â million as of DecemberÂ 31, 2023. This decrease was mainly due to repayment at maturity of $956Â million of our 6% senior notes, partially offset by $88Â million of exchange rate fluctuations. In April 2024, we repaid $956Â million of our 6% senior notes at maturity. In October 2024, we repaid at maturity $685Â million of our 1.13% senior notes due in 2024. As of SeptemberÂ 30, 2024, our debt was effectively denominated in the following currencies: 58% in U.S. dollars, 40% in euros and 2% in Swiss francs. The portion of total debt classified as short-term as of SeptemberÂ 30, 2024 was 14% compared to 8% as of DecemberÂ 31, 2023. Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 75% as of SeptemberÂ 30, 2024, compared to 71% as of DecemberÂ 31, 2023. Our average debt maturity was approximately 5.5 years as of SeptemberÂ 30, 2024, compared to 6.0 years as of DecemberÂ 31, 2023. Total Equity Total equity was $6,383Â million as of SeptemberÂ 30, 2024, compared to $8,126Â million as of DecemberÂ 31, 2023. This decrease was mainly due to a net loss of $1,684Â million, and a negative impact from exchange rate fluctuations of $94Â million. Exchange rate fluctuations affected our balance sheet, as approximately 94% of our net assets as of SeptemberÂ 30, 2024 (including both monetary and non-monetary assets) were in currencies other than the U.S. dollar. When compared to DecemberÂ 31, 2023, changes in currency rates as of SeptemberÂ 30, 2024 had a negative impact of $94Â million on our equity. The following main currencies increased in value against the U.S. dollar: British pound by 5%, Polish zloty by 3% and the euro by 1%. The following main currencies decreased in value against the U.S. dollar: Mexican peso by 16%, Russian ruble by 6%, Chilean peso by 2%, Canadian dollar by 2% and Japanese yen by 1%. All comparisons are on a year-to-date basis. Cash Flow We continually seek to improve the efficiency of our working capital management. Periodically, as part of our cash and commercial relationship management activities, we make decisions in our commercial and supply chain activities which may drive an acceleration of receivable payments from customers, or deceleration of payments to third parties. This has the effect of increasing or decreasing cash from operations during any given period. In connection with strategic continual improvement, we obtained more favorable payment terms from many of our vendors which are expected to continue in future periods. In addition, in periods in which receivable payments from customers are delayed, we have and expect we may in the future extend the time to pay certain vendors, so as to balance our liquidity position. Such decisions may have a material impact on our annual operating cash flow measurement, as well as on our quarterly results. Â 81 Table of Contents Cash flow generated from operating activities during the third quarter of 2024 was $693Â million, compared to $5Â million of cash flow generated from operating activities in the third quarter of 2023. The higher cash flow generated from operating activities in the third quarter of 2024 resulted mainly from higher profit in our United States segment, as well as from changes in working capital items, including a positive impact from accounts receivables, net of SR&A, and from accounts payables and inventory levels, partially offset by higher legal payments during the third quarter of 2024. During the third quarter of 2024, we generated free cash flow of $922Â million, which we define as comprising $693Â million in cash flow generated from operating activities, $339Â million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $38Â million in divestitures of businesses and other assets, partially offset by $148Â million in cash used for capital investment. During the third quarter of 2023, we generated free cash flow of $229Â million, which we define as comprising $5Â million in cash flow generated from operating activities, $362Â million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $10Â million in proceeds from divestitures of businesses and other assets, partially offset by $149Â million in cash used for capital investment. The increase in the third quarter of 2024, resulted mainly from higher cash flow generated from operating activities. Dividends We have not paid dividends on our ordinary shares or ADSs since December 2017. Commitments In addition to financing obligations under short-term debt and long-term senior notes and loans, debentures and convertible debentures, our major contractual obligations and commercial commitments include leases, royalty payments, contingent payments pursuant to acquisition agreements, collaboration agreements, development funding agreements and participation in joint ventures associated with R&D activities. For further information on our agreements with mAbxience, Launch Therapeutics and Abingworth, Biolojic Design, Royalty Pharma, Sanofi, Modag, Alvotech, Takeda and MedinCell, see note 2 to our consolidated financial statements. We are committed to paying royalties to owners of know-how, partners in alliances and certain other arrangements, and to parties that financed R&D at a wide range of rates as a percentage of sales of certain products, as defined in the agreements. In some cases, the royalty period is not defined; in other cases, royalties will be paid over various periods not exceeding 20 years. In connection with certain development, supply and marketing, and research and collaboration or services agreements, we are required to indemnify, in unspecified amounts, the parties to such agreements against third-party claims relating to (i)Â infringement or violation of intellectual property or other rights of such third party; or (ii)Â damages to users of the related products. Except as described in our financial statements, we are not aware of any material pending action that may result in the counterparties to these agreements claiming such indemnification. Non-GAAP Net Income and Non-GAAP EPS Data We present non-GAAP net income and non-GAAP earnings per share (â€œEPSâ€) as management believes that such data provide useful information to investors because they are used by management and our Board of Directors, in conjunction with other performance metrics, to evaluate our operational performance, to prepare and evaluate our work plans and annual budgets and ultimately to evaluate the performance of management, including annual compensation. While other qualitative factors and judgment also affect annual compensation, the principal quantitative element in the determination of such compensation are performance targets tied to the work plan, which are based on these non-GAAP measures. Non-GAAP financial measures have no standardized meaning and accordingly have limitations in their usefulness to investors. Investors are cautioned that, unlike financial measures prepared in accordance with U.S. GAAP, non-GAAP measures may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses our performance. The limitations of using non-GAAP financial measures as performance measures are that they provide a view of our results of operations without including all events during a period and may not provide a comparable view of our performance to other companies in the pharmaceutical industry. Investors should consider non-GAAP net income and non-GAAP EPS in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Â 82 Table of Contents In preparing our non-GAAP net income and non-GAAP EPS data, we exclude items that either have a non-recurring impact on our financial performance or which, in the judgment of our management, are items that, either as a result of their nature or size, could, were they not excluded, potentially cause investors to extrapolate future performance from an improper base that is not reflective of our underlying business performance. Certain of these items are also excluded because of the difficulty in predicting their timing and scope. The items excluded from our non-GAAP net income and non-GAAP EPS include: Â Â â€¢ Â amortization of purchased intangible assets; Â Â â€¢ Â legal settlements and material litigation fees and/or loss contingencies, due to the difficulty in predicting their timing and scope; Â Â â€¢ Â impairments of long-lived assets, including intangibles, property, plant and equipment and goodwill; Â Â â€¢ Â restructuring expenses, including severance, retention costs, contract cancellation costs and certain accelerated depreciation expenses primarily related to the rationalization of our plants or to certain other strategic activities, such as the realignment of R&D focus or other similar activities; Â Â â€¢ Â acquisition- or divestment- related items, including changes in contingent consideration, integration costs, banker and other professional fees and inventory step-up; Â Â â€¢ Â expenses related to our equity compensation; Â Â â€¢ Â significant one-time financing costs, amortization of issuance costs and terminated derivative instruments, and marketable securities investment valuation gains/losses; Â Â â€¢ Â unusual tax items; Â Â â€¢ Â other awards or settlement amounts, either paid or received; Â Â â€¢ Â other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as impacts due to significant costs for remediation of plants, or other unusual events; and Â Â â€¢ Â corresponding tax effects of the foregoing items. The following tables present our non-GAAP net income and non-GAAP EPS for the three and nine months ended SeptemberÂ 30, 2024 and 2023, as well as reconciliations of each measure to their nearest GAAP equivalents: Â Â Â ThreeÂ monthsÂ endedSeptemberÂ 30, Â Â Â Nine months endedSeptemberÂ 30, Â ($ in millions except per share amounts) Â 2024 Â Â â€ƒ2023â€ƒ Â Â 2024 Â Â â€ƒ2023â€ƒ Â Net income (Loss) attributable to Teva(1) Â ($) Â Â Â (437)Â Â Â 69 Â Â ($) Â Â Â (1,422)Â Â Â (1,022)Â Increase (decrease) for excluded items: Â Â Â Â Â Â Amortization of purchased intangible assets Â Â Â 146 Â Â Â 145 Â Â Â Â 444 Â Â Â 471 Â Legal settlements and loss contingencies(2) Â Â Â 450 Â Â Â 314 Â Â Â Â 638 Â Â Â 1,009 Â Goodwill impairment(3) Â Â Â 600 Â Â Â â€”â€‚Â Â Â Â 1,000 Â Â Â 700 Â Impairment of long-lived assets(4) Â Â Â (51)Â Â Â 48 Â Â Â Â Â 758 Â Â Â 310 Â Restructuring costs Â Â Â 21 Â Â Â 27 Â Â Â Â 52 Â Â Â 93 Â Equity compensation Â Â Â 29 Â Â Â 31 Â Â Â Â 89 Â Â Â â€ƒâ€ƒ93 Â Contingent consideration(1)(5) Â Â Â 34 Â Â Â â€ƒâ€ƒ27 Â Â Â Â 305 Â Â Â 140 Â Loss (Gain) on sale of business Â Â Â (20)Â Â Â (5)Â Â Â Â (21)Â Â Â (3)Â Accelerated depreciation Â Â Â 1 Â Â Â 25 Â Â Â Â 8 Â Â Â 74 Â Financial expenses Â Â Â 11 Â Â Â 14 Â Â Â Â 35 Â Â Â 53 Â Items attributable to non-controlling interests(4) Â Â Â 41 Â Â Â (1)Â Â Â Â (276)Â Â Â (91)Â Â 83 Table of Contents Other non-GAAP items(6) Â Â Â 56 Â Â Â 64 Â Â Â Â 162 Â Â Â 252 Â Corresponding tax effects and unusual tax items(7) Â Â Â (83)Â Â Â (80)Â Â Â Â 270 Â Â Â (315)Â Non-GAAP net income attributable to Teva Â ($) Â Â Â 798 Â Â Â 677 Â Â ($) Â Â Â 2,043 Â Â Â 1,762 Â Non-GAAP tax rate(8) Â Â Â 16.0 %Â Â Â 9.0 %Â Â Â Â 15.5 %Â Â Â 13.0 %Â GAAP diluted earnings (loss) per share attributable to Teva Â ($) Â Â Â (0.39)Â Â Â 0.06 Â Â ($) Â Â Â Â (1.26)Â Â Â (0.91)Â EPS difference(9) Â Â Â 1.08 Â Â Â 0.54 Â Â Â Â 3.04 Â Â Â 2.47 Â Non-GAAP diluted EPS attributable to Teva(9) Â ($) Â Â Â 0.69 Â Â Â 0.60 Â Â ($) Â Â Â Â 1.78 Â Â Â 1.56 Â Non-GAAP average number of shares (in millions)(9) Â Â Â 1,155 Â Â Â 1,135 Â Â Â Â 1,148 Â Â Â 1,131 Â Â (1) The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c to our consolidated financial statements. (2) Adjustments for legal settlements and loss contingencies in the third quarter of 2024 were mainly related to a provision of $350Â million recorded in connection with a decision by the European Commission in its antitrust investigation into COPAXONEÂ®, and to an update to the estimated settlement provision of $121Â million for the opioid cases (mainly related to the settlement agreement with the city of Baltimore and the effect of the passage of time on the net present value of the discounted payments). Adjustments for legal settlements and loss contingencies in the third quarter of 2023 were mainly related to a provision of $270Â million in connection with the U.S. DOJ patient assistance program litigation. Adjustments for legal settlements and loss contingencies in the nine months ended SeptemberÂ 30, 2024 were mainly related to a provision of $350Â million recorded in connection with a decision by the European Commission in its antitrust investigation into COPAXONEÂ®, and to an update to the estimated settlement provision of $239Â million for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore). Adjustments for legal settlements and loss contingencies in the nine months ended SeptemberÂ 30, 2023 were mainly related to an update to the estimated provision of $370 million related to the DOJ patient assistance program litigation, an update to the estimated settlement provision of $248Â million related to the remaining opioid cases, the provision of $204Â million relating to the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, and the provision of $100Â million related to the settlement of the reverse-payment antitrust litigation over certain HIV medicines. See note 10 to our consolidated financial statements. (3) Goodwill impairment charges of $600Â million and $1,000Â million related to Tevaâ€™s API reporting unit were recorded in the three and nine months ended SeptemberÂ 30, 2024, respectively. A goodwill impairment charge of $700Â million related to our International Markets reporting unit was recorded in the nine months ended SeptemberÂ 30, 2023. (4) Adjustments for impairment of long-lived assets and items attributable to non-controlling interests, for the first nine months of 2024 primarily consisted of $561Â million and $275Â million, respectively, related to the classification of the business venture in Japan as held for sale. Adjustments for impairment of long-lived assets, for the first nine months of 2023 primarily consisted of $206 million related to impairments of identifiable product rights and $83 million related to impairments of IPR&D assets. (5) Adjustments for contingent consideration primarily related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of RevlimidÂ®), of $28Â million and $266Â million, respectively for the three and nine months ended SeptemberÂ 30, 2024, and of $23Â million and $111Â million, respectively for the three and nine months ended SeptemberÂ 30, 2023. (6) Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an

understanding of trends in our financial results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other unusual events. (7) Adjustments for corresponding tax effects and unusual tax items for the nine months ended SeptemberÂ 30, 2024, include a tax item in an amount of $495Â million related to the settlement agreement with the ITA to settle certain litigation with respect to taxes payable for the Companyâ€™s taxable years 2008 through 2020. (8) Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. GAAP tax rate for the three and nine months ended SeptemberÂ 30, 2024 was 21% and 62% respectively and for the three and nine months ended SeptemberÂ 30, 2023 was 19% and 4% respectively. Â (9) EPS difference and diluted non-GAAP EPS are calculated by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares. Â 84 Table of Contents Off-Balance Sheet Arrangements Except for securitization transactions, which are disclosed in note 10f to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, we do not have any material off-balance sheet arrangements. Critical Accounting Policies For a summary of our significant accounting policies, see note 1 to our consolidated financial statements and â€œCritical Accounting Policiesâ€ included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. Additionally, see note 6 to our consolidated financial statements on this Form 10-Q for disclosure regarding reporting units at risk identified during our annual goodwill impairment test. Recently Issued Accounting Pronouncements See note 1 to our consolidated financial statements. Â ITEMâ€‰3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK There has not been any material change in our assessment of market risk as set forth in Item 7A to our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. Â ITEMâ€‰4. CONTROLS AND PROCEDURES Disclosure Controls and Procedures Teva maintains â€œdisclosure controls and proceduresâ€ (as defined inÂ RulesÂ 13a-15(e)Â andÂ 15d-15(e)Â under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€)) that are designed to provide reasonable assurance that information required to be disclosed in Tevaâ€™s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to Tevaâ€™s management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating these disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. After evaluating the effectiveness of our disclosure controls and procedures as of SeptemberÂ 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, due to a material weakness in internal control over financial reporting described below, as of such date, the Companyâ€™s disclosure controls and procedures were not effective. Previously Identified Material Weakness in Internal Control over Financial Reporting A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the companyâ€™s annual or interim financial statements will not be prevented or detected on a timely basis. As previously disclosed, in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023,Â during the preparation of our consolidated financial statements for the year ended DecemberÂ 31, 2023, management identified a material weakness in our internal control over financial reporting, which continues to exist as of SeptemberÂ 30, 2024. We did not design and maintain effective control over the contingent consideration liability and related expenses in connection with estimated future royalty payments. This material weakness resulted in the misstatement of our â€œOther asset impairments, restructuring and other items,â€ â€œNet incomeâ€ and â€œOther taxes and long-term liabilitiesâ€ and related financial disclosures, and led to the revision of the Companyâ€™s consolidated financial statements for the year ended DecemberÂ 31, 2022, and the interim financial information for the quarterly and year-to-date periods ended JuneÂ 30, 2022, SeptemberÂ 30, 2022, DecemberÂ 31, 2022, MarchÂ 31, 2023, JuneÂ 30, 2023 and SeptemberÂ 30, 2023. Additionally, this material weakness could result in a misstatement of the aforementioned account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected. Â 85 Table of Contents Remediation Plan Management has designed and implemented the following specific controls to address the material weakness and enhance our disclosure controls and procedures over the contingent consideration liability: (i)Â defined responsibilities over the end-to-end process; (ii)Â enhanced the formality and rigor of reconciliation procedures; and (iii)Â implemented additional monitoring controls through management reviews. In addition, management has conducted trainings for the related control owners. Although the new controls have been designed and implemented, they have not been operated for a sufficient period of time for management to conclude, through testing, that these controls are operating effectively. Accordingly, the material weakness described above is not remediated as of SeptemberÂ 30, 2024. Changes in Internal Control over Financial Reporting During the three months ended SeptemberÂ 30, 2024, there were no changes in internal control over financial reporting that materially affected or are reasonably likely to materially affect Tevaâ€™s internal control over financial reporting. Â 86 Table of Contents PART II â€” OTHER INFORMATION Â ITEMâ€‰1. LEGAL PROCEEDINGS We are subject to various litigation and other legal proceedings. For a discussion of these matters, see â€œCommitments and Contingenciesâ€ included in note 10 to our consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Â ITEMâ€‰1A. RISK FACTORS There are no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. Â ITEMâ€‰2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Unregistered Sales of Equity Securities There were no sales of unregistered equity securities during the three months ended SeptemberÂ 30, 2024. Repurchase of Shares We did not repurchase any of our shares during the three months ended SeptemberÂ 30, 2024 and currently cannot conduct share repurchases or pay dividends due to our accumulated deficit. Â ITEMâ€‰3. DEFAULTS UPON SENIOR SECURITIES Not applicable. Â ITEMâ€‰4. MINE SAFETY DISCLOSURES Not applicable. Â 87 Table of Contents falsetruefalseTable of Contents ITEMâ€‰5. OTHER INFORMATION Director and Officer Rule 10b5-1 Trading Arrangements During the three months ended SeptemberÂ 30, 2024, the following officer adopted a Rule 10b5-1 trading arrangement (as such term is defined in Item 408 of Regulation S-K). The trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. Â Name and Title Â Â Date Â Â Â Action Â Â Â Expiration Date Â Â Â MaximumÂ SharesSubject to PlanÂ (1) Â Christine Fox, EVP, U.S. Commercial Â Â Â AugustÂ 13,Â 2024 Â Â Â Â Adopted Â Â Â Â MarchÂ 6,Â 2025 Â Â Â Â 83,953 Â Â (1)Â The plan includes shares to be sold solely to cover tax withholding obligations. Â 88 Table of Contents ITEMâ€‰6. EXHIBITS Â 31.1 Â Â Certification of the Chief Executive Officer pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002Â * 31.2 Â Â Certification of the Chief Financial Officer pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002Â * 32 Â Â Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002 * 101.INS Â Â Inline XBRL Taxonomy Instance Document 101.SCH Â Â Inline XBRL Taxonomy Extension Schema Document 101.CAL Â Â Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Â Â Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Â Â Inline XBRL Taxonomy Extension Labels Linkbase Document 101.PRE Â Â Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Â Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â * Filed herewith. Â 89 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â Â TEVAÂ PHARMACEUTICALÂ INDUSTRIESÂ LIMITED Date: NovemberÂ 6, 2024 Â Â By: Â /s/Â Eli Kalif Â Â Name: Â Eli Kalif Â Â Title: Â Executive Vice President, Chief Financial Officer (Duly Authorized Officer) Â 90 EX-31.1 2 d874174dex311.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT I, Richard D. Francis, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of Teva Pharmaceutical Industries Limited; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; Â 4. The companyâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have: Â Â a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c. evaluated the effectiveness of the companyâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d. disclosed in this report any change in the companyâ€™s internal control over financial reporting that occurred during the companyâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the companyâ€™s internal control over financial reporting; and Â 5. The companyâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the companyâ€™s auditors and the audit committee of the companyâ€™s board of directors (or persons performing the equivalent functions): Â Â a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the companyâ€™s ability to record, process, summarize and report financial information; and Â Â b. any fraud, whether or not material, that involves management or other employees who have a significant role in the companyâ€™s internal control over financial reporting. Date: NovemberÂ 6, 2024 Â /s/ Richard D. Francis Richard D. Francis President and Chief Executive Officer EX-31.2 3 d874174dex312.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT I, Eli Kalif, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of Teva Pharmaceutical Industries Limited; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; Â 4. The companyâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have: Â Â a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c. evaluated the effectiveness of the companyâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d. disclosed in this report any change in the companyâ€™s internal control over financial reporting that occurred during the companyâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the companyâ€™s internal control over financial reporting; and Â 5. The companyâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the companyâ€™s auditors and the audit committee of the companyâ€™s board of directors (or persons performing the equivalent functions): Â Â a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the companyâ€™s ability to record, process, summarize and report financial information; and Â Â b. any fraud, whether or not material, that involves management or other employees who have a significant role in the companyâ€™s internal control over financial reporting. Date: NovemberÂ 6, 2024 Â /s/ Eli Kalif Eli Kalif Executive Vice President, Chief Financial Officer EX-32 4 d874174dex32.htm EX-32 EX-32 Exhibit 32 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Teva Pharmaceutical Industries Limited (the â€œCompanyâ€) on Form 10-Q for the period ended SeptemberÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), we, Richard D. Francis, President and Chief Executive Officer of the Company, and Eli Kalif, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Â§906 of the Sarbanes-Oxley Act of 2002, that: Â Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: NovemberÂ 6, 2024 Â /s/ Richard D. Francis Richard D. Francis President and Chief Executive Officer /s/ Eli Kalif Eli Kalif Executive Vice President, Chief Financial Officer EX-101.SCH 5 teva-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Consolidated Statements of Income (Loss) link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Consolidated Statements of Income (Loss) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Consolidated Statements of Changes in Equity link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Consolidated Statements of Changes in Equity (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1009 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1010 - Statement - Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 999001 - Disclosure - Basis of presentation link:presentationLink link:definitionLink link:calculationLink 999002 - Disclosure - Certain transactions link:presentationLink link:definitionLink link:calculationLink 999003 - Disclosure - Revenue from contracts with customers link:presentationLink link:definitionLink link:calculationLink 999004 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 999005 - Disclosure - Identifiable Intangible Assets link:presentationLink link:definitionLink link:calculationLink 999006 - Disclosure - Goodwill link:presentationLink link:definitionLink link:calculationLink 999007 - Disclosure - Debt obligations link:presentationLink link:definitionLink link:calculationLink 999008 - Disclosure - Derivative instruments and hedging activities link:presentationLink link:definitionLink link:calculationLink 999009 - Disclosure - Legal Settlements and Loss Contingencies link:presentationLink link:definitionLink link:calculationLink 999010 - Disclosure - Commitments and contingencies link:presentationLink link:definitionLink link:calculationLink 999011 - Disclosure - Income taxes link:presentationLink link:definitionLink link:calculationLink 999012 - Disclosure - Other assets impairments, restructuring and other items link:presentationLink link:definitionLink link:calculationLink 999013 - Disclosure - Earnings (Loss) per Share link:presentationLink link:definitionLink link:calculationLink 999014 - Disclosure - Accumulated other comprehensive income (loss) link:presentationLink link:definitionLink link:calculationLink 999015 - Disclosure - Segments link:presentationLink link:definitionLink link:calculationLink 999016 - Disclosure - Fair value measurement link:presentationLink link:definitionLink link:calculationLink 999017 - Disclosure - Basis of presentation (Tables) link:presentationLink link:definitionLink link:calculationLink 999018 - Disclosure - Certain transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 999019 - Disclosure - Revenue from contracts with customers (Tables) link:presentationLink link:definitionLink link:calculationLink 999020 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 999021 - Disclosure - Identifiable Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 999022 - Disclosure - Goodwill (Tables) link:presentationLink link:definitionLink link:calculationLink 999023 - Disclosure - Debt obligations (Tables) link:presentationLink link:definitionLink link:calculationLink 999024 - Disclosure - Derivative instruments and hedging activities (Tables) link:presentationLink link:definitionLink link:calculationLink 999025 - Disclosure - Other assets impairments, restructuring and other items (Tables) link:presentationLink link:definitionLink link:calculationLink 999026 - Disclosure - Accumulated other comprehensive income (loss) (Tables) link:presentationLink link:definitionLink link:calculationLink 999027 - Disclosure - Segments (Tables) link:presentationLink link:definitionLink link:calculationLink 999028 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:definitionLink

link:calculationLink 999029 - Disclosure - Basis of presentation - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 999030 - Disclosure - Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail) link:presentationLink link:definitionLink link:calculationLink 999031 - Disclosure - Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 999032 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999033 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) link:presentationLink link:definitionLink link:calculationLink 999034 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999035 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) link:presentationLink link:definitionLink link:calculationLink 999036 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) link:presentationLink link:definitionLink link:calculationLink 999037 - Disclosure - Inventories - Summary of Inventories (Detail) link:presentationLink link:definitionLink link:calculationLink 999038 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999039 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 999040 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) link:presentationLink link:definitionLink link:calculationLink 999041 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 999042 - Disclosure - Goodwill - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999043 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail) link:presentationLink link:definitionLink link:calculationLink 999044 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail) link:presentationLink link:definitionLink link:calculationLink 999045 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 999046 - Disclosure - Debt Obligations - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999047 - Disclosure - Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail) link:presentationLink link:definitionLink link:calculationLink 999048 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) link:presentationLink link:definitionLink link:calculationLink 999049 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail) link:presentationLink link:definitionLink link:calculationLink 999050 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail) link:presentationLink link:definitionLink link:calculationLink 999051 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999052 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999053 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999054 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999055 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) link:presentationLink link:definitionLink link:calculationLink 999056 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) link:presentationLink link:definitionLink link:calculationLink 999057 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) link:presentationLink link:definitionLink link:calculationLink 999058 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999059 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999060 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail) link:presentationLink link:definitionLink link:calculationLink 999061 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 999062 - Disclosure - Segments - Summary of Segment Profit (Detail) link:presentationLink link:definitionLink link:calculationLink 999063 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail) link:presentationLink link:definitionLink link:calculationLink 999064 - Disclosure - Segments - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999065 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink 999066 - Disclosure - Fair value measurement - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999067 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) link:presentationLink link:definitionLink link:calculationLink 999068 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 999069 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink 999070 - Disclosure - Insider Trading Arrangements link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 teva-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 teva-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 teva-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Period End Date Document Period End Date Entity Current Reporting Status Entity Current Reporting Status Entity Registrant Name Entity Registrant Name Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Transition Report Document Transition Report Entity Shell Company Entity Shell Company Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, Country Entity Address, Country Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Document Type Document Type Entity Filer Category Entity Filer Category Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Small Business Smaller Reporting Company Document Quarterly Report Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivables, net of allowance for credit losses of $91 million and $95 million as of September 30, 2024 and December 31, 2023 Inventory, Net Inventories Total Prepaid Expense, Current Prepaid expenses Other Assets, Current Other current assets Disposal Group, Including Discontinued Operation, Assets, Current Assets held for sale Total assets of the disposal group classified as held for sale in the consolidated balance sheets Assets, Current Total current assets Deferred Income Tax Assets, Net Deferred income taxes Other Assets, Noncurrent OtherÂ non-currentÂ assets Property, Plant and Equipment, Net Property, plant and equipment, net Finite-Lived Intangible Assets, Net Identifiable intangible assets, net Net carrying amount Goodwill Goodwill Beginning balance Ending balance Assets Total assets Total assets Operating Lease, Right-of-Use Asset Operating lease right-of-use assets, net Liabilities and Equity [Abstract] LIABILITIES AND EQUITY Liabilities, Current [Abstract] Current liabilities: Debt, Current Short-term debt Total short-term debt Sales Reserves And Allowances Sales reserves and allowances The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection. Accounts Payable, Trade, Current Accounts payables Employee-related Liabilities, Current Employee-related obligations Accrued Expenses Accrued expenses Accrued expenses. Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Liabilities Held For Sale Current Liabilities held for sale Liabilities held for sale current. Liabilities, Noncurrent [Abstract] Long-term liabilities: Deferred Tax and Other Liabilities, Noncurrent Deferred income taxes Other Liabilities, Noncurrent Other taxes and long-term liabilities Notes and Loans, Noncurrent Senior notes and loans Total senior notes and loans Liabilities, Noncurrent Total long-term liabilities Total long-term liabilities Operating Lease, Liability, Noncurrent Operating lease liabilities Stockholders' Equity Attributable to Parent [Abstract] Teva shareholders' equity: Common Stock, Value, Issued Ordinary shares of NIS 0.10 par value per share; September 30, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,240 million shares and 1,227 million shares, respectively Additional Paid in Capital AdditionalÂ paid-inÂ capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Beginning Balance Ending Balance Treasury Stock, Value Treasury shares as of September 30, 2024 and December 31, 2023: 106 million ordinary shares Stockholders' Equity Attributable to Parent Stockholders' equity attributable to Teva shareholders Commitments and Contingencies Commitments and contingencies, see note 10 Liabilities Total liabilities Total liabilities Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interests Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total equity Beginning balance Ending balance Total equity Liabilities and Equity Total liabilities and equity Total liabilities and equity Common Stock, Par or Stated Value Per Share Common stock, par or stated value per share Common Stock, Shares Authorized Ordinary shares, authorized Common Stock, Shares, Issued Ordinary shares, issued Treasury Stock, Common, Shares Treasury shares Accounts Receivable, Allowance for Credit Loss, Current Allowance for credit losses Income Statement [Abstract] Earnings Per Share [Abstract] Earnings (loss) per share attributable to ordinary shareholders: Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average number of shares (in millions): Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted average number of shares used in the computation of diluted earnings (loss) per share Revenue from Contract with Customer, Excluding Assessed Tax Net revenues Total revenue Revenues Cost of Goods and Services Sold Cost of sales Gross Profit Gross profit Gross profit Research and Development Expense (Excluding Acquired in Process Cost) Research and development expenses R&D expenses Selling and Marketing Expense Selling and marketing expenses S&M expenses General and Administrative Expense General and administrative expenses G&A expenses Intangible Assets Impairments Intangible assets impairments Intangible Assets Impairments Goodwill, Impairment Loss Goodwill impairment Impairment of goodwill Goodwill impairment Other Operating Income (Expense), Net Other loss (income) Operating Income (Loss) Operating income (loss) Operating income (loss) Segment profit Consolidated operating income (loss) Nonoperating Income (Expense) Financial expenses, net Financial expenses, net Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income (loss) before income taxes Income (loss) before income taxes Consolidated income (loss) before income taxes Income Tax Expense (Benefit) Income taxes (benefit) Tax benefit Income (Loss) from Equity Method Investments Share in (profits) losses of associated companies, net Income (Loss) from equity method investments Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) Net income (loss) Net Income (loss) Net Income (Loss) Attributable to Noncontrolling Interest Net income (loss) attributable to non-controlling interests Net income (loss) attributable to Teva Net income (loss) attributable to Teva Impairments Restructuring And Others Other assets impairments, restructuring and other items Other asset impairments, restructuring and other items Impairments restructuring and others. Legal Settlements And Loss Contingencies Legal settlements and loss contingencies The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items). Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Statement of Comprehensive Income [Abstract] Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Currency translation adjustment Unrealized gain (loss) on derivative net of tax Unrealized gain (loss) from derivative financial instruments, net Unrealized gain (loss) on derivative net of tax. Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax Unrealized loss on defined benefit plans Other Comprehensive Income (Loss), Net of Tax Total other comprehensive income (loss) Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive income (loss) attributable to non-controlling interests Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) attributable to Teva Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Ordinary Shares [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] Treasury Stock, Common [Member] Treasury Shares [Member] Parent [Member] Total Teva Shareholders' Equity [Member] Noncontrolling Interest [Member] Non-controlling Interests [Member] Shares, Issued Beginning balance, shares Ending balance, shares Stock Issued During Period, Shares, New Issues Issuance of Shares, shares Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Stock Issued During Period, Value, New Issues Issuance of Shares, value Proceeds from Stock Options Exercised Proceeds from exercise of options Noncontrolling Interest, Increase from Subsidiary Equity Issuance Purchase of shares from non-controlling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Dividend to non-controlling interests Maximum [Member] Maximum [Member] Stock Issued During Period, Value, Stock Options Exercised Exercise of options by employees and vested RSUs Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Repayments of Long-term Debt Repayment of senior notes and loans and other long term liabilities Repayments of Short-term Debt Repayment of short term debt Proceeds from (Payments for) Other Financing Activities Other financing activities Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Proceeds from Debt, Net of Issuance Costs Proceeds from senior notes, net of issuance costs Proceeds from Short-term Debt Proceeds from short term debt Dividends Paid To Non controlling Interests Dividends paid to non-controlling interests Dividends paid to noncontrolling interests. Proceed From Minority Non Controlling Shareholders Purchase of shares from non-controlling interests Proceed from Minority Non-Controlling Shareholders. Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities: Payment To Acquire Marketable Securities And Other Assets Purchases of investments and other assets The cash outflow from purchase of available for sales securities and other assets. Payments for (Proceeds from) Other Investing Activities Other investing activities Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Payments to Acquire Businesses, Net of Cash Acquired Acquisition of businesses, net of cash acquired Proceeds from Divestiture of Businesses Proceeds from sale of business and long-lived assets Proceeds from Sale, Maturity and Collection of Investments Proceeds from sale of investments Proceeds From Beneficial Interest In Exchange For Securitized Accounts Receivables Beneficial interest collected in exchange for securitized accounts receivables Proceeds from beneficial interest in exchange for securitized accounts receivables. Payments to Acquire Productive Assets Purchases of property, plant and equipment and intangible assets Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by operations: Impairment Of Long Lived Assets And Assets Held For Sale Finite And Indefinite Lived Intangible Assets Other Than Goodwill Impairment of long-lived assets and assets held for sale Impairment of long lived assets and assets held for sale finite and indefinite lived intangible assets other than goodwill. Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Increase (Decrease) in Operating Capital Net change in operating assets and liabilities Deferred Income Taxes Net And Uncertain Tax Positions Deferred income taxes â€“ net and uncertain tax positions Deferred income taxes net and uncertain tax positions. Profit From Sale Of Long Lived Assets And Investment Net loss (gain) from sale of business and long-lived assets Profit from sale of long lived assets and investment. Share-based Compensation Stock-based compensation Other Operating Activities, Cash Flow Statement Other items Net Cash Provided by (Used in) Operating Activities Net cash provided by (used in) operating activities Supplemental Cash Flow Information [Abstract] Non-cashÂ financing and investing activities: Beneficial Interest Obtained in Exchange for Securitized Accounts Receivables Beneficial interest obtained in exchange for securitized accounts receivables Beneficial interest obtained in

exchange for securitized accounts receivables. Dividend Declared To Noncontrolling Interests Dividend declared to non-controlling interests Dividend declared to noncontrolling interests. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Translation adjustment on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance of cash, cash equivalents and restricted cash at beginning of period Balance of cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash shown in the statement of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets: Restricted Cash and Cash Equivalents, Current Restricted cash included in other current assets Dividends [Axis] Dividends [Domain] Litigation Settlement, Amount Awarded to Other Party Litigation Settlement, Amount Awarded to Other Party Litigation settlement amount Basis of Presentation [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Basis of presentation Text Block [Abstract] Certain Transactions Disclosure [Text Block] Certain transactions This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Text Block] Revenue from contracts with customers Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventories Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] Identifiable Intangible Assets Goodwill Disclosure [Text Block] Goodwill Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt obligations Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments and Hedging Activities Commitments and Contingencies Disclosure [Abstract] Legal Matters and Contingencies [Text Block] Legal Settlements and Loss Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income taxes Other Expenses [Text Block] Other assets impairments, restructuring and other items Other Expenses [Text Block] Earnings Per Share [Text Block] Earnings (Loss) per Share Equity [Abstract] Stockholders' Equity Note Disclosure [Text Block] Accumulated other comprehensive income (loss) Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Segments Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair value measurement Accounting Policies [Abstract] Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet Schedule Of Assets And Liabilities Held For Sale [Table Text Block] Summary of Major Classes of Assets and Liabilities Included as Held for Sale Schedule Of Assets And Liabilities Held For Sale [Table Text Block] Disaggregation of Revenue [Table Text Block] Summary of disaggregates revenues by major revenue streams Sales Reserves And Allowances Current [Table Text Block] Summary of Sales Reserves and Allowances Tabular disclosure of sales reserves and allowances current. Schedule of Inventory, Current [Table Text Block] Summary of Inventories Schedule of Finite-Lived Intangible Assets [Table Text Block] Summary of Identifiable Intangible Assets Schedule of Goodwill [Table Text Block] Summary of Changes in the Carrying Amount of Goodwill by Segment Schedule of Short-term Debt [Table Text Block] Schedule of Short-term Debt Long Term Debt Excluding Convertible Debt Table [Text Block] Schedule of Senior Notes and Loans A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation. Schedule of Derivative Instruments [Table Text Block] Summary of Notional Amounts for Hedged Items Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Summary of Classification and Fair Values of Derivative Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Table Text Block] Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships Disclosure in tabular form of pretax gain loss cash flow hedging instruments. Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Schedule of Other Assets Impairments, Restructuring and Other Items Schedule of Restructuring Charges [Table Text Block] Summary of Restructuring Plan Including Costs Related to Exit and Disposal Schedule of Restructuring Charges [Table Text Block] Restructuring and Related Costs [Table Text Block] Summary of Restructuring Accruals Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accumulated Other Comprehensive Income/(Loss) (Net of Tax) Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Summary of Segment Profit Revenue from External Customers by Products and Services [Table Text Block] Schedule of Net Sales by Product Line Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Financial Items Carried at Fair Value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Summary of Financial Instrument Measured on a Basis Other Than Fair Value Error Corrections and Prior Period Adjustments Restatement [Line Items] Contingent Consderation Related Expenses Contingent consideration related expenses Contingent consderation related expenses. Business Combination, Contingent Consideration, Liability Business combination contingent consideration Contingent consideration Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Restatement [Axis] Restatement [Domain] Restatement adjustment [Member] Restatement adjustment [Member] As previously reported [Member] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Previously Reported [Member] Adjustment [Member] Business Combination, Consideration Transferred [Abstract] Noncash or Part Noncash Acquisitions [Table] Noncash or Part Noncash Acquisitions [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Modag [Member] MODAG [Member] Modag . MedinCell [Member] MedinCell [Member]. Abingworth [Member] Teva [Member] Teva Member Alvotech [Member] Alvotech. mAbxience [Member] mAbxience. Royalty Pharma [Member] Royalty Pharma [Member] Royalty pharma. Biolojic Design Ltd [Member] Biolojic Design Ltd [Member] Biolojic design ltd. Takeda [Member] Takeda. Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Johnson And Johnson [Member] Johnson And Johnson [Member] Johnson and Johnson [Member]. Sanofi [Member] Sanofi [Member] Sanofi. Noncash or Part Noncash Acquisitions [Line Items] Noncash or Part Noncash Acquisitions [Line Items] Upfront Payments Upfront payment Upfront payments Collaborative Agreement Milestone Payments Collaborative agreement milestone payments Collaborative Agreement Milestone Payments Milestone Payment Milestone payment Milestone payment. License Agreement Potential Aggregate Milestone Payments Amount License agreement potential aggregate milestone payments amount License agreement potential aggregate milestone payments amount. Aggregate Funding On Account Of Research And Development Expenditure Aggregate funding on account of research and development expenditure Aggregate funding on account of research and development expenditure. Proceeds from Sale of Debt Securities, Available-for-Sale Proceeds from available for sale debt securities Additional Milestone Payment Payable Additional milestone payment payable Additional milestone payment payable. Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax Aggregate Upfront And Milestone Payments Aggregate upfront and milestone payments Aggregate Upfront And Milestone Payments. Term Of Royalty Payment Term of royalty payment Term of royalty payment. Other Commitment Other commitment Other Asset Impairment Charges Other Asset Impairment Charges Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Reimbursement of research and development expenses incurred Additional Development And Milestone Payments Receivable Additional development and milestone payments receivable Additional development and milestone payments receivable. Maximum Entry Date For Granting License Entry Maximum entry date for granting license entry Maximum entry date for granting license entry. Investment Owned, Cost Cost of the investment Development and Launch Milestone Payment Receivable Development and launch milestone payment receivable Development and launch milestone payment receivable. Milestone Payment Receivable Milestone payment receivable Milestone payment receivable. Collaborative Agreement Milestone Amount Increase Collaborative agreement milestone amount increase Collaborative agreement milestone amount increase. Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Research and Development Expense [Member] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Agreement [Axis] Agreement. Agreement [Domain] Agreement. Settlement And License Agreement Alvotech And Teva [Member] Settlement And License Agreement Alvotech And Teva [Member] Settlement and license agreement alvotech and teva [Member]. Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] October Two Thousand And Twenty Four Amendment Agreement [Member] October 2024 Amendment Agreement [Member] Collaborative Arrangement [Member] Collaborative Arrangement [Member] Business Combinations [Abstract] Disposal Group, Including Discontinued Operation, Inventory, Current Inventories Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Goodwill, Current Goodwill Assets, Fair Value Adjustment Expected loss on sale Disposal Group, Including Discontinued Operation, Liabilities, Current Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses) Expected loss on sale Disposal Group, Including Discontinued Operation, Other Liabilities Other liabilities Disposal Group, Including Discontinued Operation, Accounts Payable Accounts payables Disposal Group, Including Discontinued Operation, Other Assets Other current and non-current assets Disposal Group, Including Discontinued Operation, Intangible Assets, Current Identifiable intangible assets, net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Accounts receivables Revenue Recognition [Abstract] Revenue Recognition [Table] Revenue Recognition [Table] Revenue Recognition [Table] Revenue Recognition [Line Items] Revenue Recognition [Line Items] Revenue Recognition [Line Items] Sales Reserves and Allowances to Customers Percentage Percentage sales reserves and allowances to U.S. customers Sales reserves and allowances to customers percentage. Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] UNITED STATES United States [Member] Factoring Institution [Axis] Factoring institution. Factoring Institution [Domain] Factoring institution. Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Pledging Purpose [Axis] Pledging Purpose [Domain] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Product [Member] Sale of Goods [Member] License [Member] Licensing Arrangements [Member] Distribution Service [Member] Distribution [Member] Product and Service, Other [Member] Other [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] International Markets [Member] International Markets [Member] International markets. Other Activities [Member] Other activities [Member] Other Activities [Member] Europe [Member] Europe [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Balance at beginning of period Balance at end of period Valuation Allowances And Reserves Related To Current Period Sales Provisions related to sales made in current year period Valuation allowances and reserves related to current period sales. Valuation Allowances And Reserves Related To Prior Period Sales Provisions related to sales made in prior periods Valuation allowances and reserves related to prior period sales. SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Credits and payments Valuation Allowances And Reserves Foreign Currency Translation Translation differences Valuation allowances and reserves foreign currency translation. SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Reserves Included In Accounts Receivable Net [Member] Reserves Included in Accounts Receivable, net [Member] Reserves included in accounts receivable net. Rebates [Member] Rebates [Member] Rebates. Medicaid And Other Governmental Allowances [Member] Medicaid and other governmental allowances [Member] Medicaid and other governmental allowances. Chargebacks [Member] Chargebacks [Member] Chargebacks. Returns [Member] Returns [Member] Returns. Other Sales Reserves And Allowances [Member] Other [Member] Other sales reserves and allowances. Total Reserves Included In Sales Reserves And Allowances [Member] Total reserves included in sales reserves and allowances [Member] Total reserves included in sales reserves and allowances. Inventories [Table] Inventories [Table] Inventories [Table] Inventories [Line Items] Inventories [Line Items] Inventories [Line Items] Inventory, Finished Goods, Net of Reserves Finished products Inventory, Raw Materials, Net of Reserves Raw and packaging materials Inventory, Work in Process, Net of Reserves Products in process Other Inventory, in Transit, Gross Materials in transit and payments on account Intangible Assets, Net (Excluding Goodwill) [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] In Process Research and Development [Member] In process research and development [Member] In process research and development [Member] Product Rights [Member] Identifiable product rights [Member] Product rights [Member] Product Rights [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Amortization of Intangible Assets Amortization of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Impairment of intangible assets excluding goodwill Business Combination, Contingent Consideration, Liability, Measurement Input Business combination, contingent consideration, liability, measurement input Finite-Lived Intangible Asset, Useful Life Amortization of intangible assets useful life JAPAN Japan [Member] Generic Pipeline Products [Member] Discontinuation Of Business [Axis] Discontinuation Of Business [Domain] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Discount Rate [Member] Measurement input, discount rate [Member] Impairment Of Intangible Assets Reasons For Impairment [Axis] Impairment Of Intangible Assets Reasons For Impairment. Impairment Of Intangible Assets Reasons For Impairment [Domain] Impairment Of Intangible Assets Reasons For Impairment. Reclassification, Type [Axis] Reclassification, Type [Domain] Event Basis [Axis] Event basis . Event Basis [Domain] Event basis . Development Progress And Changes In Other Key Valuation Assumptions [Member] Development Progress And Changes In Other Key Valuation Assumptions [Member] Development progress and changes in other key valuation assumptions. Regulatory Price And Volume Of Products [Member] Regulatory Price And Volume Of Products [Member] Regulatory price and volume of products. Updated Market Assumptions [Member] Updated Market Assumptions [Member] Updated market assumptions . Trade Names [Member] Trade names [Member] Finite-Lived Intangible Assets, Gross Gross carrying amount net of impairment Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Goodwill [Roll Forward] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill, Foreign Currency Translation Gain (Loss) Translation differences Goodwill Reclassification Goodwill reclassified as assets held for sale Goodwill reclassification. Good will Relative Fair Value Allocation Goodwill allocation related to the shift of Canada to International Markets Good will Relative Fair Value Allocation. North America [Member] North America [Member] Other Countries [Member] Other [Member] Other countries. Consolidation Items [Axis] Consolidation Items [Domain] Subsegments [Axis] Subsegments [Domain] Tevas API Reporting Unit [Member] Tevas API Reporting Unit [Member] Teva's API reporting unit. Medis Reporting Units [Member] Medis Reporting Units [Member] Goodwill, Impaired, Accumulated Impairment Loss Accumulated goodwill impairment Reporting Unit [Axis] Reporting Unit [Domain] Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Reporting unit percentage of fair value in excess of carrying amount Scenario [Axis] Scenario, Unspecified [Domain] Tevas United States, Europe, International Markets and Medis reporting units [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Short Credit Agreement 2026 [Member] Convertible senior debentures [Member] Short credit agreement 2026. Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Interest Rate, Effective Percentage Interest rate

Weighted average interest rate Debt Instrument Maturity Year Maturity Debt Instrument Maturity Year Short-term Debt Convertible senior debentures Long-term Debt, Current Maturities Current maturities of long-term liabilities Less current maturities Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Other Debentures 2026 [Member] Other Debentures [Member] Other debentures 2026. Subsidiary Senior Notes Due 2025 [Member] Senior notes EUR 1,000 million [Member] Subsidiary senior notes due 2025. Subsidiary Senior Notes Due 2024 [Member] Senior notes USD 1,250 million [Member] Subsidiary senior notes due 2024. Subsidiary Senior Notes Due 2046 [Member] Senior notes USD 2,000 million [Member] Subsidiary senior notes due 2046. Subsidiary Senior Notes Due 2036 [Member] Senior notes USD 789 million [Member] Subsidiary senior notes due 2036. Sustainability Linked Senior Notes Due 2031 Two [Member] Sustainability-linked senior notes EUR 500 million [Member] Sustainability linked senior notes due 2031 two member. Sustainability Linked Senior Notes Due 2031 One [Member] Sustainability-linked senior notes USD 500 million [Member] Sustainability linked senior notes due 2031 one. Sustainability Linked Senior Notes Due 2030 [Member] Sustainability-linked senior notes EUR 1,500 million [Member] Sustainability linked senior notes due 2030. Sustainability Linked Senior Notes Due 2029 Two [Member] Sustainability-linked senior notes EUR 800 million [Member] Sustainability linked senior notes due 2029 two. Sustainability Linked Senior Notes Due 2029 One [Member] Sustainability-linked senior notes USD 600Â million [Member] Sustainability linked senior notes due 2029 one. Sustainability Linked Senior Notes Due 2029 [Member] Sustainability-linked senior notes USD 1,000 million [Member] Sustainability linked senior notes due 2029. Subsidiary Senior Notes Due 2028 Two [Member] Senior notes EUR 750 million [Member] Subsidiary senior notes due 2028 two. Subsidiary Senior Notes Due 2028 One [Member] Senior notes USD 1,250 million [Member] Subsidiary Senior Notes Due 2028 One [Member] Sustainability Linked Senior Notes Due 2027 One [Member] Sustainability-linked senior notes EUR 1,100 million [Member] Sustainability linked senior notes due 2027 one. Sustainability Linked Senior Notes Due 2027 [Member] Sustainability-linked senior notes USD 1,000 million [Member] Sustainability linked senior notes due 2027. Subsidiary Senior Notes Due 2027 [Member] Senior notes EUR 700 million [Member] Subsidiary senior notes due 2027. Subsidiary Senior Notes Due 2026 One [Member] Senior notes USD 3,500 million [Member] Subsidiary senior notes due 2026 one. Subsidiary Senior Notes Due 2025 Three [Member] Senior notes CHF 350 million [Member] Subsidiary senior notes due 2025 three. Subsidiary Senior Notes Due 2025 Two [Member] Senior notes EUR 900 million [Member] Subsidiary senior notes due 2025 two. Subsidiary Senior Notes Due 2025 One [Member] Senior notes USD 1,000 million [Member] Subsidiary Senior Notes Due 2025 One [Member] Subsidiary Senior Notes Due 2024 One [Member] Senior notes EUR 1,500 million [Member] Subsidiary senior notes due 2024 one. Senior Notes Total senior notes Debt Issuance Costs, Noncurrent, Net Less debt issuance costs Interest Rate Increase [Member] Interest Rate Increase [Member] Interest rate increase. One Time Premium Payment [Member] One Time Premium Payment [Member] One timeÂ premium payment. Debt Instrument, Face Amount Debt instrument face amount Debt Instrument, Interest Rate, Increase (Decrease) Debt Instrument, Interest Rate, Increase (Decrease) Debt Instrument, Maturity Date Debt Instrument, Maturity Date Senior Notes Repaid Amount Senior notes repaid amount Senior notes repaid amount. Senior Notes Maturity Percentage Senior notes maturity percentage Senior notes maturity percentage. Period From Which Interest Rate Increase Could Be Applicable [Axis] Period From Which Interest Rate Increase Could Be Applicable. Period From Which Interest Rate Increase Could Be Applicable [Domain] Period From Which Interest Rate Increase Could Be Applicable. From September Fifteenth Two Thousand And Twenty Six [Member] From september fifteenth two thousand and twenty six. Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes [Member] Senior Notes [Member] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Amended Revolving Credit Facility [Member] Amended revolving credit facility member. Long-term Debt, Gross Principal amount currently outstanding on the debt instruments Long Term Debt Currency Portion U S D Long term debt currency portion USD Long term debt currency portion U S D. Long Term Debt Currency Portion E U R Long term debt currency portion EUR Long term debt currency portion E U R. Long Term Debt Currency Portion C H F Long term debt currency portion CHF Long term debt currency portion C H F. Debt Instrument, Covenant Description Line of Credit Facility, Maximum Borrowing Capacity Line Of Credit Extension Period Line of credit extension period Line of credit extension period. Leverage Ratio Leverage Ratio Leverage ratio. Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Convertible Debt [Member] Convertible Debt [Member] Tranche [Axis] Tranche. Tranche [Domain] Tranche. Lender Name [Axis] Line of Credit Facility, Lender [Domain] Period [Axis] Period axsis. Period [Domain] Period domain. Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Table] Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Line Items] Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments. Derivative Asset, Notional Amount Cross-currency swap - cash flow hedge Cross Currency Swap Cash Flow Hedge [Member] Cross Currency Swap Cash Flow Hedge. Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Derivative Instrument Detail [Abstract] Derivative [Table] Derivative [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Noncurrent Assets [Member] Other Non-current Assets [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Current Assets [Member] Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Derivative [Line Items] Derivative [Line Items] Derivative Asset, Fair Value, Gross Asset Asset derivatives Derivative Liability, Fair Value, Gross Liability Liability derivatives Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent Other comprehensive income (loss) Unrealized Gain (Loss) on Cash Flow Hedging Instruments Financial expenses, net Financial expenses [Member] Financial expenses [Member] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Domain] Other Comprehensive Income (Loss) [Member] Other Comprehensive Income [Member] Gain (Loss) on Derivative Instruments, Net, Pretax Gain (Loss) on Derivative Instruments, Net, Pretax Net Revenues [Member] Net Revenues [Member] Not Designated as Hedging Instrument, Trading [Member] Not Designated as Hedging Instrument, Trading [Member] Not Designated as Hedging Instrument, Economic Hedge [Member] Not Designated as Hedging Instrument, Economic Hedge [Member] Accounts Receivable Securitization Facility [Member] Accounts Receivable Securitization Facility [Member] Accounts receivable securitization facility. Revenues Other Than Usd Revenues other than USD Revenues other than US Dollar. Derivative, Loss on Derivative Derivative, negative impact Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses Forward starting interest rate swaps and treasury lock agreements losses Forward starting interest rate swaps and treasury lock agreements losses. Derivative, Gain on Derivative Derivative, Cash Received on Hedge Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration] Supplier Finance Program, Obligation Supplier finance program obligation Derivative Notional Amount Increase Derivative notional amount increase Derivative notional Amount Increase. Derivative, Notional Amount Derivative notional amount Derivative, Term of Contract Derivatives term of contract Derivative Notional Amount Decrease Derivative notional amount decrease Derivative notional amount decrease. Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration] SPV Amendment Agreement October Two Thousand And Twenty Four [Member] Mizuho Bank [Member] Mizuho Bank [Member]. PNC Bank [Member] PNC bank. November Two Thousand And Twenty Five [Member] November 2025 [Member] November Two Thousand And Twenty Three [Member] November 2023 [Member] Loss Contingencies [Table] Loss Contingencies [Table] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Litigation Settlement, Expense Legal settlements and loss contingencies, expenses Loss Contingency Accrual Accrued amount for legal settlements and loss contingencies Generic modafinil, and imposed fines amount Litigation Case [Axis] Litigation Case [Domain] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Annual Sales At Time Of Settlement Annual sales at the time of settlement Annual sales at time of settlement. Annual Sales Of Effexor Annual sales of Effexor Annual sales of effexor. Annual Sales Of Lamictal Annual sales of Lamictal Annual sales of Lamictal. Annual Sales Of Niaspan Annual sales of Niaspan Annual sales of Niaspan. Loss Contingency, Damages Sought, Value Damage claimed Litigation Settlement Amount Awarded Distribution Period Litigation settlement amount awarded distribution period Litigation settlement amount awarded distribution period. Loss Contingency Accrual, Provision Loss Contingency Accrual, Provision Annual Sales Of The Time Of Settlement Of Viread Annual sales of the time of settlement of viread Annual sales of the time of settlement of viread. Annual Sales Of The Time Of Settlement Of Truvada Annual sales of the time of settlement of Truvada Annual sales of the time of settlement of truvada. Annual Sales Of The Time Of Settlement Of Atripla Annual sales of the time of settlement of Atripla Annual sales of the time of settlement of atripla. Annual Sales Of The Time Of New Launch Of Viread Annual sales of the time of New launch of viread Annual sales of the time of new launch of viread. Annual Sales Of The Time Of New Launch Of Truvada Annual sales of the time of New launch of Truvada Annual sales of the time of New launch of truvada. Annual Sales Of The Time Of New Launch Of Atripla Annual sales of the time of New launch of Atripla Annual sales of the time of new launch of Atripla. Litigation Settlement Amount DistributableIn Kind Litigation Settlement Amount Distributable In Kind Litigation settlement amount distributableIn kind. Accrual for Environmental Loss Contingencies Accrual for Environmental Loss Contingencies Loss Contingencies On Environmental Laws Penalty Loss Contingencies On Environmental Laws Penalty Loss contingencies on environmental laws penalty. Litigation Fine Amount Of Copaxone Litigation fine amount of copaxone Litigation fine amount of copaxone. Settlement As A Percentage Of Aggregate Subdivisions And Tribes Settlement as a percentage of aggregate subdivisions and tribes Settlement as a percentage of aggregate subdivisions and tribes. Litigation Settlement Amount Payable Year One Litigation Settlement amount payable year one Litigation settlement amount payable year one. Litigation Settlement Amount Payable Remainder Of Fiscal Year Litigation settlement amount payable remainder of fiscal year Litigation settlement amount payable remainder of fiscal year. Loss Contingency Accrual Due In Fifth Year Loss contingency accrual due in fifth year Loss contingency accrual due in fifth year. Loss Contingency Accrual Due In Fourth Year Loss contingency accrual due in fourth year Loss contingency accrual due in fourth year. Loss Contingency Accrual Due In Year Three Loss contingency accrual due in third year Loss contingency accrual due in year three. Loss Contingency Accrual Due In Second Year Loss contingency accrual due in second year Loss contingency accrual due in second year. Loss Contingency Accrual Nest Twelve Months Loss contingency accrual next twelve months Loss contingency accrual nest twelve months. Loss Contingency Accrual Remainder Of Fiscal Year Loss contingency accrual remainder of fiscal year Loss contingency accrual remainder of fiscal year. Loss Contingency, Accrual, Current Loss contingency accrual current Loss Contingency Aggregate Payments Paid Loss contingency aggregate payments paid Loss contingency aggregate payments paid. Product Weighted Average Cost Product WAC Value Product weighted average cost. Product Weighted Average Cost Term Product WAC Term Product weighted average cost term. Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Five Loss contingency accrual, product liability, undiscounted, to be paid, year five Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Four Loss contingency accrual, product liability, undiscounted, to be paid, year four Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Three Loss contingency accrual, product liability, undiscounted, to be paid, year three Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Two Loss contingency accrual, product liability, undiscounted, to be paid, year two Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year One Loss contingency accrual, product liability, undiscounted, to be paid, year one Other Commitment, to be Paid, Year Five Other commitment, to be paid, year five Other Commitment to Pay for Each Year Other commitment to pay for each year Other commitment to pay for each year. Annual Sales Of Revlimid Annual Sales Of Revlimid Annual sales of revlimid. Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer Annual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler. Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population Loss contingency claims dismissed value paid to each state proportional to its share of national population Percentage Of Share Of The National Population Percentage Of Share Of The National Population Percentage of share of the national population. Litigation settlement amount payable in cash percentage Percentgae of amount in cash settlement Litigation settlement amount payable in cash percentage Litigation Settlement Amount Distributable in Cash Litigation Settlement Amount Distributable in cash Litigation settlement amount distributable in cash. Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Eosinophilic Esophagitis [Member] Eosinophilic Esophagitis [Member] Eosinophilic Esophagitis [Member] Andro Gel Rate At One Percentage [Member] AndroGel Rate at 1% [Member] Andro gel rate at one percentage. Opioid Litigation [Member] Modafinil Settlement Agreement [Member] Modafinil settlement agreement. Civil Action In Respect Of Donations To Patient Assistance Programmers [Member] Civil Action In Respect Of Donations To Patient Assistance Programmers [Member] Civil action in respect of donations to patient assistance programmers. Civil Investigative Demand From Department Of Justice Civil Division [Member] Civil Investigative Demand From Department Of Justice Civil Division [Member] Civil investigative demand from department of justice civil division. Ontario Teachers Securities Litigation [Member] Ontario teachers securities litigation. Litigation With US Hospitals And Other Healthcare Providers [Member] Litigation with U.S. hospitals and other healthcare providers. Defendants [Axis] Defendants. Defendants [Member] Defendants. Deferred Prosecution Agreement With U.S. Department of Justice [Member] Deferred prosecution agreement with U.S. department of justice. Two Thousand And Twenty Five [Member] Two Thousand And Twenty Five [Member] Two thousand and twenty five. Two Thousand And Twenty Four [Member] Two Thousand And Twenty Four [Member] Two thousand and twenty four. Litigation Status [Axis] Litigation Status [Domain] Settled Litigation [Member] Jurisdiction [Axis] Statutory Accounting Practices, Jurisdiction [Domain] Other Commitments [Axis] Other Commitments [Domain] Donation of Clotrimazole and Tobramycin [Member] Donation of clotrimazole and tobramycin. Fine for Violating the Antitrust Laws [Member] Fine for violating the antitrust laws. Income Tax [Table] Income Tax [Table] Income Tax [Table] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Israel Tax Authority [Member] Israel Tax Authority [Member] Income Tax [Line Items] Income Tax [Line Items] Income Tax [Line Items] Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Statutory tax rate in Israel Expected Impairment OF Income Tax Benefit Expected impairment of income tax benefit Expected impairment of income tax benefit. Income Tax Examination Increase In Income Tax Expense In the Current Period Income tax examination increase in income tax expense In the current period Income tax examination increase in income tax expense In the current period Income (Loss) from Continuing Operations before Income Taxes Pre-tax income (loss) Income (Loss) from Continuing Operations before Income Taxes. Maximum Tax Payment Limit Maximum tax payment limit Maximum tax payment limit. Effective Income Tax Rate Reconciliation, Tax Settlement, Other, Percent Effective income tax rate reconciliation, tax settlement, other, percent Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount, Total Effective income tax rate reconciliation, other reconciling items, amount, total Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount Effective income tax rate reconciliation, tax exempt income, amount Number Of Years Spread To Pay Tax Payable Number of years spread to pay tax payable Number of years spread to pay tax payable. Effective Income Tax Rate Reconciliation, Tax Settlement, Amount, Total Effective Income Tax Rate Reconciliation, Tax Settlement, Amount, Total Minimum Tax Rate Minimum tax rate Minimum tax rate. Category of Item Purchased [Axis] Category of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased [Domain] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] Two Thousand Eight Through 2020 Tax Payable [Member] 2008 Through 2020 Tax Payable [Member] Applicability [Axis] Applicability. Applicability [Domain] Applicability. Institution [Axis] Institution. Institution [Domain] Institution. Statutory Act [Axis] Statutory Act [Domain] Year Of Settlement [Axis] Year of settlement Year of settlement. Year Of Settlement [Domain] Year of settlement. Restructuring And Impairment [Abstract] Restructuring and impairment. Restructuring And Impairment Costs [Table] Restructuring And Impairment Costs [Table] Restructuring And Impairment Costs [Table] Restructuring And Impairment Costs [Table] Restructuring And Impairment Costs [Line Items] Restructuring and Impairment Costs [Line Items] Restructuring and impairment costs. Impairment of Long-Lived Assets Held-for-use Impairments of long-lived tangible assets Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Contingent consideration Business combination contingent consideration arrangements change in amount of contingent consideration liability Restructuring Charges Restructuring Restructuring charges Restructuring costs Legal Settlements Loss Contingencies Impairments Other Expenses Other Legal settlements loss contingencies impairments other expenses. Impairment And Restructuring Total Impairment and restructuring. Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of

Restructuring [Domain] Employee Severance [Member] Employee termination [Member] Other Restructuring [Member] Other [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Exit And Disposal [Axis] Exit And Disposal [Axis] Exit And Disposal [Axis] Exit And Disposal [Domain] Exit And Disposal [Domain] Exit And Disposal [Domain] Employee Termination [Member] Employee termination costs [Member] Employee termination. Other Exit And Disposal [Member] Other Exit and Disposal [Member] Other exit and disposal. Restructuring Reserve Beginning balance Ending balance Restructuring Accrual Provision Provision Restructuring Accrual Provision Utilization And Other Utilization and other Utilization and other. Tangible Asset Impairment Charges Impairments of property, plant and equipment Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted average shares with anti-dilutive effect on earnings per share Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] OCI, before Reclassifications, before Tax, Attributable to Parent Other comprehensive income (loss) before reclassifications Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Amounts reclassified to the statements of income Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Net other comprehensive income/(loss) before tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Net other comprehensive income/(loss) after tax Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Corresponding income tax Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Foreign Currency Translation Adjustments [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Derivative Financial Instruments [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Benefit Plans [Member] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Foreign currency translation attributable to non-controlling interests Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Other Operating Income (Expense) Other loss (income) Other Operating Income (Expense) Amounts Not Allocated To Segments [Abstract] Amounts not allocated to segments. Other Unallocated Amounts Other unallocated amounts. Amortization Amortization Amounts Allocated To Segments [Abstract] Amounts allocated to segments. Europe Segment [Member] Europe [Member] Europe segment. United States Segment [Member] United States [Member] United States Segment [Member] Segments And Other Activities [Member] Segments and Other Activities [Member] Segments and other activities. Other Segments [Member] Other Segments [Member] Corporate Segment [Member] Corporate Segment [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Product Information [Table] Schedule of Product Information [Table] Product Information [Line Items] Product Information [Line Items] Generics Medicians [Member] Generic products [Member] Generics Medicians. COPAXONE [Member] COPAXONE [Member] COPAXONE. BENDEKA and TREANDA [Member] BENDEKA and TREANDA [Member] BENDEKA and TREANDA. Austedo [Member] AUSTEDO [Member] Austedo [Member] Respiratory Product [Member] Respiratory Product [Member] Respiratory product. Anda [Member] Anda [Member] Anda [Member] Other Products [Member] Other [Member] Other Products [Member] AJOVY [Member] UZEDY [Member] UZEDY [Member] Revenue Type [Axis] Revenue Type [Domain] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of Reportable Segments Number of reportable segments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Investments, Fair Value Disclosure Investment in securities Derivative Asset Derivatives Derivative Liability Derivatives Fair Value, Net Asset (Liability) Total Restricted Cash Restricted cash Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Money Market Funds [Member] Money Markets [Member] Demand Deposits [Member] Cash, Deposits and Other [Member] Equity Securities [Member] Equity Securities [Member] Other Restricted Cash [Member] Other [Member] Other restricted cash. Restricted Cash [Member] Restricted cash member. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Options And Forward Contracts Derivative Liabilities [Member] Liabilities Derivatives Options and Forward Contracts [Member] Options and forward contracts derivative liabilities. Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Interest Rate Swap [Member] Asset Derivatives - Options and Forward Contracts [Member] Convertible Debt Securities [Member] Percentage Of Increase Decrease In Contingent Consideration Liabilities Percentage of increase decrease in contingent consideration liabilities Percentage of increase decrease in contingent consideration liabilities. Weighted Average [Member] Weighted Average [Member] Fresh-Start Adjustments [Axis] Fresh-Start Adjustments [Axis] Type of Fresh-Start Adjustment [Domain] Type of Fresh-Start Adjustment [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair value at the beginning of the period Fair value at the end of the period Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease Adjustments to provisions for contingent consideration Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Settlement of contingent consideration Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Assets And Liability Redemption Of Convertible Bond Security Redemption of convertible bond security Fair value measurement with unobservable inputs reconciliation recurring basis assets and liability redemption of convertible bond security. Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Assets And Liability Conversion Option Conversion option** Fair value measurement with unobservable inputs reconciliation recurring basis assets and liability conversion option. Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Assets And Liability Investment In Convertible Bond Investment in convertible bond Fair value measurement with unobservable inputs reconciliation recurring basis assets and liability investment in convertible bond. Eagle Transaction [Member] Eagle Transaction [Member] Eagle transaction. Allergan transaction [Member] Novetide Transaction [Member] Novetide transaction [Member] Novetide transaction member. Redemption Of Convertible Debt Security [Member] Redemption Of Convertible Debt Security [Member] Conversion Option [Member] Subordinated Convertible Bonds [Member] Subordinated convertible bonds. Debt Instrument, Fair Value Disclosure Total Seniornotesandconvertiblesenioredebentures [Member] Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member] Senior notes and convertible senior debentures. Senior Notes And Sustainability Linked Senior Notes [Member] Senior Notes And Sustainability Linked Senior Notes [Member] Senior notes and sustainability linked senior notes. EX-101.PRE 9 teva-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover Page 9 Months Ended Sep. 30, 2024 shares Cover [Abstract] Â Document Type 10-Q Amendment Flag false Document Fiscal Year Focus 2024 Document Transition Report false Document Period End Date Sep. 30, 2024 Document Fiscal Period Focus Q3 Document Quarterly Report true Entity Registrant Name TEVA PHARMACEUTICAL INDUSTRIES LIMITED Entity Central Index Key 0000818686 Current Fiscal Year End Date --12-31 Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Common Stock, Shares Outstanding 1,133,050,214 Title of 12(b) Security American Depositary Shares, each representing one Ordinary Share Trading Symbol TEVA Security Exchange Name NYSE Entity File Number 001-16174 Entity Incorporation, State or Country Code L3 Entity Tax Identification Number 00-0000000 Entity Address, Address Line One 124 Dvora HaNeviâ€™a St Entity Address, City or Town Tel Aviv Entity Address, Postal Zip Code 6944020 Entity Address, Country IL City Area Code +972 (3) Local Phone Number 914-8213 Entity Filer Category Large Accelerated Filer Smaller Reporting Company false Entity Emerging Growth Company false Entity Shell Company false X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionISO 3166-1 alpha-2 country code. + ReferencesNo definition available. + Details Name: dei_EntityAddressCountry Namespace Prefix: dei_ Data Type: dei:countryCodeItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name:

dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 3,319 $ 3,226 Accounts receivables, net of allowance for credit losses of $91 million and $95 million as of September 30, 2024 and December 31, 2023 3,462 3,408 Inventories 3,959 4,021 Prepaid expenses 1,127 1,255 Other current assets 445 504 Assets held for sale 2 70 Total current assets 12,314 12,485 Deferred income taxes 2,070 1,812 OtherÂ non-currentÂ assets 459 470 Property, plant and equipment, net 5,672 5,750 Operating lease right-of-use assets, net 364 397 Identifiable intangible assets, net 4,756 5,387 Goodwill 16,124 [1] 17,177 Total assets 41,758 43,479 Current liabilities: Â Â Short-term debt 2,580 1,672 Sales reserves and allowances 3,785 3,535 Accounts payables 2,371 2,602 Employee-related obligations 619 611 Accrued expenses 2,984 2,771 Other current liabilities 1,241 1,044 Liabilities held for sale 216 13 Total current liabilities 13,797 12,247 Long-term liabilities: Â Â Deferred income taxes 538 606 Other taxes and long-term liabilities 4,344 4,019 Senior notes and loans 16,400 18,161 Operating lease liabilities 295 320 Total long-term liabilities 21,578 23,106 Commitments and contingencies, see note 10 Total liabilities 35,375 35,353 Teva shareholders' equity: Â Â Ordinary shares of NIS 0.10 par value per share; September 30, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,240 million shares and 1,227 million shares, respectively 58 57 AdditionalÂ paid-inÂ capital 27,860 27,807 Accumulated deficit (14,956) (13,534) Accumulated other comprehensive loss (2,769) (2,697) Treasury shares as of September 30, 2024 and December 31, 2023: 106 million ordinary shares (4,128) (4,128) Stockholders' equity attributable to Teva shareholders 6,065 7,506 Non-controlling interests 319 620 Total equity 6,383 8,126 Total liabilities and equity $ 41,758 $ 43,479 [1] Cumulative goodwill impairment as of September 30, 2024 and December 31, 2023 was approximately $29.0 billion and $28.3 billion, respectively. X - DefinitionAccrued expenses. + ReferencesNo definition available. + Details Name: teva_AccruedExpenses Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLiabilities held for sale current. + ReferencesNo definition available. + Details Name: teva_LiabilitiesHeldForSaleCurrent Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection. + ReferencesNo definition available. + Details Name: teva_SalesReservesAndAllowances Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccountsPayableTradeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section

45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of debt and lease obligation, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other. + ReferencesNo definition available. + Details Name: us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesAndLoans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions Sep. 30, 2024 Dec. 31, 2023 Allowance for credit losses $ 91 $ 95 Common stock, par or stated value per share $ 0.1 $ 0.1 Ordinary shares, authorized 2,495 2,495 Ordinary shares, issued 1,240 1,227 Treasury shares 106 106 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net revenues $ 4,332 $ 3,850 $ 12,315 $ 11,389 Cost of sales 2,183 1,999 6,372 6,159 Gross profit 2,148 1,851 5,943 5,230 Research and development expenses 240 253 751 726 Selling and marketing expenses 626 576 1,891 1,726 General and administrative expenses 298 268 859 870 Intangible assets impairments 28 47 169 289 Goodwill impairment 600 0 1,000 700 Other assets impairments, restructuring and other items [1] (23) 57 931 276 Legal settlements and loss contingencies 450 314 638 1,009 Other loss (income) (21) (9) (22) (43) Operating income (loss) [1] (51) 344 (274) (323) Financial expenses, net 272 280 763 808 Income (loss) before income taxes [1] (324) 64 (1,037) (1,131) Income taxes (benefit) 69 (12) 648 (48) Share in (profits) losses of associated companies, net (3) Â (1) (1) Net income (loss) (390) 77 (1,684) (1,082) Net income (loss) attributable to non-controlling interests 47 8 (262) (60) Net income (loss) attributable to Teva $ (437) $ 69 $ (1,422) $ (1,022) Earnings (loss) per share attributable to ordinary shareholders: Â Â Â Â Basic $ (0.39) $ 0.06 $ (1.26) $ (0.91) Diluted $ (0.39) $ 0.06 $ (1.26) $ (0.91) Weighted average number of shares (in millions): Â Â Â Â Basic 1,133 1,121 1,130 1,119 Diluted 1,133 1,135 1,130 1,119 [1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. X - DefinitionImpairments restructuring and others. + ReferencesNo definition available. + Details Name: teva_ImpairmentsRestructuringAndOthers Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIntangible Assets Impairments + ReferencesNo definition available. + Details Name: teva_IntangibleAssetsImpairments Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items). + ReferencesNo definition available. + Details Name: teva_LegalSettlementsAndLossContingencies Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-

gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-

gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Income (Loss) (Parenthetical) $ in Millions 3 Months Ended Sep. 30, 2023 USD ($) Minimum [Member] Â Share in (profits) losses of associated companies, net $ 0.5 X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net income (loss) $ (390) $ 77 $ (1,684) $ (1,082) Other comprehensive income (loss), net of tax: Â Â Â Â Currency translation adjustment 174 (255) (94) (173) Unrealized gain (loss) from derivative financial instruments, net 7 7 21 19 Unrealized loss on defined benefit plans (1) (1) (2) (2) Total other comprehensive income (loss) 180 (249) (75) (156) Total comprehensive income (loss) (210) (172) (1,759) (1,238) Comprehensive income (loss) attributable to non-controlling interests 114 (8) (268) (144) Comprehensive income (loss) attributable to Teva $ (324) $ (164) $ (1,491) $ (1,094) X - DefinitionUnrealized gain (loss) on derivative net of tax. + ReferencesNo definition available. + Details Name: teva_UnrealizedGainLossOnDerivativeNetOfTax Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -

Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions Total Ordinary Shares [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Shares [Member] Total Teva Shareholders' Equity [Member] Non-controlling Interests [Member] Beginning balance at Dec. 31, 2022 $ 8,598 $ 57 $ 27,688 $ (12,975) $ (2,838) $ (4,128) $ 7,804 $ 794 Beginning balance, shares at Dec. 31, 2022 Â 1,217 Â Â Â Â Â Â Net Income (loss) (1,082) Â Â (1,022) Â Â (1,022) (60) Other comprehensive income (loss) (156) Â Â Â (72) Â (72) (84) Issuance of Shares, shares Â 10 Â Â Â Â Â Â Stock-based compensation expense 93 Â 93 Â Â Â 93 Â Dividend to non-controlling interests (67) Â Â Â Â Â Â (67) Ending balance at Sep. 30, 2023 7,387 $ 57 27,780 (13,995) (2,910) (4,128) 6,804 582 Ending balance, shares at Sep. 30, 2023 Â 1,227 Â Â Â Â Â Â Beginning balance at Jun. 30, 2023 7,592 $ 57 27,748 (14,066) (2,677) (4,128) 6,936 656 Beginning balance, shares at Jun. 30, 2023 Â 1,227 Â Â Â Â Â Â Net Income (loss) 77 Â Â 69 Â Â 69 8 Other comprehensive income (loss) (249) Â Â Â (233) Â (233) (16) Stock-based compensation expense 31 Â 31 Â Â Â 31 Â Dividend to non-controlling interests (67) Â Â Â Â Â Â (67) Ending balance at Sep. 30, 2023 7,387 $ 57 27,780 (13,995) (2,910) (4,128) 6,804 582 Ending balance, shares at Sep. 30, 2023 Â 1,227 Â Â Â Â Â Â Beginning balance at Dec. 31, 2023 8,126 $ 57 27,807 (13,534) (2,697) (4,128) 7,506 620 Beginning balance, shares at Dec. 31, 2023 Â 1,227 Â Â Â Â Â Â Net Income (loss) (1,684) Â Â (1,422) Â Â (1,422) (262) Other comprehensive income (loss) (75) Â Â Â (69) Â (69) (6) Issuance of Shares, value 1 $ 1 Â Â Â Â 1 Â Issuance of Shares, shares Â 13 Â Â Â Â Â Â Stock-based compensation expense 89 Â 89 Â Â Â 89 Â Proceeds from exercise of options 7 Â 7 Â Â Â 7 Â Dividend to non-controlling interests (18) Â Â Â Â Â Â (18) Purchase of shares from non-controlling interests (64) Â (45) Â (3) Â (48) (16) Ending balance at Sep. 30, 2024 6,383 $ 58 27,860 (14,956) (2,769) (4,128) 6,065 319 Ending balance, shares at Sep. 30, 2024 Â 1,240 Â Â Â Â Â Â Beginning balance at Jun. 30, 2024 6,563 $ 58 27,829 (14,519) (2,881) (4,128) 6,359 204 Beginning balance, shares at Jun. 30, 2024 Â 1,239 Â Â Â Â Â Â Net Income (loss) (390) Â Â (437) Â Â (437) 47 Other comprehensive income (loss) 180 Â Â Â 113 Â 113 67 Issuance of Shares, shares Â 1 Â Â Â Â Â Â Stock-based compensation expense 29 Â 29 Â Â Â 29 Â Ending balance at Sep. 30, 2024 $ 6,383 $ 58 $ 27,860 $ (14,956) $ (2,769) $ (4,128) $ 6,065 $ 319 Ending balance, shares at Sep. 30, 2024 Â 1,240 Â Â Â Â Â Â X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDecrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Changes in Equity (Parenthetical) - USD

($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Maximum [Member] | Ordinary Shares [Member] Â Â Â Â Exercise of options by employees and vested RSUs $ 0.5 $ 0.5 $ 0.5 $ 0.5 X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Cash Flows - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating activities: Â Â Â Â Net income (loss) $ (390) $ 77 $ (1,684) $ (1,082) Adjustments to reconcile net income (loss) to net cash provided by operations: Â Â Â Â Depreciation and amortization 259 283 790 887 Impairment of goodwill 600 0 1,000 700 Impairment of long-lived assets and assets held for sale (51) 48 758 310 Net change in operating assets and liabilities 317 (227) (190) (364) Deferred income taxes â€“ net and uncertain tax positions (53) (199) (666) (349) Stock-based compensation 29 31 89 93 Other items 2 (5) 597 18 Net loss (gain) from sale of business and long-lived assets (21) (3) (22) (29) Net cash provided by (used in) operating activities 693 5 672 184 Investing activities: Â Â Â Â Beneficial interest collected in exchange for securitized accounts receivables 339 362 951 1,056 Purchases of property, plant and equipment and intangible assets (148) (149) (369) (407) Proceeds from sale of business and long-lived assets 38 10 39 68 Acquisition of businesses, net of cash acquired 0 0 (15) 0 Purchases of investments and other assets (1) (38) (56) (44) Proceeds from sale of investments 40 0 40 Â Other investing activities 0 (1) 0 (6) Net cash provided by (used in) investing activities 268 184 590 667 Financing activities: Â Â Â Â Purchase of shares from non-controlling interests 0 0 (64) 0 Dividends paid to non-controlling interests 0 0 (78) 0 Repayment of senior notes and loans and other long term liabilities 0 (1,000) (956) (4,152) Proceeds from senior notes, net of issuance costs 0 0 0 2,451 Proceeds from short term debt 0 700 0 700 Repayment of short term debt 0 (200) 0 (200) Other financing activities 0 (76) (19) (136) Net cash provided by (used in) financing activities 0 (576) (1,117) (1,337) Translation adjustment on cash and cash equivalents 100 (33) (53) (98) Net change in cash, cash equivalents and restricted cash 1,061 (420) 92 (584) Balance of cash, cash equivalents and restricted cash at beginning of period 2,258 2,670 3,227 2,834 Balance of cash, cash equivalents and restricted cash at end of period 3,319 2,250 3,319 2,250 Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets: Â Â Â Â Cash and cash equivalents 3,319 2,249 3,319 2,249 Restricted cash included in other current assets 0 1 0 1 Total cash, cash equivalents and restricted cash shown in the statement of cash flows 3,319 2,250 3,319 2,250 Non-cashÂ financing and investing activities: Â Â Â Â Beneficial interest obtained in exchange for securitized accounts receivables 332 376 964 1,090 Dividend declared to non-controlling interests $ 0 $ 67 $ 0 $ 67 X - DefinitionBeneficial interest obtained in exchange for securitized accounts receivables. + ReferencesNo definition available. + Details Name: teva_BeneficialInterestObtainedInExchangeForSecuritizedAccountsReceivables Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDeferred income taxes net and uncertain tax positions. + ReferencesNo definition available. + Details Name: teva_DeferredIncomeTaxesNetAndUncertainTaxPositions Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDividend declared to noncontrolling interests. + ReferencesNo definition available. + Details Name: teva_DividendDeclaredToNoncontrollingInterests Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDividends paid to noncontrolling interests. + ReferencesNo definition available. + Details Name: teva_DividendsPaidToNonControllingInterests Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionImpairment of long lived assets and assets held for sale finite and indefinite lived intangible assets other than goodwill. + ReferencesNo definition available. + Details Name: teva_ImpairmentOfLongLivedAssetsAndAssetsHeldForSaleFiniteAndIndefiniteLivedIntangibleAssetsOtherThanGoodwill Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from purchase of available for sales securities and other assets. + ReferencesNo definition available. + Details Name: teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceed from Minority Non-Controlling Shareholders. + ReferencesNo definition available. + Details Name: teva_ProceedFromMinorityNonControllingShareholders Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from beneficial interest in exchange for securitized accounts receivables. + ReferencesNo definition available. + Details Name: teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedAccountsReceivables Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProfit from sale of long lived assets and investment. + ReferencesNo definition available. + Details Name: teva_ProfitFromSaleOfLongLivedAssetsAndInvestment Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period of all assets and liabilities used in operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOperatingCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions 1 Months Ended 9 Months Ended Jun. 30, 2023 Sep. 30, 2024 Litigation Settlement, Amount Awarded to Other Party $ 4,250 $ 495 X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (437) $ 69 $ (1,422) $ (1,022) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Name Christine Fox Title EVP, U.S. Commercial Rule 10b5-1 Arrangement Adopted true Non-Rule 10b5-1 Arrangement Adopted false Adoption Date AugustÂ 13,Â 2024 Rule 10b5-1 Arrangement Terminated true Non-Rule 10b5-1 Arrangement Terminated false Termination Date MarchÂ 6,Â 2025 Aggregate Available 83,953 [1] [1] The plan includes shares to be sold solely to cover tax withholding obligations. X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrTerminationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of presentation 9 Months Ended Sep. 30, 2024 Basis of presentation Note 1 â€“ Basis of presentation: Â Â a. Basis of presentation The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, as filed with the Securities and Exchange Commission (â€œSECâ€). The year-end balance sheet data was derived from the audited consolidated financial statements as of DecemberÂ 31, 2023, but not all disclosures required by generally accepted accounting principles in the United States (â€œU.S. GAAPâ€) are included. In preparing the Companyâ€™s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. In preparing the Companyâ€™s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of IPR&D assets, marketed product rights and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could be impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. Government actions taken to address macroeconomic developments, as well as their economic impact on Tevaâ€™s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. In February 2022, Russia launched an invasion of Ukraine. As of the date of these consolidated financial statements, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Tevaâ€™s International Markets segment results. Teva has no manufacturing or R&D facilities in these markets. During the three and nine months ended SeptemberÂ 30, 2024, the impact of this conflict on Tevaâ€™s results of operation and financial condition continues to be immaterial. In October 2023, Israel was attacked by a terrorist organization and entered a state of war on several fronts. As of the date of these consolidated financial statements, sustained conflict in the region is ongoing. Israel is included in Tevaâ€™s International Markets segment results. Tevaâ€™s global headquarters and several manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. Teva continues to maintain contingency plans with backup production locations for key products. During the three and nine months ended SeptemberÂ 30, 2024, the impact of this war on Tevaâ€™s results of operations and financial condition is immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war. Tevaâ€™s results of operations for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. Â Â b. Significant accounting policies Recently adopted accounting pronouncements None. Recently issued accounting pronouncements, not yet adopted In December 2023, the FASB issued ASU 2023-09 â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after DecemberÂ 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â Â In November 2023, the FASB issued ASU 2023-07 â€œSegment Reporting: Improvements to Reportable Segment Disclosuresâ€. This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segmentâ€™s profit or loss and assets. The guidance is effective for fiscal years beginning after DecemberÂ 15, 2023, and interim periods within fiscal years beginning after DecemberÂ 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entityâ€™s financial statements. The Company does not expect the adoption of the ASU to have a material impact on its consolidated financial statements related disclosures. In October 2023, the FASB issued ASU 2023-06 â€œDisclosure Improvements: Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiative,â€ which incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification (â€œCodificationâ€). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification topics, allow investors to more easily compare entities subject to the SECâ€™s existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SECâ€™s regulations. The effective date for each amendment will be the date on which the SECâ€™s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this ASU should be applied prospectively. The Company does not expect ASU 2023-06 will have a material impact to its consolidated financial statements. Â Â c. Revision of Previously Reported Consolidated Financial Statements In connection with the preparation of the consolidated financial statements as of and for the year ended DecemberÂ 31, 2023, the Company identified errors in a single contingent consideration liability and related expenses in connection with estimated future royalty payments, along with corresponding deferred tax adjustments, that aggregated into an understatement of the contingent consideration liability of approximately $132Â million, of which $98Â million related to 2022 and $34Â million related to 2023. These errors resulted from the exclusion of royalty payments that should have been included in the fair value re-measurement calculation of the contingent consideration liability as of and for the year ended DecemberÂ 31, 2022, and the quarterly and year-to-date periods ended JuneÂ 30, SeptemberÂ 30 and DecemberÂ 31, 2022, and MarchÂ 31, JuneÂ 30 and SeptemberÂ 30, 2023. These errors did not impact the Companyâ€™s actual royalty payments, as well as total cash flows from operating activities, financing activities and investing activities in the periods stated above. The Company evaluated the errors, individually and in the aggregate, considering both qualitative and quantitative factors, and concluded that these errors did not have a material impact on any of the prior periods stated above. However, the aggregate amount of the prior period errors in 2022, would have been material to the consolidated financial statements for fiscal year 2023. Therefore, the Company has revised the prior periods impacted for these errors. The tables below present the impact of the revision on the line items within the Companyâ€™s consolidated financial statements for the relevant periods: Â Â Â Â Three months ended Â Â Nine months ended Â Â Â Â SeptemberÂ 30, 2023 Â Â SeptemberÂ 30, 2023 Â Â Â Â U.S $ in millions (except per share amounts) Â Â Â Â (Unaudited) Â Â Â Â As previously reported Â Â Adjustment Â Â AsÂ revised Â Â AsÂ previously reported Â Â Adjustment Â Â AsÂ revised Â Other asset impairments, restructuring and other items Â Â $ 46 Â Â Â Â 11 Â Â Â Â 57 Â Â $ 241 Â Â Â Â 34 Â Â Â Â 276 Â Operating income (loss) Â Â Â 355 Â Â Â (11)Â Â Â 344 Â Â Â (289)Â Â Â Â (34)Â Â Â Â (323)Â Income (loss) before income taxes Â Â Â 75 Â Â Â (11)Â Â Â 64 Â Â Â Â (1,097)Â Â Â (34)Â Â Â (1,131)Â Income taxes (benefit) Â Â Â (12)Â Â Â Â§Â Â Â (12)Â Â Â (48)Â Â Â Â§Â Â Â (48)Â Net income (loss) Â Â Â 88 Â Â Â (11)Â Â Â 77 Â Â Â (1,048)Â Â Â (34)Â Â Â (1,082)Â Net income (loss) attributable to Teva Â Â Â 80 Â Â Â (11)Â Â Â 69 Â Â Â (988)Â Â Â (34)Â Â Â (1,022)Â Earnings (loss) per share attributable to ordinary shareholders: Â Â Â Â Â Â Basic and diluted loss per share Â Â $ 0.07 Â Â Â (0.01)Â Â Â 0.06 Â Â $ (0.88)Â Â Â (0.04)Â Â Â (0.91)Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Â Â SeptemberÂ 30, 2023 Â Â Â Â As previously reported Â Â Â Adjustment Â Â Â AsÂ revised Â Â Â Â (Unaudited) Â Deferred income taxes Â Â $ 1,748 Â Â Â Â 7 Â Â Â Â 1,755 Â Total assets Â Â Â 42,088 Â Â Â Â 7 Â Â Â Â 42,095 Â Other taxes and long-term liabilities Â Â Â 3,818 Â Â Â Â 132 Â Â Â Â 3,950 Â Total long-term liabilities Â Â Â 23,182 Â Â Â Â 132 Â Â Â Â 23,314 Â Total liabilities Â Â Â 34,576 Â Â Â Â 132 Â Â Â Â 34,708 Â Teva shareholdersâ€™ equity: Â Â Â Â Â Â Accumulated deficit Â Â Â (13,870)Â Â Â Â (125)Â Â Â Â (13,995)Â Total equity Â Â Â 7,512 Â Â Â Â (125)Â Â Â Â 7,387 Â Total liabilities and equity Â Â $ 42,088 Â Â Â Â 7 Â Â Â Â 42,095 Â X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Certain transactions 9 Months Ended Sep. 30, 2024 Certain transactions NOTE 2 â€“ Certain transactions: The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not

have, to access markets it does not operate in and to otherwise share development costs or business risks. The Companyâ€™s most significant agreements of this nature are summarized below. mAbxience In April 2024, Teva announced it entered into a strategic licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Under the terms of the licensing agreement, mAbxience will develop and produce the biosimilar product and Teva will lead the regulatory processes and commercialization in multiple global markets, including Europe and the U.S. In September 2024, Teva and mAbxience entered into an amendment to the licensing agreement whereby, similar to the initial licensing agreement, mAbxience will lead the development and production of an anti-PD-1 oncology biosimilar candidate and Teva will manage regulatory approvals and oversee commercialization in the designated markets. Under the initial agreement, in the second quarter of 2024, Teva paid mAbxience upfront and milestone payments in a total amount of $20Â million, which were recorded as R&D expenses. Pursuant to the amendment of the licensing agreement, in the third quarter of 2024 Teva recognized upfront and milestone payments in a total amount of $15Â million as R&D expenses, of which $5Â million were paid in October 2024, and the remaining is due by the end of 2024. mAbxience may be eligible for additional future development, regulatory and commercial milestone payments, in an aggregate amount of up to $320Â million. Launch Therapeutics and Abingworth On MarchÂ 28, 2024, Teva and Launch Therapeutics, Inc. (â€œLaunch Therapeuticsâ€) entered into a clinical collaboration agreement to further accelerate the clinical research program of Tevaâ€™s ICS-SABA (TEV-â€˜248). As part of this clinical collaboration agreement Teva also entered into a development funding agreement with funds affiliated with Abingworth LLP (â€œAbingworthâ€). Under the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, the global investment firm, will have the lead role in the operational execution and management of the planned clinical trials. Teva will retain primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization. ICS-SABA (TEV-â€™248) is currently in Phase 3 for the treatment of asthma symptoms addressing both immediate symptoms and long-term inflammation. Under the development funding agreement, Abingworth will provide Teva up to $150Â million to fund ongoing development costs for ICS-SABA (TEV-â€˜248). In exchange and subject to regulatory approval, Teva will pay Abingworth a milestone payment in the amount actually funded by Abingworth up to $150Â million, as well as success payments based on ICS-SABA (TEV-â€˜248) sales. During the third quarter of 2024, Teva recorded $20Â millionÂ as reimbursement for R&D expensesÂ incurred in connection with this agreement. Biolojic Design On NovemberÂ 26, 2023, Teva entered into a license agreement with Biolojic Design Ltd. (â€œBiolojicâ€), pursuant to which Teva received exclusive rights to develop, manufacture and globally commercialize a BD9 multibody for the potential treatment of Atopic Dermatitis and Asthma. In exchange, Teva paid an upfront payment in an amount of $10Â million in January 2024, which was recorded as an R&D expense in the fourth quarter of 2023. Biolojic may be eligible to receive additional development and commercial milestone payments of up to approximately $500Â million, over the next several years, based on the achievement of certain pre-clinical, clinical and regulatory milestones, with the majority of the payments based on future salesÂ achievements. Royalty Pharma On NovemberÂ 9, 2023, Teva entered into a funding agreement with Royalty Pharma plc. (â€œRoyalty Pharmaâ€) to further accelerate the clinical research program for Tevaâ€™s olanzapine LAI (TEV-â€™749). Under the terms of the funding agreement, Royalty Pharma will provide Teva up to $100Â million to fund ongoing development costs for olanzapine LAI (TEV-â€˜749), with an option to increase the total funding amount to $125Â million, which expired in the second quarter of 2024. In exchange and subject to regulatory approval, Teva will pay Royalty Pharma a milestone payment in the amount actually funded by Royalty Pharma, paid over 5 years, in addition to royalties upon commercialization. Teva will continue to lead the development and commercialization of the product globally. During the fourth quarter of 2023, and the first, second and third quarters of 2024, Teva recorded $35Â million, $27Â million, $19Â million and $18Â million respectively, as reimbursement for R&D expenses incurred in connection with this agreement, which collectively amounted to the total funding Royalty Pharma was to provide Teva ofÂ $100Â million. Olanzapine LAI (TEV-â€™749) is currently in Phase 3 for the treatment of schizophrenia (see also MedinCell transaction below). Â Â Sanofi On OctoberÂ 3, 2023, Teva entered into an exclusive collaboration with Sanofi to co-develop and co- commercialize Tevaâ€™s duvakitug (anti-TL1A, TEV-â€™574) asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohnâ€™s disease, two types of inflammatory bowel disease, which is currently in Phase 2b clinical trials. Under the terms of the collaboration agreement, in partial consideration of the licenses granted to Sanofi, Teva received an upfront payment of $500Â million in the fourth quarter of 2023, recognized as revenue. Additionally, Teva may receive up to $1Â billion in development and launch milestones. Each company will equally share the remaining development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement, and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. MODAG In October 2021, Teva announced a license agreement with MODAG GmbH (â€œModagâ€) providing Teva with an exclusive global license to develop, manufacture and commercialize Modagâ€™s lead compound, emrusolmin (TEV-â€™286) and a related compound (TEV-â€™287). Emrusolmin (TEV-â€™286) was initially developed for the treatment of Multiple System Atrophy (â€œMSAâ€) and Parkinsonâ€™s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimerâ€™s disease. Teva has initiated a Phase 2 clinical trial. In the fourth quarter of 2021, Teva made an upfront payment of $10Â million to Modag, recorded as an R&D expense. Modag may be eligible for additional future development milestone payments, in an aggregate amount of up to $30Â million, as well as future commercial milestones and royalties. Alvotech In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contained biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to HumiraÂ® (adalimumab) and StelaraÂ® (ustekinumab). Under the terms of the agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the U.S. In July 2023, Alvotech and Teva amended their collaboration agreement, adding two new biosimilar candidates as well as line extensions of two current biosimilar candidates to their partnership. Teva made upfront and milestone payments in an aggregate amount of $78Â million in 2020, 2021 and 2023. Teva made additional milestone payments of $27Â million in the second quarter of 2024 and $19Â million in the third quarter of 2024. Additional development and commercial milestone payments of up to approximately $380Â million, in addition to royalty and milestone payments related to the amendment of the collaboration agreement entered into in July 2023, may be payable by Teva over the next few years. Teva and Alvotech will share revenue from the commercialization of these biosimilars. The amendment of the collaboration agreement entered into in July 2023 includes increased involvement by Teva regarding manufacturing and quality at Alvotechâ€™s manufacturing facility. Additionally, pursuant to the amendment, on September 29, 2023, Teva purchased $40 million of subordinated convertible bonds of Alvotech. On June 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds for $44 million, including accrued interest, which were paid to Teva in July 2024. On FebruaryÂ 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDIÂ® (adalimumab-ryvk) injection, as an interchangeable biosimilar to HumiraÂ®, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohnâ€™s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. On AprilÂ 17, 2024, Alvotech and Teva amended their collaboration agreement to enable the purchase by Quallent of a private label adalimumab-ryvk injection from Alvotech for the U.S. market, with Alvotech sharing profits with Teva on the private label sales. On MayÂ 20, 2024, Alvotech and Teva announced that SIMLANDI is available in the United States. Â With respect to the proposed biosimilar to StelaraÂ®, on JuneÂ 12, 2023, Alvotech and Teva reached a settlement and license agreement with JohnsonÂ & Johnson, granting a licensed entry date in the U.S. no later than February 21, 2025. On AprilÂ 16, 2024, Alvotech and Teva announced that the FDA approved SELARSDITM (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to StelaraÂ®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients six years and older, and on OctoberÂ 22, 2024, announced that the FDA approved SELARSDI in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion, expanding its label to include treatment of adults with Crohnâ€™s disease and ulcerative colitis. Takeda In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (â€œTakedaâ€), for the research, development, manufacture and commercialization of ATTENUKINETM technology. Teva received a $30Â million upfront payment and a milestone payment of $20Â million in 2017. During the second quarter of 2022, Takeda initiated its Phase 2 study of modakafusp alfa (formerly TAK-573 or TEV â€™573) and as a result paid Teva a milestone payment of $25Â million, which was recognized as revenue in the second quarter of 2022. In April 2024, Takeda informed Teva of its intent to terminate the agreement with respect to such product candidate, which product rights will revert back to Teva in early 2025. Takeda continues to have rights under the license agreement with respect to other product candidates. MedinCell In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (â€œLAIâ€) products. Teva leads the clinical development and regulatory process and is responsible for the commercialization of these products. The lead product is risperidone LAI (formerly known as TV-46000). On AprilÂ 28, 2023, the FDA approved UZEDYÂ® (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults, which was launched in the U.S. in May 2023. MedinCell may be eligible for future sales-based milestones of up to $105Â million with respect to UZEDY. Teva also pays MedinCell royalties on net sales. The second selected product candidate is olanzapine LAI (TEV-â€™749) for the treatment of schizophrenia. In the third quarter of 2022, Teva decided to progress development of the product to Phase 3 and, as a result, paid a $3Â million milestone payment to MedinCell, which was recognized as R&D expenses. On MayÂ 8, 2024, Teva and MedinCell announced positive phase 3 efficacy results from a trial evaluating olanzapine LAI as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia. Additional safety and efficacy results are planned in the first half of 2025. MedinCell may become eligible for further development and commercial milestones of up to $108Â million, as well as royalties on sales of olanzapine LAI (TEV-â€™749). Assets and Liabilities Held for Sale: General Assets and liabilities held for sale as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, included certain businesses in Tevaâ€™s International Markets segment that are expected to be sold within the next year, mainly the business venture in Japan. In connection with the held for sale classification, in the first quarter of 2024, Teva recorded expenses of $577Â million due to an expected loss upon sale, including $369Â million of expected loss from reclassification of currency translation adjustments to the statements of income upon sale, in other assets impairments, restructuring and other items. In the second quarter of 2024, Teva recorded an additional expense of $67Â million related to the expected loss from reclassification of currency translation adjustments referred to above. In the third quarter of 2024, Teva recorded a favorable adjustment of $83Â million, primarily related to the change in expected loss from reclassification of currency translation adjustments referred to above. See note 12. Â The table below summarizes all of Tevaâ€™s assets and liabilities included as held for sale as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023: Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Inventories Â Â Â 169 Â Â Â Â 12 Â Accounts receivables Â Â Â 123 Â Â Â Â â€”â€, Â Goodwill Â Â Â 48 Â Â Â Â 30 Â Identifiable intangible assets, net Â Â Â 67 Â Â Â Â â€”â€, Â Property, plant and equipment, net Â Â Â 10 Â Â Â Â 5 Â Other current and non-current assets Â Â Â 40 Â Â Â Â 23 Â Expected loss on sale* Â Â Â (455)Â Â Â Â â€”â€, Â Â Â Â Â Â Â Â Â Â Total assets of the disposal group classified as held for sale in the consolidated balance sheets Â Â $ 2 Â Â Â $ 70 Â Â Â Â Â Â Â Â Â Â Accounts payables Â Â Â (76)Â Â Â Â â€”â€, Â Other liabilities Â Â Â (34)Â Â Â Â (13)Â Expected loss on sale* Â Â Â (106)Â Â Â Â â€”â€, Â Â Â Â Â Â Â Â Â Â Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets Â Â $ (216)Â Â Â $ (13)Â Â Â Â Â Â Â Â Â Â * Includes an expected loss from reclassification of currency translation adjustments to the consolidated statements of income (loss) upon sale. X - DefinitionThis element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesNo definition available. + Details Name: teva_CertainTransactionsDisclosureTextBlock Namespace Prefix: teva_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue from contracts with customers 9 Months Ended Sep. 30, 2024 Revenue from contracts with customers NOTE 3 â€“ Revenue from contracts with customers: Disaggregation of revenue The following table disaggregates Tevaâ€™s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. Â Â Â Â Three months ended SeptemberÂ 30, 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalMarkets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 1,822 Â Â Â Â 1,214 Â Â Â 568 Â Â Â Â 121 Â Â Â Â 3,794 Â Licensing arrangements Â Â Â 23 Â Â Â Â 9 Â Â Â 6 Â Â Â Â 8 Â Â Â Â 45 Â Distribution Â Â Â 380 Â Â Â Â Â§ Â Â Â 10 Â Â Â Â â€”â€, Â Â Â Â 390 Â Other Â Â Â Â§ Â Â Â Â 42 Â Â Â 29 Â Â Â Â 100 Â Â Â Â 102 Â $ 2,225 Â Â Â $ 1,265 Â Â $ â€‡â€‰613 Â Â Â $ 229 Â Â Â $ â€‡4,332 Â§ Represents an amount less than $0.5Â million. Â Â Â Â Three months ended SeptemberÂ 30, 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 1,500 Â Â Â Â 1,117 Â Â Â 556 Â Â Â Â 130 Â Â Â Â 3,303 Â Licensing arrangements Â Â Â 30 Â Â Â Â 13 Â Â Â 9 Â Â Â Â 1 Â Â Â Â 53 Â Distribution Â Â Â 366 Â Â Â Â Â§ Â Â Â 11 Â Â Â Â â€”â€, Â Â Â Â 377 Â Other Â Â Â Â§ Â Â Â Â 15 â€„Â Â Â 15 Â Â Â Â 86 Â Â Â Â 117 Â $ 1,896 Â Â Â $ 1,146 Â Â $ â€‡â€‰591 Â Â Â $ 217 Â Â Â $ â€‡3,850 Â§ Represents an amount less than $0.5Â million. Â Â Â Â Nine months ended SeptemberÂ 30, 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 4,857 Â Â Â Â 3,668 Â Â Â 1,708 Â Â Â Â 399 Â Â Â Â 10,701 Â Licensing arrangements Â Â Â 68 Â Â Â Â 26 Â Â Â 17 Â Â Â Â 10 Â Â Â Â 121 Â Distribution Â Â Â 1,134 Â Â Â Â Â§ Â Â Â 28 Â Â Â Â â€”â€, Â Â Â Â 1,163 Â Other Â Â Â Â§ Â Â Â Â 54 â€„Â Â Â 49 Â Â Â Â 295 Â Â Â Â 330 Â $ 6,060 Â Â Â $ 3,749 Â Â $ 1,802 Â Â Â $ 703 Â Â Â $ 12,315 Â§ Represents an amount less than $0.5Â million. Â Â Â Â Â Nine months ended SeptemberÂ 30, 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 4,210 Â Â Â Â 3,446 Â Â Â Â 1,656 Â Â Â Â 412 Â Â Â Â 9,724 Â Licensing arrangements Â Â Â 72 Â Â Â Â 38 Â Â Â Â 21 Â Â Â Â 4 Â Â Â Â 134 Â Distribution Â Â Â 1,183 Â Â Â Â Â§ Â Â Â Â 29 Â Â Â Â â€”â€, Â Â Â Â 1,212 Â Other Â Â Â Â§ Â Â Â Â 8 Â Â Â Â 44 Â Â Â Â 265 Â Â Â Â 318 Â $ 5,465 Â Â Â $ 3,493 Â Â Â $ 1,750 Â Â Â $ 681 Â Â Â $ 11,389 Â§ Represents an amount less than $0.5Â million. â€ƒ Variable consideration Variable consideration mainly includes sales reserves and allowances (â€œSR&Aâ€), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. SR&A to U.S. customers comprised approximately 67% of the Companyâ€™s total SR&A as of SeptemberÂ 30, 2024, with the remaining balance primarily related to customers in Canada and Germany. The changes in SR&A for third-party sales for the nine months ended SeptemberÂ 30, 2024 and 2023 were as follows: Â Â Â Â Sales Reserves and Allowances Â Â Â Â Reserves included in Accounts Receivable,Â net Â Â Rebates Â Â Medicaid and other governmental allowances Â Â Chargebacks Â Â Returns Â Â Other Â Â TotalÂ reserves included in SalesÂ Reserves andÂ Allowances Â Â Total Â Â Â Â (U.S.$ in millions) Â Balance at JanuaryÂ 1, 2024 Â Â $ 61 Â Â $ 1,603 Â Â $ 540 Â Â $ 859 Â Â $ 436 Â Â $ 97 Â Â $ 3,535 Â Â $ 3,596 Â Provisions related to sales made in current year period Â Â Â 294 Â Â Â 3,436 Â Â Â 579 Â Â Â 5,925 Â Â Â 191 Â Â Â 146 Â Â Â 10,277 Â Â Â 10,571 Â Provisions related to sales made in prior periods Â Â Â â€”â€, Â Â Â 16 Â Â Â 26 Â Â Â (11)Â Â Â (28)Â Â Â (2)Â Â Â 1 Â Â Â 1 Â Credits and payments Â Â Â (292)Â Â Â (3,269)Â Â Â (556)Â Â Â (5,877)Â Â Â (209)Â Â Â (121)Â Â Â (10,032)Â Â Â (10,324)Â Translation differences Â Â Â â€”â€, Â Â Â 1 Â Â Â 3 Â Â Â 1 Â Â Â (1)Â Â Â â€”â€, Â Â Â 4 Â Â Â 4 Â Balance at SeptemberÂ 30, 2024 Â Â $ 63 Â Â $ 1,787 Â Â $ 592 Â Â $ 897 Â Â $ 389 Â Â

$ 120 Â Â $ 3,785 Â Â $ 3,848 Â ÂÂ ÂÂ Sales Reserves and Allowances Â Â ÂÂ Reserves included in Accounts Receivable,Â net Â Â Rebates Â Â Medicaid and other governmental allowances Â Â Chargebacks Â Â Returns Â Â Other Â Â TotalÂ reserves included in Sales Reserves andÂ Allowances Â Â Total Â Â ÂÂ ÂÂ (U.S.$ in millions) Â Balance at JanuaryÂ 1, 2023 ÂÂ $ 67 Â Â $ 1,575 Â Â $ 663 Â Â $ 991 Â Â $ 455 Â Â $ 66 Â Â $ 3,750 Â Â $ 3,817 Â Provisions related to sales made in current year period ÂÂ Â 262 Â Â Â 2,968 Â Â Â 468 Â Â Â 5,636 Â Â Â 205 Â Â Â 73 Â Â Â 9,350 Â Â Â 9,612 Â Provisions related to sales made in prior periods ÂÂ Â â€”â€, Â Â Â (22)Â Â Â (33)Â Â Â (21)Â Â Â 24 Â Â Â â€”â€, Â Â Â (52)Â Â Â (52)Â Credits and payments ÂÂ Â (268)Â Â Â (2,989)Â Â Â (617)Â Â Â (5,768)Â Â Â (251)Â Â Â (53)Â Â Â (9,678)Â Â Â (9,946)Â Translation differences ÂÂ Â â€”â€, Â Â Â (8)Â Â Â (2)Â Â Â (3)Â Â Â â€”â€, Â Â Â (6)Â Â Â (19)Â Â Â (19)Â ÂÂ Balance at SeptemberÂ 30, 2023 ÂÂ $ 61 Â Â $ 1,524 Â Â $ 479 Â Â $ 835 Â Â $ 433 Â Â $ 80 Â Â $ 3,351 Â Â $ 3,412 Â ÂÂ X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories 9 Months Ended Sep. 30, 2024 Inventories NOTE 4 â€“ Inventories: Inventories, net of reserves, consisted of the following: Â Â ÂÂ SeptemberÂ 30, Â ÂÂ DecemberÂ 31, Â Â ÂÂ 2024 Â ÂÂ 2023 Â Â ÂÂ (U.S. $ in millions) Â Finished products ÂÂ $ 2,314 Â ÂÂ $ 2,346 Â Raw and packaging materials ÂÂ Â 926 Â ÂÂ Â 993 Â Products in process ÂÂ Â 524 Â ÂÂ Â 500 Â Materials in transit and payments on account ÂÂ Â 195 Â ÂÂ Â 183 Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ $ 3,959 Â ÂÂ $ 4,021 Â ÂÂ Â Â Â ÂÂ Â Â Â X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Identifiable Intangible Assets 9 Months Ended Sep. 30, 2024 Identifiable Intangible Assets NOTE 5 â€“ Identifiable intangible assets: Identifiable intangible assets consisted of the following: Â Â ÂÂ Gross carrying amount net of impairment Â ÂÂ Accumulated amortization Â ÂÂ Net carrying amount Â Â ÂÂ SeptemberÂ 30, Â ÂÂ DecemberÂ 31, Â ÂÂ SeptemberÂ 30, Â ÂÂ DecemberÂ 31, Â ÂÂ SeptemberÂ 30, Â ÂÂ DecemberÂ 31, Â Â ÂÂ 2024 Â ÂÂ 2023 Â ÂÂ 2024 Â ÂÂ 2023 Â ÂÂ 2024 Â ÂÂ 2023 Â Â ÂÂ (U.S. $ in millions) Â Product rights ÂÂ $ 16,408 Â ÂÂ $ 17,981 Â ÂÂ $ 12,235 Â ÂÂ $ 13,274 Â ÂÂ $ 4,173 Â ÂÂ $ 4,707 Â Trade names ÂÂ Â 586 Â ÂÂ Â 583 Â ÂÂ Â 296 Â ÂÂ Â 269 Â ÂÂ Â 290 Â ÂÂ Â 314 Â In process research and development ÂÂ Â 294 Â ÂÂ Â 366 Â ÂÂ Â â€”â€, Â ÂÂ Â â€”â€, Â ÂÂ Â 294 Â ÂÂ Â 366 Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â Total ÂÂ $ 17,287 Â ÂÂ $ 18,930 Â ÂÂ $ 12,531 Â ÂÂ $ 13,543 Â ÂÂ $ 4,756 Â ÂÂ $ 5,387 Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â Product rights and trade names Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products in various therapeutic categories from various acquisitions with a weighted average life period of approximately 9 years. Amortization of intangible assets was $146Â million and $145Â million in the three months ended SeptemberÂ 30, 2024 and 2023, respectively. Amortization of intangible assets was $444Â million and $471Â million in the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. IPR&D Tevaâ€™s IPR&D are assets that have not yet been approved in its major markets. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. Intangible assets impairments Impairments of long-lived intangible assets for the three months ended SeptemberÂ 30, 2024 and 2023 were $28Â million and $47Â million, respectively. Impairments in the third quarter of 2024 consisted of: Identifiable product rights of $28Â million, mainly due to updated market assumptions regarding price and volume of products mainly in the U.S. Â Â Impairments in the third quarter of 2023 consisted of: Â Â (a) IPR&D assets of $29Â million, mainly due to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date); and Â Â (b) Identifiable product rights of $18Â million mainly due to updated market assumptions regarding price and volume of products. Impairments of long-lived intangible assets for the nine months ended SeptemberÂ 30, 2024 and 2023 were $169Â million and $289Â million, respectively. Impairments in the first nine months of 2024 consisted of: Â Â (a) Identifiable product rights of $136Â million, mainly due to updated market assumptions regarding price and volume of products mainly in the U.S.; and Â Â (b) IPR&D assets of $33Â million, mainly due to generic pipeline products resulting from development progress and changes in other key valuation indications mainly in the U.S. (e.g., market size, competition assumptions, legal landscape and launch date). Impairments in the first nine months of 2023 consisted of: Â Â (a) Identifiable product rights of $206Â million due to: (i) $112Â million in Japan, mainly due to regulatory pricing reductions; and (ii) $94Â million related to updated market assumptions regarding price and volume of products; and Â Â (b) IPR&D assets of $83Â million, mainly due to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). The fair value measurement of the impaired intangible assets in the nine months ended SeptemberÂ 30, 2024 is based on significant unobservable inputs in the market and thus represents a LevelÂ 3 measurement within the fair value hierarchy. The discount rate applied ranged from 8.5% to 10%. A probability of success factor of 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&D. X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill 9 Months Ended Sep. 30, 2024 Goodwill NOTE 6 â€“ Goodwill: Changes in the carrying amount of goodwill for the period ended SeptemberÂ 30, 2024 were as follows: Â Â ÂÂ NorthAmerica Â Â UnitedStates Â ÂÂ Europe Â ÂÂ InternationalMarkets Â Â Other Â ÂÂ Total Â Â Â Tevaâ€™sAPI Â Â Medis Â Â ÂÂ Â Â Â (U.S. $ in millions) Â Â Â Â Balance as of DecemberÂ 31, 2023 (1) ÂÂ $ 6,459 Â Â $ â€”â€, Â ÂÂ $ 8,466 Â ÂÂ $ 675 Â Â $ 1,313 Â Â $ 265 Â ÂÂ $ 17,177 Â Goodwill allocation related to the shift of Canada to International Markets ÂÂ Â (6,459)Â Â Â 5,813 Â ÂÂ Â â€”â€, Â ÂÂ Â 646 Â Â Â â€”â€, Â Â Â â€”â€, Â ÂÂ Â â€”â€, Â ÂÂ Â Â Â Â Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â Â Â Â Â Â Â Â ÂÂ Â Â Â Balance as of JanuaryÂ 1, 2024 ÂÂ $ â€”â€, Â Â $ 5,813 Â ÂÂ $ 8,466 Â ÂÂ $ 1,321 Â Â $ 1,313 Â Â $ 265 Â ÂÂ $ 17,177 Â ÂÂ Â Â Â Â Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â Â Â Â Â Â Â Â Â Other changes during the period: ÂÂ Â ÂÂ ÂÂ Â Â ÂÂ Goodwill impairment ÂÂ Â â€”â€, Â Â Â â€”â€, Â ÂÂ Â â€”â€, Â ÂÂ Â â€”â€, Â Â Â (1,000)Â Â Â â€”â€, Â ÂÂ Â (1,000) Goodwill reclassified as assets held for sale ÂÂ Â â€”â€, Â Â Â â€”â€, Â ÂÂ Â â€”â€, Â ÂÂ Â (29)Â Â Â â€”â€, Â Â Â â€”â€, Â ÂÂ Â (29)Â Translation differences and other ÂÂ Â â€”â€, Â Â Â â€”â€, Â ÂÂ Â 97 Â ÂÂ Â (131)Â Â Â 5 Â Â Â 4 Â ÂÂ Â (25)Â ÂÂ Â Â Â Â Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2024 (1) ÂÂ $ â€”â€, Â Â $ 5,813 Â ÂÂ $ 8,563 Â ÂÂ $ 1,161 Â Â $ 318 Â Â $ 269 Â ÂÂ $ 16,124 Â ÂÂ Â Â Â Â Â Â Â ÂÂ Â Â Â ÂÂ Â Â Â Â Â Â Â Â Â Â Â (1) Cumulative goodwill impairment as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 was approximately $29.3Â billion and $28.3Â billion, respectively. Teva operates its business through three reporting segments: United States, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Tevaâ€™s production and sale of APIs to third parties (â€œTeva APIâ€) and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Tevaâ€™s API and Medis reporting units are included under â€œOtherâ€ in the table above. See note 15 for additional segment information. Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva begins with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Tevaâ€™s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (â€œWACCâ€), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Tevaâ€™s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. First Quarter Developments As further discussed in note 15, as of JanuaryÂ 1, 2024, Canada is reported as part of Tevaâ€™s International Markets segment and not as part of Tevaâ€™s North America segment, which has been renamed as Tevaâ€™s United States segment. As a result, Teva aligned its segment reporting and its reporting units in accordance with this change, and reallocated its goodwill to the adjusted reporting units using a relative fair value allocation. In conjunction with the goodwill reallocation, Teva performed a goodwill impairment test for the balances in its adjusted United States and International Markets reporting units and concluded that the fair value of each reporting unit was in excess of its carrying value. During the first quarter of 2024, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of MarchÂ 31, 2024. Management concluded that no triggering event had occurred and, therefore, no quantitative assessment was performed. Second Quarter Developments During the second quarter of 2024, Teva completed its long-range planning (â€œLRPâ€) process. The LRP is part of Tevaâ€™s internal financial planning and budgeting processes and is discussed and reviewed by Tevaâ€™s management and its board of directors. Â Â Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. As disclosed in prior periods, the excess of the estimated fair value of Tevaâ€™s API reporting unit over its estimated carrying amount was negligible as of DecemberÂ 31, 2023 and MarchÂ 31, 2024. The updated quantitative analysis performed in the second quarter of 2024, which was based on the aforementioned LRP process and Tevaâ€™s Pivot to Growth strategy assumptions, resulted in a recognition of a goodwill impairment charge of $400Â million related to Tevaâ€™s API reporting unit. Following the goodwill impairment charges recorded in relation to Tevaâ€™s API reporting unit, the carrying values of this reporting unit equaled its fair value as of JuneÂ 30, 2024. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Tevaâ€™s API reporting unit in the future (see â€œThird Quarter Developmentsâ€ below). Tevaâ€™s United States, Europe, International Markets and Medis reporting units had fair values in excess of 10% over their book values as of JuneÂ 30, 2024. In the second quarter of 2023, Teva recorded a goodwill impairment charge of $700Â million related to its International Markets reporting unit, mainly due to an increase in the discount rate due to higher risk associated with country-specific characteristics of several countries. Third Quarter Developments During the third quarter of 2024, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of SeptemberÂ 30, 2024. As part of this evaluation, management noted a triggering event related to Tevaâ€™s API reporting unit, which resulted from updated assumptions in connection with Tevaâ€™s intention to divest its API business through a sale. Teva performed a quantitative assessment in the third quarter of 2024, which resulted in the recording of a goodwill impairment charge of $600Â million related to Tevaâ€™s API reporting unit. Following this goodwill impairment charge, the carrying value of Tevaâ€™s API reporting unit equaled its fair value as of SeptemberÂ 30, 2024. Therefore, if business conditions or expectations, including related to Tevaâ€™s intention to divest its API business, were to change materially, it may be necessary to record further impairment charges to Tevaâ€™s API reporting unit in the future. With respect to the remaining reporting units, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying amounts as of SeptemberÂ 30, 2024 and, therefore, no quantitative assessment was performed. X - DefinitionThe entire disclosure for goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Debt obligations 9 Months Ended Sep. 30, 2024 Debt obligations NOTE 7 â€“ Debt obligations: Â a. Short-term debt: Â Â ÂÂ Interest rate as of SeptemberÂ 30,Â 2024 Â Â Maturity Â ÂÂ SeptemberÂ 30, Â ÂÂ DecemberÂ 31, Â Â ÂÂ 2024 Â ÂÂ 2023 Â Â ÂÂ Â Â Â Â Â ÂÂ (U.S. $ in millions) Â Convertible senior debentures ÂÂ Â 0.25 %Â Â Â 2026 Â ÂÂ Â 23 Â ÂÂ Â 23 Â Current maturities of long-term liabilities Â ÂÂ Â 2,557 Â ÂÂ Â 1,649 Â ÂÂ Â Â Â ÂÂ Â Â Â Total short-term debt Â ÂÂ $ 2,580 Â ÂÂ $ 1,672 Â ÂÂ Â Â Â ÂÂ Â Â Â Convertible senior debentures The principal amount of Tevaâ€™s 0.25% convertible senior debentures due in 2026 was $23Â million as of SeptemberÂ 30, 2024 and as of DecemberÂ 31, 2023. These convertible senior debentures include a â€œnet share settlementâ€ feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the â€œnet share settlementâ€ feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under â€˜short-term debtâ€™. b. Long-term debt: Â Â ÂÂ Interest rate as of SeptemberÂ 30,Â 2024 Â Â Maturity Â ÂÂ SeptemberÂ 30, 2024 Â Â DecemberÂ 31, 2023 Â Â ÂÂ Â Â Â Â Â ÂÂ (U.S. $ in millions) Â Senior notes USD 1,250Â million (4) ÂÂ Â 6.00 %Â Â Â 2024 Â ÂÂ Â â€”â€, Â Â Â 956 Â Senior notes EUR 1,500Â million (5) ÂÂ Â 1.13 %Â Â Â 2024 Â ÂÂ Â 700 Â Â Â 693 Â Senior notes EUR 1,000Â million ÂÂ Â 6.00 %Â Â Â 2025 Â ÂÂ Â 459 Â Â Â 453 Â Senior notes USD 1,000Â million ÂÂ Â 7.13 %Â Â Â 2025 Â ÂÂ Â 427 Â Â Â 427 Â Senior notes EUR 900Â million ÂÂ Â 4.50 %Â Â Â 2025 Â ÂÂ Â 554 Â Â Â 547 Â Senior notes CHF 350Â million ÂÂ Â 1.00 %Â Â Â 2025 Â ÂÂ Â 417 Â Â Â 416 Â Senior notes USD 3,500Â million ÂÂ Â 3.15 %Â Â Â 2026 Â ÂÂ Â 3,374 Â Â Â 3,374 Â Senior notes EUR

700Â million Â Â Â 1.88 %Â Â Â 2027 Â Â Â Â 781 Â Â Â 771 Â Sustainability-linked senior notes USD 1,000Â million (1)(*) Â Â Â 4.75 %Â Â Â 2027 Â Â Â Â 1,000 Â Â Â 1,000 Â Sustainability-linked senior notes EUR 1,100Â million (1)(*) Â Â Â 3.75 %Â Â Â 2027 Â Â Â Â 1,229 Â Â Â 1,215 Â Senior notes USD 1,250Â million Â Â Â 6.75 %Â Â Â 2028 Â Â Â Â 1,250 Â Â Â 1,250 Â Senior notes EUR 750Â million Â Â Â 1.63 %Â Â Â 2028 Â Â Â Â 834 Â Â Â 826 Â Sustainability-linked senior notes USD 1,000Â million (2)(*) Â Â Â 5.13 %Â Â Â 2029 Â Â Â Â 1,000 Â Â Â 1,000 Â Sustainability-linked senior notes USD 600Â million (3)(*) Â Â Â 7.88 %Â Â Â 2029 Â Â Â Â 600 Â Â Â 600 Â Sustainability-linked senior notes EUR 800Â million (3)(*) Â Â Â 7.38 %Â Â Â 2029 Â Â Â Â 895 Â Â Â 884 Â Sustainability-linked senior notes EUR 1,500Â million (2)(*) Â Â Â 4.38 %Â Â Â 2030 Â Â Â Â 1,676 Â Â Â 1,656 Â Sustainability-linked senior notes USD 500Â million (3)(*) Â Â Â 8.13 %Â Â Â 2031 Â Â Â Â 500 Â Â Â 500 Â Sustainability-linked senior notes EUR 500Â million (3)(*) Â Â Â 7.88 %Â Â Â 2031 Â Â Â Â 558 Â Â Â 552 Â Senior notes USD 789Â million Â Â Â 6.15 %Â Â Â 2036 Â Â Â Â 783 Â Â Â 783 Â Senior notes USD 2,000Â million Â Â Â 4.10 %Â Â Â 2046 Â Â Â Â 1,986 Â Â Â 1,986 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total senior notes Â Â Â Â Â 19,023 Â Â Â 19,889 Â Other long-term debt Â Â Â Â Â 2 Â Â Â 1 Â Less current maturities Â Â Â Â Â (2,557)Â Â Â (1,649)Â Less debt issuance costs Â Â Â Â Â (68)Â Â Â (80)Â Â Â Â Â Â Â Â Â Â Â Â Total senior notes and loans Â Â Â Â Â $ 16,400 Â Â $ 18,161 Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. (2) If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including MayÂ 9, 2026. (3) If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including SeptemberÂ 15, 2026. (4) In April 2024, Teva repaid $956Â million of its 6% senior notes due 2024 at maturity. (5) In October 2024, Teva repaid $685Â million of its 1.13% senior notes due 2024 at maturity. * Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. Â Tevaâ€™s debt as of SeptemberÂ 30, 2024 was effectively denominated in the following currencies: 58% in U.S. dollars, 40% in euro and 2% in Swiss franc. Tevaâ€™s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $1.8Â billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, as amended on FebruaryÂ 6, 2023 and on MayÂ 3, 2024 (â€œRCFâ€). The RCF had an initial maturity date of April 2026 with two one-year extension options. In April 2024, an extension option was exercised and the RCF maturity date was extended to April 2027. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. On MayÂ 3, 2024, the terms of the RCF were amended to update the Companyâ€™s maximum permitted leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Companyâ€™s leverage ratio shall not exceed (i) 4.00x in 2024, 2025 and in the first quarter of 2026, (ii) 3.75x in the second, third and fourth quarters of 2026 and (iii) 3.50x in the first quarter of 2027 and onwards. The RCF permits the Company to increase the maximum leverage ratio if it consummates or commences certain material transactions. Under the RCF, as amended, the applicable margin used to calculate the interest rate under the RCF is linked to one sustainability performance target, the number of new regulatory submissions in low and middle-income countries. Proceeds from borrowings under the RCF can be used for general corporate purposes, including repaying existing debt. As of SeptemberÂ 30, 2024, and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the circumstances referred to above, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Companyâ€™s senior notes and sustainability-linked senior notes due to cross-acceleration provisions. Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued. X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments and hedging activities 9 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities NOTE 8 â€“ Derivative instruments and hedging activities: Â a. Foreign exchange risk management: In the first nine months of 2024, approximately 47% of Tevaâ€™s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce its exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty, new Israeli shekel, Indian rupee and other currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (â€œnet investment hedgeâ€) and has in the past entered into cross-currency swaps and forward-contracts in order to hedge such an exposure. Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. Â b. Interest risk management: The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans and convertible debentures that bear fixed or variable interest rates, as well as a syndicated sustainability-linked revolving credit facility and securitization programs that bear a variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (â€œfair value hedgeâ€) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (â€œcash flow hedgeâ€), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. As of SeptemberÂ 30, 2024, all outstanding senior notes, sustainability-linked senior notes and convertible debentures bear a fixed interest rate. Â c. Bifurcated embedded derivatives: Upon the issuance of its sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential one-time premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in low-to-middle-income countries and reduction of absolute greenhouse gas emissions, which were bifurcated and are accounted for separately as derivative financial instruments. As of SeptemberÂ 30, 2024, the fair value of these derivative instruments is negligible. d. Derivative instruments outstanding: The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Cross-currency swap - cash flow hedge (1) Â Â Â $ â€”â€‰ Â Â Â $ 169 Â Â Â Â Â Â Â Â Â Â Â Â The following table summarizes the classification and fair values of derivative instruments: Â Â Â Â Fair value Â Â Â Â Designated as hedging instruments Â Â Â Not designated as hedging instruments Â Â Â Â SeptemberÂ 30, 2024 Â Â Â DecemberÂ 31, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â DecemberÂ 31, 2023 Â Reported under Â Â (U.S. $ in millions) Â Â Â (U.S. $ in millions) Â Asset derivatives: Â Â Â Â Â Â Â Other current assets: Â Â Â Â Â Â Â Â Option and forward contracts Â Â $ â€”â€‰ Â Â Â $ â€”â€‰ Â Â Â $ 32 Â Â Â $ 38 Â Other non-current assets: Â Â Â Â Â Â Â Cross-currency swap-cash flow hedge (1) Â Â Â â€”â€‰ Â Â Â 8 Â Â Â Â Â â€”â€‰ Â Â Â Â Â â€”â€‰ Â Liability derivatives: Â Â Â Â Â Â Â Other current liabilities: Â Â Â Â Â Â Â Option and forward contracts Â Â Â â€”â€‰ Â Â Â Â â€”â€‰ Â Â Â Â (33)Â Â Â Â (39)Â Â Â The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives designated in cash flow hedging relationships: Â Â Â Financial expenses, net Â Â Â Other comprehensive income (loss) Â Â Â Three months ended, Â Â Â Three months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 272 Â Â Â $ 280 Â Â Â $ 180 Â Â Â $ (249)Â Cross-currency swaps - cash flow hedge (1) Â Â Â â€”â€‰ Â Â Â (7)Â Â Â Â â€”â€‰ Â Â Â Â 1 Â Â Â Financial expenses, net Â Â Â Other comprehensive income (loss) Â Â Â Nine months ended, Â Â Â Nine months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â SeptemberÂ 30, 2023 Â Â SeptemberÂ 30, 2024 Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 763 Â Â Â $ 808 Â Â Â $ (75)Â Â Â $ (156)Â Cross-currency swaps - cash flow hedge (1) Â Â Â (8)Â Â Â Â (22)Â Â Â Â 1 Â Â Â Â (4)Â The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives not designated as hedging instruments: Â Â Â Â Financial expenses, net Â Â Â Net revenues Â Â Â Â Three months ended, Â Â Â Three months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 272 Â Â Â $ 280 Â Â Â $ (4,332)Â Â Â $ (3,850)Â Option and forward contracts (2) Â Â Â 4 Â Â Â Â 4 Â Â Â Â â€”â€‰ Â Â Â Â â€”â€‰ Â Option and forward contracts economic hedge (3) Â Â Â â€”â€‰ Â Â Â Â â€”â€‰ Â Â Â Â 9 Â Â Â Â (22)Â Â Â Â Financial expenses, net Â Â Â Net revenues Â Â Â Â Nine months ended, Â Â Â Nine months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 763 Â Â Â $ 808 Â Â Â $ (12,315)Â Â Â $ (11,389)Â Option and forward contracts (2) Â Â Â (33)Â Â Â Â (46)Â Â Â Â â€”â€‰ Â Â Â Â â€”â€‰ Â Option and forward contracts economic hedge (3) Â Â Â â€”â€‰ Â Â Â Â â€”â€‰ Â Â Â Â (1)Â Â Â Â (20)Â Â (1) On MarchÂ 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. The agreement was terminated in the first quarter of 2024 and resulted in cash proceeds of $16Â million. (2) Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. (3) Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and some other currencies to protect its projected operating results for 2024. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the three months ended SeptemberÂ 30, 2024, the negative impact from these derivatives recognized under revenues was $9Â million. In the nine months ended SeptemberÂ 30, 2024, the positive impact from these derivatives recognized under revenues was $1Â million. In the three months ended SeptemberÂ 30, 2023, the positive impact from these derivatives recognized under revenues was $22Â million. In the nine months ended SeptemberÂ 30, 2023, the positive impact from these derivatives recognized under revenues was $20Â million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. Â e. Amortizations due to terminated derivative instruments: Forward-starting interest rate swaps and treasury lock agreements In 2015, Teva entered into forward-starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward-starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. Termination of these transactions resulted in a loss position of $493Â million, which was recorded as other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. With respect to these forward-starting interest rate swaps and treasury lock agreements, losses of $7Â million were recognized under financial expenses, net, for each of the three months ended SeptemberÂ 30, 2024 and 2023, and losses of $21Â million and $25Â million were recognized under financial expenses, net for each of the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. Â Â f. Securitization: U.S. securitization program On NovemberÂ 7, 2022, Teva and a bankruptcy-remote special purpose vehicle (â€œSPVâ€) entered into an accounts receivable securitization facility

(â€œAR Facilityâ€) with PNC Bank, National Association (â€œPNCâ€) with a three-year term. The AR Facility provided for purchases of accounts receivable by PNC in an amount of up to $1Â billion through November 2023, and up to $500Â million from November 2023 through November 2025. On JuneÂ 30, 2023, the AR Facility agreement was amended to include an additional receivables purchaser under the agreement, in an amount of up to $250Â million through November 2025. As a result, the total commitment of PNC was reduced to an amount of up to $750Â million, effective JuneÂ 30, 2023. Under the terms of the AR facility agreement, in November 2023, the total commitment of PNC was further reduced to an amount of up to $500Â million through November 2025. On November 7, 2023, the SPV amended the agreement and increased the commitment amount to a maximum of $1Â billion by including an additional receivables purchaser in an amount of up to $250Â million through March 2024, which was then reduced by $125Â million through November 2025. As a result, the commitment amount was reduced to a maximum of $875Â million without any additional purchasers participating in the AR facility. On OctoberÂ 29, 2024, the SPV amended the agreement and increased the commitment amount to a maximum amount of $950Â million by an existing receivables purchaser increasing its commitment by $75Â million. Â Â Pledged accounts receivables In connection with the U.S. securitization program, accounts receivables, net of allowance for credit losses, include $934Â million and $437Â million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively, which are pledged by the SPV to PNC. Â Â g. Supplier Finance Program Obligation Teva maintains supply chain finance agreements with participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Teva to these financial institutions. Tevaâ€™s suppliers negotiate their financing agreements directly with the respective financial institutions and Teva is not a party to these agreements. Teva has no economic interest in its suppliersâ€™ decisions to participate in the program and Teva pays the financial institutions the stated amount of confirmed invoices on the maturity dates, which is generally within 120 days from the date the invoice was received. The agreements with the financial institutions do not require Teva to provide assets pledged as security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in the supplier finance program are recorded under accounts payables in Tevaâ€™s consolidated balance sheets. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively, $163Â million and $108Â million of accounts payables to suppliers participatingÂ in these supplier finance programs were outstanding. X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Legal Settlements and Loss Contingencies 9 Months Ended Sep. 30, 2024 Legal Settlements and Loss Contingencies NOTE 9 â€“ Legal settlements and loss contingencies: In the third quarter of 2024, Teva recorded expenses of $450Â million in legal settlements and loss contingencies, compared to expenses of $314Â million in the third quarter of 2023. Expenses in the third quarter of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONEÂ®, and an update to the estimated settlement provision for the opioid cases (mainly related to the settlement agreement with the city of Baltimore and the effect of the passage of time on the net present value of the discounted payments). Expenses in the third quarter of 2023 were mainly related to an update to the provision for the DOJ patient assistance program litigation, as well as an update to the estimated settlement provision of the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). See note 10. In the first nine months of 2024, Teva recorded expenses of $638Â million in legal settlements and loss contingencies, compared to $1,009Â million in the first nine months of 2023. Expenses in the first nine months of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE, and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore). Expenses in the first nine months of 2023 were mainly related to an estimated provision for the DOJ patient assistance program litigation, an update to the estimated settlement provision of the opioid cases, the provision for the settlement of the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, as well as the provision for the settlement of the reverse-payment antitrust litigation over certain HIV medicines. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, Tevaâ€™s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,915Â million and $4,771Â million, respectively. X - DefinitionThe entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent + Details Name: us-gaap_LegalMattersAndContingenciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and contingencies 9 Months Ended Sep. 30, 2024 Commitments and contingencies NOTE 10 â€“ Commitments and contingencies: General From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. Teva records a provision in its consolidated financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is reasonably estimable. Based upon the status of the cases described below, managementâ€™s assessments of the likelihood of damages, and the advice of legal counsel, no material provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and substantial damages or other relief may be awarded. Accordingly, managementâ€™s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. Â If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the consolidated financial statements. In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Tevaâ€™s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third-party sales figures given below are based on IQVIA data. Intellectual Property Litigation From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originatorâ€™s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the â€œpatent danceâ€ procedures of the Biologics Price Competition and Innovation Act (â€œBPCIAâ€), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originatorâ€™s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Tevaâ€™s pharmaceutical products, not just its generic and biosimilar products. The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Tevaâ€™s product. The amount of lost profits would generally be based on the lost sales of the patenteeâ€™s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. In July 2014, GlaxoSmithKline (â€œGSKâ€) filed claims against Teva in the U.S. District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva began selling its carvedilol tablets (the generic version of GSKâ€™s CoregÂ®) in September 2007. A jury returned a verdict in GSKâ€™s favor, which was initially overturned by the U.S. District Court. The Court of Appeals for the Federal Circuit reinstated the $235.5Â million jury verdict, not including pre- or post-judgment interest, finding Teva liable for patent infringement. The U.S. Supreme Court denied Tevaâ€™s appeal for a rehearing. The case has been remanded to the district court for further proceedings on Tevaâ€™s other legal and equitable defenses that have not yet been considered by the district court. Teva recognized a provision based on its offer to settle the matter. Â In January 2021, Teva initiated a patent invalidity action against the compound patent and Supplementary Protection Certificate (â€œSPCâ€) asserted to cover Bristol-Myers Squibb Companyâ€™s (â€œBMSâ€) EliquisÂ® (apixaban). In May 2022, the U.K. High Court held that the compound patent and SPC are invalid and Teva began selling its generic version of EliquisÂ® (apixaban). In May 2023, the U.K. Court of Appeal upheld this decision and denied BMSâ€™s request to appeal to the U.K. Supreme Court. On OctoberÂ 31, 2023, the U.K. Supreme Court denied BMSâ€™s application for further review, making the decision to revoke the compound patent and SPC final. Separately, in February 2021, Teva initiated a patent invalidity action against the formulation patents, which are also under opposition at the European Patent Office (â€œEPOâ€). On JulyÂ 15, 2022, the U.K. High Court held that these formulation patents were invalid but granted permission to appeal, which was subsequently stayed pending the outcome of the opposition at the EPO to one of the formulation patents. On DecemberÂ 21, 2023, the EPOâ€™s Technical Board of Appeal held its hearing on the opposition, and on MarchÂ 13, 2024, it issued a written decision revoking the patent. On MayÂ 13, 2024, BMS filed a submission to the Enlarged Board of Appeal seeking its permission to review the Technical Board of Appealâ€™s decision, a hearing for which is scheduled for DecemberÂ 3, 2024. Product Liability Litigation Tevaâ€™s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied, as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in certain or all of its markets. Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan were allegedly found in the active pharmaceutical ingredient (â€œAPIâ€) supplied to Teva by multiple API manufacturers, including by Zhejiang Huahai Pharmaceuticals Co. Ltd. Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. Multiple lawsuits have been filed in connection with this matter. Tevaâ€™s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (â€œMDLâ€) pending against Teva and other manufacturers, including one MDL in the U.S. District Court for the District of New Jersey related to, with respect to Teva, valsartan and losartan, and another MDL in the U.S. District Court for the Southern District of Florida related to ranitidine. The claims against Teva in these MDLs include individual personal injury and/or product liability claims, economic damages claims brought by consumers and end payors as putative class actions, and medical monitoring class claims. The district court in the valsartan MDL certified a series of subclasses on plaintiffsâ€™ economic loss claims as well as a medical monitoring class and originally scheduled the first trial to commence in the fourth quarter of 2024, but that trial has been postponed indefinitely by the court. Discovery is ongoing in the MDL with respect to the losartan claims against Teva. The claims against Teva and other generic manufacturers in the ranitidine MDL have been dismissed on preemption grounds but are subject to appeal. The district court in the ranitidine MDL also excluded all of plaintiffsâ€™ general causation experts and granted summary judgment to the brand defendants on preemption grounds and later applied that general causation ruling to all defendants. This ruling is on appeal in the Eleventh Circuit Court of Appeals. Certain generic manufacturers, including Teva, have also been named in state court actions asserting allegations similar to those in the aforementioned MDLs. In particular, state court valsartan and losartan actions are pending but currently stayed in New Jersey and Delaware, with the exception of a single-plaintiff case that was later refiled in a New Jersey state court in October 2022 and is in the very initial stages of discovery. State court ranitidine cases naming Teva are also pending in coordinated proceedings in California and Pennsylvania. Teva was dismissed from all ranitidine claims pending in Illinois based on preemption grounds, which plaintiffs have appealed for final judgments as to all remaining defendants. Teva was also dismissed on preliminary objections in Pennsylvania for plaintiffs whose cases are governed by Pennsylvania law, but further motion practice may continue. The litigation in Pennsylvania has effectively been stayed pending a decision on a motion filed by plaintiffs to recuse the presiding judge which was denied but certified for interlocutory appeal. Â In addition to the valsartan and ranitidine MDLs and coordinated state court proceedings, Teva has been named in a consolidated proceeding pending in the U.S. District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Tevaâ€™s and other generic manufacturersâ€™ metformin products. The parties are now engaged in discovery related to the surviving metformin claims. Teva was recently named in a related proceeding pending in the same district brought by end payors also seeking economic damages on behalf of a purported class of end payors who purchased Tevaâ€™s and other generic manufacturersâ€™ metformin products. This action was consolidated with the original proceeding for discovery and pretrial purposes only. Teva, along with the other defendants, have moved to dismiss the claims in this newly consolidated proceeding. Similar lawsuits are pending in Canada and Germany. Competition Matters As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Tevaâ€™s patent challenges have resulted in litigation relating to Tevaâ€™s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i)Â Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii)Â significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneysâ€™ fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial, potentially measured in multiples of the annual brand sales, particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. Teva believes that its settlement agreements are lawful and serve to increase

competition, and has defended them vigorously. In Tevaâ€™s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (â€œFTCâ€) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This test has resulted in increased scrutiny of Tevaâ€™s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Tevaâ€™s currently pending antitrust litigations. In December 2011, three groups of plaintiffs filed claims against Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended-release venlafaxine (generic Effexor XRÂ®). The cases were filed by a purported class of direct purchasers, a purported class of indirect purchasers and certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. On SeptemberÂ 18, 2024, the district court lifted its stay of discovery and the case is now proceeding. On OctoberÂ 16, 2024, Teva and one group of plaintiffs (the â€œIndirect Purchaser Plaintiffsâ€ or â€œIPPsâ€) announced that they have reached an agreement in principle to resolve the IPPsâ€™ claims against Teva. The parties are in the process of documenting the proposed settlement, which will be subject to court approval. Annual sales of Effexor XRÂ® were approximately $2.6Â billion at the time of settlement and at the time Teva launched its generic version of Effexor XRÂ® in July 2010. Â In February 2012, two purported classes of direct-purchaser plaintiffs filed claims against GSK and Teva in the U.S. District Court for the District of New Jersey for alleged violations of the antitrust laws in connection with their February 2005 settlement of patent litigation involving lamotrigine (generic LamictalÂ®). The plaintiffs claimed that the settlement agreement unlawfully delayed generic entry and sought unspecified damages. During FebruaryÂ 2023, a number of direct purchasers who were denied class certification filed suit as individual plaintiffs, which action was transferred to the U.S. District Court for the District of New Jersey. Discovery of the newly added individual plaintiffs is ongoing. Annual sales of LamictalÂ® were approximately $950Â million at the time of the settlement and approximately $2.3Â billion at the time Teva launched its generic version of LamictalÂ® in July 2008. In April 2013, purported classes of direct purchasers of, and end payers for, NiaspanÂ® (extended release niacin) filed claims against Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005 to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser opt-out plaintiffs filed complaints with allegations nearly identical to those of the direct purchasersâ€™ class. On AprilÂ 24, 2023, the U.S. District Courtâ€™s denial of the indirect purchasersâ€™ motion for class certification was affirmed by the Court of Appeals for the Third Circuit, and on JuneÂ 5, 2023, the Court of Appeals denied the indirect purchasersâ€™ petition for re-hearing. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. The California state court case is temporarily stayed. Annual sales of NiaspanÂ® were approximately $416Â million at the time of the settlement and approximately $1.1Â billion at the time Teva launched its generic version of NiaspanÂ® in September 2013. In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia against Teva and its affiliates alleging that the September 2006 patent litigation settlement relating to AndroGelÂ® 1% (testosterone gel) between Watson, from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (â€œSolvayâ€) violated antitrust laws. In September 2023, the plaintiffs voluntarily dismissed certain claims, and in September 2024, certain defendants, including the remaining Teva affiliates, and the plaintiffs agreed to settle the remaining claims. The litigation has been stayed pending finalization of the settlements. Annual sales of AndroGelÂ® 1% were approximately $350Â million at the time of the earlier Watson/Solvay settlement and approximately $140Â million at the time Actavis launched its generic version of AndroGelÂ® 1% in November 2015. A provision for this matter was previously included in the financial statements. Between SeptemberÂ 1, 2020 and DecemberÂ 20, 2020, plaintiffs purporting to represent putative classes of direct and indirect purchasers and opt-out retailer purchasers of BystolicÂ® (nebivolol hydrochloride) filed complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over BystolicÂ® violated the antitrust laws. The cases were coordinated, and the district court granted the defendantsâ€™ motion to dismiss all claims with prejudice. The plaintiffs appealed the district courtâ€™s grant of defendantsâ€™ motion to dismiss, and on MayÂ 13, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the district courtâ€™s dismissal with prejudice and issued a mandate on JuneÂ 4, 2024, formally ending the appeal. The plaintiffsâ€™ period to file a petition for a writ of certiorari to the U.S. Supreme Court expired. Annual sales of BystolicÂ® in the United States were approximately $700Â million at the time of Watsonâ€™s 2013 settlement with Forest. In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5Â million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021, and a judgment was issued on OctoberÂ 18, 2023 rejecting Tevaâ€™s grounds of appeal. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. On JanuaryÂ 4, 2024, Teva appealed the October 2023 judgment to the European Court of Justice. In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV (the â€œNew Mexico litigationâ€). Between September 2021 and April 2022, several private plaintiffs including retailers and health insurance providers filed similar claims in various courts, which were all removed and/or consolidated into the U.S. District Court for the Northern District of California (the â€œCalifornia litigationâ€). As they relate to Teva, the lawsuits challenged settlement agreements Teva entered into with Gilead in 2013 and/or 2014 to resolve patent litigation relating to Tevaâ€™s generic versions of VireadÂ® and/or TruvadaÂ® and AtriplaÂ®, although plaintiffs in the California litigation abandoned any claim for damages relating to the VireadÂ® settlement. In May Â 2023, Teva and Gilead reached a settlement agreement with the retailer plaintiffs in the California litigation and Teva recognized a provision for this matter based on such settlement. On JuneÂ 30, 2023, the jury in the trial against the remaining plaintiffs in the California litigation issued a verdict in favor of Teva and Gilead, rejecting all of the remaining plaintiffsâ€™ claims. On FebruaryÂ 12, 2024, the court entered a judgment as to all claims against Teva in the California litigation and the plaintiffs have filed notices of appeal with the U.S. Court of Appeals for the Ninth Circuit, and the appeal is currently being briefed. In the New Mexico litigation, on JuneÂ 27, 2024, Teva and the State of New Mexico finalized their settlement agreement, and the New Mexico court entered a consent judgment resolving the New Mexico litigation. Teva recognized a provision for the settlement with New Mexico. Annual sales in the United States at the time of the settlement of VireadÂ®, TruvadaÂ® and AtriplaÂ® were approximately $582Â million, $2.4Â billion, and $2.9Â billion, respectively. Annual sales in the United States at the time Teva launched its generic version of VireadÂ® in 2017, TruvadaÂ® in 2020 and AtriplaÂ® in 2020 were approximately $728Â million, $2.1Â billion and $444Â million, respectively. In March 2021, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. On OctoberÂ 10, 2022, the European Commission issued a Statement of Objections, which sets forth its preliminary allegations that Teva had engaged in anti-competitive practices. On October 31, 2024, the European Commission announced its final decision, alleging that Teva had abused a dominant position in certain European member states by (i) filing and withdrawing certain divisional patents, and (ii) raising concerns about competitorsâ€™ follow-on versions of COPAXONE. The decision, which Teva intends to appeal, also includes a fine of approximately $500 million (462.6 million euros). In accordance with Accounting Standards Codification 450 â€œAccounting for Contingencies,â€ Teva recognized a provision in its financial statements in the third quarter of 2024, based on managementâ€™s current best estimate of the outcome within a range of outcomes for the final resolution of this case. Teva intends to provide the European Commission a bank guarantee to cover at least a portion of the fine. On JuneÂ 29, 2021, Mylan Pharmaceuticals (â€œMylanâ€) filed claims against Teva in the U.S. District Court for the District of NewÂ Jersey. On MarchÂ 11, 2022 and MarchÂ 15, 2022, purported purchasers of COPAXONE filed claims against Teva in the U.S. District Court for the District of New Jersey on behalf of themselves and similarly situated direct and indirect purchasers of COPAXONE. On AugustÂ 22, 2022, additional purported purchasers of COPAXONE sued Teva in the U.S. District Court for the District of Vermont on behalf of themselves and similarly situated indirect purchasers of COPAXONE. The complaints variously assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the Racketeer Influenced and Corrupt Organizations Act (â€œRICO Actâ€). Additionally, plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneysâ€™ fees and costs, and injunctive relief. Teva moved to dismiss all of the complaints, and on JanuaryÂ 22, 2024, Tevaâ€™s motion to dismiss the complaint in the District of Vermont was granted as to certain state law claims but was otherwise denied. Decisions on Tevaâ€™s remaining motions to dismiss are pending. On JulyÂ 15, 2021, the U.K. Competition and Markets Authority (â€œCMAâ€) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK, Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMAâ€™s three prior investigations into the supply of hydrocortisone tablets in the U.K., as well as the CMAâ€™s subsequent investigation relating to an alleged anticompetitive agreement with Waymade. On JanuaryÂ 9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva agreed to indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to two of the three statements of objection from the CMA (dated DecemberÂ 16, 2016 and MarchÂ 3, 2017), and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On OctoberÂ 6, 2021, Accord UK (previously Actavis UK) and Auden Mckenzie appealed to the U.K. Competition Appeal Tribunal (the â€œTribunalâ€) the CMAâ€™s decisions that the prices of hydrocortisone were unfair and excessive and that the agreements amounted to infringements of the U.K.â€™s Competition Act as so-called pay-for-delay arrangements. The hearing for the appeal concluded in the first quarter of 2023, with partial judgments handed down by the Tribunal on SeptemberÂ 18, 2023 (judgment on unfair pricing), MarchÂ 8, 2024 (judgments on pay-for-delay and due process) and AprilÂ 29, 2024 (judgment on fines). The CMA appealed to the U.K. Court of Appeals on an expedited basis against certain elements of the pay-for-delay and due process judgments that it had lost, and on SeptemberÂ 6, 2024, the U.K. Court of Appeal overturned the Tribunalâ€™s judgment on due process and, as a result, the Tribunal will now consider and issue a further judgment on fines. Accord UK and Auden Mckenzie have requested permission to appeal to the U.K. Supreme Court and have submitted to the Tribunal additional applications for permission to appeal certain other issues relating to unfair pricing and fines. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. Â In November 2022, two complaints filed by plaintiffs purporting to represent retailer purchasers and a putative class of end-payor purchasers were filed in the U.S. District Court for the District of New Jersey against Teva and its marketing partner, Natco Pharma Limited (â€œNatcoâ€), alleging violations of the antitrust laws in connection with their December 2015 settlement of patent litigation with Celgene Corporation (which was subsequently acquired by BMS) involving the drug RevlimidÂ® (lenalidomide). The complaints also name Celgene and BMS as defendants. On JanuaryÂ 24, 2023, the complaints were consolidated for pre-trial purposes only with an earlier-filed, already consolidated Insurer Opt-Out Action filed against BMS and Celgene. On FebruaryÂ 16, 2023, plaintiffs filed amended complaints adding additional plaintiffs. On MayÂ 16, 2023, Teva and Natco, along with Celgene, moved to dismiss the complaints against them. Additionally, on OctoberÂ 6, 2023, two individual payor plaintiffs brought claims similar to those described above in the U.S. District Court for the Northern District of California, which actions were transferred to the U.S. District Court for the District of New Jersey and consolidated with the pending consolidated actions. On JuneÂ 6, 2024, the court granted in full Celgeneâ€™s motion to dismiss the Insurer Opt-Out Action, but allowed plaintiffs leave to amend most of their claims. The Court had previously administratively terminated Tevaâ€™s, Natcoâ€™s, and Celgeneâ€™s motions to dismiss the retailer and end-payor complaints pending the decision on the Insurer Opt-Out Action. The plaintiffs filed amended complaints on AugustÂ 5, 2024, and the defendantsâ€™ filed motions to dismiss on OctoberÂ 7, 2024. Annual sales of RevlimidÂ® in the United States were approximately $3.5Â billion at the time of the settlement. On DecemberÂ 2, 2022, plaintiffs purporting to represent putative classes of indirect purchasers of EpiPenÂ® (epinephrine injection) and NUVIGILÂ® (armodafinil) filed a complaint in the U.S. District Court for the District of Kansas against Teva, Cephalon, and a former Teva executive. Teva owns the New Drug Application (â€œNDAâ€) for NUVIGIL and sold the brand product, for which generic entry occurred in 2016. Teva filed an ANDA to sell generic EpiPenÂ®, which Teva launched in 2018, following receipt of FDA approval. The complaint alleges, among other things, that the defendants violated federal antitrust laws, the RICO Act, and various state laws in connection with settlements resolving patent litigation relating to those products. Plaintiffs seek injunctive relief, compensatory and punitive damages, interest, attorneysâ€™ fees and costs. On SeptemberÂ 26, 2023, plaintiffs filed a brief in opposition to Tevaâ€™s motion to dismiss the amended complaint, in which plaintiffs limited their claims only to those relating to the alleged delay of generic NUVIGIL. On MarchÂ 26, 2024, the court issued its decision, which granted Tevaâ€™s motion in part, dismissing plaintiffsâ€™ RICO claims and certain state law claims, but denied Tevaâ€™s motion regarding plaintiffsâ€™ antitrust claims. On AprilÂ 26, 2024, Teva sought certification to seek an interlocutory appeal of the decision, which is still pending. Annual sales of NUVIGIL in the United States were approximately $300Â million at the time Teva entered into the first settlement with an ANDA filer in 2012. In May 2023, certain end-payor plaintiffs filed putative class action complaints in the U.S. District Court for the District of Massachusetts against Teva and a number of its affiliates, alleging that Teva engaged in anticompetitive conduct to suppress generic competition to its branded QVARÂ® asthma inhalers in violation of state and federal antitrust laws and state consumer protection laws. Teva moved to dismiss these claims, and on MayÂ 7, 2024, the court granted Tevaâ€™s motion in part and denied its motion in part. The court dismissed plaintiffsâ€™ claim that Teva had engaged in â€œsham litigationâ€ and certain of plaintiffsâ€™ state antitrust and consumer protection claims, but permitted the case to proceed on the remainder of plaintiffsâ€™ allegations. Following this decision, two direct purchaser plaintiffs filed similar putative class action complaints in the U.S. District Court for the District of Massachusetts. On JuneÂ 18, 2024, Teva answered in all cases and simultaneously moved for judgment on the pleadings pursuant to Rule 12(c), which remains pending. Subsequently, on JuneÂ 28, 2024, Teva stipulated to the dismissal of the two direct purchaser plaintiffsâ€™ claims, with prejudice. Government Investigations and Litigation Relating to Pricing and Marketing Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (â€œDOJâ€) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On AugustÂ 25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three-count indictment charging Teva USA with criminal felony Sherman Act violations. The indictment alleged that Teva USA had participated in three separate conspiracies with other Â generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: pravastatin, carbamazepine, clotrimazole, etodolac (IR and ER), fluocinonide (cream, e-cream, gel, and ointment), warfarin, nadolol, temozolomide, and tobramycin. On AugustÂ 21, 2023, Teva USA entered into a 3-year deferred prosecution agreement (â€œDPAâ€) with the DOJ. Under the terms of the DPA, Teva USA: (i)Â admitted to violating the antitrust laws by agreeing with competitors, in three instances between 2013 and 2015 involving three separate customers, not to bid on an opportunity to supply a customer with a particular generic product (in the first instance pravastatin, in the second clotrimazole, and in the third tobramycin); (ii) agreed to divest the pravastatin that it sells in the United States to a third-party buyer; (iii)Â agreed to donate $50Â million worth of clotrimazole and tobramycin, valued at wholesale acquisition cost (â€œWACâ€), to humanitarian organizations over five years; and (iv)Â agreed to pay a fine in the amount of $225Â million over 5 years, with $22.5Â million due each year from 2024 through 2027, and $135Â million due in 2028. Teva recognized a provision for the resolution of this case.â€ƒIn May 2018, Teva received a civil investigative demand from the DOJ Civil Division pursuant to the federal False Claims Act, seeking documents and information produced since JanuaryÂ 1, 2009 relevant to the Civil Divisionâ€™s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and/or price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. On OctoberÂ 10, 2024, Teva entered into a settlement agreement with the Civil Division to resolve these allegations. Teva will pay $25Â million under the terms of the settlement â€“ $10Â million in the fourth quarter of 2024, and $15Â million in 2025 â€“ which includes no admission of wrongdoing. Teva has recognized a provision for the resolution of this matter. In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. On DecemberÂ 15, 2016, the civil action that was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States was subsequently amended to include 49 states, as well as the District

of Columbia and Puerto Rico as plaintiffs, and to add new allegations and state law claims against both Actavis and Teva. On MayÂ 10, 2019, most of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, which was subsequently amended on NovemberÂ 1, 2019, alleging that Teva was at the center of a conspiracy in the generic pharmaceutical industry and asserting that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain products. On JuneÂ 10, 2020, most of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the U.S. District Court for the District of Connecticut naming, among other defendants, Actavis, in a similar complaint relating to dermatological generics products, and that complaint was later amended to, among other things, add California as a plaintiff. In the various complaints described above, which also include claims against certain former employees of Actavis and Teva USA, the states seek a finding that the defendantsâ€™ actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints were transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (â€œPennsylvania MDLâ€). On MayÂ 7, 2021, the Pennsylvania MDL court chose the attorneys generalâ€™s third complaint filed on JuneÂ 10, 2020, as subsequently amended, to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. On JuneÂ 7, 2022, the Court dismissed the attorneys generalâ€™s claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law. On FebruaryÂ 27, 2023, the Court largely denied defendantsâ€™ motions to dismiss the federal claims asserted by the attorneys general in their bellwether complaint. Another motion to dismiss related to the state law claims asserted by the attorneys general in their bellwether complaint remains pending. Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022), Florida (in February 2023), Kentucky (in June 2023), South Dakota (in June 2024), and New Mexico (in June 2024). Teva paid each state an amount proportional to its share of the national population (approximately $1,000,000 for each 1% share of the national population), and the states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. These settlements, in addition to the status of ongoing negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining Â attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022. The States of Alabama (in March 2022) and Hawaii (in August 2023) and the territories of American Samoa (in July 2020) and Guam (in February 2023) have all voluntarily dismissed all of their claims in the litigation against Actavis and Teva USA. The dismissals by Alabama, Hawaii and Guam were with prejudice and the dismissal by American Samoa was without prejudice. Beginning on MarchÂ 2, 2016, and through July 2023, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser opt-out plaintiffs, including most recently an opt-out complaint filed by nine direct-action plaintiffs on AprilÂ 4, 2024. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. The Pennsylvania MDL court scheduled potential bellwether trials for the putative classes of direct and indirect purchasers of two drugs for August 2024. From 2019 to 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis. One plaintiff, Aetna Inc., has filed a complaint, and the defendants have moved to place all of the cases filed in the Court of Common Pleas of Philadelphia County in deferred status, which motion remains pending. Certain counties in NewÂ York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. On JanuaryÂ 31, 2024, the attorney generalsâ€™ motion to remand their three lawsuits to the District of Connecticut, where they were originally filed, was granted, and on MarchÂ 18, 2024, the Third Circuit Court of Appeals denied defendantsâ€™ petition for writ of mandamus. In April 2024, all three of the attorneys generalâ€™s lawsuits have been transferred back to the U.S. District Court for the District of Connecticut, which has adopted a schedule for summary judgment in the attorneys generalâ€™s third complaint pursuant to which multiple groups of motions will be filed during 2024 and 2025. Fact discovery in the first and second complaints is ongoing. There is also one similar complaint brought in Canada, which is in its early stages and alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. In March 2017, Teva received a subpoena from the U.S. Attorneyâ€™s office in Boston, Massachusetts requesting documents related to Tevaâ€™s donations to patient assistance programs. In August 2020, the U.S. Attorneyâ€™s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging causes of action under the federal False Claims Act and for unjust enrichment (the â€œDOJ PAP Complaintâ€). It was alleged that Tevaâ€™s donations to certain 501(c)(3) charities that provided financial assistance to multiple sclerosis patients violated the Anti-Kickback Statute, and the DOJ sought a maximum of over $1Â billion in damages, which would automatically be trebled in the event of an adverse verdict, and Teva would also be subject to mandatory statutory penalties for each false claim, the amount of which (potentially billions of U.S. dollars in additional penalties, at the high end) would be determined by the court within a statutory range. On OctoberÂ 10, 2024, Teva entered into a settlement agreement with the DOJ to resolve these claims. Teva will pay $425Â million over 6 years under the terms of the settlement â€“ $19Â million in the fourth quarter of 2024, $34Â million in 2025, $49Â million in each of 2026 and 2027, $99Â million in 2028, and $175Â million in 2029 â€“ which includes no admission of wrongdoing. Teva has recognized a provision for the resolution of this case. Additionally, on JanuaryÂ 8, 2021, Humana, Inc. (â€œHumanaâ€) filed an action against Teva in the U.S. District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. In June 2023, Teva filed a joint motion to dismiss the amended complaint, together with co-defendant Advanced Care Scripts, Inc., on the grounds that Humana lacks standing to assert RICO claims and the claims are time-barred and/or insufficiently pled, and that motion remains pending. On NovemberÂ 17, 2022, United Healthcare also filed an action against Teva in the U.S. District Court for the District of New Jersey based on the conduct alleged in the DOJ PAP Complaint, and on FebruaryÂ 29, 2024, United Healthcare filed an amended complaint. On AugustÂ 16, 2024, several MSP Recovery-related entities filed a putative class action against Teva and others in the U.S. District Court for the District of Kansas based on the alleged conduct in the DOJ PAP Complaint. Â In April 2021, a city and county in Washington filed claims against Teva in the U.S. District Court for the Western District of Washington for alleged violations of the RICO Act, Washingtonâ€™s Consumer Protection Act, and unjust enrichment concerning Tevaâ€™s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On NovemberÂ 17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffsâ€™ claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. On MarchÂ 9, 2023, the court held a hearing on the motion to dismiss, and a decision remains pending. On DecemberÂ 1, 2022, Teva received a civil subpoena from the U.S. Attorneyâ€™s office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDOÂ® and risperidone LAI. Teva is cooperating with the request for documents. In June 2024, Teva received a civil investigative demand from the Federal Trade Commission (â€œFTCâ€) seeking documents and information regarding an investigation related to patents listed in the Food and Drug Administrationâ€™s Approved Drug Products with Therapeutic Equivalence Evaluations publication (â€œOrange Bookâ€) in connection with certain inhaler products. Teva is cooperating with the request for documents and information. On OctoberÂ 1, 2024, Teva received a civil investigative demand from the U.S. Attorneyâ€™s office in Boston, Massachusetts and the Civil Division of the Department of Justice requesting certain documents and information related to the manufacturing practices at its former manufacturing facility in Irvine, California, which Teva closed in 2022. Teva is cooperating with the request for documents and information. Opioids Litigation Since May 2014, more than 3,500 complaints have been filed by various governmental agencies and private plaintiffs in U.S. state and federal courts with respect to opioid sales and distribution against various Teva affiliates and several other pharmaceutical companies, the vast majority of which have been resolved. Cases brought by third party payers, both as individual cases and as class actions, remain. The majority of the remaining cases are consolidated in the multidistrict litigation in the Northern District of Ohio (the â€œMDL Opioid Proceedingâ€). These cases assert claims under similar provisions of different state laws and generally allege that the defendants engaged in improper marketing and distribution of Tevaâ€™s branded opioids, including ACTIQÂ® and FENTORAÂ®, and also assert claims related to Tevaâ€™s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.Â Furthermore, approximately 100 personal injury complaints allege that Anda (in addition to naming other distributors and manufacturers) failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent their abuse and diversion. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,Â non-economic damages, attorneysâ€™ fees and injunctive relief. Certain plaintiffs seek damages for all costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. All but a handful of these cases are stayed in the MDL Opioid Proceedings. In June 2023, Teva finalized and fully resolved its nationwide settlement agreement with the states and litigating subdivisions. Under the financial terms of the nationwide settlement agreement with the states and subdivisions, Teva will pay up to $4.25Â billion (including the already settled cases), spread over 13 years. This total includes the supply of up to $1.2Â billion of Tevaâ€™s generic version of NarcanÂ® (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 10 years or cash at 20% of the wholesale acquisition cost ($240 million) in lieu of product. In September 2024, Teva reached and finalized an agreement with the City of Baltimore to settle its opioid-related claims for a total of $80Â million (of which $35Â million will be paid by the end of 2024 and the remainder will be paid by JulyÂ 1, 2025), averting a trial that was scheduled to begin on SeptemberÂ 16, 2024. Â With its settlement with the City of Baltimore, Teva has settled with 100% of the U.S. states and litigating political subdivisions and the Native American tribes (the â€œTribesâ€). Tevaâ€™s estimated cash payments between 2024 and 2028 for all opioids settlements are: $428Â million payable in 2024 (of which $392Â million was paid as of SeptemberÂ 30, 2024), $423Â million payable in 2025; $368Â million payable in 2026; $374Â million payable in 2027; and $390Â million payable in 2028. These payments are subject to change based on various factors including, but not limited to, timing of payments, most favored nations clauses associated with prior settlements, and the statesâ€™ elections to take Tevaâ€™s generic version of NarcanÂ® (naloxone hydrochloride nasal spray). The remaining payments, subject to adjustments, will be paid beyond 2028. Various Teva affiliates, along with several other pharmaceutical companies, were named as defendants in opioids cases initiated by approximately 500 U.S. hospitals and other healthcare providers asserting opioid-related claims, including public nuisance. Specifically, the lawsuits brought by the hospitals allege that they have incurred financial harm from increased operating costs for treating patients whose underlying illnesses are purportedly exacerbated or complicated by opioid addiction. In September 2024, Teva and the representatives for acute care hospitals finalized the terms of a proposed settlement agreement. Under the financial terms of the proposed national settlement agreement, Teva will pay up to $126Â million in cash, spread over 18 years, and supply up to $49Â million of Tevaâ€™s generic version of NarcanÂ® (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 7 years. The proposed settlement agreement is contingent upon Tevaâ€™s satisfaction, in its sole discretion, with the level of participation by acute care hospitals and health care systems in the proposed settlement agreement. In light of the nationwide settlement agreement between Teva and the Statesâ€™ Attorneys General and their subdivisions, Tevaâ€™s indemnification obligations arising from Tevaâ€™s acquisition of the Actavis Generics business for opioid-related claims, prior settlements reached with Louisiana, Texas, Rhode Island, Florida, San Francisco, West Virginia, New York, the Tribes, Nevada and the City of Baltimore, the agreement in principle with the hospitals discussed above, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has recorded a provision. The provision is a reasonable estimate of the ultimate costs for Tevaâ€™s opioids settlements, after discounting payments to their net present value. Opioid-related lawsuits brought against Teva by dozens of third-party payers, such as unions and welfare funds, remain pending. A reasonable upper end of a range of loss cannot be determined for the entirety of the remaining opioid-related cases. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and adverse effect on Tevaâ€™s reputation, business, results of operations and cash flows. In addition, Teva, certain of its subsidiaries and other defendants, are defending claims and putative class action lawsuits in Canada related to the manufacture, sale, marketing and distribution of opioid medications. The lawsuits include a claim by the Province of British Columbia on behalf of itself and a putative class of other federal and provincial governments, and claims of municipalities, First Nations, and persons who used opioids on behalf of themselves and putative classes. In November and December 2023, the British Columbia Supreme Court held a hearing regarding preliminary motions, including plaintiffsâ€™ certification motion, which remain pending. Shareholder Litigation On NovemberÂ 6, 2016 and DecemberÂ 27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits subsequently were consolidated and transferred to the U.S. District Court for the District of Connecticut (the â€œOntario Teachers Securities Litigationâ€). On DecemberÂ 13, 2019, the lead plaintiff filed an amended complaint, purportedly on behalf of purchasers of Tevaâ€™s securities between FebruaryÂ 6, 2014 and MayÂ 10, 2019, asserting that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Tevaâ€™s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. From July 2017Â to June 2019, other putative securities class actions were filed in other federal courts based on similar allegations and claims, and were transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors on behalf of plaintiffs in various forums across the country, but many of those plaintiffs â€œopted-outâ€ of the Ontario Teachers Securities Litigation. On JanuaryÂ 18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $420Â million, which received final approval from the court on JuneÂ 2, 2022. The vast majority of the total settlement amount was covered by the Companyâ€™s insurance carriers, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. On JanuaryÂ 22, 2021, the Court dismissed the â€œopt-outâ€ plaintiffsâ€™ claims arising from statements made prior to the five-year statute of repose, but denied Tevaâ€™s motion to dismiss their claims under Israeli laws. Teva has settled the majority of the â€œopt-outâ€ claims, and one opt-out case remains outstanding. Teva also reached a settlement with shareholders who filed class actions in Israel with similar allegations to those raised in the Ontario Teachers Securities Litigation, which was approved by the court in Israel in November 2023. Â On SeptemberÂ 23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On AugustÂ 10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between OctoberÂ 29, 2015 and AugustÂ 18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Tevaâ€™s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONEâ€™s commercial success and the sustainability of its revenues and resulted in the DOJ PAP Complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On AugustÂ 2, 2022, the court stayed all proceedings other than class certification proceedings pending the resolution of the DOJ PAP Complaint. On NovemberÂ 3, 2023, the court granted plaintiffâ€™s motion for class certification. On NovemberÂ 17, 2023, Teva filed a petition with the Third Circuit Court of Appeals for leave to appeal the class certification ruling, which was denied on MayÂ 16, 2024. On AugustÂ 30, 2024, the court lifted the stay. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. Environmental Matters Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site

or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Tevaâ€™s facilities or former facilities. Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of clean-up and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Tevaâ€™s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, clean-up and natural resource damages have not yet been determined, and for others Tevaâ€™s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of clean-up costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Tevaâ€™s facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Tevaâ€™s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. ItemÂ 103 of Regulation S-K promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less than $300,000. The following matter is disclosed in accordance with that requirement. On JulyÂ 8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Tevaâ€™s subsidiary in India, Teva API India Private Limited, finding non-compliance with environmental laws and assessed a penalty of $1.4Â million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On AugustÂ 5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunalâ€™s order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business. Â Other Matters On FebruaryÂ 1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalonâ€™s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.Â Among other things, the plaintiffs alleged that Cephalon had breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIRÂ® (reslizumab) for the treatment of eosinophilic esophagitis (â€œEEâ€). The plaintiffs claimed damages of at least $200Â million, an amount they alleged was equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). On DecemberÂ 28, 2018, following defendantsâ€™ motion to dismiss the complaint, the court granted the motion in part and dismissed all of plaintiffsâ€™ claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA. However, on JulyÂ 12, 2022, plaintiffs filed a new amended complaint that included claims against Teva USA but not the Company, in exchange for Teva USAâ€™s agreement to guarantee any judgment entered against Cephalon in the litigation. A bench trial for this matter was held in September 2022 and on AprilÂ 30, 2024, the court issued a memorandum opinion in favor of Cephalon and Teva USA, finding that they did not breach the merger agreement as plaintiffs had alleged. Plaintiffs have appealed that ruling to the Delaware Supreme Court, and the appeal remains pending. Gain Contingencies From time to time, Teva may directly or indirectly pursue claims against certain parties, including but not limited to patent infringement lawsuits against other pharmaceutical companies to protect its patent rights, as well as derivative actions brought on behalf of Teva. Teva recognizes gain contingencies from the defendants in such lawsuits when they are realized or when all related contingencies have been resolved. No gain has been recognized regarding the matters disclosed below, unless mentioned otherwise. In October 2017, Teva filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli LillyÂ & Co.â€™s (â€œLillyâ€) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review (â€œIPRâ€) petitions to the Patent Trial and Appeal Board (â€œPTABâ€), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on AugustÂ 16, 2021. A jury trial regarding the three method of treatment patents resulted in a verdict in Tevaâ€™s favor on NovemberÂ 9, 2022, in which the three method of treatment patents were determined to be valid and infringed by Lilly and Teva was awarded $176.5Â million in damages. On SeptemberÂ 26, 2023, the U.S. District Court for the District of Massachusetts issued a decision that reversed the juryâ€™s verdict and damages award, finding Tevaâ€™s method of treatment patents to be invalid. Teva filed its opening appeal brief on FebruaryÂ 2, 2024 and Lilly filed its responsive brief on AprilÂ 19, 2024. Teva filed its responsive brief on MayÂ 29, 2024, and Lillyâ€™s final brief was filed on JulyÂ 19, 2024. No date has been set for the appeal hearing. In March 2024, Teva filed a lawsuit in the U.S. District Court for the District of New Jersey alleging that Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited, and Amarin Corporation plc (collectively â€œAmarinâ€) engaged in a decade-long scheme to lock up the supply of icosapent ethyl to prevent and delay generic competition to its branded VascepaÂ® drug product.Â Tevaâ€™s lawsuit coincides with four other lawsuits brought by generic drug manufacturers and purchasers ofÂ branded VascepaÂ®Â alleging the same or similar conduct by Amarin.Â Tevaâ€™s requested relief includes compensatory damages for lost sales and lost profits from generic icosapent ethyl drug sales that Teva could have made absent Amarinâ€™s alleged interference. On MayÂ 24, 2024, Amarin filed a motion in the U.S. District Court for the District of Nevada, seeking to enforce the terms of an earlier Teva-Amarin agreement to settle patent litigation regarding VascepaÂ®, which Amarin asserts precludes Teva from filing the present antitrust action. Teva opposed this motion on JuneÂ 7, 2024, and Amarinâ€™s motion remains pending. As the lawsuit is still in its initial stages, it is not possible to predict its outcome and there is no guarantee that Teva will be granted its requested relief. In June 2024, Teva filed a lawsuit in the U.S. District Court for the Northern District of California alleging that Corcept Therapeutics, Inc. (â€œCorceptâ€), and Optime Care Inc. (â€œOptimeâ€) have engaged in a multifaceted, years-long scheme to stifle generic competition to Corceptâ€™s branded KorlymÂ® (mifepristone) drug product, which is indicated to treat endogenous Cushingâ€™s syndrome. Teva alleges that Corcept and Optime have suppressed competition by abusing the Â patent and judicial systems, entering a long-term, blanket exclusive-dealing agreement that has locked up a key pharmaceutical distribution channel, and making illicit payments to physicians as compensation for prescribing KorlymÂ®. Tevaâ€™s requested relief includes compensatory damages for lost sales and lost profits from generic mifepristone drug sales that Teva could have made absent Corcept and Optimeâ€™s alleged interference, as well as injunctive relief to remove the unlawful barriers to generic competition created by Corcept and Optime. As the lawsuit is still in its initial stages, it is not possible to predict its outcome and there is no guarantee that Teva will be granted its requested relief. Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness, as well as motions for document disclosure prior to initiating derivative actions. Motions were filed with respect to several U.S. and EU settlement agreements, opioids, allegations related to the DOJâ€™s complaint regarding the COPAXONE patient assistance program in the U.S., and with respect to the European Commissionâ€™s investigation relating to COPAXONE. In May 2024, Teva settled the derivative action related to the opioids litigation, and on SeptemberÂ 16, 2024, the settlement received final approval from the Tel Aviv District Court. Â X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Income taxes 9 Months Ended Sep. 30, 2024 Income taxes Â NOTE 11 â€“ Income taxes: In the third quarter of 2024, Teva recognized a tax expense of $69Â million, on a pre-tax lossÂ of $324Â million. In the third quarter of 2023, Teva recognized a tax benefit of $12Â million, on a pre-taxÂ incomeÂ of $64Â million. Tevaâ€™s tax rate for the third quarter of 2024 was mainly impacted by impairment charges with no corresponding tax effects, an adjustment to the Companyâ€™s corporate tax rate in Israel on losses related to non-qualified tax incentive activities in Israel, legal expenses with no corresponding tax effect related to the fine issued by the European Commission in connection with its antitrust investigation into COPAXONE, and recording of valuation allowance with respect to certain carry over credits outside of Israel. Tevaâ€™s tax rate for the third quarter for 2023 was mainly affected by deferred tax benefits resulting from intellectual property related integration plans, which have been adopted, among others, in an effort of addressing the global adoption of the Organization for Economic Co-operation and Development (OECD) Pillar Two minimum effective corporate tax. The pre-tax loss in the third quarter of 2023 was revised as discussed in note 1c. In the first nine months of 2024, Teva recognized a tax expense of $648Â million, on a pre-tax loss of $1,037Â million. In the first nine months of 2023, Teva recognized a tax benefit of $48Â million, on a pre-tax loss of $1,131Â million. Tevaâ€™s tax rate for the first nine months of 2024 was mainly impacted by a settlement agreement with the Israeli Tax Authorities (â€œITAâ€) as discussed below, impairment charges with no corresponding tax effects, deferred tax benefits resulting from intellectual property related integration plans, an adjustment to the Companyâ€™s corporate tax rate in Israel on losses related to non-qualified tax incentives activities in Israel, legal expenses with no corresponding tax effect related to the fine issued by the European Commission in connection with its antitrust investigation into COPAXONE, and recording of valuation allowance with respect to certain carry over credits outside of Israel. Tevaâ€™s tax rate for the first nine months of 2023 was mainly affected by deferred tax benefits from intellectual property related integration plans, impairments, legal settlements, and interest expense disallowances. The pre-tax loss in the first nine months of 2023 was revised as discussed in note 1c. The statutory Israeli corporate tax rate is 23% in 2024. Tevaâ€™s global tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits, as well as infrequent or non-recurring items. Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. A trial for this case is currently ongoing. A final and binding decision against Teva in this case may lead to a charge of $125Â million. On JuneÂ 23, 2024, Teva entered into an agreement with the ITA to settle certain litigation with respect to taxes payable for the Companyâ€™s taxable years 2008 through 2020 (the â€œAgreementâ€). Pursuant to the terms of the Agreement, the Company will pay a total amount of approximately $750Â million to the ITA spread over a six-year period beginning this year. The Company has the right to prepay, and amounts paid over time are subject to interest and increase for inflation. Such total amount includes: (i) $495Â million in corporate taxes with respect to the Companyâ€™s historical earnings that were previously considered by the Company to be exempt from taxes under the Encouragement for Capital Investment Law; and (ii)Â approximately $250Â million in corporate taxes, relating to additional disputed tax issues in the aforementioned taxable years. The Agreement resulted in an increase of $506Â million in the Companyâ€™s total income taxes in the second quarter of 2024, as certain elements had been recognized in previous periods. Additionally, under the terms of the Agreement, it was further agreed that in the future event the Company pays dividends on, or repurchases, its equity interests, the Company will pay an additional 5%-7% of the amount of such dividends or repurchases in corporate taxes, up to a maximum tax payment amount of approximately $500Â million. Any amounts due under this provision of the Agreement will be recorded in the future as incurred. Teva believes it has adequately provided for all of its uncertain tax positions, including items currently under dispute, however, adverse results could be material. The OECD introduced Base Erosion and Profit Shifting (â€œBEPSâ€) Pillar Two rules that impose a global minimum tax rate of 15% for large multinational corporations. On DecemberÂ 12, 2022, the EU Council announced that EU member states had reached an agreement to implement the minimum taxation component of 15% of the OECDâ€™s reform of international taxation. Other countries have also enacted or are expected to enact legislation to be effective as early as JanuaryÂ 1, 2024, with general implementation of a global minimum tax by JanuaryÂ 1, 2025. Teva has evaluated the potential impact on its 2024 consolidated financial statements and related disclosures and does not expect Pillar Two to have a material impact on its effective tax rate or consolidated financial statements in the foreseeable future. Â X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Other assets impairments, restructuring and other items 9 Months Ended Sep. 30, 2024 Other assets impairments, restructuring and other items Â NOTE 12 â€“ Other assets impairments, restructuring and other items: Â Â Â Â ThreeÂ monthsÂ ended Â Â Â NineÂ monthsÂ ended Â Â Â Â SeptemberÂ 30, Â Â Â SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Â Â (U.S.Â $Â inÂ millions) Â Impairments of long-lived tangible assets (1) Â Â $ (80)Â Â Â $ 1 Â Â Â $ 589 Â Â Â $ 21 Â Contingent consideration (2) Â Â Â 34 Â Â Â Â 27 Â Â Â Â 305 Â Â Â Â 140 Â Restructuring Â Â Â 21 Â Â Â Â 27 Â Â Â Â 52 Â Â Â Â 93 Â Other Â Â Â 1 Â Â Â Â 2 Â Â Â Â (16)Â Â Â Â 21 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ (23)Â Â Â $ 57 Â Â Â $ 931 Â Â Â $ 276 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) Including impairments related to exit and disposal activities. (2) The contingent consideration presented in the tables above for the three and nine months ended SeptemberÂ 30, 2023 have been revised as discussed in note 1c. Impairments In the three months ended September 30, 2024, Teva recorded an income ofÂ $80Â million under impairments of tangible assets, compared to an expense of $1Â million in the three months ended September 30, 2023. The income for the three months ended SeptemberÂ 30, 2024 was mainly related to a favorable adjustment to the changes of the expected loss from reclassification of currency translation adjustments, partially offset by an additional impairment due to fair value update in connection with the classification of the business venture in Japan as held for sale. See note 2. Impairments of tangible assets for the nine months ended SeptemberÂ 30, 2024 and

2023 were $589Â million and $21Â million, respectively. The impairment for the nine months ended SeptemberÂ 30, 2024 was mainly related to the classification of the business venture in Japan as held for sale (see note 2). The impairments for the nine months ended SeptemberÂ 30, 2023 were mainly related to certain assets in the U.S. and Europe. Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its ongoing network consolidation activities and its â€œPivot to Growth Strategyâ€. Contingent consideration In the three months ended SeptemberÂ 30, 2024, Teva recorded an expense of $34Â million for contingent consideration, compared to an expense of $27Â million in the three months ended SeptemberÂ 30, 2023. The expenses in the three months ended SeptemberÂ 30, 2024 were mainly due to the effect of the passage of time on the net present value of the discounted payments. The expenses in the three months ended September 30, 2023 were mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of RevlimidÂ®) and a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The expense in the three months ended SeptemberÂ 30, 2023 was revised as discussed in note 1c. In the nine months ended SeptemberÂ 30, 2024, Teva recorded an expense of $305Â million for contingent consideration, compared to an expense of $140Â million in the nine months ended SeptemberÂ 30, 2023. The expenses in the first nine months of 2024 and 2023 were mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of RevlimidÂ®) and a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The expense in the first nine months of 2023 was revised as discussed in note 1c. Restructuring In the three months ended SeptemberÂ 30, 2024, Teva recorded $21Â million of restructuring expenses, compared to $27Â million in the three months ended SeptemberÂ 30, 2023. Expenses for the three months ended SeptemberÂ 30, 2024 and 2023 were primarily related to network consolidation activities. Â In the nine months ended SeptemberÂ 30, 2024, Teva recorded $52Â million of restructuring expenses, compared to $93Â million in the nine months ended SeptemberÂ 30, 2023. The expenses for the nine months ended SeptemberÂ 30, 2024 and 2023 were primarily related to network consolidation activities. The following tables provide the components of the Companyâ€™s restructuring costs: Â Â Â Â ThreeÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Restructuring Â Â Â Â Employee termination Â Â $ 13 Â Â Â $ 16 Â Other Â Â Â 8 Â Â Â Â 12 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 21 Â Â Â $ 27 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€‚NineÂ monthsÂ endedÂ SeptemberÂ 30,â€‚ Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Restructuring Â Â Â Â Employee termination Â Â $ 33 Â Â Â $ 40 Â Other Â Â Â 19 Â Â Â Â 53 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 52 Â Â Â $ 93 Â Â Â Â Â Â Â Â Â Â Â The following table provides the components of and changes in the Companyâ€™s restructuring accruals: Â Â Â Â EmployeeÂ termination costs Â Â Â Other Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of JanuaryÂ 1, 2024 Â Â $ (75)Â Â Â $ (7)Â Â Â $ â€„(82)Â Provision Â Â Â (33)Â Â Â Â (19)Â Â Â Â (52)Â Utilization and other* Â Â Â 52 Â Â Â Â 12 Â Â Â Â 64 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2024 Â Â $ (56)Â Â Â $ (14)Â Â Â $ (70)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â EmployeeÂ termination costs Â Â Â Other Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of JanuaryÂ 1, 2023 Â Â $ (112)Â Â Â $ (7)Â Â Â $ (119)Â Provision Â Â Â (40)Â Â Â Â (53)Â Â Â Â (93)Â Utilization and other* Â Â Â 77 Â Â Â Â 53 Â Â Â Â 130 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2023 Â Â $ (75)Â Â Â $ (7)Â Â Â $ (82)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Includes adjustments for foreign currency translation. Â X - DefinitionOther Expenses [Text Block] + ReferencesNo definition available. + Details Name: teva_OtherExpensesTextBlock Namespace Prefix: teva_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings (Loss) per Share 9 Months Ended Sep. 30, 2024 Earnings (Loss) per Share Â NOTE 13 â€“ Earnings (Loss) per share: Basic earnings and loss per share are computed by dividing net income (loss) attributable to Tevaâ€™s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (â€œRSUsâ€) and performance share units (â€œPSUsâ€) during the period, net of treasury shares. In computing diluted loss per share for the three months ended SeptemberÂ 30, 2024, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. In computing diluted earnings per share for the three months ended September 30, 2023, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. In computing diluted loss per share for the nine months ended SeptemberÂ 30, 2024 and 2023, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended SeptemberÂ 30, 2024 and 2023 were 1,133Â million shares and 1,135Â million shares, respectively. The weighted average diluted shares outstanding used for the fully diluted share calculations for the nine months ended SeptemberÂ 30, 2024 and 2023 were 1,130Â million shares and 1,119Â million shares, respectively. Basic and diluted lossÂ per share wasÂ $0.39 for the three months ended SeptemberÂ 30, 2024, compared to basic and diluted earnings per share of $0.06 for the three months ended SeptemberÂ 30, 2023. Basic and diluted earnings per share for the three months ended SeptemberÂ 30, 2023 wereÂ revised as discussed in note 1c. Basic and diluted loss per share was $1.26 for the nine months ended SeptemberÂ 30, 2024, compared to basic and diluted loss per share of $0.91 for the nine months ended SeptemberÂ 30, 2023. Basic and diluted loss per share for the nine months ended SeptemberÂ 30, 2023 wereÂ revised as discussed in note 1c. Â X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Accumulated other comprehensive income (loss) 9 Months Ended Sep. 30, 2024 Accumulated other comprehensive income (loss) Â NOTE 14 â€“ Accumulated other comprehensive income (loss): The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: Â Â Â Â NetÂ UnrealizedÂ GainsÂ (Losses) Â Â Â BenefitÂ Plans Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â Â Derivative financial instruments Â Â Â ActuarialÂ gains (losses) and prior service (costs) credits Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of DecemberÂ 31, 2023, net of taxes Â Â $ (2,384)Â Â Â $ (266)Â Â Â $ (46)Â Â Â $ (2,697)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss) before reclassifications Â Â Â (84)Â Â Â Â â€”â€‚ Â Â Â Â 1 Â Â Â Â (83)Â Amounts reclassified to the statements of income Â Â Â â€”â€‚ Â Â Â Â 21 Â Â Â Â (3)Â Â Â Â 18 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net other comprehensive income (loss) before tax Â Â Â (84)Â Â Â Â 21 Â Â Â Â (2)Â Â Â Â (65)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corresponding income tax Â Â Â (7)Â Â Â Â â€”â€‚ Â Â Â Â â€”â€‚ Â Â Â Â (7)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net other comprehensive income (loss) after tax* Â Â Â (91)Â Â Â Â 21 Â Â Â Â (2)Â Â Â Â (72)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2024, net of taxes Â Â $ (2,475)Â Â Â $ (245)Â Â Â $ (48)Â Â Â $ (2,769)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Amounts do not include a $6Â million loss from foreign currency translation adjustments attributable to non-controlling interests. Â Â Â Â NetÂ UnrealizedÂ GainsÂ (Losses) Â Â Â BenefitÂ Plans Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â Â Derivative financial instruments Â Â Â ActuarialÂ gains (losses) and prior service (costs) credits Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of DecemberÂ 31, 2022, net of taxes Â Â $ (2,514)Â Â Â $ (295)Â Â Â $ (28)Â Â Â $ (2,838)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss) before reclassifications Â Â Â (39)Â Â Â Â (5)Â Â Â Â â€”â€‚ Â Â Â Â (44)Â Amounts reclassified to the statements of income Â Â Â â€”â€‚ Â Â Â Â 24 Â Â Â Â (2)Â Â Â Â 22 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net other comprehensive income (loss) before tax Â Â Â (39)Â Â Â Â 19 Â Â Â Â (2)Â Â Â Â (22)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corresponding income tax Â Â Â (50)Â Â Â Â â€”â€‚ Â Â Â Â â€”â€‚ Â Â Â Â (50)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net other comprehensive income (loss) after tax* Â Â Â (89)Â Â Â Â 19 Â Â Â Â (2)Â Â Â Â (72)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2023, net of taxes Â Â $ (2,603)Â Â Â $ (276)Â Â Â $ (30)Â Â Â $ (2,910)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Amounts do not include a $84Â million loss from foreign currency translation adjustments attributable to non-controlling interests. X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Segments 9 Months Ended Sep. 30, 2024 Segments NOTE 15 â€“ Segments: Teva operates its business and reports its financial results in three segments: (a) United States segment. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries other than the United States and countries included in the Europe segment. In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Tevaâ€™s Chief Executive Officer (â€œCEOâ€), who is the chief operating decision maker (â€œCODMâ€), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely United States, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Tevaâ€™s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. Tevaâ€™s CEO may review its strategy and organizational structure from time to time. Based on such review, in May 2023 Teva launched its new Pivot to Growth strategy. Any additional changes in strategy may lead to a reevaluation of the Companyâ€™s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. In conjunction with a recent shift in executive management responsibilities and in alignment with Tevaâ€™s Pivot to Growth strategy, Teva decided that Canada is no longer included as part of Tevaâ€™s North America segment as of JanuaryÂ 1, 2024. From that date Canada is reported as part of the Companyâ€™s International Markets segment and Tevaâ€™s North America segment has been renamed the United States segment. Teva aligned its internal financial and segment reporting and its reporting units in accordance with this change effective JanuaryÂ 1, 2024. Prior period amounts have been recast to conform to the reporting structure for the current year. On JanuaryÂ 31, 2024, Teva announced that it intends to divest its API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with Tevaâ€™s Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be agreed or completed at all. Â Â a. Segment information: Â Â Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 2,225 Â Â Â $ 1,265 Â Â Â $ 613 Â Gross profit Â Â Â 1,265 Â Â Â Â 698 Â Â Â Â 306 Â R&D expenses Â Â Â 151 Â Â Â Â 55 Â Â Â Â 27 Â S&M expenses Â Â Â 259 Â Â Â Â 203 Â Â Â Â 134 Â G&A expenses Â Â Â 107 Â Â Â Â 67 Â Â Â Â 36 Â OtherÂ loss (income) Â Â Â Â§ Â Â Â Â 1 Â Â Â Â Â§ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 748 Â Â Â $ 373 Â Â Â $ 109 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 1,896 Â Â Â $ 1,146 Â Â Â $ 591 Â Gross profit Â Â Â 1,060 Â Â Â Â 648 Â Â Â Â 293 Â R&D expenses Â Â Â 156 Â Â Â Â 62 Â Â Â Â 30 Â S&M expenses Â Â Â 243 Â Â Â Â 184 Â Â Â Â 116 Â G&A expenses Â Â Â 93 Â Â Â Â 66 Â Â Â Â 33 Â OtherÂ loss (income) Â Â Â (2)Â Â Â Â Â§ Â Â Â Â (2)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 571 Â Â Â $ 338 Â Â Â $ 117 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â United States Â Â Â Europe Â Â Â International Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 6,060 Â Â Â $ 3,749 Â Â Â $ 1,802 Â Gross profit Â Â Â 3,291 Â Â Â Â 2,113 Â Â Â Â 889 Â R&D expenses Â Â Â 475 Â Â Â Â 173 Â Â Â Â 85 Â S&M expenses Â Â Â 789 Â Â Â Â 605 Â Â Â Â 397 Â G&A expenses Â Â Â 300 Â Â Â Â 197 Â Â Â Â 109 Â OtherÂ loss (income) Â Â Â (1)Â Â Â Â 1 Â Â Â Â (1)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 1,727 Â Â Â $ 1,137 Â Â Â $ 299 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 5,465 Â Â Â $ 3,493 Â Â Â $ 1,750 Â Gross profit Â Â Â 2,866 Â Â Â Â 1,943 Â Â Â Â 861 Â R&D expenses Â Â Â 460 Â Â Â Â 168 Â Â Â Â 81 Â S&M expenses Â Â Â 700 Â Â Â Â 565 Â Â Â Â 353 Â G&A expenses Â Â Â 289 Â Â Â Â 196 Â Â Â Â 105 Â Other loss (income) Â Â

Â (3)Â Â Â Â (2)Â Â Â Â (34)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 1,421 Â Â Â $ 1,017 Â Â Â $ 356 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The following table presents a reconciliation of Tevaâ€™s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â ThreeÂ monthsÂ ended Â Â Â Nine months ended Â Â Â Â SeptemberÂ 30, Â Â Â SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Â Â (U.S. $ in millions) Â United States profit Â Â $ 748 Â Â Â $ 571 Â Â Â $ 1,727 Â Â Â $ 1,421 Â Europe profit Â Â Â 373 Â Â Â Â 338 Â Â Â Â 1,137 Â Â Â Â 1,017 Â International Markets profit Â Â Â 109 Â Â Â Â 117 Â Â Â Â 299 Â Â Â Â 356 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total reportable segments profit Â Â Â 1,230 Â Â Â Â 1,025 Â Â Â Â 3,163 Â Â Â Â 2,794 Â Profit (loss) of other activities Â Â Â (16)Â Â Â Â (5)Â Â Â Â (1)Â Â Â Â 22 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total segments profit Â Â Â 1,214 Â Â Â Â 1,020 Â Â Â Â 3,162 Â Â Â Â 2,816 Â Amounts not allocated to segments: Â Â Â Â Â Â Â Â Amortization Â Â Â 146 Â Â Â Â 145 Â Â Â Â 444 Â Â Â Â 471 Â Other assets impairments, restructuring and other items* Â Â Â (23) Â Â Â 57 Â Â Â Â 931 Â Â Â Â 276 Â Goodwill impairment Â Â Â 600 Â Â Â Â â€"â€, Â Â Â Â 1,000 Â Â Â Â 700 Â Intangible assets impairments Â Â Â 28 Â Â Â Â 47 Â Â Â Â 169 Â Â Â Â 289 Â Legal settlements and loss contingencies Â Â Â 450 Â Â Â Â 314 Â Â Â Â 638 Â Â Â Â 1,009 Â Other unallocated amounts Â Â Â 64 Â Â Â Â 112 Â Â Â Â 254 Â Â Â Â 394 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Consolidated operating income (loss) * Â Â Â (51) Â Â Â 344 Â Â Â Â (274) Â Â Â (323)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financial expenses, net Â Â Â 272 Â Â Â Â 280 Â Â Â Â 763 Â Â Â Â 808 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Consolidated income (loss) before income taxes * Â Â $ (324) Â Â $ 64 Â Â Â $ (1,037) Â Â $ (1,131)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for the three and nine months ended SeptemberÂ 30, 2024 and 2023: Â United States Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 1,094 Â Â Â $ 839 Â AJOVYÂ® Â Â Â 58 Â Â Â Â 56 Â AUSTEDO Â Â Â 435 Â Â Â Â 339 Â BENDEKAÂ® and TREANDAÂ® Â Â Â 40 Â Â Â Â 56 Â COPAXONE Â Â Â 69 Â Â Â Â 98 Â UZEDY Â Â Â 35 Â Â Â Â 2 Â Anda Â Â Â 380 Â Â Â Â 367 Â Other Â Â Â 115 Â Â Â Â 140 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 2,225 Â Â Â $ 1,896 Â United States Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 2,924 Â Â Â $ 2,471 Â AJOVY Â Â Â 144 Â Â Â Â 154 Â AUSTEDO Â Â Â 1,124 Â Â Â Â 817 Â BENDEKA and TREANDA Â Â Â 127 Â Â Â Â 185 Â COPAXONE Â Â Â 179 Â Â Â Â 224 Â UZEDY Â Â Â 75 Â Â Â Â 14 Â Anda Â Â Â 1,134 Â Â Â Â 1,183 Â Other Â Â Â 352 Â Â Â Â 417 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 6,060 Â Â Â $ 5,465 Â Europe Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 973 Â Â Â $ 886 Â AJOVY Â Â Â 56 Â Â Â Â 41 Â COPAXONE Â Â Â 53 Â Â Â Â 55 Â Respiratory products Â Â Â 60 Â Â Â Â 61 Â Other* Â Â Â 124 Â Â Â Â 104 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 1,265 Â Â Â $ 1,146 Â Â Â Â Â Â Â Â Â Â * Other revenues in the third quarter of 2024 include the sale of certain product rights. Â Europe Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 2,947 Â Â Â Â Â $ 2,727 Â AJOVY Â Â Â 158 Â Â Â Â Â Â 115 Â COPAXONE Â Â Â 163 Â Â Â Â Â Â 174 Â Respiratory products Â Â Â 183 Â Â Â Â Â Â 195 Â Other* Â Â Â 299 Â Â Â Â Â Â 282 Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 3,749 Â Â Â Â Â $ 3,493 Â Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the first nine months of 2024 include the sale of certain product rights. Â International markets Â Â ThreeÂ monthsÂ ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S.Â $Â inÂ millions) Â Generic products Â Â $ 477 Â Â Â $ 470 Â AJOVY Â Â Â 24 Â Â Â Â 18 Â COPAXONE Â Â Â 13 Â Â Â Â 16 Â Other* Â Â Â 99 Â Â Â Â 87 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 613 Â Â Â $ 591 Â Â Â Â Â Â Â Â Â Â * Other revenues in the third quarter of 2024 include the sale of certain product rights. Â International markets Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 1,440 Â Â Â Â Â $ 1,425 Â AJOVY Â Â Â 63 Â Â Â Â Â Â 45 Â COPAXONE Â Â Â 38 Â Â Â Â Â Â 50 Â Other* Â Â Â 261 Â Â Â Â Â Â 229 Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 1,802 Â Â Â Â Â $ 1,750 Â Â Â Â Â Â Â Â Â Â Â Â * OtherÂ revenues in the first nine months of 2024 include the sale of certain product rights. X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurement 9 Months Ended Sep. 30, 2024 Fair value measurement NOTE 16 â€" Fair value measurement: Financial items carried at fair value on a recurring basis as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 are classified in the tables below in one of the three categories of fair value levels: Â Â Â Â SeptemberÂ 30, 2024 Â Â Â Â LevelÂ 1 Â Â Â LevelÂ 2 Â Â Â LevelÂ 3 Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Cash and cash equivalents: Â Â Â Â Â Â Â Â Money markets Â Â $ 1,822 Â Â Â $ â€"â€, Â Â Â $ â€"â€, Â Â Â $ 1,822 Â Cash, deposits and other Â Â Â 1,497 Â Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â 1,497 Â Investment in securities: Â Â Â Â Â Â Â Â Equity securities Â Â Â 13 Â Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â 13 Â Other Â Â Â 3 Â Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â 3 Â Derivatives: Â Â Â Â Â Â Â Â Asset derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€"â€, Â Â Â Â 32 Â Â Â Â â€"â€, Â Â Â Â 32 Â Liability derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€"â€, Â Â Â Â (33)Â Â Â Â â€"â€, Â Â Â Â (33)Â Bifurcated embedded derivatives Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â§ Â Â Â Â â€"â€, Â Contingent consideration* Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â (552)Â Â Â Â (552)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 3,335 Â Â Â $ (1)Â Â Â $ (552)Â Â Â $ 2,782 Â DecemberÂ 31, 2023 Â Â Â Â LevelÂ 1 Â Â Â LevelÂ 2 Â Â Â LevelÂ 3 Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Cash and cash equivalents: Â Â Â Â Â Â Â Â Money markets Â Â $ 1,704 Â Â Â $ â€"â€, Â Â Â $ â€"â€, Â Â Â $ 1,704 Â Cash, deposits and other Â Â Â 1,522 Â Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â 1,522 Â Investment in securities: Â Â Â Â Â Â Â Â Investment in convertible bond security Â Â Â Â Â Â Â 40 Â Â Â Â 40 Â Equity securities Â Â Â 7 Â Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â 7 Â Other Â Â Â 1 Â Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â 1 Â Restricted cash Â Â Â 1 Â Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â 1 Â Derivatives: Â Â Â Â Â Â Â Â Asset derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€"â€, Â Â Â Â 38 Â Â Â Â â€"â€, Â Â Â Â 38 Â Cross-currency interest rate swap Â Â Â Â Â Â 8 Â Â Â Â Â Â Â 8 Â Liability derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€"â€, Â Â Â Â (39)Â Â Â Â â€"â€, Â Â Â Â (39)Â Bifurcated embedded derivatives Â Â Â â€"â€, Â Â Â Â â€"â€, Â Â Â Â§ Â Â Â Â â€"â€, Â Contingent consideration* Â Â $ â€"â€, Â Â Â Â â€"â€, Â Â Â Â (517)Â Â Â Â (517)Â Total Â Â Â 3,235 Â Â Â $ 7 Â Â Â $ (477)Â Â Â $ 2,765 Â§ Represents an amount less than $0.5Â million. * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. Â Teva determined the fair value of the liabilities for contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a LevelÂ 3 measurement within the fair value hierarchy. The fair value of contingent consideration is based on several factors, such as cash flows projected from the success of unapproved product candidates; probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; time and resources required to complete the development and approval of product candidates; life of the potential commercialized products and associated risks with obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. The discount rate applied ranged from 8.5% to 11%. The weighted average discount rate, calculated based on the relative fair value of Tevaâ€™s contingent consideration liabilities, was 8.8%. Contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in the consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. A change of the discount rate by 1% would have not resulted in material changes to the contingent consideration liabilities. The investment in convertible bond security is accounted for as available for sale with changes in fair value reflected in other comprehensive income. See Alvotech transaction under note 2. The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing LevelÂ 3 inputs: Â Â Â Â Nine months endedÂ September 30, 2024 Â Â Â NineÂ months endedÂ September 30, 2023 Â Â Â Â (U.S. $ in millions) Â Fair value at the beginning of the period Â Â $ (477)Â Â Â Â (250)Â Investment in convertible bond** Â Â Â â€"â€, Â Â Â Â 25 Â Conversion option** Â Â Â â€"â€, Â Â Â Â 15 Â Redemption of convertible bond security** Â Â Â (40)Â Â Â Â â€"â€, Â Bifurcated embedded derivatives Â Â Â§ Â Â Â Â§ Â Adjustments to provisions for contingent consideration: Â Â Â Â Allergan transaction* Â Â Â (267)Â Â Â Â (111)Â Eagle transaction Â Â Â (37)Â Â Â Â (35)Â Novetide transaction Â Â Â (1)Â Â Â Â 2 Â Settlement of contingent consideration: Â Â Â Â Allergan transaction Â Â Â 227 Â Â Â Â 132 Â Eagle transaction Â Â Â 41 Â Â Â Â 61 Â Novetide transaction Â Â Â 2 Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Â Fair value at the end of the period Â Â $ (552)Â Â Â $ (159)Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. * The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan for the nine months ended SeptemberÂ 30, 2023 have been revised as discussed in note 1c. ** On SeptemberÂ 29, 2023, Teva purchased $40Â million of subordinated convertible bonds of Alvotech. On JuneÂ 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024 (see note 2). Â Financial instruments not measured at fair value Financial instruments measured on a basis other than fair value mostly consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): Â Â Â Â Estimated fair value* Â Â Â Â SeptemberÂ 30, 2024 Â Â Â DecemberÂ 31, 2023 Â Â Â Â (U.S. $ in millions) Â Senior notes and sustainability-linked senior notes included under senior notes and loans Â Â $ 16,129 Â Â Â $ 17,214 Â Senior notes and convertible senior debentures included under short-term debt Â Â Â 2,572 Â Â Â Â 1,651 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 18,701 Â Â Â $ 18,865 Â Â Â Â Â Â Â Â Â Â * The fair value was estimated based on quoted market prices. X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic

820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of presentation (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet The tables below present the impact of the revision on the line items within the Companyâ€™s consolidated financial statements for the relevant periods: Â Â Â Â Three months ended Â Â Nine months ended Â Â Â Â SeptemberÂ 30, 2023 Â Â SeptemberÂ 30, 2023 Â Â Â Â U.S $ in millions (except per share amounts) Â Â Â Â (Unaudited) Â Â Â Â As previously reported Â Â Adjustment Â Â AsÂ revised Â Â AsÂ previously reported Â Â Adjustment Â Â AsÂ revised Â Other asset impairments, restructuring and other items Â Â $ 46 Â Â Â 11 Â Â Â 57 Â Â $ 241 Â Â Â 34 Â Â Â 276 Â Operating income (loss) Â Â Â 355 Â Â Â (11)Â Â Â 344 Â Â Â (289)Â Â Â (34)Â Â Â (323)Â Income (loss) before income taxes Â Â Â 75 Â Â Â (11)Â Â Â 64 Â Â Â (1,097)Â Â Â (34)Â Â Â (1,131)Â Income taxes (benefit) Â Â Â (12)Â Â Â Â§ Â Â Â (12)Â Â Â (48)Â Â Â Â§ Â Â Â (48)Â Net income (loss) Â Â Â 88 Â Â Â (11)Â Â Â 77 Â Â Â (1,048)Â Â Â (34)Â Â Â (1,082)Â Net income (loss) attributable to Teva Â Â Â 80 Â Â Â (11)Â Â Â 69 Â Â Â (988)Â Â Â (34)Â Â Â (1,022)Â Earnings (loss) per share attributable to ordinary shareholders: Â Â Â Â Â Â Â Basic and diluted loss per share Â Â $ 0.07 Â Â Â (0.01)Â Â Â 0.06 Â Â $ (0.88)Â Â Â (0.04)Â Â Â (0.91)Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Â Â SeptemberÂ 30, 2023 Â Â Â Â As previously reported Â Â Â Adjustment Â Â Â AsÂ revised Â Â Â Â (Unaudited) Â Deferred income taxes Â Â $ 1,748 Â Â Â Â 7 Â Â Â Â 1,755 Â Total assets Â Â Â 42,088 Â Â Â Â 7 Â Â Â Â 42,095 Â Other taxes and long-term liabilities Â Â Â 3,818 Â Â Â Â 132 Â Â Â Â 3,950 Â Total long-term liabilities Â Â Â 23,182 Â Â Â Â 132 Â Â Â Â 23,314 Â Total liabilities Â Â Â 34,576 Â Â Â Â 132 Â Â Â Â 34,708 Â Teva shareholdersâ€™ equity: Â Â Â Â Â Â Accumulated deficit Â Â Â (13,870)Â Â Â Â (125)Â Â Â Â (13,995)Â Total equity Â Â Â 7,512 Â Â Â Â (125)Â Â Â Â 7,387 Â Total liabilities and equity Â Â $ 42,088 Â Â Â Â 7 Â Â Â Â 42,095 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 + Details Name: us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Certain transactions (Tables) 9 Months Ended Sep. 30, 2024 Summary of Major Classes of Assets and Liabilities Included as Held for Sale The table below summarizes all of Tevaâ€™s assets and liabilities included as held for sale as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023: Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Inventories Â Â Â 169 Â Â Â Â 12 Â Accounts receivables Â Â Â 123 Â Â Â Â â€”â€, Â Goodwill Â Â Â 48 Â Â Â Â 30 Â Identifiable intangible assets, net Â Â Â 67 Â Â Â Â â€”â€, Â Property, plant and equipment, net Â Â Â 10 Â Â Â Â 5 Â Other current and non-current assets Â Â Â 40 Â Â Â Â 23 Â Expected loss on sale* Â Â Â (455)Â Â Â Â â€”â€, Â Â Â Â Â Â Â Â Â Â Â Total assets of the disposal group classified as held for sale in the consolidated balance sheets Â Â $ 2 Â Â Â $ 70 Â Â Â Â Â Â Â Â Â Â Â Accounts payables Â Â Â (76)Â Â Â Â â€”â€, Â Other liabilities Â Â Â (34)Â Â Â Â (13)Â Expected loss on sale* Â Â Â (106)Â Â Â Â â€”â€, Â Â Â Â Â Â Â Â Â Â Â Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets Â Â $ (216)Â Â Â $ (13)Â Â Â Â Â Â Â Â Â Â Â * Includes an expected loss from reclassification of currency translation adjustments to the consolidated statements of income (loss) upon sale. X - DefinitionSchedule Of Assets And Liabilities Held For Sale [Table Text Block] + ReferencesNo definition available. + Details Name: teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock Namespace Prefix: teva_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue from contracts with customers (Tables) 9 Months Ended Sep. 30, 2024 Summary of disaggregates revenues by major revenue streams The following table disaggregates Tevaâ€™s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. Â Â Â Â Three months ended SeptemberÂ 30, 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalMarkets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 1,822 Â Â Â Â 1,214 Â Â Â 568 Â Â Â Â 121 Â Â Â Â 3,794 Â Licensing arrangements Â Â Â 23 Â Â Â Â 9 Â Â Â 6 Â Â Â Â 8 Â Â Â Â 45 Â Distribution Â Â Â 380 Â Â Â Â Â§ Â Â Â 10 Â Â Â Â â€”â€, Â Â Â Â 390 Â Other Â Â Â Â§ Â Â Â Â 42 Â Â Â 29 Â Â Â Â 100 Â Â Â Â 102 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 2,225 Â Â Â $ 1,265 Â Â $ â€‡â€‰613 Â Â Â $ 229 Â Â Â $ â€‡4,332 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Three months ended SeptemberÂ 30, 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 1,500 Â Â Â Â 1,117 Â Â Â 556 Â Â Â Â 130 Â Â Â Â 3,303 Â Licensing arrangements Â Â Â 30 Â Â Â Â 13 Â Â Â 9 Â Â Â Â 1 Â Â Â Â 53 Â Distribution Â Â Â 366 Â Â Â Â Â§ Â Â Â 11 Â Â Â Â â€”â€, Â Â Â Â 377 Â Other Â Â Â Â§ Â Â Â Â 15 â€„Â Â Â 15 Â Â Â Â 86 Â Â Â Â 117 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,896 Â Â Â $ 1,146 Â Â $ â€‡â€‰591 Â Â Â $ 217 Â Â Â $ â€‡3,850 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Nine months ended SeptemberÂ 30, 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 4,857 Â Â Â Â 3,668 Â Â Â 1,708 Â Â Â Â 399 Â Â Â Â 10,701 Â Licensing arrangements Â Â Â 68 Â Â Â Â 26 Â Â Â 17 Â Â Â Â 10 Â Â Â Â 121 Â Distribution Â Â Â 1,134 Â Â Â Â Â§ Â Â Â 28 Â Â Â Â â€”â€, Â Â Â Â 1,163 Â Other Â Â Â Â§ Â Â Â Â 54 â€„Â Â Â 49 Â Â Â Â 295 Â Â Â Â 330 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 6,060 Â Â Â $ 3,749 Â Â $ 1,802 Â Â Â $ 703 Â Â Â $ 12,315 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. Â Â Â Â Nine months ended SeptemberÂ 30, 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â International Markets Â Â Â OtherÂ activities Â Â Â Total Â Â Â Â (U.S.$ in millions) Â Sale of goods Â Â Â 4,210 Â Â Â Â 3,446 Â Â Â Â 1,656 Â Â Â Â 412 Â Â Â Â 9,724 Â Licensing arrangements Â Â Â 72 Â Â Â Â 38 Â Â Â Â 21 Â Â Â Â 4 Â Â Â Â 134 Â Distribution Â Â Â 1,183 Â Â Â Â Â§ Â Â Â Â 29 Â Â Â Â â€”â€, Â Â Â Â 1,212 Â Other Â Â Â Â§ Â Â Â Â 8 Â Â Â Â 44 Â Â Â Â 265 Â Â Â Â 318 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 5,465 Â Â Â $ 3,493 Â Â Â $ 1,750 Â Â Â $ 681 Â Â Â $ 11,389 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. â€ƒ Summary of Sales Reserves and Allowances Â Â Â Sales Reserves and Allowances Â Â Â Â Reserves included in Accounts Receivable,Â net Â Â Rebates Â Â Medicaid and other governmental allowances Â Â Chargebacks Â Â Returns Â Â Other Â Â TotalÂ reserves included in SalesÂ Reserves andÂ Allowances Â Â Total Â Â Â Â (U.S.$ in millions) Â Balance at JanuaryÂ 1, 2024 Â Â $ 61 Â Â $ 1,603 Â Â $ 540 Â Â $ 859 Â Â $ 436 Â Â $ 97 Â Â $ 3,535 Â Â $ 3,596 Â Provisions related to sales made in current year period Â Â Â 294 Â Â Â 3,436 Â Â Â 579 Â Â Â 5,925 Â Â Â 191 Â Â Â 146 Â Â Â 10,277 Â Â Â 10,571 Â Provisions related to sales made in prior periods Â Â Â â€”â€, Â Â Â 16 Â Â Â 26 Â Â Â (11)Â Â Â (28)Â Â Â (2)Â Â Â 1 Â Â Â 1 Â Credits and payments Â Â Â (292)Â Â Â (3,269)Â Â Â (556)Â Â Â (5,877)Â Â Â (209)Â Â Â (121)Â Â Â (10,032)Â Â Â (10,324)Â Translation differences Â Â Â â€”â€, Â Â Â 1 Â Â Â 3 Â Â Â 1 Â Â Â (1)Â Â Â â€”â€, Â Â Â 4 Â Â Â 4 Â Â Â Balance at SeptemberÂ 30, 2024 Â Â $ 63 Â Â $ 1,787 Â Â $ 592 Â Â $ 897 Â Â $ 389 Â Â $ 120 Â Â $ 3,785 Â Â $ 3,848 Â Â Â Â Sales Reserves and Allowances Â Â Â Â Reserves included in Accounts Receivable,Â net Â Â Rebates Â Â Medicaid and other governmental allowances Â Â Chargebacks Â Â Returns Â Â Other Â Â TotalÂ reserves included in Sales Reserves andÂ Allowances Â Â Total Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (U.S.$ in millions) Â Balance at JanuaryÂ 1, 2023 Â Â $ 67 Â Â $ 1,575 Â Â $ 663 Â Â $ 991 Â Â $ 455 Â Â $ 66 Â Â $ 3,750 Â Â $ 3,817 Â Provisions related to sales made in current year period Â Â Â 262 Â Â Â 2,968 Â Â Â 468 Â Â Â 5,636 Â Â Â 205 Â Â Â 73 Â Â Â 9,350 Â Â Â 9,612 Â Provisions related to sales made in prior periods Â Â Â â€”â€, Â Â Â (22)Â Â Â (33)Â Â Â (21)Â Â Â 24 Â Â Â â€”â€, Â Â Â (52)Â Â Â (52)Â Credits and payments Â Â Â (268)Â Â Â (2,989)Â Â Â (617)Â Â Â (5,768)Â Â Â (251)Â Â Â (53)Â Â Â (9,678)Â Â Â (9,946)Â Translation differences Â Â Â â€”â€, Â Â Â (8)Â Â Â (2)Â Â Â (3)Â Â Â â€”â€, Â Â Â (6)Â Â Â (19)Â Â Â (19)Â Â Â Balance at SeptemberÂ 30, 2023 Â Â $ 61 Â Â $ 1,524 Â Â $ 479 Â Â $ 835 Â Â $ 433 Â Â $ 80 Â Â $ 3,351 Â Â $ 3,412 Â Â Â X - DefinitionTabular disclosure of sales reserves and allowances current. + ReferencesNo definition available. + Details Name: teva_SalesReservesAndAllowancesCurrentTableTextBlock Namespace Prefix: teva_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Tables) 9 Months Ended Sep. 30, 2024 Summary of Inventories Inventories, net of reserves, consisted of the following: Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Finished products Â Â $ 2,314 Â Â Â $ 2,346 Â Raw and packaging materials Â Â Â 926 Â Â Â Â 993 Â Products in process Â Â Â 524 Â Â Â Â 500 Â Materials in transit and payments on account Â Â Â 195 Â Â Â Â 183 Â Â Â Â Â Â Â Â Â Â Â Â Â $ 3,959 Â Â Â $ 4,021 Â Â Â Â Â Â Â Â Â Â Â X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Identifiable Intangible Assets (Tables) 9 Months Ended Sep. 30, 2024 Summary of Identifiable Intangible Assets Identifiable intangible assets consisted of the following: Â Â Â Â Gross carrying amount net of impairment Â Â Â Accumulated amortization Â Â Â Net carrying amount Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Product rights Â Â $ 16,408 Â Â Â $ 17,981 Â Â Â $ 12,235 Â Â Â $ 13,274 Â Â Â $ 4,173 Â Â Â $ 4,707 Â Trade names Â Â Â 586 Â Â Â Â 583 Â Â Â Â 296 Â Â Â Â 269 Â Â Â Â 290 Â Â Â Â 314 Â In process research and development Â Â Â 294 Â Â Â Â 366 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 294 Â Â Â Â 366 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 17,287 Â Â Â $ 18,930 Â Â Â $ 12,531 Â Â Â $ 13,543 Â Â Â $ 4,756 Â Â Â $ 5,387 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill (Tables) 9 Months Ended Sep. 30, 2024 Summary of Changes in the Carrying Amount of Goodwill by Segment Changes in the carrying amount of goodwill for the period ended SeptemberÂ 30, 2024 were as follows: Â Â Â Â NorthAmerica Â Â UnitedStates Â Â Â Europe Â Â Â InternationalMarkets Â Â Other Â Â Â Total Â Â Â Tevaâ€™sAPI Â Â Medis Â Â Â Â Â Â Â (U.S. $ in millions) Â Â Â Â Balance as of DecemberÂ 31, 2023 (1) Â Â $ 6,459 Â Â $ â€”â€, Â Â Â $ 8,466 Â Â Â $ 675 Â Â $ 1,313 Â Â $ 265 Â Â Â $ 17,177 Â Goodwill allocation related to the shift of Canada to International Markets Â Â Â (6,459)Â Â Â 5,813 Â Â Â Â â€”â€, Â Â Â Â 646 Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of JanuaryÂ 1, 2024 Â Â $ â€”â€, Â Â $ 5,813 Â Â Â $ 8,466 Â Â Â $ 1,321 Â Â $ 1,313 Â Â $ 265 Â Â Â $ 17,177 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other changes during the period: Â Â Â Â Â Â Â Â Â Â Â Goodwill impairment Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â (1,000)Â Â Â â€”â€, Â Â Â Â (1,000) Goodwill reclassified as assets held for sale Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (29)Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â Â (29)Â Translation differences and other Â Â Â â€”â€, Â Â Â â€”â€, Â Â Â Â 97 Â Â Â Â (131)Â Â Â 5 Â Â Â 4 Â Â Â Â (25)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2024 (1) Â Â $ â€”â€, Â Â $ 5,813 Â Â Â $ 8,563 Â Â Â $ 1,161 Â Â $ 318 Â Â $ 269 Â Â Â $ 16,124 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) Cumulative goodwill impairment as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 was approximately $29.3Â billion and $28.3Â billion, respectively. X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Debt obligations (Tables) 9 Months Ended Sep. 30, 2024 Schedule of Short-term Debt a. Short-term debt: Â Â Â Â Interest rate as of SeptemberÂ 30,Â 2024 Â Â Maturity Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â (U.S. $ in millions) Â Convertible senior debentures Â Â Â 0.25 %Â Â Â 2026 Â Â Â Â 23 Â Â Â Â 23 Â Current maturities of long-term liabilities Â Â Â Â 2,557 Â Â Â Â 1,649 Â Â Â Â Â Â Â Â Â Â Total short-term debt Â Â Â $ 2,580 Â Â Â $ 1,672 Â Â Â Â Â Â Â Â Â Â Â Schedule of Senior Notes and Loans b. Long-term debt: Â Â Â Â Interest rate as of SeptemberÂ 30,Â 2024 Â Â Maturity Â Â Â SeptemberÂ 30, 2024 Â Â DecemberÂ 31, 2023 Â Â Â Â Â Â Â Â Â Â Â (U.S. $ in millions) Â Senior notes USD 1,250Â million (4) Â Â Â 6.00 %Â Â Â 2024 Â Â Â Â â€”â€, Â Â Â 956 Â Senior notes EUR 1,500Â million (5) Â Â Â 1.13 %Â Â Â 2024 Â Â Â Â 700 Â Â Â 693 Â Senior notes EUR 1,000Â million Â Â Â 6.00 %Â Â Â 2025 Â Â Â Â 459 Â Â Â 453 Â Senior notes USD 1,000Â million Â Â Â 7.13 %Â Â Â 2025 Â Â Â Â 427 Â Â Â 427 Â Senior notes EUR 900Â million Â Â Â 4.50 %Â Â Â 2025 Â Â Â Â 554 Â Â Â 547 Â Senior notes CHF 350Â million Â Â Â 1.00 %Â Â Â 2025 Â Â Â Â 417 Â Â Â 416 Â Senior notes USD 3,500Â million Â Â Â 3.15 %Â Â Â 2026 Â Â Â Â 3,374 Â Â Â 3,374 Â Senior notes EUR 700Â million Â Â Â 1.88 %Â Â Â 2027 Â Â Â Â 781 Â Â Â 771 Â Sustainability-linked senior notes USD 1,000Â million (1)(*) Â Â Â 4.75 %Â Â Â 2027 Â Â Â Â 1,000 Â Â Â 1,000 Â Sustainability-linked senior notes EUR 1,100Â million (1)(*) Â Â Â 3.75 %Â Â Â 2027 Â Â Â Â 1,229 Â Â Â 1,215 Â Senior notes USD 1,250Â million Â Â Â 6.75 %Â Â Â 2028 Â Â Â Â 1,250 Â Â Â 1,250 Â Senior notes EUR 750Â million Â Â Â 1.63 %Â Â Â 2028 Â Â Â Â 834 Â Â Â 826 Â Sustainability-linked senior notes USD 1,000Â million (2)(*) Â Â Â 5.13 %Â Â Â 2029 Â Â Â Â 1,000 Â Â Â 1,000 Â Sustainability-linked senior notes USD 600Â million (3)(*) Â Â Â 7.88 %Â Â Â 2029 Â Â Â Â 600 Â Â Â 600 Â Sustainability-linked senior notes EUR 800Â million (3)(*) Â Â Â 7.38 %Â Â Â 2029 Â Â Â Â 895 Â Â Â 884 Â Sustainability-linked senior notes EUR 1,500Â million (2)(*) Â Â Â 4.38 %Â Â Â 2030 Â Â Â Â 1,676 Â Â Â 1,656 Â Sustainability-linked senior notes USD 500Â million (3)(*) Â Â Â 8.13 %Â Â Â 2031 Â Â Â Â 500 Â Â Â 500 Â Sustainability-linked senior notes EUR 500Â million (3)(*) Â Â Â 7.88 %Â Â Â 2031 Â Â Â Â 558 Â Â Â 552 Â Senior notes USD 789Â million Â Â Â 6.15 %Â Â Â 2036 Â Â Â Â 783 Â Â Â 783 Â Senior notes USD 2,000Â million Â Â Â 4.10 %Â Â Â 2046 Â Â Â Â 1,986 Â Â Â 1,986 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total senior notes Â Â Â Â Â Â 19,023 Â Â Â 19,889 Â Other long-term debt Â Â Â Â Â Â 2 Â Â Â 1 Â Less current maturities Â Â Â Â Â Â (2,557)Â Â Â (1,649)Â Less debt issuance costs Â Â Â Â Â Â (68)Â Â Â (80)Â Â Â Â Â Â Â Â Â Â Â Â Â Total senior notes and loans Â Â Â Â Â $ 16,400 Â Â $ 18,161 Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1) If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. (2) If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including MayÂ 9, 2026. (3) If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including SeptemberÂ 15, 2026. (4) In April 2024, Teva repaid $956Â million of its 6% senior notes due 2024 at maturity. (5) In October 2024, Teva repaid $685Â million of its 1.13% senior notes due 2024 at maturity. * Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. X - DefinitionA schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: teva_LongTermDebtExcludingConvertibleDebtTableTextBlock Namespace Prefix: teva_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ScheduleOfShortTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments and hedging activities (Tables) 9 Months Ended Sep. 30, 2024 Summary of Notional Amounts for Hedged Items The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: Â Â Â Â SeptemberÂ 30, Â Â Â DecemberÂ 31, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Cross-currency swap - cash flow hedge (1) Â Â $ â€”â€, Â Â Â $ 169 Â Â Â Â Â Â Â Â Â Â Â Summary of Classification and Fair Values of Derivative Instruments The following table summarizes the classification and fair values of derivative instruments: Â Â Â Â Fair value Â Â Â Â Designated as hedging instruments Â Â Â Not designated as hedging instruments Â Â Â Â SeptemberÂ 30, 2024 Â Â Â DecemberÂ 31, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â DecemberÂ 31, 2023 Â Reported under Â Â (U.S. $ in millions) Â Â Â (U.S. $ in millions) Â Asset derivatives: Â Â Â Â Â Â Â Â Other current assets: Â Â Â Â Â Â Â Â Option and forward contracts Â Â $ â€”â€, Â Â Â $ â€”â€, Â Â Â $ 32 Â Â Â $ 38 Â Other non-current assets: Â Â Â Â Â Â Â Â Cross-currency swap-cash flow hedge (1) Â Â Â â€”â€, Â Â Â Â 8 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Liability derivatives: Â Â Â Â Â Â Â Â Other current liabilities: Â Â Â Â Â Â Â Â Option and forward contracts Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (33)Â Â Â Â (39)Â Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives designated in cash flow hedging relationships: Â Â Â Â Financial expenses, net Â Â Â Other comprehensive income (loss) Â Â Â Â Three months ended, Â Â Â Three months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 272 Â Â Â $ 280 Â Â Â $ 180 Â Â Â $ (249)Â Cross-currency swaps - cash flow hedge (1) Â Â Â â€”â€, Â Â Â Â (7)Â Â Â Â â€”â€, Â Â Â Â 1 Â Â Â Â Financial expenses, net Â Â Â Other comprehensive income (loss) Â Â Â Â Nine months ended, Â Â Â Nine months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 763 Â Â Â $ 808 Â Â Â $ (75)Â Â Â $ (156)Â Cross-currency swaps - cash flow hedge (1) Â Â Â (8)Â Â Â Â (22)Â Â Â Â 1 Â Â Â Â (4)Â Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives not designated as hedging instruments: Â Â Â Â Financial expenses, net Â Â Â Net revenues Â Â Â Â Three months ended, Â Â Â Three months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 272 Â Â Â $ 280 Â Â Â $ (4,332)Â Â Â $ (3,850)Â Option and forward contracts (2) Â Â Â 4 Â Â Â Â 4 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Option and forward contracts economic hedge (3) Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 9 Â Â Â Â (22)Â Â Â Â Financial expenses, net Â Â Â Net revenues Â Â Â Â Nine months ended, Â Â Â Nine months ended, Â Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Â Â SeptemberÂ 30, 2024 Â Â Â SeptemberÂ 30, 2023 Â Reported under Â Â (U.S. $ in millions) Â Line items in which effects of hedges are recorded Â Â $ 763 Â Â Â $ 808 Â Â Â $ (12,315)Â Â Â $ (11,389)Â Option and forward contracts (2) Â Â Â (33)Â Â Â Â (46)Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Option and forward contracts economic hedge (3) Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (1)Â Â Â Â (20)Â X - DefinitionDisclosure in tabular form of pretax gain loss cash flow hedging instruments. + ReferencesNo definition available. + Details Name: teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock Namespace Prefix: teva_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of derivative instrument not designated or qualifying as hedging instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4CC -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC + Details Name: us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Other assets impairments, restructuring and other items (Tables) 9 Months Ended Sep. 30, 2024 Schedule of Other Assets Impairments, Restructuring and Other Items Â Â Â Â ThreeÂ monthsÂ ended Â Â Â NineÂ monthsÂ ended Â Â Â Â SeptemberÂ 30, Â Â Â SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Â Â (U.S.Â $Â inÂ millions) Â Impairments of long-lived tangible assets (1) Â Â Â $ (80)Â Â Â $ 1 Â Â Â $ 589 Â Â Â $ 21 Â Contingent consideration (2) Â Â Â 34 Â Â Â Â 27 Â Â Â Â 305 Â Â Â Â 140 Â Restructuring Â Â Â 21 Â Â Â Â 27 Â Â Â Â 52 Â Â Â Â 93 Â Other Â Â Â 1 Â Â Â Â 2 Â Â Â Â (16)Â Â Â Â 21 Â Total Â Â $ (23)Â Â Â $ 57 Â Â Â $ 931 Â Â Â $ 276 Â (1) Including impairments related to exit and disposal activities. (2) The contingent consideration presented in the tables above for the three and nine months ended SeptemberÂ 30, 2023 have been revised as discussed in note 1c. Summary of Restructuring Plan Including Costs Related to Exit and Disposal The following tables provide the components of the Companyâ€™s restructuring costs: Â Â Â Â ThreeÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Restructuring Â Â Â Â Employee termination Â Â $ 13 Â Â Â $ 16 Â Other Â Â Â 8 Â Â Â Â 12 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 21 Â Â Â $ 27 Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€ ,NineÂ monthsÂ endedÂ SeptemberÂ 30,â€, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Restructuring Â Â Â Â Employee termination Â Â $ 33 Â Â Â $ 40 Â Other Â Â Â 19 Â Â Â Â 53 Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 52 Â Â Â $ 93 Â Â Â Â Â Â Â Â Â Â Â Summary of Restructuring Accruals The following table provides the components of and changes in the Companyâ€™s restructuring accruals: Â Â Â Â EmployeeÂ termination costs Â Â Â Other Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of JanuaryÂ 1, 2024 Â Â $ (75)Â Â Â $ (7)Â Â Â $ â€„(82)Â Provision Â Â Â (33)Â Â Â Â (19)Â Â Â Â (52)Â Utilization and other* Â Â Â 52 Â Â Â Â 12 Â Â Â Â 64 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2024 Â Â $ (56)Â Â Â $ (14)Â Â Â $ (70)Â EmployeeÂ termination costs Â Â Â Other Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of JanuaryÂ 1, 2023 Â Â $ (112)Â Â Â $ (7)Â Â Â $ (119)Â Provision Â Â Â (40)Â Â Â Â (53)Â Â Â Â (93)Â Utilization and other* Â Â Â 77 Â Â Â Â 53 Â Â Â Â 130 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance as of SeptemberÂ 30, 2023 Â Â $ (75)Â Â Â $ (7)Â Â Â $ (82)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â * Includes adjustments for foreign currency translation. Â X - DefinitionSchedule of Restructuring Charges [Table Text Block] + ReferencesNo definition available. + Details Name: teva_ScheduleOfRestructuringChargesTableTextBlock Namespace Prefix: teva_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to

the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Accumulated other comprehensive income (loss) (Tables) 9 Months Ended Sep. 30, 2024 Accumulated Other Comprehensive Income/(Loss) (Net of Tax) The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: Â Â Â Â NetÂ UnrealizedÂ GainsÂ (Losses) Â Â Â BenefitÂ Plans Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â Â Derivative financial instruments Â Â Â ActuarialÂ gains (losses) and prior service (costs) credits Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of DecemberÂ 31, 2023, net of taxes Â Â $ (2,384)Â Â Â $ (266)Â Â Â $ (46)Â Â Â $ (2,697)Â Other comprehensive income (loss) before reclassifications Â Â Â (84)Â Â Â Â â€”â€, Â Â Â Â 1 Â Â Â Â (83)Â Amounts reclassified to the statements of income Â Â Â â€”â€, Â Â Â Â 21 Â Â Â Â (3)Â Â Â Â 18 Â Net other comprehensive income (loss) before tax Â Â Â (84)Â Â Â Â 21 Â Â Â Â (2)Â Â Â Â (65)Â Corresponding income tax Â Â Â (7)Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (7)Â Net other comprehensive income (loss) after tax* Â Â Â (91)Â Â Â Â 21 Â Â Â Â (2)Â Â Â Â (72)Â Balance as of SeptemberÂ 30, 2024, net of taxes Â Â $ (2,475)Â Â Â $ (245)Â Â Â $ (48)Â Â Â $ (2,769)Â * Amounts do not include a $6Â million loss from foreign currency translation adjustments attributable to non-controlling interests. Â Â Â Â NetÂ UnrealizedÂ GainsÂ (Losses) Â Â Â BenefitÂ Plans Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â Â Derivative financial instruments Â Â Â ActuarialÂ gains (losses) and prior service (costs) credits Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Balance as of DecemberÂ 31, 2022, net of taxes Â Â $ (2,514)Â Â Â $ (295)Â Â Â $ (28)Â Â Â $ (2,838)Â Other comprehensive income (loss) before reclassifications Â Â Â (39)Â Â Â Â (5)Â Â Â Â â€”â€, Â Â Â Â (44)Â Amounts reclassified to the statements of income Â Â Â â€”â€, Â Â Â Â 24 Â Â Â Â (2)Â Â Â Â 22 Â Net other comprehensive income (loss) before tax Â Â Â (39)Â Â Â Â 19 Â Â Â Â (2)Â Â Â Â (22)Â Corresponding income tax Â Â Â (50)Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (50)Â Net other comprehensive income (loss) after tax* Â Â Â (89)Â Â Â Â 19 Â Â Â Â (2)Â Â Â Â (72)Â Balance as of SeptemberÂ 30, 2023, net of taxes Â Â $ (2,603)Â Â Â $ (276)Â Â Â $ (30)Â Â Â $ (2,910)Â * Amounts do not include a $84Â million loss from foreign currency translation adjustments attributable to non-controlling interests. Â X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Segments (Tables) 9 Months Ended Sep. 30, 2024 Summary of Segment Profit Â Â a. Segment information: Â Â Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 2,225 Â Â Â $ 1,265 Â Â Â $ 613 Â Gross profit Â Â Â 1,265 Â Â Â Â 698 Â Â Â Â 306 Â R&D expenses Â Â Â 151 Â Â Â Â 55 Â Â Â Â 27 Â S&M expenses Â Â Â 259 Â Â Â Â 203 Â Â Â Â 134 Â G&A expenses Â Â Â 107 Â Â Â Â 67 Â Â Â Â 36 Â OtherÂ loss (income) Â Â Â Â§ Â Â Â Â 1 Â Â Â Â Â§ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 748 Â Â Â $ 373 Â Â Â $ 109 Â§ Represents an amount less than $0.5Â million. Â Â Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 1,896 Â Â Â $ 1,146 Â Â Â $ 591 Â Gross profit Â Â Â 1,060 Â Â Â Â 648 Â Â Â Â 293 Â R&D expenses Â Â Â 156 Â Â Â Â 62 Â Â Â Â 30 Â S&M expenses Â Â Â 243 Â Â Â Â 184 Â Â Â Â 116 Â G&A expenses Â Â Â 93 Â Â Â Â 66 Â Â Â Â 33 Â OtherÂ loss (income) Â Â Â (2)Â Â Â Â Â§ Â Â Â Â (2)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 571 Â Â Â $ 338 Â Â Â $ 117 Â§ Represents an amount less than $0.5Â million. Â Â Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â United States Â Â Â Europe Â Â Â International Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 6,060 Â Â Â $ 3,749 Â Â Â $ 1,802 Â Gross profit Â Â Â 3,291 Â Â Â Â 2,113 Â Â Â Â 889 Â R&D expenses Â Â Â 475 Â Â Â Â 173 Â Â Â Â 85 Â S&M expenses Â Â Â 789 Â Â Â Â 605 Â Â Â Â 397 Â G&A expenses Â Â Â 300 Â Â Â Â 197 Â Â Â Â 109 Â OtherÂ loss (income) Â Â Â (1)Â Â Â Â 1 Â Â Â Â (1)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 1,727 Â Â Â $ 1,137 Â Â Â $ 299 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2023 Â Â Â Â UnitedÂ States Â Â Â Europe Â Â Â InternationalÂ Markets Â Â Â Â (U.S. $ in millions) Â Revenues Â Â $ 5,465 Â Â Â $ 3,493 Â Â Â $ 1,750 Â Gross profit Â Â Â 2,866 Â Â Â Â 1,943 Â Â Â Â 861 Â R&D expenses Â Â Â 460 Â Â Â Â 168 Â Â Â Â 81 Â S&M expenses Â Â Â 700 Â Â Â Â 565 Â Â Â Â 353 Â G&A expenses Â Â Â 289 Â Â Â Â 196 Â Â Â Â 105 Â Other loss (income) Â Â Â (3)Â Â Â Â (2)Â Â Â Â (34)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Segment profit Â Â $ 1,421 Â Â Â $ 1,017 Â Â Â $ 356 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The following table presents a reconciliation of Tevaâ€™s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and nine months ended SeptemberÂ 30, 2024 and 2023: Â Â Â Â ThreeÂ monthsÂ ended Â Â Â Nine months ended Â Â Â Â SeptemberÂ 30, Â Â Â SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Â Â (U.S. $ in millions) Â United States profit Â Â $ 748 Â Â Â $ 571 Â Â Â $ 1,727 Â Â Â $ 1,421 Â Europe profit Â Â Â 373 Â Â Â Â 338 Â Â Â Â 1,137 Â Â Â Â 1,017 Â International Markets profit Â Â Â 109 Â Â Â Â 117 Â Â Â Â 299 Â Â Â Â 356 Â Total reportable segments profit Â Â Â 1,230 Â Â Â Â 1,025 Â Â Â Â 3,163 Â Â Â Â 2,794 Â Profit (loss) of other activities Â Â Â (16)Â Â Â Â (5)Â Â Â Â (1)Â Â Â Â 22 Â Total segments profit Â Â Â 1,214 Â Â Â Â 1,020 Â Â Â Â 3,162 Â Â Â Â 2,816 Â Amounts not allocated to segments: Â Â Â Â Â Â Â Â Amortization Â Â Â 146 Â Â Â Â 145 Â Â Â Â 444 Â Â Â Â 471 Â Other assets impairments, restructuring and other items* Â Â Â (23) Â Â Â 57 Â Â Â Â 931 Â Â Â Â 276 Â Goodwill impairment Â Â Â 600 Â Â Â Â â€”â€, Â Â Â Â 1,000 Â Â Â Â 700 Â Intangible assets impairments Â Â Â 28 Â Â Â Â 47 Â Â Â Â 169 Â Â Â Â 289 Â Legal settlements and loss contingencies Â Â Â 450 Â Â Â Â 314 Â Â Â Â 638 Â Â Â Â 1,009 Â Other unallocated amounts Â Â Â 64 Â Â Â Â 112 Â Â Â Â 254 Â Â Â Â 394 Â Consolidated operating income (loss) * Â Â Â (51) Â Â Â 344 Â Â Â Â (274) Â Â Â (323)Â Financial expenses, net Â Â Â 272 Â Â Â Â 280 Â Â Â Â 763 Â Â Â Â 808 Â Consolidated income (loss) before income taxes * Â Â $ (324) Â Â $ 64 Â Â Â $ (1,037) Â Â $ (1,131)Â * The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. Schedule of Net Sales by Product Line The following tables present revenues by major products and activities for the three and nine months ended SeptemberÂ 30, 2024 and 2023: Â United States Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 1,094 Â Â Â $ 839 Â AJOVYÂ® Â Â Â 58 Â Â Â Â 56 Â AUSTEDO Â Â Â 435 Â Â Â Â 339 Â BENDEKAÂ® and TREANDAÂ® Â Â Â 40 Â Â Â Â 56 Â COPAXONE Â Â Â 69 Â Â Â Â 98 Â UZEDY Â Â Â 35 Â Â Â Â 2 Â Anda Â Â Â 380 Â Â Â Â 367 Â Other Â Â Â 115 Â Â Â Â 140 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 2,225 Â Â Â $ 1,896 Â United States Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 2,924 Â Â Â $ 2,471 Â AJOVY Â Â Â 144 Â Â Â Â 154 Â AUSTEDO Â Â Â 1,124 Â Â Â Â 817 Â BENDEKA and TREANDA Â Â Â 127 Â Â Â Â 185 Â COPAXONE Â Â Â 179 Â Â Â Â 224 Â UZEDY Â Â Â 75 Â Â Â Â 14 Â Anda Â Â Â 1,134 Â Â Â Â 1,183 Â Other Â Â Â 352 Â Â Â Â 417 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 6,060 Â Â Â $ 5,465 Â Europe Â Â Three months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 973 Â Â Â $ 886 Â AJOVY Â Â Â 56 Â Â Â Â 41 Â COPAXONE Â Â Â 53 Â Â Â Â 55 Â Respiratory products Â Â Â 60 Â Â Â Â 61 Â Other* Â Â Â 124 Â Â Â Â 104 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 1,265 Â Â Â $ 1,146 Â Â Â Â Â Â Â Â Â Â * Other revenues in the third quarter of 2024 include the sale of certain product rights. Â Europe Â Â NineÂ monthsÂ endedÂ SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 2,947 Â Â Â Â Â $ 2,727 Â AJOVY Â Â Â 158 Â Â Â Â Â Â 115 Â COPAXONE Â Â Â 163 Â Â Â Â Â Â 174 Â Respiratory products Â Â Â 183 Â Â Â Â Â Â 195 Â Other* Â Â Â 299 Â Â Â Â Â Â 282 Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 3,749 Â Â Â Â Â $ 3,493 Â Â Â Â Â Â Â Â Â Â Â Â * Other revenues in the first nine months of 2024 include the sale of certain product rights. Â International markets Â Â ThreeÂ monthsÂ ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â Â (U.S.Â $Â inÂ millions) Â Generic products Â Â $ 477 Â Â Â $ 470 Â AJOVY Â Â Â 24 Â Â Â Â 18 Â COPAXONE Â Â Â 13 Â Â Â Â 16 Â Other* Â Â Â 99 Â Â Â Â 87 Â Â Â Â Â Â Â Â Â Â Total Â Â $ 613 Â Â Â $ 591 Â Â Â Â Â Â Â Â Â Â * Other revenues in the third quarter of 2024 include the sale of certain product rights. Â International markets Â Â Nine months ended SeptemberÂ 30, Â Â Â Â 2024 Â Â Â Â Â 2023 Â Â Â Â (U.S. $ in millions) Â Generic products Â Â $ 1,440 Â Â Â Â Â $ 1,425 Â AJOVY Â Â Â 63 Â Â Â Â Â Â 45 Â COPAXONE Â Â Â 38 Â Â Â Â Â Â 50 Â Other* Â Â Â 261 Â Â Â Â Â Â 229 Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 1,802 Â Â Â Â Â $ 1,750 Â Â Â Â Â Â Â Â Â Â Â Â * OtherÂ revenues in the first nine months of 2024 include the sale of certain product rights. X - DefinitionTabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details Name: us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement (Tables) 9 Months Ended Sep. 30, 2024 Summary of Financial Items Carried at Fair Value Financial items carried at fair value on a recurring basis as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 are classified in the tables below in one of the three categories of fair value levels: Â Â Â Â SeptemberÂ 30, 2024 Â Â Â Â LevelÂ 1 Â Â Â LevelÂ 2 Â Â Â LevelÂ 3 Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Cash and cash equivalents: Â Â Â Â Â Â Â Â Money markets Â Â $ 1,822 Â Â Â $ â€”â€, Â Â Â $ â€”â€, Â Â Â $ 1,822 Â Cash, deposits and other Â Â Â 1,497 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 1,497 Â Investment in securities: Â Â Â Â Â Â Â Â Equity securities Â Â Â 13 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 13 Â Other Â Â Â 3 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 3 Â Derivatives: Â Â Â Â Â Â Â Â Asset derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€”â€, Â Â Â Â 32 Â Â Â Â â€”â€, Â Â Â Â 32 Â Liability derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€”â€, Â Â Â Â (33)Â Â Â Â â€”â€, Â Â Â Â (33)Â Bifurcated embedded derivatives Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â§ Â Â Â Â â€”â€, Â Contingent consideration* Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â (552)Â Â Â Â (552)Â Total Â Â $ 3,335 Â Â Â $ (1)Â Â Â $ (552)Â Â Â $ 2,782 Â DecemberÂ 31, 2023 Â Â Â Â LevelÂ 1 Â Â Â LevelÂ 2 Â Â Â LevelÂ 3 Â Â Â Total Â Â Â Â (U.S. $ in millions) Â Cash and cash equivalents: Â Â Â Â Â Â Â Â Money markets Â Â $ 1,704 Â Â Â $ â€”â€, Â Â Â $ â€”â€, Â Â Â $ 1,704 Â Cash, deposits and other Â Â Â 1,522 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 1,522 Â Investment in securities: Â Â Â Â Â Â Â Â Investment in convertible bond security Â Â Â Â Â Â Â Â 40 Â Â Â Â 40 Â Equity securities Â Â Â 7 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 7 Â Other Â Â Â 1 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 1 Â Restricted cash Â Â Â 1 Â Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â 1 Â Derivatives: Â Â Â Â Â Â Â Â Asset derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€”â€, Â Â Â Â 38 Â Â Â Â â€”â€, Â Â Â Â 38 Â Cross-currency interest rate swap Â Â Â Â Â Â 8 Â Â Â Â Â Â 8 Â Liability derivatives: Â Â Â Â Â Â Â Â Options and forward contracts Â Â Â â€”â€, Â Â Â Â (39)Â Â Â Â â€”â€, Â Â Â Â (39)Â Bifurcated embedded derivatives Â Â Â â€”â€, Â Â Â Â â€”â€, Â Â Â Â§ Â Â Â Â â€”â€, Â Contingent consideration* Â Â $ â€”â€, Â Â Â Â â€”â€, Â Â Â Â (517)Â Â Â Â (517)Â Total Â Â Â 3,235 Â Â Â $ 7 Â Â Â $ (477)Â Â Â $ 2,765 Â§ Represents an amount less than $0.5Â million. * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing LevelÂ 3 inputs: Â Â Â Â Nine months endedÂ September 30, 2024 Â Â Â NineÂ months endedÂ September 30, 2023 Â Â Â Â (U.S. $ in millions) Â Fair value at the beginning of the period Â Â $ (477)Â Â Â $ (250)Â Investment in convertible bond** Â Â Â â€”â€, Â Â Â Â 25 Â Conversion option** Â Â Â â€”â€, Â Â Â Â 15 Â Redemption of convertible bond security** Â Â Â (40)Â Â Â Â â€”â€, Â Bifurcated embedded derivatives Â Â Â§ Â Â Â Â§ Â Adjustments to provisions for contingent consideration: Â Â Â Â Allergan transaction* Â Â Â (267)Â Â Â Â (111)Â Eagle transaction Â Â Â (37)Â Â Â Â (35)Â Novetide transaction Â Â Â (1)Â Â Â Â 2 Â Settlement of contingent consideration: Â Â Â Â Allergan transaction Â Â Â 227 Â Â Â Â 132 Â Eagle transaction Â Â Â 41 Â Â Â Â 61 Â Novetide transaction Â Â Â 2 Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Â Â Â Fair value at the end of the period Â Â $ (552)Â Â Â $ (159)Â Â Â Â Â Â Â Â Â Â Â Â Â Â§ Represents an amount less than $0.5Â million. * The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan for the nine months ended SeptemberÂ 30, 2023 have been revised as discussed in note 1c. ** On SeptemberÂ 29, 2023, Teva purchased $40Â million of subordinated convertible bonds of Alvotech. On JuneÂ 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024 (see note 2). Summary of Financial Instrument Measured on a Basis Other Than Fair Value Financial instruments measured on a basis other than fair value mostly consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): Â Â Â Â Estimated fair value* Â Â Â Â SeptemberÂ 30, 2024 Â Â Â DecemberÂ 31, 2023 Â Â Â Â (U.S. $ in millions) Â Senior notes and sustainability-linked senior notes included under senior notes and loans Â Â $ 16,129 Â Â Â $ 17,214 Â Senior notes and convertible senior debentures included under short-term debt Â Â Â 2,572 Â Â Â Â 1,651 Â Â Â Â Â Â Â Â Â Â Â Â Total Â Â $ 18,701 Â Â Â $ 18,865 Â Â Â Â Â Â Â Â Â Â Â Â * The fair value was estimated based on quoted market prices. X - DefinitionTabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration

X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of presentation - Additional information (Detail) - USD ($) $ in Millions 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Sep. 30, 2024 Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Business combination contingent consideration [1] $ 517 Â $ 552 Restatement adjustment [Member] Â Â Â Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Contingent consideration related expenses $ 34 $ 98 Â Business combination contingent consideration Â Â $ 132 [1] Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. X - DefinitionContingent consderation related expenses. + ReferencesNo definition available. + Details Name: teva_ContingentConsderationRelatedExpenses Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 + Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail) - USD ($) $ / shares in Units, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Â Â Â Â Other asset impairments, restructuring and other items [1] $ (23) $ 57 $ 931 $ 276 Â Â Â Â Operating income (loss) [1] (51) 344 (274) (323) Â Â Â Â Income (loss) before income taxes [1] (324) 64 (1,037) (1,131) Â Â Â Â Income taxes (benefit) 69 (12) 648 (48) Â Â Â Â Net income (loss) (390) 77 (1,684) (1,082) Â Â Â Â Net income (loss) attributable to Teva $ (437) $ 69 $ (1,422) $ (1,022) Â Â Â Â Earnings (loss) per share attributable to ordinary shareholders: Â Â Â Â Â Â Â Â Basic $ (0.39) $ 0.06 $ (1.26) $ (0.91) Â Â Â Â Diluted $ (0.39) $ 0.06 $ (1.26) $ (0.91) Â Â Â Â Deferred income taxes $ 2,070 $ 1,755 $ 2,070 $ 1,755 Â $ 1,812 Â Â Total assets 41,758 42,095 41,758 42,095 Â 43,479 Â Â Other taxes and long-term liabilities 4,344 3,950 4,344 3,950 Â 4,019 Â Â Total long-term liabilities 21,578 23,314 21,578 23,314 Â 23,106 Â Â Total liabilities 35,375 34,708 35,375 34,708 Â 35,353 Â Â Teva shareholders' equity: Â Â Â Â Â Â Â Â Accumulated deficit (14,956) (13,995) (14,956) (13,995) Â (13,534) Â Â Total equity 6,383 7,387 6,383 7,387 $ 6,563 8,126 $ 7,592 $ 8,598 Total liabilities and equity $ 41,758 42,095 $ 41,758 42,095 Â $ 43,479 Â Â As previously reported [Member] Â Â Â Â Â Â Â Â Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Â Â Â Â Â Other asset impairments, restructuring and other items Â 46 Â 241 Â Â Â Â Operating income (loss) Â 355 Â (289) Â Â Â Â Income (loss) before income taxes Â 75 Â (1,097) Â Â Â Â Income taxes (benefit) Â (12) Â (48) Â Â Â Â Net income (loss) Â 88 Â (1,048) Â Â Â Â Net income (loss) attributable to Teva Â $ 80 Â $ (988) Â Â Â Â Earnings (loss) per share attributable to ordinary shareholders: Â Â Â Â Â Â Â Â Basic Â $ 0.07 Â $ (0.88) Â Â Â Â Diluted Â $ 0.07 Â $ (0.88) Â Â Â Â Deferred income taxes Â $ 1,748 Â $ 1,748 Â Â Â Â Total assets Â 42,088 Â 42,088 Â Â Â Â Other taxes and long-term liabilities Â 3,818 Â 3,818 Â Â Â Â Total long-term liabilities Â 23,182 Â 23,182 Â Â Â Â Total liabilities Â 34,576 Â 34,576 Â Â Â Â Teva shareholders' equity: Â Â Â Â Â Â Â Â Accumulated deficit Â (13,870) Â (13,870) Â Â Â Â Total equity Â 7,512 Â 7,512 Â Â Â Â Total liabilities and equity Â 42,088 Â 42,088 Â Â Â Â Adjustment [Member] Â Â Â Â Â Â Â Â Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Â Â Â Â Â Other asset impairments, restructuring and other items Â 11 Â 34 Â Â Â Â Operating income (loss) Â (11) Â (34) Â Â Â Â Income (loss) before income taxes Â (11) Â (34) Â Â Â Â Net income (loss) Â (11) Â (34) Â Â Â Â Net income (loss) attributable to Teva Â $ (11) Â $ (34) Â Â Â Â Earnings (loss) per share attributable to ordinary shareholders: Â Â Â Â Â Â Â Â Basic Â $ (0.01) Â $ (0.04) Â Â Â Â Diluted Â $ (0.01) Â $ (0.04) Â Â Â Â Deferred income taxes Â $ 7 Â $ 7 Â Â Â Â Total assets Â 7 Â 7 Â Â Â Â Other taxes and long-term liabilities Â 132 Â 132 Â Â Â Â Total long-term liabilities Â 132 Â 132 Â Â Â Â Total liabilities Â 132 Â 132 Â Â Â Â Teva shareholders' equity: Â Â Â Â Â Â Â Â Accumulated deficit Â (125) Â (125) Â Â Â Â Total equity Â (125) Â (125) Â Â Â Â Total liabilities and equity Â $ 7 Â $ 7 Â Â Â Â [1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. X - DefinitionImpairments restructuring and others. + ReferencesNo definition available. + Details Name: teva_ImpairmentsRestructuringAndOthers Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic

805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 + Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -

Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting

Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Parenthetical) (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Â Income (Loss) from equity method investments $ 3.0 Â $ 1.0 $ 1.0 Maximum [Member] Â Â Â Â Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Â Income (Loss) from equity method investments Â $ 0.5 Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 + Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($) $ in Millions 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended Jun. 26, 2024 Nov. 09, 2023 Jun. 12, 2023 Oct. 29, 2024 Jan. 31, 2024 Oct. 31, 2021 Aug. 31, 2021 Dec. 31, 2016 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2022 Jun. 30, 2022 Dec. 31, 2021 Jun. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2021 Dec. 31, 2020 Mar. 28, 2024 Oct. 03, 2023 Sep. 29, 2023 Noncash or Part Noncash Acquisitions [Line Items] Â Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax Â Â Â Â Â Â Â Â Â $ 83 Â $ 369 Â Â Â Â Â Â Â Â Â Â Other commitment Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 150 Â Â Other Asset Impairment Charges Â Â Â Â Â Â Â Â Â $ 67 577 Â Â Â Â Â Â Â Â Â Â Â Additional milestone payment payable Â Â Â Â Â Â Â Â Â Â Â 150 Â Â Â Â Â Â Â Â Â Â Â Â Sanofi [Member] | Collaborative Arrangement [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Milestone payment receivable Â $ 500 Â Development and launch milestone payment receivable Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,000 Â Johnson And Johnson [Member] | Settlement And License Agreement Alvotech And Teva [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Maximum entry date for granting license entry Â Â Feb. 21, 2025 Â Biolojic Design Ltd [Member] | Collaborative Arrangement [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Additional development and milestone payments receivable Â Â Â Â Â Â Â Â 500 Â Â Â Â Â Â Â $ 500 Â Â Â Â Â Â Biolojic Design Ltd [Member] | Research and Development Expense [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Milestone payment Â Â Â Â $ 10 Â Royalty Pharma [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Collaborative agreement milestone payments Â $ 100 Â Term of royalty payment Â 5 years Â Collaborative agreement milestone amount increase Â $ 125 Â Royalty Pharma [Member] | Research and Development Expense [Member] | Collaborative Arrangement [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Aggregate funding on account of research and development expenditure Â Â Â Â Â Â Â Â 100 Â Â Â Â Â Â Â 100 Â Â Â Â Â Â Reimbursement of research and development expenses incurred Â Â Â Â Â Â Â Â 18 19 $ 27 $ 35 Â Â Â Â Â Â Â Â Â Â Takeda [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Upfront payment Â Â Â Â Â Â Â $ 30 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Milestone payment Â Â Â Â Â Â Â $ 20 Â Â Â Â Â $ 25 Â Â Â Â Â Â Â Â Â Abingworth [Member] | Research and Development Expense [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Reimbursement of research and development expenses incurred Â Â Â Â Â Â Â Â 20 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Teva [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Cost of the investment Â $ 40 Alvotech [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Collaborative agreement milestone payments Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 380 Â Â Â Â Â Â Â Proceeds from available for sale debt securities $ 44 Â Aggregate upfront and milestone payments Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 78 $ 78 $ 78 Â Â Â Alvotech [Member] | Research and Development Expense [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Milestone payment Â Â Â Â Â Â Â Â 19 27 Â Â Â Â Â Â Â Â Â Â Â Â mAbxience [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Collaborative agreement milestone payments Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 320 Â Â Â Â Â Â mAbxience [Member] | Research and Development Expense [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Aggregate upfront and milestone payments Â Â Â Â Â Â Â Â Â $ 15 20 Â Â Â Â Â Â Â Â Â Â Â Â Â MedinCell [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Milestone payment Â Â Â Â Â Â Â Â Â Â Â Â $ 3 Â Â Â Â Â Â Â Â Â Â Collaborative agreement milestone payments Â Â Â Â Â Â $ 105 Â Â $ 108 Â Â Â Â Â Â Â Â Â Â Â Â Â MODAG [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â License agreement potential aggregate milestone payments amount Â Â Â Â Â $ 30 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â MODAG [Member] | Research and Development Expense [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Milestone payment Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 10 Â Â Â Â Â Â Â Â Subsequent Event [Member] | Alvotech [Member] | October 2024 Amendment Agreement [Member] Â Noncash or Part Noncash Acquisitions [Line Items] Â Milestone payment Â Â Â Â $ 5 Â X - DefinitionAdditional development and milestone payments receivable. + ReferencesNo definition available. + Details Name: teva_AdditionalDevelopmentAndMilestonePaymentsReceivable Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAdditional milestone payment payable. + ReferencesNo definition available. + Details Name: teva_AdditionalMilestonePaymentPayable Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate funding on account of research and development expenditure. + ReferencesNo definition available. + Details Name: teva_AggregateFundingOnAccountOfResearchAndDevelopmentExpenditure Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate Upfront And Milestone Payments. + ReferencesNo definition available. + Details Name: teva_AggregateUpfrontAndMilestonePayments Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaborative agreement milestone amount increase. + ReferencesNo definition available. + Details Name: teva_CollaborativeAgreementMilestoneAmountIncrease Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCollaborative Agreement Milestone Payments + ReferencesNo definition available. + Details Name: teva_CollaborativeAgreementMilestonePayments Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDevelopment and launch milestone payment receivable. + ReferencesNo definition available. + Details Name: teva_DevelopmentAndLaunchMilestonePaymentReceivable Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLicense agreement potential aggregate milestone payments amount. + ReferencesNo definition available. + Details Name: teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMaximum entry date for granting license entry. + ReferencesNo definition available. + Details Name: teva_MaximumEntryDateForGrantingLicenseEntry Namespace Prefix: teva_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionMilestone payment. + ReferencesNo definition available. + Details Name: teva_MilestonePayment Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMilestone payment receivable. + ReferencesNo definition available. + Details Name: teva_MilestonePaymentReceivable Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTerm of royalty payment. + ReferencesNo definition available. + Details Name: teva_TermOfRoyaltyPayment Namespace Prefix: teva_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionUpfront payments + ReferencesNo definition available. + Details Name: teva_UpfrontPayments Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCost of the investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -

Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentOwnedAtCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2 + Details Name: us-gaap_OtherAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMinimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481724/830-30-40-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 16 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-16 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=teva_SanofiMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=teva_JohnsonAndJohnsonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_AgreementAxis=teva_SettlementAndLicenseAgreementAlvotechAndTevaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_BiolojicDesignLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_RoyaltyPharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_TakedaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_AbingworthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_TevaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_MabxienceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_MedincellMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_ModagMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=teva_OctoberTwoThousandAndTwentyFourAmendmentAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) - USD ($) $ in Millions 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Business Combinations [Abstract] Â Â Inventories $ 169 $ 12 Accounts receivables 123 0 Goodwill 48 30 Identifiable intangible assets, net 67 0 Property, plant and equipment, net 10 5 Other current and non-current assets 40 23 Expected loss on sale (455) 0 Total assets of the disposal group classified as held for sale in the consolidated balance sheets 2 70 Accounts payables (76) 0 Other liabilities (34) (13) Expected loss on sale (106) 0 Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets $ (216) $ (13) X - DefinitionAmount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties. + ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts payable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as other liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue from Contracts with Customers - Additional Information (Detail) 9 Months Ended Sep. 30, 2024 United States [Member] Â Revenue Recognition [Line Items] Â Percentage sales reserves and allowances to U.S. customers 67.00% X - DefinitionRevenue Recognition [Line Items] + ReferencesNo definition available. + Details Name: teva_RevenueRecognitionLineItems Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSales reserves and allowances to customers percentage. + ReferencesNo definition available. + Details Name: teva_SalesReservesAndAllowancesToCustomersPercentage Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue $ 4,332 $ 3,850 $ 12,315 $ 11,389 Sale of Goods [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 3,794 3,303 10,701 9,724 Licensing Arrangements [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 45 53 121 134 Distribution [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 390 377 1,163 1,212 Other [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 102 117 330 318 International Markets [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 613 591 1,802 1,750 International Markets [Member] | Sale of Goods [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 568 556 1,708 1,656 International Markets [Member] | Licensing Arrangements [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 6 9 17 21 International Markets [Member] | Distribution [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 10 11 28 29 International Markets [Member] | Other [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 29 15 49 44 Other activities [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 229 217 703 681 Other activities [Member] | Sale of Goods [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 121 130 399 412 Other activities [Member] | Licensing Arrangements [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 8 1 10 4 Other activities [Member] | Distribution [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 0 0 0 0 Other activities [Member] | Other [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 100 86 295 265 Europe [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 1,265 1,146 3,749 3,493 Europe [Member] | Sale of Goods [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 1,214 1,117 3,668 3,446 Europe [Member] | Licensing Arrangements [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 9 13 26 38 Europe [Member] | Other [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 42 15 54 8 United States [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 2,225 1,896 6,060 5,465 United States [Member] | Sale of Goods [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 1,822 1,500 4,857 4,210 United States [Member] | Licensing Arrangements [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue 23 30 68 72 United States [Member] | Distribution [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue $ 380 $ 366 $ 1,134 $ 1,183 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Revenue Recognition [Line Items] Â Â Balance at beginning of period $ 3,596 $ 3,817 Provisions related to sales made in current year period 10,571 9,612 Provisions related to sales made in prior periods 1 (52) Credits and payments (10,324) (9,946) Translation differences 4 (19) Balance at end of period 3,848 3,412 Reserves Included in Accounts Receivable, net [Member] Â Â Revenue Recognition [Line Items] Â Â Balance at beginning of period 61 67 Provisions related to sales made in current year period 294 262 Provisions related to sales made in prior periods 0 0 Credits and payments (292) (268) Translation differences 0 0 Balance at end of period 63 61 Rebates [Member] Â Â Revenue Recognition [Line Items] Â Â Balance at beginning of period 1,603 1,575 Provisions related to sales made in current year period 3,436 2,968 Provisions related to sales made in prior periods 16 (22) Credits and payments (3,269) (2,989) Translation differences 1 (8) Balance at end of period 1,787 1,524 Medicaid and other governmental allowances [Member] Â Â Revenue Recognition [Line Items] Â Â Balance at beginning of period 540 663 Provisions related to sales made in current year period 579 468 Provisions related to sales made in prior periods 26 (33) Credits and payments (556) (617) Translation differences 3 (2) Balance at end of period 592 479 Chargebacks [Member] Â Â Revenue Recognition [Line Items] Â Â Balance at beginning of period 859 991 Provisions related to sales made in current year period 5,925 5,636 Provisions related to sales made in prior periods (11) (21) Credits and payments (5,877) (5,768) Translation differences 1 (3) Balance at end of period 897 835 Returns [Member] Â Â Revenue Recognition [Line Items] Â Â Balance at beginning of period 436 455 Provisions related to sales made in current year period 191 205 Provisions related to sales made in prior periods (28) 24 Credits and payments (209) (251) Translation differences (1) 0 Balance at end of period 389 433 Other [Member] Â Â Revenue Recognition [Line Items] Â Â Balance at beginning of period 97 66 Provisions related to sales made in current year period 146 73 Provisions related to sales made in prior periods (2) 0 Credits and payments (121) (53) Translation differences 0 (6) Balance at end of period 120 80 Total reserves included in sales reserves and allowances [Member] Â Â Revenue Recognition [Line Items] Â Â Balance at beginning of period 3,535 3,750 Provisions related to sales made in current year period 10,277 9,350 Provisions related to sales made in prior periods 1 (52) Credits and payments (10,032) (9,678) Translation differences 4 (19) Balance at end of period $ 3,785 $ 3,351 X - DefinitionRevenue Recognition [Line Items] + ReferencesNo definition available. + Details Name: teva_RevenueRecognitionLineItems Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValuation allowances and reserves foreign currency translation. + ReferencesNo definition available. + Details Name: teva_ValuationAllowancesAndReservesForeignCurrencyTranslation Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValuation allowances and reserves related to current period sales. + ReferencesNo definition available. + Details Name: teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValuation allowances and reserves related to prior period sales. + ReferencesNo definition available. + Details Name: teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of valuation and qualifying accounts and reserves. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesBalance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease in valuation and qualifying accounts and reserves. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesDeductions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories - Summary of Inventories (Detail) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Inventories [Line Items] Â Â Finished products $ 2,314 $ 2,346 Raw and packaging materials 926 993 Products in process 524 500 Materials in transit and payments on account 195 183 Total $ 3,959 $ 4,021 X - DefinitionInventories [Line Items] + ReferencesNo definition available. + Details Name: teva_InventoriesLineItems Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherInventoryInTransit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Identifiable Intangible Assets - Additional Information (Detail) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Amortization of intangible assets useful life Â Â Â Â 9 years Amortization of intangible assets $ 146 $ 145 $ 444 $ 471 Â Impairment of intangible assets excluding goodwill $ 28 $ 47 $ 169 $ 289 Â Minimum [Member] | Measurement input, discount rate [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Business combination, contingent consideration, liability, measurement input 8.5 Â 8.5 Â Â Maximum [Member] | Measurement input, discount rate [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Business combination, contingent consideration, liability, measurement input 11 Â 11 Â Â In process research and development [Member] | Measurement input, discount rate [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Business combination, contingent consideration, liability, measurement input Â 90 Â 90 Â In process research and development [Member] | Minimum [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Business combination, contingent consideration, liability, measurement input Â 8.5 Â 8.5 Â In process research and development [Member] | Maximum [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Business combination, contingent consideration, liability, measurement input Â 10 Â 10 Â In process research and development [Member] | Generic Pipeline Products [Member] | Development Progress And Changes In Other Key Valuation Assumptions [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Impairment of intangible assets excluding goodwill Â $ 29 $ 33 $ 83 Â Identifiable product rights [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Impairment of intangible assets excluding goodwill $ 28 $ 18 $ 136 206 Â Identifiable product rights [Member] | Regulatory Price And Volume Of Products [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Impairment of intangible assets excluding goodwill Â Â Â 94 Â Japan [Member] | Identifiable product rights [Member] | Updated Market Assumptions [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Impairment of intangible assets excluding goodwill Â Â Â $ 112 Â X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of input used to measure contingent consideration liability from business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_EventBasisAxis=teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_EventBasisAxis=teva_RegulatoryPriceAndVolumeOfProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_JP Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_EventBasisAxis=teva_UpdatedMarketAssumptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Gross carrying amount net of impairment $ 17,287 $ 18,930 Accumulated amortization 12,531 13,543 Net carrying amount 4,756 5,387 Product rights [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Gross carrying amount net of impairment 16,408 17,981 Accumulated amortization 12,235 13,274 Net carrying amount 4,173 4,707 Trade names [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Gross carrying amount net of impairment 586 583 Accumulated amortization 296 269 Net carrying amount 290 314 In process research and development [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Gross carrying amount net of impairment 294 366 Accumulated amortization 0 0 Net carrying amount $ 294 $ 366 X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) - USD ($) $ in Millions 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Goodwill [Line Items] Â Â Â Â Â Â Â Beginning balance Â Â Â $ 17,177 [1] $ 17,177 $ 17,177 [1] $ 17,177 [1] Goodwill allocation related to the shift of Canada to International Markets Â Â Â Â Â Â 0 Goodwill impairment $ (600) $ (400) $ 0 Â (1,000) (700) Â Goodwill reclassified as assets held for sale Â Â Â Â (29) Â Â Translation differences Â Â Â Â (25) Â Â Ending balance 16,124 [1] Â Â Â 16,124 [1] Â 17,177 North America [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Beginning balance Â Â Â 6,459 [1] 0 6,459 [1] 6,459 [1] Goodwill allocation related to the shift of Canada to International Markets Â Â Â Â Â Â Â (6,459) Goodwill impairment Â Â Â Â 0 Â Â Goodwill reclassified as assets held for sale Â Â Â Â 0 Â Â Translation differences Â Â Â Â 0 Â Â Ending balance 0 [1] Â Â Â 0 [1] Â 0 Europe [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Beginning balance Â Â Â 8,466 [1] 8,466 8,466 [1] 8,466 [1] Goodwill allocation related to the shift of Canada to International Markets Â Â Â Â Â Â 0 Goodwill impairment Â Â Â Â 0 Â Â Goodwill reclassified as assets held for sale Â Â Â Â 0 Â Â Translation differences Â Â Â Â 97 Â Â Ending balance 8,563 [1] Â Â Â 8,563 [1] Â 8,466 International Markets [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Beginning balance Â Â Â 675 [1] 1,321 675 [1] 675 [1] Goodwill allocation related to the shift of Canada to International Markets Â Â Â Â Â Â 646 Goodwill impairment Â Â Â (700) 0 Â Â Goodwill reclassified as assets held for sale Â Â Â Â (29) Â Â Translation differences Â Â Â Â (131) Â Â Ending balance 1,161 [1] Â Â Â 1,161 [1] Â 1,321 Other [Member] | Medis Reporting Units [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Beginning balance Â Â Â 265 [1] 265 265 [1] 265 [1] Goodwill allocation related to the shift of Canada to International Markets Â Â Â Â Â Â 0 Goodwill impairment Â Â Â Â 0 Â Â Goodwill reclassified as assets held for sale Â Â Â Â 0 Â Â Translation differences Â Â Â Â 4 Â Â Ending balance 269 [1] Â Â Â 269 [1] Â 265 Other [Member] | Tevas API Reporting Unit [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Beginning balance Â Â Â 1,313 [1] 1,313 1,313 [1] 1,313 [1] Goodwill allocation related to the shift of Canada to International Markets Â Â Â Â Â Â 0 Goodwill impairment Â Â Â Â (1,000) Â Â Goodwill reclassified as assets held for sale Â Â Â Â 0 Â Â Translation differences Â Â Â Â 5 Â Â Ending balance 318 [1] Â Â Â 318 [1] Â 1,313 United States [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Beginning balance Â Â Â $ 0 [1] 5,813 $ 0 [1] 0 [1] Goodwill allocation related to the shift of Canada to International Markets Â Â Â Â Â Â 5,813 Goodwill impairment Â Â Â Â 0 Â Â Goodwill reclassified as assets held for sale Â Â Â Â 0 Â Â Translation differences Â Â Â Â 0 Â Â Ending balance $ 5,813 [1] Â Â Â $ 5,813 [1] Â $ 5,813 [1] Cumulative goodwill impairment as of September 30, 2024 and December 31, 2023 was approximately $29.0 billion and $28.3 billion, respectively. X - DefinitionGood will Relative Fair Value Allocation. + ReferencesNo definition available. + Details Name: teva_GoodWillRelativeFairValueAllocation Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGoodwill reclassification. + ReferencesNo definition available. + Details Name: teva_GoodwillReclassification Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=srt_NorthAmericaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=teva_InternationalMarketsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=teva_OtherCountriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=teva_MedisReportingUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=teva_TevasApiReportingUnitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) - USD ($) $ in Billions Sep. 30, 2024 Dec. 31, 2023 Goodwill [Line Items] Â Â Accumulated goodwill impairment $ 29.3 $ 28.3 X - DefinitionAmount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 6 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Goodwill [Line Items] Â Â Â Â Â Â Â Goodwill impairment $ 600 $ 400 $ 0 Â $ 1,000 $ 700 Tevas United States, Europe, International Markets and Medis reporting units [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Reporting unit percentage of fair value in excess of carrying amount Â 10.00% Â Â Â Â Tevas API Reporting Unit [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Goodwill impairment $ 600 Â Â Â Â Â International Markets [Member] Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Goodwill impairment Â Â Â $ 700 $ 0 Â X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of fair value of reporting unit in excess of carrying amount. + ReferencesNo definition available. + Details Name: us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ReportingUnitAxis=teva_TevasUnitedStatesEuropeInternationalMarketsAndMedisReportingUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ReportingUnitAxis=teva_TevasApiReportingUnitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=teva_InternationalMarketsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Debt Obligations - Schedule of Short-term Debt (Detail) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Current maturities of long-term liabilities $ 2,557 $ 1,649 Total short-term debt $ 2,580 1,672 Convertible senior debentures [Member] Â Â Debt Instrument [Line Items] Â Â Interest rate 0.25% Â Maturity 2026 Â Convertible senior debentures $ 23 $ 23 X - DefinitionDebt Instrument Maturity Year + ReferencesNo definition available. + Details Name: teva_DebtInstrumentMaturityYear Namespace Prefix: teva_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionAmount of debt and lease obligation, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Debt Obligations - Schedule of Senior Notes and Loans (Detail) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Total senior notes $ 19,023 $ 19,889 Less current maturities (2,557) (1,649) Less debt issuance costs (68) (80) Total senior notes and loans 16,400 18,161 Other Debentures [Member] Â Â Debt Instrument [Line Items] Â Â Total senior notes and loans $ 2 1 Senior notes USD 1,250 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [1] 6.00% Â Maturity [1] 2024 Â Total senior notes [1] $ 0 956 Senior notes EUR 1,500 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [2] 1.13% Â Maturity [2] 2024 Â Total senior notes [2] $ 700 693 Senior notes EUR 1,000 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 6.00% Â Maturity 2025 Â Total senior notes $ 459 453 Senior notes USD 1,000 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 7.13% Â Maturity 2025 Â Total senior notes $ 427 427 Senior notes EUR 900 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 4.50% Â Maturity 2025 Â Total senior notes $ 554 547 Senior notes CHF 350 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 1.00% Â Maturity 2025 Â Total senior notes $ 417 416 Senior notes USD 3,500 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 3.15% Â Maturity 2026 Â Total senior notes $ 3,374 3,374 Senior notes EUR 700 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 1.88% Â Maturity 2027 Â Total senior notes $ 781 771 Sustainability-linked senior notes USD 1,000 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [3],[4] 4.75% Â Maturity [3],[4] 2027 Â Total senior notes [3],[4] $ 1,000 1,000 Sustainability-linked senior notes EUR 1,100 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [3],[4] 3.75% Â Maturity [3],[4] 2027 Â Total senior notes [3],[4] $ 1,229 1,215 Senior notes USD 1,250 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 6.75% Â Maturity 2028 Â Total senior notes $ 1,250 1,250 Senior notes EUR 750 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 1.63% Â Maturity 2028 Â Total senior notes $ 834 826 Sustainability-linked senior notes USD 1,000 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [4],[5] 5.13% Â Maturity [4],[5] 2029 Â Total senior notes [4],[5] $ 1,000 1,000 Sustainability-linked senior notes USD 600Â million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [4],[6] 7.88% Â Maturity [4],[6] 2029 Â Total senior notes [4],[6] $ 600 600 Sustainability-linked senior notes EUR 800 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [4],[6] 7.38% Â Maturity [4],[6] 2029 Â Total senior notes [4],[6] $ 895 884 Sustainability-linked senior notes EUR 1,500 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [4],[5] 4.38% Â Maturity [4],[5] 2030 Â Total senior notes [4],[5] $ 1,676 1,656 Sustainability-linked senior notes USD 500 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [4],[6] 8.13% Â Maturity [4],[6] 2031 Â Total senior notes [4],[6] $ 500 500 Sustainability-linked senior notes EUR 500 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate [4],[6] 7.88% Â Maturity [4],[6] 2031 Â Total senior notes [4],[6] $ 558 552 Senior notes USD 789 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 6.15% Â Maturity 2036 Â Total senior notes $ 783 783 Senior notes USD 2,000 million [Member] Â Â Debt Instrument [Line Items] Â Â Weighted average interest rate 4.10% Â Maturity 2046 Â Total senior notes $ 1,986 $ 1,986 [1] In April 2024, Teva repaid $956 million of its 6% senior notes due 2024 at maturity. [2] In October 2024, Teva repaid $685 million of its 1.13% senior notes due 2024 at maturity. [3] If

Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. [4] Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. [5] If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026. [6] If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. X - DefinitionDebt Instrument Maturity Year + ReferencesNo definition available. + Details Name: teva_DebtInstrumentMaturityYear Namespace Prefix: teva_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsNoncurrentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesAndLoans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_SeniorNotes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028TwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029TwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2031OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2031TwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) â¬ in Millions, SFr in Millions, $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Oct. 31, 2024 USD ($) Sep. 30, 2024 EUR (â¬) Sep. 30, 2024 CHF (SFr) Apr. 30, 2024 USD ($) Senior Notes [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Senior notes repaid amount Â $ 685 Â Â $ 956 Senior notes maturity percentage Â 1.13% Â Â 6.00% Senior notes USD 1,250 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount $ 1,250 Â Â Â Â Senior notes EUR 1,500 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â â¬ 1,500 Â Â Senior notes EUR 1,000 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â 1,000 Â Â Senior notes USD 1,000 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount 1,000 Â Â Â Â Â Senior notes EUR 900 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â 900 Â Â Senior notes CHF 350 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | SFr Â Â Â SFr 350 Â Â Senior notes USD 3,500 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount 3,500 Â Â Â Â Â Senior notes EUR 700 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â 700 Â Â Sustainability-linked senior notes USD 1,000 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount 1,000 Â Â Â Â Â Sustainability-linked senior notes EUR 1,100 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â 1,100 Â Â Senior notes USD 1,250 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount 1,250 Â Â Â Â Â Senior notes EUR 750 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â 750 Â Â Sustainability-linked senior notes USD 1,000 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount 1,000 Â Â Â Â Â Sustainability-linked senior notes USD 600Â million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount $ 600 Â Â Â Â Â Sustainability-linked senior notes USD 600Â million [Member] | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt Instrument, Interest Rate, Increase (Decrease) 0.30% Â Â Â Â Â Sustainability-linked senior notes USD 600Â million [Member] | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt Instrument, Interest Rate, Increase (Decrease) 0.10% Â Â Â Â Â Sustainability-linked senior notes EUR 800 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â 800 Â Â Sustainability-linked senior notes EUR 1,500 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â 1,500 Â Â Sustainability-linked senior notes USD 500 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount $ 500 Â Â Â Â Sustainability-linked senior notes EUR 500 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount | â¬ Â Â â¬ 500 Â Â Senior notes USD 789 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount 789 Â Â Â Â Senior notes USD 2,000 million [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument face amount $ 2,000 Â Â Â Â Â Interest Rate Increase [Member] | Maximum [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt Instrument, Interest Rate, Increase (Decrease) 0.375% Â Â Â Â Â Interest Rate Increase [Member] | Minimum [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt Instrument, Interest Rate, Increase (Decrease) 0.125% Â Â Â Â One Time Premium Payment [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt Instrument, Maturity Date May 09, 2026 Â Â Â Â One Time Premium Payment [Member] | Maximum [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt Instrument, Interest Rate, Increase (Decrease) 0.45% Â Â Â Â One Time Premium Payment [Member] | Minimum [Member] Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt Instrument, Interest Rate, Increase (Decrease) 0.15% Â Â Â Â X - DefinitionSenior notes maturity percentage. + ReferencesNo definition available. + Details Name: teva_SeniorNotesMaturityPercentage Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionSenior notes repaid amount. + ReferencesNo definition available. + Details Name: teva_SeniorNotesRepaidAmount Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X -

DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncremental percentage increase (decrease) in the stated rate on a debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentInterestRateIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028TwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis=teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029TwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2031OneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2031TwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Debt Obligations - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended 12 Months Ended Mar. 31, 2027 Dec. 31, 2026 Sep. 30, 2026 Jun. 30, 2026 Mar. 31, 2026 Sep. 30, 2024 Dec. 31, 2025 Dec. 31, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Long term debt currency portion USD Â Â Â Â Â Â 58.00% Â Â Â Long term debt currency portion EUR Â Â Â Â Â 40.00% Â Â Â Long term debt currency portion CHF Â Â Â Â Â 2.00% Â Â Â Debt Instrument, Covenant Description Â Â Â Â Â Proceeds from borrowings under the RCF can be used for general corporate purposes, including repaying existing debt. As of SeptemberÂ 30, 2024, and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. Â Â Â Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Principal amount currently outstanding on the debt instruments Â Â Â Â Â $ 23 Â Â $ 23 Weighted average interest rate Â Â Â Â Â 0.25% Â Â Â Revolving Credit Facility [Member] Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â Â Â $ 1,800 Â Â Â Debt Instrument, Maturity Date Â Â Â Â Â Apr. 30, 2026 Â Â Â Line of credit extension period Â Â Â Â Â one-year Â Â Â Revolving Credit Facility [Member] | Amended Revolving Credit Facility [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Leverage Ratio 3.50 3.75 3.75 3.75 4.00 Â 4.00 4.00 Â X - DefinitionLeverage ratio. + ReferencesNo definition available. + Details Name: teva_LeverageRatio Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine of credit extension period. + ReferencesNo definition available. + Details Name: teva_LineOfCreditExtensionPeriod Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLong term debt currency portion C H F. + ReferencesNo definition available. + Details Name: teva_LongTermDebtCurrencyPortionCHF Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLong term debt currency portion E U R. + ReferencesNo definition available. + Details Name: teva_LongTermDebtCurrencyPortionEUR Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLong term debt currency portion U S D. + ReferencesNo definition available. + Details Name: teva_LongTermDebtCurrencyPortionUSD Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentCovenantDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine

items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=teva_AmendedRevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] Â Â Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Line Items] Â Â Cross-currency swap - cash flow hedge [1] $ 0 $ 169 [1] On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. The agreement was terminated in the first quarter of 2024 and resulted in cash proceeds of $16 million. X - DefinitionDisclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments. + ReferencesNo definition available. + Details Name: teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payments on the derivative asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeAssetNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member] Â Â Derivative [Line Items] Â Â Asset derivatives $ 0 $ 0 Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member] Â Â Derivative [Line Items] Â Â Liability derivatives 0 0 Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] | Other Non-current Assets [Member] Â Â Derivative [Line Items] Â Â Asset derivatives 0 8 Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member] Â Â Derivative [Line Items] Â Â Asset derivatives 32 38 Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member] Â Â Derivative [Line Items] Â Â Liability derivatives (33) (39) Not Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] | Other Non-current Assets [Member] Â Â Derivative [Line Items] Â Â Asset derivatives $ 0 $ 0 X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Other Comprehensive Income [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Other comprehensive income (loss) $ 180 $ (249) $ (75) $ (156) Financial expenses [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Financial expenses, net 272 280 763 808 Cross Currency Swap Cash Flow Hedge [Member] | Other Comprehensive Income [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Other comprehensive income (loss) 0 1 1 (4) Cross Currency Swap Cash Flow Hedge [Member] | Financial expenses [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Financial expenses, net $ 0 $ (7) $ (8) $ (22) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) related to derivatives designated as cash flow hedging instruments, recorded in results of operations to the extent that the cash flow hedge is determined to be ineffective. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net Revenues [Member] | Not Designated as Hedging Instrument [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Gain (Loss) on Derivative Instruments, Net, Pretax $ (4,332) $ (3,850) $ (12,315) $ (11,389) Net Revenues [Member] | Not Designated as Hedging Instrument, Trading [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Gain (Loss) on Derivative Instruments, Net, Pretax 0 0 0 0 Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Gain (Loss) on Derivative Instruments, Net, Pretax 9 (22) (1) (20) Financial expenses [Member] | Not Designated as Hedging Instrument [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Gain (Loss) on Derivative Instruments, Net, Pretax 272 280 763 808 Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Gain (Loss) on Derivative Instruments, Net, Pretax 4 4 (33) (46) Financial expenses [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] Â Â Â Â Derivative [Line Items] Â Â Â Â Gain (Loss) on Derivative Instruments, Net, Pretax $ 0 $ 0 $ 0 $ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentTradingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Nov. 07, 2023 Sep. 30, 2023 Nov. 07, 2022 Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Oct. 29, 2024 Dec. 31, 2023 Jun. 30, 2023 Jul. 11, 2022 Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Revenues other than USD Â Â Â 47.00% Â Â Â 47.00% Â Â Â Â Derivative, negative impact Â Â Â $ 9 Â Â $ 493 Â Â Â Â Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration] Â Â Â Â Â Â Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Â Â Â Â Â Forward starting interest rate swaps and treasury lock agreements losses Â Â Â 7 Â $ 7 $ 21 $ 25 Â Â Â Â Derivative, Gain on Derivative Â Â Â Â Â $ 22 1 $ 20 Â Â Â Â Derivative, Cash Received on Hedge Â Â Â Â $ 16 Â Â Â Â Â Â Â Â Accounts Receivable, Net, Current Â Â Â $ 3,462 Â Â $ 3,462 Â Â $ 3,408 Â Â Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration] Â Â Â Liabilities Â Â Liabilities Â Â Â Â Â Supplier finance program obligation Â Â Â $ 163 Â Â $ 163 Â Â 108 Â Â Derivative notional amount decrease $ 125 Â Â Â Â Â Â Â Â Â Â Â Accounts Receivable Securitization Facility [Member] Â Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Accounts Receivable, Net, Current Â Â Â $ 934 Â Â $ 934 Â Â $ 437 Â Â Accounts Receivable Securitization Facility [Member] | Mizuho Bank [Member] | November 2025 [Member] Â Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Derivative notional amount Â Â Â Â Â Â Â Â Â Â $ 250 Â Â Accounts Receivable Securitization Facility [Member] | Mizuho Bank [Member] | November 2023 [Member] Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Derivative notional amount Â Â Â Â Â Â Â Â Â Â $ 750 Â Â Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Derivative notional amount increase 250 Â Â Â Â Â Â Â Â Â Â Derivative notional amount $ 1,000 Â Â Â Â Â Â Â Â Â Â $ 875 Derivatives term of contract Â Â 3 years Â Â Â Â Â Â Â Â Â Â Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] | November 2025 [Member] Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Derivative notional amount decrease Â $ 500 $ 500 Â Â Â Â Â Â Â Â Â Â Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] | November 2023 [Member] Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Derivative notional amount Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] | SPV Amendment Agreement October Two Thousand And Twenty Four [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Derivative notional amount increase Â Â Â Â Â Â Â Â Â Â $ 75 Â Â Â Derivative notional amount Â Â Â Â Â Â Â Â Â Â $ 950 Â Â Â X - DefinitionDerivative notional amount decrease. + ReferencesNo definition available. + Details Name: teva_DerivativeNotionalAmountDecrease Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDerivative notional Amount Increase. + ReferencesNo definition available. + Details Name: teva_DerivativeNotionalAmountIncrease Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionForward starting interest rate swaps and treasury lock agreements losses. + ReferencesNo definition available. + Details Name: teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRevenues other than US Dollar. + ReferencesNo definition available. + Details Name: teva_RevenuesOtherThanUsd Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of cash received during the period on settlement of a hedge. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeCashReceivedOnHedge Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainOnDerivative Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of decrease in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeLossOnDerivative Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes loss from derivative. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionPeriod the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation for supplier finance program. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3 + Details Name: us-gaap_SupplierFinanceProgramObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes obligation for supplier finance program. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3 + Details Name: us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=teva_AccountsReceivableSecuritizationFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_FactoringInstitutionAxis=teva_MizuhoBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_PeriodAxis=teva_NovemberTwoThousandAndTwentyFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_PeriodAxis=teva_NovemberTwoThousandAndTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_FactoringInstitutionAxis=teva_PncBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_AgreementAxis=teva_SPVAmendmentAgreementOctoberTwoThousandAndTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Legal Settlements and Loss Contingencies - Additional Information (Detail) â,¬ in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Dec. 31, 2023 EUR (â,¬) Loss Contingencies [Line Items] Â Â Â Â Â Â Legal settlements and loss contingencies, expenses $ 450 $ 314 $ 638 $ 1,009 Â Â Accrued amount for legal settlements and loss contingencies $ 4,915 Â $ 4,915 Â $ 4,771 â,¬ 60.5 X - DefinitionAmount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LitigationSettlementExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType
Balance Type: credit Period Type: instant XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) â,¬ in Millions 1 Months Ended 9
Months Ended 12 Months Ended 48 Months Ended Oct. 10, 2024 USD ($) Dec. 31, 2023 USD ($) Nov. 09, 2022 USD ($) Jun. 02, 2022 USD ($) Jul. 31, 2024 Jul. 31, 2023 USD ($) Jun. 30, 2023
USD ($) Sep. 30, 2013 USD ($) Apr. 30, 2013 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2021 USD ($) Dec. 31, 2023 USD ($) Aug. 21, 2022 USD ($) Oct. 31, 2024 USD ($) Oct. 31, 2024 EUR (â,¬)
Jun. 30, 2024 USD ($) Mar. 28, 2024 USD ($) Dec. 31, 2023 EUR (â,¬) Aug. 21, 2023 USD ($) Jul. 08, 2021 USD ($) Aug. 31, 2019 USD ($) Jul. 31, 2008 USD ($) Feb. 28, 2005 USD ($)
Commitment And Contingencies [Line Items] Â Annual sales at the time of settlement Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $
700,000,000 Â Â Â Â $ 350,000,000 Â Â Annual sales of Effexor Â Â Â Â Â Â Â Â Â Â Â Â $ 2,600,000,000 Â Â Â Â Â Â Â Â Â Annual sales of Lamictal Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â $ 2,300,000,000 $ 950,000,000 Annual sales of Niaspan Â Â Â Â Â Â $ 1,100,000,000 $ 416,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Litigation
settlement amount Â Â Â Â Â Â $ 4,250,000,000 Â Â $ 495,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Litigation settlement amount awarded distribution period Â Â Â Â Â Â 13 years Â
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Generic modafinil, and imposed fines amount Â $ 4,771,000,000 Â Â Â Â Â Â Â 4,915,000,000 Â $ 4,771,000,000 Â Â Â Â Â â,¬ 60.5 Â Â Â Â Â
Loss Contingency Accrual, Provision Â 235,500,000 Â Annual sales of the time of settlement of viread Â Â Â Â Â Â Â Â 582,000,000
Â Â Â Â Â Â Â Â Â Â Â Â Â Annual sales of the time of settlement of Truvada Â Â Â Â Â Â Â Â Â 2,400,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Annual sales of the time of
settlement of Atripla Â Â Â Â Â Â Â Â Â 2,900,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Annual sales of the time of New launch of viread Â Â Â Â Â Â Â Â 728,000,000 Â Â Â Â Â
Â Â Â Â Â Â Â Â Annual sales of the time of New launch of Truvada Â Â Â Â Â Â Â Â Â 2,100,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Annual sales of the time of New launch of
Atripla Â Â Â Â Â Â Â Â Â 444,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Litigation Settlement Amount Distributable In Kind Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,200,000,000 Â Â Â
Â Â Â Â Accrual for Environmental Loss Contingencies Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 300,000 Â Â Â Â Â Â Â Loss Contingencies On Environmental Laws Penalty Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,400,000 Â Â Â Litigation Settlement amount payable year one Â Â Â Â Â Â Â Â Â 35,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Litigation
settlement amount payable remainder of fiscal year Â Â Â Â Â Â Â Â Â 80,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Other commitment Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $
150,000,000 Â Â Â Â Â Â Annual Sales Of Revlimid Â Â Â Â Â Â Â Â Â $ 3,500,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Annual Sales At The Time Of Nuvigil Entered Into First
Settlement Of With AN ANDA Filer Â 300,000,000 Â Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its
Share Of National Population Â $ 1,000,000 Â Percentage Of Share Of The National Population Â 1.00% Â Â Â Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Percentgae of amount in cash settlement Â Â Â Â Â Â Â Â Â Â Â Â Â Â 20.00% Â Â Â Â Â Â Â Litigation Settlement Amount Distributable in cash Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â $ 240,000,000 Â Â Â Â Â Â Â Loss Contingency, Damages Awarded, Value Â Â $ 176,500,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maximum
[Member] Â Commitment And Contingencies [Line Items] Â Damage
claimed Â Â Â Â Â Â Â Â Â Â Â $ 1,000,000,000 Â Â Â Â Â Â Â Â Â Â Â Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Donation of Clotrimazole and
Tobramycin [Member] Â Commitment And Contingencies [Line Items] Â
Other commitment Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 50,000,000 Â Â Â Â Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Fine for Violating the
Antitrust Laws [Member] Â Commitment And Contingencies [Line Items] Â
Other commitment, to be paid, year five Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 135,000,000 Â Â Â Â Other commitment to pay for each year Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Â Â Â 22,500,000 Â Â Â Â Other commitment Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 225,000,000 Â Â Â Â Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Litigation fine amount of copaxone Â Â Â Â Â Â Â Â Â Â Â
Â Â $ 500,000,000 â,¬ 462.6 Â Â Â Â Â Â Â Opioid Litigation [Member] Â Commitment And Contingencies [Line Items] Â Â
Â Loss contingency accrual, product liability, undiscounted, to be paid, year five Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 390,000,000 Â Â
Â Â Â Â Â Loss contingency accrual, product liability, undiscounted, to be paid, year four Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 374,000,000 Â Â Â Â Â Â Â Loss contingency accrual,
product liability, undiscounted, to be paid, year three Â Â Â Â Â Â Â Â Â Â Â Â Â Â 368,000,000 Â Â Â Â Â Â Â Loss contingency accrual, product liability, undiscounted, to be
paid, year two Â Â Â Â Â Â Â Â Â Â Â Â Â Â 423,000,000 Â Â Â Â Â Â Â Loss contingency accrual, product liability, undiscounted, to be paid, year one Â Â Â Â Â Â Â Â Â
Â Â Â Â Â 428,000,000 Â Â Â Â Â Â Â Modafinil Settlement Agreement [Member] Â Commitment And Contingencies [Line
Items] Â Settlement as a percentage of aggregate subdivisions and tribes Â Â Â Â Â Â Â Â Â 100.00% Â Â Â Â Â Â Â Â Â
Â Â Â Loss contingency aggregate payments paid Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 392,000,000 Â Â Â Â Â Â Â Civil Action In Respect Of Donations To Patient Assistance
Programmers [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Generic modafinil, and imposed fines amount $ 425,000,000 Â Loss contingency accrual due in fifth year
175,000,000 Â Loss contingency accrual due in fourth year 99,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Loss
contingency accrual due in third year 49,000,000 Â Loss contingency accrual due in second year 49,000,000 Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â Loss contingency accrual next twelve months 34,000,000 Â Loss contingency accrual remainder of fiscal
year 19,000,000 Â Civil Investigative Demand From Department Of Justice Civil Division [Member] | Subsequent Event [Member] Â Â
Â Commitment And Contingencies [Line Items] Â Generic modafinil, and
imposed fines amount 25,000,000 Â Loss Contingency Accrual, Provision 25,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Â Â Â Civil Investigative Demand From Department Of Justice Civil Division [Member] | Subsequent Event [Member] | Two Thousand And Twenty Five [Member] Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Loss contingency accrual current 15,000,000 Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Civil Investigative Demand From Department Of Justice Civil Division [Member] | Subsequent Event [Member] | Two Thousand And Twenty
Four [Member] Â Commitment And Contingencies [Line Items] Â Loss
contingency accrual current $ 10,000,000 Â Ontario Teachers Securities Litigation [Member] | Settled Litigation [Member] Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Litigation settlement amount Â Â Â $
420,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Litigation With US Hospitals And Other Healthcare Providers [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Â Â Commitment And Contingencies [Line Items] Â Litigation settlement amount Â Â Â Â Â $ 126,000,000 Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Litigation settlement amount awarded distribution period Â Â Â Â 18 years Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product WAC Value Â Â Â Â Â $
49,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product WAC Term Â Â Â Â Â 7 years Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Europe [Member] Â Â Â Â Â Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â Commitment And Contingencies [Line Items] Â Damage claimed Â Â Â Â Â Â Â Â Â Â $ 50,000,000
Â Â Â Â Â Â Â Â Â Â Â Â Eosinophilic Esophagitis [Member] Â Commitment And Contingencies [Line Items] Â Â Â Â Â Â
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Damage claimed Â Â Â Â Â Â Â Â Â Â 200,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Eosinophilic Esophagitis [Member] | United States [Member]
Â Commitment And Contingencies [Line Items] Â Damage claimed Â Â Â
Â Â Â Â Â Â Â $ 150,000,000 Â Â Â Â Â Â Â Â Â Â Â Â AndroGel Rate at 1% [Member] Â Commitment And Contingencies
[Line Items] Â Annual sales at the time of settlement Â $ 140,000,000 Â Â X -
DefinitionAnnual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler. + ReferencesNo definition available. + Details Name:
teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X -
DefinitionAnnual sales at time of settlement. + ReferencesNo definition available. + Details Name: teva_AnnualSalesAtTimeOfSettlement Namespace Prefix: teva_ Data Type:
xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAnnual sales of effexor. + ReferencesNo definition available. + Details Name: teva_AnnualSalesOfEffexor
Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAnnual sales of Lamictal. + ReferencesNo definition available. + Details
Name: teva_AnnualSalesOfLamictal Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAnnual sales of Niaspan. + ReferencesNo
definition available. + Details Name: teva_AnnualSalesOfNiaspan Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAnnual
sales of revlimid. + ReferencesNo definition available. + Details Name: teva_AnnualSalesOfRevlimid Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period
Type: duration X - DefinitionAnnual sales of the time of new launch of Atripla. + ReferencesNo definition available. + Details Name: teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla
Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAnnual sales of the time of New launch of truvada. + ReferencesNo
definition available. + Details Name: teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type:
duration X - DefinitionAnnual sales of the time of new launch of viread. + ReferencesNo definition available. + Details Name: teva_AnnualSalesOfTheTimeOfNewLaunchOfViread Namespace
Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAnnual sales of the time of settlement of atripla. + ReferencesNo definition available. +
Details Name: teva_AnnualSalesOfTheTimeOfSettlementOfAtripla Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAnnual
sales of the time of settlement of truvada. + ReferencesNo definition available. + Details Name: teva_AnnualSalesOfTheTimeOfSettlementOfTruvada Namespace Prefix: teva_ Data Type:
xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAnnual sales of the time of settlement of viread. + ReferencesNo definition available. + Details Name:
teva_AnnualSalesOfTheTimeOfSettlementOfViread Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCommitment And
Contingencies [Line Items] + ReferencesNo definition available. + Details Name: teva_CommitmentAndContingenciesLineItems Namespace Prefix: teva_ Data Type: xbrli:stringItemType
Balance Type: na Period Type: duration X - DefinitionLitigation fine amount of copaxone. + ReferencesNo definition available. + Details Name: teva_LitigationFineAmountOfCopaxone
Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLitigation settlement amount awarded distribution period. + ReferencesNo
definition available. + Details Name: teva_LitigationSettlementAmountAwardedDistributionPeriod Namespace Prefix: teva_ Data Type: xbrli:durationItemType Balance Type: na Period Type:
duration X - DefinitionLitigation settlement amount distributable in cash. + ReferencesNo definition available. + Details Name: teva_LitigationSettlementAmountDistributableInCash Namespace
Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLitigation settlement amount distributableIn kind. + ReferencesNo definition available.
+ Details Name: teva_LitigationSettlementAmountDistributableinKind Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X -
DefinitionLitigation settlement amount payable in cash percentage + ReferencesNo definition available. + Details Name: teva_LitigationSettlementAmountPayableInCashPercentage Namespace
Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLitigation settlement amount payable remainder of fiscal year. + ReferencesNo definition
available. + Details Name: teva_LitigationSettlementAmountPayableRemainderOfFiscalYear Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type:
instant X - DefinitionLitigation settlement amount payable year one. + ReferencesNo definition available. + Details Name: teva_LitigationSettlementAmountPayableYearOne Namespace Prefix:
teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLoss contingencies on environmental laws penalty. + ReferencesNo definition available. +
Details Name: teva_LossContingenciesOnEnvironmentalLawsPenalty Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLoss
contingency accrual due in fifth year. + ReferencesNo definition available. + Details Name: teva_LossContingencyAccrualDueInFifthYear Namespace Prefix: teva_ Data Type:
xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLoss contingency accrual due in fourth year. + ReferencesNo definition available. + Details Name:
teva_LossContingencyAccrualDueInFourthYear Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLoss contingency accrual
due in second year. + ReferencesNo definition available. + Details Name: teva_LossContingencyAccrualDueInSecondYear Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance
Type: credit Period Type: instant X - DefinitionLoss contingency accrual due in year three. + ReferencesNo definition available. + Details Name: teva_LossContingencyAccrualDueInYearThree
Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLoss contingency accrual nest twelve months. + ReferencesNo definition
available. + Details Name: teva_LossContingencyAccrualNestTwelveMonths Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X -
DefinitionLoss contingency accrual remainder of fiscal year. + ReferencesNo definition available. + Details Name: teva_LossContingencyAccrualRemainderOfFiscalYear Namespace Prefix:
teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLoss contingency aggregate payments paid. + ReferencesNo definition available. + Details
Name: teva_LossContingencyAggregatePaymentsPaid Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLoss contingency
claims dismissed value paid to each state proportional to its share of national population + ReferencesNo definition available. + Details Name:
teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit
Period Type: duration X - DefinitionOther commitment to pay for each year. + ReferencesNo definition available. + Details Name: teva_OtherCommitmentToPayForEachYear Namespace Prefix:
teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of share of the national population. + ReferencesNo definition available. + Details
Name: teva_PercentageOfShareOfTheNationalPopulation Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionProduct weighted
average cost. + ReferencesNo definition available. + Details Name: teva_ProductWeightedAverageCost Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period
Type: duration X - DefinitionProduct weighted average cost term. + ReferencesNo definition available. + Details Name: teva_ProductWeightedAverageCostTerm Namespace Prefix: teva_ Data
Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionSettlement as a percentage of aggregate subdivisions and tribes. + ReferencesNo definition available. +
Details Name: teva_SettlementAsAPercentageOfAggregateSubdivisionsAndTribes Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X -
DefinitionTotal costs accrued as of the balance sheet date for environmental loss contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -
SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2:
http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d)(1) -Publisher FASB -
URI https://asc.fasb.org/1943274/2147481931/410-30-50-10Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 410 -SubTopic 30 -Name Accounting Standards
Codification -Section 50 -Paragraph 10 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481931/410-30-50-10Reference 4:
http://www.xbrl.org/2003/role/exampleRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 16 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147481899/410-30-55-16Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99
-Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -

Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481931/410-30-50-7 + Details Name: us-gaap_AccrualForEnvironmentalLossContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualCarryingValueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUndiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details Name: us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFifthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUndiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details Name: us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFourthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUndiscounted amount of accrual for damage arising from third-party use of product or process to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details Name: us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInSecondYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUndiscounted amount of accrual for damage arising from third-party use of product or process to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details Name: us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInThirdYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUndiscounted amount of accrual for damage arising from third-party use of product or process to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details Name: us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueWithinOneYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualProvision Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of damages awarded to the plaintiff in the legal matter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyDamagesAwardedValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe value (monetary amount) of the award the plaintiff seeks in the legal matter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyDamagesSoughtValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMinimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentDueInFifthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_AgreementAxis=teva_DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=teva_DonationOfClotrimazoleAndTobramycinMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OtherCommitmentsAxis=teva_FineForViolatingTheAntitrustLawsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=teva_OpioidLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=teva_ModafinilSettlementAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=teva_CivilActionInRespectOfDonationsToPatientAssistanceProgrammersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=teva_CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_PeriodAxis=teva_TwoThousandAndTwentyFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_PeriodAxis=teva_TwoThousandAndTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=teva_OntarioTeachersSecuritiesLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=teva_LitigationWithUsHospitalsAndOtherHealthcareProvidersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Jun. 23, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 12, 2022 Income Tax [Line Items] Â Â Â Â Â Â Â Expected impairment of income tax benefit Â Â Â $ 125 Â Â Â Tax benefit Â $ 69 $ (12) 648 $ (48) Â Â Pre-tax income (loss) Â $ (324) $ 64 $ (1,037) $ 1,131 Â Â Minimum tax rate Â Â Â Â Â Â 15.00% Â Israel Tax Authority [Member] Â Â Â Â Â Â Â Â Income Tax [Line Items] Â Â Â Â Â Â Â Â Statutory tax rate in Israel Â Â Â 23.00% Â Â Â Minimum tax rate Â Â Â Â Â Â 15.00% Israel Tax Authority [Member] | 2008 Through 2020 Tax Payable [Member] Â Â Â Â Â Â Â Â Income Tax [Line Items] Â Â Â Â Â Â Â Â Income tax examination increase in income tax expense In the current period Â Â Â $ 506 Â Â Â Maximum tax payment limit $ 500 Â Â Â Â Â Â Â Effective income tax rate reconciliation, other reconciling items, amount, total 250 Â Â Â Â Â Â Â Effective income tax rate reconciliation, tax exempt income, amount $ 495 Â Â Â Â Â Â Â Number of years spread to pay tax payable 6 years Â Â Â Â Â Â Â Effective Income Tax Rate Reconciliation, Tax Settlement, Amount, Total $ 750 Â Â Â Â Â Â Â Minimum [Member] | Israel Tax Authority [Member] | 2008 Through 2020 Tax Payable [Member] Â Â Â Â Â Â Â Â Income Tax [Line Items] Â Â Â Â Â Â Â Effective income tax rate reconciliation, tax settlement, other, percent 5.00% Â Â Â Â Â Â Â Maximum [Member] | Israel Tax Authority [Member] | 2008 Through 2020 Tax Payable [Member] Â Â Â Â Â Â Â Â Income Tax [Line Items] Â Â Â Â Â Â Â Â Effective income tax rate reconciliation, tax settlement, other, percent 7.00% Â Â Â Â Â Â Â X - DefinitionExpected impairment of income tax benefit. + ReferencesNo definition available. + Details Name: teva_ExpectedImpairmentOfIncomeTaxBenefit Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncome (Loss) from Continuing Operations before Income Taxes. + ReferencesNo definition available. + Details Name: teva_IncomeLossFromContinuingOperationsBeforeIncomeTaxes Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncome tax examination increase in income tax expense In the current period + ReferencesNo definition available. + Details Name: teva_IncomeTaxExaminationIncreaseInIncomeTaxExpenseInTheCurrentPeriod Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncome Tax [Line Items] + ReferencesNo definition available. + Details Name: teva_IncomeTaxLineItems Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum tax payment limit. + ReferencesNo definition available. + Details Name: teva_MaximumTaxPaymentLimit Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMinimum tax rate. + ReferencesNo definition available. + Details Name: teva_MinimumTaxRate Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of years spread to pay tax payable. + ReferencesNo definition available. + Details Name: teva_NumberOfYearsSpreadToPayTaxPayable Namespace Prefix: teva_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax settlements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationOtherReconcilingItems Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationTaxExemptIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationTaxSettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_PeriodAxis=teva_TwoThousandEightThrough2020TaxPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring and Impairment Costs [Line Items] Â Â Â Â Impairments of long-lived tangible assets [1] $ (80) $ 1 $ 589 $ 21 Contingent consideration [2] 34 27 305 140 Restructuring 21 27 52 93 Other 1 2 (16) 21 Total $ (23) $ 57 $ 931 $ 276 Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration] Other assets impairments, restructuring and other items Â Â Â [1] Including impairments related to exit and disposal activities. [2] The contingent consideration presented in the tables above for the three and nine months ended September 30, 2023 have been revised as discussed in note 1c. X - DefinitionImpairment and restructuring. + ReferencesNo definition available. + Details Name: teva_ImpairmentAndRestructuring Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLegal settlements loss contingencies impairments other expenses. + ReferencesNo definition available. + Details Name: teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRestructuring and impairment costs. + ReferencesNo definition available. + Details Name: teva_RestructuringAndImpairmentCostsLineItems Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2 + Details Name: us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 78 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges $ 21 $ 27 $ 52 $ 93 Employee termination [Member] Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges 13 16 33 40 Other [Member] Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring charges $ 8 $ 12 $ 19 $ 53 X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Restructuring Cost and Reserve [Line Items] Â Â Beginning balance $ (82) $ (119) Provision (52) (93) Utilization and other [1] 64 130 Ending balance (70) (82) Employee termination costs [Member] Â Â Restructuring Cost and Reserve [Line Items] Â Â Beginning balance (75) (112) Provision (33) (40) Utilization and other [1] 52 77 Ending balance (56) (75) Other Exit and Disposal [Member] Â Â Restructuring Cost and Reserve [Line Items] Â Â Beginning balance (7) (7) Provision (19) (53) Utilization and other [1] 12 53 Ending balance $ (14) $ (7) [1] Includes adjustments for foreign currency translation. X - DefinitionRestructuring Accrual Provision + ReferencesNo definition available. + Details Name: teva_RestructuringAccrualProvision Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUtilization and other. + ReferencesNo definition available. + Details Name: teva_UtilizationAndOther Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Other assets impairments, restructuring and other items - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring and Impairment Costs [Line Items] Â Â Â Â Impairments of property, plant and equipment $ 80 $ 1 $ 589 $ 21 Business combination contingent consideration arrangements change in amount of contingent consideration liability [1] 34 27 305 140 Restructuring costs $ 21 $ 27 $ 52 $ 93 [1] The contingent consideration presented in the tables above for the three and nine months ended September 30, 2023 have been revised as discussed in note 1c. X - DefinitionRestructuring and impairment costs. + ReferencesNo definition available. + Details Name: teva_RestructuringAndImpairmentCostsLineItems Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-

S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_TangibleAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 81 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings (Loss) per Share - Additional Information (Detail) - $ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Basic $ (0.39) $ 0.06 $ (1.26) $ (0.91) Diluted $ (0.39) $ 0.06 $ (1.26) $ (0.91) Weighted average number of shares used in the computation of diluted earnings (loss) per share 1,133,000,000 1,135,000,000 1,130,000,000 1,119,000,000 Convertible Preferred Stock [Member] Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Weighted average shares with anti-dilutive effect on earnings per share Â Â 0 0 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Beginning Balance $ (2,697) Â Ending Balance (2,769) Â Foreign Currency Translation Adjustments [Member] Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Beginning Balance (2,384) $ (2,514) Other comprehensive income (loss) before reclassifications (84) (39) Net other comprehensive income/(loss) before tax (84) (39) Corresponding income tax (7) (50) Net other comprehensive income/(loss) after tax (91) [1] (89) [2] Ending Balance (2,475) (2,603) Derivative Financial Instruments [Member] Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Beginning Balance (266) (295) Other comprehensive income (loss) before reclassifications Â (5) Amounts reclassified to the statements of income 21 24 Net other comprehensive income/(loss) before tax 21 19 Net other comprehensive income/(loss) after tax 21 [1] 19 [2] Ending Balance (245) (276) Benefit Plans [Member] Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Beginning Balance (46) (28) Other comprehensive income (loss) before reclassifications 1 Â Amounts reclassified to the statements of income (3) (2) Net other comprehensive income/(loss) before tax (2) (2) Net other comprehensive income/(loss) after tax (2) [1] (2) [2] Ending Balance (48) (30) AOCI Attributable to Parent [Member] Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Beginning Balance (2,697) (2,838) Other comprehensive income (loss) before reclassifications (83) (44) Amounts reclassified to the statements of income 18 22 Net other comprehensive income/(loss) before tax (65) (22) Corresponding income tax (7) (50) Net other comprehensive income/(loss) after tax (72) [1] (72) [2] Ending Balance $ (2,769) $ (2,910) [1] Amounts do not include a $6 million loss from foreign currency translation adjustments attributable to non-controlling interests. [2] Amounts do not include a $84 million loss from foreign currency translation adjustments attributable to non-controlling interests. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-

gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Detail) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Foreign currency translation attributable to non-controlling interests $ 6 $ 84 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 84 R74.htm IDEA: XBRL DOCUMENT v3.24.3 Segments - Summary of Segment Profit (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Amounts Allocated To Segments [Abstract] Â Â Â Â Â Consolidated operating income (loss) [1] $ (51) Â $ 344 $ (274) $ (323) Amounts Not Allocated To Segments [Abstract] Â Â Â Â Â Amortization 146 Â 145 444 471 Other asset impairments, restructuring and other items [1] (23) Â 57 931 276 Goodwill impairment 600 $ 400 0 1,000 700 Intangible assets impairments 28 Â 47 169 289 Legal settlements and loss contingencies 450 Â 314 638 1,009 Other Unallocated Amounts 64 Â 112 254 394 Revenues 4,332 Â 3,850 12,315 11,389 Gross profit 2,148 Â 1,851 5,943 5,230 R&D expenses 240 Â 253 751 726 S&M expenses 626 Â 576 1,891 1,726 G&A expenses 298 Â 268 859 870 Segment profit [1] (51) Â 344 (274) (323) Financial expenses, net 272 Â 280 763 808 Consolidated income (loss) before income taxes [1] (324) Â 64 (1,037) (1,131) Europe [Member] Â Â Â Â Â Amounts Allocated To Segments [Abstract] Â Â Â Â Â Consolidated operating income (loss) 373 Â 338 1,137 1,017 Amounts Not Allocated To Segments [Abstract] Â Â Â Â Â Revenues 1,265 Â 1,146 3,749 3,493 Gross profit 698 Â 648 2,113 1,943 R&D expenses 55 Â 62 173 168 S&M expenses 203 Â 184 605 565 G&A expenses 67 Â 66 197 196 Other loss (income) 1 Â Â 1 (2) Segment profit 373 Â 338 1,137 1,017 International Markets [Member] Â Â Â Â Â Amounts Allocated To Segments [Abstract] Â Â Â Â Â Consolidated operating income (loss) 109 Â 117 299 356 Amounts Not Allocated To Segments [Abstract] Â Â Â Â Â Revenues 613 Â 591 1,802 1,750 Gross profit 306 Â 293 889 861 R&D expenses 27 Â 30 85 81 S&M expenses 134 Â 116 397 353 G&A expenses 36 Â 33 109 105 Other loss (income) Â Â (2) (1) (34) Segment profit 109 Â 117 299 356 United States [Member] Â Â Â Â Â Amounts Allocated To Segments [Abstract] Â Â Â Â Â Consolidated operating income (loss) 748 Â 571 1,727 1,421 Amounts Not Allocated To Segments [Abstract] Â Â Â Â Â Revenues 2,225 Â 1,896 6,060 5,465 Gross profit 1,265 Â 1,060 3,291 2,866 R&D expenses 151 Â 156 475 460 S&M expenses 259 Â 243 789 700 G&A expenses 107 Â 93 300 289 Other loss (income) Â Â (2) (1) (3) Segment profit 748 Â 571 1,727 1,421 Segments and Other Activities [Member] Â Â Â Â Â Amounts Allocated To Segments [Abstract] Â Â Â Â Â Consolidated operating income (loss) 1,214 Â 1,020 3,162 2,816 Amounts Not Allocated To Segments [Abstract] Â Â Â Â Â Segment profit 1,214 Â 1,020 3,162 2,816 Other Segments [Member] Â Â Â Â Â Amounts Allocated To Segments [Abstract] Â Â Â Â Â Consolidated operating income (loss) (16) Â (5) (1) 22 Amounts Not Allocated To Segments [Abstract] Â Â Â Â Â Segment profit (16) Â (5) (1) 22 Corporate Segment [Member] Â Â Â Â Â Amounts Allocated To Segments [Abstract] Â Â Â Â Â Consolidated operating income (loss) 1,230 Â 1,025 3,163 2,794 Amounts Not Allocated To Segments [Abstract] Â Â Â Â Â Segment profit $ 1,230 Â $ 1,025 $ 3,163 $ 2,794 [1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. X - DefinitionAmounts allocated to segments. + ReferencesNo definition available. + Details Name: teva_AmountsAllocatedToSegmentsAbstract Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmounts not allocated to segments. + ReferencesNo definition available. + Details Name: teva_AmountsNotAllocatedToSegmentsAbstract Namespace Prefix: teva_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionImpairments restructuring and others. + ReferencesNo definition available. + Details Name: teva_ImpairmentsRestructuringAndOthers Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIntangible Assets Impairments + ReferencesNo definition available. + Details Name: teva_IntangibleAssetsImpairments Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items). + ReferencesNo definition available. + Details Name: teva_LegalSettlementsAndLossContingencies Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther Operating Income (Expense) + ReferencesNo definition available. + Details Name: teva_OtherOperatingIncomeExpense Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther unallocated amounts. + ReferencesNo definition available. + Details Name: teva_OtherUnallocatedAmounts Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-

28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=teva_UnitedStatesSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R75.htm IDEA: XBRL DOCUMENT v3.24.3 Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product Information [Line Items] Â Â Â Â Revenues $ 4,332 $ 3,850 $ 12,315 $ 11,389 Europe [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 1,265 1,146 3,749 3,493 International Markets [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 613 591 1,802 1,750 United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 2,225 1,896 6,060 5,465 Generic products [Member] | Europe [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 973 886 2,947 2,727 Generic products [Member] | International Markets [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 477 470 1,440 1,425 Generic products [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 1,094 839 2,924 2,471 AJOVY [Member] | Europe [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 56 41 158 115 AJOVY [Member] | International Markets [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 24 18 63 45 AJOVY [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 58 56 144 154 AUSTEDO [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 435 339 1,124 817 BENDEKA and TREANDA [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 40 56 127 185 COPAXONE [Member] | Europe [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 53 55 163 174 COPAXONE [Member] | International Markets [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 13 16 38 50 COPAXONE [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 69 98 179 224 UZEDY [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 35 2 75 14 Anda [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 380 367 1,134 1,183 Respiratory Product [Member] | Europe [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 60 61 183 195 Other [Member] | Europe [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 124 [1] 104 [1] 299 [2] 282 [2] Other [Member] | International Markets [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues 99 [1] 87 [1] 261 [2] 229 [2] Other [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Revenues $ 115 $ 140 $ 352 $ 417 [1] Other revenues in the third quarter of 2024 include the sale of certain product rights. [2] Other revenues in the first nine months of 2024 include the sale of certain product rights. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_StatementBusinessSegmentsAxis=teva_UnitedStatesSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_GenericsMediciansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_AjovyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_AustedoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_COPAXONEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_UzedyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_AndaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_RespiratoryProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=teva_OtherProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R76.htm IDEA: XBRL DOCUMENT v3.24.3 Segments - Additional Information (Detail) 9 Months Ended Sep. 30, 2024 Segment Segment Reporting Information [Line Items] Â Number of reportable segments 3 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 87 R77.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) - USD ($) $ in Millions Sep. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Derivatives Â Â $ 8 Contingent consideration [1] $ (552) Â $ (517) Total $ 2,782 $ 2,765 Â Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets, Current Â Other Assets, Current Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Â Other Liabilities, Current Asset Derivatives - Options and Forward Contracts [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Derivatives $ 32 38 Â Convertible Debt Securities [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Investment in securities Â 40 Â Liabilities Derivatives Options and Forward Contracts [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Derivatives (33) (39) Â Money Markets [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Cash and cash equivalents 1,822 1,704 Â Cash, Deposits and Other [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Cash and cash equivalents 1,497 1,522 Â Equity Securities [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Investment in securities 13 7 Â Other [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Investment in securities 3 1 Â Restricted Cash [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Restricted cash Â Â $ 1 Level 1 [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Total 3,335 3,235 Â Level 1 [Member] | Money Markets [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Cash and cash equivalents 1,822 1,704 Â Level 1 [Member] | Cash, Deposits and Other [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Cash and cash equivalents 1,497 1,522 Â Level 1 [Member] | Equity Securities [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Investment in securities 13 7 Â Level 1 [Member] | Other [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Investment in securities 3 1 Â Level 1 [Member] | Restricted Cash [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Restricted cash Â Â 1 Level 2 [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Derivatives Â Â 8 Total (1) 7 Â Level 2 [Member] | Asset Derivatives - Options and Forward Contracts [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Derivatives 32 38 Â Level 2 [Member] | Liabilities Derivatives Options and Forward Contracts [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Derivatives (33) (39) Â Level 3 [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Contingent consideration [1] (552) Â $ (517) Total $ (552) (477) Â Level 3 [Member] | Convertible Debt Securities [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Investment in securities Â $ 40 Â [1] Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes derivative asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 30: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic

210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 28: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes derivative liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of asset after deduction of liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueNetAssetLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=teva_OtherRestrictedCashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=teva_RestrictedCashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R78.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurement - Additional Information (Detail) Sep. 30, 2024 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Percentage of increase decrease in contingent consideration liabilities 1.00% Maximum [Member] | Measurement input, discount rate [Member] Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Business combination, contingent consideration, liability, measurement input 11 Minimum [Member] | Measurement input, discount rate [Member] Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Business combination, contingent consideration, liability, measurement input 8.5 Weighted Average [Member] Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Business combination, contingent consideration, liability, measurement input 8.8 X - DefinitionPercentage of increase decrease in contingent consideration liabilities. + ReferencesNo definition available. + Details Name: teva_PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities Namespace Prefix: teva_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionValue of input used to measure contingent consideration liability from business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 89 R79.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair value at the beginning of the period $ (477) $ (250) Fair value at the end of the period (552) (159) Allergan transaction [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Adjustments to provisions for contingent consideration [1] (267) (111) Settlement of contingent consideration 227 132 Eagle Transaction [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Adjustments to provisions for contingent consideration (37) (35) Settlement of contingent consideration 41 61 Novetide transaction [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Adjustments to provisions for contingent consideration (1) 2 Settlement of contingent consideration 2 2 Redemption Of Convertible Debt Security [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Redemption of convertible bond security [2] $ (40) Â Conversion Option [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Conversion option** [2] Â 15 Convertible Debt Securities [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Investment in convertible bond [2] Â $ 25 [1] The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan for the nine months ended September 30, 2023 have been revised as discussed in note 1c. [2] On September 29, 2023, Teva purchased $40 million of subordinated convertible bonds of Alvotech. On June 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024 (see note 2). X - DefinitionFair value measurement with unobservable inputs reconciliation recurring basis assets and liability conversion option. + ReferencesNo definition available. + Details Name: teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityConversionOption Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value measurement with unobservable inputs reconciliation recurring basis assets and liability investment in convertible bond. + ReferencesNo definition available. + Details Name: teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityInvestmentInConvertibleBond Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value measurement with unobservable inputs reconciliation recurring basis assets and liability redemption of convertible bond security. + ReferencesNo definition available. + Details Name: teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityRedemptionOfConvertibleBondSecurity Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease. + ReferencesNo definition available. + Details Name: teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease Namespace Prefix: teva_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -

Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_IncomeStatementLocationAxis=teva_AllerganTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=teva_NovetideTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=teva_RedemptionOfConvertibleDebtSecurityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=teva_ConversionOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R80.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail) $ in Millions Sep. 29, 2023 USD ($) Subordinated Convertible Bonds [Member] | Alvotech [Member] Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Debt instrument face amount $ 40 X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=teva_SubordinatedConvertibleBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R81.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total [1] $ 18,701 $ 18,865 Senior Notes And Sustainability Linked Senior Notes [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total [1] 16,129 17,214 Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total [1] $ 2,572 $ 1,651 [1] The fair value was estimated based on quoted market prices. X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 92 R9999.htm IDEA: XBRL DOCUMENT v3.24.3 Label Element Value Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents $ 2,670,000,000 X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant EXCEL 93 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (,B 9ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-
!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #(@&99+9ZWE^T K @ $0
&1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)^E*#Z';B^))07!!\1:2V=U@TX1DI-VW-XV[740?P&-F_GSS M#4RG@]0^XG/T 2-93#>S&\8D==BR(U&0 $D?T:E4Y\28FWL?G:+\C <(2G^H M
T+#>0L.21E%"A9@%58BZSNCI8ZHR,GQI:Q;V3&1 M&C7F7\E*.@7Z!]0UO;BLA*M[N&B%Y*[EX7UQ_^%V%G3=V; ^Q M\46P[^#77?1?4$L#!!0 (,B 9EF97)PC$ 8)PG 3 >&PO=&AE
M;64O=&AE64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2 _;UKNW+]
[@5S(D4P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8(' _;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M'
3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M:,T@.67BGZ=90:V1V[W4%
<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*]]9>[R:0S>IU].LYKE'I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-
;88C'(CN]WV6'WV3T=N()>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A, ")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[?_1VC?"J_B"P#E_M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4!!OP_GIQ7@:XCG9!+E]F%=MY]C1T?
OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*\) M3(Q%Z'#GEUQ?
X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"
(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MR(!F64K(S5I/!0 <14 !@ !X;"]W;W)KU]
<[J7ZF@1":O,=1DMXT JW75ZU6Z@4BYNFY7(L$ M/EE*%7,-MVK52M=*<#]K%$ E7@38/6OWK-5^)F="OZZF"NU:IXH>Q2-)0)D2)Y4UC0*]N M768:9& _\",4N/;@FIBL+*7^:F[% _TW
,D8BIXTAS],,1119)2 X^]"M%%^ MIVEX>+U7O\\Z#YU9\%0,9?1[Z.O@IM%M$%\L^2;2+W+W((H.71@]3T9I]IOL M\G?;[0;Q-JF6<=$8".(PR?_R]Z(0!PTZ%T<:L*)!5HA6_D49Y1W7O'^MY(XH
M\S:HF8NLJUEK@ L3,RHSK>#3$-KI_E!NA2)3&(#KE@8]\[3E%6UO\[;L2-L> M>92)#E(R2GSA_[M]"SA*&+:'N66HX$RLSXGKG!'FL#9) ZY$BLBZ91_=3-9% M^_CG8)%J!;/@KZJ>Y@KM:@6S-*
[2-??$30/F?BK45C3ZGS_1CO,-X6N7?&U, MO7\GO0U,=$WF'^O*8<";4Z?YC%!T:MR'J<_QK!@O#H&.)JSRZ"1!WK
M<\YI4,\;KK10T0!\/1ZWP\'$S(^.GN=39_&8]F9#)^',]'=Q@SL\SL%.8AU%+!X([! M^]);^*CDAJ7O$]:B49KEA# M9G. XN:]KYF,8_#;F9;>SS,RRS8%Y/M&IYHG/I2PDC!7OLB4S<9TVZ?4=9T+
MAU%PN&T5EPT#BCOX/-21(')*/NR^$IFPMLK *WDP)4@AS#@3YMX(505 M38V(X] F[=!++%J9C0QV4F2,$T\J,!%N-B-GF8W G%2P6C;@RV;5^)65JU&? M8&'+;$:PDS)BSM_)V#?3=PG3/-
LV(56LRXJFD_]@A#8K&&[N!>']V&!P7(K M+L@D-*LLJ:X=+DGA?Y:[+0P)>>!/8AM^_M1E]/(;A\'!D&V&L),RI$0>FCL8 M\KG<)96XN-Q<1&2P#;<8FTT1=E**E&Q3"?8NVVP]#!MDG"
M3DH26[E\D512X4KC"09D(X3AQI\-W4)?KPZN, OO4M&OKA?,1J; PW\(G, M=NF!"1AD?>(B/=INPGQ'_<,F <,-_,!WP=+ VE;RR'#A.A.N($4&GB= "&3\ M7!
([4[#9X.*V/HMY9/#L7@YV*FN>5'+6:-7]4^C:>'!/BH<1["Q6ANE74- ! MBH8+UJ+94'!/"H59(*((!<)EC@*U#D[!3/>SL[Z4>&:QYP=BY=/R/'&0GZ+9 MU_/#R$=NJI>22"RAJ7-
^"5ZE\O.]_$;+=7:FMI!:RSB[# 3WA3(OP.=+*?7^ MQGQ!>R@]>K+0IA85+LY[56R/%TC4JBQF+HG16 M"E5-;[E>6PKQ\DH5^NI[0R?<;OZCUQC8W9C=76[&6
M]]+^MOUJX&K6];)4I:QJI2MBY.IZ\I%>WL5)T\!9_$O)I_K@-VE<>=#Z6W/Q M>7D]B1I$LI"Y;;H0\.]1WLJB:'H"'+_O.YUT8S8-#W]_[WOSGEPYD'4\E87 M_U9+N[F>S"=D*5=B5]A?]-
,_Y=XA!S#71>W^DJ>];30A^:ZVNMPW!@2EJMK_ MXGD?B(,&-!YIP/8-V+ !'VG]PWX:T>()PUB%YG6%1>'.V'%S9713\0TUM!; M\\,%T[4&]U75S/N]-?!403M[_"S>]D M#LVI:\Z/F_ W=,;*R1-
0UN'F)^=-V$.,=-'OQLMZ*7%Y/ M8+/5TCS*RSQT-O$"/&TL[H"&7@,85GM[Z)+JPU)BSLY]#9.V2 DF%$TQT.2="%)@B'Y7#W"-&FC)#I5 MB3_D(AE.E6\41XSBN-(.5QK$]=7(K5!+(I^!>FH<7.J-
2RG+!N 0(Y8D.+BL M Y<%P7VQ&YC/_&A_8P S/S!Q,L#GVR11C,.;=_#FX67N)&-+)9N+=>P%3%X MC\PNC7JRBH(@[^1* M L ET%&N2TFL>,97X+Z?HQ!&!R':TXYO1>>4C:
\H%1Z>A6V&;S2U70?T_;& M>&#WG1XM2F]'8T9C,T][/J1!"H(]#3K2V)=SL@4!8%UV;*AB"P+/NCR, F;^ M#DFSX4K%K+)D#')/:S3,:U\ L+"J6I-"@NPCIM%W4[V:[N"B#?(X<.XGSW2X
M@C&C138"N^SV$T>Y4\+6"5J$)94 "H1J5!+GRK2'VOWHZ=[IF1 MAJGQ?J.-G5II2JC:'O!-@-!B,O=RNF]%#[/2,;Z>'6F8'N^!JAMYZCRO78;L M="F^B'P*Y-E*#
(PJX2/\"3K>9*%>;+3TUOQXL0T6N,@',DS.D"(6:712#Q9 MSY$LS)% *[>%?I%R:F3A:D_]4*BUL&,%)O.)+ _5*$]1H1.^R@VHQS(X03+.3
M8<7+?)9CB_F04S"K+!L#V',A.\&%1ZKW(&V@2'U>@WSMS3IB%<4C\I?U],?" M]/=CC^VT"F8^G3$ZY#S$B/(1F#WCL3 ?'6OA4P%%6(IGBV&Y@YDQ%H^0&>O)
MC*5!MOA15^LV;Y[B"Q9DQ3JRL!AM1Q?$CEB%$:C9QI ML)[36)C3VGWID#G"*+"I0C'[' ;*PLLFB%5$1^0'ZYF.G6 Z62G8E96V'6PQ MDI.1*B^-HR$C8V9S4(DX4-Z3' ^3W+
$.!%4CA#98LC'B!%G(\4*[\F.A\FN MS2>OGG[NTQBC239Z6$I3_\55[/8%3?T\2,MO3?WOU=NQZST[\S [?S%+50GS MTKKO3GA__GQ/H@L:@=XUY%$4.TD@,;0&'UY]_GM)Q,Y"':+^ %YAY_'!07([
MU >BZKJ1@O2L3'K!L\."*1NVTKW@*E[0Z?&U@5=M8C8CXH'WXH&' M*^&/RZ5J)+]1;D$8DB[+:"/ M-RQJK:VIC%EW@8X97;\YJF7$7%81MQ;G7\;)%$BK#7J86?=.9W5Q$NWZ+LB M7SR
BAPR F*5)6.L'?<:(PYKC)^;DV9@:J,A*")5 520];X"5?L2P?_11]B ME(YIH;A7%W%87;3DVH89A>;7R"F?\R$VWVI.1!]"]LP?OY'YNZ/P$;#^RU#L MI!
S&S\IC!L1<'RGY\;XY$GJ;9MRFORWI_<$E5"9C=E^V;G+9N9/(&]V&Z- M?E8EY+'BA9RQQ45$'@[?N+-+Y!?]^YYCM+C#&GQU\KE!*LW:??=3$'5FU;[:[MN^VG)9_HY:W[F-P_V,<7][%,?HD^?
XURJP?HOV6Y2=AUJJJH6I8P7#1108A M->WG(>V%U5OWP<2#ME:7[N=&"MCUC0$\7VF0O_N+9H#N(YV;_P%02P,$% M @R(!F62S)X*2& @ Q 8 !@ !X;"]W;W)K>6GBGJU5FLC&"%
[A6H%NRI*I7SO9U2JV\2[@.\>#'HS! M9O(@Y:.=?,Z77F"!4&!FK .CVQY7*(0U(HR?G:?7;VF%P_&S^T>7.^7RP#2N MI/C!Y+AEC3!W\O)NWP6UB^30KLK'+K8P(.LT4:6G9@(2EZU=_;4
MU6$@F$5O"),).$/ZK8-X)YB[1ELRE==KIK R!1J>,7$![^!^@"UK1 MP"OXPH6@X] 3.!M.$]\0G-W"SSJ0FQ8D? -D@_44YL$$PB",1N2KT_);S@^ M<_+YL=RGDO1U"?NZA,XO>L/O6M#
[[8!7PID"G-N0$BM<32WUBQV9O;#V:<\X/\FXDF5)7P*](]GC!&JF@%"U<4>Y9Z)!J%&U9S7& MW)I?#H""Z4OHTS%'U%%/'9VD_JIR7E'#Z%ZB";#&%%+QWYB/4;9FBP%!& T*
MUV+^)>B(<]%S+OZ/DVO=C#,N7FT_"Z/@!>-84'@YSACWC/%)QF_4N'73,XZQ MQ:^W#>(7:*=C6C)_T&-L?__"U(Y7&@1N215,+TFNVI[93HRL7=MYD(::F!L6 M])M!90-H?2NE>9[83M;_N-
(4$L#!!0 (,B 9EF'%:C8:@< .,@ 8 M >&PO=V]R:W-H965T&ULK5I=;^.V$OTXA&1466 3B]2' MY30)T/BC#=*]76S:VX>B#XQ%V\3*HDO1SO;?WZ'D6#8Y8K:W>=E8TIDASW#(
M.23WYEGIS_5:"$.^:,JJOAVLC=E>#X?U8BTVO+Y26U'!EZ72&V[@4:^&]58+ M7C1&FW+(HB@;;KBL!G7GR2 MJ[6Q+X9W-UN^$H_"_+;]J.%I>/12R(VH:JDJHL7R=O #O9ZSL35H$/^5XKD^

```
M^4TLE2>E/MN'A^)V$-D>B5(LC'7!X<]>3$196D_0C[\.3@?'-JWAZ>\7[_.& M/)!YXK68J/)W69CU[2 ?D$(L^:XTG]3S3^) *+7^%JJLFW_)\P$;# '0R8:Y#V&,0'@]@U2'H,DH-!\K4MI >#]&M MR
X&61/[-EA-I*?<\+L;K9Z)MFCP9G\TP]580X!E93/KT6CX*L'.W$U45:M2 M%MR(@CP:^ -I8VJBEN2A6JB-(!<_J[I^1R[);X]3GH1DP^J,NN:S*I"%(C]+&P_#M@/(2+'
ML+"7L$Q8T.&CV%Z1.'I/6,02I#_3KS>/,3K_KO7Y_]WZ63#B8X[$C;^DQ]]_ M8('38B^JG4#'MK7.&FN[DNWODCAF-\/]:&8'CFF08X_:IC*9*O54AJ,8HI03'*'H@^B>4H=BCXH'2=.L.8(B,413C$[
M4LR"%#^)6G"]6!->%5!A]E ZMW9%(^(+%.,:']K,YYTXJ3E%,*E#:.9C1FYD MY@B&93CGT9'S*,CY$>JRK%8-99 'GX6Q3R'"(S^Y3CK1$O8QZ7K@])1@Y;'T(S MERW64L]J1:-.FT3A45:J>
91<4(3U1:1G\Z1.W\1D%M]$ B-7$=S!#6*>@:6 MGL@P&J3ZBUD+C8SJ>ZB\D-J[A=GIESFN&JP$J88-^OTK+?U!_T2#2#U:E\PM M;P@H=;,%P8QC=TU 0&S4LR90U@61!:G]+%:P)D
(37F0L39HV'!]LM6V!4?YH0\;%0L;8SN_2N> M^F:$+\$NW7(^14!QXF4$XHF-$C=,""IF?7'J-!\-B[ZYK#AD/4R,E\KXGE0" M7T@1 >@*TRD&RKVEU >-,E?_(:
\RGOX=@*0AA7@PVDVD">Q5%J\I(CA7]#9 M?_^*S[X,\<4K*ZGL>L$Y TK" ?3L)#+IY M7,$. 5\Y$.DX=@G[F$O*7,:((W>O,<<\)7T9TFE'&A:/C_8 PQY87+1;(4@3 MFRRB.?6 $JQ@MMCC$(C)EE=
ZZ4G#VM,> KRVT$ZH+P,OX[%717W4R%,1B">: MY=Z:B<&BG.%L6:<\65AY>FP)-T;+IYWA5GT;12I575I1H56[^9*5$5:JH>*" M^9K15=E3!.-N.Q#()?1_E M+BPSS!--/+V!PB+6EQ2=O&2M*
(M[0C#CNH*AKE\" *D/0SU0J%T 557_]U^ M7JNR$+J^1H,35+3_<'68OJFWV9MZF[^5M_/!ZY0Q"ROC>U[+!3H"K5U^FBW1 M5>P6-
006747N@0CFC%ZY9RMSO,UQSR+-.DW,PDIV*LN=00_0)P?+5VGZ,(PF MX@RCB;;92[.3M"P-3L3?F_LBJ-!\#WN E2#5;O,$D]$>W[:7$[#Y(9O#=<0[ M?.(%5?,_GGAOZ6WVIM[F;^7M?+
Z/<["VKE_XOEB%K2L*Y]0E+M7G>&^W*,; M%$5[-MVL4\\LK)Y#LPXY_$0XHJC4Y8BB/(X8JI>CU1>]E#3"HD5HL[?4RX>U+ M>\T,D[:U;;SQYNH9YC2\JT5[WO4"69Q>6RZ/.]SZ>(%Y1>;0/B\*:;W
)UFU MU_#69RU@R5!&$+JXPG)\>'*?NA%ZU=Q\VS.D767:VY;CV^/M^GUSI^R\G]#K M*47>S^CU''O_ \NO9S HV)R#M/]^9PNJ$%Q-S(-:#JIC%4!E
2L9IDES'B@L=Y5GP+6V>F2U*H6%IF=LJQ>W;'*1I9]%5=' \B4V- MWA'G6<,WL )\;I:6K+AG*84"[831S$(UB^ZN;N<3'Q\"?@AHW=&>^4K6QKQX MX[&<18D7!!(*] RB&3\V7-&?4H//-X?
V+^&VJF6-7=P;^1/46(] MBSY%K(2*;R4^F?8;[.N9>K["2!>^K.UB;RACL75HU!Y,MA*Z6_GK_AZ. &EZ M I#N 6G0W24**A\X\CRSIF761Q.;WX12 YK$">V;LD)+IX)PF-\;[8P4)4F@*
["?/DB'RKL7MTO;U&:,[=H@34'8UO3; >L#Z+PR!@^&3]#_R/*_ M4$L#!!0 ( ,B 9EFHSO%B" 0 (/ 8 >&PO=V]R:W-H965T&ULK5=AD]HV$/TK&C?326;"V;*-
C2DPDP,RS4ROOV_5*&NVY^"K7E"KT5%=,CKVU4INA[\M\ M36LB;_B&,OAGR45-% S%RI<;04EAC.K*#X,@\6M2,F\R,G/W8C+B6U65C-X+ M)+=U3<2W6UKQ_=C#WO/$YW*U5GK"GXPV9$4?
J'KIU,;7AX?NS]X^&/)!9$$FGO/JC+-1Z[ T\5- EV5;J,]__3%M"?>TOYY4T MOVC?8-/,0_E6*EZWQK""NF3-DSRU0AP8@!^W0=@:A+9!?,8@:@VB:R/$K4%\ M;81^:V"H^PUW(]R,*#
(9";Y'0J/!FWXQZAMKT*MDNE >E(!_2[!3DREGDE=E M010MT(."!U2!DH@OT9374'MK710[BCZQG-<4O?V%2_D.]=#CPPR]??,.O4$E M0W=E54':YRR?
7;!W@Q0&8>Q8S_1Z\\A%Y_]%G__GZ$=B1%UU1,9??,;?K]"I MRC;QE4Z\*\&-B\2XT'UI-^E%63#R=X>JG8+2]!@R<_C!R2 ^1LU=J& 0=J@C MGG'',S9FT1F>OZDU%2@_*O@CWN\1
RG@HU#D:>@2(;ZDH^[V0[DA.1U[$$%2 ML:/>Y,TUG\U=R=I2D?I>D_L5BG&Z%H"S_AI0@3%:DV6B* M/Z%)ZI[ERDKCL']0+#BU"FIZBNF%_;Y5FPY09E>F X/3R%V82["]L%<4ZSY6SR<8L?
\3%_PS!WBN_OF M=GA'Q KV$531)80*;E+(G&@N7,U \8VY42RX@ON)>5W#)94*#8#_EYRKYX$. MT%U[)_\ 4$L#!!0 ( ,B 9EF24M7)U0D *Y9 8 >&PO=V]R:W-H M965T&ULM9QO/?NQ=6]P-
+8HH) "\C.?OL=D"S$3#,"I^]-8MD]OQZ81PWSJ,752UY\*S>< M5\;W;9J5UY--5>T^S&;E:L.WI? MS&ZN=O$3O^?5[[N[0KR:G2CK9,NS,LDSH^"/UY./Y$/$G'I $_'OA+^49S\;
M]:$\Y/FW^D6TOI[,ZQGQE*^J&A&+_Y[YDJ=I31+S^.,(G9QRU@//?WZE^\W! MBX-YB$N^S-/_).MJ$!6S5OE:=G\:[P<8^<38[4O MJWQ['"QFL$VRP__Q]^.).!M 6,\ >AQ I0'4ZAG C@.8-
(#9/0/,XP!3SK#H M&6 =!UARAKX!]G& /?08%L5&E8NI%F+!=-3@PGD7-;+<#SJ!X8 5-'[CS_&! MMJ9QMN)&7!FW?/7>8.2=0>>40J(^,.V&65]9GF\&C4EU%U8W3 ?"*,.DV
!$&42*D6%:M3"F9O= MH @(9@P'S@7 M"VG= LR$X8"$$1#C]%SS[)-0;*U0HK+<-W<>XO;[<#OV>M&#%*)EC;W&V>HU M;BY=X3#S>9@P'Q,68,)"3%B$!.M(K>L-;";M[9+7O1VD*
>X.$LWXDMMZK&2PH1YF# ?$Q9@PD),6*1?\8[Z MW)/Z7*WZO&PM[?+O^4YL)^?-=I)!NG.562R8(PO/O;S+5SET(;;34I%2HZ:$ MN:Z\RP?"J"M?
M0,@"MCEJU&VNLM7@ZRS[4MG+FATGQ46H!*"U%I$1:MJ]DSTYR,MPK_M<\NR)6H5<1RY?W_ M,4I;1@"2J".F[!8"85-BSFUI%^E#<=1>2%D#* PH)4"8[3(I9P1%G6UONPO3 M6KADI(=
[7D\N+Y 6/KJ>T$'U!#.GATKS46D!*BU$I458M*YL6ZN;Z+WN0?8A M46UH^2VZU.<9>_.+2O. ^=NN7(E0O6I46CA@_A$0X_34M-9:)GIO^4WN(0%L M3&JZLEQ0S694FH=*\\'SP9A\A4/UFP?EC*
HTGC MTGQ46H!*"U%IT86%[^JP-:.)WHU^@X5#5$\4\'".4?K=ETJ"7!P@#+1QH#C MQX'"H-V7&@8X.4!4OY73NKI$;^O^B)6#:1HNB>H:0ELO5',7E>:CT@)46HA* MB[!H7 (
R0J:LE"+B:@)VPQ4RXFD"EL MNXJ5,\P5!L(6UERQ<@#SF/:T3-#6%Z9Z7WAP_Q>X0'KXV'I"!UG#J#D]5)J/ M2@M0:2$J+<*B=67;6L-4;PT/LG(H9,S:CO1F7NI3C;T?1J5YX"&82C<8:M(
ME18..X0("J-VS\T2/>LVUEO5;[)UJ.HI3^7NWZ4^\6C9H!K4J#0?.AVR)Q>@ MI@R'I(S H![!M"8QU9O$4'/8J@9?51:@$H+!YR-""MC5U:MB4WU)O9= MD:\X7Y?
&8Y%OA99XL4K*IA+FNZKORXM4]3%E[U"?=K2L+B;T4!/ZJ+0 E19> M/AD15L*NJ%I'FNH=Z3=_,D(AFUCY B%JGS0JS4.E^:BT )46HM*B"PO?U6'K
MP5.]!W^W+U:;^%#.CGY94^;&:1+JNE7<"=1&:RBE:,_S.2&#G-N6_*JJ%&,N/"JL-;D9AC-S^#JZ,FCO^(,.=RF_ TP MU)P>*LU'I06HM!"5%F'1NIIM'6[V@\W/L%S!?E^YF#"@^5DN)@!)%!,J;[F
M,%%,+"*W'$)QU'$DOR: PH!B ATFL^0-$'0(\[[G);2.,D-J?H87"+7YF4'- MS\R5EQ+56T:E^:BT )46HM(B+%I7MF?/^4!H?F:JHSIE[EPN'ZCMSZ@T#SH" MDRWD:H3[L [S_T,/- -
\9KE+:ZE//%HRJ+8U*LV' M3H?LNP>H*<,A*2,@J*]!D+76,=-;Q^,^W]##1E_[5 M4_F --:&'2O-1:0$J M+42E15BTKD9;'YKI?>BW?+S!5"-4OO-=ZM..+FF7,WJH&7U46H!*"P> :<'B%(W9VH,Y/0
8:#3 \4!3@\4!FW.@,-4G1X@ MJM_I:7U9AM$;#:\.:F\T@WJC5:<'M3<:E>:CT@)46HA*B[!H!\W.SAX36S_) M^'-#G[Q="$\7AX<"'%U6^:YX<^Y!75;YM?MSP>,V+.D#\_3'/ MJ]<7]<-
H3X]HOOD+4$L#!!0 ( ,B 9EE*T#J1M ( (( 8 >&PO M=V]R:W-H965T&ULK55;;],P%/XK5IC0)D&3IMD&I8VT7A \ M5%2K"@^(!S+'E[F;5YU_=-DH&@IJ5RD'BR5%I0BUN]\DVN@:8%2' _#((;7U
FO;A7R*8Z M[JFUY4S"5!.S%H+J_0"XVO:]MG<0W+-59IW CWLY7<$,[#R?:MSY-4O*!$C# ME"0:EGWOKMT=1TZ_4/C.8&N.UL1%LE#JP6V^IGTO< X!A\0Z!HJ_#0R!$ M;CQ6G%YMT@&/UP?
VST7L&,N"&A@J_H.E-NM['SR2PI*NN;U7VR]0Q7/M^!+% M3?$EVTHW\$BR-E:)"HP>"";+/]U5>3@"($\S(*P X7- ] *@4P$ZYUJ(*D!T MKH7K"E"$[I>Q%XD;44OCGE9;HITVLKE%D?T"C?
EBTMV3F=5XRA!GXZ&21G&6 M4@LIF5G\X26PAJ@E&694KL 0)LGX<A&^X$6'3!3R&C*6*:0-^-%I_,<3>!\S4J(IW@'0F#,&KP9W@^O-,4SO]9'_^S]2?)Z-1WI%/P12_P3>B.
MB;4@/R<@%J!_D=_DFTZ9Q+Y"9AE>"5,?-97^)+GK@UV3TP3Z'C8Z WH#7OSV M3?LF^-24]]O ABSV!$3.U1ZP M/E2F9 /&/?+[V;SQA986;@L+;KILXJ!UW?,WQ]D_0V=TAL[XM$Z9 O^HJ0G0
MJV*:&)*HM;3EW:VE]<"Z*_KT,_F@W1VV&^0C''#E//I+7T['"=4KABGDL$13 M0>L6>ZXN)TZYL2HO6NI"66S0Q3+#(0W:*>#Y4BE[V#@#]=B/_P!02P,$% M @ R(!F61%#I<:3"0 4C, !@
!X;"]W;W)K>?Q5[2B7Z=D@S<3?:2WF\F4Q$LJ>' M6+SG1YJI7[8\/\12?3^;K08H0W=QJ=4?N$O MO]'*H)GF2W@JBK_HI<).1R@Y"6E?_C;Y4C+AHH'K@!KAI@LX'?
MT8!4#/"6,;WMSE_0;E&*S;]H?!^T5KYBV4Z M4)YDKGYEJIV\7_%,\)1M8DDWZ$FJ?RH*I$!\BU:QV*/*I($&J._GD+TYN>W MZ&?$,O29I:GJ97$[D>H1--$DJ6[W4-X.=]R.H,\\DWN!HFQ#-T#[T-
U^Z6@_ M4:;7]N.S_0_82?A$C^\1F;Y#>(I]X'E6US29;MR_#+)J+B!.KFD\6$:G=MNQ#%.Z-U()2]!\V$BR<$BR:""R5E_X=5_X+O;[W]4DP;*$'RAZDW(AWD+]4%($!86>$I[OQV0Y
MO9T\7_K7!LWG;4@(\'C!PF^C(@@U7> :U;)S5MLY<\;):PE*+,=(#^65],=%XZYOR9J12 UM\1+\-6)20P6&=#!NN09.&09-% 9*U. M#.I.#)S!&E)%FK"XG/NS#8H//)?LG^("U"PBE/!L:
<0M@%D0(W!MS-R, M_\C&+!9S.&CGM;USI[V?#L>8Y3IH]42YXWSSHJ9$R-"Y=?-@:@Y0&V,@0AOA M34V:R ;-+S M.Q>UG8M7V)GR;#=.E:Y3_2L$50.VZ.KRXYZF&Z2$*Q)Q2B%/
M+*S'&\\\PQ,VQE\8KK A\YF!B6P,\3H\L:P]L>Q-Q\D^SG94"R#>3)2-(U(6 MKUE:3)J0_4O@H8P\O+(Q8XS-9 V /"OH 1 )?-@'WK01B].><;ZE>:[ZOTK, M,OY&!?KEIP7VO%^+Y*P=<TY'?,D>?)UK%
MHL.^1@5[3F%7C'6M.-";G0KBMVB;\T.1UG027)^$@HMJR)L9$?0' 4:UF?D@ MD#G9@438] @$ZHKO1HQZ_6K4TEUO3J)(!6\O\V&]< !=X=O3X=(:[C;(B@V
M9VYYP@9YBZX4V,A5SZU7/V7/5%RS1O(&U9V#LH6#LD5#L;5[I-&>GEM\/M", M;IE2GZF*14G5+52L\E27HHKP1/1;-7,7\H0FIUSUVC]ZS"8)/^F%AQ*OE#W' MZ[0C;&T)28B5L@%0@,W
M4%+4P5% ,B;SH*.R&TTJ^<6K8^G7/E!T**XH\:Q M&K/R^SMT3..LG+?IWR=V+,2>_J9\J9S&E$]>]QJAZ[F5[F/.$THWXE\G>T![6NZP,9ZI^"$>RQ4V)NB:_!J=Z[F%
M[H=$14&IV"X]0,6[0M^I2\4\$&M8#I;P'CQ;?)I+GGY("$#&WLQT@8NG71!L M1"YVB]S6.&%%NB_+$SH(>*%]NOL?0UK5,![""F$$20J"9J68AD-\QQ>%&S&*W MF(7'PH4G0,-
MI>F;O0Y@S%Z_@B9R/_X/SC>XD;_X*OD+Z #0+[9"M=P"J&%3 M[/?31!!-QZ2!&RV,^[6P0_A=[05;E>+ S(L R#.+D"$ FEFK7P 4!!US!&Y$ M,/:=TN\CR^(LN4+Z8:>8?8JWT&Y0M')0M&HJMW2.-
&,=.:5FG:IV?Q#Y6MRAS M5L:S<<(SF2L9J/OKK OAV)SUC]!>2 A QH%907?RM'W0R%_<4WME>EQF*ET? M8[8IBN2OLMX6FY;UO9 0@(SG9EG.R=.VOA&UV"UJO]!C_/URS(( M-G0M08/[!2P
F=M]W\L3]?"TMW$;"4O<$K8]*OH-)K:.- T&(&-L6=Q/%/41 MM4UN1"MQB]92E6V!*1HTN%>)K@#(>!Z8]@(@SURG@2#2(&;[ I*QGKG'$8$P0CK4&;DXN^!6JG_F*M>GU19DO:F,U+=RP:HF
M@>*#KG(\JS5-QSJ& "+4VK$#0&-BEFLAD+FW$4&@9<Z;$9SQL&B![&E'<;FSN0*0@5SRTTVBEC[ M@!'$M2!=CFKT).DII_ZHHZB664X70654,UNN )1RI.6B:[BB/JZVBQK12>;.
MA>"7ZI!*=>#A=9[*Z5'-QV5E6LU92G9=G,!;5\XO#O1UG+UR"N)7'[X:DBT< ME"T:BJW=RXUV)F[MO'K5M '4:X'8!@0NM@KA5W%%?5QMJQNQ3-QB^8L1KBQ+ MTM.F#-
=R$96<\KS8).@L@I)^_0Q S))7/TOD9&D?NVNTL^_6SG]R&:>O&=!* M7[]DY]$LSD=HZTKY5I^@!0_OV4(8"!D !:3#J[BB/JZVQQKI[7O.=/B[KC (% UHH" "VMFAH \J;+KJ!NEA.^>SEQ+JNI-
7.2QOK,TVLK:]4- M D<6!""!=3:WER9RTY0.F%R\(W"@^:YX.4.@HDO+$^+UU?H%D _%:P_&]0?O M9N4!UT/O)BI?[VCHR[=-/L>YDM "I72K;C5]/U=]E9&ULC51M3]LP$/XKIX@/
M(#$<4EX&2B.5,K1-JU91L7TVR;6Q<.S,OA+X]SL[;=8/I=J7V'>YY[EWYYUU M+[Y&)'AKM/'CI"9J;X7P98V-]&>V1<-_EM8UDEAT*^^%;A[**H$:++$VO1".5 M28H\ZN:NR.V:M#
(X=^#732/=^QUJVXV3\V2K>%2KFH)"%'DK5[A >FKGCB4Q ML%2J0>.5->!P.4XFY[?34;"/!K\4=G[G#B&39VM?@O"M&B=I" @UEA08)!^O M.$6M Q&'\6?#F0PN
W#WOF5_B+ES+L_2X]3JWZJB>IQ\3J#"I5QK>K3=5]SD M#31^_V)FU!MTJKJ"' M,L33C]V@';9\$H=;_#/OGXB9="ME/&A<,C0]N^:1=_W:]0+9-D[NLR7>@WBM M^:5"%PSX_]):V@K!P?
#V%7\!4$L#!!0 ( ,B 9EG?" .&PO=V]R:W-H965T>[ZS=1=OA'Q4 M!8!&3R7C:N056E=#C%560$E43U3 S3S&)C8C+R^MW7JVD!>ZNM^Q?7>XFEP>B8"+8+YKK8N1]]E ."[)B^DYLOD&3
MSX7ERP13[HLV=>Q%Y*%LI;0H&[ Y04EY_2=/31UV (:G&Q T@. EX#6%L && MQRI$#2 Z5N&B ;C4<9V[*UQ*-$EB*39(VFC#9A>N^@YMZD6Y?2=S+',\ I51E3*B5!'2.[N(AA_=0"/3I4"N
MP4L^?N@/_"]=E7Y/LO0]R:;O1+9W)U%[)]$A]N2'F1$W/!,EH-/O0JFSKGNH M*0:.PDZ$=7(>A9>*=9E2"7+HI MH% F5ES73[+UMH/FVO77%_YQ?SCI=_A3,YCJ.?*7OIYJMT0N*5>(P<)(^;U+
MTRME/2EJ0XO*M<('H4UC=0-L#L+X306\,*M.,Z^0-02P,$% @ MR(!F6;-H2W%- P U0H !D !X;"]W;W)K&UL MG59=;]L@%/TKR)/VU,5?2)I]#JQ%SA@*=U5ASX:=ONQG[I;Ok
M=RPOC#7XR:RB.=R#^57=*NSY/4O&2A":24$4K.?>(KQ:AF,+:&8\,MCJ@S:Q MKJRD?+*=FVSN!581<$B-I:#XV\ 2.+=,J.-?1^KU:UK@87O'_JUQ'IU940U+ MR7^SS!1S[\(C&:QIS*!QEB#/)#08D
T4>%,V8R,E"*2IRP$ 9/?,-KF#G^6G'=MVR14?88O)# M"E-H\E5DD+W&^ZBLEQ?MY%U'3L)[J$8D#LY(%$1CH@NJ0#MHX][KN*&-C] . M>7M&5B_D1F1LP[*:\B'G6]+Q,*F]
<%>ZHBG,/;Q1&M0&O.3CAW :?'9('O>2 MQR[VY"2;?':HF/0J)DZ^!V;XH PW[.OC[1GY-;H?D:4L M2U I>[O!K]1,>S53)^U=S8&$P6KR*3P,)5EDLC)OSU^KTTUH5 T.7>>]KG-W MK*3X]
YM;M(UY=HE[J(7=^'D:038#(KY8C"4)^!UCEFI/=9A?-8V[.UT2+OL MI5V^*YX/H##UT2/;YN8\$=(PV"?*X-U!=0L\07PJL.%!+@_=M[.3X8KN"8H?
M5*5%&]3I/K@3E[QH+R]R'YT\5Y"C+K+84,;I:CB5="R3AL66(9OD(KZ6*Q/^%?EVC[4KRV[!-QZ,ZIR/Q0 *DX%82)E-<9Z.YI(D:2%1 M>68_ MP%^L)94;?&$-?
<:WW10%#MJW1ZXXRYM8Z=&04O_@4<>4F3>UCD:R6I@V8??6 MOIY:-%7$&_NUK;.&[-'5'!R)C3AL$9YP>@< MXZ?:&JKM&%DU9RR7]02P,$% @ MR(!F62";$J5("@ \AD !D !X;"]W;W)K&UL
MK5G;W5LJ+;WE6N(ONVOOR[/C8)6N52]J\QL+KK#;OWBLUZM/;TXOCPOY4K=*G]??K)8'3=24IVKPFE3"*N6%]VK MX=GUF.B9X&]:;5SK69 E"V.^T.(FO>@.2"&5J<23!(F?!_5691D)@AI?H\QN
MLR4QMI]KZ>_9=MBRD$Z]-=G?=>K7%]UY5Z1J*:O,?S:;WU6T9TKR$I,Y_E]L M NUHU!5)Y;S)(S,TR'41?N6WB$.+83YX@6$4&4:L=]B(M7PGO;P\MV8C+%%# M&CVPJ$U?
FQAV@B.$ZBF.L@9O2" MF%/QIRG\VHE?BU2E^_S'4*G1:U3K=3WZKL!;5?;%>- 3H\%H\AUYX\;.,R2+3,A .G0FIX)];R08F%4@7) M+*4%'41ZB'0R5Q2QV%$Z?B.+H@+W#X7VQ4T084I=D(;0.)
<%DI0^]_C3L\H@ MHRC=A,PR45#29-@SQ>NDLI8LD^D_$=.!N%")<@Z50'@CEE+;;!MD/9)?&J=# M!K,HAWQC#%&8+ /(JSOU ( )2EV$6D4LNDBR"A&)!T@%$G]5TGI%6WU6I;&>
MP*+T%L/!T5_TWQ]BJZ0]4MCKIL:4-">=W@87L9]G;]R/@>RU8!.:\/E::7(1 M+,[E%R64\QJJ*L?&28?:6 :3_%H"Q^62X*2]+:L+5IF;J@@(@%[1)IF6"YT! M)(4%;>&W+"_5+LF,JZPB:FCK80FITF*H-
X8@(<-6*2L$CA?]3#PO*675@RJJ M*%A]0_=P6*15@V+#1$ CUJX23U%9>S8Q54:JPW0KEM;D8#*N!57__^T8F3G#
M+#I5[!Q(5%B;7"="YV6FDUV<(;JR$%MD6^+K+X@U4MX"U"2&O=.K0B^QI#V0 MWQ7CWS;D"BB5+'^1*0H*; U3?T)]TC$WSN]M\G(T695Q8AET+(0_&DD-W8/, M*ME*K\0\
(*TX.K9D[\VGSZ]D7KYYUT0;FO<719J5UJ05PM-2YPM[KHQ)-SK+ M>DSM'.WB9*9( ZZ64;4,PP"LPE*'2G-?<+V[)1.Q1X5OUDOZ*+\U%0 ?6NKN M9)#()KH33,9 [0$)4+13Y$Y, MEILQ1J*
(\@2X+B+Z=IV8%7""/*LJY+U M/C$^AN:L+)3:K#4(D-]$@]+2:-\7OQ&<10BS)&8V$K\@"3)-@8H#H(DU3<"E MR)_,E-'/J-P;C"RQ@FN[%YB02.I1Z6M"'U7.ID?(#9B &*^6($(!L,% 5U&X ML=*-
_OPA.)5>,U"<$G$'MGX_M'*Y%^%PA%*3())!94[F@ROP@7>PM]U\LP%*<#['L4.S'YY]+" =S2 A'PA(I MY>L2:*LR]H)8?E:\(L^N#$*F7ZM']%&5&@^!AKK71/:POBF02P6'([3Y,[(X
MM6)_QX+69Q[T:70\TW()I8:QHLXNO*PK8>Q2 M-'8)#$W 8X$HK2>G4"CJ4%F&'M@ ]#AVGFNNO-4.$.:0(MQ3]PX*Q5F6TE-QLOD2TA *I(G0I M6.)4 *TVT@KS8YV=P
3P7Z#%WBZ,;T83C636,)CJ_X,*W2ULQ^VY*2JA%5!L MQGVA._H\<'/4#*C1]<7;6-'J7AGC\<#TR2^X/Z ,_Q3W[&GLODQ\(FZ/_H%_?]3K3D)F/NBZL'W" M,*1-Y9IQ$^QOV_Y^W_C[=N?O&TZN(IY;-
]JO68RU1[G*QGIZ!;/5QNXT010JV9 M!/53Z^KFDM:MQ)JMS""@E-NZ#V:HUH$Z,1996!H.=#J!0SF:VC HM(X7O3A! MKU8H^"Q;%]1S"T&A;AN(6E#^R!P"LD2H?F-EX=.#X7B$0WF6@:
[']8D'@8/3 M>?VV,1];4RMD2 [&DQ>^CYO!)> =J@WA$N9@JC3H175X/88IF.S67)9V";]_ M"%)\UN)!BIKA4:XDG1 8"S[Z>'/$W?>N%0HJS%WU<,S:];@T/N@4TWL6G!TW M:$#O-
5B2JQ8&WOL*:NU#/246K %\?$&=D27'B2[JS6;Y-C"IYCH8C)2B[CRM MH8BTCJXM,9?8>CP)R8'JLT!)Z(O?S0;SENWMZQT+X7,"6JD09IO-([0;7<(X
M_Q,Y2IG9ZA2[0,!QVEBUGY0T1U!5<=$7^\8UTVW,]@:Q<#3V=,YPT!.CNH]EGGCOOT7GO^\+AA M=YXT[/'3'C[NW/=OQ0&Y)Z:8$X=(&M#1;D@.ZO&QS[WN'-[75RVO.Q@^KYKZ M0:-
H#3,>RUTA?Y:F\]'3X8"/2 RFMK$* 61OJWK@H[@V3!K@/!"3$S$ @F^A]X MO.[<[-$O.()J(2B1\/ZL%G$""X'2VDS'L#9LO!?/0L%R9%JQ>5KP_'/$?/ M![7VI^+P=+XO:$2"?I663K>N%M-
R^R.!QJ*%T"F%/Z]-1HWAK$.W=$D\/605 M13,):LDY$(,^)H5#_$^:X.<$[[ ,ZF ]";^GA&7$!@- 2#@:Z.H"D]'Y#^6M M$ >#_K0.V?XSH?YB>.[%\+NZ&^YY_$ ,>S-@/J/?Z;1S9SQ=481+G\D(#J!O
M]' ZC9$<& D#:KQ'=&>P=VLT[LV'GL) B<]&:#>8>]W79,+#3Q@NNL/MV*PW1?1&FEEO/)\]HQ,?0@+]P6.8Q'-WTL>M>WBRA\N))OWC9_T+@*]_@[\O#7$!PF5QJU*U-+L
[ZLVDWW+/4"V]*OM5'4\4Q MGA_72@(G(L#WI<$Q(2YH@^;//)?_!E!+ P4 " #(@&990NVM/X8+ #) M'P &0 'AL+W=O2@?37GV]+LBV'P-S.>6B)K:VM M??
GV37[]H/0WLQ#"LL<\*\R;S86UY:N]/9,L1,Y-7Y6BP,I,Z9Q;/.KYGBFU MX*G;E&=[H\'@<"_GLM@\>^W>W>BSUZJRF2S$C6:FRG.NE^;]8LO MHS+C_V8.G'>'$I#)6Y6$S MGG-9^+_\,=@AVG
\>&;#*&P8.;G]04[*"V[YV6NM'I@F:G"C'TY5MQO"R8*< M_XC?^EFB]RH0!Y94J> MB#>;B C]+W8/&.?/M]=LA'[Z3_'H^'PE*T[ZA6[6PCV5N4E+Y9LP0T3A15:
MI$P65C&>99(7B3",%RE3=B$TXQK[YP+XMP:8L MF%U*GK.3:2E#2MN1[);5@ MFI#GWI1:I56"W]*R5(&J4!;'W8N>I\<1!NC1WP1H\LGT40H^Q.W'-(4J@*BRGQZDK+#'2S8BX3ELF$
K28,S[7PDGKA6V9(W%@RU0J(W.9 M<T@Q[62-B+I'N0658?[:SO32CV1'M:2K$I)V,M* M(_$Z%L3_:_^V3VY"7%B13Z%HQU5II%'75\A[4#EU-L3S,Q9A#X"7.P.(Z?5)T7\*8BP8D2BP.5[!>2#
M&"PBW4LN8^6K,('#E4LW1.#G@[7&V-!D2;0;X>#"&3 M!7L0%%8X5R.=,83KEY]X7IY>,/&(:@C?]ME-I4W%6ZNV9GX)>$$E'\HK&GF% MZ-1Y(7_@W'^DS/"@5F:=W#VB\3INM81.76=)\/R<6-
4"K :@%E3A21MI6%HA M-I;NO:"$Y>7O1W[(^9)-L9K)N9QF(0FDJ2000-Y992O= 4HO#]%NX*S1W1F2 M@#2':>>42EH+5"6Y9&N_]6J??>1(90M*PIJ7HK(R\=$YF4(CM U(6)\+=LTU
MB$;'O=7@6K.]AVA,^FR;LOYH<+J&PJT,3W=6DV>"JH*LE4'#+.-3I7U::&,1 M5+-*^R* C)T)2K;.V,U6*CY.6(367/.<]"9I70TZ.C7LZNWM[NWD?,*V[RY_
MVW6O#T]'X^.=_KJE([<4!6,G%U=%NH+BR&PN\B'%O4R%-UBP__"@L;_7B(!2 MS!6QBMDGR@#+A(^_)[-?HHQ)121EYQ(UX0^4I MAY+P@?WY2]R%7'CJ7[@>7
MKCC$!ZI8K6"K##_:M/5WO5@[NR 3,J+ M:H9>@8*" .?K NIB7#ZPQ,XO3GSUF*ITV93)4EF(3:'2*9@3JTHG/W6O"+V M>6,7.7?5!#(MJ,F(Z:#TY"60/HE"#]
(5=F46Y:3N6I.._DEZ(:!U\HO*>/&#E^B/V5'(U/$+%QH-*;7ANIL P*>A'&LKJU-7&"\2"B!"G/AA>ZBWOO#5 M9EFQ \'/M\-M7B+@MA7A\\L*4)7K=*=@#,SNK^],,2K+'ZI<@%QRMFT$()$9
MQ:X%A*.),QX& &9,PC#1+2_43!($ZI*[_P("BBB#="N'LV!@!LI$[=;]+'ZR M2+&#H_$.N_Y\,7E/P1_5^>&3GO_9K.BWO\^G'QJ<7:N4SQMX>9N33T*;C$T= MX4//6_-
_*0UVLU]SCD.@ZS9!4$+BM,=$KBNC,DS(W;IV?+BS\N*H@\Y ,LGN MD4.!.1J%JCGF;K++X!E/K-@$8T+I<)>XRN]*NY_T&K8U;&(?KAD,FE8?H)H1 MU9H)I!F?T(3>18US*4M! VLXBP#
<@0EBCK(2U%@WBQE*IHA[U[ V\XEM^QD, MI()W1A0(5"K3X>>B[D.52\TQ#P^/QJ?U'V?'G*=_J45?W]AM'1W'9W[2<.RWAB>KU&N;^#Z;_*^+TOYQ5)3(/.$ 5PE#
MWGO&F%J@HVYSYI,9Y;D6M -X*O%5M@RI*91C',&I&F,,\-FU4RQGXL$7RG[; M1#>QX%I&@X"AJ>)>%!@F@(@\"+0:%5Y2$X=" /Z_UR: 61#J$H*W([I76:CE MM7($1>TPWV8H5XP]6#))'K"-
ADV.ZE+CER32&"+9LMLY=KS4H_XBFOB[#0*V M)0LG\M:X[<>H&E6P :1UG@>@X1GK.JSF$L%7GIED)G2V:AMS!B&ARS*@3EJ*WQ.,9UG5;0E.C* M>PM>,
[8SD[L6%1(X"T2N'#M5WHFI]JWH>(TZZ6J1LPLXC>1[=S'Q04>-^NW5 M]MV!_*5JW,3FY.[N M\M/77Z\^79*>=Y-?=P^.]J/&YRH>PP;#YWJ;U2ZCV5_+^'PJC81IZE:&27.7
MVBVZKRC^@,M/7HIW=][K4T#AZJ,,V-QY]D MM.AHNB^BAJ8N\L1, FM:IJIN4>D+C-# ^[="/;C;G;O?=L>'@\$ '4V-L+:* M^2\?(GW:.!#W/VG@UW3T$V-$".Z/DD\IE=$]]
>1I4[96\PWK]A[4;@Q*:+. M(NI%34W3$*D 8[09KK[P=]N:$-D?UGDOI.NTF;"FZ*4*?]F*I^X-""&LX*$2 M7X<[;R/F_HZ%0I\J$$VC22B1*&MH(5,'P5#C736C2D;A((O,7WK5QS)4+Q<>
M;@I&P+FI^NEP(YQ?/ 9=]Q^^@:&K-73Y_^3ZAJ^W7J,__W>6?+71I8P)-MPV MHMK8=JWHEKNQ]GG:[&Q<%:2TTB3/\/"$#4<;DR2A'LV$N9S4Q!K*J]-G=(H_
MPY/QZ<9[I5)7_,?'.';C*J6*,I/.+$@$O/ #OE>^!]M;=GBTRN2&[L6UI;J9 M\1"1XGLE0]*B3<,!.]CX[";<,,,YJD(5N_4S*B84O*R=GRDX$_XB6_[,ML<' M!VQG]> [?]/J/1,ZCA0QJK")S;5"[Y9D6(9&ZSP4
5P &,N#%$V>$:??9C[ M?&=@Z1'^'0U:@X8NR[#MH\.G$GD58X!L[X]!MCW<9SO/*C<P4?^2VOSMOE. M/?&?9UMR_Y$;>6@N"YI>9]@ZZ!\=;/JNJ7ZPJG0?:Z?*6I6[GPL4!J&) .LS MA78F/- !S=?
[L_\"4$L#!!0 ( ,B 9EEQ7?-D20< "L3 9 >&PO M=V]R:W-H965T@&&>+JIJ0 V"NHJ0J M2^LDFXIW79*\>89(D)SU7!@ E*Q\?4X#PR%EK5PJ)Z[D@7,!T(W&Z=,7SME# M9S[9C=:.?6[JUIZ/-
\YM3VZKDDD1S/AGKW,\;$F"Q\][[7_V9\=9[I355UW] MCVKI-N?C8LR6>5VM;ON'OZJ^_.DI&_1U=9?V4-8%XL;.N:WIA6-!4;;BK MSST.1P)%X-Z 6$MSMLY*W\43EU<6:Z!V9H-
;31@S^JEX9O54M.N7$&LO7D MW,6UOM?M3K.5Z1JVZ%IG@).%$6[3;Z^-/9LY;$4"LT6O]C*H%2^H+=E[Z-I8 M]JY=ZN53^1E,'.P4>SLOO5<5WNCME,DX8B(6R5?TR>'NUT6OE^=NM$ 1!
M\'8#X:Y&0%7MFCEU5VNV/*S6EMWJ>^6WR^=V+V9W2.H\UMG!D76(9 ;.V5@ M.%/+944[J9I5;0AWOV][K/NI)39B5FO6=DXSGDY'MQN#UR:X7I/K&1SG='.G MS>"]T<>VCN!4N2%S&?
9UQB3$!BF$DB*<6HUW:M/7O(/H7, MU72[UK%:6\OH\#?!E_K' SCP?$>A%F7GP>9(] S\M.8$/6X<9&15I M_$W@_XP$\#\E? +3X!% M\:4/,)W)IUY(D\$+28DP2)F4,=R017$6
V3$7U)Z=Q2QP#V/B?U<1)*GWPOT M[TOX!/F%*)Z 7CS*0/F$"U9&N7@QS^0"&06L8PFHGSR#O) #Y.5SR/'V%'*D MJX119I&\ -)IE/@L XM*CVV4IX1\5A#5.8]D47X+TL&OZ9S]JDSERPS*E:V6
MVH1*\,(P-8/U(P!T[9(IJEZJ7>!U0L<5\?SF^@?5;.=O M_2N?GT30VFQ-9>%%7W+NO"C7SQF]T-4] MP0F%5.*OH$2UCS31K=OJ7YI465JU6.+'O0FA:6VA19-
```

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•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l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| G&,U ME*G-XET1H2*98.P)JAT6KX/ZINW?/(`^0(HH-LVH,O M D0:@\]O6Y1L&"BO2/O@8&?M)V*>"D2N]AL&1JZDPY@{3,BU0<&2U@*09)Y M-@9AO$0<0P!SPF(V*P,^36D'$$53=_KN^&,\;=R:*&&8E$="_ >!8$R'QK@WC M+O#K/EF1P1V"SO!U/R<),ON4;%0\I&"!XV4379O)#(1.(X<,"&\)8@|(+_]M+RF(,SA-1;F"$[)@%T3@Z &1?P3Z# MP2;$=_SLN\>$?@W%UGR'W'AIMEF%!<3<@QU @PR1J(.<+.*JP(?I04O:!C9= M6M5)Z&0UBQ:1GT+]VUGN.%H0D)8O6 A_JPM1DG@Y!S*H0C]FKP$MZ8 K8CIT ML%\:KAKWQR_J71=DZ, M-DJX11(I7&>8O ;OBPPPKM.WB4DES3Yl4('LM?AXX"|*$U08K'E7@^DY*&D(M:?0K=-.AFVD(L R>]T\ ;&>,>K8RF]J81)!<6S+T(:-*1 [WP[\:-;CJ,]6X-16>Y<-WD3G M*ANVG (@&;ZSUUIV!:D1E@)VL\&&6:6SGK7A 8,\#68_=1 <.W&0S*;5A0RC/"EO\'#OD^]+]L@"D59*+I0Z - P$.|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|WT)(O$W M M5I(M!\:#5@RXYB'-'FR9NT-@REHS6AX%_MRBTL9TVXX7*797184MPY+BN) MX1U#HIF%?^94[^5@&_NFD\!& +/A8+F9"G0\O31 06/)N:$E!04)Y M0/DF4$G'! YtBG0VMG.D:^)G-8D5"[(< 8>(4[*$!> ^P II\(AV@:,$]' ME\0#,P.-2$6>HD_#Z4/SJ?$W30$ZK? 6=P4!XA=8;\!%# QX"=.DR\I1K3X# M)\=[/"?R'VL\1Y]I2ED_DMNKE!4D#K=G!:D%_KS$:@E(6R!=B82]\2U@-0"< M;2]A-:6'WW>Q)/N&5_):T2E8%'OLP].W3I*BCDCI&'I:UJ].N&)NO-..$_ M9CM8%R9R<'Y5L:>7YT%=]CF'9.%K=4V(*L"'DR<C;7UY=G&]^.x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s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

9@:V*+H!]'3=IU5M[10I)'BFE6_+Q%-U..XY0\,G$DHI^E93' M)+'!:>^(+|%@AD*W0%S^!NAC2'#0ENI^L8Y9+C33;8NIBU5[G93T;G?'+:- MF5;=|@>*0NQZH').;+J!9X!T$X;'> M2VN-
X+"',F%.I,_)IIFBPC)D#/%I8P-TJRF\%5N-4"R.P1B>V;#IS2?:=[20 M! 8YT&29H&?O+D__Y]TOKTFZ @AB;7'R!4#U2B$,3O0NY.359'5X:4*N,1. MC0G\M+XDWKY%W)FD.)%P!R$R1AT\.!??
90M^=)QJ@ZD%FZ8!8%1*A7@.KVF7,\0@IC-S$#I'V MUG".0ZXM:8<5I8>/6+@?$F@\2W-!6!6 >#849LWT>I8T M^"%?Q(J>:_UGZMD"RNF;)T=' ;G??_STY/!I^"="^^X!%Q=09QF"/<1OV&EF
MH"XVR#J ZK ST9FO^*H*OOSXR9%"C^1A5 AG:?N;F=Y!OTV-B-|TV=E([1]U MH]BMWU.3.M$-1S0TZ&<0:&UC$VYE<[23=LLY=4JSX%U9C8.J*W?
_]EL1CTH26QHCUFT>9R*_GHB:JG&%O)\W3*^/^.M>4)/8S+=[:^ MEL2*0'D,L+M^($!^=U8QT\$:NSG1/281U3NW2TKYKVSO-]NN/2KQK]O;G1OZ M(-?6"$-
UZM=@&C/+D=X>XWMKFI598T1_EH2/-48U- OCVBQE*)D^CQ>!_F2M M@JX(7C5&[A|Z+H:2S!Y\3#F%VLUMK6&"L I=Q'M3@GVU($WGS:(>.!M)80G? MMF!KBW?
MTC0R79])&NP=8]DD*@)IHVI M6G(S*2@SF4)-KKU&5C%T)_=RE$!-;YIF%U6UMP5V7YIEN4M$]* $^T'N+[<6 M+R'%QFJW9R$E1A33M)R9U?M\X\J8Q&6(?#73.W3AEN5)"H*#XI;RNG&AC8ZC
M0C,E&'@:6D/,3H5:<.9(.)A02S_PX[$[#]?D'6)(4KK&C:] 1O>'U]AE>XZE M/**K08!$"1YKYNSGPYU>*Q=|SPM4"J=8MH$CSRY"LY4(Y6+H#*-&9'0)-"XH
M9TJ^+HDDS96R%^X=T,XI"##*P$QS;\6O/\/?\:YB<0'"T_SIY'I;4AZD5[O# MI;O) #[??Z(@X_'1FM'4"?YEM:U:7Z)4=WA/1*_I!NWW)FS-#PI*<*S>-4K-#B0A@+PA-%*=;'BR>J=4DZ*6&^|
MZ@@^U@3U(\GESLCJ1]P0'0DTR%Z[*>5$<= B@^MFP^(8]+PHGX8]-%8 M6*J@-&.CDE9C+R-!I BI (V6'C)3XM_POMI60;%RY7LL3]! !^XF>1J?[*I MDL)+G3__B@I+6;L#X/(#-LFCI(]D5A,L-
%7DO2\K%2.(>=K)C&]D>5=FBL/8/NO9<_V8,37&W=IFUNB+%L)6*J= MW=G7&ZKC)S5XGFML)$W2;.!]HE6Q*YGZXVP?P[4+E^.M91S>[0Z?!@IS6=10 MC,X" $IPA]34[BDBG QAD9X G?-
$3!XJ)97&$"7^]>J4JT3D2AC?-X@U@<-| MXVUCNKA"=@LL)OLT=B-IG 17KW[9Q#)TQ"^>B7ABE#>7?ERB!VDV9J[AKNR MCRW:%&WX-+ R4HXY["B6TNGM6&GM-302*@A]/4(X1
(DVA)5RKT3K^J)IH)- M\!^65%"6AL1?@ZL\3HYD5SM '(>6 WQD8 XH3$&<7C)!@=';9> LW XOM:7H M%S8VK3UHYJL5U6*3+HE^#V.69#3% 3$ZA2-BA"KIUR?Y1;)W>+)\+:/IL%,A
M]0NF%>05\U@"-[KQ1Y7 W$2#W2SW6?0MAU]!40NB_OG[VGAK]^#+0=OS@,7^@:#*_>Q\F@-CQ[(7QX= M8+%S5$GA6GR0+P F(!5UJB6N$7*NB7PJM\N4/,;B)#^_E_$?]W&F6#E$E
O+DL)%N%4@A#A1PW^BOV* M[HM&H9+:LTQ_I_B)'77<%#D$Q!12&ADNH2;WJ B?:L@D7"Q&BMW Y%O-+F2Q M3"0.%Q5S<<+8J8Z7>D4NF*L=1U4V>CY4AB!0,Q8UQIY+
(FJ=F=DY(HL5Q=G"47 M.R>)ZA,OXU@7/)'-HONTTD6,E!A?O@OX(&"?/7H=U@1;DLQB9*^IJ@| M%C1RN.D:?#N P;|Y1&K%>5<;NM*LQ4F<&-H)#GYI1#W5/GRY>R;WV78O 0:^ MH(11*
<*4Z=*J$+$V'.3942OL3^UWD4*KFX<(%YTC]*8+T<[MZ,4I1?*J9&: M"ENH08CU2<&=C;|Z !C\VL8>SC&9.!9 /534MK $"V/YK66O<M#8].[$"R7J\#G=PK9M M#-/D3@"&LL*]WOQ:^Q?
Y1.HW9A\F_7^"8OTVC5N/GY887TE7]B=-81*QS>63 MY=;OJ(4]JG/&O>[P%@XQ^1Q.\L8&=9S)_'B5V;W>T-5V*K2S4R48%=>W:8T% MZY'8[.#VK2=9L]&%MI%EIXX&\F,]F93H W)C3%YCD9U&
(I1N&"3,PI_V@G. ME_O/H>'@]'!4WJ(W-N[<3[#A>1&8U#H]2FE(O_E$M]>H#*N.IA(L*04"9V# MI#WF7DC&O.':2<[!ZB3I:[630/8&K\)]4|G|-4;"RK.\1=9Y2Q^>=I^ M J4#\]X?M4Z![[0CUOU1G?
8C^.YG$-2A_+3-%H)?4&^MXI7YY'N3??E80O)) MI5G^M1"!7$C^F2Q1N5HP#07MHJ*70|=_U26<&+,OKLV:U"1=<*YC45#WR\CUN.L&CWK)?/6E(NP:(5*2X;0$YD=1UR>3SH"W#A^N M*^F?
2>(X+Z54B5"!&%E1#FJMY4Q<*_'G4/"D8 MK[V "<$Z#JB@._IM+]2>63@N04E9I4SE&Q, G#1X1\CD^/?CN*R,"^9@A2$,FC"|2|+"[C6'&(6I.S-"ODM$/A]@&YEC1@::I
M=4PY7)Y>4M::>#7Z8N>]M%@;)9:FR:Q0XLG1\?WRP7VP$YC?8M^47@UWUF*E M;7(DF%+2CKE=68-"Q=_O"AAK M]!KH ;O5.;ZS;$V;
<"C"05H$D+CWYW)6FG,K52K!26>U$V$G\612RVS:,=N M1K]A$WI;DN*@_FKL6.'?HI\>0&&2HQ U&V[M\6+OI[T%TD84Q&O:C2)!7R:) M!\PTTJ=='![(@N3'XR3[00?[M5!H.?4TJY-F7ID*^>?1XG
:!#Q]G[].I\1M/)4N!ON5I>U#PMT\#=U^]&B8IZL]-0 :##@&@I;L0TLYP4&PQNE= M?KI"# 9 ?N2(4OX4-O_==!@\[-[,)FK:/Y=U)];"4!.7U0$;\7>S<%F&&7(@%\C=:QJ3= MG?,]'S!W9,^SO0DM
04'M=:MY_A3L-G3_DJM-N6J+4 OI25+UHS8#] MH+'5"=5=RR+2;BE);52X-YA79NE29.E2 9.N72X_YJM.%3SWO=N$>'V):&[Q@O[A9ZYV7:@0FY8B[2,ZLVX*&U;/N6Z#>9C9B8"B'?Z9INTN%T
M&U+T@%ZRY[/>/ MXR\^?1Q:UZ'E9_*C4@CY%?SI(*@-: W-X]]V8A9XN]MVSJK)@Q>O_!O ?+CC-@7J0QU0S/U) MGOGTUZL/KU^]2XH!0QSOKY7>?%7KJ+M+;>)/E/$O_HWKMWE_VA&Q!FT>
[=B/ M^+/SU)T$_;)3L/L-:OMPIYY(?$J_46KEH4MUWL@ZH4=J-I26+5[_,8"_5E// MK]?8[$]_!&*8UWJ;3K?XCJ^AO?3^4ZS\WRWKUB-SS4W'].^
MIG+HW!YU'^%R+#G[%P[TKW$FB_[SA_V+YP]=!_\IX?^MOX'_=BMK^U>F-R^> M@YEG)O8?P9GS\Q?,-:-(+JON#8[<+ M>/7H\-LG]S %O@K_Z/T&A\3J W!%Z*\@Y\"@^ !\O_!@HN4?.,&-
;S_1\E[\ M'U!+ P04 " #(@&99VLZ+VF & #M#@ &0 'AL+W=OZD,[(N5!P[OLW8CCMU9M)X8J=]ADA0 M1 (""@!*5K^^9P&2DC-V)LU#7R1>L+MGSYY=@*=KZ[[X2LI #[4V_FQ0A; |
M'H]]7LE:^)%=2H,WI76U"+AUB[%?.BF*:%3K<3:9O![70IG!^6E\=NO.3VT3 MM#+RUI%OZEJXS:74=GTVF ZZ!Q_5H@K\8'Q^NA0+>2?#I^6MP]VX]U*H6AJO MK"$GR[/!Q?3X!OY6\DEJS
M(\#XVOH<]"'9Z_Y[S!VYS(675U;_K8I0G0V.!E3(4C0Z?+3K/V2;SP'[MRZWV\9?6:>UT-J"\|<'6K3$0U,JD?_'0\K!C<#1YQB!K#;*(.P6**-^*(,Y/ MG5V3X]7PQAZ"PUL%NW!^8W);2PKB0?K3<8!'?
C[.6°+9)T] M8_V&WEL3*D_7II#%8_LQD/1PL@[.9?9=AW=R.:+99$C9)'OU'7^S/KU9]/?J M)]/[KC4WQ+%?BER>#:!X+]U*#L[ISP_WUS2=TJ^_'&73Z0GMQCC&'84*=Y5R M!7UMA
O2D2UC0D.ZERL!+>=V8=0_LB#!9B0?T&->\K(7K]^@S%I#L4-BU1(B M[_,B;;WO;U2*V:X<1;\1S^&)CRZ=")+0L\^#H;7PQ&VK-Z1J9!F 9YZNE4/? M!HV&P,>Z5A2^SZ8'! M?
FDCLAZB,G3CG9":D^44$*F< M#V100:J3)O\+Z:^.GF&]^_]!II]%\1S;@KP,0OB,>MX<>ELC=(%#%,8H#[@B2L3-GWQ^.VB*Y46YO_22%>P>_CV080F6+?I M:7S*NZ=LML=!N$[?
%'BA[1S9]8L+!8J<3P3LUF<;JEL[[,I=-))A+D!CRP42L<&R;50-:0IOT1M(HVR\84#)WU4UG= MJ0; (+&BJ^<-Y,3 $'LZ#72.\U&=$'!*5":.@;DY]A3N0B, \! F#4+"^>|
MME0&:P4"SU72:2%S%4\$8@%ZT6P1MS([SFJQ(8T#"D,2K>QCFT^S@VTC?S#T MKD&?9K/A[IP !.F2?FU4[!,]>7_!KE/C4@[9 PEI)+I(]8TKN;?0')&7EJ6-
MF.OMK/A6^5@5WV^D@,)PJCK",F>;1<7X)O22C=JVO^A0=C<1YL0Y'<5!\N+YZRQ5WMFAR +ID&5T[FX0&]=W&=J6[2I5Q ';C]_+Z M]JZ?O[?@!\G?KRVY1B-EM&C@"6SA372S!(+X2L>CXP
;^IDP5,*N"J4 M#'7# ;]X+'%4%G#;W8B=[H!-TL:Q SN&3!IAV*W F,%>R9@5.#''#8T[=H[=F6:PGJ;9C^1GRP0=NC'?@[2!A&EC'_=I%T(#"QM M@#N5?#-0N&4UQ]T_1_&L5D5#
<#^!1[;'*\L%7IL'5!$:T5/G\O'.)T@MH6+^ MT/*IPNEKI'_:?\M=I$^8[?+T(?@>38#)CD*7,)V,#@\&Y-+'5;H)=AD_:.8V MX/,H7E:80M+Q KPO+4K1WG"_@OW_%]02P,$% @ R(!F6?C\!3G.!@ MS!4
!D !X;"]W;W)K&ULS5AM;]LV$/[N7T%X MQ> 4@6U)=IPT+T#395L*M V2=/M,2Y3-C1(UDK+C_?H]1\F*E3AI7EI@'_Q"
MBKQ[[KGC\4Y'2VW^MG,A'+O)5&Z/NW/GBG>#@8WG(N.VKPN1XTFJ3<8=AF8V ML(41//&;,C4(A\.]0<9EWCTY\G,7YN1(ET[)7%P89LLLXV9U*I1>'G>#[GKB
M4L[FCB8&)T<%GXDKX;X6%P:C02,ED9G(K=0Y,R(][KX/WIU&M-XO^$.*I=WX MS\B2J=9_T'^ \.>X."9!0(G8D@>-G(3X(I4@08/Q3R^PV*FGCYO^U]%^][;!E MRJWXH-
6?,G'SX^Y^ER4BY:5REWKYNZCM&9.\6"OKO]FR6CO>Z[*XM$YG]68@ MR&1>_?*;FH>-#?O#!S:$]8;0XZX4>92_<,=/CHQ>,D.K(8W^>%/];H"3.3GE MRAD\E=CG3KZXN3",6RN<93(KN#2@W-
E=,&Z=*6-7&IG/&,\3IOU:Z41FCP8. MRDG$(*X5G5:*P@<4';!/.G=SR\[R1"3M_0. ;I"':^2GX:,"KT319]%PEX7# MB4<5T3%[9PL>B^,NSI$59B&Z)^SSE^LS%H3LYY_VPR X
M9"^$\ZYS/3="L*PB6Q#9[#,0M&8Z(^KI]A%#+9&'>*32(U8\Z_3^]J_ZK,W M3.8(0J5PGNP.VS;9.;^%BD>]_2';P6^ SWC_-]AT/D)(".)2S&'ID(P_T1 M[84[+(+&"7",63
:=BY;MH8!/1N'["#J5/Q@@O6"/>B W&OMN"*E@$Y*QQ-| M'42D.YSL=7K!#CO/8U4F)&N#4C"JN -/3C-Q(YWG-)&VT!;R?-Z03@K;[Q# MZ[D@V-LM\ [-219(
4+F^%0)R_A4+P1##JTFO8M(2W[7,VU?5&Z8<^R="D%9 M<"$M%G%+^) >;*4IUTZP(.ZS3?;/\PUEC^L8[;)KL>"0'VM#*W@.L;'.!-,I MZ*O=RTIL-RWJ\-CQ?"9A91VLNZ
$"TS%)P2)&]P@]HXD^71P4=]S7N-I<_@- ML]@23-'5I%:;3N8LY0MMN >=_(4L2\;0$Y($+TC'^8^C)<" -Y0%E@' 3UZ@T-= MCWUJ(])Q3ZM5[?5;2IZE=;OCOP=3K&<;IG;N@GP6-S4E]V'&PCA,-
MF_.BL^ MVQ)E9Z5!4=:OCFS&5_6QW1Y)S?:T)+MVUS2(&T>D(MNMXUUB;:$0O,R[9L5F M\$,-@O0.:LLP468%*;)50E K2JBVC.?5_EWBC)*)16E$!)-DG<\T+"$7VA_-WW"?
(]AQDX*FV=4+SKTQ2';!WY!?R)\ML/ M)27\2@/\M+[-Z@14KZ>+1Y?^CBOXRH?8RS$^> 1X'99K8:@#9.8?5G',C%YQ MY58-!MKT7BEA9O[NNIQ])34\ZU00F7SZEA":70WF)Z2;[;[*97&NM9^J-
B2NO_W3FH7 MBZ\Y_AN7$BEJ5]QK_MH>>OGY/EO[XWFE3=LYA0'S1K;]\ZUE M3/X$)_X-B57\,-6D-Y'=1ONH6TW]Y2CY(FI*B(0'WE>=HZ"WTUB(;/&CG!'U^A-@= M?LO0Z#['%;EOZV:?2LK;-
LQG#WR$G.5;>[8^V_8N:;#QABW#]>7?(UKF"Z'J M95LSV[RJ?%^]H;M=7KWG_,3-3*)T5B+%UF%_,NXR4[T[K 9.%_Y]W50[IS/_ M=RXXZ@):@.>I1N]1#TA!\P+WY#]02P,$% @ R(!F6:.N]YH5!
10P M !D !X;"]W;W)K&ULS5=M;]LX#/XKA&\X;$ 6 MQ\[:]24)L.XZW(#;KFB[[;-B[&NLN332]+\^R-E)TV[ID6&8;@/;6R)?/@\ M%,DHHZ6Q-ZY"]'!;*^W&2>V;#IS2?:=[20 M! 8YT&29H&?O+D__Y]TOKTFZ @AB;7'R!4#U2B$,3O0NY.359'5X:4*N,1. MC0G\M+XDWKY%W)FD.)%P!R$R1AT\.!??
E@<)C60NID,HIK%W8R,L$KJ?'"@@MU+>SJ#)59CI,L62]2&=C!HQ MQROT7YH+2V_I!J64-6HGC0:+LW'R+CLY&[)]-/@J<>FVGH&53(VYX9>/Y3@9 M,"%46'A&$/2QP/>H%_,1C7|
[S&03DAVWG]?H'Z)VTC(5#M\;]4V6OAHG1PF4 M.!-!^4NS_!,[/0>,5QCEXG]8MK;Y80)%<-[4G3,QJ*5N/\5MEX\ M<\@C[S909/F'\&(RLF8)EJT)C1^BU.A-Y*3F0[GREG8E^?G)N;!:ZKF#EW\9
MYUY!@Q:N*F%QE'J"9Z.TZ*#.6JA\!]0Q?#+:5P[.=8GE??^4:&VXY6MN9_F3 M@%?8]&$XZ$$^R-\|@3?<:!U&O#<_0^N34-PJ)ZX1!8X3Z@6'=H')!#[_?7T. MV1!^_^THS[)3>"R@XX G<":<+
#7!D*7H,CFS@3XKS!U$SR6,%U!*1>R)&/0 MU*I2TQ;"2Q5QA?=63H,74X7@#5SC0D0.;T\=&$M>U&\M;&54B=8QH*\0EK%J
M*8!8H*4F!!WJ*5$PLP=^A!.\|||23*/0XO@J1S2PHM8(%.D8A.V)2\&,K(FCI M23Z3R0>GEU=?7'S,3E]%R:0VSA5=X*,.%]L.9; 8IKK!_F5FA>#<3- M:-,BMB3*.AN(DR:42*&+110KM>]"R,IA/UDBO"
MH98DML0IL0R4H!XXR2DG.BNH!)T^C4<2\+JEOR"2LQF-32#,^UG;D=I-'?]8 M>H<]GJS;_7"'LT3NA?*?$#-#QKUJZ;OQIA_9]'O?K M"7)^MB5B=MK#^Y6]\5'-4(0^_8W>I],GR1]?/#O03T8IV3?
QP7T^>"4*F]&/2/LWUB#'=*^Z%> MHE1S0AZ[XJ1;5[L:[3Q>8!W$9FMO>9O5S1WY77LUO#-O+]B?A)U+*@:%,W(= M]-\>)&#;2VO[XDT3+XI3X^G:&1\KNN>C90/:GQGJY>Z% VQ^.4S^ U!+
P04 M " #(@&99N*%2? @$ "Z"P &0 'AL+W=OCIQQS:MNMJ09RTF;SC2))[;;9XA:S!-73/] M88E";>=!'/07;_FZLNXB7,PV;(T7:*\VYYI.X0ZEX#5*PY4$C>4\.(V/EZF3 M]P)_N<.OQ?
S('*$4&!N'0*CY1K/4 @'1#3>=YC![DFG>'O? MH__J;2=;5LS@F1)_\<)6\V 20($E:X1]J[8OL;-GZ/!R)8S_PK:5S48!Y(VQ
MJNZ4B4'-9;NRF\X/MQ0FT5<4DDXA\;S;ASS+Y\RRQ4RK+6@G36ANXTWUVD2. M2Q>4"ZOI+R<]NSC-|Z9N!+-8@+(5:LA53>&MG-^O$;BD,\) *&,.9J&E)YUB MF'?
PRQ8^^0K\%%XI:2L#+V2!Q>?Z(5'=\4UZOLOD0< +W!Q!&AU"$B79 WCI MSO[4XV4_ROX'X5U)'9L-RW$>$*A!?8W! EZ_N7P!<08__S1)XO@OHG,5Q6 MZ 641&D-
J/(0F"P@KYAC_=>4]^XDM0.!/]((K]1&S P^(,@D4"7*+'D%LX%DV:/RHB* M1%)::XTR_P!6TS41].59_$W97GN+GJ/FU\R5*Y1<,IES)NAU8W73"ISFMF': MW:[;!T7WH//#1G-%;8=\S7,R+U?&TI]
<8\%)]5)9)O8&5T<71[#O3*JY$$3 M'.PM&=$D%>9\2B1RK%?DM33VV98>@B1CZ8]E-^3F?1@DA^DD@P._'8W:3=:M MR>%H.H:#O3>/>GZ%U%N1.EPNF#&\Y+GW"%GEP7V2)">TQ-
/L!&*Z3@GWM%:- M<\4G-7(_QMTE1__:'9R$@ @'XHF/X>,)TM$DXSMB#B&A=3 :$I\S M14$UE),%E^M>U0N/OS3BSM&)/)$%*RU)$.XS&$SCVRS&]+T30FH6MHMAUS'N MBV$V'G8AR[I--
NEC.!Y-"?49]-XN%$AE'2?1%/0,[(_Z!)'$$JM:BB?FNAW MBTXJ^4M.#5,K@I3K_U%U)?=%9ACWU37M0[2+S"2=_,OJ2J=JF=) \6V#!ZO,*4V.0S'D\IL7O;Y"A*N[B-N_:8 M1GT@IW'T2(E1M_EQ-7;?
#!'>FJ=JU&L_-1IR&A%L1ZO=[6XP/6WGL4_B[53[MBNFUJR&!):E&1^-A +J=%-N#51L_G:V4I5G/;RL:KE$[?I?*F7[@WM@-ZXO M_@%02P,$% @ R(!F63<@6:T!# (R$!D
!X;"]W;W)K&ULO5K9G*IU+=)<;UH5I[[GQ:>K5)9' M%R_TO=OZXD6U:0I9BMN:J*L4##ZKWF9$GLZKZ1%]^RE\> M>620*$36D(04EWMQ*8J!",&,/ZS,HU8E;>Q_=M)?:]_ARRQ5XK(J_BGS9OGR
M:'+$^,CO]+^Q,V-NJ;):*79>YR+?WG**UA3?F?+*_ZK M.[$>L< ;,M_SPZ_("UK7 BTO__;7OK]3$N%,K=-,O#P"TY6H[\71!7MW\^&: M\8C]\+>)S_DY<_+/V
=QGS+D29TV0C'9*#;;*,A4BJ5E#NZNJ[HQ#^:R3,M, MI@7N*C '=TO6+&LAF++RV'%ZPCZ6LA$YNVNT2/MHQ(YG)^QZ4T.7NS=D#TN9
M+2$F*S8YUC9+89>D)8FIRJ&^9R7^(LM%7JVT89FH&^0MJ_"\[C9EU:9L:BD4 M]&4G[*>R$7694A+![+=I_4DTZHOJTZ+H!%C)S3(M^S98K[0)[5(K(3> B!TW
M1S"#I7DN=2XW%2U18@>YH8G$,G6*5;6I,S)C#KCO1;D16+.N)>J/+!ZU&I46 M@IY/;W]21JZL<[9.ZT;28@=1!J[7*"'(O7(SQX=-#2 9<4-FUATW5V^[_?"6ZE>/;K(T%9QV@M1P$%!362375%7(
M/*70H,))N)UF6;5:IZ6D6X\LERI=+&JQT&OZHM(97&[!M2&EB,XVM'1=5W/9 MD ARQ41+YHB5G)-HDQGIK.C'L$Q7 L'9XLK0T8$4'"3DD()'D+0 J=8X1P.L MF EB:)5I1PR-
NL33052*\A;W9$AC&JI",@Y6]05]MF' MV-47S0J2^?Z'=+4^OV+B,UJJ(J?N])VWO3MO])UI>T?;9,B,!*E6 NX4!XS? M,R^OL+FL&I=7+%T!:OFG#=M>]@/L%1)>)Q
<1D,V!8OPP,4RA3CQZ$A"TA'9 M+G+(NQ4]!QJ]K6 :4TO#MYIDH(TM"I&/=O(#!.ZL!MU<)6A)Y8VO!48;L67M__O]8B;2SE4@L*$Z"!5JC_ACKVH^J\CNPT$H?)#PG!S**N%K*.043.>-JJR&PY@.R M?
XU:(&>RD%32M5PL3@NY*/4*+6TKT%\"V;$)!88:%=I:PRZA*D^I&I05*RI@ M7G>M# A0)R%TMQ2\@]=+-EV)6F9I1UW=J'Y&@\%XS+@9A$;LM68/Z:(2W5-H MT-M6)4H/,#_7PK:PS
EKG26%#T^A&I=;([&NC@ M[!-#!PPMJE"+JN<:N"&V+Q,L=1ZDZ5* MQQH$HW+@ZFIG02^/;57/-G5-=C^*M!ZQF[+5&EBUEBAI64)?YJA"30- E+GN M1#G,58WV%K-'-S$>&_:09GIFF\9P9_
PC7:%(!DTR7O-[Q/JLM5F00E"LXT; MT(PZ#3=PH_:2V2Z"EDB%O1!--WS-9:THYL6<2 67(D05][7]+O&=!^I;\VG$ M?JP>,#K4MF*S#"/4C"H 5>A-K8--4T>MX2##,#)C>D,:X$+W$)$N/C U9>M*
MFPA0C'W2/*I-#-*MN[J:T4B V:9M3Q8)6EP4HT':M=9>PS@;?-##S,J<@02= M@;!NC2XZ0P7 ,69 1!AL9X@=8@XFY.#XX^ANQ)X1F"O811/,R>"]FZR>,7_H M^Q&N?.C'=
(UY,'C3'SK,@SB90'T\V)TV<'3A+(J8/Q[LCAW,CQ($.6 \" =[M$PCWQBP>LR >W.A)H2"5Q^P$!R$>C\|9MQ\&.Q/(,S8.)_@;C .RVDL&=L-[MH4]5IJW8G#03DCXH//-&D4-
@]"28@[\29CZ<)+&^\I"N4<)W8?9BC\7PS4^" M0S#'+/9AV@&80T \"1GG\3[,2<#BF 7!+LK'?@>QW@RUIS<19OC#]>7?:#Y<.R/#34"NOI)\A3@_E)Z1L-09W\P M#)/
V!1YV\#YPPF8Q(<)Z#:)^0'@ #V/)VS"#P ';")H"*)@'S@?J')D!_>B M/> "Q]7C(#P,7NAS??4X@1=$\8!:RKS"-/F@Z[L>#3O24G.N,"T4LIU1M]J* MVE*AW%"Y=9[MSLWV^'1,%I_H_FF:?
K=V>\5,'R#VG@YQA!XFT3<2=0FWJ2$=RQ&M@N>I2$ME& M=<8D@([DX/!TZ6JEEU!)HDPQ :\:_>IK[]C?ZV&!1Y+1ZH(AC^'F<)R$@UOS MV,8&3#"GUF[N0&IO; PXB%88A2Q&U"V$.OQ
@N:WLN!J/MC.)&M]Z9^SFRAG(G&J,%H-Z- MT1O<0:N3@F+FF3>/_CDN/ G/R07<1,)2## '2P)T7S^R%O8AX1/*W\$_,$\1 M*$U3B.YLI_.8WMS 0H&N >VVMW)0=.FZ@CJFI <@H1,4-!Y=/
M24$X'E&@ N!W[(]#73H(BL'K]I30O1@I<6#WQU Q@O>O*BS,[65UC]O*V$XX)9LE:/NK*0H776LW;N1F] OB='*BK''RT;[S:'#IC!PJR[#]=7-RP,4!NPY-7UNZOK7Z9ND;V$
MU+\&ES>WTW_=O+O&.,R2R>#COZ^O?D,%8OY@6N+T'(!%03RVC.8<@T3HV7K1 MG[0Q"NZX_91!Z7_SVA\F?JBO5$6,WQPYP:.P=1GDQ)H)RJUS6A_;WU]/WUU- M&4?!YIB"6J?Y&+E.
YMVF\:DT/A-)*?:QR=NS@PBGX60ZWQW@YF>,USY_PZQ M3O2I8#*)K<>8FD/>>1 %.*M@[E%KB>)1X6S=[J7AVU;;YXQ@X5[8FN\.1WIZ M1RX;)]L,L'EF7O+_@3,
[>I<]X8;MF]+^SP+N):G5SFKZE4^-'##?A0VAGBVI M#3LV@/_@:"^^*(@^V%\$%L,:9%#B%JO/_%;A-S$K0?(+R)D7@#TIYMO06E[M-EC9V> [L"D$QZ?.>!/>1]/[(NF"8U=[BOBN9#CTB^YI[X?
KE:@7^N=Y M97X4-+]AMW?;_P"8FA^^N^7FWP

'8T0Q%JZ50348U M!=545--034U8*<]KX,\OIR.'X1%>Z-0+4:U M!-525,M0+:>T89;VO5&GPIZ,SU?=ON="^C+;=C(:*RDLUW?EK)6\:TFN5]NJ MQK44UY+?/=S.':_7U;HM5K-
2\IOZIBF6R[)9/QVLE?XI'71K'_':'1S':/,4 MJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHY MI0T3NV^>.CW_A0=RT4HI5)-134$U%=4T5--1S4
U$]4L5+-1S4$U%]4\5/-1 M+4"U$-4B5(M1+4&U%-4R5,LI;9BW?>O4J;AU2BM795/-I.7CZ:CFHUJ :B&J1:@6HUJ":BFJ9:B64]H@3<_ZI]BSO]84]92F]7TCB-.SEYTK
MEY>C:2I>CT/3%-445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U M&-425$M1+4.UG-*&:=J70)W]M1*HQS1M;ZMF_GJ8CK2IO!*F:'<3JBFHIJ*:
MAFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYI0W#=-J' MJ;C>Z:TP79?=#P5I.MT[3='Z)E134$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5 M?
%0+4"U$M0C58E1+4"U%M0S5AR=EL2IJNJ_6L M^]ZK>Z@G+\]%>F4/5;@V!VKEOUKB7SOGO6K)0>EI)W#8A_N4="O&X'_B:O4$U&-075 M5%334$U'-0/53%2S4,U&-0?
57%3S4,U'M0#50E2+4"U&M0354E3+4"VGM&%> M]\U/9P\]%;^D1^(,[6U"-1G5%%1344U#-1W5#%0S4:CFHUJ :B&J1:@6HUJ":BFJ9:B64]HP1?LRIC-Q M&=/_V#';[F?
Q]UJ*;^O[]4;?S#C'W[MG_)#4S:#"8[MD8<<5JLFHIJ":BFH: MJNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9JN64-LCU\[X6 MZOSHUQW;/2U -5"
M5(M0+4:U!-525,M0+:>T8=[VQ5'G?[$X:G;?-.7X =WSEW51D_&I:/'@!T%:BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B6
M4]HP0J=]A(KKHOY73$77]XUP*EK\&@[>-4:+JU!-0345U314TU'-0#43U2Q4 MLU'-0347U3Q4\U$M0+40U2)4BU$M0;44U3)4RREMF.M]<=7Y\2^U -5"5(M0+4:U!-525,M0
M+:>T8=[VU5;=0WPJ^H%\?H_:R='X5+1P\(,CE-045%-134,U'=4,5#-1S4(U M&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.UG-*&$=HW69V+FZR\55LT52W% M93&
[+9NU%)5=>%;M9H_5KAYFIW^:;"[;=E'.QWXZFK=H6Q6JR:BFH)J*:AJJ MZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY90VS.2^K>K\ M%[95G:-
M5:@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6 MHUJ":BFJ9:B64]HP;_NVJG-Q6]6S/=GU=N=V&[VOUU.)N8,C%JVP0C5EISV? M+#^9CLZ6J^C
&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ M&:KEE#;,S[Z?ZOR-?JH^/[.JO9622-+K]5W5%HOU=@_6:V_+1M++8M'>SHJF
M?.BMFF^FFX53QV3]R!6JR:BFH)J*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6 MH%J(:A&JQ:B6H%J*:AFJY90VC.*^Y.K\|A=.':/E4Z@FHYJ":BJJ::BFHYJ! M:B:J6:AFHYJ#:BZJ>:CFHUJ
:B&J1:@6HUJ":BFJ9:B64]H@;R_Z\JD+8=G& MP5/"8N[0B$4U&=445%-13=MI@W/ IV=CT]HZ.K"!:B:J6:AFHYJ#:BZJ>:CF MHUJ
:B&J1:@6HUJ":BFJ9:B64]HP/_LRJ8LWRJ0$^2D5WXMF7LZE>;5NF^KK M_?9I=V53U?/1;"4K0JY0348U!=74-S;1Y$+Z41;->C1(T=8I5#-0S40U"]5L M5'-0S44U#]5\5
M0+42U"-5B5$M0+46U#-5R2AMF[;3/6G'KE-_4_M9*V5? MKJ2T6-R7HR&*MCZAFHQJ"JJIJ*;MM,%Y5Y?C^Z=HHQ.JF:AFH9J-:@ZJN:CF
MH9J/:@&JA:@6H5J,:@FJI:B6H5I.:B86#$Y349%134$U%-0W5=%0S4,U$ M-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U%M0S5_<"
(8;5A"-1G5%%1344U#-1W5#%0S4T80#W)4N7DU\W17R) MMBJAFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JE MJ):A6DYIP[R=]GDK+EIZ>XI8#!PT\W6YI
M4VOE0@J+MI2*5IK\'_$D,%JYA&HRJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*: MAVH^J@6H%J):A&HQJB6HEJ):AFHYI0TCMJ]AZA[^NDG@$S1O24U&-0755%33
M4$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M0354E3+4"VGM&'>]@5- ME\)"BFZ7=G5?+*1UL>CRM=NC;6]+J:V6I51?/[O5S6C8HNU,J":CFH)J*JII MJ*:CFH%J)JI9J&:CFH-
J+JIYJ.:C6H!J(:I%J!:C6H)JZ4X;'"@Y&3U0DJ$# MYY3VD*0?U[=EVTD]^^3-]] M?/%]=?*;.1GYOC7YS1[[OC?YS=]^_V,_[.=/=\5-Z13-3;5:2XORNEN%HP_G MW0MNJIO;IR_:^N[W=Y-
WTM>Z;>OE]N%M6QCQ)0Y$0R1?GG0MZ&M@#;9"W^"WDS^G&9Z(?Y4&(/_7!='[> ML?0=\8C/E$:P[,\3O^)1I$G9??Q50CM5G]IP_;WJ5!;]\>^J5!?]\>!J7!8-\>AJ7!<%^#46DPVM?
@ MI#0XR;U;N"/WI<,4FYQ)\4RD;IW1](=<$+EUYL(PT=J]4S*[&F9V:C)-9B+F MY)Z]\)1\)A?S>:@UQ2(R38K_#*VPCPY7+(P^92V^W#GDXX=/Y_,)$W(=1E%V M/3WKJNQ>-
+$[*_N]*OJUW^FW1ZY%HI8I<9,YG[?8NV;[L<&^F[V#ZD78;R_B MTC8"?UXGQ\3N'1';LOMMSV,VO^.K8]*SWC5W]C?OM;V-;^O=^[;>?;.YPV>9 M.7W7/-C#G-JYN6WP9*^2="_G]?

Y5TN3K+]DU,E4\3O]HN;'+ M1O!^FP<9JN MV(R?=[*XD'+YQ#N3'W^@0^NG-H$@80X2YB)A'A+F(V$!"-807;\27=]$G[@O MJRP:\SD)XQ4+91;=%1&+;(S,M:@R+3[PA"]"U29#
(_I0&2)A#A+F%K!A#M-S MJJ<)M0=GW:=-=2$[])&P 1KJ&M0J6M@5->]63]&XT/U,]CQTG#<=)*SV^0S MM9MMW*+-8!/3/]ER=@MGNXV/?+8 !&OX<%CY<&CTX8WDG_4X4
X)'R.1H_: MO&G$'.K-X>XK[NDI0L.?NXV&6TW<%@ZU>J,MA^ZVHK1'MSR*?+X !&MX=%1Y M=&3TZ'68A/$ZSD=WR11O$.2UC'=BCH!J,>& MBDXJ%9T8531-
)>-1/EV]6*NED*%Z)5°>?S 9>NDU8@[5%)(F(.$N4B8AX3Y M2%@ @C6D-ZZD-T:ME,9(T2%A#A+F(F$>$N8C80$(UA =M>J4DV4<\>X44VLE MY&L5.74NJ1@'V[1GQATJ/BC-
@=+E M3E]:>=,;]LH>(FZE^5!:@*(UQ5JGO2DL[TVAB6\H MS8'27"C-@])*"U T9KJJ_/?U)P G]:9;O["XC I*H=A,I.&GN_6#%0I/D4)I+=]/D VNX/06$YLFAM !%
M:PJQ3I53\TK,5$8MV?.Z6X*>F!9S9=]9>[P8+4@:2Z4YD%I M/I06H&A-6=79>VI.W[N+!<^_9[,YC.5K5\EG(IF%49B/>$=$9".:K,\FCR34 M@?
B(L%BL$W5$E%"L?:$[W"F:V(,=-2+SYPZ4YD)I'I3F0VD!BM948UUYH.;2 MP_YJ+*(MCU>J;/JFPU8!CG:&P_YXL"U :!D"2G.A-]*\Z&T $5K"K N6E!S
MU>+7M5[:ZJ\XO'(F4U)\A7<*C,S>U@P6R=NT'H%E.9":1Z4 MYD-I 8K6U%Y=M:#&_/3&X+>QY+W5@]_MUN"G+]QQI2*NIX%'Y**,P/?O1N#Q MS@ XVHW T/H%E.9":1Z4YD-I
8K6_+9H7<2PS46,MTSS1C;P^V4+S?=RZ.H7 M2G.@-!=*\Z T'TH+4+2F?NM*B4U1V4(;6C"!TAPHS872/"C-A]("%*VIOKJP M8IL+*X>M7]*-$)ZOKH]TIG#&VQ)4K_'^".+3H
J4Y4)H+I7E0F@^E!2A:4[]UT<7NPX(XM(" MI3E0F@NE>5":#Z4%*%I3?76EQ3976KYK$!^T!?&1U?BAVS$=6JB!TEPHS8/2 M?"@M0-$*578W]K;&7#
[F^YQ3,M.)G&)/8'6VVDM]D>\@WCI_14\=VG+>I:=> ML5.ZQA<;MZ^9? R3E$1\D75E'8^R!Y/%7NCB0(E5OK/V02@EXOSCDK,YE[I! M=GTAA'H[T!U4.](G_P!02P,$% @
R(!F6:JAN$IQ! OP\ !D !X M;"]W;W)K&ULK5=M;^(X$/XK5FYUVI5*\T8"] "I MY45;J=5597OWH;H/AAAB;6)SMH'NO[^QDZ:0F%QOKU\@<>9Y/,]X//8,#UQ\
MERDA"KWD&9,C)U5J>^6Z;O&&+(AZ MVCX(>',KEH3FA$G*&1)D/7*N_:NY;P#&X@]*#O+H&6DI2\Z_ZY?;9.1XVB.2 MD972%!C^]F1"LDPS@1]_EZ1.-:<&'C^_LL^-
>!"SQ)),>/8G350Z>@U4XJGI=@\""GK/C'+V4@C@!^> 80E("@ M!HCB,X"P!(3U&;IG -T2T*T#HC. J 1$[YTA+@&QB7T1+!/I*59X/!3\@(2V M!C;]8);+H"'
E.G,6B@!7RG@U/AWE1*!L)1$243S+:8"\D;)"T@;J<1NI7:" ML@W"+$'EGDFA)SBC)T3WG*E4HAE+2&+!S]KQ M@Q:\"[&M AR\!G@2M!(NR/82A=X%"KR@:_%G^GYX:)/S_V:?
__3L)\$(JVP+ M#5]XAJ^9#6_)@B9<0O8\WP&F2(^_;,M?3-"U3Z#K\)7#^I\@A=F&+F'/ M%P7#XOA-_6S;UW4 A0;D#X+]^-.WQNZ^^.U:MKXIQ:SID74'YS:S)LVP1O-
M2;2B*EI1JZ0)U O(9IW!*RA9-"$"ZT/3%IQVIN? &IP"%!VY''9KL6F:!+U: M<"PL7E0+3M/&[WKVZ,15=.)632<[WJ8N;KI>6]>IQ:2NKFD2!35Q39-!:-?6
MJ[3U6K69D\RFJ=>,8TU2TZ+F[JQIT?'CFB0+RYED[E>2^JV2OG&%,YND?G.' M!F%-5-,FJJ]3TV00UF(S;]H$O=@N:U#)&KRSHEV@.UW.[DPY,Q>6"_259$D'
M+NF=)TDNT$)A.'ST=H;:=\M6/(T25QQG9Y MN?6MV[C=PY^\A]D.M=:)_NNA]I%D\P\B.TD!7WU\RQY4 M.U%TB\6+XEO3W2RY@E[)/*;081.A#>#[FD,PRA<]0=6SC_\!4$L#!!0 (M
,B 9EFE]T1-E , (,0 9 >&PO=V]R:W-H965TV6T=;B35!(#$Q;0)>(%YXR;6Q<.Q@N^OX]MA. M%IHLBP:8-VWLW/]GG^]ZR76QY^*[+ 4NBTIDTNO4*HZ]7V9%5!B><0K8/K.
MAHL2*ST46U]6 G!N127UHR"8^24FS%LM[-R%6"WX3E'"X$(@N2M++'Z> >7[MI1=Z=Q.79%LH,^&O%A7>PA6H3]6%T"._I>2D!"8)9TC 9NF]"4_3,# ":_&9
MP%X>7"/CRC7GW\W@?;[T K,CH) I@\#ZZP;60*DAZ7W\:*!>NZ81'E[?T=]: MY[4SUUC"FM,O)%?%TCOQ4 X;O*/JDN_?0>/0U/ R3J7]1/O&-O!0MI.*EXU8 M[Z DK/[&M\U!' @T9U@0-
8*H+Y@\((@;0?S8%2:-8/+8%::-P+KNU[[;@TNP MPJN%X'LDC+6FF0M[^E:MSXLPDRA72NB[1.O4ZJ,J0" L)2B)2%EA(G0:*/E2 M9X%48I>IG2!LBS#+$;>V1$$IT2NTYF7%F;%%?
(,R+O6%YO",8 6Y=D,5/49% M,4.$9727FV$M$4"MO>((;HFR"^5$5EQB6J<1400D>IZ PH2^T"M_NDK0\Z$4IUQ<#U&YYRI0J*4Y9 /Z)-Q_7Q$[^LP MM+&([F)Q%HT"KZ
Z0G'P$D5!-!G8S_KQ\GC(G7];/?WKU3N'$;>)&5M>_ #O MLI,Z:YTK-C7T-(@;0%_:'OTWN3BMZ'0U_#),-Q4WU-9X0R6GBZOENBMGCT) M9\'KH7-W"4M0UB M,.]&
<7^:=RYAB4M8Z@C6B&^2=RCI/=-)L%P93AI?3P9];%^<1HK!:/Z/TTTE[#$ M)2QU!.L$8=X&8?X_2\'<981&5;NFNN=(-H+PO M.0ACH.]O.%=W [- ^[_#ZA=02P,$% @
R(!F68H.UDY*! 5A(!D M !X;"]W;W)K&ULM5C;;N,V$/T50ET4N\ F$B7? M:QM(["T:H$&#!&D?@CXP$FVS2XDJ]2<=)O[XDI>AFBINTWH?$$C5S>&9(GB$Y M/S#^5>PPEN
YI9E8>#LI\YGOBWB'4R3.68XS]67#>(JD>N5;7^0!9RM0^-@+'XG^" :ST"'\LC85_URE2R\ M0#/"%,=20R#U\X17F%*-I'C\78)Z59_:L?G\BOZS"5X%\X@$7C'Z!TGD;N%-
M/)#@#=I3>5O9B M[DL5@>;AQR7;5<$V[&$[!=-6/^A,'#K\H>7.D!^-.6O)\ M8 ?7"C(3.8KQPE,281"]Y8_P%'PDRWR$X&U\C"H\C!PH2\O\99DF<[!(Z(H
MB[$MV@)B9""TO#TMSR;AW']J!F&Q@7!:&;7(#2MR0R>Y&\Z>B-8]&ZG"==CL M<-@E9;&91G9.HXK3R,GI7A)*_D&%E+XN50N_2S?, [3.J]$1X=&@$].Q"8P"
M>TSC*J:QDXQ:X]^8 >/C1(Z##C&+36.6M(A-*F(3-[$TI^P%8R Q5Y)<9#U6 MBU6 AVNP?_7J1*C M/4V'G6EJ,X*P9Z+"1G6'_UVK2M]6GU'4)68Q&O2L;!C6O,+3Z-4W<'H$J_1J
MDCY288O->-P35UV_H;,LOD&S2H!VA1AUN5F,&E.F3:XNJM!=58N]WI=G4JS7 M-1YX@Z1BJT=@+JP@V'WU.XH'-?\.YW99L*[\T%WZWZY;;IP^W9H<
M;Z..=.O8IC>NNJ)#9Z%\BVY-+5OI[B[09M0S%T)=9-LM=54+W55-9>\JB^D^ MP0*@Y"]U2C9G5K!A7/^IL[[:C^TYQUG\ B1'F:!FR,YM*\=O')Y3S+?F$D*H
M_=P^D\6)I6JM+CHNS?&^T[Z"LS6TM%^$P6REPK5]@>I+<<51=UW7&,6+9+DYUC\R*5EJ'G<8)9AK_5]PYA\?=$=5%=)RW\! M4$L#!!0 (,B 9EE>.4MSNP, ,@+ 9
>&PO=V]R:W-H965TF'/B^ M3G,HJ+Z4)0C\LI2JH :W:N7K4@'-'*C@?A0$7;^@3'CCH9/=J_%0K@UG NX5 MT>NBH.KY!KCQ$\L%5NK, ?#TNZ@DWV<@+;$# (376 L6_#4R
Y8RX+JF$B^=\L,_G(ZWLD@R5=<_,@MY^ASB>Q]E+)M?LEVUHW M\$BZUD86-1@C*)BH_NE3S<,.((Q/ *(:$!T"DA. N ;$AX#."4"G!G3>ZB&I M_AJ$QNFRHB$ZFQK+
[]@1AR:^OFG[;CKQQTVAW8 MSCK0)4UAY&'KU* VX(U__27L!K^WQF;O:6S^3L;V3JG3G%+GG/7QZYEH M(I>D5/@R*?-\04I.\9SLL<&/-2NM1ML15=:[SKI]JS;C?C#T-[O$'ZN$^QJS
M8XVD?[6O,S_6B5[-[*6>-*DG9U._66N4:$U262R8J+I4BAT!Z]76*"XURT!5 M'ZA2%.454VENU[9[T4*N41>I.XGDC"X89^:YA;^;\R%^"UOO105*=KB(.P>D
M'ZM$O0/66ZP$R0'KQSIA)VBGO=O0WCV;TWY?2&TC:,NQ>^Z\JQQ;5 YS/%9) MHH,4CU6NXO8,>]Z!H-^DW/^O8_PKA],5XNZU,)#9BL*WE!BZX*)7<@-$'Q" M*V&N -R-
%+9M%M7;!?;M(MB\L8LN\!5^Z> DIXA= -@Q;\,T*E%-,J9Q=M"5 M)R$-D#"];&LC_L[D4(!:N1G/7A6L]NJ*-=)FC+QQT].!?!(.IF&+?(9C9YO\
MNC>8]=KD_<',C:G^:SC5C'M'U8H)33@L,;3@LH?EJJJYL=H86;HY9R$-3DUN MF>.H#E1"+JC770#._C?P%02P,$% @ R(!F62:3,%NG P]PX M !D
!X;"]W;W)K&ULS5=1C]HX$/XK5JXZM=(M M20BPL =("Z&ZE;H2*KKK0]4'DPS$VB3.V0[L_?L;)UD76&^TV^:A/)#8F>\; MSS?V)#,],%Y/ADQT5&%0[%WI6% !I7
MH"QU^YXW;68C[EI4I9#FM!9)EE5/RW@)0?9X[O/$U\9OM$Z0EW M/BWH'C:@_B[6 D>N88E9!KED/"<"=C/GUK]93;1]9? /@Z,\N2H>:+>"JK?W)L;#V'1*54/&O N(*,Y?65/C8ZG "0
MQP[H-X#^)6#P B!H ,%K/0P:P."U'H8-H K=K6.OA NIHO.IX$K%<[Y.-$OB4(4[-5U3D+-]+\OX3E_(#*4"034(%D"MR&\=,9Y.FY"ZO MMZ3.[?L0%&7I![1X1UPBM;6JT2251Y#;,&'
M[?A)"]Y%%8P4_2$:6/"M*56\+OB-F,ZW- M+OKZ"8G)G8),?K/MD7H5_LJ=)&\D06-8.9@%90@#N#,?__-'WE_VA+4)5G8 M)=FJ([*S5
Y,*@=M[/,%E2RR:5_#QA5,OT\.\RNO%TRF[N%4U.=67L\;G1N% M%BJ_U[^P6ED=3GQC=1;>T(0W; TOU+O46D 6PU<%^-S*$J"%RA*@U>%+ 8Y, M@*/6 +]4+SL\I&9O4C'^)
M5\ZXRU1V219V2;;JB.PLE1.3RLG;2E93J(Y,)81BG]],HF&WPYZ!8#9-B6JM M3:V.WYJ]+LG"R;.B=5G6VBQJG=V3+_D,Q+YJH206]3)7]<>;F35=VFW5G%S, M+_R;I6^9#
[&KJYNP[_1U2WA/Q9[EDJ2P0U=>[QK7*>HVJQXH7E1]Q)8K[$JJ MVP0[4Q#:)_O.%=/ ^W]+KS_P%02P,$% @ R(!F64FD/+!&ULO5I;;]LV%/XKA%%%<,+,+;!& M(BE?E?
YQBP'1<+T*Q!LVX/11]HF8ZU2J)'TDG[[T==;%HR2=F=EI?$DL\Y/#?R M^TQR_,SX5[&A5()O29R*Z\Y&RNW(\T2XH0D15VQ+4_7-FO&$2/7('SVQY92L MMS(M[(4W&6_)
(WV@\M/VGJLG[V!E%24T%1%+ :?KZ\X4CA:!GRGD$G]&]%DZ)S&<69)^?%/:;1S&#-3//Z\M_XN#UX% MLR2"SEG\5[22F^O.H -6=$UVL?S(GG^C94#=S%[(8I'_!<^EK-\!X4Y(EI3*
MRH,D2HO_Y%N9B",%9<>L@$H%5%? %@5<*N"Z0F!1"$J%X-P1NJ5"'KI7Q)XG M[H9(,AES]@QX)JVL91_R[.?:*E]1FC7*@^3JVTCIR7XLV)\9!E_".Y8*C<"+-(5757U/17+(2"T#VB&G
8?Z/8* M8/\7@'P4&/RY.5\=.]S!A_SBW!YN);^?WRMU<"MI(KZ8TW$8SH%^,(SN(8RN,PS5M TQ%/K=2@S]WK 6@W.4 M'XRA=XBAYXQ!K;=J-4W!?,!+5>'QAF M=1=JJ8I_PX-
_0Z=_1:G"2JFBLE1Q7JHE5:R**FX3QD2(:!V%>8<;(6MX&LA) M& 89/#0' 7T-QKXSC-\5,V364+QJ*))\,^*M?X;W)B&K^T=< CK=GS.UA(@M M*U;%,O\V-^&I!_6EW233]2U>
(NTE:B')9"V5A,UY=.K8$%:]GS>X\1F:EHP; MD^E!#2\63:;1%\>2@/5.1_TN_5"FL1Z/K:44K,(Z*81-Y1' M3R3[J0'>1:ER,B*Q6J*%Y+MFS'+;OG1U;LM:-1..B,#N"^(6;(F0E*GY/^@-
MU/P&N@G.6=A5VJAU:*_>QR:I8=?2QHS0"=VMXQ>[L$N+E[?L 9; M9L KKI MQ#1ANVQZZGA4VTH&5!Z D*J)B]G+UF4:C&&>T@T$Z_4RR%B8!M14 [JY1BL@ M?4H?
3IT_E8$6B$::8: V&(83_- I=ZC[/F_PPH)]!LNP#GU-EIW0AS2506XJ MTPQ]R$!.4%!'/J-4OVN!FU9JX:M"0EZ MR=T4U.IV2EO6JJG15 BUL*-2VJAT8U '.9,0&E@Z5A,4Y-XJ:1?
CT.F^2GWY M=/OSH_70K .Y64<;$(<,= /7PS11$DNQ-"%!;D+2!L0A W% =>>=,E7G-;E M;G+1!L29MC+J$.?VP@9QS98739;=$*=Y#'+SF#,@SK#)$0SJ-33MA%A^I&/- M4[;QZ.!D
M/!>GIB5KU=1H H2;"- 9<(<->RF&$P2CV !;(\?'?VXMT_:A3QLV$,9U-' M)!18?O%@S2VPFUNT@67XE%7 ^E)BD$$6.,":>& W\6@#R[#A&*=7I_HF(:O[MFD=@-X^X9$\5&[C
2;;9&Q[JE@3!MP&87!B+C9P@7X==!O %0,IDUE9X]V* M @)>]4!2'/Z#K,9@S5D"UN618K@_4I1'1XKDZ$B1U ^9>G;D*62,V4R;W?5 M,%1(<:72;_=A$+R,$Z8&\
([N7B24/^:77H2:!LK7XA#V\/9PL6::7R>IO9_! MT0*:WJ/1W"1_@T8+T_LI'HX6JMR&;P)_?Z?"TZX6-X+N"%> *D!,U\IM_ZJO M)@LO+MD4#Y)M\ULD2R8E2_*/&TI6E&
<"ZOLU8W+_D UPN.HT^1=02P,$% M @ R(!F6:Y7!#V, @ %08 !D !X;"]W;W)K&ULK57;3MM $/V5E8NJ(!5LG#2E-+%$0JLB@1H1T3Y4?=C8DWC%7MS=<0)_MW]FUXP8:4!]XB?
0F*NV-3@:;; MI;&*(VWM*G:5!5X$D))QFB3#6'&AHVP4SF8V&YD:I= PL\S52G'[, %I-N/H M)-H>W(A5B?X@SD857\$<\+:;6=K%'4LA%&@GC&86EN/H_.1L.O#VP>"[@(W;
M63.O9&',G=]<%N,H\0&!A!P] Z?/&J8@I2>B,'ZWG%'GT@-WUUOV+T$[:5EP M!U,C?X@"RW%T&K$"EKR6>&,V7Z'5\][SY4:Z\,LVK6T2L;QV:%0+I@B4T,V7 MW[=YV $0SWY
V@+2IX#!,X!^"^@'H4UD0=8%1YZ-K-DPZZV)S2]";@*:U CM M7W&.EFX%X3 [S_-:U9(C%.P;EF#9U"BJA](_U!K8I&'#CV61=0/,;')*Y3F&X53M(7">=0';-
^\HZE23K8$_T_^']%\+I=PGO M![[^JR3\YQ7!V26"7!@UQ!E;]^<#)-/^Q+Q M2F2/TC+HTC)XB3VCGJ2.TU3RE@HL?V!HN7:4IM#KB%8L:N0+"0P-TT8?Y50E MUE"5Z145'
*%A'O+K?$[#'[]3%MGPU&\WM7]K\7IH#-IU,0['; KL+@<2PW MM<:F%+O3;K:=AY9^,J+\TS<"\YG8EM&,2ED29''^@B6&;(=1LT%2A MCQ<&:2J$94ES&ZPWH/NE,;C=> ?
=/T'V!U!+ P04 " #(@&99?*<--H\, M "29@ &0 'AL+W=O/XA55G\LUZ*0 M?[DKJU76R%^K^W&]KD2VZ :MEF/J^^%XE>7%Z/RT^^QS=7Y:/C;+O!"?*Z]^
M7*VRZK^78ED^GXW(Z.6#+_G]0]-^,#X_76?WXD8T7]>?*_G;>,>RR%>BJ/.R M\"IQ=S:Z("=I.&D'=(A_Y>*YWOO9:[_*;5E^;W_YM#@;^>T1B:68-RU%)O][M$E=BN6R9Y"'\N24=
[6RV_=_?F%/NB\OO\QM5HNKL];['^R)L_UDVYV@Z61[#*B\W_V8^M(_8&$&89 M0+<#]#X@L Q@VP%,'\ M_AV #]V0+ =$!Q[2.%V0'BLA6@[(.J"M?%N%YH
MUF3GIU7Y[%4M6K*U/W3Q[4;+B.1%.Q5OFDK^-9?CFO,;<2\G5E-['[R;S6ST MRCMO^ZGWN2KO\L9[-Q5-EB]_DZ"O-U/OW2^_>;]X>>%=Y\NEG$_UZ;B1A](2
MCN=;LU<;L]1BEGG79=$\U-ZL6(@%,#YQCY\XQH^E"W9^H"]^N*).PANQ_N@Q M_[U'?^+F#3U]MO>=+MIM3K.-C%KZ+5?G83JF+ MY;*<9XU8>'^4WFZB?;NXK9M*;D'_@;;-
AIG#S.V^?%*OL[DX&\F-MQ;5DQB= M__H7$OJ_0S'#))MADB689"D262_6?!=K[F(_OY++OUSFBR[,\@1994U>W,O- M85ZNA/=N6=;U;\ Q7[I9OQ%PO$.
M=_$.G8M"QKMJ\O]E;0H'Q7,S.MB;8X2'VNIP6A@:)LA@H*T.$\/U%90"F(C M:R/:^2IR^NJ?S8.HO*RN93*?K]997G4KXKW,GN6*>)PWCU6[366%W+0Z:-Z(
M%93'7+KM6#:JR/A&'_96^R843N*AH3 -!I$6"1,R8=KFF9H8&H5P).)=)&*G MA]*R7#S+/'$O#)#'8L-RZ/N:QV)C$^4Z9F;R:(C$1!!?ITE-4+2'Z3EBLG/$ MQ.F(3T63%??
Y[5)LYF6]/S$AETS,8,2:1YP6A\XATQ[7YY)(>%$M)KS5)LSFWMTFVS"V\NA8!T- M]I]ID1"J^\\$T4_MP @-N$6]U'E/NITWQ?Q)(I'RW2CYG1CC.K^6XC@QUG MVB2QKBD2 !5,.-/]!J
HLYPUB!)8Q*V%OOR:K=:_3SWQ8RV*VC+GN.DZ;FQQ MJ-((,ADPW7$F*-*]FT(@:LDZB!)'Q)F+G]]T;KMVNRTP-S:JI\QN.X/=9IH, MHE!WFPDB\<3P&X"R.TZI#.*6&6GGN
NWX\R4G4Z,E8HJ-B"38:P[S@3%@9Z@ M0*#(MDR5X"!N)?!2,K7N;Y<'""Q2@@!:PBAZN*D'N]HT:98]H.,RZQX0REKX M($I3$+>H2/(BD_F>3 E?9NE[KQ#P6<5,Y6EDG(V=Y@;[#S
9&R=C0&*$QBG% M!,5^;/&>$B+$K41Z-;M>INR;0<1&?17HP(!AAEDH%5=J&NK7-[+$JU\+[=BU6MZ("/>=F&%JK0V6; MH;
(EJ&PI%EL_LDIE4?)FC1"**:BFJ&PS5+8$E2W%8NN'7"E#ZE:&K^R'7%% MP45ZR=!M>W 4 9-Z_2$!0'+/T[=&".63R+(S*L5(CVLDOK;#05&[B:AL,U2V M!)4MQ6+KAUTI7GI
\3JJ*]04BX2&@;Y04*4N9--HK20 BD5<%Q\0BD\L"3%5 M:I>ZU>ZAV@H%E*XAV-PV!GL-,*E7^TY32I6ZE>TQE MA9IB,3!F&ZK0!2R&>ND3P!#];)%"H- B'JC2N?2
SCVBKD*!/I)OG,Q0-2M@ MDL1ZH@^ 0E\O?P*@8&^#Z;M-*59ZH UV1%6% DVP2/<:JE*%+!K[&M PFQ@) M 2RE**H$JK4K2,W78JNR_-NDT'!N1/0EM+=ABHJ4=F2PX>? I
/%/8N4[J3 MN77GP8K5%0/:6$92ZK8R^"HKP*21E (@("F%4-:DE"E1Q]RMLT]%(ZJBNPHC M6WK76?6][>6ZU+N;@T 1">Z) % ++"M=O&8*=!W5V]M0^ XMC8
M6@!0:&F8,"5!F5N"'J/;&70IH^XU5 4*6&1ZTP_ Q+K^A# VERGYR=SR\QC5 MS@ -Q_3NG-O.8)\!)HDN0 $0,P0H! HL%2*F!"AS"]!C5#LSM1DSUB>J_(0L M&LL3$)5Z1I*"
($NI@RM=R=VZ\DC5[F89>H)'99MQ4SI^T&MP$$;7[1"&6:X^ MY$J!CP(@,Q\%0-9\E"LUQ]V-N:]%WB:@ M-XW,0]URW4TT>&*B:C=4M@25+<5BZP=8:3?
^=G<=8PFV*RC9#94M0V5(LMG[8E?[D!YJ@#L'. 2%(J=[^=!L8"'J@:QE/=$T MH$(_U._B E !M_7RN-*?W*T_#TEV#O0BS6L4W$8&NPVP:3@D 5",&A>6 R@:
MA[8,3&E0[M:@Q\AV#@A"\Q9O5 T*FC3FFPGBD:[<(5!H*1!QI4&Y6X,>(]TY M<-.=?MW[U&UGL-L D_HM,0D BHPB$02RW6P9*!4:N%7H,=(]@#J$>I7(;6?P
MK>VF2:.T!F"8<89QDH:1D<WN9AG\[!4(1J8\M'0[A!&WP4A MC.V)#4J%!FX5>EBZ!^:EE&9NZK8RV&.F23,W!4! ;@JAK+EIH+1=X.[+[5+0 M]J[?S1R]:)]AE3?Y
3'O)AX\4U&5'2I;@LJ68K'U ZZ477!<]_!5SS5![1RB MLLU0V1)4MA2+K1_RO:?9N#N'KQ7S ="7H_K-]E.W\<%A!&SZ5,^V 10C^K6<
M*8"B,;%DVX'2=4'XIG(^P%1U4U2V&2I;@LJ68K'UPZZT:?"3MZ%>!9 Z-=<+ MJCJ%; +K!5"GP'J!U*EUO2AU&KC5Z2:K4(O#E5-@ZL\I*ML,E2U!94NQV/H1
M5D(ZF+Q=3H&IG:>H;#-4M@25+<5BZS\P314!0G<1X+4Y10CU=HUGJ:$6!B"3 MQL/4CF@Y QAJN50\5&6!\+@;65^;3(2H]0)4MADJ6X+*EF*Q]<.NJA7ASU8K M0E/O
PL%M5H!F306"G18^D(Q,=:%H@H5X:$+B*MU*7<9L7N$LBN1<),-7A:H MQ0E4M@25+<5BZP=9%2?"MRM.A*C%"52V&2I;@LJ68K'U0ZZ*$^';%"="J#BA
M7Q8Z=1L?'$:P.&%LD6!Q0K^'%$#1R/;\O'#O2;9O6YP(48L3J&PS5+8$E2W% M8NN'714GPI\M3FP)P@/K!;4X =D$UHN)@M:+B7*LE[8XT?]$B=GPX".6_G@0
MGMR0,J_[DD6[@N[*RFODQ^LJES_);2HO%]Y#]B2\6R':5X<\Y;6$-67[%I'V M;2!>MOFP?2M(7FS'=FS=#8[MNR#D9[78/!_Y!3+?WPWO=L_BJMMK*[OE^]%+
MI/ULL:M*2UG+817E#)%(O./T+0:[[W-8B6J^^Y%)>US7N66T6Y% M>Y_N7H9RV;T"1/O\BIS,"/!Y0DY2Z/.+,#Y)9%"@OTSD7[KWK8S5(6W>UG*= M5?=Y47M+<2D) "/7@ &0
'AL+W=O MY:6=ZD0B %.6S/2-; M0N"[)O;$3>]/YEXP$FSS(I$N2=G-3#_\D1(M"""$F+RG+]I8U.Z/ A=8X0%6 M.'W.\B_%@Y2E]]MZE19G@X>R?
#P9#HO%@US'Q9OL4:;5.W=9OH[+ZF5^/RP> M^TF/S_--N4J2>5-[A6;]3K.OU[(5?9\-O ' M+Q<^)/'[Z&-_+6UE^?+S)JU?#/669K&5:)%GJY?+N;##U3Z["L';8 M6OR2R.?
BX&^O;LKG+/M2O[A:G@U&]2>2*[DH:T1<_?,D+^5J59.JS_%K QWL M[UD['O[]0N?;QE>-^1P7\C);_2-9E@]G@VC@+>5=O%F5'[)G(9L&!35OD:V* M[?^]Y\9V-/
6FZ+,UHUS]0G62;K[-_ZM>1 '#A7'[D :!V(ZT",.M'&@I@,[MXL :!_;:.P2-0_#:-H2-0_C:.XP;A_%KVQ U#M%K[S!I'";;[K"+WS;XL[B, MST_S[-G+:^N*5O^Q[4%;[RKF25IW]MLRK]Y-
*K_R_%;>5UVW++R_>+?50%IN M5M++[KP/\DFF&UEXG[]Z[^+_9KEWDV?+S:(RC-.E-ZV[:%(FE<'W,UG&R>J'
M"O#Q=N9]_]T/WG=>DGKODM6JZLW%Z;"L/F9]L^&B^4@7NX]$CGPDZKW+TO*A M\.;I4BXM_MSM/W'X#ZO'LW]&Y.4971 G\%8^OO'HZ$>/C BS?)[9Z]VIK3G_ MW]U%
[[MK#X/N.PS=\N@17M,/O*MTEVGKC/7I\K(NRKENOB/+=X[(K,3ZW1^ M4CS&"WDVJ/)U(?,G.3C_\Y_\/M6U$HV"D&_&VD4^H'^A6PF+ETVBRM](:&.P;&#@; M.-
_DU3>\]^F=7'^6N;6;.0%=NQD2QI$P 8)I40CW40CAHS]$A@4)XTB8 ,&T ML(SW81GW'OT[ST ;LZ$Q9&<6(Y^%QNAO&]$QFQB#WV+$)M0^]J-]\R)G\Z[2 M4N;IMK?
%JVH^DG^1U43$E0JK:Y: T#J4)%$T/"5$A(?!TT"!1P4'2.)0F4#0] M.$JS^4[MX4X)M#5$"2'F!,%BY4<3X5Z<-,[=T8DC4-I D73XZ2$G!_@,P54VT%I'$H3 M*)H>'*7O?*=.
<6>*L#5N)^/6Y*%M%$6M/-$V(A,V-O.$Q6I,QD?RA-)*OELL MN?)$=Z7AOEGGGHFD<2A-H&AZV)0&]"-\VH#J0"B-0VD"1=.#H[2@[]0T[K0Q M:0UC-AZ;:<-
F9"X_6HQ\QEK3"YL5.3*]($I6$;>LR

$;I5!:0)%TX.CM")A M^.P %8A0&H?2!(JF!T<)1.+>ZG-FAZ"]=A":N:%MP\SE2XN-'T1F9K 8^<>B"Q?ZF:>:-OXD9DGVC8A-=-$VX8=RQ)*41&WHFIEB0X: [K-!J5Q M*$V@:'HEE)*$=
3/#A0J *$T#J4)%$T/CA* U+U'Z,H.C:LVBS!&_LQF8ZYC M6FQ\9NH+FU' [/F!*@E%W1)J^O'VY_GLNE^&<+,[=T+HQAN4)E T/4H'Q9)_ M0+4DMEP26R^)+9C\
(T0@52*0]J^9;%RU[W1J;HI:C&AK$<)BY/NM10B+5>0? MV>J@2DE1MY*ZF+^?S?\^W=9L__QA/GT_F_9,&-#]-RB-0VD"1=,CIL0AQ1=8 M4J@:A-(XE"90-
#TX2@W2_F66M%WX:.Y,S"PV[2F%K5[3W!FU&45') =5>H]Z M]=3E]_0W*+*EBA>KS/<\,Y]$+K'!J4)%$T/DU*&#%^$R: B$$KC M4)I T?3@*!'(^A=ALG919#@Q$X2E4-/FX9.F^0>?
>"-UB@](($BJ:'2JG! M %]G&4 U()3&H32!HNG!.3A1I7^=9= N?31_QSFSV9AUEA:;PPS0/ >+T>3(M=D:@5%3@5E'7Y8/,NR8&Z%8:E,:A-(&BZ<%1&C# %U8&4/$'I7$H3:!H>G"4 M^
OZ%U8&EJ))LYKA\AO\3[XMOC,;>F2@Y[W0W((F$V.UX^VWT,2&%C9T9,BI MJZYH/7!*& 9N8=A*>=VW:-QWZ#S(H!N&4)I T?2#M)30#?'%HR%4XD)I'$H3 M*)H>'"5QP_[%HV&
[GM-,)9??P!])@!9R9"BO>2\RMY").5=[^RVT/?_9T,1X M'E==T7K8E/@-W>*WE?]>OWKD)G<>6M#=3RA-H&AZC)1Z#_$EL2%4KT-I'$H3 M*)H>'*77P_XEL8VK?
JZGN;1L,S+KX+C%B ;FT6$6(W:L(C:L-:]^Y>!$2[=, MK#+F+FWD+V<>)ZE77:C^2_*E]^LFSJLY5'TH].2U[(MO(PKK^9H "^O3]@NWE19S4Z^2_*B]-*ZSZ]W1Q7WH-

OB/3PX"'HM_OM*>*% MM\@V:;D[V6]_=7]2^71[/K=Q_<(_F?N6Z]P_N;)=OR GES;.C)S,;=7=4>S7?O4_2PEO)NZKYHS?CZDLJWYU^
MOGM19H_;H[$_9V69K;=_/LAX*?/:H'K_+LO*EQ?U#?9GT)__#U!+ P04 M" #(@&9969Z!GRD" "W! &0 'AL+W=OW&226.M+L)UF^7M\ M24-
7VNU+XK'GG#DSGG$V2'6O6P"#'C@3.L>M,=TRBG39 B=Z)CL0]J26BA-C M3=5$NE- *@_B+$KB^#KBA I<9'YOJXI,]H91 5N%=,\Y47_7P.20XSD^;>QH
MTQJW$1591QK8@_G>;96UHHFEHAR$IE(@!76.5_/E>N"\O<,/"H,^6R.7R4'* M>V=LJAS'3A P*(UC(/9WA!M@S!%9&7]&3CR%=,#S]8G]L_=YG(@&FXD^TDK
MT^;X/485U*1G9B>'+S#F<^7X2LFT_Z(A^"Y2C,I>&\E'L%7 J0A_\C#6X0R0 M),\ DA&0>-TAD%=Y2PPI,B4'I)RW97,+GZI'6W%4N$O9&V5/J<698@^-+;'1
MZ"U:515UE2(,;42X;E>W5[=@"&6OL\C8> X5E2/W.G GSW!_0'=2F%:C3Z*" MZC$^LCHGL-.I"*GG32\7 >V@D\I0T3PJ MP*^OUAUM#'#]^ZDB!.[%T]QNJ):Z(R7DV$Z-
!G4$7+Q\,;^./UY0OIB4+RZQ M%]]Z?@"%9&T'Q&DG!P9(CW?ZE-A =^7IW, >BS2+CN<*HK-FXJ :/S(:E;(7 M)O35M#M-Y2HTXW_W,-
)W1#54:,2@MM!X]L[&56%,@F%DYUOS((UM=+]L[&PO=V]R:W-H965T#M/YDJ]8^BI>\TC^W/(P?+P;6X/G! M3?"P%-F#X?1\S1[X+1>?UM>)_#:L4!;!BD=I$$>
M/Z:USR2KRETE<:R!*L@*OZS[R41-0/+V6%@EP9VP\ >[S!P2@.GF8.[P\ M#=Q# M<_!*@[SJPZ+N.7$S)MCT/(D?29*EEFC9AYS]W%KR%429H]R*1/X:2#LQ?<>" MA'QFX8:3*\
[23<*E%PAR2FX+SR'Q/7D71"R:!RPD[P5?I>22)4G %X0)4C-_ M.>."!>%OTO;3[8R\?/$;>4&"B%P%82A=(CT?"EG>+-?AO"S;95$V>T?9;OGZ M%7%&)\0>V:[!?
:;_[F)0',*F_X7)I;N;FCFP\ER173=L6TG>,Y>YD^(6_2 ME(N4L&A!/@3L+@@#$?#TN0461$;0#9]O),W10Y[JKSA*J@=O61JDY,L'F4'1
M(O^:N"U*XYI+D_4_K],UF_.+@>Q@4IYL^6#ZZR^6/_K=Q#0F&$4"TUK!J5K! M@=!EJR;!EF6=D]$A0>.NI&&"T0+,S\&RWG\[G9P/MP8FW(H)%V3B,HZ$]*8L
MVN795Z((C$+DK1Z8E'WA";F4O9O,U11(($Q7)_GA M,FD\CRN>QX?R_-SC/^%R#>=?U*LVV("$@UA="<74='##!*!*8QO%9Q?%9 MK^8U9YBM@
E&D<"T5K!&:B(_^I&936E='XJ(,WXGR&WF/H6;0;$+PW9U&U0TBH6F4ZITB=4O86*A*A-4-(J% MIC>%$B<6K$[>2^=.13XAD,HYK5S;2".J5BG1ZJ'OCIJACY2C3H[2*Q8L,^H.
M61_2CQ_0X0P[4XBJ9;#0=+*5ZK&\?G4*2"*H; I,-(J%IC>%4FC6H1+-W _X MK<@]=9SFR&Y*=-:,;R2=I==3*20+5@)7<<2?R!5+OO)]<8NI3V:H:!0+32=1
M"1YKTJ^X115%J&@4"TUO"J6++'#"/[UDZ3*G=9Y]X-\V,HI#.;2;H_BL%:#6 MQ&Y-T VIQB.W&<<_0XC82HC8L!#)ZGTB1^AUMHI1N%\A\J&0AC$[+U=CHE$L M-
)U/)7ELJU<_W<+Z1)+"U;W;-P(:5,JKQGX%"[7 ML?56NL2&=0F5-15/AVIM&*RS Z%NHV"AZ40J#6.[_8IE5(6#BD:QT/2F4 K' MAC=VNFCM$DH+TN84VY!FW(SBGR$D;"4D[$/V-L#
(Q=QIF:&B42PTG3RE3NQQ MOR(75>.@HE$L-+TIE,:QX5V=3I$[:2]I-P.WG<1J!N[/4!*V4A(VK"1N9'63 M8"ZD:^4S$#"$4?='4-$H%II^\D,)$V?4JQ!V4#4-*AK%0M.;0FD:!]I&J7ET
M-I4VLH1J=).&XP=IW$<:F9*93=34;@,Q]91J0<' M5@_-:"7_DC^FT MV%5B[5F_-J5JKU_#Y3JVWDI>.+"\,(3V44O:<#:=70MU:P0+3:=8"1JG7V?&
M'%11A(I&L=#T0^!*%+G[=VL.CG*W?4#,L*1M2M5>TH;+=6R]E0)Q805BB/)N MJ]PP?E>?0D6C6&@ZMTK*N/TZ4>:BRB)4-(J%IC>%DD4NWHDRMWT&K+7*;4C3
M7.6&2W1LC6NOM>PY)M8.[/UC-8S9V8-0]TFPT'0^E=)Q^W42S$451ZAH% M- M;PHECEQX Z=3,+=/?+5BN9VDN? -%^C8"BL)XL(2Q!#+7=;"8?3.KH2ZAX*% MIC.K1(|;KW-
B+JH80D6C6&AZ4R@QY!Z\N[-K+1Q&Z,P>JGYQ#6?2=KQRJ42) M!XN2(NYM,+AAB*Z+!@HE$L-+TIE$[Q?NB-%<\@35H7 M)QC2-
%]%A4MQ;"V5./$.$2=:L.._H@:7H;.7H4H8+#2=?R5AO'Y)&]5PJ"B M42PTO2F4A/%@";,OX-L2H?V*FC%1\Q4UN!S'WI6B=(E_B"YQP(B%(;JZ"2H:
MQ4+3Z5.ZQ.^7+O%1=0DJ&L5"TYM"Z1)_SYLL'6Y_V@.UX_HGORT?#/<_P=B= M2;5;Y_)VWP#E*]7B'ZE:_/:M7*8Z&K2-.VY*%[@,QSJ$DB[^(=+%T4X]"G7
M!IQ3Y[!#%2E8:#K+2J3X_1(I/JI(046C6&AZ4]0N/L/;3(&A.M/HMWJ-UET; M6#GJY&3:1G^B9ML^?"I*]O*[Q@R2\+P0D?3FL.;)TEGC9%%<%']?.?XVORA4 MLBW-H_*FV,= +
F;?]L$Q9UGZ2M3!8:U&TY7/'G(KY9-)YG=Z-58NFY27$%; M?!'Q.K]C]2X6(E[E'Y><28*R!/+W^S@6SU^R#*J+@*?_U!+ P04 " #(M@&99"[YA?!,#_#'"P &0
'AL+W=OL3)HVJ6N2_J*P-E(+FH9$IPHT>$ \N,FUM8CMS'9:D/;'[^RD M(: V#P@T^M#8CN_N^^X^QS?:2G6OUP"&//!4Z+&W-B8[\7T=KX%3W989"'RS
ME(I3@U.U\G6F@";.B*=^)P@&/J=,>-'(K3,..-7 [KAEL M=6U,+)6%E/=VD())'\I$U S"W@FG@$N$7@1S*,VIH-%)R2Y3=C=[LP%%UU@B."5N5*Z/P M+4,[$_V@3)$-37,@'*C.%6#*#?
E&)DG";-YH2LY%47V;Q2]G8"A+OXY\@]&M M#S\N(TV+2)T#D:X@:Y-NT"*=H--[;NXCZ IYIT+>WA.=$9C&'MX.C2H#7C1YT_A(/C>P+5;<>TV>8_FH&(L"QX3(I>$B1@/ MH
947SE@@L12&"1CBX=#S1)01<72IX3LHU4$/G:![1'>1$$["$?^9@_<7@6W MUPAW1A\8SSFYG0%?@+HC?W>E<.)B(LM-BR1,QS+'.0*%:N\^C(W17IGZ?L6E
M_Z%DUG\'KH.*ZZ"Q;M-MQQ?7XORJMB!X&-:D-V_W] M6@N#I[LR:$1]X^YX3/]D@\A6S5)J]O7*_(:U>SW\4&HJX;PQW:=F(&R\?]]= M4&7X%XH:!O7?RV^97VO+;(L[HVK%A"8I+-
%'T#["+Z$JNL9B8F3F.K6%--CW MN>$:.VU0=@.^7TH=A/;_%6]>_0/4$L#!!0 (_,B 9ED6+$G?$08 ,H> M 9 >&PO=V]R:W-H965T;FM_!1'3IS(&@7<64D7,X*E:MG6L M@
5I4!2V:;,B]9DG%[[H"9CF9B0"_B@B$ZBB*GO5Q#*S47+:SUO2.Y_1,QN0COC,8:.WCHE- M92[E%WMR'5RT.I81A. ;"\'PWQJF$(86"7E\S4%;Q9PV3 RB+C(M_K-ON1!; 5[W0 #-
^AN0/] 0#Y"*F49C^ES8YWYG%-[E&&PAI!TR;6($Z/)\QD8QL,7B/OI M;D:>/WM!GA$NR T/0WSZ>MPVF(MEU/9SWM.,-SW >T1NI# K35Z+ ()J?!LU M*(2@#T),J1/P#N)3TNV<$-
JAO1H^LQ\/[SKH=(OGTDWQNH\^EQ-RJ36@BP M]9)C^]R"GRAEE;>CWDFAB@M73'--[M_B!.3:0*3_J5,[8].K9V-?/NB[T3+AU6JS,$+,",H*0176_8)U_TC6@,_Q4;X9
M:'^;2K]/=_C6#/+ZHWJ^@X+OP,GW,@Q!+9D@1C&A6?8.O[^!: ZJMKZ<<,?6 M5T-@E;#)]68PR:%:PBL(MQ9(=R9NV2"?W$YLZN+)D:26,DUM^Y!$W0O MQ,>W.8IBUQX\U#P
Q6Q1U61QY9[GWJO5\6R_"^A@M[5K!GF>5]\JHR+OD9,/ M6B<39JLJ]O,1>4Y'>VPHW66\/\;KTGK"7J?T!!TGY==L&0+Y^(.M[08[MD2; M0JNFOF6'O"?
5WCF=IL1K"*TJ'BW%H_]/BT_SB2J=V-VM_=I!_0/%7QHOSVE/ M?J%?<^!M/CUOE_/^F,&!%XQ76A[/[7G>R348I/;#J[$;[^BJ:PBMFGUIG;S^ MTVI9IY4[6KR&T*KBE3[.>\3(-
=>R@YK%<[?Z]\<<6JQ*/^8Y7_3]@DRE6(,R?(XK[@SFAMS9PT;$>+UQ!:]:M%Z=6HVZMM55-6_D4US27*H_-JJO/1CR#? MTUKU\JCJC^3.3M^XH7]6E-+%4:?1F61-
E7Z;?!_NAJZP8ZMAZ;0JJF7'HS2 M)]5,U&D)CQ:O(;2J>*7WHV[OMU4W,JV;ER]K&\>--I'? ^]+2 M2%*WD3RT&-FJ<790HWZR*;2J"*6?I$_+3])&_613:%7Q2C])W7[R&@LH\Y/V
M^_[N4:5Q4G9S,.MR M>Q5_3 2I,'LD3LAFQ7&.#2@@,>.IGFE6W!(*OZ=DR',-D,E!7YS6M55[:\,N MPH>1;GQJG"\1)MOJ**X6FZM7Z9;BSO6I=S[S:JY?TN'Y%$NU[LX9WDGW:=OE
MU-DN[PU32XZ5%,(":71.A_@N4=G&:79B9)QN)&PO=V]R M:W-H965T^^^SZ?SZ.-L4^N0B1XKI5V MXZ@B:B[BV!45UL*=F 8U[RR-K06Q:5>Q:RR*,B35*DZ3Y#RNA=11-
@J^NG')2X<3MK\$IR8YZ\<5N.H\030H4%>03!OS5>H5(>B&G\ M[#"COJ1/W%V_H%\'[:PE%PZOC/HF2ZK&T:<(2ER*5M&]V=Q@I^?,XQ5&N?"%
M31>;1%"TCDS=)3.#6NKM7SQWY["3D*:O)*1=0AIX;PL%EE-!(AM9LP'KHQG- M+X+4D,WDI/9-69#E7%1J!9AAL*U%OG$"3[8MLE,$O8B?&6U$(7 M4BBXDR*72I)$]Y)@5WN$8%
[C534L.#N?",FR%) NACN!PBB0D+PY M:IA)I;A#;A03*_*\XJ)C/]FR3U]AO\#F!-+/QY FZ0 >%E,X/#CZ&R;F ^E/ M)>U/)0VXP]=PV]S8DH42*[HR>HV69*X0)D:7#K[/L,[1_H#?
<*G6AK"H>M\^ M$6\6\V-WX1I1X#CBN7)HUQAE[]^=GB=?WI RZ*4, OK@GPT^ADOGD+LA=+F_ M=SPE]UBTUOH6^JBO1MO>,1%.LO8[+@"WA+7;JW7P'[0.>ZW#-
]LVQ9SX0CFR M;;C%2RX$HC:MIGU4MV#G &>R_",U$W;%!4#ADI.2DX]G M$=CMX&\-,DT8MMP0CVY85OQ6HO4!O+\T?%TZP\]O__IF?P!02P,$% @ MR(!F6>E)%F:B P -@T !D
!X;"]W;W)K&UL MS5?;;MLX$/T50BV*%FBCBZ_)V@(2&\$&:-H@3KH/P3[0TM@B0I$N2=GMW^^0 M4K16(JL7^*$OMDC.&>IDQFS/?UTD&.=4G<@," M5U92Y=3@4*U]O5% 4P?
*N1\%P=#/*1->/"%S-RJ>R,)P)N!&$5WD.57?+X#+ MW=0+O:>)6[;.C)WPX\F&KF$!YGYSHW#DUUI2EH/03 JB8#7USL.S>>@ 3N(+ M@YW>^R;6E:64CW9PE4Z]P%H$'!)C55#\V\
(,.+>:T(ZOE5*OWM,"][^?M%\Z MY]&9)=4PD_P?EHLZHT]DL**%MS.2";J;)9Y.!(G<9%61/[]LY&,KX.U1ZOYB3MZ_? MD=>$"7+-.,?
0ZXEOT!%KCI]41L]*HZ,#1B]@O]D,/WY%QK,)I0D9*/C"X99X:!;K!U"TFA%!-K)_5) M"E5/E#0^?,0-R)6!7/_;1DYI3;_=&GM0G.D-36#JX4F@06W!B]^\"H?!7VU4
M'4E9@[A>35RO2WM\)PWE+49==,,>PE9:2M#0@>QQMXW#\2@()_YVW]\VJ?%P M4$LU'.G7CO0[+5J 8%)A+ W&^ARCNL#*Q4.W3(#OF KB$8/?$'NXAGP)JM65 MSMU^-
<)'4M8@9E 3,_BC2F-P3.*.I*Q!W+ F;OA[I=$-.U :)6BPG_3#,#I] M5AHM4J,H[+>7QJAV9/3SI6&C.I-B"\JP)8>G@IC#$J\43 *--TS"BQ2SX5ZD
M>)OQOY(RAJ4C6O*QG]4T8R/2=R1E#6(.ZV)._V] MHNF&'2B:TQM2&FR"W6>&#QM05@#75Q(=K09V@_JI%/\'4$L#!!0 (_,B 9EE/ M^#:KXP$ % $ 9 >&PO=V]R:W-
H965TM!5$%4*-X M$L=+W@BIHSP-OK7-4].ADAK6EKFN:83]?0_*]%FTB(Z.C=S7Z!T\3UNQAT? M'^W:DL4GEDHVH)TTFEG89='=XK9(?'Y(>)+0N]F<^4ZVQCQ[XVN51;$O"!24
MZ!D$#0%43]EA746?8Q8!3O1*=R8 M_@N,_7SP?*51+GQ9/^2NDHB5G4/3C&"JH)%Z&,7KN YS0'P&D(R Y!\ "9\& MW(R F]#H4%EHZY- D:?6],SZ;&+SD[V08:ZD=KOXB-:BDK"8?
Y-;$&E'(G* M.W@YPNX'V.(,[$$!;26> !:7]9Z$ZN MC%/)4]W)5'<2>-Z?X2F$JZ^8_[*' METX>A*)RW!7;@$,K2X1J" I=_>>; 4YU?EFX<^_V0K2_/)-_9V1_=7S@3E=O
M'9=EBT%V&63]W3ODR7(5#T_*#_.UXK/]]G?MN[![J1U3L"-P?+VBLV.'\SL8 M:-JPEUN#=*#"M*8K#]8G4'QG#!X-?ZJFGTC^!U!+ P04 " #(@&99JK0: M9'4# '%P #0 'AL+W-
T>6QE!4$YG=.,E*V\H$(C:2XSHG17SH*RD)0D M)3AE/.BVVU&0$2;\T4 LLJM,E=XT7P@U]#OMCMUW,0W5Q(A MKI'#Q%UWNKOYX@F'1R7<.I1RM11!M3%&@S07]?X(?
6O0T4E&O7O"A_Z8<#:1 M#+Q2DC&^LN8N&*8YSZ6G],;49Y#*A MLKY/^&O3:,!I"G(DF\WAJO(B %"I/-.A)%9+HC1L/:H&HV2CF_@1O:UW2'
M>YENK:LI8[%I:D%5T]+8#O!OLUGN;=KH2;Q>P>YS]6&ATQ&F#[5"KR5-V=+T ME^E& ,;>P=E)4?#5>\YF(J,V^;,#C@9D[>?-<\E^Z&A0*E-MH-+W[JE4;+IM M^2Y)
<4N7:EU.RQ37W&V@YG\[SS,JJ"1\6[2N_9<\RT]6'/:>2[*YJ^P+=FJL M#BDO7>1%$T1&31#9B)KL-T%DW "1O6>[:SY&9*<)(KM-$!F^2)%!=:C<.KGN
MG%LW5@_>#X;^%W@;X750;[)@7#%1]>8L2:AX<'S5](I,]%O^#K\>G]"4++BZ MW8!#OVY_I@E;9/%FU#5,1#6];G^"]/19>/URHF,QD= E3<955\XFINGIAHY:
M?"^5C,C0"&Q<$48#[6"XOS/^731_.Q&*:M[T3ZJ$\?];%>+F1L MOE@FA"L$RQ2L1RQ2?:T#<\P8><>Q>;2P.>&"K@-4.Q'?'@9IR^X0AK"JF#=O! M.!+'& *UZ*
[1*$)F)X*O>WVP71*&<>Q& ',K"$,,@=V((Y@"T(A86B>@WO/ MHV#]G KJ?WV/_@!02P,$% @ R(!F69>*NQS $P(L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7-
>=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%H%R=.B':5_'$*L(W]<&SI>6695W?6?;FU]HOX MVK7&7XS6(6S.QV-?KU4G_9]VHPRL65K7R0 ?
W6KL-T[)QJ^5"ET[3L_.RG$G MM1F]?G78U]R-\0<;5!VT-;"P7_!)JSO_L+[_*';:ZUO=ZO#M8C2\;]5(=-KH M3G]7S<7H;"3\VMZ]MTY_MR;(=E$[V[87HV2_XI-R0=>_+5[TD#?
RU@]+@KS] M* 'D8E2>P0Z7VODP;#'L7P+C3L'&^T_;8-_J-BAW)8-ZY^QVH\VJWPW\BC'Z M&4,=#]_[(IZ[_U-&NUSJ6EW9>MLI$_9U=*KM 8U?ZXT?"2,[=3&:VIUR8BY7
MJO]1<)19L_^! 1+ O+E"2&C2B9G5$]^QHLYE]_$ MSHNYS"]G(PZ;#%AB.,DW"K1H(1Q#01("Z>3E$L:APE& 29L-\5#MEMDHL MG>U$#='. : 7=SJL1;V-,"G%),R.F1G #)
^581$"25A-LJL@?5ZJ24<%FP< MH$WT!.+2^SB))911$F:EO+.VN=-MBWDH>23,]KA2MT'8VU:OY&_M@/)%PBR, M*^7T3O8C$*&-
#VZ[]X4TC5BK9H6#-26,E%D8UVHE6[%0(;3J@?#:>@]9RP2, M22DC91^B=)T.#X!]QP+J4*:.&W!*CE*8G='_$[!J/1KS$2I(F56Q8>P!M/* MH0L1NMM([88J_B'
:\%A3,H:*;,U_I+.P/F$X5Q_Z3T7&X!>K&6465+*%RFS M+RYKV&3;#O'/#C6%;V,D6 M D&G9![|"^R]@.LH=*;,[CH8\\>RF-[!_CBDIDZ3<0X\C:>\89$9Y)&/V"!G[
MHO%11GDD8Q]ZW,>^HR6D])%QZX/,?P)CDK>YF(UR"(!'ZTP[V:+1\LYY9C\ M%+>U#IA1H\DIQ^1/=(/K!D>>%V+?,]W@44M.3J9PSZ8H3$+C$EY)V?V#DZZT+ZW72?=
MM_T\WRX>@N64A7)F"Y&A-YZ0I"Q4,%N(QL1-J* L5#!;Z#Z;1V>\GX]\CC')A\M.>@\. M]YLE9:&2V4(T9M1O4A8JF2U$8T;])F6ADME"-";N-RO*0A6SA1Z=J]VW)XQ)
M6:ABMA"^/[RO[!3='\9-J*(L5#%;B,;$3:BB+%0Q6^C^-G8T9/NY5,PQ)F6A MBME"&!.-@7[>L\%WY"K*0A6SA1#F?XPL*\I"%;.%'IDB.%P"&)-\R/DD#QG<
MUQ9C4A:JF"U$5C,*HT\T(_,7&_.:$L-&&V$(V)^\T)9:$)LX7^-34< M>=7_S0DZ^%E07=_HFTF5)U7>)!B3LM!DL-!XV-B_?M6HI3:J^0<.X6%Y+=MZ M[D3_,CSWF.9%_^SCW&\?
RCKH?UKAS;X:$[E]/ER*;K MC^UX6?;;^MRNW]MMJ66Y]+J_GU$]/]W/7+Q^GLO_3.PVF_VZ_.S6OX_E-/YC M+E[=5U;^\I:J>.T@@2.8/ M4@C2^8,,@FS^H Q!>?
X@AR"?/R@@*.8/:B"HF3_H$8(>YP]*2Y1Q29 TP9I MZX1<)P*O$X*=",1.2'8B,#LAVHE [81L)P*W$*=".1.2'BOJK01Z*^JM!'HK
MZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'K;Y&4W@=Z&>AN!WH9Z&X'> MAGH;@=Z&>AN!WH9Z&X'>&?7.!'IGU#L3Z)U1[TR@=T:],X'>&?7.!'KGR<=* M
KTSZIT)],ZH=R;0.Z/>F4#OC'IG KT=]78"O1WU=@*]'?5V KT=]78"O1WU M=@*]'?5V KU]\K,)@=Z.>CN!WHYZ.X'>CGH[@=Z!>@>!WH%Z!X'>@7H'@=Z!
M>@>!WH%Z!X'>@7H'@=Z!>@>!WC'Y69! [T"]@T#O0+V#0.\&]6X(]&Y0[X9 M[P;U;KY3[V"\/)3AUO.UQNM_)]7CY=QRN_QU^;5S,DIC9K$EFV@O/V<%) VL0I4I'TW
MC5K;YSOQD7Y7O?KY%"@M#D,_IDVURSE\82PU.QIL3>5" MZ+O&Y;+.'L;VKY3ES_UXH!B[EA:W+N;O M;BB[V*%G*3_UE.K3)=[HT6^W74.M;^Z'QG)='H92B&*N3O]BJ^)I?39[T?
3M%MJWYE= MKO?1Q_T\C\3FQ_EW_.>,7^M_L \!TH<$Z4.!]*%!^C @?5B0/M8@?5R"],%7 M*(V@B,I12.4HIG(45#F*JAR%58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K
M0)%5H,@J4&05*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4626*K I%5H4B MJT*15:'(JE!D52BR*A19%8JL"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-
M(JM&D56CR&I09#4HLAH460V*K 9%5H,BJT&1U:#(:E!D-2BR6A19+8JL%D56 MBR*K19'5HLAJ462U*+):%%DMBJQK%%G7*+*N_Z>LO[S??W+_*P'UXTO^6S^ M8_SU;U!+ 0(4
Q0 (,B 9ED'04UB@0 +$ 0 " M 0 !D;V-0&UL4$L! A0#% @ R(!F62V>MY?M M*P(!$ (!KP &1O8U!R;W!S+V-O&UL4$L! A0# M% @ R(!F69E&PO=V]R:W-H965T&UL4$L! A0# M%
@ R(!F69@YX](K" L", !@ ("!D0T 'AL+W=O M"DA@(,0& M 8 " @?(5 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ R(!F6?YAKAE* M @ U 0 !@ ("!3B 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ R(!F64K0.I&T @ @@ !@ M ("!%S$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R(!F6;-H2W%- P MU0H !D ("![T('AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ R(!F67%=\V1)!P *Q, !D M ("!KUP 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ R(!F6;G:,@@F"@ HAX !D ("!96T 'AL M+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ R(!F M64M)ED42! F H !D ("!"Y 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R(!F6?C\!3G.!@ S!4 M !D ("!7\8 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% @ R(!F63<@6:T!# (R$!D M ("![]4 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ R(!F60Q=$4:5 P Y@< !D ("!G_ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @
R(!F6>D0 MO6'6 @ "08 !D ("!/OT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R(!F6<*+H"#9! P1 !D M ("!+@H! 'AL+W=O&PO M=V]R:W-H965TL3 0!X;"]W;W)K&UL4$L!
A0#% @ R(!F651[U!/$!P OQ4 !D ("! M-1@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ R(!F6?)?)=FE#0 3I< !D ("!32L! 'AL+W=O&UL4$L! A0#% @ R(!F63&"IB\9 M! P T
!D ("!_U0! 'AL+W=O%6YF4" "(!0 &0 M@(%/60$ >&PO=V]R:W-H965TM; 0!X;"]W;W)K&UL4$L! A0#% @ R(!F65'H]S[G!P 730 !D M ("!X64! 'AL+W=O&PO=V]R M:W-H965TQP
0!X;"]W;W)K&UL M4$L! A0#% @ R(!F63'8QNCI P KQ(!D ("!+W@! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MR(!F69P!I\,_! .!T !D ("!0(L! 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ R(!F6;P+[+/ P -!4 !D M ("!<+&PO=V]R:W-H M965T&UL4$L! M A0#% @ R(!F6&PO=V]R:W-H965T&UL4$L! A0#% @ R(!F M60??$>?;!@ G3X !D ("![?8!
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R(!F68H.UDY*! 5A(M !D ("!<@8" 'AL+W=O&PO=V]R:W-H965T4. @!X;"]W;W)K&UL4$L! A0#% @ R(!F64FD/+!&PO=V]R:W-
H965T M&UL4$L! A0# M% @ R(!F6=II1/7I"0 CUX !D ("!WR@" 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ R(!F60N^ M87P3 P QPL !D ("!PSX" 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ R(!F6>E)%F:B P -@T !D M ("!$DL" 'AL+W=O&PO M=V]R:W-H965T K @!;0V]N=&5N=%]4>7!E&UL4$L%!@ !: %H K1@ +]@ @ $! end XML 94 Show.js
IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 95 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover {

background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 97 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 671 372 1 true 163 0 false 8 false false R1.htm 1001 - Document - Cover Page Sheet http://www.tevapharm.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Consolidated Balance Sheets Sheet http://www.tevapharm.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Consolidated Statements of Income (Loss) Sheet http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss Consolidated Statements of Income (Loss) Statements 4 false false R5.htm 1005 - Statement - Consolidated Statements of Income (Loss) (Parenthetical) Sheet http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical Consolidated Statements of Income (Loss) (Parenthetical) Statements 5 false false R6.htm 1006 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 6 false false R7.htm 1007 - Statement - Consolidated Statements of Changes in Equity Sheet http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity Consolidated Statements of Changes in Equity Statements 7 false false R8.htm 1008 - Statement - Consolidated Statements of Changes in Equity (Parenthetical) Sheet http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical Consolidated Statements of Changes in Equity (Parenthetical) Statements 8 false false R9.htm 1009 - Statement - Consolidated Statements of Cash Flows Sheet http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 1010 - Statement - Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical Consolidated Statements of Cash Flows (Parenthetical) Statements 10 false false R11.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 11 false false R12.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 12 false false R13.htm 999001 - Disclosure - Basis of presentation Sheet http://www.tevapharm.com/role/BasisOfPresentation Basis of presentation Notes 13 false false R14.htm 999002 - Disclosure - Certain transactions Sheet http://www.tevapharm.com/role/CertainTransactions Certain transactions Notes 14 false false R15.htm 999003 - Disclosure - Revenue from contracts with customers Sheet http://www.tevapharm.com/role/RevenueFromContractsWithCustomers Revenue from contracts with customers Notes 15 false false R16.htm 999004 - Disclosure - Inventories Sheet http://www.tevapharm.com/role/Inventories Inventories Notes 16 false false R17.htm 999005 - Disclosure - Identifiable Intangible Assets Sheet http://www.tevapharm.com/role/IdentifiableIntangibleAssets Identifiable Intangible Assets Notes 17 false false R18.htm 999006 - Disclosure - Goodwill Sheet http://www.tevapharm.com/role/Goodwill Goodwill Notes 18 false false R19.htm 999007 - Disclosure - Debt obligations Sheet http://www.tevapharm.com/role/DebtObligations Debt obligations Notes 19 false false R20.htm 999008 - Disclosure - Derivative instruments and hedging activities Sheet http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities Derivative instruments and hedging activities Notes 20 false false R21.htm 999009 - Disclosure - Legal Settlements and Loss Contingencies Sheet http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies Legal Settlements and Loss Contingencies Notes 21 false false R22.htm 999010 - Disclosure - Commitments and contingencies Sheet http://www.tevapharm.com/role/CommitmentsAndContingencies Commitments and contingencies Notes 22 false false R23.htm 999011 - Disclosure - Income taxes Sheet http://www.tevapharm.com/role/IncomeTaxes Income taxes Notes 23 false false R24.htm 999012 - Disclosure - Other assets impairments, restructuring and other items Sheet http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems Other assets impairments, restructuring and other items Notes 24 false false R25.htm 999013 - Disclosure - Earnings (Loss) per Share Sheet http://www.tevapharm.com/role/EarningsLossPerShare Earnings (Loss) per Share Notes 25 false false R26.htm 999014 - Disclosure - Accumulated other comprehensive income (loss) Sheet http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated other comprehensive income (loss) Notes 26 false false R27.htm 999015 - Disclosure - Segments Sheet http://www.tevapharm.com/role/Segments Segments Notes 27 false false R28.htm 999016 - Disclosure - Fair value measurement Sheet http://www.tevapharm.com/role/FairValueMeasurement Fair value measurement Notes 28 false false R29.htm 999017 - Disclosure - Basis of presentation (Tables) Sheet http://www.tevapharm.com/role/BasisOfPresentationTables Basis of presentation (Tables) Tables http://www.tevapharm.com/role/BasisOfPresentation 29 false false R30.htm 999018 - Disclosure - Certain transactions (Tables) Sheet http://www.tevapharm.com/role/CertainTransactionsTables Certain transactions (Tables) Tables http://www.tevapharm.com/role/CertainTransactions 30 false false R31.htm 999019 - Disclosure - Revenue from contracts with customers (Tables) Sheet http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables Revenue from contracts with customers (Tables) Tables http://www.tevapharm.com/role/RevenueFromContractsWithCustomers 31 false false R32.htm 999020 - Disclosure - Inventories (Tables) Sheet http://www.tevapharm.com/role/InventoriesTables Inventories (Tables) Tables http://www.tevapharm.com/role/Inventories 32 false false R33.htm 999021 - Disclosure - Identifiable Intangible Assets (Tables) Sheet http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables Identifiable Intangible Assets (Tables) Tables http://www.tevapharm.com/role/IdentifiableIntangibleAssets 33 false false R34.htm 999022 - Disclosure - Goodwill (Tables) Sheet http://www.tevapharm.com/role/GoodwillTables Goodwill (Tables) Tables http://www.tevapharm.com/role/Goodwill 34 false false R35.htm 999023 - Disclosure - Debt obligations (Tables) Sheet http://www.tevapharm.com/role/DebtObligationsTables Debt obligations (Tables) Tables http://www.tevapharm.com/role/DebtObligations 35 false false R36.htm 999024 - Disclosure - Derivative instruments and hedging activities (Tables) Sheet http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables Derivative instruments and hedging activities (Tables) Tables http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities 36 false false R37.htm 999025 - Disclosure - Other assets impairments, restructuring and other items (Tables) Sheet http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables Other assets impairments, restructuring and other items (Tables) Tables http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems 37 false false R38.htm 999026 - Disclosure - Accumulated other comprehensive income (loss) (Tables) Sheet http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated other comprehensive income (loss) (Tables) Tables http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss 38 false false R39.htm 999027 - Disclosure - Segments (Tables) Sheet http://www.tevapharm.com/role/SegmentsTables Segments (Tables) Tables http://www.tevapharm.com/role/Segments 39 false false R40.htm 999028 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.tevapharm.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables 40 false false R41.htm 999029 - Disclosure - Basis of presentation - Additional information (Detail) Sheet http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail Basis of presentation - Additional information (Detail) Details 41 false false R42.htm 999030 - Disclosure - Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail) Sheet http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail) Details 42 false false R43.htm 999031 - Disclosure - Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Parenthetical) (Detail) Sheet http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Parenthetical) (Detail) Details 43 false false R44.htm 999032 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail) Sheet http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail Certain Transactions - Other Transactions - Additional Information (Detail) Details 44 false false R45.htm 999033 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) Sheet http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) Details 45 false false R46.htm 999034 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail) Sheet http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail Revenue from Contracts with Customers - Additional Information (Detail) Details 46 false false R47.htm 999035 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) Sheet http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) Details 47 false false R48.htm 999036 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) Sheet http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) Details 48 false false R49.htm 999037 - Disclosure - Inventories - Summary of Inventories (Detail) Sheet http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail Inventories - Summary of Inventories (Detail) Details 49 false false R50.htm 999038 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail) Sheet http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail Identifiable Intangible Assets - Additional Information (Detail) Details 50 false false R51.htm 999039 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) Sheet http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) Details 51 false false R52.htm 999040 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) Sheet http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) Details 52 false false R53.htm 999041 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) Sheet http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) Details 53 false false R54.htm 999042 - Disclosure - Goodwill - Additional Information (Detail) Sheet http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail Goodwill - Additional Information (Detail) Details 54 false false R55.htm 999043 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail) Sheet http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail Debt Obligations - Schedule of Short-term Debt (Detail) Details 55 false false R56.htm 999044 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail) Notes http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail Debt Obligations - Schedule of Senior Notes and Loans (Detail) Details 56 false false R57.htm 999045 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) Notes http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) Details 57 false false R58.htm 999046 - Disclosure - Debt Obligations - Additional Information (Detail) Sheet http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail Debt Obligations - Additional Information (Detail) Details 58 false false R59.htm 999047 - Disclosure - Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail) Sheet http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail) Details 59 false false R60.htm 999048 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) Sheet http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) Details 60 false false R61.htm 999049 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail) Sheet http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail) Details 61 false false R62.htm 999050 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail) Sheet http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail) Details 62 false false R63.htm 999051 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail) Sheet http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail Derivative Instruments and Hedging Activities - Additional Information (Detail) Details 63 false false R64.htm 999052 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail) Sheet http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail Legal Settlements and Loss Contingencies - Additional Information (Detail) Details 64 false false R65.htm 999053 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 65

false false R66.htm 999054 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 66 false false R67.htm 999055 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) Sheet http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) Details 67 false false R68.htm 999056 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) Sheet http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDis Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) Details 68 false false R69.htm 999057 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) Sheet http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) Details 69 false false R70.htm 999058 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail) Sheet http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail Other assets impairments, restructuring and other items - Additional Information (Detail) Details 70 false false R71.htm 999059 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail) Sheet http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail Earnings (Loss) per Share - Additional Information (Detail) Details http://www.tevapharm.com/role/EarningsLossPerShare 71 false false R72.htm 999060 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail) Sheet http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail Accumulated Other Comprehensive Income (Loss) (Detail) Details 72 false false R73.htm 999061 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Detail) Sheet http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Detail) Details 73 false false R74.htm 999062 - Disclosure - Segments - Summary of Segment Profit (Detail) Sheet http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail Segments - Summary of Segment Profit (Detail) Details 74 false false R75.htm 999063 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail) Sheet http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail Segments - Schedule of Revenues by Major Products and Activities (Detail) Details 75 false false R76.htm 999064 - Disclosure - Segments - Additional Information (Detail) Sheet http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail Segments - Additional Information (Detail) Details 76 false false R77.htm 999065 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) Sheet http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) Details 77 false false R78.htm 999066 - Disclosure - Fair value measurement - Additional Information (Detail) Sheet http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail Fair value measurement - Additional Information (Detail) Details 78 false false R79.htm 999067 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) Sheet http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) Details 79 false false R80.htm 999068 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail) Sheet http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail) Details 80 false false R81.htm 999069 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) Sheet http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) Details 81 false false R9999.htm Uncategorized Items - d874174d10q.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - d874174d10q.htm Cover 82 false false All Reports Book All Reports d874174d10q.htm teva-20240930.xsd teva-20240930_cal.xml teva-20240930_def.xml teva-20240930_lab.xml teva-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 100 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d874174d10q.htm": { "nsprefix": "teva", "nsuri": "http://www.tevapharm.com/20240930", "dts": { "inline": { "local": ["d874174d10q.htm"] }, "schema": { "local": ["teva-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["teva-20240930_cal.xml"] }, "definitionLink": { "local": ["teva-20240930_def.xml"] }, "labelLink": { "local": ["teva-20240930_lab.xml"] }, "presentationLink": { "local": ["teva-20240930_pre.xml"] } }, "keyStandard": 267, "keyCustom": 105, "axisStandard": 35, "axisCustom": 6, "memberStandard": 56, "memberCustom": 105, "hidden": { "total": 17, "http://xbrl.sec.gov/dei/2024": 6, "http://fasb.org/us-gaap/2024": 8, "http://xbrl.sec.gov/ecd/2024": 3 }, "contextCount": 671, "entityCount": 1, "segmentCount": 163, "elementCount": 865, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1400, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 9 }, "report": { "R1": { "role": "http://www.tevapharm.com/role/CoverPage", "longName": "1001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "longName": "1002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R3": { "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "longName": "1004 - Statement - Consolidated Statements of Income (Loss)", "shortName": "Consolidated Statements of Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R5": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "longName": "1005 - Statement - Consolidated Statements of Income (Loss) (Parenthetical)", "shortName": "Consolidated Statements of Income (Loss) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "P07_01_2023To09_30_2023_MinimumMembersrtRangeAxis", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["div", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2023To09_30_2023_MinimumMembersrtRangeAxis", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["div", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "1006 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R7": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "longName": "1007 - Statement - Consolidated Statements of Changes in Equity", "shortName": "Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2022_CommonStockMembersrtGaapStatementEquityComponentsAxis", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R8": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "longName": "1008 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)", "shortName": "Consolidated Statements of Changes in Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024_CommonStockMembersrtGaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024_CommonStockMembersrtGaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "longName": "1009 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R10": { "role":

"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "longName": "1010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "P06_01_2023To06_30_2023", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-7", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": null }, "R12": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "ecd:TrdArrIndName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "ecd:TrdArrIndName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.tevapharm.com/role/BasisOfPresentation", "longName": "999001 - Disclosure - Basis of presentation", "shortName": "Basis of presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.tevapharm.com/role/CertainTransactions", "longName": "999002 - Disclosure - Certain transactions", "shortName": "Certain transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "teva:CertainTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "teva:CertainTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers", "longName": "999003 - Disclosure - Revenue from contracts with customers", "shortName": "Revenue from contracts with customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.tevapharm.com/role/Inventories", "longName": "999004 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssets", "longName": "999005 - Disclosure - Identifiable Intangible Assets", "shortName": "Identifiable Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.tevapharm.com/role/Goodwill", "longName": "999006 - Disclosure - Goodwill", "shortName": "Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.tevapharm.com/role/DebtObligations", "longName": "999007 - Disclosure - Debt obligations", "shortName": "Debt obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities", "longName": "999008 - Disclosure - Derivative instruments and hedging activities", "shortName": "Derivative instruments and hedging activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies", "longName": "999009 - Disclosure - Legal Settlements and Loss Contingencies", "shortName": "Legal Settlements and Loss Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.tevapharm.com/role/CommitmentsAndContingencies", "longName": "999010 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.tevapharm.com/role/IncomeTaxes", "longName": "999011 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems", "longName": "999012 - Disclosure - Other assets impairments, restructuring and other items", "shortName": "Other assets impairments, restructuring and other items", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "teva:OtherExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "teva:OtherExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.tevapharm.com/role/EarningsLossPerShare", "longName": "999013 - Disclosure - Earnings (Loss) per Share", "shortName": "Earnings (Loss) per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss", "longName": "999014 - Disclosure - Accumulated other comprehensive income (loss)", "shortName": "Accumulated other comprehensive income (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.tevapharm.com/role/Segments", "longName": "999015 - Disclosure - Segments", "shortName": "Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.tevapharm.com/role/FairValueMeasurement", "longName": "999016 - Disclosure - Fair value measurement", "shortName": "Fair value measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.tevapharm.com/role/BasisOfPresentationTables", "longName": "999017 - Disclosure - Basis of presentation (Tables)", "shortName": "Basis of presentation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.tevapharm.com/role/CertainTransactionsTables", "longName": "999018 - Disclosure - Certain transactions (Tables)", "shortName": "Certain transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order":

"30", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables", "longName": "999019 - Disclosure - Revenue from contracts with customers (Tables)", "shortName": "Revenue from contracts with customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.tevapharm.com/role/InventoriesTables", "longName": "999020 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables", "longName": "999021 - Disclosure - Identifiable Intangible Assets (Tables)", "shortName": "Identifiable Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.tevapharm.com/role/GoodwillTables", "longName": "999022 - Disclosure - Goodwill (Tables)", "shortName": "Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.tevapharm.com/role/DebtObligationsTables", "longName": "999023 - Disclosure - Debt obligations (Tables)", "shortName": "Debt obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "longName": "999024 - Disclosure - Derivative instruments and hedging activities (Tables)", "shortName": "Derivative instruments and hedging activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables", "longName": "999025 - Disclosure - Other assets impairments, restructuring and other items (Tables)", "shortName": "Other assets impairments, restructuring and other items (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "999026 - Disclosure - Accumulated other comprehensive income (loss) (Tables)", "shortName": "Accumulated other comprehensive income (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.tevapharm.com/role/SegmentsTables", "longName": "999027 - Disclosure - Segments (Tables)", "shortName": "Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.tevapharm.com/role/FairValueMeasurementTables", "longName": "999028 - Disclosure - Fair Value Measurement (Tables)", "shortName": "Fair Value Measurement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail", "longName": "999029 - Disclosure - Basis of presentation - Additional information (Detail)", "shortName": "Basis of presentation - Additional information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_RestatementAdjustmentMembersrtRestatementAxis", "name": "teva:ContingentConsderationRelatedExpenses", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R42": { "role": "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "longName": "999030 - Disclosure - Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail)", "shortName": "Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "teva:ImpairmentsRestructuringAndOthers", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2023To09_30_2023_RestatementAdjustmentMembersrtRestatementAxis", "name": "teva:ImpairmentsRestructuringAndOthers", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R43": { "role": "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail", "longName": "999031 - Disclosure - Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Parenthetical) (Detail)", "shortName": "Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["div", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R44": { "role": "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "longName": "999032 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)", "shortName": "Certain Transactions - Other Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail", "longName": "999033 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)", "shortName": "Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef":

"d874174d10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "longName": "999034 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)", "shortName": "Revenue from Contracts with Customers - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024_USsrtStatementGeographicalAxis", "name": "teva:SalesReservesAndAllowancesToCustomersPercentage", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024_USsrtStatementGeographicalAxis", "name": "teva:SalesReservesAndAllowancesToCustomersPercentage", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "longName": "999035 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)", "shortName": "Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024_ProductMembersrtProductOrServiceAxis", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R48": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail", "longName": "999036 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)", "shortName": "Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:SalesReservesAndAllowancesCurrentTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:SalesReservesAndAllowancesCurrentTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail", "longName": "999037 - Disclosure - Inventories - Summary of Inventories (Detail)", "shortName": "Inventories - Summary of Inventories (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "longName": "999038 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)", "shortName": "Identifiable Intangible Assets - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail", "longName": "999039 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)", "shortName": "Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "longName": "999040 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)", "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:Goodwill", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "teva:GoodWillRelativeFairValueAllocation", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R53": { "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail", "longName": "999041 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)", "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": ["div", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": ["div", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "longName": "999042 - Disclosure - Goodwill - Additional Information (Detail)", "shortName": "Goodwill - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2024_TevasUnitedStatesEuropeInternationalMarketsAndMedisReportingUnitsMemberusgaapReportingUnitAxis", "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R55": { "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "longName": "999043 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)", "shortName": "Debt Obligations - Schedule of Short-term Debt (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R56": { "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "longName": "999044 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)", "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:SeniorNotes", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:SeniorNotes", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "longName": "999045 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)", "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "PAsOn10_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis", "name": "teva:SeniorNotesRepaidAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "td", "tr", "table", "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn10_31_2024_SeniorNotesMemberusgaapLongtermDebtTypeAxis", "name": "teva:SeniorNotesRepaidAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "td", "tr", "table", "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "longName": "999046 - Disclosure - Debt Obligations - Additional Information (Detail)", "shortName": "Debt Obligations - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "teva:LongTermDebtCurrencyPortionUSD", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "teva:LongTermDebtCurrencyPortionUSD", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail", "longName": "999047 - Disclosure - Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail)", "shortName": "Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "PAsOn09_30_2024_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis", "name": "us-gaap:DerivativeAssetNotionalAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis", "name": "us-gaap:DerivativeAssetNotionalAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "longName": "999048 -

{"Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)": {"shortName": "Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "PAsOn09_30_2024_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurr "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurr "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "longName": "999049 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomel "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomel "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail", "longName": "999050 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis", "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis", "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "longName": "999051 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "teva:RevenuesOtherThanUsd", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:DerivativeLossOnDerivative", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "td", "tr", "table", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R64": { "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail", "longName": "999052 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)", "shortName": "Legal Settlements and Loss Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "us-gaap:LegalMattersAndContingenciesTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "us-gaap:LegalMattersAndContingenciesTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "longName": "999053 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "PAsOn06_30_2024", "name": "teva:AnnualSalesAtTimeOfSettlement", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2024", "name": "teva:AnnualSalesAtTimeOfSettlement", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "longName": "999054 - Disclosure - Income Taxes - Additional Information (Detail)", "shortName": "Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "teva:ExpectedImpairmentOfIncomeTaxBenefit", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "teva:ExpectedImpairmentOfIncomeTaxBenefit", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail", "longName": "999055 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)", "shortName": "Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "ix:continuation", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "ix:continuation", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi "longName": "999056 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)", "shortName": "Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:RestructuringCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "ix:continuation", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis", "name": "us-gaap:RestructuringCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "teva:ScheduleOfRestructuringChargesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R69": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail", "longName": "999057 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)", "shortName": "Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:RestructuringReserve", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:RestructuringReserve", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "longName": "999058 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)", "shortName": "Other assets impairments, restructuring and other items - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:TangibleAssetImpairmentCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "teva:OtherExpensesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:TangibleAssetImpairmentCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail", "longName": "999059 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)", "shortName": "Earnings (Loss) per Share - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R72": { "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "longName": "999060 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R73": { "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "longName": "999061 - Disclosure - Accumulated Other Comprehensive

Income (Loss) (Parenthetical) (Detail)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "div", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "div", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail", "longName": "999062 - Disclosure - Segments - Summary of Segment Profit (Detail)", "shortName": "Segments - Summary of Segment Profit (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R75": { "role": "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "longName": "999063 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)", "shortName": "Segments - Schedule of Revenues by Major Products and Activities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "P07_01_2024To09_30_2024", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P07_01_2024To09_30_2024_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMedicianSMembersrtProductOrServiceAxis", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "unique": true } }, "R76": { "role": "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "longName": "999064 - Disclosure - Segments - Additional Information (Detail)", "shortName": "Segments - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2024To09_30_2024", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail", "longName": "999065 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)", "shortName": "Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:DerivativeAssets", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:DerivativeAssets", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "longName": "999066 - Disclosure - Fair value measurement - Additional Information (Detail)", "shortName": "Fair value measurement - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "teva:PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "div", "ix:continuation", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "teva:PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "longName": "999067 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)", "shortName": "Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail", "longName": "999068 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)", "shortName": "Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "PAsOn09_29_2023_AlvotechMemberusgaapBusinessAcquisitionAxis_SubordinatedConvertibleBondsMemberusgaapDebtInstrumentAxis", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "div", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_29_2023_AlvotechMemberusgaapBusinessAcquisitionAxis_SubordinatedConvertibleBondsMemberusgaapDebtInstrumentAxis", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "div", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail", "longName": "999069 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)", "shortName": "Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn09_30_2024", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true, "unique": true } }, "R9999": { "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "longName": "Uncategorized Items - d874174d10q.htm", "shortName": "Uncategorized Items - d874174d10q.htm", "isDefault": "false", "groupType": "", "subGroupType": "", "menuCat": "Cover", "order": "82", "firstAnchor": { "contextRef": "PAsOn06_30_2023", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": { "td", "tr", "table", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "d874174d10q.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "teva_AbingworthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AbingworthMember", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Abingworth [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 18.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Trade, Current", "verboseLabel": "Accounts payables", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r24", "r99"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivables, net of allowance for credit losses of $91 million and $95 million as of September 30, 2024 and December 31, 2023", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r1186"] }, "teva_AccountsReceivableSecuritizationFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AccountsReceivableSecuritizationFacilityMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounts Receivable Securitization Facility [Member]", "terseLabel": "Accounts Receivable Securitization Facility [Member]", "documentation": "Accounts receivable securitization facility." } } }, "auth_ref": [] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accrual for Environmental Loss Contingencies", "terseLabel": "Accrual for Environmental Loss Contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": ["r431", "r968", "r1131", "r1132", "r1222", "r1225"] }, "teva_AccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AccruedExpenses", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "terseLabel": "Accrued expenses", "documentation": "Accrued expenses." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Benefit Plans [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": ["r4", "r5", "r14", "r27", "r123", "r1161", "r1162", "r1163"] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Derivative Financial Instruments [Member]", "documentation":

```
"Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r210", "r218", "r219", "r594", "r950", "r1161" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r217", "r218", "r654", "r656", "r657", "r658", "r659", "r660" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 34.0 } }, "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r26", "r27", "r124", "r200", "r768", "r815", "r819" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r14", "r27", "r606", "r609", "r677", "r810", "r811", "r1161", "r1162", "r1163", "r1172", "r1173", "r1174", "r1177" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustments [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3", "r14", "r27", "r121", "r122", "r210", "r219", "r656", "r657", "r658", "r659", "r660", "r1161" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r1081" ] }, "teva_AdditionalDevelopmentAndMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AdditionalDevelopmentAndMilestonePaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Additional Development And Milestone Payments Receivable", "terseLabel": "Additional development and milestone payments receivable", "documentation": "Additional development and milestone payments receivable." } } }, "auth_ref": [] }, "teva_AdditionalMilestonePaymentPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AdditionalMilestonePaymentPayable", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Additional Milestone Payment Payable", "terseLabel": "Additional milestone payment payable", "documentation": "Additional milestone payment payable." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 32.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "verboseLabel": "Additional\u00a0paid-in\u00a0capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r112", "r1011", "r1323" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r830", "r1172", "r1173", "r1174", "r1177", "r1249", "r1324" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r1094" ] },
"ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r1094" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r1094" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r1094" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Amortization", "terseLabel": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r11" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r186", "r245", "r246", "r247", "r248", "r260", "r309", "r310", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r401", "r402", "r417", "r557", "r558", "r559", "r560", "r561", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r578", "r579", "r580", "r583", "r584", "r585", "r586", "r587", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r648", "r649", "r664", "r665", "r666", "r672", "r673", "r674", "r675", "r676", "r677", "r720", "r721", "r722", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r61", "r62", "r514" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operations:" } } }, "auth_ref": [] }, "teva_AggregateFundingOnAccountOfResearchAndDevelopmentExpenditure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AggregateFundingOnAccountOfResearchAndDevelopmentExpenditure", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Aggregate Funding On Account Of Research And Development Expenditure", "terseLabel": "Aggregate funding on account of research and development expenditure", "documentation": "Aggregate funding on account of research and development expenditure." } } }, "auth_ref": [] }, "teva_AggregateUpfrontAndMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AggregateUpfrontAndMilestonePayments", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Aggregate Upfront And Milestone Payments", "terseLabel": "Aggregate upfront and milestone payments", "documentation": "Aggregate Upfront And Milestone Payments." } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1127" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1053", "r1063", "r1073", "r1105" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r1056", "r1066", "r1076", "r1108" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1128" ] }, "teva_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AgreementAxis", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Agreement [Axis]", "documentation": "Agreement." } } }, "auth_ref": [] }, "teva_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AgreementDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Agreement [Domain]", "documentation": "Agreement." } } }, "auth_ref": [] }, "teva_AjovyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AjovyMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "AJOVY [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r1094" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r1101" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember",
```

```
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]",
"terseLabel": "All Individuals" } } }, "auth_ref": [ "r1057", "r1067", "r1077", "r1101", "r1109", "r1113", "r1121" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": [
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Other Segments [Member]", "terseLabel": "Other Segments
[Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r276", "r295", "r296",
"r297", "r298", "r299", "r302", "r958", "r959" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading
Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1119" ] }, "teva_AllerganTransactionMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.tevapharm.com/20240930", "localname": "AllerganTransactionMember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label":
"Allergan transaction [Member]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current",
"verboseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r201",
"r312", "r357" ] }, "teva_AlvotechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AlvotechMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" ], "lang": { "en-us": {
"role": { "label": "Alvotech [Member]", "documentation": "Alvotech." } } }, "auth_ref": [] }, "teva_AmendedRevolvingCreditFacilityMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.tevapharm.com/20240930", "localname": "AmendedRevolvingCreditFacilityMember", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Amended Revolving Credit Facility [Member]",
"documentation": "Amended revolving credit facility member." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label":
"Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } }
}, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "documentation": "The aggregate expense charged against
earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such
assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [
"r11", "r387", "r394", "r966" ] }, "teva_AmountsAllocatedToSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"AmountsAllocatedToSegmentsAbstract", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label":
"Amounts Allocated To Segments [Abstract]", "documentation": "Amounts allocated to segments." } } }, "auth_ref": [] }, "teva_AmountsNotAllocatedToSegmentsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AmountsNotAllocatedToSegmentsAbstract", "presentation": [
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Amounts Not Allocated To Segments [Abstract]",
"documentation": "Amounts not allocated to segments." } } }, "auth_ref": [] }, "teva_AndaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "AndaMember", "presentation": [
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Anda [Member]", "terseLabel":
"Anda [Member]", "documentation": "Anda [Member]" } } }, "auth_ref": [] }, "teva_AndroGelRateAtOnePercentageMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "AndroGelRateAtOnePercentageMember", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Andro Gel Rate At One Percentage
[Member]", "terseLabel": "AndroGel Rate at 1% [Member]", "documentation": "Andro gel rate at one percentage." } } }, "auth_ref": [] },
"teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales At The Time Of Nuvigil
Entered Into First Settlement Of With AN ANDA Filer", "terseLabel": "Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer",
"documentation": "Annual sales at the time of nuvigil entered into first settlement of with AN ANDA hiler." } } }, "auth_ref": [] }, "teva_AnnualSalesAtTimeOfSettlement": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AnnualSalesAtTimeOfSettlement", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales At Time Of Settlement",
"terseLabel": "Annual sales at the time of settlement", "documentation": "Annual sales at time of settlement." } } }, "auth_ref": [] }, "teva_AnnualSalesOfEffexor": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AnnualSalesOfEffexor", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Effexor", "terseLabel":
"Annual sales of Effexor", "documentation": "Annual sales of effexor." } } }, "auth_ref": [] }, "teva_AnnualSalesOfLamictal": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "AnnualSalesOfLamictal", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Lamictal", "terseLabel":
"Annual sales of Lamictal", "documentation": "Annual sales of Lamictal." } } }, "auth_ref": [] }, "teva_AnnualSalesOfNiaspan": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "AnnualSalesOfNiaspan", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Niaspan", "terseLabel":
"Annual sales of Niaspan", "documentation": "Annual sales of Niaspan." } } }, "auth_ref": [] }, "teva_AnnualSalesOfRevlimid": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "AnnualSalesOfRevlimid", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Revlimid", "terseLabel":
"Annual Sales Of Revlimid", "documentation": "Annual sales of revlimid." } } }, "auth_ref": [] }, "teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "AnnualSalesOfTheTimeOfNewLaunchOfAtripla", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of New
Launch Of Atripla", "terseLabel": "Annual sales of the time of New launch of Atripla", "documentation": "Annual sales of the time of new launch of Atripla." } } }, "auth_ref": []
}, "teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"AnnualSalesOfTheTimeOfNewLaunchOfTruvada", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of New
Launch Of Truvada", "terseLabel": "Annual sales of the time of New launch of Truvada", "documentation": "Annual sales of the time of new launch of truvada." } } },
"auth_ref": [] }, "teva_AnnualSalesOfTheTimeOfNewLaunchOfViread": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"AnnualSalesOfTheTimeOfNewLaunchOfViread", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of New
Launch Of Viread", "terseLabel": "Annual sales of the time of New launch of viread", "documentation": "Annual sales of the time of new launch of viread." } } }, "auth_ref": [] },
"teva_AnnualSalesOfTheTimeOfSettlementOfAtripla": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"AnnualSalesOfTheTimeOfSettlementOfAtripla", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of Settlement
Of Atripla", "terseLabel": "Annual sales of the time of settlement of Atripla", "documentation": "Annual sales of the time of settlement of atripla." } } }, "auth_ref": [] },
"teva_AnnualSalesOfTheTimeOfSettlementOfTruvada": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"AnnualSalesOfTheTimeOfSettlementOfTruvada", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of Settlement
Of Truvada", "terseLabel": "Annual sales of the time of settlement of Truvada", "documentation": "Annual sales of the time of settlement of truvada." } } }, "auth_ref": [] },
"teva_AnnualSalesOfTheTimeOfSettlementOfViread": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"AnnualSalesOfTheTimeOfSettlementOfViread", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of Settlement
Of Viread", "terseLabel": "Annual sales of the time of settlement of viread", "documentation": "Annual sales of the time of settlement of viread." } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from
Computation of Earnings Per Share, Amount", "terseLabel": "Weighted average shares with anti-dilutive effect on earnings per share", "documentation": "Securities (including
those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not
included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
} } }, "auth_ref": [ "r269" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel":
"Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r41" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from
Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation":
"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or
many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares
attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the
period presented." } } }, "auth_ref": [ "r41" ] }, "teva_ApplicabilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"ApplicabilityAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Applicability [Axis]",
"documentation": "Applicability." } } }, "auth_ref": [] }, "teva_ApplicabilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "ApplicabilityDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Applicability [Domain]", "documentation": "Applicability." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": {
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than
collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r588" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": null,
```

```
"weight": null, "order": null, "root": true } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "terseLabel": "Total assets",
"documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r165", "r176", "r196", "r232", "r273", "r279", "r297", "r301", "r346",
"r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r590", "r595", "r651", "r764", "r863", "r958", "r959", "r1011", "r1044", "r1232", "r1233", "r1277" ] },
"us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-
gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation":
"Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r190", "r205", "r232", "r346", "r437", "r438", "r440", "r441",
"r442", "r443", "r444", "r446", "r447", "r590", "r595", "r651", "r1011", "r1232", "r1233", "r1277" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": {
"role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueAdjustment": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueAdjustment", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": {
"role": { "label": "Assets, Fair Value Adjustment", "verboseLabel": "Expected loss on sale", "documentation": "Amount of addition (reduction) to the amount at which an asset
could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit",
"calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
"terseLabel": "Assets held for sale", "verboseLabel": "Total assets of the disposal group classified as held for sale in the consolidated balance sheets", "documentation":
"Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } }
}, "auth_ref": [ "r1", "r96", "r98", "r140", "r143", "r188", "r189" ] }, "teva_AustedoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "AustedoMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": {
"role": { "label": "Austedo [Member]", "terseLabel": "AUSTEDO [Member]", "documentation": "Austedo [Member]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype":
"perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": {
"en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1116" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1117" ] },
"ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": {
"label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r1112" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing,
How MNPI Considered" } } }, "auth_ref": [ "r1112" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing
Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r1112" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": {
"label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r1112" ] }, "ecd_AwardTmgMnpiDiscTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI
Disclosure" } } }, "auth_ref": [ "r1112" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined
[Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1112" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]",
"terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r515", "r516", "r517", "r518",
"r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540" ] },
"ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } },
"auth_ref": [ "r1115" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to
MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1114" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1113" ] },
"ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time
to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1113" ] }, "us-
gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": {
"role": { "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]", "documentation": "Information by location in statement of financial position
where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r411", "r1290", "r1291" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": {
"role": { "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]", "documentation": "Location in statement of financial position where
disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r77", "r80", "r411", "r1290", "r1291" ] }, "teva_BasisOfPresentationAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "BasisOfPresentationAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentation" ], "lang":
{ "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of presentation", "documentation": "The entire
disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial
statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant
accounting policies of the reporting entity." } } }, "auth_ref": [ "r137" ] }, "teva_BendekaAndTreandaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "BendekaAndTreandaMember", "presentation": [
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "BENDEKA and TREANDA
[Member]", "verboseLabel": "BENDEKA and TREANDA [Member]", "documentation": "BENDEKA and TREANDA." } } }, "auth_ref": [] },
"teva_BeneficialInterestObtainedInExchangeForSecuritizedAccountsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "BeneficialInterestObtainedInExchangeForSecuritizedAccountsReceivables", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Beneficial Interest Obtained in Exchange for Securitized
Accounts Receivables", "terseLabel": "Beneficial interest obtained in exchange for securitized accounts receivables", "documentation": "Beneficial interest obtained in
exchange for securitized accounts receivables." } } }, "auth_ref": [] }, "teva_BiolojicDesignLtdMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "BiolojicDesignLtdMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Biolojic Design Ltd [Member]",
"terseLabel": "Biolojic Design Ltd [Member]", "documentation": "Biolojic design ltd." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]",
"terseLabel": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually
immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r392",
"r577", "r990", "r991" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis",
"presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "terseLabel":
"Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r63",
"r64", "r388", "r389", "r390", "r391", "r392", "r577", "r990", "r991" ] }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredAbstract", "lang": { "en-us": { "role": { "label": "Business Combination,
Consideration Transferred [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr":
"debit", "calculation": {
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
"parentTag": "teva_ImpairmentAndRestructuring", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": {
"en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "definitionGuidance":
"Contingent consideration", "verboseLabel": "Business combination contingent consideration arrangements change in amount of contingent consideration liability",
"documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } },
"auth_ref": [ "r582", "r1166" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination,
```

Contingent Consideration, Liability", "terseLabel": "Business combination contingent consideration", "negatedLabel": "Contingent consideration", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r66", "r156", "r581", "r628", "r629", "r630"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Business combination, contingent consideration, liability, measurement input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": ["r628", "r629", "r630"] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "teva_COPAXONEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "COPAXONEMember", "presentation": ["http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"], "lang": { "en-us": { "role": { "label": "COPAXONE [Member]", "terseLabel": "COPAXONE [Member]", "documentation": "COPAXONE." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 8.0 }, "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 28.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r34", "r192", "r941"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1252", "r1253"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodStartLabel": "Balance of cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Balance of cash, cash equivalents and restricted cash at end of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r34", "r134", "r229"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "verboseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r134"] }, "teva_CertainTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "CertainTransactionsDisclosureTextBlock", "presentation": ["http://www.tevapharm.com/role/CertainTransactions"], "lang": { "en-us": { "role": { "label": "Certain Transactions Disclosure [Text Block]", "terseLabel": "Certain transactions", "documentation": "This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r1092"] }, "teva_ChargebacksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ChargebacksMember", "presentation": ["http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"], "lang": { "en-us": { "role": { "label": "Chargebacks [Member]", "terseLabel": "Chargebacks [Member]", "documentation": "Chargebacks." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r1089"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r1087"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.tevapharm.com/role/CoverPage"], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "teva_CivilActionInRespectOfDonationsToPatientAssistanceProgrammersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "CivilActionInRespectOfDonationsToPatientAssistanceProgrammersMember", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Civil Action In Respect Of Donations To Patient Assistance Programmers [Member]", "terseLabel": "Civil Action In Respect Of Donations To Patient Assistance Programmers [Member]", "documentation": "Civil action in respect of donations to patient assistance programmers." } } }, "auth_ref": [] }, "teva_CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Civil Investigative Demand From Department Of Justice Civil Division [Member]", "terseLabel": "Civil Investigative Demand From Department Of Justice Civil Division [Member]", "documentation": "Civil investigative demand from department of justice civil division." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r1093"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r1093"] }, "teva_CollaborativeAgreementMilestoneAmountIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "CollaborativeAgreementMilestoneAmountIncrease", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Agreement Milestone Amount Increase", "terseLabel": "Collaborative agreement milestone amount increase", "documentation": "Collaborative agreement milestone amount increase." } } }, "auth_ref": [] }, "teva_CollaborativeAgreementMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "CollaborativeAgreementMilestonePayments", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Agreement Milestone Payments", "terseLabel": "Collaborative agreement milestone payments", "documentation": "Collaborative Agreement Milestone Payments" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": ["r588"] }, "teva_CommitmentAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "CommitmentAndContingenciesLineItems", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Commitment And Contingencies [Line Items]", "terseLabel": "Commitment And Contingencies [Line Items]", "documentation": "Commitment And Contingencies [Line Items]" } } }, "auth_ref": [] }, "teva_CommitmentAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "CommitmentAndContingenciesTable", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Commitment And Contingencies [Table]", "terseLabel": "Commitment And Contingencies [Table]", "documentation": "Commitment And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies, see note 10", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r108", "r168", "r766", "r850"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r147", "r426", "r427", "r924", "r1217", "r1224" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Ordinary Shares [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1029", "r1030", "r1031", "r1033", "r1034", "r1035", "r1038", "r1172", "r1173", "r1177", "r1249", "r1321", "r1324" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par or stated value per share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r111" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares, authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r111", "r851" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r111" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 31.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Ordinary shares of NIS 0.10 par value per share; September 30, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,240 million shares and 1,227 million shares, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r111", "r767", "r1011" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r1098" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r1097" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r1099" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r1096" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss) attributable to Teva", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r28", "r214", "r216", "r223", "r759", "r780", "r782" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income (loss) attributable to non-controlling interests", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r9", "r69", "r72", "r214", "r216", "r222", "r758", "r780", "r781" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income (loss)", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r72", "r157", "r214", "r216", "r221", "r757", "r780" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r42", "r43", "r88", "r89", "r308", "r923" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r42", "r43", "r88", "r89", "r308", "r821", "r923" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r42", "r43", "r88", "r89", "r308", "r923", "r1142" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r42", "r43", "r88", "r89", "r308", "r923" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r174", "r236", "r273", "r281", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r958", "r959", "r1232", "r1233" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r174", "r236", "r273", "r281", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r958", "r959", "r1232", "r1233" ] }, "teva_ContingentConsderationRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ContingentConsderationRelatedExpenses", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Contingent Consderation Related Expenses", "terseLabel": "Contingent consideration related expenses", "documentation": "Contingent consderation related expenses." } } }, "auth_ref": [] }, "teva_ConversionOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ConversionOptionMember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label": "Conversion Option [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r150", "r449", "r450", "r460", "r461", "r462", "r466", "r467", "r468", "r469", "r470", "r974", "r975", "r976", "r977", "r978" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1237" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r478", "r479", "r482", "r1033", "r1034", "r1035", "r1038" ] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": [
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Corporate Segment [Member]", "terseLabel": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r1179" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 6.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r127", "r128", "r718" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r234", "r235", "r452", "r480", "r680", "r701", "r763", "r947", "r949" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
```

```
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r436", "r1230" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r436", "r1230", "r1231" ] }, "teva_CrossCurrencySwapCashFlowHedgeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "CrossCurrencySwapCashFlowHedgeMember", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" ], "lang": { "en-us": { "role": { "label": "Cross Currency Swap Cash Flow Hedge [Member]", "documentation": "Cross Currency Swap Cash Flow Hedge." } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "auth_ref": [ "r1270" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Debt, Current", "terseLabel": "Short-term debt", "verboseLabel": "Total short-term debt", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r198" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/DebtObligations" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt obligations", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r149", "r230", "r406", "r407", "r408", "r409", "r410", "r435", "r436", "r448", "r454", "r455", "r456", "r457", "r458", "r459", "r464", "r471", "r472", "r474", "r662" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r23", "r101", "r102", "r166", "r167", "r236", "r449", "r450", "r451", "r452", "r453", "r455", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r974", "r975", "r976", "r977", "r978", "r1010", "r1169", "r1218", "r1219", "r1220", "r1272", "r1273" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Gross", "terseLabel": "Principal amount currently outstanding on the debt instruments", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r23", "r167", "r475" ] }, "us-gaap_DebtInstrumentCovenantDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCovenantDescription", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Covenant Description", "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants." } } }, "auth_ref": [ "r23", "r92" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r449", "r662", "r663", "r975", "r976", "r1010" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Total", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r462", "r650", "r975", "r976", "r1253", "r1254", "r1255", "r1256", "r1263" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "definitionGuidance": "Interest rate", "terseLabel": "Weighted average interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r104", "r476", "r662", "r663", "r1010" ] }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateIncreaseDecrease", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "terseLabel": "Debt Instrument, Interest Rate, Increase (Decrease)", "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r236", "r449", "r450", "r451", "r452", "r453", "r455", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r974", "r975", "r976", "r977", "r978", "r1010", "r1169", "r1272", "r1273" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r199", "r974", "r1255", "r1256" ] }, "teva_DebtInstrumentMaturityYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DebtInstrumentMaturityYear", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Maturity Year", "terseLabel": "Maturity", "documentation": "Debt Instrument Maturity Year" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r23", "r236", "r449", "r450", "r451", "r452", "r453", "r455", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r974", "r975", "r976", "r977", "r978", "r1010", "r1169", "r1218", "r1219", "r1220", "r1272", "r1273" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r23", "r56", "r57", "r91", "r152", "r153", "r236", "r449", "r450", "r451", "r452", "r453", "r455", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r974", "r975", "r976", "r977", "r978", "r1010", "r1169", "r1272", "r1273" ] }, "teva_DefendantsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DefendantsAxis", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Defendants [Axis]", "documentation": "Defendants." } } }, "auth_ref": [] }, "teva_DefendantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DefendantsMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Defendants [Member]", "documentation": "Defendants." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Noncurrent, Net", "negatedLabel": "Less debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1271", "r1272", "r1273" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes",
```

```
"documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r544", "r545" ] }, "teva_DeferredIncomeTaxesNetAndUncertainTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DeferredIncomeTaxesNetAndUncertainTaxPositions", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes Net And Uncertain Tax Positions", "verboseLabel": "Deferred income taxes \u2013 net and uncertain tax positions", "documentation": "Deferred income taxes net and uncertain tax positions." } } }, "auth_ref": [] }, "teva_DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Prosecution Agreement With U.S. Department of Justice [Member]", "documentation": "Deferred prosecution agreement with U.S. department of justice." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Tax and Other Liabilities, Noncurrent", "terseLabel": "Deferred income taxes", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other." } } }, "auth_ref": [] }, "us-gaap_DemandDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DemandDepositsMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Demand Deposits [Member]", "terseLabel": "Cash, Deposits and Other [Member]", "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r11", "r52" ] }, "us-gaap_DerivativeAssetNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNotionalAmount", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset, Notional Amount", "verboseLabel": "Cross-currency swap - cash flow hedge", "documentation": "Nominal or face amount used to calculate payments on the derivative asset." } } }, "auth_ref": [ "r905", "r908", "r910", "r913", "r1246", "r1247", "r1248" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r597" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset", "terseLabel": "Derivatives", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r207", "r208", "r626", "r627", "r640", "r650", "r832", "r833", "r834", "r835", "r836", "r838", "r839", "r840", "r841", "r842", "r857", "r858", "r905", "r909", "r911", "r912", "r914", "r915", "r949", "r998", "r1003", "r1031", "r1254", "r1255", "r1256", "r1322" ] }, "us-gaap_DerivativeCashReceivedOnHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCashReceivedOnHedge", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Cash Received on Hedge", "documentation": "The amount of cash received during the period on settlement of a hedge." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r840", "r842", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r864", "r865", "r866", "r867", "r877", "r878", "r879", "r880", "r883", "r884", "r885", "r886", "r905", "r906", "r911", "r914", "r1029", "r1031", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1264", "r1265" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Asset derivatives", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r21", "r120", "r161", "r162", "r206", "r949" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Fair Value, Gross Liability", "negatedLabel": "Liability derivatives", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r21", "r120", "r161", "r162", "r206", "r949" ] }, "us-gaap_DerivativeGainOnDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainOnDerivative", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Gain on Derivative", "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r598" ] }, "us-gaap_DerivativeInstrumentDetailAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentDetailAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instrument Detail [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r78", "r81", "r83", "r163", "r840", "r842", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r864", "r865", "r866", "r867", "r877", "r878", "r879", "r880", "r883", "r884", "r885", "r886", "r905", "r906", "r911", "r914", "r949", "r1029", "r1031", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1264", "r1265" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r160", "r600", "r612" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r16", "r78", "r81" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Liability", "negatedLabel": "Derivatives", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r207", "r208", "r626", "r627", "r640", "r650", "r832", "r833", "r834", "r835", "r838", "r839", "r840", "r841", "r842", "r864", "r866", "r867", "r906", "r907", "r909", "r911", "r912", "r914", "r915", "r949", "r1254", "r1255", "r1256", "r1322" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r597" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r612" ] }, "us-gaap_DerivativeLossOnDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLossOnDerivative", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Loss on Derivative", "verboseLabel": "Derivative, negative impact", "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r598" ] }, "us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [
```

```
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes loss from derivative." } } }, "auth_ref": [ "r598" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Notional Amount", "verboseLabel": "Derivative notional amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1247", "r1248" ] }, "teva_DerivativeNotionalAmountDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DerivativeNotionalAmountDecrease", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Notional Amount Decrease", "terseLabel": "Derivative notional amount decrease", "documentation": "Derivative notional amount decrease." } } }, "auth_ref": [] }, "teva_DerivativeNotionalAmountIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DerivativeNotionalAmountIncrease", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Notional Amount Increase", "terseLabel": "Derivative notional amount increase", "documentation": "Derivative notional amount increase." } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative [Table]", "terseLabel": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r16", "r73", "r74", "r75", "r76", "r79", "r81", "r84", "r85", "r87", "r612" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Term of Contract", "terseLabel": "Derivatives term of contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" ], "lang": { "en-us": { "role": { "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r16" ] }, "teva_DevelopmentAndLaunchMilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DevelopmentAndLaunchMilestonePaymentReceivable", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Development and Launch Milestone Payment Receivable", "terseLabel": "Development and launch milestone payment receivable", "documentation": "Development and launch milestone payment receivable." } } }, "auth_ref": [] }, "teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Development Progress And Changes In Other Key Valuation Assumptions [Member]", "terseLabel": "Development Progress And Changes In Other Key Valuation Assumptions [Member]", "documentation": "Development progress and changes in other key valuation assumptions." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueAbstract", "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r502", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r502", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of disaggregates revenues by major revenue streams", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1235" ] }, "teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail" ], "lang": { "en-us": { "role": { "label": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Line Items]", "documentation": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments." } } }, "auth_ref": [] }, "teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail" ], "lang": { "en-us": { "role": { "label": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Table]", "documentation": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments" } } }, "auth_ref": [] }, "teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Table Text Block]", "terseLabel": "Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships", "documentation": "Disclosure in tabular form of pretax gain loss cash flow hedging instruments." } } }, "auth_ref": [] }, "teva_DiscontinuationOfBusinessAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DiscontinuationOfBusinessAxis", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Discontinuation Of Business [Axis]" } } }, "auth_ref": [] }, "teva_DiscontinuationOfBusinessDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DiscontinuationOfBusinessDomain", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Discontinuation Of Business [Domain]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivables", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r96", "r98", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "negatedLabel": "Accounts payables", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r96", "r98", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)", "negatedLabel": "Expected loss on sale", "documentation": "Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity." } } }, "auth_ref": [ "r90" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current", "terseLabel": "Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r96", "r98", "r140", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "terseLabel": "Identifiable intangible assets, net", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r96", "r98", "r140", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventories", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r96", "r98", "r140", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other current and non-current assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r96", "r98", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": {
```

```
"role": { "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "negatedLabel": "Other liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r96", "r98", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property, plant and equipment, net", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r96", "r98", "r140", "r143" ] }, "us-gaap_DistributionServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DistributionServiceMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Distribution Service [Member]", "terseLabel": "Distribution [Member]", "documentation": "Distribution assistance, including, but not limited to, marketing and selling fund shares, advertising, printing and mailing of prospectus and sale literature to investor." } } }, "auth_ref": [ "r1236" ] }, "teva_DividendDeclaredToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DividendDeclaredToNoncontrollingInterests", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividend Declared To Noncontrolling Interests", "terseLabel": "Dividend declared to non-controlling interests", "documentation": "Dividend declared to noncontrolling interests." } } }, "auth_ref": [] }, "us-gaap_DividendsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsAxis", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends [Axis]", "documentation": "Information by distribution of earnings to shareholder. Includes, but is not limited to, distribution paid and declared." } } }, "auth_ref": [] }, "us-gaap_DividendsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDomain", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends [Domain]", "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock." } } }, "auth_ref": [] }, "teva_DividendsPaidToNonControllingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DividendsPaidToNonControllingInterests", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends Paid To Non controlling Interests", "terseLabel": "Dividends paid to non-controlling interests", "documentation": "Dividends paid to noncontrolling interests." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A, the filing date, for all other submission types, the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r1048" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1080" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "teva_DonationOfClotrimazoleAndTobramycinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "DonationOfClotrimazoleAndTobramycinMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Donation of Clotrimazole and Tobramycin [Member]", "documentation": "Donation of clotrimazole and tobramycin." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r1091" ] }, "teva_EagleTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "EagleTransactionMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label": "Eagle Transaction [Member]", "terseLabel": "Eagle Transaction [Member]", "documentation": "Eagle transaction." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per share attributable to ordinary shareholders:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r224", "r249", "r250", "r252", "r253", "r254", "r256", "r262", "r264", "r266", "r267", "r268", "r272", "r575", "r587", "r623", "r624", "r760", "r783", "r951" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r224", "r249", "r250", "r252", "r253", "r254", "r256", "r264", "r266", "r267", "r268", "r272", "r575", "r587", "r623", "r624", "r760", "r783", "r951" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r261", "r269", "r270", "r271" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 27.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Translation adjustment on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r652" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory tax rate in Israel", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r233", "r547", "r562", "r993" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsOther", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Other, Percent", "terseLabel": "Effective income tax rate reconciliation, tax settlement, other, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax settlements." } } }, "auth_ref": [ "r1171", "r1239", "r1240" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Employee-related obligations", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r102" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi ], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Employee termination [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "teva_EmployeeTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "EmployeeTerminationMember", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Employee Termination [Member]", "terseLabel": "Employee termination costs [Member]", "documentation": "Employee termination." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": {
```

```
"label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] },
"dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [
"http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "terseLabel": "Entity Address, Country", "documentation": "ISO
3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip
Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype":
"centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ],
"lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify
entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1046" ] }, "dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares
Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests,
if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A
[Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90
days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation":[
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss", "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",
"http://www.tevapharm.com/role/CertainTransactions", "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CertainTransactionsTables", "http://www.tevapharm.com/role/CommitmentsAndContingencies",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/DebtObligations",
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "http://www.tevapharm.com/role/DebtObligationsTables",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "http://www.tevapharm.com/role/EarningsLossPerShare",
"http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurement",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail", "http://www.tevapharm.com/role/FairValueMeasurementTables",
"http://www.tevapharm.com/role/Goodwill", "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
"http://www.tevapharm.com/role/GoodwillTables", "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
"http://www.tevapharm.com/role/IncomeTaxes", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.tevapharm.com/role/Inventories",
"http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail", "http://www.tevapharm.com/role/InventoriesTables",
"http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
"http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables", "http://www.tevapharm.com/role/Segments",
"http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail", "http://www.tevapharm.com/role/SegmentsTables" ], "lang": { "en-us": { "role": { "label": "Entity
[Domain]", "terseLabel": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities
or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include
business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1046" ] }, "dei_EntityFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-
us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix
may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } },
"auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate
whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the
Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1046" ] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or
Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation."
} } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent",
"presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data
Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1130" ] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The
exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1046" ] }, "dei_EntityShellCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ],
"lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell
company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1046" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity
Small Business", "terseLabel": "Smaller Reporting Company", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [
"r1046" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber",
"presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax
Identification Number", "documentation": "The Tax Identification Number (TIN, also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned
by the IRS." } } }, "auth_ref": [ "r1046" ] }, "teva_EosinophilicEsophagitisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "EosinophilicEsophagitisMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": {
"en-us": { "role": { "label": "Eosinophilic Esophagitis [Member]", "terseLabel": "Eosinophilic Esophagitis [Member]", "documentation": "Eosinophilic Esophagitis [Member]" }
} }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity
Awards Adjustments, Footnote" } } }, "auth_ref": [ "r1085" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments,
Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1126" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1126" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember":
{ "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary
Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [
"r1126" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": {
"label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityComponentDomain", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
"http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel":
"Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred,
treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r183", "r217", "r218", "r219", "r242", "r243", "r244", "r246", "r254", "r257", "r259", "r274", "r350", "r356",
"r402", "r492", "r557", "r558", "r571", "r572", "r573", "r576", "r586", "r587", "r604", "r606", "r607", "r608", "r609", "r611", "r622", "r654", "r656", "r657", "r658", "r659",
```

```
"r660", "r665", "r667", "r677", "r778", "r810", "r811", "r812", "r830", "r889" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesMember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Equity Securities
[Member]", "terseLabel": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other
legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [
"r50", "r1013", "r1039", "r1040", "r1041", "r1326" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [
"r1095" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel":
"Erroneous Compensation Analysis" } } }, "auth_ref": [ "r1053", "r1063", "r1073", "r1105" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r1050", "r1060", "r1070", "r1102" ]
}, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail" ], "lang": { "en-us": { "role": {
"label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r249", "r250", "r251",
"r256", "r257", "r258", "r259", "r272" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember",
"presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": {
"label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "auth_ref": [ "r1325", "r1327", "r1328", "r1329" ] }, "teva_EuropeSegmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "EuropeSegmentMember", "presentation": [
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Europe Segment [Member]", "terseLabel": "Europe
[Member]", "documentation": "Europe segment." } } }, "auth_ref": [] }, "teva_EventBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "EventBasisAxis", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"label": "Event Basis [Axis]", "documentation": "Event basis ." } } }, "auth_ref": [] }, "teva_EventBasisDomain": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "EventBasisDomain", "presentation": [
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Event Basis [Domain]", "documentation":
"Event basis ." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel":
"Executive Category:" } } }, "auth_ref": [ "r1101" ] }, "teva_ExitAndDisposalAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"ExitAndDisposalAxis", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ],
"lang": { "en-us": { "role": { "label": "Exit And Disposal [Axis]", "terseLabel": "Exit And Disposal [Axis]", "documentation": "Exit And Disposal [Axis]" } } }, "auth_ref": [] },
"teva_ExitAndDisposalDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ExitAndDisposalDomain", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Exit
And Disposal [Domain]", "terseLabel": "Exit And Disposal [Domain]", "documentation": "Exit And Disposal [Domain]" } } }, "auth_ref": [] },
"teva_ExpectedImpairmentOfIncomeTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"ExpectedImpairmentOfIncomeTaxBenefit", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "label": "Expected Impairment OF Income Tax Benefit", "terseLabel": "Expected impairment of income tax benefit", "documentation": "Expected impairment of
income tax benefit." } } }, "auth_ref": [] }, "teva_FactoringInstitutionAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"FactoringInstitutionAxis", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Factoring Institution [Axis]",
"documentation": "Factoring institution." } } }, "auth_ref": [] }, "teva_FactoringInstitutionDomain": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "FactoringInstitutionDomain", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Factoring Institution [Domain]",
"documentation": "Factoring institution." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "lang": { "en-
us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and
Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
[Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r626", "r627", "r640", "r998" ] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value
Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of
information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r626", "r627", "r640", "r998" ] }, "us-
gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementTables" ], "lang": {
"en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Instrument Measured
on a Basis Other Than Fair Value", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not
limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized
and transfers between levels 1 and 2." } } }, "auth_ref": [ "r626", "r627" ] }, "us-
gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]",
"terseLabel": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r631", "r632", "r633", "r634", "r635", "r636", "r641", "r1001" ] }, "us-
gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]",
"terseLabel": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r631", "r632", "r633", "r634", "r635", "r636", "r641", "r1001" ] }, "us-
gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ],
"lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within
fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r462", "r505", "r506", "r507", "r508", "r509", "r510",
"r625", "r627", "r628", "r629", "r630", "r639", "r640", "r642", "r687", "r688", "r689", "r975", "r976", "r987", "r988", "r989", "r998", "r1003" ] }, "us-
gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]",
"terseLabel": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r631", "r632", "r633", "r634", "r635", "r636", "r641" ] }, "us-
gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": {
"role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurement" ], "lang": { "en-us": {
"role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurement", "documentation": "The entire disclosure for the fair value of financial
instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related
to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required
items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information
pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3)
significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum
amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing
such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are
managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items
presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the
effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate
carrying value of items included in the balance sheet that are not eligible for the election, (7) all other required (as defined) and desired information." } } }, "auth_ref": [
"r635", "r637", "r638", "r639", "r642", "r643", "r644", "r645", "r646", "r754", "r998", "r1004" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level
1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the
measurement date." } } }, "auth_ref": [ "r462", "r505", "r510", "r627", "r640", "r687", "r987", "r988", "r989", "r998" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
```

"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r462", "r505", "r510", "r627", "r628", "r640", "r688", "r975", "r976", "r987", "r988", "r989", "r998"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r462", "r505", "r506", "r507", "r508", "r509", "r510", "r627", "r628", "r629", "r630", "r640", "r689", "r975", "r976", "r987", "r988", "r989", "r998", "r1003"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r631", "r632", "r633", "r634", "r635", "r636", "r641"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r631", "r636", "r641"] }, "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityConversionOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityConversionOption", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Assets And Liability Conversion Option", "terseLabel": "Conversion option**", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis assets and liability conversion option." } } }, "auth_ref": [] }, "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityInvestmentInConvertibleBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityInvestmentInConvertibleBond", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Assets And Liability Investment In Convertible Bond", "terseLabel": "Investment in convertible bond", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis assets and liability investment in convertible bond." } } }, "auth_ref": [] }, "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityRedemptionOfConvertibleBondSecurity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsAndLiabilityRedemptionOfConvertibleBondSecurity", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Assets And Liability Redemption Of Convertible Bond Security", "terseLabel": "Redemption of convertible bond security", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis assets and liability redemption of convertible bond security." } } }, "auth_ref": [] }, "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease", "terseLabel": "Adjustments to provisions for contingent consideration", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "terseLabel": "Settlement of contingent consideration", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r634", "r641"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "negatedPeriodStartLabel": "Fair value at the beginning of the period", "negatedPeriodEndLabel": "Fair value at the end of the period", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r631", "r641"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r462", "r505", "r506", "r507", "r508", "r509", "r510", "r625", "r627", "r628", "r629", "r630", "r639", "r640", "r642", "r687", "r688", "r689", "r975", "r976", "r987", "r988", "r989", "r998", "r1003"] }, "us-gaap_FairValueNetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetAssetLiability", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Net Asset (Liability)", "terseLabel": "Total", "documentation": "Fair value of asset after deduction of liability." } } }, "auth_ref": ["r1252", "r1253"] }, "teva_FinancialExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "FinancialExpensesMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Financial expenses [Member]", "terseLabel": "Financial expenses [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r473", "r490", "r612", "r647", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r699", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r779", "r964", "r998", "r1001", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1013", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1187", "r1188", "r1189", "r1190", "r1251", "r1254", "r1255", "r1256", "r1263", "r1266"] }, "teva_FineForViolatingTheAntitrustLawsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "FineForViolatingTheAntitrustLawsMember", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Fine for Violating the Antitrust Laws [Member]", "documentation": "Fine for violating the antitrust laws." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Amortization of intangible assets useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r194", "r369", "r393", "r966"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r386", "r388", "r389", "r390", "r392", "r393", "r395", "r396", "r719", "r723", "r937"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying amount net of impairment", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r369", "r393", "r723", "r966"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r386", "r393", "r395", "r396", "r399", "r719", "r937", "r966"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their

nature or by their use in the operations of a company." } } }, "auth_ref": ["r386", "r388", "r389", "r390", "r392", "r393", "r395", "r396", "r937"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Identifiable intangible assets, net", "totalLabel": "Net carrying amount", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r719", "r1212"] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": ["r949", "r987", "r997", "r998"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r1057", "r1067", "r1077", "r1109"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r1057", "r1067", "r1077", "r1109"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r1057", "r1067", "r1077", "r1109"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r1057", "r1067", "r1077", "r1109"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1057", "r1067", "r1077", "r1109"] }, "teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses", "terseLabel": "Forward starting interest rate swaps and treasury lock agreements losses", "documentation": "Forward starting interest rate swaps and treasury lock agreements losses." } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r1090"] }, "us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Fresh-Start Adjustments [Axis]", "terseLabel": "Fresh-Start Adjustments [Axis]", "documentation": "Information by adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting." } } }, "auth_ref": ["r681", "r682", "r1011"] }, "teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "FromSeptemberFifteenthTwoThousandAndTwentySixMember", "presentation": ["http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"], "lang": { "en-us": { "role": { "label": "From September Fifteenth Two Thousand And Twenty Six [Member]", "documentation": "From september fifteenth two thousand and twenty six." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": ["r78"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "verboseLabel": "General and administrative expenses", "terseLabel": "G&A expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r131", "r873"] }, "teva_GenericPipelineProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "GenericPipelineProductsMember", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Generic Pipeline Products [Member]" } } }, "auth_ref": [] }, "teva_GenericsMediciansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "GenericsMediciansMember", "presentation": ["http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"], "lang": { "en-us": { "role": { "label": "Generics Medicians [Member]", "terseLabel": "Generic products [Member]", "documentation": "Generics Medicians." } } }, "auth_ref": [] }, "teva_GoodWillRelativeFairValueAllocation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "GoodWillRelativeFairValueAllocation", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"], "lang": { "en-us": { "role": { "label": "Good will Relative Fair Value Allocation", "verboseLabel": "Goodwill allocation related to the shift of Canada to International Markets", "documentation": "Good will Relative Fair Value Allocation." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r193", "r371", "r755", "r959", "r965", "r1000", "r1011", "r1195", "r1202"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillDisclosureTextBlock", "presentation": ["http://www.tevapharm.com/role/Goodwill"], "lang": { "en-us": { "role": { "label": "Goodwill Disclosure [Text Block]", "terseLabel": "Goodwill", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": ["r370", "r373", "r383", "r965"] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"], "lang": { "en-us": { "role": { "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedLabel": "Translation differences", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r379"] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated goodwill impairment", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r374", "r381", "r965"] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 11.0 }, "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 24.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment", "verboseLabel": "Impairment of goodwill", "negatedLabel": "Goodwill impairment", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r11", "r372", "r378", "r384", "r965", "r1000"] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": ["http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r965"] }, "teva_GoodwillReclassification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "GoodwillReclassification", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"], "lang": { "en-us": { "role": { "label": "Goodwill Reclassification", "terseLabel": "Goodwill reclassified as assets held for sale", "documentation": "Goodwill reclassification." } } }, "auth_ref": [] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "lang": { "en-us": { "role": { "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "terseLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r125", "r129", "r175", "r232", "r346", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r651", "r953", "r958", "r1178", "r1181", "r1182", "r1183", "r1184", "r1232"] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",

```
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } } }, "auth_ref": [ "r16", "r599" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r16" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r16" ] }, "teva_ImpairmentAndRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ImpairmentAndRestructuring", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": {
"en-us": { "role": { "label": "Impairment And Restructuring", "totalLabel": "Total", "documentation": "Impairment and restructuring." } } }, "auth_ref": [] }, "us-
gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": {
"en-us": { "role": { "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]", "verboseLabel":
"Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement
of income or comprehensive income that includes impairment of long-lived asset held for use." } } }, "auth_ref": [ "r403" ] }, "us-
gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets (Excluding
Goodwill)", "terseLabel": "Impairment of intangible assets excluding goodwill", "documentation": "The amount of impairment loss recognized in the period resulting from the
write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r11", "r387", "r398" ] },
"teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "label": "Impairment Of Intangible Assets Reasons For Impairment [Axis]", "documentation": "Impairment Of Intangible Assets Reasons For
Impairment." } } }, "auth_ref": [] }, "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain", "presentation": [
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Impairment Of Intangible Assets Reasons
For Impairment [Domain]", "documentation": "Impairment Of Intangible Assets Reasons For Impairment." } } }, "auth_ref": [] },
"teva_ImpairmentOfLongLivedAssetsAndAssetsHeldForSaleFiniteAndIndefiniteLivedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "ImpairmentOfLongLivedAssetsAndAssetsHeldForSaleFiniteAndIndefiniteLivedIntangibleAssetsOtherThanGoodwill",
"crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
], "lang": { "en-us": { "role": { "label": "Impairment Of Long Lived Assets And Assets Held For Sale Finite And Indefinite Lived Intangible Assets Other Than Goodwill",
"terseLabel": "Impairment of long-lived assets and assets held for sale", "documentation": "Impairment of long lived assets and assets held for sale finite and indefinite lived
intangible assets other than goodwill." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
"parentTag": "teva_ImpairmentAndRestructuring", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": {
"en-us": { "role": { "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Impairments of long-lived tangible assets", "documentation": "The aggregate
amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } },
"auth_ref": [ "r11", "r51", "r142", "r999" ] }, "teva_ImpairmentsRestructuringAndOthers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "ImpairmentsRestructuringAndOthers", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag":
"us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 13.0 } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": {
"role": { "label": "Impairments Restructuring And Others", "verboseLabel": "Other assets impairments, restructuring and other items", "terseLabel": "Other asset impairments,
restructuring and other items", "documentation": "Impairments restructuring and others." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "In-Process Research and
Development [Member]", "terseLabel": "In process research and development [Member]", "verboseLabel": "In process research and development [Member]", "documentation":
"In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and
translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1205", "r1206", "r1207",
"r1208", "r1209", "r1210", "r1212", "r1213", "r1214", "r1215" ] }, "teva_IncomeLossFromContinuingOperationsBeforeIncomeTaxes": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.tevapharm.com/20240930", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxes", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income
Taxes", "terseLabel": "Pre-tax income (loss)", "documentation": "Income (Loss) from Continuing Operations before Income Taxes." } } }, "auth_ref": [] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": {
"role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before
income taxes", "terseLabel": "Income (loss) before income taxes", "presentationGuidance": "Consolidated income (loss) before income taxes", "documentation": "Amount of
income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income
(loss) from equity method investments." } } }, "auth_ref": [ "r175", "r784", "r953", "r1178", "r1181", "r1182", "r1183", "r1184" ] }, "us-
gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-
gaap_ProfitLoss", "weight": 1.0, "order": 17.0 } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical" ], "lang": { "en-
us": { "role": { "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Share in (profits) losses of associated companies, net", "terseLabel": "Income (Loss)
from equity method investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r11",
"r126", "r171", "r273", "r286", "r301", "r345", "r774" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi
], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]", "documentation": "Information by location in
statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r404", "r411", "r420", "r632", "r636", "r641", "r805", "r807", "r874", "r937",
"r1002", "r1292" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementLocationDomain", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi
], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]", "documentation": "Location in statement
of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r411", "r420", "r632", "r636", "r641", "r805", "r807", "r874", "r937", "r1002", "r1292" ] }, "us-
gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income
Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r553", "r1242" ] }, "us-gaap_IncomeTaxAuthorityNameDomain":
```

{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": ["r553", "r1242"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.tevapharm.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r233", "r543", "r547", "r550", "r551", "r552", "r554", "r555", "r563", "r565", "r566", "r567", "r827", "r993"] }, "teva_IncomeTaxExaminationIncreaseInIncomeTaxExpenseInTheCurrentPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "IncomeTaxExaminationIncreaseInIncomeTaxExpenseInTheCurrentPeriod", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Income Tax Examination Increase In Income Tax Expense In the Current Period", "terseLabel": "Income tax examination increase in income tax expense In the current period", "documentation": "Income tax examination increase in income tax expense In the current period" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 16.0 } }, "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income taxes (benefit)", "verboseLabel": "Tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r178", "r179", "r258", "r259", "r273", "r287", "r301", "r546", "r547", "r564", "r785", "r993"] }, "teva_IncomeTaxLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "IncomeTaxLineItems", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Income Tax [Line Items]", "terseLabel": "Income Tax [Line Items]", "documentation": "Income Tax [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherReconcilingItems", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount, Total", "terseLabel": "Effective income tax rate reconciliation, other reconciling items, amount, total", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law." } } }, "auth_ref": ["r1239", "r1240"] }, "us-gaap_IncomeTaxReconciliationTaxExemptIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxExemptIncome", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount", "terseLabel": "Effective income tax rate reconciliation, tax exempt income, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes." } } }, "auth_ref": ["r548", "r549", "r1239"] }, "us-gaap_IncomeTaxReconciliationTaxSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxSettlements", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount, Total", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount, Total", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements." } } }, "auth_ref": ["r1239", "r1240"] }, "teva_IncomeTaxTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "IncomeTaxTable", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Income Tax [Table]", "terseLabel": "Income Tax [Table]", "documentation": "Income Tax [Table]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital", "negatedLabel": "Net change in operating assets and liabilities", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": ["r10"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r1057", "r1067", "r1077", "r1101", "r1109", "r1113", "r1121"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r1119"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r1049", "r1125"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r1049", "r1125"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r1049", "r1125"] }, "teva_InstitutionAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "InstitutionAxis", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Institution [Axis]", "documentation": "Institution." } } }, "auth_ref": [] }, "teva_InstitutionDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "InstitutionDomain", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Institution [Domain]", "documentation": "Institution." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssets"], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Identifiable Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r385", "r397", "r400", "r936", "r937"] }, "teva_IntangibleAssetsImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "IntangibleAssetsImpairments", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "Intangible Assets Impairments", "terseLabel": "Intangible assets impairments", "documentation": "Intangible Assets Impairments" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "teva_InterestRateIncreaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "InterestRateIncreaseMember", "presentation": ["http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Interest Rate Increase [Member]", "terseLabel": "Interest Rate Increase [Member]", "documentation": "Interest rate increase." } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Interest Rate Swap [Member]", "terseLabel": "Asset Derivatives - Options and Forward Contracts [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": ["r938", "r1036", "r1037"] }, "teva_InternationalMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "InternationalMarketsMember", "presentation": ["http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "International Markets [Member]", "terseLabel": "International Markets [Member]", "documentation": "International markets." } } }, "auth_ref": [] }, "teva_InventoriesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "InventoriesLineItems", "presentation": ["http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "label": "Inventories [Line Items]", "terseLabel": "Inventories [Line Items]", "documentation": "Inventories [Line Items]" } } }, "auth_ref": [] }, "teva_InventoriesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "InventoriesTable", "presentation": ["http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "label": "Inventories [Table]", "terseLabel": "Inventories [Table]", "documentation": "Inventories [Table]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.tevapharm.com/role/Inventories"], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r366"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished products", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r139", "r944"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 10.0 }, "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r202", "r942", "r1011"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw and packaging materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r139", "r946"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Products in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r139", "r945" ] }, "us-gaap_InvestmentOwnedAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment Owned, Cost", "terseLabel": "Cost of the investment", "documentation": "Cost of the investment." } } }, "auth_ref": [ "r823", "r838", "r839", "r897", "r898", "r903", "r917", "r1031", "r1044", "r1322" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "terseLabel": "Investment in securities", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r1252", "r1253", "r1263" ] }, "us-gaap_IsraelTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IsraelTaxAuthorityMember", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Israel Tax Authority [Member]", "terseLabel": "Israel Tax Authority [Member]", "documentation": "Designated tax department of the government of Israel." } } }, "auth_ref": [] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "JP", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": {
"en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan [Member]" } } }, "auth_ref": [] }, "teva_JohnsonAndJohnsonMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "JohnsonAndJohnsonMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Johnson And Johnson [Member]", "terseLabel": "Johnson And Johnson [Member]", "documentation": "Johnson and Johnson [Member]." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r671", "r1144" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r671", "r1144" ] },
"dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss", "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",
"http://www.tevapharm.com/role/CertainTransactions", "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CertainTransactionsTables", "http://www.tevapharm.com/role/CommitmentsAndContingencies",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/DebtObligations",
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "http://www.tevapharm.com/role/DebtObligationsTables",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "http://www.tevapharm.com/role/EarningsLossPerShare",
"http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurement",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail", "http://www.tevapharm.com/role/FairValueMeasurementTables",
"http://www.tevapharm.com/role/Goodwill", "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
"http://www.tevapharm.com/role/GoodwillTables", "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
"http://www.tevapharm.com/role/IncomeTaxes", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.tevapharm.com/role/Inventories",
"http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail", "http://www.tevapharm.com/role/InventoriesTables",
"http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
"http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables", "http://www.tevapharm.com/role/Segments",
"http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail", "http://www.tevapharm.com/role/SegmentsTables" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LegalMattersAndContingenciesTextBlock", "presentation": [ "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" ], "lang": { "en-us": { "role": { "label":
"Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Settlements and Loss Contingencies", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": [ "r148" ] }, "teva_LegalSettlementsAndLossContingencies": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LegalSettlementsAndLossContingencies", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 14.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": {
"role": { "label": "Legal Settlements And Loss Contingencies", "terseLabel": "Legal settlements and loss contingencies", "documentation": "The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items)." } } },
"auth_ref": [] }, "teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "LegalSettlementsLossContingenciesImpairmentsOtherExpenses", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
"parentTag": "teva_ImpairmentAndRestructuring", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": {
"en-us": { "role": { "label": "Legal Settlements Loss Contingencies Impairments Other Expenses", "terseLabel": "Other", "documentation": "Legal settlements loss contingencies impairments other expenses." } } }, "auth_ref": [] }, "teva_LeverageRatio": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "LeverageRatio", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Leverage Ratio", "terseLabel": "Leverage Ratio", "documentation": "Leverage ratio." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 14.0 } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "terseLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [
"r23", "r101", "r102", "r103", "r106", "r107", "r108", "r109", "r232", "r346", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r591", "r595", "r596",
"r651", "r849", "r952", "r1044", "r1232", "r1277", "r1278" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity",
"terseLabel": "Total liabilities and equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r116", "r170", "r771", "r1011", "r1170", "r1191", "r1267" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent",
"crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 15.0 } },
"presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r103", "r191", "r232", "r346", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r591", "r595", "r596", "r651",
"r1011", "r1232", "r1277", "r1278" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "teva_LiabilitiesHeldForSaleCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "LiabilitiesHeldForSaleCurrent", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 22.0 } }, "presentation": [
```

```
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Held For Sale Current", "terseLabel": "Liabilities held for sale", "documentation": "Liabilities held for sale current." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 23.0 } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities", "terseLabel": "Total long-term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r23", "r106", "r107", "r108", "r109", "r232", "r346", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r591", "r595", "r596", "r651", "r1232", "r1277", "r1278" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "negatedLabel": "Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r96", "r98", "r140", "r143", "r188", "r189" ] },
"teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LicenseAgreementPotentialAggregateMilestonePaymentsAmount", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "License Agreement Potential Aggregate Milestone Payments Amount", "verboseLabel": "License agreement potential aggregate milestone payments amount", "documentation": "License agreement potential aggregate milestone payments amount." } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "License [Member]", "terseLabel": "Licensing Arrangements [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r1236" ] }, "teva_LineOfCreditExtensionPeriod": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LineOfCreditExtensionPeriod", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line Of Credit Extension Period", "terseLabel": "Line of credit extension period", "documentation": "Line of credit extension period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r100", "r105", "r1169", "r1230", "r1231" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r100", "r105", "r1169", "r1230" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r100", "r105" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "teva_LitigationFineAmountOfCopaxone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LitigationFineAmountOfCopaxone", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Fine Amount Of Copaxone", "terseLabel": "Litigation fine amount of copaxone", "documentation": "Litigation fine amount of copaxone." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountAwardedDistributionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LitigationSettlementAmountAwardedDistributionPeriod", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Amount Awarded Distribution Period", "terseLabel": "Litigation settlement amount awarded distribution period", "documentation": "Litigation settlement amount awarded distribution period." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Amount Awarded to Other Party", "definitionGuidance": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation settlement amount", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountDistributableInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LitigationSettlementAmountDistributableInCash", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Amount Distributable in Cash", "terseLabel": "Litigation Settlement Amount Distributable in cash", "documentation": "Litigation settlement amount distributable in cash." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountDistributableinKind": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LitigationSettlementAmountDistributableinKind", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Amount Distributable In Kind", "terseLabel": "Litigation Settlement Amount Distributable In Kind", "documentation": "Litigation settlement amount distributableIn kind." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountPayableInCashPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LitigationSettlementAmountPayableInCashPercentage", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation settlement amount payable in cash percentage", "terseLabel": "Percentgae of amount in cash settlement", "documentation": "Litigation settlement amount payable in cash percentage" } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountPayableRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LitigationSettlementAmountPayableRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Amount Payable Remainder Of Fiscal Year", "terseLabel": "Litigation settlement amount payable remainder of fiscal year", "documentation": "Litigation settlement amount payable remainder of fiscal year." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountPayableYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LitigationSettlementAmountPayableYearOne", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Amount Payable Year One", "terseLabel": "Litigation Settlement amount payable year one", "documentation": "Litigation settlement amount payable year one." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Expense", "terseLabel": "Legal settlements and loss contingencies, expenses", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r1150" ] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1218", "r1219", "r1220", "r1225" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1218", "r1219", "r1220", "r1225" ] },
"teva_LitigationWithUsHospitalsAndOtherHealthcareProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LitigationWithUsHospitalsAndOtherHealthcareProvidersMember", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation With US Hospitals And Other Healthcare Providers [Member]", "documentation": "Litigation with U.S. hospitals and other healthcare providers." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "teva_LongTermDebtCurrencyPortionCHF": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LongTermDebtCurrencyPortionCHF", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Currency Portion C H F", "terseLabel": "Long term debt currency portion CHF", "documentation": "Long term debt currency portion C H F." } } }, "auth_ref": [] }, "teva_LongTermDebtCurrencyPortionEUR": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LongTermDebtCurrencyPortionEUR", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Currency Portion E U R", "terseLabel": "Long term debt currency portion EUR", "documentation": "Long term debt currency portion E U R." } } }, "auth_ref": [] }, "teva_LongTermDebtCurrencyPortionUSD": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LongTermDebtCurrencyPortionUSD", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Currency Portion U S D", "terseLabel": "Long term debt currency portion USD", "documentation": "Long term debt currency portion U S D." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Current Maturities", "terseLabel": "Current maturities of long-term liabilities", "negatedLabel": "Less current maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r197" ] },
"teva_LongTermDebtExcludingConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LongTermDebtExcludingConvertibleDebtTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsTables" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Excluding Convertible Debt Table [Text Block]", "terseLabel": "Schedule of Senior Notes and Loans", "documentation": "A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_LongTermNotesAndLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesAndLoans", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 26.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" ], "lang": { "en-us": { "role": { "label": "Notes and Loans, Noncurrent", "terseLabel": "Senior notes and loans", "verboseLabel": "Total senior notes and loans", "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with
```

maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": { "r23" } }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r23", "r1218", "r1219", "r1220"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r23", "r55", "r1218", "r1219", "r1220"] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": ["r428", "r429", "r430", "r434", "r541", "r820", "r973", "r1226", "r1227"] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r428", "r429", "r430", "r434", "r541", "r973", "r1226", "r1227"] }, "teva_LossContingenciesOnEnvironmentalLawsPenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingenciesOnEnvironmentalLawsPenalty", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingencies On Environmental Laws Penalty", "terseLabel": "Loss Contingencies On Environmental Laws Penalty", "documentation": "Loss contingencies on environmental laws penalty." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r428", "r429", "r430", "r434", "r541", "r973", "r1226", "r1227"] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual", "terseLabel": "Accrued amount for legal settlements and loss contingencies", "verboseLabel": "Generic modafinil, and imposed fines amount", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": ["r428", "r1133"] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Accrual, Current", "terseLabel": "Loss contingency accrual current", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r428"] }, "teva_LossContingencyAccrualDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingencyAccrualDueInFifthYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Due In Fifth Year", "terseLabel": "Loss contingency accrual due in fifth year", "documentation": "Loss contingency accrual due in fifth year." } } }, "auth_ref": [] }, "teva_LossContingencyAccrualDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingencyAccrualDueInFourthYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Due In Fourth Year", "terseLabel": "Loss contingency accrual due in fourth year", "documentation": "Loss contingency accrual due in fourth year." } } }, "auth_ref": [] }, "teva_LossContingencyAccrualDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingencyAccrualDueInSecondYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Due In Second Year", "terseLabel": "Loss contingency accrual due in second year", "documentation": "Loss contingency accrual due in second year." } } }, "auth_ref": [] }, "teva_LossContingencyAccrualDueInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingencyAccrualDueInYearThree", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Due In Year Three", "terseLabel": "Loss contingency accrual due in third year", "documentation": "Loss contingency accrual due in year three." } } }, "auth_ref": [] }, "teva_LossContingencyAccrualNestTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingencyAccrualNestTwelveMonths", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Nest Twelve Months", "terseLabel": "Loss contingency accrual next twelve months", "documentation": "Loss contingency accrual nest twelve months." } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueInFifthYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Five", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year five", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r431"] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueInFourthYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Four", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year four", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r431"] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueInSecondYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Two", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year two", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r431"] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueInThirdYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Three", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year three", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r431"] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueWithinOneYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueWithinOneYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year One", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year one", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r431"] }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Provision", "terseLabel": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": ["r1225"] }, "teva_LossContingencyAccrualRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingencyAccrualRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Remainder Of Fiscal Year", "terseLabel": "Loss contingency accrual remainder of fiscal year", "documentation": "Loss contingency accrual remainder of fiscal year." } } } }, "auth_ref": [] }, "teva_LossContingencyAggregatePaymentsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingencyAggregatePaymentsPaid", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Aggregate Payments Paid", "terseLabel": "Loss contingency aggregate payments paid", "documentation": "Loss contingency aggregate payments paid." } } }, "auth_ref": [] }, "teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population", "terseLabel": "Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population", "documentation": "Loss contingency claims dismissed value paid to each state proportional to its share of national population" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } }, "auth_ref": ["r1225", "r1226", "r1227"] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype":

```
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Damage claimed", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r1225", "r1226", "r1227" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LossContingencyNatureDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r428", "r429", "r430", "r434", "r541", "r820", "r973", "r1226", "r1227" ] }, "teva_MabxienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"MabxienceMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "mAbxience [Member]", "documentation": "mAbxience." } } }, "auth_ref": [] }, "teva_MaximumEntryDateForGrantingLicenseEntry": { "xbrltype": "dateItemType",
"nsuri": "http://www.tevapharm.com/20240930", "localname": "MaximumEntryDateForGrantingLicenseEntry", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Maximum Entry Date For Granting License Entry", "terseLabel": "Maximum entry date for granting license entry", "documentation": "Maximum entry date for granting license entry." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": [ "r429", "r430", "r432", "r433", "r512", "r541", "r630", "r717", "r804", "r806", "r820", "r841", "r842", "r895", "r899", "r901", "r902", "r916", "r934", "r935", "r963", "r979", "r992", "r1003", "r1004", "r1008", "r1009", "r1023", "r1234", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284" ] }, "teva_MaximumTaxPaymentLimit": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "MaximumTaxPaymentLimit", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Maximum Tax Payment Limit", "terseLabel": "Maximum tax payment limit", "documentation": "Maximum tax payment limit." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure." } } }, "auth_ref": [ "r1093" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1093" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputDiscountRateMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement input, discount rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1254", "r1255", "r1256" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r628", "r629", "r630", "r1003" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r628", "r629", "r630", "r1003" ] }, "teva_MedicaidAndOtherGovernmentalAllowancesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "MedicaidAndOtherGovernmentalAllowancesMember", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Medicaid And Other Governmental Allowances [Member]", "terseLabel": "Medicaid and other governmental allowances [Member]", "documentation": "Medicaid and other governmental allowances." } } }, "auth_ref": [] }, "teva_MedimecellMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"MedimecellMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "MedinCell [Member]", "documentation": "MedinCell [ Member]." } } }, "auth_ref": [] }, "teva_MedisReportingUnitsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "MedisReportingUnitsMember", "presentation": [
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Medis Reporting Units [Member]", "terseLabel": "Medis Reporting Units [Member]" } } }, "auth_ref": [] }, "teva_MilestonePayment": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "MilestonePayment", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Milestone Payment", "terseLabel": "Milestone payment", "documentation": "Milestone payment." } } }, "auth_ref": [] }, "teva_MilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "MilestonePaymentReceivable", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Milestone Payment Receivable", "terseLabel": "Milestone payment receivable", "documentation": "Milestone payment receivable." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "auth_ref": [ "r429", "r430", "r432", "r433", "r512", "r541", "r630", "r717", "r804", "r806", "r820", "r841", "r842", "r895", "r899", "r901", "r902", "r916", "r934", "r935", "r963", "r979", "r992", "r1003", "r1004", "r1008", "r1023", "r1234", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284" ] }, "teva_MinimumTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "MinimumTaxRate", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Minimum Tax Rate", "terseLabel": "Minimum tax rate", "documentation": "Minimum tax rate." } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 29.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r115", "r169", "r232", "r346", "r437", "r440", "r441", "r442", "r446", "r447", "r651", "r770", "r853" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Dividend to non-controlling interests", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r154" ] }, "teva_MizuhoBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"MizuhoBankMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Mizuho Bank [Member]", "documentation": "Mizuho Bank [Member]." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1112" ] }, "teva_ModafinilSettlementAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "ModafinilSettlementAgreementMember", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Modafinil Settlement Agreement [Member]", "documentation": "Modafinil settlement agreement." } } }, "auth_ref": [] }, "teva_ModagMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "ModagMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Modag [Member]", "terseLabel": "MODAG [Member]", "documentation": "Modag ." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Markets [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1237" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1120" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r1094" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r228" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued
```

operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r228"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 17.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r134", "r135", "r136"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Teva", "verboseLabel": "Net income (loss) attributable to Teva", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r130", "r136", "r172", "r189", "r212", "r215", "r219", "r232", "r245", "r249", "r250", "r252", "r253", "r254", "r258", "r259", "r265", "r346", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r575", "r587", "r624", "r651", "r777", "r871", "r887", "r888", "r1042", "r1232"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 18.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss) attributable to non-controlling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r71", "r159", "r212", "r215", "r254", "r258", "r259", "r776", "r1163"] }, "teva_NetRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "NetRevenuesMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Net Revenues [Member]", "terseLabel": "Net Revenues [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r1093"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r1057", "r1067", "r1077", "r1101", "r1109"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r1084"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r1083"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r1101"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1120"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1120"] }, "us-gaap_NoncashOrPartNoncashAcquisitionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionsLineItems", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisitions [Line Items]", "terseLabel": "Noncash or Part Noncash Acquisitions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionsTable", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisitions [Table]", "terseLabel": "Noncash or Part Noncash Acquisitions [Table]", "documentation": "Disclosure of information about noncash or part noncash acquisition." } } }, "auth_ref": ["r35", "r36", "r37"] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "negatedLabel": "Purchase of shares from non-controlling interests", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": ["r13", "r58", "r158"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interests [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r67", "r492", "r1172", "r1173", "r1174", "r1177", "r1324"] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r16"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "negatedTerseLabel": "Financial expenses, net", "negatedLabel": "Financial expenses, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r132"] }, "srt_NorthAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NorthAmericaMember", "presentation": ["http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"], "lang": { "en-us": { "role": { "label": "North America [Member]", "terseLabel": "North America [Member]" } } }, "auth_ref": ["r1325", "r1327", "r1328", "r1329"] }, "us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotDesignatedAsHedgingInstrumentEconomicHedgeMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Not Designated as Hedging Instrument, Economic Hedge [Member]", "terseLabel": "Not Designated as Hedging Instrument, Economic Hedge [Member]", "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used as economic hedge for exposure to risk." } } }, "auth_ref": ["r17"] }, "us-gaap_NotDesignatedAsHedgingInstrumentTradingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotDesignatedAsHedgingInstrumentTradingMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Not Designated as Hedging Instrument, Trading [Member]", "terseLabel": "Not Designated as Hedging Instrument, Trading [Member]", "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used for trading purposes for exposure to risk." } } }, "auth_ref": ["r18"] }, "teva_NovemberTwoThousandAndTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "NovemberTwoThousandAndTwentyFiveMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "November Two Thousand And Twenty Five [Member]", "terseLabel": "November 2025 [Member]" } } }, "auth_ref": [] }, "teva_NovemberTwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "NovemberTwoThousandAndTwentyThreeMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "November Two Thousand And Twenty Three [Member]", "terseLabel": "November 2023 [Member]" } } }, "auth_ref": [] }, "teva_NovetideTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "NovetideTransactionMember", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"], "lang": { "en-us": { "role": { "label": "Novetide Transaction [Member]", "terseLabel": "Novetide transaction [Member]", "documentation": "Novetide transaction member." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r954", "r962", "r1180"] }, "teva_NumberOfYearsSpreadToPayTaxPayable": { "xbrltype": "durationItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "NumberOfYearsSpreadToPayTaxPayable", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Number Of Years Spread To Pay Tax Payable", "terseLabel": "Number of years spread to pay tax payable", "documentation": "Number of years spread to pay tax payable." } } }, "auth_ref": [] }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": ["r27"] }, "teva_OctoberTwoThousandAndTwentyFourAmendmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OctoberTwoThousandAndTwentyFourAmendmentAgreementMember", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "October Two Thousand And Twenty Four Amendment Agreement [Member]", "terseLabel": "October 2024 Amendment Agreement [Member]" } } }, "auth_ref": [] },

```
"teva_OneTimePremiumPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"OneTimePremiumPaymentMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-
us": { "role": { "label": "One Time Premium Payment [Member]", "terseLabel": "One Time Premium Payment [Member]", "documentation": "One time\u00a0premium
payment." } } }, "auth_ref": [] }, "teva_OntarioTeachersSecuritiesLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "OntarioTeachersSecuritiesLitigationMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "label": "Ontario Teachers Securities Litigation [Member]", "documentation": "Ontario teachers securities litigation." } } }, "auth_ref": [] }, "us-
gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": {
"role": { "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)", "definitionGuidance": "Operating income (loss)", "terseLabel": "Segment profit",
"verboseLabel": "Consolidated operating income (loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } },
"auth_ref": [ "r175", "r953", "r1178", "r1181", "r1182", "r1183", "r1184" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 27.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "definitionGuidance":
"Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } },
"auth_ref": [ "r669" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight":
1.0, "order": 6.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use
Asset", "terseLabel": "Operating lease right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [
"r668" ] }, "teva_OpioidLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OpioidLitigationMember",
"presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Opioid Litigation
[Member]" } } }, "auth_ref": [] }, "teva_OptionsAndForwardContractsDerivativeLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "OptionsAndForwardContractsDerivativeLiabilitiesMember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Options And Forward
Contracts Derivative Liabilities [Member]", "terseLabel": "Liabilities Derivatives Options and Forward Contracts [Member]", "documentation": "Options and forward contracts
derivative liabilities." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization,
Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "teva_OtherActivitiesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "OtherActivitiesMember", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": {
"label": "Other Activities [Member]", "terseLabel": "Other activities [Member]", "documentation": "Other Activities [Member]" } } }, "auth_ref": [] }, "us-
gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetImpairmentCharges", "crdr":
"debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other
Asset Impairment Charges", "terseLabel": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived
assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": [ "r1167", "r1216" ] }, "us-gaap_OtherAssetsCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets",
"documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r204", "r1011" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"label": "Other Assets, Noncurrent", "terseLabel": "Other\u00a0non-current\u00a0assets", "documentation": "Amount of noncurrent assets classified as other." } } },
"auth_ref": [ "r195" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitment", "crdr":
"credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitment", "terseLabel":
"Other commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the
taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration
payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-
gaap_OtherCommitmentDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentDueInFifthYear", "crdr":
"credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other
Commitment, to be Paid, Year Five", "terseLabel": "Other commitment, to be paid, year five", "documentation": "Amount of commitment classified as other to be paid in fifth
fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling
approach)." } } }, "auth_ref": [] }, "teva_OtherCommitmentToPayForEachYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "OtherCommitmentToPayForEachYear", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitment to Pay for Each
Year", "terseLabel": "Other commitment to pay for each year", "documentation": "Other commitment to pay for each year." } } }, "auth_ref": [] }, "us-
gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Axis]",
"documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Domain]",
"documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLocationAxis", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Location [Axis]", "documentation": "Information by location in other comprehensive income." } } },
"auth_ref": [ "r633", "r636", "r641" ] }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherComprehensiveIncomeLocationDomain", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Location [Domain]", "documentation": "Location in other comprehensive income." } } }, "auth_ref": [
"r633", "r636", "r641" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-
gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax,
Portion Attributable to Parent", "totalLabel": "Net other comprehensive income/(loss) before tax", "documentation": "Amount before tax of other comprehensive income (loss)
attributable to parent entity." } } }, "auth_ref": [ "r9", "r14", "r157" ] }, "us-
gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent", "terseLabel": "Other
comprehensive income (loss)", "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow
hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r209" ] }, "us-
gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax", "crdr": "credit",
"calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label":
"Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax", "verboseLabel": "Unrealized loss on defined benefit plans",
"documentation": "Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan." } } },
"auth_ref": [ "r7", "r124", "r155" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0,
"order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other
Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Currency translation adjustment", "documentation":
"Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as
economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3",
"r778" ] }, "us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax", "crdr": "debit",
"presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other
Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax",
"terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation,
before Tax", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the
sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign
currency exposure of a net investment in a foreign operation." } } }, "auth_ref": [ "r7", "r8", "r124", "r211", "r653" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ],
"lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)", "terseLabel": "Other
```

comprehensive income (loss)", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r15", "r22", "r213", "r216", "r220", "r254", "r654", "r655", "r660", "r756", "r778", "r1161", "r1162"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Foreign currency translation attributable to non-controlling interests", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": ["r9", "r14", "r157", "r213", "r216", "r254"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Net other comprehensive income/(loss) after tax", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r9", "r14", "r157", "r213", "r216", "r254"] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Corresponding income tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r9", "r14", "r157"] }, "us-gaap_OtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss) [Member]", "terseLabel": "Other Comprehensive Income [Member]", "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included." } } }, "auth_ref": ["r20"] }, "teva_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherCountriesMember", "presentation": ["http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"], "lang": { "en-us": { "role": { "label": "Other Countries [Member]", "terseLabel": "Other [Member]", "documentation": "Other countries." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": ["r77", "r86"] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "teva_OtherDebentures2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherDebentures2026Member", "presentation": ["http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"], "lang": { "en-us": { "role": { "label": "Other Debentures 2026 [Member]", "terseLabel": "Other Debentures [Member]", "documentation": "Other debentures 2026." } } }, "auth_ref": [] }, "teva_OtherExitAndDisposalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherExitAndDisposalMember", "presentation": ["http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"], "lang": { "en-us": { "role": { "label": "Other Exit And Disposal [Member]", "terseLabel": "Other Exit and Disposal [Member]", "documentation": "Other exit and disposal." } } }, "auth_ref": [] }, "teva_OtherExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherExpensesTextBlock", "presentation": ["http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems"], "lang": { "en-us": { "role": { "label": "Other Expenses [Text Block]", "terseLabel": "Other assets impairments, restructuring and other items", "documentation": "Other Expenses [Text Block]" } } }, "auth_ref": [] }, "us-gaap_OtherInventoryInTransit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInventoryInTransit", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "label": "Other Inventory, in Transit, Gross", "terseLabel": "Materials in transit and payments on account", "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported." } } }, "auth_ref": ["r1160"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 21.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r102", "r1011"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 25.0 } }, "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other taxes and long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r107"] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Non-current Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 26.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other items", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "teva_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "Other Operating Income (Expense)", "definitionGuidance": "Other loss (income)", "documentation": "Other Operating Income (Expense)" } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"], "lang": { "en-us": { "role": { "label": "Other Operating Income (Expense), Net", "negatedLabel": "Other loss (income)", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r1093"] }, "teva_OtherProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherProductsMember", "presentation": ["http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"], "lang": { "en-us": { "role": { "label": "Other Products [Member]", "terseLabel": "Other [Member]", "documentation": "Other Products [Member]" } } }, "auth_ref": [] }, "teva_OtherRestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherRestrictedCashMember", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Other Restricted Cash [Member]", "terseLabel": "Other [Member]", "documentation": "Other restricted cash." } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": ["http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi], "lang": { "en-us": { "role": { "label": "Other Restructuring [Member]", "terseLabel": "Other [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": ["r969", "r970", "r971", "r972"] }, "teva_OtherSalesReservesAndAllowancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherSalesReservesAndAllowancesMember", "presentation": ["http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"], "lang": { "en-us": { "role": { "label": "Other Sales Reserves And Allowances [Member]", "terseLabel": "Other [Member]", "documentation": "Other sales reserves and allowances." } } }, "auth_ref": [] }, "teva_OtherUnallocatedAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "OtherUnallocatedAmounts", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "Other Unallocated Amounts", "documentation": "Other unallocated amounts." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1055", "r1065", "r1075", "r1107"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r1058", "r1068", "r1078", "r1110"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1058", "r1068", "r1078", "r1110"] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "Parent [Member]", "terseLabel": "Total Teva Shareholders' Equity [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r1082"] }, "teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "PaymentToAcquireMarketableSecuritiesAndOtherAssets", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payment To Acquire Marketable Securities And Other Assets", "negatedLabel": "Purchases of investments and other assets", "documentation": "The cash outflow from purchase of available for sales securities and other assets." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

```
"localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1135", "r1164" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag":
"us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired",
"negatedLabel": "Acquisition of businesses, net of cash acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r32" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag":
"us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "negatedLabel":
"Purchases of property, plant and equipment and intangible assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r177", "r1243", "r1244", "r1245" ] }, "ecd_PeerGroupIssuersFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" }
} }, "auth_ref": [ "r1092" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1092" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1084" ] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r1101" ] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r1094" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1083" ] },
"teva_PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Percentage Of Increase Decrease In Contingent Consideration Liabilities", "terseLabel": "Percentage of increase decrease in contingent consideration liabilities", "documentation": "Percentage of increase decrease in contingent consideration liabilities." } } }, "auth_ref": [] },
"teva_PercentageOfShareOfTheNationalPopulation": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"PercentageOfShareOfTheNationalPopulation", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": {
"en-us": { "role": { "label": "Percentage Of Share Of The National Population", "terseLabel": "Percentage Of Share Of The National Population", "documentation": "Percentage of share of the national population." } } }, "auth_ref": [] }, "teva_PeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"PeriodAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Period [Axis]", "documentation": "Period axsis." } } },
"auth_ref": [] }, "teva_PeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "PeriodDomain", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Period [Domain]", "documentation": "Period domain." } } },
"auth_ref": [] }, "teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Period From Which Interest Rate Increase Could Be Applicable [Axis]", "documentation": "Period From Which Interest Rate Increase Could Be Applicable." } } }, "auth_ref": [] },
"teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Period From Which Interest Rate Increase Could Be Applicable [Domain]", "documentation": "Period From Which Interest Rate Increase Could Be Applicable." } } }, "auth_ref": [] }, "us-gaap_PledgingPurposeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeAxis", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pledging Purpose [Axis]",
"documentation": "Information by pledging purpose of pledged asset owned." } } }, "auth_ref": [ "r698", "r994", "r1012", "r1137" ] }, "us-gaap_PledgingPurposeDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeDomain", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pledging Purpose [Domain]",
"documentation": "Pledging purpose of pledged asset owned." } } }, "auth_ref": [ "r698", "r994", "r1012", "r1137" ] }, "teva_PncBankMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "PncBankMember", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "PNC Bank [Member]",
"documentation": "PNC bank." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r1085" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1129" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r1084" ] },
"us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit",
"calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses",
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r203", "r367", "r368", "r943" ] }, "teva_ProceedFromMinorityNonControllingShareholders": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.tevapharm.com/20240930", "localname": "ProceedFromMinorityNonControllingShareholders", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } },
"presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceed From Minority Non Controlling Shareholders", "terseLabel": "Purchase of shares from non-controlling interests", "documentation": "Proceed from Minority Non-Controlling Shareholders." } } }, "auth_ref":
[] }, "teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedAccountsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "ProceedsFromBeneficialInterestInExchangeForSecuritizedAccountsReceivables", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 15.0 }
}, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds From Beneficial Interest In Exchange For Securitized Accounts Receivables", "terseLabel": "Beneficial interest collected in exchange for securitized accounts receivables", "documentation": "Proceeds from beneficial interest in exchange for securitized accounts receivables." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } },
"presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs",
"terseLabel": "Proceeds from senior notes, net of issuance costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r226" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 13.0 }
}, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Businesses",
"terseLabel": "Proceeds from sale of business and long-lived assets", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r31" ] }, "us-
gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag":
"us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from (Payments for) Other Financing Activities",
"terseLabel": "Other financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1136", "r1165"
] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale, Maturity and Collection of Investments",
"terseLabel": "Proceeds from sale of investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from available for sale debt securities", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r30", "r225", "r313", "r344" ] },
"us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebt", "crdr":
"debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Short-term Debt", "terseLabel": "Proceeds from short-term debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "verboseLabel":
```

"Proceeds from exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": { "r6", "r19" } }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": ["http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "terseLabel": "Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": { "r1236" } }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": [
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"], "lang": { "en-us": { "role": { "label": "Product [Member]", "terseLabel": "Sale of Goods [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r980"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "auth_ref": ["r304", "r718", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r939", "r980", "r1022", "r1023", "r1024", "r1027", "r1028", "r1228", "r1229", "r1235", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320"] }, "teva_ProductRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ProductRightsMember", "presentation": [
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Product Rights [Member]", "terseLabel": "Identifiable product rights [Member]", "verboseLabel": "Product rights [Member]", "documentation": "Product Rights [Member]" } } }, "auth_ref": [] }, "teva_ProductWeightedAverageCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ProductWeightedAverageCost", "crdr": "debit", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Product Weighted Average Cost", "terseLabel": "Product WAC Value", "documentation": "Product weighted average cost." } } }, "auth_ref": [] },
"teva_ProductWeightedAverageCostTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ProductWeightedAverageCostTerm", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Product Weighted Average Cost Term", "terseLabel": "Product WAC Term", "documentation": "Product weighted average cost term." } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "auth_ref": ["r304", "r718", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r939", "r980", "r1022", "r1023", "r1024", "r1027", "r1028", "r1228", "r1229", "r1235", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320"] },
"teva_ProfitFromSaleOfLongLivedAssetsAndInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ProfitFromSaleOfLongLivedAssetsAndInvestment", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Profit From Sale Of Long Lived Assets And Investment", "negatedLabel": "Net loss (gain) from sale of business and long-lived assets", "documentation": "Profit from sale of long lived assets and investment." } } }, "auth_ref": [] },
"us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 },
"http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 6.0 },
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "verboseLabel": "Net Income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r189", "r212", "r215", "r227", "r232", "r245", "r254", "r258", "r259", "r346", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r575", "r587", "r589", "r592", "r593", "r624", "r651", "r761", "r775", "r829", "r871", "r887", "r888", "r995", "r996", "r1043", "r1163", "r1232"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r12", "r670"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r12", "r670", "r762", "r773", "r1011"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r141", "r670"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r1082"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r1082"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
"http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail",
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "auth_ref": ["r429", "r430", "r432", "r433", "r504", "r512", "r537", "r538", "r539", "r541", "r630", "r690", "r700", "r717", "r804", "r806", "r820", "r841", "r842", "r895", "r899", "r901", "r902", "r916", "r934", "r935", "r963", "r979", "r992", "r1003", "r1004", "r1008", "r1009", "r1023", "r1031", "r1221", "r1234", "r1255", "r1280", "r1281", "r1282", "r1283", "r1284"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
"http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail",
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "auth_ref": ["r429", "r430", "r432", "r433", "r504", "r512", "r537", "r538", "r539", "r541", "r630", "r690", "r700", "r717", "r804", "r806", "r820", "r841", "r842", "r895", "r899", "r901", "r902", "r916", "r934", "r935", "r963", "r979", "r992", "r1003", "r1004", "r1008", "r1009", "r1023", "r1031", "r1221", "r1234", "r1255", "r1280", "r1281", "r1282", "r1283", "r1284"] }, "teva_RebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RebatesMember", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"], "lang": { "en-us": { "role": { "label": "Rebates [Member]", "terseLabel": "Rebates [Member]", "documentation": "Rebates." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "label": "Reclassification from AOCI, Current Period,

before Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified to the statements of income", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": ["r27"] }, "us-gaap_ReclassificationTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationTypeAxis", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Reclassification, Type [Axis]", "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r1158"] }, "us-gaap_ReclassificationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationTypeDomain", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Reclassification, Type [Domain]", "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r1158"] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": ["http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax is allocated to the reportable segment." } } }, "auth_ref": ["r47", "r48"] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": ["http://www.tevapharm.com/role/SegmentsTables"], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Summary of Segment Profit", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": ["r47", "r48"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r1050", "r1060", "r1070", "r1102"] }, "teva_RedemptionOfConvertibleDebtSecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RedemptionOfConvertibleDebtSecurityMember", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"], "lang": { "en-us": { "role": { "label": "Redemption Of Convertible Debt Security [Member]", "terseLabel": "Redemption Of Convertible Debt Security [Member]" } } }, "auth_ref": [] }, "teva_RegulatoryPriceAndVolumeOfProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RegulatoryPriceAndVolumeOfProductsMember", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Regulatory Price And Volume Of Products [Member]", "terseLabel": "Regulatory Price And Volume Of Products [Member]", "documentation": "Regulatory price and volume of products." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r311", "r511", "r678", "r679", "r765", "r772", "r844", "r845", "r846", "r847", "r848", "r868", "r870", "r894"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r311", "r511", "r678", "r679", "r765", "r772", "r844", "r845", "r846", "r847", "r848", "r868", "r870", "r894", "r1276"] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment of senior notes and loans and other long term liabilities", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r133", "r825"] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Short-term Debt", "negatedLabel": "Repayment of short term debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r133"] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation": ["http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": ["r382", "r384", "r965"] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": ["http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": ["r382", "r384", "r965"] }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "presentation": ["http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "verboseLabel": "Reporting unit percentage of fair value in excess of carrying amount", "documentation": "Percentage of fair value of reporting unit in excess of carrying amount." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "auth_ref": ["r234", "r235", "r452", "r480", "r680", "r701", "r763", "r948", "r949"] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Reimbursement of research and development expenses incurred", "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": ["r542"] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "Research and development expenses", "terseLabel": "R&D expenses", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r1238"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "teva_ReservesIncludedInAccountsReceivableNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ReservesIncludedInAccountsReceivableNetMember", "presentation": ["http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"], "lang": { "en-us": { "role": { "label": "Reserves Included In Accounts Receivable Net [Member]", "terseLabel": "Reserves Included in Accounts Receivable, net [Member]", "documentation": "Reserves included in accounts receivable net." } } }, "auth_ref": [] }, "teva_RespiratoryProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RespiratoryProductMember", "presentation": ["http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"], "lang": { "en-us": { "role": { "label": "Respiratory Product [Member]", "terseLabel": "Respiratory Product [Member]", "documentation": "Respiratory product." } } }, "auth_ref": [] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail"], "lang": { "en-us": { "role": { "label": "Restatement adjustment [Member]", "definitionGuidance": "Restatement adjustment [Member]", "verboseLabel": "As previously reported [Member]" } } }, "auth_ref": ["r242", "r243", "r244", "r256", "r257", "r272", "r622", "r623", "r666", "r1138", "r1139", "r1140", "r1141", "r1143", "r1148", "r1149", "r1185"] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Restatement [Axis]" } } }, "auth_ref": ["r184", "r242", "r243", "r244", "r245", "r246", "r249", "r250", "r251", "r252", "r255", "r256", "r257", "r258", "r259", "r260", "r272", "r351", "r352", "r572", "r573", "r575", "r576", "r586", "r587", "r618", "r622", "r623", "r624", "r664", "r666", "r676", "r677", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r822", "r1185"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r1051", "r1061", "r1071", "r1103"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r1052", "r1062", "r1072", "r1104"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r1059", "r1069", "r1079", "r1111"] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail",

```
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail" ], "lang": { "en-us": { "role": {
"label", "Restatement [Domain]" } } }, "auth_ref": [ "r184", "r242", "r243", "r244", "r245", "r246", "r249", "r250", "r251", "r252", "r255", "r256", "r257", "r258", "r259", "r260",
"r272", "r351", "r352", "r572", "r573", "r575", "r576", "r586", "r587", "r618", "r622", "r623", "r624", "r664", "r666", "r676", "r677", "r810", "r811", "r812", "r813", "r814",
"r815", "r816", "r817", "r818", "r819", "r822", "r1185" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCash", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": {
"en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not
limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [
"r1159", "r1168", "r1285", "r1288" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"weight": 1.0, "order": 29.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Restricted
Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash included in other current assets", "documentation": "Amount of cash and cash equivalents restricted as to
withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts
with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to
known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r34",
"r192", "r229" ] }, "teva_RestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RestrictedCashMember",
"presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label":
"Restricted Cash [Member]", "documentation": "Restricted cash member." } } }, "auth_ref": [] }, "teva_RestructuringAccrualProvision": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.tevapharm.com/20240930", "localname": "RestructuringAccrualProvision", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label":
"Restructuring Accrual Provision", "negatedLabel": "Provision", "documentation": "Restructuring Accrual Provision" } } }, "auth_ref": [] },
"teva_RestructuringAndImpairmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"RestructuringAndImpairmentAbstract", "lang": { "en-us": { "role": { "label": "Restructuring And Impairment [Abstract]", "documentation": "Restructuring and impairment."
} } }, "auth_ref": [] }, "teva_RestructuringAndImpairmentCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"RestructuringAndImpairmentCostsLineItems", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": {
"en-us": { "role": { "label": "Restructuring And Impairment Costs [Line Items]", "terseLabel": "Restructuring and Impairment Costs [Line Items]", "documentation":
"Restructuring and impairment costs." } } }, "auth_ref": [] }, "teva_RestructuringAndImpairmentCostsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "RestructuringAndImpairmentCostsTable", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": {
"en-us": { "role": { "label": "Restructuring And Impairment Costs [Table]", "terseLabel": "Restructuring And Impairment Costs [Table]", "documentation": "Restructuring And
Impairment Costs [Table]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
"parentTag": "teva_ImpairmentAndRestructuring", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": {
"en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Restructuring", "verboseLabel": "Restructuring charges", "positiveLabel": "Restructuring costs",
"documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an
asset retirement obligation." } } }, "auth_ref": [ "r11", "r422", "r423", "r1223" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi
], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } }
}, "auth_ref": [ "r418", "r419", "r423", "r424" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestructuringCostAndReserveLineItems", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label":
"Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [
"r418", "r419", "r420", "r421", "r423", "r424", "r425" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestructuringReserve", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label":
"Restructuring Reserve", "negatedPeriodStartLabel": "Beginning balance", "negatedPeriodEndLabel": "Ending balance", "documentation": "Carrying amount (including both
current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or
restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r419", "r424" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 33.0 } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated
deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r113", "r154", "r769", "r814", "r819", "r826", "r852", "r1011" ] }, "us-
gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Retained
Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r183", "r242", "r243", "r244", "r246", "r254", "r257", "r259",
"r350", "r356", "r402", "r557", "r558", "r571", "r572", "r573", "r576", "r586", "r587", "r604", "r607", "r608", "r611", "r622", "r665", "r667", "r810", "r812", "r830", "r1324" ] },
"teva_ReturnsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ReturnsMember", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Returns
[Member]", "terseLabel": "Returns [Member]", "documentation": "Returns." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from
Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed
Tax", "verboseLabel": "Net revenues", "positiveTerseLabel": "Total revenue", "positiveLabel": "Revenues", "documentation": "Amount, excluding tax collected from customer, of
revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental
authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } },
"auth_ref": [ "r173", "r174", "r273", "r280", "r281", "r295", "r301", "r304", "r306", "r308", "r501", "r502", "r718" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]",
"terseLabel": "Revenue from contracts with customers", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to
transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment
related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } },
"auth_ref": [ "r180", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r503" ] }, "us-gaap_RevenueRecognitionAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "auth_ref": [] },
"teva_RevenueRecognitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RevenueRecognitionLineItems",
"presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Revenue
Recognition [Line Items]", "terseLabel": "Revenue Recognition [Line Items]", "documentation": "Revenue Recognition [Line Items]" } } }, "auth_ref": [] },
"teva_RevenueRecognitionTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RevenueRecognitionTable", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Revenue
Recognition [Table]", "terseLabel": "Revenue Recognition [Table]", "documentation": "Revenue Recognition [Table]" } } }, "auth_ref": [] }, "teva_RevenueTypeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RevenueTypeAxis", "presentation": [
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Revenue Type [Axis]" } } },
"auth_ref": [] }, "teva_RevenueTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "RevenueTypeDomain",
"presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Revenue Type
[Domain]" } } }, "auth_ref": [] }, "teva_RevenuesOtherThanUsd": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"RevenuesOtherThanUsd", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "label": "Revenues Other Than Usd", "terseLabel": "Revenues other than USD", "documentation": "Revenues other than US Dollar." } } }, "auth_ref": [] }, "us-
gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation":
[ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "terseLabel":
"Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount
borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "teva_RoyaltyPharmaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "RoyaltyPharmaMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Royalty Pharma [Member]",
"terseLabel": "Royalty Pharma [Member]", "documentation": "Royalty pharma." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-
```

us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1120"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1120"] }, "teva_SPVAmendmentAgreementOctoberTwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "SPVAmendmentAgreementOctoberTwoThousandAndTwentyFourMember", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "SPV Amendment Agreement October Two Thousand And Twenty Four [Member]" } } }, "auth_ref": [] }, "teva_SalesReservesAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "SalesReservesAndAllowances", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 17.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Sales Reserves And Allowances", "terseLabel": "Sales reserves and allowances", "documentation": "The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection." } } }, "auth_ref": [] }, "teva_SalesReservesAndAllowancesCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "SalesReservesAndAllowancesCurrentTableTextBlock", "presentation": ["http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables"], "lang": { "en-us": { "role": { "label": "Sales Reserves And Allowances Current [Table Text Block]", "terseLabel": "Summary of Sales Reserves and Allowances", "documentation": "Tabular disclosure of sales reserves and allowances current." } } }, "auth_ref": [] }, "teva_SalesReservesAndAllowancesToCustomersPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "SalesReservesAndAllowancesToCustomersPercentage", "presentation": ["http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Sales Reserves and Allowances to Customers Percentage", "terseLabel": "Percentage sales reserves and allowances to U.S. customers", "documentation": "Sales reserves and allowances to customers percentage." } } }, "auth_ref": [] }, "teva_SanofiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "SanofiMember", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Sanofi [Member]", "terseLabel": "Sanofi [Member]", "documentation": "Sanofi." } } }, "auth_ref": [] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail"], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "verboseLabel": "Adjustment [Member]" } } }, "auth_ref": ["r184", "r242", "r244", "r245", "r246", "r249", "r250", "r259", "r272", "r572", "r575", "r576", "r586", "r587", "r618", "r622", "r623", "r664", "r666", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r822", "r1143", "r1146", "r1147", "r1148", "r1175", "r1185", "r1192", "r1193", "r1250", "r1274", "r1275"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "auth_ref": ["r260", "r513", "r1133", "r1176"] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Accumulated Other Comprehensive Income/(Loss) (Net of Tax)", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r27", "r1268", "r1269"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r41"] }, "teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]", "terseLabel": "Summary of Major Classes of Assets and Liabilities Included as Held for Sale", "documentation": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Summary of Classification and Fair Values of Derivative Instruments", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": ["r79"] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Instruments [Table Text Block]", "verboseLabel": "Summary of Notional Amounts for Hedged Items", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": ["r16", "r73", "r74", "r75", "r76", "r79", "r81", "r84", "r85"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": ["http://www.tevapharm.com/role/SegmentsTables"], "lang": { "en-us": { "role": { "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of Net Sales by Product Line", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": ["r49"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail", "http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "documentation": "Disclosure of information about prior period adjustment to correct error in previously issued financial statement. Includes, but is not limited to, effect of correction on financial statement line item, affected per-share amount, cumulative effect of change on retained earnings and other appropriate component of equity or net assets in statement of financial position, and effect of prior period adjustment on net income of each prior period presented." } } }, "auth_ref": ["r249", "r250", "r251", "r256", "r257", "r258", "r259", "r272"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": ["http://www.tevapharm.com/role/BasisOfPresentationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": ["r38", "r39", "r40"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Items Carried at Fair Value", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1252", "r1253"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r386", "r393", "r395", "r396", "r399", "r719", "r937", "r966"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Identifiable Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r966", "r1211"] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": ["http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": ["r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r965"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.tevapharm.com/role/GoodwillTables"], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of Changes in the Carrying Amount of Goodwill by Segment", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r965", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.tevapharm.com/role/InventoriesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Summary of Inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r25", "r117", "r118", "r119"] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"], "lang": { "en-us": { "role": { "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": ["r82", "r1145"] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": ["http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Product Information

```
[Table]", "terseLabel": "Schedule of Product Information [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label":
"Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Disclosure of information
about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of
restructuring reserve." } } }, "auth_ref": [ "r418", "r419", "r420", "r421", "r423", "r424", "r425" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table
Text Block]", "terseLabel": "Summary of Restructuring Accruals", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit
and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r53",
"r144", "r145" ] }, "teva_ScheduleOfRestructuringChargesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"ScheduleOfRestructuringChargesTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" ], "lang": {
"en-us": { "role": { "label": "Schedule of Restructuring Charges [Table Text Block]", "terseLabel": "Summary of Restructuring Plan Including Costs Related to Exit and
Disposal", "documentation": "Schedule of Restructuring Charges [Table Text Block]" } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" ],
"lang": { "en-us": { "role": { "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Other Assets Impairments,
Restructuring and Other Items", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or
disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the
period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring
reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r54", "r146" ] }, "us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
"documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r44", "r45", "r46" ] }, "us-
gaap_ScheduleOfShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTextBlock",
"presentation": [ "http://www.tevapharm.com/role/DebtObligationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-term Debt [Table Text Block]",
"terseLabel": "Schedule of Short-term Debt", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the
normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4)
weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the
refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been
excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r101" ] }, "dei_Security12bTitle": { "xbrltype":
"securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-
us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1045" ] },
"dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation":
"Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1047" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "terseLabel": "Segments [Domain]",
"documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other
components of the same entity." } } }, "auth_ref": [ "r173", "r174", "r175", "r176", "r273", "r276", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288",
"r289", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r308", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380",
"r381", "r399", "r421", "r425", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r955", "r958", "r959", "r965", "r1026", "r1289", "r1293",
"r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312",
"r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
"http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical
[Domain]" } } }, "auth_ref": [ "r306", "r307", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739",
"r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r834", "r837", "r839", "r896", "r900", "r904", "r918", "r922",
"r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r940", "r981", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1025", "r1031",
"r1235", "r1289", "r1293", "r1294", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310",
"r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/Segments" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure
[Text Block]", "terseLabel": "Segments", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that
meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of
the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute
amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss
c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r176", "r273", "r275", "r276", "r277", "r278", "r279", "r291", "r293",
"r294", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r308", "r954", "r956", "r957", "r958", "r960", "r961", "r962" ] }, "us-
gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SegmentReportingInformationLineItems", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item for Operating Profit
(Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line
Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [] }, "teva_SegmentsAndOtherActivitiesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "SegmentsAndOtherActivitiesMember", "presentation": [
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Segments And Other Activities [Member]", "terseLabel":
"Segments and Other Activities [Member]", "documentation": "Segments and other activities." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 8.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": {
"role": { "label": "Selling and Marketing Expense", "verboseLabel": "Selling and marketing expenses", "terseLabel": "S&M expenses", "documentation": "The aggregate total
amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SeniorNotes": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotes", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" ], "lang": { "en-us": { "role": { "label": "Senior Notes", "verboseLabel": "Total senior
notes", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the
issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before
any payments are made to junior note holders." } } }, "auth_ref": [ "r167", "r1287" ] }, "teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "SeniorNotesAndSustainabilityLinkedSeniorNotesMember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" ], "lang": { "en-us": { "role": { "label":
"Senior Notes And Sustainability Linked Senior Notes [Member]", "terseLabel": "Senior Notes And Sustainability Linked Senior Notes [Member]", "documentation": "Senior
notes and sustainability linked senior notes." } } }, "auth_ref": [] }, "teva_SeniorNotesMaturityPercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "SeniorNotesMaturityPercentage", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Senior Notes Maturity
Percentage", "verboseLabel": "Senior notes maturity percentage", "documentation": "Senior notes maturity percentage." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember":
{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Senior Notes [Member]",
"terseLabel": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior
debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] },
"teva_SeniorNotesRepaidAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "SeniorNotesRepaidAmount", "crdr":
"credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label":
"Senior Notes Repaid Amount", "verboseLabel": "Senior notes repaid amount", "documentation": "Senior notes repaid amount." } } }, "auth_ref": [] },
"teva_Seniornotesandconvertibleseniordebenturesmember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"Seniornotesandconvertibleseniordebenturesmember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" ], "lang": { "en-us": { "role": { "label":
"Seniornotesandconvertibleseniordebentures [Member]", "terseLabel": "Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]",
```

```
"documentation": "Senior notes and convertible senior debentures." } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Settled Litigation [Member]",
"documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r1225" ] },
"teva_SettlementAndLicenseAgreementAlvotechAndTevaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SettlementAndLicenseAgreementAlvotechAndTevaMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Settlement And License
Agreement Alvotech And Teva [Member]", "terseLabel": "Settlement And License Agreement Alvotech And Teva [Member]", "documentation": "Settlement and license
agreement alvotech and teva [Member]." } } }, "auth_ref": [] }, "teva_SettlementAsAPercentageOfAggregateSubdivisionsAndTribes": { "xbrltype": "percentItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "SettlementAsAPercentageOfAggregateSubdivisionsAndTribes", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Settlement As A Percentage Of
Aggregate Subdivisions And Tribes", "terseLabel": "Settlement as a percentage of aggregate subdivisions and tribes", "documentation": "Settlement as a percentage of
aggregate subdivisions and tribes." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based
payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award
under share-based payment arrangement." } } } }, "auth_ref": [ "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528",
"r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-
us": { "role": { "label": "Shares, Issued", "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "documentation": "Number of shares of
stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [
"r15" ] }, "teva_ShortCreditAgreement2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"ShortCreditAgreement2026Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": {
"label": "Short Credit Agreement 2026 [Member]", "terseLabel": "Convertible senior debentures [Member]", "documentation": "Short credit agreement 2026." } } },
"auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr":
"credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Short-term Debt",
"verboseLabel": "Convertible senior debentures", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one
year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r99", "r166", "r1011", "r1286" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term
Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r101", "r1218", "r1219", "r1220" ] }, "us-
gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-
term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing,
letter of credit financing." } } }, "auth_ref": [ "r99", "r1218", "r1219", "r1220" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
"http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "terseLabel": "Segments [Axis]",
"documentation": "Information by business segments." } } }, "auth_ref": [ "r173", "r174", "r175", "r176", "r187", "r273", "r276", "r279", "r280", "r281", "r282", "r283", "r284",
"r285", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r308", "r373", "r374", "r375", "r376",
"r377", "r378", "r379", "r380", "r381", "r399", "r405", "r421", "r425", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r955", "r958",
"r959", "r965", "r1026", "r1289", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307",
"r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320" ] }, "us-gaap_StatementEquityComponentsAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
"http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel":
"Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r111", "r114", "r115", "r183", "r217", "r218", "r219", "r242",
"r243", "r244", "r246", "r254", "r257", "r259", "r274", "r350", "r356", "r402", "r492", "r557", "r558", "r571", "r572", "r573", "r576", "r586", "r587", "r604", "r606", "r607",
"r608", "r609", "r611", "r622", "r654", "r656", "r657", "r658", "r659", "r660", "r665", "r667", "r677", "r778", "r810", "r811", "r812", "r830", "r889" ] },
"srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
"http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
"http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } },
"auth_ref": [ "r306", "r307", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742",
"r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r834", "r837", "r839", "r896", "r900", "r904", "r918", "r922", "r925", "r926", "r927",
"r928", "r929", "r930", "r931", "r932", "r933", "r940", "r981", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1025", "r1031", "r1235", "r1289",
"r1293", "r1294", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312",
"r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "http://www.tevapharm.com/role/BasisOfPresentation",
"http://www.tevapharm.com/role/CertainTransactions", "http://www.tevapharm.com/role/CertainTransactionsTables",
"http://www.tevapharm.com/role/CommitmentsAndContingencies", "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "http://www.tevapharm.com/role/DebtObligations",
"http://www.tevapharm.com/role/DebtObligationsTables", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "http://www.tevapharm.com/role/EarningsLossPerShare",
"http://www.tevapharm.com/role/FairValueMeasurement", "http://www.tevapharm.com/role/FairValueMeasurementTables", "http://www.tevapharm.com/role/Goodwill",
"http://www.tevapharm.com/role/GoodwillTables", "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables", "http://www.tevapharm.com/role/IncomeTaxes", "http://www.tevapharm.com/role/Inventories",
"http://www.tevapharm.com/role/InventoriesTables", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables", "http://www.tevapharm.com/role/Segments", "http://www.tevapharm.com/role/SegmentsTables"
], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in
a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r242",
"r243", "r244", "r274", "r667", "r718", "r823", "r831", "r843", "r844", "r845", "r846", "r847", "r848", "r851", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861",
"r862", "r864", "r865", "r866", "r867", "r868", "r870", "r872", "r873", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r889",
"r1032" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract",
"lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial
Position [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } }
}, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] },
"srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" }
} }, "auth_ref": [ "r260", "r513", "r1133", "r1134", "r1176" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementTable", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "http://www.tevapharm.com/role/BasisOfPresentation",
"http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.tevapharm.com/role/CertainTransactions",
"http://www.tevapharm.com/role/CertainTransactionsTables", "http://www.tevapharm.com/role/CommitmentsAndContingencies",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
```

```
"http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "http://www.tevapharm.com/role/DebtObligations",
"http://www.tevapharm.com/role/DebtObligationsTables", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "http://www.tevapharm.com/role/EarningsLossPerShare",
"http://www.tevapharm.com/role/FairValueMeasurement", "http://www.tevapharm.com/role/FairValueMeasurementTables", "http://www.tevapharm.com/role/Goodwill",
"http://www.tevapharm.com/role/GoodwillTables", "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
"http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables", "http://www.tevapharm.com/role/IncomeTaxes", "http://www.tevapharm.com/role/Inventories",
"http://www.tevapharm.com/role/InventoriesTables", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables", "http://www.tevapharm.com/role/Segments", "http://www.tevapharm.com/role/SegmentsTables"
], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive
income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r242", "r243", "r244", "r274", "r311", "r667",
"r718", "r823", "r831", "r843", "r844", "r845", "r846", "r847", "r848", "r851", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r864", "r865", "r866",
"r867", "r868", "r870", "r872", "r873", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r889", "r1032" ] }, "us-
gaap_StatutoryAccountingPracticesByJurisdictionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatutoryAccountingPracticesByJurisdictionAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": {
"en-us": { "role": { "label": "Jurisdiction [Axis]", "documentation": "Information by state or country of domicile in which statutory financial statements are required." } } },
"auth_ref": [ "r93", "r94", "r95" ] }, "us-gaap_StatutoryAccountingPracticesJurisdictionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatutoryAccountingPracticesJurisdictionDomain", "presentation": [
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statutory Accounting Practices,
Jurisdiction [Domain]", "documentation": "State or country of domicile in which statutory financial statements are required." } } }, "auth_ref": [] }, "teva_StatutoryActAxis": {
"xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "StatutoryActAxis", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statutory Act [Axis]" } } }, "auth_ref": [] },
"teva_StatutoryActDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "StatutoryActDomain", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statutory Act [Domain]" } } }, "auth_ref": [] },
"ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR
Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r1054", "r1064", "r1074", "r1106" ] }, "us-
gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel":
"Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during
predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ],
"lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Shares, shares", "documentation": "Number of new stock
issued during the period." } } }, "auth_ref": [ "r15", "r110", "r111", "r154", "r824", "r889", "r919" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues",
"terseLabel": "Issuance of Shares, value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public
offering or a secondary public offering." } } }, "auth_ref": [ "r15", "r110", "r111", "r154", "r830", "r889", "r919", "r1043" ] }, "us-
gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock
Options Exercised", "terseLabel": "Exercise of options by employees and vested RSUs", "documentation": "Value of stock issued as a result of the exercise of stock options." } }
}, "auth_ref": [ "r15", "r111", "r114", "r115", "r154" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquity", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 30.0 } }, "presentation": [
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Stockholders'
equity attributable to Teva shareholders", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to
noncontrolling interest." } } }, "auth_ref": [ "r111", "r114", "r115", "r138", "r853", "r869", "r890", "r891", "r1011", "r1044", "r1170", "r1191", "r1267", "r1324" ] }, "us-
gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel":
"Teva shareholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 28.0 } }, "presentation": [
"http://www.tevapharm.com/role/BasisOfPresentationScheduleOfImpactOfRestatementOnCertainLineItemsAndBalanceSheetDetail",
"http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": {
"label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total equity", "periodStartLabel": "Beginning balance",
"periodEndLabel": "Ending balance", "terseLabel": "Total equity", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes
temporary equity." } } }, "auth_ref": [ "r67", "r68", "r70", "r183", "r184", "r218", "r242", "r243", "r244", "r246", "r254", "r257", "r350", "r356", "r402", "r492", "r557", "r558",
"r571", "r572", "r573", "r576", "r586", "r587", "r604", "r606", "r607", "r608", "r609", "r611", "r622", "r654", "r656", "r660", "r666", "r677", "r811", "r812", "r820", "r853",
"r869", "r890", "r891", "r920", "r1043", "r1170", "r1191", "r1267", "r1324" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]",
"verboseLabel": "Accumulated other comprehensive income (loss)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r151", "r231", "r477", "r479",
"r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r491", "r492", "r613", "r892", "r893", "r921" ] }, "teva_SubordinatedConvertibleBondsMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "SubordinatedConvertibleBondsMember", "presentation": [
"http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" ], "lang": { "en-us": {
"role": { "label": "Subordinated Convertible Bonds [Member]", "documentation": "Subordinated convertible bonds." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": [
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]",
"documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsegmentsDomain", "presentation": [
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Subsegments
[Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including
transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event
[Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } },
"auth_ref": [ "r661", "r683" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation":
"Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r661", "r683" ] },
"us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain",
"presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
"http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation":
"Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r661", "r683" ] },
"teva_SubsidiarySeniorNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2024Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2024 [Member]", "terseLabel": "Senior notes USD 1,250 million [Member]", "documentation": "Subsidiary senior notes due 2024." } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2024OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2024OneMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2024 One [Member]", "terseLabel": "Senior notes EUR 1,500 million [Member]", "documentation": "Subsidiary senior notes due 2024 one." } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2025Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2025 [Member]", "terseLabel": "Senior notes EUR 1,000 million [Member]", "documentation": "Subsidiary senior notes due 2025." } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2025OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2025OneMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2025 One [Member]", "terseLabel": "Senior notes USD 1,000 million [Member]", "documentation": "Subsidiary Senior Notes Due 2025 One [Member]" } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2025ThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2025ThreeMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2025 Three [Member]", "terseLabel": "Senior notes CHF 350 million [Member]", "documentation": "Subsidiary senior notes due 2025 three." } } }, "auth_ref": [] },
```

```
"teva_SubsidiarySeniorNotesDue2025TwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2025TwoMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2025 Two [Member]", "terseLabel": "Senior notes EUR 900 million [Member]", "documentation": "Subsidiary senior notes due 2025 two." } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2026OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2026OneMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2026 One [Member]", "terseLabel": "Senior notes USD 3,500 million [Member]", "documentation": "Subsidiary senior notes due 2026 one." } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2027Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2027 [Member]", "terseLabel": "Senior notes EUR 700 million [Member]", "documentation": "Subsidiary senior notes due 2027." } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2028OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2028OneMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2028 One [Member]", "terseLabel": "Senior notes USD 1,250 million [Member]", "documentation": "Subsidiary Senior Notes Due 2028 One [Member]" } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2028TwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2028TwoMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2028 Two [Member]", "terseLabel": "Senior notes EUR 750 million [Member]", "documentation": "Subsidiary senior notes due 2028 two." } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2036Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2036 [Member]", "terseLabel": "Senior notes USD 789 million [Member]", "documentation": "Subsidiary senior notes due 2036." } } }, "auth_ref": [] },
"teva_SubsidiarySeniorNotesDue2046Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"SubsidiarySeniorNotesDue2046Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due
2046 [Member]", "terseLabel": "Senior notes USD 2,000 million [Member]", "documentation": "Subsidiary senior notes due 2046." } } }, "auth_ref": [] }, "us-
gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"Supplemental Cash Flow Information [Abstract]", "terseLabel": "Non-cash\u00a0financing and investing activities:" } } }, "auth_ref": [] }, "us-
gaap_SupplierFinanceProgramObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligation",
"crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"label": "Supplier Finance Program, Obligation", "terseLabel": "Supplier finance program obligation", "documentation": "Amount of obligation for supplier finance program." }
} }, "auth_ref": [ "r412", "r413", "r414", "r415", "r416", "r967" ] }, "us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration": {
"xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration", "presentation": [
"http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Supplier Finance Program,
Obligation, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes obligation for
supplier finance program." } } }, "auth_ref": [ "r413" ] }, "teva_SustainabilityLinkedSeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "SustainabilityLinkedSeniorNotesDue2027Member", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior
Notes Due 2027 [Member]", "terseLabel": "Sustainability-linked senior notes USD 1,000 million [Member]", "documentation": "Sustainability linked senior notes due 2027." }
} }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2027OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "SustainabilityLinkedSeniorNotesDue2027OneMember", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior
Notes Due 2027 One [Member]", "terseLabel": "Sustainability-linked senior notes EUR 1,100 million [Member]", "documentation": "Sustainability linked senior notes due
2027 one." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "SustainabilityLinkedSeniorNotesDue2029Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior
Notes Due 2029 [Member]", "terseLabel": "Sustainability-linked senior notes USD 1,000 million [Member]", "documentation": "Sustainability linked senior notes due 2029." }
} }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2029OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "SustainabilityLinkedSeniorNotesDue2029OneMember", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior
Notes Due 2029 One [Member]", "terseLabel": "Sustainability-linked senior notes USD 600\u00a0million [Member]", "documentation": "Sustainability linked senior notes due
2029 one." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2029TwoMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "SustainabilityLinkedSeniorNotesDue2029TwoMember", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior
Notes Due 2029 Two [Member]", "terseLabel": "Sustainability-linked senior notes EUR 800 million [Member]", "documentation": "Sustainability linked senior notes due 2029
two." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "SustainabilityLinkedSeniorNotesDue2030Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior
Notes Due 2030 [Member]", "terseLabel": "Sustainability-linked senior notes EUR 1,500 million [Member]", "documentation": "Sustainability linked senior notes due 2030." }
} }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2031OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "SustainabilityLinkedSeniorNotesDue2031OneMember", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior
Notes Due 2031 One [Member]", "terseLabel": "Sustainability-linked senior notes USD 500 million [Member]", "documentation": "Sustainability linked senior notes due 2031
one." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2031TwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "SustainabilityLinkedSeniorNotesDue2031TwoMember", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior
Notes Due 2031 Two [Member]", "terseLabel": "Sustainability-linked senior notes EUR 500 million [Member]", "documentation": "Sustainability linked senior notes due 2031
two member." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]",
"terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r1100" ] }, "teva_TakedaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "TakedaMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "label": "Takeda [Member]", "documentation": "Takeda." } } }, "auth_ref": [] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tangible Asset
Impairment Charges", "verboseLabel": "Impairments of property, plant and equipment", "documentation": "The charge against earnings resulting from the aggregate write
down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r97", "r142" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAxis", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit
Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r556" ] }, "us-
gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardNameDomain",
"presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]",
"terseLabel": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r556" ] }, "us-gaap_TaxPeriodAxis":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]",
"documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r1241" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [ "r1241" ] },
"teva_TermOfRoyaltyPayment": { "xbrltype": "durationItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "TermOfRoyaltyPayment", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Term Of Royalty Payment",
"terseLabel": "Term of royalty payment", "documentation": "Term of royalty payment." } } }, "auth_ref": [] }, "teva_TevaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "TevaMember", "presentation": [
"http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Teva [Member]",
"documentation": "Teva Member" } } }, "auth_ref": [] }, "teva_TevasApiReportingUnitMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "TevasApiReportingUnitMember", "presentation": [
"http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
"http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Tevas API Reporting
Unit [Member]", "terseLabel": "Tevas API Reporting Unit [Member]", "documentation": "Teva's API reporting unit." } } }, "auth_ref": [] },
"teva_TevasUnitedStatesEuropeInternationalMarketsAndMedisReportingUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930",
"localname": "TevasUnitedStatesEuropeInternationalMarketsAndMedisReportingUnitsMember", "presentation": [
"http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tevas United States, Europe, International Markets and Medis
reporting units [Member]" } } }, "auth_ref": [] }, "us-gaap_TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "auth_ref": [] }, "teva_TotalReservesIncludedInSalesReservesAndAllowancesMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "TotalReservesIncludedInSalesReservesAndAllowancesMember", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Total Reserves
```

Included In Sales Reserves And Allowances [Member]", "terseLabel": "Total reserves included in sales reserves and allowances [Member]", "documentation": "Total reserves included in sales reserves and allowances." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1092"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r1099"] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "terseLabel": "Trade names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r65", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1212", "r1213", "r1214", "r1215"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r1119"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r1121"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.tevapharm.com/role/CoverPage"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "teva_TrancheAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "TrancheAxis", "presentation": ["http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Tranche [Axis]", "documentation": "Tranche." } } }, "auth_ref": [] }, "teva_TrancheDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "TrancheDomain", "presentation": ["http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Tranche [Domain]", "documentation": "Tranche." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r473", "r490", "r612", "r647", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r699", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r779", "r998", "r1001", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1013", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1187", "r1188", "r1189", "r1190", "r1251", "r1254", "r1255", "r1256", "r1263", "r1266"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1122"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1123"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1123"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1121"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1121"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r1124"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1122"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Shares [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r59"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r59"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 35.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury shares as of September 30, 2024 and December 31, 2023; 106 million ordinary shares", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r59", "r60", "r111", "r114"] }, "teva_TwoThousandAndTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "TwoThousandAndTwentyFiveMember", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Five [Member]", "terseLabel": "Two Thousand And Twenty Five [Member]", "documentation": "Two thousand and twenty five." } } }, "auth_ref": [] }, "teva_TwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "TwoThousandAndTwentyFourMember", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Four [Member]", "terseLabel": "Two Thousand And Twenty Four [Member]", "documentation": "Two thousand and twenty four." } } }, "auth_ref": [] }, "teva_TwoThousandEightThrough2020TaxPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "TwoThousandEightThrough2020TaxPayableMember", "presentation": ["http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Two Thousand Eight Through 2020 Tax Payable [Member]", "terseLabel": "2008 Through 2020 Tax Payable [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": ["http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": ["r181", "r182", "r183", "r184", "r185", "r186", "r245", "r246", "r247", "r248", "r260", "r309", "r310", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r401", "r402", "r417", "r557", "r558", "r559", "r560", "r561", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r578", "r579", "r580", "r583", "r584", "r585", "r586", "r587", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r648", "r649", "r664", "r665", "r666", "r672", "r673", "r674", "r675", "r676", "r677", "r720", "r721", "r722", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r588"] }, "us-gaap_TypeOfFreshStartAdjustmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfFreshStartAdjustmentDomain", "presentation": ["http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Type of Fresh-Start Adjustment [Domain]", "terseLabel": "Type of Fresh-Start Adjustment [Domain]", "documentation": "Adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting." } } }, "auth_ref": ["r681", "r682", "r1011"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDi], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r418", "r419", "r423", "r424"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.tevapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r1118"] }, "teva_UnitedStatesSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "UnitedStatesSegmentMember", "presentation": ["http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"], "lang": { "en-us": { "role": { "label": "United States Segment [Member]", "terseLabel": "United States [Member]", "documentation": "United States Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnCashFlowHedgingInstruments", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Cash Flow Hedging Instruments", "terseLabel": "Financial expenses, net", "documentation": "Amount of unrealized gain (loss) related to derivatives designated as cash flow hedging instruments, recorded in results of operations to the extent that the cash flow hedge is determined to be ineffective." } } }, "auth_ref": ["r164"] }, "teva_UnrealizedGainLossOnDerivativeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "UnrealizedGainLossOnDerivativeNetOfTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "label": "Unrealized gain (loss) on derivative net of tax", "terseLabel": "Unrealized gain (loss) from derivative financial instruments, net", "documentation": "Unrealized gain (loss) on derivative net of tax." } } }, "auth_ref": [] }, "teva_UpdatedMarketAssumptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "UpdatedMarketAssumptionsMember", "presentation": ["http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Updated Market Assumptions [Member]", "terseLabel": "Updated Market Assumptions [Member]", "documentation": "Updated market assumptions ." } } }, "auth_ref": [] }, "teva_UpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "UpfrontPayments", "crdr": "credit", "presentation": ["http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Upfront Payments", "terseLabel": "Upfront payment", "documentation": "Upfront payments" } } }, "auth_ref": [] }, "teva_UtilizationAndOther": { "xbrltype": "monetaryItemType",

```
"nsuri": "http://www.tevapharm.com/20240930", "localname": "UtilizationAndOther", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label":
"Utilization And Other", "terseLabel": "Utilization and other", "documentation": "Utilization and other." } } }, "auth_ref": [] }, "teva_UzedyMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "UzedyMember", "presentation": [
"http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "UZEDY [Member]", "terseLabel":
"UZEDY [Member]" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule,
12-09, Valuation Allowances and Reserves, Amount", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "documentation":
"Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r237", "r241" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule,
12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Credits and payments", "documentation": "Amount of decrease in valuation and qualifying accounts
and reserves." } } }, "auth_ref": [ "r240" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ValuationAllowancesAndReservesDomain", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule,
12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and
qualifying accounts and reserves." } } }, "auth_ref": [ "r237", "r238", "r239", "r240", "r241" ] }, "teva_ValuationAllowancesAndReservesForeignCurrencyTranslation": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "ValuationAllowancesAndReservesForeignCurrencyTranslation", "crdr":
"credit", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role":
{ "label": "Valuation Allowances And Reserves Foreign Currency Translation", "terseLabel": "Translation differences", "documentation": "Valuation allowances and reserves
foreign currency translation." } } }, "auth_ref": [] }, "teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.tevapharm.com/20240930", "localname": "ValuationAllowancesAndReservesRelatedToCurrentPeriodSales", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Valuation
Allowances And Reserves Related To Current Period Sales", "terseLabel": "Provisions related to sales made in current year period", "documentation": "Valuation allowances
and reserves related to current period sales." } } }, "auth_ref": [] }, "teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.tevapharm.com/20240930", "localname": "ValuationAllowancesAndReservesRelatedToPriorPeriodSales", "crdr": "credit", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Valuation
Allowances And Reserves Related To Prior Period Sales", "terseLabel": "Provisions related to sales made in prior periods", "documentation": "Valuation allowances and
reserves related to prior period sales." } } }, "auth_ref": [] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [
"http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule,
12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by
valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r237", "r238", "r239", "r240", "r241" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": []
}, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [
"http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result
of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of
Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r1088" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average [Member]" } } }, "auth_ref": [ "r630", "r700", "r934", "r935", "r1003",
"r1279", "r1281", "r1284" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
"http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding,
Diluted", "terseLabel": "Diluted", "verboseLabel": "Weighted average number of shares used in the computation of diluted earnings (loss) per share", "documentation": "The
average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of
shares or units in the period." } } }, "auth_ref": [ "r263", "r268" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted
[Abstract]", "terseLabel": "Weighted average number of shares (in millions):" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed
outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } },
"auth_ref": [ "r262", "r268" ] }, "teva_YearOfSettlementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname":
"YearOfSettlementAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Year Of
Settlement [Axis]", "terseLabel": "Year of settlement", "documentation": "Year of settlement." } } }, "auth_ref": [] }, "teva_YearOfSettlementDomain": { "xbrltype":
"domainItemType", "nsuri": "http://www.tevapharm.com/20240930", "localname": "YearOfSettlementDomain", "presentation": [
"http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Year Of Settlement [Domain]", "documentation": "Year of
settlement." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end
Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r1086" ] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-
10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)",
"SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
45-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "SubTopic": "10",
"Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-16" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" },
"r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)",
"SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r17": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "SubTopic": "10",
"Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" },
"r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)",
"SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r21": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-
55-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r26": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" },
```

"r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480000/505-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "505", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "505", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "505", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-6" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r164": { "role": "http://fasb.org/us-

gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480302/340-10-45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r549": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
```

"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481724/830-30-40-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",

"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-
45-3" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r894": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-
320-S99-19" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" },
"r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r901": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r902": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r903": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r904": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r905": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r906": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r907": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r908": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A",
"Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r909": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A",
"Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r910": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r911": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r912": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r913": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r914": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r915": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r916": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r917": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r918": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r958": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r959": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r960": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r961": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r962": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r963": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r964": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r965": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r966": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r967": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5" }, "r968": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-16" }, "r969": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r972": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r973": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r974": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r975": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481560/470-20-55-69B" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r977": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r978": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r979": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r980": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r981": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r982": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",

```
"Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r983": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-
55-91" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r987": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r990": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r993": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r996": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r999": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1002": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1005": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1009": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1012": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r1013": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" },
"r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1018": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1021": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-
30-55-2" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-
40-55-9C" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1027": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" },
"r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1030": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1031": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1043": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1045": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b" }, "r1046": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b-2" }, "r1047": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1048": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q",
"Number": "240", "Section": "308", "Subsection": "a" }, "r1049": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"16", "Subsection": "j", "Paragraph": "a" }, "r1050": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
```

"Subsection": "F", "Paragraph": "1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1052": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1053": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1054": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1055": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1056": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1057": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1058": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1059": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1060": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1061": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1062": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1063": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1064": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1065": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1066": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1067": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1068": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1069": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1070": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1071": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1072": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1073": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1074": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1075": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1076": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1077": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1078": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1079": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1080": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1081": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1082": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1083": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1084": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1085": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1086": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1087": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1088": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1089": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1090": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1091": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1092": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1093": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1094": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1095": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1096": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1097": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1098": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1099": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1100": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1101": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1102": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1103": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1104": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1105": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1106": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1107": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1108": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1109": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1110": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1111": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1112": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1113": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1114": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1115": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1116": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1117": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1118": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1119": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1120": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1131": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1132": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1133": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1134": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1206": {
```

"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-7" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1267": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1326": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1327": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1328": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1329": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 101 0001193125-
24-252039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-252039-xbrl.zip M4$L#!!0 (,B 9EDC6IXA,]("")O^*0 / 9#@W-#$W-&0Q,'$N:'1M M[+WI=^.XL0?Z_?
X5/$YR[\QYMEN;UY[Q.VHO/4[/_ M%&JHIL:,P:__UWV^O+W]O__WXG]^&=IP&]QJ6.T0 M?Q@/"1\=JN;H4ZO1ZC3.VHT]
[W:=&3\BM[_WN7YH\@"'!\,W'G]R+P:T+KWYKBWN;9V=GG\35X%:+Q=T(+VU^^O>WNV=U2$?D@!F6 M30PU,A:V9.SS]VMT;N 650\'YN037!!\|6]DEMEI-4^6O=J]8_;F,:"5R
MJT&8:L7?*RY%;K:8&G\K7(C>:(]YPIUP)7*K8QT,"!D'=[\2JR_XZ%V(W/RN M+Y'3O^]"*'-LOD0\<#7@E:HEL$K5HC1Q>W&0\&,43>])7VTB1D$/Z+^_/-W- M;K?
C[Y_=^LGFQ+!>33XB-M@%_%KKH-$Z:!Z'56,97^;5&CYZ $1&GO")7O;= MYM%!X_2@W?3>DZSM:*#VT%!1HL'_V,S6Z46SG>PI^XH#^Z;#)KWN7[NT'O>F8[GV"EWSR M/M
WM:EBV5.=_KJ'PS\84C88VN<&#E[_W"?JCP$'S=(.5%,W^?G;D-GTLQCA MD?_<*[S\P&+_I>?-QMC^+/[YYKZF;^K:WL4O1!ER^OKKWE]L4]V[Z)&^3A7S M5?%&9?WRB5S
B([@K1J;^*_5F#76R?1<,4R#PDO8^SD.FG+W3Z9IU!!_PO5[M9T0Y4Q6#C/!)RLZ[(VIH\/_VC4X&>RZ_WNTG',5CH_D"_T'L]+B MD &8I1+]$:Z:V@W\9JWP\=.]
MBW^V4W_YV@!H3"_AVYSHMX9&W_]!IRM\]6SOH@'_=]H\/3X]3OWU2V%%/;+_ M0PF_-K0KL-K9!W#4V+LX.&BV0$\RTMXC[]> !IN],E6H'-S8I]Q]NXN4)KKS MT]/3DW3C DX<--
S_RSB6KJ9Q:EF7KCN*&<+9<T@5"]Y F$'Z3 ="#] XPL6^ M:6CP3DX5FU-Q.[&4/GMUN'#>"@51 /F: JK+)B">";4.E6=*%4'&J7HHR/3I M2B;R*
([(5Z4'<9OR2IANX3B).F1T0A657"+D.XH]B$#ZAM[0O: M6(1;UI#H.ORF D465?I3I7'8;#3^=M X;,/_X&N BX8SVE=>N3D2'(6[=0<# M3J!M;"/57&D>
[2L@S..T)+;S(I$D"QD,,1!WA+1UCOZFF([X"7DRYD 3&P-" MR CAK+PQX$H?+A &4K85\&\.QV^:7''&IJ& ^NL,Z.94HZ,Q:N*^PEYAA.HP M])O"+!@./D1>@>O*-
S)5SK(QJA4+>.5!M4WD.RK0OLLV3L5H_WI\>J2,8/SX M?:"/@1XT#YOMORD6-1@,!3]A*9I#Q<-AZM*.Z7C'^&P)&;9/CC["YPK\;L;S MNPL0T>.X?79T/,_MX\VQNA-K"@+ZV
@&P5U;%S)A])W9@A,869@6PEH%:\1L M!@8IY8?C9-P#\:!!AT^C/L&?%@-;)QP1:AM0C2, 8:,@;8Q^P%[V34 !R-K] M$>(C*L9F0!"FC.!M0PLR6#2;,VO2;@BAM94A@6?[E!I
WH19KLD%JB#:L-PO MB8$WTYI6;!"&&BY2IRV]._,7C=(4$0_+73"&N@Y?1-#MHAE $@.H%A M,8S#7?<-=W3U"7Q='1XJ\(&_.\#OUO&^I]O^-30JX E4!)EM":-D")@+]:)<
M!3"**R%C[Q(LP(V_TA%JHZLRT4'L*Y!=P#?>P-"Y+@;>*JAB."!]ZC+Y)\L/ M'5H_IX5;G+M M84$P_"E9J%5!6W%KX*/LR!UP?^B\%WX105U!5TE[^ $[>$0 M+J*E,?
LZ&PC@I[8@<1C#H6@$TKJ9M? M QA8^&LLTHD8O8>106:E4P 6<7\4 M_M7PGA5O.@HP#$:*U-GFH#%%*\ #'#X81O!)DL3%ZEV170!%LS$MP5:1)2_GG8"#.NF9;G.;)G]B<:YMLU9
MWQ$6%SD%D?0!&FINPBO13W@^-;7LXL*SY,$?%VGL1XUX2_*-@,%0VLV(%:'B MY>A(,&)15 [C/PB&/!>*O)&Q0@:<"KSL0Y1O 8%^'J 2:ZB\ZN:;,J3:P'5X M1!6U.J0"S!5X8M Y5"K
KS5&).-'#?L%YY:8HWBB MKXJ8V3BWIV/ZZYX%X]>QRBI^?!/\+/=3A">Q+.I: M#T;Q6./.2MDQQ/I75B:VV7H"TRT"TALVZ^ ;H#8QDF9P'^R"_'+&J'6%08 M7$18U,[
HO8F6=0L$XM2F]"\6%0\Z[(&BR*V:'TO<^JRIGE6%-;,#&_SS)VB MW9B7:1P7S>!&7>KQIEPJ2+4EI'H*]L'[N]4J"M%A\#=/4<:M=.!O1>]='_PG
M+O@;IT5AS0P/0"GXEDV"O_72.D5BCPI([!$N FF=;@;\'=?R-]$Y=ER-;Q;2 M\C?!\G=26G[WWDTYQ[,0B\Z*SJ*S#"S:7/QP' JQCHL>8AUG"+&.-\:B3BB7 M*9QKG<]ETBK:O"/>7")?
&/1$U-!68>L07#P3RQ&PJY MFP#^$]\8!G\7A>AY8XAJG]88AN]="_S(EC.1F;HL.BMLE@J9)Y)]EC)+C=R[
MMGT(7&EA6!-2F=8&:^.1$DUA5"4:+&VL1!.=]7BY(8S_CE.6M\;8L:T[.J%Z M\YN8&'0LW#D2W/!E&OSY&Y"!BP6FXO;N.[->GJAE/V*GUW"[+V+A?
L7I9<\FD_S7,D.Q\WJ7@B.$D8E%=RS6,][C\MYNX;V M'%G*?"=V!X3N",OUSC0&N!CGBO9MW)-4=)'&CU=(E%G88NTV,;30ZDUW M5;=&^S!*AU=0']U5RD]BS6[$$C.#V?
2.3:AV:\#G!DBY,&_6E^DW M\H?)RV&;LY AQ![#D7**]M9XQ!6,E@7^AV)L >;J"F,'G].U(B&7@6[HF_APUST$'ABU@]1 M8+DWC=E^BO!3OU%MP(S!E7<1N"
[N%YO5O!WYKNT+/_2%Z+BQ]'E(J7UGJL%C M1890\IC].Y)HWD!E9IEL0JA=)N0-C")>UK/OQX"DG-IRB?N,+KUM1L]O9(SU MD1O=?$,.T-1*=+3C5F=_V>(=AC)*HX?
7LFC*)#.&ZT[D3V4E)+*CZG;S&- M$3X-K;:XCMU"MHZI0\:$HT0L=5UU,07%9A9DF:*^D3-,37E;1)H=[M2LL')6^L)!L@FHGS-.2"U.L KP* M6G]4=,58(I7E%%K<-N-
V6&QRYW6()>64<=<]9,YZHBIE$SRA[)FJ>,8L^Z]8 MQGI#5!$NI%T8761AI]@,EHT=Y11Y,;8/EQPH!=DU6*W]&;.SMUZ^F0:=?A-' M =XXAF8EN)U*=#OT;XFG.4?Y;?K
N)#\KNB(8$.HL6DQ.YWT-M5NM>0HB./< M!BQ).;JG%@N1M4)2D66WJ4;,TJM\[%6D1=DV*D79H&;-G1-IEL!<'Y@24-MI M&9ZC"*__=& ,?O&!R@@Z@\>+YYTT+#M"9["E@<1[/X@
M@AR%+'N5[[!7>8YRE0=,[/: B1Q%*P^8*,4!$SDB0!Y$4$:I;>@@ M!_"%BH M93\1F^+,\9S"$T-E1"_/:JBM'%Z0Q=3$,W!F5N*X7TY$5@U)=9*=;*27_]K(
M/)V!/+%$=K5>=Q3%ZAJ:9\!;B"6"\HB%>A^QL-O%DL57+WEBB52G.GJG(IVQ M4"LEJG-L5UEG5"1MDB$5%1*F; M: M)C'*UO>[;WV_8P'+4_BJ*UIY:%O5!5Q?
X[R=WNH[":+D4<:5$*,\7+%48I3' MM7U(>)5%6]]0:3M'+>ZF'"$[K5=)F%6-=G=[5LFN3:\|JZ2ZHJVJ^SD% M+(^\|**'0OE%B 1TX,+$]_8I9XD W'$:W%XT!@4 MOH=#$C6A)K(?
\B59WA\.]AT'N(3_C/"QI)"B;S'(V%MD$DH98)26 [EA-*_ M*#8]HEIW0CGQ=W@5W;C$B"*6CG**Y(E.3'W"C(';UR#NF)SHE:***6C4$S-:
M_]I28LLIOTTU\WD8X])Y["1Y8_(WPC5_H;XU6^:?L'LB] 7_CFDYVGD5J^// MHJ4BHGL&L.2 F!>-LFS^W;P;E]Q?=?59?QAVZF;#*N;C?_>G;4_V9J MY)493'^FMJV+K#CHD1;D>7?
@D@9BC^8EL0J=\,6-5+C?C^DLI_PN35TG?9.+ M^*'+.2:\,YI<-<4:R,-KZ*+('.+;VEZ_CX&?D3+0K:&:(_IL$UL\'-ZT_/)D M3HEN3Q^'A(](^*$OCL4,"A&0^J?#+%:*G=E)0Q8 BJ%T
\G#$MZ&T]\/);6! MH<2B)-Q(=QG0RJD\\O#A8AX^G&O=S/*5K:O]X5AVQ-&%KQ94GJ*L.3_,^1_G M*"NGJ+XP4S?_8*K;(N+.UE+XE]7]81%EG>#/E$^8ZD[U?L>#+S017UK/+BEA
M] 6!IV]AO'L*6W%%1Q='J!_!! S9 +P^8([X8")_-PTL ^WK^ S[KGWC2;\ M)WA5<&TF,"UT;QB&_I5-PE"LP?&D8DD\SJ].BG)& G-[P*P:VB0 LCI(2(.H M9DJ;%/:189Y(:[0],'Z!E]
(?!&*4']=$AFY16"9P1P)T>P"]?'CL_OOA_EKB M,IS+1I@BX5B.Z.WE^W^I-ET*Y!)B,424!.+V@/B5&O 2%1(X#2@EALQQPZ!, MX(X$Z!;3G#_,R7)C5S=0AC@B@;@](%X[W!S3*N
KB^ACJ)9"_S!"R^95BXB1 M0CM&"8N$IKY03/C'$C=C.9N:ST2HBFS[+K!CV@TW1Y?F:.S8 M@ID/K]>$&\P86(^4/P\)IU^F\2\H.HIR)7NV.VVI .J11\X_Y0#GX"F&4,
MPB",7+@T+;MK:+CEG$*FRR$=L8O'WKD3/48#M0)!=>CL6Y.*2@,MC\T5%HW M$"0PH$X8 +LZ,HT%/Q2X]>L_'>Q=!M;7-(+"0F(GV2*B8O4.K-F#H#ANA1W0 M'*_K!+0[2$2"
[B2)B]*>X4K S:_4'' R'C*5%+9O5'*^Y4L]0O@:8,,O+6&- MZ-3!I^??GR6JRES/F57O64-F\9;EL)CK!CJA$-W/4> ID0]E;A;U\[A MY3"WZX2RI]/R;\/S5=?728A8VMY1AIRQ3%=,J
MUGZF65K%W5E%"3YI]U9&V;J3D=(7RYQE:PLQ)-CJ(O!4"T+K53C91216>\.3 MM9A73FBM4).KGJAK7]FJGDC]+3P]RD?,32A=:GO7OW>OWQGZ6<#^V+2*NWC! M;;T3-
U;W2A*)=9*S<%-S/*J:H)-IK).D0]MTKVC?GNWF#0=_-Z (ALJ(/CN_ MKZA"#TZ*3QIRS/[D.,+KA(%[T\#;N*GKXHQ&FW)JQ3>*B]]R5UP8I-PKN(P#
M=4+"$[4)I"Z:O^6_3AB(I[U.TG\DG"8TB*RHS,,4UTG2755U1HX.K]5$&(3\ MX72(7,1SA55S1.L$@]3LJ!-&W)^?DPGF5!U0L(W:Z;L<362]S96U,46=ZR M2T0*-
Z!IS%T4\$B8=FMWQX+?)[H!79K/!.= M6O[/74/KZKKYALU[(KG![T1W1*EL=GG6!%+?;Z.$A+@? 6*_*J3G 2 M<90$3PQX4G&F3E"!Q-OA1ITA$>%
G41_.21\0/M$_5%G\2]PH4X0$"V[(?0" M]@C+^-6$1,Q ZH@N_06@(PN#Z@2<)] 8N];(B'"@7]J*?#[V[JN@B 2&52MF$ M]'5Z3^U:0R,#A^H$G5"I]RMAQIUI6<'"2V(-
;X"KOU%M0.LW#9*1*37%2X\3 MP])=%=3^<"Q[5%^8+.%%3=%Q15]Q]O@+-> /^U$'_M0>)2EX4B>T7'(PK)<. M!TNJ3I_?
R#AB8<,8N8*/38@M9A_]V:HG9OT0J_2OJ,4&!O*W:^&38L6*?U?X M+=Y%_W[457P^F F[?A_C OA(".W.=@:BOC/5X,$B8W,9P_PL.P7WD]&8>B3Q M3
\M#?]8>AL8Q5(Q"G8DH*!.^B@52<*WQ/'"%$/V)3JCAI ;>R[UI+Q7@-7S7 M'#%UP2$EP:*\0%Z!%5L!]H)4ZP3I52VJ!';Q@2TM=G[PAG1?D^UH2.BQ:&
<(\S$KMUO/>)W@2@C_878K'" LQM2S W3/'C<6KBNYW*(A^A:MX98_D+NZ3OF &&*E%U'G=X"7='K[XZ0ND>XZ"?_>G% ;.%XWX2?2 M72?A7Y.!7CO)QQ-=)
[$_J]0@\)9'3B?,="Q]^D3')@]*:A !0FSIL["H$L9>!^K8]>=EZ>2=LK]VL/X\ MEO8Z2?_2Y X*UU$OL MLN05=.BS!3'7,N#=%4+7C1/Q. M#;$4;@"K:0*G&+GD#.S^^^'^6N+/
M+2!%V"$AN!7[9VAD.?R^XW(R3;#2J@$(9PS9$@ 3^5LG&*9/,^N&Q]WEJ!*8 M ,RJH4T"(", LJ6?E<-+H7-7"5",X!P+F&!*6(:#N#!/)!B+EM'6#(T[R6LE M'--5]VJ&Q>W7^"00 8A?
X*7T!^D:6H]3(FLN45 F<$<"M!QY[LOW_U)MN9DM M(2A#1$D@;@^(MW +=U>]$=UM$))^<;=L&@@0&U D#E^9H M9!K/MJG^B/4!<2?_O7PC[VSDC()PY@F;)185%:))R&R
^,_(^#<9>RP_)W&! MUW4"FKN^-(!,P++%IK#%A-"2 >/E,'EU$FM=VT_LI.=$%03O]TL%G^REA.)- M%:I1^S!:1NB6$M[:HU2"K68"OV(0^[.^@PF^QPE9=9O#2B*/9!FNR$BM4JA5
M?)#6WG5^?ZY8FN8?-O+]N4YB3)MWRU!I3>,BBP0YK662P)2A64%MYAT(R;"6 MQVWEQ&*$,FD5\T!9&O#4+.C?%.IDH)]C(EI.:*V03U9/U-7KJ#D7.]5/I!N) MK>L+"!D]
[R:N*6=UJ1 QJ$U 5[1KP@U@1+Q=JB@&XFFOD_0?":<) MK9HJ*O,PQ762=%=5G9&CPVNU-(<@5AT&J=E1*XQH&G,#HT?"M%OCDHR9#5%2 MG7"QC
5UPD)!#D>^808Q5$;TZ_]->*L!K^*XY8NJ"0TJ"17F!O (KM@+L M!:G6"=*K6E0LOFF!-*L.W 52I<4ML,65P)06LV"07.[Y>IQH,)O>L0G5;@V;& /6 MUVG7LJAM?9E^(W^8_%(G5N$G-
S*1(4 1PY$Z >(*@A?='",YP(D!I\ <0[L< M8L-3Z]804X+_H-/?B>ZXZF19SFB,?WG,ZEW_WKV& ,C^0BSFKM/RS@MX9&.J M,X.F.X[ZUH"?5?@\=MHE7!W",$*#JQ!6!>RB+/.PN+8P-
F!&,S%W9GM3"&^- MP:4[H"(><'72YF\@O%(W5@Z/OU:"([7HB%T]P3VKU"#PED=.)\QT+'WZ1,0EE=1)P5]=%B.4O MED^],Z&(PDZY%2!8[A5+>YVD?VERL&SPUCJ)?
8[H.LD[8(BA5:E)5I8M0!^Q MH$YP*,@RSS1+TI/N*6O!U\@>?4,-TDS??<1<+B&MX@Y@Z"W3@8A9 TJ)(9.*F$5,\]R1 -VB MG?RXW%
(S4&Z_Z"*!B$!T+&""*:$8AF*8)Q*,Y2BWO'S_+]66F]020C%$E 3B M]H"XVE1'QK"SA'#<;>18\UF2%4&9?G*EA(#WA$[7&C!/;Y-/JG3 @<)%$H81E<6%91)A)H:
<6^GK'3<@0+1=#M*-S)PH& MS12EYK706T)(;K_6+*&XPK1T43F@%+'"(0$I M &D:$\IM;(_SR.DKY1PG:$SU1QAO72!/8[J#F]V>J>IPL;OR^EW5'8UJ-]P<
MX3X7QQ;,?'CUSU]ZI/QY2#C],HU_05'1&NPFSY/LV=[EI0*H$Q9%-H=='#C8 M"6!6M+=@Y,*E:=E=0\-&37Q2V.QU=C#9!T./[!F+X4"=4']&NOFE(+"@%X0 M0Z5U T$" ^J$
;"K(]-8\$.!6X\[]*DNW:>R!T'+C\A:X'6=@":/\JW]4;Z5 M0F3U9ATW?:ZY1&161*:QI_KJ$C:I MIF/8?'K^_;E.:$OC$RJ)L$UE/A)527,.*^0M,D21R6TG!)!9Y[EJ-
'NC3PG063PGSM2JU36*#Y(M:^\Z4Z<1Q65>9CB.DGZWN3V ML#O"KDGDXVRBB().$: O$EDG$6,S+.N)CH$)8,VP.WW4FCM]:Z&5XJ68 0[J M-Q7#Q"SBFZ-S$S6R*#N]CR7*H$Y
S(JLEQZPSNJ.681Q2[KH9@"BDN86B

7GUMYV%NI9=T;[M M-3>;AC%RPPQBJ(SHMP8V/D(N%!T=B4/V6M^GI+].H%BE4U.1(2";)J5P%IK& M7'_Y2)AV:UR2,;/]HG]Y+^4!77"PO,00N5+#DFT3]0?
D5K9[T1W1!+5U77S#;M66K/^EE9O.BX\ -)2X':LGN="G2#P M1&V'&W46?X0#=1*]R(:?B4XMGS/ I!G':@R)5)RI$U1Z)@3$/B_ NXJFZ;>&
M!$\,>%;D59W@M,B=KBIV8P*#5,HFI*_3>VK7&$29.%0OZ/3AE76V+Q$.U$GT MXK@KPC1@C7#07\T)Y0921W3I>;SI][0,JA5P2/^=T;G3)_S-/5WU3X=9H@!8 M=# D#MF5?
I3*.@D8EP PC1$^?:8&,_F]"0;RRJ%8T7LP(F*O2OTR#<7U@H"% MRUE)G^E P1TS?E!MGC7M9N_-K"08,M%>+U@DZLE))9'P$;E2^((;G=JYA4Y- MW4(B0XYZ0TYK!H(PS?
6"01H/656;D(GV>L%BB:94-%1,07&](/"Q=K3.*HF$ M](37"Q#)&E)5!Y&"8@D!P9#3VD'@5$)@+I&JE_P[4O@S;G0JN1;V0W*E\%UO M6"OA^^362_@I@N*3JL8 F6B7L*C%?
$)ZPNL%B.1XN7:%HU-9.$JLGU05#)EH ME["8J[8W:HH)G_!Z 2+)<+;KE4RV:YE,IC&4-!%[J][(+SN*%G"BYJBXRN8VSO3LNZI M?4FLX8UNOOU&M0&M7Y_3CRIUXN.3#CTN%
O3I]?B/C"%>B<0AG$] O[)+E M^_VX$G1'U/=$(-)PLP[:7VY1J^:XZ8 MNA O51&XF5FQ%6 O2+5.D%[#XDI@%QS8TF+G8;%[G&CP0[TA'6&"M-*%A+&,
MB"4D2Q@X2/NZ$_LJ@P7_V-\G-AA&CWL"WC";WK$)MDZSB3' [OY=RZ*V]67Z MC?QA\DN=6(6?[LA$A@!%#$?J]!(@KL.ZZ.49R@!,#CMV2#.UR"*S#9GJB+=8_ MZ'365LNR'/<<"
(]9XJQ7\!#V%V(Q]ZBPK]3 ,]4>V9CJS* >AV?'Z,0=V/QR M:\#/*GP>>W41K@[QQ-79X"J$5??(V0C+/"RN+8P-F-%,S)W9WA3"6V-PR<=\ M"[XM!5R=M/G>G% ;T"FF^HDZ.Y>ZU+,;*
<+4)+KK)/QK,M!K)_EXHNLD]JZN M4SX@1MTDGTAWG80/R;FI3R"-@[7";%@K-TS(KR#9V/75OKM>OV;B@Z\#P8>K*V,I;U.TK\T^=CD M\-8ZB7V.Z#K).V"(UU>]"]'9A-
F,UD+OW!?XSPNHZ8>P6;N'4 FS9J&><$NN#C>O)L"PEQ)(9 M(!&VF25*W!P]T[$M*+QAKS8%6H:A(A3D'[TW^&WZS-[G"WOX\+^&3!W&B>G2
M='3M"^V.D8=8M%H.3]FY81.=&SX<2]CHF%UZ_C*H[)B1VKJA<]7>9C5F!1Z.J%W M_S GTZ4FI$*X^,#RA'@A+$8'&=WLL3M<:, M$]OD4T^@50O#DBB4L"PP++VM=1 V:\|
@8E0N.4@@4()R&Z!,GW:^?,=MJ9K@ MJ54#S[V[G#61T74"9M70)@&0-8MU+&""*6U2.)L-\T1:HZ)EM35#XTYR6PE' MM(V&1B04PX8Q8(B$X?9@^
5>2G\0G#GFE$A,1C&9P!T)T'(D$2_?_TNUY=,H M)01EB"@)Q.T!,5L1KVZ6EAX?/+O8RB,MYFQ'3P"I@'%?J3G@9#QD*M'#X(-XW).@4.;J8C&6
MT#6@B1].Y*X;VX9E42<,;L0J2F!*FUDTFWD'0C*LY2%H.;$8H4Q:Q=P*O2ND M)M(@RHQF>RB58*NGP#]89_F\S"^6&@!YNSS5= R;3\^_/]<)5>LZN^H:'.G.
M"AG:2]S)T'YEE*7)"VLV-;&IA%):NQRGR\H)K15FO:HGZMK[J^J)M$H.0IKM MK&) MXBET5+LFW !&Q">S%<5 /.UUDOXCX32A#U-%91ZFN$Z2[]JJ,W)T>*TFBGC(
M'TZ'R,4)G@!ICFB=8)":'77"R"]6BN A5IO,.UJ&G,KJ(^$:;?&)1DSF^AU MDO]2%M0*"_K$M*DZ# O?K[|W5>"A)?@DBD/8&8!P==B%<=)U%9< MF2OR7%!D["73[/?4BG-K
?,=2+H4Z-'S$\SK!]9*;EG7I< CH MU.GS&QE?$FMXHYMOOU%M,'=D.&<38"BZ=O_HX2=F_1!(OJ(6&Q@8"70M?%*D M@_Y=X;=X%_W[?4VX808Q5$9T3Q!6!="_C&%^'Z(4W-^
8L0S/530_5AZ>:NG M>T!Z/ KJI(]2D21\2PS?5>&'Q50M$./."\S7&-(E?#<4LF>VD\0]!F.!&.! M@+D@E3I!<@V+:2]U?#U.M+GNBE6$; 8F2"M;8"LKP5Q ,$O+G(=EOH:OFR.F
M+I18Z@?I&%9(*UU:*RV!O7-@U]IB]X #5G?,GNC8Y#;(X]S"N,P13#R46)>'% M65Z_8A7GJ]#L$FNS_EX?7YT=_U45NJ:1'A%$-ZU'HP V>V76^.1FRJXZ?@,;<4:_,LW
M2BR'BSC@UA@[]A6S1)^(I[DP9_X^+'H4'>B9BOBS+#D%GS>_V2&)MVQ*)I- MXYZ!FA.X'0$71;)_IR9P ON;R64%8244':YV9^K9[9;+VTW;^ER#:>^+0@ZTF;^+0.FJV#=G/V
ME752>U_[9" VR_W.!G6'<&+5!+(M6KMW!:)S%7$[0PB;N 1QY@-5 47 MN+/31><% ^,WJC$KP@-K";(R8U=",044$V50*R"6J>:W[;):D067H3]<$46Y MV=9NU1.OK
%51L"=T/*.8]G?4?9W3 77SD&CDV&MQO'&5B/%PQ6#)4.ENEYI M?S-'9:T$+'<]REV/90*LW/6X);C+78^[W/6X&Y5KAE2NZ24EG9S$9M52Y\A?4;5?4;[H-G819VC
M"3[CS%>YX&^)^3P%#;;U+*V@P_=N+CAH!\&!M*U%Q)FTK3L,9]J;LJVXIA=# MFO:Z8C H]\1<_5G=G?XBJJN$OLO08/7L[8.DZ M2X^# +D)WKKA&?'FRS=3(X-
*6\|0A;F:BF:&,$SBIT M%,BG;A^HFY_XC@)5KFO8M'C3ARRYB'?E:6\IWLU'I)NK$(>;5IP$2> =L&(@ MC-R_F#W\;OUF6N+\SJ#ITF\4A2CA]Y.8$A,%GRQEG#U\2J]"Q:-Q(A>17
MIS]OE&1I_'"RR;P%"T%>+0@7_U9:\6<$YIH&-,X.6D$M9Q.;17T!95F4].Q M#J0QT5WETC0FE-NX]?J+:6B1M-9%-\|?NF1'U2KN*T/D9BG M:)O'&)6G<][NO9M>N-H*1? M*=H-
:FTKP_J.UB:C]]-9[@U_!T4BNA'3W+-!=*> <-#AU9M7:=$N]XU"SR!'!^N'8M.:V$MX0QG\G MND._3$57I'*<69,\Z%GDO$AQCB'Q7.UD_:1K)KN 6-$:S[K#(G S083!G[\!
MA[%J/!6WN^V[3(-.W>W=-\Y<$E95%,33O('$+!W/9P-9(L1RHE*B:0N)=H[R M6\$C;,H2E1P%V3R+M"AI$7D-L9H]?::JPQ<.GI"87(])>-Y)5.X(E35#4Y'E MMZGH67BK-
^&"TTMFHIS3@-::T0S8B6CV"' M\8 -/&"J[@*%I;<_0Q'._G(BL&I+J)#O1;!;;&U)-+$*WW'Z_1@CHY!!-R9_(QP7J-FXD'\I*GW13P7(<<6C4>A;;1'[UT@1"-:D]T8NH39@PN.=68 M?4-
4D2B$'>KB%K27%$]%K_@; BWZIP,ON9[0:#.:N4ME.'%[DI^X*S"-5#?P_41Q)=RP!?4ZRJ!>1YOZR342_!$]I=4KTJIUTD&[W6RX;Z!X,&:WL'2756GK
MU%\U\5\1+\T'0L8FA=0^N]P3W3&WADANM',7J) M^8)C/MVW9L+TWIX.!Y54-='J>$+K#J)[DGJ3D5T9SM^9Y/*$\R) MM$/S(SDHD4:P1$C M'7%VC-L\.MN)]@_E"0M-
ATN9HIBULLM/=JH4A-X6^Y#O>DYL]0?3CAKR5V+ MMQI(WS_G[YNSDT+("&H7E_N;0F'.WU$EJ(M:FAW3,4C9@+N^:!")@=][-$/S.XHJ-*X.A$=I=M%/3.]:T#Z@T/*$D25=ZB"
M':'3+TJKIW_:VBEN<4+U' MWKN./828)QI[NH=AA:\&9BEDX:_98&A#&FPZ@Z' #WE_)%,,TLI6^$BF-[39 M/(%C&T^;,G X9_>)1P^T4[K/R+V%0NPW9K"1,PJ\
[1.&+Q++Y<%R*F\>2'7O M O\9$;I4DS1J0MZEFM1.3<)"KZ2:B$I8*.18-5'Z*1? MJ5Y2O2JG7ND7>&SRM&6OIA$LIMK9ZKZ7Y\??%Y?6?+ 6)V&Q2$54-7E]R:_VRF7<.K<-$WFW
SL0ST+5XJ>20 MH\EI(V!;Q0?LE>EV9'QXO=1-F[,1^:^I4_2+9I^3T51EAL3L=C";6A0E@2T$ MSTEL<8'] MX6K9?*IU4H^*HT\'G[MW,JL=FJ$-4\|4]>#< 9)6.(<++8?)R%6LS
MPVJ[9AXG-\R)U;2880(W@-!K"_X@ P#YW%I_R*#2)DQH(8*ZO=E>@\JPNG# MZ^QG=Z7/]^>R06.V02 MD9YQ6LJX-0S2!U@5ZP/X]/S[LT3IBBB5,"PU1+S-
MG&WOC(SKT5@WIY3V*!\Q(^2<,5>\?F?82>:*66/3*JX1A2N?6K#3.)B0Q@CMJJB2R9QG+*K*NJSLC106DU?ZIZS.D0N8'+V7#O<:2Z MXSNPZS\=&#O>;1JTP
L#@D!_^<#]VU*SHYS2?H3$?*Y<5W&!ABDNI\SN30,O MHDSGC:RRG"J?$_9GH MU/)_!E*[NFZ^X5K,B'/\G>B.0.WL,MSK/U;D17^^S4Q+@;NP8C5>E3H7=S+>4[O&
<,C$H;*"H$_L6NM\A /E%.(WJC$5,$SR;M M.CG/PJ!R0N!R2/@ D*S^J+.<%[A03F%"RNYPH\Z"C'"@G$(4AD9&V3'"3<69
M$@D]E"!+3UP.3YQCC41ZXFU[XAR%*3WQMCQQWE5+Z8D+Z(ES%+HL>Y:Y[)FK M29=ESW*4/7,%@2Q[;J?LF>/,5FA!9X\3P])=XK4_'$OLR:W3TH!TO"A14ATO MYROZBFM9OE

#_K ?=:"T]O).P9/2R_TK809NLP&WX'M^W;D+NU[|>S[=B0O(_==1^XYREGN;]K1 M_J8\Y[?D_J822T_N;]K9_J9\IRGE_J9M[6_*<l)*[F_:]OZF"*59O^2EK)G) ML?2/A?"/QSE)5?K'[?
K'O.0HZ\)%K OG)6T9#>TB&LI+FC(:*I_,9/UN=_6[MO&0JZW>EDUZP)D+VS,A-8CFM8I$],\HH,VDCRRP]6LX12OAI.;M&4-9PEBG/6J!L MR[2EMDSY3HS)?
CR%;,N47SU0MF4J=5NFW$H:,MDJ2[*58Y5$)EO;2K9R%*), MMLJ1;.4(9EL;3O9RM4HRV1K.\E6WO,/,LHN8+*5H]!ELE7F9"O'F2W9>:G@ MG9>VL?I.=E[:?
>>E;UVRK,$(_>_;'O_2X[2K%\(5?[X2.Y_V='^ESSG M%^7^_!)+3^[/W]G^_)R7?5A/=&QR&ZS,=X/9T:#5Z7O#%JQX\8)V!^P2\R=3 M+&X'_/M*S0$GXR%3B[L?"L9[OF3
L^G%.3J3!9P>9U%VAE:6Q,J@G)#*BI&7 M'C#!ZHY9A 5+4"A!E0)42YA:3EB)",C=4@HFE_?U*ZP 4JFMIS2NW:X.::5 ME!=>#I-73@%]?ZZ86,0B:SX]__Y<3H'<@]D>=D?P
I545F\6B2R3L(YEF;_0 M9?Y\FK'*@F(9928+BKLK*.8E4UE0++/T9$%QEP7%O*0JI\"W.P6>EQSE%/@N MIL#S:4#?DMG]2@)IY;72NR7K8447D"PWEUEZ<@ZJOG-0.
<)*SI;O'E2[F"W/ M$5*RS%\:8;6EL J_J2XD+)GS%$P@,N.T8[DMZ*5Y;X97_H80OOM*Q^3E>6>&%U]^?DKD)%U=XY>5O M-\FOA(LKO/+9A=[B:P6DO:LKO!?
@|@+@>WE&$<_>KK$):'WP3WSFWH$LAM@F M7QEZBV_7Z^H88KC;6+>G!I^T9=|FB,BP@7V?LZINRO>&K*Q|LK-T1-]M7[= MNR&J_=)L=1IG)Z>MLSW%-KW?[U\ZQR/U^-
|S.-9!G^R|<>/,SR^)NK6PWRGL?'',]#>60]U<8]G MP'PG!K1K/IYE\.N!-N[Q#+#IG*XGN)C',PS^J+GX>#/#XS&(;!'Z\G][C'LPS^:../9QG|
M>M8F[O$LS#'X]C8M[/,O@8WSGQ1<)D>7^1\IL<76=?)P+H8%YGI\44[G^GQ14.= M_O'31BN&\V<9'H_A?);'8SB?Y?$8SF=Y/(;S61Z/X7SZQYNM12\#67'ZQV,4 M-
L/C[1A3>9+A\1@?E^'Q3@SG,PR^LQ@>9'G\+":FS3#XLYC +/WC[1B-:Z>' M33M.95*'!Z>=YJ*ASO#U3@SMG?2T=\YB5";+XS%RS_)XC,:E?_RH&:-Q&1YO MQ;C(+(_'&.HLC|
<8Z@R/QYB+3(^O]_7.>IP_6HOS)\7Z?0&O]X MZK#P]+09HS)9'H]1F2R/QP@NP^-Q*I/E\1C0IDX#X?$8T&9Y/,909WD\)K9) M_3CD(C&)6"/#XS'A09;'%UF7WLN<'<7,C+13^W=X?-
%)97I\4>,R/;ZH<5D> M/XY!77K.'\48JRR/QV52J6T=/![S]2R/QV ^R^,QP4F6QV."DRR/QUC:#(_' M%)W:J9T4/+YH:;,\'E-TRO1X3$R;Y?$8 M8VVR/+X6;(YC''26QV.\3*;'UX+-
<9R7$8]_$L];IL-5:KG_'%*B40Y_:VQR M\4ODOQ3+GNKTUSV=&?1@2-E@:)\;)A\1_3.>83K@IF-H!ZJIF_S\;W -WP'1V< X5RFND(Y>?F.:/3P_/3QBQN?0K3I]M3^/ M"!\PXP#_/E>
(8YO^+UR,2ORTESCHYF%C'+S#-L?GH7_V3=LV1^*7OLF!%?XO MS?&[8IDZTY2_-,3_[5W\[U^:QXW/,U;%?:O]\;=:ZWPK]&:E R]2HN]6\'/* MJVG8!Q;
[+SU7FJ?!#Z]DQ'00SO_^Z9CVYQX;44NYIV_*DSDBAOOC9R7$><65 MTIP4Q:O>7&+[IJX%0@]D_OW^MG=]I3SWNKWK9\4C82DAC6(2\GQ]^?WIMG<+ M5'3OKY3K?
U_^UKW_>JUF;$K&X:+0/K#%184"&^<;)^+.B4QM>+GYEQ@_'_@Y? M=W'\OOA2=$F&:8C5K$Q5#(*KZ37*SJ],U<%EN'BLZI[B+>$&G_3KWF.C^=(0 M6P Z/7/6EG)/K,-
E[Y.#UME)L[UWT6P<_%/XJ-G[/7#W5WW\?GZW/\C MJ@5S_K3'/&QG.?68DGU$]7"%\I"3_=(!%E.M3=R=&2GUYQ6#,1IT! M#E$5U-[4^T373;MOOD?
5J8/"/#OI'']>T*BUB5O[!9]L+2*=S$+9IK<5GU?" M!D#Q@N*L]OB?W[M/O>NGN_\H3]>/#T\]Y?'[T_/W[GU/Z3TH$'OT,,!HMI6'
M)Z5Y])/VL_)PH_1^NU9"84D0DG0O>WBY>=;N1(TC\A;^"R-\H;]K>JW&]KV6 MR15[2)4_?151W.U!"C4TJBD?JM:CN/O:T*Z(G=81A13K7(/'#D;PU!#??:"1 MZ<&4$GY
C:B&'4&\2,>VN_VJW=C_>&0WS *0XT:=&_C%6L%)'N^)YEZ+3C+Z M[U11:E'E#^B7_JQL_DP9_'E%1S/*>Z,;AXTCYLG,=Y'IFC; MJR.TME\X^@!83W3 +!L<@'T/5U8 UQE8DNO?
N\KC;]VG;]W+Z^^]V\ONG7)[M?_7]N?>$1N+N]AN6&%>*Z'FZ=_$A)+[A8^"525]3"S8G3YVBM6VK(YRD]8/CR#A$/**.3K1Z+#Y[;]I*=XQ=35"1HTR*AI@;Q?;I!J"=
MU9.M/\NPD;Q:26A6V ()H/B,'^ M*_[]\VZ5LJP NGV"W' TULTIMB:J%%QNO8Y2JHL7-RE;A,F"00IYS7G+XB]\ M@.C&=]^JB=&)\>M>:R_^+NG,%YQY5],XM2SO?^[@F6;V?*;5W+L
9Z1<3< B M*+^1>SIA__N7TU;SY#-1GNUYGWVXI'(<&=4E_/G >^:;L<*86I!C45WI3MAD M?@#[2EK?>G8< ^;GI^[U78)/K5#XD4I$CR:$_/K_Q\89@K^PE-I[%\=GG4ZC MU?
@PLBMFN)*K#'[RN(SY\IB#TV5CHBOTG:J.S2:81H--I=:.'6Z^+ !L :PT MFN NREHB350O-'I= /4*"M7$.8/_![1JXY76G]H!^Y.G(C;Q(0^52%WU? CN@. M%G44 CASE4N6V;:T*&
[[EN89O 5G-H/7NS57RJFFC!UN.5A\M4T%[L"XW"6U MV?JI_S,Z'%R2T%6!$;+&&%,>;'=2U1AC2XOMU@;JD^Y+MA 4I5"SA.&'_('G M#M;-
W0N:W_:8K8M)#4K4H:+JQ+*RA&2*QS#%4X29]3@\&MN?$V.U(DFFH%65 M'B?(T8K54YZG([CP4[; 7Z(L-WG<>W.:0OWINSHDQH!6#'.FH8! @;Y9$+&%
M%+W$!38O[IHV6WWA'U;(58[V+KRSA SEBHY-BT'L,U5$\VYKWX4;IV/X!]97 M(:#',/^!@W8'M]5IPBQ)$IX3<*WF"F(X=I=K2%;.0'WM&;D,"V 6YGSA%?CB M^;G>$["G8 K^8_(?
BCA!6+D.+&J:N'%:&X-&W.K2PF:7,6:N_BUM!P-H,J M_:FB#BD,$M[X RPD%;-_F#N%%KC\U/S9%?R06&)%G*8074?5-;F-:=F?#L.D M#'*Q/O5N@!='\[(VSK.YBPJ]["R4V?DLPHP-
+XM%A1I>I>"/1H8JE?>)ACY"?]Q5B:,I/ MK1"U?9 OW-3_VC!A\3]\"0.Q7N9.+!#C$2,E%BV MY-:B+QW.X1W!&1\X%;O*:O/6Z=[%?_#D@2C,Q" ZG[W=)=Z0[LWPSYW/RE)' MOPO0(?
>!\2,&=D)3J X"X*:!5D:?*A0LSE01IS@15=22KXA-%%PR.0_'V3O" M-8,G!^[L-(X0;$]TX+A;MC=>>'P^Z'E5N9\04R>?6^W6H?=9>\C$.K&Q6">6 M,]A=+@3PI=;/*<$9XC&RV,/J"N
\JQ(X07)$T>&35"&J"N#D!!&&G.5H16)_MW3BZ@(\'H0]Y2/,^9T&4#']XQ@W1I)JC,3&F^VB(88A@N)!E V7 S3=[Z%\^ M!+M,!;T:?66&V",@9G"P)-MJ?$ZB6EQN?O9O^_"&Y/'Y-
Z(Q]FY.&*M_)S-< MA=XT@R'V/6AY;/6<5MA3'<8 L^151:$IJY<56Z>;6+IXLH&7M#:QB#*G&N6' M6:$?;J?8(< O0<4&)I^N&L:*-PD-5;TWS46T[<;>Q5V\TB]&M)M,(V9W>_MB
ML[P\VR>Z,\KK AFWZ?;+3S%_>.<'WV?6E M[D.!0W7_Z;G*?&C[P$")<7UQ+."\E3:A2;_%L-U,WF(HE2N5WF/;BM_0I?OR-P:?ALXH!XS,Q?9@P2\0C!C%4 M1G2,4G
7!MZ,QY9JA&N6@ILSF+9TX4#[)_)S;)1?BF34&D*.X,M$^0DX+=(W M=T?:MI(CX%905X!D/\JX^>3^(]^!!*UL!]V_L;\%A@>JC(.L/L-9S1@6;:!]][-419W M !S[S79[OW'4V&\U@PW(/@V
%W^2Q_VH8L[&_$%2G:918+I&@*5O.KCTO__G M?WX9QZ&8CA9 3,6D>A!R]"D(&D(_8U,Q1G+G\;@CX9!=.+VD_S+F?B_SSZ! M8"%"90-5IX2CJQH*US<\2I#D_%0.! E$&7+$Y%\
T7L7/5$/ 96Y1" ;MO7+ M)P(4#H_@K2%>!WTM 674C33\OIGXIU@3'Q]_^(=O7\%O$X)ESCO3LH(3P!]> M<;_@B#YP-$6<#O'0[@EU?
[Q&IV4Q&.&UX1X6#.!V52&T#/^L@0=BI3%@%]XA MYZ_$ZA^:?/#)&]PGO/H7]YLXNAMNCI ?S'! 81[&WI>M+T)R[GT]\DZM;\PP MN5_$I9;=-;3H6Z[_=.#R-W
K)ER9P"TCE\ESD=%RSO7M6P,LEF@L\HW88H;- M;>8SQXK3%G9Y3L&*ER1X[/OHH0\!UVR;J N'&S_.>#3=,"4="$Z/L!W^
M,FN\7/AWC/213K980E]*V2WX3\9QZ'>F,;@#Z&I=RZ+V;U37;DS^W:(;AGIC M7KXG2Z'^]O9VB&>"C\$/C [A2X+RYDD*F@08[&\296=T].)H:?9>FD+^;6W18\/]>E&:)K?#Y9=
M1B'5*Q)AK;6%E8*P3U'O"8X9_(@A>E-#>//CW(+L9$1@ ,J[^+<]'0/I%H-L M#:R_^YOKSE')#WS=/GRWM%F[Z]D[8_M=Q\QVQ*\E=^,/Q6U0'=-!:7%]?/!;
M:!5]8DOL8#E:^L5L"ROGTRP07&>C_1I#RYC]I6L H\2$I_/<909NKSU7.G^; M8^V2 E<,.Q/W+[@="KTY64NHEC(!]^'N;'>GX8/VGHJ["D/)82T C&+DE1H: M!__<]S)G4!1BP8
8J+^RX W#N1": (R)MP#-5E+C\G)@$W!X_>\/H+?0FVU% MU0R_8K7-8N&D;=WY7V^6%K_G&3AO E?\HKI6_A(3./_* :3O ^HF3I\5SX2* M'"ZK,GKO@_10)V,+?
O;_^IPX7:R;&Y54,ZEF&=2L,Z=F(5=GOBKNQ)3R MDVY:UC;\W39U[ECJG-2YG>CSVF@%=% =UVJ MA:LZJ5B\HU1,\4ZEXDG%VXGBG2QW?<0:*C>Z^5:U_*[9D!HG-
6XG&G\9H+.]BV_$ *&CA0EZ#E\Q M2W7<_^P!T77(/K48B(*F!DFL%>:NT\-[WFBEJ.[@<)L/7[%+-:1S(FEQ;J9 MQ6H7S6(U&WL7_\0-K,P6B\J%]8$?=/_?:+QTTW)P6QWIFXZM?"/\!
[65)V;] MJ)A%.I5S4](BU2'M3GQ7#+KYO MZ[IN.#")K;V+A]YOUT_*[?W-P].W;N_VX5ZN%);+\Z2MK'1L5IB5PH$A:N]= MW-$!T=V@3'05KEI9ZE26I:2AJ9NAZ1;.TG3V+K#"I-
P0U3:Y-#+2R$@C4VXC M4[C9NN;1WL5W(W0*Y#/1J9AS<_M8A4\4P4+4=TNT#O-"'VF2I$F2)JG<)JEX MTW''>Q=7])6(R?_O8], &V0PDX=,D30[TNQ(LU-JLU.\.;>3O8MO,$"(@%XI
M!#ZA27]I;J2YD>:FU.;FJ"CF1O7-S>G>A6@9J=P:;A=P9AI5,S1RXY$T-#4S M-,?%,#3T'23CFYJSO8OK]R'K,[MZRX?.I(FIDHDI_$XKBPW\EE&-O8MG>!:[M\U=O7=
[9IKRR_K*G:5U&8GO9TQ4,?,Q1(5GZ M6G^L."M2M!7OUHKK_KOL=!\EYF 4)>%D%,4]&F4F]MG9*)'^N;Y)P[-1%/?4 M%(4/^C\UC]K[BO]?/\,E 2Q%(L-
6D*+X<6.UX?')S&C]GX.KUQ3Q-*U-5:V M+3F*)36^9+/VG:G#1IJU%]RB24%C5'_?>WJX^GZ)ZTV5[OV5\OWY6GFX42ZO MGWK=VWNE=_WT[7F+3?
F/$[GYW="I92DF5A7>F$6#4P2U?;"ONC([%@(WA^.Y M:-Y1X)=SIX1[/[_1^5],A\><)-ZC$^+_++Z!K\%0>!D"54WM\^S[W? '#<6IQ0G>&QA#^HGD1E]^KY)^OGN<=]"8FMN-[W
M#>6*CO&$%#PS3AQS!\\EO/3;_'A&CFZS,?@N"SPMA[? <+P]<1JQ"1Y@J>H. M+HT4/EBQQ*H")%B<3N??9"E]@B=-F@8\$%3!9B=+]J?*[3]_O^T"K_P?.;)P MY'X*PFYP\^K0E\
X"C?FPFVJ_.21(=[E4?+SON+,ZXMH"Z0E\.#I?\EH_/EJ MCA%/_A"0MBL H&Z.<>/S?KQD;Q_C7[/I@S' -HQQB89E>6=B>)]-&-:SN/IM M;E#/5-
=1@DB:*US_7[$O^2I>TIU[R5=J4(Y'B.*N;VW$#'$0(VZK/%2>L=49 M&>'1HJ+[DC@WQ#UK&40\%0>:$DU3G+&B.>)M'.YU3S3L@D$;4XXQ"<'F34,R MH4J?4D,!T:N.+GI>X#')
Y"S> RMC?NM0Z47^A(#L\1V?QAGHV#?WK3LB[":&8X90&3#O4^0/ M# *%Y#!K*,PJ@$!S5-M3/ZAYR&!2+D MB4K&3>"[[9/!\+Q8:XS'OH(S#>0MI5XWN3ZL43SM-
3!Q&7W.\81W:?_*/$?^._G7K=W_>WZOE>,V.+60$UTFS, MS@ 7MLD]*QL8[OWDDW]RTS#_T!^A0N*H5_RD"WC-5!VWV12X(Y/#!6$50+$" M Q:@?">#1B/GV080#"\CH)&Z:?
[P#EKV6V7A %1A18N!5SX8\BH/0:'B5 MWAW\CWO$(OHQI*"KVGA_\^SL:!^+->BM0)D#USM:;-?A'6L#!E5G]-7E)GU' M+7?;<(@?\"40M_T!OR(F,(2S<1<]@((SRS-
K#C"9(X&VB.Q$-/ #6&=X5\7? M"!QB RL<70/[C2=80ZBIO#I86D/[@FN!]M'>"ZRAW/#*77(P..Z/!+&[Q6C M00N25?:*$8X-TGSEYLA].XP?WB1HY@H>I\9<+%@.,"29^X?*?
TQ'P7B)H8ZQ M5S2=X/67":PO[A$G<0/CWTP\+EM\AEB^M[2&2.Q\P.GR>/Y79*K*QO#ZA?O! MW(]B?H>@;D 7W@-PF_\)K/D?,5\$#Z(AF^=_1Y=C+(P: &[,_R:0,Z'AV%D$
M6AXWA+I2/A(1L07) (3? ;@]M*&TF @-44D,]V3QV6GEVJRE#+S#PXKI=HI! M#>&A \Q#R#GT-E2.4,OQ1.A7=W5]# 2Y4$[.^HY-782#"%V4N<&/&^52#^Z< MZNZG;?-
\Z8G+$3N[6K)_O)%D_W_6/1RK.$=A^6-,.??@#>7H;\D%=.^6=LQI M4SA3$6*&**_A>P#KQXDOBCNVRIU535G!C_]J4K7.K?GE/2-;I/E7=!G><:"> MMF("!#FYCEYV-*8V]8-I-
X&$Q\'$S7+5<]<&O%'?M?G^#%Z@T3$5019Z3/S2 M !,;I@8A-M:C#4Q'W$Y5:)/P-C!1P"VP>^ANA66#H<"_A5F"-S,B+ ED)FBS M0@_
"S4P*%.1&>D$_.C0K1]@+6#QXW/$:VXJ.O=!X*W29^95,1M3(;[T M!/AQ*(X\B9!E4*#O$"S9;H3QR":F"%Z^=P*BQ!TPJ%>&9G8Z1P?B,(ZY\^]%/_5JZLS$X(T*'VKR 7A*50 3
MQ&0/(<$=#)4^YKM8TM#"A0CA:I$'EH@S\9^O$!A;KAS\ER.R/%1984'[<34% MKR=R//$!#]P8DAA>L.UZ=W#A;I\D^")0;F-LZ++-!I\"_W)<.;DII)B*L,+, M1L<^-
O&MJ!_J$$BDHCDSO_?\\"Q5[/R!6(N[^M@@D3.:P6)\N'SX6=E817& MYB77EQZ\3R\>#B5Q-)&'UP*VAT_?<6\6<<9A'E##X8$?YAYB.C38$H M6&@H0K> R3!]YH:,*
(^151=,"&ER6)P 2CDE?0 R[4 M'=[C6-+024,G#5UI#5T0L0DS$72Y12LP<"=.YM(3BI4KXA;T!KK9!_M%(>\P M1Y ,J'[[W$A 1E1N!K>$ D,K".T&)HC.P-^\>1K+5!G%?
V!E'UZ'X1>\B^*" M$7P $ (7 +1HVFR!7AP/ELATW8T/N8CDW"%@V.M@N(JZ"VS T]GWH[>,G;X. MPQM2HD,4KG)F,3!ML3&G.;;!\O_73;+@#JSV+N8C-EAU%8+?(>,BPX.@'B-[
M;_9*!,)#0 '$S]8/D+,!\"ZM,^F=W8H4[XT 6KD\:CS&&'^*SILA@@)Z1 M6YWUYV)T-QQG'-XG9E8 +PX6F!P. OR,U ?O!7K"DYX0*@\-,$8#&-+4LN'- M8$6 M7[:AV/ :5/%\)"'7%WD/\
[^?E1OB,*)N*,BGD.AI5(>5Q)Y_<^6Y,2BV_GN_F MPZX;QN]XQ5W,.VWO *6YE)#3 M,6;O0PR^^Q]+D\6>PS363"EL-24,LC!BJ);X]SW;;')71NBSR8JP6[2ZU(K/-*F.ZX:TC$
M2Z:^9X._Z3N,8^!%*Z'74F/"N"E"&>MSJ&PE'.A"F*.R"1/%*+^+V_RPPNY" M6'*OPN3E?GV*9_7M>Y[>#XY"7^1B_E5$$&YDHQ(QG1FX)'?XPE-[D<9"11/K M< /D'1OU'6Z)"4;/!
,YH%@8KD#2*29S8YGBIK9QLVA>U"7JUAR"F@FNI0,2 M2-^;N33'#-34+0<2ST?-N08(QM#^BZ1Y3*9N9,GQ'#5TX[CLQBTCN^M4,'+T MWFJ!X])MW2-HP.F,-
&^I5Z3,#F/SI_KN"5>)D6"$3XX25'H.FK-'3@_;XW>A M\"<=SQ(K/T$H9[Z#@52&4PT ,@3[R<3R"!L"L2^9/JSCP8_71=3XK:[M$-SDNC;O M6T,R"NO/+-
&@(>EHN!X"AXJ1!Y;'Q9<#H?@+Z*X>@^5S[MO\>BNN)00M$#<# M=7]WP)NK=/;Y"+S&S;.JX:A0SG9GA\E=/S$KOLXS/J^'[5#/+]5)]^+QBLIZGM!E#/"F(9X^&MZ)W
M(**HT(J,H;OD#M\:KJAZ:P1"=?3Y$I=?K,3;(J59]\0Y=Y-$Y G=%#NH9@/> MGXO)\%44 D!S2H&A;T-3%!<#:G"/"I\P+&'VJ:B-$E%N%HMFW(4?_JV:@_76 MQ:A/A/C$G0S$!-
,KT^Z+.KV7[\T*N4'I%A_U:ZBR?B;MJ;2G);2G;FHZ6\@L MED;[\S0B3XP4S80Q>A^+MG4B"?8W([[]#B;6,ZL(=LGFS$]+9Y5_?_V"FX+. M L]!4HXT MOX&%$%,_WKN"24F_V"_J?
#,P!;6-_!S$)GT*\D31M;^TJKT6J' M0RLOYK*\,K%*QMYN0'\7;.@\ J^D=XB4).V$L<9B<8"!\X:6KSV:T"2_O@Z_ M3-V8B6C4C7^PY&Y9SH@"&T*U-K'D:>P^C=L.)TPLJ9XNVXJ#6B:
$9YK]_9< M 5FXK($9LY6U,$CBK_/RUEI'-KAYI7_<:1YZ.>X>=O<)(1TJ<3RF&>[BXK%C M8ZW5P5C6*Q2ZL=S2742)NRB+E;_6J"+7D16Y35?D_.<,1]<_1YP%2B!%P4Y8
MT/!_^V\,1W%>$-]^] MO[P5!;K@K#YE06J+<,0,,$1N8_9/CUCX)6J#E+73O2\/3U?73P>7#W=WW5Z1N-M[UKTBV@T/\<_FE)LX(W0&^X3-^XK+&Q%:
M*WYLG4AXTF;\'>OZ"G7X./O6+I-]NWRX?WZXN[WJ(F5?NG<@YFOE^;?KZP4! M[PC$*]+U4[@G$L;^\%D=*P+[D%VJ=&R[:Q^#ECT_EYQ:@T"68U-M"1U5<$8S
M'S3S2^[0SQM^R(&N*6JFO3BF]3>(%I?9;Z_MIWM[.[@[]G_6?(5K*5-X424U M@TY1:!^/+5+ 3'_[PD,Q?7[C>;$096[3F3^#JH<+ XW]3!Y]+9:5CED+192U M>;4+F ?
=>ST[-3/4AT=C^W-J8:9\3QI9>],AW@N:APVP98IEZD#W7QKB_^9C MX"+ H=5H=3(A8,N(H&,RI-7][=*'T@0E&[PIHS_M2\)YU/P]K\3W:%[8M8/7OV$
MDP^/7>O!:)R]M!LO&,#MB=V2X@KV67WY_GRUAXL1&+#7^G7OX!@")A@G?!/^ M;9+Y^BPX^)5])S M=MTDJYJB;+9>VDT493L?
49ZB*%NMX]Q$*1WV1S:NJZKN1BL."3@@HZ_C^DQL M_([+:'3=?!,SZUBQ]!8QZ:9EN9OG_[H<=5W_Z1N37YE.WWYU=/]S3\'7O!A@ M!X;D;._BK+D /1<^7LE66/^2X6K' E2\?
KPAZWR&57 MCG#=-V0WH8L2O:?VSK![U$3+V3ENE=L)%EZ,>>MF2XBQ<5HV!UB'Z/_6P.5H M)IZ=4A\SYQ,]!;78@5EKHSZ<'94\MB^91?
NX3O+B0[VKMH[C=;)])VY2._O(W8,1O"#A;23YOYI=$R'MR2@73+ M[IONI@20./!B3+^A4RTCS5!M^-XTU)U%G$=[%QVYY"(OZ>5M;8]!>ELM:,F8 ML<(&M>MF!GV./"(_NH9V[7-
C-R'HR=[%T?[Q MB9P$R%>,>9M%G//A"$.K.&1D#B#.)13<>CF[Z?4)=#LS7 \>B M$5ON1KFUM/&!#.]0A$_XS,/K=XN*^&D'1OYL[Z)]+"NL.4LQ9QM_T@ IGN6W MWE*&OILUY+
(- VV@=]CM_39@R X+L"=-7,E_MEZW6RC3_<.K&![Z)Y MO-]LR0AQ2_B*,*&ZU0Y' M;JB]@U !)T^;D#'EU\)A*Z%",825=XR 4I#EABT%$'>WW2^W=
[<]/':D>W^E7/_S^VWO/[(U:PZCD[%O M/NV$0P>1RI[")0)N'8SQ\]#D]@&>= OA;-^N17)V!83N;$/5R0GN*3@Z+?F> M@@()+.\L[13W#^2Y D_ZW0^M% @-6P);E$^H>[1YT
NX!HUW;#HAYX('3QX+ MNH86]/G=19D)%RSMG^2XM[!B$U+9)9BS53O%Q4K[1^W2[0ZM0U 6-$$?DZGH M@%Y]$S??$/G1I;S'B;:['HJG38S5VB?Y-
1*MF)E;38IYF[H62O&X(0.XW5FT MZ]%8-Z>4'G"J$YMJBMD'(D3KI1H9-Y\+3RX3[F9UH=V9N/;>Q7'9#Z\IAR3S M-G,=E&3I>E[7))[C#JU3,VR1[WAD>YV4=Y"FGAZAYS\[E>LF-
RNVO"W9,8KM M),>P6P9LV3IH@RH) HR=[52P%4^;&% M#\+S$$'UL8MUL]I-L#M'R6#%3M)+&D[(5M:-%G4/*+Q;O+"M!UEN2E71Q:R* M+I'JOM%P_1!F9G_XV)_;TA>395GV
.XW*X-VL^![6 LET*2G<%R8M1U"R[]$AD T. "AY^!/^N*1F:M6L$WO^57@$G[,ES' M[E7KG<*5YAP$DEOH3'Z8^"W2%-K' *^9PCA[37KD4))FL_^O5<-=<@XYK
MIE556MG.,X44'B6^LOU&FNAPP$8^\D2]&NY3K5?;7'2":@*U\8XK[[S: M,.6_P:O6;KRB^"21^(2BDKU\P+NA;+LR:+:KS2[E.V,56](12$>*K4W;=@C] M4@229PHI
LD"5>#YX=XK5:I3I7K^=?66/VG,G6@.G\#GW"_\4NO4>\>,TY* M7#0E/@1/?.7HAJ4YKU)G76;?L\OS$=L8%/-84](. ,"I!B/V8A//?YXQQUIE4T .TBVR,*=\G'XH[KXJ/F%:3-O
M8CN@6_KVXA?C=8?!-W<2NU2Y& *H_@[BWH+B]6*.B^)Z#=MLM586)BV\(:4$ M]FWBL"0!Q\QPW=GN];;10'[_<$LZ0U5L@M\+M0"\12ASJ MNH$LU\P(Q6%V,\5OMN.*XE0S="!?
N<&Q-C4\S3PA#2*)B3!I-]F1(JP5SE4>0J0]'(]GCS/9@E_G]\;8R.S(MR1LY./; M1G+#/0W8HI]IC@73@AOBQJED1GPNSP6ZX+T=# #=R?"#?NZ_-LV=;:?
IPZ?,*!.T^/$6>.3.YBLSFEBQ_[:^^L\1"1Z5ZU%YT0Q2J8WZIG!K%WJ3 MSVLW,/6[6!07T'K6J]$6\J^"!FMZW$EW"> [0B M:?%1P63)BO6H8#)[&606+\=AB7G.0 MGK.K-9+%D!G-
JNS+H5&L=VGN0A/"2 MGE$[E4&WVJ8]T.3,:4+--86T&I=%57?<10^7MO49?;QCF_#.@Y*R 4[?X:YW M<+LFOQL@%YCXSA4#,D OW4:*F)0^@YM=A9:=9KPQ:]6JWZ#OG\B[&I/%'
\38K+:Z:9Z&5"(TH2I1;=G M@"ES._O%0V*N(?7&.OK>,;>'7!\;7WQN69HT->-?%]B.B.^IV3,#A15D [[P"WJ8 M#HNJUOI;L:5[+<'5-[%MB'V2>Y5!FP4:'?FUF@B!/Q>
(P+="4/N.PT0'4-M\ MUE[=2L"?23#5*!3=%_^.E9F!+1X_&[HW@5'4/AR/3:XY:.83T39H4F/T>W-^=F(79Q_/[\] M.UUATHC+O!>MUVW5NZV?@-N+,^:3J\O1U<7YZ1!'-
KJ%7]_/+F]'[.H;#/WD MZOL9^WAQ-1I]*K0W__CC:'0$L[AI:HX+YL!4X;Y;9?QES,'9BL)]$:(&;9>8 MKGE:T<=M:3,=?('^QCA"4T-C/A&MG9<6YB$ -*_C;EI3@$)P%PI6F/A:U4_
M(5XO.QV8)9TYUAJC<*8N\,G_:Q=>+;%9.B\FI@GU"%7&(0^S=#=04] 82^[5>_O.2L$"H('^9CFKN30?IWFVPRT@%JXV-<'%$U?^S2V= MZV'/\=N=LP"U$B5K>7]D$@?
MUQIET%Q,HQ?- M992%\4UB/&G\03$^08VGA>N]%ZXON<<<_L2M679;\U-=K;R1@_WFV(^8<\2+ M_J_A34YF+MR..VX@8#QE^FW'++U7)Z4^)4L@(0 M]^F<$6>2#_.TZ?
BOF>%P_=P"\P%0[B)6SQ![X'%<*T[+)/^7MJQ3\)=X;E>; MYKKL9)TBLNE6!EU"I3F0=0IVW0-9I]KOA?(J6*C$1?=@ 0Z @K^Y!Z^.CQL MI/@ 9O7=YX(RJ@RA#Z:J$S2;DKK(W469O
=LU_#@9A)E8J),#[BTZR*AUB?H MDK@P4[!+D1TM(#8I$03Y#[7@LYN'A$,4,,))AA!69 M@Y%V$V+S/JT!I2//%#Q?"^39(7DF*\\484F[,N@E6+M \DP9F71 GMW"K1P=
M0L[DW/(TZ\' WAV:ZW+/9<;C5#.<1]FBJ.Q0Q>-/VI=S#F2(4; > MF*:TA.68@N_K50:M>_C)CEF@4GZ$%UW"),D+,CD#;)30\=:N,+8$F$.+)5^ M-DPS!#7*CS0"D*X&/[>%"]O-
$&=TZI5!IT8U*8F*,1ZO=F^\$F*\'Z]WTJ$MP)F?P:666R@DP!:[0J@VZ"8J3$Q]X@ MY,J;<&=%SJ/*\"0I9S;V9HY?3&*+:T% CZ5*B7Q\"[K/.7(3YL?0T@7G$D L M+M &
[^U@75A.&V^%Y:<2.\GWR34%9]G!NA*:\I*49HH8IEL9])M46)**.%,P MSA[XV@2+OBAKL@FP7/ '/%2$>YXI3Q41T,3$K<2H%* FW!H;AU!?(FQ%L&,T MYP;8"&+]DS
K,LRJ]"N#5M%[G15(HLD[P&ZM,FC66R31A"6:'D+I8N:S24NL M:4DT!1MMR+Q9X19W#B?A$B9VJ7>R #,2OWPTK+']R#^5"/M M $?RS'"#<;>#1SHG)\]E"%.B\YQA
*M.A,C10<*Q4!A7G)'?$>:?0I)!]A22 M#+*GD-+XNX7!/N)@,L)E'S'J/:@X-XJYDBE_W+F8H-NM#&)NX?.IX Z-C&F M)I[E4&S1=GY!&SQ_9'L[K;8Q\7F>*59=&.,3Y#
[6^/.@NSAHEF2)5J4C]\; MB'PS+,T:&YH9=*:H,HL?T$Z,2]NR5Z9_MBG//_G.A1>I&GZP@;N.Z.2 MD*1$F@%.Z34K@VZ'>KPF+=(TK;15&?1JR16%4/:]9!DORCJ2#$@&)(,\R("R
M[YO;'85R[NR. RS@?B+>TU[*53V_(64TSQ3YQP\;U@P@F4HEV9;[5?!'7G>+ MW/EN "<-[_4<4!INDQQ:>O0N9W_-X./OW)O8\,D37))0&Z7=@5T;4U&44]P> MIN=
/Y)?..AU*H,.K1L4R'=D$>=W15UY,][-J47W'OE7D33S!N*0YGK,&UYI MK2-6V"<0'OMXQRU^;WBEJKG8QA;!QE2B[:OD0'9["GIX' @UT]O/IVXMQQ3]
M7[\&_H^JT!,RS/1V$_1Q4R0=CYR496: 3/J-RB!F@:8!2TJ$/D83S>&298;% M/LJ#WUW%1,Q$P:WL>_E2U^5KT*JI9ADE+,[8*7Q(+:^TM54U*P-J M/;4L5;QGE_I-)J'<*8* %H

Y4NY4I9I\JK/?3E2J5-E0LM5$6M$E&9 ,2 9Y MD 'EOO>./B^Y=[!;#:]%J)V3'8;]#H2,_7@+P(N^AOA>|:6 FKN509>Z$L=G M>1FLW_?%XFRG1]4_L4HPS21V7U1@]!)<8:
(\]LY(@FF>YQAW,T_#\R,].S*0 ML!B8D@,SN>L!1_,"M,NQOAPO-00$07]&W7-L<=RZ0BZ&*@\I5;'F MABTSW)MGEX8AKM_:E[858I%?.I-99KQ?J]&!AQD*.'%$U*_5*P-:(-YU.GVW
M@-/'3?T:;EGM4%5'=L).#V+U:TT\")#6!R@G1WG1/%-(,LB>0I)!]A32^D!: M4?TM?]+*%&KO MZR7S?HUUK8$)KV'NT93&<8*+=IDT/<]H=%%-S!W',K[A][
M),14HUNYA3/)@Q(HP"T9J"1@3S(@&9 ,\B #6IW>%,>>:8YE6 ^N'\5..; * M=UXMQ;,@*,/2G%?Y\<0V06[NEW@CW'=,[_%=M*-9$G4YH:Y\V:QF6E[@J^8:
MXZR25;^F&F+Y#N^:.V*'J1CZOOFJG^ N?XK;A(.N1A!SU?:)N7J50>VH&?-9 M@RG&S3'+,T9Q;HJ:$*_I]@SC@[R&E/&0F.NXGJ1 4B I'+(4"IOE
M2BV^/37,F#S%./6&Q3C[A_C;A!HBE%NO4E1;D+FF6FQ,/F?A$A1U$75ZHH_Q6KNLWTM^IXONRH71EE*37=V+
MF,F]FGFNIUDZ1&3[UW9(E_C^S2SUCCS@ADX[SD+$;T;:L8E8[)&H-^*-K4G$ M;XMX]_18;")6QU31,?19B#@=*Q:MTNKUY#8>4H*L=.$H)05("B0%DD)^I%"^ M!-
FAU(CD!IPI/BQAMSCZ:-XN@LA9P*!F_4I9#;).14A9QJ+-UH4"R=I9#3 ML>0F1=.9 \,"D$@11!Y()"GD@4220AY(7#')P$_L@1$E+WS3WA$2$R(X]%*1 MV\
86A*KWIDW._FE)OX=/QNZ-_E2KW]8([($CTXQMPTIYJ.D[LH L77ZD@(M610J*0L!"\ "SIQ+$+B;VM2%@-G_:Y>@>2G>EG=5AU%(VN&3VH?@>9'C*BI; M9246IFUYU]:'14 /
[C)TP4O'&([E9?WEWWWI& "#V>B>>OT=$;/@4XAN>? M,LUBVJ,]LSSX@NLR;P)O_!I1R-W."'G/5Y,[@3H"3G]^-RSC^/#%<#G9GF_JR=(="RUR@[!44T6/@<-ALRO29:
(D4H"@)/Z0_8$7:XRW M$\ZTL3PD_A5&@P.%1XFN1Y8X*.?!T4PV!>^)]7$>7'YO6)HU-N!=<*H>%UJ\ M'1.6)P-XAX59T,-:I.A\M/Y6;.E>2\G:-S.[(?9)[E4&G;G^KOH5'F+HK;73 MH7)?
2REC$>@%PF"!--:-5J1Y%T:+;X7FCCL.1@USA_FLO;J5@,I),,^H9'5? M_#M6!)2\"=;G*_&)M<5_OW9Z0K?@7.0]Z+UNJUZM_6S72G0F$^N+D=7%^>G0QS9Z!9^?3^[
MO!VQJV_LY.K[]7H_/_G0$CX/49^WAQ-1I]*O0D\O"T>@((@Z TH[+ MPK73!1^6I#TZ^^+_ ML=N:9F@*4+%,39'^I>:['HQ95L4DW?Z'K=*'_D."JU?^*L4M$EAZ[FTJTF:*
M.*;4:&Y(1^VI=[QUDF3+^RS=#>9)4%A+QAGRS@M1_E$-T5XTT-^X(+#2=-\1 MX&V#B!W.55 #%T]<^3>W='|%7/V\HY^6KW\SN1+;# MZ/9U[=CWAI>30]<:
[NU67+)'[;6Z%0&W8(?.Y\7>\O@ MD+6&V'O:Z;7(XF(27HJ'JS7$KM):+]7#U0K2.2$UU'#E3;C#<"G8X1,.''GB M411191:7J\#:"S5%
(>KR0EWY(H74=GJ=S!R'6^-7YCF:Y9J:F"@T_8^9K$XZ MG!U@POF=A'U?J'K+=H!OEL^K6V25O,G0TF_GC!L&?(, [.K^5GN)/P[9>D;% M3?S=>,%0*7:6;(!%Z>I!BA"K6:L,&NUX]Y-]
(HV(2R,RB)B:]IW) M+G#-$9^5';!Y_TK[,^?0?8!-:WI5U&O G>_C5;%8&!<\E%DJBR:>' MFRV2:!H2?3\0VEJB;4#$U*HP/9&F8*388S3-G?:4:-H=V""D8:!7.@<8 Z_O MN 5_>6QJ
CPN$WYY3QP! ^X)6*%J_MK_%B$$)>VI5Y P95#8Y8_42M!N;4\SF;VI$*U,28+] M(5WVJQPM[%+;H_:E<0+U'$7HK09@[5;,)Y.3?',39K=PD9(J@E(5;YKFBT>7 MMV,^N9R"Y1(#5
H22 8D Y)!'F10OK7VE*/H XF?-V"U%3#-AVCPRIQA&X)K MVQ$UN9[G&'6EU<)TL3V M6.C4C7DAC)3@'4J01?PNMKQWVS%G:$@-8E"#-'V!V#S?:/9HXT9VF.MD/=IB M6DB/L'-
\I"=T2"!,283MV+4)1/XYI)H*W1E*0TM54KFW;6<#[K8V8=RM6Z?= MNC$Z\X(N7:M,DC0<9/@\PK>VG4(XSHD^KR(/DV;QWVVK01W7M/"3,F2H920 M)AF0#$@&>9
!+0DC2S"8D[H@%PDNW(2AT4'^:AY'D+!T@*) 62PB%+ MX;?M#CP71X7F\,13.O'\X$X\[ZX_+'L%$700.1U$?L 'D<^/,"W F-\ZB/SW MX>5_8-
SGE^SL__PXO_W_Z'QK$1DN!)KB6YTNG6]-MZ#CPN.ZS_SXRZ(?"(U+ M-,R= '*QQI;F@K^1@/U/"+;O=7#@Q87L\8X[Q13."+/_NA3"DV;.. D@70$,8.BRF>N''$Y:J.#%+ "VT92,:IFF
Z1I;$%JE-L;>DY_UM'S:G M,^)Z$A%&A!%A1%B!"3O0)&NS57 L\/''T>B(Z8#.-,<%2)9&2I5 1%&A!%A M1%C)"4O"T1](@XS=9O&OFJE98\XTC_UW9G$I@V:MRG#W^<(VC'/__S.
<9UYYN(=1OZFIC.1%\&= MXK:%VUF&+X:[N.];YH_?W_*RW95=:^-M7AR3/\FUN%%*G4L!19#W^($%"66 MQJCM7F70CK=)(JE(+"HR7XJ_U@S]W#J1Z^09JPL>'-
ZM]AKD57;M#Y*&SOB+ M^F=J.3\99=FY^4BGAOTXJ^TZ'7682[4)51FL.WHO+YJ$37VKO5[,38E(D>)1 M)+\20CQ+8IR*$ZC,FA5ZPWJ!YU'K',-(8_E90MM.LW*H%-MQGS8"RE(+
JR M^CL9*TP+YJ(:G2F1/W5)1MQM]_M3C,Q@2>4URQ1^O*2>^S_0OX MSV(OVH1-U)65NCQ/S>M6B]!C[W3$3'9+4-MZ_RZN8=:32_Z0_A9:?_.P@M&M
MYU9%#T,)\AAY=!N508_%&(K00L4O4@<7 HC3:OF>C4,.' MDA="X]*=K(,^G3FX8,<=P]8E X!SXJ,MLS1Y*I7NXK%UY"(7E>&?Q($<<"#? MZ)ZH(]TF^>1:/I10I)!
M]A22#+*GD&20/854=9-.]\(1GWI\?NX;M3!HU6(NT5XM61>))O_>)W+RR==N1RN;%7DXT+.W'[DEZ]WSDNNM)DUCHL]ZT- M>G71NK#?[A1VQW;Y=*4X_0I[#>Q7V.T4O?
%E^70HOZT*>\URM"HL';#)0W%$ MKX5=R&J=-L&8/*I('G<]MJ503/FULLE41@UC,SU)AFY=T1#TU[<&X*7)%_2 M&I7F](7I]@QDFMLD=#PDYGHE@*1 4B ID!1("B0%D@))@:1
4B IY$<*,OB# MGQC\1LD+W[1WA,2$" Z]5.0V<$]Q]+3KH,;&/^KZV="]R9=Z_<,"<4 6/I^- MN6FJLZ+_7:E5Q&MUPK5XK2@+I0)<3W. 2U^O;D[/;CZ?7%U<#*]'9U_\/W;<
M$BW(_Q+06:M]J&Q5TK,0(\NOMSXL!N' N' : \MO5N\4W^I[N^O2.RIZ0H]G MXOEK=.Z&3QWN8D*,:1;3'NV9Y<$77)=Y$WACKP8U8HN0^.QJBM]RSUZX,S;<
MI5J8&'O5_/RNO1B/LT?Y!=?Q;C3K@6^3Y&OOE>SI5@:UH^6LL+02=?KZ$8O8 M\ANF&]+KQB:[%35F>;3&N1'.#5.2_J7&M)EG*]M<97N=[H>M\=: :??[S \&[P1VOS#9']7 :!?F
M^XV9_#''_/I";:C)/7CSLW(U.'>]P 0D9[:7Y4+1W\RXF 7"-:4)\#%^>:P[J#T[VDH^Q@,U_*+;_94#]:<5VG[+MEY;NY# M8Z0QTACS;3I1">,)-(DA7
/,-15((X6^'"]>8JEQC.U(SU0P=G*,2J'C$6.Y9 M(DFG*VE_$Y 4 E=;@>2KC]I\UX=\1^?WQMCPR"&F;8^+@K!Q$XXRG/!6'"6X MT#%L)*34TI1J?TL83) ,4I:!#7,(PX1Q2 K1K+'R=
5/'1=3/''CB$O;^ARJ M__C"4/M B 3S,($TS&R!&+O^J;86]+S_JX%F],9<3V)""/"B# BK,"$'6B2 MM=DJ.!;X^.-H=,1T0&>:XP(D2R.E2J" ""/"B# BK.2$)>'H#^24M;W;>I[R
M<;BK9UUT]6Q25T_57Z+>^-D4NQF:N>KJV9-=/1MT*'E>&MC$K"CQ="_!UIZD M(CE4D5SV]^RK_IXU4IG<=-L+Z4Q.NWOVL;MGL]INM@K>:Z^D:E.<1I]]T>BS MTX_7_9
BQ:1(^>WVV2])M\]R8IT\M/SLMRJ#;K5=B[<#-2E(+ J2QX:?_79E MT&D4_-",4JI+,N+N5 8]F$&2\P\)Y39+E,*\Y!Z3>#12[OK^]./JR_-RY#11 M5U17N
&37SOVO>%=@"8O=LBIK^R0D]?XOHNIYE:CD;/#._*MF?FFKE1VDV1\ ML;NU]/)I+:62>)H!P^X:T*\,&IV8Y5^*T"%>+4A0BDVLOD,[[O1B3FI3G<,[
M@P21PH[ND&,&!0U$75FHR[6+7K> A$X;PO>K^UOM9;LIO""K4C@3U"N#G)X] M1YJ< TW.3_B!RMK(K;(>B#KD-S9!]6B">I!V9*8="4L7%SGC/=3P$RUA[!*=
M8!FQ**RV[]DHU"ZBY"74JSO&2P8 Y\1'6Z9VX!DM10?;4Y=DW^0KT M#?1GJT.$"P3KZXW*()<=,_*MKD0=F7K>87F3+)NT,S64VTI2VR@EOC?Z/36>
M@#N6SCP[]G.SK%7G71AA_BDD&61/(PI)!ME32#+(GD*2 M0?84D@RRIY!DD#V%5/^6\=G"(S[UPH<+U\3APBTZ7%@=:I/3OE>-
ACA[XUH*TZR]T<$CA+N%;X%=/AW*Z>G!J#/=7#I$ MDX?*E$:O,NA4:YUXBP5)-]ZK&[FL3.E7!LUZP=OXE$U3$I%TLX9>H=E+KCEX M22M3FM,7IMLS$&9N4_QD)CK_#])@:1
4B ID!1("B0%D@))@:1 4LB/%&3P M!S\QZHV2%[YI[PB)"1$<>JG(;6"%BB16O3.OK/FE)OX=/QNZ-_E2KW]8([(MPN>S,3?-J:9C4/[O2JTB7JL-ZN*UHBP4_+N>Y@"7OE[=G)[=?
#ZYNK@87H_. MOOA_[%A@(\C_$M!9JWVH;%7(LQ CRZ^W/BQ&W\"X<.(":VM6'VVTU?=VUZ5W ME.N$'L_$\]?HW V?.MS%W!?3+*8]VC/+@R^X+O,F\,:O^Y\D\HX&?_M4,_S\
MKKT8C[-'^077\6XTZX%OD]!K[Y7FJ5<&M:/EU*\T$Q"0":^.6,28%VSWL(VH M5%9T;J%>6US:R+/A39BN.L.Y&;2&@[_8+7_21(_T[K'+_K#A,_8$MC)S.'[Z M7VVJD7J^I9ZETL^<-
)U!S=.BFND&&TOQPQ&8SM_<,35+?ULYUS!Y&>7 .RS, MXAXV$XH"K?6W8DOW6E+/-W4Y))XQ1R94!KWYL"*_5A,ABG87B,"W0BI_QV'* M
I4WG[57MQ*4SDX"\U"EQWWQ[UBI!B#3D$$=CTVN.0AZ)[@RL%34&U;.L$K7 MCSK=90K]M\/UP$P4!.]:+_R;QB8.SMN_ !2H#&Z%/P(5/D$, ?/^;__2!M&* MX=#M5S
_JN]B^+VCMF$MF7&DF%J;>;;_CB-'@V]5A^V6@SR'Q)#5G M,RZBK[#?38"/\YZH$9]HNS5JHRG5YM$PF" 9I"P# M&^80L:X;DD(T:ZP\7<%3Q\443]PXXG+5*K\4<+#43S+.P 33,;
($8N_ZIMA; MTO/^/:^;TQEQ/8D((*(,"*LP(0=:)*UV2HX%OCXXVATQ'1 9YHC:BY32*D2 M*"#"B# BC @K.6%).'IJEOUVL^S_SBPN9:#Z9#>9?WPOMO>!4EGG9AV"^;5"2'*I++IME-
V32[&_.)J*50F=LYNRCYE)MBM-$NRF::'>Z\|<10H2BX+DL:=VLP*$_-A(*0N<:A+(N)NU2J#;K7=;Z38 M6#N6U&:),IB7W&,2CZIJ5S\-^?X$Y.K+M^I3'M]%1%T"U.79&5X[]KWA78 J
M+W:FZZK.=,U09[JT ORM76(=9L!<'BJ1;XW,-W5ELI<\!!:M1EZMI$R2SF.$ MT&I6!I0H3U;PR0BN!5@_N54QJF'8.P(0^>GH[C=FA","B@>(NB)3E^LUA'6K
M0^BM(3:_NK_57K:;KHNSY-1J5P:-9KS'J<6U;D"JG -53C+&V%U;._G5U@/1 MAS0CD=WUHUL9U*D,(SOU2%B\/3#_5LQ'C-/JQ':Q"58(BY+IH,L]!2/94Y>M M6UEQC
,EPXDZTNV#T.V2R(?RE7MC E'M\OE.<[DNLI: '34!+_D+_LT)(61/ M79Y70X;Z'S/7PUC1O;77; D1^].BIV-.P&^_"X0->(.T_&F,NC\6[XV'ZP
MQ%W$*7E;9NORN!>EU:\,FO4\+J_E6]V).G(5R;F*/%1EIG]2*OLG%3 3=40=49='ZG*](/?= /\M-@])5WK*Q[CY
ME']S[,=3PY4[B+#IW+H=1+_++4CY6]/=&C=@73%MA,ZWYB0C^6:RDE^&C.&N MB"];=45,PC'N@2A5!TUY7/3T137/=![N/M:J#/_[M X5^J3MALYR0&'";=]R
M,,+\4T@RR)Y"DD'V%)(,LJ>09)]A22#["DD&61/(PJIM"?C=LHC/O7X M_"!:ZJF\HI=//Y<]E=NM4O14_C5522?6[RE>'8DG,]?AKKDM(ER&W?N-:O]?KO@2S[ETYCB;&9OX_[
:K\>K],A'7J_ M#N6W=7*[7X[6R3'KS#]^Z=7[G>/L-2=&C9/[M5:!&9R!7WS6+?2J4., MU$NNC6X1-24OSB09@3>P!A2N2 M6/7.O.#FEYKX=_QLZ-[D2[W^88$X(N?S\;<-
*>:CD'YORNUBGBM-HN*UXJR M4 [ ]30'N/3UZN;T[.;SR=7%Q?!Z=/;%_V/'NAM!_I> SEKM0V6K^IZ%&%E^ MO?5A,?H&QH7S%UARL[K3T%;?VUV7WE'%$WH\$\]?HW,W?.IP%U-
@3+.8]FC/ M+ ^^X+K,F\ ;OVZ1I)%U+:9I5@:UH^7526DF(" 37AVQB#$O MV.YA&U&IK.AVPIFN>1I3QL1U5"1X9>!/81,NFV@NN^/<8@Y_0EO '?@.OS?Y MV&.:?!,MS, +3-
DW"Z[0A,6 +L!M\4_DOR,_-0WMSC#!$L!T=?DEN*OJM>7B MC3R@"[^#3EU\>&]8FC4V-!,XJ(S)/6+?@$HMJ!N!+THK@%=5YG(.X_0XJX]) MG=]0YU+I\[F%:F-QZ?.?#6\">@ANT-
24ZL%_>G:-)$"S;_F3]H]?>HUZ]]AE M?]CP$7L"99XY>$(&^Z\VU39XWZ6"5JE"C4VP270#R2,8FNO[W 8DZ5]J3)MY MMC*#56K>Z7W8:DG ?
TAP]*O!$KO>YOZ\C!%'%-6.7>C1^VI=[QU MO+K[?<8V6K[U[TJC$]C]0JQU5 .C70BW-JZ@CA%;. OE^#OZUMTJ^='/RO[> M:BU6.5W&!08/U_ GP,?XY5')'6TE'^.!&G[1[?
[*@0%KSFNDMS_9>0[N0V.D M,=(8\W,?&B-ABZR4QL<3F;[P>V[W^[.^C$ESH8&X24FH2K6A M, PF2 8IR\"&.40LS(6D$,T:*T]7\-1Q,<43-XZX7+5&*P7L+]22"69A@ND8
M60*Q=WU3["WI>?\&R,WIC+B>1(018408$59@P@XTR=IL%1P+?/QQ-#IB.J S MS1'%H"FD5 D4$&%$&!%&A)6D#%K"CQ-(XJ03?E5[FD:E.M5V M/[G()Z'T9HFRF)?
<8Q*/1BI>WY]^7'WY5OVJX[N(J$N NEQC\FO'OC>\"]#D MQ19E]94MRG(:WW>;F&H&QQLON":K)KN)QVZ2C"]VMY96/JVE5!)/,V#870/: ME4&GZ.>#Y5\)$A9B1YAQS*?L?
$HA(#B$>@>1QX[NE&,&10Y$75FHR[6C7K>* MA*X;8OBK^UOM9;MYO#A+4]UN9=!-<#(@32ZV)N MO"L;I!Z[J$>RXNW5('1I=PH7N)0H/L%J8E%B;=^S4:AQ1,DKJ5>?W"$9)P3
M'VV9X3"W2-N/-DC+F$VC=\;#]8XB[BO+PML[!YW(O4:U0&_68>07>^U9VH(U>1 MG*O(0RE_KYE7SY"M_HA^F(UC^%7OMQ*AKE#L*(Y)6,>K43-@Y*_FX*"T^P. ML?
RGW]B#0@ZBCJ@CZO)$7:[7=K\;X+_%;C7I2D_Y&'<[\V^._7AJN'++&G8Z M7+=E[7>YYRU_Y0%;XP8L6XZW5\Q!5 6DJCG)2+Z3K.27(6.X%>?+5JTXDW", M>R!*U;957
2DJXZMSL/=QUJ5X7^?UJ%"G[3=T%D.*$RXUV .1IA_"DD&V5-(M,LB>0I)!]A22#+*GD&20/84D@^PI)!ED3R'5$F7?.HO!:6=T43[T;!.S3_FOHF@R0:C,6L(_%DYGK%
[]]=.NW(9[E<7[3N[O8* MOD\E9FW)JFMN_KMZ]7&78+/:[Q>]:W?Y-*8X71'Z=6S8W8]Y_XV="]R9=Z M_<,"<4 6/I^-N6E.-1V#\G]7:A7Q6FT/%:\59:'@W_4T![CT]>KF].SF\\G5
MQ<7P>G3VQ?]CQTH;0?Z7@,Y:[4-EJX]>A1A9?KWU83'Z!L:%$Q=89+.ZF=%6 MW]M=E]Y1MQ-Z/!//7Z-S-WSJ&?A3V(3+)IK+ M[CBWF,.?T!9PS[W#[TT^]I@FWT0+,_
"4[;F@BLT83&@"W!;_!/Y[\A/34.[M,TRP!#!=77X)[JK:>;EX(P_HPN^@4QO"?GEWK M"-#L6_ZDB28RW6.7_6'#1^P)E'GFX.$J[+_:5-O@?=>QO=Y(F.]C]_.SD6T
M0S$UNT#9*]HCVBN;39D^X*/8+DQ<,H?LS_RC'1KSS&B&]7&V)Q0LUYA-,+Q M # !H6J6$/^#_YI"NX"NU6C=UOMT+9APC(BAG=8F 4];/42!>7K;\66[K7D
MFM[T8R'V2>Y5!OVY J_Z%:F7GK^U-B90UKU4GBX,-A &"Z2Q;K2BI'QAM/A6 MR*_><9A!P*^:S]JK6PFHG 0^6!7&]\6_8T4@A$LAKWT\-KGF8"0VP>6J)4T* M:VG$@(\ZW64*_;?
#2LB$%NZJI+]I;.(@F/P%\"GHK)CT0!M/$-B"]OWV+VVP M4,R^5GHQ22I\GQ5Z%/'.@K^]H[9A+4U&D;T$VLRS_7<W-^-F(7Y]_/;\].(QY#/ "QOO>B];JM M>K?ULULIT)!/KBY'5Q?
GIT,7STB,B+Q0GHEGX((FJS@P)S!,H3O=C[M_+$QU^?///[%RS\+^W6!?&/=YR:0T1M4,4464PHV5\>C]M0[CF2*WW^;Q9N! M/H)J6++D\^T;1Q.@K X(<,4FPZ4Y=
<&V=XQN=@7%#N7(^X MB3MG 28E2M;R3KX(,?%(-O;;E$LU+N$7DTK!I#X('4A/- ?K61IE4)]&K=$J ME-&6A>M-XCKI^H%P/3%=CW_NV="]X>W4_AZ)D2+T;KB:BM4FZX'A
N>3X1G< M_;*+2*.U(=M935"DGMXU6]HS498#RI*Q_-(8^"7'%3+<>.T9W$]X[GO3. M&^R^SVNSZ))O*MS',\C7;-B*E8U)22TGQE;/P-CZV):HL^Z(\ ,TMW=++[WC
MO^LU;.Q1K:W;&+NG]"A(>#>&"!TY),O40%7&ALF9M0@N\&-\+OL2%+^K"&5'O$K?5_BSV#;>O/AFD> M!OSXCQKMG ?))#&WMA \6*U&GBXQ$<;CY.Z-
%ZY__IL[=E1Z'1R_.%EYQ<;$ M^5'+),C]!9DBZA =UVMDC _^G'!3[MEU0<)EP1YKE@(_J1]F?/FZOX".'.!C!D*9B!>%W_\#DSY9CLC M8,DW TR"PR?G(+)[\4)\X]SR-.O!N#.Y_(IH
GT[T2S?$+-?D*W7^I5!NTX+ M1&\ZT%PH1?+^N%ZK#%IKVCG3C)H;A4@/9=7K,$&W22.*HA$IN(A&9=!<=TQ M3B%;^;-$6-4VGF!/']SP:<_+4N=0SN^'8G"W+
CN[6#GW)+'M_O'N)];0;FN M.N@G!^BKWD1S*G)U5?I%.OL+-@7WV*H,UAX#]_Z*'1)HZ@BH71G4J5XU>5&F M8)L=\+6=>&LA*=VT?3G-/7<N?8[D ;MT*X-VK/4;Y9WJ
M8I1PBA7(]1Y.?K&66I&(WQ!Q^EL$ZO5^9=#I=$C$*8LX12MNU #WM!*S8LK9 M[>(1 ?GSW<:-KO%KH[<<@^HM%B<_X5!W\2&GMVM3T-K"JFHN+$))A\>-<0 MF6F28-
P23"_7 HHQZ)$-)B;!%&RP51GTDRKHP3+FWA"+!(RX.NCR_YY&"!" M##E(, Z#'BPGFCOY9MK/P9D8&>**-N *8RDZIDHAS(_G4KV"B!?7S0#.L3NW?L1U%DC"7)
M=S,7ON2J\I7%^N2R()RW4HVR'\)]X?.N\I9Q]C MN_'+59T$/\Y<453Y*;SM(TC Q-Z,/,=)*& /YINN%7.^OOYPL4IG15HJNUBY MV:P,.HFMD!44?BI2K6%&RU@PL!L6X#
MH5"Y9+"50@;B/?&>>%_\4+G\:\B[Q= R64]'=A%E^:$L@R09'F*X8#OK;'6_ M$\OW=!BK3?PKM_B],38TDQEX2B-8L#A7G8\]D?MB_$5U/Q%-ZOAXYH!A_XVU M(N,QN#
[/Q4,ZN/&$9[N7IG+D[45+*7]B',ZMH6+6 MS9Q7&6;**"P)NT&R(W(4XC,>]B@@1(NF8L\Q1Q;OS+HQ]M^DD3^'I$G;^4M
M>:Q9.]8]YQ1'O3N.NIXYH#LN?,&^QQ7&*0SEMA0>1D%N<$2@]BI.?KNUAV-@B,/!)/49QI*J66-VD*E5!\N*MW]K>8O[WBW/ M%#QE ^5)
[5>2E6=Z8*>%S1X[),]TY)F"?;8J@U8ML6:/5#OU-EY14/@0-PUM M/,4X"!).#9'O]F8.O[K_JIB395ZGU08G2!W%TQ%G"CX0JRGH$)YDQ9DB1,&L
M*R5=TQ%G"M;9JPPZM.DY7\!%X%C9'C",6+A;%6UPX2U1Y*U)N*L?"&99A/ES M\[GDWM4]EA6J3_1DP0*'1^8G7@3/1VR72/QQAFE[R#?]-!-&Q.D MU*\G+<.-
%^>L,]Q&2H9+Z9CMEX^,8$N\3,38HC==N7(P;S8-D%83&,UWS?F3 M>[CPZJ_**LH M2+A;"C<%R^U4!JV"G554_M3-ZC6G$-HI"[C9/N>)79&^:QZ:SRL8SXDLR\:C
M+Z[NYYV1LL0W75REI91V)N)--O3K4K]C2 M=R#SL$K.?;.=L#4+M@0;'=-J>[/&27NJ&#?('DACWA/O#]TWE.>.@=]9=^*KP\A MRE[3U##U /M-_-:J#!J)5?H6%)PG+=848'D[R5Z5)-
:,LMD=/#:PG[]T=JG% MFH*U=B&([B1U<"!%T65 M!1-$.^)]\3[XD?1!QHL?S,LS1I3 UFB+#^449IL M/\N_X5.Y0(=5G"ZW#-N!#SWN=P_1K/#V%>PF F0YCW W[3)"]D\@$.1.-
N6S72K RU2XB6Y@Z39)N'MOYGR/=-\/B5R@$][;85)M50:= MQ#9T%E3 2MM%[KS2/G3.Z<&KA5;NLNF&G#'LPE!Q6ZF 8^O@<6W=M1$
M_7,I,H).'9I=,Y%JLEZW2U+=%S/M)]8LP%*O,NA2WYJ$[34=E)16WTQ**NW2 MNB2TV!6TG35<=Z998PYJ4GKPLK)],[_S1%/#<\6($SLK[-*C7=.9"#515]BK
MDU#3%&HJ.Z1[E*#-1*C)+X/UFI5!H]I*['1*2NO$@F0FMN/)LAP=%.CP4,L(M&9!I04ZO12XP15FFX/G:$'['6XY#4DP5E%#J,TU9IF"1W20MDE(G.Y0)'R+> M"->HY0!O4 %P7
6'>0$[]B%^)A0)$P. ^U5Q1L"?9F9MSSMD\YX?H=^$\(SVO:0I MY0RJ4OJMRJ >Z^'().4MI9RF+6//K28UPZ66&M3.)#?D$>^)]X?.>\K2I]?S M]JWX^A"B[#7M%G,38-/ZYGM ^?
NEFR8>[U8&;0JNTY)P%G%U#_N_U.NQ=DXE M&> 83?]C M)H\49O!*A.'89E/\P?^:&4\ ,T*'J1]"P'UV?_'WM7]VUS'#X:6'GTC=&5FI]$T:C4 >U0_OA.:3U$!TH/]C5J] M,F@V*:
[+F2:D'^3# RJ#-FE"7C4A39_0K SZB37WH#Q &3 YQ4/$>^(]\;[X M>8 ##??%^KH +)(LL Y8-Q7MT-FU?3!M%?M5,T9#2OM\! M0C+-8W<=EIKM&--"A;?I6+QDTW;'LN_1
U0:P%@#;T3S7%>#>OA?YHYXQE@ MZ@YAZO1EF1!V[@KLW")9EL N>V27I;'+?K)V20L!&XXSBB;M#5''*1H?,EN< M+C">.0XV9]!W.VPTZ'"5?$@V&7_8J%<&)=\;P]0=V,(M MF!
(J"TF5E$^^)]V7G/27B4^EC:'N: MN4M-G#NQGRV,K2&TAL=H'O>/$A8?WYOV\T%U.BQ8D4V#BFQR)..$\'S"138D MXQS8,2WLY4C&"=EQEXKEJ&2E:%$*<9^X3]P_#.
[3TG2,H7CXZI6+32;W/) D MOFM8#TJ\@?"7>Q;:UN=Y#\+P&8 6+HX_=")G@CX)?:X?7_4$-#"7CV<.F/O?\)DV M'@-;/)_?_6]K%9JRN(MMV.FU &W6*H-^)ZDF M1&38.XD[><-
NUD4+Z7YJF3V*R* Z=3 (V8A"@+9F)H#2,BS6=SAEX7A%Q#J MV":\|Z"B,!^@E1QG^1P^50R^M2$:#7'#M]I,SEMO-*F>,3/!IN!JW&&U,7U-&=.-M!K:E,7GNK_M0N<6D)B\JX*
M"_D#K=4^!,^+H*7*-I@TBC+E/5L?%H4.,@K;!)(N/T_-]GSZJ_M#%O?@4C# M.T/$X]=@U.'\4&%5;&?A=8_PH(FK^M%A=SH KR,^]?CC'7>D!31!"]$? ^4 M1E^9PTW- U(
XVH6TQX<+DOVG@UO(FY\[CH:-PUVJ[VPXW2R\N@F^.Q"V1@J'X\O!9 TT!%W6% MF_6N05E?,XS#.Y5!J]]>,=\@9T&\)@Y-.G8LX<)BJ1VQ$*P?ZV3"JM@O9&P#HXYS@4[+U9)V;E
V2OHK,? M);'9E.DSCDP1V79D4&1%*2,KVW.$MR!&3)_3C4+-^?@,.%1,)VBXF,<]^!H M)DC>$?J/4E=+;/!N4!CK'FW)@S6KMR$>X!2UL":[^FXK&+K SV5V+H;^(09* M_N$1V-
&AO$6"B-L72,"W0C[_CH.Q@,\WG[57M^+?;A),#VJMIB_^'2O_V 2> MR"E!S#)C$^P, < $EX\6Q1M6G8A-'76ZR_3Y;X_SGEMB% S:9HC4Z_HY/ MPYIQ?0@8!6\UXB87R.-
GO=&J]7O]5GV.4SJ-3K^R7A1)0(9]U(O5F0C?Z\=, M,%3T40ZQ],MZS9H3VID&7L>?VI9FMNBDR-X=*GV]NCD]N_E\G7WQ M_]BQ[$"&1K70?%41Q&T.@-
BJ""@2X*ZXHKUEC!295'9+:>^F]K14CT1VSDT MR\SAO!6;[=I[?(7R+^B^8(X(")@?$:P;>6<-N@OG#R!>W@7MK0"[,]]OHF^: M3Q"K$"Z;:$^RI M82&_@'] *5@,?EQ="[C M\2; B?
\S R_#\5$W?&IC]&"Q;W!Y["M0]=KG_Z,4S)W8,U,'(0'UFB %)/#' MS)*A>I)V"QK9,"*J"@Z2
ZH0EP@_'_WV&5#*?;D!_S_^-6.H4!\.$"P(V^,O&7(]77U#&43T:KHLL^XA#:]2.1V+U7<;^YR,0.70$S'Y"4T!?\!W-4!ODH M71#T1E9#?&<=40Y_X@!FY47\9>@??L8Z%K](- M&+KC:
[3MAEA5"F703-<67P'@)Q0"[LCAM?T(\8CQ.(6X8CZUP(1BRND$^3GV M_$]@>D&&H;,:JYG.G8LEZ# M9>89GZ!S\'F/AN6S[DDS9UIH1AW;@ :E1K[B>,^O;_ZA/4Z/3P,-!VG^R9&R
MJ6/K,S)D7*0SWRP;?W9,,VJN!H<-#S%U4SAIESN//FDF:;]C-YSM2>J NCQ M$]V>]A),^O!!B-SY/42S6]^B, 84$T!83Y4FPZP+\M3$'GIPEQ,@'+O2 1_G M=N2/'7@UA4&@9-
W9>!*]&#X< W:Q(68%HF!V@0O I^ UX'P#ZL&-(CLMJ69C MY4W V5AB#4#7@2N8N1T[=J!P.MBL:4^5G&%.>(9H28$VPXDH)MP1R4.T$Z@^ M !M'_XRYT%?4\=D]7

1.QY$#=&>H;H+H@'[Q@10JOBT8)4Q"/4&,/JI:F&M6 M,S&(Z'Z&3U K(=FYA&_\SIDA@L0C"JOL9@;JIS%3 VE,T"TB 'S27 5A?_SI M8)6:L$'E7M'>U-
_;&:$++)2UW7#Q/9BQY[MZ9S;UUV:DFWT0KU";'FQ0TR.? M/+Q>D>++(#+;XATB\A4+QI8P :#FN_J*RQ^$CBG'?22^ ^$ &L[I ;BW&*' M^18-;_HSCR34#8@X8J?
S6<*;.)P+4BU!IUSY>G/)2WHH7T?O)=X.N+2HM*N MO'C>G._P75TB?S]%(ZQ06#0JI@,79:9Z5V//!A8HI"97\00:U#Q/&_\IO8T& MCW$H 3SX"7PP-9 J2V'"WX)XX^V\096@1L
M\:KT>AU6 S7<6-0U^,Z#:0.X9A.(C_Z2$9IR7FJ847W&3U8H-!J1:8_%4($H M2>H1.Y$=2,W7JO1K\SU7\ZN K$>QQ@J*PH4[E]@/L:^PJX@&XJ5BHK/0*\, M!
6>7H0QN#8PF_J3);)0D"6F HR-_N2O_H?)6!WJT38&YZZU.!1P8&0R$A', M4P_"V0 4 .)9E_N383#?SK^&YJ >[*NG8J1X?%5D8A6V KX O (>*F\M'@<#
MR<;"MV"='^7N(32AJAC9^3D0H 'XJ0O4^<0ECI?/%(%(P%H)0-&4U<-A9 M(W,:+R]L W>#N 1" +7)0#1AY-@ MP(7QS!2WFKDRER:^-@^25O(G--8&);V+FO2^HZ2WX,-
H=10Z5_V8K\ M=]JK6[B'!&=S< [VOW O8GAES 7S["5.%OG&F^38RTWDF5V5;,7>;R^YEI879!Y*S$\S"5$LH< MRRRY!E3IDC*8II-GEI_TD&T/ +A@'A8+H 6*4:/3PR2'EW"FCO$H
9)?S"?3 M$(*MH10K!"N:(^K>'(R ,*UE86@P#[CF#Q!%@X:.'<,G03H*4^#R,J0+K,9B M?P T=P&5"GK&P;E!O*W")PT7S M=:?J1F(1L#I?8K%EI@+S4=.I8*SH)FGIP$!@G#?
JOEZQ,XTQ>V*C*88CK1 MD\'1/!6+GXS]6(MQE;83D4U8N4,)21Z.70P950@HYZ=6-Z+'B&Z_C>L6B\Q7 M%^HM(#NL5.$O(M!=Z^16(D06=FJ]Y?NF6SQ8#WCSK]"
_$);58L[Z(9CB=@KN97_NS+G=/!%3$7,2X-,+P(+89U@J"=QE>8V%X[RFJ M?'LL>PREL=-0FM&AK+&L A1YKM#[!:U(M49S#\$U=Q)&:F'F8J"CT0>T9K,,(KY_Y-@AH) M6?(A(XF9*4
O#L5049A(9TX,'N2 \>XJ^!+5)(X?9,AE$43;V/])&T_F-1>/ M7 MH4<^'9]P;N#S$@$Y<_@TV=LGPSAT[AD3>&-8)5/P8E,1AB"#/6?-O!Y)^ M%'?
19;L#XS'")BQ;4>0(F:BO!:GN*#6AZA0)]<,AZGL#E6:42K66[/-MC\!' M13@\&J\L!"NAX%?*>EX2=,=E:09?"H)$J(0Y9R#1"2A5):5RM0G$)M1T7I&R MNK(R'##I-
G=%7D6F]64M@D^W6B]!6X:GB[!("Y960J4 VP5*LAI$WQ@PI;]T MFI[SZD2=U]P-19S6%Q"/+IR$$,,PDBRYX>X4>.T7[C!5@2CD';K?CZE8A47U M'HEJHN!VYQ88KECDJ2K?
YY>26&/; ;.4I2MJ-05N"TUQ"&7UJ5$T".;--T4@ M=!"1O!L=B%_J%WXS6CT9S0OYRH=6$BP[81$,N$;C_A5=A"'9%B81AQPIM8[0 M++S/$WR?RTJC"($>IL_0=6&53Y LD@NN-
A*AN>C>1?FKPX-)@;FSNS^$]2R+ MA+\8LL]FV 6J-(@H:O/O(7S_,U>KN5B0'+UY>#155=>$B:+%S^:E MN*$!SDM<0R3*R48EF% *<[O/K[CF.8+S4]KY@7'GAAWQJJ) MP2\61_6?
%V_[<\,TFAY[RZ$G[\N$+JR9'$!GMYH<:$6TM"NB8UH15>M<3X9? M6'(]]^XW/B[?-0K/>LO0N:@]LOC"%A)9(JV%\>.V>Q!$(=#V^S:\<-X?QP#3 M'%PNJMV$]48EE^8?
%XCY04%UY) OPK^594ARZDI",>,Y2'Z%:FZ7W_JV*^: M"3>8:J_^E&S:,-V+JP%/.0*NZ3)4NP?B$,)H+^%M2%45]ST\X *2!/.R60=6
MC3B10[;F]4MO#@>Y.859XD40"VJVH3W'5ZQ4X:X+_+PS9.'<2?"4D_!#+OQG MO'GFS4\|1D61/>]D\EW(T76\|*> CY)IY=&M#.HK>N5&6GE41@WI 130FY>2+6ZKPRV* M8C-
"_/O,'/Y998:0(#7)^*5L46>^T9?N[,T;U6 CQ%_![DA\)^Y1)K([S[,_ MX]P6F9[]!(T<]'!G%I^77RY59(JAOL68[YHSGLP_"-].1O@K:SP7=5(W1'%C
M@,U7;&'2U$ZLY4DMM",D.#)2GO8H57R>D9P7-U?#AT[,2Y[7G3_A:[G/.V'H M$-[>08"?40EN"&*H:@)_IY9@:554S#X9^DQN?[0"2PTF\VI@)CA84>T!*@YV M(LML\2OP&I,
\@TL,1=W5MN+E ,0_L%;)SO]C.6N%>C M=(=:>RW>(2QI(H^+[BM@!8_9[T1 "ZD;^?:ZX@%]BC8PPTF"*!=)8OHX(*M M5LKY!!P["I<5K.W],<)M.S.37]V?
X;=.$,')XINAI5_CDZ[%@^934^*]/YKA MWA_-3GU].)2<%8@ [/@F!A3V;6ELG\NQ2)F"VD&Z";E>H"?5-]KXV0PD<"D M"W:
(2Q92VE]*FS<(%60$*01)^I>:WV<)LP@K"W:&.*.*:4>9XF.6I'.LIM2,QL>9^ENXUM-!OKWY7Z MW&@B;5"_U(]JN+PMSP[_I2;^;6Z#&Y0#W(K-+^$]+W&-)8'[),Z-R\4-0/$. M@C0X
9FM@>^'K,:IL.2@E;G12$9R/XY&[%>,#52BQ&4?^0NVA4';QMR):* J M]\%]*KXX5S0?W_[RK82S/>=#E6X[$E(^_FU@WXJN\JLX.G1%"_;0:KQ\[1=3 M[<7F?2Z/?
6!!]%K<(;CR$2H34/AQD([E< @QZ%@"7G7#L:8;EM?W64W/YIPN M<2* +/X4>2;#4=EH/+O$F85[<<@*5)%IBBR0[S^7K%@EV.;8GKV^O./Q+N=S M7MR$.3&T=,&R[0Y?
RL%"6ZM6&;36G&^YIQ3>ZT)B>V"^93\"'ZO0.=\W!XPV0WM4B3Q,,)>>8V\|VQ'^5^JAG8TE70[ONK M8(^\3O3[_&Y8>%;WJVAW#PYR:.G1NYR)DX"^XXT(D'(H22K4;E4&7
M(JE=W7#N-"EW\WN3(K02>*AD?$ZK,NA0X%<@GY/[@++=!G=3K?7C71DMA\LYL(585B0X)FD+!B]TFQ$Y1H[@.5#I9C M+W>&(OF38TO:#!)6['JRBDTK0'NCXDOO'1V"
M8]Q5T'E+,G5HO20%^T[&8EN50;?@6W)R9;'Y!_%RM8%P?/)2SYV?IL6 -.2> ML!!%KK[62S /0[GZG:,2IGF>8]S-9&](SV:W_$D[G% %^%&\G3B='D0K-<(^
M.WK#/62=NXFP3P%+*E:>B-UV:Y5!)][]%Z40WGOL-O=A2[>.IU)0T)*&V//F MKKL-BEO2$7W":&?UE[9ILQ[C13OB J*.J"L\=93\V>0HOVJN,99'GQOF#,\D$0>1 M!_ZRU TF?
6SASQ;7W!GAH$\E*]+)_?P$7O\4CPVCDT8 3FH[8)+6KB,5XB_> M.-N50>VHMFJIC^+HG5#UNS0_EM!J"[78'9MW$K2#_(ZZ*ZQB52J0@LW4YH.$ M/5\O.+19]+M" ZV@&*W._Y*13
M-(;UXXM1,AR!"T'Z:8%LFL^ GIJZC M":9P;J=W%#KY=?5!L'A2[,(Y:-.7A4/0U)FL]0]S)<[3D;'!.;'SLV,K6V7Z M%G)W\NNM#XL2 ,:%;0^S7^ M.=@F=UT\A=MBO^[26>!=?
9.^:R_&X^QQ/@]IU@/?9CFVO4_91:^#YKO<;DNJ MNCK-;WZ(]B;[>]\IS#'>Z5^1X[ZE,U*';FO2&RV\(9BR]B3N]>=U#Z=3;NGS M:W_6*UO<._JM5OUG>_MGP-4JK<-?
Q$'Q:PUJ):=8V)QZ;\I@X5:KSAC?X4SQ MY<.V<.,Q"TO,'] *<:UX1WTO.-Y]%Y8+0>TBUL9>8NWL)-9N5*SKSGO']8\% M47!Q6F;@YV5/Q2^:^:R]NA7%J@T8@()A4_K5I+'L,I;?
34/IO&.#29!6>XNI'G>ZR_/RWQ5>?U=1T M9YLZ9N@6;ZT^%Q_KACLUM=;#R1TGQ6.(_RQ5)+>4=NPEM!& M9#%1FWFV_XXCF8QO[6[9PA_LXCV:>WF/_DXZ6:]M-
RLD#K."DQ1W4]W;L_\- MV?7OPYOOPY.S'[?G)\,+=GYY^F-T>W-^-F(7Y]_/;\].651[BS7$2]N#.WLV MFJ.(,C1<:/YF6)HU-C23C?R,@UOH88;.)&:[.!L6BR?W[6!'@VY6UDVXP-*7
M%6Q^B;"Y%SF9.D\1HG*/$-H%L:(:91'I5.OXHPY:<@WQ M$'7WDB]VXQJZ5U:N-NWVQ/;W[KKV%>]>9;"F4PU) M/7:I)R/"OC#>=:=?OINCR4R"I9GK;FU/,YDFY)_)%)>Z\DM=S_N

^JHUJ M;=WV9G)O[Y-P3B:P?ITFL&0DG(RX&M(J^\6:KU;NX[A^LS)H5GMUFO)2$WI> MIL$6! '--3T@2.ZQRST9(;;1?/OM->W3XQXV)CX)
<8I[1U'=_2NX;H>^L:@H'[F=!P/)X]SDRQ/T+G]\;8\,H" M!#>T+;CAG@8LT?V=_R%.G$I&9 40=^T- %@1T4.UUXTUH?BI+ @B847(6<-O
M^!_N]XUUW95482M52%BN8NFGVH]W2?T3P/?Y386O9 M;./U^HN_FMC9E&8+)CF\#!AW.LS0?/E_-$2[/6K@RZU?:Z MP]D/._S>X#'3T)#<3;
=FF!SZT^2\1!=]!#-7E(%B!2]QK2((4K:,IRAT]R& M%$I]#BU]V;1R/^WVJ' [&]GG9=&C3R7=:_\6-,+;HGO2VDY1 MO<5.4>N:CFS7KVW?GB4IMW]K1OM(17ZN?
B.!]E)Q]%9[3R^SHO8.2[=%5[%: M(.W1S*I@(]RSEU7!1KFNE56\;O>W2+=2-:]Z_$G[<@)SD&98MXYFN7+J%.
MMS0[D>VLD%>W9ZS!Q%I[_9@ISC$OQ+HO6[55ZZR9[,*18°#3I,?.(0)!TMY MG&K6*YMH+A/J*#I4@ EI)L2*UEC%B;;8"J4Y#G;^E1;T;'@3YDT,1X>IR!$1
M)7YM#,#*X4PX2O'.U+'UV1C^-CRFVW"597OPN"=>E=>/L:%Q>-A+7(1Q_\D# MFPW?QIYR!TP:*!94XI&12.BSX7)UI*3.G[AI3Y%DT"X7[F(]|&[FPIWAL8[A M_ND>L1
C5%F$RQ[A8I'O,NX!<,&WM0>'JZ'#! 0#!Q(T;X;'5L+_W=DCD F, MU]D=//#YB&T 0Z*%<,;J^3B\>S$X"#D['3RWV'#J&":V[&I5F2A3T2P+X-(8 M-=%;4$H@"P7^ !])-,!_@AP?
YI*1.CD?%: B^,J=8;L&/%US& A2%[,"4U6^ MYBOJ3EA)\#N@0V"C7!.!/DK[<69ZQA2AAX58Z@&_I8-:" L^8C]@\.I;W'E4 M^L%745@-4?=LF*;_:*&^TE*X^&Z(:&5
XA+!'_%%@&NZN-+A#[CL9CNO>"5: MD[+9L?T(OALG/N-OU7'0FH_DP;3O8$I4ME7%MC0RN\C.9@[8E30HN/^/H]$1 M S$%;=:BHM)#(XK*"EN63"(SZH9HIHI@WET&:#&?
#_P-,;GZ]// M]8A%!FJW4I>CB@%F!9%!6"VT*;#A"8)6ZDH?H]@1T4MJQR9FM M\F7O=PUSJ_)5(:0 BE:7 V30V5\SF('@8I!Q2#FGFA'6SMGTWK&57L 3N>O9
M%H>+7J53QSD$!",Z5\A6^W"W-3WV!0X:/@ Y#\"G'_+&0TO_[M_V6MUU$06U M0BBHXZ.@G]\U1:/,*GS*N!P'J-SUS'%GVMQWS)W)6^Y5Z87$)0MJ(;4"GPJS.L[4>="(]BI<
M7!:-P&*K#04M=B_R=H&U]=J17O^%RBFPQX96"[DP$G(^!69=#< MY(X+$:5<:! ,3#!(T#%9YXQED!F> =Z]VP[/DS"U^N+/8=7:_D:J-7703' M*XBO IH>'[&/&&HV:L-&J_?
I2#UGZ(JT1!"K;^2=%)GIVHM&:0C@ M+-X-*>C%Q74@\/G;OIS#$>0F.JNK52JD'-&4ATSOX"($IB9>PT2A?IYHC@FR
MJ(IGJYC0",Z'8O>&\UB5<06F;"3NPF#+L4WN@RV9A9$NG+_P\4Q2C*!*Q")A MT ;"LRR@)*#6<\"78PXF"& <45D*^@D^#;P^*.P4HFQ#+.2]BBD#;CN[!W\V
M"LPIE@Q;OYL]%0Z.XF)O(T@>L-$+CT_@B[K MP48>+.<]41<*J^U1WWYN@9\93Q!7"]5T9W=_\+&8_E:D/:HAWP)(,>(!ET&D M[S44ILH5!5C,N>N8EM M/(&_,DL?
1,9WX%Y0UXJN4.HQ+K 0IJ!3,9^LSQ]4YPD$D;;8X#E6A^6A>! 7 ML?&KM_8U=U!ZWVQ'N!L7%R,@$A8>%C=8K#_?/AIUS%6SV'F#[N9,DGP!RNEP MX_%NYK@\2-
\OIA/>7%R2]S%DVP_=GT\M9+W+-94[6W\- M\-;4QNH40\#;$/(: H<%_6@&8(C#C;4)0P-3_@M0QY)#.7F6JA8N9)ZJ!\0O^ MQ4<,]S:&W@N31O-HKK>+V2\!5X0VAI-
@BTM8;V:\YIDM@79>8.@>!S7=#I*$ MIZ45J>H;0=PZD#*?=?92EFBV;3XI;LR@)],A_0>LA!] D8"/XXD!'_N6/U:5'W$#FJG#/_NA=%5Y]B"T1NT)X>% >]RJ
M/Z5A1O8/V\&XVH_/ER">2LJ^.8D* "4?K^;E^? WKA[F8JZ\L5\U$]@ D3-H M3(ZFROY;,^6:=-3"8*9F*-T8_2S(-.Z3.<39+I(ZM$W-^EN; D?9Q? \T>1' MM]4/PL$UY19F9[ZBE: =
#\G*E"LLUW$?)&YZGYR'XB;GZBE%DG9] M]8[,EJ+8X>F<^9L$H]\K)1.]1EVL+I9:K@7Q H*K/_@HDB99#7GGR\/WAN."VU5Z(]\-)5;<'&96@JH! M%'E#!43-
_>%J+%%13EP'MM+?Z#FRS(J%@]D@B4JR0]FU*H/&\@["',EN=6D< MR0YDARM_4UE5%8>$](D/A ?KKH(+PJ'=:W*ODY^(69$NBV4[.0A1+-
;HO.A[RUOSO>6A02W&?!&WL[!;7VCY MVIV1Z_=/#]?H/N;7_JS+W@D!#3%O/E\:7[0)P<91K:!WE]$U%D;WGKWPL0^E ML=-0FM&AK#6OW._-7Z'T"YTI%N=
<,=;PSSC:+$1NM,)(HTG+]S<)V%T_=C/D MUAOZ48#=['MT)2C:$/=L2U"T8:[K2[#)[MD>)M+:R43::WMU()>6YGD6YF0/ MN[)NV=XF\U7,D6;9]T:FJY=JGY#D6/.-
Q4LK5($3K747H: :"EP9]R+2V/ZL MLM^*0Y@Z2> A_G)\I&(HLEZJSYZT/R&D>V ?Q;[?VXOZL!H[*:$(HMUM^36/ MXG1VW#=@V< +%CP?(P)XRNOJZ&!FCKF,+%%F00G3B6-
/K/FP#!<7Q:K,>X88 M'4)-D>C.?H:'!A?*.']UG-*X6]XLL&;%=^V6"=Q.@#TJQ+8*T232 MB2QRJ(HSESU ;*.2"U(!JPM58RNJL78LP'JSJ@97'YKO77&0E ?]Z4Y$PL1! M!KQ>
EW)1=V]+8IHWJZ6JH:WYXHLV!,''W_$YD5+F!\3,L%R*K]^:O.Z?;36 M2>ZA*:1H^H%H^CN(I@_1YQK!W,T%L[@J:,JM1O/*H2-VIHF,G-Q6)-87^5]R M-
58V7(GN"EVN$@@J*?'^%O/X>$]&] OM48%W2O#N%F!)D$QJ_&TQH MD5E3ZZ&OX0XUMH7)9? M85+7N#>XWT%'I/@< TNP5E*WLBG#I=AK,!3) :W*_JL!
[ZOJAJ@ZPO\-74,+ M;]!E=5W6]<> M@N(JF7]&>U!:):M5YOA';;SS[_]6)7(43@3/$1.OKT)3#(.KC#^"+[+-QP3J M#B/[T'J=3R$DA9.E/"3'IR3AIW>#0K"SU >,"PRJ.PFX-
"4T&/I*\/3=[[TS M>G4AX&-##_S%Y'6N-*-AH#+(R6OP= 9$C"N0%7Z,+;L6BLUMK"_6IE/3X/-N M6',B9(V6Q<%/Z?R!6SZ4@]MBW076F;@S<.]PXZ'Y]X2#A3B+SU:><1(,W!.F
MH;#: E03I4%K9_MZ,)'K/ 9@M:Z0HQXJY*C_%!93Z&KV_Y^]=VUN%$GVA]^? M3U&AF3[1?4+V"'1OSRK";;MGO*=OQW;/QO]YTX&EDL4T!BT@V]H/_V16 0(!
M$D@@"KDZ=CTV0E"5^:NLS*R\M%L9HMF!^6RFS2W!ZZ?\MOR5&0HOO_")"[\@ MU.Z;#^O@J"P69,F#\#;QO96;[^6P#+L?YLFX\^B=%/O/-:4@ *P6.[M?
N]P7Q\.1]V9:24U6)UU& E M3/&NA/)N03TOKR"A7_1JKL\IDM%[%QK)$3,7P<\Z,246!XND=P?%W]Q5[0"L
M7JA%ZK_!@.:6$WD>\U[^N7C4;2WY^*'?!8;$NR.L(R'D5CMMSU^88ZW?\1UK M;[4)?/-Q\:C=\PWPU@5-HMQ7 B(H;++LG:E^A7!"N<]YW5E5)C!H (3UVC4Z
M*UCH!^@X"]B;@UR+C2!8J^H6 "R6@Q8R0B(E#W#K_>?"6'IV=3#PX+FLH!9E M!H-NI_M.IJ95W]][HE&-K?*)MDN; M:"LTT5;U$^TT1OVD#B/;+L0ZQUA-3F.-$_5 M-
W$U_^[V(-[-N1J;PD0S43>E[L!14+>7(Z_#3> LK5[;0\RJ%] M'PRDP58+*3$+9IFV0_M^J+0"HFF5P")F@1[1HCPS>0%3T&;
M8&D[IZLZ<('ZQ;0Y[BKW#C<(;!N/WH"2GLJ!KO72$4],P,YN/GJ7-X MTY-E>*G2/D%Q1[69WAFI]<5(B<<-F+&LN0%55U7;(W?#;ZQHV/KQT3RMM&P3 M$YY#A:ZCR;?PM?
&,#7E+H/UU4$#MZ[.) 0H75EHK/M5+*<,75+;XL+M8?.T1 M7^9A5.@"N S\|/RZ)K.[V JPL/(=GC]XK#@E7Y'?L Z](A^=B.VQJNSNL&)M MIK^6Z0LB'ZLIL)4[H8\|E],KSL%SV2>
(KXD'O?5!H FVA3'?L$ ZG3@?8<7= M IF^3L^?-%A4\)"/EHU7;BD8*JQAU"6]C^U^O1]J;R4\O=^K%YY#X%\GE7]A MVUX;C^T%7YBL/V2D'C-
+F@16,+"'5FVG&HD#./I([VVLR.%5C>DD &JR?DSC MSD P($(^7IY[.:=P]?;Z\Z?S+Y?7AW%?G-C+IY_O@(9_\XBDIN=\963GB;)\ M_U@9PP=PL#13Z@%.%H9+[!E=8'
&5IRQW1FN :=)_E[%J5CJ<>);LTU4'O& MX8_Y5^>.9>N:F_219OY<&A9S/J&O9+(T^*L(_5^:+SL#MY.)T7\|GC&DIA01 M,]W-%?#7RQ836V#T7UD9
]WTC(&$X.G@YOP$[N4B<+_*[(%=IM?/-;V!R.D# M@UQ3&;Z6] 'QX_J'^1)T6C*P7_ IRL#^PN4TH#[7(E$.$=J?MKGO9=[\"]4T M+^W;=T0D'+VR4.2RST&9WP.-
=D\I5INIIX:P:X]G+.3'H:YKT%6L:')PW#]! MT7?\1O2O3KZM?H/J:%D%G'BK#V,4KM:C/9^T% MU>HK?,HEIE=;]A_>6[P $_91W+!75.^(;?7[#V^@Y^;$^VUCX.Z/VX @&&&\
M%L[B4Q(;R 2^'I21JSO6*P6]1RJ2PE3H/1K36,G]4U>=T M5K[R=EL88C#'2H.FJW'/B=)ND<>'W]0>>?Q$WG;Q]\=/[PCLMPL_O 9D$<#8 M@!4"PI,\X=:+$]6QFLD3-
9%ANCE=..QY]&6N\6(1:"QSFY@7C,-M+,$UXEG4 MB2X+-O>XOV)[4-:@^*T^MX*F_:23"DM=7IODDH[]EI(H&G(4@]9P/3HZ -1F M\33>9+Y%X[7\[K:14M'\UE6A:']!^?
4MF]$@GDT!V,$AS?G=W=67[_][_>6J M)/&$LM)D/2!/US.2-IX2>D$):64I57X:J/16@0A*[P>G4%7N[$Z&8,E8K#"/ M/(]7#MPSAEA(^JC;J^/S(RE'ZG6EQ@2 '+:6SNK<&X4C'Y
M^,N)DMOB]%^ M:B!%YT0SIAIYB^.EMK$L/F'Q_']/NOVVW_O4)J FD2"#L2ZC9&BJ@L?C#2FME'">/[Q"^F M%#K)8U8,M1_9,6$T<)(+[9"UP_(,8E&/_IC]#[S#/Z\M%,I/ULDJ?
$A%L8$5 MTWA/_2'Z]B,SS5G;*N\YBR"\,V57"0W02Z]*",ZMP=:^*M93Y>[N%[)&2926 M [Z>2A4,/"&@-GW[#0*;69,J7 VHWC'UG;D5@UY[Y]?AI"P6,^OMIY@[Y40+
M7J^_.MYIFUU.B03>$,P1>K7?3RU((V1-Z>=@LDTLK]+42M#^!('*&J86+G'_M.NGT6JU6D$D5-=N\OH;M9EQ[__[_75W^OS(/54/4>,?
#BB=T,?,\Z.R@S(MA7.$S*6'&R]I@)VPGO(!^*&VC MS":D@U7D+/P>Y+S@:,AFF_-@IK#T&.[D3(OV]^#'2 MCKK^D69585'>!NHP+R6=Q#<-7-4'KHWOT6+[2@A2]))"&E5/:B-
O)SR2CB5(MH^A+2*+V)PZW^?G4&B:BAG0UKS3W9J,E:Q"J&@I"505 >Q<,ERU8CZNG;JBV M7KK.%N^/'C[C_>=7:V6E?]E;B$!T/7C,8=.IR";QTN/-PZ//=!X[B:!1QGH
MMX>M= V\C)\6/),[)S'W/^P<2]F$5\XEMN#74!@*G76T*?6B.F,CU.Q5#U&_ MD@06&0<]SYAZJ.W&Y31&$J_+:M[M(DN<;KFR.SE@O7HT8SAT:TO=VDC28D0N
M,YF,=*NH*4@-M/1S+,'#="'2K\H6?S!\LG MK]#B")'3")%SYI,3$8DP!4P&(;Y>F2HO_HE]U_=)>A\IONKK.8@G02^G>V\Q
M\H(ED<).UVCEF'Y/Y,]^Q1+ZP"4^^L%1D*$P'WL1ZJ!+.D!7)AL]P<:"R=';MCDY(H/.29PUZKP75VF3J)FM<-M_+;%G MPEMXL,(A'FZP7@[O ((T# ?Z9NQJ/+?I#(VF)\JS;3[! S]:-
JQS\X(E;(Z7 M=ZMROWAVB7\9C$$ MW?Z!17[=:2\5TGT "EMO6\H/@"I*<*8EV6NS9UW>/)+Q$LF&%RD:D,5/V$H?G4";3T[_6E\XFAG.
MQ?/[&1:ZBA*UFW*X.6R,>ML6T5I.4%&,M>F4LJ+VN$#OK2>ZT:R*\X%,M2=0 M'%$Y73TV*R,$7<>)J8*E<+[;:HP&6RRO)H9!P^8'F]@Z"+S.5?JZ8"T4#K<4 M-
G3+I411BXV,5O)5QE;4HXF-[ATJ-EK)5[%;:=7"4 <^ ?#&O_<9#:&U$T*ZN0<7V4OZ$H[+=Z M_49NA67ODR+N"&=-$1U]#]8/_?N?312?VG%>1^D<#P_OA;\^[R_Z.
[Q9@']OPS@]?;RZO;DXN MOG[Z=/[M]NJ]_\MF37&=*WR7Z??>G-VS(I?O6]Y6\K[E[2(X4IO]G$2WIK[Z M!C24R =KY]E\^KYRHP2W)_XGTS-:Z<_X_3=OF(&V%5(5=5;6_#V8D?
J$9*80 MT^$W#8YXHR,>!U<,/^U&%KD[*>(YL:>!N@%8,?_14 .@<#;Z#U!.6VB8,,%/ M?FFQ?V?)%([I(VLRN-2H^/C"C/:[*89^D@_;^! 3@N6QH8KURL>3&0[1V[-P
M74"6X@:7BXNOE$CMO8ET1(CNBHDE4>7DO.P?"Y;P>PEYI\++A^/2 Q>X]/UJ>YEC;B:R=,V^)%8$U.^ MI(1,M,U\4O&#U.HD93\Q$E-*RJKX7:)B.9"*I?
@2]1LVIK5=+'UO:%ZB&_WW M0O=*W$B!FKS ?+)]0Z*!$7?EDZPZR3L[/TH)6OEC"]9*>VU&J-X'KW@HO6(M).A7WK[;:V*GE=#4&/AZXCW?[Z;,=G4IF1,6Z"H!:3WAZ
!"N*ALX4KZT032FY$)XL;$\36S^XH7%V@_W;UM-@O][ER;>HDD3-1IAL3J,N/,4 M?X32M,NE4-Q9KF;X^39>);.)IZ825*;F07&2I+P;KU#).)Q\=J\9FCFFQ)G1
M"BVX7P^_=WV=YE#P*_.B];"/\C'8;_7E<-GF6Z\QZA_R#/>()4V[$$3:X$G MKJ)ND\4,L08:R^ODA?2.[!^[V4O)6 &K2[;2
M^JW&2"GVD.V=U"/E*=N!%U)2H4U>%/(/#5"&M3@W5Q7Y5'><(ISJ];$I MIG(<>D[=65VVX=@YM.%X1$K,ZSQ3DKP0AQ=\><%/=,DGU00GBO)F[07A?EVI
MJ@+W;W^_MW_PRS/\E1KG; MH,CMJN!^(Y/2N";4^-<[;];E)79P72_6WAC]SU8P)G^OLB+<[/VIU=Y8C64G
MWFH[\X_$:TRL0W06WS1NU4WH%"SD*2E\UNDK'9B^>^"ZW@?ML='?[U=P>86 M9SNVU"#[=+"H<\.(@W9KJ%O%?=D[X?A[)QR@R8%O9=W0)PKF$S;5P@6)1LN_ M='=V
7L$"'Y[O\8&Z2U-O+8.7;"95NT/VO"$@W(Q-S"_WEV1-F%.:^6,>+3C M&_#8HY[72'CL$="I3Z]4L*:UAP>;/@0*A.U-,#J#37"*/N/KU"-1 4TRMF)) M57H1+ W3L51*IU=LI3&U#,-
ZQA:(7.V>K,@!-T=::7BT=R(8<\SPLZ/L#@YGQ66>1' [FT#>9TY\+5S/S^\9=EH3Y+,_V;%ZUQ_2B.M 6 MYV?Y TD93M#N1!FD]3L)QK:[WSSF=(_[S<..I>(4V5*;L-S-;-
#M'^&^F4.H MB4WW4KKKQ35A 1 AUY](ZR^U-Y1&7F43@42'P:H%E M("7J).H.B;IK'*NI<4\D" C#".ZA0==Q?;5X9>0$!Z+NF*:=7?=U-
SUT*S8#.4J+&N2.64D$%LK!W2=DR>WA+QUB,6^DD1"S^^ MV=9D,78_,V><8[O>WU_M6VH_Z6-Z_J([/[[?PB=!!-,?U'J J,#QD)S=Y@+"UC1 M&% KD%?#QJ@C6O27!%-
Q83N5(VR(AWBBGSW1 MP"$0+-AAW_,SP);RED=W8'E(*?;&/4*[FLFA4K5;KURH-*#'>@(W<#E")IJ M$%,.X_N-4:?9;DN76]&FQ^OLQ2<9(\X0Z^-
VDRR1:T4R1C(FF_/M=]GIE?/I M"#]]IH7(9?]RD.U>;^CM;TM' MUO52@.EMOY*7Y-K"$@1LH>:G >Z\9ETMO[WG?Z6TQ.H.WV3JAG[F(]&_._$_
M\A'\/R6<:PRV!B[[FVE:5=6\F_+FY\2>EE0<-"+'WRNG+8"K=X3T2XO]V^XN M*+I\:('-1=K%EKTM^62L/@A2:PZ@;>TQB@2*Y$.^)A%BT?X8J1YODD 2NR2(
MQ8GCY4>&7@&2%955S*^[TI#S@"IZ>R8E4D ^;JT2GXL*(L9" :7JD_BX4SGW M+4@L[(2V%J?I[=#9:%O8"NY#K&?;[%:3_2+QDHH7\8NV#X>
('$7I5X\^T6HU1MUM)240I@%+!5+O2[)T6IG&VY48F%HZJ@X.*U=AAHSJN8BJU MLB+VJ[\N5U7JJA*TY'JGU89%)T6P6& 1OLIZIX4Y))4D DA#HG!#HCH4=2NJ
MU2]ESWX;E4BI)IT6%@25**H=BLH!_:0JYT%\1H.*':IF"Y76.H*JT&1]$X+ MBZ/VI*,P!3EIHS:4;"P:]$EC&"3Z^5-NY4P M*CJBI7ILM4O EI10U<:W5(^J3F,TD,X0L5 E##BZ:,H?
4JW.433)>V"6O&!9 M-K;Z:KZ2$V)RHDXS%'^$4/LOWZ@C Z8/PN**BW04ZP,J!P: QZ@X%/B4^GN4N5%BD M,FR,5!&2/0\O JIA?

RE<5%N8%#7H'K+#!%YAEYG55/)BQKRHE93K,$0Y8H0·M9XB2%^(,,6'S_UW6O^9\DO6O9?UK62\ZU>]2>5I,1Y1@ON]/M6+:U__^@\·M)TOYZ\YQ5;*
*(4!D!UKW(JRU^+P0=9_EJ6OY;K0);_%H85LOSU%B>/+'\M2,1.·MK9+B9/GK7<\RE<1FTH*6O^ZH'K87'G0%/M=^E7@1OOQU1V7E17N]0?7(D9AA·MF*EI^6L5LP.;_98
0))P"L&I?@6PU0Z(I*&L@"@6CJ]#_^8·MD"RE!>L69*% M<42&A*R·7=*R$K4"MMIKC$10"B58=C$G*BLTJO8;(U?(U(I7"9B;5L!6L9N7·MJ&6(A;7ZE·W"%+((=]%+K Y%L-L*2\-
M·M=Z1%5^JK\HVADJ.L2$B_#·N:V"%28M^)KC2I0RV.VV+(-)5,@]1 0"YF9X*]>]UVK·MF2-2IF4A;"E=*&0[DI;QR:+O&%6+·BX=PBEN]QU:O,>%2OH%27UMMA
M/#H;ROKJ8L%*&'1@T[@26U+']>HCJG?T&NN<2D[4CA·UFJ'X(Y2K09012DZ(·M,D+!#ZR+4"""RJS\))35KJ*!6<78[,(QZS5;O*$)KC@,%E9;4[K!JK'T17"(2·M">
(=1'=8],>@I58/#PF2_9QEY>!#;8SZK?*.#"4ZJ&C"""9C>]C:,;)?80/*H·M75BOLQ"KY$4·>5&K*=9@B')%B#·$R0MQAIBP^?\N2W9S/LF2W:^J9'>F%1B:·MX2!2(8^_(·EQ"?1;(U>
<6NMXBE6DXY8·008*2D)2·W_K>'PH?;*9G=_N=S,^&>_UG^S-/80$+$UUC·66%#X-%=T_!#H-%9SQK·M2Z<1%-L+/_NWM4ED(5G"@/-
,3UV;WBR0%|ZYP)#],_6"NP*X8+M8X-J·FXX·ML\9OV^:RPU347%-11Z>26B^_M;ZE**>]?IQ__N5P047"*BKF+,CXNT9F-IKJ·MO[C6N#&Z8_N%-27H$>·E.K0·#]MEM8&2"5.4!
M8V<#& ^YUR66%\U0Z_7JKW/R[<_SF_G%U??[ZXOSC^1ZR^7WV_O;JZO;LFG·MZ_7=U>7)(K;>DWQB^7"DUT+ER'3]#273LA'W=3,L:X9)'"R.K6>Y MOOIK:8
M8$GW=R2/D"&%2/!\>VUWT\6O·M)V9:1V3"\BL0K!$1U+$'T^0U<45.Y'<=V]·MU\+.'EOMPW ;$+PY_O.U?IWI\(6&7#"4;1A5GCK9^S]F_6&OK_5).U;ONB#F·MO%KHU+VV?
8:F)VO93,AI>.))'S9A,_1]$0RHVQF9.MX(OE0·A^2GU7A+WV#V%(E M:/_=Y6PL56.4D(·9&IWDHUCQ;·L2G;TE&#O·\!6MWD%"CY/I$+A/$%+M(K_:·MH1·20X(/,5·8=@8#9M]·
·;5$T=Y*<>·.!JC85,__M$[F8=EQ;HO8RZ;8·H[Z4NN(·1?P^>)ET%3(>4XKD2,K6S&ZK#$19A3NDY(*$D
MZAXE5'ILMPU&@T10K1!4#A"PN'):PP1!#8;C/WZ(]RZ1*VO'E56'OB7=+]MP·M/D@I5_"Z)7(H9>MU$Z(N"TB\8C'=E;!E8NKOI@2I6-)MY^M8XE$50U058ZL·MP3:C3;6T
QGI@_z#^3·CRT$Q*8M2T+T[;(RD@uD<·!U^:2}2&^A·M.+"]?5N2G@<&0P@P9L43W207FJE··(·(
M/RC,QER>$H0PK'#S@:);@G'@HG1GNCTYF<,FOOOD$K**S)C]?$,>QDZ6L@S·MA96LX2.0L\(f),R&*=N4W%:L78&OT<·,F4#U\?"M@$:K$\-ME[X8(#·RMB6
ME@(ZYO@*>T$W]7X(^C?T5T 9=)1!0QA=;_<.#.UAG@X,[?V:&,BO" ;UXH_1·M:[(#H-VJ><5G)A')35C!7·G%XZD$+0AUDDL)7+I8·MN3(DW0\JD9C72-+\T+U5),4/W46%S\[>K#
Q[9O?&56M8/?@E\M?QB4+92,<·M/,>|2;:O@!R4C7!$]:?QP?+·:RJYIV8N·'O)B:IPSW·EE38,&/+XEV:P$|*5·M+#W)[Z|ZSIYFH'>=[Z:BOJC$0.5?_@W7WL;R+7IF]HK(·L\+=K><
MEYB·VR,>I6'M;XF=# [7Q#N]UNL)4FK\I2(UP,·W^D·WV/:_A\A/\/JJ:+@·M0VF,NIW*\R%>#$I"S@V1(* V1H·NY=447P\$/+^·+*.S'M6RE·MZ1M6O1[VLTTA·M/?9!%%AT&J-
A/&\&HJ(D5#·?1JRR$!\G7!0F%#UG8QX41Y94L\FOEQM.·M+·Q&9<3YQLC"A&.V6·1Z^7+Z?:O[7GGE1@D>'SQ"N7H&K/I%K57YHX)'O1O!
MP\·HVZ^S%^"HL".>FVC0PD)+0[7.BOY1040L·I) ·:8R489W/F8X*'/5P,@U4·M $U'"BR"@*:N/JA!&V#4;JK].OLKCPE)Y7"YP[C<[9>UR"\K0HYA_-8.3!?
N)8#)]C"L5"M\9T$RAz;SR'\5OE!,@1A4FB?<@2M4+2 MK?]J-WB&+0"/Q(X0*DQ=O5A#]*!+948 ")7#7K4|\LKHJHT.]@L;K!J7U!/Q
M:AD>C0\]98?.%FYX2;$))'KNZNIXVKCBVA@M);?E2@$CDJ·IR/H#]:U"HUPD·M/)!HE8>IF&W,>IV"W4Q2;SDPXMXD5##'D9"#8H];9·PR+NSB!3]-$1/=$ON·M*Q4"HAX13T-
T1:O2%UTA4&KK'QJR^)=66UHTU:&G#,YV6RW€V,9:.&;/N](=·M1,T·ME[27M)>TE[27M)>T?PVTEPD.69OZI'1\EWU]4NHJ"WTHO=$PQ[X^=3XZJATZ·M1#IP5EA?
G_Z@6A6O;@:·6ITK*]C7!C<)XF.3>@0[_!8P,X^LH'7<(6>{@5>2 MN@I&E@SJ7-"Y9NP7Y^QW(RPPI$25#=\·!HNZ'NPJK+%/?2U#G>M_U@DHY,&2-·M2
0;=0BL;08(SW/;\A4RL!9C\8CK8BAB?N-Y·27U)?4E]27U)?4E]27U)?4G] MXZ_^LQS@!QZKC4C*T'·4T8'!%1(^0AW@.6[X99i>16+/BN4T;SQ·#EP%8PJ&
MG,VM0OK"S/J1PMUM_I_$GSVWO+XL'JFMC_G?:·?J)K<85S>&?J[=PVRZ.WC] M+34H, ^!^*&JG·1RH2I;E7·GG9R[:W>=S^?4G*SN_:$T,CP[\JUNO .CF_D=
M>'>/0VT4FG]DODE7V)W^#Y]]86AYR(KE#S]6RB.W·#6[XGNHE?.LL]2TZ;·M/)14=Z)D+QX1EKW++:Z\?P5]#5?7WWV9.N]94S.HE(·#G[V%\!JV6@D9F·M/]5?7&O<&-
VAN"76E%R@(XH5PM0B@H=LH21)(&YH0$D2,O0Q9]_@M*M'A"G& MR_ARGL?;. O7\[_8?/IX:;=EO=M"">;B/Q{(IP(@TUZ{1U10B)*$4STW3.ZN·M_CHGW_X\O_E\?G'U;>
[ZXOP3N?YR^?WV|N;ZZI9\NOY\?7=U2:)(]=<4OU@N·M/-FU$/HL-HVU*OJHFYHYUC6#W+IP@16'K?4TWWXWM<4s[L3).Y)O8>=?(PSU·MQ6ENH"(R\32FAC'?)A/=?/A'H]5@?
Z-?VO\!+FL<5J.!T!^·WEQ>W9OPQ7@·^WO*F\;WE2"#W>4>,,BWFI9R:'3[MPJRVJ_9GS,^L- 28-5:?ZCT5ZM2<]B·M\]Z@G+9PU?·(X6%1_-V [=$P6=0%RZ>&+
)>T+B$LNAU\2U)Y<,I.=QA+_·ML(X5"E\=XT6-LT(H65)0·CGYV]66&*;M_>EF!.^'?+U\,E·M]]*X5Q_+1]EB^>P3@)]!QV6&NV:\6XY*CDJ.ZNA'=7BG42FB,^0Q%'#S>_O]
M]/;T5]#/"!#/P.8·[_)LA0=AV^LHP!^J;/!/S5QH]I(356%E#=]RK$%*5HFB·M_FBS"H%]S35@^(#]*&F"/FV:W+Y/.#@: 614U4%L@'635D\.A·M0[RR!JK2&·V'=:Z*7S;
(B%760%4;HTY7@\'8W\IRAJH;=?P"H.8AJ6Z5C50·M60OP?E<6P+45.IA(RM.,5#*.A3+<==<W&^.,+$QHIG5X:(XV1V]MS$;:IC XI(KAX56Z8WAIVR*M=
(>.2$1[T<0=B61F)'%.P(Z"8:·M·D;=9]J=9YOP]"·BEANIW8++IU5G-}}1@:,>3J:VTACUZWSX<%28J:L+JJTV·M1L-FN]8NJ&,'4CE,,B.3>TI9QJ^,)RK/JY3.·MR.T.TEUV1DX#T.Z-
U·=&T"'<5KG[KK>[8$$4*MZ/H/%Z92·1PGF5'T-8G+M0·M@T)B:'<,'JP&'JF=5*F:R6H5<;'5@7-E@Z+B]1-M>6C[R$ZW'X·MJ%*62[98O$LZ6;!OU=8QM7'-J1A*56B)\P_'*U!(
(U+X5*?-PJ>*;? H(9$/·M$D)XG3(CIM,8]8J-F)9XR8<7]<*D.ET,D^K+G:7;G44DAU('H[:ITME8(2#$·M\2·M!$H?9(<\O:@0)Z)YC3(C9\"B8_IRUZD,/.4P=HB,'78*C;HNWSMT_%/
M=[9F.@9OZS'1IU·JTW\)S;HCG;VLWZT;"'5R4,'Q\L0F>KJ14HY>+FVY,E/·M.:[Z_2$D9'Q35VF,Y/XL"DB$\#3EQO!ZK26&!,&0P/%·W77GC)\U872:0!NC
MTG06&9(MJ"BIUD&57[QT&Z/23%()GIS@$OIBM3BQ^:[?MIH$__TE[27M)>TE[2?O70'N9%I&U3]·MG;O, M8<'IUV])5D$;2S4+?9JIT33'5D&R$<0!T2%2 D27MPIJ=>ISS0
@Q"%T5GST·M6HU1IU^HYTZB8Q,ZQ$MNZ&$(2[O.13YK!@&Q$AEZV"JHV/(ZDOV;V% ^/M(5> M&Z1"G8MOU@P5HAWW9L8):Q74+C832D)E U3*82-%=0Y7"76(SG";<]?
R,1: M@,4OIG^MB%)Z]R4U)?4E]27U)?4E]27U)?4E]0+/NHSRP%^X*G:B%DG:!OI·M)K>B1B3I4O+X<·C1T<;5$CYF'>]9Q/%&0.F8YC"M:>C;V6
MB/|>CR";|L'.B·<&@9="9[|W% Q_^EXSGK6ETPB>·PO,,"'</>|C^G7G<·1:>·M/>L3=P:S:+TY&QM4LQ$<,S#"(H.)'5'"T:*<|OKQ$?]7V5>?/33<6\;D+(J[·M\.?LXXGNS
UM^5XW$4AXMT9F·EK!O{C6N#&Z0X·0:THNT'1F]?ZT492,H3]" ME!T%/_QWAY'J·366^LZLX&!09#6JT',2.!S^F)·X<-K5(V# F ?ISP^0%NX
MEG_%YA3#2SLLU#TB"D(C)'PVN3EV=_77.?GVY_G·Y.,+]^]WO2'GG\CUE\OO·MMWWY-/UY^N[]\LHG^HUPR^6"TIV+00A*VMAO5,^ZJ9FCG7-(+T)4?;-A6>@===5+GA]?
7NBG0(R_93·MSHA/")TZ[Z.,V$2^V_&,3A8&_3H-".GUA&(BM#!2#E-)V4O9/<,A4)TWN7;3·MQBA$C"8QJ8M;@>YV59LX%4=W<#'"97=&X5GH?]7-AX!RB?N:H]] FXKE*9!
M@6%;T9@:QER;3.·=_VBT&NQO])KZ?\SRKZAOLCA;O1<,_9OC/_?X·M>O%Q?(,M87S$&Q;Q6+9:X]?=N7N65<7/^)CVUAX%.·=_P_]%0·UQX.K7W?>6T
MA4*3ATK^TF+,MA])),IW@IP\<2#(1JP%UAZ7.*)^A9N214/*PPJG450CW)·MA,U,N^3C,·^4TG@eEXE·$8);MUR859"]?3QK<9_3^E06]QJ;U89*^^?V^^GM·M*?
D5VU\"\0RL(O@N#S^S'(S+4GV94AG·IM8=,&3(W+:PHF,U1?H.&3D26&O^·MU//^PK(GSA,I?IWIXR*:XD4XY<2-8!KG95BJ/+W\%K%34'VVEQ!"@/F-EL55)
M96Y65H%VHSU|[6K&/S5X_P,_W8R'3AZW/5'0XL"%"/9GWK5X@U+,*MEK0C)·MS,,*,"RI/"PKTETJU^8W/O6*\UV<-"NNO·MS=6$FR5+O#IV(&R5E<4A%;]-
@BW8]E"RN5BN37.O0^OS*=@·MH5R:=YPH%4@%,P<+%NRM8&#@X/I2K?*ZBL%(F=3%LHQU7·MI>#^1-W?]A-
60KHL%MY%8ECXEG9^V>W,>HT6VI9:,O'NH.^MNA[R8/]>1#/·MQ=C%=L;_WAPYZVKF@P|/.7<VTA@-5 M:8=B0SN=#6&VRD"0.-ON*LX6_03Z5&=AG7I·0Z(Q(NX4>HL'?
R]I#|AD8079_MV)8#DD.5[26>HFN/Z&#U;@)^OI=_&Q'1<;]I-OI@:Q@#67?VG(_'B]>%P1*C·M@#'[WV2I-X?>22\))+PDO 2
MAEY%P^O5VCM'D%0D<[F.*Y=+DEVB73BR2[1+M+|>LLW2TL%EHYEHFZPH1! M>_D=A$7%'^6[H:#778PL3$\ZX=K!M&]W'"%_PV/_;#\K/UMV1>&YCBEE?GO
M8S/W7K/3&L@@KW+1L K\$A@-V.Z]WQP.*N_Z<'QH")V'G8<,@>H]+0: #[6I M5M]5ZO7AHQ;R [L2MIM9Q/ZAH+8UO@#M]A8&& 'PJ;2K[P#V7%#H0YB8: @
A%/[MODQ8K<)2N[.U"64X>R49^/O9:HQ<7Y!:0]TAM3']#F3%D@.;:H*'H8U@·MJ/_·*A(8=K+4!(5'IS%2AU)65&ZH"0]/+L"C5_^L3I'@L=5.$Q0*6.9QG'D[·MX%<_!?
&E0K\Q*]_>ISQEV\UVNPZ*I[&F%YH]GK%:0Q/Z1·UK'LYU>;4++H-- M%Q3NNO&(>&Y.+E$A(1RG1·R!$G=D^I]Y=:?8)B9ZB]T·M7@AF2=\-$N4V>)69=·4I7J=545E!R0')
"L+:2LKZ#PA87;JOG>2!Y(D@>2!Y(&8@/A]8^,7Y)$FM4]9ZYZ2H8U'O·L'·M_AZ,G>Q;O(D_3G>!^.,X!=&202R.V5WEID,;K<2;AI3=X63+X#0[:%8QTAL
MD]6Y=_U2]Q1+:,#GN*=GR&)MZWR8:F<,WIY:A6]@T93[3@·5CNF#HQ:#OH'OV MDV;KUL+!OBJ@N[,]R%ASZ8·EZ_#([6T]!O=HXW\O=$=*0\·ASIH[@_?PBEHX·M7%@
"RROS!H#01ACIS" 6\3$B\@C5!9C"2X*";F)HQQ[Y8·M3[" 7@M·4QI6E<&_·=F/4Z<1C*TL&]'(X@'9@@OVXPSP1H";LI67B\PCTC.MO·M-_^M/<[/+BM6*>[HD\;BI_MG#ED-
*I1*N#-0(6:P!+P-E7-C@7')/]BVAA[R&/[*P55@+·M3)C!<#]8F3YHYAM!]7 H5U4>M26,P&NDQ&^,)+MR%[·L1+6[?28T!/3';N^D15·MK.1>AT8"8MZPS(<30^=
(61\U2)]==S10&8'E6Z3I:BQQ67KU.C866#'W#\N:·M/(.]U"]P6SW>'7+W)M'(=,]P%[2P!UD\]W24>45C"L3=[·3G0O^!]0OZI7&Q8·MW(AN!LEP9\FD?I(95MQ^
PTWOIQ'C3L8X\'7B+!5OGJM_O:%U@1F@*!=DLD"·M&&Z1Q7S"&L;QK0TEU^)QSHU7FSYH-I(*J*Z/*5NBJY8!QB SEWWIV'N>AR%6 M'GHC2!(C)(P* ,K'43)L?0U(KRVGC!?
P:,;SWJKX-!F!!UY M77NY,8 ,2NW\)3JR-&&\!79K·%&L?G#O/WA/ 5#TO68\·M:TNG.0I·*7CV;VN3R#"KA/FF9VZ·KM9<.SIE148LG]GGJ^O#6I&J/LV*!: MC·
[&6>.W$J:BYII*.YU1L4#(2'_FTUX_SCW_#L_#>P/KV·M^E=L/E7>RG<'IN5;79U,JRO=6[U'B&N((B2QH/]VUMY=_75.OOUY?O/Y_.+[·M^]WUQ?DG_/A1E@&_36]E:] M=?
76WKQ^+=·]Y1V_\?E]*VQDR1[(!@\!%S;I3GU;]9^4SXC;]@2R.B)GZ(Y12#,;')B.SKDYN9C!LZES;7[% ML(MQ5[Y8N_^F,1> M]3Z7] 04UN>BM#*'19HMSLV"?RVFFA5[ZD>|
(/=XZJX$_0MW7·MPI[#W>LJF!·FL'635A$7_A4MQTW·M>L>[G"YP4J[0%N:-E'<'S;M!C'G;4MP·MU"%,·:2*7;D$,"H5^\'>A>1E+ST+.TBD3F/4CF?@BN-92#B1++·39(<*#]L45K
MD]Y@;J;4=A]96%]<(QGRUMH6T<^'XGKS5WU5·O'I^@\TH.#?\@X*PU>8S!",;MD8]@[8_O7!'IS.1NALVS&9@11!%W1[=_$]MKL6V+E"8L?.%92^9QHP[E4V1
M,C@/KA2_U2MA8"$?"3=(?>.@S:0"?1I,$&5'6OPJH5IW3N·6B;B=7.^6#W<·MWUZ,K07<;0-# M,./&T&%H-N)APE&S66Y\6#@P<|>YL!O=9.!Y((%00$]70P3 _%ML\N?0&/7
M#=U=2]GN:GV4UG5W7]&^X+C!&26>X7"+KVA>Q M2+4C9<#;("Z]E7X#"SW\S/7[H;S$OFD@&:=P">6F+MP>*[=2OZCNE6TYP.2EM+;
MY+7DPE;)%M*_@'8W2"_]B7[4=!MK/=·S@)8;ZD@%ZU=IE6-]7?@6HIZ%<,2 M+.MW5>Z]):#B$* HR?[>Q/LVV&+=YD PM>NU·J!TVWS=%>.C0#EN+TQ·X2""
M_>XC!,R57D'X)$]0&DX;*8H*YW+W0%Q. MCFCB!O_\)5N :=CD_ZU8W*1,(·=1*2]>CI>@FI_P4+FU:+MDWT'>@ =1AE?" M-B#H3 4?7FGR5-#Y"CX\R0ZAAB?
%E"##DQ20·DUO(/U%YWV.D ·7.A MV4M.91YTVIG^ $VT8^4ZCI:RV*(HT3T.1\7I*LZ[^D=YWB4>;ZL), 6Y/) 1·M1@?
ALD@G5$,60*@J0O'\J+@M[O'3)F!T6C*RM&1@B'JJM!$6B@PJ+1\;Y;!. M/70\Z?&?$[7G+V1B+,"5@9 .CB+&5Q//GV2%7!N2(9(A4E@),C[)"F'&)\64 M8.,3.PU+X,,A9@0'7==A ^U
[0Y"@JS_·=U&CVCU<0('BU1?=RI>!T3X9#E.IKZK%8<0 M=&32BP@@,% U*Y_L-%'-97E4?,.50BBP3!=A <.#0A#1)'&TI6 AA22F\4 M@8:.QBIT.7:AU6H56IHCK
<74W)>=&"5ARM10Q_2Q·%·;'$@G;*$TKEB(QA M*2+C6/RIA[?B;3HV-.?1HSJ=H"__Z:"E18X),0YP^!79[1T$F^C/+1/=I MLSGJ7^3SOML26H2^$^@PH/33?
KJD+%1H;70O'7SGA=56&+#5MIO*9"CZ\6F6_2G9(=M2,'769]>##DXP09'A2·M0·DU/%DKH9!"VK=T[C)KF9.SW>*UM,E;Y5WU1VZ"5."K_@PMU ^ZIQQM$I1X
M[#YD4>T(C[NRLO9!&%Q-9>TP]U45RVMW>Y+5);-·A*.K",.5S"U2>K+&=FDL M%^M$*A\Z6HU16QE(;)2%##9$.F/+!]D.LM5UH/*/<+F+X*)%__Y#[O;.BEG5" M^_]/C5Y;
<4B!'8&2%7)M2(9(ADAA)HO_S'M"LO4_8H-[SX[.SR($1D@B(·M>F]C\5B<)X$YXG3(F!K&7)M,P_+·]1Z/58'\C5>'_[4TT9$HYKF;#N#]\O;F\·MNCFY^/KIT_FWVZOW_B\YD]G8!-
ZWSOBLE%;&32+>5W45N%;!HMD#4UX$A<;·M.1ZG8?2AA\FX;#),_F/L8;X\3NM#;"7M]'G@O%H\+C'EHN0A7M\VRU$>YM!= MTG'X(JQMTV>L83.?
&Y;+V"KNM18DE_S%&BBD_/QF^·3C;6,,IG7·\"XWJ8·M/1:SCSW{AJ=Q/SJ?\SV,&N>#U"AQDMF[=>TV214E.=@VR2:QJ3.G8P2,L3PE·M(;FW)N6\QWQ9L"/-J-@+@5]1X^!G4
_+'UB9ZPM_DY1HC-#;2]PYM8&R#M%= MA]PO',"_XQ!W9EN+AQG^Ex)\]]UTQ/?)O2=(4SHAS 'G- D_R&'?I
M/R57VGB&R\2=4B>NWN0_D>BP%$)O0N:=DG.0F=Z#HA_! >;86$PHP5FP\]C^ MF4-@*4T6'%,X%"Q'A>||_W8-<[+@W;H](7,0K3K,^"U^36V=,3K +>Q/Y>P=
M^ZIF1O>@D">(>*X@$!DN3/7$D^3>'AGLH+%JA-,"/3'T,04);SYX,P3S·BPV>9N&0^TP"L8[H@LA26 *P)$^^?C.PVIHTVG·MNJ$#;PASM)Y&R02399-
DG\4HJ[GJ4I^X$+1L'603Q*,2^L1R:XA,5XX#N<=F\] MT5.0@12H V]5NJP>F+,BG\=H^!I?;'#57QD5P'Y"@7,/"$$VB2E(%?*D&0L& M%R3"·E$0K[RG!9#&>]1<;@.F@;3QBQS-,-
%GS9Z<&};UD[·6_Q1)0QT?A3Y> M7[WIE/Q+!'];22]LHN/U)U9P!8'>'%SP0,/Q^@9ARMCS8&G&!;S=Q_G,[FG M0$$'!%EWQH=%X487IZK!3H;/#R'TAL
^))G573V$%WJPQXFC"OXWW1DG3)+ V·M<,8<,7Q(,&;#]TF+ WD(XM0$&;)I-ACZXT>1W8J9Y,V"\@CAKMDV[K@;;+!L·MG'.0]H@@SB?M$6\^)1?!E(%,?U.V^#F&
[S4D$HP@@GV/[I3MV39]HB8\[,&V·MGF%V7!*RI'CML2Z·M@]"CHM -]57P]D#;@]=98S8))L9Q /$-@2_EA;NPZ3,10I1!FCX9T>FCTB6O·M@AG59MG7.)/!!#,F1WBHVX#Q_]O
1L4"·U+ *=AS?GVZ.L0FR.5*T-)%A_K=\!32#;U3$#B%4V1V4JG2'R[8@RXW\;M ^·N·MDC@+]P_6PRFP@G']H;"LI$?Z(H1-51'<G>@C<"4/V%!%W!AM!?^·FN)]&O\G,·M*A@$?
1FCANEMZ&/83I9XB[?15]%Z7*XZ8TW94O^WM]1AC'S!P&T@^1EQ*0Z4·MR^T99>L/?U·N:U$43)+R@9'' DO)!HLIW(++?P7@*%!ZBX(T871Z!&4·K-Z?
M:'S",]BZ3].U)_^3(/[,EACNPA%:\TW:$Q'·Y_$L8@%W3N%B,,.$U?IL·?%M_·M>..!],6[4+]SDR6]2@(\FIPEJ·$W\·DS6='67+P0L3NLX[-$XO·#,]=P;;BF]·M%()M#@B%
.WQ\,4O58)&"EA+GFPS+//AQ$;9A_;/:>(C?-WFT\VW X#4O?Y·M%>@X/<1Q*EO\]EB0&KR@09!+K'ZL%'<(+GK?8T+H=@=/H, M?]POHV(K4M?RM];H·
OC4"8ZJ"^N93M;@97]6 W!"+$7=9>F/2!:((;F$-O*·MP;#_·#0Q3H"*/W@#1B2MQI')/A_]G,+\UOT48?_AU=,OHN]P[7CRC\8=O.86 MU%*V]_!
(#""LPATX<">=G+MK=YW/Y123BO&?R·MXKUF/&M+1Q$,/OSLW18FD6%6">/-,SMU;7:SP#GKU1\;LG]GGF^R#:A9>7// MQ@:,5;/3KSUCGLJ*GHN:,2CLZ%1*37?UU3K[]>7[S^?
SBZOO=·M]<7Y)W+]Y?+[[=W-]=4M^7?3]^?KNZC+37BGJ%+]8J$&#)@>(90=03#W\&&QZ·M03AD·I5 U&F^_6YJBPD:#>}(OO68?XET=C@&+72WWL\X#_RKQC)0M4QT&#,;
M+:H.PUU+1W=\MU`,W%HI5|SZ B(;Z69?8$!BN5'9:8MLQ'0+4:1RKZOCK,"·M_46V6XW==<[CD'$\L8I/C\'-HJ=VO+41:H_P·M7F/4SJ-
IXF+++GVQV$0GJ>TZ6Y$(YG'M3SJDY24D(-*S.N?+N1Z3\TL/DB·M3,#S8I1TL3.=[%JP;ZP$E@0++_#MH)"Q@:L:A)|)0V>=L0,#TI?V@%AHT"$Y M\9VQ(#B-*

Q9%5&*P4/H9-.^RH[&2%\.:W;R;^?Z#U#V4!=9/+#;[->U[\91-MS/[3;XQZ91MMI2,F;/WHS@:F)EDQ67P<&PV:5,F4VZH>A%E^-XTFF=9QDTA-MS*-JL(#!A'XLLA](8E-4ACA5(SM/1%JOG<5[6QSN:#ML<_&@P2W;G+,]I'[/-MD__$4['5B>::<+ND]^XE=R_"+]&A_,&PQC\S%CZF((KFZ*^Q%W33@4S@E1ZL-MQ)+2ZK9_+=Y!83R-4HF=QKN\\CU!X\M(WAPPDLB29[OE=,6K'BO1NHO+?9O-M>_V;Q,/N4N4B\WZAULO<5DQI8OFG"9H3_P4WM&116ACA2WWD47+QLP8F@NXN-M#\;8TA96K=D07S-YE)DA$*8$(N$*(L'-=@+)4*2$)*^A4FRETOV|O&LQ7RE-M%ZA-W9J'0[@6_;6Z11I4ZM@FL56+-^+??3V|/R:-HR/6<_\Z|/"L@2VW("KN5-M YE]fTS3ARPC+9Z-'IX% 3HSN#K9Q=N[%TQ=<\'Y"^;BH[+:]-Q[07Z-MM7W#[P;LOJOIE-<:604,,:Z]R_Q(%S:=Z.[Y@TV9QO\^Z(6/W**ORQ+ET]DM-MRF?0&+5.BVWB]Z80B28"%{)N;9<^:6LX\$W'_T\I\CD-M6[)MT]9^RZ%+>LJ*SX\1_U#:H_G!ZR2[R]ZK'"7[';[4M:7P[_L-0IWXU\;-M&]OT.F6U],C4WV"[_/6>G.%,.],]LL=C92TW)0<.PH%]?$?'I4C=65A'SXG&-MT4B5J;@M]Y"-A*K5DCI,2QK$P\7KIB6)Pl*R%,.NA5SZJE2,A.\,/(KX1%>-.M7AL/=]NKGE[VH.I\RXV"7=6E7&+-D;FMFV-I#CJ4EX^XGB]TL#.I$)\'PJ9'>-MD9%8_^6BEG%Z]P<%OX")F&.LF9K/T6(K*ENRZ*.&V9_X71Z=B=MY^-MOM/-K1,,N]^03=6!6$Z=0[<-S6^3H/FU:,"2NC/#^N@.-M=5V#'2_X53FF5&.U/'BU8I9#:'FYHV[2ZF>)A???P@:,:SI%)6.)]5QV2_LQPP-M(CR'I0-,)DL:PVPPL%<7+#?>_]1/(\1&-MG>QG)CV52<4W+)4_;OB]DGVB3T-M!>2-[O->!BY+6'-!\#6[&N.,:8O/'AM8_VJ]K{)]/_ZR.1V1F$$]_X)2N]L-MS?#TI.8J*RU;],T:U! %^*:6;$NI&^IO;-G+APYR5#<|:>X"G7)%/.-:E!TO5]-M/.F:,#X@21AM98N]N+3K3T&-<33SKFG"R,/<39V8XS9Q-VJ;H<"G7C-==Q%,<_>UN4]P-MTTY[#;+M3!\VIQDK-/AT/,==O|=NC'[G"45F!V'3FX(DO1#-*"/E=0!1!G8-M'W05OP))0NYKP=0\NM4=(K|PHGJ[OI#)R7^H,<69/E206@-54<\2A/5-&79*-M840=E^].G-]GOPJR28?9WU<;HV&W5ZC/H#B>*SZX=7WFX/KAU]-F@H],,@"-M5$06L=-[=6I/^,5>]B$6KB+DY7IB6V!^T.\#W4R4E\UYJB0?7$C. (;8H[J2B-M6*VBF'L%%Z%VI!%:A!'|;?^BS-M&YMH2]>A.'I@1M>AS[Z^5-6K504KDM(#4_4E)*;4ALL51NLB./#/5L5N-NQF^UOZHD'UA-S\[H8/5%10/R<)@2?2CVQ&CTQ-PI"[),NPXKU-MQ-SKMA"M06DW1MUN1^]%>B)%7&+_QSOU$Y//%9U\.+/CX=?!VD$O8PZE->{8NC$F9!0IB!TGE8M5*8?^T6HR2@-M^U"1[L-*U,*]>(X.1*5V62FOSH%8P5%SKQJ7MMH"27%[NHK4&(O5&/-SNQA[-M456-W=+*2NM>]2\>6E_,@H,P^]0-77REMEB^MEB5E&ZCE&[W11.Q-FVQ*IYWMRN:Y=",*?JKTF\%)?;!$?3-GHPM2!GS<#"0RJ-8RN!6$(1YQ_V&-M?:D)5]0)YERQQ:@$-Q#-T4]@8=7-BMA]Q#8W2^/W=),N+MBN'!<33>U>]T-MZ7\"-_VD$[_=5-D^Q"K/[$W"P"6<:#9Z)6>?!V?VJOF]TTR.)Y7V0-'.H/-M/.U+{"^A%7=?S(+,"NH:MAOLPQ1>2\F.)5>N:E99<5/$%9Z2$[;.JJ;.Q1?[+2ORRFD#/-M/X>:-[&@RBH[U2J=54*.;>YJP5%*TO-Y%'&2@VJB,3K9.K](3;/8<_'\W"|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|@U?4Q+-^C.:9Y4.:",_U+HG*_"-M^5EMA(%92'35#$!(;CH);#ML4QK9!-MPK&A=%8>2NQ_=6?4)D9#E/IRXU'$%IMZ[4O!+P9]5@GP"Y-P!<)@,.,3[L&'=]8!]XMRN!URC0C";JUACY)VT1G+O!FB"$-UQ%IHYIH#QY7;@=P.LHN32S]E(S0F'W43-M$72!-/IBF9Z2\856L3GT&]->L=D:KV)GV(659>\3?:Q;?,A-0IZLBCTZ:-HG-M3U:/G@?2Q5'@R2K1S-DQT'X-*]S>5,P0A59>7R<7N&B"GQH|-M-3]!\$,'ISB8T(!#?WK#55%IY8/UKJR4[5]:I-_9LSYQ9^\5YW9Q<.C<;_OM@G*W6FT8FW7Y-@O.O=|ZL|PU-N/-VB>HVNGJ4=UOQD_S-_&C;-M0X@!GI*-[NB3Ij:::CC$M8@VGNGT*9EK8^D0XD1*B)-YM=E6C3YM-M8.8#=9TFT2)3"^^ZQ-MV80RN"UCSX('S>X%!\ME_G$UT9VYHR_>ZB:.$85DP-M5A=FYB%N;M-'??%(YMH2S|>-2H;OFP5V;8P'80R\|_V^V/*C/NJD_+AYY-M'(,IXIA-S^^FA19^HW/^:N?<-7Y<0,I.M4*JI#PYN3-M->)A*>5@K3J-M)-#*-[*U8*!U9Q2PK)MC?-0ZVM,829,FS;ACD'C[00/9J0?C-DH"=O9@#>:EF-M&SJUB4TG]'&.SVT2?0HK-M7_<^L*(V(! XLPT6'RZ)Y?(_;+F^TK2$S8OR_2M:)NHI.XF-M^MML6U&KWU=VH57:5E02K3I(JW8_?5\!F!/-A&V#-M?!+_%HFSG26)8IITG(#'?1)0NWT7D-M_I&^:?W2.,:_\PR3E8N@:RO=/D>XE-F8G[:_**9_5E0@0@AMV=7D2JLZI3LOI2-M>*W@B97KQ>/>+>>)>EH19U*#5K\Q&B9T\(K4C$+S7W%>=E"L2(Y/W+?+-Q94*-M(<&ZP%!W$QB#@BA.@3?1>()<@C(A+T<4B2DBX3N1F$KV/7-G"6)A24EG?X-M+(!0&&*L;-QR*ULH%$."8MRB"F:T)W4)DW)A'[GP/A-B?ZD8;U$YQ2T8\]03P:CS3!/89BBQAG&V!.._P0TK<-U$[8;-MHT^1[!GR##//]!60@=-^]'S(#@_-M:0:-^A28!YH[980H#S<1_NG?$XK#S$GCB*;F#QT?+!.#9#"("S1?V=NW>>D(G-M!LH7&/@#-7'F,%\:Z&/[+]&;X+!_@WQ]R?-7J+9$SJ-@6&.@1AS8P'X&(]M-MI",?/=OO_*&'^!\]VDCC??PH'ZZ0,*L'F$L5C29(?U02BG*@)BQE<$^B-O? MT!>T!.G(<_/Z?W]39==PY]+-A<@4VAS^'_6/F>]M)0(#+_2[>N:E99<5/$%Z9[-ML;7Q@9'7;?:E)K(-#^@I>Z#\IB9YQH!DOT9I$P@38-UBSGC6,A?%VQ&/BGF\S=1.$6)0H(-MO@G.VGLR"-6 QG.&=P#5]^"6]9&$Q5HS\?UK,^-!1Z;E-K3&Z&9\]f]+-#H_F-MZ]#-[]@U^.6WE=>^L(-.Q^^.#?3?"WC(U=-:/[/?.1ZLS-MGO!*'VP415E(T/AT_9(T*LC"89[DZ-30D&GAB106]@#;17ELY+UF_]^046#-MRPK$OR=%N6FFVXY+_@UZ!B8AP*I%=#1AR>V^YOHAP/F[71T!IR]f-DYIK4@0-M-*Z6)%!W7G.=$-IZ=48!6/[MTU5,=ZXUQTXB*9Z?X0YMV8G'O9)++7ZGFGTK-FHD/C]U=]G,A!);.:MO)AFO)ZL"^(A)%AN0&)G\0AZ+QKIH/E8CT-{9^/"U\#XV!Y9SM\-MYO<]YY4)X[7I-[[.LI=X&/VH.P]3^-$-]-DZY4@VH$&!$JB($W9:C,;51^$-SMQXSY>P7%)G,&M,PLGDX6VPJ2BM/O=5%=O.,S\)9EMNH_3H\7O?>=ZTX;_P8-M@_UV3SDC43/WSK]A?O;<8OR,+^-WAT;L'PSC8D?@@2,);.I3$W0I^.4!@@RPM=LH0AG%F3/&-:A(=E1!QZAYZ\<)X)G6K^96!15O@)/$<+<3H-N)!5K:TAG6KC&5SQ(Y1B=K6<-MF[B'&.C:T/A\$R:VFL:ZBV*7[V.8)&ZMMN4X)]IX3-UJ:UZPD?6D.]6I"2R2-M-U$T^0&=./"9S]2[^Q0-JR.AV%9$#L,T]L{-[G,6<26K=]4X*@6%/^1CZ&8>-MT0,\E|-_)92L>T-_\/"Z39A!,AZ)1I*#7C:H"GZDWTIAQ)9?|O\'SA'-U^-M)CD4G?&AN4L:(I'PA\,:_PSHQ8!TD.;HP)O+-^BFF-SO7+G?&T0TCX&Z(194-M&11_"}\]KN#KW149$+98E#.RHB@LY(^D#-HS3E2B!51]GQY]L)!.:UMYG%8L-MANY51QSOH:SEX[QV&N;>;-<4Y'XR$H.+"QW@&,YYALB&Q=>1^A-M<.C1]QJF.&QX5NZCK4T/RQ!0%UNJ^'M-0E+H^$(OT%U@WSA^.XE",9EHI;(R-M802YXL1[9>SUUV&/B0D#).R.B^]UP@/.>@C+SJZ,-<#XVA#N<8,*TX(ZK+G2-M':#UNI-^U'F(<\5+/%.O:}&QV1),C"L+3;NUN*15))*GG#-=4D5BN=A-M|K'[-<>']A2HE<]B_F\,]D<5*-8N4^E-IKRRI>P|>LF6+WYRC%1CVQE3#F$GYY9F,%M0*)EZ-MA#;RO68P#Y-SHQ3U0_H(9DC-#WPV]I^F0_EYM)|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|Z\!+PUY8&!63S5=)R]L:))G'\;?S7Z*.\_M$_R5<\O[6F-MKWGZI@MS[%6>"&[QA\-.Z<8C10939,?V]\ON2^*N418J0UC-M-1,?-M87L!$^\N*\I9)FRL4;"W8H;-C%\;RV>"H;BE;)"]"%-L/00D$#B(&XD-M4;UGAY'Y#NKD=E7^=C66VQ7<_6%SF1^1=]WOM.I'[14>R[+!S>&7:QM:#-M":]+GFRX6E)4!@E4T8DU4\""QNCEW[&D,7=XLI(^F"T&3WF$W1!&1YE!M/!L-MP8*?!]L/H.PD$@L,<58$<;&.66Q+M0]R+5(=C,$Q?-KF'1M4%/[4:.M,_"%TUF_S)MWBL-!'29^LBJCUE"50=QS':3?>[/2;?BXW[<|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|Z1>$-DIV5"E_'H=D13Y,.;@R,9,[L'P.0Z^LIR-MK%G4/7)|=1Y?.8*@[/?>%G.]?PU5-?-K6,DE+|8O%-5]9X^-+C?+?U*K$,9:GEX&(8B+B4,$8;MEH1AI=)P7QA|L5Q[@=;SDN\5:FV'O-=%.!;-%&Y26%H$O[>5_[N93.51R)-M7@D0:9G__^RI;7/;6)(V^OW^"H3>MV_8$91&)+5633A"]=M5ZK(MC:6JGKE?-M'"`)Bf@"-0X6R>Q??W-[&P"N(D5*YD1/MR61P%GRY,GER2=WX|O&\>`T\|Y75-M-^YO2W7C$Q^P"=MT.XK2V(0-NZ.[<6>I_>]UX.4.,3T<<;L>]/-M=U[F!H5R2V$SFQ;*LYU0SA;*-\^A*C>):&N^9P;_CW?>]=NKS+-^-W8G?PMH-MQ1]=_HX.0Y6RN|XMAQT^\)D'3U1O$R'2@G/VG=G:-/ZSI'3V]@-U[>+-@0-M\WBAAI@GFVP@O<3L3A:::W>DV|X\^76@J9Y,WZD6UCYZUCM;+M{&M\V+MV<]W-M;9VW>H8_>OGE:NT\X5.1_-P8K1KF8N\CK4V#QU\G]Z'63=*LB(%HPST4QCY-M*9ARP^-O^31KD_O=?_3#^A)E5*YOJ.+P9*;554=:>'1Y/G7;=-%%*KLZ48:YD'-MMA,@0FZ4)@]AC_K[L>6'>YL&|WY*?5*1P39*+.Y:[BJ&.GW56-U1&NS#!@:A-M\Tl;$'3V%EZ>86]8:DUKMV2T2/'+'N-3/@*K(8LM&Y%$8A*/7R*5KFI?2YL,07$/8">8OYQZ-MKA+9UQM4W2^(Q69W@\]%,.I 00R\CO^@:JE!CZ<+<+NY/ZV@D==Z2>-M.QFIHD0':]OW/IK9LQ^Y([F1@[4=R@W?XCO-VVSAO7WPWGAW;ZM*(TJTM*XD# M#_3$$./8J#*Z P]6(^CFU&&-RL SST\#+PVZ*+.]E2/,MY,]YH\8)"V"?>FI-MQ,9U/#FU44YFG-8E,YZ.!U0AO \2P;._1Z%-&KK]U/(VL)>)X&6G*>0/=QX=[!TY/5LH!^_]@7<\A5*\8NWKC3:R\ +'K=_U1V_?"3&ZY7*Q"%>MS>>]-<\/MEA1'U*V$1FVI$*]Q4JK'%-]Z&1#;65]G>KL7[-M)^O#^KUHj^Y>U^!%NO%|?:IWKNCS319[&-05N)SVP7;NHB"ZSXMD=FH[$N2-M3\V9S+!H7_?-U77D3I+0B<3>XB'OFUTD6XH35>]^2>KEUB,U\)K4X:.VXER=S-M+\=);O.O^YEF70|-/N\XE_4&,>=R>Q'.Y2>R'!]NX]=_6##=2\=;]E#KV[(3-M7X(<+HB'(^Z"-L5D_7?^I%F$8\>L_(/MP@!]4E\Q#*'^2MV]I=@!Q:=J.W:G-M8ZNV8X?9WF&V=YCM'69[A]G>8;8Y.6#2^77)F^Q+D'.,O?FX?),-J2_:7'L]-M]SON,07CBMO5KU-Q__*L'6;9"FLI6V+34C6! MB?;D:,=$NVGI6H&ENJW2=?Q,TO7* J[:8=8&\,]D&'95"5]I9^5NDY7[0;.G-M@MA_IK.]ZR6Q<4E{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|\1'$3*UXPJ2,]9*6]E5W=.UN M7=S>Z>-X=$XYNK|_.ZXP-I-2OTEY/;F_U#*R15Y,-HYSCN/|S7S^%X! MMNJ;'&'&ZIG3-8FWS,$(6NS@'=]@(%%C96 P.Y' MU#MQT=R_T*!^8BCLSTZ0#E<81FZMY?^S\69]';=4/?-K,/;PW3[C4C7/REX_^M4;8]8>4K.AQD%OO-3_=VZK^XJ;>)KY\4)XV!SWL:'0@NQJD@2'[#NPL>?(. .M-*B=,.9%Y'M=:,.RZWY7.KOA;^&N6>RFH(B[|$>>?Y\&J)4:I?ZI73\;>'W1-MBS]TXNPE4_(I;_&D\KGN^:!'V^/6R01#D M FZG|K):.P3?X:07:4#G,@NFO1NA[W.UHIVD3@Z\JQB:?%_-US-HEG_%:T?V(MN;^/80.RC|KE>O *Z9>;#WQLTMO/8(JH//+X?"0FR@%_%7=.L")3324GRM@-M0._4Y'13=GL03I MC?'B^@L.0M#3W_T+B5X1C3AI@N*-&EXMX]AAN<7I+3A7*H-[Y2G#>]&;$KX]+_^C)!_36I-D"*/&WN)*-M-83LH-H<{5\0Y87&7$R"L#*P+/-]$$?>;PAE1XQ_:L=S=!+2.4, SFK71@W M?-*G[H/,,HJCX0V21U@;&#|\=DP*2/X:|%C)X]}5\!?31\"0RIZACQ83^1Y:-MA<'>QAG?OO!<4C.YURIRW-$9N]70A4&DI'JXP57%X].D0]-S/OP7:JD /^@K M2P<4>|?/0AXD*!4RA:=&%348ZRHL,%_UN@-MX26O9*6,3\HKC32]:IDH[3%M:'^C%>UE=!A#=*WEIZ3-[35C'ZF&BZ3>WQ5:.M1<_%7K8><^VHCCJL9*W)FL9EWHICI2PK.(UQF26V%N#\%W?WP^_X@[(&9_A/_M#[F\]YX=GQU67WR6>66Q3_DS,5-]CMU>W*@K6HZ]R4-M6BJV16S*22WIV=..RA,W93GM,Z^@\,:GM9F\DIK>DE71;;=:>7N8-XPO5<-MNL3DZQFL"IE-9#GKWYJ0)SPTI%0T7LBE6TG;1)T ?Z0KN@&F6)6!S MX]UJ>03V+O*P^A%?P';\0MP98X_@>CR 9)C)=^V(K3MH\Y@I%OZD3$VK&A.L MCX6Z6K7P_,%BD>/OEN#&+K<+%,(%Y_EM\$HSC@<-5O-M1>/[M<1/7F7M)I\8>V%,)BV,$|P^_\=35FIA%D1VI?;L'$@QCGMV_30!SOGQ/S!+ MVM9]F./,7AM4 CZ].(5'^'@IMOS/ M EPL6+03KQB) ^6,"EXNGS?!(QB+XQC:$6B?8E!BC/-M-W5N:1/*/Q?+;W[NB\-M6E?F&!7*<<:]TJ$)^+ <$#6 GTV +B'55'% M%YEP AH4V@I\.&PB_?.'9DCFV$O"?VU$QIV/<9TCK'&&VT_KL('9/X,DMF#V M51J(OTA>1?-#FCE]9Z$NZ!.%HQHOHD)XJX%+L%9E_8C7I5SA%Q-MW&7,_- KN$_]X>; C!G08.\P8J?UN'+M5M=_TK^.:/[\M 6UBE70BPs<>%7/4%7K-54[$<&NL*+ MKV'V-Y5'W,1=G"1_'@&B\(0\2:5$(LP+4_A@W7>8O/BI5Z2/H\>S(:ON_;> M.S*$]L>!GY;+#.C18W'1M?(HK0]A3[*%L/7=@2\&4=V>=L:T.^C8Q>BOP-_Q MH\4(#?^Y;LO"6_K!3V@M/X7X/.M<[W5T;A[3.X&29'!<4 #YA$^.[[#U3,[M<@//27J+[M9T0^9<&S+G"Q@R1Y.3-QVQ8V#GD^)^H(^^9>1.W1XR\2;MS?N@ MBY9=V?5^KC,R,;\^PE?-6NU7+V9S'>^^.#V?D'SA*Y.Q4[?X=`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}2?-IV.#%%68$ZQ,1G)2P<56<2"X"&Z^7.Z0C*\9R7B_0S(BDK$8C:(P2,76M";P,P?I==^!5?!,LAVYF<.X]\UOU-^$%Y+R-M!)&%&3%V^#3YL1FH>3X/SAOX^$E#QJ$K8F],("I!RW3H#LBHY=AL9E>VD#% MZQ725]EY(\SH0>K';.N2NY947<83CJ,AX3F!-(75#3)%G0$7$5YI8P\-?$T, M O.J#^(@!6.&%PQ&TVP=PH?&F:XRIZ_0/^2AJBR*&,5*<>96?<) Q=6E#3X MWP*V2DN$@!>QO+M!_^A5E16;*//1LC"Q(78.%2K?A?>&G/BP]\TCQFJASK4Z% MK.R!=P'BF10Y+%K,R=BADM&(EA%%6.M;:5)ETK.=1LD"O=)'X EZ'63 -IMA M%,I><{J]'?*5C!)X*S$?79IAF2IHV*%A4E:G3H5#-V/=;4&3+,S2CPF\?J7&)J MQO)=&FS[BFR)R?0J9\9,^]KG[SJ9;2PK&?ZL/WKE'^J3YLT>+ MHVSR-1Y:J]3F)^ MLD _;=2+YQ+!,.V5&3,M[CQ2PYH4:C8M1<$GF-#@'9S5G AG'PP]0-/M?29]K$C5CI" M16G9"]OTU^;R@RJ*8~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}?)ID9/)N"+!5K1:ATY\I=U\"?&5Y]$.L%B+2%*W1%1E,G.&@_EZ7L3'-MKYQ"V%O8Z"-E*M!6P(L2_M?08_P']$U.R'2RL!?Z;2@4[_"+OR1QU8W\<,@9 MA)X_],)9(>(W,4?!&6NXX,.@#]\,RLA $H6KLIT#%M9P!6%*K]39'CK,-6X-M*MB@>Z\'IZ&'8S5!U'R2$6<$5ZL%!@E'TLJ;C0CD9\+P3Y.03VYH7-5_93Q MV6" 6-,QMZ(DJTR*IX.S>%!M),*<\EAXWA%HGA0XQCI?$&)Q*![#A4)Y9HH M/N3BD(?P/H& 9/#H$2Q $61"8$=/P82->YT3W5)6(/Z@\!\YE[/W6SY8+CF MYHX54)@LED6GJ^RQ[PCSU(L)WR/8CRRO,PYXKN,4_>X;O+%/#4J7,5%5+ M-S=R@+N-~JB?)3%\:"Q6'WS\ Q5+,31=(XXHD*7"K-=79$RF#*$(-(Y;6Q68 M8\LRS0S,_(-_@VP,DJ2'QY%CT# #[#U@X@_^Q#8&MQ9$##P"8H6:4IL,VHA M,Y"K!R1!#F+X:P|/S[V?4M)-"?

#'6X.Q;W,R5;L8R8&HT>J$!J% 7?O;^*WKUH^@Z6;PDM*!)RB_9/^CE5&<(. M#P+_ 5/IB7$=^#/PAF(XLK+BZI;D,P>6<1@\9NZBNOM/CX&)-22=ZRA)9 MZ
M0",/9/'#F%9D;2F@>O;"YB3E%TC M$!:T,F"%=4\,)3QX,I#P)AO %<.J6-L5]"1ZI[6+UKM?7TE(^["N)*1JLCD7
M[DRDJFU'S8GBAL]^VVCGW44!N#S@1::WM8UW>7"+3*7]HQ1*_/"-=WFW%Y&- MH[E.\;;B]Y>HQ'AA,URR$..%S7)2'<:4J[9RTWKV).#:=F_MU>O@^=OLXJ>/ M)X)C)]D-
3\LX]<%J)$^+\I*@4\F]DD:A8+M6+4*FBD^4KRD TL@V6<7+0XNS MP0\T?P33/\)'&;L?J3#]I3!>6*M#XC"]P+^](JIJM" M,6':+88"AVW%F02_B#+PTS +.LS@N9*4/2YT+J7NP/'-
ZLEH$ M$Z:]?8:[VNA?P1N/)8*L(NON.G4"!>,4?KI>,(0=&S>4UX&?4+\-J=* HA[@ M.R)!*?U*4)B2J, U5[QC!(86*F227O '+@!1VV88 *"]H#%/I2&+T*3\64
MNGH;#K0,1]5SP7$-R0-1'\%?N!_A?PYZHK"R8^]AK)4E-H_D.F,*>U A^"\^G-\[,C"CX+P<^!]Q$'CF1"UHJK]*S$+5/480]$"MT9 MET9IE2[H2U=(G&6%>W@W")NS/5Y9AU]"
<+KN<<%N4@PI8EN<(.>.,KB95W&< M//#*X1P40_0O-Y=7%XHC6A>Q80VFT;MF[1)KN?4JZ@WBO4154UT#O<,'WETU MR.O*,0A;!&="+"Z>O1F$F;H)V*MFI5V.
(7<"I0/I:I!'6)K3C9O"J$*PD^ . M#6*8=#=0-P;F..(^4L4XB?/)(G=@[G?J##US(/Q7-1"U)(DJ(^%^N;1^+%X%
MFE9%2@VQ<1TR;'S?'<3A_Q9RX:H!R[5M[1=MI]'F>L@;N.HN-.$6AH![P4A, M2HK ^SK8Z\,'QEDHAB,JE8"!)6RU]=99
M+_3[.7>Y&@9<7L<&%7M%+%A8]06[E(]'G!0RH@7>FC;L\)J!O[J(%N>FMI!! MZ%;]1?BS/)MD&JA/;V;?8+4EE>JE110X"6.C-9VEY)Q M4CN$N@5<6Z[M&E/JA+3H
,E!37H0/+!D[$?2V1P.I*W3.?TU6;GP%62_J2_I M\@A-&UCM?DB7A4E1DA#4O9UZQC_2Z.U\,ZQ A$XTEZAEIEFXEJDRWDF)E_U* M>SAU+W&>3!_6C[>7M_H:)_;@[2N(]
[TY,ISFMW.'5HXMB >X'H:=T^3MG(K MJYP$2;1R7Z^N0#)%:C#MQ96-X!9&4;^('$%")T?4..E*R;#"^<-3%(U5TA*L M2-"2H.PPQP8*,82SOZ'3HDP>E$7;N*@U;Y2-!G]7/?
9@ZPFLP0E(D.Q>$M@@ M"!.?B=":$&PK2T[D/U(:'^2>[#R-0ZSQ'M2K>V&_CSN W@N_G0J Y9\'WGO9 MW8D7FAJ"F#?, .)(+GRS[O
T8%9Y58PFR0(9Z$;\J6#YP0?]2!"!S8255*I) M<#9^C?SOR>TPS >_4QME9<'_>ON[[O'2#R.8J/+[K6BC5I6$1@TS$ &XTB[) M/- (6O5K.&?
O@P@EGW5QV0;VU3YQ33@'J0J*,73]%,0QC)*(C0(366';AMU4 MYH%D$&J8_8W/Q+Z.G*UFC1^:H%(74]L9U9D/ D3T]&%3P/X78[L#PAY3D;QF MN32#(*0"_.I-KBX9D%;+H/%
(^5UF<"YJ4_MU57>+%IX\Q9GIH&KL*F'IP?> M!5S-*4;)P*C'9+Z/;T&$!7[8'ES??TA2FTL9'"U)UZ-+*5\7W5>SRWQ^><-A MWAA>5_X\?N-
CT*/[]Q(OLA"KR%%T&'H]F,FW4X_CO%'!VS)5LT9OWB7S(SF/ MET)R8J/S]O'!+*PJ;8*L/%M,AEOWQ;P]*':9] Z>/+*-4OEXPJ0JX1P
@>Y*L.*5(.P/+4U5I#]3ZPLR))J9B>KQWCL!GHG\'$ MH;E&]RZN_!B\,1H &@A@GZ=&KMTA')BB'^E+:"<,M.E"%P1=0<2E@; Y"]@S M0[$ODRC;'+JE.1_AZ1.83CD3MTC>
[N0%,8+R>!>979GO=*M +O-SF^*GR]2F M+Q7C,FL=MQQ],C^'*W[Z?(<^V>H9[M GVXH^F9]QEZ"/D[E'UP,_ =?/A\FD MZ/VUFAJ_$1)/5\^X8&&LLA<"_;
<2^AR"0D2>^C0:8$2_0S*'3[_A#"!^\1+] M&X2%Y'9#4]- %&'9J7A[E,?R?@'O+4^B_<]C3$/?@F77Z5#BR8_'V@#4F:;/ MM_I1'Z(0/IRMS]GRWOBC\+O?\>.W%(SZ[(^EORO[1[\?
>+^!0(NA/ BBG@D: MUB[:S26%!V2Y#9U8U?NL\3(W-=VV-=V2Z^<5(YEUF)D$ 8$KV&N0[:(MI'*8 MC'N2\+?%)Z G.TY'M2F*J<"L_T;="WTD*NI*4US+T6!@/A8-
*UR9GKLA+QZ M2/X.IFXBY460T6#DI"7B)-$'X-.^N3#ADXI1F3Q]SJY:UA!*6#'&>=DI'!3 MGLB<+B"_X3==]_N8Q%5GY\/-M3H[TNXR&O/J-H\;\PIV5CM$AJTIN<: V3U1
MO_4PE:-JV?7&VQ&(3/>QP#JIW!_3=V*=5I5B$E,^79GTS36EC6/]F9KQT7S= MFMZ6(U&R-B0W=Y0+Q?S'+PG&S8VXTTK@\12/5P6US:@87)7$W+M*5K>M&OJ$ ML/L997=\
[S$-FS>.F8<,Q+#\'I%RB=#XNH+7 -)>8"M=ZE>%C MQ%QC[HQ]X2-!WYXX>[T^:L0P5[T0% Y5K(59=Q#TBD@R%J52:I[#3%#/V3:2 M9TO>]I/.GVX!H,>)DZ@ /!Q%#,S3H:+*
($QID>H=);DD2R9AVS3\0-&9^IK_ M *O?XJQ(,12N#K$=3[?RZ-;GX%[K[^N?O32!U?)_I$8J>I ITF"03.Y-J9>4PZE6G%R%Q!]W4>% M:70,+]
D4BT4&"HQ2GU3C9[.4IJEP&Q5D(6$_4%)BZU5]D@1:QDA27*2M/@% MQE'B^FAHVJ9R>)Q7KJF@ML"Z3DXO8LY4PHWHPL(B_CM.'F,/C)4TR7PL"?3" MX8BHV
.&AHJ<6BMATOUWBN<%/@/"HOAM[J.DPXTT9<5HAP.%N-&'&XR&#$8+ M=HNF!8$ID-V%>_F8I!'R7^.$&("J\EEG7 &;6$:$O(TBR(D**UO#G###T!X% MV3((%(,[-
$*,3!'K"DJ?J8I+D@[CPI)6?+\RMBYNKK2C(I29/867P=.N\K\> M?-#"9 6I;E! $+BO]_\-@K]"'_[]6^$/_-"[*:F3R^3 ^Y3WP!H-47[UVC0, M%S(%PGVAF/""^-Y'ZX#28GJ/[M%B2F#
[_"(?)&99V#)05H.LD&$H,>#$Q)23 M8E:8_OKE_><+5:VOBWE)ET[8!Y)Z/AH-S)C+OX9!CH9VR-(RA.>"H_B'#\>(2JS2@+X?
B116$"+A[@G&.X!0\'/AX[@_D8P1'L^39S56F%I^3G M,YJ_V3Y, CZ$/42B@]6?T;D(8\I6RMF<7.:@.=05[D%>JR@G.F/*L&')LP!H
MR5L>)RFA<$9%3KTZ\&MH33%AA52@H+*'H0R3..16BO(I;896\X5:NM7RXR)W M.>3$WE! -R!56G7H<\3ZTCC"I6%6(!8O(0U@C19PLSY4Q$JYQRJEQIAI?<;;0?[B6XG
M)U5'6/=#! H>U_QFM PE AB.&4P3A]+;*$8B8=Z>LM:J J#0@EV_R-@00:LT M%3="Q2] M(=X?>CLNBQ?)^4P%]:Q^43543L?4@^(AN5H5""!E.J[TR(2NPP'
M;)XK6$[Y,VVO"I_)[#]$Q%LQT+"+,CYC(U?>I5B)M6)BJVM6J"0A@HP,&!E" MER+!1V2W%=T-AY#I:L#[3ZX0A4*E_0&'5UMLF/ =LFL)ST3-2-%-@U!K.&^I
M5^WFY6BAR,V$PFJN. E>P6NMJX2YY!@&U3#Q#'+(&N0GB.!M'#_ &7\(-.$^C' CG MAP?!'@2K(^N%5Q@O3]"Y]"=J%!6F,.=?9(W.AH2H*B6VF3J(B%_A:A3G2*H1
MTQ*4=5I$%(VPU GL,!(;&*T]:7:7S9 >26)YF0E B/LA6"SG>R!)?%>H8/8P MX3@G09*Z#&]4,0B!6]J%(N[3\)9A>D]V#>CLE8*P%D\IE57("UD6L0+)S((" MB=U"0'EHQX?
T"%S8P(KY2JR>CH^^NQDC"((>)=V"/1%1_*\(6]-Z%FQ-;85R--< MC$>F^=Q$,B;UHQQ0UT]Q76!%O6CL<=M)L&SS7K-B
M1R8T58D>J61U)0*%L.Q@X$=]_J3(U)@9N,WN@/R%UQ(^_3 MA@H:F*BGFU=0Z1;.ZSWJ('L86YF16ENCGC-Y M5S+XL F66 MNA^?0=YEOE?WR.A-=[/K7-
50A0UH*1R*U*ZT"0 [G$!^)% B5LV@AIY+8Q?,0%M[93&=M)Q88E M_F;4B)HM @/+<4$%5YKU)./4-X6!4BYQ*3VRX64"7++@6\2%1(4C6'H(1B6X MW?
OH*0L)&.$(@BC:YX1L+RWN2YT=#F!%ZRJW2PP7$N;@G'E-;:?) [O'%39K M..)\GI :E*"(F:$Q*RVA(4+I2R%8N?P=#H#&UJRU7G GTZ#R3B5@5 M64')$('T,*Q#?
E!70\JL09,X!LQQP> ?!7F5>G5N(^NFIUCYU#=JENRQ78_- M:T+K\R9\RZ:EJ@.CQKDT&&(KP]=P1QO=V[74,7Y1Y:3 -O)3[.5)&YPY6TS5]2J+K%OZ8MHP9@@$I?"2.)#D.G)T
MVV%]94#1#ZD'XP2U1#N ME%CP7XK9I6'@??#&8> C03?I?DTWH)\7QY@0YJ4G/H92T;ZA%G=>S:>=QT;< M1FKT?%61#27/9I8'L4@[7"3+"8H0E_?@U;;KN03;AR:-[^(Q;\
MTYH%Z4/ 3(-2B6X=,]Z@@=;+G!L>6BT9* ?E7+V4?0SI<*#F\)%LW]:R)4X) M'F1/BG#[JJ9:MG> \&V2-[GK1!XS\@0LP@I6)R)*H$R0U)Z1<+0<="EH0G\' MX;@Y-@-P!M,[-
Z2Z18X VP/7S6*'K!^5BT M&2R,FFYZ9]ZMV"!L$*T["].TU5FNFK9E&Z.!58AYE/)F0XAJ,*]REPH0SU5 MQ[_& 2EA*2[J,V255+AE^^E[P-[<>AQ:$*;>%_!V%.7$<:EQS#1&.N(L
_V' MZ#/2D@]!'/E]_SNQCZ@+_@/8!=]AG/_]=8W4&8:?0#7)4#G,VOA&G2E9][DZ M,Y>N9T7K-""T+%N]H44XM7#DK&*'T\:;FK-:0U 96B6I*&*^R\@RB2CCZYBI
M5'I2ZI"'H%)&*]50.41A/Q?4.&:0'6"!MFD(UT"M9!Z=N$BYW*MYHMYD4$>Q MG('2$2!2%E'G5VHK;M16>#<.[@=9+V&)U<=O;C*M_L%H20HRBM5ZCI4+[2/ MR[7M*5
%*H=0G4S73:1J.!CU6+01)X*K[("A[L["7(QD(74+PJRHM0Y.)A"^=%1S M0CYVW >U[QP_O).LOS(!BP_R-9 S4E?@^1S;8L'G#U\5M*+]/-"*Q7A+FB^- MN*2Y&'-
)Y0#UN+>EB,OZ3U_/PE M%J="$^D)'I/ZE#_;_?O:!9OI)/]Z^[MQAI;';JS&N;9FN9!S'?G#)*?\M^5+ M?X+5[.9^M'9/NNR(6JY3O2LZR^?D6
]C%>Q^*A*\A+UATGJU7$+D0"0.=H:V MZH\C0($<H>2Z&1YJHQB&9,RWM436B*IO0\=3+!@!+RU(^S?I"F!M>QC&-O M*GA4=V$"$OB]'E?^5,=BE?
I4/;SUR\"3_#LUO+J^\ZUO+?#MX!RLI2L[^(OO MSH\/9W6==QV[LD"C<[?ZB9\RB>GAV7H\VC9ZM.T%/-JY?-9G$#3CL1Z>;2HB M>S%*PTB2#E/N'S?3W;#A9_BK/I+O?
@G];.3'ZZ1Q4C%73\5Z0$ZE M!LNB:\4N,V9.HFV4V_;()>*J++=%$Q2C=2]OJ8F2:^Q?HBFZZNYEJK/J]\-T M:#A\)U)0WU'O.*F$U&1,F#+DX1_;HZ\|1:R#&>/56
I\Z:IW.L5B!J93EMV^ MLFOZ4 =.^)"4 DTF.N4D"B7R'DR;EA5=PU#%R4(1"TRI?(\"RC<8#G"8^Z: MMOP9T 62"&<(*5).AWF1*PJX+IP.ZF'C1QCI%N[PVC?IO ""SY(4IJ_K*:NV
MS?H5Z%-,&QE=.71]].V00M?MNP3^W3ZD?Z_'PCG:>W?4G!2Z7KN%,V'^Y];\ MS^>=_W*&SO'>N^9!<]6&SOJEKD3LWVQOS-@I[O&NAR&<-
W06,R^P\C50S1*GW((%H8Q=&K(#BN7%%3]Z&UI8HW)R1(IZIOUBEM M80<1^\AYUI$E,Q:"WB #&6.GRJI9"O3N:[BF/1@R*7LEYGWS")LOI,Y,+!4T
M4[%W^&^G_Z,%1ZE>.,\C1LM?.A1)U[><;N)8;\UG'KG.R]:R_C M5PL"58[*?XB8K^(N6G!9OJEM_@IONV2\-J?9Q.Y]/C9!G OBMYU:B MH N="NSMBG[^QP2=+N^3WP&G"2FJ
@N[:M4I-..(OCS#CFI[I!Y5ZF#SK.)5 M8Q.4(&>*HXG^I&V-4EC!JM?#:A&Q4J6[>_ 7;&!;@'\M\DSU9)H9QXIW6=-5J;N "*ZWSO7)NE3_US%C:?9 MLDQ3G7KC E6J.2^^V?
<.O3K;L9E5';;KIA*18M M%N'GX'O8373$7&KUJW$K30E>H@NP>1Y4!:5AMBXR00JD >B/WZ[^=!#LUON- M@6:Z=E0<$)H#9^\DU89=/)09"
[]ZP(DYI;O*A%66/7L1@P!+PBPB=)&L5(7W M=.) A_G4W+CGL<:C"WLV!FB(,$$X9AU.!#)A9YGL7Y*T:K);"01[W:Q?UZW; M1<: ?MX9P^-+=9:*B\&J]Z\WSFGGJU;XK[
^/AU8NA]EOMAO=[K9/;$(OZ[B M_D^PA?S>&DT>&?9=6CSX/7^]+_(NJ.QVC6^Q*APK=>M>K;!XV/BH1QRAR*_ MI35V$WE[N_
I:]\1(X2Z'=,KPNL?/0M>O[48%6+KI5$AMA:C0FQM-15B:S$J MQ-:."O&'8$%L+<:"V"JQ('H3#O&V LF7* AX:5-R/?E7N+>#/WA+7/F%N-
#;"W.A[B0U\8Y:NUYB<6M*W/KHR^:S\WD,.8U M!55AP(2V\&7'79/I,VBBJRV#VWT&37@4/VJB,C!CD^8]/:\@]8A+K [M>^@M(1+#?
TA2Q<%@+5W#BEA(@X1)+W4KF6E&+OX>ZS),))LC\\I)LL(HAE-] M2*=M1@@10938[IG&"P00KR&(V?GI8_4MH=4TP20;57<&FB>@$3/06@I/? M(VN<'E#GK#?
<:'KKM%+)/CG@$ O-$U>%U FU&:;UQ?*:HZN-W])KSSZH"BO6 M#OM@#H$/*K%?\ZA2F+XV@#X==/8,3F[CM;BW3X(HW@V"S9BI-B:C]Q*(J9"[MM*5 U<%)]H MI[9 TX!_>-
HZ6[VFL>:X>45SC,=O)@IZ*3UCS7.5:F:YS3S9>W=T-$FA#NO5 M3(T7MB!&JG+LYG(I*][HHF^=PX=<6]:,&II;*;.Z9"/\@EEX&3IB87S"^ '+ M0\2@SXEG$+F.%.>
<[NG+S9DZE"7SO1[V#$:8C>[ZWI':867,"FFFJ1\N1KG_M-]F7)N=&J7JF9PS8<+V\OKGX[^LO'VJHI]A):\V!)=!A"GS;M6[VI#)A!.;N M8Q)+,
:F,Y1=H$6#DX1NSR:.Q]7;UZ22F$*2)D^9/6JOW;3]K[H!&VHK'(>+ M@&B4\/9Z(%/VP&H"K%\WY'1DQM6H]$E./U4^B*'GY9SWGVEK^A&^>T$9]NO^93+ROR=Q+:;B4# 5
M1]]N=1_C#]C2CV"18:0C=*?[L:C]8&/VZ=@B]= A3P%P'BSM?-?"0RE?0:7 MRDD=_Y=> <389&\I$N!WNTG:HYPYJ98+^+E@ZC90$"/3WO8I;EG*AJ/C@]5
MWMKZ,/K8!I.#4$[%6#?-,Q< 4QU,1 >7J":RVG%4!:U P_O,FUPFR/0Z""]% MQ3V4< 4AEY@.EF;+_2BHZA#^JHEB5;R =0V%'PI3;X&A%7CY0>44"N9@LB(K MXUB([[1JZ"YL-
0925$)6VU*._K4,;?FTES-;?R\][33FR=-^0^_CR._+C2 M&5PW5<:_ZJ*@R37@B[.@\#@4A\6U& ERC_*UQ#TH[=\?J_O5%-*[V'*EN5&61]"
(^W0%RP]C3,"\I)S*:S=RP)+IV3[6FIB5K\MC/G3*;% M,G/\,TB"'9HBBTUPYJP(EVV@]@+Z06X2AZ%_.A'.)S\>^$/$RZMFJS@<52=8 MQ'T_3!V:>F&73T:)+M5"G X"V?
%T%QGWBA0V^0;2L/2P^JL31 K IT>A!O'5 M[X*I&("VN(K[4<$,^ 083-(4S$;O.KWW8WE=AH/51^CKU>4U_L)"%.D]C<:- M*B>K[M^C^,W9H-
,4.-0T>AB8'@&$P2+T9RUMOUA!>$\844&_[,!B.&72?H57 MP1V)L,N(,.$SU/3["-MCP$+:?/D-NW@;%S/ C+4\J#&+^5[5 >K6 -P-0-1[MI6N.E6\PG[G3@EJBR ^CR>?J-5-\$2'FK
M9!J!1#,<683WP::(Q@$K47://1*"((=_-PR(Y0"__!!4VHRC(L M&D8:D\"N8_K=]5KP11WQ9 -/5H$$CKG!1Z"34]?'S@S&T@QB]FL;>"JP 1&= MCM++,FV#E_QY&QJ'<&NY!]"!M?
W74FKV7_YX"%J[BC0FNX9"JJA Z%P'JLX' ME1XE_1>4:4WV>#>;P1B[>)!^P17'=4.U>R,Y0*:TF(\),,X[(]K'D;=FA5S MOXB70DLK1I+/%PI"J10P-
OWN*8)QX606(\8:?:B6CS4:,MR)=N2]M>QYE#L5 M93#=:/#-;QA!X18?,HEV\Z1L@;5Y>=^RSF7^?MT%""N-"C0'2*1$@KH1'ZR> MY07@1K#_(S=A8\J*RA'3\X?G<>,@J_^0G5
7B:3&]N1^QV/.K?/:FT6NQF]. ME'Z1;80E?F/5EIJ5?\MQ]-(YU[#VI%Y!<1+9NTO#3H$&G0U"5K_4.JI\@'KZ MXM#%
(]3:)JLYG!1V%\N(;VXD!U>==_3W[08EY&NKM>]C&8D1'#49/19G4EW* MSV?)/O86"59?4[KJYXW\|3X<%O$#Z7J#7=I$!6B92"8QY[>]-SHGG\1J=U$$8(!P'JU#
M*E3[Y@MD;#CSYK9'A2:.?VOJ !P'\46/:Q:P%B*[LPA128I2PH$H%K[+,!Y86JM$VTE\ MKM2,7$)LQ,*1#AV2=';%+9#D%D,/1/T/EYW5650/V^ZL@GUJNF(;T(56]S:W
MIH7FYR+?79EE-TYF6H,74:$C_=ZF,E\ 1+L:7WWH?/FMQ?CR6UO-E]]:C"^_=38%:/VB M /BS$;3;#I%?C#*_=;Z#R&_Y%'<0^:V'R"]&GM]^?O)\FQM!R/.M2+[N?C8' M-
5$="Q"'Q%S2(E2RJ_;U8!GWJ<^\8K^U:-U-%[?E,T*U?(0,*R$D/+A^<8#$ MS7[>323)IL)+.C))?U1^_T3BU+S">S.Y)X#=!'!V3P &M001Y@XPGX$LJO2' M-
U*5[=OA.\S>*/)!$(!?/M^^M;H*$#U"6MQ[7X,'1*RL$SWY)D)^V! Q)KW@ M;27;1',!!?HN>$&P7C=EM?5$*)+4VSS(S.YD*53U\'B"^=FGVHZC,QBM!#= M:&RMRTUR%??
=/DDP"@T"(\?NZ*ZP('\-C-+7HWS_6K-\74A,D2D/Y$#0,A.? M!BU]7>G'B5KE"ALH[!D%2.S-['&K32L;JK\EV>/*<_6AI .&:X246K:T-ZH9 MIM*66V4UPW+BKLSHH5^,RM+NNX
R)YE)^4^%9(L4NP(FER[%V1=\,)Q)3HP MOGGTTPR^ [?YA$CR2MI/2"K/DCJ=P%"DF%+"U&$^=$Z;Z55RLK+I._D=9 EB]=ZSB-+#HPG:!*XF?? MN@HVT3%D[C
C&,EJ)I6KD+@QH^J6?BROI#JKBI)V3/R+_TX2^FVX=66UJ_3F 627F3XUR6H[X:@:F"K)CWBON=[@"5YC#-=,_D>;>(+$T8WQO][TO 8<@Z23NKB)5,)\4? MI;\)D2O*?
>ZVP$JZA+U4=$(G,A!-978!+V,F[,C0E*Y;*AHN>;FJN*(1GC4$ M@,V<4MT@'-':?WQ_8;4@=NQZ 0AD,QA2+48MS1RJ(&.N%\4VAP)I\<8J=BJ-
MZZGUM2SB;ZM*=CI7$QMXLI,U *P*$JK!L!.0Q3R1*H41*D_\A 99$9XMH-37 M=+A576?NUA1#G,N6C5*I,G
M*8@()P8MBD,Y.V4T::O&NA0$$+KK97B_,CSKYHBMNWWL;B(SK2]W)V%2T%.+ M[*T,$V,#4AK'U+TN#>[]M%?_$B/%5G6]GA]$'+ER_BO/D(^;@ M[3K6?\$AO8@O0
U\1%NW9)D8.LJ[9#(UY4IJ(HZ:8)DL1)]:98LS*(-R';U2 M['TRZ%FQMC9CR0C3&&L3)?5KC^F5M58IK"@2M1CEMVT)?(:G^-U!@0M?T_K, MAO:Y[4AJZZ-
15HVQDWAI_!8%B.T\+):0"]B=/,K0)XTG_]>;'.KN]^E@^& M""D'RP3R.S'N,@2N5S@E70+0?LW3 MU9*J950QEO+:V=
<(03)R!76DIEA<%8/DQ,K'9HQQCX6UYDXQI84'WD=MF1&Z MSEP"&-XJ.QC54ZBB6FL]C:4PDD"E#&%*]B@:E,ECB")>BAF**/?C@$,N+'CX M-
AN%0S$L9+PA:F>8:E;X3$W[M8@"K]EZTWVKKD1>V,S' 60P!NT)S3E]QEV:G42&HGY$6:YY-RN\Y.6?W-E@TX;=HOPQD(6?=99F'ER@R?KN ZY%,>MX[@W\PJK\[*)BUQ\:V"E
ME<09%,TEU\[(J>#2+D:M";8QZT!WQN1NA I0JSFS_KB]\!!U[Q3=LV>(ZY<5 MG5$2Q."6ZU5AM1&@[E89+J&(UB[V^^M_:A?[0NO4]U) K'L0]L#X%3 L7C0,
M8HO9QJNZ<=7]8-&3#@6HVO6,U!VN]X3U^7 (MJ9"U=&9M0J4I629@,O&72R7 MB1VK%C&^OGSO*59@$X3-ZEV*T6!&/?J,&]^GNE(*(W5Y54'EI/>ZY1;.B<>;
M4E%Z!"^/DGCLW<*:#7W&!)OL)=^IUM.4 V>N3WPBA<$1*]L-1U)>IF#LN+W* M?AB%8#YCV02-@+?IU2'L3I9 V"V#0V@O1G';WBC%[5(37(SCMKW5'+?MQ3AN
MV^T7B['KI+A^BP'MZDEN?QBFV_9B3+?MH[F.\K9BOY9 \;VP&2X)XGMALYR$ MX5LA3?WJU?!B_+;M-?/;*NN28%=NUS>0'G1+N4$L55M\EZ(Q"DTE73*JP)Q,
MAM2CSAB^=ADFV\M)OT_5WW8YN5U4:0^C:O)Q"_F^ZI!NLC[.UWY"FJ("\,? M8=P ?SWM^$/_WY16;& E(=BO\',2P4]!GO3 PNQZ;ZZ^TL_? 5OO!\5"=CA
M28Q4(&^Z8&L,&ZN/0.[S@^6NN5>\ 0DL-#_95/JKT_!N-%IH3I,\HD@NN145H3 M/5)=@JL]JQN3O-2P'W"W#L#=[4>+F)>5!&2. ZJ M:9P;2\1Z6!Q&J)!Q5V06W
HNMAF,,0)Q3KZ80] M*6##%%B:8WY@K$*T$97GRG=4OR1V8@H,?I4\/YBP72^H1NE*O7PDX\9]KM!+ MT^1<,_,8$7K[,W-?F1I:V,D@4Y6B^@6Z7@ZSP!.8,DG Z
7[.)FQURG&H-SQ M!7K'S&L2Q"9-2N&HKF'7J%:(CB>?W$ZWQ4F8;^]%_&Z,]%THX<.LSA^9\?BO M^^+O,^,3&@;ZL\CR].T]C@^><-V_M-;R(N[=Z;6SR:)* \W6QI1UU$:FK!E)
MH4>B@,.@@C7VDO)H>_8^*Q'NGI5!+H[]+;OPQS/R#WQW\#SSB M%:WY4IQM1TAXVIK9.A!+?BDXB,,GPV7SL\Y-XY$ 5-L^/?]Y0.T'.EF/:2LV!]U@
M5(0/862G"!#O$PS)BE>Q;["TO$OZG YFVUDJ,C0D*OP1=B3P+AF3PE1:M6%O M.^#-1@NE\M!(<6HDR#P]/,>@. SS7U10,N+S#Q0AH(=1XL8 32CH$"]3Z1F?9I
M!075@W:A73M?SHGC4I27?")=KHE@S\Z7U)2OMN-0ODI+F3RF5&,4+L^!/! M-D_N[WKXKDYW-VS7!KE B/"8U"E MEIW#?OI1M@X&]&Q;=WP(6S?
+ZF*+ZU@?,8&#*LKK.*'BI4SUSWA,D_B^EQ > M1G>=7MQ.8UZO375\?B)DP=>@!8MU38#D8+][%P+8]GY%PP"F X[(6-;PJ80>)]Q;Y8V%E=0[-4H!'0,7@.,M*A#
MU=)A%KDB;:525[(?F^<-N\0PJ]L@50(BP7T#'3=E%2Z[H%4]6]DNX3/FZE;3 MNWO2RB:&3,#R'7#4->A8?(H H3FC1 Q^!OBA02T3_08&,Q+"B6,8)D7Z!DA M3O%[T-
/YD#2\1P^B$_9DTU2"I&>"PDPMS Y&-D!V1[+'Y>3;C+ .9,<"*!XJ MP(ZU8UZ&1>I*Y+2%KVJ=#0/?[0&V)((5\ZZR"(8"GU9U&AP-7KK8R=9(<-?" MDKGU-::@OF!5%85/+Y2RM-
5L8#(75EG:LZ:NR2615JQM MB4U![M9AX'NKZ)AX&O)=OL1&R0UA_IO*G"Q@.8>K*M XUQ?!N M8A6)3GOJR-BM,^<$V:GPN_/+S^_&5KPZPJV79B.RU\1?'J7JJ-J;V2+X]?5
M"ZPODGJ=-$&#-[A.*$7Z4#QA'=C3QT#?"H["*0_585U0\EQ+)).&#[C))5H' M,\Q3N[7.90F@/WT1+)IY4")!CEUT6 I+I@:(;4.1>SJ'1GT !;'(_D:G^!Z MDTC93%D1Y@CJ03;J?
POW:D5AB?"Q M:C4][=55_/X&[@[M(G$PPV+2$)6.U0_H7<%_1J.0DLEX/DA3O&UXGQ),^/G@ M:>!?=,^M%OSIUP T;X8 MZ='"]*:(?&=+3*PDSO4B #ZAJ@JJM5Z@
Y,;6N#H[7NE9RBT< .#NTLP=T8^ MQ8TUHKOD*L]N<3C7_2\RD!L]CE44(!YJW_YP =^^";Y]X_#P$/^_VI<(]0@M M]I1UN0E2M,?ABK[NRP3O!L&*YC@JTL">9$M/&C(/
M.6>D;)W+Q90FEUG87?O+LG@6-]Y*N9O,CFHRHLK]%5O@RDNP-&/!=._Q/89> MP.N\!W5JEQFXCCCY"'+.*EJ3;GY\HR=%6WY*8%T*OC94;L1T@>*N2D)S[!*/ MD4\G-
Y>Z]4U-FE6HLSKHW^8_*?S ?B?R)#;7HPAM_W2&'+;BS'DMK>:(;>] M&$-N^VSR9FTW>+^$VY^UDMN.JU^,'K=]OL/5;_4,=[CZK<75+T:*>[0X*>Y"
M[EBM,=0A\IX.ZKR&1(.UZ:/[#"]IVY>X+3;-,!=-^_98L#\K?;S+B(?H>]E M3XY>^9O_Z(?L_C%DG/TN;<7"8U,$1(?RJ"%&L6!,M^!#*7\L(B_ND+_T:^$/ M:SP\Z:
<,YNQ#$H'SY:7R".V$,)^/7L)RV4A3_K [^+YCM($LW<0F*5 J.I\-H M0K5'[0;RBP1I*9Q,>T/M+5P.8R?;Y013ZYCB9K>H5+Z"$PRUPO?&X5&?M)A/ MISY^Y14,R2C?
3S31HYV#,W Q2KM@Y59=5-7*G M(ISJ@*M@O0W5/BY0X:<7Q@$10]QRAVV/V/##5NGN/F<5I M11=LFF&KCV@R"*+4CNAG]4&Z743) 3W@OC=8"]DREX,PLCO!=%HP)_"]+
[: MZR$V5=/L8%KF)B8!2EOO;/MU;&U[P[L(\MCWKN+N08."H14BQSKN519+S1\$ M'^P&3K-08GYQ-.5"\|:&\ZHDBB,LZ@1JIK92_/A2YSJP13=W>=1=C_\G2?^6 MB_"[GZE[-

DLF;MS]U]VL8NVE4L,*S]](U=HF:N]W;1)H)3)IG1'*7_!*-FA M3#Q,I?@+CW^!@629Z(3$..XX90H'\ (R1L#$N@^)#-P3&G:K1:S%5V7Z5Y_9 MH[TC0_R3+N8(ZIT39N8C-
$\8&7V>5Y)_#=>7U3>_I1F>],CPAS*3+3"'[X#SRBJMV!A,S=GI+ZB42B_87I2PO[22>750O M?@]N;,9IB9*G;V?%<(B&L..#4F5-5,^W.";Q>D-#AIN.Y]P7E8$YR #[#%;/8^QJ=JX
M"_$DJ.V;WB4Z@XWGP* BB%N6DWT?G"M;P%S"7L0[" MI4"4KH,N2M*T#KL>STIO\RX3A#N0D2;8193U;XFH#&1O_3*]FS<4- MM5>EXV&P(5<,BZHP)]4OL[(.CP^;;[IOWX
KCP1.C)6AKU)0 D,5IA>BM25(M&Z!T5=:-P/?$?IVR=Q9."(>.!6/[OX?=OTDGWS(^PA@7.*5,;<;0_QX.BR$E MI[" <3&8]WNVX&_I:75%*)IKWDDV?OO,;]6
[:_8XW4>'/7Y,BSTQT=U64B7 M@QZM247=+.#)I(AZ%*-&=&^73(H.@I*"CF6R6BV-X=YZP/X;R.Z)) L-$U>1 M9Z'.Y1]EOP2;2) M$H&*S^SP M*^X> SB G^%O@^P'WX/3O7?
MH_F*/Y(RVFW'R>'>N_,Y%#AR*$PMNYRY MX%.H*WZD]4:4Y>E\)93GSUQ"2507U?:%3BCU3)4<_(:$0'Z#8O"Z;(%_:5H5 MJ9Y"(BE.P=\+7'=;08T[?
F8(Z^URN=0/,^,,59QE"B!H&'+#Z7WD M_87<;/-WJLF3>T[MD'>PZAQA-]G7(2O5E]IWX%/<_Q)#4+?=-!QARHS3(+(6
M3%,J'CSOAQ>!UTUI+*GR200)7^E!8Z$O\0W8962_XU,T5:)AL'\%QE5"SHV. M(A7#IO=-RG-<5ZK[=*&&Y*)_"\#S&W3QK>24/E5T)O2A=,1&==)0\9)),J.# M]*4:B7/E1E;G8(9?
%IL*B5]3M^!1N?'/MS?>UX CN/L]8J;+F)2PUK=,J#0> MD3+&Y?]:54\93867;?(1>T40W;-G@>@>+<:P?;11ANUEYK<8P?;15A-L'RU& ML'W4_D$@NLY'?
U!^[:/%^+6/=OS:VSW#'0YX6W' 1XOQ:Q\MS]_]U"2K1C4T M&Y1CS%4;= 46^I>?(45!GBAX9]EZ;%Y;]U]!M:KIN8K M.E]XJ:KV;TS5ONY_6DU36I1]3MI1L7]?7M]<_/?
UEP].1U/I6>PV+/:E!N\Q MI_4F>3X@ QN!6*+0MEJ_6%.1:1$):>#SE@)4,>S44&;JT$K+' M+JT_W5';;;646"5&>M_5C#3$ 8WY/OL9^F^,@J@VG^5THX9**B&$PQU0";:L
MI\,6R8\F=H7IA ^37<5F8W+[/ZJ?K_>)_4_(_]67%M5#YB1)]3!*Z1*1I>V\8QGC] MZA:>)'$7U)X\D_=*(P8[0T"W_P145)Y'_ZW"!] HA!7\P%YVD7?C(L11?\ M-
:$:0(23O_54:_J.&^PW=62UN*86EY;RPFU**[@HCL83!&DY!:'4?XE65[6M MJ.TO.%6I5 7243*F2(*Y[##&1\C$G#"/0AK@?@K^%48A&YA7Z0/U1#'L5PI*
M1&O6C1()E4MQV;H%8SN;B%Z/PB0$>\%]%SJ'$[267]"WQ*$M?-]'R/]&4'+0 M3NW&\>'AM-(N,&)4O8I#?^5C)D[Q6U7YDW#W;6X'JT$S&1)9A;PNH>62+NY4 M-$-N1T>U?
W'K?#@.K9M=UU \EKCY-(4@6S/8D 26^:\D19G6Z#(S>T%B]0Z\ M2RK?<&@H$6S-O4E&_IA8OX@PD2Q/71)C&O[ZF1-,1[X_,H>X[,<>A4M)(4](MN?
>D#A/(33&+%.P+=N\H^V_7@S!Q8)]89\22BO<(MFN&-QOHI]1^\4 XN>/P M9.I&RRH1* 5':+"2@Z)KG)A!39=5S5<\%@Z14D=WOU!$->)_C%:K.Y"Q0
M3NG7Q>7=U7^MV8KZ^.'+W?77B_6]11%$9DEI1R:!H!6@7$Z8N;$W8ZLI#[+! M"+OSXT-L'YZ1.X..&P)#:\LGU=FOS5"1W#G,H%S8I*BYRJ_-:3\=K] +\I'
MTT97$3/TSU&,#2_F6@ I])(2R EGL_94';"!\;&@8OB\H+BC)(1W[KP-@8T9F.P2X>9 M9Q*SQ'G%O=3&\.ML!+_&#<'"!UQ;FFEYT?X_^3\Y\ MC1(?
E"$32L(J(U172\.)5Z6!]K$8.6%?[FKRS,B*TS_I1W;@C:R D(-4,MD$3]HB(WCN3CNZP[58\80&S MHM,3?R.S&^>9T@P'[[S,V^Q7-$I8]F*$.F46HEV;-K?ZG1=4%G#QZ"/GQ5U"
M#8)NT"(KEV6N_W398HO3MI[XX.)L+*5?W%F]!B^$3T0QKX MO;&F720Q?=N (X>_YYM(EN=+0=P2#C!NUM*\MRPE)O&?]G0?>G'MQ%
MA+*S9XSE)FTU7QG>.T,,H^D88HHKIZM,$&8<5*76A2!14W=_QOSTQ#"P&L;_MPYFK.UZE9G0T:\O/EMKR8UB @!,,'2\;J,H>D^N/H$1^VO7C-5JF;T"-)-\Q MLC<8]T#-
#0COA@<:>4M V/SQV_E:^8G9UCR4R@BXA$!F!_BEI3;RQA_C%EXA MI')@F!X7VLS5<#B>G.R]:U4I*O^AE-^TIH8K$&)>@2<)\7+0T5.8]E$--:>@ M1BD,"!9)
(:846G9TD3MZ%$]W M%S'D*L2OA>T-$DNR72CEJT(@GC\/ G$QDM"CET82>K082>C15I.$'BU&$GI4 M(@FMH0-Y(1!$;\9:>EN/#UR,)_1HQQ.ZW3/(\H4*(6$; M9NY+8,
(SD^WMABGKCW'0 MGY9CDA"TR:?0[Q @X(^8:*$*I!U[7P3_(KH,<# F>5+:F?W&45>SK0OL]$H< MDM,6TD"&%,9EIRHMK"CO)U86_TDN9M1";]-8G>$8M=>2.R.E^PH/'/1B
;P M!:S9,0C@R6)'I61=:S:UQG^;%@V2E:H00G,,,D9(2X- M*.'>%RRP>H%T\>S[#PF"S14!6S=BAKAR.G@$KTO=!CYNXR&5D5:F+%,.^G\' M+R-
YP5@J@YTRRV1M@M_#TA+YO1LX#,:)V$T;2?W^68]K09"-D8+5;00],1;J0^:5V)^7:N+T- MWV#\L1<788;$ P?>+0$,F'N. 7J:A+74_]D:CHL@&S/@!UY24/6%R6#C0C%$
M%_Z8!GP"-1*5T1-4;@)_8RM>D0T^4I-+0KI%R)WF@IP MKG69^CER_?K[NFU9W8.>/Z-_:B6L3S71HGDD>B!_9+^I!0(7E)YE6!1NE,@^ M^\5R!IYEZV0V20MZ=\\(5
K>F2MZ-'J5W0>2,'I.2S163VDH"%P$H(/S,8. MB#GR+XI !;T+5)]WP24<]]'M:Q7)2+#UX@_F'P@)N_[':BW#>W]/+)_ MUMQ[=SH931-,U^A<82$V>0[G]:K5"V;AUF?):2A^*VS)*
(&-G O\N]UL#!" M4"@;G+CUX8@CI&@HU%U#>#2ETI7^HM"C@K*;<1EM!FP7H83,"VU3,3;GEKYU M3&=5^)-YOTK3)L/V7T7!Z8W!&0QC,G\8T [&D:*= K.0()QDOCC?
LL^%3$%U M.?I5=;KO%/!E+)]%ZV&"559Q##2$@T1!]_5M<+^(AO=UD,_:76Z$[WZ&UX MMWIL@0("0P)\O@85CWM_AKAG6!Z$"X^-)Z3Y 4Y\;BMO<6S7!5E\L@9"
8NTP86@HHCK5!9L$L^4*O8"]MI"P4KS0I)>#U$QTU6ANR[\>:@HU[?9FZ"ZTA5+\O;):.QBY8;NBFZKF+K""2
MEWXV]]\C7C5!8YA,/V=@.3<6L=PL*2T#08\#ZG1%Y?:DSP\$7]LEKV+:.\0$ MH&!ZR;\#Q200IKU]M]0F*[I4:@/7]8]MPQ[WB1X+"[15=8VI-;ZP%P+,!RR!
M9DR)SUS.5(^=9.@6Q;CM+AVT+D6'*:=!7:%.^6BALNW]! MW/16?Z0N<6MS'8:'PD;8&ZI>D74)^EB^[I6O*G!^"]Z-;V@=UA!^ ZDS"%*K M=IZR(?
TH>=R"HA:R;FNI#T:JR1"CBH K0 M0(E"/A$?]2T)]P>7#W-5#7GT7I&9ZC!W?/#^88;\SW4K+^4+BD6"B[2%3\#B
M2:BLP&TQPA(6(5P\ES"\/%X..V%="%VE:BQI(DH.A;KIB!#,H"P/#U55;=(09*P MRY'8]U.FZ6PC:4'E5+Z1$5=MW+5$AR0G'WY-K3^QHA&-4ACDK5E&(Q8F7UXE
M^6C3;IQ+6!$C*OHL3>'3;#C1O5(O2[MUGNMCF<$I?\$E]V2IX23]9U\!50_5 M$$T,U3 /6433;L4I56M$?(53?WGJ$"WANW!]3BDF L+!PL&:Z,IB-7^Q.I#
M]41(51'*LO!O07%YW0;',$2]T&($AH.W"A#GRJ_Y&78W8Q:@L##AF&& MV\>OT?@G'+5>G3Z;XL/ I4_>NDIIVG=U1 M9=$V@[*YLQIBM.
(:KN3$"B_B+3I'D;-4W])D"P+SPU\)L[''^]P'S2HLM::V M,OU1.C,,,X!.?B5I@59.-TV$<8DWX62E^9AIT0.ZF.@9GQ]&Q4;QCF^/TX\2*5U^=SS@TB M\7VVDBNQQI?/0]NE2-
=X9KARIJ0N%E1-^NN&2(]% =H1%GW M033V,42KN-VX8AUCG:S#9)V+D9\?MW^4TJ,=_3EOIT+2L:,_W^X9[LJ; MMK6\Z7@Q^O/C9Z8_OZ[49K8.M'[PJ_3G-T$<9^/HP9\G
MU%H*CU0[]!S:SE!]9!(V(\6 "OY;A2CM&MUIXWZ,K&F:8%-BF9VQE8,48**$]D ME'QM+-%D8]@]Q^YOI)!@"2FX(%DN16;>H(+.M*=,85%I0V6#HN:Z0W\GC4>
M:N,MZ.NB8[5GMAZ M6T%?E;=BAAP.P7.SF=SU**QURHHNT;5K:#F(!FRH"AS(OA(A7"$1:)NU/]_K M^V2(2.7/LZ4+ZLM 0D'&]'NQR1,QKE2/94]$ZXY4)6Q@%5@P_F,1_
MB4.5#Z2;CK,_*EDXP0RX[?%]^UQ5K'Q&NH-$8YNH!JK&9DDYGP MRUWK1D$>FDP P7:(^/0R3+M%]+0ELI/#K4!(9'@C'*H'$B2??LD#KEF?M(@(M:&-
\8@F4)+&5%]&\&Z5M:NM.VV9!HK"OVL+CEB'JP\19Q.'V_*E7@]4A3H2Q MDFR[=#WUAN:-S9@V5J3%WG*Z8R(]#C SOD!Q)L6GAT@F2[97=G^]2%+E#_%#
MF":*A/BSCS&EN8S$M22%Z;P@;J<"\<#J $(M49#?(,T"9_R6EFC@.W> M+G$20V9QPMREO9NJDH>!Y#:"D+XFGT5C):0**]Q&!DNB(<+X//U:M;V4 M"< X=SGC+[SXN A\,M!*-
;_<"![M(H(-1F/12MD07:I8(%]$"=]-:\"*19G? M7;SAAR+!#8(A=H(]%VNC[E!B(CG5,!%-59HEANH;UC;I:AVQ\OZV>(]VBY%% MRB%D\C#&/KJWF:Q.)) OE3Q3:2W[*ZI92YASM]?
09/BQ8C*3Y&Z7 MLMD*8$# #C3)I>2SQ.TP2C ^B(K:]-H#GZY[%&>DGLYUMW+U^NQGU@7)4'X6 MBRC3W7U<+=UXCO6>I,U932#
=ASDK!H,S+:A+P/1<67L22(]E#"9PPV4U#*A M]<6P7>>)V(E#%E^.NLZBX2[%]@TPIJZ$*WD5NS7;;FB*27,IV7$XE4)E/291 ME\^'-#(:;2R(S MX@-OJ#($%,V&4F1\%<%MR$2?
#+M-Y <6:S6#:%RG6@@R:<"Q ?;TZ')]SE8; M?.RDAW1M3SEMT9 -TQ#@TB-7G*#C00:-& !2@9WSN9BBLE&UB=X7BYJ-(:6< MX +EP@PM9[H+O(_9$8?
0*>H3'E4'.^"^&.9Q[[PA7'<@$.C.&"YX M/$N;P%7GP5"%RMJX$%^#^R(2'.B*3\CM_N*%0#'HHCN5>DNE?E\N%0+FJG@ M3L%:2.V-:]@/Q3%Y*":J3>_QERC85M%%?
N6;#S[EZH_'4FJ!#1=Q M% B@2M6-Z H(O,NC,'A0]A,#"7"X7,1KCD.N_;A M8>.PAB.*0U/]!&ZK1P$BXL*&6FK8=4?+(.W1>9/@"K5OU+J+@3.:R/3,CA-
M4=78OZ94CH9&"OYXPX51*]?8&$&7'+U/H@&(:CV+"L8YTJM&IS(M<&N*H.> M>SR!5>/+C7EQ<\4_XTNHT<\GKHMJ8!R1/(YU%)88K20GD];*/6BZLPP!]#,)
M7*&B'L\D!RY+TG7L2AH\^H8?52=CI]\.SU#&FK,@:L=+0=2(67P&=PM+FSKA MN(:$];*BZ%+>;Q0*V=\-5,VK:P6$S8K.#1'[QC*P"K0]6* [Y) 5")SQ[:H MUG_'@,IH,/PF-
(94300U"I+P)C70PQMU"*NL36UTWG)_K-I/3C@2H8-A;ZT M6$F@;$92AD874K,2[-^4%'E7S =2P[:2+-8+/EZ,+_AXQQ>\-8":Q?B"CW=\P=L]PQV@9FL!-8OQ
M!9],Y@N>O"N;;')*0:!-Y^&NRV5VU/H!T2@JCF4CP%&Q!]2UWFZ6#.]I5=P] M:!#FAHU$W25"PV,Z;"?#(^]5"0\\:H#9"R8"1$R/+A!0?ZKE]"*C(:"-Z0J MM$N19S#WK=!UJ0.*,2
I3;%+RGTDXZE*>$% MA<45]I(%S,N0=6'W9)"Y]Z)?@+B6CH+>YS8#&?Z "Z(6>U]_AY8OM;E5'/1, M\!W1))D-P(FL :Q!B0IE*-!P/,JR:C08AL=T$&__+OL3I<-]W^\,%IM6HO-
^VUE9'C/"5FH_(% MZ3G?]Q-NB6SC3Z3D*-=Z-84$]7F7:%;NYKA\^* A'3$QSC"ST,3&4MN\U;"W M69IKD^/7(%O'IX-V[L^24!]O>-I3:Q00WPHL)OPLRTJO4V70S[S@H#)/FT]
M:BKE6V?FUE0!3,-0HDKD:HO7;!Q]%:-&QRI1AX0*#H5_1 K_I*?NI'H\BBS# M*5-*5I7*Z8M0GS;\0/4F=7DI.#YE:=HAE6)AY@F!A.H%&G"%W$]^S?6(%Y+= M?
KGF5J9IJHOYP/LM><3,>8.+176;*@TZM,:D0'@Q&#E5?".#2CBE6+$*M"&@ M2*P<,P%3%=^%C%B1/N&GC8VB;V58D7LPJ7 / P*)_%7T[NDOJH:YLOZBPR*K M'!K&@?
%H:;S%.QAF.IH&.I@H4<(2'VI+*@N]"S"GHLFP/Q7:!J-BF&#G[V*(MW"ZQ"!NQ;HF6YB':6V+BUX9%MA?V.##(8D2R6[97L&S6]4%[75:&7.0D.*;
MRFQBV*.Z4+15Y@1*#3&SQ$95W>.3V5PVZ"?\BI>?DP*KCXX!_@M>20%@S*[YL$TS4V E?1;;FE 9P3;@T;NPF]S&L8>;= M<[+9WBQ=[>[225-
@7,^"LIT:&P'GAWF)82TY#TK91?%DG*?322'TA@(,'8"^ MYG%H:*T>8*^$TU?)5I-BZX!/*C3H+C4L 1!SQ0\;(HF3,HHB)^C!+>659P' MV6LC>C_#)01ZJL":9_'1M#[[$(7>)
[COY:+Y?_WAZ&=XU(6]^;%^"--F>76.3!,23(,\D%" M(#[S,/DPCR7\3]?!0FC(/2*?.N#YXGABKJS(N;2 /Y/FA/=Z"&%3U-RO;K[J MF2O(NT9XW?
)N]/$=8QU]WY)0/[T(V[N+GY1SVA@Q07L0GROQ!-,_+!G5>E7 MUH%=/WR(NLW0H./.0<4(/0WUJ-FKA(K'W&G![!5#1 $.4..5]*O)2CCX_!/?]].1@5OM66%F-
W*ZIU3NQZUB6TW#:WE." MJL 3A+5BNPD%3 N#$A+R.%05$"ZJ,?Y<]'];TYKKOZ2]:UKFRFO4KS4DA M3AO^CBF.=-T3_5*XD3&O8!6[!&;'9-*2P]_4_?
K93^%86^T4GGB[XM/_B8(U M+EVM%T.] MQED.G4.JMK.;(.BI!W) V*_^;*38T'7]0QSB.8L>-55TGQ:O'[_TV6;,K[-D M#/;-'U(9B*H40_0+VELP$1:
(NH4AZ'V6<^4"GF])$F2\GW'&L4>E"*ED#]FI MTEXEU6-;,VN5%F6M]?!2)RO XRW:SJL/MZTMBA>"ES,L-[EN8IT@4Z$L[M&]IL&7$1#0=H>)T=7K-3^R8L:E\OA*LN. H5;
&2P(0JB$#));$!&>B_#+ M_!'TG6$L#"5G-<667IYI7)9$21"%CU^P8E5&&E6/)Q6)Y,O2/2*;NJN$@O(I M5]67),45B">2P3IWUB6*^RBO27IJ3T8^8IP97.3K$45++M&I=S[-
?]#W$AUZ MYW(:(LL*F KCW]9%&^J4 8^E$PZ=:QQD-"IO3Q]TD:C8?KS.T-PWX EA=E M@MXZ]Y$Z>B%U;I >3^@OHKF(Q/()3 :K "^+#$/%!F [CGMP(--6F91(*B]
ML=:;EA,O[Y2!K?;28!Z:4(9\KE\1S+#U/.Q@)XNQ@YV\.':PD\78P4ZVFAWL M9#%VL),?GAW,^N]5\(/-PC-Z&PMS6WC2+O?]U>@-).WDBG'(U)W.ZLJQ79VO">Q4[:S>][S
M)45+L,T9F=22E!/OKS_= $CQI@LED@(I3.W&ML0+@+XW&D^GS.-G9!ZX QBU MZ.LKEK>0N79F*],/K((L- E^A.6B ,,\;9B1WP+FF7;"]4[S&".R+W4\/Z MBWJ+DVCO)
[@+A9"_\?.5? MHADH#,J+]$":/;VZ.%(\81F*N7U 'O3EQO!0O+UH'S9VOKS(S$#860V-T79UC]Y,FBPP&K4/$!Z19IV %"DP_A?<:[0P31N$4? M0:*1H05HSO@OW*CF7:Y"'"[:
#%9G-CC^3-_?7#\."@T%GV<>=<%6?*K'Q%^1 M4)L'EB[%;0/1&=OO+PZF8,,AZ8D'C<_4[284AOD3M4FS_R\5=VV/@CD]Z 6D M*9H(.B9+ H"\'8?
EIYN*3P^T6X%^2_T1B9:*#GYR"/;)+K%UE4/94F/(JL4! M*]*K?T27UK+:K_ZX1)]>F?\/_L.T9?'S%(659NW@Z5F[<;!$(+8X;"Y?BE
M(NG9D""$TQ8U'IH^Z+562LUVQJ,\TF7FQNN["Z)I;(]=TTX))P#QC)_4/=F(M 0NI3KVT1%42HA'^9XXE:ZQ^.>2=A HA#1POPQ^R. ;AFAJC@,LN^"T?(1R"
M<&Y94_08@Q5P3&&@-X;=-0WL6;V\D3O$"/CS[V'U4FB<\4'8.3B\B[\&=X33 M *N]L!*95WS-X3W7 0K41^8V!+1*8-SD0!\$MH+/,A *M$-+7PM(LH)]6\O8 M]YXS8?
[LVPHM3ZO@Y6DWAIJ^5S[>GH&%RMI^ 2:C2S(6*5L>MB?XQG3N@+Y. M)@4KDR$+S)YP5@[YW_%;TB]5_*PV#^LJPCCL]_QW+,\5..^/?AV497/(-ZP*
MY/$V6@F&4>/RXY"3/^>NYQ>TA X(A:)V7IA&%T-<]*?"CJ$V BZ%8^$B(*!@ M':8,P%UH:1P+MIJV@GB<@]^&$;DYO+NPB>L7)![,/["J=5YE*HJ>4Q(,:_.FT_/[/\VX M 4]+L".:_'S-
W!40=A8$DUNZN[PD'BO" M_'31_/0E\)<9]Q1OV7=?VNRN7]AK[N,_\KS=[4]^+O]QO 0^; $ M#W. [*>UM *=S*4]\790W9\4OOAI+DVZ7K+;5%[XG'UB1&
[CO!IC80KAY1N"1)X[) MWOJOC%R\D?/SG0\2;O$5[6L8IB=X8/#M%0PS#69F-G=HV%SI@;5ZKV]]KK1F ML]D8ZJV$K7K#X=#\LXJ!H(EH+5C6B0G+YH3P!7P2+
(CB7WODB]UD3H-2GJ"- MB%^7!*_%KAE8?_GW#%=K+HQ17]O<>A7/(\W*^$#$'5A5F0(BQ>'93I6@^0W M.\&36D6H> ?[E6&AFY .$\O?4BM^BI>5\"D5#L
3'*=B'0M8'RILSP.*.3BV MCMX4 7T6&! & FVQ-0UW(N+P>3H>$(]!Q;#F[V;0#I*UMWRT^>$BOV("7GPO M3O,&!X,C@#A,4?D/0Z@/UF^3=>?B'LO1^VN0Z?(!/M6OW8W
<2XOURK%37\FX4.G3GV_C0J;M$29#@.(]=YAOT MN ,'5['OV:$D&%*S3_P6F]C!E+S%F_SSM_ZH%F!]7Q$1QECXAQ'4P^#ZHP@8 M%*OEPXY>$;:K!-$
,3.*GY^FH@G#NR]:508-2[PP>W"2XBS8O>[WO)9,?A] M:UOR_>Z'??<$2A8$[P(W6>_XVN'2P?5?^>+S9V%EPU<**GE2$-@9<+_>&/92 MT,ZBX
2^_@&&L$>#UP_\BU]VR0=S9L%]+-9.7 M;B%BO'?I^&0R=WZ @^Y2*TJ+5F/HFC_?HV#Y!!$KX7MX,_94L*B@9RQN/D S MXPU1D'[6]0DM"VMCQZMH07ZX
^PWX&&FA1&2G9I#F^[.[_\4RB#2A01"(X=W M/&3/L\|_KV\A"U"(-N-87NP 5I(MQ-/VH]%8?6=<=3]AH;G#:O2!92S6VV+1"A 1#=#]PR[+B(DQH4X8OD8@^S(@
M#\K((WQ/]OI%@\T+"_'E# '4A0QS9LQ,9)%+%KBRCS\;/TX99[TUS7?B"'\. MFIR!*@Q'$K@:F_A88 M81"@.NCP)Y'\8>LA4+9* ')% (X2;QG]Z6X]]**9WDO+7CI&7=V^3H7&QC*
M1OLN(I=VU],^U:UC6MP,U7+Y5[HH3RDE58:]Z.$E?"<:.AW#G,.C $*U" ,& MW#$*. R;P"^TQS)WT.1XX@]S=FZ?N[L3'\Z39U+FB$@B4(3#*@L,'Z9/L'N[M-
8%G6T>\,ZR/6L*.GG! 8VPM)NR>N\P%M<+249 #M$.F).K,,H58L +\PG=D M [C>&X1(S5<\!CN9H7H>9QZ<=V4=9+$[G,AU^Z4^0?]6 '8>U/3O M+2UU_SD?
5.%'@EFJE.'Z6'[7O?$"P\Y-@95?X)NSN.H;'EU#FP/K M;.%OO@,$WSQS^&^7]SY +\SO+&+$,+B"UK0< 7BQQ#PGR"!/+8%%N^-BP_]P M^)+MNVC:$BKY]6
X:&SW_C8H"MK0#E_O8!]'F^1/L>NYSXB,PP/8=)X%0"] M"71,0[V.V5>X06FZHBNOB*N#HC;LL&$XN%7]DG\:5JQ!#[K?+.#G6SG3!56# M;9U4*8)@/N5AG>-%?
V_*]XO%$T^#W:605#^/P8:2'X#"2NSB,Q#>C M^6[MXO0M_SSH(\G7):P28"WB;2*CKU\LTT(U.!N,Q[]AJAPW5
ML='#/#;*O!=FM$72T"WXM&BO%SXMVFIJ_0,\+:H'IT6YOX2PJVB0P_5:F'5S MYH@K[']=0X(#$+&I:<; T9.GTA5U>:J:7[#+ZZ9Y;])HA)KE^N F/!_Z@S@O] M^'KW.F.-NURO<+
[1HWYK*^(B)#<'-_8V\,G#OWWPF)4:T^ETAAE-Z_'O#<1V MA+]%MI+]G30@X% YP#$?KV_.+V]>GUU__CSZ>GMQXO^RVM6(^R7<\ ST-Z?W MK-GX25-
0[*3I&Q88J,I<0/)+D_UW*B%CQ$"?6LVC3/R@ MZ%!!.ARTP.H59Q3T:ZLIHC58^99:><7S!I;R!?*\"IW*H>);!I3Z*^[%B$(" M]YT*F399-#[V7_D/[!\4*L;(80T+$!-
S%+;%C\,AY3^O"PF6AD3VU&MBO8 MOE0$T?D]^VB'C'5X3X:(39G<6 '/![PW?]Y_,B-HB[?I6>Q?L/.TF/BFECZ+R<*A(V>?
83T^XW*,V"+\0:>33[;SS4V<+R@3(^X3#)MG97N#GM88]I-% M5[NL]KM\E.2^]5P@D0N$I8C05F\,D[@4NRRQHNP2RI9P=#1,V2[62O:30)R*
MM@72MBRIQ2/ZQ8EM$1Y73"[/B&[]'S$ M?H44>YP_WXOBT<7"G(779>0X> Z ^8-G3_CKI35B%=]X99UZRV?3N#>GIO>] M[0'+.")LW<:PE00(K:
>/3@.*4L=X]G&Y%D2Q2'R&A:OA8Y2X52,GR,,K@L<-.LD>&HF3.E"Q!)B&$&21!'R5W/FKD8[#C!_7W M+=@IE\\(@!O"I4 <[\ ]'YO4#>T>1D[$[-'[Z-9DGZ3JI"Y!%?; /5&DSK2O
MG2^M2V\1 43O@WPG$:JJN,==50DOT=D9E+Q]%O):9C\WJB_:Y-C5.L;)7KFT MY(RG*,OD)]9G/T5%IO-X_[9Y1/!_[Y9Y-='#H!4:8;XZ6]YYRC]"10E91]@H M(]]R'6FJWT?B-
5=+U+*53;DJ+% MN]4MK3'LU"*O+R,=R\OJMW3,!=3-M$B4@5-'SJ"+ MR#%V0^;3?1:L0G"UH^7'22:(12TY2W:$#"ZN\2XMU\6 M/1
]Q'MCG!3NU,L@RT@2+8GW[V40U](7SD9=?-,Y,8D'O12#N9]?;213A($#&E"\P31]3EHA:2EXT=TE[)HO MY,-&7)X89\:W7EHA#DYG7")XUN\M&G3FX(VZL"&4_;##Q,/.1N3?
5!#7[:;Y MJWCDREK .X&#P(Z9+EAK[S77K7;ZR?]ZY(E.>9T;9WY'? M/MA\H=-7WL U)##962-=-^0A3.2M&PC3N_A(LW.Q8-[D6/V.;GZ[JZP&8(= M,L/%W+%G=(]MZIZ-
5^&MIVLY-]I<[\A??W@QDM3T EV,;97 ,%C8'Y5@P]-' MX (Q<9SK[V))X8/Y\XQU+./NV/05$S"L;2.[G_6%-43K.K\WGFT]VGB91;T? MMO-7]%43DZL@*<.;C<,-HFG<5_/%9F;C'X]]
Q3QK8?-GAY?12.YM2M?PXAX M*23*FO XM"PIT6T.AF6],Q-5#RG!9LA57Z-GZPN)XBOL?BH:2M0@/?"N9ZG\ ML"H.DGMQ2["&@]23L=%W< [CQ]18R)[2)+2QX+Z?.%FGG
[8C6%/\VL"VO/ MYUOU&9@,XY'QG6=B*HF_!DR!GWP5_K>X'E.DR$'P7M'&5S23SS)0LLZR&\+R M^0^CKL>: T_\/K2._6I,O==@#'C3:#]ESB/+BB5BA"D%TVM.[&?@=#(V9B[K
M:_H6G\V:-)IC<&L<>LZ583O3 >IZF14!"KB9OO8=V-9PC!T--"SRQ*J^Q"Q)S/F>XRB MK&RNBR@K8-=HLTM=# M43N0X\1+4-/I:#T[QR3^,>!MDOM1I3US8-
".&=7;ZS(ZZ]1%AD[:]">6^]!P M$TS_H[VTR Z/]=V)C&=I._%HO^?-&W9]JQ]&CF9 XLGBVN]:=' Y]^R.K7RR M/&7MM%(&G&5Z>FQZ.[007S.7+::B9YI**SJ52GB9K;J?U[_[>?
YJNIU)1#J-999G>4G[5FW.E]GWO:9X8'.FEXO'EFAO9M:9B1[\[K=D].TJYI-.]H FS^+NUN/?766NU M],.RXO""]L"3,^1BBVTN:[U3 M-\;M8]OUW).T<"9L
/2XH[9,U<54FR0'#KCGU>N^61P]X&,_:0K/BIT^2#M= MT&N^V>B4]>^+KVACG_7H6E)6.3C!V00_*[:/]CK"R(>JLL'KQXGDWM5PIQ
M%'6>1=%$3>#="MHK_>XOV2V%H1C6F'YAWNO"=&'PMQ)L"B!-*G;7JFRA(K?O6Z@ZS<:P7P>M M*C<;1%6KA&R 19?%=;>H-2+@(8)+*TK(0@D5_1T2FG>52F,
[M>G,*2T1BR\X MZ!3;E+/6CL%APG J6LA#BQ60]*H(1!6!R+5_7/4BD/_YI:\-VJ=7\%?&4A!Q M9[TVGZ7AJQK4):B*$%41HBI"5$6(]@C9>[5%%<:H$=#]-
80I2C*H(V;M^514A&VI5"4L!NHVAEH06KJ!:E9L/I"\) MZ36&G>+,:ZUW?@ZQ$$%10A9*J/!/E83(B=O0Z:?B-E30MY"6B"64A Q2,2B4 M8Z#*$"KE&APF+>
(E(7'$OS3X%5\/+4%@8<$(0WK!T,3=#81E.6!3 -74#D.U M=!"!,S-4RZ[0+#XRBYL"S8)H.$&;$FL#I!9C/';FH) 56,O2.IUN)U.=SF#W M,IU^H8]0!1D5+@OP\^!\AHD=)/$O-
O'.MN39[7X+5R+P7*H6@G]]WB,@SB(=1W?O/,J?E? >)O38B-*N"W.IG- M%>(2FCPH-J;]JF K/\%,Q!Y:4\]?M&JD*XN@_9Z-9(3XW4+!OA3QB[6.$5)" MX-

]MJUJ<;8HK#K$T5%%"44)1HB;ETGO:#EK2!4SM"(52Q=(X_7XH/0!_/U_L M[)KL$.1.;SFR8;TF^/CY.H:*X*D$+X9\N*&7[\GF-:FO&CGVAUG8K6BA:*%H ML?[
@ZJM5[7UJK9>UHI>55NOV$'5ULNP]*JV7M76J]KZ/=36MU0F-:WH5IJGC8=:W6_ MMBY_?%554KTQ"TAB_;JYPT J'MB4!XJA:"]W_"Y55J_*ZLNLKI7)5D;*<2$X
M[!77+5'17C8C&2%^JU# 9$7\8JUCA)08-+;*["Q0H_*;0ZPA5I10E%"44'7U M^=?5J]V@U++;?7O](I;N:PHJ21ZRY$.Z^MJ,Z@4>A=#O5;9$$LU\NL/LWQ8 MT4+10M$B4UD]K]
FFO8F]H)^LL8^Z8^S0OQ(R:1(]\>&'KW$?V=HYN(;-J@3 M'MN<1KQZ7LW/BHGE*N8/2OCYK+1F\TUCHT@J9F#X[>TW<=L%:Q\VX1CUP$+\
MMI89T^_+'FWM$$B%7D_8^Y>P*4UGLZQ/X,Q^7/N>L^L.0.X"?A_N-8BX[GC M4&O\2CS'L-PIBQ^.283GXRP>;Y6!?XMV%0;W(](7 J>8Z$%!$I6K'V*/8XY+ MI
/&:#:CUB3H@Z%][VQR5ZAO1B#!B9&G?))H11&;THY]-9)5L8UAN[N@0.3' MDO8>&)7'1D%9_7$@'?<4"7YB3'\8KVXCF-53($EB*W'_CL5? 3Z,B1[I^,I M-1Q4Q4^-V+F#!">'^5\
[]O:2(_0_#E?N$E:ZF[6R]X-!GAQTD'_Q['%C>,=4 ME_U SM"K!GX7FLT8ALM]4U8V_&]0DAR2*B%4B?U7YB0'PR+!N"(/2J%RBK'H M'W=,*Z%;(ED9/,7D?^+P51,'F_:E?
U)KN3WN\FST MF5Q>G7^[O;NYO+@EGR^_7-Y=G),HT:HUQ2O;P]8X-K(B,[S8'(A\,BW#&IO& ME-QZ\ '7R=%IKNH^=&$X%AA@]RMU;I\,AQ;>9V@0[C/4QW;C5:,#KB?]R2SA
M\.TWRYA/0&(G[YBV]S_?E-&6N)FA"?8CASS*YMO,/'I]=T&T%F%-F;13XK,7 M>?O9=MUW9$;!1B"?G6RT0MTE%C'L<8(GEJWSU$?#!3&@_LBP)&0*@UN,C>#_ ML?W4' 7L_I7
X$QT6XE%/=#(\!4E;Z=L0H;G.>;]G'NX()MW],4(.E*!QPG2 MZ;SRQS[!BE"Q0=B^RJ^CO " QQ"L*W$FF/>#6U-]#YXSMP#5]C"(1SA^X'%
M<#0/\^GTE;Q0%Y_"NE^98_R53P(S/;#N.!B]>7IS^\UEOVJG[]B48;8LP8.I M\K0;OH9OF/">6CALN,^T)T=L*6"H>9ZXV4B $[R<\:T>>##N/%C;XP@?IG!C M)+@)>,T?
ZHJ@(\UW2>F^%S*!0L,^0V(Y%'^76B;,>$+O891S8*XC MXIHHH7S"<5_)D@*AC!9IGON?#?X%!/CR ?23PS.C2*;;,DRT#79^--8F_6WA$ M[J,V8_&<'Q3M!0N'X58P
,BPH*.]!1M+Q[G'Y"];D F+E1NO)]=Q+;]OTG]R M)Z\@BSZ#P6^FSAB). >MWLD9P4KY"W5+@1M,SZ3N!?HX='*+G,+W_>8N#FC'\7Q\37] V@XBM\/A;:C+
MJT_!/E0SL@_UWJ5CW(OZ 1X2<&!T&ZJWKN-SH8L0;G:\2XM8/&U9#)*(7,7/O?5)8]3(E<3 M8+SQG">(W2W\Q$"Q<@.\6N[_+08^XN.^8G'6]<,Y'Q"3)?=Z,?BXA/6E:QX"DV
MI(+/W3L$DFC_^"3X=$/!UPY/-2+/_'4UM\1=+\$F6UF*;[?GWV$*W]F#PLRA MA_TQUWRT@%\R,$EKG?N;\!^12%)-H=T8-H];:;
""T[N;)#F2/O(AN9@Y:*/MJ#K(RQ!JNWL,DM&83 M=>I *X E4E7JCGG3_6C3>"5:P75GH8J(%15D^Z@7ZZEZL1SKQ1*E8JJ.2]5Q
M;57'5:UIADJC,M2CL4T242ES\9^YZ;WB39877E6S*L M=E"8-1J/Y\^8:*0"$(P8X9G MX1=X\H?I M/9G6$>Z:;4Z5U-HS5KL&=[B4[5B9?!^-7W)/I_:/DS1S7KN>#0-]BYX-G7ZF
MG@V]W1LN=&5_Q$&W?>A6'&S^BGI\N>#!3TSL<0R@M"'24YRX-TXXR" "!\;"78G^+[,V=!6CLS/F#V.@:],=2/6OVV @N4 MAE\PF2AN/#/8*3OF6Z=.=&O\PNNQ^9&MPDU\$?
C'X N.0D5M M=S8/(C<#-JE*#J/;&-8D@5$$![$"51T&U]<&[4)&5\%%D4.J]A"R;RQ4O<8P M[723XAYYE++LP7L?]++JX"NC;\61M]R0ZR2P]IX0A"DX+6,_"(^K3AZ5LH>9
M[6%FV>LL,_[RA!L\]5MU=@$&32&NK*2VUG)/3"5Q/Z6UFP,"[25 M%62*9Z_PF+-3?=+ M/.-GG>+Y=4R@4_XU7;8UD;=MTHT76V5;+\K4#8G[2,'LC$GM53JHSHZ
MJ0JUH5H;.$JHHIPE.P)D$YCV$VBWJNJ415CJ&A/NA$J2L@R0D4)64:H3KOF MDQHYLQULWV'S=C$B(:)2(NPR%5NH29S]F-C7[#;&!9X@*CBO*/*8=2B5$[+
ME!M];JQH>H4J&A5SULRK4Y10E%"44)209H1JU[V 77?CP8,K(.+\386<$9"* MVF^Z?X*E\?LEZ.W&,+5=E(I"=]MY+X*;I-QXCW"3VGVOCFZ2>O,]PE6ZVH&O M#%?)N@$?
82BM,>P5R%$J(U*SF$-10E%"44)10IH1JEWX(C"GE_;"5J#3V8$] M*Y00$?MD+,XX:O<*K,]4_)*17RJ!M\#2'FW%-O*PC=2Y#9]K$'0ZW\/PBFEV M81I94Q<^OS#0Z5YWH!
(76SG>APGHJFBA:*%HH6@AV1!3$ACP+^X\1(?'&Y<3 M37L3>T$_V;T^F5E@+>XC7>9$)B,V].@E_CM#,Q??L$&=\/3-:20_@C[]O=&L\'^%@W-V-]BHB$WR/4,!\;]\?
KF_.+F_=GUY\^C MK[<7)_XO&9,X; (G3=$"7FLVWS0V2A;%C#V_O?TF[D? VH==.,S?P$+\MI89 MT^_+GC?:
(244>CUA[U^#2CFQX3,/RVBF\PDE!OFUH*VW*]M"E]6QIS"@QTML MC$?=S;;B"BD@UKN-8;([#I=@T3J/8%$1>7#L9WPJ-G8F?GME$FIR3$*MAHD1 MFC2B?$;D/N3
$N'!DHSM &&P[T/K*.32%,OI'I.(5EJAA,(\IB?U3KK2C*D^ M2=0!%^.!_F:A&/C83YK$F'NVT UILM_IO]G(N1?OZ 57I_[8Y!%=V1]10.:] M.@WHNQ7OXPHJF$_NFP7TFL+B3_C?F'-
T^:]O/_/^PZK3[CXH)-)W?((LB5=U M.NQWA(5M%U9':55=)#YQYVJ//*%[Y(('TS*LL1GK"%_N&$!I>\Y<<>+>.'$T]N:& TS I_B(#N0>^8&=*%X MQL>:['$8,\>TP<>@SHLYWJ>
(OAW;$.Z_(V.'3DPE(OL1D3O;B^G(RCNU^1Y1 M"2BMM9>%"S+0\>VWX]MC\BLQ+2)2?QFCX[154Q6,.54PGM-QN(!18P6,NBI@ MW*DSN5Z9 L8>5HATM'H@*=>#7ZI1P-
@'QAFH D9YV*82!8S89DP5,,K#-)(7 M,+:::)[ZK0)91A4PUJXX2-%"T4+10M%"LB$J3*I,;8KK3;M .?'>Y(>$3I5O M@_96J#"P594<1DMK#%L%'G%1')0'!U4BJ]'2&\-
ZY#2*X"2%)2VO>,D>R+<: MPW:!26:U';2UG^6?55BX472"M?7 4#!ZP3%LJXA[7W7RKI1&DZA%?<5=!VSZ
MEZ^&JQ%/K;&2>V"J/6R7;,Q*'85>62'U)+OKU05NRI>=#F;_Y!"QX10E%"44 M)10EI!FAVC'V#M1[2/SZ"U>S6V3GMHVV3K,*)V3I&SDX7-2OS'4\N6D
M&C&2;#JI"G6BK8'*@%2'HR1/@+2;N2= #J>"]!!C#$4)10E%"44):4:H3K[F MDQHYLQV'NN!XX.%P/R&B4B []K:7(?NQL2^H-8:=IHHL5#V,6I2ZJ)ERP\^- M-8U>K*9146?-
_#I%"44)10E%"6E&J/;="]AW-QX\N)BSM]4T+EK1W$9 L\M MVXDW&\.^VGO/?^^]"&Z2T$_VLD]F%EC#^TC/.9')B T]>HG_SM#,Q3=L4"<\?
7,:R4_@,C5X,Z70JNL#]O=%LL+]%>S/VMYAHR UR/<.!<7^\OCF_N'E_=OWY\^CK M[<6)_TO&) Z;P$E3-(37FLTWC8V213%CSV]OOXG[$;#V81<.\S>P$+^M9<;T
M^[+GC79("85>3]C[U^!23FSXS,,RFNE\0HE!?BUHZ^W*MM!E=>PI#.CQ$MOD M47>SK;A"*H@[6F/83R(*M\!=6_IE++U]7\D1^A^'NU<2UKXR:W?
+#P9YV4CZ'.YCGK^/WF0*_R<%&Y*6OO^<<>T$L8ALD%@S#W;_\3A:X8?19]6 MIOU(;6:Z06?9BW^-R-<_1C=?1F<7W^XNST:?R>75^;?;NYO+BUOR^?++Y=W%
M.8DT*:W6#*]L#YX,RAW8D/E-F&DAG_S.X^1V >QL3\S1NZ2,NX0V=H3MA/9Z;[ACL\=RA:%$^3NWQ7\N\AW;(>V@W M"
7O8(:"ZLPIOP5L#9V,O'3CU.MU%YZ"UNX.]')]N,S<>'UW0;0.82?IM%,B M%LX](5'-F#Z#[A)[&HXP/.8E]!!= 7@]@SZA@H*";(P?W*!TJ>[-
"1WQ1KPN9^0U6N@Z44LPEOC'4%_%50#4P@N M$:,Z7C.<0DCR]OX=N9@[0!1_&$<$K-OXR??]789)SR\Q+!RY;1VQS\0D_@\L M_ 1<8:3@& (? PC%2_*#F\885#@F=?<,'@
MWN/HZZ7+E\AT)N!*@WW!BWVF9N$5O \H9,T?X)>Y@X@&+G5>S+%@!>"1O",[M>^Z]G\(+(*H.XCJXPL,U@U$_4#8*@R"I'L#KL'$J,\>>S,<>FPY?A]F3 6L\
MIG.6F6#'90S+9.(-GNWC$].ZQL.#.36!LGEU/=&ZX)G&*,_66% MCUX)K*#Q^.C01W9-^%'&/5 UX$>A1"R>(8!+@7H/IH>/P*EPJV?B8O(^(4X@ MEB&V1PD&?HYHIR-?
>$+4E7@$3((+DFP0&XP.%]RX(I[BCK1'K.)^&U*Q*LY MW[LN6G'XW 16HPZ;JC6F^^$@H7#\=0268*?#3!>)]T @E(.QBB]AI.'I@'3" M=S?_8SS/3L\)_3D#N<.%O&6??
E]\@_VR2CXA*T#ES5Q^LRATY0%.R:QX4UL MN#F2;7M&U_:_@E429A4(_+Q'T43U9SP*_PWICGUJN$0@[[_ZPH S @Y><"BH MY&?\'IO:+&X%B2+N$Y')8<$<8B]%B\8=.'R:
=+Z[A!<$JX+*Z'GK7CZ^<'9U'T$;_ M]84>OINCV:(\>>F9SRP7B3^/R4?#Y;K-G8,OQ)]XA([,%W@!YEOY8DV-N35^ M0GT&+[/@I5_-%U@Z>,P_'/N']Q0,X)B,@-B^ZX$F!SPHQC?
68I X^"DUF(P8 M\%)XPU0D";$($:3FC'-5,.6(VGFT[AV M S04OH4F57% 9WW,$)M>\!_..7@V;"US,4@'L"O:T"',M(ZPO-6 PT-4% MQ]@C9_"JB8&:UK+)U
8Z.PMG&%8=G2FD:.0%5[#23V3$HGQC(:+,5_LG^%B& M\\K3 AHK3FT?DT^,;?&%:'=#;^5DB[XKC7M6Q@%L4388(3J7]Y1:\%:TNI.4 ML"!0$6RIV"H+D3'Y"*8A)P-?ZS]
[P7^,0DF.9%0#/\.9L&I>1C9P6%TA7H2" M1SAFY$]?PJ^.:3,3;=H3M#1LN^?)@.O%E,:&RZ@.K,9<3&&]%L,(:1%A._GN MAT=>J>'L1S2NK>AT6V*^@E<-RX*)CGUN19\
$\43YMS .*GKL;6&"&"1DGC+ M&9BAEGF!3W 4<_^Y[_8,+,)IB6O/1.Q=X%D;+,+PHTS^.D9LH!IZ#V/A)("7 MA384XH-%!/E@.BYRW/0!61JFU &>>J)_+Z^\V?
@;BO2Q^0/^P=XHXXPCF0, M@3E/Y*L0C_46><6G:L;$ZM7A#@>?'+ ""A;U^ MN/:CAZ_,4<.]3%1 ?BQ\9X?SO(5G'WO14+@=V2F+;-[Q9=ITTXT]>?G[1S-P M;R>+:[]KC:',^_T;;?
>G[?9'CJPF+^AL6 ZP0W8R6W[7.(YDW^.CSCQ864H0 MLJV"'TN%O/5H@ILM#-OO3BVZ";&4OI$&B13Y2"((8B\1K&8@$GSD)TVQ5XA2
MD<+4W=:;QN^KV$84+HL7^!1RJT3[;B)6VS\X-TO3?;?^H+TU-W 0A78"8YX%H.JJ"8*&;5SD1UQ;]-[^EL[L+CJ'/Q4R1@1VQ[MF4Z21UR;O;3TVG?N#W!/0*0(4H^V?
A3)7C^G5Q@R>0?;RQ_I>B?]1.O.&&N* M/S+Q!W=5Y.",;F.H'>E=Q1E2<$;$EQ)>U)X9I-<8=K4E2"T[LT@)P=]1?3"B2Z?C>PV$6!H M"2R5I#;R
.+86!GM81C0&^I2PQD_C:S).7BI4WO&0)3X&BP%8\ M4!P/2&A1<9.AE<2UDMFDUC\^CA\A/0Q;^P]J4<>8@G2-)L^F9;)#*.8+K;C! M[8&$-8MR6A4[5,?
J]AO#KN*#_?"!A)87H>^KE9BNC7UEJ*3AL2:JX?A:(IYG MRNG"9.T;*SI%.4?'B* OL> M7L%NJ+9M_F?K]=G3=DL$"ZSV!?\Q_P@A-2J:[^EIC6&O7?UJLTI07R;76(=X
MOE?]395*T%V^=$ZOA6G>HO95ZQH2[-!(J3+CD]TE5310-"B;!GO*3Q>E!#=Y M;E[7J/&MNN;#!H!>W>QX7LOZ /6/F^L>I@> = $B0!!D^W J=.>Q-[[=_D M@!'+%T]O,
[B\)0G5C>Z5$;WNALXJ:IM*)3 MJ72WNY4K25(6-S2@XAO791?G+)3L^93,R"VM3-S27L$M%>CBMD4WOJI-<2O\Y6>B2+C/=0QB5QS;='^&UF0?@=[!7A=\G;
M\T\B**PYA?"KV$9:ML%F0XHK9S\T#PDHC M_!Y*Y9\"^U)*P)["#P8']0U'$OQ1^9^$.FJD$&\JNU%6=(P1D2 MUA7V&L/.H*@S5^J%<9O3I+[-E]LVSU9F!)]M+KL#W%3*4W3?
U465+X%F.#R;5JADE&?- MLHN&5J!H),Q:3:#.#@OY55% 4>#0*:#.0"CTX]QQ4"5/A VPF6^O^BTB*D%] MB1)?]RT;U6__+(2=)KNQ
M9$W6(B$KJ.0\KOFP%+15(0@K!&%I$(1#E-*S V-+PE_;P^"ULL#@[8ACUROD M]ORMB0)D*0>0Y0I^*!0\Q3694?#:BBMRYHJJXX#Q1#!1 'A[6G\%@+>GA8_D M0HG"OE-
&LX[8=P=Q($(!WVT.7Z55HQGNH-,8=FL!QE,+_I!IP[C;&+:.>NVB M.J8JSLC$&1)N*?<89F:S*- (=7Q"0=]M"H15%6O;1YVJ%X86J8@OIRD=-(;Z MD::I\Z?
%DUTZ.ZDWFXUAOU]:XWD5RRKPNS+0JJIAQVE>:5C%7D, M- P'0IF>,L_R,8F$YKP%YKPH?:)B7H5^MP/>555L%>5+UYH@O H ;V-=G@_2&3- M-
2UG!J@+_0M5"/+B_NF:7J!&2%CSFH!\'!;FF:* HL"A4T"E!!7H7S[P7Q7) M_VDM+-7NZ=5/_%2"_C*%"(C[=J2U%.5+H;Q\&3ZM@ZV72\OPU20F.#3 ,T4# M10-
%@S7Z++;S()Z.H%R^%EL40O^D&D_2O)C]HU:*5>"\Z0<+^AS[8:.T4=-E UQ0H5*BM"C.S6 MEL$#];O=RNM4^8DOD2G5L7S[:-"NOBF5G^SRV4E=:PS[W:*JMU4LJU"ALKBG
MN:.X2&YR=;TQ;-<]+A^K"*3@<:JR6[U6^;6CTDD-.=M,.?5LN:U,=H*%6HS M'!C9;7*G,>PID(KR.4$FDXL;#S78=J@<#TAH47&GH5-4%6@WTA(!0 M1*$]Y0/NLBT86[-
G]']WLWNC9+J,*BIQA5*(,/",+$>PH&&,+$Z0_CU6T,0XL:/#ME M/;-/KYMI>KW8])X"NRP"T@'[[U0(!DC/Z0]SXCT!ES7?G(ZGU'!0+I\81-G* MN6PQE5ZFJ?
2C4R$)Q(AP8!O6&]IQMY>DG_]Q&&R",+2)K& 4'PSRY*"/]HMG MCQO#.U05Q'X@>*07/;D/OQO#J."L6LYH262V0AF&,7 MS(,$$XD*$6)1+[G;-(_[I@1A8,)B--(,L*8>
[;_B<.7&3_:0K9[F62[Y\MV M1J[L9^+*P0JNW,AX[9"3"2T[2<5@6<^[=Q?_&I&O?XQNOHS.+K[=79Z-/I/+ MJ_-OMWWY//EE\N[BW.28+T*3?'*]N#)GHWRR%*&$'!-R"?
3,JRQ:4Q) M$(&YE9[FVV^6,9]@FNG=IO/XF3*/GY%Y]"-@.)LH+Y*+91ADDD%L>+2%,NDN M=367.6'AE&K[32:G#$3MB<(%TZG]P[0>"7,HRSOI%UV
M/<,)EH&]EAM;$1#Q3\9SQX'5.$/+'X1*YC,XKA@&P= (M^1DH+^)J:P5VQM" MPXG'@5LQ-68N?.S_ED8(G*G#_IU$G0C2 U]S-T(M KBTYZ.L+D$ R_6UA_"L MV-*VU-
*JI97_66H"WD6RXZ11+I_$P."KB5);K,3ML\NK,4Z^,:=:)5(_97T MQB7O#< YNXTU8R@0>;-0T,X[="3Y[+D3R7]GGF32+RJ3)(H)]@>7+P_E]ZS,
MEF+1ELW>Q0UD9ZXG$;ABD4SQ7FD&HGA0\6"JLB_Z0.K*N:X=.K[4E/+?:;PQ[[278VUN2 M8ADQU[!#ZQ#80?9CS(/&L--;N%'5Z^+)71 1>D?+6 MMO+6Y(-
^:G<1P'U)9P>EELMPVB1DBAXP18&Z63'%6M]-0J; 'C #I2D4)BX(%9V(;Y7;_G[:@LF45VD(U\P(S7.V,2C;! !2#OI.4?H2*+ ME"-49)%RA&KS9X?
LPIWM&5/BT)GM<,P;@6JD,@S;91C.; >6$MS_?J%';;M MKK>6]&A6X4(9B059>('MN#?U)5T"%2^4D4^0A1=PC_A(ZZI=XCVF$63AA59C MJ!_U!DN:D:D]
('F\M*_,%_.A(>T'8K/6HTBN%],S_>;>-733EK0)W-E/&TVG MK,N@+V62= ?LX#Y]ONF\=W75SOFQ1E0]R\H:G<8P7Q=.<49&)TY6SL]9,49 M>_3HRF&,C?FA!X[=DJ[#:D](I5-
5EEN1I1J3EG^$BBQ2CE#M">V\)Z0V@G9* M, 1>GC5AKN$HR-7LV3GLLYTAK;BLGXH7UJ88I&6. =\J4MN&>]PJDI4YNDV^ M=U1<9*F88VVF05KFT'
SJ9]S[EIM)A7@WHV>8;+@UUFV1XSIU!ZS[F.>'7A\ M)P7Z>NF$7IT RN^BW*(P->!*#;@F$6"K1!4!4_DO.^EPH('?:/+GW/50'WZR MG?!Z;!3^%6-C=?#.V\59V,-QOS(3-
^*$%4/<%A)7U>B52-S4*L8XK8;PW9; MI5SV0-P2)+<#Q"T0\:[N@4]I7LTU+YIS7010,)]GANFP>.>(.-3UG/G8FSO8
MJAE;)?,".R#7L_M;;3V@)74R'GTQ3BX7ZW,37AT_\;!9&KR@PI=/,%[1-KRC M8^8AWWKF=X>B57>C=(&J-4)@'1%%E>TLF$<1*C<;PT&K?KBQ52%S2<*L
M#4!;]RJ7):ZM3_0/VY[\,*?3D#]46W=G=63AK\1"@C;>["\DK.B!0NPVU4YL MV93-1Q$^F#_IY/U_J6-'B:KA O1U33]-$!8^UP;M0M96T;?,;$]/9U442G9+
MIVWQR9Y>JS'L%4A9E>S)#S;3L!Y-A+1(9GP.S,7AD4&P(".V'J%(88].3AO" M 05273YI2]"4+"VN2%L::4MTESWZ-GTP M@!T5!.Z1R"6H2P3@58=I]D'D\OR=/J9B52^=?
1*Y>$GNL'@9QH.T0EBB_%ML1;B>,?^_)Z^#MI26<1RR5J"?L0"94T=_BN'KB4Z M-YB"[2AY+9>N)[N\?=VLMO2\7Q$OE2NH?#F1^#MI7=+ FL@QGF?5U1Q^6&Z
MM"K2D&6$BBQ2CE"11&D!^R?3,JRQ:4P)_3FCEDO=(V+10SW/>65; M=M0-O."KLL\P7>S-#)KHY:N]U#U0N0Q_WZT\U MU-P'E"'4_] S?L)3Y=A7_[7479O%9LTGQW[FQT+FX
N*W1Q8P(]LI?AU=[A.7TQ8 M8--[O03W$$$\1]8D^I2+_\SAZR_4>[+AFQ?*L6-EV:IO#_JX&U2K[;Z<>49Z MEBEG^[\]Z-7R5,7!:)@]%12T!UUVK*V5+Q)'O72,_%Q3]!!KM%RQF-5
M=0IP40M<\8D]1V J6:.%?(98M2A.$4811A%&$6:SS ?\:\!3H\,3]-"T-[$7 M]$.)AZ79"1T_$X/GGXG"A=C0HY?X[PS-7'S#!G7"\SZGD1P'+A.$5O?.[T,Q
M5Y@E3H>,Z70Z,R83<&_^WF@VV-]HVOV_Q41#3I3K&0Z,^^/US?G%S?NSZ\^? M1U]O+T[\7S+6;+)G#1/^:RT9O--8Z,L4\Q=X+>#B8\Q%>:/0F/"'! LQ&]K
MF3']ONRYIQW22J'7$_;^9=V[GRB9&)Y!9N!X K7I!%T_XL",\>$W\!K->T) M>3)>*+FGU"(.?3%=W@+2H0]3.O:(P3]$7]BTQ+WL:F!:2!ZZ^/R:B^RJN*;7F
M\,S[5QC4GT@+QY[,QP+4RPAZN9Z(!?"7@?O@5_-G(-TX%IWZ[]!)BX7ZWK#W\EBCI\0C,"RG\U=6 CJN!]?OXKW0WQR2YT7&$2R%6&.&*L&9BXU:H N=C"#4P$?=4F0H&
(@(+7]]_F)C5>OJFKY< MCKI)ZC%:A749R'A MM\3_! \&&,;BN0C^Y(B7[4+TWVW_K4S1@MFQ-3QADE-YL>OV-R M&A;/L(YFOM0N:B3;8)**(3*8G(A9V$[?
[LR;-5+:EFOUBG,MFHOB6$.M_,J5 M;RFA5*8DA37>?CN^/2:_8MP$1)GB#L*[2K$*<\ZV.U^Q05I'JKJ-?U"+!5V^ M&Y\U?27IEM?J':]0T(C;77C1OTWOR0\<+WZ.IW/D.\0MA_]-
[HR?&U54?!>K MZ7ZA$W-L&A;\@EZ,ZW@B$KUV1!PZ^FFZW[F+RCU4$43S&^8NCO/6SRQ\G+M M/->_QL6;"P'5PGH-[:A9(*R68JFU+!79#*T^2PT:PWZK6JBSVCI7H6I:?O3/
MZW_];WH2I==YW=Q?JUT_.XZ'IY)W;5 MA%-O#-NMCE+S8%O M409I9X/T$??Y_C)&UN0.),2:&%53)VTP37L!H%!,M=0R59ZI.BH8D=9VG5U_ M'?W?ZZL+I?QW5O[^4E9-
/+N-X7YZ\RI>6JKSJ\I+O<9P4";HC8I&$AK]V_^[M./]?I["-?W;_^ED]5)XV+D#^$!5&9IWXP4U>659*1!8U@,0#-SDDJ8 Y]X^7JBA1 M>8C4PPF+[VS/F*K3-OM*>19CS-J-
H7ZDZ[5PD*K*(_EE,XOA$08]V!^466%0 M(Y?G,#&Y%"WDH<6'Y?AH&PTOY$GT(X>9$T@WH<>E."\QG*>UT$#),^%<*5.F M6ZG?4MO_,X!HBH S#=/0]?
SE"L"4;P]!J!L].6F^!38"6$LSU@_YT*V0 !"H'5G8ZGU'!0-I\:OZ^;S3:3T;--IA6= MS%*7+0W$NY6-8=HK&*9,A,-44(X-0)HN_C4B7_\8W7P9G5U\N[L\&WTFEU?G
MWV[O;BXO;LGGRR^7=Q?G,72]:DWQR@9/';$:(QU%%KT_X_=K?0TWWZS#(AH M8&[O-IW'=OY$=KVRA12VLTEA9RM]DL4V]+^#:?A;.2A_Y_3A^#WCE(0_MB' M7^
"FZYY;TY-[_7DR9Q,J!7U4QF7/Q,P8#>.ZK<\]HS&&$7_ MN_"^:S>;;1.GZ8RV.ZY50G-MEM;,!B$5@V/,$PQE)TA><>)K3;381&KLY,N"X1E*?
S_ZS*^VVEOMA3)+7H#.+6!0]7Q$UM: M#VL*!JE-5'?CA)+H'DY'*9D\4)FL%:9I2^NC3+9[:>TC*RJ3^;L>-?(P.'QJ MG=V*U4I:Z;%TWZ**6)O:
ONE3=1T1DJ44QW*:HHBGH31+%3(U%4^8L* NPJ MI2:14JL#8+"N886[IC(659VAL45FY+&PY3&6L"VZ]W&4*]3>E%E-&0%B%?*2R+E57W >[W7
M&/9J%!\I23Q,2:Q^QP"]CV50]9%$E:FH6F\"I= D4FB5[[6@#UC11:M&*DW) MXF'*8N7;5;2:3!;[K?K(HLI0R-H90ZDNB517?3I]M+#E3B>MIUI%-9@2R<,4 MR?JT2FGIC6&
[WH6<-0(J/\2.((H2LE!"I0,KUY-%057(X3!(WF.FU6H,NT?- M;EK+M(KZ 4K(#D[()&_2TVHWAIVC=K=&6_6U=K8/LQ.-HH4\M/BPO"M0V$W5 MXXU(EHTW]M:_'2*4?5_+!&7?
7@;^'IH)]I>4"@M^T\FUJC@YV0!V2S&]%W/' MGE&%<"\1EN_=DT,IX>CVA ';IR#YWCN_I^CM2L]; ?=OZ/DH3/OME@WB8ZEV7!1VO\H+AYNW1S=?>"B5^4A)-GCQ8A+(
MG<9PT*M1 :B2Q8.3Q>@>385EL=L8]OO=^LBB*L9>=:1+8?4K_;4=5O]V*JX8 MG=5K##LU4EE*!@]3!C.#],LD@WVLMZZ/#*J:4 5FI]19CB[%9O!9,FFT 7@5
M*BE1T1DJ,4SW*BHGANTFB&&M2TM5/B+P'VZH.S,=P[.=U\/8Y5!*K,2MCA!W M":U7?GZUK36&ZCA*56>H!#+7_0XI!%('@52)BP-/7#"H@]^4JZ$T6SZNQN;0 M&?
DJM4\P\>^:WFX.^MH &XS4"?E;2>1A2F0NOH84$HF=,9HUDLA:GY,]1"@4 M10E9*)%_E72]BJ$5_(SR#'+QU8O)*J"E/]+KA(FAQ.O@Q"L/Q[L8\>HRT.AV
MC8K^:NU*'R;,B:*%/+18 3G#,4.(IKV)O:"?Q)])NL ,I"9RPE0DR6-#CU[B MOS,T<_$-&]0)#R9.(XXT1[IAT OE MW$5%YR?\#'N.&STIK--XV-0I=4()OV MF[AFAK4/VUH,-& A?
EO+C.GW90]P=HA=0J\G[/VK]A^(PTVWB\=QX0/XO^E, MR'_F0"OXUGX@Z.;"EVC!*;O"!D=E ME$8EF?62S+I@$[7[*)D]O4:2J4X#*G0B50&-\I9!1VMALOM.OC\ZJLS>A
M!'*KMO.5$L@.=IS7:E29IX[*:PBI<]R=# J!Y+2T4"E=0\7K$C)9 UELN+ M11T=9+)7Z\-^*E>AD(N4%BMA6T0&H)1."_197_D82CIK))VU@3'J(-C'0"4U
M#CRIH7",E&JK&XZ1CMN^@T%]5)MR/)1TU@;32!^ =/;U^DAGK0]B'R*23]J[J M5MXYRS]"A6^D\(U4Y6;9/GPQZ89>8]@ZZK655ZY$K1ZB)BW64:>/HM8>U"CS
M7FL7^S#Q=>1WL@^3+@KW2.$>28Q[E.?1XHT&EIA3QK>F S4]F(]K$0LN(1S; M8P>PIO"_$9J-I]1P4-,\G3X;/\,H16GBLB'PTT8Z*K1H_<@!ZL080X]+8:L8
M5R69*BYQB2/OW"&DS*^CPPY/._I_!@L(GZ&39UIS0SA*\4\6P%B1'['+F!MV M!V.XI5/*?*[1;$:MB9<+ MQW"+Y?D?QQ&SYDS0@]*45C3Z3RZOS;[=W-Y<7M^3SY9?
+NXMSLM225V"*5[8'3_9LE$;F MDQL>G9!/IF588].8DB /XE9ZFF^_6<9\ J(]>;?I/+;SD:*J*T4W)138%E+8 MWTI!@,@?)'1G7\L$W=E;!G89@:,Z38.^+ U
J4A$S;!'F2=6Z&$OGVQX:*5D MA"]15UM,/X$I 3G_B_JG)102FQ1(;'?@F2\#*TU!9,/<7#*PJ/0**##6LJ 1 M%39GS!,%Q:H. M+F;T+#9 ?
I10=>D0:M<(F$F)XF&*8F805@E%D8$*U4<45?9"0;$JK9:C@[$9 M[*.$B@WQF&IT9$M)XV%*XS8@K!)*8P?QD>LCC2I7H3#0E/;*ZDOLI)>D %MJ M#1K#

*T9"J_@,E5RF>Q4UD$NM,>S7:'NRU@ -AXBVI2@A"R54AE"4H:D*BGU[`M\\5D&?J-852=H9*Q,CWS8F0,(N#.0*N/C-7:U3Y,S"U%"WEHH?#/%/Z9 MQ/AGZ7!BWI/I3,A_YD*
K^9I+'U\%_A*>)DMD^7V9CD*?"(%2KQU&=NA7ZP M_WA$1RV? Hl0X!$5.45Z%<+!Y(@1#'|"(2]HP_82<6F5$!44P16Z@C3,J.SB*
*M+N@*Y%>,\A2<@M3;C0l.0>V*+. ,#5/FSV[UF8Z@=M=LU:KV=42B5@-9+0&L& MKM#3F(#]JJ_[81Q94/ *2I'5!EZAIS>&W<.M@E)B64.QK '40]_5&+:50W'@*
MF0T%M:"TVA)GDH'[7NWOMQK!5(PP9Y6\HR:P'!$:OTQAV:II6D>7 MOZ+ZQ[O;H.?T;HT.G2<70PEIW3 8VCT04KU&X"BU/AEVB$? -<]6Z\LY9-A&]*
M"BD%R"]+-J3R\XO)/_2QC*+?U.OC%-39O5.^M7(#3], M4 #Y'?'#I(L":U!@#;*#->1Y6FBCT24FMI5%BT-,/)B.ZQ$K=%)W"YB)Y.&E M"-W4VHX]&V>3I^-GV%XA3216858@$-
*Q')+LR"RUL/W)N*C&1 MT. -2^" &?DGNBXMFXJ1,8]AI+2](C 21\%B^M@H*#L1%HCP/06?#41X^L-X M=1?+^Q2(N\A,#-A IX(XH-
*1#"N)T04%T898!AS3C*E@[!O:2(_0 #A^4('RD M7:-#=!\\N2@X_J+9X\;PSNF7X%-T;M&]_;#[\9RKDQ9_11+TS_NF%9",45R M+8@LXG_B\-D(\)%]*;_EYR97+N?=Q;I&Y.L?
*HYLOH[.+;W>79Z//Y]+J_-OM MWC2S"K#8$1A/RR;0,:VP:4Q)$2FZE MI_GVFV5 * ES>[?!/+93CCRXNYH_LV.2T7#WDV$Z_S*F73(V8&](@0R//"QH8UO$((X_;W*/ M$R< & M.Q-
*F5RL..I4.057P(_1'"!['MYM<**E4'M$)K%X]:42B@Q!*E(Q^:1"W8I020 MG4*YY3/:!SX]37{(HYI30%<4V#,%6HH"^Z!_]'"D+A8]NF>T:S5,FGLB(1W7
M@UEE6H;"]'_YER4M;)>"E79R)K@CXN%'DM)\?2C"/WV@K5 M(P8W7%]SN>G;3YNR[Y9BJ72=1A77QNT=Q]86H\ZKD>TVJRW:DW7?]0E[D[=S"FL].1<+N9&T
*MY>46"\.U.L-]*2UDJZ< B^"]RIOU=2B'+C^*49OM(K6&Y6-TFM+P%U:+]3U ML/@&,RHO?6N#1<'8O(4D_'/=]H>NRVTR^;+?]JM? M.V^#]4T#//%.F/).U:)45>
*<4HRLZA>]*RKKHI5GMZ\-*M.TB-7EMH+$EOX%A M.,.8HRSHWJ, =AM#9:N565*+{]G6D4M:](K4%O4+ODO+MIU3QWPQ//-%)=C4 M&&4>H_+
*(UXER>)CO73I^;_Y_V1.X)TG_ <[XSMH]EO)*F1F D#+!\J "Q5 M*D&-4=HQUL_L]TJ+WF?H@/&2&?#A?AC.A#F3Z)G5*O^N@HI,03 !=F3 M&_H6R0V&P0C1RHWAT=L?
QBSR"]5X-" <&+.\5!QD4H?(I5:% 8K<:]@.$?OT M-"Q4!Y\]EY\UK*Z5R\. ,J/'HUQBJ-47GTRJ-7+L@6B_)V4Q\D!$%6CE\O
*M^)D33YQKO2AV|W402UY0V#1BMVF!Z\EWG^)=C;A.B5XIHE$ZM2CU6Y0UCK/?;^O,?KXW>7.NA0"=A>4G M\'2S1{2M?1]}673>'73;[<:PT\DWZ5ZG\+-
DABF0T)V"""9TTTC7JM7:(S745 M)10E%"44):0983UV\P^CS7>I"""]YWQ%/5;PLH-W+LO!=&R#U#IJM3IU O+ MF1O6..5YLL.6VX^9V,&%>-<%G&?
@"#R'7(ERK+E.4'<%G9XN?:+X*EB.8C1^ MKS'4ZWK],BL@:Q2B'V;,,,44+10M%"T4+R8:88G8^:!W!57/+A1U?52W3'U% M>]/]HWI;2d0!U=MRWQ10O2WW0@'5VW)-7*1Z
*M6ZH"5-7;4HWQ,,98V?("U=M2SL8$W1WMASTL85-K]E6M0KU"\-7ZU%]E2.1 MJA@4K2KJYZNKWI95D[>:],9L-UGSZDXIFF>KPW9J493^^(OXQAE=DZR=P9:>"1G
M"S8\I_?>DG9^Z6##TM#B6GE9]>E$;J^ M,M'&JE%D4,!2*,8!A6TQH=P%FO1RD=5?Z@Q2CS&RGK<\K5];2>/R#(3H-JT MJC%6:8SU,_NJ3:N*+_8>7V52*7[U5L,V#5HEZ3C?
*UK#W:E_E.)0XI46:UYQ*5^3]R^ZK<#& MDJ\WAA+:,A6HD3)[.0S6*I+!ZA<4RI= TE/0"OTF"2}\L98I3$J3UEBE1P MNWQ1UO106K@3O@4P:4D9(\&7(YORB7/EF<^4J8-:\H; ,S
*M?YRI($"N>V8_WYL6DY&%/)R%16=5U!2MQ)*T M/TJ>W"!-3=Z@)O!U.7/"FN M3U8H.JAW85[PV>8\H3<;PW:O'H%]%11$(8*M M:XVA?M3K%]?F:QVUM\#KG-
*AS!#*7U3',9X@5B%$4+10M%"T4+<)F!_XUX*G1 MX?TP\)]X3A+K:F]@+^]&(>6E8K>-GD7[R(HR/#3UZB?_.T,S%-VQ0)SQW<1H) MSG&9P)>X=WX??
*<)OECE=,J;3]>CP_O=&\'^1KOL_RTF&O).7,]P8-P?KV_ .M+V]>GUU__CSZ>GMQXO^2,8/!)G2#/.6STIK-<5'.B4Q8\]O:[^)NQ&PJF\O
M'!,7I\M+)C:Z.7OF9(>D2.CUA+U_*43=S$N0AT2PR+&LSVW/+C!=8GW!!_]MND.#^N9Q)RPEHNW\,8D(34Q&#I][?JL38RTKQR#.@N.FBS)+^'B,BSXAAD<>
M(#HA+QB>B%8]%N5!S _3>R+&^#]STS59%>=J;O(#BJOY.W7,\186(K10]GC M>C_]<2G+'EOUY+',3*TS&.*YUYY1$=_CJ?S"1UV>*-8__%*D0G"S,?\"7
M8T:6.2<%!F%W1);.N4+S/=1^WJSP\- N)).1E[IJM%L1JW)XMKO6G1P2Y:% MY7ECRX(?A43IGD+0"*(T_6&\N@TQ_,A,V1_A26PRK90!9YF>'IO>4Z %1/)\ MP/X[%3(
*GD1(;YR.I:2]+]1PT$EY:OR^;BY;3$7/->56="H1#DXHA;"$;,?I)^ M_L?LUA]"!=S;TTGL)%WX>_9UPEA\,,B3@WF%7SQ[W:C>,2M@/Q!4(Z@K/OON
*M!.RP8/45*QGE?!:C_T]@ST**2^BMQ.8(2S@$PR6+\8:>DR:K"5^O?]PQK83R MCNR-&'//]C]Q^%KB1XUMV**5B2W&PEPX?:$KUYFWKF]^->(?/UC=/-E=';Q M[>[R;/297%Z=?
*[N]NIF\N"6?+[] $U:6A"?1QP+7L,7.7_VV,\E9I[%J M,FD^0S@:_S\RBP\!@D%?##*A0(MG6.$)N/0T[%N!>L5/PEX8F%\QGQ3/[=YP MX2'PBT%FCGTO$L."IGCZP73'&&#\
*(N&OR,+5_0%1A3%!=$SRUNR?3#;_^F1[(MI%X.KJ+L^,>JV&_8K M#++<+V'SCE6Y$?H0Z/ D)AACSW;<(^.Q^"J MNHN5<<"1_]0.?
S!L9_9&.\J.09;\)JY9U05/@NYD//;?&$%D8I@5/<^BCX;!KC3$L MQ M?%S7F?'>?H>7 (-1UI,M2N "6&/@3. V=A6LNCUWQLR'!_<04:S8:F> M9Q P4C;-
"9+#G@4/YC.%Y4H=/H84#P%[SFQT %#+P2/!K46%!_P?K!(_E!N: M()\QFZ9]CW-DRT ?YU,#2/,.O#S@)-S@/N8$N5/NY@[!HP>":>B!)'$F/PY M=\-
\SG%H4&32N9HS4_1]>/G4Q$$:P%&"$7*OOORR&/;O4O;TQD$.WWQ[_% M@1%^*;SA%[_N[G5&V2'4+[#$S_-G?]WKP(TPMK3-OQEKG[#8+]"[:)FANTB
*MA,XX3FX6O4&NV_=2&C_35V+G15ZWE,VMEA+\/BT)2?V&,VZ@UPU4;8\Q3CX" M@9V.4:,@BD -,F&A4W8$+J9&T1BQJ;M!(@!RBS-JX UHKC8C"#_F1L.F/WIZQ$!]?
*0,036H&M#.LD_T, M+/[L-6?KQXL4I1O\(S#WXB;_<{J2,0E36:=86.-6>3YF=FD]9\V>@ 76811$O M!Z2H\V#9;OS<5;4 U9\KV?@Q=264V_(#!.H3Z
*4L.?:*P"'!T(1^4DM'T!1P@\"4]#RTZ)BQ8)/6WK-XC MT[^PP3U+@N1GROS.G"\;2'GI'7QH-%4?E!WL*V@$)Q8K!1X,Z?X37P)=Q M**]O"U(9Z<@48!!C&PP]C&F9<,3T \A'ESB
*+E.,P%7F.]."GIBVAW:? ;#78EV4OAZ:]>]\UB5X4[_*0ITENXKS),IMT>V\: MOP_7;OSZN=:6?W7RWXWNU]/O9UL*N59@LZSBF1,2XBB+9(T1QW(GL0WB2' MQ\0?-
*K:1.2QN+?B#(YO%)]IQ$,LO-#]ER;[;TE96D[U5B)7&LL29=QCS)A& M@Q @#%G>D]NVM D%33+A*W!+9QY$[B*9)W95:>-K-8\(*LW($/(AL^*6K;B% MSU=^EFD5O3+E]{^4
*LYMB]IBF-EMK+$!DO'>VV_'M\?D5^9,!H)\UT6$]$TBK_AM G$42XT2C"€<8+07;&:/M\%ZM^(@P>[G"_HC_HX/[(' MZ,5P0+\QU#0-IICB@&,U;9R5IN3?
*]MO>]&M!8A7"H1-KF.KW(*L2)\NJVNB MJH:#OH^L2:!S%KS&DK^IWT$1EN6Y6]%LERM[Z&;SNF]=\N3A7'XR#)ZEX3@-M4%!5@DI+4Z4I?]{@Z#*8D(O,;C-
*T4]7=E';+3[LMV(MCWV91:8N[)JC)^]PC MF58M359GA75#)_29<878%D[?*ZN/&E1.2 Q4]MHM%OGZ(.2?"OX@?UD[?@ON^
*MY$$A1^4U;'^>_"1_2,I;>!*\?5@(5FD&+,*.*@^N7##P/7!A+UN1E;)&K&J6UY-X=E8U?5BNJP7SZI:]9, <)6X9'DAYU^QW?/4W$ZW2F'DZ MI(M]Y.R_[X:"_9SXWY: "^;TMY M)
*[(H^JF.V63RO*3FIN*9!N[NN0:CRK-7H9FEXJ'M,.P6O0/*7]>I2DK**U[M2449N+++]Z<3D8QH46%Z7S9NA*A58]8QUD1L?YFJL H<G[:U51>GKI TBE*/KO;
MQL1[O!NAUD0AC12#.[$<3S,?"]5N##N=?&W4?G9;ZTW8F!EVAQCHHK7RF MA[#KWY*C, ^V7V40Z.!DZ4/HI-8W3!94_O;;>"2157(UKT3UWAJR7ME;'"W-MKG-
BT/XPUO@PR5T'S!2_U8N# MRY#MYZ[+Q_0QK6Q8N,T-JX1'U];<2;1!YQ)CE@/#S;,.^,GUO#CU]5..P), M++ D/H$O.V):,MWOU@=^?0 'O ^G$?'TV'Z-
*%ZT_65>5VCM3&QA]T$H/(B"!O M14=27/:QFXI?$3$#O&/%8M@)!36(<-?A&,"Y/CGW 6*Q9$G9BLO2$B=V27,]^<1:0+2SF(CN2(0!P"M[_B!$/_HM:(&&?V&7N=_UO!U.]Y$%-
*W>9N>BAT;Z=8CLGHHE.3N!]V,]IOTLG MIYZ>I9-3?[=&3DMNSW_7N2)]G+KUZ\QS$7146PCA;U&/-)#T]K%EUI$]
*[XU#:I_4#AYENKE&W70P1_J]N,\!^5FN0L(!F\C:_V9+77HBO#.QF?; M>L20!-^ZK%=\;@U%.CV],=2Z1YJ>:PE3#ENU>G0>)]^\EVO/?
*(0'B1=QB'L790VFR9895#B\S7>+'S>Y3.=F.H'X'> MKKR^EI=@E$DI;.I, &N2C;]>TPI$U*4(^K$,ZB@+!H_9G-SB.YLSYBJ#/]P M(TX1,X.8DOVC7K/Z0!YR$K&HCM@1(O88$?
*O=TEKOU<19.+33,HH&^Z?!TA-+ MX>?UCT/E!NG5!WI01!_L)P6>C;^9)$HJM3>RU2FHDRPYG6195+?\,%Q"@QWW M>U:Y#W8+'P[_P1C_HAX)SR.QU3-SS+'?!"]#@?
*C*2M(JE8QWNM%JL27__HW\ M[6\)?9KG4:L/[9L",.Q1'P[V=%*,TX_O{6U:,?S4X5,LLQX87BATDGAD<1IF MG=8;DHU4$$GJ(*V9IH0:A/V*V[0/O?
*=O)_W_5Y.Z[59L27N"R_;CVT,+.\'N MOF!?T:9VJA]_^!OYD+)!O!YIE*4LP<6"R)2A+96902F\@Q'F@.OXRN1O^X M^)=Q002=<<:.I/9,;\GY>W9MO;R^LK,KHZA_^//O_O[>4MN?
Y$/EU>C:[.+D>? MR=GUU?GEG7_-S<7MM\]WD+KKQSN$;F8,__=A^\\E54TG)[[+=,,?* M[F,#."9WlL2-96,4XN2TJ ??_<5@XT69WULT*1X5Y>=4\5)C-G/LG\SX3U?)
*MJW<$[A^ASI.I_4IQ>VGLV,"@G7[P8CRZ.G>?V)OO<0R&@\_$$MZOB8?38'9A M^N/X!5'!IS!P>S.@&WO:$YT"PSSC>5B*BS>%-,3G'@*+LR4J-_M*?((@0F73WIV0 Z=)M,:V\
],=@Q132P(#7/^1.\=X(7[I)HK2.B#=IMMA2F MRU:,G8_!97+Q\-, &A^CVL#\R0/\0D_]-QYD2L%E 9E-=*BU-[W&\#4IKN M$Q^-I-
*FAJ*Q>D7X@>NP8^"G39+7WTCU^4KSO!6\;AQ-DXZA M+VOA'7VN6_UVB7;Z+B+5E^@068S$(*Q?N'P=DPL#B!L,7[P/50!X%%QF4D'G/_$_8S9KC+M>@6*!3VQX*[/D;/2,
M\V&ZC^)0^SUH)CR.SBG&>1P$_AD/M,)\ G 9S?_8SS/3L_9_2'%QG413@R_M6.S_86ZQ[!5HP1D$-.9_?9/E+!74?#C5W"$?<6&.M68.8.!M!PR]W D[E>,,AG/OIZR1[F.K!
*M8(S8M6,PUP8*1ID3/0A5\T?#"0>KA0B+65DQVV512(>9MK^<CI[U.XPT+?`M0/B8!&)###[.0_R0(T:D$(E0B0O^P@'R^<3\#N $>!):%5[%Z>&^P3Y[\ M_09<3:ABJ-Q7\\5F4
[_<.P?H!-N/50WCZ]EJSK@F"_&]SBS_P/!]X\M>5" M$A^F*X89"+^]B/(?\(,_Z"N9@94%)7!"WIH"!V:7%EC 2WIM"-?AKN$1&?WS^E~_N],3OOV_MB_-=GA#H&(3;>
*]V1$TK#FCF.- K@UIRE-8)'^5EGF]@G&3BQAZ?$BG!F\R MV"&RL.:]GYO3_|_>EW:W,21K?[^_ L=7ND?*H1B"N^(Y/D?QDG$FCG5E9V;N M^PTBFQ1B$.!@D6;FS<0!%
<0/676"'!1G=U5755==530_D&TOZ6{\SF M)HBX(+@\V _6B0040/^OYA?*6EC.E$EM*IX69R/-F?R)Y;,U'L2 @.($*>BS5!+;5F-G%3FBC^X6OZ\L)^E/.B8=2LX@7= MS^84?
JQP\/QL,'P!02EX.H@ HD' 9@,-LA KT(-(6)5&@.@-7F)$;&"WLA M4U_=,,,=4965$@C#P[M#DE H&CLIHL ,]X C8&)XVQ6PIV_$2%A1*7$F8!)SX=7TGLFAZ504D\65O2>)+E90Y M3K]*A[15#-
*^/Y1P'6G>?$L^COO["7XNS%N=5XOQY&>.R() 7& L(<.Q9L]9L M9E"'.5-"_HIC&O1DH]W//K=*8]2-E&)AB277W.R=+QH_\TS+/"^J$K2\;'G9 M6EZD?
EXC&:MV2TF**U>]P1!.;2PY2,WM#{(O*X0/WZN%3PO?OH1OI46T3!;[M9JNO))}-Z^TEL;U$$/NE"^)0I%|;TW*HY7!_K5OV%TL M2_ 9;B5$FOTU^V_%_N_3U^'&Q'N4X-PRE+
*]B:CRY+GD0PS'^R_%Q8%Y7C.E" MPTG'V'GVSDED#=3)6;|_?Y3)H#R,YWK<,W+6Z>6$2TN'EHY]2, MG&)O[>LZ*_05\\'FT?;_;]V.K9M:MH|GR^AUO1%VZD'=%6,AX:3?
*RQDML MCN.CG:PU?M:L%/?Q-6-KQMZ6L?]%J6&X*9BY-/:\(=W4HVEA^^1#@@WCCP6[MQXU&<;>WEF[?A[<55#R$R?D^)3916]JKA^BMREX%?7?H(-W@)$D&".(&)YKS
*M->>7R/D,&-7 7B(,'6FCRU.^LW6D8Q00@H]E,9KO(SUHI>;C6 M\]#E86_!FJOOB^,X6N7EV"\,1G MP-B% =#^":WORL1G@R:3N3FLSL:>^N(^A5#(VR1.Q?S/+_"LK)%]+]W:
*<9Y0 !O/J3,?NVZ MG_>R,Z:7>5WKM_(W>_2*N9XL\MS)5H0H34%]@BV,5F%I1#@#@>GGKNYE!859 MQX2U3)L(3":#PXYO!&.YZFFQTF*U+[%ZJXK'4O???"T7FVJJ[EUUQ0L?
*=WK MUBK1FQ>/P4:36&T>?DU5+I0U;+N65)G)/% :1[XG5FW9))>3]X&X,.+SOU$Q MK"RRA=|/,@4RB!B ?>_?XR(1&L(:#+#!?$ 5&/8C@4UP%(\U)<2G[^]59F!?/\-
]^3FLN:N"B)BE,1&2=@5>;+$;;_I6I"^%#ZKA3CE/ E5A(L"N.2 MN^1 5(5#U1V"6DB!D_\#S,V]WVQY(N@CDG=QIU>S<'VMD0U"ZSZNL!*C]Q! M)
*[6E6(:E^&YMB@HX1&E#*Y108H%A*.&ZF0!.Q) (0S%BN!]C$]*L99ZW6?%XF!TQDPVZ)2P#2ZU"]_3X0HU;@61!@IW(8C@(N"TPNXX), M25'}S1_)XY8]V!
*[!UH1;,1^UYNL:AE@,'=KGVZV(5\+5OZUB(:.@Y@?]L)[4YWIYN#VF\+VC_K M\<,NM_6B66WECU;IB7647=.2WOCQ;_?^CV_,>1++>B/^.49/Q?U3AV.6VFR(
*MM=*VQ32GJ_KM%9GBIOYL.CZ!+)_OL'>E/MS/RE{4CMV*[9EGT^YKS_NQXC^*MSF GW&:SL\U<2I6?X[^=%YM4'VLU_!++>?RZM5K[3;#2V?^]5YRO6=>&.W00 M?C-
*K_>NNYK>]\ML.3FI^UZ]]?%88\Z73*XX0=JE1\U&3\O/F_9+-SJOM19%+CAVS[TRNO(S9112 M!>H%)[Y?GH2ZQ%Z.YF1)D35=.;%5A[]I6:$(ID<*:TS_5]HAQ_'G25B;*Q.
M9<(,Y01CMDRN>BR=EGA<<]A'6HNF9DDY19].FBNW1.8NS-532=7@IK_4/6, MK5Y[*U=7Y_P.ULM+SJA*VUU^&]*EY]'A^]->KF4>1KG8HJWN)S?X-
BV7\#2&-4%LZ[\2V!?56YUK^PGN:3G\RLO8Y+E0Y5'N])V(RZW! M5H-IC6#;'1$$1O@'YPUZGEP.]^ S\)A,N:3AY8/6QF29_%6]22+P*8F;<_ M!>^?$#C"'N0KX./^9;%)NM=^)N
*H# 0YL!2#>B#!WL4,GJ'&2E@;/-I^2 M<"(&%.(OW=L.X[TQZ)F!VII1HK _M9^!,$-/>,7WWN"SX(0T2?&,X*PFR#B MMSLV?K7%/.6P&WC(% M6D&81IP*L3\Q8Y2D$5D[&\
(1+6&XYBZC|[.I6LI%D&1#AISC63G&H"=M>9: MA&$CO=[Y?EM U^).S\AN'2_R_1 ^_^;S&(B^,!S0VFC@G;=,U'ZO"4&G?JVI!#_M0&GC|>?]PF%+]__OT!O>++G]
*[^_>_^/&_K[Z]W[F]_?W_I_5%@XD<<,OVAEMS9(O>!KVFLHMN7[UXW)X#GBX+D'VV@>LIB0MW_M\+Y4(%RC"2VI3,E%!*J>HV+6&M?M"J8-E$B"?
*JN"!8U'F#=Q%%D3+ZOXX^;7 MS_\OY,H]^A4.5>N="}H/07;!8ZCG1Y;1&MP9<8)Z$WYBT-BH4YLE6T8AK;0N&G;RI EI=LIBTMM:*Q7(RJ7X21I1U7&LW
M#71';ZMC9!^ZHS{@#%H3D(_;$<$3?"CH4$I[\BM[OK_*15U2(;8=#HFV 3A7!_T+=A(5BGN;#XVQ$N M(-30FX'Q9@RL:1 Y\-4%#]?]PF%+]%&"@=K'/XMB!849?
8ZL#>+PBJP MREX;%7,T?7-9HWP+?(SOL#H=:)>N#(>XG>.%;FP 'BG8_O6V(E"G#M_BD& M!$EBOOM3L7&[H!91^ #+_@N(I&8,O_JG/0B]OZQM)DKS7$@T;,5=,7WP$8.!
*M!\1P)QY.$R:7(9_X3V0_6@YR"\SK_=2^%>X6TZ)9]2C&K_XVZ]L_G,+-Q,-"M8V15+PB-_.9ECV",0)H\" $("=)SJ"0I*W]KQ>L0?'T:,%$SOOK1=Q#';69#
M2TTT(BJO.SN,OEO;K)$E,JT/0 L8H 82M;!3A5 W/J[@NQH=$R'Z?51%/_#M M:4@-THDAK2FP-I(U%#EFM?-C.HW+NY!YP_^"OT+=NA@OPGX3RJ[@E_8%E!\J M^>"7O7KW"-_
*[Z/:K42$4B_0H=D)!%J-K;;1+_>+C2)5?(*9Y?E.(&O$(= M1&_TC_^\^/+\;0"]WJZZC/KO$9."6NE(2TBC0>@+CY@0W!;4 M2H1TD!;
[,"^/G2NX^)'MA^$BY3/%^!J#U%N[*T4P&\W=\8L?7",B@.\,0, M0HP9PM $NZ/0&L &"2=2.5D#./3$V *600$,X"P$AAI;EN_",NP@L ;V/1S MPB0:6/[=C'L$\S<(?Z4CWQXD?
*4(;$43@%V>PHH):D*I>.2??6_W&NM0EIYL M8A(6,/TZ_=5V7[NPV9>%]QDS !3,X!'.G(E8I[!H=?_SW_VFV7L=&.*[']} MOPG$I8*7+S|[A3\))$L%W(P06P/_/Z3TK $57-
[.K:;;KU^S8?;K1OPR_,IS2:I" M^^KM+W>W()?W@RBT7.%%@:%&3ZASP(0' MV2,1%M^GMH]:G5;?]!I62,L6EN_8(H#7P^Q8$07&@P5$OA=@P0!W9#I1]H& MF&R V&
*(^_*9F)#[7/'=*A+3WD>]-0>_;YP'WMPR@>[#H2UQS-3T?.%8H3QT M<*RQ4^NSIU7A?&NTUPM)\XPG801&*)L4I< 9+.Q_5PJ$JD!ZMCL2Z:5W7 MC2\1^#MJ8BA]-
*#IHZ:&D'R,OQG10C$1#RYFDM@,VP1?C"-;G^3-X-9 L0$R> M&3&1V31FL ?2GV&AQ]>0@0!FZ>*57'CW",[%"XT118BMV38S&^N'Y.W)CG4# M_A]NDWE] *_D8WSBXPQZ-
70]1K:#6'@R4]!9<907YG!]^O)=OX1 (8T41 M?PQL\@G.1&OP .P4XF8ZCA@SNP+[OW=LXS?8,XG%1TT 8:AZK(M5KP(<4: /3TD=1\/%O,ISL7^3@H>C/1CU@0#
*(^ET_5>;TX'Q^126S0>*E-);&A;<%(0')"2MZ53 GS[[%APE:HC;.MKS<_JS%JB#L(N^".E=9X1.]0QDKP_^?H@&!Z\"H81 GW4 QL5E31[&L S74 M>BK=1R$"&L;_6$LQH U-
*L";C.,FKV9<8@3$Y82'\9@147$1(1+0K0]B2,KS MK>T/D(WA73?1. I":=MVR;A%W6C\&?EXHB!)06]8 @;+@T,?SC^69 L-U:%- MIQ;1,V;KD?6(2&*N\;OWF$(BN]8I-
)'MY&+O90(.11HBI 6"4G_$=7D(< L M3D0B_N/SF?88#VGK"18)7Y^9O6X>.A7F,K0FUABU[&6E8..&SXZ(AKW%+8O(LN(:Y-QX":68M3+D7D4[H7DL]J3Q'+3H3; M-
*4/R.$.>@W_G%XF?\-_,]_LM2D2_5!LL5P5N$#);E5$KNPV-6BE'/B'4 M2K)N+&GXUI0/@A8.+8Q/80]8&HYA9'}KR"@H6??D;!PX0XV?;FX)#.+;+& M(J(@!%@)'}U!G921U*T@A)
*[S]_X--O+ K95G]6DP+'(!29XCJQ"R@'D28HB3=XN#@X1%_,A]$^S8\$3V%82@3@N%Z(>:01:R|+-#)\|-VNW M28_X0BOC5=''2%?@JW(,Y\,$KI M#6
*1,V2Q:87AC^2A"%#*655L+V=&:+*S2!G*$,%4 9@ MERI?^@YBQVV4vBh'_V13';)&(Y7LE0V3[P+39K5),HHWBAV=CL M0N =D.V)?ES470!?
O\0W MEKIO2-%9I"R%9)FW5]Y:\!1.7F$I)YB@SK]4H*ZI(!$X@D+09(MHL1RD\OG4<33SV:3]=/S'U"D1{[; MPFO!^3=37%.2^0!B1%=#J2EDW,6$;+C;G4;GXO[RHGFI=!?

=)O_="U"(9,!8 M7<[*3Y/[V7=^G2ET)X;#)'+[FW7O^9C"@):'^O&[N]_BRV%NI(2Y@\;?@;7" MAP%*E'J2OU$/UXV?X_S&!Q$LCBD'M10#)TM2<9AX.?*E^'Z8#VREJRPG=N+C
MQ2*0!)JLU*4(W9&-W'AN9Z+1-$=G%J4V7$HHV5"K7R17[R'AEQ;38+V3MDGL^\Z0/HK;_XRF:"GTO'
M3A[@(J_+Z&AFC;8@FYMM_O]$]MQX6.4$CO=0NMY&MLQIT0351*;49953H&: MB5U:-]ZJ(%:-=0,[^,KI5J,F(R6G4MI'.S)G/('4+#GSNIMOL)IUJ3%
[0=PV._&U#^($J9DAPWWZD@3$ @I#V414F/\0".QX4]GG=1 Y%B88 MQR=0G+^YA%'5?I$_Y:3?PN^ML>T-Q]Q7,1B1F[E%J4/-^ 5DT)UM5:'$]S'W MUMCVMIJ*(B.))Y?&9
K;4JXW"GZ&'Y(NN&BF938$HVGS@1KQW0Y"O@>*H[!) M>]U4O(9#;Y[K#1R*>&.&^;TWI+".VHK/,*G'*-B6B/\0@3V9AMMLQM'I'\;G
MR^D>OFQ&;7"%4C)+A[Q*2;IHG7-.13\?]\NF7'1[ST^YD.6LG&^!US2P4"Y< M8V_\GBL5[Z, ;UV2TISTRFK)L[!,I0Z8S^.FSQ,QM M;(YM!E!"/
MR!J[+8\6G'51D*$S[%@$\A!&/@42\#9W*/"J4E"/='"9'#4Z,;C\>Z:^ Y_< MQDJX!_3=0LR/Q3=-'V8!3-'"4QNOE! ^% Q]A5NZ#[T7C!R*%\UO MA>CTCZ(-LFQZ#+X\7:\P]6_MJ:
V]H=I?;RZ+NI))'=!X>**88H4Q=[OO<\Y M2VF-,+=5+[V=\75#MS,NJ^'DZWG,G&]M['0 ME6=PX[J1^AM#?D2%G_D X$^_6(X(^$]+WEN@7-"#<'1(XA7O0;V@-2O][(+J MY"\O-
[2\?V"C>]M&NZ5W3ST)9.];:^" X?-=.,8MIFS &WZF?(E;5([20 MX &T'Z(1_6Z!0C&^3'UK9EQ_OKV--RJWRU_8+G:G-'FS!9DZ&Z%;/_##]J> M*6+/A'@)#^J'H&@_*JA2;<6H]EXI^
&V"QA:,02P84\PS8[!W.,<<4SF4VGEOI&Y6EZ4 M-.*+*WZZKA(>8\U/"!\SO.:^A=P7WZ8?-^/=*=Q^X*D@I X C"(;&#'H/V9I M\D>^P%Q%RGZCU$-
&Y*\O8XU]PL)0OGF"/8SP)TGWA3GDG*E*,UP"98Y(M_"' MV>S$R+FR>%%6.#Y9-B5<)^@IEI.&R.TV#2S)X*17]0 A[B# -\&C^V+DB 'C M ,<(.P1#A;G8\#:1I,JK2="
<4]#8U#)'O0>!9Q061G:VG&O.:PJ\B2#<(ZHB ME,5F$\\G% J7"EM2/Z:*MP2;5VFC "%O8 'P6RRBC8OVWG]7!$ *,>:RK+) MN41(*FQT9K*(.1 Q 3(31P0
2G)A[ENE"Y/R0+7U5'"8:6QQ9IJRSN,^KO.8 MZR]11[3W8 F;^Q.4X:Y7PV@>H M>02(U156'\69.ZROJ4I#XDGAZCH=F: :I(L#@*3]3CI!56T@UU#%K"L919X@
M=H()92V&8/1\KM].%5:_]1PGA6U%$\DL@' @_3 "8;19V\C""60FXZR7W3R4 M76(.8JYGLJ1 79G M$J,1;R(6 C"*1_)R:_@(0Q,
(,8QS+Q*T/6QR(JO7J:7#GRJ=7DKJYRB'$U%]@PF;+9I%M9 M7#D;"W 6586=!#@ O:<:BVW:3)CFCU:$GI>B.#\')8@*)2X!#29[[(%-%K1P M0L;C0[W@$)
;8XDKH$<$YDG9.A(B)77LX4&'8#6$L(58=0R2(QR!>BY3=TO(M2+DS#W\N:Y+QR[7:J-6XHA,KJ3&+.W4@X("!!I7@0[O :&:_<36T9FJPM*Z4 MR$ *ZQZ!?%P&XDH751F@;?
$SA=")O:("I887P(Y4M'"EUWUFX4K[F I7=A > MOZY4TZZ*)@T85S[PWL@6/?&V]EK]>3N+_Z MB#[BX,5D+9=XZ]-IM/5U="G"];/MXM4S_/<^R< U.\9D?!(B]DE\"[U'6XO8
MYA>KO:W2Q_35ZO%?;NFKU;UXQ!OV!^D C,AF'0A(T-EQ<"L"%6AXD#=SG M;M1J1B"$"MT07F?S-:&XO$UC&-Y1:\! ?@__)[#A!Z-F,N0472)7 MQGN)&*Q"/Q1(J@#(2?
9B\1??"P(L ![9X8$03G@*4YX"QOS'%*166MT@ZX-JA1QG) M ^DP&1=+H&[NQ*,#6F"XA9DC<7H+])(Y1FF6RBG630>2:#4-!:J>Z5Z]%2JB
MV3%7PR+.27:G>\QR_8'BYL.D%SU.!2DT1\)5Q-$GW J9^$++^71HF5#3*%\F MFITYJ-#L>=?-"T6SW=I$*-9I>E#K$T\V+,+.,H\J68*;+< 34I_64HH?W[=] MMLG0]L6
LC40D#J:8&E#)N7$&I+&9T1+V $+M#[#Y49QMT;*;?)\ZK Y]JU) M%:#JK_16V/3=;-XN&?7&[%XQ?;[H/;Z;2%+G;JT!'P)
M/TY;KPZB=>:/MYJ1UX\U8XZ;4&PQW8BOA6'W/4KYB[4,]0.7[Z\;7^1$Y&N' MGD!0_##)D)M@?YB_DGOVN'LF#Q^*-8I@)P9!,>*N=X-Z[?YJ@6F9.8'I],PR
M#P5ISJ>W7F(V4_Z#-QH%C#\J'U3[CSN1WWE*^1K:P2#BQB;WWF.U.PNT=!;3 MD68Q;:?%N9EXK'KVK)B_9I!>%>:VS*57?G4MJT]5V$7&$N0"E)Z)XY'48R83
MCHP3VW,ISK+[0>M4,&2OF\]+Q>GWCRD5YUC&V,594Y#TDC+S(_#.K(*U]V5GV)C;@2:> M5SI'IF:VR\J2T3R@_%RE]8GD8'7O>YK"7G3Z=2W E#:OYHLG0_:F@^_#[KU
MK0Z,/:C*$S Q.@7Z956):3[0)N=&65PGH4=+ZUU092)T7KS)J2.< MR 5;R8(V.1-5^9E2!1T,K&[XC?P&+O^[MA."'>#RW
M=P=:7&67.*_#4BI@^KU02L&/NR/4,U&+*&L4LSUR5>7IM+KCFL->V$Y3LQR9 MUW347+DE-;7_O2R.F2E<^:'JR46MGHY@OGK3O*YO=>E5Z=RB5DO?EY?+ J=K
MM+;X,!EZ$19\'.A$VV 2QVX@O QZ'MDBCF(2FC-W1\^_:1RX_>#_9!B@O07 M99KQ6X&YE5=FGC#6WUY8)ZNY>-Y1[G2J,16B]$_ Q91H!M2FZ*Q1S^*.(?(>
M?'9.U>L2U!\V<\/>5,9($$QC\:X(;ZMC@ ZL-=!O1L02%V$8B4 L!WC7/JU)!TG8J?3$-! MK$!]^.@:C@=": PB'QMMS6#=_B2H);!M";3<_N+4:/R(+!*<0W MW$/L !?#R:4:
MW\^OF?_U4$'F%49(#IN+L8XQDHUE'=S\BU M.P##K.Z7$B^95N6*L6K&9L-64.,06);X/@"U-1:&;X7"&#FPG$@V$8.!SKHY
M!G%%B)_B.$8T06XYU)0F"NBNR":E<'HYV9.3Q&X@ K7DP\$5Y23;9 LH-D M"'B3A$2C:]JD14N^^TNQV;72D^LLG-S4"^SR)_=%"+0HA-$?*ARE01K7#?O# MN
/L=14@2@RUZ*L HE%,<^#%3]:?H)9N8WE&",8$2.PPATTA-(UEP!FPI@FM M:9I>4PH<32-K_-1O/Q-9X_K4D#5V-"5 YXS M"]IL;0.K4A(7[N!]J0"W1GU95!^1:]U>]02-
ZTHF:)1(@'Y?EP4@\(FN"BA' M05 ,\B3J #I:,%Z]:1]/-<3AB- Z]IJAZML5;S_?WOS[\^_O3T-S5-&F*)T(
M&N<$_*;MDAXOM6&1NB8.IK9OA9X_.ZSW43:/=+>R/4]$4+K:S@!ML141]J$M MJF]HT(WS8>I*2G=:FQH6!5UW306@PK6NKCC=I9^1NLZ.%T')Z'0BA5;J-JXHI45
MB=*/.:V:?3_;NN^G'/G8^GYN52JP)G-L/F&(LL828;E@@< Z ZQKPD3_>]L+ M;'B;E9007*)0;5@;5I/%8=>];#OL1:5A.ZH!ZY_GB[NF0 P1/T3E6Q;\.(@< M*C&"W?DFJ("TT.9ZI"
:/.!3MCMRJ$3)H@L0$021S[I&:0_^+3<,5B5A"VO) M?(%L!W-RK,@=/(AA3.:5I3.'8!^93I+CFT_A X[^Z#G11.Q_#SYXV%$<5.E$5FK?>U'(U82@;4-9
MX1V*04A$"H10]5OXC]E\G6W4K8J;Y)>%:YU4'5BZQ?7Q<&*2H;],[)>ZLRI M)6,H$JW4.<=!\& R*/MVZ#F@$9EHBW50P6K3C":"QZ,!:QJJTL(IH/V:*/4 M3JB@N=3OT0+5?&\
[=HBMS,$B@]%=+DQ$.\B:VK*_,LY'T_'J+I\:P+3 &\7 MV>2 *N=CHC+CLN>:\54\HB)&;4U["LNSQU(>QOAA&-?@$IU=7*4OQI9/9Y=B MCZ/CV\7WYF7Q<+>QDH>+ED
7.5C5N*P_GUE;C96\"QG?\6!!DN/W7M/\C I2 MJ4.-W_@(YT74L)9(PX;Y\Q!8ZJF#,PFV2^N$VZ;S:3N M?0H_>;00UD)JI<$EGJ+?@S%N]!6 ,M/K MD[?\;40)0HKX=),9-T)
QX!L1MC)2[.IJ&LR<-;(XF.10:R71=(1H?-)-[) M)4Y#S%R+;!;2]V_3M>1W=,XE9DL CB':WC#X.R"1XTU)*U[(MF27QGO9)$(9 M+K)F_>AUAY0S;E%YR]@]A]$8Z2Z9S\3_"?
GK'O=7^WA];/'Q5FWW=_$MM^W M"&3(PH,O*[9?29SDR$1=V:DWS[-&(G8Q/%^S]J\/=G+V$KFS)VH*EB*+JL'X M#[RK"A,B 0&HCIBH+H1*V@\D*OEFB!D5_DP'9
XR)VN\F7FI:1ZST."Y@0L(M!KX]I9,#IH*$F:/T73J^:'R<5*AH#D[F4(EC.]4%:91O;0.S#3YEEXE,$VWMYIGFGG% MV2U)<1[5_A[4$F\5N&O)A=E;K8UL\:7Z-(N>E]GT M)
((IGZ4%PI<#(8;R4F3]?6R-X/%LRW$P[CD*!$%=Y3E';EHU[V@[^H[V2.]H MM]/H'UT9H_=%2*03O#B]2@UI?'E?KIN/A-?KG=J M^'(:HRX#FV.V#P-
2EQ%#PE8K%73NA'9H_^A.>P-2.YKEOFP@L94_6J4J"L&$ M\>O.^!_;S=CV$I_R1_Y'IK5[(_Y7FB/\/RIK9!N8,8WCM19TO>HE-EU38VU@ M=4EIY27;:*&#<$#G6D,'E,H!+
[WT,'WY>A(X :V&KL![]:9]72^M1GX_2K)L M"C2O]5E)?+"5.&@XMVA*LV6!F6" \-\Z2:G:6K7 \&YM,FY>[<]EZ]S$GJTI<4'C8W^R]:B M+>VW(Q=LAZ6L3)E=O8*EIX(B:+V:N:
MNU\F"YCZCI'BI3OLN'8J1JN&]]7T/$[#]6504M.SL/&J0;(U2/:;\BKB$\:* M^>J%;/)"%\@_.&O4L\)#A^09\=D[(Q1*_#C9S MZ68O+D7O'P4VQN+*Y!@#]S!@&9_7EDQ+
(03R.TZ"/XA0#&!V#QZ,)V%X4T&X M7BR.M)-89)W%_D6YQ4_30T@TQX48HXCG((K.#12$X!>W.FF0Q($'+$_P8D80 MW0>AY2)*@X'0.A(&"JF@9-A:ZX_R
+A%L:I&J=B2MC2K3<#QWS! D3%DKF3D.D]V1F-"WO@UR M!IMH>T,IE 'CV@ MBEE@AG;@1XP&)V%E8)?I_V V[M@#2:VG]T/.-MD!7\QIL-5,Q5@SO'>@-1^L
M1Y0>5!O1R!J$$2DJ+T&E@P^E^I S#.*WUXUW_/AF8!8U>E["+RHRQU3Q"BR" M<.UZKX-X,:A92/W'>,F)T,>]"@B,QYX@)JX/7]0),L\."#^>P&?QO0@& Y9"
M"BO2#KZEE:J"B@0S<>Q;B M-\ZE?2D"Y@%D3Y!Z<#QX%M\MOD\]]J 6BR& MF5")K/CA"8-UP?CT(2P6!"24,4@UDB9! OJ[]P1? M^&372-Z'F:L_ES:MX#GC:3;!XSBMVX$J?
\)L8$&(9)W&[V8F=@V?_#.$0,'A ME-I'H$YX 9Q^5OI\5!Q2B]GV7@@@O?6-@).$Q0TGZ)081C ,SB?F M"F0$*WA0]$E-*2U7=>-?Z;%A-^W0BUD+0<9CXZ8<5_(H&TO,QO$9#:
M1=?IGH!SAC8QA"6/[1!4MH3?CQQ)(. +,1J)1/SOHP"1DTFZU+3D5UF!4'2J M$5@AR!-\:<-Z,QOO!6&,^__[16]!'70#J=9+7:OL^L^XRW4^*V 7K$0#--3AG
M[5VUE#'[SX2^7]@*9@YG$OO(P'8F]L8BS#-I*7%+@05@^NE&"2+DPP%FL/9$ MAS=<<<,1,50'>WIFTN9!=R:_FO5[9CF!1ZM!DO@V8I[#4HJVX=JSC;7B?(B7 M3*M2X,NP*#
[QF4M6G&HPT%D.PC2M!=3YR_JB:%>1>N+B%NE^-C3.:M/ G_2WF2"K%7C4-A)@G?&WM& M_>&FGE$U\0&[&A]0CGQL^(#[C7(5[NETH(!7(8C!@FB"L,0)+3&#Q9P@V6NX
M06#T]C/A!J]/#6YP!\E:+P>(CI "Y?%-8L1_,V:@5"0(';AFF%*1!!:RW =W>DLGXHJ'Q#KAE>T-A/+)%;X/%6-E%MZ]>/ KE <^9]3B5 MV\!.EL24.WA?*B-'HV(NJB&?:U9=
[8SR=J^*Z<2E$D"C];QZH[%Z2M(/LAOY M"91*-S4^#\C%5H4F)T*$UK'#*E3?K$A:QY^ YM" VT@$CI9^;NL:?%V#+Y%?BR7-J^K(MHAGRA0NU=Y(SO^;&?
YFEZL+8E*DRG,^?WU+"9KWMA?8\#8K2?V\+%8#R#4B M[5[Q5/3V7 &)N;,"DE9)!21SI2) J;'(5%=P=8AZ?4#U;*H$-\B1^3Z(?F6
MN"3*HNH2$5"5%KQ+\5ZF.)8'>/2<:"*.LUAEW\4C:P1!7F'R=+%@,Z[;74#B M(LR>KAV!Y[DRNL:KKQDW6%P/&@@^48727[PH?##^X0%+U(R??>LOVZ%](%P!
MT"4TPPR7E5*QU6XM(17DR;T MT;%$C?+V@'='I0 M??:BH4++'V+5U' 6?,/R3]NBTR-=T,\%R%A>"LO JE(#!3@48SP\83- 5P8/ M]C0>GQF>P#>XW#[T[?M(U15+^L2TH/K?
@89\\@;$QYOH847[' .R8M4C]KHN7M M+661Y>RNA396L, "J!6P_KDQO^/3RA8Z0JN, !F>P#/$?]<: MH;%Q E09^)X_>5-R)>0A*NL3E(8).\E8L6A]%*^72AC,5#IGE>2]=?
+JRAC M*%+.5G%O:]^T^0":!R<;#'Q[JLY5I,D M^8[A7N3W\'_"\K$\&@3@'1B%CCE_(5U_&C*.*I&5==(4KG'NZPEF._+(K
MG!=K'-6LL[C"W$EY<[YG:/GZTFSEW>5\>*J[:10)'D((&83XDAYFXD"K $+X MX'O1F)&B%OL=L5>%%IET+RI[_]J>A0=FIWSKQ/+9J;7&0S ;99R_Q[S5"G_ M2-
W6#H4"RCBZ/(6U;MW$=NV)Y>3B9,T"CAOO4]&WM5(XEL; FB(9C3&Z&>2@ MIOT/1ENK+ L_W(F\/K1B-JY7^BV]\WP>LS=6 MS?Q9\KF=/+*NR:#.[%6S*E!#YKT
=AX1$($>*I1>PR 'O-5VLHAC-[P<_CJ A(W@B!5KW1 M2,$GHW4V G?02P=PR J@E>6PDXGS7*1WVFZS1B/;P4"U\4D,[8#AVOCW*= < MA-
Q*R7,,KIH!+ZXIM&AOC2@%TD&^QU/DWGL4^Q?]SVX6\KD58SYGXNGA@X7W MP[#<$*% @;08D0]"6CRP0XS,F+Z1MI-832W'"SG4Q83"E_&F6,1N"NN,7\?Z
M)R")'D@%?"]H1QT1\G8@HXYL'^;V8#DC*=X=1NRFZ:N@G%P!A28Y[V&2P7R] MM1\] E#]A>U]:=G/LF":P! #8.-[@LNU,+)&0*N^&..MA80(C9S01H!91+F4
M0+HP&J+;^6PBI, U>5HV?^4SY:W,IT^@)/&%UM@7B!'KIPB #SO. ?@HRF,T MSLE.D7A7<^[@R%K<'&I&' 0X6QW'\D'88/T=^GAQ.L&1!LA0:)#!YQ5I,4>W MD2.4Q$!GX?
X@Q&1,[4HD<)&XYA7. <[MI1'(?1_@7QF5W%(@<>J2-0W^S%1&%X30)FV? M#A[D%Z6!E#Y.F: Q4"YE1Y#)>X&-MR]KZG]#ZSMN&<(Y9QX !<17J12P@PD0 ML0A?
VO)=&"]0#T[1YGC U5=RD[34/\)W#*H%5O>/RF@?XL_E)8B^_W,)9:\ MIQW'[L!0(O[2))3AGC8)"^)?4D0[N?6U7;1"8AAEU6M@4$ZO@=TP;JJ?QU[Y MM!C(JDP_J[5:S35AE];B4\
LX1A8=U59&(X8(= I'BA-O1H_FDHM6-KT(G// M-Q=.R%UC9ON34-+&2I.3X5^S5RK96:C=JJGKD>S#\DUKGEK=4$;]!J>;_5W>
M)XJ?/(QY_#X#2#R!.4B[/=WA8.'%U0IHXD7@QWX*FO2LWU^1]+6">5\^1J3_!MA_HMRTK5:"T9 N6*=-%XDB9BJ!SPA-\.[0#ZJ"& M25E,&F0',0
7DL)\3Y[_K68,_6B,DYA$CK35X5%G=L7>KX4Q1X2;->*?#5.D MQ6=B,R+0F[EDIHN3'60:XYR84NX M$EXUKU5VXPGBL$!"2EYQ0L3I R;DO89QU$ 3>SATQ(*1DM_(%DA&-
$7YO<4A MC!:-85^F:9[^M7PJTS])+8+[X] ,/_%^RF:+H>R(Q:8^-LA0!(,'?& Y!U_Z M*"<^A3V[4E^ 5,#8DC\Y:U#$>QVP87JA?@DB8?OH=B;71*J=6 ML^,?)VYBG-\=JTV.&?
N$=GEU)Y:%67@J,)*Z\/'2BEMMX0"61MX$DW5.=)!K M[,DDYJVB.I!6H!\H'?K-7JYU\ MTGKGJ)/641\Y'BQMP>5\,8K,5^^!33>YC_Q &G'QK?;"S*P &%!YS[$ J,0
'2AUV:5FRIP(#W4MLU93S@ WD5B49IR1-';4L?(I5:X"CW$; M6*%:I2V[V*(J/Z2&#'*I5Y,=@G,),,XKCX/52RN2]+*?G&RJ(9C&?072U]O,
M0)UZ9Q.7IKN^W.$9OD':!V_N(=$GWK!/L4%^J[;NV6E>Z45LO'$_8PXV6G-S M6>/?Q"QSO/#-T *7(L5\^+O?T8^+VVG(>^U3:5W3ZSZO=4V[\=S6-=EQ6IUR
MQFFVSG<#T;3;M@#SB FE-0$H'&\J>WXYS2D-5*CCFZT5I9_L,=*\[J3\[EON7-85#C=?UV\W' MMN;6WT+G/C
M=UW$C;RH/OXRJSJ60HOE%8"\6@)C*_YJ6_2K5>*/O6R08L7L/;'V(O:G?8Z M>DVS5G[?18_6-SN,QKSN"PO\RZNOOYDW,2 V"W(0+;"M>QWP!Q:QQ(6)BB":
M[D4/[%:M]5YW>NUMU)HYYPD^!]7S(Q:!8^J=IW)Z?_:>A,-_OF.LC1?,YQ_? M?OGQR\W/-YOR:>N$^+39[N_W^+T3P=3VB25W??BF46%:^NQ5#/P2C>?W$S\" M!W-BNYL*>_-
DA+W[NMGO;GTH;22"G[#:8>H(X\LL #O8N E];[I#TTI#A>X/ M*O3YUMUQ(XQ^='.9&)1'_\5RO9&]%"=4[_D:Y5G%/?_D#:VQWO+G&L=5W/+? M"/L0L[G@*0JT>78P-
7,D[[6>=)'FB>]WXO?GY.$RUMUH[K]O6\I1>BITJHE M::'I5$>5B.5PBE%<,:@R.V39+$,P*T1.RE:@J^$X12S$\L2Y##$L+H,9/GF^ M,P2.$.E<))6HF!\"4^A2*468*O#OL7BT-
E2EH"%Z[=>L38T+(*D71!/KGA.= M_NTYENUO-2(0W;'_HB%K^?F^AR&WFZ\ULIU[S+68AC#\%WLR]5Q[BQ'C,8P; MH/)64QN#$3])2/G>#6>/MK?%D!O^U.!?73R*(W2SY=
<#3=.(]> M*. 152-)16^<=9=)<2/F!S_+(JCT1(P =>'%Y;%AVK*F*=/P+I$%7"4[!&L"^$E+S(H"A59A1+!N?V4MH4P:EM_E<>A65QAF?SL'8K>\ MAG)"-[*J=35$# A*PG+'-OH-
M-X2.\#%!1S@ $),O!A@%2"$3 &G.FKG^#E1-A>^P1S:Y/':RBCF,APU41..E M[8VPN.*:X\XQ(Q_\XGE#@LU)=OF0FVP98S6A9,.,P0/FLM,>=!O9-/]T8CDB M:L3-$Q *A>O-
T*2)W#4UJW7C=V_5N]$(B&=9<..[Q[SQ$D\@+^$UA&S)X9](MK$O$/SDD;T@X%1+_UKSX/P_0Y;FZH/,\76 6+Z4X $_\)L8PA2\B#!U9(X+4 M^@U+GC%^1.
Q@\/@\2T^!MJ=QMPV.+2((+<(A-9)$' &Z]"D5NQ\RVP_:^NO MCWGG,W"V%[\1#M%1P]F>-9(N*O[DXM&V"[%6DZ](A=CS&L3KL MKL?3(FEK=T B(GJ.!9S.%SD&2K806?
7CR4/328V) NT32B&,M#8]"P:\HALL,-D5KG'6 M[V]VLHJ\$KB5R%SXC(-H+ZZ:U" M^EQ-E7Z^)GU'5,E')G9.E0.@_,").2 @:ES@5S6?#-IHUI+YF72;^O KXG(> M
H/=5Z>6R:YJ_?D7NEWJ41$ "1*$<_.W>__'-O"S$F2&;I^^>T%8U][Y5J(*V MH'UE%]W2#'<8W7!!N1IGZ%M*&RNXW'8O=E$K__K>&GP;^U[D#]^D[S88"#$:
M5:0(]=6;;)H$VT#/*)%8QG'S]O4RCCC;XL>*/(7/:6)WLMY/15VWM3.\8\GYG)2D!1O4I/UP$E)VT=SJ7N]4?.3.[FXC7M8Q],M\ MR1*BT^[H ^G5FU9I,3U]"JUTCR(WB6-9'-
TZ"3'JZI@P)F,U=3+6 MR=YI:6KJ&\+RKC;>%BEP/9'86&>K>HA3B8VUVKNSL?3I<&A]IJE9@=.A^C?B M'Q9#<)S$.='LE64^5YH*_=VEE>ACXM"*35.S
L=$94Z#MYLAWQS&G2BQLOJB MU=S*ACZ4*U$B"4H+M)WNZ=!B73+T(KSR.Y!"VV 2QWX^5)F>?],M0??3*_"' M%!.DORCS$'TFI"A/$-'IX*"T%"2=
[%>$2'!3WX:_I@+^&7(;LGLA7.I?%'"^ ML2]&CAB$A&("Z9 =>5H,:8=?!:(+-IZ 0CL#_#^5.LSVX6I37C,($93'VR(MJ9T(P +^WSV(X2&A"%>C>SXQPOK8A=$0.A*L(^5.
<]N%+*!VS4"0R?7(E< * M5S"4 JVD"W/"8VYF\9C7P6PNFMZ]< 66&N)X9AY]]%G32P%&=_/S2Q#\S6/& M<4?8V"P*YDT8^O9]%"K 3&R2L6_>PUDE\-[M5O'>"7E(:
)73>_31D#OZW"] M&265(=OC^X<+?MTEKR#7Z:O2>-*FQI.6(Y\6GO0[VXD(0^T!Y"8P/DL-M*TBKE ,DPR'NK=1;W0+][UI'?.IR=S_%G./B&T8&\IX MRRT^9.G3
9K>*'X6DNHR/@W1OV6+WA / MOLB?R0=]!WL_LM/4V/@)R]RAF!:9>5NZO$NB^_"']AL$GI3%C,4AD<1T%$) M']]]^8,_NX4_:HQ'S08_R'>00KGF3T*;45=<=#>& FRZ,"(A
KX2UN !2! (M&"94O@@(\/YEZH:LUG5:H[9<+\6<-8U\[$3+O9:5MD+* 44FS'6#+->AX%K3 MJ>]]M\'] 96"JJ?;6Z68\KVI-E9,._)^&'<>SV/&F9\9'QRL@9(*&V9Z1]U5
MB3JRMPA^<52>4G8OVIUSQ=#9/I#8&'@"VHW#T&ED?2[T FE+-0$>8H-COV[\ M+ 96A/)%XS$MD($8H8B'2OT@(,\('PBB^S_1&\="8#!-[)$]L)CE8 ?BU\\, MWPZ^@8:]&6
W+6 \9U9+6[TX(>H1 &N*FP;G5RD(E$ MUX/_C3L)L$D-CLG4!_+Y0'M6*I'OU8R???#T@P=CBC?1->,.;&P;*.1C;*L& MFMBUAOC__.J:\>7)AN-MY,/I43-^MI\D*+N BAI OO"
0_.#=5YZB5RHCR;(?=V=\"IL;] M51#.[=T%*U=UV).[+">";8ZE+79O!79P^9-QXX^QM::+.S 5@8?=B;J]\YKQ M-?*_X:XYMF_AA\W&.6ZE]1?V-,!P$3:M!XW5A(__^.;#7 18Z+-
'EYXV&^?< M>5I\1W:-AX;/T5=[)A54:]GU5/C)N 5+!*;_E^.%,UK4>8[UU(=?GL00G_SF M>SSW]GG,:R'/POP?^*T8CT">4 M2L%-1(M6'R079
_'"=1>;#ZLWZN)2L5M>:S^/#!W/&4M3F/J/GOFG,@::^B M:&;'!UR^_YSJ'BH#6-P>7%&O)MNU@&%@+QO/+##>P OH8>Q!%ZR+J*U^7;.Y MP?SSW686C-
?;?/K[WNV_RUF'<*8$"%=&QJU4'*,(S5($K<%3%J:<67O2'=K/ MQ"FEU7QO.7!,H0TOP+RS2 W9OC&RX#^LGW+JE]1N#0].#-F1'N1C/!9P15I^ M ='/F>'L%\]K8LT,;P#J$U4BF
J!^$^$'6;D*X.4H]8?EN.H[62/WGJ3"1X MI$^6<;?9YR-T$$W(NG[$*_\11P7P9^HPLY"<0F \,-.!ECG$\P/0.6&(68, M&US-P/>5K@=834[XX$7C!WPK^$N^/1X+5%O8J
5HWJ+!1Z6-2"C7WE=(5(, M]&P(GL&0P%OH4L4RT(JTD:[)EJ:-/W*TU-%V# 0/L&517I\T5U, MW&5Z2R>C';#;#N:3Y\XD/5^92 +1+CHPZV],]4?KH-]4=$7!3]%2.@+,.B%
MM'UA8SP_X' ?=]]UT/Q+%*3R6$AO(L]<(1K]EN#MF6,6I&Q]3J M+S'U$UL1=(=LZDO=Z^$4RJY#M0%\OEHZE=Y\U\WG]>;K=X^I-]^QC+&##.$# M-I[;P?MVFG683-
YLY+N8K6M"AB:==*2]7']"_E,W*%S,)_OO%[>W!H5'L]R7 MW9JPJ,RW-Y5Y:CS(KSOC?VPW$TR36N!'_N><__%&2B&0#<'_-$-VX<">5 M)XJ\5:\HZ=8:70T A-VTMJ+">4FVQV'Z-
=;:W;+0834/Z,(\A._T*2'M=&#_ M6[7F=5E=3:M,ATZ[OA70[_X59>GUZ;5^5R.* R?2O0VNHKTK9V/(*_:/7HI51EE](67XZ+679Z^LV MS^":M>H5\\]+YP/=. #YH%G>J.F-
SF7..^G1F]/2HRTM/^BTO70UVM3'*;%! M:4&9IP(]5UTH M34W-PU#SN-9P#'/07%DQN-SJ>_PJBYXO["L/DVO6>LVRFN%5V6AI]NM;W;15 M.JO)K+6;.F,#F*!;7LSG=
W7*F/\:GH>BIY'MHBCF(3F3(WFK=&\=XWFG;78 M@9'@<40^8&P? @^$&4I4.2P1'<",L:Z> 2YF-Y1[O2=B N+ M+5>"0AJ$J4"HX?6
MFEH^01(AQ!;6:QG!@ST*"9ORNQA$A'0"SP(3DN0AOJ(';'AO.W9HRQIO>!A5 ML?%DAP]4Y7UK/WJ$6_:+[SW!9T&(<%WC&>%@*;257RTWLOP9JUFS)C&G" ;/ M,NP@
02TDEGBX!^QJ,RU)&C^)XG")TO)Z\9M&M9?H8D27B$LT K"-+ _H:XP MTD8:R+5SQ/A ,8MF,;!^6G*ZKE^A>3)(SJH3B+8BQRBPW!IC#
MI^$PS,"7G5'E3.8WZ]ZV&MGL."3S+@7T]LGZ$WCHUO>&T2!D'K]!4%%F^0,) M:R'TA35 "["V":UMFEZ;E:Q-(S'TV\]$8K@^-22&'02.7TYU_'Z!# H\;L!1 MK" EBJ!.I![?-
^UNA8^O F93)+GW?USWH[=TC&_P]1>5\^HZE] R%W=LQP0 M=&3/6[XW,(DC6[2&E%@N9\NU=R%$">,,S5(%(;$-(D1)W+6#]Z7B8QJP8E%2
MMW#!$1S$YF[5[WB;M>OM>J$>Z'JO5!*T>_J&\]4;\]A+0BJC)&Y^_?S/_SN) M]&6S747E4#H5.IH*8 -M!==P?KE[!5%]\^+FCR]?W[_[?!JZHV96TK0HFPY] M4R?
1O7K3TM9%23KBY_>_OWO_CQN*DW^]>W_S^[N;T] 7.MF4K'"-ZH+54EMY M9-K8*-2HY//MS;___[^-+1'3U] >E5$2?_R_]^]. M(Y:AX=(HH*.)\.;W'V]*FHZV+98%,MRA=1):

WO6:YDA.O2W@C X$3I<;(I1>--6P 575UCVZS$7A+-P*7 M(Q\;(_"M"C#7%!W(-%*I,DCJ,1%\8-LB7;/=9E9.2G2-H4@]=+NY EVSDWU^ M;7EN#6AEN\[,&$8"1TA7 ,-O \0!2F\L/;7<@8B?,C(4F3|Z7[UQ/=@O,8A\ MWW;'BC8(PU"CDFX;QIS!)$:.!H-K4,9>+PRL?/2>:B/V75Z_;8XJ3Yl;8*K'# M\|L?7N&B9DEQ[7:,;K[9XB*1IG_/68GP[QPS9OS[=N RWI6"$! M%GC;'X3M7F>U%+3R0M#.H5L_V40;OM\TFZ^_BD<+[;0$Q^-1.!)$3!0)[^=#^P"@DURI208|QYU=GG MP#N?;S!4|LZW&FM@?- IS]&.5'U!=Z6;/\1M//|6TV_M+4,!|V.'M M=O1}Y'M382AD0OM%,I5HBLGA(*L->6]ER 6I#-8#2=?:9 $]4P-0TB!, M:W^4 &28[4U1/GXO(&(O&E|E@//!?>\/S.9KE:B2? G0@Y0?GPZ\[X'|O-* M64U>YWHC_E?:$_P_"MIQ&PR@OVF0G760I%5/+6G5>FU=E?;JC=EH5*UA;JE< MT+[6F?,E<\%+SYU/7W.<1 I]LV::6DI>O>ETRV1JO!]567ZET75;^ M726!KE/<_'KQ)'2IV=/R\^I-NSSQJ:@B[6Z%N70R;*"1I\KJ;YJ|:CX)9=EM MZ-('U!?UTHH?]DM.[H$AOE@JU)F,70^(W'C)/2H>;VKOT&+E"<^U52CYO56 M5O?)L,&QN^Z549:$$FCX&.Z\L-V!-Q&7IZ$OM9CO0>+V=S*@R^O)BJ_/B4C-"MD>2'4RF^UC@?FIHJ2G[2=-1'T9E-3T+&S)EA1R?L=VQ57$@.I M7T\5RRVNGBU0A(%'#M.:)8,5^]D$V>B^D=Y4{?B;@|UW)Q M7R/8=D<$@1$^P >-->N=|^496$DRNK<'DY,C'!B:W7V@#66>NBJT.A&KP>;[B M72K9@,K>^3M8R!\NH13@9Q+YX!^@OH;>1+9 <>_&J\^[8(|@_#!K,/:0FVX&H?UHA_;|Q*(0CL0R MR A8TX36-$VOR4K6I#$E^NWG84IT.YMA2O1+P'+8[1@[B-J_"%0"1(R0*I>D-MB/\F4>(_2P60*/"XX7M(3(SFMJ7US0M>PH;3,'X.U<)>P,I.;)%OVRX MDC3M=_"^G89[5S#.]F JVT"D'/E^_$TCN"RM6A6;MN5_&V MNU02)!15)$'9%_ZZFK21%L'"=DH/U5=@]$"%?1,5=R>'15V"$]P"C4+U2W$!2L-M C5+|W+|@LW|KUYH.56_9*@J7+5&2B_]>-YA$%4CNE;@4Z?T;JX M3!>7242S5%K]^OI35'2&3P46U[:H<@<9VS3HW%A>;Z]YG4[^Y,C[^V|JKWZIH3*]E7OSO55[!2|1?]JZWVP MD]H4HOX$),.9&<-(X#A3WQZ(^'ZX3B7GF3 CRR02.QCC=_#PKZ)$&;C#FTL M\0R,(,*.UOB>D4-5GQ9=+(@@B'R68261_-O5]49')7A5:?3^O.HIL[=&#%MY M,>SV2Q3"H]KJG0L?]Y.=QN=U3O=R^UT!|O9PTZG2;6_P{0B'Y;OX|,.-VU?O?+?=EE MH#L3\|)=ZW_D?W3S^@-F'I]&\W]SUF_H3#E]6U|69?PY>NA-/-#K;+5ZS0.Z MZO/$&]? W^U7,V2[;"NWKJF'AE\X'7=W1B_A]P_=N8EYBDWK^[JB"YN5EY;Y M65$MJ4HMEK&0KUFOF&=>.A]T=*T$!IVUR;E[M_TD6]8W MM.O^ZDWWI:M1LZ%=CU+9X*4;G.?:LOYB*^=,]RHOZX;_X"2X;&T%UW4JG''Q MK0>R&H'G5'IU-?2#IN:.D\T'357ZJ[U.PJ=GE,7>HU^QG"SY=TM5"Z=J=79 M:NTGP@+-1GTKZUW#R[Q4.\1-SV.P7%\&)34]=<=Z#2]D.1,KG46@_"B"\"W)* MV0XV@J4$X?(/B9? QJN9'ESUBWFUR573/>PJ^'EF%C6?@45-A, M)P):%]D!QQ79J(4,QW/'J&34@JQDYCA,EA#Q^FY[&WM8"_AG*/D\8 006*P5 MA -@/X8N1(P;P)X) #:@7:|WX(@3]/F&8'04T,H!EXVEFX8M&MFO!FF'*,X2 MWW84_>'7,5HQ;0@F"..$*X%"Q\5A7[^:59-YL&5,OL$F/Y)[^]9C-_')63[4F M=2*,GM%N__/?_6:S\9KNS>EO\ [4:BPV/>^%3RG!{@_+$>SC./GB_0,..^F3]I M"<)X&P/3@0ZI&0#]25\?Z!LA!92$!@$ECBA)4[32[22)6KDD'fIF<@AUZ>&'M'+*#NYF?@SV!N"!2/9,4\|=!D2OQGJ3 A!1Y? T&Y^.,Y:F.K@-D4 M2>[i'|?lZ"T=_1O\ +77U3,P.Q80BW&&5JP".-D&;Z4D[MK!^U)A. T'LZAP(@?KZ|^??GW]^? MA.9Hl,70O-%@:U15LQV2U!|;6E=&19Q2]VJ-KT6@%S]+'3P/G0)V .WWKW.E!YEFG_WN7(+\L54*K.] M7@*%L)%"KE0",?6+-$(_^CSW)15>%>D_7DIU3G]-C^I.KOOM?,'(B7)!57]3 ME\(%K;4-K/-=D%NYDJW3982M"XOI\UBOD3T.\WS0RC?#;NRC9?TQL $(S0|) M/250M:]<&<|3*-C@?)5OTVIONG>;S*'5+NX;6%.DKS%&7XH,N+23906!|$1A MW&+6.*AI? +L#H[AYG3>*+6,H4J=!|SS/2IWN'O3 =IO+S)LI7MSK3OU+&_6 MHZJZ#V"S!H+HD?0WG_HVO!5^G1&/F|N/ 5?=VOZ0"M6Y5%Z&)@;P4A\K8.$M MT0C^B'P\%@+A/IH#6<@/7)WAJ?D@|ZLW7A1> 92#Z0(_E\QL3.&0 6\"><M$C0N5N#Z\!EL.TXN+IO$8XA6-GVP_D,"%'TA_G$17['#[X7C1^(3:W1R'9L M+$K^) (8VR#X"&_#O4[676)>;_@\)D0'^_)@X&/CV/;JD>^]1-M[-]9^^OF80U;..[!DX!-IY7B!\%406<&G8N2$PI?QIEC$;JH@FE_'*B,@FX,JRF$B|X)V MU!$A;T EV0%-@?B*&Y"PS_9(7/$K?WH$80M.+1/-M\%D08LW2>%8W_NX|@3DX-P7/,0 V/@>^0+/CG"(/ M.\X[^^A*|399}^=EIZ#%UVODL1?Z53Z8*J-P!M04@3W'L7Q6*_8RT(4C1E9 M\4%6GU>I14G6;LP=CUF2M5>0;$MZU5'%[PBR MP' Y*,(6/#/";(^3ZR=]PD M4,.DYLRS28WV$-\3"^(B]P+;.IP65/_M&UK?<.F$*/V&T L?/$E??]FK66N M"0?VSW>)R=-X!B9/-6_<>OK&[4AOW+82N?<9N*4)N!C2[V!]OP;1:07XTB)X M)S^%TG/6;*^ZQUHC2'N#,=I.D>8N(@]W UDLBM*I7;?7V-9F>R-]>@Q7BW0G MV*^WUEX MG.7AIWZ[8XN#;<]G-0>@@"]L;*.Y IQYN29WHAG>G+=.C_I%>.M7IVZ3C[NNSJ.O\.CI3EIX$9F7.8(0]DK77<,0|@NZ"QE ,(CMJLB"X&* MVMBNZSV2>C.FIE2@-W(|.,\K6'5%IK%$G3@#F;C^+8TY>KQ$!,#:/6?7.K7PM.Y[= LR5XT?XS;XR M.;8\ZA&E|"_5"#Y3|^|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| ,%>LU=!|+R2>XZ4A7_)CX#@?GB 66C M=#SDFMF|HH"43X>&618=- ";MTNC4HJN<$Y*FYK7&6'_UIM7I'K]57<"?005!F'!\&RNOOHD9.EB*TO_\E0D MJ2S,>'W^A'1Y?IJ'3A4["Y1_Z/3-(|?6JG_HW$Q@\B _") D84 X_4%)UD\E MRM3N<=NK,,=J:NY6F2P'4_N+?.V34-CM=EFV<:6IT#OR4.ZAE'5YDO,YR?4+ M-DGVN5 O3T+0KENZ6R+81;TCMXH|(T^_S*>|GH2<4 &?EI0WO=*HH(^DY? V3D^0EAT=8WCUIG7LMY#KI:6,&.7A-H" /YHPL:YYW=|S#+1\3KD/-ML.XXKZEY@E%$+-BV=OJ|#^5I)"+5G.K++-+?78CK=%JC0:Y05-=.GP7'.09\&%3L-3LR36 _.<2B?HL1R MT@NSUMBN8O!0#D6Y1#"WY-Y&=Y$B|7-T(OP|OI *F^#21S[":5)E>A*7_Q?\ M%PO9TN_'+B)7$HJR7T|!"RU&&D(HHAR,1_Y 4^ ZYOE"3"+YWG(PAV*DH01! M"5,@HS8D]#}\^SRL4/ R5=L+##97398H-TE^5>9X^$_R4I[B@,2/B M5A%,[-$U-DQ@J=\6AB2FY2SNALB :XE(+)"(W4,P'1)(;2D27]Q>&;'4QBX, MA\AW8#FI76/HP'8>B,\KT# (;&.T*1E*0>S%V*5DSF?&*0 4NFN.]<(4L+3PK M>8IF#M(|S9/FIC#9U<1*OM98R7+DT\)*1HS4+-3C3:Y!{GI(3<^]0MWO>]0: M2\F/0MGDK80SG;A;&?>-F(.[N)D@*NK'1]"0:M 1(CN?V"'#H M5&XL/IQ/G740.3G;Z8X, 0> ^MT?V((/?&3?F?H3A(G+GC5\MI!)B.@N'[18$ MKJ, ^XKU$D.Q@\X$XC3/923#WCR7FKR42#M>]RXA CKF:<- M<<$4&$9ORVP#8$N^(@M9130')*^!A\;UXO^K.FFL)3Z]H|0ZVKO2>635[_LS34 MF!W-R9(5B,'B\5$X&O5K<^/A, ^UZ6L>L[SXR1#:,5]JW^0<'J_@OP$+W(D@ M=7NW>3NJEL,$]XO3'_A9?/-[$3YA*" W M79G-/T@:ULM611.)*8;MCQ7J.2?XP&DW|8%V/A"?7Q3Y7LWXV0<7/?(@PIG@) M43/>6JXUM($^_)Z:\>7)!H$9^<#)->,N A,!OOO0\E5C0T 56;"@PPN|,' MP+>$8X-\B6_"%O0(2?R'D"Y%&I|'8 SM&T2A,7S"4P'|Q0B,]7"(K]C$D\ M\F@Y8(U9V-D'7I3;WMY^,&Q\#-+;+)9R*P,,F&{WF>'#ZW,B? F9S\//^N7%A.4ZB!C41N_HJ7'1]>]%=C!-M)9NASR*.ZE9;A "WH!]AF7\Y7CBCQ9_GF) 6?Y[A//RHR:O\\B2&^.@WWW.) M3N;Y_OGIA@'OD9MK.8&=>(\R C8LQ'3<% H? Q&X$^^\8C4"=4+H%MSP >64A MPBW$+7.<1.,!!0{>7|32P8KU-@O($7I,/H&@5%0FJK ME]\L,+"& DOH%YKUOC?Z[W*B(0A]@.ADJ%R4)AE%Y("""8#'K1AFEYOT^O4S ML4F/"7]O..\'|)Y*X=-9I)=LWQB!HRP5%BG'_T06G/4^2!SIQ!H>HN@3DF+D M\SP6=T5-?@'1SYGA[!?;V+-#&\PH":R.#,$XC\1ANKE*I-O|O|PE.U)L/-T>8(P0W2!8KDS ZU%'XF6LK.0 MM!@-"0)J3@(.GSR56HV76@WN)2C)B1W*.AM7_U Q)>60S 28>^R)O!.#M"-BU@[EJ/|F>RA58<MX$B6MJ*9(7@1L/;! 3K3$$I;3L0YV,6]B|IFK=?)|0"U2/<6\AW/VJU:NY<__M8^GWS]B2W70]Z9\[L"'"!/\CFDM*@M2D)R#;3P;D?1 -<%ZA)83]BU"N@8J70\22!!R4MH'M> 4H>&-)QOT"ZD_>O\)N;*'SP?-IW@ZYZ MR,. -2(QC("BZ"Q*UK_!9>#EXGZ'5K*E\(XY7JR%6*_H.\0C_0*<2O5_WZU M=EVE#.7QV.V%A'.G7!?.RHBMEN7PD@+BB(@(7EE)'4$?"L:@\ M 2T# LE:"7MN2P($*H>FO5BVGS'2 4[RMU;P0(=O0):F5,TP|W>QM9?N $-^ M!5A@4WH _\^>!\AAPH1[DP G> L 7>%U.)?N\U8D2# M;K&G:&Q(;PCC*6#&A%? M!.Y)/*=T*]#|:9IB>%$.PC90,PH M#E\|0@V^O1-MLAWN-0DL9(/I90UB8SDQM} J.C/K4K#N)6=%+/HV&-Y$S=V@SI$D0@9T$-A/9 MW+,KQW;_<;C%EHWKV:MZ%/"3T*1I9A848@$&B?]3HY'$C(P!6*7Y%HC?M4&Z("%,N+++\ MS=*1V(_3?]^EOY<2S0IY@\%]R3G>M9EZ|NUENE?6*$'YSVV /T8WS2/&KF+ MJ9:K]WIW/%!A3[$'"Q+ M<;XY7LMYK4./P1HP8*FB%116H\6K4 8JW$#79E,,'L2C'+Q-"1+8C/M/&&IP^]T3<)) MQ\@C?&/,>/BZ-%"B46Y0%'F*>9J>0K-<2? UH8V+/',QMT^,N)I#.!\MZLUEJ M'^4JQ=D"RT>EZGRV_O2H8P,WUSS*9GN?B-=-5!.LEM-#K9Y5VY/G9Y)H%ISW M3J4"V 1-<<3Q00P=FII#7U 13CP)3[Z"2%-TPU"G"(HG^& (5BW! M_Q0R?1&1UQ (\1U9"&C<.A\.G 4#5[P<>;2-I%[&123TTOZ-FMV1*1B:MM7%P MV" :C6 5P.B4K% #2-,%$0<|'UF80ZK"406!,+TD|Y=$0$D'6.#\>__2F(:' MUDSZ9WJTE*-QY()AU(54I' ,U"8*%AJ2[2D4Y"OVB^,;|$H=2J?NEG@T;F'F MR%&XOP2@=0-S!8%".%L4A'C-;FTK.5)UD#A'VD:OBY$,X/8A|B+HFW>>KZ_9 M0"-6+GR(+Y4'|V_N>;[;2.1%S$Y.,C\G7T=*6Z%2:)H.|%%ECP2LDE\D@,SI-M&T_OZP&9/(H>+8) #0I, KM*Y/$8>QT\ ^ *(:5A: _)&(#O#4OXN -J124# M!)1)QZ>4)*XW"4HQ"(E* [":*8;4*!^$:>2 *62" PA*A@T$,",.N,31BX?PIG# M)/E8M/B>_&4"NTE#1+2@U'BLF-"P\C7\/V)2IE]8B7TCCDA7(0]>=5WE\FV1@1\TA! F=" M^%$NE?$3L82? 1@YKG>3GSH@FCTX-0FAD0MY-[J2LE)0<|$0?<UF0/0,)BV^ M:HS:R3,9A,>Q#MZ?3POR97G9!6I2DQXK^.PPK8US"9A9F3ZA"K7\Z/!0>XR% M11)M^?TL>9QL(2/C6-X? OB"+>Y.0I0;[!^YW4R>1E*2!/"MBDP%*Y\>NQQ*S: MICBW%M-_G\T]&U/LSH|/&NU+ Q@RGDV%C_-G%+>]9UF=;OP%QZPA.4)4;2. MLQTGW^EGFP>IF,"T3XG?N4YG+?6? =S8(L|f*4V5_;L!ARF3TXIE("Y7*M3#: MH\HJ?:-U=@U:"X$D<00&SJ!ZN YW6@,FK[YJ3_D[.++(0#HZ>QIXFEE02QO$ M07+'K>@R9H\A7G.8;FWYX_%<$M_6<=S"VA ML:"I36ITZGN/IH/.D%3?);VW3JS31Y$?1+(@RK0 6+/*0$UTN\|2]EXR?;7 _@/_$Q@[6,)[OW|A+89&B6C&O3!9.O9'SU>N9MR6@Y=W"^ M%OSRQOPN>B9GR 4L_A1.OI+Q#"3KZBVG/IGNDPE(A\@2_* B 0LLGG 1_]Y% M;QY$\|00W7?X8W_@=9=48 Z/GGZ-@1W0%.BI2Q*6#KU4-KZ/JE#2%(5#/162 M8:P.|QG,,J8.[*(%KA=&T5&+8C! (185-C%>@JV;R\U0'1'Z';"OHPUY$U6EF M("V',/V9T!*%00(L.+.8H2B%IIB*(B(*+R3'.#'B)5DZ#U(T"R]/|J6S%@ M9]R9,$04Q,$5' BL B& (BVHR<[66W'@V2*4V3F/WDHK;X7%QP2Y,NR3;=_4P M=4M%*77A0<:.?V<3(6B"1)8A^0B%EXXCSG_HVOU'"D%%+A;VR^PMWU;$)O+3 MB0.B8.5L8\//F(2V!X&,H")IJ9G[-FRCR.(%C0_,90),[T#P1 `M#=&,(_L-1;(",^)3?.#DT3-_"F>1A!4?3_"A/5N|I&<.S5N>+YA+5%I61+X MJHBS;+2!&$8ATVA@^7:7J=1+I7H3&1)O(EU0?B\; Z2JAT9"BF@^6V(M# (FQ MO95T4XO09-4V%CX-=-;@7<21;+'J|&21P!HLAZFRZ=QS[W]IM2Z5:-+Z|\R4 M^LK^OGUY;9QA[[O5&WFRV]YLZ3|]SA@JL.=8< ,;W0K4N2J|/*(P,;(?"N!F4 MSHTS EWAV" UI!PGHT(LG;?0P%%LQ@U\(ORA8"QT"52N8W\?>?.2E-]3Y45^.MCTZ5P(N2SIBNTO-/BY02%\#*6#)%Z^/R*]W5$-$;+!]3T_'/^[%:IE^[.K7W M+ K*63Y1<|SS%"Q!R<5&H2RHP M>[&4/ D?F\IX9LN1#SIYB7;>^OM2TL/+GJX212/RV"QR|"C\U(N"T'_4*1T< M^,CIQ M!><@70:SH,> IERJRDJV T>+4BY,ZS\2EXZGU.&IBAOUI4'(2R;84RTP0;${(S2V@D"R8KDQ4T=CPD)QG619@RNOLA M:\FY7\E(|1^@DW[C[1-72M$3]1EZ[9/KVIPX1#5WB/'WOFB3_AFW M? ZQ)OSG$6HC_)=BWR+<&$CJ:*;<|F=[3OJ"\@N$IX+.CF39?0% MIP++8YN.G(8YH(**BVH=$$J15"1C[5#Y#(E-YPFM,FMBRA>[0LRYIE/0Z# (@P -/> MQ4,SDRJ3*=H8O>?E76Y4HMWSKFSI[8C<1X6N/(\0=@S_J2AE/6EPWJE>91"T7XT M.E%>9<$/!3\LQ ^Q LAT_9.EQ7'H"L)"^:,4M2&WZM01399WGBGTL(LDOU > MLWC- AD7L %&0EM .(,O74)KO'M^]D(,&:+1I<&56/L$\]-?TM-(ZWW&R7U\#\&1 MWJ.W6]@C!4EJF!Q*_,>-T*>*F3&O45X5>J;#,/Q8I4PPL?IZ>R_BC&6/P;)CUDD MNS$SS1#4R3CI)*0+^/?I] >O5;>OUI[TW= 4E5[8'TAC52EZD M&_0N;D+VW*.)-[^9W7LU$@M();VKY0K:"U1(:OQ4H?]EK13U.M1 *Z.Q>"&U MY2\$[+3J<>,$%:G\ <_7+*L|GI<^'Y\Q%4TN3".R;F-;W6Q\),,Y+$\+=E"3"' MGY85S[+9=4@U;B%BS'6;>%]|.)=A?)Z8L?+&<#/GHO>/091C$1XVP 5/6]I> M%<57A$;_; $)- M&:GD0M>V\6^+6B74*HO_[T;I&)+$FM+O[^YZY^[Z|^N,A\|MWFW]#C2/MXH "M)?&NE72P>UVFX3/^Q!97E[\ +F>+4RS1[?(\W;45V|E1C MY7<4^HE+/RA,|F$IRC+_\? >K?:B873&['9O="\FX=3D8!.4)O],L!4([(#7 M|]*K!\V=-NNJ!XT-6'1!G?FGH\.*PN:3K;.6PO3]||\F?%.[GE# M6K5EAK0*,3"\#1]5G18#]>HFB,&".B>$!.M'&W Z;S2A2I*^LJ*BA,\T07_] M((@MXC:1(>%Y552]4U0|$066W517=Y5TH\SLP8O,K*#4IGMW2,5PZ6M?]>= MJTZLDW+[5LRKJ_X*1,6"7%XCH=#"]B|[:"%&;MIXVC>N;K6RV1J>T MQW00%#KE)87J=|%QEV\E,I&*H"IK,/YRCW:9-690A[2"NHJM|!%:DVX4Z#0.RI|>VT[5C;!-.Y,(.T)$;H-.)LU0BR6%8#8=;_F<|RM55U-4"B4 MEU0HNZU1BE*@#3Z<^B:H^S7"*(HLSPOKF@Y?/)SIQ393EV&Z>ZT\?36/@B_Z_7_\4>M;K3S>D;+V^ M@4 +;"#Q\;T)]QPT/M$28;5]Y)S=T;_FR1V5&[:,O43A1# <:]"V|^H1H|#/ M5(\DMVTM] ^,10O|S1V#)- /U EY>1;W!=0$,<]'G8:ZO.:US9VA^>]FN|PT%0K|#"/MVI W=8-V C,6D&?$Z3UX6XWD-FK5Y>&*?S!,A[+ZY(U?,Z? ^(&QKP!:XJ[9!.3 MVPZ/=QNOTSSJ<.F>~;,Z1FN4;&BDXB@Z7E!MQ*/"1UQ%Q*B\D!'^=NMEP_%F;$!!H!.(M%%>R$G:?@<MUI=`H86;.*D_-MY8 MWI.=" (M|A.F[MGL;&'L.W5VJ7;-<>(0_CE6X5RG7%VJRLOT1TDJYLEW1S(+Z MEX>/+-=V'8)7*2\9A+?#'F'[\AH4.+\O?.%;SS@Z&S"\;PQ4EL^6%:0OO#TEA6_5%XA*KA<_V^=JJZPG- >A19[W9L3 M-F"[D!L%|2 /A#$<;1.R6EX: 'S7/<;Y-;$):X$=,MQHV\4-E-15+8P]FS7 M@'> 5ORI00!3Q8G5MZGJV5>.R MQE6^=SDUK'!E:E(B/%XUFZF]G4G%9Y0V#W_P- KO3J+'4J;$VIH;KVI'I7RW3 M`!AF=3=/\68@C)X9FL8(=#56-/?@|[X1PL .4/?^61J,6C&@+P&>!X'(4]0AVLD=2H9:-_;C/ M5@_ $GC=9% V/L/|\>QP%/C*=F%J0QXS$&|J>*$PJA;.Q(O\60;,S8B/Z;K\ M'2"VL:38ZOW=Q2$=%!$AXZXQ2,48>CP&5*)$V;`^\;CY4@3+%C%1A0;/|QG_ M1*8? LA%;J!0.C'OA"YB|I3/!0^D.$@0@#1*|)^D6'GU3;U181DES%9ZU\!!|F M.#*|\S@5;QX_Ol7-/^)BW_;?:1WM#/|&PFPFD^]X=-.%#O8-.G0#GU8&7QP M)X+0OF4JMEV8QNG%9>N_%^?M.6UCF.HAWL*,YG&)M@67Y!K1"#D_P,GA2|, MMU#FJ,/T%#33M!{ WLM'!LVBC<970OC4 M<0$[+PD$A,=W0,_%$P*CT*(9|,%V|4.8# ^59C&_7+0..# (Q%"^^2BZPP*,7T MDE$XE3$&G[13)"V">2G\0.Q+0M0FF^RYX<$S\;1^[?QA#$4/)RO \+N.S<7* MG.;BSAB'|8TW#G_QO-X]Q(QA)W?2O\0*=-7,TA62WYMJ[? ($O2'Q_NNGHUKU M\"0P6I<=^&[D^43ND6N'+$UT!<.& L@\&GUFY58RL&0?-=.=#,8F/[,DW7EWZ6#C.2*K5352 AIR//=V MWP&"ZZ&V$E+'VB_39K04VR-]VP?!K).9\L- ><.P,KX&KL R1EIO=&LYC!N M[,"1 C3-0J6LUK <5,E]. \MZ!#?)P2VF1M&P,O !?\Q<;W &@/A<+@#;RL:HMU&FI,,T%=89&I\WS=V#J^CDWBS 60&GVE'":0(_"TDOD)Z=F/B =| [Q%,\\?$KHPMX M:N]*S*9'>7*!V7Q"+L5"X5E& C[.5EZ>)5.MOLR+ZSMFZC8W7@ LTID0.V0X M$3"'*1X,(!PL.74,0Z?MP8*)A:W2%8X-C96#Q5!#U076B9PN4Y) 52H_!$#:- MX40<*0E0O8"-"2X8BHT^G!GX8.CHHLL+1..:C5]R3/F+H]V1$X\V:.^)E >%& M#JK07 %&++I\T;>W_Q?HOP_?HK3S\3V:.M>]@7@K4F;XMJDR7NBM2 ;/JUV2PQKA/GZH(6B\!BD9;<E**>1K2?(!M L.5-5*G6=.[:R>< <QHXL M/$??)PK3#V QE2/4"EYT:\'55?J>VH\VGMJ?WPQVCPZC$/?0-Y%SN:M:HXGE->.:Z((" [6KZ/81S69),!LCEAVCH(?.Z(2Y\1@Z."BL"`MWTHY8B%,*C`L@2>%BS(&U!LP7PQ.'=-.-A<6W_F9)NRM7O*5VRY+MKO5Y30 MP%SD9\!?3[|VRNJVA-YPS\-9.] -:.G$AYSZ M3OY|[OI PSH $WM ,M/G&#UZ$4HfQ1/#42^T;(HDX^B_A).@?+|*Z8G@O(9 M032$@1^5,Q\ WU+$'IVC9(XC.<>2AO*;G9!04:(C5*N.C,40;@&NK\2%L>Q.D$0P63UT_<|%_ZVUB- 4K^VR8>Y"= M]+B_\/NWUOE-YZ9UT_3.SPSXX(OZ[(./]>FF7B^MO5^UKH_7SQ;<;XVOK MZK?VC7'5N?YMKOS.BS#&S0!A%@-P>E$%$\|$H*3?!9)G"00:#RLHQ/8@D% M P2"K)9P@$]W,&1WV%+7EV< MML^(3Y?!E8LITK/$.CAEZ >;5Z!%+0$FP.K-2{HL(H2X^2!LO,T*;,2Y$F* MYZFLO3V0$#T!BG:6*,K4!VR7>?0*T[!9[5N[F<;>T)VGX9R,\;/? US2I3% M!"NCJB!6KJ6O!:L&#XRE7HOCH-7C.B;(865#ECN4_I8{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})^G;(WD09@ "RGPAJ^4^0LY&56=P9#6C6FX>CK:,^E@G?8/$9\[0NG15,TDL#.K MD)&A[<-2VI%73X= {@V&*.L^93Q":/AS1RYD8GV:R($A_LSU@*7O@Z'5Z@ZJ5-M/)MB;,?2>^L(#"_ORTWX8%1)AM$B?C7./G,16R:/=(HI^D)!/C3EP=.F;?. M,SE:TLBH26-<3QK_^B?RPI/,F?

&'TE+@MQOT>D,G=D-2^[P;DI?URNQ*RKJ9 MM.(<^V;1%<^[E#/;%QC8)(=8%6B@:C!2K*M%+0UYJ96IPA>V(QS!;L8REW4FGI0.2%7/"#,V$YJ"U7M\4'E MB#O2WF+, I-
4RY[C]?YO[\KJH'%3Y32Q429UZT0=U6,8)]J,Y_VA MDFA:_].XN]NHOB6C?LIMA?(%=?7P^#^W]N?RHL(EWL%+'N03LS+DM(Q1G: M^-P<[IY(& XL88S+_?
EV+&35SYV2Y4HGW3UT[MF4]L8S;S*@V[,RJF6/I^%=O^]+:WJ-*IV/B5;WS[861+ 'M!^FLY@:_F@SV, MAKP^SBM^[/KO/UTGF"LLQLBWMR9E![2C??CD=$EG?LRS<- M.-J0#
<7\9%E"]/M/&@V4)C;!DA%82A)KD1 M_E"VO'@FGS10P<:5R\V$2QK%:4PZC<\^-PX>.XX$6]:ZO6W=F;;3&H:90VD% M%ZY^&-B.&W5UE&KB2SK+B0%K76D?
E2O30EZU.$$2VZ:CAXQA*A,= MU;>;%AQ;1GHG%3#+;?P_)2>R@,%[5*ZCP1N;NK/QZO:D:3":S%%D+FP(% B0 M6\$!E?
7P'[):S^+"8_.!FHH,X$L*U'<=68#S&FFG]Z*B4//%EY^UIE5%[-0K+S14XR M!)ZC]/**<>K5>*A7J^5!"*.=XO/9VX(G-5@<17X0 MR1L/K[EWEDI0U]1OKTV_:
[HBV+]X<,2CZMI:JU1J_.C_&2PN%26GSD#;S+&] ME%*]"5^\G_B-'K5\G_."]1YR;=6'7)MZR..=,HM#7N205WW$TT]XOCZI^NE7 MCRB4>%I.TT&UWJAPGUX).YE(,
<>5YG2*,7:66*J5:KES?OV"%-,A9\WX[\]7 M7XP;\|%SO>&CT7'Q:EI+&&>>%2%^9T>W_OKTUU5O??L!' 8JTK\F'/*N'\%I MZ\OZCN!4W@*(?W^QW>]=K/7;\0,Y:W]>WX&
<(6K0+LY#.X\OK9_7=QY?S*YP M@N(LY%E<7K77=Q:7?(-O(:V2$SEXP=,XI3#N)=ZW2GWL3.X_?6:&)AC-CC#V M.),B>_#IA\<79E#G:D9
MQ\&=M<.#:"A=SIH8SR$LYJTQX]1!3O+]<;_MV'A MOK'HWF>Z)0;;.F"VX >[R?>XZ-FWNCS VGOV!?:M#,W7@*VO.[^2UX3V9[M?BG^(755\4W5+CJAI1Q10=U];7?6DTH
V=9_% M^Y/@-5TQ,)T^WOV- U&=!S\@VXA&+OR*!H3S&WATR]-3;0ZV-J"?#>%G9/@! M%3S,'-2O3@CJSSI,_J\;2YK$P7HS"]E938=?K'S Q)RL@_AL_]'BWU[^VKKZ MVCIM?
[OIG+:^\&>=\[-OUS=7G?8U__>7SM?.3?OL^88N\M $2Y>^2INZRWUL M788S5UM\,,[!FDVJ"9M<3#BG];P>BOGT\^.'EYCH[*90=;Q0:=S*7M16>A^\ MY\FW"=OX#;
[KIRW!0ISD'B)BM%^$/)2W$%MK3R,-M%-+4 ;%P4T^.$*XK^3D MUFH8?TIR;W_8EJ @#EWR57I9;VR6J4U(,XUL>H2W,2],S2#6[$9K";R+BT! M7VVW,WQ ,?
WS?]7J/Z#:&0^?3_P=02P,$% @ R(!F6;<^N0CU:;6_BN!;^CL1_L%CM:D:"4CKM MZ(I2) KI%(DMO929G?EH$@>LR0MK)U#VU^]SG(0$2EMZYT6]N\R'#G&.CQ\[MS^-SCI/6]?
CW0;MU;75Z[7*I->Z/!U;;^EQ[USAJM.K))=KKJ0%K70Y[7]CE MA^YP,!Q=5/ZX[H^M"KL;?QE8%Q5/!J(V$W(ZBYHWH?*Y5Z$^K%R"BZX((J': MK5[_4V:_E$XT:_[GZ$P&%
<8].0W@0[B1Z=6ZSCT) MHRCTDR8W#**:EG^)9B._=KDOO55S+'VAV8U8LE'HM^)BD?L2O' EKK*;*$BZ:Y8 M-.-1DQ&* I_R =[#_Q:['@"JM'\+)GI^;IR01#J7
RMS=3D<]:Q1#6H8=&[O MK&;VXTG4VU.LL,3-1>6XPKK68'#;Z?7Z-Q_6UW>WG6YV_4>_-[Z^J#2.CW^M
M)'A&3$R+L5;&YV**\HV%Y%]ZW,]9UN8^FS&%X(IL9!B*1P\5ZG9GS%7H*>W M0OL\5!$+ W:%;8>UKH8@:K;)S&0D:GK.;=$,PJ7B@-XXKOVW52>K-@M=-A8+
M7B[=@D4^K.)(VMQC_<")=:0D< VD#Q_.N2&261S\&=$?XL*!6GM3Z^054NN2 M:Q *U/%7["L(X@EG*JH)PU)>.2$\!&'$;/CE,F \6+$XB%0LL$ \$C[V22(2 M!S@P4H(^+K?
1I%@(ZK H3.P8:+9I$0A;:,W5BFQ_E5@X()3C38':#"F1^&* M!B$#6RH[]F$6H#N@.$(Q$-V>,1W3G[S_4BB1.J$9^%)[@CLRF+*EC&:8H9X+ MVR DOW- "QW,[,
G6%N@3[5<EVLF):/>&ANJ M-H!LKF?,]<*E7FLD]. MJ/[-5#]]A50?Y[3X[9?&Z?MSG1(YS1=I6PQ=5^+2*7/N!*&EJ"9G&!UP" F
M((:))_6,S,G,1TR@N$#7CM2V%^I8B7*)PH4*O82@ X GO MK'LDL,%4L XVXE'LP>+Y#.8=KS7.WHBW61I#0SS?Z\Q)>FUTDY3D!XG0""^C MW;^@OT02-+E]@9=+ST-W_R?
H;@Z='L6&SN&&LL3F(4W;1[KK2>4B36^>/:EK M_@IU[0@MIT1*D_WD$F2/*+!*F9G-8[U_%\J0)M#T>J@DZ0IC!0\()PNI382" MF0B,(ZH]\]A6#)!*>-SH*A%D
3(7A2ISG*)6G'']<8C$D9!'G2AQY)"EE, M??%K(F!8+B%4PL&A"OK!\IJ\>GGM'2X>J.R9GN52'FF,VM@>8H-"%W@.&)7K M,. 4H[F&_J@R0N.4*R?
C.60G^41Z,EI1CK@KP)'FC20,V1.U;I@6*BN3"MRG M,YK':@ZU:9/3VG:H' / U%A3$2!5]2 ZW!%S4C.9H(!,A079RSFBYT%:/U1: M]BN4EEAP+S8;/-%.N"[J'[D 8?
1V'9,EK'N$JN1RJ[+)U&54A)Z(-#JIGB9A M'#T^_#[1E*^M!=6&[O-G"6R259UF9TB7 7C.DW3P4'W]0"$XKU (*5.+F MK"TM,\R=!X+8OWRAC*Q<"FT[5L3(0@JTY=
(/=81^]/H#CC0=!Z>'S>Q-$DFF M4D>(,5'6PX6JL-5O&6> P75S/$@GAT&\QO0VR1%G7*_S1 H21H7",>'3K$,: MV5;,DU^%EQX5;ME7GUJ:=2GZZ-H\);M#^-
GWS./L%0KKY6<>YE7+6H_5?*NF MR%&41KYKPT.Y](+$<+/PR7!QU#Y1J/0Z#3,-9.7+*!+BD8@X">GU'^XY$L", M@S>0#N*/IOB&_ZGTRJ0N_HPE]-4F0*$_-
^)SN&)@+N5$"YM"L6):5V=\HEK65@#MZCY*@F29E&1J9C'\N%A3$S24/ISN/Z0\+U[RSJ M*:]R%7;8*K@H3$0 G7 MLS")"Q#55 !)6[ETK=D;D?/9R;?_NM1#+M]$=O4T_Y<\E-
M,PR/:(N]$$,Z[&-B>?H+L08U3;_"I4WW3-SMLI^.3;_7DB.NJ[O^.YHDZ0_ M;2%V ?GI(&Z5((=!9,))=R:%RZQ[8<=TGL"&28)99$JFX58="C NS8]6/?U0
M,&%2G;XW1*/Y3/%O4$L#!!0 (,B 9EERT_<-VP<)XH 1 9#@W M-#$W-&1E>#,Q,BYH=&WM6FMOXD@6_8[$?[AB-*-N"9HDG;16A" 1<#IH6<@2 MIF?
Z8V&7H=1^,"Z;A/WU>V[9QH:\Z.V'LKOD \'E6[=NE<^I>V[A]O7T'\-. M^]KJ]CO52GLZF ZMCO5GX_WQNY-V,[U$>S,SH/;EN/^9+C_VQL/QY*+VQ_5@
M:M7H=OIY:%W4/!7(QD*J^2)NC<+(%UZ-^U"U A<]&<0RZK3[@T^Y_9URXD7K M;^_.5% CX:EY !_2C4VO]DUNYHMHKH)&'"Y;1\OXG++K61C'H9\VN6$0-[3Z
MEVP=%]>N\)6W;DV5+S6-Y!U-0E]@I.YP\'%T48LXSEJG?=FQ[A=JIF+B25.[M>=EI-V]XUH]%<'+Z'4.PS9J8&'K69#JX&O2ZT\%X1.,KZET/K"NZ&HRZH]Z@
M.T03[EJ3E^(I/ODQ\=W\/KG]O3N:TG1,MU;/1/G^Z(0CG5Y;=-N=7'9'UFUC M_.?0^DS=WO2G!-H9U,GR%/T=Z''K9,LH5NZ:XH6(6\2#EV!4^/T MSN@>A!' MK?-;,-/+
<^.$F=&]'%JYJ\OQI&]-&B#!L'MS:[7R+\|&NSNS&J5N+FI'->I9 MP^%-M]\?C#YNKF]ONKW\^H]!?WI]43L^.OJUEL8S(1VO/4D75%N*N6S,(BF^ M-%2@E2-;8A4J)S/LYYU/?
ZW1I^S)8MZ;IYQ2[O@=^-[/NY1O;74JKRAM+R)] MZ^,\IYV8!K00*TF17"EY)QT\5Z7IKT1$0*6W1OLRC&(* [K";D/MJS'PF>\M M"Q7+AEX*6[:"\"X2"/WXJ/'/=I.M.A2Z-
)4K4:W<+ 1V*ELFL;*%1X/ 270< M*<0U5#Y\..<&2&9Q\#'A#\;" 5I[0^OD%4+K4F@ "M#QU_0% /&D,Y?U%&$9 MKIP0'H(P)AM^A0I(!&M*@CA*)!9(Q-+']LA $@@.B%2 CRML-
$44 CH4AZD= M 6;;%H&TI=8B6K.-+[Y(#%QRJM'F(!J,Z7&6XD'8P%:1G?@P"] =H3@R(@#= M7I!.^*/H?RU(X*IC3G8H7F*%>2MM$R'Z7""UT,,\5NCDT6Y?7 MX2G\E_?U P&>)
<#[_R8"2')5 (0Q6 M$U8%^F.-V5+JO I=U7JS@1P6VESCP M"=26X%.O5ERA>+M> G7,&&:2YQ6XLZZMQ)!XL7E8P M[T7C^.R-?)O+&![BY5YG3MIKJYMB;1^D1.-XB7?
_$O]22O#D]@V\6GDY=/<_M"MTM0N='L<5SN&&5V#K(M'VHNYE40=+LYMFSO!:OD->.U&K.H#3JIZ @/<'
M.BLS6R1Z_RZLD&;@]&:H5'2%200/2"J80L2U]\FTD85BM(E7!PJ()^,+UF MKYY>>Z>+!RQ[H6>U4F0:PS;:@VQ@Z K/ :,*'0:"<[30X!]71FB4,)_:4K5NFIM M !B]6\?D@G6/5)5>
[E0V.;L,B] 3F4:GU=,L3.*GA]\GFXJ-M>3:T'WY+(%F M>=5I=H9L&1#/>2H'#]77#R2"\PJ)D,'L025NSMJR,L/<>4"(_IAIQ(?1&)W*2,"R4CDF?9AVRS+8F3WV17G94N&-??VYI-
J7H MDVOS'.T.Z6??,X^S5TBLKS_S,#^U;/A8+[9JSAQE:A2[-CQ4*U\A#+<+GSPN M@=HG#B.]D6&F@:U\%<=2/I$19R%$'M]S% (S#MZ .L@_FO,;_G/IE5-=_I4H
MQ&VHG02V.4%\^]29P2'C_.\>&O#1,Y<7"MC'3FX.MFPE@=5,0FUJ]SNL#$NB M5-X;460*$_/[3GX,S0!\E '5RF.Y*"VUT^/%1_9WX:"GEIOM_5&Z9+4,S(%[
ME!SU5)1I*#*=^%@N+(R9299*'SVN/PBN_\^BGG65&V&'K0.+TF0$P-G\1ICA MOI[*$Q6L0F\E6:,$6*GTM\XH2R+27WKA6N+NW2),,X?88A58P,*M6OD6Y?;N
M967RW5\HZ6,56C1"2/Y,1NF#_U"GDZ.34]I]FZ7D^.0KR6%>@]I^$:G@RRZ, M=V&>(Q.H+K/AN]*LPR]MI93I9%_ZVWPJGDMAFL?P!+?H*V/(AGV*+,^_&';
M33/LCS(JFN[)G*W2+T?F[RO!T=3-XG6C;6S^M/F7QO_Y8]]+.^&3 OH$X4@W MD63_:J0WD))EZXV'!ZGTK*,D9R][2:P;]R;+^UF]F9@BJ$FOV"(1O->XK\! M4$L#!!0 (,B
9EFN-WY,MP0)L1 0 9#@W-#$W-&1E>#,R+FAT M;>U8VVZC2!!]M^1_*#'**)%\(Y+)^(*$$ <=HO;8'2";SV#9-W%H,;-/.9;]^ MJP';Q)N+LI-)]F&CR*)O5:>JSZENZ(W55MMWKU
MK(&]]7P8>H.I\0,&Y_IT/+7[RO>1Y9H*..Z/L=E7 A;2ZI*RZZ7H3"*^(H$B MUT"YA"9T&@K*U9YA76[FWS)/+#MGM1,6*D "=AVB#>J+=%5OMIFV(OR:A541
MQ9U&++J0M^>1$-$JZ_*C4%03]A?M-'=MGZQ8<-]QV8HF,*&W8$?29C?LQ_Z_@- 2S2C*0(=--VK:&E:ZXU MGS&&:8-VL3(QX;61)OHEC;>CKV O]GZ-?AG M%[9SH4U<<*?
0/(.+FE/3:^"8>AI/LWW2J'P4-,T!S9C.7-. (LH-MJ^-TTV^ M':!/3J4ZOQN8/T'17CK0:C1=I\2;852N$112&="%8%,(M$TL02PK?UH1C M,,$]V#2.N(#(!Y?>$)@M"6IL0=>"+4@
5NBM$\$9&AVS%1/4@T.Y_O.GYO&7 MKAZM8A+>R\99]PC0P1 5BO$,IYB0C2"7N*R:Q&BT$T:WG,2*VFQ4O_7J+J%M:3K/3"7#%##X#4N1
M7\G7#5DHK6)^\W6POPS[!//Q(5[S9$W0JX@*(D"TIU^ZF00P)<2+8KDUQR6M M@"SZVF!L;DP-IK9AVE6L\&-MYIB=S<.S[-VGN@*9F;[24$ WQ^.99AC6Y'S;
M=F::OFE_MPQWU%>:C<:!DN&Q(1'W 84^*#&YIM4YI^2/*@OEMG;(3<2\?**Q M67Q\L O*-?8&3PX4N,Q+ R9E6R:RP^:P>51<4QQ[LHMGGP,,7PL^KOPAXH
M%VF0Z]U?!RC^!?(MD-+9RHG3/]>,TQ42/9'\2/+*T6P?$E0XA^;)H7>TY=1. M?%OA9<0]EYI?V\?=E/^2$6DR\,>6/Y(9Q<#_)]I/$*WU'R4:"WUY74O9@T>0 M('B1\[
W)M@XRP$9XCJ=-DKZC67N;AFY^^!L;A=6 2W10.L]/\+'NZW*;._YT, M]MFYS]X-X9"L19*_J7I4>3?/E*#F#\9#F>QV83=U@^$)R< K,>1NGY+ _?_ MINR:1]RC?-=U!TD4()!/C?
3OE52H)_5'[A4/*?ENB7@,R+N#^'5O8^J#RUHJ MD%?M_*M\[5T%RZ7\3O?P[W MOQ^+>E@OVA(E,U[87V;2%EGUJRH^B\7BG_^ZF/K.''-!&/U\=/;N],C!U&4>
MH>//1V$P.O[IZ*]_^?=_^_-_'!]_P11S%&#/&2Z=F[O[1^>WJ^<'YYZ* %$7 M.S?,#:>8!LZQ,PF"V:>3D]?7UW?>B%#!_#"0#,0[ETU/Y/=?(H;.\|6[4_E/ M^=?IQ^-'-L?3(>;'YZ?
G[YW_/GW_Z?WYIP\?_\?YW]]7_SL^!A3"G> I<@+$ MQSAX1%,L9LC%GX\R_(\1[,)XE/%"TB=7EZ 5#X&<'>,3V_P"(5^\/GH]Q#Y
M9$2P=^1(-5#Q"2K7HJ:*YTJ^7KQC?"R+G)Z=_/;UX44A3>CZA'[/E5X,N9^4 MOSB!ST,D<%)\42H?4S^[O+P\45_3HI(064.:Q-;)EO>"M$*V\(>3Z.,*Q1JZ MOSUD0(3B>
(S0+"T^0F*HBL8?E.*2PBX+:<"7>0@"N^_&;'X2?\Q7"#F7;5)7 M(_Z:J^)A4EU:?L@5Q MW4ET2ON2*4D1<45U6?GYX=GY^E-G,]C]Y?T^F5?]J[EV,2?T%CV(R*YK_Z9
M4O2P'.B(XG@0I_/BF63@B$ GM]^A?UM[2[ZLQ@87]6W@_)"C^*<]MDFJ M,=$?W<'('WOX>DF"Y MP5"%PAH#_=C 0!%%AU GHGDP2Y6F&XQ_:VMJ#/93"X,=!L)J,R
QN?/9ZZ:A M+RVF,(O+R_C/3P1KL]$R+'\AZH-FLXJ:L]4>XUY@ @=<$0%7BG #\2L))M>A".2BDL=ZWEQ,J_6+HM9C M6LY($G/_4&KVO=%U69J[9L"/2D&&1$T
M].56*Y"+.2+_Z@F1>OW6EM"J^$-)Q1DRSHJ.$Q';ZU_8*/12U"38>MJNZ=-CF92R[@9!$!5\]G[$W)G3R!1*:#ED1=1#UGEUD$IW3TSSP,>
M(_\%!T%T%@ZJ!D\5K".D7C!U4\O4*JDURF71*(J"FGBIU'^!IK.;&M;2V*.T=524'*=H. M61'_3X=GR:NFSU19 ASVS&RWB%.I!:'.K3!_D5_C8(;*+UKUES:12?7DV&HF
M%:QH[)F">ZX;3H$/CIKQVH.JNH6U9BAM.#,4XU;NYHZF2'PTY>_AT=0+'JL1 M(=)]^B^M@"^#*'U5<>?M7HN;477+:PU16G+6/7SJEY M\'TU1>+-SJJ\)M6Q:4-
9E)Q7Y59<(=G=5K]2:O:TN:QZ"_? M7Q77](3GE=^LDM8LI,3]6/-SA Q->>'B,'!9!0N>7NAC_LCF,3=H#^"&3R.R>W3V!LD06$UB^!G[WAWC+|C'&YK%%EEJ&U')<:1I1
DV)PL.QIP('PPT"J$3 M0X0?8D^IBDA;P702G'(3[0!21S8_![#N:^O;>$:S<8QI14';-DK>J]S1SW7^ MZ"=E=1A-2V6@\YCCRV<*20M445TO5M^)_O@088'7 ML-
G4)ZAM)"4_7.U&DEG.*O9.PE]-*2L$^]H>,B?#:?_._):U=+VB6AN6/'O9 M0^E<=\Z=5N^I6=:<0F^V[&R(>]K,!)$$*J7W2-!V#";Y&G"_A3'$*^17[HZ3PU3(^^\A:OQ-*
M.M._+SD>T^B*G)$S64""""782MD[$%TJD]>3Z*^9]L+V)Q;3^Q.[):EM%R7G8 M::LXN FSK63CY%ZGH-:2^NBIPY2]-JPJLXF9,!X,,"0J'N9&YD8UM!:J#L+*
MT"UN:H#X<2"I1R4/YBHH'U/"^",+<'1-%E%1SVC:>EK3501JK3>=8N$H'O&5 M6T3W=HG4Q!+:2;$M$:UM2UXJ0]L>)KL*6V^<\QJ4UUJPY$*JL.!A"C0*>TV7
MH+*Y*^U%*SYQQSB4Q9XZ(LX;=!NDM;:OR 32)(0VM\I-@,3+6J%.GB(L\5'X MH;G4M*DZYB,C.10"-EDTC643_5$EN79MR)B?MF&M2W!R7VA8,2ZGIVE8>72J
MRBHL3YV%:H@?VEM-^S]Q2"7Q!;C "V<'Q3L/SD1< >09\@*9X4=O !ISLN4 M?DZ 0\/MJLG(.2G;:B!X0Y'J;.3L#H"NN7XHN1XM-%<)N]!D53A)1/PPQ-9O
MJ356\!U0TK:=DH.R:=LY+/R;9B+;:/&V1+3&+ODPZ^8O.]BY?H:SS1&I9G6U M5BW'$!;RHAU,63-SVN;P@'IEM::J2*>K+KTIB@?+M+R(NO)9-JV9M;%UKMK6 MTMGEU[R#-:
(21Q7<9ZD\EZA$9??:.=/4JG!?EE$;MFH)F[9%ESS)YBUZ)0JT M:1?P 9U8FBB<,4\#'H&$6\:11'$5'LGD!,S!4BK%R(OERN4".#3^6H-ALNW-
M%W%='B*_W3!;A[*VX97)E@.;:6>13>NMKHDJ&T9)3^T>E<#X8SRQF2-5NS*CJC?2PY,K,Y0Z)^N>9=PH.] MUBI?&_G1HK[6DB6W8C-
+'J(]\NE@TL5/$H/*V8CD0NAJE=2:J^083%/'Y-8[M2>!I1'3OC9)N_ NW^*1Z/+E,4/>T*K=MK2AHC5CR V:-F-G_ER_X)>RBBUU[MO^E)]+9QM5*GH-9<)5]@QER'!+TCK9.W5
M!2&M/4O>.DUFJ-R(FC*-?6PQ6P<%V>H'NZ?JV]@GFU;2VK-FY#SE']Q3V=A/@9CFPRTK:'D0*K5NU=E0H M2(["Y%PX$:I#&^K0Q-H-D#5NVM95-
ZM@UZWKL,MJL+Y(HV$2I?9I+TI-IO)) M31!ML^AH3EW;FDJ^KX8KD13*JOE 5&V<^"S.9R4!'98H)U)7Q%/)Q.!,J<7%Z3^D2.\64S\I I1SQEH,N?^.\?')^>GI162L
MHA9BQ@D)Q-T2E=<+1>-,&N9$E9)$V QS&%Q/$O!'SDD' DF--Q4H;Z3=$L=' MPZ;BR"K8WSU)9--N*DFA-W0LSPF:S2!Q;?0WI2QJTO!/*0SC@4/1%(L9/^08XP;'>
%Q32A@?'DG_UT? M3I;*[8I(0W0Y^WJ8-&D.27'XHW9CR Z2,(/7ZF?K1U9%ICD =DC&B.0M3+< M4QI&[%LR-NI_7L!/ #'0.CT^/3L^/],CV%13_5LT']-=[UB$PT;#NNO%TD=U
M#2>3F(H)4]/1[N,)AZ5CS86**@U]^./QZ?GQ^8^-6S2,"6U;M*)1%!A'5TP4 M_\]'^H261TZT, =^8;,B8>I)YX0\0;LD5&5\YCY MOKID'6"
(ZK5D]KI8NC+\$V*/N3\2EAHHW1R'XK5Q@J>\|S=K'LMM%S:A:;3A=PNY]#^Z,'1L6>QJY[K&H4Y_OTR"_),6E[*MZV-%WI_P:/L%S] M>9E[N7(*D9"^R8K1 R]H\<3B]U(L#?(-
,74XV(]( )T#C%-E04@.+]2]<&L= MM@&BSH:U\MC0'X+:P20[-J1U!+7SQ=(-=GTY#4=K%/?-UTLUX'35BZH>HXQE MRKP((!7@17/G._)W)Y 8]\D9^"Y%/7
M!JT+J+FH:I))O!YO(9H.0'-15K<"JIX9RTS ZHG9MY#5&*&!,K2.NMCO\W9* M:(JLN? P82;9K^5TD%S%EY,F#V!]!;^_F?PFX)JK8#4\W,MUTS"4\X!L6U,U
M1@917C7E.9\.I!Z6KU\I5Y:/P53X>8E^WIL:EL1EMLVA#R0AJZ"S# TT[<]9@%W+>BXP-6C9:+@@ M6+8RNRV[R+4Y\&>V1'ZP?() 9[OMI))SIEA:/ MJDM,._-%73-
@R;@Z&.R-.58?OQ*YZPJD,';%K VFLY5<@;0=,L#Z.EPCV50YVZ\+8#2]8BI.Y6,3&GWH(4)J6M')D6 M^&G$\()/'IE"KKEHJE@/_49M[VRYFHI<#3:K:22I.HG+KV035Y;\9-WS9P+,
MX.S7#9BL.GAE@PD+!:(>D'R5!99W+.0]6=13#--.8%,'QN@,7'=19C'V[&-2W-#GK6;2:**JI6YXQU)K; M1X51413O9E4$LK Z1*X#8!@*M,IB:7>PK^;=7 C(JA/%?
Z7]47;.I)^F+S'$ MH29/"J7JRG86ERW@=>87RP%USYBNXO%AIA,EHA#V?+L#HH%GF91(BXB7G(3Y@N; MR_D""B!_U7ZLAY#4AV00PZ2"H8;
(_6Y7K@J^)HTL"#FUWXBRL$&1'7HKM(S[TS=Q"P^%6Q\-61>9IN M';8;MF7="*0SL>,GWR##ZYLXRTNLS2ZTB-Z,/&-(<"PG #W@;0F;KJC,?B#][8]$[0VMP0CR19*Y53TUC
'T['\%/78^DZYH8N0DE2_A+*=9-U MXZSA;]#<9 WB$3F!O6!*&']DLK7?A%A2_6"WR=4 TJEX[W=%O/?;$.^]Y0&C M!I NQ;O8%?$N6HDG(
]*E#)C"4]$R.FF2/]L\,HLR]H0U;8$[U.[MV8;H]J2 MX*>[)_7I=D4^O]S%1IY#M2W!=[&1YU!M2_ =E'HKRXR?[#?M6EBZ%=)^,ZZ% M94N-]\>=
[+4_6A!\!Z7>2H.V+>AF()V*]W&'^NO'ELU6OVT<3#C>&3'S:#H6 M='>FF_;FF(^[%"3_;"M)OM^AX1\WTK()"GK,]S7C:\7VK]-H %@X/.C>$"F
M^(GC*0FG\152NUZ_=0A,+@NFYG[&,PAA[2K-1HUG=W2\.SO.RG!(O+U=7ZIJ M)&85"(-H.<4>,FG_.B'NI*J%7[/0]ZYP;S;SB0NH+5_F-K$R=BPM5J1$D; M@
8W["#'.IX%:E"X(Z, RV^3JBNG+V1A=? R0F:09@-NT6+O&<^9/X=8RYGY6?@:P5_GJ%! M/ 67BZ")K>D]QZW-C!T3LCH)%WB:KKNLKJ2Z6AN]P6]G1>RL+E>Z7$.KD)MH MG]
?K9Z*$U&"58AR[E-\G1+-Q:V@KS-W:#N0=F\8K15] 8W,3EDZ8^GSI=7 M-,MF[+?KV:@'Q6#[0*@<* GRDXST=K<(.N[-!7G$09RVQ:X(%7P-]C"EF]|I
MNT^*_]OL9AJ",DY:M'HF[IOP;*V.JWD;="#&7Q&'B%$5")K=[4,WA5#1 >SY M0[Y\8.[W-+)2P L@ME)2M ;958JXS'NON1&]P_QX=9(A;@+1F4]2Q^H&V\P' MN!E%5_9]>?JEG-
5L0QHTNVCZ"S23[#IS^Z'8WP@G$[M$WLUY\[R^6:I/Z I<0/4Q7O4C2R7Y;P5P1X)$C-DZ8)G->>NY'J0>[.Q@I#) MOJM6>CU8_F/OAL (,E2,JOSVVTJI;P2LU9#3'PTFN-CG^Z-?
B%SP>F]@Z[5H MMC,25;(<\"./+0K&DCA6%1!3[:TF;\S*DCA;%D%C_@URON_"[V@ HP]\7>@ M#U2AL:> '>@!56@Z4X!^NDGG&8!*Z-\)[:(;U#B+;X:H.TW J4%V2=^GMW1. M.
(OS53Z@5_&$*;QT8T3YB_[HFLW00HHN0%40^@P"C)M7Z*W M"CV4W2QYO^DE"ID3N @.7+\DN'*#[W]^$A#>";1*KH^%S_3!;D ^M;MOPF, MA5$P9OF,P1OD8=X?
W1'A(K^&MM*&!MJ5Q<=ES72XGJ9L0WU.(5)S8TT0M M(%;D9B'?$<$S2&Q(#IR4H_*M!<\ L2'W"W89]7;!XEDD6Y;\$8M@\(K].?XJ MOTVZ.(
U%;T,9LV$I1=UU_'ORM>IYP$QSW;,WR+7WLR\$<-V M'!7/>.Z3:2<=LJE78L5Z&Z+U@I77(YR3,?%O5?R-=T\#=D>X"++NP%]),.G! M._;HCOC8_CE22[3;&KNO?42FXH:
(*1$">RHI)HR: P;M4N7KD[UQ%EUO0/Z MW0?B98(XB!'G[GMBL]#F.S?;E:"[R2*S"8_YR1:@5]K6GZ6K#V@+/H%["H&U M]N^-
&@#K4OJ<%S)BM4M^T0119XW^E@E"V6Q"?.+>"OD'&DLD=B.'-V P.?[T M./N"?0CK[5]BE>MQ6[@\&8PC/XF?F9B1@(YF28OR_V,D1], M7+D$DFUO3CS;?:0-0)-LT2,L-
Q(TL/;D4(%AFYN7*UJ67_0HLC73.Y=+)6E" M(=LW5$QG F7W=^)=18^W+F<+C 97K7* M*?J#^?"VRX -Y92]=(G=::,!'J,KF_B.\5\(@WTP'8B?L'V# MLQ88DV1B+IOB
5K8>Z0QS[!-9']*R^X#C66FS?4.5W'= 'OY9\MBRE>8XA&Q M=(Q0#TE7!PHIY=L%FI*H_R8W N]IYJNZJ7Q/94O/O7%N1R?M47:K+W!RPI8@ MP]D:JO#Z'AW M9?+'$
;S_@B.@<3+#.)VU>E0Q+ \3&_KW*T.#I/+FC36'CBN;#E^BUQ;K>EN MX2!R,)'5QI/ST_/3E4+>:H&W&9&!GS-.FZ>R#UC:*U;P;+-=S)&SFJ^GDK/) MZBRM8.M5V2+'-
OK/$+/[%FR9KT$:UP#)XHPO>ZZM)WW+-MH/TO-JOJK&#?7 MOPK5S=SAL62#:K9M[%"D:-46.N8F:60@W9,+V7;I6&ZR,R]+QT M6*<.B"Y% M@R@C:[?@Z\%HLV'>P,'F-
KH^%).)UM M*U?]AGHY4UC:/:[AWY6,MPL"U&^(F#&!?%N/M5=Q;3-]% C:?;:]FK>!NVLZ M\]D28XC8C/TI=J-]/P-PT<+JK'_3*D&0-O9+XH95P>-(A./MMWA8 .$SMQ&
MWP*Y(8ORZB6'JW8$K&3"QFB@M+D)KXC <6+Y1E%"-&5FT817SSO+!1 1WPG8=&RYZPSRF9'=B MJ^+<7(#L@^QO(<8:_B8/\,06C4=:B#^;JW@BNTD0-
\)H+MH73"4(5U+PB$L0 MM2N1EKM!A%[_J?=;__'6;K1=@6ESV%?P],AW%&=RI1ZRBE_+W<"['PK9X>R^ M;5?@:;12G1')AO%E?"G,*GX]>Z,HJN:@!+!;:[IA3R=E W_]D<\N)
MO;,<#6;D/[!G%W".HW&:<6!GR=52XMC&S9(A9M7%4L'7L'NJ332!4!ZXQF._MDU;S-_1'O(T<78G0GZD(&#GFQCGAP;T+Z,0J2?@#B8Z';2]+#;$9O>V3WC!, M@J>27.CW-
'5X!_(O 4'M"GB&LZW8D/8X#:)+$>'J;NI7]1[*L*:LJ' ?!Y= MQYN%ZET(1N$)",7V&:Y&P%!ZA001"8BE!F11&DO/(+R1;)WYF;H1H"<$5IN_ M5))G[.'I+(Y89G2.>4 DJ2M&O?

C*2Q?IX:Q9R%# G3=3A!P6"]%0^:]MD[(T M7?GSMH4XN@X'U-3HFVU%_]JF6"M89Z>>:.SC 4=4(-?^,9N&N<%^S?>4@#^^?)H.\Y35[;3PF3V/D1T^[[DH-#ADW"/J_;
["R&/9)UX#B(G#'YZ#I_NZ(KU :EU!N=:1NH]GF@=#OV,N4> /A&R(S"I"&'8$* M=4#4$>U$N!,\17_Y?U!+ P04 " #(@&99D8,]40E)!^* A @_?CI)XDGWAY.??_KK7W[\6[?[&6)(
M00S#SGC9N;SNWW5^.Q_>=/J8Q0 'L'-)@F0&<=SI=J9Q//_8ZST]/;T*)P@S M$B4Q?P![%9!9C__]E_2!G>';5Z?*_]T^KY[1Q9P-H:T^^;TS;O./T_??7SW MYN-W[__5^>_9[?
^Z7<%%A/#7,6"PP[G&[--)X3G/8QJ](O2Q]^;T]&TO;WB2 MMOSXS-!&ZZ>W>=O7O=]N;T;!%,Y %V6BK*A$-V5TKS]\^-"3?^5-&?K()/T- M"4 L]6CDJZ-
L(;YU\V9=\5/W]9ONV]>OGEEX(G1 202'<-*1C_\8+^?PTPE# MLWDDV):_32F'LJJ/]^0002*!08GH-(2#J:0ABSDX[H],NP MO\&YZ& ^!70F41,M>IH>>O7Q-
HKY_X4EL<&DSXUQ!F\(VX])552 [#I=42>:N!\W=.!O/;Q@G=)*()LE,QF@"X%I*O?+F$, M4&3-KV5OA_(<\@[1!(%QQ&'C<\LCXI_.&.-#9OU83:.J4M7UO /E'L132-,>
M^[,Y0%1:PQ"RF"9!G%"^NISA4+;J<8.U.19P!?5 M)!+#2O:MF DJJJ%BKU*& $2!(.$+W WG>$,6^!Q#',(PET8\9/^U1*[T)-AX M0B365D(WU24>P/@3Y HZ
6PLE]&$=1\!F/>$'GLPBEG^B]2LU&KVP^\IGGFG M$1C#2#[J]^T&O>9XNH032"D,4Q@>P'/*PQV,-7SJB+;1.Z.;8@ :Y#WSCSO0
M;6Y/LA8])F83T5L7<6O/Z2>4S,H5F#V0V+.=,,X'F8MG &Z#A(:0\AWJ2><) MHL=I+#\V"$MA_-\1'"2<;:Q#1-'>8S 4')?C\,85#O>4S"&-E_=\QHCYC'OU MGP3-Q5RL'R!Z,H]1T3-
>#LY;5^!<(\QEO>&+2+B]L]##8R+T&" 3Z^40O7,% MT6="PB<411HPUDT\5ON:R7(%?^=LH9B+4Q*^';R!W(,?"A8&DR\L-0G=@J&G M\Q@* ^?E^+QWA4\JRX5Q
=]JY['^MS@MU_?WKO0M3@#XNB7^$6O7 D3"<3J+ M+P"E2VXTOX H@1H<+.D]P&?+IK9ALA2D'+X?G V7("")]'0#R'GF:QM?U2Q& MCY;,?
[#T_)=C],$51OG!U5*_R=ILYC\&F_PJ_,%3=XX(G ,47CW/(6;0/"(4 M[?V'0<&X @\?"0S&&6-_4>BC&L%#,[\\Y2]P>02L3EA(/I,23+OXR!*Q)TB M_S4@F.\5$QAFVT:";?
=B^W7J/ZR'2*> O^0$H+=U@'NL9[HW"(Q1A&($&=]M MC6(2?)V2B*N%B5U7O-28F9FTP8%48,:.9<>F;JOW;>O?D$!ASLY.2PK,F6>I MLL:^0&*A?=.)XI??1]SM%->6 MD"
[D0#V+(O(D)NJR6>;AZIC;RK]"YL\.2W.V\!TOA MJG(BVVGFN9[+F5;E5 M![9ZNJRX)Y0J>XX MIFB:#<-4KHTFH%*VO<$J#*6%=@43A/Z;H*L"I/LV\VL'\K MF%VF0Z.
,Y<%NV_^4&AY#RDB(N]3Z!Q>PO3?U<[PZCF8 OP(AUS$J\D$!KH5 MH&E&&AQZ(NB<\WM/R0)Q4SE??F$BS>P:88 #D7(>Q&AABA&KTHG3H>K&HK:G
M@2KJ\BQ)>0CG8)E-"?E!I(@QTFZ?5"1.3:&ZX>]NIE2"&3.:N^Y0&TVY3UP1 MMBV:(\)M2S)CMG/#P'$I PA#=LW5<)\Q?4VHW.55FZ(K]]1RD"O+ZUD6=9%_
M89MR\]YG+!%QA1>$:8N*V! ?$;XJ$3W+VRZR;#L+:VB."$"K6;CF,.5+)#C' M(1-'5_)0^&+W4%@9Z6=+W5*0*LE8;SJX J[,7(2UY/%74;0?81D;[='T'3B_?L=P"4$!+K:!N-?
B6>K^S:G%9PT2H QIK)UO0MA3U"A*:D_H;7L@54J_" MX_QW4L[^>:[5U)7S14)%$O#NH1]>CDJR]>F-BLJ),@/A23+M,8M_TL?AWQZ M4Q:\E3[,]>*ILJLG#*;>
[Z/4XQFL&TL+,UIR;<""Y=P3B%?125B7-29B!3_ M0W[53$M:JI8:@I5L-9=9J*$@Y?:,!E)KKYPJ]A+2_';2]9FJD)P:28HSKW0LO5B[8%J M_+D*?;09PVJ2FDM+-'\:Q]E/7P&F.XU9-
6HI5F6B^%99(M]$K3=K!EQ4!"W' M2"66;X4CY,WZ.5]T0Y&(3$S[2I5!"W'2R66;Q4DI+=2(E>>\K!*@]! 6*&/ MEJ-:05+?2E*D9RB#2?%<98 /.L'1F,2+/.W;6=?+Z-6^
L>W)*QZAD<= Z$Y M#1S[^V5J0;G6]]&XJV.R(_C>R%?NZ?ALH+(*[&NC.)V)%>_+;K3FQS8'%BGP M6JIF*Y:H^*BYU%3M3W(]1LVHEQ1.J5=9YJS6
M'A6DFU#2;WXL_2%/E$F7VY)WR_"F-$Y4Y/O!-;[$LEP:&30SW/;ITM-:@; M_Q)^6W2)UM NPWS3YNQ\6*.!EW-"_G1.QR%.QO/YIBYJL]R),RHR[9ES.X0+B!.8FR8%0?PKBJ<7
M"8NY5/3J.=NHBRA#_E^H=U?WZLTIC"5FMWOCM(=0GGF.HH#58"("WN2K)2!= MH "R$8ETV>XZ(M]!T_%N]!(;KZ;((%>!N,R\Y+86D;F8S;/W)Z[-*TNU[V.9
MO144Q2$EVLIX:H+2CJ9# 6 MDFH8I,\0<[DBD= 4SA!&+*;R^-J,E)&R+7 9!3%6E5PZCDR#*D.C4DJ!PX)(FU'7J6#9^+V#]H'INX1M04;U9 M[6EH7!*
(6BQR*90,JFK:B;04@=J*8RP$U722$8%(ZF'7W&6J:/_N)H48UOA7\66DA MXS"M9Z1;PI04K;@%*.';NY(]]=[]',>M3<7[EKWKY]1['7Q@G,(>??E_=;N' M4.9J-
8V&'_1#;GIH@@33VQ[E2*B*+@<37:-+\=Z_J,$8A6MU<2"]OV(B;'!@ M:5B1)]K[29&1.ATV=NALCR.S4)X%1F@8+KPRT;+TTSZ='1?(2C'M7W?5R&3)
M%VO,C8D[/NNY36$H;^%DM)ZXKJ$+;:%& M*VK'[MFN_G>W?A92>#:[K7@>@J=;/B@I E%UV#3$[4%-(X1GT5$KEG\E].OJ M?K,R:CKJ]L"FD*S<*?
5NQ,DXWTLTIQ9*"N_Q47)N'0O5Q#)?>'F)Z5"Z MSU7"1@&?UA-1BJTJ9=4=@_'N(,^CSY]FOC38I6ARSE(7BO"7?N" LKH5SYLCL+ZRO4"AVV ;)#9?1JJU0XN-$EX39^,F*335R:
<7H/ MJ$4YQD-Z]B1?/;TX?A$UV'7M?;:YA6*J)*+;:<6S?=T@0"G?0QA$@#$T04$Q M\& GZ=9L./OVZ*V]5!E).P:SKS:\VW!MLB^NN<](@-+R+'%:H7-?DZFC\Z.T
MGCH48]PCN@A'5>A*KR6==WA0K][:S@NM5$:%&+>@VENYGF!H#!C\Z?]02P,$ M% @ R(!F67LV:SJNE 8LD) !4 !T979A+3(P,C0P.3,P7V1E9BYX M;6SLO7MOY+BR)_C_
OL=>GO_[FZG\WTP9P=9?G3[CJMLV*[N&2P6"5G)=.JV M4O*A)+M\%OO=EZ0R4_E@\"&1(N49X-[3+IN4XA=!!8/!>/R7__IC'?_TAG 6 MIO;S3R@)TT64O/SSYR)?
_C+Y^;_^7__[__9?_H]??OD=)0@'.5K\ M]/SQT^7US;>?_ON7A]N?;I(L#Y(0_729AL4:)?E/O_RTRO/7?_SVV_O[^Z^+ M991D:5SDY 79KV&Z_HW_<_RA3\]]'\](_\D/YV-?
OF6OJ'U,*_G)^=#W[Z MO\|&_QB<_V,X^G]^^G]G7_^_7WZA5,11\O=SD*&?"-5)]L^?]][SXQG'OZ;X MY;?SL[/^;]N!/YW8WN__?>OMX_A"JV#7Z(-E-TL^AC>O-YT M.OV-
_94,S:)_9&S^;1H&.>.CE*Z?P!'T7[]LA_U"?_5+[_R7?N_7']EB1Q<9 ML\AWK]E_P/"W\H_4W;A-$8/:/D3H_0?^<5PCEV<_T8=^?[@Y $D?\+H*\)H) MF([X3?"$WRS1=A]@LOQ6*
(_"(&Y.Z-'C#%+]F)/_I9]*=K>\(5_;&MVF63W6 M0H^R3FUS9BL]UQ*.BW3]BM$*)5GTA@R* 'RN+1RK('E!V4UR]:\BRC^:TW_\ MO';H-KN8Q
^WA2C(5M=Q^FY@#55/LDVK8;X#CVV(XDN01>3I]QAEY*ELAU4F ME3NW*5<1SH,H><)!D@4ALVO46<>;VY">!_2&D@)=XW1-))-C\MSLKRA?7119 M3O0/5J=.X4D-
:;U)R!OR%$=(G:J#.4W?OR"/BI91\!P3]4R,O9>(_#3+,AW3 M1OR0AA3^GJ:+]RA6_QJK"0W??(F>\[OG.'H)]-;TR;S&=.#HC3R+;J!9CMF9 M(ILEBS_0XH4<2V;DLWF+
(]3K*M\^O1ZCP&8TU!C6BGH(?6AIC;T[#]]^1?0R7W_;-^C6(,(/Y M@.@Z"O,"T_63+-BH&[(3JA.I_^"&2*X"G)"'9LS*1OB1D(.4J>5/;DC1+ R+
M=1%3.X+A;&J5*S^O(=V/Z(4)2YFP:D+#-U^3=?)G$!?H*PJR C.]H$P%?[)Y M:^B);HR-;*+M$VQ;1IJ4*C_/G)6D22%GID6+299M:2TB0& MF-V65:5-K>9S6]Z/->'4?
7P[.Z$F&,VG&MH5-8D\GF9AA]2D2/0(\[Z,V6(1 MT?\&\4VR3/&:_?(2D2U1_0RH^UCS*.@-RJ*(T=V2?C9A?K>DW\S&-W27;/;X MVRA!
[+,AW]"^K[TY7#/O]XTO!XXTUTSB$F/>>F2::O\7)CZ0QN^Q;8F: -GL M);81/A;K=8_[I:741:\O&!4VC=T#;*9V9>/K\%_IGCSS\<(QKO-'>NV:R!2?9O'\8^*C MK?U\B[@J=@H&&
<2I]3Y#)\3=.W>WA4\K=!%@_$%-_'5:D!UQN1W\Y6-CI6J" M-O,RIXB;F" 6WFR(%R:^7*5GF?4D[.GJ58KS)X37=(0FX7H/M88)5&*OZ4Y M*B\VB"%F# ?\Z!;1-/ER&K_'+$X3GXO.
(]OR=>T4VHHZ541MEUBNE8M&#G M(&V@5M[>.D\NXB#+R&9^3<_13\^)T<.MF= M&UCV&6;1[5 MYL(U2&-;_#6C\TV\K(68#!-@&[_'7B2'$1=:S<>;B_\PO4CRLES+Z/L-
PTLM;YH@)96;T MG1:BRTQ@U'YN.S?QFB@TG]H.AB8.BB:O,!1GL/NLM_Y"G"XC75^8VL-,4;S; M3(]NF\C;%N2+99:9B\QA-#$%Z_T+
M1(KLE9+^\!,'K;Y1EOZ$XS^AOZ",SQD7&0806ZU.T)X]@8.G8WZY^Y-1> M>(]154(@8:8H;J-L%R;8C4=!U$B1U*-X]N1"A[MQB]K5C#"))6'SVU"XHI0@\/B&?VR@VZ04.
[3FY";I/G,Z'>S?2 CBJS.*(G* M[SOY^^ EB&J!!5IL7T.IJ5]<@E4)2<.#-\2T+D>*:^LY^IM*S6U^,=]E/N_B M); MXG2MQ*W-.U,IO>52_$>8)CE975>E/YXLY_)@4?T]3C.T(,8
+@A#BHR0G;Z6 MENO//Z5X@?_?^[5%E*&PE]?TK??%B@JY4-^J,1"_C%G%P9721[E'[,?$6_Y M<$;-SZ=6!")05P(![?'\0#@0X7PFGUMD,/:&7S]7Z^L4&5^>'!HHU[AZ:6
;86Q'.9_.@536^"0Q]SE@DKT"-'PZ< MGX_M,)YGAS54Z!S*^9P?.N#\18'IV5-9 $?CY^<3EW+@L%8D Q[Q?%&,6A4% M#4.A=]#D/[3$SUL0,W]AO@TI9:=?@6B4YL\'Y^Y%Q9,
7V+JF/@2'+?[,84A M"W5[0"$BM!(CXAO*-V!%WY1@VGS0[Y*\I%#X8IJT*J9M.L4'H4T@EOUA\X&= M X,E,9R0SF?[M%6VWV/T&D2+JQ^OQ*I!\L^".WX^&'9)$# &X&!VUJI(]]:
MY?(X'3P?C+HD# ((GZ9^3Z=AA+X&.Q+;_CM'C=A<&0WX8L-*U B[O7C4]9 M86.I_=#YP*EEK;WM-_,*K(#Z!_C&EKBJ!3X?>&!YZ\HGW:]>UZ2_1A&2 M%KLPRI).L7D
3YKW/5"+"LR%ZI_T/\H8BFS?L>Z"\%R4@Q)JUX.PV=QH M6$&0H8?H997?+;]G9:JQZ*,1S2/PIM-Q-S2:&A! 5NWZ"JXI&]%M]$;U[V%. MN/AS$D^<]RUY^@U+2@$%(*9V?
055'5I0(-LA\\%9)UA_0"_Y'8]]LBPQ*; M=S[H=8+!>]0"-X/MGO+W@L_(UO68I^'?JS0FE&1E*7D%M[_J(^9]I]^ UHV, M%B9 D.TZ"?8H5K^Q@2?-
^TZ_)RW^2T7(PP8(K=US/:T0(#_5[XV:#YVZ."4\ MA8Z2A^0#G-0I4("_IW/G0Z=&^ MEM340 &RTSKK \J-I6^B[7T1J-&.ALV'3@]]^FJ,1S_ U79/Y&<*W5+X("2$?K,
ZL^;TW_H'BQ76*Z2X'&XP'@\EPY(N!J_A= MJ*,"Y-'NN5WK0^$M+*>Q2+6^$0 %$*OJ[)Q?71_HG1!/Y\W[O@C)P"$1@ =(MK]W#_?8VCM[#;(^+Y2"1X@TW;/_K6D* +F-JM
MKMPD@ !)M1L"<)LF+[1&Z$$-2I'.Y(V?CWSQW&C)!\8"B*;E$("#2[TMR ^U M;TDVEUT*3GPQ$_4^*V5L@!C;=3;HJD% 8?CBL-/[PD L@&A:SCP0=3H$!228 M-1_Z08&D$.
[00*UKE1%\'TQ(^I* M28(-$%]]S@OZA:<)HU2:674T=#YRZMJ6_&$ M6=FL#Z7=['3P?.S4QUM+5@ *0!SM>BQ. 6G9@?.Q4_=L+7$ * !QM.MY^!HE M*284W20YPB@3;5C'0^?
#KM]^Q=Y]BQND\Q]%SD;,(FI1Z M3FBOOS2.60\)J3#-O& ^].6RQ-QIK#8?@(7CS.W!98F:+X0[=3[TY8;%@(,$ M1@B(<7NJ_>VPL%V;I>X.BJ!VJ.[=N-U/H&
[=N[$=QX5NW;LQF#O!H?=3U[VS ME%C7I.[=^"1]&R+<_[IW8Y_JWE&6G3+VA%[_Z]Z-O:Q[I\1>S^K>;W6 9H]GSCV%&B(416.%Z7X*EH98=FLR%?
D&/WORLH5"^QXUGSB]%Q15U!< M&#Y4VCNA\2;+"CWAE#/FD^XH0A$$'^KJ';AD-\0R.E6=T?MSYA.GD3Y:@A&# M$-?
>;_>LO8.5W2VK"XT.G;.G]=Y^UCUG3^VXC77/V5,PCX%#[Z<^9T_M7#,W M.6=/3\(%(<+]/V=/+2GK6N?LZ8ESE$NO_^?LZ_TZ9V]Z!M+VY#24 MD[K0:=_9BR++R1:
(KWYLKD-HY1;R?PMQ)$2-I\VGOE6JA[>&NO#\.'%G^=V2 M5CABMQ\(OT4ARA[36'PT@";-IXX#_33$)D'AP['Z=TR;I[(>I)Q[(V:3QU' M]&GP_YAL'X[)M%
((P4Q+Z%_23H,IJUFX2;NO/N3P7T7$ZH 2\LF:R>A2$NJ_MVD^=]\Y*Q E4H0-D%Q(DID$HN.H/AWEJ8+%1,E\H ;%<0W* MO<;S' G(IA!R??/+G[)>#807Q?
&W%2LKZIC72O!I<"<01+YYX05?A ""B7KU MT(=0+0"R_>6X"/,"ESJ4A43#GX-LXGQP-AEZU[+^BZ4T9@H8 \5QJ$'[T>4 MYZ4KKDS-IO:%.#]3>>Y\T#OON!9/)"K M_X]
(!XH7M>V/:)3L+YS1!$MW? 4@_5Z4L?^6)BEWR0@D LXAN+KC0Y"@*)P M?;5DMA["*"D(O;O..MD7M$PQVG450=EQ#@+1W8=/*4.3OZ)\E2YH[[(LATQO
M!U3,>SW_]TAG?/&B2O\.S>9S^4*.DV(G(S"#8.J.>T.(P8O"_F:_>A)A =.31K[LA38YQY_O0OH]R*Q8R>\#.=[@B/_MJH1&_C%_")(7!"1V'/R]@FC'Y&^2VG'_0-QP1!,)WEH,?
SK@6+FL;P<45%L MR?Z3)GS # 08S2'<=.:';5:[S@)ISO,6TD$DO/]*6+8NUD+N'XRIJ'=RNR!: MOZ=RW[.NA=H[]\,T M9?Q2LDD9Q5X8H[:RC'OG=O:*)K9HR?
4#^8"D^Y]HW#OW*=.8,>V4MZ<4^Y]K M3,AT;68VX+!?Z<;:01-N>RSJ*?5CNGTP,%6JM=\C'%%[*J3%6M E*O^K<#?2 M_.&$G;Y=EP@$;
JO#QG'(BS7*4;12U(6C@L_GG"09(1X*IDP?X5LXC)V>(_MB]($5^B28.>%A*%.8_Y-+0G]!=>49P:RL('LG.\) 1C3JFB_$Q926N^22*# M-Y:X*%@J&K,)!J=W<7;DKLT
'_*HA8LT2B@4MA#OEO>EG4/6Y[-[V^;X'R M#4V:$I&)",3U2V/*=U2:;A%AN$W$1YVR-"U MZ+A'D!,GL+1I%'O@68UUL@ MZF!-
).O;7!#UA$VP^1:+7D^0)1!)%K_#^Y05O0/,;I)-:YL.W:.TW*BR]CW* MP([S3?L>9: :V\,H]N(>I9&""=Z/]#ZL#;!.%XHF$M.3&D=S8:[.;+20#(6A"1"_FXOOJQ)RB_;H;V2OB#
MD4C@6(+?Z>E*\#& 9A5F%?MGR#TKU&02V4P>U_L>EA\R'2PY.(Q.I ,$Y!);3 MRRMM@4F0^.#9+[-_I#+9'T:(=YK3I2V&4^*]<,KS?7Q248BFS7M#I['*VJ*1
M@_'"_=V5SN(]M]WE=9U0YC![X1-7;!QWT&JMY[8_N*;$3B@W4:RV]>A(>K,^ M\JT9G(#M'-+]J4=K.RK N[ZR D&I(_*B1"U3P.77?,F*49?A,*R#ZC?TSOXB M=J KS)^/1V=]
[^I=RK8E951>U+<%2"[5=0-)'CV +%W?*A+KRY&+R8LZN%7$ M:?:4 HXT1OUSD*$%53-$Q["8L0=$S* M]T8=,DS;X887=6Y9AR&T8%FB[(.Y8P1E5S\0#J-
,:,=*YV[S2X>C#JE_/51> M%,4]KK>\C6.E$"YIYQMZAJ(8H#/4'^4A3"!K4Z_8,F\RZM!.8@6\%\5X^>1N MXZ'9)U \9]$B"O#'YHA.=LT@"265\VL^=/=IC3MD]!N"*ZD5[$W 6%?+1?
7& M;=OD-:/'QG8NI;2CQRB_(,OZE&*_HL>,E83JC>T$2#2* F/\/I ,A^AN5'_J MC2VY/S7+/C&6 3S=)[4;A9X(J:[CK^JPUX.:3L$/>4VG_3'SWL3)V8:[.$\9 MS*'5AU@I2Q&[EJQ&P[I:
XP/H5*&(D+'EI+[3$7LCD]JVB@ \B%DRIA\7.\8 M]@0EVU?:=;DUC-@=^Q@"-09/QP ""T*?]MR\URG^AMYG89@6K/OG/4X3\F.X MZ0PJWI6TGC,?
C,_'EDI.6=JHZN'S(L3JB3S[;CE;E'3((P\YPTM E@)%E7>O M>C+@RU.(THMP*W-B\V53:TE^LIVN[8 HP56Z[FV3]K/(<<>[@A(BGUHM>/ZF M&0?9ZCI.WSM5J'7:
[NY4VT4\M;.PM5W$4S![CD>Q%RYB:X5:)Q[:=*FXKB*Q>H=;)B2KG4^Q_H59"IFLSJ0&'_4K'M>/9W-X3G]DY^QO6,?J8
M?/!)F_&C[5"Y/C"J,U_'F;8/[_,XIRM4KO5@6]*3*]SBE!"^^?'PG1]B;Y(ZHD(#Z^&9A3J#D$'[N5#)U>4G-? MIXW7$9X[S0(VNTKL<(_B^&;]&D28;6YBI<^?,.]/S\[Z3O>
MN4K882)U&>@ M@T;UQKOE;9J\W$9O:#'+,D0.SLGFAS]0O+A.\6,0HVLJ"T3^+M,C:<04$Z+G+2J)>JPQHL,;)9(_N4XD5QT5<2=,!_TSJTET_@E;T5&
M>)&:S789#KYM>,S.\,RM)ZCM-:#/&Q-YUX"2+]TC+..7&"(\ M:Z5JO@VI>)UGS,_==B9O5<'K,T:24>V;9]B(1WA^WG>Z),QZDG1Q Q)OUQ\) M$%VN3D-W 8*'$7YZ5UI#^RY
B@^0M)8G$-;BNP(P7U!">!A&05S5=;CZ$;** M"/2\B<("$^K^3;10&<^=$36(HC=Z"PQ:\<9>L+T/Z[OMY5I7AGPE;X$UP&)I MN85W\+&M*!7^JX@P(E@7!67-
QB$AND^2S:TJR_AXVZ2Y$NJA!H3<;A#9_OJ] MC!CJO,#$6OE29$0=$JHEUX:RV;0U_=FH]YFDK ,:$'*[WKF3=5E1RHI\4N9L M_B(LGZ;QF/EP.)RZJ330TK>M
AZ0O@G_W(:>'3E?_PW8G6GM_L,HD<,=MP$ MU77-)\W/SYVZ8TWNWS7! Y)U6 N1G#&_!CDE^8,0?)'&,6)-XK.[977.5%7F MBD\K]=SY9_K,FS !6!1M]\?XV&9M[H-A*YC#%
5]K_@D\F$X]=[;T?=:X('4 M&2]"^_1DK_X0@MSI\=VLV'5Q Q+WPF5W'25!$AIRX @>1OCI]#AOQ($CQ0=(M6LM5)W;@4/VRK=SZ+4TNJAJ=[.)H!=:\U7_(+C!YZ./!3"H+V!%3
SX@6!.> MN5TX.*W$S6KM7IP67H4OSY5F5UA\5,-U1%D#-R##=AUF#^AU8S24ESU/"*\O MT;-(V4)3"#BGI2#,2%,-)2 [AWXP0AH[TV_+'E^D_*]4??)\>#;J>>GJK"E2 M#V?
ZU8ISA4^3G#.?'(V'7AY;6E FGRD@!#;3;O\9D=J#FS%+U/A2=14^#RBK@4>6 #MNJ;4^6#D?$I. MZ)_(B-+%#107:=<7=;5=^[FFRP;\,: X#%U*Z;JQ&.LCK=:6#]IG_K/L=*
M+@K66;N$$ EXUXH,7H(N> .LSG:CZ&PIM:9?KU,CM\6U4T(%ED*[";>-<"BX MZ(T\O[RVG';(AA_$)4GZX.I-'^#V:G[R;#PX!6B
MP0U@!;3K>3SA0NVUH/DDQH>QVX2,5E9%;;X ZZ/EMFS%ZVM9>3:(MTE"-\DR MQ>NR'H%\NU!\ E&]';(SM4 !@C01AW<:]'WW3),WZ=F\<>"]D8=7[5_=EES2 M$1CG5M
\+X!5H>44E5S\DB-,'&"T@/JL2N]^I0_8(AI;ZL+8DG3KX04DN%WG M'A23[VKST>%P/#YK]W:G;G%Y0NK(4@:9;GWY+=> +8M/MQ=5YOTI'Z MIDF%U)VTQ*(50K+6X53'(V^D
#%#9"D'P%#%Z"W3 4^Y$):UIJF.!.5+.55; M$O.KI/XM8>T+,WL>49Z7^GRVIJ;H[#T@!!'CAEW6$ML@_Q!(5.LY6[MHX#:J M07M3K]27(/?ONWW)
<@B8NK=$[.4FKVL"$YW#+S1N#\>M_M=U#7P&*E^-!#: M@,$+9$T'XA5#SMT"\31Y+ MF-KKCWWS4XF7A1&\8MNQA9/NIB89#I(L*+/@.J3M>J-IRU[;NIW2;-W(:;=*
M8QQ3TG,ES5YH.6O-TD:6"E V:MK!N?. B?>_7QJATU(*2[V&:8QMI^SET.Q_ MRS1*I^M38",F&SWB 5Y[SAYW&6548Q48B2P;C=D4C'>M+SBZ7A^2Z_/8 WI#
M28%H6#3+%R,$9W]%^>JBR/)T33,G.V2OC*?=<+X30OUPO9<<4[-7&,V?VUX9 M6ZJDW,A>*?DNMU?&<*UCK^R5L2U-7L]>&9]J<8#F#M@KA$XO[155)OOEDN;L MC?
M;HXK71O41\]][$;4R9YN:@BTS/K?Q,K%C4S8S7D[;EL#$=\%XF;B*1X39)MU7 M)Q:"#>WPUD_C19')OADOAUNAK@TCG4TQ.RW%J[DEJ$-R;='L^JEVR7H9M5OE
MI[[U,K9SQM>W7D9@@RAG9N>%K9KV,N<=6/O%=L%XL!;C6M5Y&W)LZ M#LU=L%[&/3^M%T4F^V6];+= /:M%,(MB]"V@5[0%R*&XME)HW<>[YWB35]$I
M5\NDY=9(M8V5B:46=MK&"N.8FK'":/[B1L9*R7>YL3(1=!;R:4.= MV.KX4<]886R3[:,30;<.SWCKI;&BRF2_C!6Z$^H9*L ,BLV[L%V!ZA?#<&^@ MX.@MH'TQ;Y*,[#
4%VVS]@=:O!S6 >Z0Z3(]Z\@MT=12>05MTX5Q3,UT831_ M;M-E>N;A+='T-"$?)KX#ILO46=4*F&VR775JHR2%'=YZ:;JH,MDWTT5QC]2U M;^H_EG+)NWLEP29B
*MK2XDMYJHR!J7^-LTR&JE,$* D[)J1-.C(9=1TZ,EE M%..8HI$T_/274=.!AY=1)=\5C*1!-RZCID.O+J,8VZ3[]['_;EU&$3C^-)$4F M^V4D,1A?
@SQ'.&,MNO>V115K2&D^Q>W=!95@6] !Y=J^N4C7ZRC?FC:=-6LF MPZY<6PU]N;8:JE];#3__M=70QVNKH>*UU; CUU:V.B37O+8:JMRH"+H;>\9; M+\T:52;
[9=8(=D4];X_>@R@G_+OD@C>*6NA<6SPW"?D1/04_.F;A3-K]!.I; M.);R0/0MG-,$&R'-G]S"F=C)+6YFX4RXNP.?^"Y8.+;2/FI:.*QV0=WD)W@:1>E=-T/!)J" Q;6MPBJOESE9-
^O7(,+,UF+] MU(HP+S"]1$L6;%1I4W3(H)GVNQ*NT_O'J[3__SA.I:Z,C>[B>HKANO M;9.],FBF?;_"=?HJD23]CH3K]#T-UU%DDRW7E(R8+=V?VHQA(/V+XMWQ7FK*;
'X;\PP2GWJ4;!EG62O MW=+MOTE34NJC4:/%:K\,F\><[..K-":OSLJVO]_2'.G=%"D_@W'@W+?X7MFV MH0O.M3GT6&Y=7;)W>M.N!/5.?0GJG:H']4X_?
U#OU,>@WJEB4.^T(T&]4[^" M>J MKH,(_QG$!?J* DH?VYTZ9,F,>V?=L&3&/3N9I_HE@'LG*;U"FC^W)3,^LZ-7 MFI4 [IWT1H&)[X E,^Y9.H36+ %\=I)@"M#<
4N&T.FE):/*9+\LF=UV6.W8 M2MG6PGD4IZ7V8PW*,/;@ H8UW8+IW\W4YZ=EV]\>>O MJS?VL:[>6+&NWK@C=?7&?M75&ZN4?!MWI*[>V-.Z>]L;B-0]S%X S1TP=
B=7AHZJDSVRTMS&67!RPM&91>@N^5FQY0:0%KS*6[O MPH8%VX(.*+&)T\A:)5853:-&^ U1NVL6Q^E[D(0HNR@PWBI/N96J]Q@*R])E MN5%9-<#&%]FH-
:MTVY2=5EKLG/TYWM76]=S^'_L7$?I.]I.BZ8*:?[<]N=X M8&5U'VX ;3L:AN0/V)Z'32_M3EZCZ#H+94L;^!W$VP.>KA<^]IN%H2R:!E1VHY[M7?0S)EV)1AJZDLP
MU%0]&&KZ^8.A)CX&0TT5@Z$F'0F&FOH5##51B=.9=B08:NII,)0BDWTU<4=2V<:6BE#HVSQC MY50V1O,GMWDL%81J9O.,U5+9&/%=L'G&7J6RC?F%G3@T=\'F&?
N9RJ;*9%]M MGMV6J&7;G,RB&+U+71-M 5(HKFT5V@#^[CF.RHO.#KII)EVISSSQI3[S1+T^ M\^3SUV>>^%B?>:)8GWG2D?K,$[_J,T]42@=/.E*?>>)I?695)OMJLCRN4IP_
M(;RF6Z2>W<*?2M%Z%_4MV@S4\-@+?[I-DY?M6Z]^A'&QB)*7BS1Y0SBG+B!& MC5($E/Z3YL/AJ#^R=(=N5%Q- ;J.A;I$.'HCUBLI3#]_/86IC_44IHKU%*8=J:PE0E
MU7_:D7H*4T_K*:@RV5?;E+MGZMFHXD=0]-Y=%HHV!SU@ M01)&07R?9DP2NZH2!H2N^R;*0SNN+"=KHR9\L=G6\0!OD[Q M^FYYCU$>_/B=L(B6A+\
(LM5UG+YO[.3]U:YT)C+\FOEY;S >#":3L7<1EIRU M89T#_.4Q=J1A6&N!:O5GW]+\$F712T+[#LRR4V0[-F;[WP3"2\(?FEU#SFA($O M7H2!NA=A\/F]"'T?O0@#12]"OR->A(%?
7H2^R@%WT!$OPL!3+X(BDWWU(AQL MDIL8H=/Z4F4!Y;B,]K\("7PQ"=R;SK] M=>Y\TI^>]79!F7Z?4!BI?M0DVW)-Z92RI?M3GU,82/\J0^QX+SVK; 'X?UIA
ME/J41+!EG<28WM+M_YFEI-3'4XL6JWT]N>CLI7H&4ZTG,VY-?+OWD&PQAB"[M3F#8=@SLG-W4FXXZDKDP'7F2N< XINC7'7WZS(7IR,/,A9+O"G[=43D:\XH/WR[G&ZC'*Z

```
MA=,JZ+O],KU(DRR-HP7=^%6,)#,OH)SS+@M"L+$81>U7W%FYH/^*%L3*8Q$ ME*Z]@OE7Q!S#A-!=K?PO'P3TH@A9?/XCPF]1J-;1R=H[*5^]JU4K,E,L,\)U M,@>O V;W+/-
QK^5 K?I],.TL_AI],$]<"D*:/[=E/N[9V>$:]L$\J3,)$]\! MRWS*Z7-EKFX(V9 M6&!ZI?DER*):1>&:OX?P\=R[]%?1-F,!O _F^@Z- HCO2?I,@U+* KRO17YX M>-
'JO6KP=92;OCG'14O)(@]\B#,Y^CXXR,@G\RU-<#TM9.+QE%N6XBGMKICF MF%V'J3#*6 I,1N"S13Q;+**2GKVCZB7*@RAN\51WA7&*+U),>,A*51&.WN,H MQ?>(_.]BMOA/Q?
YK' ;/7=^/FC9>U/SJ'@^=''"8X"U2F=*!NY3'RG/ M+;6R:7*B++DN/5 RTOT_3YZ/+<6WUCI.GO/;T9Q2[/]ADI#IXUE2D<,MG"0S MG.]I?
O*OBM_D'_.'('E!@*HX^#OY(/V[$.8H"0[1U@Y:*KS]>F +\KA;CB"D M6DI;D*H(#LL GNZ3:NVP89JKKO5#'?;*%$.[-PCW."7?:/YQ'P=)3LRLJW\5
MT2O]"LOT%$!]:,PFD.UX@PPK%VU(XOQEQ]*CI(([K<9L M62 T:JNK0%HBG/ M8Y!\>;:;G]"*/%TKS78%*U.W+5?:*\-B*R_1ID:"1,\*9A%[U+_MO
M,28@7]2A>4E)]9\!CXK,C5Q="HNN/PY';8MPCJ:=4&TR!,"]J0%GASKSP<^# M.ZXBW]5]JHRG0@EP0 R,.#):$$&KC6466'(M-*Y 3^%AE;:&:'BRRYX1@7- M24$T^=H7:RL1&D!
6@X(H/C91FFNW8/EX-'>*E3"X^O%*UB3B;1?J MDRLD3E,5C<=/U>0 (,MV_0U?BHQ RS)BK#Q'":/Y$$FTA;(-V_T0F'0UGE:Q MQ(ZGWM6B,,428)6T5PJ$$[I:9070XM!A7I:,VY;
[3RX0SFF5]RU[""^_!#&M MA/VX0BC_7S&NY9K9"+GE4]I>KJPB^7O42\-C&S]\QY9S.WNWS=EO 6]$$AE8-\YJG)5M)2HU.K.?\8#0A"--!P6V* MP.<#J[XL/ @?
MG)>M95[W>2\>G[244 'C:L0Y,<0)0%1QL1J?8O2(HL_'M!K MBLE13"@DV;2**TZ2>.M(2@N2O?9;LBXRH&=!.G$'X,QIR1I;MF,-)O@0.KTK
MZ%25NA2<&SBC*T1=]@M(CP0RY#X$4E>DT1)*I?>B("1O:"=<^8*6*=Y4-7T* M?J#L:Y2D.,H_;LC1!!/.$+8=/J6\(ON*\E5*_O*&-ER4AJ&U0D4E@2X[*J5K MSQ5'?
0@FWV':N&:_H(2(.)>NOY,9%3*GS1[:62MB]%[$D%<%! 6RK 95 )PV M8K$M/@"P%^'DWU"N9"0$'&MR7H,76"-]K@T8,MR@4NECE MDRO CDO?*DF$+TY-
E/9B\AM]N,3\CHL%S0Q-,>-^GN/HN MQNQNJ[PMT/K(Z[R@8ISC(ML-EH<%3IC(&C"Y8=-6*RC?BN?OX[J_!CVA=K(7P?D^Y#E/NK&1T M_>P@JCA]**)K?
1\0@'=6D[I9:@HUA5RUFY.Q5"@ #@AK0=^!1L=83J6PH#US(E=81Q($T0D?^-HOI>]1UF3#OE[2G%_C>*ZOO9 M=%B1PYZU'"Z>,_2O@JBYJS=4]E*058KESYCWS@>]
<=^#W@2U=8TR0A_;_7*( ME)8G!>=LH+GN5B!EO+*\CF'YT$[7BL1<*T+;HO.K>]81N=+JZ-SQ&VAN[_7E MGXR2P(X1^>">V):GV]/YDBT-F$'V" ]J-#7>SH3H?
$A9TN.TA+J6DX%H%K-ERB-T_^,PDN412_);0Y7 M#1(-WWHBIVY+ RA^'H^ M#).)+&& \T_!WV@A8?G^F U=T^'8:=QM?5Z#8$PD]P),GCU'R]&[&BR5;
[2^HKF0S&1%@NMY_@MS5$H M6\T'HW:7=99Z)ME?RS <$[FM *N_!L\_(I2$<'@8;UA%G=,$\?K,%N$QD6<* M<1LM(O+2.)9P^W 8.^=/W5:O:\!J"
(R)Y$^(S^DB>)'PN!JR\:,XS<5MP%\> M$&=]B>YQNBC"_X_(OP6A:(H;-Y0@K++5QEB6,X:%6U(8NE )5&9,,(+'$]P MN+JL$+,6% .$P5E_(J.R<.VB,2H4:?,H^X'R%[1'*
<*OY+/_^!:L1=J+-Y2@ ML%,1H#WM!<.RUV1(&I?Z6N!P%61H]D*V0QH;=$RE)%Y5C>^3)KU,/1U,^.$J!K4NV^7"VX<&
M!*NV>P%N0$BN+88VI"4S'/KMEG4J,V]VG;=OZ4ODH4*"6?/Q<'(^LF-_M*LJ M54 ",FRWAA- J/0C%,XK(5HR9)3UIHH,M*1W! Z07[L%E&S*SQ>5:E>04J7: M;CK! \H0X=&*&-
&7Z W%Z2NE?--@0QHNJS"[A.VT+9;:]P7MC.H( 8&VFV9P MB\B)BO;1H36_BB!^0G@MV2*A*0S8V(/Z-HWW1RE"0'3MYAOPJ)1J5GA2":D!AG ZJ MK@.Z[(J5X (X;B+N?
O=2<#/E#:M<_ZZ\J!*.B=C+@0 PV$1X?6,&NU89)CDM M52(F8NT?49Z7E4K(8?(V"ND)LJ)_$\-+_B0/$==_4H75R4ELBD :7=TM NE>;"*=XB[,4_+:I_?T M:94669
LZ$[R3FC[N$X+/"-4+AC:[88CWI!K/FZ7%>6V9T23#Y:S<9M@!B#Z M=F,Y+M*8"#JE?>C?T!Z3I)^]>&+%/Z=Y.>:D7@,V4)"IW3"02_2!5I ; F;4;\6%' M9KZ81[:$)S."AB9<0-]?":
DOP\^V"8 &3='P^;]<3M:- M4P.NN6RT@ +R,I$\R*]>@AR=T#1;TUP!2(*U'UCF05NZ M[6U-K@;@ ](VD<&R(^*Z2&A'R;MD%H;T[:Q;'Q1MM8CR O/*HS=^9G7P=!JE
MUESLQI@ "+_=I)E[G(8(+5B;A<> -K69O0513,\QURFFOWE$88%9MTIJ40D, M2MU'[9@Q<%K=R$A5_4;8@870KAN&-:NX2->O&*VH7?Z&]GIPI!A%+\D%ZQ ? M[F=
4)\3_5?,8CT?4!@'618MHTTP[ZX/".7+[.[BY@$%L.%?T)*\Z"GX(5AD/I&YJTK3[Z[UZ#U?@1+56CXLV1:Y.:H0-,K6J\K< MJFI1=]='/;"
T$P$"=$H1[+3;BHFBH]ZO+$[.MU&RS<7BA0<((1V'5-;O;*. M%)HTJ5QXT0$KM)APQ F=9AG+:T3O"E,J+58!?D,A9+YA5071: MM@!9J=1]5H>SXEMP4.R#A
M=F.RJ@:+=^]D"<[(@LU$^S9W?'7)XK3:JY$O6@X0D)N1^J]'2T?^ <(SJIKB M'?>\*D($Q&(BLNGP^[X-BB1U"JG_U)VF1RX[32OP_D!6( #_
M&TN/G%4'!IEVRMM3BOUO+#UR7[JW 8=;:"PM*16PJXGT.TI?,-D7HS"(!44Q MP/$$CL,\=UU5H@#%6L=HF43*C66?*&&9:W \P>TJ!UZ!O1QYB(%8ZP?=ICQ<
MZRKS@K'7[7F[6; -OQ1RFCSCTI$FU_,OS]RY%']D6!S5N=:LK /&7Y,L@_M MF>]CM'@AA^W[ K\2*U>2)\4979[V1I.H6@3*WN$*AX?^C$?T2A-L.&.KU"Y
MKJ0J8[F2H#B@O&B^;%I6KO<4NT(SVVG90#(;CMZ8+[G*WWJ(LK^EN:/PM*IH M28<,:&U@)CHT&Y3>+M*!O$TA'1&>M@,Y=EVV7UD4,DE*0)KH^.RY)'U1J>V( M5*IB3:1
7I.WIY@H>HHDR@O&34$M/6A\1;?#9H^ZVE(=D<7&T[SWBTN_P3,J MFBV%CZN5V5-BJ:(H., LMJFV) S7BLN^5*3*RL3M%\W_R&BT)'Y#M#3*+(]3 M]R )4?:4[NX$[XF>
(/HX> %OQ30?0P[\3I(Q:M^;U<(G:9'MP67O8[%>!_CC M;GD99<$FO82\G.90LIG9EX^OP7^F>///QQRC8)WIW@8W-X'XU-T*+H]5I\Y' M)MH]-\<"W3FK3",8[-
RY<>^>]3@+F&M2-)_[+OK<3M"+5A4E!1FSUH#FQ>7SABSI1?3& MJHI)2N?S!A,2G18F4F.Q@'035ZFU3,Y[G"Z*,+_#CPB_1:&HPR%O*,%JIQZV M]3,SC,;$I6H36="
[D0U1F?!\!HXG."SEX2J=EV'6@F* ,)BX4W4O"]>;L%&A MF+U2-5'VD](J[;%Q,(XH72=)S@HKGF\%<:B7W(RVP_U-0K64^P?C"/U.$I9K MU7ICXD5VF/*\RNXKAK[* GB5';U$
("-1". M[:% ?;"[6Y*LS"H_-^!*T-CW:.2XN4:V(SO&>BNN?CDR0&#M=AYVW\-TY"J^ M2%U2? DW 0S(_G^VWL4CYR%0[A:!5'.WZT_AQ#OOASM?_0CC@C:+H66DR?\M
MQ$TN:CR-*%.GW6V;Q.36A@N(WJ0#5Q&=(--.>7M*<0?"R0?. M0S,;<+B%<'(-6^C/("[*_D^[+8[L=]NMCYJ*DF.MV@,(<#L!(E:43AULUB+0 MC0E3&EFE,IV
=77O7D2Z#]1:'+M_4G6M4ML7K]%H>-"F+M]ZD]!S$5K< M;!N0[K45^8;@NWW]A\Q'0R>7G/H?%]E-USD,N"]0X&$8J<=@=H MR/L3) 9BZZ&"_V@1A4&T(.2QN]+?
TS>$$WJZ"N**>#'K=9Y!\#B-4&TD&7V@ M)D+KH=8;K)O:8(%'^G00(R'[QHX_7X*8_JKV^6:LX[ZN +TO%'X> >HDR\32)RH#*DF)L!_#0-O;)K0F)*J*\NW]SE!TPMX3
M;V5A";RQ\|'03(;R[M'"0(3C<>3U;4<@P%S@K$$^O9\ZYF!@R2^J?OT',/U M.B#E_@<;#)S%EH),.^7M*<7^!QL,W =N-N"P7\$&VV_PXYHP,%NAQ>]INLB^ MH9R&
()8[L,"P5)A-V.+$RZ^U!VCC\2&T8$?L0_#^E1QC(_$03#'(S?<@;KPFZ@^?H-GJC=RN'!(H.T#K3YU69 MQG8P5=D0 O)D]>C5'T+PV?E&A-7IU3G/_UAT\7WJ0_YP[$%Q:6V)2#T
#);_M'H#AU%6_-9!IDO,IH]A_#P ATT59^*\BRDK6B=/1@!E$%7M0OZK9UJ$$T8=J^#P"Z8\8R?O12N<2F*ZJ
M6"D)0%UF"%A>5,2W+C[7>Y%M.7K6H5V@:S9]&R_B().UJM!X"N&!PV1?L\I6 M&[87;=T%5%U/E;H^DL9K\6LBDU! MX8?
H927KRL(92LASFGIF0!QB:*Y[)M3N)3(XFY#G==TXDL*SE\O06D\+!L5E MO60A@T%Y")#8ZZ;0LE!LZFH 3+16@$0PV64T?O_*"DVY3=W3@7^9B*?1/WGMJY_ M6]Q6-
("::*>@*QY09ZE,HY2/SEQ=BVEP5D133/9Z%ZBP7]AX>V]$2:ZK@"(^YP#N'A%L MK]6 !?ZZUCSU&2W5)_;/XE\)K];%6LCR@S&,=#=)Y]!J/64UGV)[=?-E3 Y^
MR)F\/Z8DV5G(@R*3N11+*M2WXZ_]BH*LP"Q,YB9Y+7*%$KS0E!+8IXE[D,($ MY-=N\ ./2NE%"SRI!.>ZV;R4]>H2.X(%A/^V&_%@1V:N-W?;PI.9 /UVPQR. MZ67GHB+)'X):Q?
@PA3(FC-DD/E_T H M3!-:?Z4:)7*'U7D6PV@I,KEM+UDC_(",351LU*5+[+ZI][02IYU+-D576R/Q M&!#W$2, @6OY'/P7N.O]UC_)2W?H=FM(/*"07OQ'RRADKDJ%HPTT9=X['_6F
MEOK9.CC;R'$"$FPW)YA'IM10AB=MT+EN*")GOKK0CH$!8FN[X:$5L;E6N/;E M)U6@)FHY7M%Z"U^"+!)> !^.*IMKCONV^DVT;<\*T &<-Q$04;U5;)8X_0%TXOD9'&QHN[Q
M["9A57;^&_JHRJ%F6;%FE$CB@1H_>-<7V$V;(OFWP)&F6=" V$WX6![02Q'3 MT1_WF$:E)8L_T[A8$]6L%NVE.K_"XZ3?42TAUL(&R,J$K^3[ZX+6_\:X+]1
MKOS]B6=5/'!73D]7+AJ( &FTFU$!&SG?,[0LXMMH*2J)I#)]MP0M92TWC^._ M5:F.I T5D&^[;HK9.L5Y].]---4Q<(%DQ1/GPXFO21E*PE1!!\BOY9*7 I?9
MKCT]K;7Z'E6EP7B93SK/F0^G3N^&FDJW!EA V.VZ-K;!CA?I^CE*V.*\8-&0 M+P0*^2F+"%7LU[=1\!S%4?YQ?!LF6 (&GEY&H71Z;9CD K!HMIK1;3')]J6" M8-#G+"XY:C?
BHO7BDI:N"@P4EQR=7/S4Q>=%<%CCQH^'\J3"BB=A6&Q+EC#UWW':3VQ @\CC'#2[:H% M00L1^U#C5$"[N"^,>"(!V %782V1[M!)BIS:=P%NW=@[=]_N(O]IA2X"C#^B
MY(4LNX(ZP[>#OWQLJBFW[O_;4J#B[#L9.Q],V_TP*J?&EA9U-][!C/G04N%L MH<\.8*#,0<>AW MOG+56+Y9*F=3TG_'8?R Q$$,'^KKT7,5'@TP[Y>TIQ1WH
MZ])S'L'<@,/N^[K0F[\TCA;,,F.Z4E#OXM)O^T,(M4XN76HQ^Y1P$PU.H&(" M28YP&6 8Q&4^@.3V&)XQ'YX[J_2FQ64E'"8:BP!,9\E+%ZSY6R2X# ;'$@)] M;'
';!I&8+Q;AUX;P>^/'*97?]RF2=BJBVJ:V0#E)EIF-'=1;W?^;6#S!IDL MP% XCS#!JU1LJ>VO@NPT=J6VN7V1!80?C"/VN"@%I\!<0S"D0>WTUVA"$ M:ZO?
O$2D5G^[\0B/Q7.FJ,H.1^Z2\";=\E^HP#'14,.D9.3?S?'8"H[K2CDB M/DLEPP%CHLN&-[+Q1KT9%9*TT+>):A5?T2+*'M KC?1)7KX3MDD.(N"$BG(G MU274ECWG7*(&R&*'C2?
R/]GL-3J@02P$P92*:DOFER4QJ$*RUT2C1F"00CP0 MV3R=QI5IA=4<$FVB80;4$(N\Z"_RH@<4!WGTAJZ#"-,:+F@6L\?P S95IU8' M7Z?9#$JLKX7)7JN-&A]!EN M_4L-.-
Q"L+*&UC\XW$L+T!^-W=0C[/6]=I6?*A4U0#YDIA]0J%"F_&1TA^/GPI+J+\"S%/#9 M]ZJ&I%3+:*#RX1A8,\RP;\GN-!7OV8>K29P"\>&L5UL.KM67>8%\JE35@<\5
M/$ZUEP*:3Y"JVG?E/E=@+T<>8B"?(%6U[]SK;EXP9E-56TGE<]-E2F&)'[)> M"8>S--4'&D0@V"MV?R?
0O&JLJ[0W'%%O(DNU/I>%NUN6O5#/;+^JTVVH>0Y0$.$I5C,O]L2PNSE+P?2NV)1>,O;Q5 MF3PVU'Q/LE<41LL(+<2V##2^A.)2VX@YS)&(%(J]O-26I>*#LC(M'JDR:[L'
M>N.@C^%9_]S.!V3;Y2<&Y$7NJJ&0 @K)U8V$&K<5),0!Y$46JTD9N59Y]H0E MS9@T<;YFB6KT]6C!%'=6%NKA'3YGR4([O]+0X[?I0@-;7GFU:!#9Q\4YQ=M@
M@,4$6CO9FU,W7:2;BDT!E(E$VL;J]+A)YA-YE\0R@:9LP$UM=4ZR;: HX?(B MZ99'J70KA"=5 %UY_K5$H"X]#CP3F;P>R\|7B\:V(*7VC<-P\7NBI0CQP0MM MJKE-
7[Y)KG[0SE!WR\/D.57;5>NA\T'O_,RWC&]!E* !I"92CKW) ]\9&$X+ M5VB)4 &))$G9?M#R)7K.[Y[CZ(79SEEE(CRNR/)[0GA-1[0>O4Q?>I-D.2X8 MVQ1BF($9\]&D77_)
(1VR*&;.Z/EH:B<"1!C!+&0??WF#M'_J&.;1U$Z&O98E M#[/^0%(@_?['+X\M5>RO%[_,F';*VU.*_8]?)F2Z-H@;<-BO^.7#SU#B(C@=
M3)2K!UX!15TB@^%#:/(A;4JMRJ$I!)2K1CLR3JO(Y1B(#P'+AJ7C6HN9%Y/1 M,&; (\&(F69DU$CLDQ;/(HK9:6-C\=+G>*-5X/C0Q_C/ $=4
M'S\$N]CL2\E&$*5LY_+2AF+B$V\\AGG7D63SJDU+DLV_ M]GJ2;'XSG\7QAJP(P<6Q1<,)$E<';#Y3#QDO)]UXQ+,C(;C612:DT49\M,8.
M45IVUT$8Q;!O#QY,.TT,++7SL6D]"9!XT=[GD#[IULT;7@)R?3 7,%I%,D=0 MO&CB8TXVKO69#2%Y%C)]J!=8Z!O* M7U*,T_1'6(#D=3; X+9Y>XQ,!47C1
>@V35ZV(0BEW2F*#>*,GH_/G#0; M;2 1$(6)*&4C6X]<$H>T.ZU(7W/;.*!>$I3L,D@')5&*OZ4YHM'NMVF09!T. MU1F/VHWS;AZJ,Q[9N?BH%:K#V*=B">W1_JE#=
<8C#TI!PZP_D!1(O_^A.I.> M3Z$ZC&FGO#VEV/]0'4*FZ]-T PY_KE"=\)KGU;Q00M"4,3F8%PG1K"N4O@ M*E3JDW= IDX3K(V*B_.8HE!
3'#VC(:'J\TIYE\)@7$0V8BF*>&=)I\1$/. M.NO6IJ,/SD0@4 TQ/;VG]<6TFUPA<=J1W:B8^.!,A K5$1.9V>![VIM>H7&: M_&I65 \$Q%$^L(:-5%](XYV\.C:J9F@ '
F(HKTQ32N+:/Q$09;V3WM"XB' MS$1,$2B=+">4!L\L3(9>;Z&%OIS4GU'AZMJIJ29&$R%&C62GH JU'E.AZ]JA MJCY,BW%$ E4P:;*+33A(/(KX:J8D 7 FXHYJB*F)
3\YM7%M50]V("8^.(OU M&I4^\JD!?3@]QM6U4U=-C!:+*ZK19&8[FW(42-<.8_5AFBC+V$B("AI3ZS$5 M.H^BTXP)D0_31)G&!D+LGS67X/89%:ZNG;-K8C11HK&)
['I&M.C>8W;HQET[ MB->'::(L8R,A&M&B>X^IT'V^LSD$TT111>TC0U]6GT,ZL\+P62[.N,@D]13M M2&=06SJ#$PQ=P# *1NU55A2#Q)M U6U$Q\X@%6=ZNJRGCHJC@!
MGZF'C)>3#@BA6U55"!+7NLB$-*1:R&4&15M5!\8CC_P#M_JY=DKX /F:< P8 MK3HP'GOD\A8*0PD)P/9V4RWV#DZ"CV9O%*'=HVM9I4_BA'J \^V643%07< G MOY>2)$
4@$3:[IVP1(2FQ764!$F(+M(LS[ZE2;E1YM^0N.: 9.Y\[--E@>)6 MHH0)D%V[9_GMRCHH1J#P/1V,)W@\NH_3^J(X.("\U^TJ]*MNQ'U U]0*Y5$8 MQ!TN(C%IN49-
\R(2$TLMC6H5D6#L4S%L]VCWHHB$BZ3P2<_.X:2QTZ44BX(4 M*QBFZTRX3CN>G%O:29HDA3-.J\CE&(CI8A4>2,>UB\:\F(Q6O'":H.R1$7;\ M)6C=0G*1&2A_X3Y!V2=/3$,1\
<$9*(/A,C_95MO@]N7#0V:Q/TU[ZD3(;I[&1;5_P.I,0'YZ1>AHWD9$NU$)U("H#GIFJ&Z>1D6^6RVA<4 M ,Y-^0QSR0F"3$*,LF&!<\H:1Z>33JV-
RDBLE@C@^Q[3]$:W6.TCHKU??#!LD*$8A!, MJ:CNEI&N"LE$G8M:F:\/0?(")>8?_'U'[L#3UCR<*$P8@(G*%?7Y#7X&1R,J MDBT954IYKGP.
ISF$&ZO#H4E7KN.E6S.=%ELI(G*$Q+F?PU^1.MB+63_P9B* M?"<'>=$*/F4[3+F]^A(RAA->21F^/Z8BV\F>JLEPD'(312, &^8>X2A=7!.2
M_UI%X8IG5%VD1;SX@F:OKW$4TGT(V$L;/6]K.4_./"V(P]E[S0$V4:K"H(#! M,/R&3ZPPNVKP:4YDAI8"AS$F2F9T:S&XMD;\7Q5F2W< JX/2^(A><[8!74?+ M'-$$SJ?
W]&F5%EF0+&;)XNF=_.[C,?HA/N?6>%2%ULE>;?(+YJR"I@PQ4='# M2$IVODGV?R+OD20X\H;O[!I+E0YL9CI*\7A1_^.82FE.'7_"#IBM(@?*:8]2
MMJM)BP/+FZHA9N7E>CNU+3CI9MAND9&]RP!P4P3'5K"<>M\5/A:^L,2 O"@D M'0Y7$.6RA@!(;LLC;&MG79):%<6ZOZDZFK)HYBH&D($,0%",Q)Y4>GL!_0: M1 M0'XJ&
[ZCU*:%2* %E- #OC<15[.V7&]$+BUS*)U4;KD=A25IRD& "I+'= MB%NO>C5;+**2F)MDF>(U^VV'"UR-]<*Y/"AP-;9DA=4J<#56+8VT1[L7!:ZV
ME907*"K%1GZHI$7^,;]%+T%\E>3DVP1N+E% HWR]I1BTX6GK##6M0>E 8>-UHQJK.LO,"*;)3EU MLMACB;_X=/!\[&M!/(XND<$P4";*L#RDKD;><
+=M4<8XK"*//9!&"@)Y8M$ M7&LLLZ*1*;%V/?0/Z"V-WZ+DY9!1%F.;@;')NJ6JD MS:U(B,5$<29OPOT8*$O!2,U",[?L5I/0$1P3M9<\DY$O>Y)I84EWII8=#,5S
MAOY5$"UQ]495A8+OAS]C/AB-1GT[/@:K#B )'!-5E6Q(2>YI@.:4T"RY4=6] M01*^*TOK")2) DI>RLL7A6A'<-+$]'8=$D?DRB/4>>,9-+?ALO+O14E<1W@L
M5E!ZPD$2KH3)TGM#YJ/)>7]BYW1D8],!Z;=8]6CS.G%"ZL&@DBI75C+((YB5 M1V1;+%Y4FYFNM7=3KDKU<\N"]2A!=TNM.!EH"@4XF7;PT"[#8Z^444-!W5+W M$)8?
#R532Z"N?"DOG$ M.ZNZI%=CC)%KZ599LY;;EG, =X\(-E%DJ37^NE8R]1DM3=XVD>$V>\$("2[@ M3P?->^>3,UM]:JT=P
(%BL([=XH/C@<#=N0YJK$HXA7(JX>$V^Q]DXSOKI6 M!V88+%4-)LZ]98D?>0F[_6(5_5YW;@-$$$S4IQ&R5:56V&%IB7[/E?M>Q"B0 MI1SB3121,
<]4+S1"8^YZ5NGE\!.\"##^B)(7S6HBA]/F8UN[8K.T;>6L5AX< M#\N^[!?+N%HN49A';TB8>5_K.02_I:S,EL2IA,]$U1A Y=&(@VU$\$6!,4K" MC_L4TU=]?
[R$E*!X%B':HT830J$HHS%1TT5?!%??'VJ(@,R:C_TLME-#!#LT M%BNT"%Y_\<=U#1&0681HCQI\-!+!#HV)0BVFK8+T#24!.=J@+,01(TW=-#B= M6]YN>UET3-
U$$,"2%'=Q=RFP*7__)<4X?:>AO\$K^4O^H7E! #V&N='=UORK M(==:" $1MYOX;KK\6.]\T)MTW-;C P+$9<))L+]\KF@A)GJ&+(]^X)X&3]F= M$_L>)14H[&N*B YF/ KW*
(WA(DU_T!+5X&TI+8\:6?7*:9C MT8*Q0+?^&+ R+J.,%ITJ,*'J*7@NX@"3]ZR/7WZWK,@GK\ZBEX3HD,4LVU"_M!^E64)G,]BMW%=2-A)^9)Q2J?6;S=3N>6#H-
<&NHM2IHCAYH@Y=>U'2K8QIM MP&WQTG4@CC_C3]@QPY)#4^FRI#UI<^TK!J0N- ,UVVSA^QN;XI:D-^?A7%$^H::8*&PNQJ.W3J]U;ZL*"#JAY('VKK
M\2SZARC[6UH$!)Y68738+A6L:<:%J%T779*V5) MR 0I >E#S3^[@O1ESVU'HK+=5RN( SB<7^ TR[;71(_OP>M%D*VNX_2=^4C$ M%4Q4YE9PG%;,4OZ&.(=@;9@^E VL
,^R#.6'NXW2A\B95Z%TXCEVZ W19X^D M.J&/CM*+.,BR:!F%Y2DB65P'$?XSB N4[;-S[W$.NC=LJ1#Y1P6CY[U^Z_%4 M6R+D+1L.1A)2+05_2/HU0$R3?1+[5'OAU;/5J8%
M!-9H!G8S&7\@9!@ZOUO MU-#K#UU9[C#;3MG+H=G_7@V43M?&=",F^^69,G450.![D4DE5RQ*0'SP+IET M_A)4KE*QE/BMZ>JS9:T_.KO8-\?3S2]TQ@ER:=3WP=? O.A M\
<.WE!PLMP1+A<893;$XC;.M)208B%_>&W-7(N0,YT4VIKIMH0#'BQX0-GS> M!)ZK8A :[*_AWBZ!>=$+PI;M%MXDL0!TF('E<(Y;=I
MJ.+A@*90UG3$>:H(Q41_"2L2DNYD\"0*S56;7$6VJ\OJ )(7G29L2,L7J\.& MV*3V1KN.C[M\A7"IQ'-V#YQ)30UHRKP_/>M-G6YDTD^&+S(I(B]:4C JR6$_ MU)<6?
Q;=*9RF+S81EQ"2%]TH]E?5;10\TU39".E]7R?S*$"G^7<&/C$(E!?= M*;C!(;\3>+?$VOWRL?'0/:"8(<]6T6L-3Y;\@929#@-^3?FXE(%ZT>F"0Z+J MY*D#XO6BXX5Y0?
IBDK8N46F5Y[8KK6SQ[R+Z]@/ZF"V@ MI(SAZ?3RQ'%5CKIA:U)0)EISV);AUCP0U5E1?02%[;BXGE%9'@.3= ?Q,33W M'A-;X@=561G562B[)DSC1CC?)/L>Q2,5U<6 77*O6W
^9-7;$Y[/QP9S4C0:P>S\*M9Q13>%;Z;Q92SH(FWWIN\F(78D>LR) ML<>*>:E=QPIF40[U^YW;Y500^1#;#- I593">25"UQU\542@);PC<#X$.=L4 MGR\;G5TYMI'&?
ATE01)&07SUXY6@%EP8B88S@MVZL=0^#,Y>)H/D0UAS>9^5 MKE\Q6M&U20TK"E=Q#U.9SO".[9S +6YF6M"\"'J642Q5D&H/8* GEFK@*V]T M6N*I)^$CN%X$2+A&X;?
9.GT'SL9J:AEATK_.WF+V(\K8A3E^V72=R ME>Z]KO/@Z]61&/3.SX:=.P1)P'@1^FVR4@$%-G)]M)$P75521Y"\B/TV+RM? M=*4-
H4E58=LI\+:+2S#83N.@ZNK.A<#*+^E^7X,):].;#=C)X88.*>]L[*25F))AS\|3:"DJG>OL T0^!$Y:"TH8GKL^CZJ( MH&8L @/G0^BD3?'Y_H?P!O:&DD$63G
R<#\Y&DXE3LU'M8S@4 M@ 2,@>!'N]$[A-"I6V.]-M=ED'P(9#3FG*;KR<-2A&+30 +&AU!%H_Y.BLMU M?*F$Y[INS@TD'ZJNFA>5+_N^#9G)=OMV/=/-*^925%-
+AG93S_/F(^'+203& MBZC$ S<.QXGSA(,%^86"U#2>4[+ :6A3;7G6@>E%;**,]*LP3=)U%(HSG1H\ M;3X8C2:V4C"<2ET$UHL015_BVD:3\W-+QSR+EFQ#L%Y$-IH-
A&+0.AK7MA6+ MT+ 28/Z$88HE-%\,8B=RE09SM!NW6%UC<[GQ#>7W&.7!#X&X51_!7"9G3HUK M_0LE;7"2:$6/;F!GBT54DGF3+%.\+LV4[EVE]LXGKMJB:_>-
M&64Z/>-9$Q3 MNT0MJ?;B"M5:W\AS2Z?^9N4I.?L,3'T7^D;NCB->](UD;#ME+X?F+O2-[#EO MKM:(R7[UC;11LXI\SG8JJ!I7,AIP?"B\8J/@$4'GNJ.D O=E8@.!^7!M:4ML
MKM6@??D9[38)7/W/PC MR-'A 86(4$-4Q2,*"TP8^6]V4K@.0E:Z4QP1H/>4 M32SK=.BV[X+"]W,HN*90?;CX-!]I2#CE8\UWP7XG1^/#-:>=(#6"STY4J)D( MPY+]6F([ .;%):@]R?
FRY]D3H=1QZKZHK9/&&N<3'YNV:1XJE(%Z<.0V.%P,AIZ&!(K4K 2*%[< M.YH,LV3 /(V(W3)=55)'D#RM?=)45KYH21M":Z,C9H;S/<&1?U5"(_^8/]#F MTH"^._C[?-
(;3\8=46]\RNW5,U%A,NC\.AI1DNM*1_$Y!W#WB&![)4U M7JG/:&E?,BU"!93-%81DZ":B-,H+@5DD'+_U78[.[%R1&%<=ZFA,5.G0X#ZX MD4IF5#2[Z@6NSE)%47"
F6B^V*XP7"L@^U(QVT 1D,[7Z-_%*OT2)'^+;Y>. MQU6U4"RU*A7?'^FL;0[_A6A,M#H$N'V?A')6'PRJD#BYIVO(9QB*I/]@H^O4 M%XR8:UNTX1X,VHJ_/_6P6@>XR\(0
.9JG65ES!6K\*-A%76N#',)QT3LY4 M&&PD&* I@[W8& UQ6KH%FNB;\GC_YXR\?<'(W9)R1U0>T5E/[^G3*BVR(%G, MDL73._G+QW5:8+$&K__$"KN3]_+)XS]*^"YO^]T=1/
```

M\BJ),QN8L84V''3DW:#!PC1;?>"GT.HU%<*SJG@N>Z;J<)_9E'' M=.."I1!0T#[:),(;2U/R-M/$FON!7F(\L0 #QNNQO&#LQ1F0"!M0E/FO?Z9T!K5=5/%@>@ -F<[9[++#ZG< MA9G?+5?XK6GPABXC]=Y44:X19J(^R4!N\8Z-(K$5VM[(23.$'EH^1 M"_D4OP=X02C%,;M'RA%&6?Y "'}\#UYTT8PGC(*LP!^W:?CWSHVXZ5. 7A0W @>RS[,)S<7M92SV; D)V5;N,QDEK;_+C27-;FIGO7;D;M2\8! -(RE7W5-HU-MI MK$ZH36U(@-S:C==_+%Y?XPCALAPZNL?!"P[6=\|Q],+V[+WM?ELVMPCRO.R'"5U- [!FFF0!14$UIDQ4.$5#RCA=@PR80U4*2?YFDF(X7-71!WXD/8NYO^!R& 0 M'2B,.ABYZNX(.C4\1O1R:.U 8E=#1.DBC$9-,*(PI2<6J;PJ3\V7Q (O)):? M#IP/QKV>#VFB&II$@L1:Q5,M*0C#4T7#2QR6SG)*J>@"WLH$P8%AK9)IJ^)P MK:%,R\5HA=):\MEY1W]'U(7VNHI"_3)?QVP/EI>Z3,YDCF"D<*Q5&6U9,#YH-1L2DM;X;3>ZJ=+%E2MDTZY8 M=#Z'9U&[TVD46MWCNA22%[5##]%]S,(0%V1-YA=6ERPZ1D.=0 M91HASHYFXKH/|5C&<;F&;;\TP&E?>RP?T6N!P1?U\V¥#\8R*%^DMY M/H'ILNPIS/E3*6EB3F!49E0-3V"RN_*/^ M$,(AXU#ZFK3NCA!Z-MTY-DHZ966F!',(M!P;7>3$X$$DKWN2*W= $YMV=TTO)=E_-6V\IO"E38FFAJU*1#7 MFXUYR4AWE/)>C6TH(DO3Q!^ED#; J&2T^<7|\R-'(-4?YU,W->04EO8AQX|) MMM>!2++PKPJ(@AK&=IZ-.WJ;(X#CK*60P9#" M,Z?-A@3,E4F' |-9"R*S\O!A\S4IF%9;%MV|1FFTJ"@1G^+XHQF|$V?;KW1| M5MW.DRHQB*=.9_T)F,WK5GJ"D(#E,5N11?16O3/ M0OKHF^0!9;\HS. ^6EVG9?C!{2N_)#Y2T+(NR? *]NP!AB>/#P*-W%?/=%&"I M*UK3R"WV0V*DWB1O*"MAOJ%+M Z2Q35APB6B-QME&9#_*,B $+'AE^1_;JG& M;/[D'0 &W9. ^,> 6VS/=)7F H_0)!>&*K+Q^%!:8 *,19X]HNH#MHA&EO!# MV-HL;^&SV.NI>N!?4,;IZGOV19]!+L0TDH/5,7'!?&^~@.,551_Y9A;!CK8OBD*BX3';PiZP/"H+D*KE3EN[*TCD"9 MZ'_EL;Q\;-6>V&'!O"E38FFAJU*1#7 [A)P]D%I$0RA+ MO'6MYTTQ6=[_Q807HD8+6T;>Q(Y6M|'L "P6NSO5[+-*2,N=|5S=^(AX)>+[M.?$6&SPUXZL76[(Q@UO|405%,9H00|E&0K+UO-;TGWG\-?D3K8BUD_\&8'? EN M-ES1"CYE.TRV%SUN]HJ2Y4%>0+YVT?"* 7;R/=M)V94!,]'-QKBTY/F=W D5 M,%=MUY79KB8M#BPO.MV8EY?K'<>VX*3[402.UH,J1EAR.ZB'4M47H/Z*D# "6!$&/!:=6A&^ M;-C^+ W9%(LIA%4YAWA9XPZN+K0X7+9("_Z35;HOF8RJE'RY_0@7, M57U^>9;:K28L#"!Y!7NZV9SL_"_11/FTY<2G4+NFM>054@"!,1%?LO?UN>;5++1/P # <;M?]P&OY4W:LGKT'A")B1[!MIZ6_U6[%I_9SZU MU_.HC ; 4$W:X3X;@(YF6P#EY0]@6+ZM^?CZ732.B@.+C)R^CX]Z M=\L_(XP"4,>]SB^3C,Z=]+\Q:[8J@00D9MA) 1#SA(NW8!'4%]GF 1LX3O+@ M6Y#9"4I ;,8=&EQJ9F1K?HT;"&WS@!),]XX4=5$"G7,,^T5VU'Q#[I=!D82K M>]KQ9/H&B]7F&TX$)L (B,NX5X5'2RV]>#[_ ^8S;64BD(#$3%1 MSM^ ^4P;F0@#$391O@,^;N<$D#%Z+D#T5)C7,YYR$EK&DW95<3*2# =D,W M-L>1ZQ1?)6\13A-*?!"?I/81G-14\&0GW?OIP^3D#"1@I&'K_U+CFD*GC/ M|A%Y+=>%K? N(S M)Y1SUF=7 "HC,1YE&I"WHO7BH*VC+K-?B1)F"3<_&L75KJ M>>><^+UUT@&1,N$GVU'ANWFZ;@ T(V81G!=ZM[X,/ND__#Q3@.Y4/43R_PM,YUV5]G(#<3#A7I/0\ M(,H0\L*[Y764A4%,":PM1>[3*]S=|+P80 WTO37AB>%[RB\+=$-VA66^$LI3 M86Z%HW,WM_4P K(RX881T9(6N+ZP=I,K)-UTFNF#!,1EP@ MPMP*AlLB+Y;$<<(R,J(!P6FY1&%;,*H^6E5DRLDW71OZH,$Q&4DE(5+S#>4 MY4_O"Y#?\G25N 906UVA:6C'C)!E(#$S/M.MM3IHF8_JC|BALI6(ZD1V)J4=7S.K73&KG>56JB(3.*V//KMC5N2L:.SP MEDR[84:U(-'>%5/RER ;:^,@X17#.A?B8HD)P*IQ6J=&V; 5SMO!M-4GS;ZL MU?$!8C01QG1$!&U^_D%CXX)0>/(QQVJQ7E(ZFY[8J[,49[? MOA8Q^UGQ@L+H.RO&==.!WAIOH$5E(E!J/P!V0PWY%M07B.K\"E!'_?)U<$*" M,Q(R)8N5O$DN@FQ5T5T[U/3X05N(_7Y'O|M=9%IC85M*G+T _0RIHW?PL MZX.%Y.C4);0I=;0IE5.O"-3^Y|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|LG8S8$",-Q$Y71C#/="]1OFO'0C,'$8O4FR/,H+QBJ!5CD: M5@'K@*=,"@!@KYG\Z-UKQ+9SBHS*WO/YVU\!.ITB-%AY)NT&X> ^HHZ0G&8(%)IDQ'XU[MTZF[RG.:GY8,!2 <$\]KO5<'ZRAA7S'Y\49+1!CGI44KF>88%&M% D6G%O>;"M%53]FB7U:/<9. M4M3IQA3;4ZA> 4NBI7H/=1\Y<1UD"96*5VF\)}IDC_2NQ$ATQ>.U,Z4[/XL6* M=9AZ)"$ECU4^N_[%*]61J.SRMGQ;%47HI<;2 WBFT%2E*V?F(TF%Q;N);T2 MIP9B,,^MLO%#C"@W^{@R_MM8(G+P>Q"(M/I%D&8D>BS3\H2VDHG)OM2@R5>&[Z58DV:@,,0B#5SKI8G/ MW4&C?# [CVI';\ABL'P7MTD5AFBIG7TQR.-0L52$XV=GH_,)TI@.1.I7@T=1 MO6];Q$>.D]9P:Z#1:D8)R8K!#[%,M^&CJ.GW%XE?YU2]*2O2^DK]!MV5K%SN M_&Y5Y$601.*F0SV? U'0W/CW\E3"$&O \U6D8KI8K7MF%)Z,*NN$P1XQ_7XN9 M7$8^E8Z/8M4_[.BDK8M MW#3Y?^4\CG2"P!M4U!0 M&Y1KC>&R2Z|=/I^R(,D799!B\|&6%%=!/O^\]2'_^FT2OY) [>HKM!UN1))0N@[7<&JK@32@R&XS79 M/S&^27!)$O]/@G6=S?N|Q 8/XAQ<@#;Q&.CI+B!1F)0-; 1=E*Q^1@D=U*DX M4+ ^&^%#8E0W-/W13NGMY"GX-=| [53RKM2+"^8[NFK[X$@Q4UI^EA3KH>:32UI RXA:7A=#B7"7 MK-QA?6S+SCPNT52.KU89$,:>9'$:)5TJPQ]>D@7K?I:.[:BQRXBZENLL&H^"D M@"7&? 9EQK'7>.;@8\NB8)U;UK>-0)9@.>.KLY/3457X)O>D5C M2@:*Y',3DY?]7<;@R5P!,-T# -9,%T(T">]H(B=*I>>DX&5E?K,PBM'8fYX_ M((QB-'9C'+(>1C&2]PJ6H#KT,(J1HRA\0?2 F;'<35 '8BS'"*D:L#;|\P"DZ= -MWK<_DA]+D8514$FAO8F#J?Y-PBA&)QA2(4WVG6Z0#BJ,8N2HJZ+%, I.>D>G M_$C>37%/PR@H(NB-5[7&D(51-- [#_':.W9*?]#3*LHSBY/4-2Q/ZS[L^:1+ M-^_RG()OP$[4O?;-?A QA%8\T6??O4RC4@RMOU4TO,0#U?]AF K$ZE2BO! D M84]K6+943^1#4(C(\@=?'4Q3H;?X^.SL^.CI'F0$@V K%HH/5$N>B2%^,K1&E MN%) &+F).QN"0Q6%[P/O\![37^B?=3X]N&.N$T39N6CA%%Q7K\F!:W:U)U19#&N^[>?5$5O<|?5\MED'WL/ MY(V1R1H:4_;"F'- 'U43/#'=OO+0I/R]0"9D"6'1#-?$I9>5GTT4<,*.GD+\FDH:P.LL9K78^;;<.D?)\(-P"&7&[!EA1C-2G4Q>QK[!34Y^. M:!I#B< RZ6AGZD(!!@I0)9;6H; QCLD/76S2A&");@10,/AX^JL">LMSH1.K M7AQV, ^.$'UV.CSCIO.O#[2I+WTCUVU(SC&PH$Q.T9E"TD#?IU8ANP74B89;? MQ,MN)\'B)LA^D")7$RR? 086%32DTY%F+P(+/0T+W=\H)*X\)7[_<.#E+)!LU MLT#3? PI-X-APTDA(;[9X)+2#<8-B_B=ES[3\Z^;5\/%_MJ'E=)#8[4RL6" M2U1+KD^1%4YH@8$F2^K5U $&BI3!S1[2^EY7)^]O#6RA8)\_S*1WX;,1+)Q ME:5N<[H>V"1ZHTF;E_@Y+[(@%/DS#&I"<+%K1-9]+|\806&$A:N]4WS0"AIM7I0"O3>M?F?&U-_M*# ,E4W@9*A,,.TH)CP&FYI7)>_BERC/K]6&GI(@)96]_OQ:?Z#)< MI&\|\C^[7&TERTJZ\\)]5G)'H:T(1A{1]591AR@.>RL@!K? %LP,,Y4NRF'R'_M@/#@:8JB=%K2? U<8E$$(LDD,&FB+HBEH*5#HFF_!J.O)*'-%U3*,,2DBF'G M(-[T2:]NS4AP&$K3D%BWP8@3B>)M6)GX 77+%"U7I6X*DQ?$1 =F]M63(5& M7I/3;9JDIDK6SJEO+Z<7OXUOKALG$I7[S4QNW4KU[2).5E3LBI2F/&TYCMXL M2'X3)VD6%Q\U#A3=EC:?4I9,N'"%/*5_>2=5GK!B$7F4HE6!HPQXO.L2BF5) M-'|M_?.8&Q?.2;1:D+N7ZDJ=7W[PA]TM3CJ}Z#>^R M1Y*]QZ&JOHIH*$/AQ@W@85O1@'*6JV6F$G8&JH3*I:.^$(P#A)-FH5D.!,7Y)YILK8%ABHU M#'=97-,_T_1<* [2]*,K0=1*F&S_5!5'}?=57=.M\"D0WF'RU24S.?P{(!(&0F2*%!3*QG.Y 1)LND]LAJ&C>PT"=U?=_?3_[N!MO5:SO#F*P0 Q-/+F?TFDV6'7AC19C6?]!/62 7"9W:3=#*8; M+PZ(WZOO)KLMN8T\(@F/#R1_BS.Y_*.25.VJ;#R3%,0_W)-C#0Z'23[<)UE+ MK"9;,):3)\Y*ZTY-G.004"3:.ZM|.QFI>!0!6DBX(;>370!55F8!0L=9Q.T"L$0W M B@H\F? ZZP+!.4N)"*=IJN#;NG$,KW$Q@N^*)EK+@,R(7W6&*B]T2-Y,)ID(? M.J*U"!QFI|BH<8,A9%G'N1D,&XDHTDL C\|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|>\|&((RWMA6VXXD4HL;O3!^?,XH#[N5+'^^:Y<02X_>D4S&A M#Z@#&,,5B[UY>2|_FG_^.R89Y6+ ^\8V5G|;0,E!4,+'Z4[5AQ ,K=I% MY]E\5W+H1,+368]WD2-8F48,80,B(0\ [J6^XP8:.)\=I^K;P(@A5$ DY+B7 M^L8--- ..D[5MX$1143 VN>#GR.O%D&N\V))YU ZW.RX?,JB>1E)=039N,ST$9<;C<(\2I1,8$B!N,3 M60:L7]Q;FL>*@B&JX10-:+,M"+W*>4 1Q%$V7'ED^*NCF$:OX@D4$6@+++@C- MJIBP$?JA*K3'_'84&BJR">$Y3;$TTH(U9&H(62?"K.E T;]=_ D=2F:]284 MLBR=HJ{(.ZT"S@-R28Z,XWV]%_.9X:4?XK645L2R4<+P MCC^5[?J?T^QGD$5US;,\$\GB=[X]> .D\CS:YV'T6(WGJV9Q$=6/O39:.V MXO!]@E83N@9;L5<-[KCD'@&90A!^6D_!R$5 S:*. 16ZE.6)/D+R=JBZ.SS MZXM)QEC>7B/VD_- #9_AK+GJ%2>^<%&I5?Q4K#/@(TZE;_K^D%S)H\%?2.A* M<=8MH1^"@CS^#-ZTADSQA-GX'.3U8/U%Z\&%7I-A4T_^]2GG'>2%3']4GXB MST4"'[5F9EU]^OP8-*#,EZ* [L"%1O.=:1$$^IYRP_V{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|GBSFZT4 EXE_(XR4,B'#F+,]RP|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|!?NBA7_Y.4]3D^Z#@C#YF3HHX#!9_I2,F%P9>O7H MU'/G#1.#UH:Q?0Y',ERVZ@X*W+(|IS22;TF)S%#5A["/4\&ZB+ DL9W5+P56&QO2_H2G KJ4"E20[" DSN9F"VWY(I_VC<%7.2/UH%@L*M9U STSF=?1;H- ML9-A3&:F)DF<9K?TILE+[*QR>@U+]H 8=E4DT=H(C=VZ^Z-FH^/3HY.1J!5; M]8J(C-=#4%]PABGUF+_? #9(H;*WJ.?!#1)[HH9[N]$0Z-X,90G4R>)+=QW1 M86ACM!W$4GW1.\0!53-FP"^;M\NR$K\_^]F.LCE9A$3+?PF.?'^+\R+W: 6K MU/!,B0I"55S9ID"/BY\_"\O?OZ++@"CCWT2#X9; [F-[MM2]2N5Z3_P:?)Z6YKGGZD*R@#T%2L4^%;!5ODE>4DS4HV!"G]1O29.THPGN\'O\|D+ MNM%LN7ZGQ4OU5G.TZC-B-/7N_(D!9I:&+K%]9655?#C^-S:U=?E&/QO\R0^$ M?4E">C8HOT@\C16MA:?K_TQ-)!)7GRF0VKSH>9|:.S48[%"T3#2FDD)>J:6 M4[MS=5V7&.B+Q1?BFB'#1P31C+W@7"K|SILH.,;^BSWR.&U4 M[+U[<^0XDB? X_YG==\#UK,UDFD569=:KN[IW=BU24F9K5IG22JKNG2M;;Z-(M1(A3##*;9"BE/KOO?GCP#>+|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{>[18-Z?>+/P[*X6[M4-ZZ.9AM+0VH:N@YUR'(s9 V!:)Y7TX"6.!,;*1"W@*@Q<^^#0(VG5GQ/U=A M3-!9@=[;'A3D_1QKX%&TVI3_07AIXM0&"~^9+/6^.#.79^$8!L8H1+815@"P:X)N$;4^C_SL\M6AWT?@(,&'=YMB%"MB>, -4%7X9[%$CWHD:+ZE[(+!$#P3^94L\ Y783J B(M-E]* (28;O8[$CHGL0<6G=$SMZW@C)Z)70!B/$HRNGE,8O-!F]H,"&H]_'7G M4S0AH@W:3FP6-J&@IYOS)OQT$[Y@>-.!JZL59R/=0)B> < 53!<^ .@H1Y^M5$W M==LB5 $O4FA6M['#A708Z8L8T@%D,0 T[!%&T5ER.'KQB]'S;#<$!3@[/&I\ M-=&*%,VPW,L96(7U}? OF7_4A^R9_4A>'&BZ#^-/]QS3YDC^Z8%-# 0I2'=<:.M"\)3-B6R/C=MEN(>%LA$W*]:-H%G\R$K>)M=[)?=#]73S[CVR8[*&TO+\IL/7K\-F=W;(9*=LA MA9;/RBZT#>S#0I\=[/"D@=.K&?;(9-H GVP)/G2G\]PWQ'/CT9P!WY,U)C9 MWJ.AQK0N&KV:GGDYW2>6W4FG)7@,;Y-+0WQH2LIVF)&LDYF%CV=54- ?TJI M8 %H;AG\ ZX''R)/|[B@TP8(CEW.NG- ,_4JV W@$3N,/"G2|\N$6^_D+KC(M?@@SWXO^G7KI!_87W1-,@60@I5?E5KO.R:,$QD:U$7H@0TVHG#. E"*4'N/>-NF^S8Z>+<#ASH#=1G)NJ0 M/52S/2=5- T7?3-FY_N=_>O?3VS_%2?RF,"C_@&_!C6@Q,+!4] = M="7,SD]D!!:(0'\(XS.E5<,37G9P->O@41B$=^#W MAAK*[.877,5V4PH0Q?Z8),&7,.K+|*@V 536!E]=")0_X>@>!F- 'D?;A+O?2 M?)[[^D^C&.N-\5)UD)\7L3!!"XO1*5@'8N0NMU5C:X6=_4"\ 3,>O2%<.:E M/>S"],.RG QCGN /9 W^O,U\T 9[V "/G>/|%?4R>AON"_/KW2^97#--APYF M.LC#!XL$RG:^;$\$P88(DC?)[@TCDAXHTGG$;$$B3D#24HY39O0_04\G7."E MG%*X8 M$.ZZ87Q|&81[2C.T1[_+$_^TQB0(VFWR_F+\XO"AP[P)09P.(I;P6 MK4FKTPSQ-3K4B2ZWIR^O+N\O+^{IO\N>C+[(OJVCOOS>_SNFU@R%75>]AF(. M6I?S0.6@ Y1.=<_K@\1+*@U0KT MA0+!$"/(?T4.R#$5>-/"8I/D,UM6!!*PA5G"- F4FY\BRJ05.!|%3RZ M:$M.GSRA F]__OZM4 /^E[_=>1'-;FE&TR>Q'&W+QQ[|>VTK!8!ZV+E6D,@; MD[(U8E0 M!M*U(N&*4_@JRJZ>%OG.Z=%+|_3!\W|C?*

D9\U,:B_]X\'+N>23BLOW(AC7A-MW#(K%/)T &*"CVG(/L)^RZG/?_RF.<^@C_!NO!=^=<)+XC@\>S!2(3S!Z^=>_M^W:M.:+XA@F"YQ=4U+'2<%$?*

9'/<0MRD=M&#Z>.Y.8:]A,\|URX);<;">O;?AX-MPCM-(GQOT(*AI8".#G6RIC(^=#TKPE#.???<##TTU-WT6[""=$@\Z'-8^5>#8-M\3-8Y|K>B=WV^Y25X-@=PHNX*XU,_TRCX$.2\AV^'IXN1%"NC(UWT^T>)R",_M@G 2'$,\60;C\TLP!\@)02UW" X^3L[1,%-0FA9XWZG!4OWT8=@-9!\=SGK3

M*X%QZ:DIUG05Z29'$N_EW+ _.$E/R'OV8I@<QO:)0RU/L;8=:T+%IAZ37M(KTK#L?(\MBO\NT");X"/>E?

$[&H?,^XXK_B/>$.O.T97K(F[&B7=0U\|$<,7E,Z$;;]#O\MQW]V@GZT9F9:H=EIN$/=BTQA'WX@-VH-A/K8I^7EQ\Q/MM&B/;OHE-ML3Z\J<@65>" [OBCX#")/Y[":@(=/+2.7?

(>S$MUP!IOY^8T!;4#ED$@\NEG)-M,YM!SU";C?^E?%.SS?,T?#CE(KU-GI ;;Q5'>(,$NZ=/'LD>&>>>5=%30H)[A-M#7|5LY)W-

&?)X9#$@AEKQ0^E*61Q#Y5/X9V):$)$EVTLU[$AEUEVH@<6_L2!-MZ^LT"&,O29&8%MGYGR_OR-MOWKTE1R\E3YR,_"J&_S)N;K'XEWRA^3-/P'-M#=GX4?;(?

OOM]YP<>$YP=>:#O$XU0BF_;-MH"O4#-'@%B8R.0A"&3!]XX7!97SY4/F_!K43$L!&9&LY5H)8ZI:$MZ4)V0M-M&J/%(8_@7:9?XZG.WX2Q_(?:+P5H6+

(9.7I(£ADX(""_L;D7QC2X\0%*>P23;-M^O[ILVG%&-H3-M[-N6@5*;\">O6EH[#EN7_%N7HMD;)R'8GVA5:*:46#Y[,IO"IXVC3$G($;S/]5>=DI?G#:L?8T!35\O

MK\IQ1M&HM6V=3QU^E]S&=,^G\]/%@-UCN]PM#BI\]T?R[NU/U;XR:>^,35(-M#Z^NDNBQA72..>C\$OG<8ZSJX=#^P!#^H#';>-M6\SOOL]$F9,]C?VP]\F?

$Q7P\:>[ZJS"*U+$S<;(]YECE>!+_9?D,R2D4<:MIEL(L(\0:+;#]J.TVT(-HZ%L,M @,K[L(<;8$>8:,48)!$BQSB)4=U MY%,8)RE,K'YC-N@7.YT_JDT'.:,'SU$^$K]89T:)?

3/BV!*R.QP(,PCUF1=!-M:3 <%DU1\;P#3!?4.L0@!0&]0G-W2-M?8K%7D52;+?-C89T14FPS=N@1O)K!^V1*_O*#]0fY+6$$'.D[9XHQ)?2=CML-MLXPZ-1U<>..EURE;PW,:B-

/R&YK>\2-0R]F=E1HG!-$@C3DJD1$2G@-.#D,K+-M'L*(B:#&49I)8F52K*,4*Y-B=4(6L0_X'!%H"!NTP0];F<3'LVT5WNFF1"H5-MCO+T<&]6&DE

:@IT17$0H1/5ZY$(70H,BB"#D(X"B!CNX>-OZ3 \'(% MM0O0H%PM@'X=X+\+;=ME&1W#:$,%5MK,!'MQ0,"5Y<@US:-%9Q+AW:,2$O-MLGF)>!RDC^)_9?$]?8

QA]WTH04F]+5,/?\A2<^3TT.^.T5E0NU;ZM/PB1]/-M."1P'!8/9-CK0-FUZ=*KQINZ"H1(@';6TB#,"0_%P_]/E7KZ5VX_RO4YU'(/^+GH,]Z^XU7Q=-[XHT8?M-M;-OB;!#U[;0-7$I1

0NR4#3BO9>%_@!U*-HCZD+)L5T1-D2T78<2Z-CN91$3-MQBU$V##<@@,*@,_#Z)0;3U.T%(@@KKEV@7'1>AU-UK.N81,3S!UTV.#<@@8(

MH/!*>6EG&FS9GL7;T\G_N3D>B>WM]>G/,L]$>#@X+L,]PI0!4(/V058V04I M^B"R$_&$1YZU-_JU_;=YI3%^JIS;.8]*Z*K-E52=!=N%'(C'JAN\RZ?AK##O"H/#M4W?$[Z^

M&:2<9WE<+NV:?LI$LGI1]I;G4CC)^B2\15#X-E1W@+)"-M>V136$>+9--6H(1!3S0^T0],=OZ6COL??PWSQ[-3EB<'FEX\%^&K6WX7D(D4-M_0:[-*HWT)1"8Z156Z7-M5/:T0

:4)-MY4CNG)-GSR",#3PN)%A,(1I9;S;S YH8:,4S49%&C+0E0,%26 M7^\^)DD@XGQI^A3Z-+M+(G,\E)X(-"3*P+L:%96)A$ZBN0C.+@D(_*C!HA-M.;]8AJH>=LRH05$VP(""_6/*?

+*--D9TP>V6@'"N/X@E:<'@UUMZ0$@D^=L>V+_\A4])PM6U%RY($"1>WI>J7R_WX*-M4QIHKTJALC>RL25U7]E<79R:N&8UWTR;>61:^$-M=SM_=D]G+WNQH0@:0Z$K

0]C+F86\I^]P_%/YZAE[6?48]6-G:S$,+D,J'B!-MRMC\Y*6_49Y3IV#28*%,1)-Y\TR\]_6S9"(-KE-5\I*X8-F-T1(<*@EP;<(P-M-83*?

UJ%RMMQKSSQMH(>QB6G,4V]B+&Q#0YA'/*K0WI88-=:*R6DZVZ50G%'-M)85-?Y\&6XFGR>*U9<%5YQ&B")W>KD*G'55#V3VXZ86+=O,JZT)EW_f_5NA

MMJ+N^F6P=Q6L-WDM;BS?T;U8^Q>ZYW/T5MQX/4OB+(687(D"2&YC-M#6H!)09$6_Q8M1X@MNYS$B>]1#=@\0PT@<;?U;/Q'E/"=$6 M*>192HM#K-V)\?

R4!5B'5%(K\KNJ:H4]8$H&;B?*R+,P/C&.."D/"+.-]NDO2 MH@S7O?=,LVX.\FT2 /@HDRP,_LFC3ZW1&3G"X65>.\76,L0SB+P:R\!QR_BT<)^U_MT$Y M,J+R6-;!

[<8=GI;_&0X=*_C,,;"K0W\V&M"E-7#A9?P6J_Y!&E-5N*F6 GQ! MZ^.;8P-8TSJ2K6B-M'$=S+M0/_+J82FN'3>QfGSSP2ZXQ;<:6FCW;[@6UPAN

M\%0'=GVNYR2G4>L78FT5Q\HFLVR%,7DECZ68@#+G'[^B\K(L85M*OB;S)YM> M',Z^(1fOP4V:OZ(LZ$'.7ZB?/SS78I)3L(;E7$;A6\[VFXT 34&+M[XGCIV*.M]E]9D2FK>"LX-

$?FT=`3<`8*^I&#]FY+$Z'J&LP!,,UKXS2Q'-Z(OB /S$=(M:C4^ZZXN.9?(I3U_-V%FO,8"E:-QK0C4PU4O/JZJN:L:N>TY'79'XR7A,>

M:YE9AGLT;7!"^AS1U'58Z"W3B_3DYZ=4OLP0T2[ZF&H[(5ADM8,,^DA"GIV^ M0408%9%DT%_>+8P,KE(CK3>D-MXB.GZ?Z1\C-,'H?G4QIDO&IBL?HD#[D7QC*,

'T6R022'?.X^_DCU\6J2O-MX\2^EZ8OPC(<>!61XK24"L/A)VE @TVCWX"_),/>&L^0QS'1K'6:94Q4]K?R M(R+],77UUX2WV\MD>?Q*-WUB1/29BW@*LT?

^(=:.^1IU@I4ET8*XB3;4ZW'OMO1[A#@@RA]MT!ZF6N1,WA>5F_@-M-DGWUNWA[N;)8 +F^P2@09AQ7)5-0_D-J2>MKQC>HI+B2UA&&)A1.@Y].BL MX6.WT!FUIVM$ZE:=Y=+-

>|_V=//M-E#IYCN<*^8Z>8G<@B6;KYOCEOI'MYOLF&/W89.CN;T1?*SE.<=U;.1RM0&T9)Y^SN,I\H6X9R<,+H8=CE+O0*HL]M\7KQ;$AN[WY9QX'.'D"A9?TX@>>=1>DW0?

J.JHU2(ITV>&.7?BN81@V0WWNE_QGD@8OR95 M9Z3N#;WTSRR"UY)Y57/4BC[CH.L<;8_&+=*"#W:/W(ORFZ]U5$N_O:7HXIP\F M3=23@#!.U?*MOGXMFW(3SQN_8<@^$-

X%P+\[[MRO(LWTN\A'B-\M&XKWS- %/^^9K1:.X5>E?[@4BPX-DEYT.3F[+&$OI\#_]8F.^%CPGTO=@!#P.Z^2A>YWQ/+AGO7(.^G+]"2ERU*

M7:%'(X6L=OE="61;XFBQ2\9?S169+EKBNA-MCAAI\=/*8E[O.%F5/[J*SA:T^"O<2)F:VZJJG!8RN;WR8:UUID1:%K>S/"# M#S1WW%<9:+ "RRW;DDY ^5+

[JK$Z,HS]%6VKK.@QAHR/W59IRLR6X789?SLE M(LK.U(BROI5A$##54F5EG:711AYE\G@O(B[);^()A!*S,XAUY&*M+.;1R!); MQ601X.=43';> ^>]=KL%U9#7Z7}@6;EK*P-

,VN\U40SHS,+ $*&LP5#;-"D)X M!Z3L01B&1A^M7$P(OMF&RD%, #DXW0Q4&W9"SR<.IF-N?"ZZ^+UC0ZO\-6H-9OC MRYC'8 KN,)D0-NIZST\ECX M/MGZ?S^%*?

WDI;!1D1/VCOJG5'XNEEE4MUE&]5[_F)[UOPQ4JK9(.5U'-L& M%-V0NA]2=T183\5-B>P+^K9Q1I$+-T#?AUYD5LJK,:W-V9AW<6 M&C=9S3,0(7>/L32=0<9QM"30U[5 1-?

9*AM&_:AU\E3>Y??X"5FS$=(&E3&&/ MAX";_'847-?\N*.PNC+W?1:W?:?N^CQN^JKN&E,7]K]!73R,EQO(X!+2ZM7$(8N&C*TA'?)32]!W M-

8.NX14Z:JSX"[TTE@"+FH[#L*;$OSH>*Q+?(C6UK A=C_=O(M9C@+A#'@%# M8XR%&8/P019LX@*1;=^9QK"-[UD21=07S]B0=V?X885K^(5K;UB!&<{26D(V

M6#\;4O8DP%KW)<*>ZL[PE7(NJ4LE#?7"H45[#(.Q,0YD&(:GWQ"+K[ZG,=V% M?NA%=7*SBV?_D";Y5G&1(MF M<>U<]UXG_[J,2?D!PKY

&I\H$RADI/$1O%OI10:H,23EI33O)?[%/I30^?BU1Z("16< M^$$$U=[;#:.#%W.,W2.*RMZ_)D.[A)@G4O'D[LF11OG+AAQ9HUSX;#QC_5'< M1_),,. RZI#?

VJQ@N^$*1>L^7H=#S%/M:S85W9QO!*<;.\$^YS;(./.VN.OL* M@E*$"5Y+MNZ@% ?H.AYU.^ 6OB80K]<1'V%$&=.RR.]5DK&_SZ?%RWP.J_;/ M?.-EJ?=3?4B'HA:E,7,4S?

USQHV'IU&SCXC_^3*. ,U^\B'X(MXS"G()?+.&";$?X/07%9^7F21%S_W\-]R<(OHH]A@@ +/Z3F9,1BJG@XW\(TCS\1^ _.!9W(Q6@:VOF M7GE3UVC-

ZVT<(RKNO_A\-4DW_*7,L3B&P*HO.5XTB<[&>TPWT %?76 . 5P@ MJE%6ZRG+;C3>1> 54]A?F'11 M[H4Q^]M-(B/2]'D#!O8"EC]@!'2]198=E$Z*;/ MHA8'%+D0]9__Z0_?

O7OW)W%(P;7]5(G,?B='G==0 /O&[9!Y:9 M6O,'9UQ% %HG0\:R4A^ --WSSPEJ39%*FXES/;O&!5P;9O8!NTEH41)TH5 M"R-(0(-M#K]Z[CS*JAI5H0T#U@?T

0C_(9+U/R!MNW7CKZM!@Z&WL"A64*%5AHB-$]HT*H>PKI+;7@(F_2$"7T=44+3HX-@ M]WR=CL=(.+\7E0;A,MXEZ4$>)#L4_'+M =*M MR8PKW3__T[N?

WOZID3B\VCFI*#!O(#(5OW$8+'<K%2O>,]>^87$1?/%P0]?\P"_2_4 (VE,R]?ODF=6#6H="ZU/-M?9S.B[X*N,QU8%WF[#VG?L3V^C+?KS\BB;9#!]\YM%UDTN4P)B5QD4U[;]-

J3=S(7NQWU\^M=:1]OO9Q>Q]SU-MX___XN\G9K8B*DPD<_U"_M95)#N)@_8?&BT-NYY%O@:X0UIFM+J0D5_AUQ65 M@\8_1'@&

<$9<'!0V^MB0NGOY(']=/_6(,#9@L&,WGWJQ5E4!*=5L?#\)QR M9,1_4/UP0&[8%9\E3 [N9N0>T#L563.+VA:9@$:K"2T'9H,;8R+'R6#&H!D!

MM'#@8!Q5WYDLW(9(9DA/7.&&5"QU+*SD"N=@&'WDV\&*OIB'KJ44PYI6P\Y_MQ[2>.":A:UAQ[.'Z;>Y2)O3KL8C+&;C9C=11X/-N]J)\45/5=|#B1:)48)$V MTLWL$"\G#W0?

QC&WXSR)A1!@H7&YB*T1XJL9%;[,7&X\EE_,^IQZ_M$APY_]ME]BOH[ECY1DY5U]E9B49Z9'=?L77,RTW2]f? M6MX-+#U"Y1O^XD',.,'TF.2%@G@N*EA765)%

8\7)D\%=]8>Z0TQI7GE7A-M9K4[*&E=%/:Z3.5G7!J^.,,Z3.5G7!J^.,,[@G0)LR7$I5-U0KH=]2LU..H@4K MSB]DT.E0[+VD3LMWTJ%4<6IST0"MZNQ(U$+\TJ%K$;Z?0Y-

6\A..\B7X!T. M]?54?^4ME!43]$UTWV@JKZ#[AA)VLL^3@Q<:TP!T6V),>,6E8GM4-MM=/>'E*0B;!*\W O/*X[FN&O!+5A&"?>.E^8L!%@/[03- M4 F[D*KI2=W!AL@N2-$'OTV6(?

>BF]F7X"*Q"&/BXXEYM;&O^$+ JTGLY'3,M*&E6=<#S:)Q4-PK2<(S2R]Y9&:624T))O2S,KGAS(6O/=:;,]85L.%X=H' YV=*%|[$%6H#X^XN NW,?A+O0]AE89OL>D[I.4G9)?

>;=$!(MVN+34 M8!P,'6(:JCG WK7ST!=3)/DZ5NY*6Y"MOW5XNX#'ICNV$ MQ?^LR"W"H[X\68KF/,S\'E.*379ZT'44'?L\LS3*,?^2<+:!26K296VL/?IY MLEQY@Q+-

TQF&M9;3@P TI]#FT1-S_\@6.%IL7 I>"WF@1#Q$Y8\@^$T(^SLO MDI'22-R%'+FSWYI&$M3P]#+BD8PM%!$E#*TL;4S9Y__I@EB_IGBV4-0?XOT0W_PF-X M?)6]9M\A P

0GRO?M#!J" MO\ZD?$,N=Q5FBI)Q24QY\T/"YT!LI\6/HD(\^],I#OBY?'(X\-'_POCD,R.H M0-C;2\Z*&'O17\[Q6OVA&'7^S?K1-!N54\3G(B7%*T\O]C)-,9IP+4"8]0"E M_$03,

(0^T9B$H@$'_ O<+++6A0>:?Z$TKD=!#$L'^U2>6WBTE@L+[\3(S5P M5MU5B#<'14HMGC.+S32-_,E*B7K^8S1L@GHI#Z3)2H^5$7T1W#;F)>1:>]"' M!XD*C^S3Y'3D665S-

F(1GYKV!2C_,$K9\,1=;>!@E[]&S:M2!2ELIL3-+. ^[MPGL@HN%W/5*H!U;+LRG4@@U@>.0M^*/R3(Q^T6^A;P!O3/30?U0O= >,,A^K

M2#@R\LA*]L^'KOJ<'#T)S@I&HO1,]0"@M@F9- ILI"67WY"+9^]PC&0!'X.5 MK?#2]!=7WFLV9XQ*JLOAR#\H'C8S/]0?M0K]4_2 MLT,^:\E_K<:\GWK(I.+^2?

SR*GC=F%WXER^W7"E/E*>7.N,ZRX;FK\R2G9VR M/#G0U&&KX-P#Z)6OJU3f+:B@E&I7TDKC7E*O9+\Q<.,4N\]!Tf8&,+J<.[EW ML1XXFAQ,)SRB[6KF%M OB NOU2_HD6,-

AH%RH+AG 7QE($QZ_:E!]T<3+V1 M"C2UMHE[-:=VT;IU$K *&^XP#6]B:>L<8"'(Q3Z;R7 Q9#)3_2\"-[PCI4!/ MLV['C@/N<4QG6<5$)%YM5SH99$P'|@.H&D,E[**LI!

<;'+7>TNJL*@9[>)S MU'0"66H=.VX&VX$:U&Z[2*,:/A,*5V#&1PD5\",&7<@SZJAZAFO@G2&GVGEG MO(&:^V%:8Z1",.5N@*H.]ZJ48YP,:UA0!L#> 3! Q\D%NC(X M"29AF>U

MML9#OC[WPSSD:JDNTW@C8,3%'&HIT%!B,B$*3-!-X$#>DX>H"#U%]0(L.#$C M&\O\I>$3&[DG>ADSS1*1 [S$QI]HL&\E6AYH(R?T"JHB4Z17H5CV1AK=B4UA

MT6&SVO@*S?)D"=@(GXR#M6[\VRIHPI=MUZX'9]I5A!4L/@<'@C\94IO\/Z-AW^.M,&DIDL.AS$OV^^458X_&_M!E,V _D&F!D]HHO&/6]/(Q>+.'!2UEHR9426\P

M9C9A'E'2O1=]\G)NT;JLN:Q+CO20CR8=)5(>U'$Z4A#V(!_09DF6Y23DIW MQ4L5MOI ?38X!(?*<\$A(%S/;N"B7T.[6MM"@(S,=UX)T%5O=EG\M2C>.*2.

M6N"PPG6*:L(#PW4,5*!7=B;NU:NZLGCW^APIAWGH*0QOFP0L"+E=_YK(<$%D MOO#M11&Z$1XGAB@"OC+@.]SDVJ$SX6S,=:8B-8K6&I&"?"*;ZE?B_>-@@BU M*

(@-.TII#QMP3"#_]U.8OSCXXY]V&D.#N\[@ 0C18B=O=/Z+*/(<.)TPEW)R! M[#&)]:7DHW/24Z'>=H#^H"\ACM ,]4>;H/V7TB!*$X.YI(IKV9(N369TOW

M2:X[+=*D)H=C2A_9XLOON4+IP;^*N%U%K8Df%*-*5=RA (51/;KGGM.MR$#- MK]$R*:G:KL0LVX9> 9!EW%'P,M!(NU CHLC1,"N 6M49 MR22A4(]):H#+!AS8=O4#V\&+K-

X"$ MEB"F@K2P;2:B -UP,A[SZY(3?"Z"EMJGX(N?.SC#^.X^H\T.$7T>G>1HDE2 ME]0IE7E,MG%PDX9)*FLH;]MJOTYF=EJWD*[N-/D5=[!H3A28Y4V21H_BFD+T M6190;?

3*#+EX<8ENSI<:D>L=N3P<>9X9]E^\1D]96NPZ)F4FRJLPIN227^$0 M]C%25NF[XS6>4#WP&;1$<,N77,"7M

MH4)1QC[N34I7Y99;GWHYB5*KT5FS$@4E98GPLD!K4U:VA2WB.M:A75K(Z;5(MBS=@;;E[3-+\GJ8'GB9JF,KH2%'T1BN'27D$T1M>DXB(!%_KTZ$YQ%J'CIB! MIE<4,\HF'.=

<)?&^[/?BF1_/.VMSEC|_-.WYDB.^YW2B,Z8G]$.=45(J62)8 M)^2^4I.J'!+H2/XD%0CY==TL,K<4BL;\SIK'99<),CS$2H'CD=LZVT&&K=/Q MSBQ3N2598S(#+_=D!.AXEZ0'>0-

PE/?OH@!>0B+V\3;&+,>V?%XLF8M8.QSJ=YT7,,<"UL7* Z&52Z3 M =$D: /P-UR'ZDR0LW:AF8%DZ&.8WA:5&?DM-_#O@=$L-XECX6HWB5QP^<:

M!.XROBNCC,3&798OO"F]%U8!G#.HY_ OK4>+1XS2*&5G^]JJ9C7)ZD/DIJH" MV@AQ7M]>9+&Q:YP!\$"::IT4JU\!))>E^<%=L5\;JX$#S,U;_@*V4R*%0"Y"Q M%>.<\J+)_*'G-

BMR=C;DJ]3*FF+15#A#;'ZV<:!(>Y5(_(PXJT?E#\4BXLZ(M/I-MQKT)4K,B(^=D,EM@'V]@G5S7B#;LZTU*W _JP]\^LJU.]EJD>63CS$LH M$L/ LX6K?

^S787578%+TMGH%]F3"$5G]L. M]O@A2KZHTKB=G\W^&:C#M?G'IR=0L0Q*N8Q)&:K"/\(#3^5GR$?Q\ CI_F? 8'O'._192Q!:AX)!UT>G$$%0G^5UE MH9/<0'/(':5.

[KE.\N0DQ.=HVG$T/19H:APJ8H[4W38SR\4A=.]?[MFWKW=G M23,P-G! ,RA^[A!3;OI5C|ES">_D>9=B3TLZPS=U"XGO\R"5\3T7#8$%MXJ\0&OEEVQ6=_ V&O-

ZS&XSW69ZJM;YZ]NBE>^KH9 WK_ Y1FI-D[HI9](" NB+-(.M63LT;2%O6+/B;9F\C,FYYQ'0_1&89)Z@!B) M6\K"HS"XG7L]9&FGLBZDR:[,.?<\>.P,LW??

7*6Q%D2A0&7R<56S/4!0),Q MVYBH:W^S8[%=+KLFLN_24G"LED'L&?:?5FY]8C1U9;*":CV>+K)FR2TQK,:^J-M=

(W&O'H'LL4KSL/\Y:}AP(Q:%8=8/+3G7%\\,SS%7G1VRG)F\]+I_0L3*V4\N M$G^4>T?3H!WRT^XX#=QLFK-/G*JT9%Y'(1)*;LC57_\;++L46Q'RCY78V4@ M!ZOIVW$G13[=KX=

(9.!:A\NRD,X9TG MHW#0CW?+6*>^%#^?9+[-X)K)Q1_Q M,_/IWLO"4<]ZY_@.SH/?64;(^'2X"MK;Z#)BE=\AS$^JOD3$U9HF!8:LMH+ MJJ-!9?

8_OPQY%%/>6,PUV&79E0PPROC^;0+-AVS YN_Q,D#0R_BW%[&QU/> M=@U=S- RG\-(_CSO>.ES1F[L5N_@ M_I+Q4.UB'D1$OIWIE1_IS$Z3A':HN,2S6

MM/$P6:C">5>HW3MR!:G;_,E]HH>'I=Y&J *K66'G%D.CCZ$M'+UZ}S2G+FGM MS QZ!%/*GGO\R"5\3T7#8$%MXJ"(Q=&=+A5>

-R$0U,H%%6PT"7BO,"AYU3O%5,TV5=[.@P[#? MG]C>B&;967)X8'X-YZHM9 6K%_P?&(9Q;:K[OA8.XU0?,)^K,4-!;9PP.8476&%=,QF:"G77=D@I*"F"09

MKE(]0+PJ7A5NGT.3VVVD C0Q9NZ[4"Q"MNJ$#&5[\BNG0-I#+RL#1-HX8*FK-M'@Y PE2#[^3@A8]#8A>YI,-7A4]" 4"2-.M2AQGE6(%*M''E]!1M4(&HQ4V: M\"11+_S-

2NI\%@=0:/9EL-(UE.NF$@(297 M:PTU[>_G6&L)6&.J/'&$=5.,X(65[9?VP*ZXP4ZV";AXRD,>,JHKU(,2]!;X0)L,YZ:Y2E,3EGT0E)Z3%+QTD8C M (;YU:B SA1K\+_2]ND-

SD7P@<'#G;/S55=0[QF+V>JHMZ_W1?>HCN9\2)E> M/UP'D\46N#N?QA[CX:.R/+>%X3&NE-_1[;INTSO?<MC5B31D]L UGTA6KH)WTVITS2#@/HS&Q$O>[Q.;

[PT+_ZQ]?]^"T4^ULSF MX#C2 P+75:(N5(NFO#8*IR3EOYNT.B\$YA@/05)(M1N$Q:ZB#0(BZ'K1X,)R MM:2E0+#[*M=:V]YHBGIGM

CK&.N.!<&ZXM4#%S20^Z+]D_WZQX6&?A=25QP MM"$E-F81*%2B^M#Z[!W M,N/@G)=[2T1"0%&9CO[S M4]KW&GZ&/L!$*=)KL3@5G-6]$*=N0U+T2*YWI.O37$TT>B6-

;A%\DL5&85>, M K\0*$8AV9&T^ 5^61 T1H'J1P$N%'P&76@'C]]%$=S"S-<'!?@#]9LT\2D-M,EX,F[<1O]YMG[PPXCD3/B0I_\L=+[HF2C^>TP=38IOA7<%F^!TJ9T];7-&%

M+%+/2?BT\L:DIMV0JM\WNR1]PYNAY?Z=5V*O)"=,,))Q^0,N?%9U@YP,>!20 M>S(#CT+Q%)\D",2QOA=UW2GV/YHT/*Z$8-Z%@PQJCK*21MWTD((,PT68)HKB
MPO+_[1,%;IUWQ5=[,0<%E]N*O=#,P"^[HKSK67(XIO21;8O")RJK9%PE6<;, M# WW\=DI36GLOXA$89Y("LG<$?&OJ"@=YT=>EH6[L*@R4Z7\X[9K>WUV>4N]
M*/P'#7XY)K&P9>E5^'>>494**SXA;*/FA#6E^BLAOX>CT\L,5 M'AY.C!$Q1M9KY8QF)(Q]?ARA# BDB5A$S[I&91$EF^5>K\E.S][PEOHT?'*[MZ1O0%?S=WQ Y#1H-
X0S"=S4V_ZC&J;G.H$1[A$'XUESLX@# MYH%WC1AS/%]FR^?P<#I<,+OW1COBX!,\9/.[#B3PV7"=)5'
MB8J7E$3\3LY%X")S($IJ4L:GBM\Q'DM,EHP*R0(1@<8DVY>2185DM$\RP+2@ M@Y#821<*#T/'-*(@DP9_$Q:V],%]YI]A_["[/ M=M=Z:"]02]U@Z;JH.>\X'+*+GE [5%]Z=C$C*:8:
[+4"#WH<8EMK(2);#S68"@&C>[*M"\D[RM2Z8'JNR95G6WPY](_2Y(_^;;P,O93ZF5: ME1S8R4HR<2BR#4^#(+L@91_K2\LQ4,:^Y!SR,2@_TNZ5<2TY.OJ1.B13QX(P MG2-?
Q_Q3"9. ^B9-@I.?7Z=W-'UB6VQ# NK^ID"9>C5\]CS0XLV$GU2T1$M! M/3O+4/EW39AHIMHU 6)IP&;,ERX^FQF33AO:PT*WEV,G,*"EE5Z*OS1_L51/']():.3$ -G4>W[11"2[?
$$MKKZX M&+!Q"$/QI@89# 4;N")9ZZ_W-492#*V![2 'M:#ZC QC@=U<(5T/",0HO L9 MP*1-@CZ(&CUBKBN->TRK(,- MJ@.QI 38T#=[%G8(@<#_[O20T;^?^(KSQ/[//?
N4Q=AK*0"!K^=:J<=1M22B M*>%M5V K+>/>18MET+&@8C64!AI"B MK_73A5.3#Y171[1,DROD^A[&STE.16'-?>LL:4.X8B>P*H5CI%260"K3L1K-#6-?]F1^)EW
MA5K_<&4B@VGZ>$2WZR[BPMFM.N/,*K=RSC+ MTY/!WS(U!G2L>WE5PYP?>*Q>V0KU5'9&AB'W 'I,=#< >D @@-=8.-Y.@@9D M8UGU#CHVF"7B%VKJ ,LX-
")H:W^;A:I^3V*O_THS!L1ZZ#>X)$('# MI5P"FRNP>".GNXO;D7,]84M][><)Z^G^2W+_F)PR-NC1B?:'!]I*E@D&<0 MB1D'+[*P@@EFDWJ%/%N9)+UR?
E'T1D1W&U)U2)H]DJI+WJ+H=%-4&D'*@3/O M.)1-D(O1S0!MY5QG.J[7IM4W:<+^,W^Y85/(+S(N_GX*153XK%IN_\HZM=YA M=*9;@?(C[+_X9\1!0?
6AK\MI($_K#9PKL5NB[8;PUD0T;Y3IFUV%GFCZD-B5:(@ M_)6>S]^V1@G;!R>Q*/Z,>D5@PXUR&6 ##O7Y)XA MGW--'H7I*UF#AP46LY_E0,2BN%M@T\3YQ^,^R=E@1'6_9?
+8H!RH/>^>E#4H MV=AX&7FD45"7=@]C0<$^FR41+SO)&CUX[#,^)=DCI3C5 V?6).6UVCQJM#8_
MN*\JJ:Q#^M$+XXP7+C66?)K_4^OTF5W':;K]Z2_R6Q3U%1^3]8!I]AK++ &, MV^K\BJ5T:H)[/DBAUF9X1)Q)PZC.8V/47M=I3GJDGVXY9.A.H]>OP#XX#(04 M*]*+M5(SH$/X!
(W7P7MMRKWU?9[!,[OQ7C0ILN?H=)VJK@ MV/9AJ(0ZRB9?BUYKP#U!K37(7IM6UY4YYURMRP[7J=:HV6'JS\B-PM? ME%26^UMQ218G\9OJW[TBKE2E>Y
]=95NPWIMJGP9YVPJ0V9L))\S!\]H.E^G MBNO'8HY0FK)O4A[U?RWW8^[#[D*]=)*PE]@J)OYX+K$ MVNQ#Z9%\3G+*GTA<)5[<*&?YFV3Y^$9[:-HN0+#Y')[I.S
M4Y8G!X:M&\K&@TFWURZ(@[L!2Y\V6#XER13O@91=R$0$529"AJ:&@/5![.Q+$2F]]H@E;7<&:&(93; M"1G-8G!66"P'8+KO?M=8W]#0'@K !H[->$ K;#@[RV @MJ&C!6(;-
:#.*/^ M-_ODZ5MQ_):^2!P7_ZAA7/SA;VST5,PV?P0 :(N7[M3^\OGR_N*1($)6NVZ MIX$M=OIZ^\A;H8N5U'[D\$^![PR9>M/P2>18JG.HWH;9;]:$TR8RT(R]1O[5
MM+=E_6DHEY, -BLO78N0LMI$AJ($O?P;,%2V1T]< MO9@ .$J@QY%>"?0@ E&"FX@&>[8>W9S28Y+9J@7VM@:$?#^WRA%UT8H4S59@ M*
W#W(6&88PQ$&&UAYKV>*C0&A 5%RNP'L;AMF #P5Z:*"\>UU'J)3CO/2$Y[E,"B:T=#%6;F3XH-(% MTA@0A1%Y!27%"I2B-QYK")PPU>'*$ OE3HJO%E>&L!8#J*ZP(J3
Q5F!HBA8 MUPV).LD_^.G(C>QB6/$^$@YAGU<.^QC#.O M^,Y]TPZ4#TV4'+0"L],.-%=9F\/NE)>%,7&!Z<8EW^ UB^*L J&]$%#36\9QVNVI*B,3*D1[._!E!;4=/C+I@A M
^DG;..@X$&\<7=U&S1D\%Z$CG^=4\'C.0N",G7#*OP,5SG,+".X&T8 :;P/ M(WI T%_%0)8%4HIXLLQR]&^A \2_30*U /2^< 00+WQG9AH2[DZ(Z>+="2XP M@)UD]D$!6W?
K"L@[9OR"?%CES$;2%EKRHL^>>EO M--<7:[520,6/&;E6*P\U&I.B-69]R@6Y!XM^L^.F%?T&!!JGZ+<)PW^0K><* MWI29JOP\?!+I)"U%9_L;@Y64U?#:
[_/6#5$+P0[BV;/S#*9>1F2TB[8N#@LG MI9H5'HN]:;HX\7I)6CU3FP"]7.KPI63C%C\C:=)T_J#>)/7-;O,94M_4@OCS MO+*)S!=4/4YEN^KRY>M[6;O!X.
<[T@/Z_ZX2*0[WQ1FY\Q]I<.)YL]Y]]^;M MSQM2==9\@,[/?LK^-F1[X*]\9@?^D:9A$K"-7YK;MA)C)2Y^(5Y.'N@^C&-^ MV)_LB/ST0A)=Q-9(ND!E]M\7ZJ6(>CD/WEMN[CK
[N0*+P-ZK[TT M5CDO&E@H9U].O(3&7%M51Z%NV)?3^6R7VMW*+%>/O)/LENCO*[%:#K*[V*RC M$%EB%B_ASD1\C[%5BX)[3DLU".0.=JHYXR.MU,);LG/*;SXY;D?
ORH=K&9C MUI)KKKU9U2E6690),I^E- AS*='1>Q&70>O=R:BP'+:943&YF$>@+XXVSB4P M];<.G\ H\7"GP%2'<'4^P2#9FP45@W"WHYP&)Z_X+$ >L/8#H7B&Q7\DFG6K
M_ZY LU^B.:\[7-OBSY\U6R*+7#M8S<+?D&F>99_P'E'#DU8D\'H\A"YVA_D' M7>"N0!FM,5!NY*M11'THTCA4XL97K4/6]:B?.79K"%0G):.7'N:YHUQ+3;*C\CB-
Y%RX_T2#T/?"@*W-(EKM8_)$TUAP&=4K MMUDMAO4!I34#)>N.R'&>/7KIGQLC_S6(>>AI"V8 ^'I5;D;H-IB;/Q2J8/FKG MOZ5TRTZ^DV8-'-
GY/,K\E,96C[+5",ZC;/.F.AGB=UR/BK'3F\^[$3@[X#9'JPM7 M.%0?9%=-$.M]S\,HX&O]_IGOO-%?<-H=7^9/'=5YM./*5KR[ORV"EEP9EEC6IBU#9.*"R
MJ/9R*$E7H396K&FUQ@HT6*7Y:Y+^=AG?I G;5 W7&A,UAMH8I3'H#:?C>\Z" MX!?PBARJ!\VK!O0-620?#U)$0MR(NGE
M&O*JZH.4G;Q>2:VQ,1.J6NCALPF3+KAX2G&]X[N4G%Z%3_R$NLVMK2;9D$X@ M$PT/D4UY9U(0<^]&DK\1]$0!,&X!,V0A09,<#\:JD@%Y,%!!E-# S/N73]Y_
M).E9Y&6VE/6#>@%4PV'2]9T&&6#Y\$)$%T3T@?JH%%].2&4<@=FN-HX ++8Z MUEQ]]@[V8L&#>UJ'6FJD' ;930NPO"/D!Z*!\7%!2Y)%V;>HIXCAMO",5@0B0',K1B2I9'L
M%$(R&Z*QO?PKAZ+C;N3K\.>O# $]MF.?*^P*Y/!RK<0[5U XP"57(BB4MM# MDN;A/XKJZ%V>#,ID(P14(ZL,7: U"?@YJH(U'+69+$=8R^'UR@&I)F[(ZBJ(
M&ZQ@MJB'HQ>F? E5&5%N@DQ;U6']0&Y9!TJH>(X5?:\6]=X0(FUA9Y54T3-" M*T'W12>HF[XQR%4V?V-@"Z*89<'6L^3P$,IB?6<)V\+$>\8L^Z\L#&@J_GS% M-
C5A%.8OGZB7G5)1[O4R/IY,M_BS] ZHQ/.,AE+WI^B5-+K=D+ICTNIY0ZJ^ M-Z31.Q'=XZC\PN/B-\?%K\?%;X]+5(_+H3$N8=^X0)J(&76H:SAF5"#D7>4O M&=V=HJMP9XJD<"-
?Q:ZR)<^@W=>&2%K"B=>VJ32*9?61R4E*%O5(MHYMI0I# M]VVEBL'!.I51_YM]\O2MB"Q,7Z1*%?^HM:GXP]_^[:9'5YH_FA"BY[/]#
MA,S_>T8M1CRW5J2OQI<[;A%/^CS2F:>C?A$?*&M,REMM\WF\A@CKY MM_'>G=2B/2D)2!6YCGX^[30-K9-JISF8 (SS,),.U*G8]I<>A"9ZRH4("A@V MWKO
Z+0GUSM2N91X$4+NT] "AM,<+ $,;12/&QDZ.+3A*D9X($:F#)D.-X@@ MQ)QT=QG=Z@D]SKV>!-"A-_"M)L'L[+W74L?"-O9=C]8V\&B L080FHB00:,U M.SK8K"
6SCX'+M!9@;41EI"YT[=>3JWA;2[$B&#JE<4*J@TIZ0@G1(YJFRQ3 M*&4*2IE2DTR8*J-'GDUU]+";DGG'<+%PRQA(8EZ.K&YEV@6,ZPLL<\|X20V7 M3]=]UVQ%5[R&
(&FT1=Y.3)GF=K(=[#EV2\:#.=>SI8P;*(1Y'S:VM[6JI]9] M&JN@V!NZ:=,]24D7F.M%U'3F.8NUSX *=V4H,7O#L'.^] M+#2>R'=;02WC"G?=B18-B&B![13WCV1K)5UP&)U62,?
A?!##.9?C67_4[%*J M[>!1IC4H+9QA^W:Z$=5@#?'6>,5VDR;[E-]9Q<'9(_LNS_HMDA+] M-_I2EW#-LM/AR/_+WAO0 &"Q$ZT(V*B@#8.6^.[H% 9$4:W%-(,0
4VDW1+44&1!.3NH[>CX. MU(T1#5NS$,P;U#@9*NO%LPH\^DW@L84,-WY9"NK:RS@@:= M=5:@ I:MB[0?AHQ?&5^:=Z)!.$&#N))L.4!M2D).2 MGC0Z(+P'\HKW,6/VIY^E?
#'=X.].W!'OSK.=::U6Y;A%N",6RG55N^%BA ME112)>UR] TO*=13TA%.*)M**E)43)BR?_SM\$=0T!3("6Q^ZPBD:D:(5T(S@SLQ!::<9 J8-F M $Q8I$3@W)E(-Q4:+J4-
;:&6(0VG_05GJW:8H2.#.$:/#3$AH;44+ X#)]L_ M:'#]LAV,3>?)-I,H#(0 XMQ$\W['U!C(MFMY[8YDJZ$\Q$)\U6,?YJ;I-(\Q M(ZTKVS,S=&PH'TMCB3K[4%K>E?P2M>[>@:
(##;F]U[]G^R M[3&\I4<>Y!#O?XE#?5E%.PF4>VWF6SF:YZW)[N:25.T))\!TMQ>6 ,P1=T!0 MRQ^'@H^36SY\$OY%SD):S<*)4;!],^*F9;V60$#>E4N,][0H!%L5R?!
<;PI=^@#X:+<13+]/7E)W0XI M;>02ND*+YYXB8%.8L@#22@*Z!R-2=U'N#$>@+#T-3;?F-6\.YJQA4>!0Y*FGM982#"D96IC804;.<,P&_& <)33^OX-93/(M'.4]O=Y5=Y*7\
<4SK^E]O3LK'N)LQ3L<5^,[!0+7T-E-\-P0^K^^+5ZXZ(V MC(GL5%ZW%V^;9+]85>T7&@F^(R+'UD#L^$ \E0-!JX'H//):C?:.4@FCDH_2 MA\6.^N_8MECD;[YC3'EIF!AN?
#1M@0[Y=9RJT??R9^1+'N/ -D_TC:.ZW+P7 M'_LESH[4%[%\QCL>0WNH^3=PK,/ AC1:H]_S6,>\!0O;@$\]Z^6VB 8"?=G% M*4V.M!7Q501\;>-@\%G4;-V#GB'/,A[]I[6R:R+
[WA#9^Z8_PD[D9I$G3.VC MQ16<,,V,&_4T>#[0@#C/Y_0AOXRS/!7GR[8'>+VM =W=?FY-C]>NDGC_AHW_ M@7!:4A-GN$_Q("2!]#@-..JZD@80+1<.4KSU, 4#M9I A7VT^5)"/
4P"# 7>VR:B:I]%[L=]?G;LOJ8VAG\UG[05,(N MH05LQ6$-ZT*4HMR0JI?&1<_L"A30'<]+Q=_6G\+ BWUE+F:4N!*0UZ5<@RT8 M+L)?:;A_% G*V"+/+YQ"DTQX-L)1XEB M@)@?
R//\]F6QS.F@*+>UH @[N>VBXOV)<.F.#6KS$6H@@/&K7+CON3V4''+ M+TZB2J8H]![":&8QAF7E/2 0P&NUO?W-T0"L3P_2102J!9Z9:3P@F^VP"1Q34X2=5QMS^^V\ M@0
T69B&Y_X4475C]-OX2]#&S%Q)"WA:DC (MO?3E3IR*?4YRFIV?*&OYHR4NQH$2+#;&18J^5#*2B$@J(L@(H^-#_"-JD,PH M@:04L9#BXI=;\F[S]NU;
<@BCB"?.0M=6=ZRUHV5@@>86,3,1<%ESJH("< Z M_<-HG?YA13K]PUB=_F&E.FT0J F47^[.F4Y_]^/7H=,_C-/I)8 V5:>= ->G MTS\LK],_V.)7'2CQ=?H'0["A4:=_P
UF'2505Z>_^UK6Z2[6''5Z$:!-U&DW MP/7H] \ OO?WHW7Z^Q7I]/=C=?K[E>JT2:"N3O_^#S]_#1K=19JC1B\"LXD: M[0:W'HW^?D:-SG(OC.6E^\L5:T\#A\(ZP?
7#LPK()M("MM"(-^F_[BNQ7\4A#MV P^_CD9D9ASW36U0XCAG.#Z(MCF#MS'5,Y[SC6[696>:\DVQ,ZR?]=L9=V%[[0QW2;Y".Z- >(2=60:_,]J9 M 3@VVIDDIJ
&YNT,UN7M*DW+VQGLRMO5VQ17*;6.R[O-UV=2WDZU)TL@=CYC MXHQ<@R5Y"VE%OOMYENU0JYLUV9*V?*/-R7<_?PW;H2'":JW*'[XVF](#X<%F
M92G\SF99!N%8;UP8CMEV"-; S+(/:G6S+@,SRSZ(3KN87[_E<1H MJGZG^8=VNBY]%A0^)$O 9U-_MK%G5'WW&,E.OK#>L*A;!V
+KU;^/T\9Q*_7^N9Q._G.9/X/;Z%F%=8PU7*NZ]N]Z">">/@& M8B$$S[>'&()DPS;B]^ '$K^?P[ZLT[C,8EE6;U7^=SR0^/UD>[)N8S*')0'8 MH5AMAYUR!7L3TV@;_4)DXS!&(.4
8EVJ[XHTU\T(HH/@QN61O\TY7]^[4%7PW GJN:+P2\J9KN"L ^9?]IWHV_AGZ/:,< MK_)M\A4H?4>>PJ\BSUWI5WFIZ H_ MC<*#7"K^.,7!_W%=#OZ/$QS\'U?
LX)OE6OWYW0#L.2O\.AW\90"X4$JG*8K_ MP[H4_X<)X_[#BA7?+)=Z%_BU[.Q5[#EG>5JGXKL"L&^E_V'4SGYZ:9E:AAX# MT-L*LI1,BSL-],7/:/5CC!S>)
[D7M:8;M5B,.M=*D1AUHH'*$^YHFM+@0QCS MHG=G299GGYE4LAS&9VHJ%>- "UJ&T"Y)?[6I+#MQ"B)(-J0F8O]-9RR0-*P" MRQAY1#V6@ L5ED+YG ZW'I\CPM0:?
(JPFN"@-2O[7<9^2KW,XI69**!<,2/7 MVF*3HFQ$V1S3XUJ2?3#WRHZ@A/AQOO190(-"J@D00L>;R1;R45.-OA\.:D:$* M0,\LM*)=+WHZ@=C9Y M(/BXY9,?/ DY:RY?
P1Z+F3A**NP"[A\|GVX/R<=Z^7=UA_T P;U5V\GH-B@,O)9Z*N:#5O?ZY#JH(:EC6ACYG;#FK79L(3O3"0.M$F9N#70-I^36=$A/9 M=BG7R7)F/(YQ>4N02L;Q_"87E+2O;P
@XG9A,\.(SQ:"4?-2*O -94(S$?9] MBX<+$8+*]?)N5+S*[M8DV.HW1 @)B4,IQ%$K!(8JZI&D4\B%8314+6>9B;E4 ME#$1)L$'-MI_?0S]QSZG\RPY1<%
[NCT>H]#G]80UI7PG]@>EV!,D[DZ2[(KP MOHCHC&@.SD6'Y#TE=9>(Q7AGF?B6LJUBUIWT<"6SCZF^VF+&DWM[[\D]X_)*?/B M8!L']U_8WU[NPF?S?
=VHKJ#4=YR#M>RSS?$-Y4X[K"'(C.SS?D.:@))=T34!-$ M4""M=1QM!(BPUB[X_0#1N',XT)Z'=TQX]WN:;G"!#@C7.E2&MCC!X;;7$?(, M$B?,:79VD4+&^UTO*Q1
0'M+GY+H*8SW9RD-0AZ=(1(A60%LH0,$LTV"+E*J M]D02D)("&>7+RP$)?R=<=57!"503-L5;MLL(:# 4\P-HH;:]CI)T,5.0D75B M9_ D+8V]@X&B7#"V*1^'? MYAY_3)-
L_B=S(|)WK)S?I&'LATM&38JJ-7"RGT? MZLE]B7I2TI""B/Q"[L@YPIN'<8((]14]TM!CJ4@=XH88"N=&Z9::QP@H)Q6 MM_GG@P-KKCL0 W<7O]R.4%I!M0*EE=P/5=H+-
KJWZU):@R &D#"J-2IM U.N M2CLWH*8J[/R1.-O3@_IYF?AL>^ =#O"_IH\3:2O9)8'U64 M9*1!MZ*MEWYZ+/LO_=S W#:&,;W>=!(V93N1\<,953O)C&YRZ>
MWG+6M1K8;@2FU)Q0\GK+8!+MIANLXIKP!0D;#1[8W*#<9#G&'FO:0@2P:CI7H$-YN5:&' M2W .&MYBPHH2XF(""@ZTK?&'6@I,>&NC^#0P00U!7(I[5)B;HQ MH &!^ED2
MLV4D#_D+%<:%-9)+TQX0YCJ.NS!IM).GI;@!6[.S#0EL(TJZL#9"9()7?I]Z ML?]H? /<:@+ED;?Y4E(3RU^Q']WV#%[+V5UJY)Q<7:<1G&MS5W1G?HO::00,
M)>W25X$)^_%G[R#V 0KKB:;C2"*\UNHY6K2]V-*2(!\BZUY \6C$E'SV#FO8 M>]@&W.7L%_X!5 \3R!$VX" M"]LH!N+WN3!U'F9^E&2GE%[&]][#*?+2#TEZN-
Y]3CBK7B3#KZ]WY^SK3XS] M)YJ=TRSYX"0P?/Q3X'A?3EQDN),ZF^1"YC4GR+ M\(_QZ]KR'%7\#*G!ZV;MN@GOUXCUAPW:$,FMB;BX_\K63,%B0M;M&5@B&35\."(
M$8U;LK?-,IJWQ\QP(F&A XW"-4N@1N"6[8D@V'1G#:LRBY(OY)'A"SE-NP.VU#!B!V!-6/7%J)7Q\W=LS,[8@'U@X\75 MT5(XSHT6:AUVE*07-O4S$TY(."7AI,(HK:
TVY!9:BUMX%/DM$8M-U7P*T:Q M;)5K&9/:\7),;+5&#Q!9@''(%,&.E:_K-0$$"M_5N1D^" M"G#M06 O4E##Q!9B'A?HYDLC&VB ?'_#+L@:->9$#;H/<)%&W0U46S*O;TN&
M'&$&+!3L[L 9?>H>P1EZP)OHFHUSFGMAM'U@__9\MYVTGAAE.VV0Q;"G;J!, MDC$WI"!$AIOK'.EWI+8) @:;[JY,VQ(%1MH[@AHSFMLD*!,[G5,<(/=>65DF M'P2B[STV?
CZ]>Z0TO^)?L&\2]22 H#7PW<5$T92(MJ1LC+I77(I[2'#;D--% MN0TV:'"W;AM-1,B0U^Z^=+!!W3TN*0$V],V;2#N$0.!_G3_2]#,34F:7%,?V M]OSG1BI
!3!SW\6/:$WJYO(*"3L]^D@9WC@* :D%#F#JJH$#DN#T0![6YU>A M]\ C@4.'2@ 6.FA=,$C0CZ2"@#0HUJ /B\H!KA(V7/4JA0U4X&HQ9&WH)4%2 M!B>+>K92:VH8>Q-
JT.SHAR2EX3Z^>/8?V2#3LR06ARQ6U%CH *%CDT"I22;; MDY* E!3(=G1Y.2"5P0E778UP A7:(7/VD3G[5TF6O7\ISL%O:23V =EC>+0< MN8SM$/DPVDEFW;UALRGJ80V&9-
C'[>YH=3F"=XN.NP (8Q!^\,/V+%YUH\[& V :7DOL,%N#VI2'3J;LVNY=K$=]FG(95*AJUJ=& MU8_SJ=+/4KB8[GE8U$1E,LE8_?:5*)6"PX&*I8 01+D^)W%0!;E93[YZ6P.J
M3#^W7>1\3G*R\G!+ $$@5<. HJX6&" $>$N0'(XI?>3YO_E.WT\.E&_P6X]E MREW_=L=F]);ZD9=EX2Z4M]_OZ2Y)Z;WW?./Q(VSK%I7CW^7=#^\
(0_BTX1]>T/DUS%O"Z$&TF\-9%@, M9,2'"O^F:"']Z[]F6DCY0,S5+W%*O2C\!PU*%J_C)N?M!^4&.S2T(T #,UC& M+N#K#IH&@=>;;1L,0WH/."LP6=H/8>S%?NA%A#X?
&:IMB&QNEN&5.IQ*.UJ MZSB(3GBB78WD13&0YE?9VN90#['U_-HQ@N3P+L[DBN+0ATR6NW>#%)]N8\AZ3^G:P8K0I[T"=,+?"FX$ATW: M4 QBA8GWL.08#:@G7
'J;)&!^LWS*B)EYQ%H#2=>;B!SU18$+Z%VL7MC7C[3 M_":EN?=LT!?W+@ U9X!<7#H$JJ(D$HV%*-==1L* MT E;2=;7+7VB\QI"+5][.-1N7*@.2D;86X99^,5;)NH14!K@ZB=?
J#; MOMR8TN(^]0+V!X=[P$']@-X0#I-PS)7;AA2]H%\BKD%6V'O&$?A5;R!'@'<5 MZGG!ABDYA+XY@^2DWE:DJOW2C@-QV90ZJ!9!\#4IL0'E0U79 /$)OM[6
MJWF.V.R6^I1YE0\1O:/^*0WS\!_BS*,LSO/_E?>UO9'C2)I_A5\.F%FXYVZZ M<<#MEP6R;%>W9]V51CFK>V<;AX.<8J8YK91R):6K)8M"]P+RX M; 85$7PB2 :#0?
5"T+877ZM$:^DFF9!U!ZCK 0V[:-]E@EQA!B&GM]7I/,P. MEJZ @#6J?>MN0/-N0(OA@![J/ER]:]/L!7A@:/<:I5^*6.8PQ&U]N04)IV,=
MMONQ*G['&B+:$L"^;1G..,,E9_CY#LQ058@8F./J<# RND5:1G=9DD0YY&,$ MX_"08CVM(H*Y7#3E79XH?H-8\V'0#_X! DL1>-8Y3V<[G:,]:,J+'D**ZT<2
M_"Q)9/Y=17O(E,'60N"@_TX4QJ^9>;-)XE^.HN.37QVS_^^:88UR] M04)YP=)WA!9WZRTU9K'\@AH#K$?4=(F:/A'KE-?(+Q#M%C7]LF/=WU'7,ZJZ
MALBW64T91:,,TB@C9\HHN#(BJHRR44;"E!%URDB$RO"7Q./&/H;)/@$9A]%D M'2XN()< [)3(>@DP)0)9 @AX5\V?_/A/N02 F4)E0R"?0F7Z]XP=EIY:[3=Q MO$UYF,D(/D(Z$
2))5"!B.=4-R0,33^%_Z38CSD6%(,AA MQ4]Y=LRCT_8E(4?NSJF_+KFWW![:_-*GK"#L;_??2I9(\I+@^Y1. +G0__=4 MM<*W/,)V#4V-H=Y\ ]4?0?57;E#WG1O4?HF]-M]E+3X'
03NJEQ^"KB M0[IGRWCYL^E:.F]/!^LE4-14&+^NVE !;.67"9(V@D25($0BB+=MN"FRAJ\(M^X25V5/ ;D9E!"_(3?",]WB#>(K7XA7> -_?M7E#>&3+8>RW;)_:G?_*KLOG MC#!
[M;NIL&J$]3$)S -'8[Y56&>-V=ZD:0Y=3,N"^0*5-?-["?,P8!?C1O$> MDA T*ZS+[O"\=5E'![TNZTE@L2YKJ):EYD),EZ7Q1)!P-=E8V09K>[K]GN-;L441JS0\ZO]"_7CQ2<
MZA3=)3WZFE$723T)F3W]@MK>NE0&5/>':(>HZ;'*?>!](M8I?([K<@,IK?E MH[\ S#^3?UY>LP]1^KL:HM-VOH GX' ,IZH)8FW@T2'3Z&#,5U6GT1)FIEI= M)20_I7L]Z$:-
?"%NS-M8+T^?;@/!FE"+ Z"MIT(CE)FH\H4V< 6K3]D;_Y30 M;]*5@>;.M"&UMXO4IM),[VQ5A/*)E"TH(:]=+Y:,COW_AC= .[P-;VA;@6TE MF]A1R@5&,2 /P2J&\EB;!2
MXG1/<#%XJUX0]I 1>(QA2'F>E,!G-S8&+=%OO"W0Q>45&/<9#5%C91S:4 ,% M!MR/!H\?J8@@0?ZH>%=(A)='Z">1UI0 %/83%&FA/X&0'_B3LDD8Q&69\/A+
M75=5A7\5E4\#4'(_?>VD:8VZYC>H)@ R #L)\#%*4-&VK.Y]L.L=_!BWQ=)- M6]H7U"CTV)I8A1Y8 +/"=;/?YYC!] M*8^*B9&U BS9K59K P.U3CV-]X[V+BVVK6X.,O8#?K4(
"R:;:)J.1*F>EX0 M/KS-3B=2\L/)-#8*@9B1^0H7ZOD? Z&CX+'! (C'@7Q%B$TQ-4@,N@35$;G M6^N/R2J6JXKOF)/"6[J4J)6-%C4!T*B &Q:&@L"@=M"VW8^2$N*1*8I7?8_
M1PDN-N6.G/#VT(4-9.:M(?)6 E+#^V0'R]LC3H V)6(D:'OH1;(@ZCO.$Z+@ M0D0E*E\Q*ID@V:&W$XHQ.9%]&$V (-=PU!C&D'J\Z2VJ:0IN2GN5VE&4LPQC3&!=R:UH%%/;F-$/3
MJQC4)Q(5YT@4SU.T!3&GCE.=-=4MH8U)RW [PA*&84QIA BY):T!!WM#LM:R M_VMWHZ.;N^@4'7'QG%V.KZ7EJ:J(%NY$52B)[C3U!M5DJ**[09PRB,-5(X&J M1FB?
1'3K,"E!#GB@* >6YC!1CJH%TXPHKZ&Z-KMAM3UQ?$>*,B5I-2"8P?V MKZH+Z#WF+.G:'9'X+(+]ZTTH'T@'/_0R33?0=1]!.DAM/(9X$PB7T ^8H1,2R>Q!BP=>0D7PU=6??CS
M$QNZRC\G"_Q$VT$X?J*3:;Z?J/L(TD]HY3, FD2^@/S$")F6?F(-6#KR$RZ& M+ZKZ6-=/?,)?'Z-+NG^=M]D0D,/Z")$\-AZ"TJ.J@P"W&A;""?"%A$LJX4+= M:4CQ:. ;U@7C L^P=-
Q2P;AY$N<60 MH]+..P2VP7 \=E[V%SV>9VTO1/3!.(AYFXNA@PAMCK\433J.DO$KG:YLNO,W65G(95'S;IF/(T1Y0W07$5 TJ MH+]IVAZ?PTD:")QF4_3R,1R4C&
(/=N/!&"9L#,]5%^X7^1])BJLE!7L*ZQQ] MRU)I;1(=E?]EO(1[Q3J(432KV2U[?JTB EVHVTO!*G$UZSC^#IM8"H"5N I/ MDJ7WZF"R7&L[&PY7UMI;_!>;)TREI[(<\?:P.1YS3'G
SY>7F%29C 6K^4S7 M]<(E\[+NO+V9,UO>R8,YO1UL@3:HZXP']9KN4+^_JK Y[Q' *ZPB>U2@B*6$ M-[*SX^A6]J(O.ROW5PIE]_=,T#*T#]\
("@#J1MXGF&%?/XSX%%U9Q.'O.,JW M)FL-'3U\|' BD55,K:9&C)RNX&&7(HY$J^?"1MR9FQ+>%;N[MX >Z-SR4KTJG9$0+$T*52F)Z!1!12G;JQVG!O,L"F?8]F:):IIC*1-@>GLD$
MZS@L<*>(D'H W8S0Z H#YJ6KF&WR/. 2+[\MB;?*<.$2;UTJEPE(E5;!6 M/T&?L=FO [W%=N]HL#Q8/F.2OYHWP_![M '8?5\26[/G00E.');5:V52X*A\ M)7DW_&E)-XYDS?)P[
X@>RV)I\11S@ M3*^72H&EHI(J5*N?HL_4[%>"WE*[=S58ZUK^)UR4NZ\X><,_T[^]2H],3:EA M;5\@C;'Q,UI4$:.*.ACC-Q5+!*@4?RM168EU$HH%;/TR!!J8_ZKP6V#_R\:K M&
(W7N@[[L#!I@M85V <;Y7Y@Y".$Y9+*():>.<&]@@U\!*AG!#X'<10*A\. M7I6\O>0Y%KXN,Z<3\'J($MGT=8O;@H(U44B5$6V$$@%R+Q8)OD*B"HEFQ1)5
M,'0X,3<92D_1E7F5XBDB\GN&1K104[%$$OT0W-T M#IV%)JE1OM L$1WM4RC[RYK31Q*]D(24UR]I3#?!+%L.Q]J$-7==@^]%K?1@ M5?&> Z'M]P;U>
[Y!989>,%^=WU1GY1_)6QA/\#A3C&"7>X/.M6*23C$7@6+. M7#'\'/<@4 S\KMC>?HP?%K TGJ"=B"H+SF'?[\"-S,FAF^5'Z(?>EQ^9D]HU MRY$(-/,>'(DTE\^Y
87L2G8L^6H=3]+K.GQ'TM?#FGX$('=O;>BN9*R+-7V)]S('ZVO&D3,!JI+@WHJ<>!.A M"7EQ)]OR%>>WV>E$2A9?-HZE:N@\.@&=!&,4_:H(P@JN#E/F/U$F("DD8(

M&UN1$;P6G!6.^M]E3]&5U3"-]LI+L%HR7Z>%>OYUL&= H415@5I*!I7U.E>2 M_4"2WS&;PDYR7/G)(U!GNWH\:I[MHZ-I"OT4AP.689[7&.-"_I;&*J"P?
SA#K^GVE8R\;KJ"06W*[@&/RQLYDN2> M+E)S'#^D9?:1Y$79?S&0+5PWZ2:-HX\DP=)YTUW_ &:[5"-*L]F4P]=XJ@^@ M^@N(?0+Q;XQ> 66?
09M/]#]W&\2_!.LHWJF2(%R3$PN3>;-PS,O6 :Z$H,IG M1A6"VI>%:@3A&D&$(>C $31\S?1K'T&O[$LKW=.[32)R*NY(<2)%@6.>ELIV MI+N,+;J>2Y;EG&?G+&?:C))=]E
6SZ]1SK055;][RLZ71*AM23JXXV\"73]P MK3EM/+#Z(&J_6.40_@!VF759HI_%O6_R_Y$OXSXI[D7JS^.NJ_#WWSX RL3 MZM+%*I:MNJP1KEG/N>3A!9']H/:^0F3<(O*-(Y)%U-
BFEF]F"X[(V6S:TGIW&8^"YC3>\M]-Y=HDL(\J'3?^@,VV8?A M8,%D\Y5SO!,USV83$<+EJ8EGT-65J M.E03WH@OL/M)5OJF!VF)WFNPO!>@ #(C@XL.5;F
N;"_3SU'[1E3O3MMT M F90&MFT<, MQ<_X]")/]- 0^=K-Z7@?(Z/?'O4(T&\5B6=X^Y'!VU[,"$F#O9<_&!GMM58= MBD5I6W&>_8B3SU&)-
^4VQ5WP2&VF!H3^$JWT,DQ3.R@-HD2(4;'T($K7?_08 MT&QGR].*$Y7HK_\#WFJ-P35*1?*)+,,R89 MB;M8C-IL9:V]W3J0<3O)!N<-42_&! YGM::'Z?A*-2\8[9^S.#J0E"2]D-TQ
MQ_P']/3CP8W9*[QF/(>T55M^R%H[ICEC/2=LTRY^K.4=<[ZG4/N7AZEWKQYJ,<6L_ MB85F.D9>;DVH1!542(KR&BK9 <4M5/C5M@HJ40>5<]>]4W?YD+[AHEJ*O.$[M?
(K2^"/%Q1T^1WE9)* 'O:*J6\3Z M15W'S$W47:.*JND?.]L]4 3G)=BPKF]K,,]Y?7K/LK9RNF-Q-HMV)(>_>?YS9!:D4/%KYI^>49M?XAVB*JJ
M"%V7J.T3W@27C[\D70YT\"USY]R"@-\6_?*7Y[^@UQ8&;%K,. Q>.QB :;M M_$-;:JA]D$$[7YE")4"#]8Y=?VPGK;K!I:[;V0=C)8BQ,C"H,(!A;X"J ./< MT9[S]%8PPEV*Q/??
MS@6!M=8)JO36N@ZDYENK;D2$UDJ) *[7=5<(J9P7 M6>A W=SGE04QOZI;JKQ=")=@%*J>I/4K] R""_V=%@D!(#;DET"FZ CA]H=2 MY3J$V-
_Y6(R1*K?,)'-52^$1)7*NQS"I6X9R:&:H]C%0-#KW@Q0&4=HM>PJ! M72XGZ?$I9QDV>W:1[V^7G!0QX0DWFOG'MB.?N+*5<0RW?I, IJMY8S9!WZP! M
P=EGS'MU&?;42"@%,HX\8%-!ZCK ;5=W* A: .81>>-J@ULY4,*\5J+;L4N M;@[W-HMLQ3Y^FR*$%;M*U9K72OROV,<,:-V6C 0&U(W)$!' +Y&K7(=0IS= MTFX2GK>'VR0K_K
=N>(H%,FIF)U:.1F_'KVRI7<5V/Y(4OPQRW\A&:O$F1YWKY3/ MDI3YI2@?HZ^:9 =3:E]F8RS-6.N,D#_4TY+R4J4M,6+4\!9C-UH#^B;SM6#DYF#N-6OF_X6ZLJZH!HBW0;[P-
MQ.&- RZ]&9IXO <&M>)@&QG.0G5Z692W/&XNY6N6D_+Z*3IAS99-1>1Q<:[D M7:'KMCFKK72"K:>VK@P^]QIZ)(WW&WH8 9J =G>J)@,W ^E.504BT#HZ\L!
M;P[J#;@)I/R81)%'..DSHCTYDY/X- 4YWQ/X*9#^ ESJS-O5?8:Y S@;P& M-BYV!(]T'_)0XI/TRHFHI?>=09]+U4*1M4.\(>@6P0&[_O<*$R2(]POKP,!N MS[!0OUZFB?O#
>_9U>J6:U:^[#-F8T(2P@7=E!]QC/,H:4^L!HT5,XJ3WCU. M/FZT,2G3V/2*>J/.2_->[YA]=_JSE%W*#HBNFD*$,+,<.NHJ).VI&+R6G@D M1=7, CD7.C2/\;3IT#:65-_]QNK.X/CA=
(Y(7MWM:+_Q :?X0$K9G&M&ZZT6 MKYDD$^.LR5!'A[8?^T97TT*4YETHNER@[4H+A(S,!>Q"+YJ]1K@;IAP5[? MD#.KV[OR.#D/L-]_BTZD.@*CO\MQ5% OU/OK&:?L-
[M7?'O)<\H7G7)(%LL< MP?)^O2_5YVM L9+K=8J:7EDAN$$3WC/[+3M(J3M'5>^0FP'G"F'XQ3V%D$8A M).U#' \5LJ\5'0L]HKLD0-6KJIZZ.!"TN.6 M?J6JQ/J$%?
7%>KZHG,7ZZSG^W ! MYM^6"OV4X^\8'&MD_BEAP@,[IUF %?@C.+1:N"!(U+I:??TZN^+>-V4M&Y:LA7-W53Q-L"6+LUT\RHSS73B8AI?X7!E>@8 M%@-?'QIF!< 7:]O_7523J
O]95?2O. IM0MCG,(> XMKBJ6>'\MD?^@ZO*EJ MU+V#X*6M'GJK51ZWS$=Z8'\H>GK(*CV94>-\[J!2"0QDV^^=5>7)7I=5@=8-_4KS=3\LS*:A.X]'<*[4H+.M*MZ
MBWE/":120E0KH10I 22%Q0+OTI06"[!#&C,/2.#3N:S^;F_&DP[@#7@JT[*) MN>JL;MH8;5#6:B.QR12,*XE)+7$DE#@ TY2@U] H)=!=L&O]=&&Y/-O#WW&4
M%_G'$"_/B6JWZ58GZ)I2^=K-&4HP!5A&Q)P@X&:KHJA="J@->HP+=M M^8,/UUO*T3'+K]L#VYXV+6)=!<*Y/?HL1#=;ZLD[2W5KMNI@[5%+ 'JM#E!
MKQ7YEJ%W4K)O&72!#5;"H;XPY-P>@S!8G=23TI*TI^^H#75 [E6MN4$JN(/> M#@Q9 V&8O!'^S4W>"/Q>3)ZN'VYS'!/*4IY?#UG^-JW!IU&U^/?
I\EH\3,V"BUXX&!O=#5=2PEM LJ+W1(@!7%'W9S"@)0K2<5#;^;QW#NR?&UW+WFV>7X2AO^K^X$R?AE"T7 M ,_D&,BE?&J&TZ.Z \1ZZ!_*!O*$S@PAZ9?^C[U8$
_JF")3]KJ.*2P7V-'F M?$[(/GHA"2FOJD=K!0U]V82(QS$H!FV@7Z^5*G4PT.MJU.CXPEJSKBY[##J5 MKA[D34&@)YV41^ #G)=URI4#< 7-
VD/03,/N[GL7)2DOBC=/Q,W\W4@<\S>] MM]6V@/9Y$F6.;M2MITG#VW(6&ET!9FI/)V@(#5%.<(>V*!]G%2I,L!!^3=+ MS;H"7>_UE%+EW*;M?$%.P*'JY9L2VL')-#H
G$R=CD92[3]$+2%&T^@EHQ+> MA\@U*QU39_$+EO:Z/72Y<2H;%;?U-;(23L=CRYJQ7/"N(4B8UYKE[-"[?@@& M114STO0I M/^.BS"_[\I*3]+A)>[7/-B_T+]%>6MG"A-
(7<(VD&"MU0,0?/._5#ORM(80# MM/G0#,#M>5R,@.Y@?-A)05=@;WWXWV9%62A?L#&CA3>!@2161L I 5_!\2Y3 M +8]Q9VA=:\$NH7VO<) K6?
NC[KR].;T@9C]HZ)VN8GV'T%+W#L3+K(5+A1' M,$&DC3-8!XXN'(+=R/7]ZNX9-<"EV5Y%8):G_4C><+PIZ'*\^ DG\<JE+R%;U'(_<4Z0%B>N2 MCIL\IZ-07<^]?
64_/J35C>3M04+R2.ISV+\J+-,;!QYMVY]6QS;4?!GU/GV# MNI[0H"O4_SQMQAE@E8,K%OB;S!+2&]3RX=S+Q/A 4L*^\N.%Q%&ZGWCV('3= M4\V^3^1<'V\X?\GT?C<
U.V[3S.="-6#HM[7T;[%7-1B3DJ9R"#G7*%F_75.POYWL-C18NP. M@DEA -P$4/P.Q5B&X1R %,^K$!#N#Z11-GKPKT3L32>.#K9(Y&1>$M M'5/%M2)TQ(+-
ZT[VO&2OT@]8\0Y6],P0',-L4C_(,$LKG8D0%O?-^\TA@[[# M8%D7*V,9=[B*IU5UY;8YW1>=<_Q*?4-;0?W^6\G^^9+@^Y0J+!?J2QCC6^6[M($'F=30HQ_-
)#1]TX6FZ7=O4/ME7EVFJH68Y6CP]>;WOW4,H!X'[H_$#+?RR%N_R$,AYO6,U1NI/%A2*M;$8?4%$7C63Z,\V:
M&G7DP"EGLP=0N5$W&3TON'S>O^+XDN#M0<*?,M]K5B\>L6DGW>2Z0TW-/+8< MJ8#)8,&(Z=,09R!V;(HSX H0<*<\5'L#G+]A3=D@+258&%XDA7H:V%'.0$L, MK2@
7!19BB9U0%D*)3\%BFC?(R/5ERJ2T_@L6J3@?!)$87B9.%_@2D:K\>^U MO)$./Y-"1SKP^'G%\71.LBO&SYAN?%FBA;00DI;"YRN,4JXGCRW4+5';%*B:
MT0+667G>)J<"LF:1(68FKQFJ >,%YO43:SU;T^)<3N(1Z J^A0=A8\<("G5K MYD, MPXI8W3K8 *]FG]47*BP(P]C7?]HG+?.Z.I]):<OH!)U<@NX)"BVV M A,
(+CCCO?]&6,]WI#AG192H2BD(F_HZU17S.5DAT%;\(+=I!U='P2W#WHYU M%7@8G.>N#0:C@UQW.G9G0>IJ"I+&0%8DW54*5
:R(UZ):2AK4I1_6!\8B\&5Z2J[%>VN!"X,SO[G\1R;\>S,^/78& MUN<).$;F-V, <#, <=W>?SK@8)-8[PY-PQIMO>GM?MW-GE?]:,9OB
M(SMOKAY7>"ZCO+2*5LC9_X")$T9ZR]1PN*[Z[)^G\:.&*<]*;@&BYR,@*V, ME(Q0[:PNRWZ?7Z+D*<_>2"%.E34A@JG ,N5=4W:E(D MQ5KX54Z)MC)(N06J
MFR)!C*)8RHPF5$AQ2EL%ACBEY(DY)_5_=TTYG.OS/R$37T9G9C/LI;"69%0GZ)QG9YR7UQMTILVJ30K^KPLY M0]5IMH/9] 4T$XQY3MG>I"6)27)A-^&?
\9Y.@2R/_/[;/KG$./Y(16=W(2Z5 MC]@>[J.<[0@*NF1_IGQC\ZQN-Q\"2?QVI"-5TG3_$ZC[!FH^@A@(4>\SC*CY M$'L-$/%/A9)#_OXU!I..
[M(:Y1GK+DW1B[M:R/"'J[@#34+\JE_UZ,C6U=[D MF2Z)74)FXX>L 9^.QH,=C;V.!R,"=$%&#]7K2<&=@?)Q=PF>@WBJWILX\&:J M?ZS>%&A>#.8V2^DVL60;GB?:(\YS'#^7V?
YW;8*VEM*CN>BE$-2.;"A02X(X M#7#:MA]9?!J*(<;&=F((L/>PM'TTR)W]PGP>6J67DS79]8[QT?HM/-WKB3X M.76^G3E>YTZ,[#TXGZKD['J>I^G__;B=5B,KF=-
-7;_[7;H;J7)^Q>3XR@I$ M1.PBX1&C@C4OT%=2OJ*(?O2[5G7X<,#[$E']X$8Y9ZH<3O".W$BLL:;1ZL>[*I[NPEW/B&;HNZ@*NPGI>?V+]_#F$ M-4=((GLU\9F8GECS3$#
[N4^])Q_P(Z(.1KD&F-VCS]O8LZ6>I-3>/MR@%TZ$)IVU?Z']T9F\UR,J,U3U M"72CVYT"N#WO!_9,:GM.N#W7.LC'7P*]'+X,]I.[X\LP[RGG>L@:6T9LLCVY
MO>2,ERHG=Z[1N^C<:SZW UU,LPJ'G59+__WW$'7'J.K9KU\PRUU=5375BK3H M^0#V%%B&J.] 15.-DZ< 5:X#-H7;E9U,$[Y=&8F_4BN2Q4K+Y5.6\TQ!RS7" MXJY]EVY9I@?
QI*E8! \]1-VYMQ6$JM[[BEKYA,OZ10#1,;+(P"W#6HV52],+JHUT!<@E[Z&>[JQ^PVU"XU<5M1M?*Q3FK;GS6 M@8: S=T0ZS:F;@ATWW'_71ZE15+=&XK_<2E*MJ?3YOZ8=@
3XU?+I IS?Z0K M-7),ZXW__HHZ>HE] B<+S99Z(FF/O"7A51/(-P.K; '^,2%HO!6ZC MXO5CDGW]"<='7,'+QA+->H(Q24,I5;;)NN@OI&\0ZPFQKA#OZR8XDYPI]1W. MR5O$#]
(_DC1*]R1*Z-*!W7X.TB9M(*PP3AO\^K;2._8B.HX_X)3^4#[1X2KF M39=&'<'8J)F,*A.M>T!U%XCW\9[FT'DJ&(H;F"%:(%=AFQ:P!=^H*C?5GZ@" ML[2DRJ3L'!]2BA!]
MQ7Q/V>Q,[7Q^3JYITR0A-3Y?MLS?XTP/3[E&?6A M3 1VE/B,CWQ1M\MNL[3($A+SM^),W@ATTK_?\WLG&A$@"=^,='4O7'3^7@Q(5JW!F?5 UK1XCYIY M-
TY%6:_"G0GY*:E3\?$9G]FR@55PK-FGJX02G^C*3"W D/]'@\SXU;[HL\C. M:EJ;U(ZI"%#[J1O4^QC/+T>'+#>RQ*DA/D*GY?\W4*37DCSK6O.D-L^ZIKRT
MCGK[\>8I]#/=,XF6/WH2KY74I7R+HPT=8IM(0TWQ9^EHY72T8K: MT:*S?E'3.GWOXTO:?J/^L'*.$C7W.C\)^17[EE[3^@XX2)C61-=3I[ZRHLT=
MNH7"+SV%1U5;__6,NZ,PN@2D'-/%X3^%4O:/Z.0T/H]_%9P+G$3[9Z"36D?< M>CV*U6%C,0[&@^\^!&I<7*\-$4+T Q>SIE M%< LL+IVLJP?:XODYR^D,:5!#?
-32:\WP,9>"6ZM5"^"5X1H<^ZW_M+<3#M-ZW$ Q^[A/DQRBMXVS=&7WUF-X3'=!F+MH>VAM9SVT%)(-D74?]^[P[MX$@C$P?;Z_<KFLW*_;Y9RU]V
Z[H/)%/7*6@FJ>\N$>/YM;JG/(LO^_(A M/63YB7-I_@"=E!;D33FY)*I'SVHJU",+Y9%-@SCY(VL:N'DQG"D/ MCP9YI4HJC\:BYE[P;O8428_0:9GKRN#3) RP-#8& R
M"&;]B%.XK="7G=PR#IB5JFT*&J:SY9N_VLG$/(""EP<@@#N4#($;AIR5 M<74^<[M]VOS']M.]V]J;&K7R9TH2[R7:U;@!I-\N9]&8FXM$>6,>*0VUD%,;: M=&4!'W
:X]\CNBG:Y9CN'R.U*4B;^[().;^3JA+WG^[N_WW#-\6[S_>;3W>; M]>Q$\U3\BJQ[LQX-4@9FY ,F1O:T2.>N;&QS*4H<9VK+&C7RE@LVXFV2553] M'7*&T;+XY7EW?[>%MQ#A.
^3S58;9+.\L@6#O0#_GW%Q)CEK?JWW2FI3D+?W M914*CJ>7G-NF;9@'T%A6XMR;#>FP,C G+T QLJR9:J^WD,XF&NWZ;0.P9-NH
MIEWV1]#)939S_J85]5IKI2$UFU!F:6_I_:?:PC21,&%3K_>>)GR*DR6>='$D M#V9@PR^X02A ,+V4M2("S"]DN4#"DGGA']G;53,Q])MXFQD&?$W\Q]^VO_P= M'FT"Y0W]
[U1S2S+&_XECS5 -FGC+"A_P-4GK_<_[._E0>?!?2]CSE^$]'=MA M3O=T8!?MNMYP>L$[2KCY1J17A"?-_.VQQOQ-5\J\!6)-T&^L$>2^1*C-T79$ MJ$HW8WB7G2(BNA
K:P@PCBV/ZI&LF@4QED.MRD9SJ%+/R4#CHCF]<^8/UZ8P MCG%ZD$5O(E#-M*J,FXFY9OZV08WZ.7:97B&D5@4C. P"4C6*)>G)%E#W%-2 M-]5(6N:G,1
MPPQJ9E%L^HRH8.<3Q990@"C%[A!L%G$F ?#<(=ON6H (Q@24.V8C*D@34.ZE MI0 *:W9P*@.H&#.K3A07CMX>*(Q8S:*Z%*\Q(1>31>)2\3YX9YXU9_*AKWM[BA[&2F?SG
M'?^%A'^?YJ!'T-@(]/#Q OV/$=H34&Q7WM MC;=^-03/:-CK_SSAR+:LOF?!8'W[O^D33VWER4 M=O^\BB'Z">!&Q2OEAOW?_7]=R%N4L'FGE>>.%/LD8^RKPKGF??@,[EI(-
@F3 M4B(.;/Y#C_P&]6;JK@N@T*\+"??L!]R1@T: ;<$XB0?;(M&+C3VD;[AZ&,'2 ML'2$'JU)*\,88#V"H(QF@2"(I*A@/IN[=4A#,4/4V#K,X.3%).YP3JVS)&_U MC*DP@FE3C[
7\#G&1]>D6C?!P-J*45#LRH9^C%;9N'O&9V\A9P3207L0I XY M5L"U:7AU!]E_K9A-\9$_%.JA=KQ-0@H"(HCX M@(AWU=:5MJ_<,/I32^+^>56[';N)#+NLC)
(@]LE2M$@WO5*H>('Y9[JFR MNANV[%= >]S0(YPG/ IJ$]0-^)83!K V7.X%7/J$JWC4QQ 5#SG0"N+:ECGN ME3Y^R@K^3//]MQ*G!7E)\'UZ.>%
<]PJCF^Y!UR>S]&&RG+GI*FX/"W$WG:/? MNNY1KW_00*5+P.@7(_/1 K$_7,=RYG8-M_]T;#&\S_=N+YM$1:&Y?J"@@5C?"SB?E*/@RWG> O2Z@5N>0=;V,IQ(E_8RD$
REP_L:.^1_2\Z6D?Z9ZH;--:W-SK'D?([W3?PIJA MIATPH V99F&GFX[G[EG5$)"M LIT7R1'B1=4LWR.\OK<'K]K<2TC\(AL*<^3 M1]!Y0]2U!$;W"HS[!+8:*V-HJX&RM&;J,
1M4#E53."U?JJ$9W'MS-'1!7@Q M52OFP4L3:C$R+:RZ.D#,RZM:Z3H?GAZYJKUM8V"PMF6H+5.#\ED:W@R>82#3 M7LT\!_;$&_I_2[T7:VM__(G@G([0Z_41O]&!-H[H*CN
">^J95+<@VK;5S<, M-K^$$OQ=72*@T+ !^A1Q8@/H^36G_CVZ*7/FD6"S?B",RU!".T2&$<3U*1J(MN=F@4VIU-M#T:WP\WEMP#_!7[4Y=205A6$+N55F"%<$-XB3HK\"
[=SLY=#R# MF(<60=Z#MMQP_BEVW'#Q^X:\N=V"6#C*4Q7R#OMZW(SMK$M.6X]L^Y9\96/6?XURN/;+.7%Y KA74S-4>R\SKP= MT\Z4=7(R5_6#:$>H[@FU72'!Y1JXW 2G)
(, MCF^S4V;'.&?C>JC'==^.:]SA/.DZ S@*;*Z8/*1%F7/MZ/81,@J?2QRJ91\."B_!R5 M^/EK=-9&E&4$7LND27B>5A6K&B+6$K&FP.%C8\ZKVT_]1?-W 2^;S< TK92F M0I*OEY7>
<%ZRZ\5W^*6T2'S74OI]84DCA>"%HH8",9+0A/!8GKZ^KJZF:.^O45%'&@ M@3$:NR[1]H":3E'3*_T-ZOI%@X[[(1. 2,FZRL@.B#3*B!MED)3OJ6ME[?* M2.3*\!8]
<64A@T!*4.9A%%,)%QF.(BY%7O9F6/JO;G:E__A_OV)R?"UQO*$. MF7(LG4\5;3UX-!6G8_4W[5#=$&@IN0K+/KR#%A6-Q6LAX2=,2$?N];F,\G(3
M_^-25_1E>S>Z=1/\21="G-.;S_#B+&DG,0#6]#O>%O7Z@8T^ DCF-3@Y'Z>3 MP.5\D/H):DI9T0"+/RXTILIQ[7T*?:7?0OV/ MU1FP:/BY_J-E_(,WO5P:WNU:]<;I-
H1D,8>V=N[UJ@%'TF: M,N50)\-^<>9RLS=,ZS M-U+P<[5#EDL#:&#A5%@G,0C"_@$\A%'H-ABH]B;QTWB%>.E["E)YBGSH*;K' M(E^XITA:3R$-$T^"RH"5.MQH_QF798('3]
([W+:8?/0=[%V,=.=Q W.#>I\. MITC":JKL_LJ6Z"'-0?ZLTM6JW=PDP9?NDW=LKY]QC$\|S6=[Z"4S?,A85AE/ M9A]*P7/TOM:Q,_5^\HK^?
I!Z$WO0>@KZCACN1']O!W&7).WX_!Q.<\K>E=C MT=-3Y4);/;TP/142/;VS=?PBC["'8A[>77A^)GO,V__,L? M;F:2V:Z7:6A5PP6=.4)9C]&<.A32?WDBQQ.7I R1*4
M"RQH'*U3FXNLM2_;D'*KB%]7+>$QH=;T !J-2\8[>?+2Y;')&57 D;;7DTE M3!-*7R@PDF*2PM0CFL38 BCJ:#XT ZAX'A>C1<+R\1F'/P"J,#)OVU6^:N-0 MBAQ-*8775Y1E7$\?
4GXI>Y70;E OTGU'BGV2L3@7U+/*IE+LLC)*8%]/5L)D M^H"R$B-+7#M.29:G68F+*(U[!E3P/\3XA7Z0CJC.S]MVX\WI6\LW36(U[%R M>>Q*3/2)=<%CS/W)KO[C72?
K0[I/+C'UN5_2&.?H^37+R^]V.#]5:VKX>7$> MKH>3)""HS69,5Z.>MJ/>GT*K7E#7C:O]=_55#C565_)2E!&=P:L3C4=*C>-> M"Q/'8]F57^=C*Z?2,MD1\+ C5/6$!LW 75%
(0GMV.K-P+7 \<*"V<#Z.QKES M0,5PG)-JG(M>L[X7JGYBGZO^17]XB0K\;_\?4$L#!!0 (,B 9EF+8@?4 M99@ #-&"@ 5 =&5V82TR,#(T,#DS,%]P&UL[+WI50K&WW9YKD5JR=
(XRI9%4W??.V%@814(1/,4@U5R4J1Z;=Q^ C C& M L="(NB LLS.J59* (C//RP.A\/]O_WW[ZOHIS>29F$2__WGWJ]G/_]$8C\) MPGCQ]Y^+_.67R<___?_X7_^7__:__?++9Q*3U,M)\-
/S^T^7US=??_H?GQYN M?[J)L]R+??+39>(7*Q+G/_WRTS+/7__VVV_?OGW[-7@)XRR)BIQ^(/O53U:_MT;__H_K@3P_]7_H/^E/9Z-?OB9O9/5,TE_.S\X'/_W?9X._#<[_-AS]/S_]
MO[,O_]\OO[!>1&'\Y[.7D9]HK^/L[S_O?.?[M/I]+?RK[1H%OXM*^O? M)KZ7EW*4]NLGL 3[UR^;8K^P7_W2._^EW_OU>Q;\S&20)A%Y("_E9__6_[^ M2O[^U[^A!V$KM7LB'!?)
MZC4E2Q)GX1LQ2 '8[JEP++UX0;*;^.I?19B_M^__87O=]-OL8!(W?BI$7K:\ MCI)O!L90W=*I^VI8[D"S+5%\|K*0MGZ?DHRV6F[9REWEUFTK59+F7A@_I5Z<
M>7ZI**F+CE>W97\>R!N)"W*=)BO*3)[2=K-_AOGRHLARNOZDZKU3:*EE7V]B M^H4\24.BWJN].FV_']"FPI?0>X[H\DRUQT5(?YIEF8YJ(VZD90_)TGP+8S4 M9V-
=H>67+\ES?O<1Y1#8?8?L_FTWT0_2HIM-MM<9:[Q&K59AOVF_6 M46$;K5<,ID0]>=^U5HR=.BV_?T?WL;2:VS>K5R],2Y@/A(TC/R]2-G[BH"QU M0W="]4[J-]P2R967QK31K-
2R2?I(NZ-^M.17;MFCF>\7JR)B>D2)LZU6KMQ> MRWX_DD5)EG+'Z@HMOWQ-Q\D_O*@@7XB7%6FY+BCW@E_9O';VQ#9&=>$(6C"O MJ6GV3=#"J;4VS9XJMV=.@]/L(:?
F";4YW9F> VEUI M?-J]U6RW8UU!$T[3YKO9I37!:+9J:,?6[.1AM1/LWIH]$C5A?B>?!4'(_M>+ M;N*7)%V5O[PD=$M4/Y_J-FL>!;LN"HJ(W+VP:>/G=R]LSJSM5G?Q>H^_#6-2
M3ALZAW;O =K#-?-]V^2R9^3#%A*W,^:UQW*EVOV%B0G2^COF<7XJ,BKH+)OY M_RK"K/QR]EBL5E[Z?O?RQ?NO)+V(/+H140ZK_8B9)JCN%$;E=DJ7[Z@(2##+ M?
B=1<)VDCUY$VDOEE+TZM39O8J"T^\BI$6Z9N PS;[%(2:4CLGE\9.F5OO[F]#7Y:D@LO3=_9,6F5 M%%2K>-D4_O2^UO0U09OY&"KB-
FK<";YL2!8F9JY26V:M,3MK]3))\R>2KE@) MS8[K-7HR!"0.D_1KDI/JXHKJ<<9PP$UWB*;-S&G]';,X34P7G2:[LA=N%R8J MT+(OU6*44>6?E25!>9;4!GJ2KWR
M(\=MQ>8ZONFK%3S=FIKXN^]8QY)D]X1)O/&VS^A@S;+$#]FZRLQ>>Q7O(R^N MK+[T'V7AGQO-L+](KZ?%EYT M\C&L]/&.)6)B,3/ZS1-X#YK J-UN-
]X,FB@T6^T&0QL#19M/&/+5V$[KC;TP M35Y"75N86F.F>KS=3]NF^C7 CICRTN7ICM-NX\80FABQBNU=0)/F^T0N YC MC^JU]+OECNRE:4B"6;ZMHXG'R+=.@-
<$5]KMGI2WS1]WQ+ISO[^N$OR1T?WD MELZ-J'\3OQ;:I_^3]L%&^;39)[KK4#G<73RKO)5*EYRE%Y]XF6C0 M@5(RKSN^5+=4$'LB(M]S$@6\R M'D]':\2GZ-
(F*,83;1'HT6Z1^6 R&O<&' IFZ7[GO-3?M$=_/)+_?E")=8G? M7LMY\(N_#*,M=2]ILI*)9_WA1-+I(J.=2%ZKM?SGGY(T(.G??^[]_!,%\D)2 M.O9N*^A@1\M>YB3-2%GRA,3,:.\#AN
Z\A8 ,WMEYL.S\=EX;#\U_%[SN3FW MDIO-X+H.,[I>_T_BI=?T-YED_AR4KI!/[>=+UG\^@FIA]C MS^;>"!V4WAJ@D$E^E4H($U>8E(F+33K+(>F\EJE<2/>>+_6=Z-
9W=%SL+> M,I\0\%Y2GUV!![?%\])Q% T5Z9RK3NP*F.",+. XS9:3RI%O/K,")?"Q8Y7KA]U<7*%7[JP*0".PZPI&THZ52!]).4 MJL-5; X6A^."O5U*Z5X=\W;[&KMU8*,Q*H
M4XG!@1.[&@J 3#N-+A6D61"D+"Q*]3^W84QZ0B(YY2OX?5=(%"$;LYMMKNL M<5S0'^_2I^1;K$)?7;J"[L!]@JS_'4V&UK68.X3>AZ-_J_P5;H]\BI4 G#& M7":$
'!HLXEE,R"KK5UI[E5%JU.M,\8QH/, 8W8:3MBJ,4N))YAGNT6J8>D M0]Q. \S8:2QAZ;2B^V42BT]WA\4JL Z8M,". RS9:36ISZCI!3W.+!+)@K=7 MLC([.+-/\?
L.T&6SR>1QY471)OJAD*Z]DO/A<#@9.[#XB?H.T&6S[>1J15(6 M_N!SFGS+E^SEG!>+9QFW1K5!.Z/6BS$ --IL(WE:_5H"%1GFU^4X^>]2_FV[1H M.T]
[Z'FI=#D6O'C1J3X_;_X0IA6D,MRX2N?+@G,L1T=M6>[/0:E][-E$%K MUL>_[R&D/!R4FI\CZ>,"H7,40O3:L6[W42=5UGUMH7G?21[NO(LDO3=GL?G2)[>
M$C+XS"Z;L]SF.:LK?WVE,D[*#_1SKT"F@1\^"0I=OE\7T*I4?SY .F?)V>.SK8[*T,L:K$GL^V6@VP?B$XJ2 M;CY?20[[(*M4FP^0-U-=KJ5@['F0TX3B32*&=XI*0.ENL?D
^22H2^%1Y^UY MC].$LON4O'IAYS37=\MT164DS\]I4KQN@W[2W_IE(-Z"!'>OI/)#5-A(&SV-O?9+UW)&_)K&OLRG7Y>=]*U9@!3+A[EOTCJB9HIS0O2)_
M9_&W691M=E9_918Y\00559OWK5AS%5B5HK#HR5&C25JI 2S@I)>1AW"QS.]> M_LBJ)'2BR2JJ1P4SG8Y=6875H%CT:*D)S]=A'.;D-GQCN\U^ID'Q-!97G/>1 MKT:565;
8='#I284;Q+T"I-M8EY'WGN:=VH:J&RZ,%2 MRT&@?N,*5YKWD>>Q%G=2^GGH+'K=U,SP*QP#[=3:CY$-O=+^(#,#/L <%\X M'<>B9[^9P]G8.=1(:LR'R&=[4Y+*M;.A-@
MY>%H/9V5T0%#0-N,%9 7=FE/F_E)1R 17W+%\[,;>26(1*55YR55W_U0M#;+*_'Z,YR M#1A7Q 60[X]=:P=5:>IAE^1A9 M-6NV##0
"8P05VQD3RGQLB)]5]K!CPO/Q\BW'XUX!G 5*K;Q:85E3%9L"'T MA!4#[% B6JKW?(P> ZP!HP .@%']9WTXIZDO89RDFQR1)!/MTX=%YT/WKR6Y MF
!*77G,=RR([=/_>Y;*E7*4YVGX7.2E^V'"#'M)G-,NTUXL% :"F0_,A_;< M8IH[>#>6!##H]#W-T!T?N,)4,[=QJ\Z']EQ]&K#!P1B!(=#>,(<<8O]^E/*2 MY*%/<7VL>-/C8<=K>[-
XTU@)#[1E":VS1V@^?KQI[*?S'*'OLP-U^B/'FQY; M%&]Z+,AAL-/='SO>]-B6R,70+)+TW?%XTYL';-=)>ID4S_E+$1T' 55X!*;3 MSGPTF9QCO]$$Z
2L@HW@&0IJC79KL'//157$N[0465 ;R^Y)^DBU2\6[/JCV M?()N:-(8!*J ' ^"7:,L(66S(E\F:?CO^K A)ONPUGQB2RX539*Y0-R.<7V$
M[B;+"CUBJQKSB4O+MPB$VQ&M]ZXQUC!+A*I7.+MUYA-;3C0JI(IAG"KJ=?>F MFJU0LKN7^@*R0S--]=%M-Q0L,T"-^63BA#%FBGQO(A*?DOUE"EZ2?"3[RQ3= MZ>1(Z'+

[RQ1^VFPE-;KVERG2%@+)6F)_F<*>|HYH &WM+U-T+QW)+)+TW6W[MRP-Y(W%!KJE8F#L_6^;_&>;+BR++Z1:07GU?WU:R&'[T_P*QAU:#UN936^QO
M^[3RQT!3@.Y;8K+\[H5%V2RO)TGZ%OHD>TPB\=$-JC2?VG+=I$*Z!(?;YI;/ M*57F[]/D1>B"NU-J/D7WKM;@[K#CILPG.$X4+/(;%19+AW9)5Z(H*6.,KP,2
MU8N/_Z\B+/,%4.!TI&9L M7[<:MSGMGMBC!:LMW2Z2&C#5HZ_@C*1V+*/XO M7OHG8<_WUNA%2AM8B0K%%NU-A7X9$$,V&S1V/Y.8I%[$XD(&JS .V;$]#]^(
MG&))32H>=![KG45?!8VI1&9-V08B?!U&G;]9O7IA6IK?./S)JE"H]MUP'1.G M!L/QI&6;&/4UKM*.*IB4W I4%O;=9PGFH@ $;AXQ: +6PXZJ"WE:^'F15KM& M^2
'GH:RBO/!V61H8:)L:#XJXS&56,SP4EJ:XQY)GD=D$[* C3U9+ ?ENO-! M[[R'__)0E4\M2!\AJ=@V%$UUG['>_<5Y;,05Z;+EPO35 =,ZZ]C^@S/4P[M=Y,"?
H]+4SFX9(T"$1A+,89CV_B:Q EWJ K8!.M0B;ADI9+@:)U4S(I'H?5X MW9C/P[B@@+IQS!>2+Y.)1[/:_G@G*)AECB=1P%JRM'-9S]1.)B=B*#M2@TG#)BB9$X7CN-;.K"SSZ7;*F
M:6!JG=X-6YFL;HHD.F1=B*)VP;P&==Q8(C8DC9'D]=AL^61=NRTJ09?,< WQ M.9ZY;0^U*OL4N7V^Y8K,5GTWEKD-9UYOXF%M'K4H./Q"5>83EXZ!0A2.YW8[MQ/;)RT)?
@]&R_'R*O.8*&5(CM09B*H^;)8Q>AE&1"]_R #7F4^3UU@"KNU!P ML[2UYO6?A.6V)\'LC9[[%^1KL7HFZ=U+];;EKLBSW(M+-QGYLJS;U'SJDCK=
M")WC">-4,C3B=ET[>)V^XBZVPJXN1/) $@0V\6 M(S-+;);F.TS2?]4LTG_,'[QX08#GBGM_KR':8K$ZEOP^57#W#3U=[)"A+X0M MU"*.JA(U3"0=&!8Z0 ZGWX:>,G9#SY_<
M%A>5';'O$P1V^R.'-^F=6Q3?I)3V,2G''?ZQ(YSTSNTZ=W/FDJSW;A\8M+VZ M^K8L?@$EY(-UJ$"0]2UMLB58W+[KJQXU2OG<+49A(S]UU:;PN/NGRIG9#6M\
M8Z:415&U>6^(?+359E4.Q]@5E:/>H -;KA[5K14'O7<\$<.Q-<[PW:*9#]#9 M8HL%\X!_:+280VWJ\N>U]->@.-(<89RI93C?RPC>&UIXTR?@_*COIFYU4)G3 M=1AGKC/[3@TM/
2%J99'5/K/! 6[.G5.G199JFI//68 MEQSY2KZ5?Q$K:@KUY^/16=_"F.ZR35D9E[$4$E8-@FJ3:C$*#AJ@$\:6ZZDV M8X"+JG6J">P+CHWS?_:4
%;^$O>SEY'R13!=%4OV'@A56;,P)^O\OI6,'HB? M+.*RE7+*".](3OOI>6_DU'&@&WD8RR&![C+1)R0H@SJ4T_2NA))=?2>I'V;" MK?.6Q@OEVY#B_315LN>/\V)8E4BY.R;WE#B
+'>>-Q??MC6UY>[@C M\'UJ.!VVT-'=:#S?WACI*H\C:X",W9Y:Z)XNB]_K?9?'[]TM,^]-D"PA7(D? MD\+IK=L.YR=Z\&/-&1%<[S2 N.UI;NC!S]@6IRB8)S[! CQNNYNW?/ SMM.C
M> P>O ,;KN)[US"7"?I5_)MYOM)P3)[+^[3)*8_^M593+(>:[4S'XS/QUAQ M2O67Z&;8#'F81]V_'*!MW[W,@JKO\D<#G.*5$)!/BN^\KSGLO:-[7:S=%CU_V**4';"JY>8B
W@R9W9DTZJ7+:^CY!M2 M8H3MY_7,IT?5*$=]-ZRF4ULF"RA%-6/I%)X35D;0;YC?8&+9WG:<9A;LMCV& M4_/Y#+;J,=,["_3=D?46D3CH[#TK6 M\)'[?6%2)"1R]-[M*!Q?
2CBCCQR3L7]*D2#O6UV/#8DH3(4Y:?KL$$@H5O?V[N4VB1>WX1L)9EE& M\HP-\/*'WTD47"?IHQ>1ZS .4W7H14[:^JE&$DGI9> MO)$*9PQU^GTZ/9%=GKL:CPAB-
14(!FG5.\S.M2/R];-SP0HHKTQEA.Q]VO52 MJ"J3UB%D6CYB!-;$R_6W*^D\>=]9T(N0.K.8J:X6X=2P9;O]F= M-Y=A*;&\2*EN]ZG(Z!).$4LNXF6UY[WST=FH]['&B
YL8(BX8OT]F@\UQC+@ M-1/K^B_"X)H:S.F?I(R7MME9"3L* MEB8%<)MIV-+_!SYLL"DSM(0/C NU"V]-FTZS)+PQ+*]4N]\50SES..)4V*<46Z(3$OE> MZC3[E!9\8/"HFX*QUR-
U&1HQUU"I(9MIS X:7>3 >-%W4;;*R'<=QE[L&S+R M"1JC3-CR3*R-D4^*$'@#VI'KL]C(Q];$313TKTE\48<(+B]BEV $>?U&MH]W MAG8>H:4\PL:Z!@(!@6NY7?
[W(KEXBAC1E\7]Y\R)2^L.P+&X^70_+B\DXV/_%3DG!L#K!U^;G?5LBZ2C9 MODXF F @NA+EH94$JC"DQX^HUGF\=F5=R5\P1KOM".7.PI2S\/#%D X0"LX5
M#^!3+:9MUPQ;$AJ=?MQ58(%AI&THKI*\T>ZG^5^#:2-?Y&-#MX,)/"0,7,KT MV$H*"O>81MJO_%&F3EUO&@8.#+7.XF 8&6C,Y>@ *#UGI>D[W??+\/&2@22M
MOY87LKW;,/7P^-*0!S!^7#&%'\FO\3C2;*F4X!C[-6UU_$[\DZ:HB72&]AUH+ M5&EQRMB@!0L8!!V9[0$_H.-WAW?/+%8+,RFW?OUH/&M+PVVJX 6V1S7(?/2 M $84;CR+C8?
4)?$C*M?*2R M7Y(\]"D^MS-8#8?CT=8%NF,8FDFLRJ[:$I)!)$M@2^:C,93-*NI>]SI)8AXJ MEO&9+2;1?:8DM KA&,J*U3W+9G+RE&*P)2VZD"C@ZEF(RE""+<0I?-LL"T@I M
&P5I]%D/<;@;-:L6ZJ2+TJI/Y(\K[2]V8JIY[-O'D5!E;;2:XMJ+?F[@%^M M=C;ZW@#;/5+ *"\(-(=I*-W6.N@Q;>5S097,V">=:K>?O"RDRNS]3KOJ*BQT M5C]N4Z"7RJK,^Y-I?
^L:9[=..AKWQV,D>Z.R')7TT0T2]_71AIM9*0"[-,\- M)\J;V0:#L^HF;SC'P6.XB,,7>MJFBW1E>6()M.D9W0])]D17P4^T-W*Z&[3 M+!5JKS^VS_J[X9H_.(P@-J3857(C@[-
-5MY*MAHCLK. M>Z-MPAN[M\ >NH\))#RE?:\G\!3Y4#G%1]B9(;B"W^<([OA'3BM.$2*9-6%Y M'_/"Z?('R2S>4&&D,D .5Z0PHZ3]-V3W,'I3Q]FW+\/,CY*L2(E(W].HS>!C
MW]M"G'!NXK1 &;)4(-V_/9 W$A>$O3PL0UA0N-D_PWQY461YLF*A8+ITH3OJ MRVY7%#0[Q1;FO?%V?[9Q#:8%CV_:L4O *6N 8WJP^ MB!8XQMJ/8'G+M, QO-
O\,%K@&/OXJS"CI/U'U0)/O4NK6 A5FYCW)MA^[2") M?,XUD;FM.[(PF3$=8"Q&0Y=)/:NOOM@Q?MC:8 #6]:O7<&K:(#.+:VE03I:X #)&*6-Y2#7 AXUR1'MHKP$. M;(FC L\H:?
_=U@ YFX"*UB>JQN1BBSO (5E\;A70.*[=!;2Y\"5DH_PP77R' MZMXF(7V9HG._%UH*H%8[E,")&SY1M*/(\Z:)8!65Q F< -I*':2IDCBQQ>%E M5_ J2N($U.
(_BI(X0;K'A^4M51(GYKSDG542)[9X2L,S2MI_UY5$:"]0TQ6E MM9F4;+E>.:0.4AE50;FM.6XT@A] 2QRY\9JS-QXCVZ&:"%912QR#EJJ/I26. M;'F.NRMX%2UQ!&?.LI(@?
2T1ZU4*+&^IE@@_/_EQM$3T6"+R&27MO]M:XF9; MT-,.!;68$&TY31]2Q6=6#L9M;9 EO+A[CM;O0+LT';(O:VE__KSWN3R,W M,=W2BS)(VRP.?
B?!8C]74Y=#3;%/FBI@XU99B%!'+HVGV%&_VHM939F-LWBR3JRV'C$.R(;6T-5JW===R":S#SS'LMTF6L>J&EJ&JU0XD<.')3/1UB9S)I(%A%973X8]Q43P>6W527@E=1
M1@4M/]N*Z/EX/WBY>SSA_N"BM:I M5)\)UI:#_"%]?+9U8+FM1PKT@H^O/DZ&KMR #Y%OP)L(5O%B?/B#7(P/;;L8 M'RI>C __,7XT*J+\:'*Q?CPKXOQR= 6FQ4\HZ3]=UM]5-
H65/1(O8:8[&PY M.AP2RN>_$3ZW-&_<_T&<&/NVW'WL"E[EWKC_X9T8 M^U8Y,?95G!C[?SDQ3ON6'9LX,TK:?QN3H3;]=7W5Q)GXNM?06D&SQ:[[*',
M]RF2@W!;1;ORTIBJ81GS"[PGZ2/]*^E0#=M\?O-I!6T,JD+I&#MB@YN.D6UP M$ADJZF;C'\, -QW;MI.,U0QP9<<_MFXVMLD 5\I;JIN-_S+ 32W+?\R;4=+^ MNVV
.]P!5*QO8!TF$0M-;U,X;;$,BMM*W7]Z=M9SP]16=A5Y70.DIZ3/;?IO2*.+K%3F M2I!V/='8R%VNT&TZ;TBE.S5#NMI<"<^BU'0;<4LTNDVW#>ET[5C!4.=* =CE MM\J?
4PH8#"EU&"12Y6691+2_6;4+?$URHG>[JMQ&*:YS6VXLCEF$:->%9T@+ M?"/I2&2H:-#[M05Y93&U[93%5?&4Q_?"O+*96O;*8JKRRF/[URH+*P);;/'A&2?OOMD'O< ?0
M5/WDM9F4+'Q/,87?4ZB#6]\-G%#]1OWD)-R*LA13?TKD?P ZM_XS)9E;%?P"NI?V?$/K?Z->TA&!5C> M,O6O[/(/KOZ->[:E^E:X]3CLO]OJ'V\74%'\A/689&SQ?
3FDB\^N"ARWE;U/ M7A9F=R_W.^V6@[Y+(]_,]Y.B?)U\GT0A>Y^LH._!E>;#\7EO&RJVHS7/7Y*@ MB,C=RU6:)NE%0GGWRRPMLSBX3\,DO2?
TO\$L^*\BJ]YD*YVC6C1;B0'Y(*W M$K"NFD!^*NVSHS!)),VI3O"4>G'F5=@[GYHMWS6-70GC/L8.XPX)3_&L]8,$ M9Q_;%IQ]K!BR!N) M"W)-
!;%/LDNBC3=#'CYN4&O&2806]ZSB'EN@8Y/|\B1<\)- M3 C);3!R0_,?8V<.D8M1T5@,IQ#Y4-K^>&#+ MCK4K>!5C\0#_N7G/9[:YN=]/*.D_?\HZN1U&
(B18RQ@^4U$:RB;@D'S_M8NB5V!%^NX%5T M2SAH[T?1+<H[!RLNC>[,B^KZ4#\BO,>Q-7$C!-L!,P"26HIM5- M?I L3!/;LC!-
%+,P33Y\%J:)55F8)BI9F"9_96&B,K#%5@3/*&G_/XI6][A, MTOR)I"NV)>BI=ORJ3#ZV:.V'I,GT.R$B&_U+;Y-XL>GOU7<_*H(P7EPD\1M) M:9X/&K-Z0\2@VYJ6PRZ
MJ6(,NNF'CT$WM2H&W50E!MWTKQAT5 :VJ"?PC)+V_Z.<-+C;A=Z)0]P$DY=.!A*=H#QK\(/:@OBUKY:[@5>Q!_0]O#QI890_JJ]B#!G_9@Z8#V^Q! MQS-
*VO^/8@_:V_C7X5\^O3_1;]^]7"29YF6T!!Y(Q,Y6;&!KVHF56F+2L^7! M1JN%0 +P5):5;@Z-,]\O5D6)KCP97B0K^HTEB;/2HDG+$69SZORL6"6+5C@H M[A=D::1[CKQ)*[N*/$,
Z2D=%#?]-W14C*P\)98@[0J1M9&[_*2XZ;RAL^*I M&=(])I;P+'IXMA&WY*BXZ;:APV([5C#.B:4 [+*]\.>4 @9#IT4$$NLL AHJ M@)Z>V*CE4K03^Z[M-HS+=,=VH-
U^ZK;._MR]NGB8=EI!<82J4+5^Y,@[M^D(M^^0MEJ'B?NE6REMZWS#ZZZ7;=&2+ MI1F>4=+^NWW?\$#\)/;#*%QG$+A[):E7IC)-DY.[=9#GE *CI/UW^RBT$_-VLQ_P
M$O2N]83@CFI.?I$R#X-/7A8V"B#<_CM4\N>V..T=#@>9.FH.OMOGHZT<%.#_ M$2?/S*^M2HCQ6N3[YTR5\7>*SS$>[+OR$0W#$TK!;8>S@UG)D0F=J%^3.&VV
M^IEHGLG9%EN\YFAKC]HM?[425_DBLF8M",(*S8Y5XI+D7ABI'\$!;UK>Y^!S MM:S*_'SK&FWWD?I\B'2QJ"9!I<-TB>%#^Z:=8R?;Y$E_O=&3:LMV#,X7380N/
MPRJ,?"&K9Y**.*E*4)!(U[<<60-D[/;4[4/B?9J\DC1_OX^\.*?*(O/\?F4C MLGK@!$PCC=I42+88$L!)I@W'[:,8").!!/>GS\G1;SV#(KICWX5%4SBU/)X-6V9@7DA27UILU\+L*
Q=KL=I-, MTR2]2&AW?=8'YO=SGX9)>D_H?X,=/7)'+K<*;G6MVJ6;E/7KM4&@P%#2MH=I M+Q' /?U%4IX4:$?9,YB@?"K#GB:4S["OOK^2.",\[M4KUS,)6;DRP-[^L&@H M V
(N&(V^U1D5"A91I7-YS NT>[+(-P(8>/@]2Y8.QJT5@L3V9)]?$"9$@HP MPMI;ZM!GJ;VM ML3;!)%'HATJ/BN!*6W+/.P[053]@4QSJ.ZQ(/:=:-UZ+!?DULR)S@"&K!RL M<-
SJYJ"/[HIJECEU&P'LC=IQ:++N3 183NXR&G1,!+"+.E;L,A0+ =8[.3DY MS2P$\",Z;8.=V0Q8$G8??1)[='VB>M9;F!19]%Z%(R*!D&)9M5JB2%Y-37C6 M N5ZNC-+
[4";Z80=Y.&4N[IY41ERM#-E3Y(ET %M2=**6]1GR /$''<< M&-QVKMM&YJF#.PI6%T[I6A9N6X+ (:&*W9 C'O+]1 V.Q<2I+%X%!;U&3^7Z MB;PDZ3H6Z)/WG61?
PCA)P_S])J9CF,J6"GZ_E>IB_ O)EPG]RQM9\R!U[^ND M%S6';IO&I>,72Z9N>RQNI;&^1OA$8CI!129$H$8M$^RH^9V,,S%^QWT6ZRAV
MXA<(ZT(U=&0_U%-3#T!VW'7Q*\F5E*.]_FIAX.2 &QTAVPQ+MA=J:\Q*,KRM4"0'Z$I,:9& M]C$P4UZ4EC!]&49%7E^D*W"]KE$+!?F9J4&V>=!,>5\B\7VY[N-6AZTBUM] M3D
Y7*E>+S^X;411!*9\.+%>KY6@1-XC98$:\@>W*'#@FG*MQ+*&,O/N3DRT MKTG,0E)1N8B,HF"E6C0?_,RO* +'O2YU!X9$(!_<&"!'?S(7R8)_Z?RR2BO'*B^AC4=$#4E0$I9-
R6O*6 MYVGX7.1EK-.$[9-)G-,N1^4]W7O>HAYFMUKHA>BH#LVSM#PD8LEMO>?1" MU6Y@8CX&X H=((?3;Z?>['SQOH>K8B4D:*_,%BKJNQQ],/ M;''!/BR=?)T4 #?
T_,:)EX\4\MB.YW)'- A)XV# >JCRD9]+,=%BAZP[Y5)@ M7E2&7LQT/PK-/FN0.,\/L9_6FR.6^^ M^PLCZ:!.%%ZHCGA3]K@2N(+5I4%K_[63ZXC'^\D]KUL>9?>>VF^_L?,IT,R
M*^G(9*86I?H4%?)&T9@*_@S60/WQ\T+WL5]W:+"Q3R>(YB/GN>K;E"JZE/8Q M*<<=MC#/E8ZUNWC.R+**IRK-U*E*9&%_^;7F/?.![UQ']FKMO&$4T9GESFE
M'=/2>.!@G;4\L&-2R,A2YO@0E5W&E.8L2Y,W<,NOY8!]CRRG28G?0TS.6EPV MJN+.@B99JX$:= %$/LBV7J>%R-R._\&#QGY,B7S!EM:E D*^3!0RITXV!Q5J MWBTHX7.81,E_A?
XER<)%?)O#0<1$Q3?>B M_/V>&8X\,7F,5]2,@FM.8S4JRTIP^QKD?I++R.S!=U0F"/6(3Z)(ZUB_7D? MZS6SF+-C?C4AX;YE!_2<1R].7D*QHK-;9J-33["R!C80/$?A 2'AOBX'2/J/
M9!EG5+IQL/Y)S!=0?(MS@J3DF*%.!9WCC[3762K9GO.^ZPGZZ7WW+Y*K5_5& MJ*B1#9JM;V-UP9[LX7;W T1Z)7M;CX>1\A.QGW'J.JP $F'? MP9)YW=PGJ57)!M&BJ\:3%^@
W@ MW!5OFP=*"A7HDBHTE^2-1,DKP[I.E"!UGU.H70D*V5-2C4IHF5?'" P&;4M7 M]PO +:%*,4O!PEY8%%[T1-*59,F'JI32&"-?A+9>[Z7H *Z=B17)P2==[N%*
ME5B0O7RDG*E3?8 *>.5@M#3L#UR=KWPH %\VA\11#IY28D2::7QI M XP<]!?@!,W!9VL" B;)<:':5N>JQ4*"": (S]MGTU-P9^(5JXUQ2'8&B91% ME' 0 *2@.?@\DCR/*F1QB?Y
YT^BW5@D$Z44C9XIG[V\$$ M^'?%GL0>+MV]S-*4;0F"Y598OIX_R*;#UN<*.3R ;P>L2#NHF!L!%8]7_V;7 MT"HU+&BV5,L/V= @9Y<_*MK@!<;+Z:/7
/O#G9\GM(]/WY*G95)D7ARPM>T; M!?)^G13IC$(*2M%LED#Q)M&PN:T7,_9E0QMJ.9N)"7$ (\:5K"<7240'2<(" MA+R1'?%*5Q5QQ5KRR"9KN1>%JZ!1% M;$
>7KHM61'/PE9*@P#J ">L0QA!@-@W2H$4U1N@\XD MY+=!K2>\)E9@8."ZFOWQ2@43Y_?>.Q2XD%=LWC^WW+O@0/8"H(T>*! 60%9'3ET 6?N*W_9(<(!G&B* MU>EHM?
SEBIQ7+:@ UQV9Y "N#RV+]TE._QMZT6Q!?[7P6'$U-CK)&6_ M>21^D9:YKMA11J#&ZS:U%>/ \GM:X6@R@AX81*Z8^LIPU!?)BG9V29=BNC7O MQ.A.4A(NXHLRCZ^_Z\C-
+*+L7U')]P/Q(R_+PI=P[?JYC1/.)#J[N[AY(%X4 M_IL$?[PF<2GA]#:D) 5E\4_DA7[HR?LN&* V=7,;=Z#OLJYMO62!B84;K6N[M]ZR/DU0.RKJ^2MTZIH7+8ZL97"
F*G*@+Y*NJ%ZQCE$F/I#SRFX18GMHMR=4 M"@\@T)5LSIN5. AEU)SEQ"FV49R5GVTS MGZ5LF%) M--BKE))=EL^\S@:C_':GX7$:=;1DY^\#%$$"E'9DN 4HW5^1;KTB]I?
Z-.NU4DO%Y9-' M6^# <, -S"^Y[JRNL6YB/V5O(QM>#^\W4LO$916Q)6Y@+.!:#=?)LZ^H3OM^ MR2ZNDO0S577S,%ZL;T#+/X%+OUKU>M=S?Q]H@!A(NX-
K/JP5UL.UC/Z/FIX/ M5*QSL%N>:D='JU?!"O#RQ6*R]]OWOYXOU7DEZPZQ62W;V4 MUIFL?.7F/8=1>25)U\&HH+V89;^3*%C?6-J00#9KEBDVJ_.0#KI-"7L99J]) MYD6?
TZ1XK<1*5QSZ6S]A:T]!@KO7==I4=NZ(:0_>J\LQ$<06K5()6!(+'.:' M?RYK#=J>[+$G'DEKYY7L:Y*3=IC3L M28M[XM'X.4F";V$4&5W6#AJ=]X>69-
@YX0#C8G8[EZ_6FIY[\2*D,ZG26 SO MDMS&ZPEK22ZTD^Z9B*JM&E(AM4T=/JV$5EQ[1@=7#JMR,=^S+!C6; MG5:WTAT@AP_J2KV!L+?.;^W0T.
(]**F>D'SVPCAC;TY,C3>E3]4/3CZ^F5U? M(*T3>V./S)TI9U@S:]GRO'<^GH[/D8/B-!UTQL"WSD@.#[!N+G,?R!NA$-DK MMXW'T.--LJ*GSOIJ^R9F;LQ55H2N[V;7W7P@?K*
(J\2Q\IM9N-)\ MM,W;V,8WXO@#3R*/"* X[0RRV4TF*(['@Q"+/3>?&?%_721OOP4DK(89_:$> M7?0?\ULZ\Z(K.M'!?
&6<4A0FT@6C7/C[9(&=M^<^4,Y1U72+%*ZM82^%PGR28#EJ0"0#N>Z\TD!AH6W5C(> MR>(0CC!5+EB>2@SI+*S "X=(,0Y[+H$V2V1IW4G?*R[7_ZBI7/]B_L_MXFWY-
(70T7&TKF#'R'8$R>S+R)1A;WP48 MSC1Q3;N:I'1U8K##O"C%+DCF!96O02*MT;K35AU-:R-Y!Y2)DWO!-6J@F!J3 M$@V*]'%PM39"&R;P>)3>"@*QRZK0P>W2E),B =C"C=C-
'EQE+*9)^E8^)IA% M4?+-BWV2/27;JX![DOI,_O0PJW9##W4V760.:"*0V\CA #E[4U"EMP1;9_Z M78:9MPZ:QYP&7M8ULT_OY2/]3\?\Y1XJZSS2R2@=PHW29*:E.5IMYHJOS_0
M[9-*M?GH'-G?3DG(H!.!!-@/<"5UCOQH1$Z"PM74.?CLXX-<3?61COV@M&57 M4WT[7WUU=S5UCGP[KSNO%.#\T%=46)F %'C1NJ*"T_^@OE.2$'E5L =8PDSV
MNT7H^H,T_12D?TS7<=?MN;(R>XFX#:>*.9MTZ 'Z;NCJ">E*<;N>;#PAUR+) M)#<4PGI4>L@74;I;G@8L0W=16'Q7>*1W$GOE*'#D0)D*O "$'N,P=+UDU'QV
M$]/F*O]C+_KBI7^2'$Y@+JE!MPULMHZ%SK&$R1"8N@DR2E3U3-?/P[?2^5N2 M5IQ7F()#3FRA1H^@\Z8N?#K4&N_3)"C_"Y]).E;Z$.^,U!1*B7L]+T-#G$P
M$E,W/MTSR&SF:SB9\ 'EJ<20/*]%G,"\@=!P+T(:N_Z5*$#EU!N.;H (5F9 M%0CAJR"<_I_L/J<;YM8!2*7,[96CR)'LRXV9X_0?8,ZAP"YY&CZ7C@!K.4A9 M!.M0B2!MBHT9E6
!V'7&/[@222V14H=376"YU:A<\#?+1NNM Y ,ZK-1J+] M7##C$TFIR/+WK]Y*I+_RBF[=?4;(<2V;J+%20 "?6/[!$BH?R&N1^DMO)^GS M(4*A8JM^8[V8 @4'@@-
LP\X2]>]E)_22QO7++U[*PTPM#:GJ5 MHP*N]4_O&MP^-%:-BNUE7RF ^C>[<="E>[5F2[7\D&,7R=GECXHV>('Q"-/MGK:^DL2%!%=BV%'9/>#L^@E
MS3AQ<)8!\LV!3%"2,ZM: U142*X+NC.O"2X+G6:-#0&I0Y%* M=2HF9/.D#IU-!L0N3E376U#GJ?JY2:AVLXT(O)<82.SVHM7(?#1$UH_4&>-J M2MI841UZ0=Z?
O5SFSK17B&*Q>JY*>3O"@NK("Z5-)4'H>V% @96W6)^3-Y+& MS/;E135L,6TZ;5!)(/L.MF)5'RJJ-R^4-YF>Z1=T?/I_2I@]*D@Q(?L6MJ(/
MP&.CP^X#R8M48*_+D2Q(#O%MUPPC[#8ZZ +V[84''9EE2EXY =]K8C4P(CK MYPL0_)30Q?Q8[6I*>2M!D$KU+C.PQW%C!D@.2OJ&B+4D#CN*BP> MZY^\B/VJL?
%A79]*RJXX00<<-K$W[$$SY77\2M(P"1YS+\U-S5XQB@<2L>0& M+$!.F3[AONH 6ZR@N=VX02HJI-V]R2@P@177I;G=@+BG6%)SP^&P.2H@I%W^
MU(.!C]1Q_V>)2D286S#S%6INIMXV034AN*O&M@L#M&U=I-NF?RHT=(YWAJ MMC; [5$AV75-W'9QD$$UY69MY>I@3(G$2KW>@1()IU37=[.NE,BK&"%EU4U,
MA<3BHI(Z\.#.[SIW?]I\^YVE#(N2K$A50@H*:LT'VY6IS4*[(Q.AY]-A.?IY MY"L]J6PX:R,?Q<=W=AI@W>,)I+Y/#]CKC^SE-,#RV >E?4S*<8=1O9SDRYC4
M),@K2]%C;NDJ,T32=[<=C[:+^748A]F2!)^3),B^DIRYAE<:BLHV"=>F0L+T M.H-YXRMKRH@LC.W7A/8'[]L7>GY,0R_29QVL3$6$&3J\,>D20/9$"VS%^3^3 M],^;^#Y-
ZEGW2X-A42IHV_,>LR1&X'(2ROI+=8;^+2\A"*#C] #2H,3..] M+KU"%&['&=RBHH-59PB@2TN? E9#KF#6TX M7H3T)_90+KC/SX?B\TWE3O\]CVEU.;L,W MYIBQWV-
9F@;U1B@^9#<6?3;XTU$7\]PYO]1_GHS/$D* 2F>^3=-AIMZTUFUCL,_]?19A5D07$KX"!&G1A0GY+ MUFX158+GMHF&!XW]F!)Y?F-I72H@Y
MC(7/J9'-0N6W&$]*703#V_B[HDU$"FE1(_?HX M/BD@AP(@H[0:1,)K*>?24S2T+\/7PDM3#8 Q"NKL-)\,.[WL2*LJ9' 64_5 M()EZZ6:*/>:=G,1Y&!?
K4*?;,R5_"9578I9!M#L$,XNI!DA3S]5.SB>X?*I4 M8W!'9YBOS=38T*'Q)FIA!S=[(\/+/ZX0,O9_GT^'@V&6,^)S:DVQW@<2[C! M^B],&+U3HL*(M(+RI0TPG,+R?R8&7Z?
M+/&^R[G9K=,A1/Q$DZ1&VZ?W-# M7,))(9K*$&$'X5*#.ERID@CR=8N4+G66#U"92NF SW.I1A=Q_N#E\G2-\LJ5 MA) #12H0J,:\ !\P CIR78*>
(ZY>O3!EW6>OSO<7MP>*+8E9((:ZE,@6T*2M M4CI8;DT&302ML ,C \T2I M&;%!HUEHE'-2GKFTH-3!$#N0 #)+3FY=:;R / MQ&<74>%+Z)
<$*FB&4)5Y[WS4FV)ED#2K&LHQ I1C&:):4B[5#>%*:Y$@GPCD MA*D3?8@+H/KT-BQ@"[ABS\D^>5DHM/[OEZK2'8[[Z+'X#>SG F0 5:[39)&R*XHXN%@R\U!V$Y?O M;?
^3O-?AKK*L6)7=EUR9MFYXFY@4*S22G$S>_8U1V,!HP?5(>B"+(F*EW^]3 MYB$0!_](HF)%5S*URW35^K4D,,,MZ0Z 1N@ GG'C@__Q&K @E%^\]$^2*\][M<:U:>IBA1'0YU<
$,.E*V''!+G*KD$I9I3I59Y -:2?W5S_"HP)5Z))P4#_ MR,A+$=V&+Z*G]2K5MXLA]JLF=5)U!P4 %A@;KH2 " \6UEY 7 MR>HYC$N^+DH?MP45 OTI"RF>=5@>
[SF,POS]\,I*,'P,M%YY0#@^KDS* 1AP M[=]@X@=FJN-7"PK]&(&:MI'?NL'8>: F["L8?3;X,UL7LSV!FAQY0(V=F$Z7 M8.T#*1^R/6&A''M /4(.8*3-M/: @7';&*^\[1O9D6O/G4?\A
P@.$,!J=Y(M^IQ@S/6GU L($P#,+E24"L!>4X(JNV)P]D2ILCBDP0AYCS$@$6+^L &WQ!'WQ16I:)PP'#<:#EM\QL)FX43J MWUC;ML;?K4/6TY)<>&GZ'L8+.N +=BFS*?SI?
1VIM'-K*8'#TD472?I-R\- M!..34WH^F&+9=C>]43?D[M68#[%"TTK%*3/.ZP>_'QV0UK$H5!*=YRSQ7$.^$7GO>G/73'%XWY
MI(#$D.&QFR@.QUB$0=R@XA5XQ'@H$DY42#Q 8LC"V V-!C-5G%D365EI,DJ0 M6!@[O[NT%)A!%26\<(@4X[#0@"CKN.:MX",W'3YBIG/B^JWI](+KCA
M&O/A.69J'AV"E)#@AG(''"L?^%V426M"P6TU6)9"LS,U#T 2C $WFCKW5*V6 M/.F/1PYA]1\WSS?0PE1J$P7TW<; Z3HFQXU2M7%\7LM$YADHK$?%9TU< *G* MKX'(5#AU+*
[7AGB9)]]>.8H<.T:^G!B T6,*\W._Y/:UW,2= ML[@*%+3(ZB:IE$_(P[*U#+#760$W4C8Y6&R+K/Z%!&'V0%[9)7Z\^",.90<' ML$(-$SNDE9
CG*J!LE4*'6CYX@G^I]L]AKN]5Y,H*!*C1=[1]2E4!64]?CJ M2-OC9DNY57!J/"H['IB3OT)Y;P10F(K)CLRC GU4.,B.0P %8KZJ;IL*S_Y* MTC)J)ZK M@^"3HOG)*S\?#D?
GYRZ0I0;#5!QVY$WP.DE)N(@O"MKAV']_2KTXBTJDGZGF MIS@GY8W,ASU+7 :UYJDJL-8AV5O.W6YUHA[R :6A3M2#@U]K6W0JG>@JWJ/*
M!3_I^U+"2Y*7UQ'N.4T/S_O=&M+,.4V?6W*4.!(G8$H3X?@!G*;/;;5EGQ^% M%P+[_Z&=IL^1[G9!:1^3W]I;HN.9I0;& M+@_JIGPJY%4X*EV+ 7ES$Q.D0"H'CUT>U9U9JH?GV-
=^^O,30&&A-W5C&QD) M=A[^-C2;"=J@ K/.6EIRJ&))D^(ZE3=VMT>^61"$%82;^"5)5^47T YQL_CH M+3++6A_OB4'/PU!:QX)^S_&D;"/?3,ODK_"D; / M6\"LI$G[2#A .EF
TI8="0=PNB%'E)03N?CV;?66.)YJ&H@,'13=\O#M(^N5 M"KP A![CL#",7WVAI$XGI,*2"P\&W;WTK:/^2Y&S N'2#$.U)>VG;P) MQ$JNIB#\?;:4D+CWRO:!7; *ULSMWZE,L/VO]=;

(@YY;&#U.A1KA^^>=$A0D MXDPZD#5 QFY/<5_/ME,W'GT2>VF8J*@:NV5+!ROT5PP--0TN$%./;#N*S+*& M\$>#,&'6 NCN9?]9AJJBKM7H?- [
M/[/OP6O)M((2WPRKJ2?.SC^#W>I+UCW-$@P !2RFWCDC.>Y=DN?\[CD*%V63 M6;UV/B[IT"\BZ8J5Z-R#K_RHCJL>O\)\M#7O==?OFYA^O&"#1>:/QRD]'TV1
M[[!%DN3/$A#&QW>X&TV1E1U0]OM4@7W_R,YV8ZS ZZ"TCTDY[K#;SG;[XU%B M#S@N3)<99 51<4+)(+CM1[>/2BG]-52%B@/941*B2(700QRHWG6 T;74U"[H MI\-
\MDA):9B@I49BNZNX%EV*D&_2Q#QP+*XJ@"STJ-.8E?_PTI"M1P]>+K.T M'A:E2QCRN4MS7>4#L#!E14/^I.OI<6$J F2G$SXI<@)W^^^>;]TFMHXH$]=. M$;I (5]7*4XU?L?
M<;#;QMM?][B:/.OG8C[Z]_,9U&TQA,2.*BPJ#@5 =*1 M@4_&/F'RGMOHCJ>Q0%:[][7GAQ%\#(<+LUCH ZQ\"@WW.0$*R[SR&O,HW>IX MQ2LI()\2$^"_):WWDI[UWY0S'&
<68OM)D#A,TJ])3IC;]FWBQ9FSWA+CX011 VWB M+3$>67!- 4E219G<@?'QO27&(ZMT_QW9'U_,<_O^D;TE)CV+O"5*:1^3$IL[LO$(^8X/HDB%T$,<-GI+E*FF:;=I=^F&G'VL
M8$.-B=3$9F, (A&$NQB.F*)>>2N"J547\BWIY<-#=:O09WC8F-[AX?"VRE^T M';<\;*C^& V(;3-UAYRQ[=H6JP\/UVFC <5/WY+F%&\KUS*P2N-M23$?GBE7
MCNXHIC5;S..=ZK4+A>'_H4 MCQOS.SY ;]=#CG;D\K"9\MDPS&R64XS><^E2QNZR2*#/L7H;M43<.Q,W1(GK M\-&*=X7E6ZN96B[N'9F; S7E(]+5DCYILVM/.#*PZEJNW<(.P,-
U&VE <9M# MUN3X%((5YO0D%//AF?(QZ7X9GQI8PZ>'$G'O5-T0)6Z4IE:\F]F^IYPES[W# M=G.@IF(L(0P A55>JYE:+E8Y!A@; 'R@)XO!=.H!T#]KS_ZFC5HB[ME@&J($
M>,>VMBF@Z1E9^7>:V:J>7R$>TV$%!@ &"; M[*"C2U\6E$5:LT;_<>Z]N=@ 9K&-.)GCL!/\8CJRP2 M!Y2JC (EA,#8P+5%&0WT,1Y;-96%1"IA
2ASY?'@SF%+,%EW2E'45EWT*TW% MH_X#K&F;?%P.Z&&7C4^)1Q 'P*>ZH6=:\1F3!5V? XQMM>KE=1BS^$P7299G M7Y.X4A+SKT0Y&S:_%J3A 0P8;0I>98!@
Z%K[&=#P$NZ+YM>,8@.=: M^!IS\1#L@76/L\X&Z%N+& M=#P$+-_#4RSL #Q+8]UT%@]A^(%L) \=\/:G"(>PM"],W5#E)9&L\&,AS"V M*Z.5,?;Y0"V-=8,:#V'HGK&E.5!G(^&
<)![["T#T;3$.4SD;".6$\A.%'/+A! M0)V-A'/"> A#]ZQTS8%:&@FG@W@(0_?,#9Q;B]6Q&1E%!JJ(3R%*W*?DE58K.Z]]_(1G#C5 M%5REQNO:04H5%&[F481$1Z\> '%(-
G[^Q;HP*H9"#I;PYTW%3PFZHX@<,X= ME*AQ(FFLL-0!=CC]-A4;IAM^OGC?PU6Q$C*T5Z;&BF14$,G^F"6X[P[&?_D2 MQG*R=LO4@)'V+$VRP+[CQH(!](M[DH9)
<$W!_G,9^DN>JG21%%'PB"7Z/0 M9VL]L%>U:F^C2T_.+(RMQ=G;S($U%61&>ZTU."+ 9T8M6ZP%A13RP!S-AH8/ M1RZFXMF8&D ,T"-YS"9 M!DW5HD':+DQ2RQDT;45B*L*-
(=5.\YU^OHX]\42_(WFERBN^W8_M"KTA?:XJ MQ6(J" X^J](7J_P*6VE@!]J04J7&, >5J9 YW7.\8T %UWNP;"T#9*N' D5\ M;L606D?.L>G-^6V+
((.3Q@ER>;GI)JO]5IEO42&T$L6I^-Q@'RBB! 8)JEVL\0#8A M%R\I:N4!L5NIOJ"QRH>KP0 40&$(_MLU7K' WGUP@!L\L9$\9 M#Q_1-OXUC0,I9RYS9
3QO255ZI53JLT+/R2FJ^@Z:Z@Z+S,=#)') :1^3.\XE1HR =O MB!H5(G3JEBS!0@PH#V8(BX$B1U%TDJ,'?VF^L M24P/^GG('"\H..DJS"U/]43D62ID"-A?822H<=
[0@YB/[0IY+5UR(0BXL=RL MBF(^/K?JRJ'F2(710QQ61G*;K4H[IZYRJURW,O&.)M.Q54P>H#&5,PU!#>\ MXCDC_RJHU*
[>V/!6.)KR:\P'H]&H;]5UL/Q*H%B*LZ:%;3*CZA0G4H>R"8E M&5?*#!]@,A53#9UCN1(#(5+,W4&YBGU(O]I?"EW$Z1 M^6ARWI]8I=^"ZRG8=U/AR@Q3('Z:ME>H@H+Y;
(@G5UC\![TV%3<,0>$,8W+W MHG5A"55ATIA,'3M&R+"8"@AF![.W[%B>]\-4B-7!@V)K/$C:A$B^(B8.^VXJ));9 !/R M("*[+V?
[/3>L3:+NHP6]$O*@$KIC_Z5KOX=D'A()%Z2!TW?+HELUOAJ];?'8 M=FQ#ZO7&=]T'.&P,@]68U0LO3=_#>*'YX':_VGR,M6LI$:;",0\0;@BM$SZ\ MO7IY(7X>OA'A,Z]&
[5#)6770:C 4E!":BJ-EU#N"W25NO+,N"MJ'V'^_3U+6 MR3\>+Z%=5UR+PK7*,U](J#(>4U&LNJ+OZH^'!O316O,Q]A6,0?JV>$R%E>J* MOHO?
KQO01VM1N%8=SUO1M\5C*GZ4%1OK1?)&8H\>A$GFIV$)2EV-.JY;74Q: M\!:TG3HE .9N9"F>(7T=+O=3DJ;)-^9WY[W2O^3OFG<-4#.E;1X[%E6#X= (MHZG@5-A'Y?
8Q3'KG@][$>4V:#PDW6!6T>>^,URL632&CW:ML.N#.#5?9&H#Z M5KE9*.S>BIAP8U)!')(WDM(3V@.3,LC:;J$MIH%5!E\%GD 4)PL&U554DC1\ M\]B)NQ9'-
HN#WTFP8.89=A@/\Y!DC\5JY:7O=R]?DPIK9;G)KI.4E25!*4"$ M ":*_=>,7G:IF@*U9F>.6L$%V(SE"PI2,11GQH8A(O4A@ZK4 D%>;A3X4B6:@\Q0 !N,PYM@,DB=WQ5J
M;\5TCFQ*5^(1.MGIP304" =C-!SOR0]A]J?TA3=[WPLN5U ME'PKCY?BI^8J=6OLZ*%W% GBG#*T@1J*SF.*9/-KXJW 3>K4GZPEC?FLJ/M]
MIE.Y&@I$A+E'S;*,Y/MB4=JD./5JT2!9NCOE7K;#R01D*.(18LQH7>OL1>1E M6?@2^M5XB(-K+TS_X44%R7;9V&G."I-MU8F&EMG]RO->?0O4-2!Y(.J]DK2K M^-
Y"BO*43<5=0!_'C7%B>XRPI/\/DMPSS]R..I>?XAT@H/E?.G K/FE@B>6DH@W Y.;=(B3^6!_&)!2)2F%;Y"XW:\ZM,;X>FBANR-(R&P MN>&]@N9V(.NO"3V-;*!*">>49E)
5H(:$0Q#<3N4]2DN4JCN;XTU7+X9*T!Q M.ZSU*:X]J%RL,8B#M#6XZJAPN1WS^CI)"5VHKK[[2Q818X-2NEH+Z[$IA)X@
M74H[S>FMAE$4]&RN[\6^.1%7NR3QR4A^6WBJYR4H2I, MG@Z8H11AF J0C;16\]!)=V:X$A,*\GL4"5_J).\A,A4Y&XGFNWQ)TFJERLOK MITRZ&T-
5YOWI66^*O%Y+^>+3+,7D;B#M$AH])/KZ)/-KL471PJFLRK(0E*G MVA;,YMO0>V;O)D.B-Z6/ZC'1()^:#CKQFW2D'9CDHSX:%']6DRVP\1F(I"CD[DUBUJURNJU&^4F(6K
MLZL$:^ZO#^F3T2V%92I6N9W\;U0>43 1U2:8P-"#]!D=!X?06DSR4]]9^/7/&Z+#MK MS78LE:ELLNZ# *>P/'V4?>I[B_+H5BC<8E8*W! M'?8&&]93;_3+3/2(7 KDM+
[.!,VH#AC+;V*J3I%'RDR9G4#Q0E-0BXFUWW=J MS59!X^Q+:P"<=,T6UJO$@FS_5*%-B_#;):]K[X.8R_V0R^Z^OY*XDQPR2$J M7J+#-G"HR9^S+LM 8;V6-
G2/E:QH/YJED,;6')M4%F8M M6,Z^,Y:AE"[5:@V4@IH@;\Q:C#8;% =H#3F0VC,L%.^VH8J58) W $T.]0;" M 4Y<=](/<]_=G_8F9]8XFCR%=RD/:QZ1-*)2]])[ ]F41ZL- MT1B;/>8=],
[/AD[IC!(@IKQ7;:"T^7->)HT1LBHH(4J5W0-$[KJMGOY!;RDC MZYYQ'Q (]>7J\$RYM&)>K]PV]%,J;=K6;-9Z6MHQ"E.NJMTS^4><$B*_TV"
MC99R=^A0L*/)"$C6:ZB^D[!F#!RSRA\'+8 Z[I*'X:S;._>:2.8V0OMZ0/Q M]T*%?2(O2>G=^"^A5;:(TBYQ9\[KMF$4^[]KP3+E1V7YC.0N"L)Y
M$[\DZ:K2MVRX>E1,:Z^KQ:BU.N^=;Y\(V'Y5V;-(YVHJ:+7[RYY(Z;(R]5/# MY%SGV/8;ON3W68)[_K&3<_60/$AA>1_SPNFRV\FY3A%7%0RR Y[5I.#:YJ[<0%96Z M=Q
]T0V$*Y>7ICS4AL/)""MO=I-)+X'A_-6B$0>U4AK6^2/L$:7*[@$BR^X- MLS3?X9;^J^:5_F/^P)(5 O-R[^_S26\\L>T!+F\:\GMMV1V@"BO@0?J@1(41 M:2[QI0TP_*?
89GA8KGZ!C&3EUQ$Z MARXA'E-/_DV1=!_[',SBX.D;_8NUH)".45+V.&0;@MLZ M)1.:U>.Q>,[(OPKVT."-/4^AGY+8L8 :&WD,!PX<"W2P -PZX"G-02W3 T&Z=96)%R0!D[?
2+0;"=? MD[=RRG)5,#K<)+%9E&K7 L TBH&4<.AK@ L@MB-/G ;L/M&:+>C=J5[+ >F9 M@5%^(6 P>XYWMPVS?!]/K$FWIV.R\PA H#(CAQB@)FZB0E5AMI\6GKQ'UD
M34M>6>;H;XUCXZ'$.3-0@ %XA^"*N\J.& [>$ZK-MX-*\U[_S)K'>&SCF4*J]]1Q6FK.XE/8D MJM5=-$ X ,M.9$#9/A_RLF7U'(@$=W$9LDB)8TZ]K;6N;\U=KB[5,E0 XPXD
M/#E^^O65Y%7>;5%D U&UVCKKR *O#0J@VX'8G8_%ZVL4DK2*.4ONTV21>JN[MYRAH)B&S-,CE.K5[H?6^"4H'!RT M4 %\NO*6#L*JI#GN5ZD?F3NF1"@!
N)D:)L@+3!0/9%T=?>RB3:@Q/1^E5HP MSIJ/!(ICL*%J6Y0E^29BOTIEZ-W)IX8"U6:"XJ@,_VH:6Z" MD4V,M#+)&AVZ8;P@5/.T)2+?1;):A?FFDWL=U(K!I]7.O#
<8CCI=2(^D+PN^ MQZ_ .HZLZ#81-']A%4+\ 8+O#;!?D0L)V.<,!O"A8_-L')WP_(^YH7390MC M\$F>&-_2O:@Z^5[0O5CP ORXX'PP[O6PW[9JS"4)"D/!];IY&;Z/0^BP+BI>
M@4LZV[-0SD8N_)W MR;@DBT,PPOD(EJ_@(TY(.3$<,J5HG,W6=32L;Q6\+^%*;#X@7ZYH3%1E/&[' MM*NWE?KDOLX5*2(9KL64062?/REE -
-24&Y'H]L7R_O,]]."+F_YA9>F[_27 M__"B0MTZ -1GDK)M-U:D7P/>R:+2=6.I$YA3?F0#W60;$**- ;S^YN$G(?.; M2K7Y%-N3NH$L.09Q)9CVV.%4=>#[- D*/[]+'TGZ%OHB6P*O*
(6-^?Q(B91C MU1=&8H]]3I- -K37:#+A(08L3P6 9&$54P+2!T% ->=!X67B($T^DXBY1L_R MNYCV\%T?'KT\48$YUP\J+97.\$HPJR<(X>:7R"?VKC/[@+<(\S,1*F+ 2U5>0
M';ND1'#4, 5(%AH-.[N1!@1B=N[DI_,)! M/PN%03>B\I%8^EZ1N?Y'S>7Z%_,_'CG$U7^<3[&BLBD(?9^EPTZ;2AS1X>2Z M*M+D59RH8+<(Q8EDR-
4FA]]U4UDDW/'S.AL[:)P50$'+.8'M[76&F2%$0(B, M/0X*VQ)1W+V&21C4W1:?!/BE2W 3Q*U+*G7."4 "Q;I\$TG@O81QN/-08VN3 MDF2@D-:<3WJ3,58^BJ;\:<"R+2W%1?
@61C.?]>?&[HENOF&P#36]#GV.%:F@Z(DQC-Y4QPZ@!IP1Y$[^1K!+0 M&[DD*R\.KJGX+@DS2U"5W,/H MP+FC-*1A\D0\?TG;W23S9EY6BGN_:@,;68RP<@4T5@D:
(;0M:TC=V7^&^?*/ M[/"PUS+V*7U&7DR]^)%^5+GXJ0KG]O82#=5)JW6 O*&@5>;2@8@OQ7YI!L M/NP->ZYY2:EB^BM[R#I_+),'\@-5&5?
#!]@^M$SAI1R0'[_(6=)B=T#1+9E M";FD'XT#CSGJ"C%[)=B(2S.>F/'KNN$0&S+&U+W4ZPF'99;(\)T:X-$+&3C ML/>VI0]ID#FRQ#+!3%+8=)(
.$QE_C#.B5[^2(JG=]:S)WGD5KXB)@[[;BI) MA\GUBGV4'DPR>H0MI;GI>WF:^37[E6/5D"]NC1O=GHFP(F2("0160S-P367^
M,#4Z]%.1,:L6TM5WJZ43P&$JU8=90G33DE$P(R27'I%P01HX?3>5D<,4$*-$]"7A2QU@A]-OR](^2/CYXGT/ M5\5*R-!>F2U6K U-)/MCEN"^NYNO82?>"95Z
1D+1<5KJ6%F1VWS!DL&RMT$ M"(?0Y&^MN!5J:2"'T)92I<8P!Y6I3 <(-S.ESYJ*VZ6D1BT/Y)#X"G0!5S0* MP$RE0$ @F@F#-ON^SB-$5[A[%F>%10KX]/X?
11IF05BZK,ENU[4:VDH/*VIP MZXOWYG!-Y5&P:[#L0I9?U&LU5$L/^2%G"]+U1Y%$#J9R-'0_BDKWI-V@3^*% MA5>\-F [^D1?"LI4R@9\>J6+ ;]"+0UDQ4%*E1K#'%0
QZ=WW('NY=:>Z'<46.)=OC7""="-YLUS'<;D M.DG_$2:1QY:NIR6%D(=Y6F3YK?=-XDRB5KL6 '+LSF9$-P)L(SF' 1O4K>"
MH,NJ5>D>YZ)GES(R@,V.0B:!P>KBPHL>O8ADL_PI7)&[E_J-&>C9(JHTG_8P MK_^4Z>!0J8 +(+&C $=R$N]>KEY>R/<$7&MY9>?3]>K"S'Z42,+M4PE4&4[G'WS*!:J=I?
JW3V+>:AV#R%O9S[%2O[29B"T@ H, M$M3@V,W# %YZ*V]!LL>D6"QSS00$QW6IA.PT-*D-!C5XP #]9:2#N3+,*,G M\.?2 [9R0(*6^P9-52]QD Q0K3>$-H"!P8#J=&5=2I(R?H?
+NX062F!(:-NO MT/)_\^&6SZ-9H 3MX;"M.>^=CZ?3B8,ZOC9 8!!T%#=<1>E_6I)#,\#=RS_" ME'C@SJ!:OWI^8O ,936KQY@=><[G4#:T'8^2S/!-]' M. '"+3*5<7',J!KS&K4@?-U
)0@7#WY-<0*$6V1QV^+X2K[=>D7L+YLMYT?5 MUT*PT\&T*=D"E #5%MGK>"@:K>7']==B^%A;MP@FD.NC(YM?4[8;+>3']==B
M^%@;MP@FP'9'QCMMV\W6\,!N:)^E5_!:F2]%1$A3!^5RUB5)FYR[>=3='"HP.W'Q[1_V]B_?Q>-^R M>T([S+W0T6VB$L:YLW;<)D@!VCO*T"?=$9AG5;6TL9Q&K][W)
8SV(IK;=* MGSLXK77Q :SBFM]V-JML5J>+I&K*8I$2BHP\%L_!.APM"U#Y1+IKDZ M-+*K?C$F@ ,#!-=B!^LU]]X[TVC^)_'2.Y4%0%R_EH2#IOCF2 '.<8UV4B0/
MA'G@TJ[>O5R'F>]%#%KC$/?-UT6Y(;N@2_Y4C@6 M%.K6$G#0;Z,92H!G7/.>"$52I,V)WE:N9>"J(5V)X#! #S1RO & MKU"WEH"=L;I;$B-?
%_6X+G.+7:M12Y$7G1[+H,719KRGZ+I-U)'[W10DV\)%Q@IN-:^0RP;VQ0]D)8O:^^] M$+[,4ZB[D< 0-9:ER85!BA+@&==H=Y\F0>'G_R3A8IF38/9&4F]!+I(,?&(
MUZB#);G*J2(V@$E<4QS<]R>2KO399+5JU*[JZ!KX %8[,J&=SN^=X;\-O>

>*\J&)-B@9C9 8!.@_XGT BV$ &C3M@&E@(QR+92: MWJUO#@W'5A0R463-U?]#=Q%!4,S967?!777!J#"&\,T@,(2+W'0M1B"1P4OD M#:M72@6;3F?
36OUX#C9]$1Z+N7=.KE\";\Y*19/Y=?*69\CKL&(DE)42=C.S M;>EY)WQPE"7LU.M]@

$5X M&BGPA]O$F:?!S83QM Q3R$YEJNE:S Y>1IY$",!8<_2%L:HLA$918VW7@G;P MJO,T4@"&FRMND8V$P5+_A/%=3$XQWO8:KT7MH%O=B<0 C#A7'DT?Q$A3/@0(
MZVT%A)IGL.4X44<(# %:?07%A0509\UK MY5E>/]XJWL)%&%U1'8+VZB;.D^LPS?+=M[E,KYC%5$[>=1C!@5=-M5]+TL&) M?3I) &/**G?)B\@+5]EEF*W"+"-
!>7_(+I6>$K9UL:#RA.JPKTE:H7A*;O+L M<4G)H-+QJM_=)Z]%5/ZL>%=G])NUQ%V]#^I,.L!XQ'7KW'V:6;W^I7/UE5G[V)Z8_DR?M. M(09!6,&XB5^2=%5^Y)+D7AC]W-T0W7:
(3D4_2K(B);-G.BD]7V0L$=2:]\[/ M1@86VNTGRI0&T$JZ7XI^NX=TQ:TN&WT%PN%9S,B7,);G0M\MPU8#;%;V9'[,"Z^_P$MFFYG1SE)/D2(9,Y29X?07
M<$YUY!1*%^T+VL6PBF].CQKL;"7)/@K687+#-$EVNS)H.V7NH +I=\:J^R5*/1+L(02U*5H4*!"LG MH@9? -%B3 #)KMC_*:XJOY!<@;>05-2HW9(,
M/M)C/A$=$N+V^@Y0YTZ$AGC!WK#>%ZF_]#)27TQ]>K_P[%W8AM2DA MFY<-6V3BQ+R1TYC![1 " \85YV 8/ !=NB8T;)&)$\E=U"J
M/4QC<#T6SQGY5T'!7KTQ)WOZ*"],6KL=HWU1(8!(%7;E!;9P*=T M.0#KE/+ 5MIE7"DS?( )X%C;L&:(8XD-NW1296O2HT]BC^I$@MLX;MGY:-R? M]#%?&RC>S8E[#
["F;1CKB+4UA#_B[)7XX4LHV)R%Y2O\2#>KV6\JAH0DSDBDAH<3SZ]?@*1(44+C M($$V**=JJR:; !3Z>1I77P!"$[0-8=I, I$\6>WN@^?8@ D&MBW2EFYOKBR/ M%E&3 * '-
ZSU>-3@9!*TWDMYB[6QJ>&OP!E"H U;4N4J4DEM"L=M=CG_4U0 M'_U3G4# N $"M.U*9@D0SY.:C:44!C.,!P 7I($S=H (;2N1*2)>?H8OZS"- MG<"[9S7-7M91F*
[6M.$%,W/EB0:@<5WW$Q44F"<^D!P.D4V% WA&?O)ZM]OX M;E&@0K3ZG30LDY_'F+N3ZB(H'CY C;9IQ-04K(U6O"1RFI:BH;YD)49<1A%'
M$H"D[DT=8$!]G/A)FF$JF#A'S2H4++_A2@@(1P2^CAR $0I&U(,+>@%5KW=9_W!Z]HQRU9D(CE+@[QR $RAA*I9;7R*
MSZ$$V91R,:&#F,!D2WHLKJY'M[=6G)+4IK1,#H!8;7O)*XE^A.:FZL&PG:T? M9 C3OXN($]/%Z5@H5L-X_R9+;F22[N$-OUO:FBZM")52F.9&)0:T!;?\7BX# MJ\CPB<*45V5(_6
UW]%MB@TUOB/+,*HV-?@UZP:?JO"QPDVAK!'-A024 +>0 M7Y$ E]N&V6;VU=_"NSF_=27E4/9P!3D MH:2,*9R)*5_67E!XZQ\:,MC/>>+ M%:AG=J"7R0HHT.!RS^I29W*6?
Q6LH)M_D\]4#BDKG#::!T5= 8%B"8/+8#N9 M%?>_R':7Y/^NKQE"Z@@LR(R$,8MCDL25*3)^(G$2I6Z21O30 M,0N\K%6&T;.[)EZZ(?.E;D_=,H6 PAW_0/7;@AJ$BCT7H_'MA8%)
?\2>S,S M%E8G5.G+QHD96J&,)& M.$-&K7'8;(W*HL'4.V_0"YUW'B.-9'2PM*).I>% U\HRP/^ZK\2+S]A_$$V MWJH!(PMS.NK$;WL%RM# MQ2\]LJ37._:5SZGO.8%+>M7P&O
4BFC%]9"*FC,\,)UF1G1'(!AJ+4W@_)(= MQPY,-?4W"7QR>"G.+L&%CQ\\T#3^X&(TN#6(MP/ 'L <3T^)[H@+#4ME,E=@,$V>#>7*MG\:JPUB9LK\/\YNS1S:I<&NJR*6+
M^)Y9\&*?7@GN@W1;['M*)]X.?CNSMR%K'QXW#8MXVJ<>V>-;XB6Q8RY?P_I?/EH:/?KP+ M8VF[.B8,H6N-[/Q)0]P7H9$,9;9LJ>P*_[#:52 M;/V.2Q4S/PV3Z%56Z$_2DZ
VR[434DW38EFY6 >\()WGM8*@/0P3);\(V09T)/],RV*"W9#O1@:BI8PQ>=7+(^%#QAIL%O$ MYQX (J47ZD+QF" 7]VS&KT2@8;^#E%_[2^/ 5_8C<#$4A5Z+\2W]#>07-DQM
MU2IR&K+-:A<- M4F=S_D;K\K'G\S5:3Y ?--2EPX31>@*_B6>EV;.IT1K+H]F<%16C->Q_/!>C M-=;)&<9;:K2&#\38Y9CJ#E=!P4).4R;]H.S-IW-((AJJ@5F-,W%%0VYC)AQF
M+7$8;SDY-0E0K<(0/86ED[U?542_BFN(@QV8D)@!G2+D>41)Y$ U\@)D%7&$ M-3G%;,$]F)B8=4DTZ9(*,FR;;3]6G FRRZWM]M= 7-0P6[-
J44BHJ@9%P>TZ<*.DF9S"WM3Q&X:L?\|-DY9V8 MY,@!3(T959:NM?6U3JPI-K\G_L;_-X>[,*U!'*;,MF0;R#MF(-E&O@S]886 M6F0O26<++>P.4;?2\%;:^Z
V,^TTF\\\S_%_A(LPVB;NP^'4!EDH3$%HRWU#(]@@N0 M8YXT)*_XTL.M1Q5S'CW3#=5WH;AIJ"D#!\FQUVYB2O2R,!Y:CQL/EJ2HH+IKF@\6]5E&W8 =#=!DA099
>]G#3V_&J.\N&-'*OM$"%%S;7H>FX&92HBXMWM'4%$<@&,"QMC%O%\8^ M>T6L?^_NO1,%5*RL'N,CB9[IOQ(C'MSV916*D96CDJ6R,)N
M^B<85]:D/=N^X1VC9F'<0W]:FIL(NU/1_/L,:>2R)8:5IA/-K(%E8=A&"T/8 MG1/[KD#-N.T7UZ.;*58 1Z^*(Q;?PJB/%JKPD8%9&7P5E*'HD>,Q[/-V,W4X
M!F#@=>O^)/YJS6I&LKZ0,I,XGJ=)G#B!QW^8J.&7RA>RK]Z#%K4! M9_"%\V:NFV[3K.) EN;'>36'N8_Z]Q#]DS(#HX)?J-:0%3&]N)SVZP_:!TE) M_3FUAOE0D8]['J)X8_?
D.^E':Q>5VY43(AL>L]\W&7NT+V@S?D#.F:(5T_M2"8>4D25"&Z)+V0_;$/>$$,QK4T6O'SUJ)X0D[@RA/TR6*;8+DN5F:8GCB&G M0/\L'TDE=0)PV^W#L>XF<(-[DG'A_I7'"D)(:
M[M4^D %U8\49!Z(0L%#IB3=P"WXE[&<*#3OO/Y#D@Q.O/VW"GW\0;T4>,Z1U MM$+E2SE^R,_BM%0/+3D';D.OI/[('ETGWAT)Z!\2]C!HW&SQ4/A0AMXM\J,;
M+;5$1\QA6[05# HZ^B'^1HX9LH>XI6HH2CALX[:BF4G)&:SYJ0S!,?+RH76Q M:"SAP.W=BG+3G7:^?'%^M=>1_9=R +$#39JRWDJ)3B P9='>M:@?VEJ3YJY_
M1Y9A1)Z(NW'BV%_Z>26'./]K*O L22+_1YJP^?@2YJPXP=#&!6XPRBTCHUM64QW?9+ MFP#/$H+',,H8UUSC6GXZ!QG;96QXL3.%B:F4T21,G(U=:B=&0)3EW.*KB\G5
M%7J*4X_*I@I'Z[15FQ>X_6G5_/JF\.6,/*R'0A T3@<20.OT+> XJQONS1/[M"0,+;IZ"=PZTK>,[O'KJBJ+GDV=-DJQPV8!"JT9EN(7UH54C;),?@)YJ:-5(M8-
"S+7"G<6C5"/NB"N"N%%HU@N^3YQ!:-<*ZR8G@EH=6C>#+UGL.K1I-D \9 M2C--3YS?H54C]%=4Q,% MB["1[R_H^:[?BJVMABTS/;?_.,$_2UD<\2",3QF8'H'I5LG-
^B/FALB2VY(MSX4]ZW*M$ZP,.!AOB1T]'_*PR[66Q^O]XP![;54UI?/Z,620K6P=S4T=\8== MZ+002&IUK[5CDB-'-JHP W#*D02UXBCP&--]&H4[4HP6--Q 39E@R-%9/*#K
ME$@&CYI(#+"2W=GR1U6Y'+2L0 MK%]Q523HS+#;ZR7AB>R843M8E;>N8,7,Y9_"2'SOJE^[5'Q8'?TB(Q#9T=7U MC;53X'"S58$S0UX!.Z:K*>M$00K+W1,VXBOV+&?
QA1V7J8YXY9Q -+$Q]E'9Z"7NYR[9$"=$W;]K<+8Y\]881P[(M8 MN8D,2=%9KVK%)+?#_]"KCIPB '_E.@W>J,A%/8UW1D_4OW?A+LL2_?7C@0Q MJ53>_2?UJ21?
BJ[2]@.*DR4:/%5!BMVLC+*XM,6,4 1AQ-MER5^4/GS(!KZ MYT)ZH2\,ZL1 P8[#0U C*2" E@SE!?'/)*"0;:A\,V_K!SX[+[(=4ZXJDIX, M'NP\/XS]3 D50&EP;9?9)>#
(*P.K@:P+DQ2[+$+?_@LY' #QVL9,CSUKX;// M?$[I\ *7#,R/2>%X1]XM.1* 8@SE\9&', A55PYIG[W9X>KV'05"Z*$"J(NZ M'16[V&PU ?;F 3](J<@%H&5-^[S=B_.+Q-_\((S\Y&V?
RDSWV/I7\KI&WTBR M#NF_O)*B7(I !7L<144?=A$2!*7&PAE(I-.V/A]2=;3A]ISN[JZ)EV[(?%D8 MU^*[MV_.7V%$J?)2-S/(5_';O:?!SZ.5$Q3.^DI+F'X'WN,!)O/E)S^@(/K.
MIDRN$@7/&/W^8C0M'Q;NZ2I>LE;0]"6@VK[-ABHML"KK2\7!+N9IDA;@&JZ(MPCO(49]BO;RLRT6=25B6LTY!GXZ1+L$PWJ>\<(9L80JZI.A8H8SSZ)E$K[XK
MJ@K':\KDQO;1-9I8HL3!E7(Y(=90IQ8G#"""=LS!)!<:A)20 9!(6S,&L]L MG;X;?R.>3_?T0)(W"31G B)=B52 YYCYQ(+8F$D^^RM\?1.S<]!D,;FXN1PA MG2D;FF-'"&;V/N]QV[@?
M4,E>(N($ MGB-F!6C.!$3*\6[(CU@00\G=AC-N/LP?9^=/]R+*:JW8@@@EI1MP QW_+@I MV5"MBW^))]E,#IJ492"NA[7)0R+@IE=#6XMT!9O5YCK2G;3HG(\=BM3@Y](
MO/,CUORMD%',"-2>R8@4.-&0'XDDIM)US0<[[&45$\5IRB1#G4KO)F$$E2&:S,-.VBH* =60 ROM0$L3*1M(C)8,\K :ZX(13'5.JG*?OKP3C!0P._82825JT_(<9B.HY&/]P,SE.=
M_*I0V$W0BVDS]O;5ZH OE\U4#B5:'AUZTNX4^RDA.$P'D-Z]]>."E0,9E;]& M1;[&7J7%; 7]<:BOH/XQ\Z&T%8(]B>(8!]^3P/4, Z9ZJ
MP@R'2XDDJ'&/!FK2!RX)DCS'ZC%4L%/INU\(MCJ1%C2DUKP-"F[1"+X8*74SL200T,^T51385 M%-N_&Z-AR H3'-U;H<8-0"Q?'E.AM&A$\O1=Q3&ETIW-%.QZD*;GM[K8N!&^

M{7MX.RAYD.'UPHL@GWBPI^_3NERI_,2_7SLIX^\X/?U;\M^Y4)X,V#)^*F4?$TPT,81/O_>^?$ODJ]#I,_LQA/KWJ=Q"8&+W.*&?L-B@[R
M"F&>;_Y"8ABR_>XC;'MA(89DWOAQK"9\#R<<,,;)'<.B+;$!9<-V$((7)/M-MX.ZM_,,?/HDH<.NWKZS$M.1&K_8!"B=R&9).IVL3,"STYS71FX.#87PJLl0H
MH/4="4QR0+$.P1(541=XV-['"4K8OP2Y-X@RDD?0U:T$ONNPBFXT:<"A1!DC*-M87L%>>)=-J+.^L@3%EFVD"^IK4@L;(<@3;]R(^G$)"K+AL%/J:U(.VP]XL$=F
M9ZT/&R>6^87-/A1'6Q;fG@Z.//F'\2P\0I"#60;2]R#\$9/HE6&5S8RRAG-A MDJ^043]6&OY)RB&R>U*B*4K6)<-PX-;S::V>W*O.4IM)_2P(.3A\4=%N-K
M6RXGG;#,URP1%KA%A5KKQ4>R==@S6UG6CUPK>,TI#LBA:Q@Z-2,Q<-=H7IS_MF2%7[/X2G>!WH%C89;ON12M$6-A;3"E[RMUW$^)]<.*U0DDE7H<|.&1DR\FA-M!|)5|<
MTP37/%/FG"M>7M+A]AH[>K%WQJ5HF*K.U'!PU,&Y>W__>|.\V9[V-MHV=V6XP;/=UN(0QP*SZ9TPXQ>FK3K8Z1^EVW]J^F#"'GV2DHD$3SNL7&RL)8-M\VP\;$I_"J.?
3N3MJR;$'TGDOSI9)8-#6(1GFR8?HX<{6\X\W?+/_PT!PRW-M=%?[M;,"PSH:2!E9G+9'LGO0;&UZ_;XHDAZW(EAK77B\G""FPZR*NK+W-M\98-%-USI-4;__XI.3D.>?SDYJ
MJN%W6(QOD(VZYIGE.Y\(:?E,EUO-2$U]D/E/AT'?Y(?B0:]CM)SWWMQIM+9\]E-M7TJB@X>I2FV(5_T6N_Y7A80IH[#3QC8VU:OI@1SF)FJ#H>UNCGQFDK)_I-,
M[*_.IA:7\M&/W4W(8!&MH'THP+]=BJ<3-07N*Q'M9-03R-YJ@;MN\S34A-M("MZ4??ZUX5\I8P/X?;'GS]-P2S,%[_*/U3[%.)B@3TPEPNT)0&7Z,XGH'/
M5$F/&J,#:)FZU1A;RTJ('TB2H:RB3'-GBHHM'LRN=48&-I"N.A2[[M'^6A;P-M.;'H/695VL/@GM6[B)FMZCY(M\5$43^U:\'ZMWY-1Y?79V"(.7+8:8<8H)@#-MJ)MTNMV_=:.7S3}?
(6U7V&F9[*6J-'ZVC5?$QXZ')(98L.?]YK(R.@T'-MIOYJC"-SN&^?\)X=QZ).G"&BO<8V@@E1=Z;"H;$93O+_\|%^\.KFYULNI*-MP9?84-&>'@D%/>-'+7(1D>Y6?+
!0H|&:ZAJ3S^4?'\-^^=MT*R2EUB87$RER-M!8+\E!C^F"TLC"/CQP_D-!RVR65%"FI4X(<[9@O+T4CX^9/XJW5"O-DK/=A+-M%C=N6RK[S276R\#J?G/:NQ;.@=WERPX6^%Y
:A+CN-9Q#&(3B+*(!BJ,],_MV84GF312&.Z4-X(1.*I&L.$7;1F!;4\I5%6>R!UX,99EAX-M'/(!&:=GJ!#E316OZ-M/SHUB!\Y/E"8C=TY_GI^.#D#[3S5&F,1/2!F5A;-
>201>_G,6=$MX4O@1G3P-MY")_-M%)BL_]M#(=_>I2=,)OJ;@[:91ZRS.CTV/&.S_\>#L.)_IS%WE-MM5KSN]V_O>4J3Y[<7_-ND-
;C\S:W9[#WU;GNVDF>06;/\S:X\3+V^;;HET]S-M]-(ZI-""79YV';/#-MEE,!C6\44%-,P770%!U9X-5C1T"/;;#3S)3^'_TU6-MYE#Q-WL4)B/DG:TS:CE'[6;HH,8Y
(J2CSYFDF0#$VL%OW5Y<E'@SB906W"CE"(P[)@)0#SI-M)5'8CP*#?-V3LJ9%]J%4N*$+P)%\MMF0:.4$V1G%<>6G1JPY,@$]%B,:\Z@RIGTN"24'O84A5=$=-M9^
\P9L&NDCCOE34ZXQ4X0U27S7V?SJ5/(L\JK$E]<78X&YRKI+[6N!.D,-F0N\]WY-M3$X!M*LBK8;.LO!JV2RfT\.5B?$,/:GM)52-+#8%/LZG(.%NY9Q_J4@&"
M')CRZF(R0K8HBCCC>1K;R(GZ-)E0!P(V7"?PW,IY$F?_-MX)$?%$2ZVBGQK_P9BB^R5;(1[YKRV5/FZOV8*">C,TC!D1X=.L:!LV!7-CLUI-M!3P:%LFBQP)1^-]-6S439-V!7DV/_\?
&]\,)R7_^!U!+-0(4-Q0-(,B-M9EDC6IXA,](")O^*0/"-0-!D.##,Q,2YH=&U02P$"%,4"-#(@&99-M*-$0-@-%KV@(-9#@W-#$W-&1E>#,Q,BYH=&U02P$"%,4-M-"-#
(@&99KC=^3+<$";$0-$-@-%UX@(-9#@W-#$W-M-&1E>#,R+FAT;5!+-0(4-Q0-(,B-9EEI&^;;2R$-%R)-0-1-M-"-5KG-@!T979A+3(P.C0P.3.P+GAS9%!+-0(4-Q0-(,B-9EF1
M@SU1!P\,+/-5"-=0(-P\T979A+3(P,C0P.3,P7V-A-M,"YX;6Q02P$"%,4"-#(@&99>S9K,JZ4-!BR0D-%0-M@-$.&,-=&5V82TR,#(T,#DS,%]D968N>&UL4$L!-A0#%-@-R(!F6=#O
M-G(OKP-:P4*-!4(-|!ZP#-'1E=F$M,C-R-#-Y,S!?,&%B-M+GAM;%!+-0(4-Q0-(,B-9EF+!8@?499@-#-&"@-5"-M-5%-XML-102-d874174d10q_htm.xml-IDEA:-XBRL-DOCUMENT
0000818686-2024-01-012024-09-30-0000818686-2024-09-30-0000818686-2023-12-31-0000818686-2024-07-012024-09-30-0000818686-2023-07-012023-09-30-
0000818686-2023-01-012023-09-30-0000818686-2023-01-012023-12-31-0000818686-2019-08-31-0000818686-2024-06-30-0000818686-2018-08-212022-08-21
0000818686-2008-07-31-0000818686-2005-02-28-0000818686-2013-04-012013-04-30-0000818686-2013-09-012013-09-30-0000818686-2023-06-012023-06-30
0000818686-2024-04-012024-06-30-0000818686-2023-09-30-0000818686-2023-12-312023-12-31-0000818686-2021-07-08-0000818686-2024-01-012024-03-31
0000818686-2024-03-28-0000818686-2024-03-31-0000818686-2023-11-072023-11-07-0000818686-2022-11-092022-11-09-0000818686-2022-12-31-0000818686-2023-06-
30-0000818686-teva:RestrictedCashMemberus-gaap:FairValueInputsLevel1Member-2023-12-31-0000818686-teva:RestrictedCashMember-2023-12-31-0000818686
teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember-2023-12-31-0000818686-teva:SeniornotesandconvertibleseniordebenturesMember-2023-12-31-0000818686
teva:ProductRightsMember-2023-12-31-0000818686-us-gaap:InProcessResearchAndDevelopmentMember-2023-12-31-0000818686-us-gaap:TradeNamesMember-2023-12-
31-0000818686-us-gaap:ConvertibleDebtMember-2023-12-31-0000818686-us-gaap:FairValueInputsLevel2Member-2023-12-31-0000818686-us-
gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember-2023-12-31-0000818686-us-
gaap:OtherNoncurrentAssetsMemberteva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMember-2023-12-31-0000818686-us-
gaap:OtherNoncurrentAssetsMemberteva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:NondesignatedMember-2023-12-31-0000818686-us-
gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember-2023-12-31-0000818686-us-
gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember-2023-12-31-0000818686-us-
gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember-2023-12-31-0000818686-
teva:ShortCreditAgreement2026Member-2023-12-31-0000818686-teva:SubsidiarySeniorNotesDue2036Member-2023-12-31-0000818686-
teva:SustainabilityLinkedSeniorNotesDue2029OneMember-2023-12-31-0000818686-teva:SustainabilityLinkedSeniorNotesDue2030Member-2023-12-31-0000818686-
teva:SubsidiarySeniorNotesDue2025ThreeMember-2023-12-31-0000818686-teva:SustainabilityLinkedSeniorNotesDue2031OneMember-2023-12-31-0000818686-
teva:SubsidiarySeniorNotesDue2046Member-2023-12-31-0000818686-teva:SubsidiarySeniorNotesDue2026OneMember-2023-12-31-0000818686-
teva:SustainabilityLinkedSeniorNotesDue2027OneMember-2023-12-31-0000818686-teva:SustainabilityLinkedSeniorNotesDue2027Member-2023-12-31-0000818686-
teva:SubsidiarySeniorNotesDue2024OneMember-2023-12-31-0000818686-teva:SustainabilityLinkedSeniorNotesDue2029TwoMember-2023-12-31-0000818686-
teva:SubsidiarySeniorNotesDue2025TwoMember-2023-12-31-0000818686-teva:SubsidiarySeniorNotesDue2025Member-2023-12-31-0000818686-
teva:SubsidiarySeniorNotesDue2024Member-2023-12-31-0000818686-teva:SustainabilityLinkedSeniorNotesDue2031TwoMember-2023-12-31-0000818686-
teva:SubsidiarySeniorNotesDue2027Member-2023-12-31-0000818686-teva:SubsidiarySeniorNotesDue2028TwoMember-2023-12-31-0000818686-
teva:SustainabilityLinkedSeniorNotesDue2029Member-2023-12-31-0000818686-teva:SubsidiarySeniorNotesDue2025OneMember-2023-12-31-0000818686-
teva:SubsidiarySeniorNotesDue2028OneMember-2023-12-31-0000818686-teva:OtherDebentures2026Member-2023-12-31-0000818686-us-
gaap:FairValueInputsLevel3Member-2023-12-31-0000818686-teva:AccountsReceivableSecuritizationFacilityMember-2023-12-31-0000818686-
teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMember-2023-12-31-0000818686-us-gaap:MoneyMarketFundsMember-2024-09-
30-0000818686-us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel1Member-2024-09-30-0000818686-us-gaap:DemandDepositsMember-2024-09-30-
0000818686-us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member-2024-09-30-0000818686-teva:OtherRestrictedCashMemberus-
gaap:FairValueInputsLevel1Member-2024-09-30-0000818686-teva:OtherRestrictedCashMember-2024-09-30-0000818686-us-gaap:EquitySecuritiesMemberus-
gaap:FairValueInputsLevel1Member-2024-09-30-0000818686-us-gaap:EquitySecuritiesMember-2024-09-30-0000818686-
teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember-2024-09-30-0000818686-teva:SeniornotesandconvertibleseniordebenturesMember-2024-09-30-0000818686-
us-gaap:TradeNamesMember-2024-09-30-0000818686-teva:ProductRightsMember-2024-09-30-0000818686-us-gaap:InProcessResearchAndDevelopmentMember-2024-09-
30-0000818686-us-gaap:ConvertibleDebtMember-2024-09-30-0000818686-us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember-2024-09-30-
0000818686-us-gaap:InterestRateSwapMember-2024-09-30-0000818686-teva:ShortCreditAgreement2026Member-2024-09-30-0000818686-us-
gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember-2024-09-30-0000818686-us-
gaap:OtherNoncurrentAssetsMemberteva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMember-2024-09-30-0000818686-us-
gaap:OtherNoncurrentAssetsMemberteva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:NondesignatedMember-2024-09-30-0000818686-us-
gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember-2024-09-30-0000818686-us-
gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember-2024-09-30-0000818686-us-
gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember-2024-09-30-0000818686-
teva:SubsidiarySeniorNotesDue2024Member-2024-09-30-0000818686-teva:SubsidiarySeniorNotesDue2024OneMember-2024-09-30-0000818686-
teva:SubsidiarySeniorNotesDue2025Member-2024-09-30-0000818686-teva:SubsidiarySeniorNotesDue2025OneMember-2024-09-30-0000818686-
teva:SubsidiarySeniorNotesDue2025TwoMember-2024-09-30-0000818686-teva:SubsidiarySeniorNotesDue2025ThreeMember-2024-09-30-0000818686-
teva:SubsidiarySeniorNotesDue2026OneMember-2024-09-30-0000818686-teva:SubsidiarySeniorNotesDue2027Member-2024-09-30-0000818686-
teva:SustainabilityLinkedSeniorNotesDue2029TwoMember-2024-09-30-0000818686-teva:SustainabilityLinkedSeniorNotesDue2030Member-2024-09-30-0000818686-
teva:SustainabilityLinkedSeniorNotesDue2031OneMember-2024-09-30-0000818686-teva:SustainabilityLinkedSeniorNotesDue2031TwoMember-2024-09-30-0000818686-
teva:SubsidiarySeniorNotesDue2036Member-2024-09-30-0000818686-teva:SubsidiarySeniorNotesDue2046Member-2024-09-30-0000818686-
teva:SustainabilityLinkedSeniorNotesDue2027Member-2024-09-30-0000818686-teva:SustainabilityLinkedSeniorNotesDue2027OneMember-2024-09-30-0000818686-
teva:SubsidiarySeniorNotesDue2028OneMember-2024-09-30-0000818686-teva:SubsidiarySeniorNotesDue2028TwoMember-2024-09-30-0000818686-
teva:SustainabilityLinkedSeniorNotesDue2029Member-2024-09-30-0000818686-teva:SustainabilityLinkedSeniorNotesDue2029OneMember-2024-09-30-0000818686-
teva:OtherDebentures2026Member-2024-09-30-0000818686-srt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember-2024-09-30-0000818686-
srt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember-2024-09-30-0000818686-srt:WeightedAverageMember-2024-09-30-0000818686-us-
gaap:RevolvingCreditFacilityMember-2024-09-30-0000818686-us-gaap:FairValueInputsLevel2Memberteva:OptionsAndForwardContractsDerivativeLiabilitiesMember-
2024-09-30-0000818686-teva:OptionsAndForwardContractsDerivativeLiabilitiesMember-2024-09-30-0000818686-us-gaap:FairValueInputsLevel3Member-2024-09-30-
0000818686-us-gaap:FairValueInputsLevel2Member-2024-09-30-0000818686-us-gaap:FairValueInputsLevel1Member-2024-09-30-0000818686-
teva:ModafinilSettlementAgreementMember-2024-09-30-0000818686-teva:RoyaltyPharmaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-
gaap:CollaborativeArrangementMember-2024-09-30-0000818686-teva:AccountsReceivableSecuritizationFacilityMember-2024-09-30-0000818686-
srt:RestatementAdjustmentMember-2024-09-30-0000818686-teva:BiolojicDesignLtdMemberus-gaap:CollaborativeArrangementMember-2024-09-30-0000818686-
teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMember-2024-09-30-0000818686-
teva:AndaMemberteva:UnitedStatesSegmentMember-2023-01-012023-09-30-0000818686-teva:OtherProductsMemberteva:UnitedStatesSegmentMember-2023-01-012023-
09-30-0000818686-teva:UnitedStatesSegmentMember-2023-01-012023-09-30-0000818686-teva:AustedoMemberteva:UnitedStatesSegmentMember-2023-01-012023-09-30-
0000818686-teva:BendekaAndTreandaMemberteva:UnitedStatesSegmentMember-2023-01-012023-09-30-0000818686-
teva:COPAXONEMemberteva:UnitedStatesSegmentMember-2023-01-012023-09-30-0000818686-teva:UzedyMemberteva:UnitedStatesSegmentMember-2023-01-012023-
09-30-0000818686-teva:GenericsMedicinansMemberteva:UnitedStatesSegmentMember-2023-01-012023-09-30-0000818686-
teva:AjovyMemberteva:UnitedStatesSegmentMember-2023-01-012023-09-30-0000818686-teva:EuropeSegmentMember-2023-01-012023-09-30-0000818686-
teva:GenericsMedicinansMemberteva:EuropeSegmentMember-2023-01-012023-09-30-0000818686-teva:OtherProductsMemberteva:EuropeSegmentMember-2023-01-
012023-09-30-0000818686-teva:AjovyMemberteva:EuropeSegmentMember-2023-01-012023-09-30-0000818686-teva:COPAXONEMemberteva:EuropeSegmentMember
2023-01-012023-09-30-0000818686-teva:RespiratoryProductMemberteva:EuropeSegmentMember-2023-01-012023-09-30-0000818686-
teva:COPAXONEMemberteva:InternationalMarketsMember-2023-01-012023-09-30-0000818686-teva:OtherProductsMemberteva:InternationalMarketsMember-2023-01-
012023-09-30-0000818686-teva:GenericsMedicinansMemberteva:InternationalMarketsMember-2023-01-012023-09-30-0000818686-
teva:AjovyMemberteva:InternationalMarketsMember-2023-01-012023-09-30-0000818686-teva:InternationalMarketsMember-2023-01-012023-09-30-0000818686-us-
gaap:ConvertiblePreferredStockMember-2023-01-012023-09-30-0000818686-us-gaap:OtherRestructuringMember-2023-01-012023-09-30-0000818686-us-
gaap:EmployeeSeveranceMember-2023-01-012023-09-30-0000818686-srt:MaximumMemberus-gaap:CommonStockMember-2023-01-012023-09-30-0000818686-us-
gaap:LicenseMembercountry:US-2023-01-012023-09-30-0000818686-us-gaap:LicenseMember-2023-01-012023-09-30-0000818686-us-
gaap:DistributionServiceMembercountry:US-2023-01-012023-09-30-0000818686-us-gaap:ProductMembercountry:US-2023-01-012023-09-30-0000818686-us-
gaap:ProductMemberteva:OtherActivitiesMember-2023-01-012023-09-30-0000818686-us-gaap:ProductMembersrt:EuropeMember-2023-01-012023-09-30-0000818686-
country:US-2023-01-012023-09-30-0000818686-srt:EuropeMember-2023-01-012023-09-30-0000818686-teva:OtherActivitiesMember-2023-01-012023-09-30-0000818686-
us-gaap:ProductAndServiceOtherMemberteva:InternationalMarketsMember-2023-01-012023-09-30-0000818686-us-
gaap:DistributionServiceMemberteva:InternationalMarketsMember-2023-01-012023-09-30-0000818686-us-gaap:DistributionServiceMemberteva:OtherActivitiesMember
2023-01-012023-09-30-0000818686-us-gaap:ProductMemberteva:InternationalMarketsMember-2023-01-012023-09-30-0000818686-us-
gaap:ProductAndServiceOtherMembersrt:EuropeMember-2023-01-012023-09-30-0000818686-us-gaap:LicenseMemberteva:InternationalMarketsMember-2023-01-012023-
09-30-0000818686-us-gaap:LicenseMembersrt:EuropeMember-2023-01-012023-09-30-0000818686-us-gaap:ProductAndServiceOtherMemberteva:OtherActivitiesMember
2023-01-012023-09-30-0000818686-us-gaap:ProductAndServiceOtherMember-2023-01-012023-09-30-0000818686-us-gaap:LicenseMemberteva:OtherActivitiesMember
2023-01-012023-09-30-0000818686-us-gaap:DistributionServiceMember-2023-01-012023-09-30-0000818686-us-gaap:ProductMember-2023-01-012023-09-30-0000818686-
teva:EmployeeTerminationMember-2023-01-012023-09-30-0000818686-teva:OtherExitAndDisposalMember-2023-01-012023-09-30-0000818686-us-
gaap:ConvertibleDebtSecuritiesMember-2023-01-012023-09-30-0000818686-us-gaap:NoncontrollingInterestMember-2023-01-012023-09-30-0000818686-us-
gaap:RetainedEarningsMember-2023-01-012023-09-30-0000818686-us-gaap:ParentMember-2023-01-012023-09-30-0000818686-us-
gaap:AccumulatedOtherComprehensiveIncomeMember-2023-01-012023-09-30-0000818686-teva:ConversionOptionMember-2023-01-012023-09-30-0000818686-us-
gaap:CommonStockMember-2023-01-012023-09-30-0000818686-us-gaap:AdditionalPaidInCapitalMember-2023-01-012023-09-30-0000818686-
teva:TotalReservesIncludedInSalesReservesAndAllowancesMember-2023-01-012023-09-30-0000818686-teva:OtherSalesReservesAndAllowancesMember-2023-01-012023-

09-30 0000818686 teva:ReturnsMember 2023-01-012023-09-30 0000818686 teva:ChargebacksMember 2023-01-012023-09-30 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2023-01-012023-09-30 0000818686 teva:RebatesMember 2023-01-012023-09-30 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2023-01-012023-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-012023-09-30 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-012023-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMemberteva:FinancialExpensesMember 2023-01-012023-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMemberteva:FinancialExpensesMember 2023-01-012023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberteva:NetRevenuesMember 2023-01-012023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberteva:FinancialExpensesMember 2023-01-012023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMemberteva:FinancialExpensesMember 2023-01-012023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMemberteva:NetRevenuesMember 2023-01-012023-09-30 0000818686 us-gaap:NondesignatedMemberteva:FinancialExpensesMember 2023-01-012023-09-30 0000818686 us-gaap:NondesignatedMemberteva:NetRevenuesMember 2023-01-012023-09-30 0000818686 teva:ProductRightsMember 2023-01-012023-09-30 0000818686 country:JPteva:ProductRightsMemberteva:UpdatedMarketAssumptionsMember 2023-01-012023-09-30 0000818686 teva:GenericPipelineProductsMemberus-gaap:InProcessResearchAndDevelopmentMemberteva:DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember 2023-01-012023-09-30 0000818686 teva:ProductRightsMemberteva:RegulatoryPriceAndVolumeOfProductsMember 2023-01-012023-09-30 0000818686 teva:AllerganTransactionMember 2023-01-012023-09-30 0000818686 teva:NovetideTransactionMember 2023-01-012023-09-30 0000818686 teva:EagleTransactionMember 2023-01-012023-09-30 0000818686 srt:ScenarioPreviouslyReportedMember 2023-01-012023-09-30 0000818686 srt:RestatementAdjustmentMember 2023-01-012023-09-30 0000818686 us-gaap:AllOtherSegmentsMember 2023-01-012023-09-30 0000818686 us-gaap:CorporateMember 2023-01-012023-09-30 0000818686 teva:SegmentsAndOtherActivitiesMember 2023-01-012023-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember 2023-01-012023-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember 2023-01-012023-09-30 0000818686 teva:RespiratoryProductMemberteva:EuropeSegmentMember 2023-07-012023-09-30 0000818686 teva:OtherProductsMemberteva:EuropeSegmentMember 2023-07-012023-09-30 0000818686 teva:EuropeSegmentMember 2023-07-012023-09-30 0000818686 teva:GenericsMediciansMemberteva:EuropeSegmentMember 2023-07-012023-09-30 0000818686 teva:AjovyMemberteva:EuropeSegmentMember 2023-07-012023-09-30 0000818686 teva:COPAXONEMemberteva:EuropeSegmentMember 2023-07-012023-09-30 0000818686 teva:AndaMemberteva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:OtherProductsMemberteva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:GenericsMediciansMemberteva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:AustedoMemberteva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:COPAXONEMemberteva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:AjovyMemberteva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:BendekaAndTreandaMemberteva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:UzedyMemberteva:UnitedStatesSegmentMember 2023-07-012023-09-30 0000818686 teva:OtherProductsMemberteva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 teva:COPAXONEMemberteva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 teva:GenericsMediciansMemberteva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 teva:AjovyMemberteva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 teva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 us-gaap:OtherRestructuringMember 2023-07-012023-09-30 0000818686 us-gaap:EmployeeSeveranceMember 2023-07-012023-09-30 0000818686 srt:MaximumMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0000818686 srt:EuropeMember 2023-07-012023-09-30 0000818686 teva:OtherActivitiesMember 2023-07-012023-09-30 0000818686 us-gaap:ProductAndServiceOtherMemberteva:OtherActivitiesMember 2023-07-012023-09-30 0000818686 us-gaap:ProductAndServiceOtherMember 2023-07-012023-09-30 0000818686 us-gaap:DistributionServiceMemberteva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 us-gaap:DistributionServiceMemberteva:OtherActivitiesMember 2023-07-012023-09-30 0000818686 country:US 2023-07-012023-09-30 0000818686 us-gaap:ProductAndServiceOtherMembersrt:EuropeMember 2023-07-012023-09-30 0000818686 us-gaap:ProductAndServiceOtherMemberteva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 us-gaap:LicenseMembersrt:EuropeMember 2023-07-012023-09-30 0000818686 us-gaap:LicenseMemberteva:OtherActivitiesMember 2023-07-012023-09-30 0000818686 us-gaap:DistributionServiceMember 2023-07-012023-09-30 0000818686 us-gaap:ProductMember 2023-07-012023-09-30 0000818686 us-gaap:ProductMemberteva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 us-gaap:LicenseMembercountry:US 2023-07-012023-09-30 0000818686 us-gaap:LicenseMember 2023-07-012023-09-30 0000818686 us-gaap:DistributionServiceMembercountry:US 2023-07-012023-09-30 0000818686 us-gaap:ProductMembercountry:US 2023-07-012023-09-30 0000818686 us-gaap:ProductMemberteva:OtherActivitiesMember 2023-07-012023-09-30 0000818686 us-gaap:ProductMembersrt:EuropeMember 2023-07-012023-09-30 0000818686 us-gaap:LicenseMemberteva:InternationalMarketsMember 2023-07-012023-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2023-07-012023-09-30 0000818686 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000818686 us-gaap:ParentMember 2023-07-012023-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMemberteva:FinancialExpensesMember 2023-07-012023-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMemberteva:FinancialExpensesMember 2023-07-012023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberteva:NetRevenuesMember 2023-07-012023-09-30 0000818686 us-gaap:NondesignatedMemberteva:FinancialExpensesMember 2023-07-012023-09-30 0000818686 us-gaap:NondesignatedMemberteva:NetRevenuesMember 2023-07-012023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMemberteva:NetRevenuesMember 2023-07-012023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberteva:FinancialExpensesMember 2023-07-012023-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMemberteva:FinancialExpensesMember 2023-07-012023-09-30 0000818686 teva:ProductRightsMember 2023-07-012023-09-30 0000818686 teva:GenericPipelineProductsMemberus-gaap:InProcessResearchAndDevelopmentMemberteva:DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember 2023-07-012023-09-30 0000818686 srt:MinimumMember 2023-07-012023-09-30 0000818686 srt:MaximumMember 2023-07-012023-09-30 0000818686 srt:ScenarioPreviouslyReportedMember 2023-07-012023-09-30 0000818686 srt:RestatementAdjustmentMember 2023-07-012023-09-30 0000818686 us-gaap:AllOtherSegmentsMember 2023-07-012023-09-30 0000818686 us-gaap:CorporateMember 2023-07-012023-09-30 0000818686 teva:SegmentsAndOtherActivitiesMember 2023-07-012023-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember 2023-07-012023-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember 2023-07-012023-09-30 0000818686 teva:AjovyMemberteva:EuropeSegmentMember 2024-01-012024-09-30 0000818686 teva:OtherProductsMemberteva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:BendekaAndTreandaMemberteva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:COPAXONEMemberteva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:AndaMemberteva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:GenericsMediciansMemberteva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:AjovyMemberteva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:AustedoMemberteva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:UzedyMemberteva:UnitedStatesSegmentMember 2024-01-012024-09-30 0000818686 teva:GenericsMediciansMemberteva:EuropeSegmentMember 2024-01-012024-09-30 0000818686 teva:OtherProductsMemberteva:EuropeSegmentMember 2024-01-012024-09-30 0000818686 teva:COPAXONEMemberteva:EuropeSegmentMember 2024-01-012024-09-30 0000818686 teva:RespiratoryProductMemberteva:EuropeSegmentMember 2024-01-012024-09-30 0000818686 teva:EuropeSegmentMember 2024-01-012024-09-30 0000818686 teva:OtherProductsMemberteva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 teva:AjovyMemberteva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 teva:GenericsMediciansMemberteva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 teva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 teva:COPAXONEMemberteva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 us-gaap:ConvertiblePreferredStockMember 2024-01-012024-09-30 0000818686 us-gaap:OtherRestructuringMember 2024-01-012024-09-30 0000818686 us-gaap:EmployeeSeveranceMember 2024-01-012024-09-30 0000818686 srt:MaximumMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0000818686 us-gaap:LicenseMemberteva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 us-gaap:ProductMemberteva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 us-gaap:LicenseMemberteva:OtherActivitiesMember 2024-01-012024-09-30 0000818686 us-gaap:DistributionServiceMember 2024-01-012024-09-30 0000818686 us-gaap:ProductMember 2024-01-012024-09-30 0000818686 us-gaap:LicenseMember 2024-01-012024-09-30 0000818686 us-gaap:DistributionServiceMembercountry:US 2024-01-012024-09-30 0000818686 us-gaap:ProductMembercountry:US 2024-01-012024-09-30 0000818686 us-gaap:ProductMemberteva:OtherActivitiesMember 2024-01-012024-09-30 0000818686 country:US 2024-01-012024-09-30 0000818686 srt:EuropeMember 2024-01-012024-09-30 0000818686 teva:OtherActivitiesMember 2024-01-012024-09-30 0000818686 us-gaap:ProductAndServiceOtherMemberteva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 us-gaap:LicenseMembercountry:US 2024-01-012024-09-30 0000818686 us-gaap:LicenseMembersrt:EuropeMember 2024-01-012024-09-30 0000818686 us-gaap:ProductAndServiceOtherMemberteva:OtherActivitiesMember 2024-01-012024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember 2024-01-012024-09-30 0000818686 us-gaap:DistributionServiceMemberteva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 us-gaap:DistributionServiceMemberteva:OtherActivitiesMember 2024-01-012024-09-30 0000818686 us-gaap:ProductMembersrt:EuropeMember 2024-01-012024-09-30 0000818686 us-gaap:ProductAndServiceOtherMembersrt:EuropeMember 2024-01-012024-09-30 0000818686 teva:EmployeeTerminationMember 2024-01-012024-09-30 0000818686 teva:OtherExitAndDisposalMember 2024-01-012024-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2024-01-012024-09-30 0000818686 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000818686 us-gaap:ParentMember 2024-01-012024-09-30 0000818686 srt:NorthAmericaMember 2024-01-012024-09-30 0000818686 teva:OtherCountriesMemberteva:MedisReportingUnitsMember 2024-01-012024-09-30 0000818686 teva:OtherCountriesMemberteva:TevasApiReportingUnitMember 2024-01-012024-09-30 0000818686 teva:InternationalMarketsMember 2024-01-012024-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000818686 teva:RedemptionOfConvertibleDebtSecurityMember 2024-01-012024-09-30 0000818686 us-gaap:CommonStockMember 2024-01-012024-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000818686 teva:ShortCreditAgreement2026Member 2024-01-012024-09-30 0000818686 us-gaap:IsraelTaxAuthorityMember 2024-01-012024-09-30 0000818686 teva:ChargebacksMember 2024-01-012024-09-30 0000818686 teva:ReturnsMember 2024-01-012024-09-30 0000818686 teva:OtherSalesReservesAndAllowancesMember 2024-01-012024-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2024-01-012024-09-30 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2024-01-012024-09-30 0000818686 teva:RebatesMember 2024-01-012024-09-30 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2024-01-012024-09-30 0000818686 teva:MabxienceMember 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2026OneMember 2024-01-012024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2031TwoMember 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2027Member 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2024OneMember 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025ThreeMember 2024-01-012024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2031OneMember 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025TwoMember 2024-01-012024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029Member 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025OneMember 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2028OneMember 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2024Member 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2046Member 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2025Member 2024-01-012024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2027OneMember 2024-01-012024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2027Member 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2028TwoMember 2024-01-012024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029TwoMember 2024-01-012024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2030Member 2024-01-012024-09-30 0000818686 teva:SubsidiarySeniorNotesDue2036Member 2024-01-012024-09-30 0000818686 teva:SustainabilityLinkedSeniorNotesDue2029OneMember 2024-01-012024-09-30 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-012024-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-012024-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMemberteva:FinancialExpensesMember 2024-01-012024-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMemberteva:FinancialExpensesMember 2024-01-012024-09-30 0000818686 us-

gaap:NondesignatedMemberteva:FinancialExpensesMember 2024-01-012024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberteva:NetRevenuesMember 2024-01-012024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberteva:FinancialExpensesMember 2024-01-012024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMemberteva:NetRevenuesMember 2024-01-012024-09-30 0000818686 us-gaap:NondesignatedMemberteva:NetRevenuesMember 2024-01-012024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMemberteva:FinancialExpensesMember 2024-01-012024-09-30 0000818686 teva:ProductRightsMember 2024-01-012024-09-30 0000818686 teva:GenericPipelineProductsMemberus-gaap:InProcessResearchAndDevelopmentMemberteva:DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember 2024-01-012024-09-30 0000818686 teva:NovetideTransactionMember 2024-01-012024-09-30 0000818686 teva:EagleTransactionMember 2024-01-012024-09-30 0000818686 teva:AllerganTransactionMember 2024-01-012024-09-30 0000818686 us-gaap:RevolvingCreditFacilityMember 2024-01-012024-09-30 0000818686 us-gaap:IsraelTaxAuthorityMemberteva:TwoThousandEightThrough2020TaxPayableMember 2024-01-012024-09-30 0000818686 us-gaap:AllOtherSegmentsMember 2024-01-012024-09-30 0000818686 us-gaap:CorporateMember 2024-01-012024-09-30 0000818686 teva:SegmentsAndOtherActivitiesMember 2024-01-012024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember 2024-01-012024-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember 2024-01-012024-09-30 0000818686 srt:MinimumMemberteva:OneTimePremiumPaymentMember 2024-01-012024-09-30 0000818686 srt:MinimumMemberteva:InterestRateIncreaseMember 2024-01-012024-09-30 0000818686 srt:MinimumMemberteva:SustainabilityLinkedSeniorNotesDue2029OneMemberteva:FromSeptemberFifteenthTwoThousandAndTwentySixMember 2024-01-012024-09-30 0000818686 srt:MaximumMemberteva:OneTimePremiumPaymentMember 2024-01-012024-09-30 0000818686 srt:MaximumMemberteva:InterestRateIncreaseMember 2024-01-012024-09-30 0000818686 srt:MaximumMemberteva:SustainabilityLinkedSeniorNotesDue2029OneMemberteva:FromSeptemberFifteenthTwoThousandAndTwentySixMember 2024-01-012024-09-30 0000818686 teva:OneTimePremiumPaymentMember 2024-01-012024-09-30 0000818686 teva:OtherProductsMemberteva:EuropeSegmentMember 2024-07-012024-09-30 0000818686 teva:EuropeSegmentMember 2024-07-012024-09-30 0000818686 teva:AjovyMemberteva:EuropeSegmentMember 2024-07-012024-09-30 0000818686 teva:COPAXONEMemberteva:EuropeSegmentMember 2024-07-012024-09-30 0000818686 teva:RespiratoryProductMemberteva:EuropeSegmentMember 2024-07-012024-09-30 0000818686 teva:GenericsMediciansMemberteva:EuropeSegmentMember 2024-07-012024-09-30 0000818686 teva:OtherProductsMemberteva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:AustedoMemberteva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:COPAXONEMemberteva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:AndaMemberteva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:BendekaAndTreandaMemberteva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:UzedyMemberteva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:GenericsMediciansMemberteva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:AjovyMemberteva:UnitedStatesSegmentMember 2024-07-012024-09-30 0000818686 teva:AjovyMemberteva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 teva:OtherProductsMemberteva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 teva:GenericsMediciansMemberteva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 teva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 teva:COPAXONEMemberteva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 us-gaap:OtherRestructuringMember 2024-07-012024-09-30 0000818686 us-gaap:EmployeeSeveranceMember 2024-07-012024-09-30 0000818686 srt:MaximumMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0000818686 us-gaap:DistributionServiceMemberteva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 us-gaap:DistributionServiceMemberteva:OtherActivitiesMember 2024-07-012024-09-30 0000818686 us-gaap:ProductMemberteva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 us-gaap:ProductAndServiceOtherMembersrt:EuropeMember 2024-07-012024-09-30 0000818686 us-gaap:ProductAndServiceOtherMemberteva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 us-gaap:LicenseMembersrt:EuropeMember 2024-07-012024-09-30 0000818686 us-gaap:ProductAndServiceOtherMemberteva:OtherActivitiesMember 2024-07-012024-09-30 0000818686 us-gaap:ProductAndServiceOtherMember 2024-07-012024-09-30 0000818686 us-gaap:ProductMembercountry:US 2024-07-012024-09-30 0000818686 us-gaap:ProductMemberteva:OtherActivitiesMember 2024-07-012024-09-30 0000818686 us-gaap:ProductMembersrt:EuropeMember 2024-07-012024-09-30 0000818686 us-gaap:LicenseMemberteva:OtherActivitiesMember 2024-07-012024-09-30 0000818686 us-gaap:DistributionServiceMember 2024-07-012024-09-30 0000818686 us-gaap:ProductMember 2024-07-012024-09-30 0000818686 teva:OtherActivitiesMember 2024-07-012024-09-30 0000818686 us-gaap:LicenseMemberteva:InternationalMarketsMember 2024-07-012024-09-30 0000818686 us-gaap:LicenseMembercountry:US 2024-07-012024-09-30 0000818686 us-gaap:LicenseMember 2024-07-012024-09-30 0000818686 us-gaap:DistributionServiceMembercountry:US 2024-07-012024-09-30 0000818686 country:US 2024-07-012024-09-30 0000818686 srt:EuropeMember 2024-07-012024-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2024-07-012024-09-30 0000818686 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000818686 us-gaap:ParentMember 2024-07-012024-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000818686 us-gaap:CommonStockMember 2024-07-012024-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000818686 teva:AlvotechMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMemberteva:FinancialExpensesMember 2024-07-012024-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMemberteva:FinancialExpensesMember 2024-07-012024-09-30 0000818686 us-gaap:NondesignatedMemberteva:FinancialExpensesMember 2024-07-012024-09-30 0000818686 us-gaap:NondesignatedMemberteva:NetRevenuesMember 2024-07-012024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMemberteva:FinancialExpensesMember 2024-07-012024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentTradingMemberteva:NetRevenuesMember 2024-07-012024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberteva:FinancialExpensesMember 2024-07-012024-09-30 0000818686 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberteva:NetRevenuesMember 2024-07-012024-09-30 0000818686 teva:TevasApiReportingUnitMember 2024-07-012024-09-30 0000818686 teva:ProductRightsMember 2024-07-012024-09-30 0000818686 teva:MabxienceMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0000818686 teva:RoyaltyPharmaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember 2024-07-012024-09-30 0000818686 teva:AbingworthMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0000818686 us-gaap:AllOtherSegmentsMember 2024-07-012024-09-30 0000818686 teva:SegmentsAndOtherActivitiesMember 2024-07-012024-09-30 0000818686 us-gaap:CorporateMember 2024-07-012024-09-30 0000818686 teva:CrossCurrencySwapCashFlowHedgeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember 2024-07-012024-09-30 0000818686 us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember 2024-07-012024-09-30 0000818686 us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:MeasurementInputDiscountRateMember 2023-09-30 0000818686 srt:MinimumMemberus-gaap:InProcessResearchAndDevelopmentMember 2023-09-30 0000818686 srt:MaximumMemberus-gaap:InProcessResearchAndDevelopmentMember 2023-09-30 0000818686 srt:ScenarioPreviouslyReportedMember 2023-09-30 0000818686 srt:RestatementAdjustmentMember 2023-09-30 0000818686 srt:RestatementAdjustmentMember 2022-01-012022-12-31 0000818686 srt:NorthAmericaMember 2023-01-012023-12-31 0000818686 country:US 2023-01-012023-12-31 0000818686 srt:EuropeMember 2023-01-012023-12-31 0000818686 teva:InternationalMarketsMember 2023-01-012023-12-31 0000818686 teva:OtherCountriesMemberteva:TevasApiReportingUnitMember 2023-01-012023-12-31 0000818686 teva:OtherCountriesMemberteva:MedisReportingUnitsMember 2023-01-012023-12-31 0000818686 srt:MaximumMember 2023-01-012023-12-31 0000818686 teva:AlvotechMember 2023-01-012023-12-31 0000818686 srt:RestatementAdjustmentMember 2023-01-012023-12-31 0000818686 teva:AlvotechMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0000818686 teva:MedincellMember 2024-04-012024-06-30 0000818686 teva:MabxienceMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0000818686 teva:RoyaltyPharmaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember 2024-04-012024-06-30 0000818686 teva:BiolojicDesignLtdMemberus-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-01-31 0000818686 teva:RoyaltyPharmaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember 2023-10-012023-12-31 0000818686 teva:RoyaltyPharmaMember 2023-11-092023-11-09 0000818686 teva:RoyaltyPharmaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember 2024-01-012024-03-31 0000818686 teva:SanofiMemberus-gaap:CollaborativeArrangementMember 2023-10-03 0000818686 teva:ModagMember 2021-10-012021-10-31 0000818686 teva:ModagMemberus-gaap:ResearchAndDevelopmentExpenseMember 2021-10-012021-12-31 0000818686 teva:AlvotechMember 2021-01-012021-12-31 0000818686 teva:AlvotechMember 2024-01-012024-06-30 0000818686 teva:LitigationWithUsHospitalsAndOtherHealthcareProvidersMember 2024-07-012024-07-31 0000818686 teva:TevaMember 2023-09-29 0000818686 teva:AlvotechMemberteva:SubordinatedConvertibleBondsMember 2023-09-29 0000818686 teva:AlvotechMember 2024-06-262024-06-26 0000818686 teva:TakedaMember 2016-12-012016-12-31 0000818686 teva:TakedaMember 2022-04-012022-06-30 0000818686 teva:MedincellMember 2021-08-012021-08-31 0000818686 teva:MedincellMember 2022-07-012022-09-30 0000818686 us-gaap:DemandDepositsMember 2024-06-30 0000818686 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 us-gaap:MoneyMarketFundsMember 2024-06-30 0000818686 us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 us-gaap:EquitySecuritiesMember 2024-06-30 0000818686 teva:OtherRestrictedCashMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 teva:OtherRestrictedCashMember 2024-06-30 0000818686 us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleDebtSecuritiesMember 2024-06-30 0000818686 us-gaap:ConvertibleDebtSecuritiesMember 2024-06-30 0000818686 us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember 2024-06-30 0000818686 us-gaap:InterestRateSwapMember 2024-06-30 0000818686 teva:TevasUnitedStatesEuropeInternationalMarketsAndMedisReportingUnitsMember 2024-06-30 0000818686 us-gaap:FairValueInputsLevel2Memberteva:OptionsAndForwardContractsDerivativeLiabilitiesMember 2024-06-30 0000818686 teva:OptionsAndForwardContractsDerivativeLiabilitiesMember 2024-06-30 0000818686 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000818686 us-gaap:FairValueInputsLevel2Member 2024-06-30 0000818686 us-gaap:FairValueInputsLevel1Member 2024-06-30 0000818686 teva:ModafinilSettlementAgreementMember 2024-06-30 0000818686 teva:OpioidLitigationMember 2024-06-30 0000818686 teva:InternationalMarketsMember 2023-01-012023-06-30 0000818686 us-gaap:RevolvingCreditFacilityMemberteva:AmendedRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2025-01-012025-12-31 0000818686 us-gaap:RevolvingCreditFacilityMemberteva:AmendedRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2026-07-012026-09-30 0000818686 us-gaap:RevolvingCreditFacilityMemberteva:AmendedRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2027-01-012027-03-31 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberteva:PncBankMember 2022-07-11 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberteva:PncBankMember 2022-11-072022-11-07 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberteva:PncBankMemberteva:NovemberTwoThousandAndTwentyFiveMember 2022-11-072022-11-07 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberteva:PncBankMemberteva:NovemberTwoThousandAndTwentyThreeMember 2022-11-07 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberteva:MizuhoBankMemberteva:NovemberTwoThousandAndTwentyFiveMember 2023-06-30 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberteva:MizuhoBankMemberteva:NovemberTwoThousandAndTwentyThreeMember 2023-06-30 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberteva:PncBankMemberteva:NovemberTwoThousandAndTwentyFiveMember 2023-09-302023-09-30 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberteva:PncBankMember 2023-11-07 0000818686 teva:AlvotechMemberus-gaap:SubsequentEventMemberteva:OctoberTwoThousandAndTwentyFourAmendmentAgreementMember 2024-10-012024-10-29 0000818686 teva:JohnsonAndJohnsonMemberteva:SettlementAndLicenseAgreementAlvotechAndTevaMember 2023-06-122023-06-12 0000818686 teva:AlvotechMember 2020-01-012020-12-31 0000818686 us-gaap:IsraelTaxAuthorityMemberteva:TwoThousandEightThrough2020TaxPayableMember 2024-06-232024-06-23 0000818686 srt:MinimumMemberus-gaap:IsraelTaxAuthorityMemberteva:TwoThousandEightThrough2020TaxPayableMember 2024-06-232024-06-23 0000818686 srt:MaximumMemberus-gaap:IsraelTaxAuthorityMemberteva:TwoThousandEightThrough2020TaxPayableMember 2024-06-232024-06-23 0000818686 us-gaap:IsraelTaxAuthorityMember 2022-12-12 0000818686 us-gaap:SubsequentEventMember 2024-10-31 0000818686 us-gaap:SeniorNotesMember 2024-10-31 0000818686 us-gaap:SeniorNotesMember 2024-04-30 0000818686 us-gaap:RevolvingCreditFacilityMemberteva:AmendedRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2024-01-012024-12-31 0000818686 us-gaap:RevolvingCreditFacilityMemberteva:AmendedRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2026-01-012026-03-31 0000818686 us-gaap:RevolvingCreditFacilityMemberteva:AmendedRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2026-04-012026-06-30 0000818686 us-gaap:RevolvingCreditFacilityMemberteva:AmendedRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2026-10-012026-12-31 0000818686 teva:AccountsReceivableSecuritizationFacilityMemberus-

gaap:SubsequentEventMemberteva:SPVAmendmentAgreementOctoberTwoThousandAndTwentyFourMemberteva:PncBankMember 2024-10-29 0000818686 teva:AndroGelRateAtOnePercentageMember 2019-08-31 0000818686 teva:FineForViolatingTheAntitrustLawsMemberteva:DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember 2023-08-21 0000818686 teva:DonationOfClotrimazoleAndTobramycinMemberteva:DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember 2023-08-21 0000818686 teva:CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMemberus-gaap:SubsequentEventMember 2024-10-102024-10-10 0000818686 teva:CivilActionInRespectOfDonationsToPatientAssistanceProgrammersMemberus-gaap:SubsequentEventMember 2024-10-10 0000818686 teva:CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMemberus-gaap:SubsequentEventMember 2024-10-10 0000818686 teva:CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMemberus-gaap:SubsequentEventMemberteva:TwoThousandAndTwentyFourMember 2024-10-10 0000818686 teva:CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMemberus-gaap:SubsequentEventMemberteva:TwoThousandAndTwentyFiveMember 2024-10-10 0000818686 teva:LitigationWithUsHospitalsAndOtherHealthcareProvidersMember 2023-07-012023-07-31 0000818686 teva:OntarioTeachersSecuritiesLitigationMemberus-gaap:SettledLitigationMember 2022-06-022022-06-02 0000818686 srt:EuropeMember 2021-01-012021-09-30 0000818686 country:USteva:EosinophilicEsophagitisMember 2021-01-012021-09-30 0000818686 teva:EosinophilicEsophagitisMember 2021-01-012021-09-30 0000818686 teva:EmployeeTerminationMember 2022-12-31 0000818686 teva:OtherExitAndDisposalMember 2022-12-31 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000818686 us-gaap:ParentMember 2022-12-31 0000818686 us-gaap:NoncontrollingInterestMember 2022-12-31 0000818686 us-gaap:CommonStockMember 2022-12-31 0000818686 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000818686 us-gaap:RetainedEarningsMember 2022-12-31 0000818686 us-gaap:TreasuryStockCommonMember 2022-12-31 0000818686 teva:EmployeeTerminationMember 2023-09-30 0000818686 teva:OtherExitAndDisposalMember 2023-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2022-12-31 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2022-12-31 0000818686 teva:RebatesMember 2022-12-31 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2022-12-31 0000818686 teva:ChargebacksMember 2022-12-31 0000818686 teva:ReturnsMember 2022-12-31 0000818686 teva:OtherSalesReservesAndAllowancesMember 2022-12-31 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2023-09-30 0000818686 teva:ChargebacksMember 2023-09-30 0000818686 teva:ReturnsMember 2023-09-30 0000818686 teva:OtherSalesReservesAndAllowancesMember 2023-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2023-09-30 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2023-09-30 0000818686 teva:RebatesMember 2023-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2023-09-30 0000818686 us-gaap:CommonStockMember 2023-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000818686 us-gaap:RetainedEarningsMember 2023-09-30 0000818686 us-gaap:TreasuryStockCommonMember 2023-09-30 0000818686 us-gaap:ParentMember 2023-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000818686 us-gaap:RetainedEarningsMember 2023-06-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000818686 us-gaap:TreasuryStockCommonMember 2023-06-30 0000818686 us-gaap:ParentMember 2023-06-30 0000818686 us-gaap:NoncontrollingInterestMember 2023-06-30 0000818686 us-gaap:CommonStockMember 2023-06-30 0000818686 teva:EmployeeTerminationMember 2023-12-31 0000818686 teva:OtherExitAndDisposalMember 2023-12-31 0000818686 us-gaap:CommonStockMember 2023-12-31 0000818686 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000818686 us-gaap:RetainedEarningsMember 2023-12-31 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000818686 us-gaap:TreasuryStockCommonMember 2023-12-31 0000818686 us-gaap:ParentMember 2023-12-31 0000818686 us-gaap:NoncontrollingInterestMember 2023-12-31 0000818686 teva:EmployeeTerminationMember 2024-09-30 0000818686 teva:OtherExitAndDisposalMember 2024-09-30 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2023-12-31 0000818686 teva:RebatesMember 2023-12-31 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2023-12-31 0000818686 teva:ChargebacksMember 2023-12-31 0000818686 teva:ReturnsMember 2023-12-31 0000818686 teva:OtherSalesReservesAndAllowancesMember 2023-12-31 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2023-12-31 0000818686 teva:ReservesIncludedInAccountsReceivableNetMember 2024-09-30 0000818686 teva:RebatesMember 2024-09-30 0000818686 teva:MedicaidAndOtherGovernmentalAllowancesMember 2024-09-30 0000818686 teva:ChargebacksMember 2024-09-30 0000818686 teva:ReturnsMember 2024-09-30 0000818686 teva:OtherSalesReservesAndAllowancesMember 2024-09-30 0000818686 teva:TotalReservesIncludedInSalesReservesAndAllowancesMember 2024-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000818686 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-30 0000818686 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0000818686 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000818686 us-gaap:RetainedEarningsMember 2024-09-30 0000818686 us-gaap:TreasuryStockCommonMember 2024-09-30 0000818686 us-gaap:ParentMember 2024-09-30 0000818686 us-gaap:NoncontrollingInterestMember 2024-09-30 0000818686 us-gaap:CommonStockMember 2024-09-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000818686 teva:OtherCountriesMemberteva:MedisReportingUnitsMember 2024-09-30 0000818686 teva:OtherCountriesMemberteva:TevasApiReportingUnitMember 2024-09-30 0000818686 teva:InternationalMarketsMember 2024-09-30 0000818686 srt:EuropeMember 2024-09-30 0000818686 country:US 2024-09-30 0000818686 srt:NorthAmericaMember 2024-09-30 0000818686 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000818686 us-gaap:ParentMember 2024-06-30 0000818686 us-gaap:NoncontrollingInterestMember 2024-06-30 0000818686 us-gaap:CommonStockMember 2024-06-30 0000818686 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000818686 us-gaap:RetainedEarningsMember 2024-06-30 0000818686 us-gaap:TreasuryStockCommonMember 2024-06-30 0000818686 country:US 2022-12-31 0000818686 srt:EuropeMember 2022-12-31 0000818686 teva:InternationalMarketsMember 2022-12-31 0000818686 teva:OtherCountriesMemberteva:TevasApiReportingUnitMember 2022-12-31 0000818686 teva:OtherCountriesMemberteva:MedisReportingUnitsMember 2022-12-31 0000818686 srt:NorthAmericaMember 2022-12-31 0000818686 srt:NorthAmericaMember 2023-12-31 0000818686 country:US 2023-12-31 0000818686 srt:EuropeMember 2023-12-31 0000818686 teva:InternationalMarketsMember 2023-12-31 0000818686 teva:OtherCountriesMemberteva:TevasApiReportingUnitMember 2023-12-31 0000818686 teva:OtherCountriesMemberteva:MedisReportingUnitsMember 2023-12-31 iso4217:USD shares pure utr:Year iso4217:EUR iso4217:CHF teva:Segment iso4217:USD sharesfalseQ30000818686--12-3100-0000000IL10-Qtrue2024-09-302024falseO01-16174TEVA PHARMACEUTICAL INDUSTRIES LIMITEDL3124 Dvora HaNevi'a StTel Aviv6944020+972 (3)914-8213American Depositary Shares, each representing one Ordinary ShareTEVANYSEYesYesLarge Accelerated Filerfalsefalsefalse1133050214http://fasb.org/us-gaap/2024#IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments2026-04-30http://fasb.org/us-gaap/2024#Liabilitieshttp://www.tevapharm.com/20240930#ImpairmentsRestructuringAndOthershttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent331900000032260000091000095000003462000003408000003959000000402100000011270000001255000000445000000504000035375000000353530000000.10.1249500000024950000001240000000122700000058000000570000002786000000027807000000-14956000000-13534000000-2769000000-2697000001060000001060000004128000000412800000060650000007506000000319000000620000000638300000081260000004175800000043479000000433200000032300000057000000931000000276000000450000000314000000638000000109000000210000009000000220000004300000-5100000034400000-274000000-323000000-272000000-280000000-763000000-808000000-3240000006400000-1037000000-1131000000690000000-1200000064800000-480000030000001000000010000000-390000000770000000-1684000000-1082000000470000008000000-262000000-60000000-4370000069000000-1422000000-1022000000-0.390.06-1.26-0.91-0.390.06-1.26-0.9111330000001121000000113000000011190000001133000000113500000011300000001119000000-500000-3900000007700000-1684000000-1082000000174000000-255000000-94000000-1730000007000000700000021000000190000000-1000000-1000000-2000000-2000001800000000-249000000-75000000-156000000-210000000-172000000-1759000000-1238000000114000000-8000000-268000000-144000000-324000000-164000000-1491000000-1094000000123900000058000000278290000000-14519000000-2881000000-4128000000635900000020400000065630000000-437000000-437000000470000000-3900000001130000001130000006700000018000000010000002900000029000000290000001240000000580000002786000000-14956000000-2769000000-4128000000606500000031900000063830000005000001227000000570000002780700000-13534000000-2697000000-4128000000625000000812600000-1422000000-1422000000-2620000000-1684000000-69000000-69000000-6000000-7500000013000000100000010000001000000890000008900000089000000700000070000007000000180000001800000045000000300000048000000160000006400000012149560000000-2769000000-4128000000606500000031900000063830000005000001227000000570000002774800000-14066000000-2677000000-4128000000693600000656000000759200000690000006900000080000007700000-233000000-13995000000-2910000000-2490000003100000031000000310000006700000067000000122700000057000000277800000-13995000000-2910000000-4128000000680400000058200000073870000005000001217000000570000002768800000-12975000000-2838000000-4128000000780400000079400000085980000001022000000-1022000000-60000000-1082000000-72000000-84000000-1560000001000000093000000930000009300000067000000670000001227000000570000002778000000-13995000000-2910000000-4128000000680400000058200000073870000005000001-3900000007700000-1684000000-1082000000259000000283000000790000000887000000600000000100000000070000000-5100000048000000758000000310000000-3170000002270000001900000003640000000-53000000-1990000000-6660000000-34900000029000000310000008900000093000000020000000-5000000597000000180000002100000030000002200000029000000693000000500000067200000018400000033900000036200000095100000010560000001480000001490640000000-78000000000245100000007000000000700000000020000000000-76000000-19000000-13600000000-5760000000-1117000000-1337000000100000000-33000000-53000000-9800000001061000000-42000000092000000-5840000002258000000267000000322700000028340000003319000000225000000033190000002250000000331900000022490000003319000000224900000001000000001 Note 1 - Basis of presentation: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"> a. </td> <td style="vertical-align:top;text-align:left;"> Basis of presentation </td> </tr> </table> The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission ("SEC"). The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023, but not all disclosures required by generally accepted accounting principles in the United States ("U.S. GAAP") are included. In preparing the Company's consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. In preparing the Company's consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of IPR&D assets, marketed product rights and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could be impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. Government actions taken to address macroeconomic developments, as well as their economic

impact on Teva's third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. In February 2022, Russia launched an invasion of Ukraine. As of the date of these consolidated financial statements, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva's International Markets segment results. Teva has no manufacturing or R&D facilities in these markets. During the three and nine months ended September 30, 2024, the impact of this conflict on Teva's results of operation and financial condition continues to be immaterial. In October 2023, Israel was attacked by a terrorist organization and entered a state of war o n several fronts. As of the date of these consolidated financial statements, sustained conflict in the region is ongoing. Israel is included in Teva's International Markets segment results. Teva's global headquarters and several manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. Teva continues to maintain contingency plans with backup production locations for key products. During the three and nine months ended September 30, 2024, the impact of this war on Teva's results of operations and financial condition is immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war. Teva's results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"> b. </td> <td style="vertical-align:top;text-align:left;"> Significant accounting policies </td> </tr> </table> Recently adopted accounting pronouncements None. Recently issued accounting pronouncements, not yet adopted In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.   In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures". This guidance expands public entities' segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity's financial statements. The Company does not expect the adoption of the ASU to have a material impact on its consolidated financial statements related disclosures. In October 2023, the FASB issued ASU 2023-06 "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative," which incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification ("Codification"). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification topics, allow investors to more easily compare entities subject to the SEC's existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SEC's regulations. The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this ASU should be applied prospectively. The Company does not expect ASU 2023-06 will have a material impact to its consolidated financial statements.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"> c. </td> <td style="vertical-align:top;text-align:left;"> Revision of Previously Reported Consolidated Financial Statements </td> </tr> </table> In connection with the preparation of the consolidated financial statements as of and for the year ended December 31, 2023, the Company identified errors in a single contingent consideration liability and related expenses in connection with estimated future royalty payments, along with corresponding deferred tax adjustments, that aggregated into an understatement of the contingent consideration liability of approximately $132 million, of which $98 million related to 2022 and $34 million related to 2023. These errors resulted from the exclusion of royalty payments that should have been included in the fair value re-measurement calculation of the contingent consideration liability as of and for the year ended December 31, 2022, and the quarterly and year-to-date periods ended June 30, September 30 and December 31, 2022, and March 31, June 30 and September 30, 2023. These errors did not impact the Company's actual royalty payments, as well as total cash flows from operating activities, financing activities and investing activities in the periods stated above. The Company evaluated the errors, individually and in the aggregate, considering both qualitative and quantitative factors, and concluded that these errors did not have a material impact on any of the prior periods stated above. However, the aggregate amount of the prior period errors in 2022, would have been material to the consolidated financial statements for fiscal year 2023. Therefore, the Company has revised the prior periods impacted for these errors. The tables below present the impact of the revision on the line items within the Company's consolidated financial statements for the relevant periods.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:57%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Three months ended</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine months ended</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September 30, 2023</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September 30, 2023</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">U.S $ in millions (except per share amounts)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="22" style="vertical-align:bottom;text-align:center;">(Unaudited)</td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">As
 previously
 reported</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">Adjustment</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">As revised</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">As previously
 reported</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">Adjustment</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">As revised</td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other asset impairments, restructuring and other items </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">241</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">276</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Operating income (loss) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">355</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">344</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(289</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(323</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-

color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family:
"Times New Roman"; line-height: normal;">Income (loss) before income taxes</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(1,097</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(1,131</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times
New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-
family: "Times New Roman"; line-height: normal;">Income taxes (benefit)</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(48</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(48</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New
Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em;
font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Net income (loss)</div> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(1,048</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(1,082</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid
; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em;
font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Net income (loss) attributable to Teva</div> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">(988</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td
style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,022</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-
break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-
bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Earnings (loss) per share
attributable to ordinary shareholders:</div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">
</td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td
style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div
style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Basic
and diluted loss per share</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">0.07</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.01</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">0.06</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.88</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(0.04</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.91</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> </tr> </table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid
#000000;width:11%"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-
size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-
align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height:
normal;">Represents an amount less than $0.5 million. </div> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <div
style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <table cellpadding="0"
cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td
style="width:70%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td>
</td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-
family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September 30, 2023</td> <td style="vertical-
align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-
align:bottom;text-align:center;">As
 previously
 reported</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align:
bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Adjustment</td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-
bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">As revised</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr
style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
colspan="10" style="vertical-align:bottom;text-align:center;">(Unaudited)</td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-
family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;
text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Deferred income taxes</div></td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,748</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,755</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td
style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New
Roman"; line-height: normal;">Total assets</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,088</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,095</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-
break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom:
0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other taxes and long-term liabilities</div>
</td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">3,818</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">3,950</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times
New Roman"; line-height: normal;">Total long-term liabilities</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,182</td> <td style="white-space:nowrap;vertical-align:bottom"> </td>
<td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td>
</tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-
top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total
liabilities</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">34,576</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-

align:bottom;text-align:right;">34,708</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times
New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-
family: "Times New Roman"; line-height: normal;">Teva shareholders’ equity:</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New
Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em;
font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Accumulated deficit</div></td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,870</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(125</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,995</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">
<div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height:
normal;">Total equity</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">7,512</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(125</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">7,387</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ;
font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left:
1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total liabilities and equity</div></td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,088</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,095</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> 1320000009800000034000000 <div style="margin-top:12pt; margin-bottom:0pt; text-
indent:4%; font-size:10pt; font-family:Times New Roman">The tables below present the impact of the revision on the line items within the Company’s consolidated
financial statements for the relevant periods: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0"
style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:57%">
</td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td>
</td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td>
</td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td>
</td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-
align:center;">Three months ended</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Nine months ended</td> <td style="vertical-align:
bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-
align:bottom;text-align:center;">September 30, 2023</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September 30, 2023</td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="22" style="border-
bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">U.S $ in millions (except per share amounts)</td> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td colspan="22" style="vertical-align:bottom;text-align:center;">(Unaudited)</td> <td style="vertical-align:bottom"> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">As
 previously
 reported</td> <td style="vertical-align:bottom"> </td>
<td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">Adjustment</td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">As revised</td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;text-
align:center;">As previously
 reported</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-
align:bottom;white-space:nowrap;text-align:center;">Adjustment</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
colspan="2" style="vertical-align:bottom;white-space:nowrap;text-align:center;">As revised</td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-
inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt;
margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other asset impairments, restructuring and other
items</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">57</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">241</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">34</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">276</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top:
0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Operating income (loss)
</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">355</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">344</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(289</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(323</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-
align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-
height: normal;">Income (loss) before income taxes</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td> <td
style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,097</td>
<td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,131</td>
<td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td
style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New
Roman"; line-height: normal;">Income taxes (benefit)</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">(48</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">(48</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size:
10pt; font-family: "Times New Roman"; line-height: normal;">Net income (loss)</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(1,048</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(1,082</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times
New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-
family: "Times New Roman"; line-height: normal;">Net income (loss) attributable to Teva</div> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td>

<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(988</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,022</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Earnings (loss) per share attributable to ordinary shareholders: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Basic and diluted loss per share </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.07</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.01</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.06</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.88</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.04</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.91</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </div> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:70%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September 30, 2023</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">As
previously</br/> reported</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Adjustment</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">As revised</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;text-align:center;">(Unaudited)</td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Deferred income taxes</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">§</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,748</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,755</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total assets</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,088</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,095</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other taxes and long-term liabilities</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,818</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,950</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total long-term liabilities</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,182</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total liabilities</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,576</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,708</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Teva shareholders' equity:</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Accumulated deficit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,870</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(125</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,995</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total equity</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,512</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(125</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,387</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total liabilities and equity</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,088</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,095</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> 460000001100000057000000241000000340000002760000003550000001100000034400000-289000000-34000000-32300000075000000-110000006400000-109700000-34000000-1131000000-12000000-12000000-48000000-48000000088000000-110000007700000-10480000000-34000000-108200000080000000-110000006900000-988000000-34000000-10220000000.070.07-0.01-0.010.060.06-0.88-0.88-0.04-0.04-0.91-0.9150000017480000007000001755000000420880000007000000420950000003818000000132000000395000000023182000000132000000233140000003457600000013870000000-125000000-13995000000751200000-125000000738700000042088000000700000042095000000 NOTE 2 – Certain transactions: The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company's most significant agreements of this nature are summarized below. mAbxience In April 2024, Teva announced it entered into a strategic licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Under the terms of the licensing agreement, mAbxience will

develop and produce the biosimilar product and Teva will lead the regulatory processes and commercialization in multiple global markets, including Europe and the U.S. In September 2024, Teva and mAbxience entered into an amendment to the licensing agreement whereby, similar to the initial licensing agreement, mAbxience will lead the development and production of an anti-PD-1 oncology biosimilar candidate and Teva will manage regulatory approvals and oversee commercialization in the designated markets. Under the initial agreement, in the second quarter of 2024, Teva paid mAbxience upfront and milestone payments in a total amount of $20 million, which were recorded as R&D expenses. Pursuant to the amendment of the licensing agreement, in the third quarter of 2024 Teva recognized upfront and milestone payments in a total amount of $15 million as R&D expenses, of which $5 million were paid in October 2024, and the remaining is due by the end of 2024. mAbxience may be eligible for additional future development, regulatory and commercial milestone payments, in an aggregate amount of up to $320 million. Launch Therapeutics and Abingworth On March 28, 2024, Teva and Launch Therapeutics, Inc. (“Launch Therapeutics”) entered into a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248). As part of this clinical collaboration agreement Teva also entered into a development funding agreement with funds affiliated with Abingworth LLP (“Abingworth”). Under the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, the global investment firm, will have the lead role in the operational execution and management of the planned clinical trials. Teva will retain primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization. ICS-SABA (TEV-‘248) is currently in Phase 3 for the treatment of asthma symptoms addressing both immediate symptoms and long-term inflammation. Under the development funding agreement, Abingworth will provide Teva up to $150 million to fund ongoing development costs for ICS-SABA (TEV-‘248). In exchange and subject to regulatory approval, Teva will pay Abingworth a milestone payment in the amount actually funded by Abingworth up to $150 million, as well as success payments based on ICS-SABA (TEV-‘248) sales. During the third quarter of 2024, Teva recorded $20 million as reimbursement for R&D expenses incurred in connection with this agreement. Biolojic Design On November 26, 2023, Teva entered into a license agreement with Biolojic Design Ltd. (“Biolojic”), pursuant to which Teva received exclusive rights to develop, manufacture and globally commercialize a BD9 multibody for the potential treatment of Atopic Dermatitis and Asthma. In exchange, Teva paid an upfront payment in an amount of $10 million in January 2024, which was recorded as an R&D expense in the fourth quarter of 2023. Biolojic may be eligible to receive additional development and commercial milestone payments of up to approximately $500 million, over the next several years, based on the achievement of certain pre-clinical, clinical and regulatory milestones, with the majority of the payments based on future sales achievements. Royalty Pharma On November 9, 2023, Teva entered into a funding agreement with Royalty Pharma plc. (“Royalty Pharma”) to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749). Under the terms of the funding agreement, Royalty Pharma will provide Teva up to $100 million to fund ongoing development costs for olanzapine LAI (TEV-‘749), with an option to increase the total funding amount to $125 million, which expired in the second quarter of 2024. In exchange and subject to regulatory approval, Teva will pay Royalty Pharma a milestone payment in the amount actually funded by Royalty Pharma, paid over 5 years, in addition to royalties upon commercialization. Teva will continue to lead the development and commercialization of the product globally. During the fourth quarter of 2023, and the first, second and third quarters of 2024, Teva recorded $35 million, $27 million, $19 million and $18 million respectively, as reimbursement for R&D expenses <div style="display:inline;"></div><div style="display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">incurred in connection with this agreement, which collectively amounted to the total funding Royalty Pharma was to provide Teva of<div style="display:inline;"> </div></div></div><div style="font-size: 10pt;display:inline;">$ 100 million. Olanzapine LAI (TEV-‘749) is currently in Phase 3 for the treatment of schizophrenia (see also MedinCell transaction below).   Sanofi On October 3, 2023, Teva entered into an exclusive collaboration with Sanofi to co-develop and co- commercialize Teva’s duvakitug (anti-TL1A, TEV-‘574) asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn’s disease, two types of inflammatory bowel disease, which is currently in Phase 2b clinical trials. Under the terms of the collaboration agreement, in partial consideration of the licenses granted to Sanofi, Teva received an upfront payment of $500 million in the fourth quarter of 2023, recognized as revenue. Additionally, Teva may receive up to $1 billion in development and launch milestones. Each company will equally share the remaining development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement, and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. MODAG In October 2021, Teva announced a license agreement with MODAG GmbH (“Modag”) providing Teva with an exclusive global license to develop, manufacture and commercialize Modag’s lead compound, emrusolmin (TEV-‘286) and a related compound (TEV-‘287). Emrusolmin (TEV-‘286) was initially developed for the treatment of Multiple System Atrophy (“MSA”) and Parkinson’s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer’s disease. Teva has initiated a Phase 2 clinical trial. In the fourth quarter of 2021, Teva made an upfront payment of $10 million to Modag, recorded as an R&D expense. Modag may be eligible for additional future development milestone payments, in an aggregate amount of up to $30 million, as well as future commercial milestones and royalties. Alvotech In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contained biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to Humira ® (adalimumab) and Stelara ® (ustekinumab). Under the terms of the agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the U.S. In July 2023, Alvotech and Teva amended their collaboration agreement, adding two new biosimilar candidates as well as line extensions of two current biosimilar candidates to their partnership. Teva made upfront and milestone payments in an aggregate amount of $78 million in 2020, 2021 and 2023. Teva made additional milestone payments of $27 million in the second quarter of 2024 and $19 million in the third quarter of 2024. Additional development and commercial milestone payments of up to approximately $380 million, in addition to royalty and milestone payments related to the amendment of the collaboration agreement entered into in July 2023, may be payable by Teva over the next few years. Teva and Alvotech will share revenue from the commercialization of these biosimilars. The amendment of the collaboration agreement entered into in July 2023 includes increased involvement by Teva regarding manufacturing and quality at Alvotech’s manufacturing facility. Additionally, pursuant to the amendment, on September 29, 2023, Teva purchased $40 million of subordinated convertible bonds of Alvotech. On June 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds for $44 million, including accrued interest, which were paid to Teva in July 2024. On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI ® (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira ® , for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. On April 17, 2024, Alvotech and Teva amended their collaboration agreement to enable the purchase by Quallent of a private label adalimumab-ryvk injection from Alvotech for the U.S. market, with Alvotech sharing profits with Teva on the private label sales. On May 20, 2024, Alvotech and Teva announced that SIMLANDI is available in the United States.   With respect to the proposed biosimilar to Stelara ® , on June 12, 2023, Alvotech and Teva reached a settlement and license agreement with Johnson & Johnson, granting a licensed entry date in the U.S. no later than February 21, 2025. On April 16, 2024, Alvotech and Teva announced that the FDA approved SELARSDI TM (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara ® , for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients six years and older, and on October 22, 2024, announced that the FDA approved SELARSDI in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion, expanding its label to include treatment of adults with Crohn’s disease and ulcerative colitis. Takeda In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”), for the research, development, manufacture and commercialization of ATTENUKINE TM technology. Teva received a $30 million upfront payment and a milestone payment of $20 million in 2017. During the second quarter of 2022, Takeda initiated its Phase 2 study of modakafusp alfa (formerly TAK-573 or TEV-‘573) and as a result paid Teva a milestone payment of $25 million, which was recognized as revenue in the second quarter of 2022. In April 2024, Takeda informed Teva of its intent to terminate the agreement with respect to such product candidate, which product rights will revert back to Teva in early 2025. Takeda continues to have rights under the license agreement with respect to other product candidates. MedinCell In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (“LAI”) products. Teva leads the clinical development and regulatory process and is responsible for the commercialization of these products. The lead product is risperidone LAI (formerly known as TV-46000). On April 28, 2023, the FDA approved UZEDY ® (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults, which was launched in the U.S. in May 2023. MedinCell may be eligible for future sales-based milestones of up to $105 million with respect to UZEDY. Teva also pays MedinCell royalties on net sales. The second selected product candidate is olanzapine LAI (TEV-‘749) for the treatment of schizophrenia. In the third quarter of 2022, Teva decided to progress development of the product to Phase 3 and, as a result, paid a $3 million milestone payment to MedinCell, which was recognized as R&D expenses. On May 8, 2024, Teva and MedinCell announced positive phase 3 efficacy results from a trial evaluating olanzapine LAI as a once-

monthly subcutaneous long-acting injectable in adults with schizophrenia. Additional safety and efficacy results are planned in the first half of 2025. MedinCell may become eligible for further development and commercial milestones of up to $108 million, as well as royalties on sales of olanzapine LAI (TEV-'749). Assets and Liabilities Held for Sale: General Assets and liabilities held for sale as of September 30, 2024 and December 31, 2023, included certain businesses in Teva's International Markets segment that are expected to be sold within the next year, mainly the business venture in Japan. In connection with the held for sale classification, in the first quarter of 2024, Teva recorded expenses of $577 million due to an expected loss upon sale, including $369 million of expected loss from reclassification of currency translation adjustments to the statements of income upon sale, in other assets impairments, restructuring and other items. In the second quarter of 2024, Teva recorded an additional expense of $67 million related to the expected loss from reclassification of currency translation adjustments referred to above. In the third quarter of 2024, Teva recorded a favorable adjustment of $83 million, primarily related to the change in expected loss from reclassification of currency translation adjustments referred to above. See note 12.   The table below summarizes all of Teva's assets and liabilities included as held for sale as of September 30, 2024 and December 31, 2023:   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:10%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Inventories </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Accounts receivables </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Goodwill </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Identifiable intangible assets, net </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Property, plant and equipment, net </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other current and non-current assets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Expected loss on sale* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(455</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total assets of the disposal group classified as held for sale in the consolidated balance sheets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Accounts payables </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other liabilities </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Expected loss on sale* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(106</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(216</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-

align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Includes an expected loss from reclassification of currency translation adjustments to the consolidated statements of income (loss) upon sale. </td> </tr> </table>
200000001500000050000003200000001500000001500000002000000010000000500000000100000000125000000P5Y3500000027000000190000001800000010000000050
02-213000000020000000250000001050000003000000108000000577000000369000000670000000830000000 The table below summarizes all of Teva's assets and liabilities included as held for sale as of September 30, 2024 and December 31, 2023:   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:10%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Inventories </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Accounts receivables </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Goodwill </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Identifiable intangible assets, net </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Property, plant and equipment, net </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other current and non-current assets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Expected loss on sale* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(455</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total assets of the disposal group classified as held for sale in the consolidated balance sheets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Accounts payables </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other liabilities </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Expected loss on sale* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(106</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(216</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Includes an expected loss from reclassification of currency translation adjustments to the consolidated statements of income (loss) upon sale. </td> </tr> </table>
16900000012000000123000000048000000300000006700000001000000050000004000000023000000-
45500000002000000700000007600000003400000013000000106000000021600000013000000 NOTE 3 – Revenue from contracts with customers: Disaggregation of revenue The following table

*disaggregates Teva's revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15.
   <table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"> <tr> <td style="width: 60%;"> </td> <td style="width: 4%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td style="width: 4%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 4%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td style="width: 4%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td style="width: 4%; vertical-align: bottom;"> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Three months ended September 30, 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> International
Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Other activities </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="18" style="vertical-align: bottom;text-align:center;"> (U.S.$ in millions) </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 60%;"> Sale of goods </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,822</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,214</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">568</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,794</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 60%;"> Licensing arrangements </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 60%;"> Distribution </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">380</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">390</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 60%;"> Other </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 60%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 60%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,225</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">613</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">229</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,332</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 60%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0,*

0, 0); line-height: normal;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">$</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:59%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">United States</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">International
 Markets</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Other activities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sale of goods </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,500</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,117</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">556</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,303</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Licensing arrangements </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Distribution </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">366</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">377</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right;">1,896</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right;">1,146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right;"> 591</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right;">217</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right;"> 3,850</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td> </td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;">
</div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">$</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:59%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="font-

weight:bold;display:inline;">United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International
 Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other activities </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="18" style="vertical-align:bottom;text-align:center;"> (U.S.$ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sale of goods </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,857</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,668</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,708</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">399</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,701</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Licensing arrangements </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Distribution </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,134</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,163</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">295</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,060</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,749</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,802</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">703</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,315</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:60%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months ended September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">United States</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">International
 Markets</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Other activities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sale of goods </td> <td style="vertical-align:bottom"> </td> <td style="white-

space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,210</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,446</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,656</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">412</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,724</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Licensing arrangements </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Distribution </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,183</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,212</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">318</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,465</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,493</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">681</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,389</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </div></td></tr></table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;">Variable consideration </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Variable consideration mainly includes sales reserves and allowances (“SR&A”), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SR&A to U.S. customers comprised approximately 67% of the Company’s total SR&A as of September 30, 2024, with the remaining balance primarily related to customers in Canada and Germany. The changes in SR&A for third-party sales for the nine months ended September 30, 2024 and 2023 were as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:39%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Reserves
 included in
 Accounts
 Receivable, net</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and
 other
 governmental
 allowances</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total reserves
 included in
 Sales Reserves
 and Allowances</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="30" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance at January 1, 2024 </td> <td style="vertical-align:bottom"> </td> <td

style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">1,603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">540</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">859</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">436</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">97</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,535</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">3,596</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ;
font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-
size: 10pt; font-family: "Times New Roman"; line-height: normal;">Provisions related to sales made in current year period</div></td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">294</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,436</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">579</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,925</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,277</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-
break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom:
0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Provisions related to sales made in prior
periods</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(28</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top:
0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Credits and
payments</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(292</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,269</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(556</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,877</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(209</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(121</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(10,032</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,324</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top">
<div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height:
normal;">Translation differences</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">3</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div>
</td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td>
<td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0,
0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-
top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid
rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt;
margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom:
0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div
style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-
top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div>
</td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td>
<td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-
bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance at September 30,
2024</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">63</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,787</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">592</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">897</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">389</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">3,785</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,848</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-
top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px
double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top:
0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-
bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:

normal;"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:40%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Sales Reserves and Allowances </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Reserves
 included in
 Accounts
 Receivable, net </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Rebates </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Medicaid and
 other
 governmental
 allowances </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Chargebacks </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Returns </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total reserves
 included in
 Sales Reserves
 and Allowances </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="30" style="vertical-align:bottom;text-align:center;"> (U.S.$ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance at January 1, 2023 </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,575</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">663</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">455</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,750</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,817</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Provisions related to sales made in current year period </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">262</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">468</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,636</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">205</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,350</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,612</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Provisions related to sales made in prior periods </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Credits and payments </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(268</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,989</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(617</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,768</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(251</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,678</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,946</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Translation differences </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-

align:right;">(19</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td> <td style="white-space:nowrap;vertical-align:bottom">) </td>
</tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-
top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt;
margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom">
<div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div>
</td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td>
<td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0,
0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-
top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid
rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt;
margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom:
0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div
style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-
top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-
break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;
text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance at September 30, 2023</div></td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,524</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">479</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">835</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">80</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,351</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,412</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-
size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-
bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt;
border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div
style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div
style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td
style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-
top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px
double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top:
0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-
bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15.
</div> <div
style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-
spacing: 0px; top: 0px;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor;
border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"> <tr> <td style="width: 60%;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">
</div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td>
<div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top:
0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top:
0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="width: 4%; vertical-align: bottom;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-
spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="width: 4%; vertical-align:
bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div
style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="width: 4%;
vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr> <tr
style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing:
0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div>
</td> <td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three months
ended September 30, 2024</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top:
0px;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-
spacing: 0px; top: 0px;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-
bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">United States</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top:
0px;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td
colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-
spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div>
</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color:
rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing:
0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">International
Markets</div></div></div></td> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width:
1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div
style="font-weight:bold;display:inline;">Other activities</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing:
0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div>
</td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div>
</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> </tr> <tr
style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top:
0px;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td colspan="18"
style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div
style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top:
0px;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td
style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times
New Roman"; line-height: normal;">Sale of goods</div> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,822</td> <td style="white-space:nowrap;vertical-align:bottom"> </td>
<td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">1,214</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">568</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:
bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">3,794</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:10pt"> <td style="vertical-align: top; width: 60%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-
family: "Times New Roman"; line-height: normal;">Licensing arrangements</div> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom;
width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td

style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 60%;"> Distribution </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">380</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">390</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 60%;"> Other </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 60%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 60%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,225</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 613</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">229</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 4,332</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 60%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:59%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">United States</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">International
 Markets</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Other activities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sale of goods </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,500</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,117</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">556</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,303</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Licensing arrangements </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Distribution </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">366</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">377</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times

New Roman"; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-
size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-
bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div
style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div
style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td
style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top:
1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td
style="vertical-align:bottom;text-align:right;">1,896</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right;">1,146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right;"> 591</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-
align:right;">217</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"> 3,850</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top:
3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-
top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px;
margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top:
3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt;
border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;">
</div> <table cellpadding="0" cellspacing="0"
style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td
style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;
font-family: "Times New Roman"; text-align: left; line-height: normal;">Represents an amount less than $0.5 million. </div> </td> </tr> </table> <div
style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE;
font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:59%"></td> <td style="vertical-align:bottom;width:4%"></td>
<td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td>
<td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td>
<td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-
align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months ended September 30,
2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2"
style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">United States</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px;
top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">International
 Markets</div></div></td> <td style="vertical-align:
bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid
#000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">Other activities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px;
top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">
(U.S.$ in millions)</div></div></td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size:
10pt; font-family: "Times New Roman"; line-height: normal;">Sale of goods</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,857</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">3,668</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,708</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">399</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,701</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top:
0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Licensing
arrangements</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">68</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">17</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">121</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ;
font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left:
1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Distribution</div> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,134</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td
style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New
Roman"; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">49</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">295</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-
size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-
bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div
style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div
style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td
style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;

border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,060</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,749</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,802</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">703</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,315</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left,">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:60%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months ended September 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">United States</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">International
 Markets</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Other activities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sale of goods </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,210</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,446</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,656</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">412</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,724</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Licensing arrangements </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Distribution </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,183</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,212</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">318</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,465</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,493</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">681</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,389</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td>

<td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </td></tr></table>
182200000012140000005680000001210000003794000000230000009000000600000080000004500000038000000010000000039000000042000000290000001000000010
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:39%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Sales Reserves and Allowances </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Reserves
 included in
 Accounts
 Receivable, net </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Rebates </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Medicaid and
 other
 governmental
 allowances </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Chargebacks </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Returns </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total reserves
 included in
 Sales Reserves
 and Allowances </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="30" style="vertical-align:bottom;text-align:center;"> (U.S.$ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance at January 1, 2024 </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">540</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">859</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">436</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,535</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,596</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Provisions related to sales made in current year period </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">294</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,436</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">579</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,925</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,277</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Provisions related to sales made in prior periods </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Credits and payments </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(292</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,269</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(556</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,877</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(209</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(121</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,032</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,324</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Translation differences </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-

space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div>
</td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td>
<td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0,
0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-
top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid
rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt;
margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom:
0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div
style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-
top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div>
</td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td>
<td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-
bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance at September 30,
2024</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">63</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,787</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">592</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">897</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">389</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">3,785</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,848</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-
top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px
double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top:
0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-
bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-
align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-
top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px
double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top:
0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-
bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-
size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div> <div
style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-
family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:40%"></td> <td style="vertical-align:bottom;width:3%"></td>
<td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td>
<td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td>
<td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td>
<td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-
family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">
<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Reserves
 included in
 Accounts
Receivable, net</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div
style="font-weight:bold;display:inline;">Rebates</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px;
top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and
 other
 governmental
 allowances</div></div></td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-
bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">Chargebacks</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-
align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total reserves
 included
in
 Sales Reserves
 and Allowances</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px;
top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr
style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="30" style="vertical-align:bottom;text-align:center;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td> <td style="vertical-
align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top">
<div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height:
normal;">Balance at January 1, 2023</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">663</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">455</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,750</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,817</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td
style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New
Roman"; line-height: normal;">Provisions related to sales made in current year period</div></td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">262</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">2,968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">468</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">5,636</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-

space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">205</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,350</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,612</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Provisions related to sales made in prior periods </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Credits and payments </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(268</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,989</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(617</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,768</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(251</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,678</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,946</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Translation differences </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Balance at September 30, 2023 </td> <td style="vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,524</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">479</td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">835</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,351</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,412</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>
610000001603000005400000008590000004360000009700000035350000003596000000294000000343600000057900000059250000001910000001460000001027700000
11000000-28000000-
20000001000000100000029200000032690000005560000005877000000209000000121000000100320000001032400000001000000300000010000000-
10000000400000040000006300000017870000005920000008970000003890000001200000003785000000384800000067000001575000000663000000991000000455000002
22000000-33000000-21000000240000000-52000000-52000000268000000298900000061700000057680000000251000000530000009678000000994600000000-8000000-
2000000-30000000-6000000-19000000-19000000610000001524000000479000000835000000433000000800000003351000000341200000 NOTE 4 – Inventories: Inventories, net of reserves, consisted of the following:
  <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div

style="letter-spacing: 0px; top: 0px;display:inline;"> December 31, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Finished products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,346</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Raw and packaging materials </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">993</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Products in process </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">524</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Materials in transit and payments on account </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">195</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">183</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,959</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,021</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table> Inventories, net of reserves, consisted of the following: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Finished products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,346</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Raw and packaging materials </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">993</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Products in process </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">524</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Materials in transit and payments on account </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">195</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">183</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,959</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,021</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>2314000000023460000009260000009930000005240000005000000001950000001830000003959000000402100000 NOTE 5 - Identifiable intangible assets: Identifiable intangible assets consisted of the following: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:42%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Gross carrying amount net of
 impairment </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Accumulated amortization </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Net carrying amount </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2"

style="vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="22" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Product rights </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,981</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,235</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,274</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,173</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,707</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Trade names </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">586</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">583</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">296</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">269</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">290</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> In process research and development </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">294</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">366</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">294</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">366</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,287</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,930</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,543</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,756</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,387</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table> Product rights and trade names Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products in various therapeutic categories from various acquisitions with a weighted average life period of approximately 9 years. Amortization of intangible assets was $146 million and $145 million in the three months ended September 30, 2024 and 2023, respectively. Amortization of intangible assets was $444 million and $471 million in the nine months ended September 30, 2024 and 2023, respectively. IPR&D Teva's IPR&D are assets that have not yet been approved in its major markets. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. Intangible assets impairments Impairments of long-lived intangible assets for the three months ended September 30, 2024 and 2023 were $28 million and $47 million, respectively. Impairments in the third quarter of 2024 consisted of: Identifiable product rights of $28 million, mainly due to updated market assumptions regarding price and volume of products mainly in the U.S. <div

style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">   Impairments in the third quarter of 2023 consisted of: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"> IPR&D assets of $29 million, mainly due to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date); and </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"> Identifiable product rights of $18 million mainly due to updated market assumptions regarding price and volume of products. </td></tr></table> Impairments of long-lived intangible assets for the nine months ended September 30, 2024 and 2023 were $169 million and $289 million, respectively. Impairments in the first nine months of 2024 consisted of: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"> Identifiable product rights of $136 million, mainly due to updated market assumptions regarding price and volume of products mainly in the U.S.; and </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"> IPR&D assets of $33 million, mainly due to generic pipeline products resulting from development progress and changes in other key valuation indications mainly in the U.S. (e.g., market size, competition assumptions, legal landscape and launch date). </td></tr></table> Impairments in the first nine months of 2023 consisted of: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"> Identifiable product rights of $206 million due to: (i) $112 million in Japan, mainly due to regulatory pricing reductions; and (ii) $94 million related to updated market assumptions regarding price and volume of products; and </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"> IPR&D assets of $83 million, mainly due to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). </td></tr></table> The fair value measurement of the impaired intangible assets in the nine months ended September 30, 2024 is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The discount rate applied ranged from 8.5% to 10%. A probability of success factor of 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&D. Identifiable intangible assets consisted of the following: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:42%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Gross carrying amount net of
 impairment </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Accumulated amortization </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Net carrying amount </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="22" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Product rights </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,981</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,235</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,274</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,173</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,707</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Trade names </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">586</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">583</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">296</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">269</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">290</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> In process research and development </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">294</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">366</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">294</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">366</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr>

<tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,287</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,930</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,543</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,756</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,387</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr>
</table>16408000000179810000001223500000013274000000417300000047070000005860000005830000002960000000269000000290000000314000000294000000366000
NOTE 6 - Goodwill: Changes in the carrying amount of goodwill for the period ended September 30, 2024 were as follows:
    <table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"> <tr> <td style="width: 54%;"> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> North
America </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> United
States </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Europe </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> International
Markets </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Other </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Total </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Teva's
API </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Medis </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="14" style="vertical-align: bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="6" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 54%;"> Balance as of December 31, 2023 (1) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,459</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,466</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">675</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,313</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-

align:bottom;text-align:right;">265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,177</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Goodwill allocation related to the shift of Canada to International Markets</div></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,459</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">646</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 54%;"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 54%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance as of January 1, 2024</div></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,466</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,321</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,313</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,177</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 54%;"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 54%;"> Other changes during the period: </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 54%;"> Goodwill impairment </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,000</td> <td style="white-space:nowrap;vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 54%;"> Goodwill reclassified as assets held for sale </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 54%;"> Translation differences and other </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 54%;"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-

align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 54%;"> Balance as of September 30, 2024 (1) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,161</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">318</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">269</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,124</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 54%;"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"> Cumulative goodwill impairment as of September 30, 2024 and December 31, 2023 was approximately $29.3 billion and $28.3 billion, respectively. </td></tr></table> Teva operates its business through three reporting segments: United States, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva's production and sale of APIs to third parties ("Teva API") and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Teva's API and Medis reporting units are included under "Other" in the table above. See note 15 for additional segment information. Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva begins with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva's estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital ("WACC"), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva's assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. First Quarter Developments As further discussed in note 15, as of January 1, 2024, Canada is reported as part of Teva's International Markets segment and not as part of Teva's North America segment, which has been renamed as Teva's United States segment. As a result, Teva aligned its segment reporting and its reporting units in accordance with this change, and reallocated its goodwill to the adjusted reporting units using a relative fair value allocation. In conjunction with the goodwill reallocation, Teva performed a goodwill impairment test for the balances in its adjusted United States and International Markets reporting units and concluded that the fair value of each reporting unit was in excess of its carrying value. During the first quarter of 2024, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of March 31, 2024. Management concluded that no triggering event had occurred and, therefore, no quantitative assessment was performed. Second Quarter Developments During the second quarter of 2024, Teva completed its long-range planning ("LRP") process. The LRP is part of Teva's internal financial planning and budgeting processes and is discussed and reviewed by Teva's management and its board of directors.   Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. As disclosed in prior periods, the excess of the estimated fair value of Teva's API reporting unit over its estimated carrying amount was negligible as of December 31, 2023 and March 31, 2024. The updated quantitative analysis performed in the second quarter of 2024, which was based on the aforementioned LRP process and Teva's Pivot to Growth strategy assumptions, resulted in a recognition of a goodwill impairment charge of $400 million related to Teva's API reporting unit. Following the goodwill impairment charges recorded in relation to Teva's API reporting unit, the carrying values of this reporting unit equaled its fair value as of June 30, 2024. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva's API reporting unit in the future (see "Third Quarter Developments" below). Teva's United States, Europe, International Markets and Medis reporting units had fair values in excess of 10% over their book values as of June 30, 2024. In the second quarter of 2023, Teva recorded a goodwill impairment charge of $700 million related to its International Markets reporting unit, mainly due to an increase in the discount rate due to higher risk associated with country-specific characteristics of several countries. Third Quarter Developments During the third quarter of 2024, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of September 30, 2024. As part of this evaluation, management noted a triggering event related to Teva's API reporting unit, which resulted from updated assumptions in connection with Teva's intention to divest its API business through a sale. Teva performed a quantitative assessment in the third quarter of 2024, which resulted in the recording of a goodwill impairment charge of $600 million related to Teva's API reporting unit. Following this goodwill impairment charge, the carrying value of Teva's API reporting unit equaled its fair value as of September 30, 2024. Therefore, if business conditions or expectations, including related to Teva's intention to divest its API business, were to change materially, it may be necessary to record further impairment charges to Teva's API reporting unit in the future. With respect to the remaining reporting units, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying amounts as of September 30, 2024 and, therefore, no quantitative assessment was performed. Changes in the carrying amount of goodwill for the period ended September 30, 2024 were as follows:
   <table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"> <tr> <td style="width: 54%;"> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td><div style="letter-spacing: 0px; top:

0px;display:inline;"> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> North
America </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> United
States </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Europe </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> International
Markets </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Other </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Total </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Teva's
API </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> Medis </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="14" style="vertical-align: bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="6" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 54%;"> Balance as of December 31, 2023 (1) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,459</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,466</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">675</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,313</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,177</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 54%;"><div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Goodwill allocation related to the shift of Canada to International Markets</div></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,459</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">646</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 54%;"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 54%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance as of January 1, 2024</div></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,466</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,321</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,313</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,177</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 54%;"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align: bottom; width:

1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 54%;"> Other changes during the period: </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 54%;"> Goodwill impairment </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,000</td> <td style="white-space:nowrap;vertical-align:bottom">)</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 54%;"> Goodwill reclassified as assets held for sale </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 54%;"> Translation differences and other </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 54%;"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 54%;"> Balance as of September 30, 2024 (1) </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,161</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">318</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">269</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,124</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 54%;"></td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt; border:0; width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%; vertical-align:top; text-align:left;">(1)</td> <td style="vertical-align:top; text-align:left;"> Cumulative goodwill impairment as of September 30, 2024 and December 31, 2023 was approximately $29.3 billion and $28.3 billion, respectively. </td></tr></table> 6459000000008466000000675000000131300000026500000017177000000-6459000000058130000000646000000000058130000008466000000132100000013130000002650000001717700000000001000000000010000000000-29000000002900000000-970000001310000000-50000000-40000002500000005813000000856300000011610000003180000002690000001612400000029300000000283000000004000000000.1070000000600000000 <div

*style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"> NOTE 7 – Debt obligations: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"> a. </td> <td style="vertical-align:top;text-align:left;"> Short-term debt: </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:54%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Interest rate as of
 September 30, 2024 </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Maturity </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Convertible senior debentures </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.25</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2026</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td colspan="8" style="vertical-align:top"> Current maturities of long-term liabilities </td> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,557</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,649</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td colspan="8" style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td colspan="8" style="vertical-align:top"> Total short-term debt </td> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,580</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,672</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td colspan="8" style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table> Convertible senior debentures The principal amount of Teva's 0.25% convertible senior debentures due in 2026 was $23 million as of September 30, 2024 and as of December 31, 2023. These convertible senior debentures include a "net share settlement" feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the "net share settlement" feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under 'short-term debt'.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"> b. </td> <td style="vertical-align:top;text-align:left;"> Long-term debt: </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:61%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Interest rate as of
 September 30, 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Maturity </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes USD 1,250 million (4) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2024</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">956</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes EUR 1,500 million (5) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.13</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2024</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes EUR 1,000 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">459</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-*

align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">453</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes USD 1,000 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.13</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">427</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">427</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes EUR 900 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.50</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">554</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">547</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes CHF 350 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">417</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">416</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes USD 3,500 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.15</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2026</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes EUR 700 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.88</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">781</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">771</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sustainability-linked senior notes USD 1,000 million (1)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.75</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Sustainability-linked senior notes EUR 1,100 million (1)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.75</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,229</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,215</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes USD 1,250 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.75</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2028</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes EUR 750 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.63</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2028</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">826</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sustainability-linked senior notes USD 1,000 million (2)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.13</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Sustainability-linked senior notes USD 600 million (3)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.88</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">600</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">600</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sustainability-linked senior notes EUR 800 million (3)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.38</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">895</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">884</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Sustainability-linked senior notes EUR 1,500 million (2)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.38</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2030</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,676</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,656</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sustainability-linked senior notes USD 500 million (3)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.13</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-

align:right;">500</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Sustainability-linked senior notes EUR 500 million (3)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.88</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">558</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">552</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes USD 789 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.15</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2036</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes USD 2,000 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.10</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2046</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,986</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,986</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total senior notes </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,023</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other long-term debt </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Less current maturities </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,557</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,649</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Less debt issuance costs </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total senior notes and loans </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,400</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,161</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"> If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(2)</td> <td style="vertical-align:top;text-align:left;"> If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026 . </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(3)</td> <td style="vertical-align:top;text-align:left;"> If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(4)</td> <td style="vertical-align:top;text-align:left;"> In April 2024, Teva repaid $956 million of its 6% senior notes due 2024 at maturity. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(5)</td> <td style="vertical-align:top;text-align:left;"> In October 2024, Teva repaid $685 million of its 1.13% senior notes due 2024 at maturity. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. </td> </tr> </table> Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest.   <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-

family:Times New Roman;text-align:center"> Teva's debt as of September 30, 2024 was effectively denominated in the following currencies: 58% in U.S. dollars, 40% in euro and 2% in Swiss franc. Teva's principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $1.8 billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, as amended on February 6, 2023 and on May 3, 2024 ("RCF"). The RCF had an initial maturity date of April 2026 with two one-year extension options. In April 2024, an extension option was exercised and the RCF maturity date was extended to April 2027. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. On May 3, 2024, the terms of the RCF were amended to update the Company's maximum permitted leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Company's leverage ratio shall not exceed (i) 4.00x in 2024, 2025 and in the first quarter of 2026, (ii) 3.75x in the second, third and fourth quarters of 2026 and (iii) 3.50x in the first quarter of 2027 and onwards. The RCF permits the Company to increase the maximum leverage ratio if it consummates or commences certain material transactions. Under the RCF, as amended, the applicable margin used to calculate the interest rate under the RCF is linked to one sustainability performance target, the number of new regulatory submissions in low and middle-income countries. Proceeds from borrowings under the RCF can be used for general corporate purposes, including repaying existing debt. As of September 30, 2024 , and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the circumstances referred to above, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company's senior notes and sustainability-linked senior notes due to cross-acceleration provisions. Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued. <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left,"> a. </td> <td style="vertical-align:top;text-align:left,"> Short-term debt: </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:54%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Interest rate as of
 September 30, 2024 </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Maturity </td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Convertible senior debentures </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.25</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2026</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td colspan="8" style="vertical-align:top"> Current maturities of long-term liabilities </td> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom;text-align:right;">2,557</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,649</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td colspan="8" style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td colspan="8" style="vertical-align:top"> Total short-term debt </td> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,580</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,672</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td colspan="8" style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table> 0.00252026230000002300000025570000001649000000258000000016720000000.00252300000023000000 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left,"> b. </td> <td style="vertical-align:top;text-align:left,"> Long-term debt: </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr> <td style="width:61%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Interest rate as of
 September 30, 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Maturity </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes USD 1,250 million (4) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td> <td style="white-

space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2024</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">956</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes EUR 1,500 million (5) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.13</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2024</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">693</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes EUR 1,000 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">459</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">453</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes USD 1,000 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.13</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">427</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">427</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes EUR 900 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.50</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">554</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">547</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes CHF 350 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">417</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">416</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes USD 3,500 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.15</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2026</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes EUR 700 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.88</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">781</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">771</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sustainability-linked senior notes USD 1,000 million (1)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.75</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Sustainability-linked senior notes EUR 1,100 million (1)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.75</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,229</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,215</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes USD 1,250 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.75</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2028</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes EUR 750 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.63</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2028</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">826</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sustainability-linked senior notes USD 1,000 million (2)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.13</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Sustainability-linked senior notes USD 600 million (3)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.88</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">600</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">600</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sustainability-linked senior notes EUR 800 million (3)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td

style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.38</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">895</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">884</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Sustainability-linked senior notes EUR 1,500 million (2)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.38</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2030</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,676</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,656</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Sustainability-linked senior notes USD 500 million (3)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.13</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Sustainability-linked senior notes EUR 500 million (3)(*) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.88</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">558</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">552</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Senior notes USD 789 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.15</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2036</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Senior notes USD 2,000 million </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.10</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2046</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,986</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,986</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total senior notes </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,023</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other long-term debt </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Less current maturities </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,557</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,649</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Less debt issuance costs </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total senior notes and loans </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,400</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,161</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"> If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(2)</td> <td style="vertical-align:top;text-align:left;"> If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026 . </td>

</tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(3)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">0.100%-0.300%</div> per annum, from and including September 15, 2026. </div> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(4)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">In April 2024, Teva repaid $956 million of its 6% senior notes due 2024 at maturity. </div> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(5)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">In October 2024, Teva repaid $685 million of its 1.13% senior notes due 2024 at maturity. </div> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">Interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. </div>
12500000000.06202409560000000150000000000.0113202470000000006930000000100000000000.0620254590000000453000000010000000000.0713202542700000004270000009
05-090.001250.003750.0010.0039560000000.066850000000.01130.580.400.021800000000one-year4.004.004.003.753.753.753.50Proceeds from borrowings under the RCF can be used for general corporate purposes, including repaying existing debt. As of September 30, 2024, and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;">NOTE 8 – Derivative instruments and hedging activities: </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange risk management:</div></div><div style="background: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"> <div style="font-weight:bold;display:inline;"> </div></div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first nine months of 2024, approximately 47% of Teva’s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce its exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty, new Israeli shekel, Indian rupee and other currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (“net investment hedge”) and has in the past entered into cross-currency swaps and forward-contracts in order to hedge such an exposure. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Interest risk management: </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans and convertible debentures that bear fixed or variable interest rates, as well as a syndicated sustainability-linked revolving credit facility and securitization programs that bear a variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (“fair value hedge”) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (“cash flow hedge”), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. As of September 30, 2024, all outstanding senior notes, sustainability-linked senior notes and convertible debentures bear a fixed interest rate. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Bifurcated embedded derivatives: </div> </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the issuance of its sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-to-middle-income</div></div> countries and reduction of absolute greenhouse gas emissions, which were bifurcated and are accounted for separately as derivative financial instruments. As of September 30, 2024, the fair value of these derivative instruments is negligible. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;">d. Derivative instruments outstanding: </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cross-currency swap - cash flow hedge (1)</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the classification and fair values of derivative instruments: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:55%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Designated as hedging</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div>
 <div style="letter-spacing: 0px; top:

0px;display:inline;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> Reported under </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Asset derivatives: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other current assets: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Option and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other non-current assets: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cross-currency swap-cash flow hedge (1) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Liability derivatives: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other current liabilities: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Option and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr></table>   The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives designated in cash flow hedging relationships: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:54%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Financial expenses, net </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other comprehensive income
 (loss) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> Reported under </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Line items in which effects of hedges are recorded </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">272</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-

align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">180</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(249</td> <td style="white-space:nowrap;vertical-align:bottom">) </td>
</tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom:
0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cross-currency swaps - cash flow hedge (1)
</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td colspan="8" style="height:12pt"></td> <td colspan="8" style="height:12pt">
</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div
style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td> <td style="vertical-align:
bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid
#000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Other
comprehensive income
 (loss)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-
family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months ended,</div></div></td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-
align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months ended,</div></div></td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-
bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">September 30,</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-
align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div>
 <div style="letter-
spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-
align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2023</div></div></td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td
style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0);
display: table-cell; font-size: 8pt; font-family: "Times New Roman"; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div>
</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-
align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-
color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family:
"Times New Roman"; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div></td>
<td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">(75</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(156</td> <td style="white-space:nowrap;vertical-align:bottom">) </td>
</tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom:
0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cross-currency swaps - cash flow hedge (1)
</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(8</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The table below
provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-tax</div> (gains) losses
from derivatives not designated as hedging instruments: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0"
cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"> <tr> <td
style="width:53%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td>
</td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td>
</td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-
align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-
bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">Net revenues</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ;
font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-
align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-
bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">September 30,
 2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align:
bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing:
0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2023</div></div></td> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-
align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2024</div>
</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2"
style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">September 30,
 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-
inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt;
margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: "Times New Roman"; line-height: normal;"><div
style="font-weight:bold;display:inline;">Reported under</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14"
style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">(U.S. $ in millions)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-
inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt;
margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="font-weight:bold;display:inline;">Line
items in which effects of hedges are recorded</div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">272</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,332</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,850</td>
<td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td
style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New
Roman"; line-height: normal;">Option and forward contracts (2)</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size:
10pt; font-family: "Times New Roman"; line-height: normal;">Option and forward contracts economic hedge (3)</div></td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td> <td

style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td colspan="8" style="height:12pt"></td> <td colspan="8" style="height:12pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Financial expenses, net </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Net revenues </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> Reported under </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Line items in which effects of hedges are recorded </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,315</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,389</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Option and forward contracts (2) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(46</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Option and forward contracts economic hedge (3) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr></table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"> On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. The agreement was terminated in the first quarter of 2024 and resulted in cash proceeds of $16 million. </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(2)</td> <td style="vertical-align:top;text-align:left;"> Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(3)</td> <td style="vertical-align:top;text-align:left;"> Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and some other currencies to protect its projected operating results for 2024. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the three months ended September 30, 2024, the negative impact from these derivatives recognized under revenues was $9 million. In the nine months ended September 30, 2024, the positive impact from these derivatives recognized under revenues was $1 million. In the three months ended September 30, 2023, the positive impact from these derivatives recognized under revenues was $22 million. In the nine months ended September 30, 2023, the positive impact from these derivatives recognized under revenues was $20 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"> e. </td> <td style="vertical-align:top;text-align:left;"> Amortizations due to terminated derivative instruments: </td></tr></table> Forward-starting interest rate swaps and treasury lock agreements In 2015, Teva entered into forward-starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward-starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. Termination of these transactions resulted in a loss position of $493 million, which was recorded as other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. With respect to these forward-starting interest rate swaps and treasury lock agreements, losses of $7 million were recognized under financial expenses, net, for each of the three months ended September 30, 2024 and 2023, and losses of $21 million and $25 million were recognized under financial expenses, net for each of the nine months ended September 30, 2024 and 2023, respectively.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"> f. </td> <td style="vertical-align:top;text-align:left;"> Securitization: </td></tr></table> U.S. securitization program On November 7, 2022, Teva and a bankruptcy-remote special purpose vehicle ("SPV") entered into an accounts receivable securitization facility ("AR Facility") with PNC Bank, National Association ("PNC") with a three-year term. The AR Facility provided for purchases of accounts receivable by PNC in an amount of up to $1 billion through November 2023, and up to $500 million from November 2023 through November 2025. On June 30, 2023, the AR Facility agreement was amended to include an additional receivables purchaser under the agreement, in an amount of up to $250 million through November 2025. As a result, the total commitment of PNC was reduced to an amount of up to $750 million, effective June 30, 2023. Under the terms of the AR facility agreement, in November 2023, the total commitment of PNC was further reduced to an amount of up to $500 million through November 2025. On November 7, 2023, the SPV amended the agreement and increased the commitment amount to a maximum of $1 billion by including an additional receivables purchaser in an amount of up to $250 million through March 2024, which was then reduced by $125 million through November 2025. As a result, the commitment amount was reduced to a maximum of $875 million without any additional purchasers participating in the AR facility. On October 29, 2024, the SPV amended the agreement and increased the commitment amount to a maximum amount of $ 950 million by an existing receivables purchaser increasing its commitment by $ 75 million.   <div style="font-

weight:bold;display:inline;">Pledged accounts receivables In connection with the U.S. securitization program, accounts receivables, net of allowance for credit losses, include $934 million and $437 million as of September 30, 2024 and December 31, 2023, respectively, which are pledged by the SPV to PNC.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"> g. </td> <td style="vertical-align:top;text-align:left;"> Supplier Finance Program Obligation </td></tr></table> Teva maintains supply chain finance agreements with participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Teva to these financial institutions. Teva's suppliers negotiate their financing agreements directly with the respective financial institutions and Teva is not a party to these agreements. Teva has no economic interest in its suppliers' decisions to participate in the program and Teva pays the financial institutions the stated amount of confirmed invoices on the maturity dates, which is generally within 120 days from the date the invoice was received. The agreements with the financial institutions do not require Teva to provide assets pledged as security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in the supplier finance program are recorded under accounts payables in Teva's consolidated balance sheets. As of September 30, 2024 and December 31, 2023, respectively, $163 million and $108 million of accounts payables to suppliers participating in these supplier finance programs were outstanding. 0.47 The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cross-currency swap - cash flow hedge (1) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>0169000000 The following table summarizes the classification and fair values of derivative instruments: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:55%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Fair value </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Designated as hedging <br/> instruments </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Not designated as hedging <br/> instruments </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> Reported under </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Asset derivatives: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other current assets: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Option and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other non-current assets: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cross-currency swap-cash flow hedge (1) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td

style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Liability derivatives: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other current liabilities: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Option and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr></table>00320000003800000008000000000033000000390000000 The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives designated in cash flow hedging relationships: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:54%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Financial expenses, net </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other comprehensive income
 (loss) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> Reported under </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Line items in which effects of hedges are recorded </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">272</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(249</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Cross-currency swaps - cash flow hedge (1) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td colspan="8" style="height:12pt"></td> <td colspan="8" style="height:12pt"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Financial expenses, net </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other comprehensive income
 (loss) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> Reported under </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Line items in which effects of hedges are recorded </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(156</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Cross-currency swaps - cash flow hedge (1)

</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr></table>272000000280000000180000000-2490000000-70000000100000007630000000808000000-75000000-156000000-8000000-220000001000000-4000000<div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:53%"> </td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td> </td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: "Times New Roman"; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">272</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,332</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,850</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Option and forward contracts (2)</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Option and forward contracts economic hedge (3) </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td colspan="8" style="height:12pt"></td> <td colspan="8" style="height:12pt"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months ended,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months ended,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September 30,
 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: "Times New Roman"; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,315</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,389</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Option and forward contracts (2)</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(46</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Option and forward contracts economic hedge (3) </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-

align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr></table>2720000002800000004332000000-38500000004000000400000000009000000-22000000763000000880000000-12315000000-11389000000-33000000-46000000000-10000002000000016000000900000010000002200000020000000493000000700000007000000210000002500000P3Y1000000000500000000250000000750000000500000000100000

* NOTE 9 – Legal settlements and loss contingencies: In the third quarter of 2024, Teva recorded expenses of $450 million in legal settlements and loss contingencies, compared to expenses of $314 million in the third quarter of 2023. Expenses in the third quarter of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE ® , and an update to the estimated settlement provision for the opioid cases (mainly related to the settlement agreement with the city of Baltimore and the effect of the passage of time on the net present value of the discounted payments). Expenses in the third quarter of 2023 were mainly related to an update to the provision for the DOJ patient assistance program litigation, as well as an update to the estimated settlement provision of the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). See note 10. In the first nine months of 2024, Teva recorded expenses of $638 million in legal settlements and loss contingencies, compared to $1,009 million in the first nine months of 2023. Expenses in the first nine months of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE, and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore). Expenses in the first nine months of 2023 were mainly related to an estimated provision for the DOJ patient assistance program litigation, an update to the estimated settlement provision of the opioid cases, the provision for the settlement of the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, as well as the provision for the settlement of the reverse-payment antitrust litigation over certain HIV medicines. As of September 30, 2024 and December 31, 2023, Teva's provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,915 million and $4,771 million, respectively. *

4500000003140000006380000001009000000491500000047710000000 NOTE 10 – Commitments and contingencies: General From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. Teva records a provision in its consolidated financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is reasonably estimable. Based upon the status of the cases described below, management's assessments of the likelihood of damages, and the advice of legal counsel, no material provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and substantial damages or other relief may be awarded. Accordingly, management's assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved.   If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the consolidated financial statements. In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva's agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third-party sales figures given below are based on IQVIA data. Intellectual Property Litigation From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator's patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the "patent dance" procedures of the Biologics Price Competition and Innovation Act ("BPCIA"), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator's patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva's pharmaceutical products, not just its generic and biosimilar products. The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva's product. The amount of lost profits would generally be based on the lost sales of the patentee's product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. In July 2014, GlaxoSmithKline ("GSK") filed claims against Teva in the U.S. District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva began selling its carvedilol tablets (the generic version of GSK's Coreg ®) in September 2007. A jury returned a verdict in GSK's favor, which was initially overturned by the U.S. District Court. The Court of Appeals for the Federal Circuit reinstated the $235.5 million jury verdict, not including pre- or post-judgment interest, finding Teva liable for patent infringement. The U.S. Supreme Court denied Teva's appeal for a rehearing. The case has been remanded to the district court for further proceedings on Teva's other legal and equitable defenses that have not yet been considered by the district court. Teva recognized a provision based on its offer to settle the matter.   In January 2021, Teva initiated a patent invalidity action against the compound patent and Supplementary Protection Certificate ("SPC") asserted to cover Bristol-Myers Squibb Company's ("BMS") Eliquis ® (apixaban). In May 2022, the U.K. High Court held that the compound patent and SPC are invalid and Teva began selling its generic version of Eliquis ® (apixaban). In May 2023, the U.K. Court of Appeal upheld this decision and denied BMS's request to appeal to the U.K. Supreme Court. On October 31, 2023, the U.K. Supreme Court denied BMS's application for further review, making the decision to revoke the compound patent and SPC final. Separately, in February 2021, Teva initiated a patent invalidity action against the formulation patents, which are also under opposition at the European Patent Office ("EPO"). On July 15, 2022, the U.K. High Court held that these formulation patents were invalid but granted permission to appeal, which was subsequently stayed pending the outcome of the opposition at the EPO to one of the formulation patents. On December 21, 2023, the EPO's Technical Board of Appeal held its hearing on the opposition, and on March 13, 2024, it issued a written decision revoking the patent. On May 13, 2024, BMS filed a submission to the Enlarged Board of Appeal seeking its permission to review the Technical Board of Appeal's decision, a hearing for which is scheduled for December 3, 2024. Product Liability Litigation Teva's business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied, as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in certain or all of its markets. Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan were allegedly found in the active pharmaceutical ingredient ("API") supplied to Teva by multiple API manufacturers, including by Zhejiang Huahai Pharmaceuticals Co. Ltd. Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. Multiple lawsuits have been filed in connection with this matter. Teva's products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations ("MDL") pending against Teva and other manufacturers, including one MDL in the U.S. District Court for the District of New Jersey related to, with respect to Teva, valsartan and losartan, and another MDL in the U.S. District Court for the Southern District of Florida related to ranitidine. The claims against Teva in these MDLs include individual personal injury and/or product liability claims, economic damages claims brought by consumers and end payors as putative class actions, and medical monitoring class claims. The district court in the valsartan MDL certified a series of subclasses on plaintiffs' economic loss claims as well as a medical monitoring class and originally scheduled the first trial to commence in the fourth quarter of 2024, but that trial has been postponed indefinitely by the court. Discovery is ongoing in the MDL with respect to the losartan claims against Teva. The claims against Teva and other generic manufacturers in the ranitidine MDL have been dismissed on preemption grounds but are subject to appeal. The district court in the ranitidine MDL also excluded all of plaintiffs' general causation experts and granted summary judgment to the brand defendants on preemption grounds and later applied that general causation ruling to all defendants. This ruling is on appeal in the Eleventh Circuit Court of Appeals. Certain generic manufacturers, including Teva, have also been named in state court actions asserting allegations similar to those in the aforementioned MDLs. In particular, state court valsartan and losartan actions are pending but currently stayed in New Jersey and Delaware, with the exception of a single-plaintiff case that was later refiled in a New Jersey state court in October 2022 and is in the very initial stages of discovery. State court ranitidine cases naming Teva are also pending in

*coordinated proceedings in California and Pennsylvania. Teva was dismissed from all ranitidine claims pending in Illinois based on preemption grounds, which plaintiffs have appealed for final judgments as to all remaining defendants. Teva was also dismissed on preliminary objections in Pennsylvania for plaintiffs whose cases are governed by Pennsylvania law, but further motion practice may continue. The litigation in Pennsylvania has effectively been stayed pending a decision on a motion filed by plaintiffs to recuse the presiding judge which was denied but certified for interlocutory appeal.   In addition to the valsartan and ranitidine MDLs and coordinated state court proceedings, Teva has been named in a consolidated proceeding pending in the U.S. District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva's and other generic manufacturers' metformin products. The parties are now engaged in discovery related to the surviving metformin claims. Teva was recently named in a related proceeding pending in the same district brought by end payors also seeking economic damages on behalf of a purported class of end payors who purchased Teva's and other generic manufacturers' metformin products. This action was consolidated with the original proceeding for discovery and pretrial purposes only. Teva, along with the other defendants, have moved to dismiss the claims in this newly consolidated proceeding. Similar lawsuits are pending in Canada and Germany. Competition Matters As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva's patent challenges have resulted in litigation relating to Teva's attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i) Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii) significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys' fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial, potentially measured in multiples of the annual brand sales, particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva's experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. In June 2013, the U.S. Supreme Court held, in Federal Trade Commission ("FTC") v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This test has resulted in increased scrutiny of Teva's patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva's currently pending antitrust litigations. In December 2011, three groups of plaintiffs filed claims against Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended-release venlafaxine (generic Effexor XR ®). The cases were filed by a purported class of direct purchasers, a purported class of indirect purchasers and certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. On September 18, 2024, the district court lifted its stay of discovery and the case is now proceeding. On October 16, 2024, Teva and one group of plaintiffs (the "Indirect Purchaser Plaintiffs" or "IPPs") announced that they have reached an agreement in principle to resolve the IPPs' claims against Teva. The parties are in the process of documenting the proposed settlement, which will be subject to court approval. Annual sales of Effexor XR ® were approximately $2.6 billion at the time of settlement and at the time Teva launched its generic version of Effexor XR ® in July 2010.   In February 2012, two purported classes of direct-purchaser plaintiffs filed claims against GSK and Teva in the U.S. District Court for the District of New Jersey for alleged violations of the antitrust laws in connection with their February 2005 settlement of patent litigation involving lamotrigine (generic Lamictal ®). The plaintiffs claimed that the settlement agreement unlawfully delayed generic entry and sought unspecified damages. During February 2023, a number of direct purchasers who were denied class certification filed suit as individual plaintiffs, which action was transferred to the U.S. District Court for the District of New Jersey. Discovery of the newly added individual plaintiffs is ongoing. Annual sales of Lamictal ® were approximately $950 million at the time of the settlement and approximately $2.3 billion at the time Teva launched its generic version of Lamictal ® in July 2008. In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan ® (extended release niacin) filed claims against Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005 to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser opt-out plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers' class. On April 24, 2023, the U.S. District Court's denial of the indirect purchasers' motion for class certification was affirmed by the Court of Appeals for the Third Circuit, and on June 5, 2023, the Court of Appeals denied the indirect purchasers' petition for re-hearing. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. The California state court case is temporarily stayed. Annual sales of Niaspan ® were approximately $416 million at the time of the settlement and approximately $1.1 billion at the time Teva launched its generic version of Niaspan ® in September 2013. In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia against Teva and its affiliates alleging that the September 2006 patent litigation settlement relating to AndroGel ® 1% (testosterone gel) between Watson, from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. ("Solvay") violated antitrust laws. In September 2023, the plaintiffs voluntarily dismissed certain claims, and in September 2024, certain defendants, including the remaining Teva affiliates, and the plaintiffs agreed to settle the remaining claims. The litigation has been stayed pending finalization of the settlements. Annual sales of AndroGel ® 1% were approximately $350 million at the time of the earlier Watson/Solvay settlement and approximately $140 million at the time Actavis launched its generic version of AndroGel ® 1% in November 2015. A provision for this matter was previously included in the financial statements. Between September 1, 2020 and December 20, 2020, plaintiffs purporting to represent putative classes of direct and indirect purchasers and opt-out retailer purchasers of Bystolic ® (nebivolol hydrochloride) filed complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic ® violated the antitrust laws. The cases were coordinated, and the district court granted the defendants' motion to dismiss all claims with prejudice. The plaintiffs appealed the district court's grant of defendants' motion to dismiss, and on May 13, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the district court's dismissal with prejudice and issued a mandate on June 4, 2024, formally ending the appeal. The plaintiffs' period to file a petition for a writ of certiorari to the U.S. Supreme Court expired. Annual sales of Bystolic ® in the United States were approximately $700 million at the time of Watson's 2013 settlement with Forest. In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5 million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021, and a judgment was issued on October 18, 2023 rejecting Teva's grounds of appeal. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. On January 4, 2024, Teva appealed the October 2023 judgment to the European Court of Justice. In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV (the "New Mexico litigation"). Between September 2021 and April 2022, several private plaintiffs including retailers and health insurance providers filed similar claims in various courts, which were all removed and/or consolidated into the U.S. District Court for the Northern District of California (the "California litigation"). As they relate to Teva, the lawsuits challenged settlement agreements Teva entered into with Gilead in 2013 and/or 2014 to resolve patent litigation relating to Teva's generic versions of Viread ® and/or Truvada ® and Atripla ® , although plaintiffs in the California litigation abandoned any claim for damages relating to the Viread ® settlement. In May   2023, Teva and Gilead reached a settlement agreement with the retailer plaintiffs in the California litigation and Teva recognized a provision for this matter based on such settlement. On June 30, 2023, the jury in the trial against the remaining plaintiffs in the California litigation issued a verdict in favor of Teva and Gilead, rejecting all of the remaining plaintiffs' claims. On February 12, 2024, the court entered a judgment as to all claims against Teva in the California litigation and the plaintiffs have filed notices of appeal with the U.S. Court of Appeals for the Ninth Circuit, and the appeal is currently being briefed. In the New Mexico litigation, on June 27, 2024, Teva and the State of New Mexico finalized their settlement agreement, and the New Mexico court entered a consent judgment resolving the New Mexico litigation. Teva recognized a provision for the settlement with New Mexico. Annual sales in the United States at the time of the settlement of Viread ® , Truvada ® and Atripla ® were approximately $582 million, $2.4 billion, and $2.9 billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread ® in 2017, Truvada ® in 2020 and Atripla ® in 2020 were approximately $728 million, $2.1 billion and $444 million, respectively. In March 2021, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. On October 10, 2022, the European Commission issued a Statement of Objections, which sets forth its preliminary allegations that Teva had engaged in anti-competitive practices. On October 31, 2024, the European Commission announced its final decision, alleging that Teva had abused a dominant position in certain European member states by (i) filing and withdrawing certain divisional patents, and (ii) raising concerns about competitors' follow-on versions of COPAXONE. The decision, which Teva intends to appeal, also includes a fine of approximately $500 million (462.6 million euros). In accordance with Accounting Standards Codification 450 "Accounting for Contingencies," Teva recognized a provision in its financial statements in the third quarter of 2024, based on management's current best estimate of the outcome within a range of outcomes for the final resolution of this case. Teva intends to provide the European Commission a bank guarantee to cover at least a portion of the fine. *

 On June 29, 2021, Mylan Pharmaceuticals ("Mylan") filed claims against Teva in the U.S. District Court for the District of New Jersey. On March 11, 2022 and March 15, 2022, purported purchasers of COPAXONE filed claims against Teva in the U.S. District Court for the District of New Jersey on behalf of themselves and similarly situated direct and indirect purchasers of COPAXONE. On August 22, 2022, additional purported purchasers of COPAXONE sued Teva in the U.S. District Court for the District of Vermont on behalf of themselves and similarly situated indirect purchasers of COPAXONE. The complaints variously assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the Racketeer Influenced and Corrupt Organizations Act ("RICO Act"). Additionally, plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneys' fees and costs, and injunctive relief. Teva moved to dismiss all of the complaints, and on January 22, 2024, Teva's motion to dismiss the complaint in the District of Vermont was granted as to certain state law claims but was otherwise denied. Decisions on Teva's remaining motions to dismiss are pending.   On July 15, 2021, the U.K. Competition and Markets Authority ("CMA") issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK, Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA's three prior investigations into the supply of hydrocortisone tablets in the U.K., as well as the CMA's subsequent investigation relating to an alleged anticompetitive agreement with Waymade. On January 9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva agreed to indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to two of the three statements of objection from the CMA (dated December 16, 2016 and March 3, 2017), and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October 6, 2021, Accord UK (previously Actavis UK) and Auden Mckenzie appealed to the U.K. Competition Appeal Tribunal (the "Tribunal") the CMA's decisions that the prices of hydrocortisone were unfair and excessive and that the agreements amounted to infringements of the U.K.'s Competition Act as so-called pay-for-delay arrangements. The hearing for the appeal concluded in the first quarter of 2023, with partial judgments handed down by the Tribunal on September 18, 2023 (judgment on unfair pricing), March 8, 2024 (judgments on pay-for-delay and due process) and April 29, 2024 (judgment on fines). The CMA appealed to the U.K. Court of Appeals on an expedited basis against certain elements of the pay-for-delay and due process judgments that it had lost, and on September 6, 2024, the U.K. Court of Appeal overturned the Tribunal's judgment on due process and, as a result, the Tribunal will now consider and issue a further judgment on fines. Accord UK and Auden Mckenzie have requested permission to appeal to the U.K. Supreme Court and have submitted to the Tribunal additional applications for permission to appeal certain other issues relating to unfair pricing and fines. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements.   In November 2022, two complaints filed by plaintiffs purporting to represent retailer purchasers and a putative class of end-payor purchasers were filed in the U.S. District Court for the District of New Jersey against Teva and its marketing partner, Natco Pharma Limited ("Natco"), alleging violations of the antitrust laws in connection with their December 2015 settlement of patent litigation with Celgene Corporation (which was subsequently acquired by BMS) involving the drug Revlimid ® (lenalidomide). The complaints also name Celgene and BMS as defendants. On January 24, 2023, the complaints were consolidated for pre-trial purposes only with an earlier-filed, already consolidated Insurer Opt-Out Action filed against BMS and Celgene. On February 16, 2023, plaintiffs filed amended complaints adding additional plaintiffs. On May 16, 2023, Teva and Natco, along with Celgene, moved to dismiss the complaints against them. Additionally, on October 6, 2023, two individual payor plaintiffs brought claims similar to those described above in the U.S. District Court for the Northern District of California, which actions were transferred to the U.S. District Court for the District of New Jersey and consolidated with the pending consolidated actions. On June 6, 2024, the court granted in full Celgene's motion to dismiss the Insurer Opt-Out Action, but allowed plaintiffs leave to amend most of their claims. The Court had previously administratively terminated Teva's, Natco's, and Celgene's motions to dismiss the retailer and end-payor complaints pending the decision on the Insurer Opt-Out Action. The plaintiffs filed amended complaints on August 5, 2024, and the defendants' filed motions to dismiss on October 7, 2024. Annual sales of Revlimid ® in the United States were approximately $3.5 billion at the time of the settlement. On December 2, 2022, plaintiffs purporting to represent putative classes of indirect purchasers of EpiPen ® (epinephrine injection) and NUVIGIL ® (armodafinil) filed a complaint in the U.S. District Court for the District of Kansas against Teva, Cephalon, and a former Teva executive. Teva owns the New Drug Application ("NDA") for NUVIGIL and sold the brand product, for which generic entry occurred in 2016. Teva filed an ANDA to sell generic EpiPen ® , which Teva launched in 2018, following receipt of FDA approval. The complaint alleges, among other things, that the defendants violated federal antitrust laws, the RICO Act, and various state laws in connection with settlements resolving patent litigation relating to those products. Plaintiffs seek injunctive relief, compensatory and punitive damages, interest, attorneys' fees and costs. On September 26, 2023, plaintiffs filed a brief in opposition to Teva's motion to dismiss the amended complaint, in which plaintiffs limited their claims only to those relating to the alleged delay of generic NUVIGIL. On March 26, 2024, the court issued its decision, which granted Teva's motion in part, dismissing plaintiffs' RICO claims and certain state law claims, but denied Teva's motion regarding plaintiffs' antitrust claims. On April 26, 2024, Teva sought certification to seek an interlocutory appeal of the decision, which is still pending. Annual sales of NUVIGIL in the United States were approximately $300 million at the time Teva entered into the first settlement with an ANDA filer in 2012. In May 2023, certain end-payor plaintiffs filed putative class action complaints in the U.S. District Court for the District of Massachusetts against Teva and a number of its affiliates, alleging that Teva engaged in anticompetitive conduct to suppress generic competition to its branded QVAR ® asthma inhalers in violation of state and federal antitrust laws and state consumer protection laws. Teva moved to dismiss these claims, and on May 7, 2024, the court granted Teva's motion in part and denied its motion in part. The court dismissed plaintiffs' claim that Teva had engaged in "sham litigation" and certain of plaintiffs' state antitrust and consumer protection claims, but permitted the case to proceed on the remainder of plaintiffs' allegations. Following this decision, two direct purchaser plaintiffs filed similar putative class action complaints in the U.S. District Court for the District of Massachusetts. On June 18, 2024, Teva answered in all cases and simultaneously moved for judgment on the pleadings pursuant to Rule 12(c), which remains pending. Subsequently, on June 28, 2024, Teva stipulated to the dismissal of the two direct purchaser plaintiffs' claims, with prejudice. Government Investigations and Litigation Relating to Pricing and Marketing Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice ("DOJ") Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August 25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three-count indictment charging Teva USA with criminal felony Sherman Act violations. The indictment alleged that Teva USA had participated in three separate conspiracies with other   generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: pravastatin, carbamazepine, clotrimazole, etodolac (IR and ER), fluocinonide (cream, e-cream, gel, and ointment), warfarin, nadolol, temozolomide, and tobramycin. On August 21, 2023, Teva USA entered into a 3-year deferred prosecution agreement ("DPA") with the DOJ. Under the terms of the DPA, Teva USA: (i) admitted to violating the antitrust laws by agreeing with competitors, in three instances between 2013 and 2015 involving three separate customers, not to bid on an opportunity to supply a customer with a particular generic product (in the first instance pravastatin, in the second clotrimazole, and in the third tobramycin); (ii) agreed to divest the pravastatin that it sells in the United States to a third-party buyer; (iii) agreed to donate $50 million worth of clotrimazole and tobramycin, valued at wholesale acquisition cost ("WAC"), to humanitarian organizations over five years; and (iv) agreed to pay a fine in the amount of $225 million over 5 years, with $22.5 million due each year from 2024 through 2027, and $135 million due in 2028. Teva recognized a provision for the resolution of this case. In May 2018, Teva received a civil investigative demand from the DOJ Civil Division pursuant to the federal False Claims Act, seeking documents and information produced since January 1, 2009 relevant to the Civil Division's investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and/or price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. On October 10, 2024, Teva entered into a settlement agreement with the Civil Division to resolve these allegations. Teva will pay $25 million under the terms of the settlement -- $10 million in the fourth quarter of 2024, and $15 million in 2025 -- which includes no admission of wrongdoing. Teva has recognized a provision for the resolution of this matter. In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. On December 15, 2016, the civil action that was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States was subsequently amended to include 49 states, as well as the District of Columbia and Puerto Rico as plaintiffs, and to add new allegations and state law claims against both Actavis and Teva. On May 10, 2019, most of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, which was subsequently amended on November 1, 2019, alleging that Teva was at the center of a conspiracy in the generic pharmaceutical industry and asserting that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain products. On June 10, 2020, most of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the U.S. District Court for the District of Connecticut naming, among other defendants, Actavis, in a similar complaint relating to dermatological generics products, and that complaint was later amended to, among other things, add California as a plaintiff. In the various complaints described above, which also include claims against certain former employees of Actavis and Teva USA, the states seek a finding that the defendants' actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints were transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania ("Pennsylvania MDL"). On May 7, 2021, the Pennsylvania MDL court chose the attorneys general's third complaint filed on June 10, 2020, as subsequently amended, to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. On June 7, 2022, the Court dismissed the attorneys general's claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law. On February 27, 2023, the Court largely denied defendants' motions to dismiss the federal claims asserted by the attorneys general in their bellwether complaint. Another motion to dismiss related to the state law claims asserted by the attorneys general in their bellwether complaint remains pending. Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022), Florida (in February 2023), Kentucky (in June 2023), South Dakota (in June 2024), and New Mexico (in June 2024). Teva paid each state an amount proportional to its share of the national population (approximately $1,000,000 for each 1% share of the national population), and the states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. These settlements, in addition to the status of ongoing negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times

New Roman;text-align:center"> attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022. The States of Alabama (in March 2022) and Hawaii (in August 2023) and the territories of American Samoa (in July 2020) and Guam (in February 2023) have all voluntarily dismissed all of their claims in the litigation against Actavis and Teva USA. The dismissals by Alabama, Hawaii and Guam were with prejudice and the dismissal by American Samoa was without prejudice. Beginning on March 2, 2016, and through July 2023, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser opt-out plaintiffs, including most recently an opt-out complaint filed by nine direct-action plaintiffs on April 4, 2024. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. The Pennsylvania MDL court scheduled potential bellwether trials for the putative classes of direct and indirect purchasers of two drugs for August 2024. From 2019 to 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis. One plaintiff, Aetna Inc., has filed a complaint, and the defendants have moved to place all of the cases filed in the Court of Common Pleas of Philadelphia County in deferred status, which motion remains pending. Certain counties in New York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. On January 31, 2024, the attorney generals' motion to remand their three lawsuits to the District of Connecticut, where they were originally filed, was granted, and on March 18, 2024, the Third Circuit Court of Appeals denied defendants' petition for writ of mandamus . In April 2024, all three of the attorneys general's lawsuits have been transferred back to the U.S. District Court for the District of Connecticut, which has adopted a schedule for summary judgment in the attorneys general's third complaint pursuant to which multiple groups of motions will be filed during 2024 and 2025. Fact discovery in the first and second complaints is ongoing. There is also one similar complaint brought in Canada, which is in its early stages and alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. In March 2017, Teva received a subpoena from the U.S. Attorney's office in Boston, Massachusetts requesting documents related to Teva's donations to patient assistance programs. In August 2020, the U.S. Attorney's office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging causes of action under the federal False Claims Act and for unjust enrichment (the "DOJ PAP Complaint"). It was alleged that Teva's donations to certain 501(c)(3) charities that provided financial assistance to multiple sclerosis patients violated the Anti-Kickback Statute, and the DOJ sought a maximum of over $1 billion in damages, which would automatically be trebled in the event of an adverse verdict, and Teva would also be subject to mandatory statutory penalties for each false claim, the amount of which (potentially billions of U.S. dollars in additional penalties, at the high end) would be determined by the court within a statutory range. On October 10, 2024, Teva entered into a settlement agreement with the DOJ to resolve these claims. Teva will pay $425 million over 6 years under the terms of the settlement – $19 million in the fourth quarter of 2024, $34 million in 2025, $49 million in each of 2026 and 2027, $99 million in 2028, and $175 million in 2029 – which includes no admission of wrongdoing. Teva has recognized a provision for the resolution of this case. Additionally, on January 8, 2021, Humana, Inc. ("Humana") filed an action against Teva in the U.S. District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. In June 2023, Teva filed a joint motion to dismiss the amended complaint, together with co-defendant Advanced Care Scripts, Inc., on the grounds that Humana lacks standing to assert RICO claims and the claims are time-barred and/or insufficiently pled, and that motion remains pending. On November 17, 2022, United Healthcare also filed an action against Teva in the U.S. District Court for the District of New Jersey based on the conduct alleged in the DOJ PAP Complaint, and on February 29, 2024, United Healthcare filed an amended complaint. On August 16, 2024, several MSP Recovery-related entities filed a putative class action against Teva and others in the U.S. District Court for the District of Kansas based on the alleged conduct in the DOJ PAP Complaint.   In April 2021, a city and county in Washington filed claims against Teva in the U.S. District Court for the Western District of Washington for alleged violations of the RICO Act, Washington's Consumer Protection Act, and unjust enrichment concerning Teva's sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On November 17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs' claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. On March 9, 2023, the court held a hearing on the motion to dismiss, and a decision remains pending. On December 1, 2022, Teva received a civil subpoena from the U.S. Attorney's office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDO ® and risperidone LAI. Teva is cooperating with the request for documents. In June 2024, Teva received a civil investigative demand from the Federal Trade Commission ("FTC") seeking documents and information regarding an investigation related to patents listed in the Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations publication ("Orange Book") in connection with certain inhaler products. Teva is cooperating with the request for documents and information. On October 1, 2024, Teva received a civil investigative demand from the U.S. Attorney's office in Boston, Massachusetts and the Civil Division of the Department of Justice requesting certain documents and information related to the manufacturing practices at its former manufacturing facility in Irvine, California, which Teva closed in 2022. Teva is cooperating with the request for documents and information. Opioids Litigation Since May 2014, more than 3,500 complaints have been filed by various governmental agencies and private plaintiffs in U.S. state and federal courts with respect to opioid sales and distribution against various Teva affiliates and several other pharmaceutical companies, the vast majority of which have been resolved. Cases brought by third party payers, both as individual cases and as class actions, remain. The majority of the remaining cases are consolidated in the multidistrict litigation in the Northern District of Ohio (the "MDL Opioid Proceeding"). These cases assert claims under similar provisions of different state laws and generally allege that the defendants engaged in improper marketing and distribution of Teva's branded opioids, including ACTIQ ® and FENTORA ® , and also assert claims related to Teva's generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding. Furthermore, approximately 100 personal injury complaints allege that Anda (in addition to naming other distributors and manufacturers) failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent their abuse and diversion. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages, non-economic damages, attorneys' fees and injunctive relief. Certain plaintiffs seek damages for all costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. All but a handful of these cases are stayed in the MDL Opioid Proceedings. In June 2023, Teva finalized and fully resolved its nationwide settlement agreement with the states and litigating subdivisions. Under the financial terms of the nationwide settlement agreement with the states and subdivisions, Teva will pay up to $4.25 billion (including the already settled cases), spread over 13 years. This total includes the supply of up to $1.2 billion of Teva's generic version of Narcan ® (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 10 years or cash at 20% of the wholesale acquisition cost ($240 million) in lieu of product. In September 2024, Teva reached and finalized an agreement with the City of Baltimore to settle its opioid-related claims for a total of $80 million (of which $35 million will be paid by the end of 2024 and the remainder will be paid by July 1, 2025), averting a trial that was scheduled to begin on September 16, 2024.   With its settlement with the City of Baltimore, Teva has settled with 100% of the U.S. states and litigating political subdivisions and the Native American tribes (the "Tribes"). Teva's estimated cash payments between 2024 and 2028 for all opioids settlements are: $428 million payable in 2024 (of which $392 million was paid as of September 30, 2024), $423 million payable in 2025; $368 million payable in 2026; $374 million payable in 2027; and $390 million payable in 2028. These payments are subject to change based on various factors including, but not limited to, timing of payments, most favored nations clauses associated with prior settlements, and the states' elections to take Teva's generic version of Narcan ® (naloxone hydrochloride nasal spray). The remaining payments, subject to adjustments, will be paid beyond 2028. Various Teva affiliates, along with several other pharmaceutical companies, were named as defendants in opioids cases initiated by approximately 500 U.S. hospitals and other healthcare providers asserting opioid-related claims, including public nuisance. Specifically, the lawsuits brought by the hospitals allege that they have incurred financial harm from increased operating costs for treating patients whose underlying illnesses are purportedly exacerbated or complicated by opioid addiction. In September 2024, Teva and the representatives for acute care hospitals finalized the terms of a proposed settlement agreement. Under the financial terms of the proposed national settlement agreement, Teva will pay up to $126 million in cash, spread over 18 years, and supply up to $49 million of Teva's generic version of Narcan ® (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 7 years. The proposed settlement agreement is contingent upon Teva's satisfaction, in its sole discretion, with the level of participation by acute care hospitals and health care systems in the proposed settlement agreement. In light of the nationwide settlement agreement between Teva and the States' Attorneys General and their subdivisions, Teva's indemnification obligations arising from Teva's acquisition of the Actavis Generics business for opioid-related claims, prior settlements reached with Louisiana, Texas, Rhode Island, Florida, San Francisco, West Virginia, New York, the Tribes, Nevada and the City of Baltimore, the agreement in principle with the hospitals discussed above, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has recorded a provision. The provision is a reasonable estimate of the ultimate costs for Teva's opioids settlements, after discounting payments to their net present value. Opioid-related lawsuits brought against Teva by dozens of third-party payers, such as unions and welfare funds, remain pending. A reasonable upper end of a range of loss cannot be determined for the entirety of the remaining opioid-related cases. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and adverse effect on Teva's reputation, business, results of operations and cash flows. In addition, Teva, certain of its subsidiaries and other defendants, are defending claims and putative class action lawsuits in Canada related to the manufacture, sale, marketing and distribution of opioid medications. The lawsuits include a claim by the Province of British Columbia on behalf of itself and a putative class of other federal and provincial governments, and claims of municipalities, First Nations, and persons who used opioids on behalf of themselves and putative classes. In November and December 2023, the British Columbia Supreme Court held a hearing regarding preliminary motions, including plaintiffs' certification motion, which remain pending. Shareholder Litigation On November 6, 2016 and December 27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits subsequently were consolidated and transferred to the U.S. District Court for the District of Connecticut (the "Ontario Teachers Securities Litigation"). On December 13, 2019, the lead plaintiff filed an amended complaint, purportedly on behalf of purchasers of Teva's securities between February 6, 2014 and

May 10, 2019, asserting that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva's alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. From July 2017 to June 2019, other putative securities class actions were filed in other federal courts based on similar allegations and claims, and were transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors on behalf of plaintiffs in various forums across the country, but many of those plaintiffs "opted-out" of the Ontario Teachers Securities Litigation. On January 18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $420 million, which received final approval from the court on June 2, 2022. The vast majority of the total settlement amount was covered by the Company's insurance carriers, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. On January 22, 2021, the Court dismissed the "opt-out" plaintiffs' claims arising from statements made prior to the five-year statute of repose, but denied Teva's motion to dismiss their claims under Israeli laws. Teva has settled the majority of the "opt-out" claims, and one opt-out case remains outstanding. Teva also reached a settlement with shareholders who filed class actions in Israel with similar allegations to those raised in the Ontario Teachers Securities Litigation, which was approved by the court in Israel in November 2023.   On September 23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On August 10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between October 29, 2015 and August 18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Teva's donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE's commercial success and the sustainability of its revenues and resulted in the DOJ PAP Complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On August 2, 2022, the court stayed all proceedings other than class certification proceedings pending the resolution of the DOJ PAP Complaint. On November 3, 2023, the court granted plaintiff's motion for class certification. On November 17, 2023, Teva filed a petition with the Third Circuit Court of Appeals for leave to appeal the class certification ruling, which was denied on May 16, 2024. On August 30, 2024, the court lifted the stay. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. Environmental Matters Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva's facilities or former facilities. Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of clean-up and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva's potential liability varies greatly at each of the sites; for some sites the costs of the investigation, clean-up and natural resource damages have not yet been determined, and for others Teva's allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of clean-up costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva's facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva's results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. Item 103 of Regulation S-K promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less than $300,000. The following matter is disclosed in accordance with that requirement. On July 8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva's subsidiary in India, Teva API India Private Limited, finding non-compliance with environmental laws and assessed a penalty of $1.4 million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On August 5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunal's order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business.   Other Matters On February 1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon's acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery. Among other things, the plaintiffs alleged that Cephalon had breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR ® (reslizumab) for the treatment of eosinophilic esophagitis ("EE"). The plaintiffs claimed damages of at least $200 million, an amount they alleged was equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). On December 28, 2018, following defendants' motion to dismiss the complaint, the court granted the motion in part and dismissed all of plaintiffs' claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA. However, on July 12, 2022, plaintiffs filed a new amended complaint that included claims against Teva USA but not the Company, in exchange for Teva USA's agreement to guarantee any judgment entered against Cephalon in the litigation. A bench trial for this matter was held in September 2022 and on April 30, 2024, the court issued a memorandum opinion in favor of Cephalon and Teva USA, finding that they did not breach the merger agreement as plaintiffs had alleged. Plaintiffs have appealed that ruling to the Delaware Supreme Court, and the appeal remains pending. Gain Contingencies From time to time, Teva may directly or indirectly pursue claims against certain parties, including but not limited to patent infringement lawsuits against other pharmaceutical companies to protect its patent rights, as well as derivative actions brought on behalf of Teva. Teva recognizes gain contingencies from the defendants in such lawsuits when they are realized or when all related contingencies have been resolved. No gain has been recognized regarding the matters disclosed below, unless mentioned otherwise. In October 2017, Teva filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli Lilly & Co.'s ("Lilly") marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review ("IPR") petitions to the Patent Trial and Appeal Board ("PTAB"), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on August 16, 2021. A jury trial regarding the three method of treatment patents resulted in a verdict in Teva's favor on November 9, 2022, in which the three method of treatment patents were determined to be valid and infringed by Lilly and Teva was awarded $176.5 million in damages. On September 26, 2023, the U.S. District Court for the District of Massachusetts issued a decision that reversed the jury's verdict and damages award, finding Teva's method of treatment patents to be invalid. Teva filed its opening appeal brief on February 2, 2024 and Lilly filed its responsive brief on April 19, 2024. Teva filed its responsive brief on May 29, 2024, and Lilly's final brief was filed on July 19, 2024. No date has been set for the appeal hearing. In March 2024, Teva filed a lawsuit in the U.S. District Court for the District of New Jersey alleging that Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited, and Amarin Corporation plc (collectively "Amarin") engaged in a decade-long scheme to lock up the supply of icosapent ethyl to prevent and delay generic competition to its branded Vascepa ® drug product. Teva's lawsuit coincides with four other lawsuits brought by generic drug manufacturers and purchasers of branded Vascepa ® alleging the same or similar conduct by Amarin. Teva's requested relief includes compensatory damages for lost sales and lost profits from generic icosapent ethyl drug sales that Teva could have made absent Amarin's alleged interference. On May 24, 2024, Amarin filed a motion in the U.S. District Court for the District of Nevada, seeking to enforce the terms of an earlier Teva-Amarin agreement to settle patent litigation regarding Vascepa ® , which Amarin asserts precludes Teva from filing the present antitrust action. Teva opposed this motion on June 7, 2024, and Amarin's motion remains pending. As the lawsuit is still in its initial stages, it is not possible to predict its outcome and there is no guarantee that Teva will be granted its requested relief. In June 2024, Teva filed a lawsuit in the U.S. District Court for the Northern District of California alleging that Corcept Therapeutics, Inc. ("Corcept"), and Optime Care Inc. ("Optime") have engaged in a multifaceted, years-long scheme to stifle generic competition to Corcept's branded Korlym ® (mifepristone) drug product, which is indicated to treat endogenous Cushing's syndrome. Teva alleges that Corcept and Optime have suppressed competition by abusing the   patent and judicial systems, entering a long-term, blanket exclusive-dealing agreement that has locked up a key pharmaceutical distribution channel, and making illicit payments to physicians as compensation for prescribing Korlym ® . Teva's requested relief includes compensatory damages for lost sales and lost profits from generic mifepristone drug sales that Teva could have made absent Corcept and Optime's alleged interference, as well as injunctive relief to remove the unlawful barriers to generic competition created by Corcept and Optime. As the lawsuit is still in its initial stages, it is not possible to predict its outcome and there is no guarantee that Teva will be granted its requested relief. Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness, as well as motions for document disclosure prior to initiating derivative actions. Motions were filed with respect to several U.S. and EU settlement agreements, opioids, allegations related to the DOJ's complaint regarding the COPAXONE patient assistance program in the U.S., and with respect to the European Commission's investigation relating to COPAXONE. In May 2024, Teva settled the derivative action related to the opioids litigation, and on September 16, 2024, the settlement received final approval from the Tel Aviv District Court.
2355000002600000000950000000230000000041600000011000000003500000001400000007000000006050000058200000024000000002900000000728000000210000000
  NOTE 11 – Income taxes: In the third quarter of 2024, Teva recognized a tax expense of $69 million, on a pre-tax loss of $324 million. In the third quarter of 2023,

Teva recognized a tax benefit of $12 million, on a pre-tax income of $64 million. Teva's tax rate for the third quarter of 2024 was mainly impacted by impairment charges with no corresponding tax effects, an adjustment to the Company's corporate tax rate in Israel on losses related to non-qualified tax incentive activities in Israel, legal expenses with no corresponding tax effect related to the fine issued by the European Commission in connection with its antitrust investigation into COPAXONE, and recording of valuation allowance with respect to certain carry over credits outside of Israel. Teva's tax rate for the third quarter for 2023 was mainly affected by deferred tax benefits resulting from intellectual property related integration plans, which have been adopted, among others, in an effort of addressing the global adoption of the Organization for Economic Co-operation and Development (OECD) Pillar Two minimum effective corporate tax. The pre-tax loss in the third quarter of 2023 was revised as discussed in note 1c. In the first nine months of 2024, Teva recognized a tax expense of $648 million, on a pre-tax loss of $1,037 million. In the first nine months of 2023, Teva recognized a tax benefit of $48 million, on a pre-tax loss of $1,131 million. Teva's tax rate for the first nine months of 2024 was mainly impacted by a settlement agreement with the Israeli Tax Authorities ("ITA") as discussed below, impairment charges with no corresponding tax effects, deferred tax benefits resulting from intellectual property related integration plans, an adjustment to the Company's corporate tax rate in Israel on losses related to non-qualified tax incentives activities in Israel, legal expenses with no corresponding tax effect related to the fine issued by the European Commission in connection with its antitrust investigation into COPAXONE, and recording of valuation allowance with respect to certain carry over credits outside of Israel. Teva's tax rate for the first nine months of 2023 was mainly affected by deferred tax benefits from intellectual property related integration plans, impairments, legal settlements, and interest expense disallowances. The pre-tax loss in the first nine months of 2023 was revised as discussed in note 1c. The statutory Israeli corporate tax rate is 23% in 2024. Teva's global tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits, as well as infrequent or non-recurring items. Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. A trial for this case is currently ongoing. A final and binding decision against Teva in this case may lead to a charge of $125 million. On June 23, 2024, Teva entered into an agreement with the ITA to settle certain litigation with respect to taxes payable for the Company's taxable years 2008 through 2020 (the "Agreement"). Pursuant to the terms of the Agreement, the Company will pay a total amount of approximately $750 million to the ITA spread over a six-year period beginning this year. The Company has the right to prepay, and amounts paid over time are subject to interest and increase for inflation. Such total amount includes: (i) $495 million in corporate taxes with respect to the Company's historical earnings that were previously considered by the Company to be exempt from taxes under the Encouragement for Capital Investment Law; and (ii) approximately $250 million in corporate taxes, relating to additional disputed tax issues in the aforementioned taxable years. The Agreement resulted in an increase of $506 million in the Company's total income taxes in the second quarter of 2024, as certain elements had been recognized in previous periods. Additionally, under the terms of the Agreement, it was further agreed that in the future event the Company pays dividends on, or repurchases, its equity interests, the Company will pay an additional 5%-7% of the amount of such dividends or repurchases in corporate taxes, up to a maximum tax payment amount of approximately $500 million. Any amounts due under this provision of the Agreement will be recorded in the future as incurred. Teva believes it has adequately provided for all of its uncertain tax positions, including items currently under dispute, however, adverse results could be material. The OECD introduced Base Erosion and Profit Shifting ("BEPS") Pillar Two rules that impose a global minimum tax rate of 15% for large multinational corporations. On December 12, 2022, the EU Council announced that EU member states had reached an agreement to implement the minimum taxation component of 15% of the OECD's reform of international taxation. Other countries have also enacted or are expected to enact legislation to be effective as early as January 1, 2024, with general implementation of a global minimum tax by January 1, 2025. Teva has evaluated the potential impact on its 2024 consolidated financial statements and related disclosures and does not expect Pillar Two to have a material impact on its effective tax rate or consolidated financial statements in the foreseeable future.   69000000-324000000-1200000064000000648000000-1037000000-4800000011310000000.231250000007500000000P6Y4950000002500000005060000000.050.075000000000.150.15   NOTE 12 – Other assets impairments, restructuring and other items: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:74%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> Three months ended </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> Nine months ended </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Impairments of long-lived tangible assets (1) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">589</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Contingent consideration (2) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">305</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Restructuring </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-

align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">931</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">276</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"> Including impairments related to exit and disposal activities. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(2)</td> <td style="vertical-align:top;text-align:left;"> The contingent consideration presented in the tables above for the three and nine months ended September 30, 2023 have been revised as discussed in note 1c. </td> </tr> </table> Impairments In the three months ended September 30, 2024, Teva recorded an income of $ 80 million under impairments of tangible assets, compared to an expense of $ 1 million in the three months ended September 30, 2023. The income for the three months ended September 30, 2024 was mainly related to a favorable adjustment to the changes of the expected loss from reclassification of currency translation adjustments, partially offset by an additional impairment due to fair value update in connection with the classification of the business venture in Japan as held for sale. See note 2. Impairments of tangible assets for the nine months ended September 30, 2024 and 2023 were $589 million and $21 million, respectively. The impairment for the nine months ended September 30, 2024 was mainly related to the classification of the business venture in Japan as held for sale (see note 2). The impairments for the nine months ended September 30, 2023 were mainly related to certain assets in the U.S. and Europe. Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its ongoing network consolidation activities and its “Pivot to Growth Strategy”. Contingent consideration In the three months ended September 30, 2024, Teva recorded an expense of $34 million for contingent consideration, compared to an expense of $27 million in the three months ended September 30, 2023. The expenses in the three months ended September 30, 2024 were mainly due to the effect of the passage of time on the net present value of the discounted payments. The expenses in the three months ended September 30, 2023 were mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of Revlimid ®) and a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The expense in the three months ended September 30, 2023 was revised as discussed in note 1c. In the nine months ended September 30, 2024, Teva recorded an expense of $305 million for contingent consideration, compared to an expense of $140 million in the nine months ended September 30, 2023. The expenses in the first nine months of 2024 and 2023 were mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of Revlimid ®) and a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The expense in the first nine months of 2023 was revised as discussed in note 1c. Restructuring In the three months ended September 30, 2024, Teva recorded $21 million of restructuring expenses, compared to $27 million in the three months ended September 30, 2023. Expenses for the three months ended September 30, 2024 and 2023 were primarily related to network consolidation activities.   In the nine months ended September 30, 2024, Teva recorded $52 million of restructuring expenses, compared to $93 million in the nine months ended September 30, 2023. The expenses for the nine months ended September 30, 2024 and 2023 were primarily related to network consolidation activities. The following tables provide the components of the Company’s restructuring costs: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:70%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Restructuring </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Employee termination </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>   <table

cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:70%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Restructuring </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Employee termination </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom">   </td> <td></td> </tr> </table> The following table provides the components of and changes in the Company's restructuring accruals.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:65%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Employee termination <br/> costs </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance as of January 1, 2024 </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(82</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Provision</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Utilization and other*</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance as of September 30, 2024</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(56</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(70</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom">   </td> <td></td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:65%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Employee termination <br/> costs </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top:

0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance as of January 1, 2023 </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(112</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(119</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Provision</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Utilization and other*</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance as of September 30, 2023</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(82</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Includes adjustments for foreign currency translation. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:74%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> Three months ended </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> Nine months ended </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Impairments of long-lived tangible assets (1) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">589</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Contingent consideration (2) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">305</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Restructuring </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:

normal;"> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">931</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">276</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left,">(1)</td> <td style="vertical-align:top;text-align:left,"> Including impairments related to exit and disposal activities. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left,">(2)</td> <td style="vertical-align:top;text-align:left,"> The contingent consideration presented in the tables above for the three and nine months ended September 30, 2023 have been revised as discussed in note 1c. </td> </tr> </table>
-8000000010000005890000002100000034000000270000003050000001400000002100000027000000520000009300000010000002000000-1600000021000000-2300000057000000931000000276000000800000001000000589000000210000003400000027000000305000000140000000210000002700000052000000930000000 The following tables provide the components of the Company's restructuring costs: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:70%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Restructuring </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Employee termination </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:70%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Restructuring </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Employee termination </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height:

normal;"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
130000001600000080000001200000021000000270000003300000040000001900000053000000520000009300000 The following table provides the components of and changes in the Company's restructuring accruals: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:65%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Employee termination <br/> costs </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance as of January 1, 2024 </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (82</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Provision</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Utilization and other*</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance as of September 30, 2024</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(56</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(70</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:65%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Employee termination <br/> costs </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Other </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance as of January 1, 2023 </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(112</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(119</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Provision</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Utilization and other*</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Balance as of September 30, 2023</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(82</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-

top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Includes adjustments for foreign currency translation. </td> </tr> </table>
750000007000000820000003300000019000000520000005200000012000000640000005600000014000000700000001120000007000000119000000400000005300000093(
    NOTE 13 - Earnings (Loss) per share: Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva's ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units ("RSUs") and performance share units ("PSUs") during the period, net of treasury shares. In computing diluted loss per share for the three months ended September 30, 2024, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. In computing diluted earnings per share for the three months ended September 30, 2023, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. In computing diluted loss per share for the nine months ended September 30, 2024 and 2023, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended September 30, 2024 and 2023 were 1,133 million shares and 1,135 million shares, respectively. The weighted average diluted shares outstanding used for the fully diluted share calculations for the nine months ended September 30, 2024 and 2023 were 1,130 million shares and 1,119 million shares, respectively. Basic and diluted loss per share w as $0.39 for the three months ended September 30, 2024, compared to basic and diluted earnings per share of $0.06 for the three months ended September 30, 2023. Basic and diluted earnings per share for the three months ended September 30, 2023 w ere revised as discussed in note 1c. Basic and diluted loss per share was $1.26 for the nine months ended September 30, 2024, compared to basic and diluted loss per share of $0.91 for the nine months ended September 30, 2023. Basic and diluted loss per share for the nine months ended September 30, 2023 w ere revised as discussed in note 1c. 0011330000001135000000113000000011190000000-0.39-0.390.060.06-1.26-1.26-0.91-0.91   NOTE 14 - Accumulated other comprehensive income (loss): The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:58%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td> </td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Net Unrealized Gains (Losses) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Benefit Plans </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Foreign <br/> currency <br/> translation <br/> adjustments </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Derivative <br/> financial <br/> instruments </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Actuarial gains
 (losses) and <br/> prior service
 (costs) credits </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="14" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance as of December 31, 2023, net of taxes </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,384</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(266</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(46</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,697</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other comprehensive income (loss) before reclassifications </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Amounts reclassified to the statements of income </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height:

normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div
style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Net
other comprehensive income (loss) before tax</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65</td> <td
style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top:
1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-
top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px;
margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr
style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt;
margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Corresponding income
tax</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top:
1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-
top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px;
margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New
Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family:
"Times New Roman"; line-height: normal;">Net other comprehensive income (loss) after tax*</div> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(91</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(72</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top:
1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-
top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px;
margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td
style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New
Roman"; line-height: normal;">Balance as of September 30, 2024, net of taxes</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,475</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(245</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(48</td> <td style="white-space:nowrap;vertical-
align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">(2,769</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-
align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px
double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double
rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px;
margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-
bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0);
border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;">
</div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-
COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-
align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times
New Roman"; text-align: left; line-height: normal;">Amounts do not include a $6 million loss from foreign currency translation adjustments attributable to <div
style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-controlling</div> interests. </div> </td> </tr> </table> <div style="font-size: 12pt;
margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New
Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:58%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td>
<td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td>
<td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman;
font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6"
style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">Net Unrealized Gains (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align:
bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing:
0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Benefit Plans</div></div></td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-
bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">Foreign</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">currency</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">translation</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">adjustments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">Derivative</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">financial</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">instruments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial gains</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div
style="font-weight:bold;display:inline;">(losses) and</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">prior service</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(costs)
credits</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td
colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div
style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-
inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="14"
style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)
</div></div></td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-
color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family:
"Times New Roman"; line-height: normal;">Balance as of December 31, 2022, net of taxes</div> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,514</td> <td style="white-
space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(295</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td>

<td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,838</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other comprehensive income (loss) before reclassifications </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Amounts reclassified to the statements of income </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Net other comprehensive income (loss) before tax </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Corresponding income tax </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(50</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(50</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Net other comprehensive income (loss) after tax* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(89</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance as of September 30, 2023, net of taxes </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,603</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(276</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,910</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Amounts do not include a $84 million loss from foreign currency translation adjustments attributable to

style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-controlling interests. </td> </tr> </table> The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:58%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td> </td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td> </td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Net Unrealized Gains (Losses) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Benefit Plans </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Foreign <br/> currency <br/> translation <br/> adjustments </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Derivative <br/> financial <br/> instruments </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Actuarial gains
 (losses) and <br/> prior service
 (costs) credits </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="14" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance as of December 31, 2023, net of taxes </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,384</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(266</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(46</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,697</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other comprehensive income (loss) before reclassifications </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Amounts reclassified to the statements of income </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Net other comprehensive income (loss) before tax </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Corresponding income tax </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Net other comprehensive income (loss) after tax* </td> <td style="vertical-align:bottom"> </td> <td

style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(91</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:top"> Balance as of September 30, 2024, net of taxes </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,475</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(245</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(48</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,769</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Amounts do not include a $6 million loss from foreign currency translation adjustments attributable to non-controlling interests. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:58%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Net Unrealized Gains (Losses) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Benefit Plans </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Foreign <br/> currency <br/> translation <br/> adjustments </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Derivative <br/> financial <br/> instruments </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Actuarial gains
 (losses) and <br/> prior service
 (costs) credits </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="14" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance as of December 31, 2022, net of taxes </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,514</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(295</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,838</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other comprehensive income (loss) before reclassifications </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Amounts reclassified to the statements of income </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div

style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Net other comprehensive income (loss) before tax </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Corresponding income tax </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(50</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(50</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Net other comprehensive income (loss) after tax* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(89</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(72</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Balance as of September 30, 2023, net of taxes </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,603</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(276</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,910</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Amounts do not include a $84 million loss from foreign currency translation adjustments attributable to non-controlling interests. </td> </tr> </table> -2384000000-266000000-46000000-2697000000-840000001000000-83000000-2100000003000000-18000000-8400000021000000-2000000-650000007000000700000-9100000021000000-2000000-72000000-2475000000-245000000-48000000-27690000006000000-2514000000-295000000-28000000-2838000000-39000000-5000000-44000000-240000002000000-22000000-3900000019000000-2000000-220000005000000050000000-8900000019000000-2000000-72000000-2603000000-276000000-3000000029100000000840000000 NOTE 15 - Segments. Teva operates its business and reports its financial results in three segments : (a) United States segment. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries other than the United States and countries included in the Europe segment. In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Teva's Chief Executive Officer ("CEO"), who is the chief operating decision maker ("CODM"), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely United States, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva's CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. Teva's CEO may review its strategy and organizational structure from time to time. Based on such review, in May 2023 Teva launched its new Pivot to Growth strategy. Any additional changes in strategy may lead to a reevaluation of the Company's segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. In conjunction with a recent shift in executive management responsibilities and in alignment with Teva's Pivot to Growth strategy, Teva decided that Canada is no longer included as part of Teva's North America segment as of January 1, 2024. From that date Canada is reported as part of the Company's International Markets segment and Teva's North America segment has been renamed the United States segment. Teva aligned its internal financial and segment reporting and its reporting units in accordance with this change effective January 1, 2024. Prior period amounts have been recast to conform to the reporting structure for the current year. On January 31, 2024, Teva announced that it intends to divest its API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with Teva's Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be agreed or completed at all.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"> a. </td> <td style="vertical-align:top;text-align:left;"> Segment information: </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0

auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Revenues </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,225</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">613</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Gross profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">306</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">R&D expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">S&M expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">G&A expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other<div style="display:inline;"> loss</div> <div style="display:inline;">(</div>income<div style="display:inline;">)</div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Segment profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">748</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">373</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:60%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Revenues </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,896</td> <td style="white-space:nowrap;vertical-

align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">591</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Gross profit </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,060</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">648</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">293</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> R&D expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">156</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> S&M expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">243</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">184</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">116</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> G&A expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other loss (income) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Segment profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">338</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td colspan="4" style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Revenues </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,060</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,749</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,802</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Gross profit </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,291</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,113</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> R&D expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">475</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">173</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> S&M expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">789</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">605</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">397</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> G&A expenses </td> <td style="vertical-align:bottom"> </td> <td

style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">300</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">197</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other loss (income) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Segment profit </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,727</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,137</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td colspan="12" style="height:12pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Revenues </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,465</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,493</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Gross profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,866</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">861</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">R&D expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">460</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">168</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">S&M expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">565</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">G&A expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">289</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other <div style="display:inline;">loss (</div>income<div style="display:inline;">)</div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Segment profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,017</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">356</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>   The following table presents a reconciliation of Teva's segment profits to its consolidated operating income

(loss) and to consolidated income (loss) before income taxes for the three and nine months ended September 30, 2024 and 2023 </br/>   <table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"> <tr> <td style="width: 70%;"> </td> <td style="width: 4%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td style="width: 3%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 3%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 3%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="6" style="vertical-align: bottom;text-align:center;"> Three months ended </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="6" style="vertical-align: bottom;text-align:center;"> Nine months ended </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> United States profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">748</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,727</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Europe profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">373</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">338</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,137</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,017</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> International Markets profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">356</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Total reportable segments profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,230</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,163</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,794</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> Profit (loss) of other activities </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-

<table>
<tr><td>Total segments profit</td><td></td><td>1,214</td><td></td><td></td><td>1,020</td><td></td><td></td><td>3,162</td><td></td><td></td><td>2,816</td></tr>
<tr><td>Amounts not allocated to segments:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td>Amortization</td><td></td><td>146</td><td></td><td>145</td><td></td><td></td><td>444</td><td></td><td>471</td></tr>
<tr><td>Other assets impairments, restructuring and other items*</td><td></td><td>(23</td><td></td><td></td><td>931</td><td></td><td>276</td><td></td></tr>
<tr><td>Goodwill impairment</td><td></td><td>600</td><td></td><td>—</td><td></td><td>1,000</td><td></td><td>700</td></tr>
<tr><td>Intangible assets impairments</td><td></td><td>28</td><td></td><td>47</td><td></td><td></td><td>169</td><td></td><td>289</td></tr>
<tr><td>Legal settlements and loss contingencies</td><td></td><td></td><td></td><td>64</td><td></td><td></td><td>112</td><td></td><td>254</td><td></td><td>394</td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td>Consolidated operating income (loss) *</td><td></td><td>(51</td><td></td><td>344</td><td></td><td></td><td>(274</td><td></td><td>323</td><td></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td>Financial expenses, net</td><td></td><td></td><td></td><td>272</td><td></td><td></td><td>280</td><td></td><td>763</td><td></td><td>808</td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
</table>

bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Consolidated income (loss) before income taxes * </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(324</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,037</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,131</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. </td> </tr> </table> b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for the three and nine months ended September 30, 2024 and 2023.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:80%"></td> <td style="vertical-align:bottom;width:4%"></td> <td> </td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">United States</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended
 September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,094</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">839</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"> <td style="vertical-align:bottom"> AJOVY ® </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> AUSTEDO </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">435</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">339</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"> <td style="vertical-align:bottom"> BENDEKA ® and TREANDA ® </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"> <td style="vertical-align:bottom"> UZEDY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Anda </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">380</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"> <td style="vertical-align:bottom"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,225</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,896</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:78%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td style="white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td style="white-space:nowrap"> </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-

bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">2,924</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 2,471 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 144 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 154 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> AUSTEDO </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 817 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> BENDEKA and TREANDA </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 127 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 185 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 179 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 224 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> UZEDY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 75 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 14 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Anda </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,134 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,183 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 352 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 417 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">6,060</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 5,465 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:81%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td style="font-size:11pt;white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td style="font-size:11pt;white-space:nowrap"> </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended
 September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="font-

weight:bold;display:inline;">2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">973</div></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 886 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 56 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 53 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 55 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Respiratory products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 60 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 61 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 124 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:11pt"> <td style="vertical-align:bottom"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">1,265</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,146 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Other revenues in the third quarter of 2024 include the sale of certain product rights. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:77%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td style="white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td style="white-space:nowrap"> </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">2,947</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 2,727 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 158 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 115 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top:

0px;display:inline;">163 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 174 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Respiratory products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 183 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 195 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 299 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 282 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:11pt"> <td style="vertical-align:bottom"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">3,749</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 3,493 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Other revenues in the first nine months of 2024 include the sale of certain product rights.   </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:81%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td style="font-size:8pt;white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td style="font-size:8pt;white-space:nowrap"> </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> International markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended
 September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">477</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 470 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 18 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Other* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 99 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 87 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size:

10pt; font-family: "Times New Roman"; line-height: normal;">Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">613</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 591 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Other revenues in the third quarter of 2024 include the sale of certain product rights. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:81%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td style="font-size:8pt;white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td style="font-size:8pt;white-space:nowrap"> </td> <td></td> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> International markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended
 September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">1,440</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,425 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 63 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 38 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Other* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 261 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 229 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">1,802</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,750 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Other revenues in the first nine months of 2024 include the sale of certain product rights. </td> </tr> </table> 3 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"> a. </td> <td style="vertical-align:top;text-align:left;"> Segment information: </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td

style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Revenues </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,225</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">613</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Gross profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,265</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">306</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">R&D expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">S&M expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">G&A expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other<div style="display:inline;"> loss</div> <div style="display:inline;">(</div>income<div style="display:inline;">)</div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">$</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Segment profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">748</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">373</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">$</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:60%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Revenues </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,896</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">591</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Gross profit </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,060</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">648</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-

align:right;">293</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> R&D expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">156</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> S&M expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">243</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">184</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">116</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> G&A expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other loss (income) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">§</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Segment profit </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">338</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td colspan="4" style="vertical-align:top"></td> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Revenues </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,060</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,749</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,802</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Gross profit </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,291</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,113</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> R&D expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">475</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">173</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> S&M expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">789</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">605</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">397</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> G&A expenses </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">300</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">197</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other loss (income) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td

style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Segment profit </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,727</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,137</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td colspan="12" style="height:12pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> International Markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Revenues </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,465</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,493</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Gross profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,866</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">861</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">R&D expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">460</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">168</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">S&M expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">565</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">G&A expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">289</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other <div style="display:inline;">loss (</div>income<div style="display:inline;">)</div></div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Segment profit</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,017</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">356</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>   The following table presents a reconciliation of Teva's segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and nine months ended September 30, 2024 and 2023 :
    <table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"> <tr> <td style="width: 70%;"> </td> <td style="width: 4%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td style="width: 3%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td style="width: 3%; vertical-align:

bottom;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="width: 3%; vertical-align: bottom;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="6" style="vertical-align: bottom;text-align:center;"> Three months ended </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="6" style="vertical-align: bottom;text-align:center;"> Nine months ended </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> United States profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">748</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,727</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,421</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Europe profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">373</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">338</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,137</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,017</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> International Markets profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">356</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Total reportable segments profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,230</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,163</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,794</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> Profit (loss) of other activities </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Total segments profit </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,214</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,020</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,162</td> <td style="white-space:nowrap;vertical-

align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,816</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> Amounts not allocated to segments: </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Amortization </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">145</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">444</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> Other assets impairments, restructuring and other items* </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">931</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">276</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Goodwill impairment </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">600</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> Intangible assets impairments </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">289</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Legal settlements and loss contingencies </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">450</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,009</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> Other unallocated amounts </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">254</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">394</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Consolidated operating income (loss) * </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">344</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(274</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(323</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 70%;"> Financial expenses, net </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">272</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 70%;"> Consolidated income (loss) before income taxes * </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">324</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,037</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align: bottom; width: 3%;"> </td> <td

style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,131</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 70%;"></td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align: bottom; width: 3%;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. </td> </tr> </table>

2225000000126500000061300000012650000006980000003060000001510000005500000027000000259000000203000001340000001070000006700000036000000100002000000-2000000571000000338000000117000000606000000037490000001802000000329100000021130000008890000004750000001730000008500000078900000006050000003910000001000000-1000000172700000011370000002990000005465000000349300000017500000002866000000194300000086100000046000000016800000081000000700000000565000000300000-2000000-3400000014210000001017000000356000000748000000571000000172700000014210000003730000003380000001137000000101700000010900000011700000029900000016000000-5000000-1000000220000001214000000102000000031620000002816000000146000001450000004440000004710000002300000057000000931000000276000000600000000010000000070000000280000004700000016900000028900000045000000031400000063800000100900000064000051000000344000000-274000000-323000000-272000000-280000000-763000000-808000000-324000000064000000-1037000000-1131000000
The following tables present revenues by major products and activities for the three and nine months ended September 30, 2024 and 2023.   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:80%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">United States</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended
 September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,094</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">839</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"> <td style="vertical-align:bottom"> AJOVY ® </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> AUSTEDO </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">435</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">339</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"> <td style="vertical-align:bottom"> BENDEKA ® and TREANDA ® </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"> <td style="vertical-align:bottom"> UZEDY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Anda </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">380</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"> <td style="vertical-align:bottom"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,225</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,896</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:78%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td style="white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td style="white-space:nowrap"> </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> United States </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-

bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">2,924</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 2,471 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 144 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 154 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> AUSTEDO </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 817 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> BENDEKA and TREANDA </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 127 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 185 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 179 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 224 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> UZEDY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 75 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 14 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Anda </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,134 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,183 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 352 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 417 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">6,060</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 5,465 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom">   </td> <td></td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:81%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td style="font-size:11pt;white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td style="font-size:11pt;white-space:nowrap"> </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended
  September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="font-

weight:bold;display:inline;">2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">973</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 886 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 56 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 53 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 55 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Respiratory products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 60 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 61 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 124 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td> </td> <td style="vertical-align:bottom">   </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:11pt"> <td style="vertical-align:bottom"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">1,265</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,146 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Other revenues in the third quarter of 2024 include the sale of certain product rights. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:77%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td style="white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td style="white-space:nowrap"> </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> Europe </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:11pt;background-color:#cceeff"> <td style="vertical-align:bottom"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">2,947</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 2,727 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 158 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 115 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top:

0px;display:inline;">163 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 174 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Respiratory products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 183 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 195 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 299 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 282 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:11pt"> <td style="vertical-align:bottom"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">3,749</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 3,493 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Other revenues in the first nine months of 2024 include the sale of certain product rights.   </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:81%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td style="font-size:8pt;white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td style="font-size:8pt;white-space:nowrap"> </td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> International markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Three months ended
 September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">477</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 470 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 18 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Other* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 99 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 87 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size:

10pt; font-family: "Times New Roman"; line-height: normal;">Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">613</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 591 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Other revenues in the third quarter of 2024 include the sale of certain product rights. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="visibility:hidden; line-height:0pt; color:white"> <td style="width:81%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td style="font-size:8pt;white-space:nowrap"> </td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td style="font-size:8pt;white-space:nowrap"> </td> <td></td> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> International markets </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Nine months ended
 September 30, </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Generic products </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">1,440</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,425 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> AJOVY </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 63 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> COPAXONE </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 38 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> Other* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 261 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 229 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> $</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">1,802</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;display:inline;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 1,750 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Other revenues in the first nine months of 2024 include the sale of certain product rights. </td> </tr> </table>
1094000000839000000580000005600000043500000033900000040000000560000006900000098000000350000002000000380000000367000000115000000140000000222
NOTE 16 - Fair value measurement : Financial items carried at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 are classified in the tables below in one of the three categories of fair value levels: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:74%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:

0px;display:inline;"> Level 1 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Level 2 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Level 3 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="14" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cash and cash equivalents: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Money markets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,822</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,822</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cash, deposits and other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,497</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,497</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Investment in securities: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Equity securities </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Derivatives: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Asset derivatives : </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Options and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Liability derivatives : </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Options and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Bifurcated embedded derivatives </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">§</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Contingent consideration* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;

border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,335</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,782</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom">   </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:74%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> December 31, 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Level 1 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Level 2 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Level 3 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="14" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cash and cash equivalents: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Money markets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,704</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,704</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cash, deposits and other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,522</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,522</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Investment in securities: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Investment in convertible bond security </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Equity securities </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Restricted cash </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Derivatives: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Asset derivatives : </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Options and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td

style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cross-currency interest rate swap</div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="-sec-ix-hidden:hidden124099082;display:inline;">Liability derivatives</div>:</div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Options and forward contracts</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Bifurcated embedded derivatives</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">§</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Contingent consideration*</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(517</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(517</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,235</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(477</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,765</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;">
</div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">Represents an amount less than $<div style="letter-spacing: 0px; top: 0px;display:inline;">0.5 </div>million. </div> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva determined the fair value of the liabilities for contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of contingent consideration is based on several factors, such as cash flows projected from the success of unapproved product candidates; probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; time and resources required to complete the development and approval of product candidates; life of the potential commercialized products and associated risks with obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. The discount rate applied ranged from 8.5% to 11%. The weighted average discount rate, calculated based on the relative fair value of Teva's contingent consideration liabilities, was 8.8%. Contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in the consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. A change of the discount rate by 1% would have not resulted in material changes to the contingent consideration liabilities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The investment in convertible bond security is accounted for as available for sale with changes in fair value reflected in other comprehensive income. See Alvotech transaction under note 2. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:67%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months
 ended September</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">30, 2024</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine months
 ended September</div></div>
 <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Fair value at the beginning of the period</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(477</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(250</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Investment in convertible bond**</div></td> <td style="vertical-

align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Conversion option** </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"> Redemption of convertible bond security** </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Bifurcated embedded derivatives </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"></td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"> Adjustments to provisions for contingent consideration: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Allergan transaction* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(267</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(111</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"> Eagle transaction </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Novetide transaction </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"> Settlement of contingent consideration: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Allergan transaction </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">227</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"> Eagle transaction </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Novetide transaction </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"> Fair value at the end of the period </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(159</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan for the nine months ended September 30, 2023 have been revised as discussed in note 1c. </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">**</td> <td style="vertical-align:top;text-align:left;"> On September 29, 2023, Teva purchased $40 million of subordinated convertible bonds of Alvotech. On June 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024 (see note 2). </td></tr></table> Financial instruments not measured at fair value Financial instruments measured on a basis other than fair value mostly consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs):   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> Estimated fair value* </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> December 31,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;white-space:nowrap;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Senior notes and sustainability-linked senior notes included under senior notes and loans </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,129</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,214</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"> Senior notes and convertible senior debentures included under short-term debt </td> <td style="vertical-align:bottom"> </td> <td style="white-

space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,572</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,651</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,701</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,865</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td> </td></tr></table>   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left,"> The fair value was estimated based on quoted market prices . </td></tr></table> Financial items carried at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 are classified in the tables below in one of the three categories of fair value levels: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:74%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> September 30, 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Level 1 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Level 2 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Level 3 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> Total </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="14" style="vertical-align:bottom;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cash and cash equivalents: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Money markets </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,822</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,822</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Cash, deposits and other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,497</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,497</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Investment in securities: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Equity securities </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Derivatives: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Asset derivatives : </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Options and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Liability derivatives : </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td>

style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size:
10pt; font-family: "Times New Roman"; line-height: normal;">Options and forward contracts</div> </td> <td style="vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">(33</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ;
font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em;
font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Bifurcated embedded derivatives</div> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"></td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-
inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt;
margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Contingent consideration*</div> </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">(552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td>
</tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div
style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div
style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td
style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top:
1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td
style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New
Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,335</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td
style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">(552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,782</td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height:
normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px;
border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top:
3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-
top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px;
margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-
align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div
style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE;
font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:74%"></td> <td style="vertical-align:bottom;width:3%"></td>
<td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td>
<td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-
family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom:
0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">
<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom;
padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-
align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td
style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-
bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-
weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-
bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top:
0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr
style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td
colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.
$ in millions)</div></div></td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-
size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size:
10pt; font-family: "Times New Roman"; line-height: normal;">Cash and cash equivalents:</div> </td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-
family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size:
10pt; font-family: "Times New Roman"; line-height: normal;">Money markets</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,704</td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-
align:bottom;text-align:right;">1,704</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times
New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent:
-1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cash, deposits and other</div> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,522</td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td>
<td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-
space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-
space:nowrap;vertical-align:bottom;text-align:right;">1,522</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ;
font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em;
font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Investment in securities:</div> </td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td
style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-
family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;
text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Investment in convertible bond security</div> </td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td
style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td
style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-
align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt;
margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Equity securities</div> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td
style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-
align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td
style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td

style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Other </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Restricted cash </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Derivatives: </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Asset derivatives : </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Options and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Cross-currency interest rate swap </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Liability derivatives : </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Options and forward contracts </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> Bifurcated embedded derivatives </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">§</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> Contingent consideration* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(517</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(517</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,235</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(477</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,765</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">   </td> <td></td> <td></td> </tr> </table>
 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $ 0.5 million. </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </td> </tr> </table>

182200000182200000149700000149700000013000000130000003000000030000003200000032000000330000003300000055200000055200000033350000001000000552000000278200000017040000001704000000152200000015220000004000000040000000700000007000000100000010000001000000100000038000000380000000800000

4770000002760000008.5118.80.01 The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs: <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:67%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> Nine months
 ended September
 30, 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> Nine months
 ended September
 30, 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;white-space:nowrap;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"> Fair value at the beginning of the period </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(477</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(250</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Investment in convertible bond**</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Conversion option**</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Redemption of convertible bond security**</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Bifurcated embedded derivatives</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"></td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Adjustments to provisions for contingent consideration:</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Allergan transaction*</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(267</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(111</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Eagle transaction</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Novetide transaction</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Settlement of contingent consideration:</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Allergan transaction</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">227</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Eagle transaction</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Novetide transaction</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Fair value at the end of the period</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(159</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">§</td> <td style="vertical-align:top;text-align:left;"> Represents an amount less than $0.5 million. </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan for the nine months ended September 30, 2023 have been revised as discussed in note 1c. </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">**</td> <td style="vertical-align:top;text-align:left;"> On September 29, 2023, Teva purchased $40 million of subordinated convertible bonds of Alvotech. On June 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024 (see note 2). </td></tr></table>4770000002500000002500000015000000-40000000-267000000-111000000-37000000-35000000-10000002000000227000000132000000410000006100000020000002000000552000000159000000400000000 Financial instruments measured on a basis other than fair value mostly consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs).   <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times

***New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;">Estimated fair value*</td></tr> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> September 30,
 2024 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> December 31,
 2023 </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;white-space:nowrap;text-align:center;"> (U.S. $ in millions) </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#ceceff"> <td style="vertical-align:top;white-space:nowrap"> Senior notes and sustainability-linked senior notes included under senior notes and loans </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,129</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,214</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top;white-space:nowrap"> Senior notes and convertible senior debentures included under short-term debt </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,572</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,651</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align:bottom"> </td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#ceceff"> <td style="vertical-align:top;white-space:nowrap"> Total </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,701</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,865</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td></td> <td></td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"> The fair value was estimated based on quoted market prices . </td></tr></table>161290000000172140000002572000000165100000018701000000188650000005falsetruefalseChristine FoxEVP, U.S. CommercialAugust 13, 2024trueMarch 6, 2025839533 Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. In October 2024, Teva repaid $685 million of its 1.13% senior notes due 2024 at maturity. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026. In April 2024, Teva repaid $956 million of its 6% senior notes due 2024 at maturity. Including impairments related to exit and disposal activities. The contingent consideration presented in the three and nine months ended September 30, 2023 have been revised as discussed in note 1c. Includes adjustments for foreign currency translation. Other revenues in the first nine months of 2024 include the sale of certain product rights. Other revenues in the third quarter of 2024 include the sale of certain product rights. On September 29, 2023, Teva purchased $40 million of subordinated convertible bonds of Alvotech. On June 26, 2024, Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024 (see note 2). The plan includes shares to be sold solely to cover tax withholding obligations. The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c. Amounts do not include a $84 million loss from convertible bonds of Alvotech. Amounts do not include a $6 million interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. The agreement was terminated in the first quarter of 2024 and resulted in cash proceeds of $16 million. Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan for the nine months ended September 30, 2023 have been revised as discussed in note 1c. The fair value was estimated based on quoted market prices. Cumulative goodwill impairment as of September 30, 2024 and December 31, 2023 was approximately $29.0 billion and $28.3 billion, respectively.***

"YDJ7# G6.K-QI'1T;S^])4; TS^*QJ MFFJE/RY%FHN:%N#YO$+KM%](0?M_$1?_ 5!+ P04 " #(@&99AT; J&() M "(&@ &0 'AL+W=O=1;.E>?]ODT7(N>VITM1X,U.FYP[M?#7SOBV-X)F? E*M^,AB<]G,NB\[UI1 [9*XO=>64+,0GPVR5Y]RLWPBE5U>= MN+,9^"SG"T<# >O+DL_%G7!?RT\&W_J-EDSFHK!2%\R(V57)CY ,R1Y+ _ O M*5:Vl9G12]9:? Z,OOV17G0$Y))1('6G@>"S%6Z$4*8(;WVN=G<8D36Q_WFA_ M[]>.M4RY%6^U^K?,W.*J,^FP3,QXI=QGO?]'J-D'B_@R'OY3ON^/6ET2MF2!K:Z(-?JI\- MYV1!FW+G#-
Y*S'/7[[DT;.E5)5@NN*V.0,3=9=!]-TGTTUK/FZ G>4#/&?M- M%VYAV6V1B>S^ #Y\;AQ+-HZ]21Y5>"?*'AL.NBP9)">/Z!LV"QUZ?2= >:&/ MZJ$D.:HN\K+45D(!&=%8
MG\'KDI/Q[JR=KUXF^J58"NO\AL%K2QLA'4)R'MW"4[=N#:%X^)3*8?31VW]* M*'I#.H;'9/6[(_$OT]^50] M6L&?UGLT'++C@X/1&SFK# $H8X20#'6@;>>)Y?_\4WPZWAV-WL(/Y !M!5RR
M$OHX>?OJ"6U'HU$"/\,C\D@$0H;=X7"$YU&,=R\V0B]8TAU/DF@OB?[GR!X/ M3IZ);$@^ANQ1LK?=>\B&S"//OO\&L5X*XR2]!9MJ&*I%U^QD@+\#>?!49HWK M+(B?\C/Z##^,3
E&/H9/S_A;\V:R/O*]-=K:UU2/19&N$2 G4/H= Q8%LRM> ML@F;_#W9=78HN\[^[]FU!*] (K'/K_H4>?7L)OXI[!I3:IV,QYO4.AU%M?G/ MPK?,PJ.7\5Q7L(R&9-%],/"'#7]CZ!5[R"WTQ&:.^JH--
V$.KU";::Z,!QT5- M_U:2(3%3 !?9OSO28U_$DB.&V$P0*TRG-MANPZ$QMBUA_WF'?2.R&$6FG=I M]+0&P^N5)X:T6]*FM.(-L&?4A'G!U1K]=XLT.5GAWD#WC3:K9P7:.HIQWA5
MZ"E1$&KK6&]9(3)UJP]UQL/.+2K;CAUO"EG;!@6HGMOR8B&Q/),NUN3@;G@> M#.4]?V'+ !XS %X;VP7_3Q=$9YH@6(K7[*G_,SHW/L J920 3-5P4M(+/$:
MCZQ*80[KDAFRP5ZT@TW2K8G[TEV$)U551KS*2/N(-)758&1DVT.D*E)4/IQF MH,V(.=*59'F*0"O#H"BD)5_[SS""VH]:0$P* @CO!7,XM7@I!%PC:3U$ 3Q# M&-.
(55XJH,XO,Z.=T&6C.*P4X3KH_@70.&N066]':<0FH3(7AHBE_&,;I5!T M6@L,* ;+U%-:HP^#F%>*8VO6C?$&1%\+2?/N'!GWVFXK@P-AM\;5\"H9SW[' M2:4%\5 9*5L. SJ
Z;XTC"NBJH8#4340)KW12PI9'+\.4YIDX@2]^8Z,+D*E M4EH-)!H >C>%\G5R!\!4 7QE&U_8A]'EA/)0FM/(+0R4E[[NL]" ;= YC=ZVBDFX-
'Z@O749'?;4."#R<>@W_VMDF(^X";KEG\DJV\Q07PP@KM M:M,A-G_-.,%1/I,UT?DMW11_2@N B"^Y5#ZP-&#!$D-FML+?VG,C9BI42#JV M>2I%=<2(!5V0+,5V)W&*NU%+E 946;",PO+0
"LBKDL?*W;%$YLN\ZV-.4H M&0U 8Q[GP*_VSAS)B!@4A/P-E?9$;U\]'H'29B+WK^O8<>!2/B&H_DZV"K&Y@UP-K_7(O0U!LB0;Z^7OW+WP*AT.V M0Z)$?M.,\3^U<;&U!6;1!&^3L44K;P1=S.U?(
U#;9P*0;1@D9JK];6TLC;X M[HM&G&*5K]C'HJ4C.0LZNH%+EX#IPK?=%\Q'9O0&*::B)1W=!?_OA%M2E:/ M#/RS@MO):4C]K;<\;+0Q, @E">ZGOY0A]=,_"#^8X5_8[;Y9H@OV]J-90((
MS#8U_KX3Z.P+"1LK*F$EESZ@?E62'$+#\W7HR I1%]'C7OL^K\"IM0J;1WVF MKGR[9Y+#$QIA?W@(]WVAQGNDM0NJMJ - 0'6IQ( )G6HZYY;6^)UF[.'DL4W MZODMF="
<6ZNO7V9B"E_@A6VM<7P<*"2%Y""6MU>)=(K:O30\4O4%2BCMQ^?1 M;5/_MV*O=BX5V_YZGK'LP/NI\?@^N!<2I5$ZZ*[EM!LG9_1AW$WB MDWU;C\=NU\Q"& >;8D_"#L?
AT3AAW4O&D.Q[$X!>AR[*^ZU?!W!*F/O?0(CNHIZ%'PJ;T>9GEIOPZ\)6 M//Q&\QLW:*4X?8L9I@YZXU$G9 CFB]LE_ZUAJIW3N?^X$!R1(&\GVGX7'\A M \V/3!?_ 5!+ P04 " #(@&99%V&T)*@$
X"@ &0 'AL+W=O*M!U63+UO$ A]U,O\ X3=WRS-79B,)OLV :7:!YVMXI&PR-*P4NL M-)<5*%Q/O7EPN8BMOE/XD^->G\A@,UE)^<,.KHNIY]N 4&!N+ *CSR->H1 6 MB,+XV6)Z1Y?
6\%0^H'IUN5,N*Z;Q2HJ >&&V4R_SH, UJX6YD_O?LR[HRO-K K10\YZCA[_E*&T4$^>=?!I/;II+O6,Y M3CU70O6(WNSCAV#D?WHGVO@8;?P>^FQ)F["H!<+ &JY+,&H6T-VA8
MP14J0!L/_B!CN*9Y#?,]@ 43K,H1EI8VYV?)F!DJ24?7\4,6!NDG#,FL /6EH/P* M6/.*4N!,P#%A#702M?@"'QFYWJ'BLM"7G?NM0H2R(2!: L)WZ_1TID.${]05 M]@.K(OC_5.=AL(0N4(PE%X*2T-
##IYSTK#?06Z806&F9I"\ZO8>*U06E5EQT MYE3\XE_:N*X[-')EH$A(W%9E0UEH\G]?IW%!>"]C6=!K;8G+E4NZ3 A&TSDVM M+'$9=5Y+!%Z0F!] 5&20(_T
M28ICZ(79F,0>&=E_JL=%Y_J5_@JIYG@ ,>R)N!\($:$$/3]I<.INC2S\+SUHQ M8Q1?U8ZT8"3<$VD@\P_1CZ$WSEX#A1;H"U,554X?8$[. @N@5 715#TWRULI
M"E1$1GNRYJY5!1>U9;,%.L'I@C_P*1/ZMY'09T1S-&S"H7'VEFUMIK#= M<)J@6P8"[49-6X(FNOX@.5!V<{;J,!+S%8<_XQJ5HHA?=:P+03^EF]?VFR2= M>VEH8SJR:HA#:H!=L\(X:9G<&-
H:'%EM?C.H2CH&V(H+,NS!& 6S((,@"DD: M)WX+>5XWC/H!M=@JDQ@%\4'[%"_N)^FH 8S[J9IU7+=/&].>(_:VZ>+SMT M'I1E+=QO0[#<%3$\N&PO=VIR:W-
H965T5D&8>E=;69W%L\A(K9H;J M1DDK:Z4K9FFJ-[&I.;+"!U4BSI+D.*X8E]%BYFVW>C%3C15(#2L$KE(8K"1K7\^@B/;L<.7_O M\)GCSG3&X)2LE/KF)M?%/$H<(1286X? Z+/%*Q3" 1&-
[RUF=$CI KOC/?K? M7CMI63TI\X84MY]%)! 6N62/L1[7[@*V>BH+6T=6,VD8,Y2!OIW;"70#&;QI13.,Z*!WY'/&+^&%PP=]#3?L M]])P)9@Q.)SA@@;6),% ,O9B@MN..UM=RB]QI?
BDQZ>09KV+/%>-)+Z; @MQJZE:. M/AQ!+9BT7B!^;WA:,<2&H#2!2>\ 6Y*@O $:6R^IY% [^3@!$OC^OJ;.0?44 MRE !I;.E6^B/Q.8)KX3EDF!CM#Q29*+BI%07!1]NFAMP=-%+TW ZY"T@1
M.151"5XPEW;%2$*X.^VH4IG])LFCP6MV4.H9G]Z_#NC(+%[0/JC,;GUTQ$. M7A27)LJ !7%=J/!)83]+7?HW+]L5/4$L#!!0 (_B 9EDCJ;%<\04 %\0 M 9 >&PO=V]R.W-H965T\ M>^ZY.[/*MZW]Y-
;&>/A<5XT[&:^]W[R9S=QB;6KMINW&-+BR;&VM/7[:UY"WMZW&Y]53;FPH+,UK6V=V>F;F!/QFR\F[@L M5VM/$[/3XXU>F2OC/VXN+'[-!BU%69O&E6T#UBQ/OF_9FS-)^\,&WTMSZ^Z-
M@3R9M^TG^GA?G(QC,LA49N%)@\;7C3DW546*T(R_>IWCX4@2O#_>;?\Q^(Z^ MS+4SYVWU1UGX]7YL8T6P-+V];P:!MQ$2>'1OAU?[RQ#B;7>EX9=W@\\W@F2<_F,/C$
M(((^^92^CHW0+]$HG5ZMK%EI;QPR+B#C8'Z'@/_9VMT.;(_TK]W7P'CV+$]P M-VZC%^9DC!GDC+TQXU.X7BA;87I438K\(3T(U.NS8U^_2KC+#UZ@5U30+Z" M+H]2>*\K*)LN>2D+\-
\]W6%F.:B,P!D#3>L-,#4=7:\M?M9=_S%#Q!],^]Y ML4,(1A^;TM.*#Z;^L+58,.!]XXUM=&_ ,WZ-B!T29RJ/6Z&DT^3]^F!V@> M$KNJ<*L['%U!!Y-6K5MX8!%&>?XY$R"2C)@G(&(TER.?
BD75!D0,&VM;E8& M"P7RE@O((8$,I!]*Q&0O6)(> ,,1@LF/\,5R>00BCT>=C?T6 MR8'GN#'&/SXZ !YQKN" +$GH'01SDN,)T<^#5.',13M4/@9;"+[PRZ(LX, ME'B$>I(,J+,)U-/T(>I,=?
E89CAR2P=$>A9G@3PF4SVP%0H[E M2@)5%L$R1%I%,E09M"@/V$:I(N23C*C.6"2R_%N0[N*]CN"9MBF'MBE?VC8)
M3(>&A'Y&9A3PEKJ9;A;FJTWR'S0_IVXTS%^:>:#"!U.4"UT68>/Y6ML5+BP^_MT0:_M8WK:1&X'8G_30USG1%)X'V\+-NMN0CZQ*?(A "$"6!\DI24#)%R2 %
M5:8\#5%3HHN>RI/1A6U2OH%2XV[TL1AWX(+/M:Z,'3$8FLM1A#NC+:P.,9L M"^2-I/BC6I7FR(@<^P_#4D6I]4W4SGC>]\RK!S M?C/UOSU^785B3^]2A!$O)808H!/A)X0!XE6,'^-
>\FQ*,1")\RA*-YMT>% M/?1\BHQ)Q]@HSP+K$I9V9$S[!159],(1'F;=8,<$^G%3)P,63$1^VR=7C"(,_M(%7-5\L2U%;BL&@Y(%5TV3V[R:2Q<.RL[1+X]SMVTFQ7 BZQ9SSOS;QXQHM.
MZ1=3(UIX.X0TR["VMKV.(E/4V# S52U*.JF4;I@E4^\CTVIDI0'0\\7UMG2:.+5]VQRW:YW.C MR8I&EI(W* U7$C16R_ FN5YG+MX'_.+8F9.]."4[I5Z<\5 NP]@5A (+ZQ@8 M+:]XBT(X(BKCS\
9CBD=\1_9+_WVDG+CAF\5>(W+VV]#*]"+%B!V&?5/<# M!SUSQUAO]P KB*/P&D R#U=?>)?)5W MS++50JL.M(LF-K?Q4CV:BN/27BQKG7)N,5V"ED\@31.9U_P M9:/,S//-/N/K>PY4!2=*/Q+Z-
<\)> *29H8(-1K4K\Y1*&I68[%T;ELC5$I0 MUW.YOPY(D<5FA|K+NL.B,)))X#0ZH5EP_CS=3N$,N*2[%H+:UEP$!UQRNN 2 M6JW*0V$-!:23+)GUZ^PR>&(=,$D!K'AA>T["6)16=QW'P.$;3H=6,5-
B!\)T&D$!^?@!UD!:.2? [)51;<03;)YSD5,9O$ M:?+1)44G?=F@WOOI,^!Y^A8=O>. W_1]_2^\?QT>F29A!@16!(VGW^8AZ'[B M>L.JUG?Y3EF:&;^MZ9%"[0+HO%+*'@V78'SV5G\!4$L#!!0 (_B
9EGI M$+UAU@(D& 9 >&PO=V]R:W-H965TJ?3)E7T&\H&2+#=!P\[H;'=/8?6I=']2I>$L=U??TY;&)LV'NX! M8L?V+S^[ML=([J1YT"6#(4\6%GCBE.?6%Y^FLA(KJQJO!H*60]J(&5:7Q=*V
MYDU0Q;W0]P=>19EPIN/F;JFF8[DUG E8*J*W5475\QRXW$VR% M-QW7=_.K,/2U4J'F'5!R5H'03 JBH)@XL^!B'EG_QN$7@YT^DHG-9"WE@U46 M^<3Q+2'@D!F+0/%XA"O@W (AC3\=IG-
XT@8>RWOT;TWNF,N::KB2_#?+33EQ M4H?D4_M-[=R]P.Z?!*+ETFNFW^R:WWCT"'95AM9=<'(H&*B/>E35X>C@-3_M("#L L*&=_M0P_*:&CH=*
[DCRGHCFA6:5)MH),>_$2@KH]#*,,Y,%SD(PPI& MUQS(0A@J-LR*,ZW!:)V9PWZ?.P9?,R&>%D'/&^!PP^_1^1&"E-]\E7DD+M-,M]Y#D@6FX9SH/3P*NH.Z3R'=)Z(?Q";SHD'G4X,4?X,5M2&1!3A?
AO=Q/0[_"M8R]XM"U]K&GM8'D:=T$INA2$"IQ-]9UFV MK:,/S.+>0!!:R0RP<@HT4)65 MA(HD=C6<%;M.L(=L&^)G:23W<'O:*TQ=TK1M:.L*^EP=71B"7N:E#6 >V%E&:OV <.VW_Z M#U!+
P04_" #(@&99]!(H"]H# ";" &0 'AL+W=OV(]64GY9@!?LJD?6$+.(346@>+R#@O@W (AC?_VF%YCTBJ> M[@_H?SC?T9<5U:"0_%^6F6+]#3V204XWW'R7V[]@[T_?
XJ62:_28L$E9&H5O&>]9V9]29EO&.6F_T!4'?3_Q#<+:EWZZAYC7$-$5B!%YDL(4 MFGP6&60_ZOM(I^$4'3C-HYN 2ZBZ) XZ) JBW@V\N/$O=GB]:WAUP1&9DT5! MQ1HT88*8
LB"*K5C8DT>2[D1QDHT 5GMR!+66' F4DAN6K2=_8536'J8:MH M4. @S8[MI<>M M;U*9@KP*9E#A\T9A]Y(OPH 2U'8!Y>1OQ%7D11K*6R_P3G_;1B%@P=-GB!C
MNM5^{2Z[Y,Z2+!)$)ZNC[UIQR*E)G"5E^@G1/(W0T8M(.[U$EZ?3Z(UP=8O2 M2SCJ/>#%L-:+$BLPZ..S[,1AC&N4N..@$PX&K2;L%!U)'5?L>4ZM&T;Z6.B"_MY2Y*"RIH1NWUCYXl4?4&1I-

V3>2>]#M#M'1&)^DEYUZ+XULHVQ%'%,_/D:&E15ERA;D+_$_/[;#3A $&)TK M]T>#"E).M68YPR2@][BWX2V 9ZY ->7PB[:CT<^&+\FT7A05FM=UD+$\QSK' M'" 'D1'I0G8;931 A^+0%@'I(6:?
G%?QA6ZJR_A&/OM)[/(8)C:?<3ATV;0U M'R:=,.JU+,)B4VXL\W;SJ8-UV!FW9\UR67/J#^R< H0:W=6-0DM=^A>G8TM\WD?:P'SE&\ M'MO8=&LF-.&0HVK0'>"@4_4HK]&5F[\K*3!8>:V!?X]@+
("^#Z7TAP.UD#S M/S+['U!+ P04 " #(@&99A4?UWV4JJ;WK)N8'O95'I\^'2 MF/IT,M'9DI=,.[+F%:[,I2J9P:%:3'2M.,LM4UE,?->)R43U?#BS,Y]41=G MLC&%J/@7!;HI2Z;6E[R0J_.A-
]Q.?!6+I:&)R<59S1;\EIO[^HO"T:1#R47) M*RUD!8K/SX=OO=/+D.@MP:^"KW3O&\B2F93?:'"3GP]=4H@7/#.$P/#UP*]X M41 0JO''!G/8B23&_O<6_;VU'6V9,=SUA3FJUQ]X!M[
M(L++9*'M$U8M;1 -(6NTD>6&&34H1=6^V?>-'WH,B?L$@[]A*W>K2"KY34S M[.),R14HHD8T^K"F6FY43E04E%NC<%4@G[FXYC,#F2= G9AHES!K0&L/+&5?
6I&N>;0;>>$#VD9'!X/C>N77@%8@*@UT4 M%)'1X$I6#UP9@7$!S2LA%!.&E: WK4*E4&:Q,4W4DW]9^(0=G$(7QZ' MUIY?I$%E6)7#1\DJ?2@3IJK!SZ\F#D(M[7ZWX7H8& V MRE=6^?
O;:_20'[E; C@.1Q [KMM&)X2??TI\SW^#+R\-WT :Q;L([^Z_(D+D M]A"B$7B.%VP1IK@6I\$A-K?']D-H!&&4XC\XI&N?9=I)019_2O]]*6F/(72B M3D84A1"%CQBN/KR'H.<-KZ^4AQ*\>%^I8,?\P/&ZU
[&P31LG_N*3=V^G"1I MF:8P33R83KW!+1ZD6*#:M%^?8/)\X_EV+SWEDF-O=/QZA(9.HRU>2V"?+\%L M(^/M8P8[F+Z?TM.+_BJAXHXMV:S8YP%_[/@]#K9,21!"XL?_T!^^U3WJ,B7]
MN_X@S+B/&%C$:1>QU"['+_=N<@@MZ-"2-((D"5\>JVC?WG"+%[CV!(SI&;W8 MA]&^ALG6@X%GEZ.7VWL K?,>H44)_OW]/)HF:2^+-KLJB'$^H/\^@[\3^M#Q MVKT;DO5ILGEN*T:?
V4O'6,CHE23IX+-9X@%:[!S"X(,W^,BUQOO-7J$Z;@O2 M"'<*U208M9263VC=L"KCD$EMD#1.B Y+T^B0(E1,"BHF5+GB<>C:$I:,O=@;
MX#:$FSG<\0<&AKQRK%FUMO*$AGF#Y';05)E$%+JG,YI;-$PQ5+<5M,-J M(UVS-6E.N!0L#$65B9H5XRZ68\B%SF2#1-:Z?(L.K*19#+U YFKMP!W"/]K' MFQXOITL126)U1RS%[J]_"@(6/:IJB;[5K*
MMVTG]8.\[4<_8?(+/#T*/D=6%TOO$%3;X[4#(VO;5\VDP2[-?BZQ+>:*"'!] M+C%5-@,2T#7:%W\"4$L#!!0 (,B 9EG"BZ @V00 ,$0 9 >&PO M=V]R:W-H965T5T 0^@O^1W M$D?
M4DO,,N"*"4XDS,?>N7]VT3?R5N K@[7:>B8FDID0W\S@)AY['>,0I!!I MHX'B;067D*9&$;KQ1Z'3*TV:A=O/&^U3&SO&,J,*+D7Z.XMU,O8&'HEA3I>I MOA?
K:RCBZ1E]D4B5O9)U(=OQ2+146F3%8O0@8]S=Z5.1AT,6!,6"P/KM#%DO MKZBFDY$4:R*-&HS#S94NQJ=8]P4Y4%+?,MPG9Y<@60K:C)#&%=:+C'A6A'* M8Y) O&!\X1+'-
%FH]TEH(Z&K4UVC8:VE%AY\+9"=ZP,R2?!=>)(A]Y#/'K M]6WTN70\V#A^$=0J?(#\A(2=%@DZ0;=&7U@F(K3ZNF_I-;[F&ZMTRVKB MK#)CM476"7"B)>6*6DQCG20@!A5;<*I1CBJW
FL6&25H[*R!F<+E,Y V75<0 M%0._U3"Y,PD,&\TO)P\GY&<$:(L38WRH\:E%$H=1TLI@4?/1*UI3HY)1%5" MYAA*8:OI'^'"7WX:!'[P 6_^L/L!)_S^L*8LW;(LW4/+]CI%,@5>(>4,-KW<&X\7)4>
MQI5T.VM,2['&U5XYC;UM:/I'FK[A_8QD_8;(0J5,ILBTV*;(%2JSPI/:06\RIA>27A:CUZFW".9C/S[4!R*58,<8\>N(\1]UVPP$Q:1J)X*K:H MY_JHB3)W43:FC%,>,>RQ\(1?
-1AIBW!$:%$UD:%@8CXX+#UQ#(W'1 *0S.U= M8/:N%JF8JV+;ZZGO"1S",D0=![<9F/EUPJ*$P'P.!D(8IT6SVQ0D1$*B9Z@A M.#7D"
8=TY3MM1ET$4I5U%!O]/==0)Z2O3G_/>F]-0&]SN[^U(^MHC9BML^KW^WTMO/3?,+G9;85AX/ 6M@:]#B*N=HMI!D>DBW_U M^UJM"O2$BXQ%&^2&>TU@9SATH#ZL+._I!3] 45YU #]HA?
ZF"_BM<# \I"S% M_M[M[W?5?[4\3=^VG[)P)\QRMCR?G[MCZ8NX.]Q__MIA)[B"(IS'%IY^04OP>D.S"[@1:Y/:3.A,8CKWU,@&*EC "^GPNA-P CH/S5 M8O(74$L#!!0 (,B 9EE"XK>_=@0 ,$+ 9
>&PO=V]R:W-H965T M*6Q3M@RZDR)DSAV=&L]@I_=44C%GR7 IIEF%A M;74V')JL8"4U U4Q"5\V2I?4PE!OAZ;2C.9N4RF&\6@T&9:4RW"U<'.W>K50
MM15X\?!];_VSBQUB65/#KI3XC>>V6(:SD.1L0VMA[]3N1];$XP!F M2AAW)SN_=IJ&)*N-566S&1"47/HG?6YX. @P&[VS(6XVQ ZW=^10?J*6KA9: M[8C&U6 -7URH;C>
XQ(/Y=YJ^,IAGUW]8@NF"36&64-X65&N@7)K/@+CQNHZ ML[7F>H_Q.Q[GY(N2MC#D6N8L M/]X_!/1M"/$^A,OXI,%[5@U(,OI(XE$\/F$O:2E)G+WQ>_9_^'DM&%$;XNFY M\/3<'-
)S]X8>O_8&Z>EBY:13S+TS4]&,+4-(+L/T$PM7#X5FC)2>+H9TD9]A MW]%, .&#RS6X1@Z.1@$R@K0DI'T+>H^#^P'YGG)>A("4L/T2==DQP%5X $XH:NFSKQ7V2@,-$?
8/=!62K0*4!'I^D4;O,$? MMTH>GU:RK[0HY&/V;P65!P1>*0/4W7VC[GI/W:>&NBY!G_3=+6C'^$8)^!6@ MWX;12JLGX-WQF:FR4M(=):#&F2N8H?+EA^]F<30]-Z_J4H;0SX*.3'DG$SKU M?
RS.X+JLA'H!@Y9IJ+E>#Z#\!&^31J\S$L6M3F.OS !01O/Q^9LL/4;3K/I/ M0"4("M*K2:(Y29,6%:079LT)):6MDM)_IZ2++-,U%9T5[Z3)?RZ0O3Y,AT!0 MHUE!(7_
/DU/ZX4V>,^Z^71R:BJY8['[9"XI)%#&,'D!Q$]4UDA.Y']!6+:F MJ2M;O:E[N/.>G/=F,>D'MQB-ZVEZ"1:W'IP9W%/\]FBYX']Z*.T?]P.>8Q23 MR?B5WS?UQ;E.)]YU-&X@0-G^WX)-G"<-=Q
MC.?'<8Y'+D(7[3QY/\XI_!$2 M2+/1WP6:O.78D_NAJ6I8I_/?H7WR?P6LUG!!BP91UUHSF;T0JZDTPH'HKK;# M@[:J9'KKFD<#M-72^@ZKG6W[TPO?EGU;[IO;+U1ON31$L UL'0VP'=2^8?0#
MJRK7I*V5A9;/O1;08S.-"^#[1L%_H1F@@[9K7_T%4$L#!!0 (,B 9EGL M?5$O$P0)$+ 9 >&PO=V]R:W-H965T.:IRY'THSEM$UFFL83R^TS1"Y%-""@ J#EY-=W 9**[3BV MF[9/?2$.
[O'M\6%VME/Z@ZD0+=S40IIY4%F[/0U#DU=8,W.BMBCI3ZETS2P= M]28T6XVL\$JU"),H&H4UXS)8S/S=A5[,5&,%EWBAP31US?3')0JUFP=QT%^\
MYYO*NHMP,=NR#5ZBO=I>:#J%>RL%KU$:KB1H+.?!67RZ3)V\%_B-X\[42ZOI+R<] MNSC+\Z9N!+-8@+(5:LA53>6M7-ZO$;BD,\) *&..8+!B:X'F:!9:\NTLA'GG M9]GZ2;
[B9PIOE;25@1]E@<5=_9 P[X$G/?!E\JC!2]R>0!H=0Q(EV2/VTGTB-M4F\O>T8BWOE$G-])Q!N?B'#P2YN(7XDOJH05NWDP&8_Z,;E!0WUA*R[I[F]5C%FK^;JQKFY@%:SPF@'3-M"-ZQ=$:X!#
(#K;UJ'H'+H\;#57])I0LGA.X>7*6/J3:RPXJ:Z49>)@<'5R>0*'+J2:"T$ MS-'!DA%,4F$NIP0BQWI-64MCWSOI,^/??39(X>4E+/,U>0DS7*=D] MJU7C4O%9C=)/=7,5,I:*7G?-T7N[9R]JA<>?
QG$O:,3>28*5EJ2(+LO8#"-;Z,8T_=>"8GZMJMA MQ_^':IB-AUW)LFZ33?H:CD=3LOH"^FP7"J2R#I-H"G(#AZ.^@<-!A%*K&LKG-M-OI]TDDE?\CI^=.*3,K-_XA=R4.5&<8]NZ9]B?:5F:23?
\BN=.K:9OAE=PZR M[-\@6-8V9I)\-\$\MGC:M7:2/$JP8?0TPYS,-U!L<@?'4RCOI#3.'J"8O3:_'<<>V@B"&^-237JC1\-+83T_YV/V^>M6/69_%V M6'W+],9Q2&!)JM')>!B ;@?
]F#5U@]=:V5IA//;BF9FU$Z_I=*V?[@'.RG M\,5?4$L#!!0 (,B 9EE4>]03Q <-+\5 9 >&PO=V]R:W-H965T MJ7B_$#R 1O?#Z\8##Q^K^JN>*V78MR(O M]=%@;LQB?
SS6T[DJ$CVJ%JK$EUE5%XG!8WT_UHM:):D=5.1CSW6#<9%DY>#X MT+Z[K(\/JZ7)LU)=UDPOBR*I_SQ1>?5X-."#[L55=C\W]&)\?+A([M6U,K>+ MRQI/X]Y*FA6JU%E5LEK-
C@83OG\BJ;_M\%NF'O7*/:-([JKJ*SW\G!X-7')(MY6IJR$*"YD%]4GE.AN#&'ZW-03\E#5R][ZS_:&-'+'>)5I^J_)]9:N9'@VC
M4C5+EKFYJAY_4FT\/MF;5KFV5_;8]!7H/%UJ4Q7M8'A09&73)M]:'%8&1.X+-M [QV@&?];B:R7IXF)CD^K*M'5E-O6*,;&ZH=#>>RDA;EVM3XFF&<.;Y6]X#8 M:+9[D]SE2N\=C@W,TL?
QM#5QTICP7C-1LR]5:>::G96I2M?'C^%.[Y/7^73B MO6KP6BU&3+A#YKF>?,6>Z&,4UIY\R5Y#.%;-6!LNNZRK66:VQ?JJ*4J1?;U(MINIH@!S0JGY0@^-DU-O-RB9/0+A]YV9>*\6*!AQ%X*#?
PJCB3M44GT/Q.;=E M9NB+28P"ALL:"<=^+HVJ2VLGR=F7I/ZJC'9V;T?7([:#64"%/,='O>=S_3A9&>>&+ B9")P+,T=L.4VYR_;8AQ]X M$!XPWMXX'4RM.SLLE!&N(A3DM1L[[8 K9=$E7B;
(W*):8A#8J9F9X\6.._([M!$9O@EG\G3#S810'MN626C_FSV%V Y<%B,V+Q3:8 Q9X<&T+S!(01Y)Q'FS" M' L6!$R(YRCO>D]0T_TFS'[("69!8',>?A?,YTB%_R>9 PLBO!Z&,FY0=[UU
MG,70BSE8S[E@411O(BU#GW&0*_(WH0ZCF 6NST0<;D(M7)?Q.+2;P'E E2,[N.MO "R)M) %TZJ<9GEF0:(*?Z,>D@_1!X/#S33:U. UA6C!F-T ME6=I0I
#Z!JC83TKIU6AV"YYO(>,2*G_6M_U'G<*Q5YU+TWR#?'C#9('3[8H MD8WR]>6WFYSM2#Q@6W>-#08YZR8V$[$QUM]MY0S;2J1U(CXKU$T=>2(YULMI MN=JE)+*-ZDR3 '8EG:TT[FNE&U-
)HDQI%KPRZ%2K154WJZT[A?*TAPF7+&.K M$T,>(,QA&$NGV=*[M0$3*DL_*_LRDR&871X0^?PNB3VOG6W+%%S:*5P[A4<) M@XH\L152L[(R+-$GIY84($EG8)^ZU";[3T-
'VAZX])F4$J6(MPF1:$WQ9\4B MR6H[;(AXM:F74[.LB8C$AL9[K$6A/R)K*'?\$%L-ZEV(O:&JTD>LV8H5%#.7 M6>9[!VAX+-\H!+Q$PM(:).5]1H!NSH^LA7](^)CRU_E5W5M0C,E5T>X.:9/' MR
9*%86_9^Q&LQ@PTT0YY MC"?$!2+O-;=<4-7_R*@JP6;2E2(8[Q)_46>X0T!9E;)Y\J PD:+SRT.F&[+@ MV$%G$EN]\)*(@@QLQEIK?2W#.ZT:#G1=ULK1K$=!4[K:M1HQG%98DJ99FV\K
MDA1KJHB\BO'IB+VBK&6OK.7KRAIGQ'0)3L'9<\!_G4]L+L_25^GH#/[%0.V MJ>Q7S6Y7V6S+5J [R)Z5K33\],)X]@J./17'S0/465(M*MJP2:#))FY*+ZJZ/.H4KO
])F&WB[V3A%;A=!O/.ZQU;,\C412T$4.O2_X4 M@2]P2H+BTHL,9:O"R;(?2[*_K?,?&<'"7=F[WQW+[+D!5:0)LNZ46YOA9I[5 M*?MCF=38-2FQK/\H4_DR5;:'3IJ,FRILD1C5SLYJ^@.A1QTP[\
(&:54M"8". M#>__.+]ROBB](/MV?+"VD(=^AQ!M^E[D]0AU6M]*UQ<1FF6U-FNZZGM06EOA]9ML.PJ3B_IV)*Z;8R MT6]C!S?D"E>@&W TZ<@00-
MX\4JZX,#7GU_>E0S;ML+QRD^U0M7W]M;_6O^V_SLY:7[*/75O?FU"\MYGI<;1>H:A[BCT!\W,W8.I%O87W5UE3%78 MV[E*4E53!WR?5=BTVP>:H/]G>_P74$L#!!0 (,B 9EEH0OQ&+_<.L4 M 9
>&PO=V]R:W-H965T%364N/FEFBBSC^N%:I&I]T0I;FX'/ M\GYA::!W>;[D]^)6V"_+3QJ_>I661&8B-U+E3(OY1>LJ/+L>D;P3^%V*M:F] M,]K)3*FO].-=K,DD+Z^\;[6_=WK&7 M&3?
B1J5_R,0N+EK3%DO$G!>I_:S6_Q/E?IR#L4J-^_67G8R:;&X,%9EY6)X MD,GON>67YUJMF29I:*,7MU6W&L[)G [E MUFK,2JRSEV^YU.QWGA:"?1#
<%%H@XI:U[_@L%>;XO&=AA$1[<:GPVBN,GE!X MRCZHW"X,>Y,G(GF\O@?G*@^CC8?7T4&%MV+998-^AT7]:'A WZ#:\<#I&SZE MS\./J3E[*W.>QY*G[)T5F6$W7&LI$L8MV\9E7P@.6B
>G9DEC\5%"T0Q0J]$ MZ[)F3#IC\=;8G(RMW"$04 'VN,!D?D^ DX9Q0]XB$%@X$[J*!N-YPEZ+N!P- MW>B-<2U8G')CY)P,R)S9A6#6G2B;$0]I3.6"M+JIA198PJVX5_#)6:OYE(J5
M2,U9T'0@>$]3+&3^&97/;M3EJ=!^TOWMLN.R%HFTQ0L-,?!#3<+YWA,+^); M(6$%F(,!($<\-WZJ[&Z\+.-(KP_/FG:11&O^ 1G@Y_V3?@))WJ#CBY5$9" M 1E1V)_&]/!TLKMJYZ>3"=
[E*V&LXP"\-G00TB(D9\$;>&H?:D,L'#RG:)0P@@A":A?M_/,]G_^*1Q/=D>#&_@!#M!1 MP"4CH8^3MR?/:&N/1A'\](__(1$(&70&@Q&>[1!S1QNA(Q9U)M,H:)#H7T?V MI#]\(;(A>0C9HZAQW
UD0^8 LA_/(-8KH:U$MF S!4.EZ_,;]O&WAP?/,6M2 MLB!\SL_@,_S0,B88N1@^O^(?Y@$SEV38A:P\ED0ZWQ*"C-?Q:N M%N8.O8QGJH!E%"2#ZH.!(];OCH(3]I1;J(G5^K0,-F$/I5+II%%&/8[SLO5;
M2PMBQ@ NV$,GTF4'&HEAU4@,7]Q(;+NH1VW%^YJG97N5L"^&*OLFG[S+EX4U M^YJ,@];W-QEW*.9SE:+"DPE7\>!86J_ZJ[T^Z_9T%O\%_EOG6L.I?]@P.]N?6MUOS
M.&GR>R;N99Z3J;*+68(1*MD"L!V-^@#HX>QVTJ@FT8BX 2%W[U".PDVI<(1D ME8C,39,'3Z9-K&TC<^Y2^P6D+FE+C^_J^;/PN\ O*K;4:B6-2RYTCO$3K$%* M3%.A[T$P))W<\-A3O!V-
783"$-4P>,/OX71- &G'38/2Q\%O:B4L-#X6H"H: MH2.T-O4W!A^"O^$%BZ().J1HC_EAR,;A?L,1K#:Q(*@>[J)@4^';X8B2Z OS M$-+0!G9=Y*.[1PQ)<,5BY?I&9\UG<-CG&D@LD7OHI/@/'1PTI X:6%
(%;\/8 MO,8:0;>LYM5@P!9\11P1I H6*4,:EDB#.Z7QKN<*%2R,L:AM] M:W?+\TW2':'P\.WSL.G:/;.R9S8YNS3HKY6^@W2PKV=W92SBXN!H'*^!=@GH M47P04_,X<]CP_N'44YF8@9?
($7IA;PR;$3IS*RGUC;&RLZ MKVSW;MI.RS[=UYECW-.J8K05.]FYN];;_?WUYG9W/R_8MLSCM" Z%B"E;H8D M53JOT55H]67O"O_6LK[C\#?N :=1U-GIAC:;\[_=JU_[3F?UBU=)^S9LI: ME;G7A>"(!
E@?J[@<_F##%3?-R__#U!+ P04 " #(@&99]A G9(,# !' M#0 &0 'AL+W=OS;K5:UK@8?N9_9,+'H-94 U3R?]@N5F/ MO8%' ^!30.0/H5(#.SP*Z%<"%[I>Q.^%FU-!DI.2>*#L;V6S# MJ>_0J!<3-
E$>C,)1ACB33*AFFL@EP333(QUV_8L3R!WC',?UR#?HE*7VL\J!:>E =,:!,")W4IBU)JG(M(3\F\#&:.J3H.:1IU,HX@^R*Q.$O) JBN,&AV<_#HP9XV@Y_@ W" P?OM$03 MUQL4.
[[X#%^JE%1D*I4JCY8F5.1DKAA:YX"?'/?J*R8*GEZCR3UHW$.P'?+X M&W*16^SI/YLVIERXT[RPO:&&>D,S&'LN-]0.O.3=F[-7?&P2]9)DZ87(C@3O
MU()WVMB3R5:C16N2R6+!1)GW&:8H$RNK*C8URT&Y@0;G)^WTCV'C7I2@G@/9 MRWV7=,/^R-\=2MQ*_%J)&Q;L1O6"1\IU:^6ZK:$=YAZMG-\)6UU\%^&/ZC#'_RG5]ZTE?ZU675)LG3P
M0ODP/G/-77LGAC#X440%_W2IMZ1055IIPAE=,(YU%6@T9U)AP4.H(4O*%-E1 MO@5;2R%<5&7TGIDUUM+?MTR[:DQ?->VV?U#^%:!6KNZVF[D5IOS?JZUU;3]Q M%>V)?
1H.9V&#_>9Z.+MNLH6+J3!(M2221!&:SFTG:W8M,+V@)MKBE2)>D[.;?%Z1D MT_@P1+8G;2YBB<+['$(\A,CW!:3+QZ+\N=HR5EN_[K*\NAIMZ_K^8CRNUENV M2ZKSXI[E_)7;HMPE-
7]:WHVK^Y(EFS9HEXU=VYZ,=TF:CZXOVVT?R^O+8E]G M:*QU73EIBA^;IZ0S=7(;O:(96Q= M-XB$_WE@"Y9E#8GOQR]'Z.A9LPE\^?B)'K:=YYVY22JV*++_I9MZ>S6:C:P- MNTWV6?VI>(S9L4-
!PUL76=7^;ST>V]HC:[VOZF)W#.9[L$OSP]_DU^,;\2+ M\5X)<(\!KAP0O!+@'0,\. M6=^_^3%@WC? L9^.G-TZZ'#(6[\LDSJYOBR+1ZMLVG->\Z U71O/;9+FS?GQ
MN2[YJRF/JZ_?)U5:6<6MQ<^NBN5UTKKVS/K,3\3-/F/-2V1WSVW^LL55M$ZYH\>@?\[2NWO*_/&'-,OX#E27XYIWKMG%\?K8D<6A(^XK M'?&L#T5>;RMKE6_81A._L?/#?
%C_J8^O[/NTSN[<(W S^S^W/+LMY9KN[YF M?Y;]PSU==_Z8>OC'U"-S. WG1O78'+YD:Q[NO*I.^JOKPFE_===@!._Y%/-: MGO<*;U6616DMBK(\?"8<3I*/9N'FH_6BXJEVE^UYX&1=LT
M;1RNZ<5[L\X71WM6'((F;5!S??AP?=;_P\OS:ZV":9BDY7:9.XY8IM0;>-. M)V*;R-B'H89#P@@21D$PP7#!L^$"L^'N6.BJ0K+!4VWB^+UE*PW&G4J-0T\B3_1L9NS'45$@80<(H"":8:O)L
MJHG1"^2EE:P;QF]&V9._ZN17IAVPS,A7[#71'7')%DNUT42VEX;CV)XTKH6Z M5HX\LD7&C@PU&!)&D# *@@D&FSX;-K'8*V7K#W::T;M!93]=C/)7NH M3;JE;$O?SXLU4;R8+/2AAD'"""!)&03#!,
([=9?EL5P]&89?+Q\R<(IUBG*3YDGY]?#R MML@VK*PNM/DX&YE]@-)64%H(I4506@RE$2B-HFBBZ5^DMAWC.-GDMM=:YQ[B M9B]')OO6DW5'L9.#;8'DD:@-
(JBB?;HT\2RLZ)C');ESBD9IHZ15;D=VP)31[9CN*(Z"Y8!1-=$27 M#7;,N=O#>-#?!VJ:U76"J3(\:)IYGB-G=OO1PGZTR-S3P5[0B3KRA1"!BE(4 M331#E[EUS*G;HQE.6$#-I7J!-PUD"VB:^5-
[)EN@%RWL1XO,_1ML->V^!9YL M-6AZ%D43+= E:)V9,:72Y-B$),D_+/;+/JV_ZI,ER.SC$DI;06DAE!9!:3&4 M1J TBJ*)=NYRRHXYJ?QNO=[O]EG"[XF;^:7I.JVU/IYKJ@#^/)C(@YJNG3=7 MKWO[\
<*>O,CB_6AA/UID[NK0\U&W;YH[_M4:@H1=%$-W2)2M>[B9UHOS,S! M)E23V')J=055##6*9XX]5^YJH;EZ*(U :11%$TW8I?1=U&QL,VBP_K,W(9* MACI)99(W5#*&T@B41E$TT7A=
(<$%3/4V,P9[3IW+/9/K35#%4*/(1SO5=-!T M/Y1&H#2*HHFFZ]+][K>:0VX&#W:B.DE\)D^#@"J&&L6SN>S^"*H90VD$2J,H
MFK@VOJLV>'_^S'0/.C,=2EM!:2&4%D%I,91&H#2*HHFF[RH\WN^$6*AI#:01*HRB:Z+RNFN3][FGOYLC!WM/. MCC_E/6AQ2+,+6N]!JSY0&H'2*(HF>N_%]^" YM2;.8.=J)LO+]]YK*":82_-
M"*H90VD$2J,HFNB\KN;BF6LNI^;RF\,'&TY327%MY08;*AKV$XV@HC&41J T MBJ*)ENO**=XW6D!@Y@[VHJ:X,G,4*T*K*[TT(ZAF#*41*(VB:*(3N^J*!UVX M8*8-
]I]V<8#\K1$KJ&C83S2"BL90&H'2*(HF.K KK7B U1)FQF#?Z99!!/)W MLZV@HF$_T0@J&D-I!$JC*)KHNZZRXB&7:'C0$@N4MH+20B@M@M)B*(U :11% M$^WVE&4,T82B-0&D711,-U)1(?
NPC&C!ML0.WJ%B6% M Q4-^XE&4-$82B-0&D711 MVM1+_Q,J;YR4(QM4V9LI@YT%7VT!I(90606DQ ME$:@-(JBB3[NZB[^7[;:QH=6:J"T%9060FD1E!9#:01*HRB:Z/T7OT1@KOS@
M5MN8A09;72W7.'(U'*H8:A3E=>P15#&&T@B41E$TT99==M!RDDU2=!ZT&06D$2J,HFNB\KAKD?X.U-F;F8]J?X%_]B"T(J235#T(
MK0=!:01*HRB:Z,&N'N2;ZT&]5CR8&8,]IUMEHW@.6@W22:J>@]:"H#0"I5$4 M3?1<5POR!ZZRZ;W@P0P>;,0#;6(V(K3: M-.;F68.%0U?$94'6*AH#*41*(VB:*+7NLI18*X<&98XF",'NTV[MD5U&
[1(_M](JHXC9HD0A*(U :1=%$MW5%HN#$@IJ^BQK,G,'>Q!3;G$D^<#027#/I(15#*&T@B41E$TT8DSTJ9_@L7 MS+BA!IQH?KA$ MG5LAUT\VF[2A\)?2G._:
[L"L&+/RHF:6LS[7O3OC:LM8O>0]N[[P+MZ[H[&R?>%<+!W-]I5S$>JVOYLX%V2B?\7EK[0: MXVZ7KB_ODSOV(2GOTKRR,G;+=\\^G_+QNDSOML]/ZN+^:N2,K)NBKHM=^W#+
M$G[AWS3@K]\6_,TX/FD$'HORY_8MN/X-4$L#!!0 (,B 9EE!D:OQ0 , M #H -9 >&PO=V]R:W-H965T8TYN55((9FJJUK[<* M6>I (O.
[03#T!>.Y%XZ=;:'"L=R9C.>X4*!W0C#U=8J9/$R\CG=ON.'KC;$& M/QQOV1J7:-YM%XIF?L62NQQAEEFB6@;7TI.KW)I@_;7+G:*Y99IG,GL T_- M9N*]]"#%%=MEYD8>WF 9S\#R)3+3[A<.Y=K
@V2GC10EF'8@>%X\V5V9AR, M\=0#NB6@^R.@_P"@5P)ZC_70+P']QWH8E 7NE_$[A(7,A?74MME1/.[I! M32N0=$+3'&:H#$D1WA(I7)-=_\M3F+*,Y0G"T@G],$4K=^@X0G+SN$L0@+1 MX
6\6T9P]NPJPOG][S'O^S])!F] M2F$]Q]=[@"]62BJ82:6*LZ'0R$)QLBZ0'BEO?#??SK#X+^ZFK1)%K5)%K=$=E*]?E6]?A-[>)TG M4B"]T?]3 M_ZSN\ZIN[AIQ4F&!E6&!HT9FK,
[+G8"/LY1W**J%6HCPU.%VB99U"99W!+9 M21F&51F&?^N8&;99O3;)HC;)XI;(3JHWJJHW^J/'3"/[4TM4D(V.CHC@8G!Z MC$1M.HQ;(BLR[Q\U@P+5VG7A&A*YRTWQU:ZL5:-_Y?
K;'^S3SN6L4V./Z&)0 M]/'?Z8M;Q9RI-:=_7H8K0! !D !X;"]W M;W)K&ULO=UK3^-8@L;QKV*QH]6,U-N00%*7K4*B MR_?[W99&\\(D!C*=Q+03J*[5?OAU0L"8A$.R]6_>%"'X_(Z#BSSX]O#E>U7_
MOK@IRZ7TYVPZ7WP]NEDN;S\?'R]&-^6L6/Q:W9;SYBM753TKELVG]?7QXK8N MB_%ZT&QZW#\Y&1[/BLG\Z/S+^CF_/O]2W2VGDWGIU]+B;C8KZA^_E=/J^]>C
MWM'C$^'D^F:Y>N+X_,MM<5U&Y3*Y]>OFL^,G93R9E?/%I)I+=7GU]>BB]SD? M#E<#UDNDD_+[XMEC:?52+JOJ]]4GQOOCKT2>/RJKB;+L/JNUYN
M7M!@Y8VJZ6+]K_1]L^S)D32Z6RRKV69PLP:SR?SA8_'GYAOQ;$#O[)4!_-O??6[CUN[M[>V[OWN,%[6UO\U2&/F[RWMXV;O;6WW5[_)CQN^M[7E7QWRN.E[6]M^^-J0QXW?V]KZK_X4
M/F[]_MY;O_^X]?O[_ZP__;#OO?7[CUN_O_?6[S]N_?YZZQ_O'FMW_GD8EF< M?ZFK[U*]6K[Q5@_6;Y_K\J>/EG7SU4DS;GG^K:R731Y(<5W,%\7Z MW7-
FLZ&JZX]%FI92'E>J_LE(]R:GFRYN%I,S'Y7C'>%,_O2M M\8%X_/"M\:%X_*>WQD=OO/Z^_#ANMO#39NX_;N;?^D+1O)O_*O6'OTC]D_[9 MCA7Z)A[N5O>_2B>?UL-/=PR7]YB]UW]UN"(>
[HV6SG7EU3=F+YK93WNO M#M?VF'TSO+=CN"X>?G%W+1QNB(?+Y>AQ>&^XZR=!/#PJ;YOA)Z^^=FN/#2<8 M;HN'.T4M_,X[>[_VG?]MW/U?>W_'<&__U[YKN+__RN_:[L'/?>?#G]ONT<]]
MY^.?>^W)_L-/=@Q/]_A?U__XZFO/]OAY/SE]];7G>WSG^SO?*COOW*=/ 7VZ M]DY??>N=CXK%C535DE_42^GQ\XO1'W>3Q>0AF_]I-Z,D8UG.%O_:L%14D)I.80F(JB6DDII.8
M06(FB5DD9I.80V(NB7DDYI-80&(AB44D%I-80F(IB64DED-8)U[/GN+U3*2? M/^SH?JMFC7VS.H!YW^3H?%3-2NGO=K58_.,72:WJ[W3XJ3NA0T[HDIA'8CZ)
M!206DEA$8C&))226DEA&8CF$=>)W\!2_@SWBMXG;V62=D;NB3B@<&G4D)I.8 M0F(JB6DDII.806(FB5DD9I.80V(NB7DDYI-80&(AB44D%I-80F+I8.O7PM[@
MI/MK849.F$-8)Q2'3Z$XW",4+Q:+MTZF]"[]"(M)#&9Q!024TE,(S&=Q P2,TG,&F[]3 _='^D[8=%!L\6&7QXL8Q#KI-+8AZ)
M^206D%A(8A&)Q226D%A*8AF)Y1#6";X/3\'W01A\SRXPFDVFY6)9S4OIMOBQ MCK_F8W$Y+7?%GU]-/Y(3"8QA<14$M-(3"SV$QFO)":3F$)B*HEI)*:3F$%B)HE9)&:3F$-B+HEY).:36$!B(8E%
M)!:36$)B*8EE))9#6"=>>R=/^;JZYUJP"^ML'>"MRU$YN7_M&*^8.S1,44U& M-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M0354E3+-MKS MBQ(&)R].I.34E-WD?-
;8T!,FIUS>E]/J=IV9J]M/IL7=?'2SXXSI&X$JG.7@ M0"4U&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1 M+=MHG2MW3[83%9JSFZC]-E'[PD0UJYOY8G6O9I.FCX^?G5N-
RN5R^G R=;6$ M/1F5\T4I75S7Y>;9Z7VU+)L,7GTY+N\+X4E7\.Y0@ M]= 6)%2344U!-175-%334CG_^WA[QG ='+UJU -5"5(M0+4:U!-525,M0+:>T;EJVG5%]<6=46/THILL? MDG]3U#-
Q/858.C@ST5XH5%-0344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0 M+42U"-5B5$M0+46U#-5R2NNF:[]-U_Y??PRXC]9"H9J,:@JJJ:BFH9J.:@:J MF:AFH9J-
:@ZJN:CFH9J/:@&JA:@6H5J,:@FJI:B6H5I.:=W<;6NA^L+ZB_/N MC;'%4Q_C]D7#.P,7[8/:"^*+KO'3&5T2@755%334$U'-0/53%2S4,U&-0?5
M7%3S4,U'M0#50E2+4"U&M0354E3+4"VGM&Z.MC5/S4-1CL9E/9.J*ZG>'"46 MG5$52@>'IGB]!M*/LJAWA;>,KH>":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CF MHUJ
:B&J1:@6HUJ":BFJ9:B64UHW2=LFI[ZXR>GM/=)B5MTU3TSFH[HL%CMO M817/<7#&#K9W3%=]AMT=4[20"=545--034U M -5"5(M0+4:U!-525,M0+:>T;IRVA4Q]8?'$:YG,-KC
MA&H*JJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%: M3FG=N&Y[G/H?WN$Z*+3 "=5D5% 0344U#=5T5#-0S40U"]5L5'-0S44U#]5\ M5
M0+42U"-5B5$M0+46U#-5R2NOF;EL)U1=70EU<7]?E]?JO\]S-QZL_S%/- MI6(T6A]I7IW7?;ZS_+QAL5SM+(\GR[MZ]X%HM X*U6144U!-134-U714,U#-_MW&C/NQ2WKJ&ST"EM5'-0S44U#]5\5
M0+=SGOU&$3AFC6H)J*:IEJ)936C[CR[CJOFH M%J!:B&H1JL6HEJ!:BFH9JN64UDFVT[8>Z51]O_X$YRE:L(1J,JHIJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH% MJ!:B6H1J,:HEJ):B6H9J.:5U<[??
YJZP2.(\N;VJJ_E2=&.J6#@X5='Z)%13 M4$U%-0W5=%0S-EKG".:+LT(F.J.%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6 MHEJ&:CFE=;.R+44Z%9#=SA;BI8AH9J,:@JJJ:BF MH9J.:@:JF:AFH9J-
:@ZJN:CFH9J/:@&JA:@6H5J,:@FJI:B6H5I.:=W<;5N3 M3M]H36+O:A'/=G "HT5(J*:@FHIJ&JKIJ&:@FKG1GM^Q\O+(LX7.:*.:@VHN MJGFHYJ :@&HAJD6H%J :@FHIJF6HEE : U?;>J-
388W#>5S>OW%'#5I=A&HR MJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHY MI74SM:TN.OWX#L>(T9XB5)-134$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1
M+4"U$-4B5(M1+4&U%-4R5,LIK9N[;?/1J;CYZ%NU6!\:7MZ4TF1^7RZ6KUXJ MC)8:H9J,:@JJJ:BFH9J.:@:JF:AFH9J :@ZJN:CFH9J/:@&JA:@6H5J,:@FJ
MI:B6H5I^NEU6=M:>0NI$YEE;J70FKE2ZF-Y7RW)T(SP$+#8.34M4DU%-0345 MU314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;44U3)4RRFMFZMM

MJ=+9.Y0JG:&E2J@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J M1:@6HUJ":BFJ9:B64UHW=_MM[HI+E=[^6^6; HG%SL!%^Y90348U!=545--0
M34UX&Q'O]?'%Q>.A^B4$:K%J):@6HIJ&:KE ME ; T;9PZ4QS,EKO3=+O#Y>RL^U_WFW@U#LY(M&4)U514TU!-1S4#U4Q4LU#-1C4'U5Q4 M\U#-1[4 U4)4BU M1K4$U5)4RU MI[1NF+; 3K?
I_%W=L[KG M+JF0/GB7E-1D5%-0344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U:*,] MW^7X\.*/!\9[+)/LL4R*KGF&:CFE=0.O+4DZ$Y9!;%]5]+-%A>+Y#DY!M#)
MU1144U%-0S4=U0Q4,U'-0C4;U1Q4".9?H?NLO8Z%HYJ.:BFH=J/JH%J!:B6H1J,:HE MJ):B6H9J.:5U,[M0#H3%CV:CFHUJ :B&J1:@6HUJ":BFJ9:B64UHW=]M.I8&X4^EG
M:B#$],%QB[8NH9J":BJJ::BFHYJ!:N9@N[NK-WAQP?!F&='?-+?1M7)0S44U M#]5\5 M0+42U"-5B5$M0+46U#-5R2NM&8]N0U#P41:-3CB?S;^5T*C[6*T0.
M#D%2DU%-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;44 MU3)4RRFM&ZQM$]-@\ ['>M'V)52344U!-175-%334M;N\>Y/71"']4"5 M1+4*U&-425$M1 M+4.UG-
*Z8=E6)@W$E4D_>7<-VJ6$:C*J*:BFHIJ&:OI&ZYQ^/'EQ_M% IS11 MS=KY CZ^/#F*MBFAFHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ&:KEE-:-Q[9-:2!N M4W(\^4(3GQA%FY10348U!=545--034U--5"
M5(M0+4:U!-525,M0+:>T;JBV34J#=VA2&J!-2J@FHYJ":BJJ::BFHYJ!:B:J M6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B64UHG=X=MD])0W*1D3T;K M3H?V*.]MM6P^3(II\]SC#3+;1WZE8E;=
[3Z-*I[QT!1&-1G5%%1344T;[BB! M>7$WB([.:*":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9JN64ULW6 MMEUI*&Y7ZAXH_MEF)?%D!\-
V#@X5]$*)5134$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5_.&.6JP7 M)SD"=,80U2)4BU$M0;44U3)4RRFMFY9MV5+S4)26T=WEHOSC;GT<^'[U[[,C MQA?3^VI9CFZ>/^>-
EE7S4.J?],^DBR9>Q^MCR!=/9W"%1Y&%ZW)PZI*:C&H* MJJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:3FG= M?&X[FX;OT-
DT1#N;4$U&-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#5 M0E2+4"U&M0354E3+4"VGM&[NMIU-0Z"S26P*F M+)=RL2S.O\S*^KIE>KRJ@G3WN>+_M'QUO-*[[/1V_&\ MV?
OL[WH^ZGU.UL\?M].>?[DMKDNGJ*\GS9[NM+QJ5N'DUP_-;P?UY/KFZ9-E M=?OUJ'^*B3!F57*F1\%0>+GF')O-K%KSW(V$3O-*"?/$JE= MGF/Y>D^8.$R]T#LN?*&;K38+_FQ2X
U9$OVM>)8P\VLK&'?GBP(8\82E0B"N%V#I:DEFW'K#&LXD4 M!R2--%@S QL;JPW>4&[2N-02OE+0T[,%D1J2C;Y*S!6VH57H&MWO% @JA>;I MCQU5]+B^++.-Q!H]X7^$1
N&E2+*+,QAH!7"/$.?*%Y1!EKPY9&G;)>1#&&% M/A*6(:@]M,2,H+OOF'7J#@.6),F;VF_@:/#2!-=;A=YSV-&AO^C7#Z,> SZ$MHYO=(SO?=1K<4F*&Q0'5R@*HH$+ MJ%_]@:2@'EKUN
_9<(4ZTBW74 DE&#=:V2 ?JN$8=]Z(^2^BU4K]>H8)AKNVY M2. P+:)ZD[2<3O-08.T+3)TD][6I+>]I)_UEDAH-E*2BI,+?EW/;6A=K+?M M"FBRMD7.BO8"-@Q.'2OHQ7W_4L = !H*$W"0P55-03-
Q]HJ@M?OU8#AL(#JD M.C(?GC75L!?QJ]"859$SK1$"C#*J"@&H:"/%KD"I:9Q0R65CW!X;H_'%]$"C MD<+9+!C-L'%VA:&*4H)LJW>WQK =[*:O;9%1E[/1R=GHYTZP K]V'E^5C8M< MC)
(F7ENHB^[4\,+>EE(5-SM=2)QT<9LN'C3I'$)A5S6?>E+8WY1^OIH'CNV# M5@C;4ETA/'6HL+]%E=5\%L+_KZ2'K7Y['84MGQU2K<3X9W?DG,B-?3HH9$NW MO"[7J_7S9&XOY?
Y)O'S;/&&YH7!M8F0-JL'-"/:7Y7.AG&A1V!OW2FBXO]OA M%IY81!H!^+X60A\G9H/ZT3;[%U!+_P04_"_#(@&99+>%6YF4" "(!0 M&0 'AL+W=O)AX<)-
K8\VQ@WUMQ[_G[*2A2%UYXB7VV7??]]TY=]G. MV"=7(1(\UTJ[<501-==Q[(H*:^$&ID'--RMC:T%LVG7L&HNB#$&UBM,DN8AK M(7649^%L9O/,;$A)C3,+;E/7POZ:H#*[<706[0_FB&7\
[#"CGM(''N[WZ)]#[IS+4CB<&O5=EE2-HP\1E+@2&T5SL_N" M73Y!8&&4"U_8M;Z7:03%QI&INV!64$O=KN*YJ\-! .,<#TB[@#3H;HF"REM! M(L^LV8'UWHSF-
R'5$,WBI/:/LB#+MY+C*)_C%O4&865-#5.CR7*='(N@"J:! M'JV#]W!3EM*742BXT^V_X(OZYA9)2/4VBXG%>,BXZ(@G+7'Z O$5W#-;Y>"3 M+K'\.S[F)/I,TGTFD_0DX *; 0R3=Y
FZ>@$WK"OS##@C5[->]"2L(0%"4(' MC_=8+]'^.);H21S?5=>N$06.(VX;AW:+4?[ZU=E%\O&$RE&OK.D-;H";N=W!"<6$["@="ER 4#PFA M"S;)P,-@,>AZ@'_"8YFT7%>!RX^?;9X,+BZS>'NH,#
[H#@9:AQG@H#_;36VC M]*?]F+EIN^N/>SNC[H5=2^U X8I#D\$E"[!MW[<&F2;TVM(0JP[;BD&PO M=V]R:W-H965T6LI*2[_+]\)5DQ33_B+;BHY>9V#G\4=2E;WS(M*^GR-2^^EX]"5-
YOVTU67DT>J^KI8CHM[Q_%-BD_Y$\BJW_SD!?;I*I?%NMI M^52(9-4VVFZFH>_'TVV29I/E9?O>EV)YF3]7FS037PJO?-YND^+W3V*3OUY-
M@LG;&U_3]6/5O#%=7CXE:W$KJF]/7XKZU71/6:5;D95IGGF%>+B:? PN^,QO M&K2*?Z7BM3SXV6N&3^<1;B8?D>5-]S5__+KH!10WO M/M^4[;_>:Z?U)][]==N]*$KOS][M;B)Y^8/'
MTC)9KPNQ3MI0U^]TD-*[^]V[2?Z;%V_O>'57(MF6WH],5$FZ^:DF?;MEWH_M_.3]X*69=Y-N-C6DO)Q6]6":0YK>=P?^:7?@8<^!$^^F/MK'TN/92JPL[9F[_M_<+1?EJ?Q/V9#-_.Y*?
0";P53Q\\XO_)"_V06H[G^O3FQ#:<\WKG[^Y=.1ED M/ZU(RR,]O-XYXOWRW$UJ?-B*8H7,5G^ M\0]![/_%=LJ1,(:$<1!,"0[=!X>ZZ,M_YE6RJ; \&Q!;#'; X[9Y\Y?F94D) M"2^G+X?GUA21>>2K(F:*@I
$D:KB%E5-YHN]2AEEM!]EY!SE;;(1S<3[6YZO M2N^7&[&]$X5URCDY0Z<<$L:0, Z"*<&(]\&(1\H',3(X2!A#PC@(I@1GM@_. M[+Q\L&L>'7[49PNJY0.+B/A$RP>F*/!G?]#E
U.UF(74G@[F^T'.G8/\.;UO MOMYF:^]C42396M3?=BMW7G "ATX])(PA81P$4Z*RV$=E,5)>6""#@X0Q)(R#-M8$IP E^:__^\S-"U/_RH4NVO^[5%$^EYP:()0CTMV$2D)RT$!P8H<(ZQGH)5
MD=X]MQ/0E0[8'3IIR0%6++]W]]8<$F M"HRL8(IJNZ$G!8LHF/?D!.F6 K==^IQ5HLC:65B/]B8IOHLC1L(-'#P!D30& MI7$430V-]'C!?*P< 35[4!J#TCB*IH9(&K[:5E.R!$+XT,;!T3/$:8H6@1Z
MCC!%P5Q/-]RFFATL9*J; =(ZA6[KY,X2WO^\T],=ZIKO+P9,4NKD&I7$430V>=(TA'2N/0-TDE,:@ M-(ZBJ2&2;C)T[PX>SR.1^35$SR*F9*'G$%.B6QENT1PL?:KCDU8L=%NQH_GC
MY&5/=T>#IR1T"PY*XRB:&C+I*\/96%D#ZB^A--:E<11-#9'TEZ%[$_%XUIA; M%CCTM&'1Z-;%H@F-;QX634_-1"CM6>BV9T?SQO$547#1A=.U[/L3=^34U>@D5LVBHQN$V M3<_V*9&&C+@-
V2X?M/6^:94*MP-QLP;/.^C^')3&430U*@?EEZ/57V(+,+$5 MF-@2S#%,(I$FD9Q9A=FU5U*#F1LL(F.SQ"*:Z:59W"**YST^A$B?1=P^JS<] M#%H!=7%)"=_"@-(ZBJ>&2MI&,5:=)H#812F-0&D?
1U!!)FTC.K-8DEB)+ MO9;JVB;2]T^91406QK<*4T3["B^(=%K$[;1<>>,=2Y_NW@;/3NCV'I3&430U M;M(_DK$*.@G4-D)I#$KC*)IZ\8>TC?3,HDYJUEGJ&R@6B;Z$89/H!1H638\A MH=)R4;?
E%>DDHC4%I'$530R2] M)#VSUI.:M9?ZFN=Q"3LNX4Z).KJ#:^%.J?"TIXOC:YUN^.!)"-VO@](XBJ:& M2?I(.E;U)X5Z1RB-06D<15-#)+TC/;/ZD]JJ/XU,88KF>F6&11,NC(M*+:(X
MZDD7TGU1M_OBST7^)-PY ;H;!Z4Q*(VC:&HLI$>D8U5[4J@=A-(8E,91-#5$ MT@[2,ZL]J:7Z\O!CVIUABRJ@1EHP561F[(+85'1![(DADJXJ R#/2K
MT6TJ\RH2BXK$>K4HMZDH[2GQC*2OBMR^RLP8[UC8=/"%Y"M^N@-(ZBJ=&2 M/C$:JZ8S@GI$*(U!:1Q%4T-T<,.7,VLZHZ,%F]<6B7[Q";-HPEC/&::&]%QY M%DF'%;D=EIDQCJ]0N)
Q]T7PY*XRB:&ASI#*.QRC^96DE5MYME51'*K'< MH,%S#KK;!J5Q%$V][Y7TA?%819HQU!5":0Q*XRB:&B+I"N,SBS1C2Y%F&.J+
M%!95,%_HBQ065>S'^DZ'1171OM7+6)JKV&VN[/EAT%J%NX?!LQ*Z[0:E<11- MC96TA_%8)9PQU!-":0Q*XRB:&B+I">,S2SACLZ8RF(?Z-PJ;*M(W1IA%1>>1 M?
C&9314&/;NDL;16L=M:]2:.=RQ9N+L:/#VA&W)0&D?1U* =W'-SM)MN8N^Z MB;WM)O:^FV.8QEB:QOC,8L[8K*X,]9MA6#1&*:=%8ZQS6C2SGD+.6'JNV.VY M>C/'R;58[@X&3T;H9AV4QE$T-
532/<9CU6[&4#<)I3$HC:-HZHUZI9N[*_S"K MTUNQ>WK$[D65/[6/1[C+JRK?MC\^BF0EBD90__XASZNW%TT'^V=X+/\/4$L# M!!0 (,B 9EE1Z/<^YP< %TT 9 >&PO=V]R:W-
H965TG%T4O%)NV MA94EEY*3[K\O)3NF1 ZY4KJ>Q)/G'^[R[:YI?Y@MK@[95MR+YI?# M1ZF^S2Y>UOE>E'5>E4B*S?7D7?QVR5G;H+/X?RZ>ZMYGU(;R4%6?VB\?UM>3
MJ%4D"K%J6A>9^N]1+$51M)Z4CC_.3B>7/MN&_<_/WG_J@E?!/&2U6%;%K_FZ MV5U/YA.T%IOL6#1WU=//XAQ0)W!5%77W+WHZVT83M#K63;4_-U8*]GEY^C_[M\SP0O0;*#]P
GQM@LP%U-"#G!J0+]*2L"^M]UF2+*UD](=E:*V_MAVYLNM8J MFKQL+^-](]5?<]6N6=R)1U$>!=K(:H^65=E(-;"U$M'LT++K7L@:3=&]FC_K M8R%0M4'W62%J="=J(1_5AZQ%F@]9N5)?
OWTOFBPOOE.-?KE_C[[]^COT M-KL\:;DT;LT)BB6R5L5Z,?R[58#]O/5+R7H/%S MT#?8Z_!>'-X@$GV/<(0IH&?Y\N:$(X=J)N[NTZ3O3=?Q3SZ 0HWD+-!\/02//5Y M7]QD13MO4-:@![-
RS(OM^TD.PB95VLH]),_WOEK5ZG'!6$IOYH]]D,"C.9Q MDO=$'"@&S-*4U6[!^$ M!-=)?T=C%\I0WH;#TF-U'!P49Y>A!B"0M^$ 8#T .# LS@[[$Y2;:Q5DXT!% MK)D>>ZD9$A;GGOKZ<&HN%I
1=]V(&LZQG\Y!:''NHR\M,M7[3(;:-:UC/ZY? MRHO8QNP4I]A4"%GQN4.DIG'LQ_$(8,0V4ZUA])D,%6KJQG[LCD%&;$.5$U,C M8!,[1&KLQG[NWHD'-3EK/PJ\+D:OA(&\#0/6'(_3\"CP[@U&#T
@;\,.3F\1 ML'^+,!X%9X>#72N/S.D)6;&$P1,4:W1C+QE#XN#RG\DN9@&V:3@GFJ2D2,,/IW+%)QQJ[V(_= M$53-CG-_0U@,G5-!$U7[*?K&"Q@(-U-YHDI$[!BO;1M*%03%OL)>ZNN^"K+
MU]TUKYJ=D&A;/0I9MA<_*U"FCZY\]/#W,G;Q#.5M."::Z3@)3@_LW2:,'H! MWH8#H/<+V+]?^!OTL+-Q1LW]%V#$>QN@H5C->NQ/VD.RP\[766*M:K81=9&# M:& 3/["#D(/8=,8F.0";*7%
(S5=S*P283!T$)KVS;C^!QW"#V'AE5F(&&-'$06"B"4S\!%[N,KE52<7J MDQ\+?C>C#^(#>1L&K9E.6/A"A'>;,'H GD;#H#>*Q#_7F$\%HB=<<^9N: " M1FGJR'F)ACCQ)^8!L4#LG%S=:,P,
[#BQ'%B3C2+B9_%8< '9:;&V'("+NN M@\8S\>/YQ62PL3IE\\3:HI2_V4O1/-499^+OA=C%T60WD;!JR93<,7J&G0"G4H M;\,!Z-6H@Q>I[9S;/J.!C)AK>FJ*TUYJ"8O#5:MIA!?396VC:/Z0#5<
M:;B"-84JUM90 LFM*SMD&J[,#]?_=N=*/B#X'8Q=#T-Y&X:K0[-4*TX4Z M-/.PK0[,MU:,!DZIK(M&JDL7"&:V<",L:72-IJ[+K9F*OL"4ZNVJ""?'V#*>P\PG::K[#\W^\+B@[_/
MT6OGOU&Z9AKI+'SIF@4M78?R-GP 4V\6>.C2-;>S;<*(>3X#627,,:.YACU__MM=(UM_/Q.,+6$0A@EA)G(!K:_!5JUQRH79OR@7-SU\.O7'.\!5L3* MT&:]%S7V0FZ[]U=JU#W7>GI]X?+KY1V9=]V;
(<;O-_';Y>E-%^WF].+-;2;5 MDE*C0FR4R^A-HH3)T[LLIR] =>A>!WFHFJ;:=Q]W0LU^V1JHOV^JJGG^TG9P M>: H\1=02P,$% @ R(!F6<\V'_:V @ D@< !D !X;"]W;W)K&ULK95=;]HP%
(;_BI554RMMS1<)I8-(*U6U2JN$RKI= M3+MPPP&L.G9F&VC__8Z=$%%P42]V W%\WM?/.7:.AQNIGO02P)#GB@L]"I;& MU)=AJ,LE5%2?RQH$SLREJJC!H5J$NE9-9TY4\3")HCRL*!-
!,73O)JH8RI7A M3,!$$;VJ*JI>KH#+S2B(@^V+>[98&OLB+(8U7< 4S$,]43@*.Y<9JT!H)@51 M,!\%7^/+<=_&NX"?##9ZYYG83!ZE?+*#V]DHB"P0<"B-=:#XMX8Q<&Z-$.-O
MZQET2UKA[O/6_<;ECKD\4@UCR7^QF5F.@HN S&!.5]S@V& M,GZ&$0_3:W)ZZ&'H4$4:QB6[;)7S;+)&\M.H3XG:?2))%'2 M\\C'Q^774*(\=O+TM3S$ G152+HJ),XO?4<5?G_'27)KH-)_?
(DU3CV_D_WH M+G5-2Q@%^%5I4&L(BH\?XCSZXDOS/YF]2CKMDDZ/N1@ M&.5>SL8LVT$8)/D>IB=FD/HILXXR.THY:4MGOP8L8PG:2Y<=K)PE^T7TQ$21
MGR[OZ/*C='?;BED\HRCV7M,6]04[,6*[1EK*E3 ^[/P *1YD>]B>F(LWBMKO ML/M'L7](0[F/IW]PSM)!-M@#.@SJ14F\1Q3N=$Q[6]U1A6=,$PYSE$7G?4Q(M-3=
,S"R=DWT41ILR>YQB99#'C$;@5* MLS"DXNF*!?'FHF?UG@]\XJNUS_TY^<)7;$[)C\GMT+M]6N*ST,6I3R.D&#+ MB]ZE=49L.Z]0E/C"V2;=VD;YK=S'\?=\Y]J_Z WR*V(!\V2.H.KC@2U8$.0D
M=1U_5=!>'3.ON+W]3"?%S:N;N;N:M(=\MJ19(#_%F]]8=4.C MG.?%05K\19NJ[*"'O"R5<5A55E<0\JC\I(]50VQ5P/B%"KBJ@/>M8%<5['TK M#*L*PWTKC*H*HU8%:_A"A7%585RT?=E814L[5-
+YN8@W2.2E%2W?*-)5U%8- MS*.\9]U)HU7\JS(^?B&^C6[B2*Y3Y$8^ M\SOJ.^;Z,T/]OFJ+ND'P=<5IF/$O9,@M0P)>L*^%&_*$)AX0YD#_7 M$D;,*9FA)T9%:DCNJ$[NZ+\EMRNA)7)
<(/,QT,/<&H[/^P_;>>HJ,]++.+ME MAL.A7L;M*#.Q]#+$>(L_^'2,ZP8<&QOP.DPH%VK0)KN?#?;H!9G/HQ5:Q;&__M46_D[H]]\;VO%$O MES +T=
<;%MXS\0W]@VX833/!BC;F49+)$^3SU(LSM2^H9'79KI8U1CM4?"!A M#B3,A801()B6_VF=_^DQ!Q=3R'1#PAQ(F L)(T P+=VS.MTSX^-^E:7J2)HB
M+P[O>52\AT[4COIV$ZWR!UYMIMQGHCH3J*\/.#RZ02%;5GHZ@]E=&NPI7?3 MT]9[:&&\Q$/SO$]$%S(B 8)I^;,&S3?1@5FPZ2.H8)O#'?H(@](<4)H+2B-0 M-+T;;!D2UC%UNZ)#91V2YH#27%
:@:+I6<=-UO'_*M]5^-'VD+8U^E^8+_'@ M9+\>T06-2*!H>@H;,\ M#RC--:6YH#0"1=.[2&, 6<.C:CNH 01*$0E41#V%C3=EO6).':CM+>^E,VM YE"5-4B: TIS
M06D$BJ;WA,95LR9'E7!0&PV4YH#27% :@:+I66^\-,OHW1Q?PD'MMHIFMDX< MT)CN7C$)5$P]C8U'9IE-LD-EO.7(=&8.TH%:@-(<4)H+2B-0-'V20V.VX<$Q M91R#>FN@-->4YH+2"!1-
SWKCK6&CBW-T&3>'/[A;6+L.2GLD#AK1W2,B@8JH MI[_QRK#9*#M0PG]E$1/<0[<\83D*W8K8S[S\$6*.5MUU?F5R.F7"KI8*UU@ MJ1(([%&NF4!_L"?TA099^3._$HLL3/+-U/B.,-
_2P=T"U*8#I;F@-)%T[M: M8^CAHT[/PJ->'2C--:6YH#0"1=.SWGATV#PE"&8>BCG(P4F=IM?3^&688;LPR;S3)M0FY2BC42^?SH5S06U-0#I3F@-!>41J!H M>KH;8PV/CZJQH"8:*,T!I;F@-
)%T[/>F&C8/#<-2&,GKT_VZRAC3=O*V5'& M'K>E<[(S-,:#<5L[C^%2X<:EPF:7:A_M5,/=3VR5!53&XDF-=KG'BJ'NESC(M0H8^+G='R)UM#VI8@=(<4)H+2B-0-+V'-_88GAU5;D'-+E":
TIS06D$BJ:O M,FG,+ML\LPQ&;LU!#EYO NIY@=+=509*7>!O6M M0&D.*,T%I1$HFI[UK56%KTQ$@Y%[V.6%L.L+81<8VKOC?PNW]1[4E>IOK5@. MF5@5:\OSGR6R2);K1^NC]?
KURV+5=NOXE76VL#J..]:96ZY.;_#E8GFE_"NN MY#Y@2O5J<#I1KSE1KC\O=V2<%.NE[V,IX[#87#/J,Y$74.>7<2R?=_(_]7\! MF/\+4$L#!!0 (_,B 9EDQV,;HZ0, *\2 9 >&PO=V]R:W-H965T M M-
WUEP41.E3L7%E*8!DE5.1N[[GQ6Y!*',6L^K:DUC, M^$[EE,&30')7%$1\>PHTSS2.I\R^D6'VM9S4+J3BA>ULV904';\)U]K(4X<<'C!P:\=_/_K$-0.017H
MD5D5U@-19#$3_("$L=9HYJ#2IO+6T5!F7N-*"7V7:C^U6&; %%U3\IP#6C)% MV(::PSLI04GT%JV.[Q?Q-?H/V]:9[K-R9G MKM*$S6/=M";W[DC.OT!N!>4-"KR?D._YH<7]?MC]
5+MCBOWH.ON:ID:K?Q& M*[_""R[@O:>,*GC[4>==9HG_SX_:'BT5%/(O6ZQ'\-.;LKU5I8DA;FCZU&" MV(.S^/$'''L_VR(?":RC0]#H$ RA+SX(+B5*B1#?*-L@4O =4XCI-4CI:X4\M MA>\'T1E-
BU7@)Z&=)O;:5NR-4?HU2J?V<1*<<;19)=Z%XLY/B;(!D@ M1@H8KOUAF.]-^K'0ND&W?1]?M?'C43O_6&A=+=K>CZ_6_&OD3C^:G/7J#9]GX\2O/'_<;N3[USAGVC %]:H]KNCX?; M_Y*A4O 4=
Z8["(BW2+",OWEM->?A*5Y];(#[;;]7-0P M +:. 9 >&PO=V]R:W-H965TKYG;W1;4OB#V)43'X FE::3_\@D.,!__PXY[J M2E>W,69^__%P>#K'>,Z>D_1KMN(\-[ZOHSC[,%CE^68Z'&:+%5\'V?MDP^/B
MG8GZ6/.51&/./J9$] MK==!^N.21\GSAX$Y>%WP*7Q6"X?G9)GCD=SS_O/F8%J^&.\HR7/,X"Y/8 M2/G#A\&%.9V[D[+!=HU_A_PYV_O;*#_*?9)\+5_,EA\&H[)'/.*+O0Q3_?
M^!6/HI)4].//"CK8U2P;[O_]2B?;#U]\F/L@XU=)])]PF:\^#$X'QI(_!$]1 M_BEYIKSZ0&[)6R11MOV_\5RM.QH8BZJ%4ZK!J>J M%295@XGJAS9'KUMNI%K#W&WLUM8>'VKRNKE-
Y>UMOFYP<[O%AR]:W KY.LB# M\[,T>3;2- MY,&X6@7Q(\^,,#;R%3>N@C3]$<:/QL4Z>8KSL#[?71N_O?G=>%,BYL5ZQ4Z:G0WSHL=EW>&BZMWE2^^L [VSC7D2YZO, M\.
(E7W:T)_+VX[[V5-Y^TM>>R=N;E@0P+#;5;GM9K]OKTI(2[_CFO6&/WAK6 MR'(Z.G0M;^X_Q=+FGGIUNVMSJ%?O:DY_[K/[/]=Y)F]^S1=%<[.KN; E[=V>
M9V]Y=M^>]X45[QBSG*^S_W;M(B\8IQM3GMBGV298_^#XLR=\?0;'YS__6_F M>/2/+GD@81X21I PBH3Y2!@#P03).3O).3+Z^25_#..X/)#?!U$0+WB7W*0(
M7;DA81X21EY@XRVLO+K]=FZ>F"VO=R,?SB]FUPU(EM*^TUNTQ'6!* MZ+DF6E"7&2K\&%[27$5Q,$R*!?/ MXIRG\7;M(#+F0?J5YYU7#]+BNEI%PCPDC"!A% GSD3#V G/W9#O:2590WWBG
MOK&:^L+U)@C3\B*U2T7CUN[R;CP:B7O+=<=*3G,EK[U28PTB[;#NIARW!NR= M.6IVRN]8ZZ2Y$@/U2]A,)[O-=**VF5*^B((L"Q_"XO 09,5_6;'C&RL>+8V'
M)#6R(.H\94GQNH4@"S(03%#8Z4YAIU*%_9$&<1:] MG'Z6X<,#3WEQ]=-Y2I&"=+6$A'E(&$'"Z&F'EMR&EI %&0@F:&FRT])$JJ7B M3K[G"GK2&@YS;)9WK/L#56O/^GF#2L[0UAV2
MYD%II*+MGU_&CMNX2K_I&=,#)E4'NWGCJ%3^]JCR3(D]UV6+LJN=>%/JNOYJ METI>75NP4 L?2B-0&H72?"B-533AGD<0L"C%VJ$WY;:KHF4EIVA+"FK30VD$ M2J,537K40Q9D*)HHI]I^-
Q7]]V.M-3E?6VA0CQU*(U :-65F=B4TJ'F.HHE" MJYUV4VZU:SAL"GA/:;+AF!.0'9:TBG^AI*\Z T J51*,V'TAB*)GYU MM,X5+'FNH&2OR1FZNH/2/"B-5+3]D\JI,QXW[+6>,3U@KRFQ?:6U;H_J 5-B
MSW79HO+J4,&2&L>_VF&35]?6+#2*@-((E$:A-!]*8Q5-X9+/JO,%2VX8*[IK MC:*+0ZE3-DJ<"&NZ:G*0M*6@R *41*(U:[61@TOS*/K0B0]%$3=71 M@"6/!OKM-
:OM89^Z8[OAL/64.>"PR5MI"PN:!$!I5&D49T>-H@_M*>OJZ?X= M@RBT.AJPY-% YU6\U':3 [6/8="$ $HC4!J%TGPHC:%HH@CK,,$ZP=AN%O1A M BC-@](((E$:A-!]*8RB:J+TZ:+#D08.:[0:-&J
T#THC5OMQ@?&)VW3=Y$-Z MR'5KHTW;,IN7<0H=N#VJ TP%/==%B[*KDP9+_@7X7^VY0?,)*,V#T@B41J$T M'TIC5ON!AK%SX-+0KF,'6VXB*[INLJZ?[]R.BT.HXP);' ?\JKMW3-MG8-
F_,^8\V68&9_X)DGS4H*?X[#'8I-7T#ZL06,"*(U :11*\Z$TAJ*)JJP# M!=O%6&PV])D"*,V#T@B41J$T'TIC*)JHO3ICL.49@Y+%)F=HZPX:*T!IQ&X__M*F"-FQ9;SY >L-A4T+
[*2K='U6U^%$W\,=HZ%W#DN8"&"R=(31^1?)PU/#BI M!2U0.F MQ)[KLD7EU<&#\Y=.,B"OKJU9:%P!I1$HC4)I/I3&'.6Y!IPZ@W @LPW(*=IR M@J804!J!TJBC-
ML!M"A#T41)U0&#\XMG1I#SM<4&C1"@-*E4:?W9Y%\:$&& MHHE"JR,$!S9!@IRD+2EHC "E$2B-.NT8H1F;0@LR%$V45!TC.#\[3X+3]KMM M\
[1IQ1TU3X*\E;:LH*$!E$95!G%VU"#ZT(ZRCHX*MPSB_&)UB.#*0X329BO. MB7=Y<;DO_\J;'*1[X(+2/"B-0&D42O.A-(:BB>*KXP87-%>""WTT 4KSH#0" MI5$HS8?2&(HF:J\.(5S-7
ERAK;NH!D#E$8JFF3NO9N> 3U@MKGM!QG75NJT$@"2B-0&H72?"B-N>WG'X1] M1U1B'36XXWS0]H08:BB7+:FZ/X%T^2(.=K M"PT[$3%V)F+L5,3]DR1 "S(4311:G1"XL$D2Y"1M24%3-BB-
0&G4[9\D-5J0 MH6BBI.J$P/W921(JP/C0.?C%9NLI<\!FD[?2UA4T$(#2J-(HSHX:11_:4];7 M4U%H94(@+JD-7K?7-;QZ6C^5Q[-OW'AL7Y.5I]#B7N".;_*M*V?8H[>&-;(< M(XB7QC5?5$O-
[5+;>"Y/N9M-FGP/U\5=1?3#>&--WH^,^P);'C++5F^LT_?V MZY*WQ1D[V_!%V8'HQ_NN'6J8K3C/KX,\.#];_217_$HRHQ%\A3GUF93O#.NQ.S_;!(^\N)%[#./, MB/A#,8ZC]R?%$3<-'U>[%WFR*
<9W8-PG>9ZLMW^N>+#D:;E"\?Y#DN2O+\H" MSTGZ=;NMSO\/4$L#!!0 (_,B 9EGN!\6%3@($<% 9 >&PO=V]R M:W-H965T-+ 43* T3$G0 MN)F1Z_'5//7Q(>
[P];LV>"5K)5Z],Y=,2.Q3P@YYM8S4+=L<8Z<>R*7QN^> MDPR_],!]>\?^.6AW6M;4X%SQ'ZRPU8Q<$BAP0QMN[U7[!7L]9YXO5]R$+[1] M;$P@;XQ5H@>[#-23W4J?^CKL
<:35P!)#TC^%9#V@%"YJ,LLR%I02[.I5BUH M'^W8O!%J$]!.#9/^%E=6NU/F<#:[5:IH&>=P"JON(D%M8%Y16:(!)L%6"'.J M]3.3)5P+U4CK(P;<^AE66+I[M7"\I-
JM%5J64WX"QPNTE#GC%!Y6"S@^.H$C M3WGC<.X*S32R3H'/(\K[;&^Z;)-7LEUA/8(T_@!)G$P.P.=OPQ>8._@XP-.7
M\,C5;2A>,A0O"7SIWXKW\ZL[@3N+POPZI*JCF1RF\8UZ96J:XXRX3C2HMTBR M]^_&Y_&G0QK_$]D+Q>F@.'V+/;O.\T8TG%HLH-RI9Z*F3/LG<$A[1W@1"/U, MV6;)QY&K_G9?
TX&@R[V@+M=H[YG[$?.-ZI)) QPW#A:/+LX(Z*YM.\>J.KS\ MM;*NCX)9N4F'V@>X\XU2=N?X9AIF9_8'4$L#!!0 (,B 9EF< :?#/P0 M #@= 9 >&PO=V]R:W-H965T.1'K-*7\^QTD;#LQ;..]X"E>
MKJ0N,*?CG"YA#O(Y?^3JS*PI49Q")F*6$0Z+B7%KWP1V7PN*&G_&L!5[QT3? MR@MCK_KD(9H8EHX($@BE1E#UMX%[2!)-4G'\4T&-NDTMW#]^I_O%S:N;>:$" M[EGR5QS)U<2X,D@$"[I.Y!/;?
H7JAH::%[)$%+]D6]6U#!*NA61I)581I'%6 M_M.WJB/V!(K3+NA5@MZA8/"!H%\)^J<*!I5@<&I(PTHP/%7@5-+GU)!&E6!4 M#%;9N\70N%32Z9BS+>&ZMJ+I@V)\"[4:D3C35IQ+KJ[&2B>G 6/1-
DX2\@NY MC:)8VX,FY"$K3:[-\MD%2>/DBZKQ/'?)YT]?R"<29V2F5.JZ&)M2Q:%I9EBU M>5>VV?N@S3Z9L4RN!/&R"*(6O=>M=WZD][OUUQUZ4_5?W8F]]TZ\ZW4"YY!? MDKYU07I6;]
2SWVW_+=UUBEW3V^]W]:;I[?>)O?_W[T'_SGXQE#T:S_W"U[__M1W[^]KNZ0AXDI.+O-HN6F$$[1B>-&Y'3$":&FN$%\ T8TY]_LAWKU[;QQ82Y MF#
/$^9CP@(D6,,E@]HE@R[ZSB5QFM.8J]0JVSQ20IP"HG/Z9NI8UMC<[__] M<9W!81WWN,Y!#:\SW'.'Z;@YVSJ,*3BN--JKT^C58=VKP\Y>_0,V5)#G+)80 MD;FD$L0%\=9T2C
SRE]!"D*SB,P@BH5ZKFI,)R0"JI)7GU<$;8@"S7GDPU-UJ!?9.$M!"%T>4@Y M_ZXU-&7K]I30V>JYIBIAU_MYX=(^R!V8#7J8,!\3%B#!&EZYJKUR=4+>NGU\ M(#O7Z"S6F8,ZD><:
1/F8L(\3)B/"0N08 W'7->.N<;)0=>8+L&$N9@P#Q/F M8\(")%C#);:U6URQ,+XS*DKWAT9W4^<./RK-0Z7YJ+0 B]:TP-[ZFMUI@?;O MGJ[,T@T\=]) I;FH-_^5YJ/2
BQ:TS:]G6UZ.!FFXF"Y!9/FHM(\5)J/2@NP M:$VW[!8][<[5LI/S#.JB)RK-1:5Y%>VCY:W* L>5#E?)L*(JQ]7")+!0 M35F7HZ%!>+E-5YY(EA>[1"],2I86ARN@$7!=05U?,";?3W0#]6;I]%]02P,$ M% @
R(!F65;LN#,D P E0H !D !X;"]W;W)K&ULK59=;]HP%/TK5E9E9-K;22#[X[B-3"IB$-K2KK]E#MP9 +6'5L9CO0 M_OM=.Y "32.MX@5BYYZ3*:") Z74"2_NN;E;%?=D9C@3<*N(SM*4JN<; MX'+3]T)O-
W''%DMC)_RXMZ(+F("Y7]TJ'/D%2\)2$)I)013,^]YU>#4(PMP M$;\8;/3>,[%6IE(^VL$HZ7N!500<9L924/Q;PP XMTRHX^^6U"N^:8'[SSOV MK\X\FIE2#0/)?[/$+/M>QR,)S&G&S9W QAN
^A90=T9S9<[6D!H:]Y3<$&6CD$"3)FG%MXSS(:=>)+CN M^.I5"1X);52&U6_(PW<,(",#J?Y3EJV*.*/1YD2EG#N-4RQ0P#;0N*2['(ZXDS.F7 MAN%KJ;E;I_2D,YT2^%G^_*EBELEBCL
M!$<*\Z#F@<)V5*ZP52AL56=6BC4HPZ:X1S4()I75B+G.%AN%=Q M02T(HN91859^YITFNH6);J6)<7XD/)?IKT;BH=PJ6Y)*U#O=A,'+'1]\?T.6 M7HG!Z[.C?K1-U3&Y4G_OXD]!+5P_I,E,9L+D/4
Q6_1&PO=V]R:W-H965T>B2^9N+F^\.0% M)4$6+Q2I(RF[_O8'4+) D" @LLN^22P)^\/N$EP]!"'P\CG+OQ<;2DOTUS9) MBZO)IBQW[V>S8KFAVZB89CN:LD_66;Z-2O8R?
YP5NYQ&J\IHF\R(97FS;12G MD^O+ZKW/^?5EMB^3.*6?M_OZK_5D7/HEE$!9UG MR9_QJMQ<38()6M%UM$_*+]GS[_08D-<#9PJ,X=0JCS<1&5T?9EG MSRCGK9D:_Z-*9F7-PH]3?
N#ORYQ]&C.[\OJ&+DKT:9'CQ_#@5ZA^[9X%KM M$XJR-;JG:9SEZ-]920L4I2OT,8M8HQ]O:!G%R4^L]=?[&_3CFY_0&Q2GZ"Y. M$JYR.2N9;[R'V?
+HQ_S@!^GP(T1W65IN"O1KNJ(KV7[&8CH%1EX#FQ.MX#W= M39%M72!B$4?ASXW>_(8NF3FNS&V-._8ISW:E9^OR?)L69;YGITV)'CZR!NBV MI-OBFRI;!S5'K<:KP?MB%RWIU82=[@7-

G^CD^H=_8<_Z614JD)@4N',*W-&I M7_^1E5&"BL,X2ODX4H5[T/ J#5ZKGJYQ6"7^J1Z'JE40A*=6DH/NR4%7Z^!' M6A3L3,MS?
EA8(=GG<1FKO3P(N;7^WQ'7]1M>*EIAS^GPTCMYZ9F]7/%!%!?% M/DJ7%"VSHE2ZZ;4=\(*&DXHV@:5VT3^YZ/<\TE7%2'C%4+GIMUQ@:;*LAJ.* M5@'VL-
K5X.1JH'7U4[FA.6+G)#OF>S;FT<,=W2YHKCP5M5)]3T4@,2GJ\!1U M"%J#0LC @<2DP+$EON4LT+%YE*N7&M(8F,]77ZO:4:I7[GNTH-3D/!"1!P(Z4H]R4,$#J'N M\(7\H@Q;;]H5MMZJ"Q?
U9D/S(" %ZRGE+(SZ8!#IRHC;*G;-;V'N=6:YTRKW/N.!U.0\"'#"/FRYTX)8[^"!U.3@!8IA M/8L-*'=ZP0>B3MK!"F.YWF'N>]I#Z4F MYT$@'H%%/ **>%!JAD0D8(H-A:&XP[:PH8V"-+;#&!L":N=T&
M%(P)*>&8]T>OVOFN*XS2$[!J#8 E#LX8!B,.TJ)WJSH1$)0+$A ,5N XKK.LUCTP84 MU^DJ)P)0[!Z ,O_]-V2?.:&MU^U]1HV!)[; $QL63VQ0/(%2DX,7>&)#X\E1
ML'&U@YL#=@PVL06;V,/9Q&#:64S&8!-'L(D#P2:.@DUPDTTN>\9!:4FYT'0B0-+)PXHG4"IR<$+.G&@Z<11TXF-FWBB[WEH M9+6E,L/QQ&#**HJG/%9CX(DC\,2!P!.GC2>V[3?YQ&GSB=1*=E$
BM/S)I1__M;D4!!10H-3D+ E <6$!Q0 $%2DT.7@"* PTH3L?-I*"YSDK?\]#(!*,XPQG% M8,HJBJ\\5F,PBBL8Q85@%%=Q@R=H\J/;9A3?[UC#XPI&<0V,LB_**$ZC19RP
MQ+]C'W]G(ZL8/D^K[Z_OJ0:E)F='D(L+2RXN*+E J?1=#,V)8!YW^ (?@ZDN>B,M*6N;WFQH+FHKD2$6^1A$=%EI M]W39G2:WDX 1GN0;.,M?%P^UP?&Y=!.4O*#4Y.X*_7%C^XH%WZ0VA2
')WC1&VW-MUZY;Q& 4I/S(,C0@R5##Y0, MH=3DX 49>M!S6IZ:[[Q6'=/W/#0RP7?>\#DM@RFK1H'R6(U!:9Z@-]B3LM3 ML!8[KYL'1\%:]5:RB[4?B_6=TSJWHH R%92:G 7!5!XL4WF@3
6E)@:T#"*ZK)PU MI^7WF=/R!6?Y?WM.B]=%S[(.&3VK-((B&)2:G*#:E@"P".:#(AB4FAR\0# ? M>EK+(%B=!IXZ<1T+NELW)/5=#,V)@#=_^+26P507O1'[U*5Q#.P+!/8%$--:
M!A%-5H(V,'JMRA@H?N7651@# 8S!WP9&?ED:G(F+^MYZ[\$Q!BX& A<#6%P, M0'$12DT.7N!B (V+!D'=^%?CHF\W:Z*^BZY;@8#,=%@ZDN^F&XJ#<;F@N! MBP$$+AI$=%EIXV(0-
J=,@S8M!D''0K- P&(= /TW"6M^OYZ%X8Q2#$0I!C MDF(2HI0:G+PM>VHH$G1(*BY8 K4I.BTJ^(8I!@(4@R&DZ+!5!>]B11M2SD^ MQB#%4)!B"$&*!A%-5D+%#5#/;_ZZ/%3< /6Z=H$)!2N&
().+YU9%?6^]MRT; M@Q5#P8HA+"N&H*P(I28'+U@QA&9%@Z"&"T(U*P:MJ45]%T-S(E@Q',Z*!E-= M]"96M+%R?(S!BJ%@Q1""%0TBNJPH?C79NGX.%;^:[+I^#@4KAB"L>'9-!"5% M*#4Y-
X(40UA2#$%)$4I-#EZ08@A-B@9!W?@_=TY1W\70G-2V-1U.B@937?1& M4E37Q'$V.JWO= K!BB8536)>3>5?DS?'Q&LKJ3"Z1%T8L57;(M7JN5[.#\+S MM@S4"_?>-
@]*KI$)4LL$\"ZI%NPVJ5!RC034-DJUH%?-O2JVELVU?@IJZ'MP M=+6=3ZWA*^=,MJPZ*7\.:K ;'%5M'U,+8O7(AJX'!U?;;-0:OIC.9$LLIZ/(C,)]=W>>V_WKHQ/L]4A;(UBLL"
M>6_EZ\+5GE:6*#H]SN)E^D"X[*=EF;&ZI1+V KS:$?SZIE%_#$6990_TK*X0!'*4OJNC+<4L6&Q MC?=;M(M>JIK#/+*FV'W[SIHZ[EN4[:NWR@UO&:?+>,>.=K3-]JSI,PL"+=@'
M/*R:FX@%L=^QZ&B4)S%+0DY7=+OC#[VY0/&:>;C'QPI$:,?2E98QTNJ H6 Y M?7!AC@[W42I\J-A$+-4L__S2EC)?^&.L"K3D MX_'PA*#3NZ=G97VH'A#5>A_C]W->092?$?
Y993<3W1P>T'7'4A"G!4KHFG5I M3?EZM_SPR*O#BS+;50^!6F1EF6VK/S >G)X]=_Q]0 M2P,$% @ R(!F67HF]38># 1Z8 !D !X;"]W;W)K&ULM9U1;]M&%D;_RD MBA1((Y$4*3FU#22>&31
O0GB9/>AV ?: M'MM$)%%+TG$,],0E?327/KS+BR_EC3&5^#:? M+E@N"Y->KE::SX;A:)0, MYVFV&!P?KI9]*(X/\]MJEBW,AT*4M_-Y6MR_-;/\[F@0#+XO^)A=WU3-@N'Q MX3*]-F>F^KS\4-
3/AFO*938WBS++%Z(P5T>#-\%K/9TT*ZQ>\>_,W)4;CT7S M5L[S_$OSY-WET6#4;)&9F8NJ0:3U/U__B9G-&E*]'?]KH8/UF,V*FX^_T_7J MS==OYCPMS4D^^T]V6=T<#:8#
<6FNTMM9]3&_^\.T;RAN>!?YK%S]7]RUKQT- MQ,5M6>7S=N5Z"^;9XN'?]%O[06RL$(8_6"%L5PB[KA"U*T1=5QBW*XRW5QC__M8(6X72'N.D+2KI"L/ON'#VOU2I8FO-*O#^?9==IDW0I?A-
G]=Y[>3LS(K\29V:1Y87X5UZ94J2+ M2_%GGM8O>O$A+[;KQ(]Y?U'5F.!1C.RS->KS1_&B M_5CWP50?V,D?6KRHX]@'TG[0FV7QV&?D?/;1>@>,5MSQ#S=P8P_[Z]3,STWQ MWWW[A!?
3%.#7Y3*],$>#NL*6IOAJ!L>__!0DH]_W!4G") E3)$Q#,"?8\3K8 M\8H>^2K+NT59%;?UF:@2?_U9OT"\J\R\W)OOF,R7A$D2IDB8AF!.OO$ZW[C+
M@;M8';B%6:;9I4CG^>VBVI>NE]4WW0=8LH(UETY?CY-I?#C\NAD:.: B87IW MZP_B9+WU3A;).HND>Q;UY=9MD57W8FF*B_K(JR\0]R7B)?9 Y $6!!MO:O1J M% 315BKDH(J$Z0?8@?L&?
A#+9!W+I'LLS2DS>!G&H_HR;G7EXSW;><%]TR%A MDH0I$J8AF!/U=!WU%#W;3RBO\LULOE?U0)[3 MW<%.C0_J(]\MAB?>$?O&1L(4"=,0S(DM&-G?;T?=:W#SRU3P,AYUJ\%^[!1HU M1A3-
S='*I:"'77K0&)T+-&J94)I$:0JE:8KF)FZ]53!A"S2JJU":1&D*I6F* MYL9LG57@529]I49+\Y>^$_^8O=-#=11*TQ3-3<\:J<"OI':NFP^Z%F52[YR@ M-(G2%$K3%,V=HV!-5CA"BW*
(ZBN4)E&:0FF:HKDQ6WT5>KW)TZ^:_=S>>:,> MJZ5MGCH.=BZ:T2$U17-CM'HJ].LIISHW\VZBCM_\^;F]8T3U%$I3*$U3-#=O M:["'B*W.J+I":1*E*92F*9H;LU57H=>9/%*=SW2Q-
VO47Z$TB=)42PNBC4(? M;7_QJ:DQW0RMEPI[S%QJ?$;4^2M!/[EWDJB90FD*I6F*YB9N#5:8L,49U58H M3:(TA=(T17-CMMHJ],^WZNDS6EKLUJIMG^$?LW=ZJ(U":9JBN>E9&Q7Z;=2.
MSYAT+ M[#/\W-X='ZB_:FF;IX[)CL] A]04S8W1:JG(KZ7.;LLJS1;I>3;+JOO?ZA]_M,9>B?/I7@_[Q>L>+ZBJ4IE":IFCN?F"]5A2B53M"=19*DRA-H31-T=R8-[KR
M_).R>EY*M[1'OAKTC]D[/;;OCFV\>PY+%5E+%?DM58=B_3#1+NA:K%&#A=(D M2E,H35,T=S^PIBN*V6*-ZBV4)E&:0FF:HKDQ6[T5^2=H/?T2&_5<*$VV-.>4 M$NQ>8Z/^BJ*Y.5I_%3U;OZ"?
W#M)U'FA-(72-$5S$[?.*V+;!B-4=:$TB=(4 M2M,4S8W9JJX([1YL:4[IVVT?](_9.SW48*$T3='<^UA8@S7NV4(XZ5B4_=R^ M1RM*DRA-H31-T=R\K>H:LPV$8]1DH32)TA1*TQ3-C=F:K/$S-
1#ZN;WS1I56 M2W/$]/:90Z%#:HKFQFA-U?B1]D%:3/O'ZQTOZKQ0FD)IFJ*Y^\'&[:;&;-5& ME19*DRA-H31-T=R8K=(:/[FI<&_*7=KU3OQC]DX/-54H35,T-SUKJL:/M!)V
M*];):/0P:*=ZC4HLE"91FD)IFJ*YNX*576.VQW",&BZ4)E&:0FF:HKDQ6\,U M1GL,6YIS;[_=7BTTU^6S9W&GY3__?IKEY^+\ZR;_XS #HS#*5) ME*90FJ9H[OU#K5>+V8;&&-5I*$VB-(72-
$5S8[8Z+>[0T&AC?ED_KDP]4"4^ MII5IGEX4)BU- M1S>J^U":0FF:HKE[@=5],=MW&:,J#Z5)E*90FJ9H;LQ6Y<5/[KOT?Y/JY_;. M&W5Z\6YWZ'1G^B$ZI*9H;HQ6U<6/-
&!VG37>M5O>/U[O>%'KA](42M,4S=T/ MK/6+V<;,&-5O*$VB-(72-$5S_V2,U6_),S5F^KE]\T9I,MEMS-QS_VQT3$W1 MW!RM7TN0SLRN1=L_6N]T41N'TA1*TQ3-W0NLC4O8OLP$U6(H3:(TA=
(T17-C MMEHL0?LR6]KFUZF[=SCQ#]D[/%1VH31-T=SPK.Q*_+*KXP5VYTJ-SF!#:1*E M*92F*9J[%U@UEK!-F0GJOE":1&D*I6F*YL:\\2<9GZDIT_MG3LW^9\3GD5F+E5M*S*7,R/>A6GE&YA=
(D2E,H35,T-V]KP1*V)3-!)1=* MDRA-H31-T=R8K>1*T);,9+X>_YB]TT/E%$K3%,U-S\JIB5]..7-W[-0=SVSPO:&B,[E0FD1I M"J5IBN:&;^769,Q6:-1>H32)TA1*TQ3-C=G:JTF'_LM_/F&O'248;TW8BR;Q
M=O5&A15*4RA-4S0W62NL)GYAU:%Z;TW7WALL:J]0FD1I"J5IBN:&;RW7A.W& MG*!R"Z5)E*90FJ9H;LQ6;DTZ=&,"U7NZOWH'X4[U1GT62E,H35,T-UGKLR9^ MG_6^/EP_97,C/A1FGM5%^D-
Z_W D^XHU.G,+I4F4IE":IFA.UE.KOZ9LX^04 M=5XH3:(TA=(T17-CMLYKVK-Q\C2M;HNLNA>R+M9[@_8#3]-[(48'+X4(1V&R M-UM4=*$TA=(T17.SM:)KZA==CY;KCK+$/TSO0QLU92A-H31-
T=SXK2F;LMV- M4]2)H32)TA1*TQ3-C=DZL:E_PA=TN=V.LM/=.-Z^VO9O3N]@40N&TC1%'\Y-<6U.S&Q6 MBHOF:^.C07--OEXJ"G-5!Q^\?A,.ACO+9?!:!B/.\JO+YZN&-22]-T;R@_OE5GE??
GS0#W.7% ME]5F'_\?4$L#!!0 (_,B 9EGT11 -6P< !(] 9 >&PO=V]R:W-H M965T$*E^LD779%QH&$A2N)NSS!&W81&:6=\ M4YQ[Y.,;ELLX2N&1YG">6O]Q"S]6W'[&Q./$6+I=0GNN.;C"
[@&>37[)&K M7]TM)8P22$7$4L)A?MNY,Z]]\TH+BCO^C& M]HZ)+LJ,L>_ZAQ?>=@R=(X@A MD!I!U;\53"".-4GEXY*VMFFJ87[QQNZ4Q1>%69&!4Q8_%<4RN5MY[)#0IC3
M/)9/;#V%JD!#S0M8+(J_9%W=:W1(D-O)DDJL"-Y_2126X.$QA](;@LA)<'INE MJTIP=:S -#9OSB@<5+[RPB\6E71\P]F:<'V_XNF#PG2%7MDD2G5\/$NNKD9* M)\<6S"3Y?
19'"ZK]*LAG"&D3ZF,?'2,@*UDS]9(&D4_ZKN^/ILD4__TI^ M)E%*'J(XULJ;KE3YT=1N4*5]7Z;=>R/M/GE@J5P*8JRV KGJ0VZ?9VSS-^UXK\8'R<](WSTC/Z%TT9&C2+K<@V,I'#7*K7?X,F9(;
M;\KM=KF?IZURY_BR-\G=XS,_:'J7QS^Z88/<.U[>E+I_O+S?XJ/^-BK[!:_? M%I5>*B3/55LDR;FIH8,(L3)B-"7,P86X)NRI@NK>^&AOGP\N; M[FK?
\I@I>I@P'PE6L_QP:_GA#UG>_OK49/E6Z*F6QX19F#_;$^9@PMQA@^4' M!X['3-##A/E(L)KC1UO'CW[(\9.IT^3X5NBICL>$69@P&Q/F8,+<48/CC=Z! MY3%3]#!A/A*L9OF+K>4O6BU_T-
<_(Q.V@I2J7K\%(N!1IHW?9/I6[*FFQX19 MF#_;$^9@PMP/P!XY"P!"0>:<)63&N#)+E"X$R=,0.)%+($\3AP0T)3,@N8"0 MS!DG"TB!TY@$C*N:D$H@6:Z.!(@S$J5!G(<*0CAD]%4?P$LDI#
[0E>@YN1.$ MS8D:8*OQXPQX6:#-4/N,T#0DM+A%)Q]J>G$<"?)'3KFJC>-7\@2Z"B:J"M:? M)8EI?/[CC*2,T(3EJ11D#5S)+>>:1B)8B*AU/% MC5PJVI+%ZC$+D#H5N=1?JC9/=QVIPJ4J,T!>@?
+R76S+7H>J\JBG!KJ(5)4P M$B*\)PT#=LPO>5APGPD6*UZN]Q6;Y>MU=N$I2M0C?"A%&1.8, L39F/" M'$R8BPF;8L(\3)B/!*O%A&GLIJ&,UF;BD:M^3)2I%K?L46SZ":KKL=^K8&4K M7@P.HVT,-
<\]M29X:N"@TBQ4FHU*5-D6E>:@T'XM6#X_=2@#SG:4 .AK8_+ %.2,/]"5*\H3<;SZL MD@E5^5#7&J,&=6T *LU"I=FH- ->5YE:T_1ZV>6D8ASTJU!4"J#0?BU:/AMTB M ;-]E<#_)I
>J,RY[E%9;XTF4%<(H-(L5)J-2G-0:>X[K_4NX^6"R+<65$Y1 ML^.ATGPL6CTF=LL(S'?6$50M1%"V$/ BJR7]&?"(-:T5OF\GGAP4J*L(4&DV M*LU!I;GOO%>6PF<]9]
<8#JCK"U!I/A:M'@Z[)09F^QJ#]P?=Y%]RIUJ/$$)R MU,W/^4S /[D>G-BK8HC2-GI'7:J 2K-0:38JS4&EN:BT*2K-0Z7Y6+1ZM.UF MO,U+W-$[ZK0W*LU"I=FH-
>5YJ+2IJ@T#Y7F8]'JX;&;_S9;IQ+'7Z":]7C2 M&\L: Z(=T#\?&HW.?T]VT;0SR/J8S/Z8S'E'-C@WFLKFMLM.=N>',N%]3.9C MY;WT6W=OLV,"?%%LKA4DT+/&Y0ZK[=GM!MZ[8MOJP?
E[\]HQ&\Y/S6NOW)Z[-MPY>[A1\H7T2I(#',55*&>L,=PLL-N.4/R;)BJ^6,2&PO=V]R M:W-H965T8 MN;E;O9BIRF:RP%L-ILISH1^N,%/UW!MZCQ.?Y2ZU/.$O9J78X1KME_)6T\CO MO"0RQ\)(58#&
[=R['$Y7$=L[@S\EUN;@&SB3C5)?>7"=S+V \(,8\L>!/WM M<8E9QHXHC&^M3Z_;DH&'WX_>W[O<*9>-,+A4V5\RL>G<^\6#!+>BRNQG57__M-I\)^XM59MPOU*UMX$%
<&:OR%DP1Y+)H_L7WEH<#P# \ 1BU@-%SP/@$(&P! MX?\%C%O V#'3I.)X6 DK%C.M:M!L3=[XPY'IT)2^+/C8UU;3JB2<7:Q0R[U@ M[D$6QNJ*CM0:$$4"*28[6>R:HY%6HH$+6#?R
+6%3XI/3F1PF:N*021"^$ @ M3.#:8F[@S0JMD-E;PGU9K^#-V5LXHVW@H\PR@IJ9;RD%#L2/VW"73;BC$^&N ML1Q &)S#*!B->^"KE^$KC D^=/#P&.X3<1U[HXZ]D?,W/NG/R%TA+&4LC,N=
M";ONB(3[CYAO4/\-_\!2*V-@66F-1?P ZUJ4L!0FA?=4>@UOG7D?,2]&PK?# MU)0BQKE'Y6]0[]%;_/S3, I^ZZ/IE9P=D19VI(7.>WB*-&GB3)E*(S$%=V)3 M94(#5S'<_* JGGK2J($#QB_[&#=P_P?
MUPBPE\?P-7E\)6='/(X['LVEK0)$#<2_9+X*9OS_DXD>+8?1K M9W.4XL1[-A%U.4?_%=P-W1]"QVE7Q^=PAWL!=/BH21:RL H$Q,?L2+=J+&C2 M3L.5V&E$ULPY-
8K#.GY&H;O71!RS'%EL9:5+94B+M;0IM3Y34@\#WK1HMHE5 M7HKB 3)%,TF%[T67XNR!C$@<\8#& NQ2? H.:HB&' M!]:6UK=24R+?*J%IC6]BO@S=E4W!4+]K+%T6I58Q8F+8ZFP840=Q-
^^@3W[^ M01?)4>]<-R8V..^FNKO9KN%?N<;X?'XR74[ZYJ/ITCT0_"?WS>N"#I3JV$"& M6]HJ&+R;>*";CMT,K"I=#]LH2QW1?:;TR$'-!K2^5&ULQ5AA;]HZ%/TK5MXT;=)K$R=
H0.D+KQJE=:]:FA['Z9],.%"K"5Q M9AMHI??CGYV$A&S!!3UK^U(2/?1 P@T6.:9&+BQ%+FUZXK MHAA2(BY9#IEZLF(\)5+=\K4K<@YD632EB>M[WL!-"?6*$N:0B8HRQ"' MU<2YP=_3;@KPBLR
"0I;\0Y<[1#7U0I-7Q3:%-V*#XJ/6M1_5I4O\#K'<43=)T1"4M$1*UC(P'Z<@_I M OA7]"]29E16R]!?CU%,LC6@D&62*W=(EG":PE95!+&13HP?/^_/)>/4-W$E+1 MR3FPR=D26(MSK^;
<,]JG6%^U%^V9=[X0)<2@@-![]7;JC=WM(05316NN?CU7 M_W?:^CTE"YJ4&XW)V\8ASUUG2V M/0>UG@-;WA[8Y&P)K,7YJN9\9?30?I&? MGO-W"=,W^-
M4T9IM6,\VM.;OD#,A*NM&3VB^(SD*B8C1K0I&12_\[/0/++N(M3M_$C=.>N^B6P%K"CFIA1[:,/K+)V1)8BS/VFF3E_?]MO,(P^;RC9-AM='R0 M^K!QM@],HM^?
4LQ#GKO:MM#:DC:9#_NV3(ZMQC-;:&W>34##QBQTHLV#GSP< M^#_ZO*/FF-&;*(7-6>H7&/W4W&*>].Q5MX36UK6)@KAOS>U6 YLMM#;O)K)A M8SHZ/;]4.(=NO@B"'RW?
530ZXODF8F%SQCK7\[\BRYA'/ML$EM#: C:7> M&5X>T94WDN7%*=>"2KYBC&YO]$'9_5!Z?0_4$L#!!0 (M_,B 9EG@S.'X+00 *86 9 >&PO=V]R:W-H965T2LSWCWT0"(-
%SEE(QMQ(I\RO;%E$"&187 M+ >JOJP9S[!4KWQCBYP#C@NG++4]QQG;&2;46LR*M@>^F+&M3 F%!X[$-LLP M_WX#*=O/+==Z:7@DFT3J!GLQR_$&5B"_Y
]6+LFWZYB^>6HT<$*412([#ZV<$2TE23U#C^J:!6W:=V M/'Y^H=\6P:M@GK")4O_(K%,YM;40C&L\3:5CVS_":J 1IH7L504?]&^LG4L
M%&V%9%GEK$:0$5K^XN=J(HX<%*?;P:L\2UM:+IAV+V"V\U7X3J1%E)KKX2Y2<7 7"RPUHL=$>% MY%N5!%(@3&/T">(-H1MTK;4DDH! [0J$PJQ-7K@,)#X&9W]KO)1G*//3 AE
M<\M9A@Y8H9X%V5 L(4:$HB46";I5^5GS'R'%.FE$0G*!S@*0F*3GJJ\C1RQJ M\\,PT==[R)Z_ZULOZP"=/;A"W0?=R3--7 F2W5%.E [:B:CIMR.KPWIF.(M[AF5B4 AC2'N_Z_2][_&TE3:V/]Z+/C=
<+7$%^@8;.1^0YGM\QGN7[W8== MX?R_WL.?[KTQ&<,Z68<%SW^#]X=,@*,ERU1-3'2Q*K(V8AG4J= E>2]45^(K MD>,(YI;""N [L!:__N*.G=^ZYMLD+#)"PW!&LKXM3)^01_^N(Q_:R^H3L)
MF>A4PS>IADE88!(6&H(UU!C5:HS>L4ZBQCHAY3HY2U65/N_2I42."Z3>7NP6 M[M29V;OCZ7YM,_#\RZ91T&$T&35MP@X;=S2NC1I1C^NHQ[U1WQ**:41PBN!9 M[:/T_Z*^JM
+.S4/3<("D[#0$*RAR*169&*J*DQ,JF$2%IB$A89@#36FM1K3 M$]?'1T1!=JE1@D9'R].>*U:T&'3KA?!:YO)>-@J!:]MILZTNQ)]D:Z MY*K(H>66W%;UC.#5E3<("D[#0$*PAI.L.
MJ1)2D0P)8I06&*6%IFA-38Z.C*[Y[47%/%[G[=U%AXG;*B@_-@D[3 9^=SUQ MO4/(GLF*Q0Z95M2D<9]->2UR6#2+B(=-M-V%>FP\;Q6&;&/[MTRX)OBPE.HRKBE
MLKS5J%OK2]7KXBJQU7[C7BW=CO9 7\(6]WP'?'F#>X_YAE"!4EBKKIR+B:IW MO+P4+5\DRXM;OR_=02P,$% @ MR(!F685:K5.P! "2 !D !X;"]W;W)K&UL MO5E;;]LV%/XKA%8,8,"9!$5]\RVT 3*FV
I@B2=7LH]L!8M$U4$CV2MC-@/WZD MI$B6(LOQ>MJ76**^\QV>B[[XF.,M%]_DDE*%GI,XE1-KJ=3JTK;E;$D3(B_X MBJ;ZR9R+A"A]*Q:V7 E*HLPHB6W/JOJSNA;ZS2Y:()325C*=(T/G$>N]>
MAIYC##+$'XQNYA]_%Z16 MZ=,8[EZ_L-]DP>M@GHBDUSS^DT5J.;&&%HKHG*QC]<"W'VD14,_PS7@LL[]H M6V ="\W64O&D,-8[2%B:?Y+G(A$[!IJGW< K#+RF0;#'P"\,_+=Z" J#X*T>
M>H5!%KJ=QYXE#A-%IF/!MT@8M&8S%UGV,VN=+Y::1GE40C]EVDY-,15L0TRQ MT&TJE5CK)E 2D31"'VFT8.D"O3>U9(I1B<[18]Y0B,_1O:#GBCRCDP^Z'^4I M^L2EU)@;P1-
4T4KTF2M]+]DB)8I&B.GND"7YKM,33!5A\:EV\^41HY-WI^B= M@=^Q.-9-)<>VTA&;?=NS(KJK/#IO3W0^NN.I6DH4IA&-6NQQM_VHP][6F2[3 M[;VD^\KK)'RDJPOD.V?(<[R@93_7;S?
WV\+Y/N_A__9>2X9?]IZ?\05[^#YK M'7R@&YJN=9=\O:/)$Q5_H7^;#=/:+26^K2DZW1KIO90K,J,32VNKI&)#K>FO MO[A]Y[>VBD"284BR$(BL5KN@K%V0L?N'=>/K)_T,W2J:R-
9J!)#5@"3#D&0A M$%FM&KVR&KW.-\DH,#HQ GR*]'_?=E$_0_J%.S.RK56[K5"YCW[FPWS!V$S/ M]_WQO9FMP(M*'_8<^HHW()R/=_MU6%A&\SUAZ,25DM'OTQ'_X<)RQGZ79#(MK'4I3*?
_8WL:D@Q#DH5 9+4B#LHB#J 49@!9#4@R#$D6 I'5JC$LJS'\"0J3 M^^CMO.X-W;@^B, '$6$7HA;\J Q^] /U))SQE"=LECVDG;+2N8UC&QF2#$.2 MA4!DM5JZ3C7Q.%#"4C
!%024#8.RA5!L]9KL3*'N3Y"7PLGNFS]JZ$L+Y-QK M?,7!;2"W(3*M1'MTQO6J/'B=>;AA*4EGC,2(/J]H*H$'HV[O1_QM&]#DVJ^=7M',B@]&;P2@""IMH;"16+[$Q9HAE?IRH_:2I7
MRW/K]]EI;6/]RKV\=EO6L7L9YJ?2%7U^2'Y'A!8BB6(ZUZZ&PO=V]R:W-H965T#\WX21FEO>E5NN\NF5VS-XRBE=QG) MUTD29L\?:,PVUSVE][+A<[18\F)#?WJU"A?TGO(_5G>9>-3?
*?,HH6D>L91D M]/&Z=Z-[Z0XE ?&OA4/G/EU;U"TB,9TQ@LB%/\]T5L: MQX4DVO&]0GN[.HN"^[^_Z&9Y\.)@'L*F:USSI*JL&A!$J7;_\,?U0NQ5T 9OE) K0JH70MH
M50&M:X%A56!X6&#T2H%156#4M8;SJL!YUP+CJL#XH,"K+^M%5>"B:PV3JL"D M:P%E\/+.#3H7V;W9G=]MY>7M5CJ_W\K+&ZZ4[WA_>RZ6)[(>\G!ZE;$-R8K] MA5?\4D9#65ZP"!
[BI#G/UB(H>4["=$YL.E]$ MZ8+<%+$5\8CFY%_D9CZ/BH@+8['_MM\HXN^=3GD8Q;^+/?ZXU\F[WWXGOY$H M)4$4Q^+Y_*K/16.+*ONSJF'&MF'J*PW32,!2OLR)D<[IO*6\+2_D93OBQ=I
M]TJI+Z_4!U4*?F1/9V0P?D_4@:JUM.=67OR>KLZ(-GBUN-Z]=K7MU>Q>^["E MN"DO'H29**Z\6MSZM6.W?ZWQSJ_5[LJ+?YKQ,Z).7JW=DQ?7Z6SWTK75[LN+ MN^M4VOC@9\7C,Z(H;:=-
(PBT77>AE9[V\^[BJR^>(PZG2?[?EH9]V$+#=J@8 MCUSFJW!&KWMBP)'3[(GVIO_\AW(^^'=;;"$Q'8D92,Q$8A82LY&8@\1<).8A M,1^)!2"L$?7#7=0/9?KT,WVBZ5I<_QE?
THSP99@6E_FVJ)="IT8]$M.1F+'% M)B56S(V>IH.SX?BJ_[0?S<@:+21F=VF^@ZS116(>$O.16 #"&E$ZVD7I2!JE M];7Y/4GI8GN5CA)1'V^+5"EV:J0B,1V)&5OL?.]4GQR$*;(Z"XG9QVT?3K2#
M*$56Z"(Q#XGY2"P 88TH/=]%Z7GG*/59GK\G]SP4@V@Q[2;L44RJ9RRAA&7D MEB6B^F6Q1E9.SLOM7XT?O-CR$%,QL163]:R%6?4[^0Q8XDX?U(>I>MB!>?
3JCI/@C$P]3GK$X+B0GY50TMNV"XB /UT5B'A+S MD5@ PAH]T7C7$XVEYXS)LDV8S4G.PXP7;VY4O;E$G"R4Y)MPM5T(Y!D-\W7V M3&(V^T;"14;I=I4P%F<;5O;^R"M^=2^!XGI2,S88J.]"_3A'
!9G34^&@\< M5&TC,1V(!"&M$WV07 M?9/.T7<;YDORF#0OPK#XNU=K!$K-4R,0B>E(S$!BYN3H?%?.F^>[A:S/ M1F(.$G.1F(?$?"06@+!&6"N#^J_9 VE@W\QF;%T,3;'YP57,A-
9I036[TQ$XT#I=J.:U'L'@HGD$ M/K3. *4UHW(OQT211N7]>K6*(YH1,TK#=$;)7<8669B\)Y\>XFA1+DTE0S?C)2^]'X4,4E]D[;9=G:%LLJ&;_TI$Y MT+:X4,V#:CY4"U!:LZM0ZZY"
[=95/%9=Q6K;51"VZRE:XUVJGASO2$V':D:E M-4?4VN$5'%FE!=7L+@?@0*MTH9I7:8U9_O'U&UEE@-*:05DG?2G2[)+]K*^4 M5=F?85(,M,F=4GQQHTMPNJF5#-@FHV5'.@F@O5 M/*CF0[4
I37#O,[R4N1I7BV39W)/9^M,#+++^VN9YF^&L&',]DZ\!31YHUC[X MAB:!034=JAE0S81J%E2SH9H#U5RHYD$U'ZH%**W90=0)9LHV,P:0_:U T\N@
MF@[5#*AF0C4+JME0S8%J+E3SH)H/U0*4UNP#ZO0U19YI]+85=F@N&E33H9I1 M:8U\4VUX.#V'IIE!-;O+ 3C0*EVHYK4ER)/Y'K+ MN)W\38+HK_62D0]A^FU_\T?V5/Y>?
&1L)!_G0[.\H)H.U0RH9D(U"ZK94,V! M:BY4\Z":#]4"E-;L4.K<-.4"-LZ'IJ5!-1VJ&5#-A&H65+.AF@/57*CF034? MJ@4HK=D'U!ER2M<4N<,U_]9N)H;!]5TJ&9-1.J65#-AFH.5'.AF@?5?.4X
MYU$='23Y!J@JF[;F034=JAE0S81J%E2SH9H#U5RHYD$U M'ZH%**W9!]2Y>ZH\=^^T*8,<.[D;@*;L034#JIE0S8)J-E1SH)H+U3RHYJO' M.9'CHRD#JLIF=-=)@*H\"?"-4X;[C[?-
^4)K7P"]61Q4TZ&: =5,J&9!-1NJ M.5#-A6H>5/.A6H#2FIU&G5*H#F'3 F2FU"U4TZ&: =5,J&9!-1NJ.5#-A6H> M5/.A6H#2FGU G36H=KTOW=&G!Z+T]4\/5.K^QRR.EE%OY56?'.;0Q$"H9D(U
M"ZK94,V!:BY4\Z":#]4"E-8,\SHQ4.UZ8[M.L__C+"UE,#@*;VBF'U0SH)H) MU2RH9D,U!ZJY4,V#:CY4"UHBYF)J>5#-AVH!2FL& M?9W?I\IO/H=:RCLI6UC>II-
[#FBF(%0SH)H)U2RH9D,U!ZJY4,V#:CY4"U!: MLS>I,P75"6R-#YHF"-5TJ&9-1.J65#-AFH.5'.AF@?5?*@6H+3FMT+5^82:
M/)_PC7<(D:NG]@?:\9W51H=+"GJ7G0QHNTRH9D$U&ZHY4,V%:AY4\Z%:@-*: MT5LG[VGR6ZG]G^8#\E1@>9M.CGUH&B!4,Z":"=4LJ&9#-0>JN5#-@VH^5 M0 M6K,WJ=,
-14U']"@.8!038=J!E0SH9H%U6RHYD U%ZIY4,V':@%*:_8!>U\3 M^]8[!K9V]COBL5^66S+30R/_E!I0.LTH9H%U6RHYD U%ZIY4,V':@%*:X9W
MG=:G25.&D!.&^[L_R4U"TWEYY^^;ER^7(I]FG!7SB"\;1KXLV3HOOHGJ1OS[MLA%//Q.3K;.&LW[(Z?=U4=1X*GY*YQ[(_*I;J*9#-0.JF5#-@FHV5'.@F@O5 M/*CF0[4
I34[ICK74(/=H5"#WJ$0JNE0S8!J)E2SH)H-U1RHYD(U#ZKY4"U M:Y^OJ24ZR$/IU<)S1;TEL9Q3LI%A&(PO[>59/2QN#O9Y8W: MZQ]M-Y1+2VG9;BN73KF]7_/3JU6XH$$&8+:(T)S%]%%4-
SL9B<))%B^7N 6>K MZY[2(P^,PZMC,-M#]^]E)2*&D M&97R0F+[GG./?4^22W?#Q:M< "CTEE F>]9"J67'MF6T@ 3+!E\"TRLS+A*L M]%#,;;D4@.,4E%#;F07+#%)@$G"&1(PZUD#MS-
IFO@TX >!C=RY M1V8G+YR_FL%=W+,<(P@H1,HP8'U9PQ H-41:QI^-XG "\'>,<"_!S@'PL(6ZMBXH"^H7A_93=_\SPA];^=:]CT)V"1/XNLVA&&)03FD]% M1RYQ!#U+?PLDB#58_;,3M^7-
/M@832MUR6HY7F,,W!NA\TG:Z]WG7&88SO!OLQX6%, MR[_:CQD=QKB.<[T?-*[<]%?K4Q/97GV:17V:E?491)%808QPPE=,(?U=0O3(MDI45JGE8J&NW^:%2E8J^^@P?
DW%49\9Q2<9VV]W/.,F"= NW8S6G\:XK*Y:] MTWDD(.9I4VF.6=\:*V:)O':3MVH?Y6[! F0*_/.%?;@4E0 M_"OH_P-02P,$% @ R(!F63\5]?SP(@ %+L" !D
!X;"]W;W)K&ULS=U[;]M:8N[AKT*D/<44R$DL^;Z;'2#;O-_O)##H M'XQ$V\1(HDO1R4XQ'_Y0LFR:,;TL[?-+T<%@1K;%9U&FHM=<)%]^^EXW_UC?
MEF4K_;E,WPNKFMMU\X^/G3W?%31F5;7+G-]U7'Y^4>;4L5^NJ7DE->?W[NR^3W_++ MT\T"VV>D5?E]_>RQM'DI7^OZ'YLOC/GO[XXV:U0NREF[(8KN_[Z55^5BL9&Z M]?BO'?
KN: M[E[0=@5G]6*]_5_I^^ZY1^^DV?VZK9>[A;LU6%:KA_\O_MS](IXM,)V^LL!T MM\!TWP6.=PL<[O R6Z!DWT7.-TM8'#UNN:.]%WG:V'MO[MVWSRN-$G/V_UUQ=YW.R3O;?
[Y'"#3_;>\I/'33_9>]M/'C?^9.^M/WW<^M.] MM_[T<>M/]_^W_O2/?>^M/WW<^M.]M_[T<>M/MUO_X\.'U_:33R[:XO.GIOXN M-9OG=][FP?;C<[M\]X%7K3:?]%';=#^MNN7:SU?
U;C^1B(1FKAV#9?$#_32[;HEK\N_1O_W)Q?';R'U*U MDIQJL>A^MO[TL>U6;,-_G.U60GU8B>DK*S&1G&[8V[6DK.;E?&1Y2[S\Y5O+ M.V^,/WT+<,7 R84 ^-AMDJ?M,GW<+G],A:
(W:S](DZ/WTO1H>B(ED2S][5__M?63%KL2,7,X^2,>3+7,L8&0QX];?/DA'EUMF*F 4,6/>KSIF^B:COL4LGE[4 MR]XW?S?W-!VDZ>?-
MY^WQ3_+Q;2=@_$,8)0FEO^T^1,>P8/\WH6B=0C'C M%-V[9WKQ)A,=LKW>>FGQ_EM-M/&3/?ZU'UV\^59,]UB;AY].7%'P-_M[MG2T9;+M?_.;+* M?SS0)^/T9H_UM_5=,2M_?]?
MDJ[+YEOY[O.__#!XY+@^B04D M%I)81&(QB24DEI)81F[(YA TB\NPI(L\.BDB[6%:SMEB,9:10.C0C24PF,87$ M5!+32$PG,8/$3!*S2,PF,8?

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l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`5#%$M0K48U1)42U$M0[6W'A\[PM6Q:MP<"RC=4RHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH M%NRTYJ/1QY>C4]..B?4NH M%J- :@FHIJF6HEE/;,'/[OJ43<=\2F;GM;5..[^BBS4RH)J.:@FHIJFFHIJ.: M@6HFJEFH9J.:@VHNJGFHYJ-:\!@='+MH!A6H*JJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVK!3AM&[OA> M+CIPA&HQJB6HEJ):AFHYI0TC=]I'KK@#RJGGQ76UJA925+;MXN%^=_V=[T07 M"(GE@Z,4;81"-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U& MM0354E3+4"VGM&':]HU0I[^P$>H4;81"-1G5%%1344U#-1W5#%0S4?>%&TIK>^_SJMOU;JJ5]W3NF1NF^IKN1Y-8>&(!Z"